<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Aging Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Aging Neurosci</journal-id><journal-id journal-id-type="pmc-domain-id">1239</journal-id><journal-id journal-id-type="pmc-domain">frontagineuro</journal-id><journal-id journal-id-type="publisher-id">Front. Aging Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Aging Neuroscience</journal-title></journal-title-group><issn pub-type="epub">1663-4365</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12497847</article-id><article-id pub-id-type="pmcid-ver">PMC12497847.1</article-id><article-id pub-id-type="pmcaid">12497847</article-id><article-id pub-id-type="pmcaiid">12497847</article-id><article-id pub-id-type="pmid">41059020</article-id><article-id pub-id-type="doi">10.3389/fnagi.2025.1631640</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Aging Neuroscience</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Regional CSF volume quantification using deep learning for comparative analysis of brain atrophy in frontotemporal dementia subtypes</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Lim</surname><given-names initials="KY">Kyoung Yoon</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn0002" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Yoon</surname><given-names initials="S">Soyeon</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn0002" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3072782/overview"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Park</surname><given-names initials="S">Seongbeom</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="S">Seongmi</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2426858/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="K">Kyoungmin</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ahn</surname><given-names initials="J">Jehyun</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="JP">Jun Pyo</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/946895/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="HJ">Hee Jin</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/908700/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Na</surname><given-names initials="DL">Duk L.</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/337865/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Seo</surname><given-names initials="SW">Sang Won</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/309052/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Kwak</surname><given-names initials="K">Kichang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2766190/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/></contrib><on-behalf-of>K-ROAD Study Groups</on-behalf-of></contrib-group><aff id="aff1"><sup>1</sup><institution>BeauBrain Healthcare, Inc.</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country></aff><aff id="aff2"><sup>2</sup><institution>Alzheimer&#8217;s Disease Convergence Research Center, Samsung Medical Center</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Digital Health, SAIHST, Sungkyunkwan University</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country></aff><author-notes><fn fn-type="edited-by" id="fn0003"><p>Edited by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2205353/overview" ext-link-type="uri">Xiao-ling Li</ext-link>, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, China</p></fn><fn fn-type="edited-by" id="fn0004"><p>Reviewed by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1847294/overview" ext-link-type="uri">Hossam El-Din Moustafa</ext-link>, Mansoura University, Egypt</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2095429/overview" ext-link-type="uri">Raul Gonzalez-Gomez</ext-link>, Adolfo Ib&#225;&#241;ez University, Chile</p></fn><corresp id="c001">*Correspondence: Sang Won Seo, <email>sangwonseo@empal.com</email>; Kichang Kwak, <email>kichang.kwak@beaubrain.bio</email></corresp><fn fn-type="equal" id="fn0002"><p><sup>&#8224;</sup>These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>22</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">481075</issue-id><elocation-id>1631640</elocation-id><history><date date-type="received"><day>20</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>02</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 09:25:15.110"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Lim, Yoon, Park, Kim, Kim, Ahn, Kim, Kim, Na, Seo and Kwak.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Lim, Yoon, Park, Kim, Kim, Ahn, Kim, Kim, Na, Seo and Kwak</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fnagi-17-1631640.pdf"/><abstract><sec id="sec1003"><title>Introduction</title><p>Frontotemporal dementia (FTD) encompasses heterogeneous clinical syndromes, and distinguishing its subtypes using imaging remains challenging.</p></sec><sec id="sec1004"><title>Methods</title><p>We developed a deep learning model to quantify brain atrophy by measuring cerebrospinal fluid (CSF) volumes in key regions of interest (RoIs) on standard MRI scans. In a retrospective study, we analyzed 3D T1-weighted MRI data from 1,854 individuals, including cognitively unimpaired (CU) controls, patients with dementia of the Alzheimer type (DAT), and FTD subtypes: behavioral variant FTD (bvFTD), nonfluent variant primary progressive aphasia (nfvPPA), and semantic variant PPA (svPPA). The model quantified CSF volumes in 14 clinically relevant RoIs and generated age- and sex-adjusted W-scores to express regional atrophy.</p></sec><sec id="sec1005"><title>Results</title><p>Each FTD subtype exhibited a distinct, lateralized atrophy pattern: bvFTD showed widespread bilateral frontal and right-predominant parietal and temporal atrophy; nfvPPA showed left-predominant frontal and parietal atrophy; and svPPA exhibited marked left-lateralized temporal and hippocampal atrophy. All FTD subtypes demonstrated significantly greater CSF expansion in these characteristic regions compared to DAT and CU.</p></sec><sec id="sec1006"><title>Discussion</title><p>This deep learning approach provides a simple, interpretable measure of brain atrophy that differentiates FTD subtypes, requiring only standard MRI with minimal preprocessing, and offers clinical utility.</p></sec></abstract><kwd-group><kwd>frontotemporal dementia</kwd><kwd>deep learning</kwd><kwd>cerebrospinal fluid</kwd><kwd>brain atrophy</kwd><kwd>magnetic resonance imaging</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This research was supported by a grant of the Korea Dementia Research Project through the Korea Dementia Research Center (KDRC), funded by the Ministry of Health &amp; Welfare and the Ministry of Science and ICT, Republic of Korea (RS2020-KH106434); by the Korea Health Technology R&amp;D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health &amp; Welfare, Republic of Korea (RS-2025-02223212); by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (RS-2019-NR040057); by the Institute of Information &amp; Communications Technology Planning &amp; Evaluation (IITP) grant funded by the Korea government (MSIT) (RS-2021-II212068, Artificial Intelligence Innovation Hub); by the Future Medicine 20*30 Project of Samsung Medical Center (SMX1250081); and by the Korea National Institute of Health research project (2024ER1003-01).</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="1"/><equation-count count="2"/><ref-count count="43"/><page-count count="9"/><word-count count="6481"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Alzheimer's Disease and Related Dementias</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Neurodegenerative disease is a common pathological hallmark underlying various types of dementia, including Alzheimer&#8217;s disease (AD) and frontotemporal dementia (FTD) (<xref rid="ref35" ref-type="bibr">Rosen et al., 2002</xref>; <xref rid="ref39" ref-type="bibr">Whitwell et al., 2007</xref>; <xref rid="ref11" ref-type="bibr">Erkkinen et al., 2018</xref>). Brain atrophy is a key feature of these diseases, characterized by progressive neuronal loss, cortical thinning, and sulcal widening (<xref rid="ref16" ref-type="bibr">Im et al., 2008</xref>). These structural changes are closely associated with cognitive and behavioral decline, making the quantification of brain atrophy crucial for early diagnosis, progression monitoring, and therapeutic evaluation (<xref rid="ref4" ref-type="bibr">Brambati et al., 2009</xref>; <xref rid="ref26" ref-type="bibr">Marino et al., 2019</xref>).</p><p>Frontotemporal dementia (FTD) comprises several clinical subtypes, including behavioral variant FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), and non-fluent variant primary progressive aphasia (nfvPPA), each with distinct neuroanatomical atrophy patterns that differ markedly from those observed in AD (<xref rid="ref34" ref-type="bibr">Risacher and Saykin, 2013</xref>; <xref rid="ref14" ref-type="bibr">Ghosh and Lippa, 2015</xref>; <xref rid="ref11" ref-type="bibr">Erkkinen et al., 2018</xref>; <xref rid="ref40" ref-type="bibr">Yu et al., 2021</xref>; <xref rid="ref10" ref-type="bibr">Eldaief et al., 2023</xref>; <xref rid="ref37" ref-type="bibr">Taylor et al., 2025</xref>). While AD is typically associated with atrophy in the hippocampus and medial temporal regions (<xref rid="ref12" ref-type="bibr">Ferreira et al., 2017</xref>), FTD more often presents with frontal and anterior temporal lobe degeneration, with variability in regional involvement depending on the clinical subtype (<xref rid="ref25" ref-type="bibr">Lu et al., 2013</xref>; <xref rid="ref32" ref-type="bibr">Planche et al., 2023</xref>). Identifying and characterizing these subtype-specific patterns of atrophy is critical for improving the differential diagnosis between AD and FTD.</p><p>Traditional methods for assessing brain atrophy, such as visual atrophy scales by clinicians, rely on subjective ratings of atrophy based on visual inspection of structural MRI scans (<xref rid="ref36" ref-type="bibr">Scheltens et al., 1995</xref>; <xref rid="ref19" ref-type="bibr">Kipps et al., 2007</xref>). While these methods remain prevalent in clinical practice, they are limited by their labor-intensive, time-consuming, susceptibility to inter-rater variability, and lack sensitivity to subtle anatomical changes (<xref rid="ref9" ref-type="bibr">Duara et al., 2010</xref>; <xref rid="ref5" ref-type="bibr">Cavallin et al., 2012</xref>; <xref rid="ref6" ref-type="bibr">Choe et al., 2024</xref>). To overcome these limitations, advanced techniques, such as the measurement of cortical thickness (<xref rid="ref13" ref-type="bibr">Fischl and Dale, 2000</xref>; <xref rid="ref7" ref-type="bibr">Chu et al., 2024</xref>) and voxel-based morphometry (VBM) (<xref rid="ref1" ref-type="bibr">Ashburner and Friston, 2000</xref>; <xref rid="ref35" ref-type="bibr">Rosen et al., 2002</xref>) have been introduced, offering automated and more quantitative assessments of atrophy. However, these methods often struggle with segmentation inaccuracy due to the subtle intensity differences between gray-white matter boundary, leading to inconsistencies across imaging protocols and scanners (<xref rid="ref23" ref-type="bibr">Leung et al., 2010</xref>; <xref rid="ref30" ref-type="bibr">Pagnozzi et al., 2019</xref>), and they typically require complex preprocessing pipelines and spatial normalization steps that can impede their clinical utility due to high computational demands (<xref rid="ref38" ref-type="bibr">Tustison et al., 2019</xref>; <xref rid="ref2" ref-type="bibr">Bhagwat et al., 2021</xref>; <xref rid="ref42" ref-type="bibr">Zhou et al., 2022</xref>).</p><p>To address these challenges, cerebrospinal fluid (CSF) volumetry offers a practical alternative: its strong intensity contrast with surrounding tissues enables robust segmentation across sites, and focusing on sulcal and ventricular CSF provides a reliable proxy for cortical atrophy (<xref rid="ref20" ref-type="bibr">Kochunov et al., 2008</xref>; <xref rid="ref16" ref-type="bibr">Im et al., 2008</xref>; <xref rid="ref8" ref-type="bibr">De Vis et al., 2016</xref>). Building on this rationale, we employed a previously proposed deep learning&#8211;based segmentation model (<xref rid="ref24" ref-type="bibr">Lim et al., 2025</xref>) to automatically quantify CSF volumes in 3D T1-weighted MRI scans. This approach serves as a proxy for sulcal widening and ventricular enlargement&#8212;key markers of neural tissue loss&#8212;while providing a practical and scalable solution aligned with routine clinical workflows. It facilitates intuitive interpretation, rapid clinical integration, and consistent application across diverse imaging settings.</p><p>In this study, regional CSF volume measures derived from the model were used to evaluate differences in brain atrophy patterns across three clinical subtypes of frontotemporal dementia (FTD), cognitively unimpaired (CU) individuals, and patients with Alzheimer&#8217;s disease (DAT). We hypothesized that each FTD subtype would exhibit distinct CSF volume-based regional atrophy patterns that could be statistically distinguished from those of DAT and CU individuals.</p></sec><sec sec-type="materials|methods" id="sec2"><title>Materials and methods</title><sec id="sec3"><title>Participants</title><p>A total of 1,954 MRI scans for this study were retrospectively collected between 2016 and 2023 from the Korea-Registries to Overcome dementia and Accelerate Dementia Research (K-ROAD) project (<xref rid="ref18" ref-type="bibr">Jang et al., 2024</xref>). The K-ROAD project was conducted between 2016 and 2023 in collaboration with 25 university-affiliated hospitals across South Korea. Its goal was to establish a genotype&#8211;phenotype cohort to advance the development of innovative diagnostic and therapeutic approaches for neurodegenerative diseases, particularly Alzheimer&#8217;s disease and related dementias. The participants in the FTD subtypes included those clinically diagnosed with bvFTD, nfvPPA, or svPPA. bvFTD was defined according to established diagnostic criteria (<xref rid="ref33" ref-type="bibr">Rascovsky et al., 2011</xref>), while nfvPPA and svPPA were diagnosed based on diagnostic criteria for primary progressive aphasia (<xref rid="ref15" ref-type="bibr">Gorno-Tempini et al., 2011</xref>). All FTD diagnoses were made through a comprehensive evaluation that included clinical course, neurological examination, neuropsychological testing, and brain imaging. CU individuals exhibited no subjective cognitive complaints or functional impairments, with cognitive performance confirmed to be within normal limits through detailed neuropsychological assessments. The diagnosis of DAT was established based on the NIA-AA criteria (<xref rid="ref29" ref-type="bibr">McKhann et al., 2011</xref>), requiring evidence of substantial cognitive decline, including memory impairment, that compromised independent daily functioning and aligned with Alzheimer&#8217;s disease etiology. Of these, 72 participants with follow-up scans and 28 participants with structural brain lesions were excluded from the analysis (<xref rid="fig1" ref-type="fig">Figure 1</xref>). Structural lesions were defined based on the presence of any of the following: (1) white matter hyperintensities due to radiation injury, (2) hydrocephalus; (3) traumatic brain injury; (4) territorial infarction; (5) stroke; and (6) brain tumor.</p><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Flowchart of participant inclusion and exclusion. A total of 1,954 participants underwent brain MRI as part of the K-ROAD study between 2016 and 2023. After excluding 100 participants with follow-up scans or structural brain lesions, 1,854 participants were included for analysis. Participants were categorized into the Alzheimer&#8217;s disease cognitive impairment group (CU, <italic toggle="yes">n</italic>&#8239;=&#8239;845; DAT, <italic toggle="yes">n</italic>&#8239;=&#8239;667) and the frontotemporal dementia group (bvFTD, <italic toggle="yes">n</italic>&#8239;=&#8239;137; nfvPPA, <italic toggle="yes">n</italic>&#8239;=&#8239;70; svPPA, <italic toggle="yes">n</italic>&#8239;=&#8239;135). CU, cognitively unimpaired; DAT, dementia of Alzheimer&#8217;s type; bvFTD, behavioral variant frontotemporal dementia; nfvPPA, nonfluent variant primary progressive aphasia; svPPA, semantic variant primary progressive aphasia.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1631640-g001.jpg"><alt-text content-type="machine-generated">Flowchart of the K-ROAD Cohort study. Initially, 1,954 participants are included. Excluded criteria remove 100 for reasons like follow-up data, stroke, hydrocephalus, etc. The remaining 1,854 are divided into Alzheimer&#8217;s disease group (1,512) and Frontotemporal dementia group (342). Alzheimer&#8217;s group is further divided into CU (845) and DAT (667). Frontotemporal group splits into bvFTD (137), nfvPPA (70), and svPPA (135).</alt-text></graphic></fig><p>The study protocol received approval from the Institutional Review Board (IRB) of SMC (IRB No. 2021&#8211;02-135). Written informed consent was obtained from each participant, and all procedures were conducted in accordance with the approved guidelines.</p></sec><sec id="sec4"><title>Acquisition of 3D T1 images</title><p>All participants underwent brain MRI at each participating center using a standardized imaging protocol for three-dimensional (3D) T1-weighted turbo field echo sequences acquired on 3.0&#8239;T MRI scanners. All images were subsequently centralized and processed at Samsung Medical Center.</p></sec><sec id="sec5"><title>Deep learning-based segmentation method for CSF regions</title><p>For the automated segmentation of cerebrospinal fluid (CSF) regions, we employed the 2D nnU-Net framework with a PlainConvUNet architecture (<xref rid="ref17" ref-type="bibr">Isensee et al., 2021</xref>). The network follows a self-configuring six-stage encoder&#8211;decoder U-Net design, in which the encoder progressively reduced spatial resolution while increasing feature dimensionality, and the decoder reconstructed spatial details through transposed convolutions. Multi-scale feature fusion is achieved through skip connections between corresponding encoder and decoder levels. Each stage consists of two plain convolutional layers with a kernel size of 3&#8239;&#215;&#8239;3, followed by instance normalization and a leaky rectified linear unit. The nnU-Net framework automatically configures preprocessing, data augmentation, training schedules, and postprocessing pipelines based on the dataset&#8217;s properties, ensuring robust and reproducible segmentation performance without extensive manual tuning.</p><p>MR images used for model training and testing were obtained from multiple sources, including SMC; the Alzheimer&#8217;s Disease Neuroimaging Initiative (<xref rid="ref31" ref-type="bibr">Petersen et al., 2010</xref>); the International Consortium for Brain Mapping (<xref rid="ref28" ref-type="bibr">Mazziotta et al., 2001</xref>); the Information eXtraction from Images project; and the Open Access Series of Imaging Studies (<xref rid="ref22" ref-type="bibr">LaMontagne et al., 2019</xref>) (see <xref rid="SM1" ref-type="supplementary-material">Supplementary Table 1</xref> for details). All scans were converted to 3D NIfTI format and processed using the SynthSeg in FreeSurfer (version 7.4.2) (<xref rid="ref3" ref-type="bibr">Billot et al., 2023</xref>), which simultaneously generated silver-standard segmentation masks and resampled the images to isotropic 1mm<sup>3</sup>&#8239;&#215;&#8239;1mm<sup>3</sup>&#8239;&#215;&#8239;1&#8239;mm<sup>3</sup> voxel spacing, resulting in standardized 3D volumes for supervised training. The silver standard masks defined the following regions as RoIs: CSF adjacent to the cortical gray matter in the bilateral frontal (L_Frontal, R_Frontal), occipital (L_Occipital, R_Occipital), parietal (L_Parietal, R_Parietal), and temporal (L_Temporal, R_Temporal) lobes, as well as ventricular spaces such as the bilateral anterior lateral ventricles (L_Anterior_LV, R_Anterior_LV), posterior lateral ventricles (L_Posterior_LV, R_Posterior_LV), and the CSF surrounding the left and right hippocampal regions (L_Hippocampal, R_Hippocampal).</p><p>Segmentation was performed using 5-fold cross-validation. Model training was performed over 200 epochs with a batch size of 64, using stochastic gradient descent as the optimizer, a composite loss function combining Dice and cross-entropy losses, a learning rate of 1&#8239;&#215;&#8239;10<sup>&#8722;2</sup>, and weight decay of 3&#8239;&#215;&#8239;10<sup>&#8722;5</sup>. Model performance was assessed using the Dice similarity coefficient (DSC), a measure of spatial overlap between the prediction and the silver-standard mask, as follows:</p><disp-formula id="E1"><mml:math id="M1" overflow="scroll"><mml:mi mathvariant="italic">DSC</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mo>&#215;</mml:mo><mml:mi mathvariant="italic">TP</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>&#215;</mml:mo><mml:mi mathvariant="italic">TP</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="italic">FP</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="italic">FN</mml:mi></mml:mrow></mml:mfrac></mml:math></disp-formula><p>where TP, FP, and FN represent true positives, false positives, and false negatives, respectively.</p></sec><sec id="sec6"><title>Quantification of brain atrophy based on regional CSF volume</title><p>To assess brain atrophy, cerebrospinal fluid (CSF) volumes were obtained from 14 predefined regions of interest (RoIs) segmented on each participant&#8217;s raw T1-weighted MRI scans using our automated processing pipeline, which includes the segmentation model, as detailed in <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 1</xref>. For each participant, the CSF volume of each RoI (denoted as RoI_CSF_Vol) was normalized by intracranial volume (ICV) to account for individual variability in head size. To further normalize these values across participants, normalized RoI_CSF_Vol measures were converted to W-scores using multiple linear regression models that included age and sex as covariates (<xref rid="ref21" ref-type="bibr">La Joie et al., 2012</xref>). The W-score is calculated as follows:</p><disp-formula id="E2"><mml:math id="M2" overflow="scroll"><mml:mi>W</mml:mi><mml:mo>&#8722;</mml:mo><mml:mtext mathvariant="italic">scor</mml:mtext><mml:msub><mml:mi>e</mml:mi><mml:mi mathvariant="italic">RoI</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mo>&#8722;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mi mathvariant="italic">RoI</mml:mi></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>W</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="italic">RoI</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="true">(</mml:mo><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:msub><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>W</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="italic">RoI</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:math></disp-formula><p>where <inline-formula><mml:math id="M3" overflow="scroll"><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>W</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="italic">ROI</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="true">(</mml:mo><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:math></inline-formula> is expected CSF_Vol for a given RoI in W-score model with age (A) and sex (S), <inline-formula><mml:math id="M4" overflow="scroll"><mml:msub><mml:mi>V</mml:mi><mml:mi mathvariant="italic">ROI</mml:mi></mml:msub><mml:mspace width="0.25em"/></mml:math></inline-formula>is the participant&#8217;s CSF_Vol of RoI derived from segmentation model, and <inline-formula><mml:math id="M5" overflow="scroll"><mml:msub><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>W</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="italic">ROI</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the standard deviation of the residuals in W-score model. Given that increased CSF volume is indicative of brain atrophy, the W-score was inverted to align with this biological interpretation (<xref rid="ref24" ref-type="bibr">Lim, Park et al., 2025</xref>). Finally, the spatial distribution of brain atrophy was visualized by projecting average W-score maps of each FTD subtype onto a cortical surface.</p></sec><sec id="sec7"><title>Statistical analysis</title><p>To compare participant characteristics across group, Chi-square tests were applied to categorical variables, while one-way analysis of variance (ANOVA) was used for continuous variables, including age, years of education, Mini-Mental State Examination (MMSE) scores, and ICV. When significant group differences were found, Bonferroni-adjusted <italic toggle="yes">post hoc</italic> analyses were conducted separately to compare each FTD subtype with CU individuals and patients with DAT. For regional brain atrophy analysis, W-score distributions for each RoI were visualized using boxplots. Group differences in RoI W-scores were assessed using one-way ANOVA, followed by Bonferroni-corrected post hoc comparisons between each FTD subtype and both CU and DAT groups. To quantify the magnitude of group-level differences, Cohen&#8217;s <italic toggle="yes">d</italic> effect sizes were calculated for each RoI. All statistical analyses were performed using R software, version 4.4.2.<xref rid="fn0001" ref-type="fn"><sup>1</sup></xref></p></sec></sec><sec sec-type="results" id="sec8"><title>Results</title><sec id="sec9"><title>Participant characteristics</title><p>The demographic characteristics of participants are presented in <xref rid="tab1" ref-type="table">Table 1</xref>. The cohort consisted of 1,854 participants: 845 CU, 667 DAT, and 342 FTD subtypes (137 bvFTD, 70 nfvPPA, and 135 svPPA). The mean age of the entire cohort was 71.1&#8239;&#177;&#8239;8.3&#8239;years, with females comprising 58.3%. The mean MMSE score was 23.7&#8239;&#177;&#8239;6.2. The average years of education was 11.6&#8239;&#177;&#8239;4.7, and the mean intracranial volume (ICV) was 1,481.4&#8239;&#177;&#8239;131.4&#8239;mL.</p><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>Characteristics of participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="top" rowspan="1" colspan="1">CU (<italic toggle="yes">N</italic> =&#8239;845)</th><th align="center" valign="top" rowspan="1" colspan="1">bvFTD (<italic toggle="yes">N</italic> =&#8239;137)</th><th align="center" valign="top" rowspan="1" colspan="1">nfvPPA (<italic toggle="yes">N</italic> =&#8239;70)</th><th align="center" valign="top" rowspan="1" colspan="1">svPPA (<italic toggle="yes">N</italic> =&#8239;135)</th><th align="center" valign="top" rowspan="1" colspan="1">DAT (<italic toggle="yes">N</italic> =&#8239;667)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, mean &#177; SD, years<sup>1</sup></td><td align="center" valign="top" rowspan="1" colspan="1">70.7&#8239;&#177;&#8239;7.2</td><td align="center" valign="top" rowspan="1" colspan="1">66.6&#8239;&#177;&#8239;10.7<sup>*&#8224;</sup></td><td align="center" valign="top" rowspan="1" colspan="1">68.8&#8239;&#177;&#8239;8.6<sup>&#8224;</sup></td><td align="center" valign="top" rowspan="1" colspan="1">67.0&#8239;&#177;&#8239;8.6<sup>*&#8224;</sup></td><td align="center" valign="top" rowspan="1" colspan="1">67.0&#8239;&#177;&#8239;8.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex, female, N (%)<sup>2</sup></td><td align="center" valign="top" rowspan="1" colspan="1">516 (61.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">58 (42.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">37 (52.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">66 (48.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">403 (60.4%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Years of education, mean &#177; SD<sup>1</sup></td><td align="center" valign="top" rowspan="1" colspan="1">12.1&#8239;&#177;&#8239;4.5 (<italic toggle="yes">N</italic> =&#8239;845)</td><td align="center" valign="top" rowspan="1" colspan="1">11.4&#8239;&#177;&#8239;4.5 (<italic toggle="yes">N</italic> =&#8239;134&#8225;)</td><td align="center" valign="top" rowspan="1" colspan="1">11.5&#8239;&#177;&#8239;4.3 (<italic toggle="yes">N</italic> =&#8239;66&#8225;)</td><td align="center" valign="top" rowspan="1" colspan="1">11.4&#8239;&#177;&#8239;4.4 (<italic toggle="yes">N</italic> =&#8239;131&#8225;)</td><td align="center" valign="top" rowspan="1" colspan="1">11.1&#8239;&#177;&#8239;5.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MMSE (<xref rid="ref1001" ref-type="bibr">Kim et al., 2024</xref>), mean&#177;SD<sup>1</sup></td><td align="center" valign="top" rowspan="1" colspan="1">28.3&#8239;&#177;&#8239;1.6 (<italic toggle="yes">N</italic> =&#8239;845)</td><td align="center" valign="top" rowspan="1" colspan="1">20.5&#8239;&#177;&#8239;6.1<sup>*</sup> (<italic toggle="yes">N</italic> =&#8239;108&#8225;)</td><td align="center" valign="top" rowspan="1" colspan="1">20.6&#8239;&#177;&#8239;7.0<sup>*</sup> (<italic toggle="yes">N</italic> =&#8239;53&#8225;)</td><td align="center" valign="top" rowspan="1" colspan="1">19.1&#8239;&#177;&#8239;8.8<sup>*</sup> (<italic toggle="yes">N</italic> =&#8239;113&#8225;)</td><td align="center" valign="top" rowspan="1" colspan="1">19.5&#8239;&#177;&#8239;5.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ICV, mean &#177; SD, mL<sup>1</sup></td><td align="center" valign="top" rowspan="1" colspan="1">1,486.7&#8239;&#177;&#8239;131.3</td><td align="center" valign="top" rowspan="1" colspan="1">1,505.0&#8239;&#177;&#8239;139.9<sup>&#8224;</sup></td><td align="center" valign="top" rowspan="1" colspan="1">1,500.6&#8239;&#177;&#8239;108.0</td><td align="center" valign="top" rowspan="1" colspan="1">1,482.8&#8239;&#177;&#8239;129.1</td><td align="center" valign="top" rowspan="1" colspan="1">1,467.0&#8239;&#177;&#8239;131.3</td></tr></tbody></table><table-wrap-foot><p>Values are expressed as mean &#177; standard deviation (SD) or number (%) as appropriate. Statistical comparisons for continuous variables<sup>1</sup> were performed using analysis of variance (ANOVA) followed by Bonferroni post hoc tests. Categorical variables<sup>2</sup> were compared using Pearson&#8217;s Chi-squared test. A p-value &lt; 0.05 was considered significant. &#8225; Sample sizes for Years of education and MMSE variables differ from the No. of participants due to missing data: Years of education: bvFTD (<italic toggle="yes">n</italic>&#8239;=&#8239;134), nfvPPA (<italic toggle="yes">n</italic>&#8239;=&#8239;66), svPPA (<italic toggle="yes">n</italic>&#8239;=&#8239;131). MMSE: bvFTD (<italic toggle="yes">n</italic>&#8239;=&#8239;108), nfvPPA (<italic toggle="yes">n</italic>&#8239;=&#8239;53), svPPA (<italic toggle="yes">n</italic>&#8239;=&#8239;113). Summary statistics for the overall cohort are provided in the text. Summary statistics for the overall cohort are provided in the text. CU, cognitively unimpaired; bvFTD, behavioral variant frontotemporal dementia; nfvPPA, nonfluent variant primary progressive aphasia; svPPA, semantic variant primary progressive aphasia; DAT, dementia of Alzheimer&#8217;s type; N, number of subjects; SD, Standard deviation; MMSE, Mini&#8211;Mental State Examination; ICV, intracranial volume, Asterisk (*), significant difference with cognitively unimpaired individuals; Dagger (&#8224;), significant difference with dementia of Alzheimer&#8217;s type patients.</p></table-wrap-foot></table-wrap></sec><sec id="sec10"><title>Regional variations in W-scores among diagnostic groups</title><p>The boxplots in <xref rid="fig2" ref-type="fig">Figure 2</xref> illustrate the distribution of W-scores across RoIs for each diagnostic group. CU individuals generally exhibited W-scores indicative of minimal atrophy, while all FTD subtypes demonstrated significantly lower W-scores across all RoIs, except for the right occipital region. Comparisons between DAT and FTD subtypes revealed distinct, region-specific patterns. Specifically, bvFTD showed marked atrophy in the bilateral frontal, parietal, and temporal lobes, as well as in the anterior LVs and hippocampal regions. The patients with nfvPPA demonstrated predominant atrophy in the bilateral frontal, left parietal lobes, and left anterior LV. In contrast, svPPA was characterized by significant degeneration in the left frontal, bilateral temporal lobes, and hippocampal regions.</p><fig position="float" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>Boxplots of W-scores for cerebrospinal fluid volume of each region of interest. An asterisk (*) indicates significant difference with CU individuals and dagger (&#8224;) indicates significant difference with DAT patients. For visual convenience, W-scores beyond &#177;3 standard deviations were excluded from the boxplots, without affecting the underlying statistical analysis. CU, cognitively unimpaired; bvFTD, behavioral variant frontotemporal dementia; nfvPPA, nonfluent variant primary progressive aphasia; svPPA, semantic variant primary progressive aphasia; DAT, dementia of Alzheimer&#8217;s type; CSF, cerebrospinal fluid; L_Anterior_LV, left anterior lateral ventricle; R_Anterior_LV, right anterior lateral ventricle; L_Posterior_LV, left posterior lateral ventricle; R_Posterior_LV, right posterior lateral ventricle; L_Hippocampal, left hippocampal; R_Hippocampal, right hippocampal; L_Frontal, left frontal; R_Frontal, right frontal; L_Temporal, left temporal; R_Temporal, right temporal; L_Parietal, left parietal; R_Parietal, right parietal; L_Occipital, left occipital; R_Occipital, right occipital; Global, sum of all cerebrospinal fluid regions of interest.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1631640-g002.jpg"><alt-text content-type="machine-generated">Box plot grid showing W-Scores across various brain regions, labeled from L_Frontal to Global. Each plot includes box plots for five groups: CU, bvFTD, nfvPPA, svPPA, and DAT, color-coded in yellow, green, blue, red, and pink, respectively. Data points range from approximately -4 to 2. Statistical significance marked by asterisks and daggers.</alt-text></graphic></fig></sec><sec id="sec11"><title>Effect sizes and spatial distributions of regional atrophy patterns</title><p><xref rid="fig3" ref-type="fig">Figure 3</xref> illustrates the effect sizes of W-scores across RoIs for three pairwise comparisons: each FTD subtype versus CU individuals (<xref rid="fig3" ref-type="fig">Figure 3A</xref>), and each FTD subtype versus DAT patients (<xref rid="fig3" ref-type="fig">Figure 3B</xref>). When compared with CU individuals, most RoIs&#8212;except the right occipital lobe&#8212;exhibited medium or larger effect sizes in W-scores. In comparison with DAT patients, bvFTD exhibited large effect sizes in the bilateral frontal lobes and medium effects in the anterior LVs, right temporal lobe, and right hippocampal region. The nfvPPA subtype demonstrated large effect sizes in the left frontal lobe, with additional medium effects in the right frontal, left parietal lobes, and left anterior LV. In the svPPA group, the most notable effect was observed in the left hippocampal region, followed by the bilateral temporal lobes.</p><fig position="float" id="fig3" orientation="portrait"><label>Figure 3</label><caption><p>Forest plots presenting the effect size on W-scores of the cerebrospinal fluid volume of each region of interest. The plots show the effect sizes for comparisons between CU individuals and FTD subtypes in <bold>(A)</bold>, as well as DAT patients in <bold>(B)</bold>. This highlights the magnitude of differences in the distribution of W-scores across the group comparison. The dots in plot represent Cohen&#8217;s <italic toggle="yes">d</italic> values, and the values on both sides represent 95% confidence intervals. Cohen&#8217;s <italic toggle="yes">d</italic> values less than 0.2 are considered &#8220;very small,&#8221; less than 0.5 &#8220;small,&#8221; less than 0.8 &#8220;Medium,&#8221; less than 1.2 &#8220;large,&#8221; and greater than or equal to 1.2 &#8220;very large.&#8221; CU, cognitively unimpaired; FTD, frontotemporal dementia; bvFTD, behavioral variant frontotemporal dementia; nfvPPA, nonfluent variant primary progressive aphasia; svPPA, semantic variant primary progressive aphasia; DAT, dementia of Alzheimer&#8217;s type; CSF, cerebrospinal fluid; L_Anterior_LV, left anterior lateral ventricle; R_Anterior_LV, right anterior lateral ventricle; L_Posterior_LV, left posterior lateral ventricle; R_Posterior_LV, right posterior lateral ventricle; L_Hippocampal, left hippocampal; R_Hippocampal, right hippocampal; L_Frontal, left frontal; R_Frontal, right frontal; L_Temporal, left temporal; R_Temporal, right temporal; L_Parietal, left parietal; R_Parietal, right parietal; L_Occipital, left occipital; R_Occipital, right occipital; Global, sum of all cerebrospinal fluid regions of interest.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1631640-g003.jpg"><alt-text content-type="machine-generated">Two graphs compare effect sizes (Cohen's D) for different brain regions. Graph A shows CU vs bvFTD, nfvPPA, and svPPA with red, blue, and green dots, respectively. Graph B shows DAT vs the same conditions in similar colors. Dots are plotted across various brain regions: frontal, occipital, parietal, temporal, anterior and posterior lateral ventricles, and hippocampal areas, including global measures. The scales differ between the graphs, with notable variation in effect sizes across comparisons.</alt-text></graphic></fig><p>Consistent with these results, surface map visualizations provided intuitive spatial representations of the key regional atrophy patterns in FTD subtypes (<xref rid="fig4" ref-type="fig">Figure 4</xref>). In bvFTD, there was widespread bilateral involvement of the frontal lobes, with atrophy extending into the parietal, temporal lobes, as well as anterior LVs. The nfvPPA exhibited prominent atrophy in the left frontal and parietal lobes, along with the anterior LV, aligning with its typical left-hemisphere dominance. In contrast, svPPA was marked by focal atrophy predominantly localized to the temporal lobes.</p><fig position="float" id="fig4" orientation="portrait"><label>Figure 4</label><caption><p>Surface maps visualizing W-score based brain atrophy patterns across FTD subtypes. The surface maps show group-averaged W-scores for each FTD subtype, projected onto a standardized cortical surface, illustrating the spatial distribution of brain atrophy based on CSF volume. FTD, Frontotemporal dementia; bvFTD, behavioral variant frontotemporal dementia; nfvPPA, nonfluent variant primary progressive aphasia; svPPA, semantic variant primary progressive aphasia.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1631640-g004.jpg"><alt-text content-type="machine-generated">Brain imaging illustrations show lateral and medial views for three conditions: bvFTD, nfvPPA, and svPPA. Each row represents a condition, with columns displaying left lateral, right lateral, left medial, and right medial views. A color scale on the side ranges from 0 to -2.</alt-text></graphic></fig></sec></sec><sec sec-type="discussion" id="sec12"><title>Discussion</title><p>In this study, regional atrophy patterns among FTD subtypes were investigated using a deep learning-based segmentation model that quantifies CSF volume. The findings revealed significant differences in W-scores among diagnostic groups, demonstrating the algorithm&#8217;s effectiveness in capturing region-specific atrophy patterns. These results confirmed the initial hypothesis that each FTD subtype exhibits distinct spatial patterns of brain atrophy. Such precise characterization of atrophy may have clinical utility in improving differential diagnosis and disease monitoring in patients with FTD.</p><p>The results revealed clear and distinct atrophy patterns across FTD subtypes. Compared to DAT, bvFTD showed notably greater atrophy prominently in bilateral frontal regions (large effect sizes, Cohen&#8217;s d&#8239;&gt;&#8239;1.2), with a slightly stronger involvement observed in the right hemisphere. Medium-sized effects were also present in bilateral parietal and temporal lobes, anterior lateral ventricles, and hippocampal regions. Interestingly, parietal lobe involvement in bvFTD, although traditionally less emphasized, could reflect more advanced disease stages or clinical heterogeneity within this cohort. In contrast, the nfvPPA subtype demonstrated significant atrophy predominantly in the left frontal (Cohen&#8217;s d&#8239;&gt;&#8239;1.2) and left parietal regions, consistent with known left hemisphere-dominant language impairments. Similarly, svPPA showed pronounced left-dominant atrophy in temporal lobes and hippocampal regions, with the left hippocampal region exhibiting notably large effect sizes (Cohen&#8217;s d&#8239;&gt;&#8239;1.2). Such marked left-sided hippocampal involvement in svPPA aligns closely with previous findings, highlighting medial temporal lobe involvement beyond classic AD pathology. These observations are consistent with previously reported subtype-specific atrophy patterns (<xref rid="ref34" ref-type="bibr">Risacher and Saykin, 2013</xref>; <xref rid="ref14" ref-type="bibr">Ghosh and Lippa, 2015</xref>; <xref rid="ref10" ref-type="bibr">Eldaief et al., 2023</xref>; <xref rid="ref37" ref-type="bibr">Taylor et al., 2025</xref>), further reinforcing the validity and clinical relevance of the proposed approach (see <xref rid="SM1" ref-type="supplementary-material">Supplementary Table 2</xref>).</p><p>The 3D surface maps also provided compelling visual validation of these subtype-specific patterns, clearly demonstrating left-lateralized atrophy in nfvPPA and svPPA and widespread, anterior-predominant atrophy in bvFTD. These visualizations enhance the interpretability and clinical relevance of the observed structural differences, emphasizing the spatial specificity achievable by this method.</p><p>To further ensure the robustness of these findings, an additional propensity score matching (PSM) analysis was conducted using age, sex, and education as matching factors. After excluding cases with missing education data, 331 CU and 331 DAT participants were matched to 342 FTD participants with complete data (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table 3</xref>). This adjustment reduced group size disparities and allowed for more balanced comparisons. Some regional differences that were previously significant (e.g., left temporal region in bvFTD, right frontal and left parietal regions in nfvPPA, and left frontal region in svPPA) were no longer observed after matching (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 2</xref>) and the overall effect sizes were somewhat reduced (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 3</xref>). However, the spatial patterns of atrophy remained largely consistent with the primary analysis.</p><p>These findings extend previous work conducted in Alzheimer&#8217;s disease, where stage-specific atrophy patterns&#8212;particularly in bilateral temporal lobes, lateral ventricles, and hippocampal regions&#8212;were demonstrated across a cognitive continuum from cognitively unimpaired individuals to patients with mild cognitive impairment and DAT. In the current study, quantitative CSF-based measures derived from the algorithm revealed significant hemispheric asymmetries&#8212;particularly within the left hemisphere&#8212;across FTD subtypes when compared with CU and DAT groups. Importantly, these findings were achieved using a quantification approach distinct from conventional methods (<xref rid="ref36" ref-type="bibr">Scheltens et al., 1995</xref>; <xref rid="ref1" ref-type="bibr">Ashburner and Friston, 2000</xref>; <xref rid="ref13" ref-type="bibr">Fischl and Dale, 2000</xref>; <xref rid="ref35" ref-type="bibr">Rosen et al., 2002</xref>; <xref rid="ref19" ref-type="bibr">Kipps et al., 2007</xref>), yet consistently capturing relevant structural disease signatures. The ability to detect such detailed patterns highlights this method&#8217;s potential as a robust structural biomarker, particularly valuable for clinical evaluations in cases involving focal atrophy of the frontal and temporal lobes. This ensures reliable, scalable analysis across different clinical settings and patient groups. Given its reliance on standard clinical imaging modalities, this approach could be easily integrated into routine neuroimaging workflows, supporting clinicians in the early and differential diagnosis of dementia subtypes. With further validation, the algorithm may also offer potential benchmarks for future adaptations to more accessible imaging modalities, such as 2D MRI or even CT scans.</p><p>A major strength of this study is the practical capability of the deep learning-based method to quantify brain atrophy directly from routine MRI scans without complex preprocessing. However, several limitations should be acknowledged. The analysis relied solely on CSF volume, age, and sex, without incorporating additional factors (<xref rid="ref1002" ref-type="bibr">Sakka et al., 2011</xref>; <xref rid="ref41" ref-type="bibr">Zhang et al., 2022</xref>) or direct measures of neurodegeneration such as cortical thickness or voxel-based morphometry. To complement the primary analyses, cortical thickness data in a subset of participants were also examined, which revealed broadly consistent and biologically plausible regional patterns with CSF-based measures (see <xref rid="SM1" ref-type="supplementary-material">Supplementary Figures 4, 5</xref>). Future work may examine the combined use of CSF- and GM-based features to improve both anatomical specificity and clinical interpretability. Additionally, the lack of clinical and cognitive data limits structure&#8211;function interpretations, and the cross-sectional design prevents assessment of longitudinal changes. Finally, the single-center design restricts generalizability, highlighting the need for external validation. Nonetheless, our findings demonstrate robust subtype-specific atrophy patterns, underscoring the method&#8217;s clinical relevance and value for dementia research.</p><p>In summary, this study demonstrated significant differences in regional atrophy patterns across FTD subtypes using a CSF-based deep learning algorithm. By focusing on clinically relevant RoIs, this simple and practical approach facilitates intuitive interpretation, rapid clinical integration, and consistent application across diverse settings. With further validation, this method holds significant potential as a robust structural biomarker for enhancing differential diagnosis and monitoring disease progression.</p></sec></body><back><ack><p>We thank all contributors and participants for their contribution to this study.</p></ack><fn-group><fn id="fn0001"><p>
<sup>1</sup>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.r-project.org" ext-link-type="uri">http://www.r-project.org</ext-link>
</p></fn></fn-group><sec sec-type="data-availability" id="sec13"><title>Data availability statement</title><p>The anonymized data for the analyses presented in this report are available from the corresponding author on reasonable request.</p></sec><sec sec-type="ethics-statement" id="sec14"><title>Ethics statement</title><p>The study protocol was approved by the Institutional Review Board of Samsung Medical Center (IRB No. 2021&#8211;02-135). Written informed consent was obtained from all participants, and all procedures were conducted in accordance with the Declaration of Helsinki and the approved institutional guidelines. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="sec15"><title>Author contributions</title><p>KL: Data curation, Writing &#8211; original draft. SY: Investigation, Writing &#8211; review &amp; editing. SP: Writing &#8211; review &amp; editing. SK: Writing &#8211; review &amp; editing. KKi: Writing &#8211; review &amp; editing. JA: Writing &#8211; review &amp; editing. JK: Writing &#8211; review &amp; editing. HK: Writing &#8211; review &amp; editing. DN: Writing &#8211; review &amp; editing. SS: Writing &#8211; review &amp; editing, Supervision. KKw: Writing &#8211; review &amp; editing, Supervision.</p></sec><sec sec-type="COI-statement" id="sec17"><title>Conflict of interest</title><p>KL, SP, and KK were employed by the BeauBrain Healthcare Inc.</p><p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="sec18"><title>Generative AI statement</title><p>The authors declare that no Gen AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="sec19"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="sec20"><title>Supplementary material</title><p>The Supplementary material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fnagi.2025.1631640/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fnagi.2025.1631640/full#supplementary-material</ext-link></p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Supplementary_file_1.docx" position="float" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashburner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Friston</surname><given-names>K. J.</given-names></name></person-group> (<year>2000</year>). <article-title>Voxel-based morphometry--the methods</article-title>. <source>NeuroImage</source><volume>11</volume>, <fpage>805</fpage>&#8211;<lpage>821</lpage>. doi: <pub-id pub-id-type="doi">10.1006/nimg.2000.0582</pub-id>, PMID: <pub-id pub-id-type="pmid">10860804</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhagwat</surname><given-names>N.</given-names></name><name name-style="western"><surname>Barry</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dickie</surname><given-names>E. W.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>S. T.</given-names></name><name name-style="western"><surname>Devenyi</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Hatano</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Understanding the impact of preprocessing pipelines on neuroimaging cortical surface analyses</article-title>. <source>Gigascience</source><volume>10</volume>:<fpage>155</fpage>. doi: <pub-id pub-id-type="doi">10.1093/gigascience/giaa155</pub-id>, PMID: <pub-id pub-id-type="pmid">33481004</pub-id><pub-id pub-id-type="pmcid">PMC7821710</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Billot</surname><given-names>B.</given-names></name><name name-style="western"><surname>Greve</surname><given-names>D. N.</given-names></name><name name-style="western"><surname>Puonti</surname><given-names>O.</given-names></name><name name-style="western"><surname>Thielscher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Van Leemput</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fischl</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>SynthSeg: segmentation of brain MRI scans of any contrast and resolution without retraining</article-title>. <source>Med. Image Anal.</source><volume>86</volume>:<fpage>102789</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.media.2023.102789</pub-id>, PMID: <pub-id pub-id-type="pmid">36857946</pub-id><pub-id pub-id-type="pmcid">PMC10154424</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brambati</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Rankin</surname><given-names>K. P.</given-names></name><name name-style="western"><surname>Narvid</surname><given-names>J.</given-names></name><name name-style="western"><surname>Seeley</surname><given-names>W. W.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>H. J.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Atrophy progression in semantic dementia with asymmetric temporal involvement: a tensor-based morphometry study</article-title>. <source>Neurobiol. Aging</source><volume>30</volume>, <fpage>103</fpage>&#8211;<lpage>111</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2007.05.014</pub-id>, PMID: <pub-id pub-id-type="pmid">17604879</pub-id><pub-id pub-id-type="pmcid">PMC2643844</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavallin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Loken</surname><given-names>K.</given-names></name><name name-style="western"><surname>Engedal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Oksengard</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Wahlund</surname><given-names>L. O.</given-names></name><name name-style="western"><surname>Bronge</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Overtime reliability of medial temporal lobe atrophy rating in a clinical setting</article-title>. <source>Acta Radiol.</source><volume>53</volume>, <fpage>318</fpage>&#8211;<lpage>323</lpage>. doi: <pub-id pub-id-type="doi">10.1258/ar.2012.110552</pub-id>, PMID: <pub-id pub-id-type="pmid">22371624</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choe</surname><given-names>Y. S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>R. E. Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H. W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M. K.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Automated scoring of Alzheimer's disease atrophy scale with subtype classification using deep learning-based T1-weighted magnetic resonance image segmentation</article-title>. <source>J. Alzheimers Dis. Rep.</source><volume>8</volume>, <fpage>863</fpage>&#8211;<lpage>876</lpage>. doi: <pub-id pub-id-type="doi">10.3233/ADR-230105</pub-id>, PMID: <pub-id pub-id-type="pmid">38910943</pub-id><pub-id pub-id-type="pmcid">PMC11191633</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nan</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Atrophy network mapping of clinical subtypes and main symptoms in frontotemporal dementia</article-title>. <source>Brain</source><volume>147</volume>, <fpage>3048</fpage>&#8211;<lpage>3058</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awae067</pub-id>, PMID: <pub-id pub-id-type="pmid">38426222</pub-id><pub-id pub-id-type="pmcid">PMC11370799</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Vis</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Zwanenburg</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>van der Kleij</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Spijkerman</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Biessels</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Hendrikse</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Cerebrospinal fluid volumetric MRI mapping as a simple measurement for evaluating brain atrophy</article-title>. <source>Eur. Radiol.</source><volume>26</volume>, <fpage>1254</fpage>&#8211;<lpage>1262</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00330-015-3932-8</pub-id>, PMID: <pub-id pub-id-type="pmid">26318506</pub-id><pub-id pub-id-type="pmcid">PMC4820466</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duara</surname><given-names>R.</given-names></name><name name-style="western"><surname>Loewenstein</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Greig</surname><given-names>M.</given-names></name><name name-style="western"><surname>Acevedo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>E.</given-names></name><name name-style="western"><surname>Appel</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Reliability and validity of an algorithm for the diagnosis of normal cognition, mild cognitive impairment, and dementia: implications for multicenter research studies</article-title>. <source>Am. J. Geriatr. Psychiatry</source><volume>18</volume>, <fpage>363</fpage>&#8211;<lpage>370</lpage>. doi: <pub-id pub-id-type="doi">10.1097/JGP.0b013e3181c534a0</pub-id>, PMID: <pub-id pub-id-type="pmid">20306566</pub-id><pub-id pub-id-type="pmcid">PMC2844658</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eldaief</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Brickhouse</surname><given-names>M.</given-names></name><name name-style="western"><surname>Katsumi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>N.</given-names></name><name name-style="western"><surname>Touroutoglou</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Atrophy in behavioural variant frontotemporal dementia spans multiple large-scale prefrontal and temporal networks</article-title>. <source>Brain</source><volume>146</volume>, <fpage>4476</fpage>&#8211;<lpage>4485</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awad167</pub-id>, PMID: <pub-id pub-id-type="pmid">37201288</pub-id><pub-id pub-id-type="pmcid">PMC10629759</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erkkinen</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M. O.</given-names></name><name name-style="western"><surname>Geschwind</surname><given-names>M. D.</given-names></name></person-group> (<year>2018</year>). <article-title>Clinical neurology and epidemiology of the major neurodegenerative diseases</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source><volume>10</volume>:<fpage>118</fpage>. doi: <pub-id pub-id-type="doi">10.1101/cshperspect.a033118</pub-id>, PMID: <pub-id pub-id-type="pmid">28716886</pub-id><pub-id pub-id-type="pmcid">PMC5880171</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>D.</given-names></name><name name-style="western"><surname>Verhagen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hernandez-Cabrera</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Cavallin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Ekman</surname><given-names>U.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Distinct subtypes of Alzheimer's disease based on patterns of brain atrophy: longitudinal trajectories and clinical applications</article-title>. <source>Sci. Rep.</source><volume>7</volume>:<fpage>46263</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep46263</pub-id>, PMID: <pub-id pub-id-type="pmid">28417965</pub-id><pub-id pub-id-type="pmcid">PMC5394684</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischl</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dale</surname><given-names>A. M.</given-names></name></person-group> (<year>2000</year>). <article-title>Measuring the thickness of the human cerebral cortex from magnetic resonance images</article-title>. <source>Proc. Natl. Acad. Sci. USA</source><volume>97</volume>, <fpage>11050</fpage>&#8211;<lpage>11055</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.200033797</pub-id>, PMID: <pub-id pub-id-type="pmid">10984517</pub-id><pub-id pub-id-type="pmcid">PMC27146</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lippa</surname><given-names>C. F.</given-names></name></person-group> (<year>2015</year>). <article-title>Clinical subtypes of frontotemporal dementia</article-title>. <source>Am. J. Alzheimers Dis. Other Dement.</source><volume>30</volume>, <fpage>653</fpage>&#8211;<lpage>661</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1533317513494442</pub-id>, PMID: <pub-id pub-id-type="pmid">23813692</pub-id><pub-id pub-id-type="pmcid">PMC10852906</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorno-Tempini</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Hillis</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Weintraub</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kertesz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mendez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cappa</surname><given-names>S. F.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Classification of primary progressive aphasia and its variants</article-title>. <source>Neurology</source><volume>76</volume>, <fpage>1006</fpage>&#8211;<lpage>1014</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0b013e31821103e6</pub-id>, PMID: <pub-id pub-id-type="pmid">21325651</pub-id><pub-id pub-id-type="pmcid">PMC3059138</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Im</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>S. W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S. I.</given-names></name><name name-style="western"><surname>Na</surname><given-names>D. L.</given-names></name></person-group> (<year>2008</year>). <article-title>Sulcal morphology changes and their relationship with cortical thickness and gyral white matter volume in mild cognitive impairment and Alzheimer's disease</article-title>. <source>NeuroImage</source><volume>43</volume>, <fpage>103</fpage>&#8211;<lpage>113</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2008.07.016</pub-id>, PMID: <pub-id pub-id-type="pmid">18691657</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isensee</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jaeger</surname><given-names>P. F.</given-names></name><name name-style="western"><surname>Kohl</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maier-Hein</surname><given-names>K. H.</given-names></name></person-group> (<year>2021</year>). <article-title>NnU-net: a self-configuring method for deep learning-based biomedical image segmentation</article-title>. <source>Nat. Methods</source><volume>18</volume>, <fpage>203</fpage>&#8211;<lpage>211</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41592-020-01008-z</pub-id>, PMID: <pub-id pub-id-type="pmid">33288961</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K. W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. P.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Korea-registries to overcome dementia and accelerate dementia research (K-ROAD): a cohort for dementia research and ethnic-specific insights</article-title>. <source>Dement. Neurocogn. Disord.</source><volume>23</volume>, <fpage>212</fpage>&#8211;<lpage>223</lpage>. doi: <pub-id pub-id-type="doi">10.12779/dnd.2024.23.4.212</pub-id>, PMID: <pub-id pub-id-type="pmid">39512701</pub-id><pub-id pub-id-type="pmcid">PMC11538854</pub-id></mixed-citation></ref><ref id="ref1001"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jahng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y.</given-names></name></person-group> (<year>2024</year>). <article-title>A comparison of item characteristics and test information between the K-MMSE~2:SV and K-MMSE</article-title>. <source>Dement. Neurocogn. Disord</source><volume>23</volume>,<fpage>117</fpage>&#8211;<lpage>126</lpage>. doi: <pub-id pub-id-type="doi">10.12779/dnd.2024.23.3.117</pub-id>, PMID: <pub-id pub-id-type="pmid">39113752</pub-id><pub-id pub-id-type="pmcid">PMC11300688</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kipps</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kril</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Halliday</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Hodges</surname><given-names>J. R.</given-names></name></person-group> (<year>2007</year>). <article-title>Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale</article-title>. <source>Dement. Geriatr. Cogn. Disord.</source><volume>23</volume>, <fpage>334</fpage>&#8211;<lpage>342</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000100973</pub-id>, PMID: <pub-id pub-id-type="pmid">17374952</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kochunov</surname><given-names>P.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Coyle</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Lancaster</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Kochunov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Royall</surname><given-names>D. R.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Relationship among neuroimaging indices of cerebral health during normal aging</article-title>. <source>Hum. Brain Mapp.</source><volume>29</volume>, <fpage>36</fpage>&#8211;<lpage>45</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hbm.20369</pub-id>, PMID: <pub-id pub-id-type="pmid">17290369</pub-id><pub-id pub-id-type="pmcid">PMC6870647</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>La Joie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Perrotin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barre</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hommet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mezenge</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ibazizene</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Region-specific hierarchy between atrophy, hypometabolism, and beta-amyloid (Abeta) load in Alzheimer's disease dementia</article-title>. <source>J. Neurosci.</source><volume>32</volume>, <fpage>16265</fpage>&#8211;<lpage>16273</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2170-12.2012</pub-id><pub-id pub-id-type="pmid">23152610</pub-id><pub-id pub-id-type="pmcid">PMC6794030</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>LaMontagne</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Benzinger</surname><given-names>T. L.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Keefe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hornbeck</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2019</year>) <article-title>OASIS-3: longitudinal neuroimaging, clinical, and cognitive dataset for normal aging and Alzheimer disease</article-title>. <source>medRxiv</source> [Preprint]. doi: <pub-id pub-id-type="doi">10.1101/2019.12.13.19014902</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Clarkson</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Clegg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jack</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>M. W.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection</article-title>. <source>NeuroImage</source><volume>50</volume>, <fpage>516</fpage>&#8211;<lpage>523</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2009.12.059</pub-id>, PMID: <pub-id pub-id-type="pmid">20034579</pub-id><pub-id pub-id-type="pmcid">PMC2828361</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>K. Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.</given-names></name><name name-style="western"><surname>Na</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>S. W.</given-names></name><name name-style="western"><surname>Chun</surname><given-names>M. Y.</given-names></name><name name-style="western"><surname>Kwak</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2025</year>). <article-title>Quantifying brain atrophy using a CSF-focused segmentation approach</article-title>. <source>Dement. Neurocogn. Disord.</source><volume>24</volume>, <fpage>115</fpage>&#8211;<lpage>125</lpage>. doi: <pub-id pub-id-type="doi">10.12779/dnd.2025.24.2.115</pub-id>, PMID: <pub-id pub-id-type="pmid">40321440</pub-id><pub-id pub-id-type="pmcid">PMC12046248</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>P. H.</given-names></name><name name-style="western"><surname>Mendez</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Leow</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H. W.</given-names></name><name name-style="western"><surname>Shapira</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Patterns of brain atrophy in clinical variants of frontotemporal lobar degeneration</article-title>. <source>Dement. Geriatr. Cogn. Disord.</source><volume>35</volume>, <fpage>34</fpage>&#8211;<lpage>50</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000345523</pub-id>, PMID: <pub-id pub-id-type="pmid">23306166</pub-id><pub-id pub-id-type="pmcid">PMC3609420</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bonanno</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lo Buono</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ciurleo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Corallo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Morabito</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Longitudinal analysis of brain atrophy in Alzheimer's disease and frontotemporal dementia</article-title>. <source>J. Int. Med. Res.</source><volume>47</volume>, <fpage>5019</fpage>&#8211;<lpage>5027</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0300060519830830</pub-id>, PMID: <pub-id pub-id-type="pmid">31524019</pub-id><pub-id pub-id-type="pmcid">PMC6833431</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazziotta</surname><given-names>J.</given-names></name><name name-style="western"><surname>Toga</surname><given-names>A.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lancaster</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zilles</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2001</year>). <article-title>A probabilistic atlas and reference system for the human brain: international consortium for brain mapping (ICBM)</article-title>. <source>Philos. Trans. R. Soc. Lond. B Biol. Sci.</source><volume>356</volume>, <fpage>1293</fpage>&#8211;<lpage>1322</lpage>. doi: <pub-id pub-id-type="doi">10.1098/rstb.2001.0915</pub-id>, PMID: <pub-id pub-id-type="pmid">11545704</pub-id><pub-id pub-id-type="pmcid">PMC1088516</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKhann</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Chertkow</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B. T.</given-names></name><name name-style="western"><surname>Jack</surname><given-names>C. R.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Kawas</surname><given-names>C. H.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease</article-title>. <source>Alzheimers Dement.</source><volume>7</volume>, <fpage>263</fpage>&#8211;<lpage>269</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jalz.2011.03.005</pub-id>, PMID: <pub-id pub-id-type="pmid">21514250</pub-id><pub-id pub-id-type="pmcid">PMC3312024</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pagnozzi</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Fripp</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>S. E.</given-names></name></person-group> (<year>2019</year>). <article-title>Quantifying deep grey matter atrophy using automated segmentation approaches: a systematic review of structural MRI studies</article-title>. <source>NeuroImage</source><volume>201</volume>:<fpage>116018</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2019.116018</pub-id>, PMID: <pub-id pub-id-type="pmid">31319182</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Beckett</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Gamst</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>D. J.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Alzheimer's disease neuroimaging initiative (ADNI) clinical characterization</article-title>. <source>Neurology</source><volume>74</volume>, <fpage>201</fpage>&#8211;<lpage>209</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0b013e3181cb3e25</pub-id>, PMID: <pub-id pub-id-type="pmid">20042704</pub-id><pub-id pub-id-type="pmcid">PMC2809036</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Planche</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mansencal</surname><given-names>B.</given-names></name><name name-style="western"><surname>Manjon</surname><given-names>J. V.</given-names></name><name name-style="western"><surname>Tourdias</surname><given-names>T.</given-names></name><name name-style="western"><surname>Catheline</surname><given-names>G.</given-names></name><name name-style="western"><surname>Coupe</surname><given-names>P.</given-names></name></person-group> (<year>2023</year>). <article-title>Anatomical MRI staging of frontotemporal dementia variants</article-title>. <source>Alzheimers Dement.</source><volume>19</volume>, <fpage>3283</fpage>&#8211;<lpage>3294</lpage>. doi: <pub-id pub-id-type="doi">10.1002/alz.12975</pub-id>, PMID: <pub-id pub-id-type="pmid">36749884</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rascovsky</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hodges</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mendez</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Neuhaus</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia</article-title>. <source>Brain</source><volume>134</volume>, <fpage>2456</fpage>&#8211;<lpage>2477</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awr179</pub-id>, PMID: <pub-id pub-id-type="pmid">21810890</pub-id><pub-id pub-id-type="pmcid">PMC3170532</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Risacher</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Saykin</surname><given-names>A. J.</given-names></name></person-group> (<year>2013</year>). <article-title>Neuroimaging biomarkers of neurodegenerative diseases and dementia</article-title>. <source>Semin. Neurol.</source><volume>33</volume>, <fpage>386</fpage>&#8211;<lpage>416</lpage>. doi: <pub-id pub-id-type="doi">10.1055/s-0033-1359312</pub-id>, PMID: <pub-id pub-id-type="pmid">24234359</pub-id><pub-id pub-id-type="pmcid">PMC3975244</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosen</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Gorno-Tempini</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>W. P.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Schuff</surname><given-names>N.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2002</year>). <article-title>Patterns of brain atrophy in frontotemporal dementia and semantic dementia</article-title>. <source>Neurology</source><volume>58</volume>, <fpage>198</fpage>&#8211;<lpage>208</lpage>. doi: <pub-id pub-id-type="doi">10.1212/wnl.58.2.198</pub-id>, PMID: <pub-id pub-id-type="pmid">11805245</pub-id></mixed-citation></ref><ref id="ref1002"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakka</surname><given-names>L.</given-names></name><name name-style="western"><surname>Coll</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chazal</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Anatomy and physiology of cerebrospinal fluid</article-title>. <source>European Annals of Otorhinolaryngology, Head and Neck Diseases</source><volume>128</volume>, <fpage>309</fpage>&#8211;<lpage>316</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.anorl.2011.03.002</pub-id>, PMID: <pub-id pub-id-type="pmid">22100360</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>Launer</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F.</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>van Gool</surname><given-names>W. A.</given-names></name></person-group> (<year>1995</year>). <article-title>Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability</article-title>. <source>J. Neurol.</source><volume>242</volume>, <fpage>557</fpage>&#8211;<lpage>560</lpage>. doi: <pub-id pub-id-type="doi">10.1007/BF00868807</pub-id>, PMID: <pub-id pub-id-type="pmid">8551316</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bocchetta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shand</surname><given-names>C.</given-names></name><name name-style="western"><surname>Todd</surname><given-names>E. G.</given-names></name><name name-style="western"><surname>Chokesuwattanaskul</surname><given-names>A.</given-names></name><name name-style="western"><surname>Crutch</surname><given-names>S. J.</given-names></name><etal/></person-group>. (<year>2025</year>). <article-title>Data-driven neuroanatomical subtypes of primary progressive aphasia</article-title>. <source>Brain</source><volume>148</volume>, <fpage>955</fpage>&#8211;<lpage>968</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awae314</pub-id>, PMID: <pub-id pub-id-type="pmid">39374849</pub-id><pub-id pub-id-type="pmcid">PMC11884653</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tustison</surname><given-names>N. J.</given-names></name><name name-style="western"><surname>Holbrook</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Avants</surname><given-names>B. B.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Reagh</surname><given-names>Z. M.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Longitudinal mapping of cortical thickness measurements: an Alzheimer's disease neuroimaging initiative-based evaluation study</article-title>. <source>J. Alzheimers Dis.</source><volume>71</volume>, <fpage>165</fpage>&#8211;<lpage>183</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-190283</pub-id>, PMID: <pub-id pub-id-type="pmid">31356207</pub-id><pub-id pub-id-type="pmcid">PMC10204115</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitwell</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Jack</surname><given-names>C. R.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Parisi</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Boeve</surname><given-names>B. F.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>R. C.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Rates of cerebral atrophy differ in different degenerative pathologies</article-title>. <source>Brain</source><volume>130</volume>, <fpage>1148</fpage>&#8211;<lpage>1158</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awm021</pub-id>, PMID: <pub-id pub-id-type="pmid">17347250</pub-id><pub-id pub-id-type="pmcid">PMC2752409</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Mai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>An MRI-based strategy for differentiation of frontotemporal dementia and Alzheimer's disease</article-title>. <source>Alzheimers Res. Ther.</source><volume>13</volume>:<fpage>23</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13195-020-00757-5</pub-id>, PMID: <pub-id pub-id-type="pmid">33436059</pub-id><pub-id pub-id-type="pmcid">PMC7805212</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Du</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>G.</given-names></name></person-group> (<year>2022</year>). <article-title>Dehydration and rehydration affect brain regional density and homogeneity among young male adults, determined via magnetic resonance imaging: a pilot self-control trial</article-title>. <source>Front. Nutr.</source><volume>9</volume>:<fpage>906088</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnut.2022.906088</pub-id>, PMID: <pub-id pub-id-type="pmid">36211525</pub-id><pub-id pub-id-type="pmcid">PMC9539665</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ferraro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Choice of voxel-based morphometry processing pipeline drives variability in the location of neuroanatomical brain markers</article-title>. <source>Commun. Biol.</source><volume>5</volume>:<fpage>913</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s42003-022-03880-1</pub-id>, PMID: <pub-id pub-id-type="pmid">36068295</pub-id><pub-id pub-id-type="pmcid">PMC9448776</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Ther Methods Clin Dev</journal-id><journal-id journal-id-type="iso-abbrev">Mol Ther Methods Clin Dev</journal-id><journal-id journal-id-type="pmc-domain-id">2616</journal-id><journal-id journal-id-type="pmc-domain">mtm</journal-id><journal-title-group><journal-title>Molecular Therapy. Methods &amp; Clinical Development</journal-title></journal-title-group><issn pub-type="epub">2329-0501</issn><publisher><publisher-name>American Society of Gene &amp; Cell Therapy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12493141</article-id><article-id pub-id-type="pmcid-ver">PMC12493141.1</article-id><article-id pub-id-type="pmcaid">12493141</article-id><article-id pub-id-type="pmcaiid">12493141</article-id><article-id pub-id-type="pmid">41049692</article-id><article-id pub-id-type="doi">10.1016/j.omtm.2025.101587</article-id><article-id pub-id-type="pii">S2329-0501(25)00182-2</article-id><article-id pub-id-type="publisher-id">101587</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Elevated tripeptidyl-peptidase 1 corrects multiple disease phenotypes in a mouse model of juvenile neuronal ceroid lipofuscinosis</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Banach-Petrosky</surname><given-names initials="W">Whitney</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Larrimore</surname><given-names initials="KE">Katherine E.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Sleat</surname><given-names initials="EH">Elizabeth H.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Bazer</surname><given-names initials="A">Allyson</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Samuels</surname><given-names initials="B">Benjamin</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Tan</surname><given-names initials="Y">Yalun</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Melton</surname><given-names initials="AC">Andrew C.</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Ichida</surname><given-names initials="JK">Justin K.</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Logan</surname><given-names initials="TP">Todd P.</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Lobel</surname><given-names initials="P">Peter</given-names></name><email>lobel@cabm.rutgers.edu</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff4" ref-type="aff">4</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Sleat</surname><given-names initials="DE">David E.</given-names></name><email>sleat@scarletmail.rutgers.edu</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff4" ref-type="aff">4</xref><xref rid="cor2" ref-type="corresp">&#8727;&#8727;</xref></contrib><aff id="aff1"><label>1</label>Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ, USA</aff><aff id="aff2"><label>2</label>Department of Psychology, Rutgers University, Piscataway, NJ, USA</aff><aff id="aff3"><label>3</label>BioMarin Pharmaceutical Inc., Novato, CA, USA</aff><aff id="aff4"><label>4</label>Department of Biochemistry and Molecular Biology, Robert Wood Johnson Medical School, Rutgers Biomedical Health Sciences, Rutgers University, Piscataway, NJ, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author: Peter Lobel, Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ, USA. <email>lobel@cabm.rutgers.edu</email></corresp><corresp id="cor2"><label>&#8727;&#8727;</label>Corresponding author: David E. Sleat, Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ, USA. <email>sleat@scarletmail.rutgers.edu</email></corresp></author-notes><pub-date pub-type="collection"><day>11</day><month>12</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>03</day><month>9</month><year>2025</year></pub-date><volume>33</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">497247</issue-id><elocation-id>101587</elocation-id><history><date date-type="received"><day>14</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>2</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 15:25:14.893"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>Juvenile neuronal ceroid lipofuscinosis (JNCL) is a neurodegenerative lysosomal storage disease caused by the loss of the endolysosomal transmembrane protein, CLN3. The main protein component of lysosomal storage material in JNCL is subunit c of mitochondrial ATP synthase (SCMAS), which is normally degraded within the lysosome by tripeptidyl-peptidase 1 (TPP1) during mitophagy. Previous studies have shown that TPP1 expression is elevated in JNCL, a potential compensatory response, while reduced levels of TPP1 exacerbate disease in a JNCL mouse model. These observations suggest a role for TPP1 in JNCL pathogenesis, and it is possible that lysosomal perturbations from the loss of CLN3 in JNCL could reduce the ability of TPP1 to degrade SCMAS. To test this hypothesis, we introduced a transgene that overexpresses TPP1 in a mouse model of JNCL and find that constitutively elevated TPP1 prevents SCMAS storage. This is associated with correction or significant reduction of other phenotypes of disease including neuroinflammation, an elevated plasma biomarker of neurodegeneration, and a disease-associated loss of brain mass with aging. From a clinical perspective, these results suggest that TPP1 augmentation could be a viable therapeutic strategy for JNCL and other lysosomal diseases that accumulate SCMAS where addressing the primary defect may be difficult or impossible.</p></abstract><abstract abstract-type="teaser" id="abs0015"><p>Juvenile neuronal ceroid lipofuscinosis (JNCL) is an untreatable, fatal neurodegenerative lysosomal disease. Sleat and colleagues have shown that increased levels of tripeptidyl-peptide 1 attenuates disease in a JNCL mouse model, suggesting that administering a recombinant form of this protease may be a viable treatment option for patients with JNCL.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>neuronal ceroid lipofuscinosis</kwd><kwd>subunit c of mitochondrial ATP synthase</kwd><kwd>tripeptidyl-peptidase 1</kwd><kwd>neurodegeneration</kwd><kwd>inherited disease</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">Neuronal ceroid lipofuscinoses (NCLs) are a group of over 12 genetically distinct but clinically related inherited neurodegenerative lysosomal storage diseases that primarily affect children and young adults.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> These diseases are typically fatal, and there are no effective treatments for most. While enzyme replacement and gene therapies are feasible in principle for NCL diseases arising from defects in soluble lysosomal proteins, addressing those NCLs arising from defects in lysosomal and other transmembrane proteins continues to remain extremely challenging.</p><p id="p0015">The cellular hallmark of NCLs is the accumulation of fluorescent storage material, ceroid lipofuscin, within lysosomes of neurons and other cell types.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> For many NCLs, the major component of the storage material is subunit c of mitochondrial ATP synthase (SCMAS), a small hydrophobic protein that forms part of the pore complex.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> SCMAS is located within the mitochondrial inner membrane, but during the course of mitophagy, its degradation within the lysosome is initiated by the lumenal protease, tripeptidyl-peptidase 1 (TPP1).<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Originally suggested to play a role in pathogenesis,<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> the role of SCMAS accumulation is unclear, and there is a school of thought that it reflects rather than causes disease (reviewed in Palmer<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref>).</p><p id="p0020">Mutations causing a loss of TPP1 result in late-infantile NCL (LINCL),<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> and in patients, there is a rapid and extensive lysosomal accumulation of SCMAS, reflecting the critical role played by TPP1 in its degradation. However, other genetically distinct NCLs also accumulate SCMAS including juvenile NCL (JNCL). JNCL is caused by mutations in the gene <italic toggle="yes">CLN3</italic><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> encoding an endolysosomal protein, CLN3, that may be involved in export of glycerophospholipids from the lysosome.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> While neurons and other cells of patients with JNCL accumulate insoluble aggregates of SCMAS, they do so at a slower rate and to lower levels than in LINCL.</p><p id="p0025">There is evidence to suggest a role for TPP1 in JNCL disease. Using mouse models of LINCL deficient in TPP1 (<italic toggle="yes">Tpp1</italic><sup>&#8722;/&#8722;</sup>)<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> and JNCL deficient in CLN3 protein (<italic toggle="yes">Cln3</italic><sup>&#8722;/&#8722;</sup>)<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> to investigate the effect of TPP1 genotype on disease progression in the JNCL mouse,<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> we found that heterozygosity for a <italic toggle="yes">Tpp1</italic> knockout allele has no effect on survival in an otherwise wild-type (WT) mouse, but it significantly shortens the lifespan of a <italic toggle="yes">Cln3</italic><sup>&#8722;/&#8722;</sup> JNCL mouse. One possible explanation is that loss of CLN3 could alter the lysosomal microenvironment in such a way that partially impairs TPP1 function. This would result in a slow accumulation of undegraded SCMAS in the lysosome (<xref rid="fig1" ref-type="fig">Figure 1</xref>A), reflecting or contributing to neuronal death. Consistent with this, reduction of TPP1 activity by heterozygosity for a null allele would accelerate storage and exacerbate disease. Support for this hypothesis comes from the observation that TPP1 activity is elevated in JNCL,<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> which may be a compensatory response to the loss of CLN3 impairing the ability of TPP1 to degrade SCMAS. If this hypothesis is correct, JNCL might be regarded, in some respects, to be a later onset and more slowly progressing form of LINCL. Consistent with this, there are patients with LINCL with hypomorphic <italic toggle="yes">TPP1</italic> mutations that resulted in slowly progressing disease, which was originally diagnosed as JNCL.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref><fig id="fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>A model for SCMAS accumulation in LINCL and JNCL</p><p>(A) In lysosomes from a normal individual (left), SCMAS and other mitochondrial proteins are delivered by the process of mitophagy. SCMAS degradation is initiated by TPP1 and resulting amino acids, peptides, etc., exported from the lysosome for subsequent metabolism. In lysosomes from patients with LINCL (middle), TPP1 is absent, and thus, SCMAS cannot be degraded resulting in its accumulation and potentially subsequent disease. In lysosomes of patients with JNCL (right), the loss of the CLN3 protein perturbs lysosomal homeostasis in such a way that the ability of TPP1 to degrade SCMAS is partially reduced but not eliminated so that SCMAS accumulates slowly over time, correlating with the slower clinical course of JNCL compared to LINCL. (B) TPP1 activity in brain of 12-month WT and <italic toggle="yes">Cln3</italic><sup>&#8722;/&#8722;</sup> mice with or without transgenic TPP1 expression. Statistical analyses were conducted by one-way ANOVA using Tukey&#8217;s multiple comparisons test on log-transformed data. Note that while all possible comparisons were tested, comparison bars are only shown for significant differences. &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.0001; &#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.01; ns, not significant. Bars indicate mean and standard deviation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0030">If TPP1 function is impaired in JNCL, contributing to disease, we reasoned that elevating TPP1 levels could correct such deficiencies. In this report, we have tested this hypothesis using a genetic approach in which we crossed a transgenic mouse that constitutively over-expresses TPP1<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> with a <italic toggle="yes">Cln3</italic><sup>&#8722;/&#8722;</sup> JNCL mouse to determine the effect of elevated TPP1 levels on SCMAS accumulation and disease progression. We find that elevated TPP1 essentially prevents SCMAS storage in the JNCL mouse in multiple tissues, and this is associated with a significant decrease in neuroinflammatory markers and correction of other phenotypes of disease.</p><p id="p0035">These results indicate that TPP1 dysfunction plays a role in the pathogenesis in JNCL and provide a rationale to investigate TPP1 augmentation as a potential therapeutic strategy for patients with mutations in <italic toggle="yes">CLN3</italic>. If this is a generally applicable model for pathogenesis in lysosomal disorders that accumulate SCMAS, TPP1 augmentation may also be useful in other NCLs, especially those due to deficiencies in membrane proteins such as CLN6, CLN7, and CLN8 where correction of the primary defect remains a significant obstacle.</p></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Experimental strategy</title><p id="p0040">Our overall experimental strategy was to determine the effect of transgenic overexpression of TPP1 on JNCL disease progression in a mouse model. Four experimental cohorts of littermate mice were established: WT <italic toggle="yes">Cln3</italic><sup><italic toggle="yes">+/+</italic></sup> animals with or without the TPP1 transgene (Tg) and <italic toggle="yes">Cln3</italic><sup>&#8722;/&#8722;</sup> (JNCL) animals with or without the TPP1 Tg. For clarity, we refer to these groups as: WT/Tg+, WT/Tg&#8722;, JNCL/Tg+, and JNCL/Tg&#8722;, respectively. The TPP1 transgenic overexpresses murine TPP1 from a CAG promoter-driven Tg integrated at the ROSA26 locus. Based on enzyme activity measurements, this mouse constitutively expresses TPP1 at levels &#8764;10-fold and 50-fold higher than normal WT brain (<xref rid="fig1" ref-type="fig">Figure 1</xref>B) and liver (data not shown), respectively. In brain, expression is ubiquitous, including cortex and hippocampus.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref></p></sec><sec id="sec2.2"><title>SCMAS accumulation</title><p id="p0045">SCMAS storage in peripheral tissues, liver and spleen, was initially investigated at 6 months of age by immunohistochemistry (<xref rid="fig2" ref-type="fig">Figure 2</xref>). In WT controls (WT/Tg&#8722;) or WT animals expressing the TPP1 transgene (WT/Tg+), we observed no staining for SCMAS in liver or spleen. In contrast, JNCL mice lacking the TPP1 transgene (JNCL/Tg&#8722;) showed characteristic dark punctate inclusions of accumulated SCMAS storage material. However, JNCL mice expressing the TPP1 transgene (JNCL/Tg+) showed little or no detectable accumulation of SCMAS.<fig id="fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Elevated TPP1 prevents SCMAS accumulation in brain and peripheral tissues at 6 months</p><p>Representative images shown are from mixture of sexes as no sex-related differences in SCMAS storage were noted. Data were quantified in terms of area of image occluded by inclusions using ImageJ/Fiji. Statistical analyses were conducted by one-way ANOVA using Tukey&#8217;s multiple comparisons test on log-transformed data. Note that while all possible comparisons were tested, comparison bars are only shown for significant differences. &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.0001; &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.001; &#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.01, &#8727;<italic toggle="yes">p</italic> &lt; 0.05. Bars indicate mean and standard deviation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0050">Similar results were obtained in brain (<xref rid="fig2" ref-type="fig">Figure 2</xref>). In JNCL/Tg&#8722; animals, storage was widespread throughout the brain with some regions of particularly intense staining, e.g., pyramidal cells of the CA3 region of the hippocampus and Purkinje cells of the cerebellum, while no SCMAS storage was detectable in control WT/Tg&#8722; and WT/Tg+ animals. Again, JNCL mice expressing the TPP1 transgene (JNCL/Tg+) showed no detectable SCMAS storage in the brain. These data indicate that in brain and peripheral organs, the accumulation of SCMAS can be prevented by increased levels of TPP1.</p><p id="p0055">To determine if elimination of SCMAS is persistent, we repeated the analysis of SCMAS storage in brain at 12 months (<xref rid="fig3" ref-type="fig">Figure 3</xref>) in JNCL mice with or without the TPP1 Tg and WT controls (given the absence of pathology in WT mice expressing the TPP1 Tg at 6 months, this control was omitted in subsequent studies). Robust SCMAS storage was detected throughout the brain of the JNCL mice but not in WT controls. Consistent with findings at 6 months, expression of the TPP1 Tg essentially prevented SCMAS accumulation in the JNCL mouse.<fig id="fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><p>Elevated TPP1 prevents SCMAS accumulation in brain at 12 months</p><p>Representative images shown are from mixture of sexes as no sex-related differences in SCMAS storage were noted. Data were quantified in terms of area of image occluded by inclusions using ImageJ/Fiji. Statistical analyses were conducted by one-way ANOVA using Tukey&#8217;s multiple comparisons test on log-transformed data. Note that while all possible comparisons were tested, comparison bars are only shown for significant differences. &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.0001, &#8727;<italic toggle="yes">p</italic> &lt; 0.05. Bars indicate mean and standard deviation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0060">A hallmark of NCL diseases is the autofluorescence associated with the storage material. Despite clearly preventing SCMAS accumulation, elevated TPP1 levels did not prevent autofluorescence (<xref rid="fig4" ref-type="fig">Figure 4</xref>), which presumably therefore arises from other components of storage material (e.g., lipids).<fig id="fig4" position="float" orientation="portrait"><label>Figure 4</label><caption><p>Elevated TPP1 does not prevent autofluorescence</p><p>Animals were 12 months old, and images were acquired from a mixture of male and females. Autofluorescence was imaged using the TRITC channel. Autofluorescence from brain sections from WT/Tg+ animals was identical to the WT control (data not shown).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec><sec id="sec2.3"><title>Neuroinflammation</title><p id="p0065">Given the uncertainty regarding the role of SCMAS accumulation in disease progression, it was necessary to determine whether prevention of SCMAS storage by elevated TPP1 was associated with functional correction of disease. This goal was complicated by the extremely attenuated phenotype of the CLN3 knockout mouse.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> For example, survival of the JNCL mouse<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> is only marginally truncated compared to WT controls, and while the JNCL mouse has been reported to have locomotor-behavioral defects, most reports indicate that they are nuanced and highly variable, with dramatically different data reported by different groups.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Six- and 12-month JNCL mice were analyzed using open field activity, RotaRod, and pole test, but animals failed to display any robust behavioral or locomotor phenotype associated with the disease (<xref rid="mmc1" ref-type="supplementary-material">Figure S1</xref>). This was not unexpected and has been reported previously by others.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref></p><p id="p0070">As an alternative approach to measure the effect of TPP1 overexpression on disease progression in JNCL, we considered neuroinflammation. A number of recent studies (reviewed in Takahashi<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref>) have suggested that glial dysfunction may be a key driver of pathogenesis, and thus, therapeutically targeting both neurons and glia may provide the most successful approaches to NCL diseases. We therefore investigated the effect of TPP1 Tg expression on glial activation<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> in the JNCL mouse.</p><p id="p0075">Activation of astrocytes was determined by immunohistochemical staining for GFAP (<xref rid="fig5" ref-type="fig">Figure 5</xref>). GFAP was detected throughout the brains of both JNCL and control mice, but there were several regions with JNCL-specific staining including somatosensory cortex layers 6a/b and ventral nucleus regions of the thalamus, as reported previously.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> While not completely restoring GFAP staining to WT levels, expression of the TPP1 Tg resulted in a major and significant reduction in GFAP immunoreactivity in these two brain regions. Activated microglia were analyzed by immunostaining for CD68 (<xref rid="fig6" ref-type="fig">Figure 6</xref>). We detected sporadic CD68 staining throughout the brain of WT animals, and this was increased in the JNCL animals as reported previously.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> Elevated TPP1 resulted in a minor but significant decrease in sporadic CD68 staining observed throughout the cerebral cortex. The most extensive microglial activation in the JNCL mice was found in the ventral nuclei of the thalamus, and this was decreased significantly by elevated TPP1 levels. Taken together, these data demonstrate that TPP1 overexpression results in a significant reduction in neuroinflammation in the JNCL mouse model.<fig id="fig5" position="float" orientation="portrait"><label>Figure 5</label><caption><p>Increased levels of TPP1 reduce astrocyte activation in JNCL</p><p>Astrocyte activation was determined by immunohistochemical detection of GFAP. Animals are 12 months old, and images were acquired from a mixture of male and females. Regions with JNCL-specific astrocyte activation were identified as the somatosensory cortex layer 6 (upper) and ventral nuclei of the thalamus. Graphs depict percentage area occluded by GFAP staining. Statistical analyses were conducted by one-way ANOVA using Tukey&#8217;s multiple comparisons test on log-transformed data. &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.0001; &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.001; &#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.01. Bars indicate mean and standard deviation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig><fig id="fig6" position="float" orientation="portrait"><label>Figure 6</label><caption><p>Increased levels of TPP1 reduce microglial activation in JNCL</p><p>Microglial activation was determined by immunohistochemical detection of CD68. Animals are 12 months old, and images were acquired from a mixture of male and females. Diffuse CD68 staining was detected throughout the cortex with images derived from the somatomotor/orbital layer 5 region. Intense JNCL-specific glial activation was identified in the ventral nuclei of the thalamus and is shown at two different magnifications. Graph indicate percentage area occluded by CD68 staining. Statistical analyses were conducted by one-way ANOVA using Tukey&#8217;s multiple comparisons test on log-transformed data. Note that while all possible comparisons were tested, comparison bars are only shown for significant differences. &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.0001; &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.001; &#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.01. Bars indicate mean and standard deviation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p></sec><sec id="sec2.4"><title>Neurofilament light</title><p id="p0080">Neurofilament light (Nfl) is an established biomarker of neurodegeneration in a wide range of neurological diseases (reviewed in Yuan and Nixon<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref>) including JNCL.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> Nfl is a major structural protein of neurons and is released into cerebrospinal fluid and plasma in increasing amounts during neurodegeneration, inflammation, and other disease-related processes. In <xref rid="fig7" ref-type="fig">Figure 7</xref>, we measured Nfl by immunoassay in plasma from 12-month JNCL and WT mice, with or without transgenic TPP1 overexpression. As expected, we found that Nfl levels in plasma from the JNCL mice were significantly elevated (&#8764;2.7-fold) compared to WT animals. Expression of the TPP1 Tg had no effect on Nfl expression in WT mice, but in JNCL animals, TPP1 overexpression restored plasma Nfl to WT levels. These data suggest that elevated TPP1 reduces or prevents neurodegeneration and/or neuroinflammation in the JNCL mice.<fig id="fig7" position="float" orientation="portrait"><label>Figure 7</label><caption><p>Elevated Nfl levels in plasma of JNCL mice are restored to WT levels by TPP1 overexpression</p><p>Statistical analyses were conducted by one-way ANOVA using Tukey&#8217;s multiple comparisons test on log-transformed data. Note that while all possible comparisons were tested, comparison bars are only shown for significant differences. &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.0001; &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.001. Bars indicate mean and standard deviation. <italic toggle="yes">n</italic> = 6 animals were analyzed for WT/Tg+ and <italic toggle="yes">n</italic> = 12&#8211;14 for other genotypes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr7.jpg"/></fig></p></sec><sec id="sec2.5"><title>Brain mass</title><p id="p0085">Several studies<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> have shown that the brains of the JNCL mice are &#8764;8% smaller in mass than age-matched WT animals at 12 months of age, presumably reflecting cortical atrophy and neuronal loss that is observed in both JNCL patients<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> and mice.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> We analyzed brain weights in WT and JNCL mice, with or without transgenic TPP1 overexpression (<xref rid="fig8" ref-type="fig">Figures 8</xref>A and 8C). Consistent with previous studies, at &#8764;7, 12, and 24 months, the brain mass of JNCL mice was found to be significantly lower than that of WT animals with or without the TPP1 Tg. However, elevated TPP1 levels corrected the decrease in brain mass associated with JNCL and restored brain mass to that measured in WT mice. In contrast, liver weights in the four genotypes of animals were not significantly different (<xref rid="fig8" ref-type="fig">Figure 8</xref>B).<fig id="fig8" position="float" orientation="portrait"><label>Figure 8</label><caption><p>Progressive loss of brain mass in JNCL mice is corrected by elevated TPP1 expression</p><p>(A) Brain weights of animals are plotted against age at euthanasia. Open and closed symbols show male and female animals, respectively. Data for male and female animals were analyzed together by simple linear regression, and <italic toggle="yes">p</italic> values for all pairwise comparisons of the slopes were determined and corrected for multiple comparisons using the Bonferroni method. (B) As (A) but depicting analysis of liver weights. Pairwise comparisons of all combinations of genotypes revealed no significant differences. (C) Brain weights are compared after assigning animals into three different age groups (per genotype: <italic toggle="yes">n</italic> = 25&#8211;32 for 6- to 9-month group, <italic toggle="yes">n</italic> = 7&#8211;15 for 11- to 16-month group; <italic toggle="yes">n</italic> = 5&#8211;8 for 21- to 26-month group). Statistical analyses were conducted by one-way ANOVA using Tukey&#8217;s multiple comparisons test on log-transformed data. All possible comparisons were tested, but unless indicated, comparison bars are only shown for significant differences. ns, not significant; &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.0001; &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.001; &#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.01; &#8727;<italic toggle="yes">p &lt;</italic> 0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr8.jpg"/></fig></p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0090">In this report, we show that elevated levels of TPP1 essentially prevent the accumulation of SCMAS, the major protein component of storage material, in cells within the brain and other tissues of the <italic toggle="yes">Cln3</italic>-knockout mouse model of JNCL. However, the role played by SCMAS in neuronal death and disease has long been a subject of debate. While defects in SCMAS degradation were originally suggested to cause NCL disease,<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> there is a school of thought that SCMAS storage and disease are not related (reviewed in Palmer<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref>). However, this study clearly indicates that elimination of SCMAS in the JNCL mouse by elevated TPP1 is correlated with a partial but major reduction in neuroinflammation, which has been identified as a key driver of neuronal death.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> In addition, transgenic TPP1 expression corrected other phenotypes of disease including elevated levels of the neurodegeneration biomarker Nfl and a progressive loss of brain mass.</p><p id="p0095">It is possible that elevated TPP1 provides therapeutic benefits in JNCL independent of its role in the degradation of SCMAS; thus, lysosomal SCMAS storage may simply represent an informative biomarker for disease. Alternatively, a simpler explanation is that the accumulation of insoluble SCMAS deposits within neurons is neurotoxic and contributes to neuronal death. For example, many cellular abnormalities have been linked with JNCL,<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> including defects in membrane trafficking and autophagy,<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="bib33" ref-type="bibr"><sup>33</sup></xref><sup>,</sup><xref rid="bib34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> and it is quite plausible that SCMAS accumulation could compromise lysosomal function, which in turn could contribute to such phenotypes. We do not suggest that SCMAS accumulation is the sole driver of disease as transgenic overexpression of TPP1 almost completely prevented SCMAS accumulation at 12 months but, while significantly reduced, some level of disease-associated neuroinflammation persisted. The pathogenic contribution of this residual neuroinflammation is difficult to evaluate, but it is worth noting that other phenotypes (Nfl and brain mass) were completely corrected. Clearly, further studies are required to definitively establish the role of TPP1 in JNCL disease and to ascertain any potential involvement of SCMAS storage.</p><p id="p0100">Finally, it is worth emphasizing that discussion of whether or not SCMAS itself is a driver of neuronal death may be irrelevant from a potential translational perspective. As noted earlier, we have clearly shown that constitutively elevated TPP1 prevents SCMAS storage but also corrects multiple other phenotypes that are directly linked to disease progression.</p><sec id="sec3.1"><title>Effect of small-molecule drugs on TPP1 function in JNCL</title><p id="p0105">Several studies in <italic toggle="yes">Cln3</italic> knockout mice of small-molecule drugs that stimulate TFEB-mediated expression of lysosomal proteins, promoting lysosome biogenesis and clearance of accumulated storage material,<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="bib36" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> have shown promise in ameliorating disease phenotype. One of these molecules, gemfibrozil, is also thought to reduce neuroinflammation.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> Given our findings, the therapeutic effects of inducers of TFEB-mediated transcription of lysosomal genes in JNCL mouse models may simply reflect an increase in TPP1 activity, and consistent with this, gemfibrozil treatment of JNCL mice has been shown to result in elevated TPP1.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref></p></sec><sec id="sec3.2"><title>Mechanisms underlying the effects of CLN3 loss on TPP1 function</title><p id="p0110">It remains to be established why the loss of CLN3 impairs TPP1 function, resulting in the lysosomal accumulation of SCMAS. Loss of CLN3 does not simply result in a downregulation of TPP1 expression or loss of catalytic function as TPP1 activity is actually elevated in JNCL patients and mice.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> One possibility is that disturbance of the lysosomal microenvironment in the absence of CLN3 might interfere with TPP1 catalytic function (in a manner not detectable after cell lysis and processing for <italic toggle="yes">in vitro</italic> enzyme assay) or access to SCMAS. For example, a recent study<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> indicated that there is a lysosomal accumulation of glycerophosphodiesters in JNCL, which may act as inhibitors of enzymes involved in glycerophospholipid catabolism, resulting in an additional accumulation of lysophospholipids.<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> It is possible that locally elevated levels of these various lipids might inhibit TPP1, although they have no apparent effect on TPP1 activity<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref>
<italic toggle="yes">in vitro</italic>. Alternatively, these lipids could induce conformational changes in SCMAS that lower the rate of its degradation by TPP1. Interestingly, a mouse model of mucopolysaccharidosis III B also accumulates SCMAS even though the primary defect lies in degradation of heparin sulfate,<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> and the authors of this study speculated that &#8220;it is likely that some unfavorable condition in lysosomes slows down the degradation of SCMAS, allowing this very hydrophobic protein to pack into closely stacked arrays that may be even harder to digest.&#8221;<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> Finally, it may be possible that rather than directly impairing the ability of TPP1 to degrade SCMAS, loss of CLN3 could result in increased delivery of SCMAS to the lysosome, overwhelming the capacity for TPP1 to degrade it efficiently. Of possible relevance, loss of CLN3 has been reported to interfere with mitochondrial function<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> and cellular autophagic pathways,<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="bib34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="bib41" ref-type="bibr"><sup>41</sup></xref><sup>,</sup><xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> which could potentially result in increased mitochondrial turnover. Regardless of whether CLN3 loss impairs the ability of TPP1 to degrade SCMAS or increases lysosomal influx of SCMAS, increasing TPP1 levels would be predicted to reduce SCMAS storage, as we have demonstrated in this report.</p></sec><sec id="sec3.3"><title>Translational implications&#8212;TPP1 augmentation as a potential therapeutic route for JNCL</title><p id="p0115">Universal correction of the primary defect (i.e., replacing the mutant CLN3 with a functional copy) would undoubtedly be the most effective route to therapy for JNCL. However, this remains a substantial challenge given that CLN3 is a transmembrane protein; thus, enzyme replacement therapy is not feasible, and gene therapy to correct such cell-autonomous defects continues to be challenging. Our results suggest that supplementing TPP1 levels in patients with JNCL may be a feasible alternative therapeutic strategy. While this does not address the primary defect, this approach focuses on a secondary pathogenic event that may, at least in part, drive disease progression. A major strength of this approach as a therapeutic strategy is that there are established methods to achieve TPP1 augmentation. One approach would be to conduct intracerebroventricular delivery of recombinant TPP1 in much the same way that patients with LINCL are currently treated.<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> However, before any possible clinical investigation, it will be necessary to demonstrate in the JNCL mouse model that delivery of recombinant TPP1 has the same therapeutic effects as constitutive transgenic overexpression, in particular, with respect to elimination of preexisting SCMAS storage. There are also continuing efforts to develop TPP1 gene therapy therapeutics for LINCL,<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> and if effective, these could also be potentially used for JNCL.</p></sec><sec id="sec3.4"><title>TPP1 augmentation as a general approach for lysosomal diseases that store SCMAS</title><p id="p0120">In addition to LINCL and JNCL, there are other NCLs that accumulate SCMAS, including CLN5, CLN6, CLN7, and CLN8,<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> as well as a number of unrelated lysosomal storage diseases, including mucopolysaccharidosis I, II, and IIIA, multiple sulfatase deficiency, and, to variable but lesser degree, some lysosomal lipidoses.<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> If impaired TPP1 function reflected by SCMAS accumulation is a common pathogenic trigger in these diseases, then TPP1 augmentation could have application in a range of currently intractable lysosomal disorders. This is especially true for those arising from defects in transmembrane proteins, where gene and enzyme replacement therapy may be difficult or impossible and additional proof-of-principle studies using mouse or other animal models may be warranted for such disorders.</p><p id="p0125">In conclusion, this study clearly demonstrates that the ability of TPP1 to degrade its substrate SCMAS is either impaired or overwhelmed in JNCL, providing a mechanistic explanation for the accumulation of this material. Importantly, we also demonstrate that elevated levels of TPP1 overcome this impairment, essentially preventing SCMAS storage but also significantly correcting other phenotypes of disease in the JNCL mouse model. These data provide a strong rationale to consider TPP1 augmentation as a therapeutic strategy in JNCL and related diseases that accumulate SCMAS that are refractory to approaches that address the primary defect.</p></sec></sec><sec id="sec4"><title>Materials and methods</title><sec id="sec4.1"><title>Experimental design</title><p id="p0130">All studies (brain weight measurements, neuropathology, behavior, and Nfl measurements) were conducted in a blinded manner where the respective researchers had access only to animal tag numbers, which convey no information regarding the genotype. Genotypes were revealed only after the collection of data. Cohort sizes of <italic toggle="yes">n</italic> = 6 mice were used for all studies except analysis of brain weight loss and plasma Nfl (see respective legends for details). Experimental cohorts were divided approximately equally among male and female animals.</p></sec><sec id="sec4.2"><title>Animals</title><p id="p0135">Mice were maintained and used following protocols approved by the Rutgers University and Robert Wood Johnson Medical School Institutional Animal Care and Use Committee (&#8220;Preclinical evaluation of therapy in an animal model for LINCL,&#8221; protocol I09-0274-4). Both the JNCL model<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> and the TPP1 transgenic<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> were in a C57BL/6 genetic background, and genotyping was conducted as described.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> Animals were deeply anesthetized with sodium pentobarbital/phenytoin (a 1:4 dilution of Euthasol; Delmarva Laboratories, Midlothian, VA) and euthanized by transcardial perfusion with 0.9% saline for biochemical analyses. For histopathology, mice were anesthetized, perfused with saline, and then perfusion-fixed with 4% paraformaldehyde in PBS. Brains were excised, fixed for 48 h in 4% paraformaldehyde in PBS, and then transferred to 30% sucrose/PBS at 4&#176;C until they sunk.</p></sec><sec id="sec4.3"><title>Neuropathology</title><p id="p0140">Immunohistochemistry was conducted by NeuroScience Associates, Inc. (Knoxville, TN). In brief, mouse brains were embedded within a single block, and 35 &#956;m sagittal sections were cut. SCMAS was visualized using an affinity-purified rabbit anti-polyclonal antibody raised against SCMAS amino-terminal peptide, which was custom-prepared by Pacific Immunology (Ramona, CA).<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> Immunohistochemistry analysis of GFAP and CD68 was conducted using rabbit anti-GFAP (DAKO) and rat anti-mouse CD68 (Bio-Rad). Sections were prepared from tissue blocks, immunostained with the primary antibodies overnight, and visualized using a biotinylated secondary antibody (goat anti-rabbit IgG, Vector Labs), followed by an avidin-biotin-HRP complex (Vector Labs) and diaminobenzidine tetrahydrochloride to create a visible reaction product as described.<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref></p></sec><sec id="sec4.4"><title>Measurement of Nfl</title><p id="p0145">Plasma NfL concentration was measured with the Simple Plex Murine NF-L cartridge on the Ella Automated Immunoassay System according to manufacturer&#8217;s instructions (Bio-techne GmbH, Minneapolis, USA). Plasma NfL results were extrapolated using the in-cartridge factory standard curve, with a quantification range of 2.7&#8211;10,290 pg/mL. Quality control (QC) samples at three concentration levels and a pooled mouse plasma sample were included in each run to monitor assay performance. Six QC samples were prepared by spiking sample diluent at 16.08, 643.13, and 6,431.3 pg/mL and spiking pooled plasma (BioIVT, NY, USA) at 16.08, 643.13, and 6,431.3 pg/mL with human/mouse Nfl control (ProteinSimple, CA, USA). Two sets of each QC were processed along with unknown samples, and the plate results were accepted if the analytical recovery of the QCs fell within the range of 80%&#8211;120% at each QC concentration. Analysis was conducted blinded to the mouse genotype.</p></sec><sec id="sec4.5"><title>Statistics</title><p id="p0150">Data were analyzed using GraphPad Prism 10. Experimental endpoints measured were compared using ANOVA with Tukey&#8217;s test for multiple comparisons using log-transformed data comparing the mean of each genotype with the mean of all other genotypes. Data are plotted on a linear scale using the adjusted <italic toggle="yes">p</italic> values obtained using log-transformed data. No statistical methods were used to predetermine cohort sizes.</p></sec></sec><sec sec-type="data-availability" id="sec5"><title>Data and code availability</title><p id="p0155">JNCL <italic toggle="yes">Cln3</italic>-knockout mice are available from the Jackson Laboratory (Strain# 029471) as is the parent construct for the TPP1 overexpressor, a TPP1 ROSA26 knockin mouse prior to Cre-mediated excision of the LSL stop sequence (strain# 039035).</p></sec><sec id="sec6"><title>Acknowledgments</title><p id="p0160">We would like to thank Dr. Robert Switzer and colleagues at NeuroScience Associates for their expert assistance with the neuropathology analyses. This study was funded by a grant from the <funding-source id="gs1">Rutgers Health Advance</funding-source> program (D.E.S.).</p></sec><sec id="sec7"><title>Author contributions</title><p id="p0165">Conceptualization, D.E.S. and P.L.; methodology, W.B.-P., K.E.L., E.H.S., A.B., B.S., Y.T., A.C.M., J.K.I., T.P.L., P.L., and D.E.S.; investigation, W.B.-P., K.E.L., E.H.S., A.B., Y.T., and A.C.M.; visualization, D.E.S.; funding acquisition, D.E.S. and P.L.; project administration, D.E.S. and P.L.; supervision, D.E.S., P.L., T.P.L., and B.S.; writing &#8211; original draft, D.E.S.; writing &#8211; review and editing, W.B.-P., K.E.L., E.H.S., A.B., B.S., Y.T., A.C.M., J.K.I., T.P.L., P.L., and D.E.S.</p></sec><sec sec-type="COI-statement" id="sec8"><title>Declaration of interests</title><p id="p0170">D.E.S. and P.L. have received royalty payments as inventors on patents describing therapies for LINCL, the late infantile form of Batten disease, that are assigned to Rutgers University and licensed to BioMarin Pharmaceutical, Inc. The research described in this study is protected under US patent application publication no. 2024-0158772 (&#8220;Methods For Treating Lysosomal Storage Diseases,&#8221; inventors: D.E.S. and P.L.).</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="book" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Mole</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Goebel</surname><given-names>H.H.</given-names></name></person-group><part-title>The Neuronal Ceroid Lipofuscinoses (Batten Disease)</part-title><edition>2nd ed.</edition><year>2011</year><publisher-name>Oxford University Press</publisher-name><fpage>444</fpage></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Simonati</surname><given-names>A.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>R.E.</given-names></name></person-group><article-title>Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview</article-title><source>Front. Neurol.</source><volume>13</volume><year>2022</year><object-id pub-id-type="publisher-id">811686</object-id><pub-id pub-id-type="doi">10.3389/fneur.2022.811686</pub-id><pub-id pub-id-type="pmcid">PMC8961688</pub-id><pub-id pub-id-type="pmid">35359645</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Fearnley</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Lake</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Haltia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinus</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Jolly</surname><given-names>R.D.</given-names></name></person-group><article-title>Mitochondrial ATP synthase subunit c storage in the ceroid-lipofuscinoses (Batten disease)</article-title><source>Am. J. Med. Genet.</source><volume>42</volume><year>1992</year><fpage>561</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1002/ajmg.1320420428</pub-id><pub-id pub-id-type="pmid">1535179</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>D.N.</given-names></name></person-group><article-title>The relevance of the storage of subunit c of ATP synthase in different forms and models of Batten disease (NCLs)</article-title><source>Biochim. Biophys. Acta</source><volume>1852</volume><year>2015</year><fpage>2287</fpage><lpage>2291</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2015.06.014</pub-id><pub-id pub-id-type="pmid">26093153</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Ezaki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Takeda-Ezaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kominami</surname><given-names>E.</given-names></name></person-group><article-title>Tripeptidyl peptidase I, the late infantile neuronal ceroid lipofuscinosis gene product, initiates the lysosomal degradation of subunit c of ATP synthase</article-title><source>J. Biochem.</source><volume>128</volume><year>2000</year><fpage>509</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.jbchem.a022781</pub-id><pub-id pub-id-type="pmid">10965052</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Fearnley</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Medd</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Martinus</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Bayliss</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Lake</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Jolly</surname><given-names>R.D.</given-names></name></person-group><article-title>Lysosomal storage of the DCCD reactive proteolipid subunit of mitochondrial ATP synthase in human and ovine ceroid lipofuscinoses</article-title><source>Adv. Exp. Med. Biol.</source><volume>266</volume><year>1989</year><fpage>211</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1007/978-1-4899-5339-1_15</pub-id><comment>discussion 23</comment><pub-id pub-id-type="pmid">2535017</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Sleat</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Lackland</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Sohar</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pullarkat</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Lobel</surname><given-names>P.</given-names></name></person-group><article-title>Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis</article-title><source>Science</source><volume>277</volume><year>1997</year><fpage>1802</fpage><lpage>1805</lpage><pub-id pub-id-type="pmid">9295267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.277.5333.1802</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><collab>The International Batten Disease Consortium</collab></person-group><article-title>Isolation of a novel gene underlying Batten disease, CLN3</article-title><source>Cell</source><volume>82</volume><year>1995</year><fpage>949</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90274-0</pub-id><pub-id pub-id-type="pmid">7553855</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Laqtom</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Medoh</surname><given-names>U.N.</given-names></name><name name-style="western"><surname>Cangelosi</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Dharamdasani</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kunchok</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Heinze</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>R.</given-names></name><etal/></person-group><article-title>CLN3 is required for the clearance of glycerophosphodiesters from lysosomes</article-title><source>Nature</source><volume>609</volume><year>2022</year><fpage>1005</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05221-y</pub-id><pub-id pub-id-type="pmid">36131016</pub-id><pub-id pub-id-type="pmcid">PMC10510443</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Sleat</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Wiseman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>El-Banna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Price</surname><given-names>S.</given-names></name><name name-style="western"><surname>Macauley</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Sidman</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration</article-title><source>J. Neurosci.</source><volume>24</volume><year>2004</year><fpage>9117</fpage><lpage>9126</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2729-04.2004</pub-id><pub-id pub-id-type="pmid">15483130</pub-id><pub-id pub-id-type="pmcid">PMC6730049</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Mitchison</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Greene</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Junaid</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Pullarkat</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>de Vos</surname><given-names>N.</given-names></name><name name-style="western"><surname>Breuning</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Owens</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>W.C.</given-names></name><etal/></person-group><article-title>Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The Batten Mouse Model Consortium [corrected]</article-title><source>Neurobiol. Dis.</source><volume>6</volume><year>1999</year><fpage>321</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1006/nbdi.1999.0267</pub-id><pub-id pub-id-type="pmid">10527801</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Sleat</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Banach-Petrosky</surname><given-names>W.</given-names></name><name name-style="western"><surname>Larrimore</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Nemtsova</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wiseman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Najafi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Poole</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Lobel</surname><given-names>P.</given-names></name></person-group><article-title>A mouse mutant deficient in both neuronal ceroid lipofuscinosis-associated proteins CLN3 and TPP1</article-title><source>J. Inherit. Metab. Dis.</source><volume>46</volume><year>2023</year><fpage>720</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1002/jimd.12619</pub-id><pub-id pub-id-type="pmid">37078466</pub-id><pub-id pub-id-type="pmcid">PMC10330656</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Junaid</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Pullarkat</surname><given-names>R.K.</given-names></name></person-group><article-title>Increased brain lysosomal pepstatin-insensitive proteinase activity in patients with neurodegenerative diseases</article-title><source>Neurosci. Lett.</source><volume>264</volume><year>1999</year><fpage>157</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/s0304-3940(99)00095-6</pub-id><pub-id pub-id-type="pmid">10320038</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Sleat</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Gin</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Sohar</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wisniewski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sklower-Brooks</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pullarkat</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Lerner</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Boustany</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Uldall</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder</article-title><source>Am. J. Hum. Genet.</source><volume>64</volume><year>1999</year><fpage>1511</fpage><lpage>1523</lpage><pub-id pub-id-type="doi">10.1086/302427</pub-id><pub-id pub-id-type="pmid">10330339</pub-id><pub-id pub-id-type="pmcid">PMC1377895</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Nemtsova</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wiseman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>El-Banna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lobel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sleat</surname><given-names>D.E.</given-names></name></person-group><article-title>Inducible transgenic expression of tripeptidyl peptidase 1 in a mouse model of late-infantile neuronal ceroid lipofuscinosis</article-title><source>PLoS One</source><volume>13</volume><year>2018</year><object-id pub-id-type="publisher-id">e0192286</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0192286</pub-id><pub-id pub-id-type="pmcid">PMC5800698</pub-id><pub-id pub-id-type="pmid">29408933</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Cotman</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Vrbanac</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lebel</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Donahue</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Teed</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Antonellis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bronson</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Lerner</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>M.E.</given-names></name></person-group><article-title>Cln3(Delta ex7/8) knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth</article-title><source>Hum. Mol. Genet.</source><volume>11</volume><year>2002</year><fpage>2709</fpage><lpage>2721</lpage><pub-id pub-id-type="doi">10.1093/hmg/11.22.2709</pub-id><pub-id pub-id-type="pmid">12374761</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Katz</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Tullis</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>B.</given-names></name></person-group><article-title>Phenotypic characterization of a mouse model of juvenile neuronal ceroid lipofuscinosis</article-title><source>Neurobiol. Dis.</source><volume>29</volume><year>2008</year><fpage>242</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2007.08.017</pub-id><pub-id pub-id-type="pmid">17962032</pub-id><pub-id pub-id-type="pmcid">PMC2268761</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Kovacs</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>D.A.</given-names></name></person-group><article-title>Finding the most appropriate mouse model of juvenile CLN3 (Batten) disease for therapeutic studies: the importance of genetic background and gender</article-title><source>Dis. Model. Mech.</source><volume>8</volume><year>2015</year><fpage>351</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1242/dmm.018804</pub-id><pub-id pub-id-type="pmid">26035843</pub-id><pub-id pub-id-type="pmcid">PMC4381334</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nelvagal</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Lange</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>J.D.</given-names></name></person-group><article-title>Glial Dysfunction and Its Contribution to the Pathogenesis of the Neuronal Ceroid Lipofuscinoses</article-title><source>Front. Neurol.</source><volume>13</volume><year>2022</year><object-id pub-id-type="publisher-id">886567</object-id><pub-id pub-id-type="doi">10.3389/fneur.2022.886567</pub-id><pub-id pub-id-type="pmcid">PMC9013902</pub-id><pub-id pub-id-type="pmid">35444603</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Tarczyluk</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Nelvagal</surname><given-names>H.R.</given-names></name></person-group><article-title>Towards a new understanding of NCL pathogenesis</article-title><source>Biochim. Biophys. Acta</source><volume>1852</volume><year>2015</year><fpage>2256</fpage><lpage>2261</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2015.05.014</pub-id><pub-id pub-id-type="pmid">26026924</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Pontikis</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Cella</surname><given-names>C.V.</given-names></name><name name-style="western"><surname>Parihar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Chakrabarti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mitchison</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Rezaie</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>J.D.</given-names></name></person-group><article-title>Late onset neurodegeneration in the Cln3-/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation</article-title><source>Brain Res.</source><volume>1023</volume><year>2004</year><fpage>231</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2004.07.030</pub-id><pub-id pub-id-type="pmid">15374749</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nixon</surname><given-names>R.A.</given-names></name></person-group><article-title>Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies</article-title><source>Front. Neurosci.</source><volume>15</volume><year>2021</year><object-id pub-id-type="publisher-id">689938</object-id><pub-id pub-id-type="doi">10.3389/fnins.2021.689938</pub-id><pub-id pub-id-type="pmcid">PMC8503617</pub-id><pub-id pub-id-type="pmid">34646114</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Dang Do</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Sinaii</surname><given-names>N.</given-names></name><name name-style="western"><surname>Masvekar</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Thurm</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Soldatos</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Bianconi</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Bielekova</surname><given-names>B.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>F.D.</given-names></name></person-group><article-title>Neurofilament light chain levels correlate with clinical measures in CLN3 disease</article-title><source>Genet. Med.</source><volume>23</volume><year>2021</year><fpage>751</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1038/s41436-020-01035-3</pub-id><pub-id pub-id-type="pmid">33239751</pub-id><pub-id pub-id-type="pmcid">PMC8035240</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Dang Do</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Sleat</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>K.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wassif</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Dale</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>F.D.</given-names></name></person-group><article-title>Cerebrospinal Fluid Protein Biomarker Discovery in CLN3</article-title><source>J. Proteome Res.</source><volume>22</volume><year>2023</year><fpage>2493</fpage><lpage>2508</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.3c00199</pub-id><pub-id pub-id-type="pmid">37338096</pub-id><pub-id pub-id-type="pmcid">PMC11095826</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Palmieri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nelvagal</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Lotfi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stinnett</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Chaudhury</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bajaj</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bondar</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Bremner</surname><given-names>L.</given-names></name><etal/></person-group><article-title>mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases</article-title><source>Nat. Commun.</source><volume>8</volume><year>2017</year><object-id pub-id-type="publisher-id">14338</object-id><pub-id pub-id-type="doi">10.1038/ncomms14338</pub-id><pub-id pub-id-type="pmcid">PMC5303831</pub-id><pub-id pub-id-type="pmid">28165011</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Autti</surname><given-names>T.</given-names></name><name name-style="western"><surname>Raininko</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vanhanen</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Santavuori</surname><given-names>P.</given-names></name></person-group><article-title>MRI of neuronal ceroid lipofuscinosis. I. Cranial MRI of 30 patients with juvenile neuronal ceroid lipofuscinosis</article-title><source>Neuroradiology</source><volume>38</volume><year>1996</year><fpage>476</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1007/BF00607283</pub-id><pub-id pub-id-type="pmid">8837098</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Autti</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>H&#228;m&#228;l&#228;inen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mannerkoski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van Leemput</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Aberg</surname><given-names>L.E.</given-names></name></person-group><article-title>JNCL patients show marked brain volume alterations on longitudinal MRI in adolescence</article-title><source>J. Neurol.</source><volume>255</volume><year>2008</year><fpage>1226</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.1007/s00415-008-0891-x</pub-id><pub-id pub-id-type="pmid">18677643</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Greene</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Lythgoe</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Nussbaum</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Mitchison</surname><given-names>H.M.</given-names></name></person-group><article-title>High resolution MRI reveals global changes in brains of Cln3 mutant mice</article-title><source>Eur. J. Paediatr. Neurol.</source><volume>5</volume><year>2001</year><fpage>103</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1053/ejpn.2000.0444</pub-id><pub-id pub-id-type="pmid">11588978</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Kollmann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Uusi-Rauva</surname><given-names>K.</given-names></name><name name-style="western"><surname>Scifo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tyynel&#228;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jalanko</surname><given-names>A.</given-names></name><name name-style="western"><surname>Braulke</surname><given-names>T.</given-names></name></person-group><article-title>Cell biology and function of neuronal ceroid lipofuscinosis-related proteins</article-title><source>Biochim. Biophys. Acta</source><volume>1832</volume><year>2013</year><fpage>1866</fpage><lpage>1881</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2013.01.019</pub-id><pub-id pub-id-type="pmid">23402926</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Shematorova</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Shpakovski</surname><given-names>G.V.</given-names></name></person-group><article-title>Current Insights in Elucidation of Possible Molecular Mechanisms of the Juvenile Form of Batten Disease</article-title><source>Int. J. Mol. Sci.</source><volume>21</volume><year>2020</year><object-id pub-id-type="publisher-id">8055</object-id><pub-id pub-id-type="doi">10.3390/ijms21218055</pub-id><pub-id pub-id-type="pmcid">PMC7663513</pub-id><pub-id pub-id-type="pmid">33137890</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Fossale</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>P.</given-names></name><name name-style="western"><surname>Espinola</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Lubicz-Nawrocka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Teed</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rigamonti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cattaneo</surname><given-names>E.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Cotman</surname><given-names>S.L.</given-names></name></person-group><article-title>Membrane trafficking and mitochondrial abnormalities precede subunit c deposition in a cerebellar cell model of juvenile neuronal ceroid lipofuscinosis</article-title><source>BMC Neurosci.</source><volume>5</volume><year>2004</year><fpage>57</fpage><pub-id pub-id-type="doi">10.1186/1471-2202-5-57</pub-id><pub-id pub-id-type="pmid">15588329</pub-id><pub-id pub-id-type="pmcid">PMC539297</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Wavre-Shapton</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Calvi</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Turmaine</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seabra</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Cutler</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Futter</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Mitchison</surname><given-names>H.M.</given-names></name></person-group><article-title>Photoreceptor phagosome processing defects and disturbed autophagy in retinal pigment epithelium of Cln3Deltaex1-6 mice modelling juvenile neuronal ceroid lipofuscinosis (Batten disease)</article-title><source>Hum. Mol. Genet.</source><volume>24</volume><year>2015</year><fpage>7060</fpage><lpage>7074</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv406</pub-id><pub-id pub-id-type="pmid">26450516</pub-id><pub-id pub-id-type="pmcid">PMC4654058</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mohan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Al-Attar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Flight</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Warmoes</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Deshpande</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Loss of CLN3, the gene mutated in juvenile neuronal ceroid lipofuscinosis, leads to metabolic impairment and autophagy induction in retinal pigment epithelium</article-title><source>Biochim. Biophys. Acta. Mol. Basis Dis.</source><volume>1866</volume><year>2020</year><object-id pub-id-type="publisher-id">165883</object-id><pub-id pub-id-type="doi">10.1016/j.bbadis.2020.165883</pub-id><pub-id pub-id-type="pmcid">PMC9126413</pub-id><pub-id pub-id-type="pmid">32592935</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Espinola</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Fossale</surname><given-names>E.</given-names></name><name name-style="western"><surname>Massey</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Cuervo</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Cotman</surname><given-names>S.L.</given-names></name></person-group><article-title>Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis</article-title><source>J. Biol. Chem.</source><volume>281</volume><year>2006</year><fpage>20483</fpage><lpage>20493</lpage><pub-id pub-id-type="doi">10.1074/jbc.M602180200</pub-id><pub-id pub-id-type="pmid">16714284</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Petcherski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chandrachud</surname><given-names>U.</given-names></name><name name-style="western"><surname>Butz</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W.N.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Haggarty</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Ruonala</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Cotman</surname><given-names>S.L.</given-names></name></person-group><article-title>An Autophagy Modifier Screen Identifies Small Molecules Capable of Reducing Autophagosome Accumulation in a Model of CLN3-Mediated Neurodegeneration</article-title><source>Cells</source><volume>8</volume><year>2019</year><object-id pub-id-type="publisher-id">1531</object-id><pub-id pub-id-type="doi">10.3390/cells8121531</pub-id><pub-id pub-id-type="pmcid">PMC6953052</pub-id><pub-id pub-id-type="pmid">31783699</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Jana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Poddar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pahan</surname><given-names>K.</given-names></name></person-group><article-title>Activation of PPARalpha exhibits therapeutic efficacy in a mouse model of juvenile neuronal ceroid lipofuscinosis</article-title><source>J. Neurosci.</source><volume>43</volume><year>2023</year><fpage>1814</fpage><lpage>1829</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2447-21.2023</pub-id><pub-id pub-id-type="pmid">36697260</pub-id><pub-id pub-id-type="pmcid">PMC10010460</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Soldati</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lopez-Fabuel</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wanderlingh</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Garcia-Macia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Monfregola</surname><given-names>J.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>A.</given-names></name><name name-style="western"><surname>Napolitano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guevara-Ferrer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scotto Rosato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Krogsaeter</surname><given-names>E.K.</given-names></name><etal/></person-group><article-title>Repurposing of tamoxifen ameliorates CLN3 and CLN7 disease phenotype</article-title><source>EMBO Mol. Med.</source><volume>13</volume><year>2021</year><object-id pub-id-type="publisher-id">e13742</object-id><pub-id pub-id-type="doi">10.15252/emmm.202013742</pub-id><pub-id pub-id-type="pmcid">PMC8495452</pub-id><pub-id pub-id-type="pmid">34411438</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Nyame</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hims</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aburous</surname><given-names>A.</given-names></name><name name-style="western"><surname>Laqtom</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Medoh</surname><given-names>U.N.</given-names></name><name name-style="western"><surname>Heiby</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abu-Remaileh</surname><given-names>M.</given-names></name></person-group><article-title>Glycerophosphodiesters inhibit lysosomal phospholipid catabolism in Batten disease</article-title><source>Mol. Cell</source><volume>84</volume><year>2024</year><fpage>1354</fpage><lpage>1364.e9</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2024.02.006</pub-id><pub-id pub-id-type="pmid">38447580</pub-id><pub-id pub-id-type="pmcid">PMC10999246</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Ryazantsev</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.Z.</given-names></name><name name-style="western"><surname>Neufeld</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Ohmi</surname><given-names>K.</given-names></name></person-group><article-title>Lysosomal accumulation of SCMAS (subunit c of mitochondrial ATP synthase) in neurons of the mouse model of mucopolysaccharidosis III B</article-title><source>Mol. Genet. Metab.</source><volume>90</volume><year>2007</year><fpage>393</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2006.11.006</pub-id><pub-id pub-id-type="pmid">17185018</pub-id><pub-id pub-id-type="pmcid">PMC1892176</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Chandrachud</surname><given-names>U.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Simas</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Heetveld</surname><given-names>S.</given-names></name><name name-style="western"><surname>Petcherski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W.N.</given-names></name><name name-style="western"><surname>Norton</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Unbiased Cell-based Screening in a Neuronal Cell Model of Batten Disease Highlights an Interaction between Ca2+ Homeostasis, Autophagy, and CLN3 Protein Function</article-title><source>J. Biol. Chem.</source><volume>290</volume><year>2015</year><fpage>14361</fpage><lpage>14380</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.621706</pub-id><pub-id pub-id-type="pmid">25878248</pub-id><pub-id pub-id-type="pmcid">PMC4505505</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cotman</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>Y.K.</given-names></name></person-group><article-title>Lithium rescues the impaired autophagy process in CbCln3(Deltaex7/8/Deltaex7/8) cerebellar cells and reduces neuronal vulnerability to cell death via IMPase inhibition</article-title><source>J. Neurochem.</source><volume>116</volume><year>2011</year><fpage>659</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2010.07158.x</pub-id><pub-id pub-id-type="pmid">21175620</pub-id><pub-id pub-id-type="pmcid">PMC4517618</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Vidal-Donet</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>C&#225;rcel-Trullols</surname><given-names>J.</given-names></name><name name-style="western"><surname>Casanova</surname><given-names>B.</given-names></name><name name-style="western"><surname>Aguado</surname><given-names>C.</given-names></name><name name-style="western"><surname>Knecht</surname><given-names>E.</given-names></name></person-group><article-title>Alterations in ROS activity and lysosomal pH account for distinct patterns of macroautophagy in LINCL and JNCL fibroblasts</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e55526</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0055526</pub-id><pub-id pub-id-type="pmcid">PMC3567113</pub-id><pub-id pub-id-type="pmid">23408996</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Markham</surname><given-names>A.</given-names></name></person-group><article-title>Cerliponase Alfa: First Global Approval</article-title><source>Drugs</source><volume>77</volume><year>2017</year><fpage>1247</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1007/s40265-017-0771-8</pub-id><pub-id pub-id-type="pmid">28589525</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Schulz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ajayi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Specchio</surname><given-names>N.</given-names></name><name name-style="western"><surname>de Los Reyes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gissen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ballon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dyke</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Cahan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Slasor</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jacoby</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Study of Intraventricular Cerliponase Alfa for CLN2 Disease</article-title><source>N. Engl. J. Med.</source><volume>378</volume><year>2018</year><fpage>1898</fpage><lpage>1907</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1712649</pub-id><pub-id pub-id-type="pmid">29688815</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>De</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Selvan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>I.</given-names></name><name name-style="western"><surname>Yusufzai</surname><given-names>N.</given-names></name><name name-style="western"><surname>Greco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kaminsky</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Heier</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Ricart Arbona</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Miranda</surname><given-names>I.C.</given-names></name><etal/></person-group><article-title>Assessment of Safety and Biodistribution of AAVrh.10hCLN2 Following Intracisternal Administration in Nonhuman Primates for the Treatment of CLN2 Batten Disease</article-title><source>Hum. Gene Ther.</source><volume>34</volume><year>2023</year><fpage>905</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1089/hum.2023.067</pub-id><pub-id pub-id-type="pmid">37624739</pub-id><pub-id pub-id-type="pmcid">PMC10517331</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Elleder</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sokolov&#225;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hreb&#237;cek</surname><given-names>M.</given-names></name></person-group><article-title>Follow-up study of subunit c of mitochondrial ATP synthase (SCMAS) in Batten disease and in unrelated lysosomal disorders</article-title><source>Acta Neuropathol.</source><volume>93</volume><year>1997</year><fpage>379</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1007/s004010050629</pub-id><pub-id pub-id-type="pmid">9113203</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="other" id="sref47"><article-title>Protocol 19998: Separated PCR Assay - Cln3&lt;tm1Nbm&gt;-Alternate 2</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.jax.org/Protocol?stockNumber=029471&amp;protocolID=19998" id="intref0015">https://www.jax.org/Protocol?stockNumber=029471&amp;protocolID=19998</ext-link></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>El-Banna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sohar</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sleat</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Lobel</surname><given-names>P.</given-names></name></person-group><article-title>Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis</article-title><source>Mol. Ther.</source><volume>19</volume><year>2011</year><fpage>1842</fpage><lpage>1848</lpage><pub-id pub-id-type="doi">10.1038/mt.2011.130</pub-id><pub-id pub-id-type="pmid">21730969</pub-id><pub-id pub-id-type="pmcid">PMC3188738</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Sleat</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Maita</surname><given-names>I.</given-names></name><name name-style="western"><surname>Banach-Petrosky</surname><given-names>W.</given-names></name><name name-style="western"><surname>Larrimore</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>L.</given-names></name><name name-style="western"><surname>Maxfield</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Samuels</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lobel</surname><given-names>P.</given-names></name></person-group><article-title>Elevated levels of tripeptidyl peptidase 1 do not ameliorate pathogenesis in a mouse model of Alzheimer disease</article-title><source>Neurobiol. Aging</source><volume>118</volume><year>2022</year><fpage>106</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2022.06.012</pub-id><pub-id pub-id-type="pmid">35914472</pub-id><pub-id pub-id-type="pmcid">PMC11258943</pub-id></element-citation></ref></ref-list><sec id="appsec2" sec-type="supplementary-material"><title>Supplemental information</title><p id="p0180">
<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Document S1. Figure S1 and supplemental methods</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.pdf" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc2" position="float" orientation="portrait"><caption><title>Document S2. Article plus supplemental information</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc2.pdf" position="float" orientation="portrait"/></supplementary-material>
</p></sec><fn-group><fn id="appsec1" fn-type="supplementary-material"><p id="p0175">Supplemental information can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.omtm.2025.101587" id="intref0010">https://doi.org/10.1016/j.omtm.2025.101587</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">464</journal-id><journal-id journal-id-type="pmc-domain">sageopen</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Journal of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">1387-2877</issn><issn pub-type="epub">1875-8908</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Sage Choice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12495103</article-id><article-id pub-id-type="pmcid-ver">PMC12495103.1</article-id><article-id pub-id-type="pmcaid">12495103</article-id><article-id pub-id-type="pmcaiid">12495103</article-id><article-id pub-id-type="pmid">40879406</article-id><article-id pub-id-type="doi">10.1177/13872877251371236</article-id><article-id pub-id-type="publisher-id">10.1177_13872877251371236</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>Effects of an immersive virtual reality reminiscence intervention on engagement, behavioral and psychological symptoms, and well-being of people with dementia: A randomized crossover trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-7788-5815</contrib-id><name name-style="western"><surname>Pereira</surname><given-names initials="M">Miguel</given-names></name><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff1-13872877251371236" ref-type="aff">1</xref><xref rid="corresp1-13872877251371236" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Leite</surname><given-names initials="C">Cl&#225;udia</given-names></name><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff1-13872877251371236" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5966-4050</contrib-id><name name-style="western"><surname>Campos</surname><given-names initials="C">Carlos</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="https://credit.niso.org/contributor-roles/software/">Software</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff2-13872877251371236" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7847-2401</contrib-id><name name-style="western"><surname>Coelho</surname><given-names initials="T">Tiago</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="https://credit.niso.org/contributor-roles/software/">Software</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff3-13872877251371236" ref-type="aff">3</xref></contrib></contrib-group><aff id="aff1-13872877251371236">
<label>1</label><institution-wrap><institution-id institution-id-type="Ringgold">203255</institution-id><institution content-type="university">E2S, Polytechnic of Porto</institution></institution-wrap>, Porto, Portugal</aff><aff id="aff2-13872877251371236">
<label>2</label><institution-wrap><institution-id institution-id-type="Ringgold">386292</institution-id><institution content-type="university">Lus&#243;fona University, HEI-Lab: Digital Human-Environment Interaction Labs and LabRP/CIR, E2S, Polytechnic of Porto</institution></institution-wrap>, Porto, Portugal</aff><aff id="aff3-13872877251371236">
<label>3</label><institution-wrap><institution-id institution-id-type="Ringgold">203255</institution-id><institution content-type="university">LabRP/CIR, E2S, Polytechnic of Porto</institution></institution-wrap>, Porto, Portugal</aff><author-notes><corresp id="corresp1-13872877251371236">Miguel Ara&#250;jo Pereira, E2S, Polytechnic of Porto, R. Dr Ant&#243;nio Bernardino de Almeida, 400, 4200-072 Porto, Portugal. Email: <email>miguelpereira.to@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>107</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">498304</issue-id><fpage>1517</fpage><lpage>1529</lpage><history><date date-type="received"><day>21</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>2</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-05 00:26:29.067"><day>05</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_13872877251371236.pdf"/><abstract><sec><title>Background</title><p>Virtual reality (VR) is a novel technology that can facilitate reminiscence in people with dementia. However, few studies have explored the role of VR's immersiveness in enhancing therapeutic outcomes.</p></sec><sec><title>Objective</title><p>This study aimed to analyze the effects of an immersive VR reminiscence session compared to a non-immersive session, focusing on engagement, behavioral and psychological symptoms (BPSD), and well-being, using behavioral observation and physiological metrics.</p></sec><sec><title>Methods</title><p>A randomized crossover trial with a seven-day washout period was conducted. Engagement, BPSD and well-being were assessed before, during and after each intervention using both observational scales and heart rate variability analysis.</p></sec><sec><title>Results</title><p>20 participants (average age 80.55 years, 90% women) were recruited. Significant pre-post differences were found in behavioral engagement (z&#8201;=&#8201;&#8722;2.67, p&#8201;=&#8201;0.008) and facial expression of apathy (z&#8201;=&#8201;&#8722;2.12, p&#8201;=&#8201;0.034) during the immersive intervention. Additionally, lower apathy in terms of purposeful activity was observed during the immersive intervention (z&#8201;=&#8201;&#8722;2.24, p&#8201;=&#8201;0.025). These results are particularly noteworthy given the sample size, which, although small, highlights a clear trend of behavioral and apathy change.</p></sec><sec><title>Conclusions</title><p>The results suggest that VR's immersiveness can enhance engagement in dementia intervention programs. As VR technology becomes more accessible and safer, continued research is needed to explore its therapeutic potential.</p></sec></abstract><kwd-group><kwd>Alzheimer's disease</kwd><kwd>behavioral and psychological symptoms</kwd><kwd>dementia</kwd><kwd>engagement</kwd><kwd>heart rate variability</kwd><kwd>reminiscence therapy</kwd><kwd>virtual reality</kwd><kwd>well-being</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="award1-13872877251371236"><funding-source id="funding1-13872877251371236"><institution-wrap><institution>Funda&#231;&#227;o para a Ci&#234;ncia e a Tecnologia</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001871</institution-id></institution-wrap></funding-source><award-id rid="funding1-13872877251371236">UIDB/05210/2020</award-id><award-id rid="funding1-13872877251371236">UIDB/05380/2020</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts19</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="section1-13872877251371236"><title>Introduction</title><p>Dementia is a progressive neurodegenerative syndrome marked by a decline in cognitive skills and daily functioning, often accompanied by behavioral and psychological symptoms in dementia (BPSD),<sup><xref rid="bibr1-13872877251371236" ref-type="bibr">1</xref>,<xref rid="bibr2-13872877251371236" ref-type="bibr">2</xref></sup> such as aggression, agitation, apathy, and depression.<sup><xref rid="bibr3-13872877251371236" ref-type="bibr">3</xref>,<xref rid="bibr4-13872877251371236" ref-type="bibr">4</xref></sup> These symptoms negatively impact the quality of life (QoL) and well-being of people with dementia and their families.<sup><xref rid="bibr5-13872877251371236" ref-type="bibr">5</xref>,<xref rid="bibr6-13872877251371236" ref-type="bibr">6</xref></sup> In 2023, it was estimated that 55 million people worldwide had dementia, with over 60% of them residing in low- or middle-income countries, and around 10 million new cases annually.<sup>
<xref rid="bibr7-13872877251371236" ref-type="bibr">7</xref>
</sup> Dementia is the seventh leading cause of mortality worldwide and significantly contributes to dependency and disability among older adults.<sup>
<xref rid="bibr7-13872877251371236" ref-type="bibr">7</xref>
</sup></p><p>Non-pharmacological therapies are recommended as first-line treatments for BPSD,<sup><xref rid="bibr8-13872877251371236" ref-type="bibr">8</xref>,<xref rid="bibr9-13872877251371236" ref-type="bibr">9</xref></sup> as traditional medications can lead to adverse effects, including increased fall risk and mortality.<sup><xref rid="bibr10-13872877251371236" ref-type="bibr">10</xref>,<xref rid="bibr11-13872877251371236" ref-type="bibr">11</xref></sup> According to recent systematic reviews, various non-pharmacological interventions, such as sensory stimulation, cognitive therapies, and behavioral management techniques, have been shown to reduce BPSD and improve cognitive function, daily living activities, and social interaction,<sup><xref rid="bibr12-13872877251371236" ref-type="bibr">12</xref>,<xref rid="bibr13-13872877251371236" ref-type="bibr">13</xref></sup> ultimately enhancing independence and increase QoL.<sup><xref rid="bibr6-13872877251371236" ref-type="bibr">6</xref>,<xref rid="bibr14-13872877251371236" ref-type="bibr">14</xref></sup></p><p>Non-pharmacological interventions have also been studied as beneficial to the well-being of people with dementia,<sup><xref rid="bibr6-13872877251371236" ref-type="bibr">6</xref>,<xref rid="bibr15-13872877251371236" ref-type="bibr">15</xref></sup> primarily assessed through self-report scales and observation, with some studies measuring physiological metrics that translates into improvements in well-being by analyzing heart rate variability (HRV) and the autonomic nervous system (ANS).<sup><xref rid="bibr16-13872877251371236" ref-type="bibr">16</xref>,<xref rid="bibr17-13872877251371236" ref-type="bibr">17</xref></sup> These metrics, though less commonly used, offer deeper insight into the effects of such interventions on brain activity and emotional states.<sup>
<xref rid="bibr18-13872877251371236" ref-type="bibr">18</xref>
</sup></p><p>Reminiscence therapy (RT) was introduced to dementia care in the late 1970s<sup><xref rid="bibr19-13872877251371236" ref-type="bibr">19</xref>,<xref rid="bibr20-13872877251371236" ref-type="bibr">20</xref></sup> and utilizes materials such as photographs, familiar items from the past and music to evoke memories and encourage people to share and cherish their past experiences, enhancing well-being.<sup><xref rid="bibr12-13872877251371236" ref-type="bibr">12</xref>,<xref rid="bibr21-13872877251371236" ref-type="bibr">21</xref></sup> RT has been demonstrated to be beneficial for managing BPSD,<sup><xref rid="bibr22-13872877251371236" ref-type="bibr">22</xref>,<xref rid="bibr23-13872877251371236" ref-type="bibr">23</xref></sup> such as depression, anxiety and mood.<sup><xref rid="bibr24-13872877251371236" ref-type="bibr">24</xref>,<xref rid="bibr25-13872877251371236" ref-type="bibr">25</xref></sup> It leverages individuals&#8217; stronger recall of early life events, promoting engagement in therapy and self-identity.<sup><xref rid="bibr21-13872877251371236" ref-type="bibr">21</xref>,<xref rid="bibr26-13872877251371236" ref-type="bibr">26</xref></sup></p><p>Digital technologies have introduced innovative reminiscence tools, notably virtual reality (VR), which can enhance memory recall and encourage reminiscence through immersive experiences.<sup><xref rid="bibr27-13872877251371236" ref-type="bibr">27</xref>,<xref rid="bibr28-13872877251371236" ref-type="bibr">28</xref></sup> VR is a term that refers to the set of hardware and software components that replicate a simulated environment, enabling users to interact with three-dimensional computer-generated environments or 360&#176; video footage.<sup>
<xref rid="bibr29-13872877251371236" ref-type="bibr">29</xref>
</sup> VR comes in different forms, ranging from fully immersive systems to non-immersive. Non-immersive systems frequently use a computer monitor to interact with the virtual environment.<sup>
<xref rid="bibr30-13872877251371236" ref-type="bibr">30</xref>
</sup> Systems that offer completely immersive experiences include the user feeling physically present within a virtual environment using a head-mounted display (HMD) or a Cave, by reducing real-life stimuli.<sup>
<xref rid="bibr30-13872877251371236" ref-type="bibr">30</xref>
</sup></p><p>According to recent studies, immersive VR is safe, well-tolerated, and able to encourage engagement and give dementia patients enjoyable experiences.<sup><xref rid="bibr28-13872877251371236" ref-type="bibr">28</xref>,<xref rid="bibr31-13872877251371236" ref-type="bibr">31</xref></sup> Also, Rose et al.'s study revealed that dementia participants frequently reminisced and spontaneously reenacted stories from their past when they watched 360&#176; videos of places that appeared familiar and important to each person's life experience.<sup>
<xref rid="bibr29-13872877251371236" ref-type="bibr">29</xref>
</sup></p><p>With inconsistent findings, numerous studies have also investigated the efficacy of VR for decreasing BPSD and enhancing the QoL for dementia patients.<sup><xref rid="bibr32-13872877251371236" ref-type="bibr">32</xref>,<xref rid="bibr33-13872877251371236" ref-type="bibr">33</xref></sup> In particular, some VR reminiscence studies observed that this intervention can be feasible,<sup>
<xref rid="bibr34-13872877251371236" ref-type="bibr">34</xref>
</sup> safe,<sup>
<xref rid="bibr35-13872877251371236" ref-type="bibr">35</xref>
</sup> well-accepted<sup>
<xref rid="bibr36-13872877251371236" ref-type="bibr">36</xref>
</sup> and promotes positive levels of comfort, pleasure, satisfaction with the experience,<sup>
<xref rid="bibr37-13872877251371236" ref-type="bibr">37</xref>
</sup> and engagement to social interactions.<sup>
<xref rid="bibr38-13872877251371236" ref-type="bibr">38</xref>
</sup></p><p>Despite these promising benefits, in the context of dementia care, VR reminiscence interventions are novel and under researched.<sup>
<xref rid="bibr36-13872877251371236" ref-type="bibr">36</xref>
</sup> Moreover, most studies that evaluate the effect of RT or RT using VR on people with dementia evaluate using questionnaires and behavioral measures, with few studies evaluating people's physiological metrics during the intervention.<sup><xref rid="bibr36-13872877251371236" ref-type="bibr">36</xref>,<xref rid="bibr39-13872877251371236" ref-type="bibr">39</xref></sup> With all this in mind, the aim of this study was to analyze the effect of an immersive VR reminiscence session compared to a non-immersive reminiscence session, in terms of engagement, BPSD and well-being in people with dementia, using behavioral observation and measurement of physiological metrics during interventions.</p><p>Considering the objective of the present study, the following hypothesis was determined for this study:</p><statement><label>H1:</label><p>The application of a reminiscence intervention using immersive VR (HMD) contributes to a greater engagement, less BSPD and to a greater well-being in session compared to a non-immersive reminiscence intervention (monitor), using 360&#176; videos from locations relevant to the participants.</p></statement></sec><sec id="section2-13872877251371236"><title>Methods</title><sec id="section2A-13872877251371236"><title>Recruitment</title><p>This study was a randomized crossover trial, with each participant undergoing two interventions: an immersive VR reminiscence session and a non-immersive reminiscence session, separated by a seven-day washout period.<sup>
<xref rid="bibr40-13872877251371236" ref-type="bibr">40</xref>
</sup> Which intervention each participant performed first was randomized.</p><p>Ethics approval was obtained from the E2S &#8211; Polytechnic of Porto (CE0031E). Institutions were contacted via email to recruit participants, and consent was secured from the participant or the participants&#8217; families, adhering to the Declaration of Helsinki.<sup>
<xref rid="bibr41-13872877251371236" ref-type="bibr">41</xref>
</sup> The consent form outlined the study's objectives, procedures, confidentiality measures, and participants&#8217; rights to withdraw at any time without penalty.</p><p>Participants were recruited through non-probabilistic convenience sampling from dementia care institutions accessible to researchers. A sample of 22 participants was recruited considering as inclusion criteria having diagnosis of dementia. Considered exclusion criteria were: severe visual deficits that prevented them from experiencing the videos, severe communication deficits that do not allowed them to express their life stories, as well as describe their sensations during the intervention, score of 7 on the Global Deterioration Scale (GDS)<sup>
<xref rid="bibr42-13872877251371236" ref-type="bibr">42</xref>
</sup> which represents an advanced stage of the dementia process, having a diagnosis of Lewy body type dementia due to the likelihood of visual hallucinations, and having severe motor limitations that prevented the active exploration of the videos. Within this sample of participants, 11 began the intervention with an immersive approach and 11 began with a non-immersive approach. However, 2 participants were excluded from the study after it was started, as shown in <xref rid="fig1-13872877251371236" ref-type="fig">Figure 1</xref>.</p><fig position="float" id="fig1-13872877251371236" orientation="portrait"><label>Figure 1.</label><caption><p>CONSORT flow diagram.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251371236-fig1.jpg"/></fig></sec><sec id="section2B-13872877251371236"><title>Measurements</title><p>The level of dementia progression was measured with the Global Deterioration Scale (GDS).<sup><xref rid="bibr42-13872877251371236" ref-type="bibr">42</xref>,<xref rid="bibr43-13872877251371236" ref-type="bibr">43</xref></sup> The Engagement of a Person with Dementia Scale (EPWDS)<sup>
<xref rid="bibr44-13872877251371236" ref-type="bibr">44</xref>
</sup> was used to assess engagement during the session, the Person-Environment Apathy Rating (PEAR)<sup>
<xref rid="bibr45-13872877251371236" ref-type="bibr">45</xref>
</sup> was used to assess apathy, a commonly BPSD, before, during and after the session, the Observed Emotion Rating Scale (OERS)<sup>
<xref rid="bibr46-13872877251371236" ref-type="bibr">46</xref>
</sup> was used to assess BPSD during the session, such as pleasure, anger, anxiety/fear, sadness and general alertness, the Observable Well-Being in Living With Dementia Scale (OWLS)<sup>
<xref rid="bibr47-13872877251371236" ref-type="bibr">47</xref>
</sup> was used to assess well-being during the session. Furthermore, a questionnaire was developed to characterize the participants regarding sex, birth date, marital status and education years. After each session, to evaluate the participant's self-perception of the experience, a Likert scale from 1 to 5 was also created with the following questions: &#8220;Did you like the experience?&#8221;, &#8220;How was the experience?&#8221;, &#8220;How motivated are you to do this activity again?&#8221;, &#8220;Interested in seeing other places?&#8221;, &#8220;How well did you manage to watch the video?&#8221; and &#8220;How comfortable was the activity?&#8221;. To analyze the psychophysiological metrics, electrocardiography (ECG)<sup>
<xref rid="bibr48-13872877251371236" ref-type="bibr">48</xref>
</sup> was used to assess engagement and well-being during the session, through the HRV and ANS activity.</p><p>The GDS<sup>
<xref rid="bibr42-13872877251371236" ref-type="bibr">42</xref>
</sup> is a scale that identifies the stage of degenerative dementia and encompasses functional and cognitive deficits. It is a seven-level rating scale in which level 1 reflects no cognitive decline, level 2 reflects very mild cognitive decline, and levels 3 through 7 are defined, respectively, as mild, moderate, moderately severe, severe, and very severe cognitive impairment. Each level is associated with clinical stages ranging from normal (level 1) to late-onset dementia (level 7). This scale is completed with the help of professionals from the institutions.</p><p>The EPWDS<sup>
<xref rid="bibr44-13872877251371236" ref-type="bibr">44</xref>
</sup> is a scale that assesses and measures the degree of engagement of participants during interventions. It consists of five categories of engagement: affective, visual, verbal, behavioral and social engagement. Each category is divided into two items, one of which is perceived as positive involvement and the other as negative involvement. The total score varies from ten to fifty points, and the higher the total score, the greater the positive engagement demonstrated by the person. Each item is scored according to a five-point Likert scale (from 1 to 5). In terms of internal consistency, the Cronbach's alpha is 0.94.<sup>
<xref rid="bibr44-13872877251371236" ref-type="bibr">44</xref>
</sup></p><p>The PEAR<sup>
<xref rid="bibr45-13872877251371236" ref-type="bibr">45</xref>
</sup> is a scale used to assess participants&#8217; apathy before, during and after sessions. Apathy is measured by looking at six indicators: facial expressions, eye contact, physical engagement, purposeful activity, verbal tone and verbal expression, on a scale of 1 to 4, with higher scores indicating a greater level of apathy. This scale can also be an aid to assess engagement based on apathy levels. In terms of internal consistency, the Cronbach's alpha is 0.85 for the PEAR-Apathy subscale version.<sup>
<xref rid="bibr45-13872877251371236" ref-type="bibr">45</xref>
</sup></p><p>The OERS<sup>
<xref rid="bibr46-13872877251371236" ref-type="bibr">46</xref>
</sup> is an observational scale to assess two positive emotions (pleasure and general alertness) and three negative emotions (anger, anxiety or fear, and sadness). During a 10-min period, the researcher chooses one of six possible defined time intervals (e.g., 1&#8201;=&#8201;never; 2&#8201;=&#8201;&lt;16&#8197;s; 3&#8201;=&#8201;16&#8211;59&#8197;s; 4&#8201;=&#8201;1&#8211;5&#8197;min; 5&#8201;=&#8201;&gt;5&#8197;min; and 7&#8201;=&#8201;not in sight) that a target subject demonstrates each of the five emotions. Higher scores indicate longer duration of expression of that emotion.</p><p>The OWLS<sup>
<xref rid="bibr47-13872877251371236" ref-type="bibr">47</xref>
</sup> is an instrument used to code observed expressions of well-being in people with dementia when participating in activities. The person is observed for 30&#8197;s. All items are scored dichotomously as &#8220;1&#8221; if present and &#8220;0&#8221; if not present. It consists of eight categories of well-being: attention, initiative/responsiveness, relaxation, happiness, pleasure, expressions of identity, mastery and relationships. For each category, a scale of 1&#8211;10 is used to evaluate the relative frequency during the 30-s intervals. The higher the score, the higher the levels of well-being. In terms of internal consistency, the inter-rater reliability's Cohen's Kappa is 0.82 and the intra-rater reliability's Cohen's Kappa is 0.98.<sup>
<xref rid="bibr47-13872877251371236" ref-type="bibr">47</xref>
</sup></p><p>Heart rate variability (HRV) data were recorded using electrocardiography (ECG),<sup>
<xref rid="bibr48-13872877251371236" ref-type="bibr">48</xref>
</sup> assessing emotional activation through time-domain parameters like: Mean HR, since its variability is closely related to emotional activation<sup><xref rid="bibr48-13872877251371236" ref-type="bibr">48</xref>,<xref rid="bibr49-13872877251371236" ref-type="bibr">49</xref></sup>; SDNN, which is the standard deviation of all R-R intervals, to analyze the cyclic components responsible for HRV; RMSSD, described as the root mean square of successive differences, to analyze parasympathetic nervous system (PNS); pNN50, which is the percentage of successive normal sinus RR intervals more than 50&#8197;ms, to also analyze PNS.<sup><xref rid="bibr49-13872877251371236" ref-type="bibr">49</xref><xref rid="bibr50-13872877251371236" ref-type="bibr"/><xref rid="bibr51-13872877251371236" ref-type="bibr"/>-<xref rid="bibr52-13872877251371236" ref-type="bibr">52</xref></sup> In terms of Frequency Domain (FFT Welch Method) on Low frequencies (LF) (0.04&#8197;Hz, 0.15&#8197;Hz), to analyze the mix of sympathetic and parasympathetic activity and the baroreflex activity, and High frequencies (HF) (0.15&#8197;Hz, 0.4&#8197;Hz), to analyze the PNS, were used: Peak Frequencies and Absolute Powers.<sup><xref rid="bibr49-13872877251371236" ref-type="bibr">49</xref><xref rid="bibr50-13872877251371236" ref-type="bibr"/><xref rid="bibr51-13872877251371236" ref-type="bibr"/>-<xref rid="bibr52-13872877251371236" ref-type="bibr">52</xref></sup> Moreover, the Total Power, which is the sum of the energy in the LF and HF bands, and LF/HF Ratio, which is the ratio between sympathetic nervous system (SNS) and PNS, were also analyzed.<sup>
<xref rid="bibr53-13872877251371236" ref-type="bibr">53</xref>
</sup> On Non-linear indices were used: SD1, which is the standard deviation &#8211; Poincar&#233; plot Crosswise, to analyze quick and high frequent changes in HR variability; SD2, which is the standard deviation &#8211; Poincar&#233; plot Lengthwise, to analyze long-term changes in HRV.<sup><xref rid="bibr49-13872877251371236" ref-type="bibr">49</xref><xref rid="bibr50-13872877251371236" ref-type="bibr"/><xref rid="bibr51-13872877251371236" ref-type="bibr"/>-<xref rid="bibr52-13872877251371236" ref-type="bibr">52</xref></sup></p></sec><sec id="section2C-13872877251371236"><title>Intervention</title><p>Prior to data collection, the evaluation protocol and methods were established by the research team. Authorization for the assessment scales was obtained from the respective authors, and translated versions were utilized for outcome evaluation. Researchers received training on the protocol, followed by a pilot evaluation phase involving relatives and older adults to test its effectiveness. Adjustments were made based on pilot feedback before initiating sessions with participants.</p><p>In the pre-intervention session, participants and their caregivers identified a significant location from a pre-filmed list, and the characterization questionnaire was completed. Researchers confirmed this information with caregivers to ensure accuracy. To maintain confidentiality, each participant was assigned an alphanumeric code. During this period, institutional professionals completed the GDS for each participant.</p><p>Regarding the intervention, each participant was exposed to two sessions, separated by a seven-day washout period. One session involved viewing a significant location video using the <italic toggle="yes">Oculus Quest 2</italic> HMD, after a demonstration of the device. Participants first viewed a neutral video (library) for 2&#8211;3&#8197;min to familiarize themselves with the HMD, followed by the significant location video for 5&#8211;6&#8197;min. In the other session, the same intervention structure was used, using a computer monitor and a mouse to explore it. There was randomization of participants regarding which session they would perform first, carried out by a researcher not involved in data collection and intervention. Sessions lasted 20&#8211;30&#8197;min and took place in the participant's preferred setting between May and July 2024.</p><p>During exposure to the two experimental conditions, the participant's peripheral physiological activity was recorded using the BITalino Core BT/BLE amplifier (acquisition frequency 1000&#8197;Hz). More specifically, the heart rate (HR) and HRV were collected through ECG with 3 electrodes placed on the trunk (positive electrode on the right clavicle; negative electrode on the left iliac crest; ground electrode on the clavicle left). The procedure consists of a non-invasive, painless collection with no known side effects. To apply the electrodes, it was necessary to clean the area of the skin where the electrodes were applied with alcohol and abrasive gel, to remove any residue that could interfere with collection. The electrodes were subsequently fixed using tape (adhesive tape suitable for application to the skin). Precautions were only necessary when cleaning and preparing the skin of participants with skin problems and/or open wounds in the positions where the electrodes were to be placed. After placing the electrodes, the participant was asked to remain relaxed and silent for 5&#8197;min so that their physiological signals could return to a normal state. After 5&#8197;min, physiological signals were recorded at rest for 2&#8197;min. Physiological signals were also recorded throughout the period of habituation and exposure to the significant location video.</p><p>Various assessment instruments were applied before, during, and after the sessions to evaluate engagement, BPSD, and well-being. During the sessions, in both interventions, the researchers asked several questions, following a previously defined guide, to allow greater discussion and communication with the participant. With the aim of discussing the observed behaviors with the entire research team and the researchers present could focus on the parameters of the protocol and the personal stories that the participants were describing, the session was filmed, in accordance with the consent of the participant and caregivers. The camera was placed in front of the participant to capture their entire body and all their movements and reactions. Filming captured participants from entry to exit. After each session, the participant's self-perception of the experience scale was applied. Data collection was carried out by two properly trained researchers who followed the same data collection protocol.</p></sec><sec id="section2D-13872877251371236"><title>Statistical analysis</title><p>Statistical analysis was performed using the IBM Statistical Package for the Social Science (SPSS) version 29 software. First, descriptive statistics were used to present the characteristics of the participants and the instruments results. According to the nature of the variables, categorical variables were presented as number (n) and percentages (%) and continuous variables were presented with the mean (M), standard deviation (SD), minimum and maximum values.</p><p>Subsequently, to be able to analyze the differences between the two interventions, immersive and non-immersive, through the results of the different scales, the paired samples t-test was applied, whenever the normality of the variables was assumed. When this assumption was not assumed, the respective non-parametric test, the Wilcoxon signed-rank test, was applied.</p><p>The statistical assumptions for carrying out the tests were validated through the normality analysis of the Shapiro-Wilk test variables, with the normal distribution of variables being assumed whenever the p-value was greater than the significance level. A significant level of 0.05 was considered when carrying out all statistical tests.</p><p>Regarding ECG data, data preprocessing and measure extraction was conducted using the pyHRV Python Toolbox pipeline. Processing of ECG included signal filtering (3&#8197;Hz&#8211;45&#8197;Hz), R-peak detection (Hamilton-Tompkins algorithm) and lastly feature extraction.<sup><xref rid="bibr54-13872877251371236" ref-type="bibr">54</xref>,<xref rid="bibr55-13872877251371236" ref-type="bibr">55</xref></sup> Outliers were removed using the 3 interquartile range criteria<sup>
<xref rid="bibr56-13872877251371236" ref-type="bibr">56</xref>
</sup> and the statistical significance threshold was set at 0.05. Descriptive and inferential statistics were computed using SPSS. For inferential statistics, parametric tests were used whenever data distribution was deemed approximately normal using threshold criteria for skewness and kurtosis &#8211; less than |2.0| and |9.0|, respectively.<sup>
<xref rid="bibr56-13872877251371236" ref-type="bibr">56</xref>
</sup> Additionally, two-way repeated-measures ANOVAs were implemented for comparing the three conditions in the two types of interventions. For these models, sphericity was tested using Mauchly's test. The Huynh-Feldt correction was employed whenever this assumption was not met and the epsilon was higher than 0.57; otherwise, the Greenhouse-Geisser correction was used.<sup>
<xref rid="bibr56-13872877251371236" ref-type="bibr">56</xref>
</sup></p></sec></sec><sec id="section3-13872877251371236"><title>Results</title><sec id="section3A-13872877251371236"><title>Sample characteristics</title><p>According to <xref rid="table1-13872877251371236" ref-type="table">Table 1</xref>, the study included 20 participants, aged between 68 and 93 (M&#8201;=&#8201;80.55&#8201;&#177;&#8201;6.69), the majority were female (n&#8201;=&#8201;18, 90%) and 11 participants were widows (55%). Regarding education, the average number of years spent studying by participants was 4.75 years (SD&#8201;&#177;&#8201;2.07). The most common level of deterioration, classified by the GDS, was moderate cognitive decline (n&#8201;=&#8201;10, 50%), with a mean scale score of 4.15 (SD&#8201;&#177;&#8201;0.81). For more detailed information, consult <xref rid="table1-13872877251371236" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="table1-13872877251371236" orientation="portrait"><label>Table 1.</label><caption><p>Sample characteristics, through sociodemographic variables and dementia stage, through the GDS scores.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251371236-table1.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="3" colspan="1"/><th align="left" rowspan="1" colspan="1">
<bold>Sample</bold>
</th></tr><tr><th align="left" rowspan="1" colspan="1">
<bold>n&#8201;=&#8201;20</bold>
</th></tr><tr><th align="left" rowspan="1" colspan="1">
<bold>n (%)</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>Age (years)</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;Mean&#8201;&#177;&#8201;Standard deviation</bold>
</td><td rowspan="1" colspan="1">80.55&#8201;&#177;&#8201;6.69</td></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;Min-Max</bold>
</td><td rowspan="1" colspan="1">68&#8211;93</td></tr><tr><td rowspan="1" colspan="1">
<bold>Sex</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;Feminine</bold>
</td><td rowspan="1" colspan="1">18 (90)</td></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;Masculine</bold>
</td><td rowspan="1" colspan="1">2 (10)</td></tr><tr><td rowspan="1" colspan="1">
<bold>Education (years)</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;Mean&#8201;&#177;&#8201;Standard deviation</bold>
</td><td rowspan="1" colspan="1">4.75&#8201;&#177;&#8201;2.07</td></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;Min-Max</bold>
</td><td rowspan="1" colspan="1">0&#8211;9</td></tr><tr><td rowspan="1" colspan="1">
<bold>Marital status</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;Married</bold>
</td><td rowspan="1" colspan="1">6 (30)</td></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;Widow/er</bold>
</td><td rowspan="1" colspan="1">11 (55)</td></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;Single</bold>
</td><td rowspan="1" colspan="1">2 (10)</td></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;Divorced</bold>
</td><td rowspan="1" colspan="1">1 (5)</td></tr><tr><td rowspan="1" colspan="1">
<bold>GDS</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;Mild cognitive decline</bold>
</td><td rowspan="1" colspan="1">4 (20)</td></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;Moderate cognitive decline</bold>
</td><td rowspan="1" colspan="1">10 (50)</td></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;Moderately severe cognitive decline</bold>
</td><td rowspan="1" colspan="1">5 (25)</td></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;Severe cognitive decline</bold>
</td><td rowspan="1" colspan="1">1 (5)</td></tr><tr><td rowspan="1" colspan="1">
<bold>GDS score (1&#8211;7)</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;Mean&#8201;&#177;&#8201;Standard deviation</bold>
</td><td rowspan="1" colspan="1">4.15&#8201;&#177;&#8201;0.81</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="section3B-13872877251371236"><title>Comparison of engagement in the different interventions</title><p>In terms of engagement in the session, the results indicated that there was no significant difference between the immersive intervention and non-immersive intervention, t (19)&#8201;=&#8201;1.058, p&#8201;=&#8201;0.303. Analyzing the mean EPWDS scores, although there were no significant differences, considering the maximum EPWDS score, the mean obtained in the two interventions indicates that the engagement in both sessions was positive (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/13872877251371236" ext-link-type="uri">Supplemental Table 1</ext-link>). According to <xref rid="table2-13872877251371236" ref-type="table">Table 2</xref>, the results indicated that the behavioral engagement in session was significantly higher on immersive intervention (M&#8201;=&#8201;4.33, SD&#8201;=&#8201;0.52) compared to non-immersive intervention (M&#8201;=&#8201;4.05, SD&#8201;=&#8201;0.58), z&#8201;=&#8201;&#8722;2.67, p&#8201;=&#8201;0.008. Regarding all the remaining engagement indicators on the EPWDS scale, it was possible to conclude that there was no significant difference between the immersive and non-immersive intervention.</p><table-wrap position="float" id="table2-13872877251371236" orientation="portrait"><label>Table 2.</label><caption><p>Comparison of the immersive and non-immersive intervention according to the EPWDS categories scores.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251371236-table2.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" colspan="4" rowspan="1">Mean&#8201;&#177;&#8201;Standard deviation</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Immersive intervention</th><th align="left" rowspan="1" colspan="1">Non-immersive intervention</th><th align="left" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Affective engagement</td><td rowspan="1" colspan="1">4.20&#8201;&#177;&#8201;0.71</td><td rowspan="1" colspan="1">4.23&#8201;&#177;&#8201;0.67</td><td rowspan="1" colspan="1">0.816<sup>
<xref rid="table-fn1-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Visual engagement</td><td rowspan="1" colspan="1">4.70&#8201;&#177;&#8201;0.38</td><td rowspan="1" colspan="1">4.63&#8201;&#177;&#8201;0.39</td><td rowspan="1" colspan="1">0.499<sup>
<xref rid="table-fn1-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Verbal engagement</td><td rowspan="1" colspan="1">4.55&#8201;&#177;&#8201;0.39</td><td rowspan="1" colspan="1">4.58&#8201;&#177;&#8201;0.44</td><td rowspan="1" colspan="1">0.813<sup>
<xref rid="table-fn1-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Behavioral engagement</td><td rowspan="1" colspan="1">4.33&#8201;&#177;&#8201;0.52</td><td rowspan="1" colspan="1">4.05&#8201;&#177;&#8201;0.58</td><td rowspan="1" colspan="1">0.008<sup>
<xref rid="table-fn1-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Social engagement</td><td rowspan="1" colspan="1">4.23&#8201;&#177;&#8201;0.47</td><td rowspan="1" colspan="1">4.13&#8201;&#177;&#8201;0.53</td><td rowspan="1" colspan="1">0.356<sup>
<xref rid="table-fn1-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-13872877251371236"><label>
<sup>a</sup>
</label><p>value obtained using the Wilcoxon signed-rank test.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section3C-13872877251371236"><title>Comparison of behavioral and psychological symptoms in the different interventions</title><p>According to <xref rid="table3-13872877251371236" ref-type="table">Table 3</xref>, the results indicated that apathy on facial expressions during the session was significantly higher on immersive intervention (M&#8201;=&#8201;2.30, SD&#8201;=&#8201;0.80) compared to non-immersive intervention (M&#8201;=&#8201;2.00, SD&#8201;=&#8201;0.65), z&#8201;=&#8201;&#8722;2.12, p&#8201;=&#8201;0.034. It also indicated that apathy on purposeful activity during the session was significantly higher on non-immersive intervention (M&#8201;=&#8201;1.75, SD&#8201;=&#8201;0.72) compared to immersive intervention (M&#8201;=&#8201;1.50, SD&#8201;=&#8201;0.51), z&#8201;=&#8201;&#8722;2.24, p&#8201;=&#8201;0.025. Regarding all the remaining apathy indicators on the PEAR scale, it was possible to conclude that there was no significant difference between the immersive and non-immersive intervention. In terms of pleasure (z&#8201;=&#8201;&#8722;0.25, p&#8201;=&#8201;0.803), anger (z&#8201;=&#8201;0.00, p&#8201;=&#8201;1.000), anxiety or fear (z&#8201;=&#8201;&#8722;1.00, p&#8201;=&#8201;0.317), sadness (z&#8201;=&#8201;&#8722;0.38, p&#8201;=&#8201;0.705) and general alertness (z&#8201;=&#8201;0.00, p&#8201;=&#8201;1.000) in the session, the results indicated that there was no significant difference between the immersive and non-immersive intervention (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/13872877251371236" ext-link-type="uri">Supplemental Table 2</ext-link>).</p><table-wrap position="float" id="table3-13872877251371236" orientation="portrait"><label>Table 3.</label><caption><p>Comparison of the immersive and non-immersive intervention according to the PEAR scores.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251371236-table3.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="2"/><th align="left" colspan="2" rowspan="1">Mean&#8201;&#177;&#8201;Standard deviation</th><th align="left" rowspan="2" colspan="1">p</th></tr><tr><th align="left" rowspan="1" colspan="1">Immersive intervention</th><th align="left" rowspan="1" colspan="1">Non-immersive intervention</th></tr></thead><tbody><tr><td rowspan="6" colspan="1">Before</td><td rowspan="1" colspan="1">Facial expressions</td><td rowspan="1" colspan="1">2.85&#8201;&#177;&#8201;0.88</td><td rowspan="1" colspan="1">2.85&#8201;&#177;&#8201;0.88</td><td rowspan="1" colspan="1">1.000<sup>
<xref rid="table-fn2-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Eye contact</td><td rowspan="1" colspan="1">1.45&#8201;&#177;&#8201;0.69</td><td rowspan="1" colspan="1">1.40&#8201;&#177;&#8201;0.69</td><td rowspan="1" colspan="1">0.763<sup>
<xref rid="table-fn2-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Physical engagement</td><td rowspan="1" colspan="1">2.80&#8201;&#177;&#8201;0.95</td><td rowspan="1" colspan="1">2.85&#8201;&#177;&#8201;0.88</td><td rowspan="1" colspan="1">0.796<sup>
<xref rid="table-fn2-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Purposeful activity</td><td rowspan="1" colspan="1">2.45&#8201;&#177;&#8201;1.15</td><td rowspan="1" colspan="1">2.40&#8201;&#177;&#8201;1.14</td><td rowspan="1" colspan="1">0.785<sup>
<xref rid="table-fn2-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Verbal tone</td><td rowspan="1" colspan="1">2.85&#8201;&#177;&#8201;0.75</td><td rowspan="1" colspan="1">2.90&#8201;&#177;&#8201;0.85</td><td rowspan="1" colspan="1">0.763<sup>
<xref rid="table-fn2-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Verbal expression</td><td rowspan="1" colspan="1">2.40&#8201;&#177;&#8201;0.75</td><td rowspan="1" colspan="1">2.15&#8201;&#177;&#8201;0.88</td><td rowspan="1" colspan="1">0.059<sup>
<xref rid="table-fn2-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="6" colspan="1">During</td><td rowspan="1" colspan="1">Facial expressions</td><td rowspan="1" colspan="1">2.30&#8201;&#177;&#8201;0.80</td><td rowspan="1" colspan="1">2.00&#8201;&#177;&#8201;0.65</td><td rowspan="1" colspan="1">0.034<sup>
<xref rid="table-fn2-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Eye contact</td><td rowspan="1" colspan="1">1.35&#8201;&#177;&#8201;0.49</td><td rowspan="1" colspan="1">1.20&#8201;&#177;&#8201;0.41</td><td rowspan="1" colspan="1">0.180<sup>
<xref rid="table-fn2-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Physical engagement</td><td rowspan="1" colspan="1">1.80&#8201;&#177;&#8201;0.83</td><td rowspan="1" colspan="1">2.00&#8201;&#177;&#8201;0.86</td><td rowspan="1" colspan="1">0.248<sup>
<xref rid="table-fn2-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Purposeful activity</td><td rowspan="1" colspan="1">1.50&#8201;&#177;&#8201;0.51</td><td rowspan="1" colspan="1">1.75&#8201;&#177;&#8201;0.72</td><td rowspan="1" colspan="1">0.025<sup>
<xref rid="table-fn2-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Verbal tone</td><td rowspan="1" colspan="1">2.25&#8201;&#177;&#8201;0.55</td><td rowspan="1" colspan="1">2.20&#8201;&#177;&#8201;0.52</td><td rowspan="1" colspan="1">0.655<sup>
<xref rid="table-fn2-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Verbal expression</td><td rowspan="1" colspan="1">1.65&#8201;&#177;&#8201;0.59</td><td rowspan="1" colspan="1">1.50&#8201;&#177;&#8201;0.51</td><td rowspan="1" colspan="1">0.257<sup>
<xref rid="table-fn2-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="6" colspan="1">After</td><td rowspan="1" colspan="1">Facial expressions</td><td rowspan="1" colspan="1">2.40&#8201;&#177;&#8201;0.75</td><td rowspan="1" colspan="1">2.55&#8201;&#177;&#8201;0.61</td><td rowspan="1" colspan="1">0.405<sup>
<xref rid="table-fn2-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Eye contact</td><td rowspan="1" colspan="1">1.25&#8201;&#177;&#8201;0.44</td><td rowspan="1" colspan="1">1.20&#8201;&#177;&#8201;0.41</td><td rowspan="1" colspan="1">0.655<sup>
<xref rid="table-fn2-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Physical engagement</td><td rowspan="1" colspan="1">2.35&#8201;&#177;&#8201;0.88</td><td rowspan="1" colspan="1">2.35&#8201;&#177;&#8201;0.88</td><td rowspan="1" colspan="1">1.000<sup>
<xref rid="table-fn2-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Purposeful activity</td><td rowspan="1" colspan="1">1.95&#8201;&#177;&#8201;0.63</td><td rowspan="1" colspan="1">1.85&#8201;&#177;&#8201;0.67</td><td rowspan="1" colspan="1">0.595<sup>
<xref rid="table-fn2-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Verbal tone</td><td rowspan="1" colspan="1">2.30&#8201;&#177;&#8201;0.66</td><td rowspan="1" colspan="1">2.40&#8201;&#177;&#8201;0.50</td><td rowspan="1" colspan="1">0.516<sup>
<xref rid="table-fn2-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr><tr><td rowspan="1" colspan="1">Verbal expression</td><td rowspan="1" colspan="1">1.80&#8201;&#177;&#8201;0.70</td><td rowspan="1" colspan="1">1.90&#8201;&#177;&#8201;0.64</td><td rowspan="1" colspan="1">0.480<sup>
<xref rid="table-fn2-13872877251371236" ref-type="table-fn">a</xref>
</sup></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn2-13872877251371236"><label>
<sup>a</sup>
</label><p>value obtained using the Wilcoxon signed-rank test.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section3D-13872877251371236"><title>Comparison of well-being in the different interventions</title><p>The results indicated that there was no significant difference between the immersive and non-immersive intervention in terms of well-being in the session. Analyzing the mean OWLS scores, although there was no significant difference, a tendency towards a higher level of happiness and pleasure in immersive intervention compared to non-immersive intervention may emerge. It can also be observed that in both interventions all participants presented themselves attentive, responsive and relaxed during the intervention (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/13872877251371236" ext-link-type="uri">Supplemental Table 3</ext-link>).</p></sec><sec id="section3E-13872877251371236"><title>Comparison of physiological metrics in the different interventions</title><p>Relatively to the time domain results (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/13872877251371236" ext-link-type="uri">Supplemental Material</ext-link>), for the repeated-measures ANOVA for mean HR, the sphericity assumption was not met (p&#8201;&lt;&#8201;0.001) and the epsilon was 0.618 for the condition effect and 0.589 for the condition * intervention interaction. Thus, the Huynh-Feldt correction was employed for this model. The results indicated a significant main effect for condition, F (1.235,19.765)&#8201;=&#8201;4.333, p&#8201;=&#8201;0.043, partial &#951;2&#8201;=&#8201;0.213. Post-hoc pairwise comparisons with a Bonferroni correction indicated that mean HR in the baseline rest condition (M&#8201;=&#8201;67.55, SD&#8201;=&#8201;2.58) was significantly lower (p&#8201;=&#8201;0.020) than in the exposure condition (M&#8201;=&#8201;69.79, SD&#8201;=&#8201;2.31). However, there was no significant main effect for intervention, F (1,16)&#8201;=&#8201;0.026, p&#8201;=&#8201;0.875, partial &#951;2&#8201;=&#8201;0.002, and non-significant intervention*condition interaction, F (1.178,18.852)&#8201;=&#8201;0.279, p&#8201;=&#8201;0.641, partial &#951;2&#8201;=&#8201;0.017.</p><p>The repeated-measures ANOVA results for SDNN indicated no significant main effect for intervention, F (1,16)&#8201;=&#8201;0.069, p&#8201;=&#8201;0.796, partial &#951;2&#8201;=&#8201;0.004, condition, F (2,32)&#8201;=&#8201;2.501, p&#8201;=&#8201;0.098, partial &#951;2&#8201;=&#8201;0.135 and intervention*condition interaction, F (2,32)&#8201;=&#8201;0.256, p&#8201;=&#8201;0.776, partial &#951;2&#8201;=&#8201;0.016.</p><p>For the repeated-measures ANOVA for RMSSD, the threshold criteria for skewness and kurtosis assumption was not met (skewness&#8201;&gt;&#8201;2), despite being very close values. The results indicated no significant main effect for intervention, F (1,16)&#8201;=&#8201;0.007, p&#8201;=&#8201;0.935, partial &#951;2&#8201;=&#8201;0.000, condition, F (2,32)&#8201;=&#8201;1.729, p&#8201;=&#8201;0.194, partial &#951;2&#8201;=&#8201;0.098 and intervention*condition interaction, F (2,32)&#8201;=&#8201;0.458, p&#8201;=&#8201;0.637, partial &#951;2&#8201;=&#8201;0.028.</p><p>The repeated-measures ANOVA results for pNN50 indicated no significant main effect for intervention, F (1,19)&#8201;=&#8201;1.466, p&#8201;=&#8201;0.241, partial &#951;2&#8201;=&#8201;0.072, condition, F (2,38)&#8201;=&#8201;0.006, p&#8201;=&#8201;0.994, partial &#951;2&#8201;=&#8201;0.000 and intervention*condition interaction, F (2,38)&#8201;=&#8201;0.611, p&#8201;=&#8201;0.548, partial &#951;2&#8201;=&#8201;0.031.</p><p>Considering the frequency domain results (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/13872877251371236" ext-link-type="uri">Supplemental Material</ext-link>), the repeated-measures ANOVA results for Peak Frequencies on LF band indicated no significant main effect for intervention, F (1,19)&#8201;=&#8201;0.112, p&#8201;=&#8201;0.741, partial &#951;2&#8201;=&#8201;0.006, condition, F (2,38)&#8201;=&#8201;0.857, p&#8201;=&#8201;0.433, partial &#951;2&#8201;=&#8201;0.043 and intervention*condition interaction, F (2,38)&#8201;=&#8201;0.076, p&#8201;=&#8201;0.927, partial &#951;2&#8201;=&#8201;0.004. In terms of Peak Frequencies on HF band, the repeated-measures ANOVA results indicated no significant main effect for intervention, F (1,19)&#8201;=&#8201;0.297, p&#8201;=&#8201;0.592, partial &#951;2&#8201;=&#8201;0.015, condition, F (2,38)&#8201;=&#8201;0.480, p&#8201;=&#8201;0.623, partial &#951;2&#8201;=&#8201;0.025 and intervention*condition interaction, F (2,38)&#8201;=&#8201;0.182, p&#8201;=&#8201;0.834, partial &#951;2&#8201;=&#8201;0.010.</p><p>For the repeated-measures ANOVA for Absolute Powers on LF band, the threshold criteria for skewness and kurtosis assumption was not met (skewness&#8201;&gt;&#8201;2 and kurtosis&#8201;&gt;&#8201;9). The sphericity assumption was not met for the condition * intervention interaction (p&#8201;&lt;&#8201;0.001, epsilon&#8201;=&#8201;0.576). Thus, the Huynh-Feldt correction was employed for this model. The results indicated no significant main effect for intervention, F (1,14)&#8201;=&#8201;0.029, p&#8201;=&#8201;0.866, partial &#951;2&#8201;=&#8201;0.002, condition, F (2,28)&#8201;=&#8201;0.465, p&#8201;=&#8201;0.633, partial &#951;2&#8201;=&#8201;0.032 and intervention*condition interaction, F (1.153,16.140)&#8201;=&#8201;0.231, p&#8201;=&#8201;0.672, partial &#951;2&#8201;=&#8201;0.016. For the repeated-measures ANOVA for Absolute Powers on HF band, the threshold criteria for skewness and kurtosis assumption was not met (skewness&#8201;&gt;&#8201;2 and kurtosis&#8201;&gt;&#8201;9). The sphericity assumption was not met for the condition effect (p&#8201;&lt;&#8201;0.001, epsilon&#8201;=&#8201;0.594) and for the condition * intervention interaction (p&#8201;&lt;&#8201;0.001, epsilon&#8201;=&#8201;0.547). Thus, the Huynh-Feldt correction was employed for the condition effect and the Greenhouse-Geisser correction was employed for the condition * intervention interaction. The results indicated no significant main effect for intervention, F (1,14)&#8201;=&#8201;1.386, p&#8201;=&#8201;0.259, partial &#951;2&#8201;=&#8201;0.090, condition, F (1.187,16.619)&#8201;=&#8201;2.493, p&#8201;=&#8201;0.130, partial &#951;2&#8201;=&#8201;0.151 and intervention*condition interaction, F (1.094,15.321)&#8201;=&#8201;0.449, p&#8201;=&#8201;0.530, partial &#951;2&#8201;=&#8201;0.031.</p><p>For the repeated-measures ANOVA for Total Power, the threshold criteria for skewness and kurtosis assumption was not met (skewness&#8201;&gt;&#8201;2 and kurtosis&#8201;&gt;&#8201;9). The sphericity assumption was not met for the condition effect (p&#8201;=&#8201;0.014, epsilon&#8201;=&#8201;0.732). Thus, the Huynh-Feldt correction was employed for the condition effect. The results indicated no significant main effect for intervention, F (1,15)&#8201;=&#8201;0.460, p&#8201;=&#8201;0.508, partial &#951;2&#8201;=&#8201;0.030, condition, F (1.463,21.948)&#8201;=&#8201;0.295, p&#8201;=&#8201;0.679, partial &#951;2&#8201;=&#8201;0.019 and intervention*condition interaction, F (2,30)&#8201;=&#8201;0.471, p&#8201;=&#8201;0.629, partial &#951;2&#8201;=&#8201;0.030.</p><p>For the repeated-measures ANOVA for LF/HF Ratio, the threshold criteria for skewness and kurtosis assumption was not met (skewness&#8201;&gt;&#8201;2). The results indicated no significant main effect for intervention, F (1,13)&#8201;=&#8201;0.272, p&#8201;=&#8201;0.611, partial &#951;2&#8201;=&#8201;0.020, condition, F (2,26)&#8201;=&#8201;0.015, p&#8201;=&#8201;0.985, partial &#951;2&#8201;=&#8201;0.001 and intervention*condition interaction, F (2,26)&#8201;=&#8201;0.739, p&#8201;=&#8201;0.488, partial &#951;2&#8201;=&#8201;0.054.</p><p>In terms of the non-linear indices results (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/13872877251371236" ext-link-type="uri">Supplemental Material</ext-link>), for the repeated-measures ANOVA for SD1, the threshold criteria for skewness and kurtosis assumption was not met (skewness&#8201;&gt;&#8201;2). The results indicated no significant main effect for intervention, F (1,16)&#8201;=&#8201;0.007, p&#8201;=&#8201;0.935, partial &#951;2&#8201;=&#8201;0.000, condition, F (2,32)&#8201;=&#8201;1.729, p&#8201;=&#8201;0.194, partial &#951;2&#8201;=&#8201;0.098 and intervention*condition interaction, F (2,32)&#8201;=&#8201;0.458, p&#8201;=&#8201;0.637, partial &#951;2&#8201;=&#8201;0.028. The repeated-measures ANOVA results for SD2 indicated no significant main effect for intervention, F (1,16)&#8201;=&#8201;0.124, p&#8201;=&#8201;0.729, partial &#951;2&#8201;=&#8201;0.008, condition, F (2,32)&#8201;=&#8201;2.858, p&#8201;=&#8201;0.072, partial &#951;2&#8201;=&#8201;0.152 and intervention*condition interaction, F (2,32)&#8201;=&#8201;0.171, p&#8201;=&#8201;0.843, partial &#951;2&#8201;=&#8201;0.011. In terms of SD2/SD1 Ratio, the repeated-measures ANOVA results indicated no significant main effect for intervention, F (1,18)&#8201;=&#8201;0.177, p&#8201;=&#8201;0.679, partial &#951;2&#8201;=&#8201;0.010, condition, F (2,36)&#8201;=&#8201;0.970, p&#8201;=&#8201;0.389, partial &#951;2&#8201;=&#8201;0.051 and intervention*condition interaction, F (2,36)&#8201;=&#8201;0.086, p&#8201;=&#8201;0.918, partial &#951;2&#8201;=&#8201;0.005.</p></sec><sec id="section3F-13872877251371236"><title>Comparison of the participant's self-perception of the experience in the different interventions</title><p>The participant's self-perception of the experience questionnaire results (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/13872877251371236" ext-link-type="uri">Supplemental Table 9</ext-link>) demonstrated that generically the participants enjoyed both interventions (immersive and non-immersive), with a tendency to evaluate more positively to the immersive intervention than non-immersive intervention, despite reporting slightly greater difficulties to visualize the videos in the immersive intervention.</p><p>The results indicated that there was no significant difference between the immersive and non-immersive intervention in terms of the participant's self-perception of the experience in the session. Analyzing the questionnaire mean scores, although there were no significant differences, a tendency to enjoy more immersive intervention compared to non-immersive may emerge. Also, a tendency to watch the video better on non-immersive intervention compared to immersive intervention may emerge. Considering the maximum questionnaire score on each question, the mean obtained in the two interventions indicates that the participant's self-perception of the experience in both sessions was positive (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/13872877251371236" ext-link-type="uri">Supplemental Table 10</ext-link>).</p></sec></sec><sec id="section4-13872877251371236"><title>Discussion</title><p>The aim of this study was to analyze the effect of an immersive VR reminiscence session compared to a non-immersive reminiscence session, in terms of engagement in session, BPSD and well-being in people with dementia, using behavioral observation and measurement of physiological metrics during interventions. It was found that the behavioral engagement in session was significantly higher on immersive intervention compared to non-immersive intervention. The results also indicated that apathy on purposeful activity during the session was significantly lower on immersive intervention compared to non-immersive intervention, however apathy on facial expressions during the session was significantly higher on immersive intervention compared to non-immersive intervention. Regarding the physiological analysis, the mean HR in the baseline rest condition was significantly lower than in the exposure condition, in both interventions. As for the other measures evaluated, there were no significant differences between the immersive intervention and non-immersive intervention.</p><p>Regarding engagement in the session, the results indicated that behavioral engagement was significantly higher in the immersive intervention than in the non-immersive intervention. This suggests that the immersive intervention would have been more engaging for the participant to watch the video, pointing to locations and attempting to touch or approach objects. This is consistent with scientific research, which indicates that participant engagement during an intervention usually increases with increased immersion in the activity,<sup><xref rid="bibr37-13872877251371236" ref-type="bibr">37</xref>,<xref rid="bibr57-13872877251371236" ref-type="bibr">57</xref></sup> demonstrating good adherence to these immersive interventions,<sup><xref rid="bibr37-13872877251371236" ref-type="bibr">37</xref>,<xref rid="bibr58-13872877251371236" ref-type="bibr">58</xref></sup> due to the greater ease in evoking past memories and offering greater opportunity for the participant to explore and interact with the environment through body movements.<sup><xref rid="bibr33-13872877251371236" ref-type="bibr">33</xref>,<xref rid="bibr59-13872877251371236" ref-type="bibr">59</xref></sup> This result may have been observed due to, combined with the immersiveness of VR, the fact that it was a new and different way of participating in interventions may also have provoked greater interest and engagement.</p><p>Interpreting engagement in general and the remaining engagement indicators, it was possible to conclude that there were no significant differences between the immersive and non-immersive intervention. This result is not in line with the scientific literature already cited, which refers that interventions with greater immersiveness tend to be more motivating, thus promoting greater participant engagement.<sup><xref rid="bibr34-13872877251371236" ref-type="bibr">34</xref>,<xref rid="bibr36-13872877251371236" ref-type="bibr">36</xref></sup> This result can be explained, not only by the small number of participants and number of sessions per interventions, but the fact of carrying out activities using new technologies, such as VR, can be limiting to the participant's participation, due to lack of knowledge and the fact that handling the software can be confusing.<sup><xref rid="bibr37-13872877251371236" ref-type="bibr">37</xref>,<xref rid="bibr60-13872877251371236" ref-type="bibr">60</xref></sup> Furthermore, greater immersion may also have been a distracting element to the participant's involvement.<sup><xref rid="bibr57-13872877251371236" ref-type="bibr">57</xref>,<xref rid="bibr61-13872877251371236" ref-type="bibr">61</xref></sup></p><p>For BPSD, it was possible to conclude that apathy on purposeful activity was significantly lower in the immersive intervention compared to the non-immersive intervention, indicating greater engagement in the session. This result is in line with scientific evidence that tells us that immersive activities may provide greater interest in the activity, thus also increasing their motivation to engage and intentionally participate in the session.<sup><xref rid="bibr36-13872877251371236" ref-type="bibr">36</xref>,<xref rid="bibr38-13872877251371236" ref-type="bibr">38</xref></sup> Contrary to this scientific evidence, it was possible to conclude that the apathy demonstrated in facial expressions during the session was significantly higher in the immersive intervention than in the non-immersive intervention. This result can be explained by the fact that the use of HMDs in the facial area may have limited the participant's movements in terms of facial expressions or even limited the researchers&#8217; observation of apathy's facial expressions.</p><p>When it comes to the other apathy measures evaluated, through the PEAR, it was possible to conclude that there were no significant differences between the immersive intervention and non-immersive intervention. Handling the non-immersive activity with the computer mouse or the use of VR itself, may have limited the participant's own attention to the activity, which may have influenced the results when it comes to apathy in interventions.<sup><xref rid="bibr37-13872877251371236" ref-type="bibr">37</xref>,<xref rid="bibr58-13872877251371236" ref-type="bibr">58</xref>,<xref rid="bibr60-13872877251371236" ref-type="bibr">60</xref></sup></p><p>Regarding pleasure, anger, anxiety, sadness and general alertness, there were no significant differences between immersive and non-immersive intervention. According to scientific evidence, greater immersion could have a greater positive effect on mood, happiness, pleasure, agitation, depressive and anxious symptoms compared to non-immersive activities.<sup><xref rid="bibr29-13872877251371236" ref-type="bibr">29</xref>,<xref rid="bibr36-13872877251371236" ref-type="bibr">36</xref></sup> This lack of a significative difference can be explained not only by the sample size, but also by the fact that immersive activities can amplify emotions experienced by participants during the intervention, both positive and negative emotions due to the high degree of presence and realism provided by the VR.<sup><xref rid="bibr57-13872877251371236" ref-type="bibr">57</xref>,<xref rid="bibr62-13872877251371236" ref-type="bibr">62</xref></sup> The fact that there was only one session for each intervention may also have limited the observation of significant differences. Overall, in this study, both interventions showed positive effects on the participants, also making it difficult to conclude significant differences, combined with the possible difficulties of the assessment measures not being sensitive enough to identify differences, especially considering the range of their scores.</p><p>Regarding measures of well-being, it was possible to conclude that there were no significant differences between the immersive intervention and non-immersive intervention. Analyzing the results of the OWLS scale, it was possible to verify a tendency for higher levels of happiness and pleasure in the immersive intervention than in the non-immersive intervention, which is in line with studies that report that participants could have higher levels of well-being during activities with immersive interventions, due to the stimulation of memories of autobiographical memories, promoting their sense of identity.<sup><xref rid="bibr36-13872877251371236" ref-type="bibr">36</xref>,<xref rid="bibr63-13872877251371236" ref-type="bibr">63</xref></sup> The methodology of the instrument used could have been a limitation to observe significant differences, as OWLS is quoted if, in the evaluated period, the first four items are not rated, it is not possible to count the following, even if the person presents these indicators of well-being, which may have influenced these results.<sup>
<xref rid="bibr47-13872877251371236" ref-type="bibr">47</xref>
</sup> It was also concluded that in both interventions all participants presented themselves attentive, responsive and relaxed during the intervention. This result is in line with scientific evidence that also found that these reminiscence interventions can be an enjoyable and relaxed session, where participants are attentive and focused during the session.<sup><xref rid="bibr37-13872877251371236" ref-type="bibr">37</xref>,<xref rid="bibr58-13872877251371236" ref-type="bibr">58</xref>,<xref rid="bibr64-13872877251371236" ref-type="bibr">64</xref></sup></p><p>Regarding physiological measures, it was possible to conclude that mean HR was significantly lower in the baseline rest condition compared to the exposure condition. However, no significant differences were found on the remaining physiological measures. Immersive reminiscence interventions can potentially unbalance the ANS. Due to the fact that it was a reminiscence intervention, capable of promoting the person's interest and causing relaxation and pleasure, there was the possibility of the PNS dominating over the SNS,<sup><xref rid="bibr65-13872877251371236" ref-type="bibr">65</xref>,<xref rid="bibr66-13872877251371236" ref-type="bibr">66</xref></sup> based on a decrease in the mean HR and increase in SDNN, RMSSD, pNN50, HF and SD1 values.<sup><xref rid="bibr50-13872877251371236" ref-type="bibr">50</xref>,<xref rid="bibr67-13872877251371236" ref-type="bibr">67</xref></sup> Despite this, reminiscence interventions, being carried out with new technologies, such as VR, can promote interest and engagement in the session, thus increasing the participant's motivation to participate actively,<sup><xref rid="bibr36-13872877251371236" ref-type="bibr">36</xref>,<xref rid="bibr38-13872877251371236" ref-type="bibr">38</xref></sup> presented by the dominance of the SNS over the PNS, based in the increase in the mean HR, which is in line with the results of this study, and increase in LF, LF/HF ratio values.<sup><xref rid="bibr65-13872877251371236" ref-type="bibr">65</xref>,<xref rid="bibr66-13872877251371236" ref-type="bibr">66</xref></sup> This dominance of the SNS may also be combined with fear, nervousness or anxiety when carrying out VR activities, due to lack of knowledge about the use and function of these technologies.<sup><xref rid="bibr37-13872877251371236" ref-type="bibr">37</xref>,<xref rid="bibr58-13872877251371236" ref-type="bibr">58</xref></sup></p><p>Regarding SD2 values, although there were no significant differences, there was a tendency for these values &#8203;&#8203;to be higher during habituation and exposure conditions compared to resting condition, which is in line with what was previously mentioned, that immersive reminiscence interventions can promote greater motivation to engage in the activity, thus increasing SNS, combined with the increase in mean HR also observed.<sup><xref rid="bibr31-13872877251371236" ref-type="bibr">31</xref>,<xref rid="bibr38-13872877251371236" ref-type="bibr">38</xref></sup> As this variable is speculative and more reliable over longer-term recordings, it will be necessary to further investigate this relationship with the ANS.</p><p>The inability to observe significant differences between the types of intervention may have been due to the positive effects caused by both interventions, evidenced by the participant's own self-perception of the experience.</p><p>In terms of the participant's self-perception of the experience, although the results indicated that there were no significant differences, it was possible to observe a tendency to enjoy the immersive intervention more than the non-immersive intervention. This result is in line with scientific evidence that says that immersive intervention is usually more appreciated, more satisfying and interesting for participants than non-immersive intervention, with good adherence and participation.<sup><xref rid="bibr34-13872877251371236" ref-type="bibr">34</xref>,<xref rid="bibr36-13872877251371236" ref-type="bibr">36</xref></sup> Studies also support the safety and feasibility of using VR to promote autobiographical memory activities.<sup><xref rid="bibr29-13872877251371236" ref-type="bibr">29</xref>,<xref rid="bibr31-13872877251371236" ref-type="bibr">31</xref></sup> It was also possible to observe the tendency to see the video presented in the non-immersive intervention better than in the immersive one. The comfort factor of the HMD in conjunction with the participants&#8217; prescription glasses, may account for this outcome.</p><p>This study has several strengths, notably its exploration of the under-researched area of VR reminiscence for individuals with dementia, focusing on engagement, BPSD, and well-being. The inclusion of physiological data during sessions is a significant contribution, as it is often overlooked yet essential for evaluation. The study utilized diverse instruments targeting various aspects of each variable, allowing for comprehensive assessment of the interventions and their effects on participants. Observation-based measures were particularly relevant given the communication challenges associated with dementia. Additionally, confirming participants&#8217; life stories with caregivers to select appropriate videos enhanced the intervention's relevance, acknowledging the memory deficits present in some participants. The personalized nature of the interventions likely fostered greater engagement and impact.<sup><xref rid="bibr26-13872877251371236" ref-type="bibr">26</xref>,<xref rid="bibr68-13872877251371236" ref-type="bibr">68</xref></sup></p><p>However, the study also faced limitations. The small sample size may have affected the power and significance of statistical analyses, compounded by the limited representation of only two male participants, which restricts the generalizability of the findings. Unconscious bias was another concern, as researchers conducting the interventions were aware of the study's hypotheses. The static seating arrangement during the immersive intervention aimed to mitigate adverse effects, such as nausea or fall risk, but may have restricted participants&#8217; ability to engage fully with the 360&#176; video, potentially diminishing the immersive experience. Conducting only one session of each intervention may have influenced outcomes, as participant condition on the intervention day could vary. Additionally, the use of a computer mouse in the non-immersive session posed challenges for some participants, affecting their engagement. Variability in recognition of the habituation video may have led to differences in participation levels, impacting results. The need to remove the HMD between habituation and exposure periods may have affected physiological analyses, while the different progression of dementia stages throughout the participants could also have influenced outcomes across the two interventions, as there may have been a transition effect from the first intervention to the second intervention. Finally, the absence of a passive control group or physical reminiscence activities may also represent a limitation, as it prevents definitive attribution of the observed changes to the intervention.</p></sec><sec id="section5-13872877251371236"><title>Conclusion</title><p>In this study it was concluded that immersive intervention significantly enhanced engagement and reduced activity-related apathy compared to non-immersive intervention. However, no significant differences were found in well-being and the remaining BSPD, despite the results suggesting a tendency for a greater positive effect in the immersive intervention, such as happiness, pleasure and enjoyment. These findings highlight the potential of using technologies like VR and computers to improve adherence and engagement in dementia intervention programs, given their increasing accessibility and safety.</p><p>Future research should involve larger, more balanced samples to allow for robust statistical analyses and generalization of results. The possibility of introducing external evaluators or blinding procedures, having an impact on blinding bias, should be explored in future studies. Exploring the use of swivel chairs for safe viewing of 360&#176; videos may enhance participant engagement with significant locations. The effectiveness of presenting the habituation and exposure video in the same video without interruptions and without having to remove the HMD, enhancing the effectiveness of the habituation period and transition to the exposure period, should also be studied. In non-immersive sessions, simplifying video interactions&#8212;such as showing the 360&#176; video on the computer automatically or on a touch screen&#8212;should be considered. Furthermore, it would be important to carry out studies with a greater number of sessions for each of the interventions, reducing the external influences that may occur on each participant and could provide better insights into engagement, BPSD, and well-being. If possible, always hold the sessions at the same time and place, without disrupting the participant's daily routine. The best conditions for immersive interventions, including session length, frequency, and the utilization of various VR hardware should also be explored. Future studies should also ensure that habituation videos are universally recognized by participants, potentially by using familiar settings. Evaluating the effectiveness of various washout periods will be crucial for this population. Future studies should also include long-term follow-up assessments to evaluate the sustained effects of immersive VR. Moreover, assessing the impact of family involvement in interventions could deepen engagement with the memories associated with the presented locations. Investigating these interventions in more advanced stages of dementia or evaluating these outcomes and exploring intervention strategies in home or hospital settings, warrants consideration. The portability and flexibility of VR-based interventions provide an opportunity to provide adequate reminiscence sessions for people with dementia across several settings and disease stages.</p><p>Furthermore, continued use of observational tools and physiological measures will enrich data collection, particularly for participants with difficulties in emotional expression. Future studies should consider using assessment tools compatible with immersive devices, such as facial recognition technology or equipment that allows greater freedom of facial movement. Future studies might also explore additional physiological metrics, such as galvanic skin response pupillometry, and neural markers (e.g., functional near-infrared spectroscope or electroencephalography) to better understand the biological underpinnings of VR-related emotional and arousal responses.</p><p>In summary, incorporating immersive virtual reality as a non-pharmacological therapy tool presents significant clinical potential, and its feasibility in real-world clinical settings warrants careful consideration, particularly in terms of accessibility, cost-effectiveness, and integration into existing treatment protocols. Such research aims to provide safe, beneficial activities that improve the quality of life for individuals with dementia and their caregivers.</p></sec><sec sec-type="supplementary-material" id="section6-13872877251371236"><title>Supplemental Material</title><supplementary-material id="suppl1-13872877251371236" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-docx-1-alz-10.1177_13872877251371236 - Supplemental material for Effects of an immersive virtual reality reminiscence intervention on engagement, behavioral and psychological symptoms, and well-being of people with dementia: A randomized crossover trial</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-docx-1-alz-10.1177_13872877251371236.docx" position="float" orientation="portrait"/><p>Supplemental material, sj-docx-1-alz-10.1177_13872877251371236 for Effects of an immersive virtual reality reminiscence intervention on engagement, behavioral and psychological symptoms, and well-being of people with dementia: A randomized crossover trial by Miguel Pereira, Cl&#225;udia Leite, Carlos Campos and Tiago Coelho in Journal of Alzheimer's Disease</p></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>The authors have no acknowledgments to report.</p></ack><fn-group><fn fn-type="other"><p><bold>ORCID iDs:</bold> Miguel Pereira <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0009-0002-7788-5815" ext-link-type="uri">https://orcid.org/0009-0002-7788-5815</ext-link></p><p>Carlos Campos <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-5966-4050" ext-link-type="uri">https://orcid.org/0000-0002-5966-4050</ext-link></p><p>Tiago Coelho <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0001-7847-2401" ext-link-type="uri">https://orcid.org/0000-0001-7847-2401</ext-link></p></fn><fn fn-type="other"><p><bold>Ethical considerations:</bold> Ethics approval was obtained from the E2S &#8211; Polytechnic of Porto (CE0031E).</p></fn><fn fn-type="other"><p><bold>Consent to participate:</bold> Informed consent was obtained from all participants in this study. Written consent forms were provided to each participant or their legal representative, and signed consent was acquired prior to participation. They were also informed of the confidentiality measures in place to protect their identities and personal information.</p></fn><fn fn-type="con"><p><bold>Author contributions:</bold>
<bold>Miguel Pereira:</bold> Data curation; Formal analysis; Investigation; Validation; Visualization; Writing &#8211; original draft; Writing &#8211; review &amp; editing.</p><p><bold>Cl&#225;udia Leite:</bold> Data curation; Formal analysis; Investigation; Validation; Writing &#8211; review &amp; editing.</p><p><bold>Carlos Campos:</bold> Conceptualization; Data curation; Formal analysis; Formal analysis; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Writing &#8211; review &amp; editing.</p><p><bold>Tiago Coelho:</bold> Conceptualization; Data curation; Formal analysis; Formal analysis; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Writing &#8211; review &amp; editing.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Funda&#231;&#227;o para a Ci&#234;ncia e Tecnologia (FCT) through R&amp;D Units funding (grants: UIDB/05210/2020, UIDB/05380/2020).</p></fn><fn fn-type="COI-statement"><p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn><fn fn-type="other"><p><bold>Data availability statement:</bold> Data, analytic methods or materials are not available to other researchers. Clinical trial was not preregistered as cross-over trials are not required for preregistration in the involved institutions or by the ethical committee.</p></fn><fn fn-type="other"><p><bold>Supplemental material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-13872877251371236"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desai</surname><given-names>AK</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>L</given-names></name><name name-style="western"><surname>Grossberg</surname><given-names>GT</given-names></name></person-group>. <article-title>Behavioral disturbance in dementia</article-title>. <source>Curr Psychiatry Rep</source><year>2012</year>; <volume>14</volume>: <fpage>298</fpage>&#8211;<lpage>309</lpage>.<pub-id pub-id-type="pmid">22644311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11920-012-0288-5</pub-id></mixed-citation></ref><ref id="bibr2-13872877251371236"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leng</surname><given-names>M</given-names></name><name name-style="western"><surname>Han</surname><given-names>S</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>Identifying care problem clusters and core care problems of older adults with dementia for caregivers: a network analysis</article-title>. <source>Front Public Health</source><year>2023</year>; <volume>11</volume>: <fpage>1195637</fpage>.<pub-id pub-id-type="pmid">37637827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpubh.2023.1195637</pub-id><pub-id pub-id-type="pmcid">PMC10449331</pub-id></mixed-citation></ref><ref id="bibr3-13872877251371236"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bessey</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Walaszek</surname><given-names>A</given-names></name></person-group>. <article-title>Management of behavioral and psychological symptoms of dementia</article-title>. <source>Curr Psychiatry Rep</source><year>2019</year>; <volume>21</volume>: <fpage>66</fpage>.<pub-id pub-id-type="pmid">31264056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11920-019-1049-5</pub-id></mixed-citation></ref><ref id="bibr4-13872877251371236"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savva</surname><given-names>GM</given-names></name><name name-style="western"><surname>Zaccai</surname><given-names>J</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>FE</given-names></name></person-group>, <etal>et al.</etal><article-title>Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population</article-title>. <source>Br J Psychiatry</source><year>2009</year>; <volume>194</volume>: <fpage>212</fpage>&#8211;<lpage>219</lpage>.<pub-id pub-id-type="pmid">19252147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1192/bjp.bp.108.049619</pub-id></mixed-citation></ref><ref id="bibr5-13872877251371236"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wetzels</surname><given-names>RB</given-names></name><name name-style="western"><surname>Zuidema</surname><given-names>SU</given-names></name><name name-style="western"><surname>de Jonghe</surname><given-names>JFM</given-names></name></person-group>, <etal>et al.</etal><article-title>Determinants of quality of life in nursing home residents with dementia</article-title>. <source>Dement Geriatr Cogn Disord</source><year>2010</year>; <volume>29</volume>: <fpage>189</fpage>&#8211;<lpage>197</lpage>.<pub-id pub-id-type="pmid">20215750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000280437</pub-id></mixed-citation></ref><ref id="bibr6-13872877251371236"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>C</given-names></name><name name-style="western"><surname>Mukadam</surname><given-names>N</given-names></name><name name-style="western"><surname>Katona</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Systematic review of the effectiveness of non-pharmacological interventions to improve quality of life of people with dementia</article-title>. <source>Int Psychogeriatrics</source><year>2012</year>; <volume>24</volume>: <fpage>856</fpage>&#8211;<lpage>870</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610211002614</pub-id><pub-id pub-id-type="pmid">22244371</pub-id></mixed-citation></ref><ref id="bibr7-13872877251371236"><label>7</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>. <comment>Dementia, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/fact-sheets/detail/dementia" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/dementia</ext-link></comment> (<year>2003</year>).</mixed-citation></ref><ref id="bibr8-13872877251371236"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>F</given-names></name></person-group>, <etal>et al.</etal><article-title>Comparative efficacy of non-pharmacological interventions on behavioural and psychological symptoms in elders with dementia: a network meta-analysis</article-title>. <source>Nurs Open</source><year>2021</year>; <volume>8</volume>: <fpage>2922</fpage>&#8211;<lpage>2931</lpage>.<pub-id pub-id-type="pmid">34472717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/nop2.1049</pub-id><pub-id pub-id-type="pmcid">PMC8510770</pub-id></mixed-citation></ref><ref id="bibr9-13872877251371236"><label>9</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>National Institute for Health and Care Excellence</collab></person-group>. <comment>Dementia: assessment, management and support for people living with dementia and their carers. <italic toggle="yes">NICE Guidelines</italic>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.nice.org.uk/guidance/ng97" ext-link-type="uri">www.nice.org.uk/guidance/ng97</ext-link></comment> (<year>2018</year>).</mixed-citation></ref><ref id="bibr10-13872877251371236"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seppala</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Wermelink</surname><given-names>AMAT</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Fall-risk-increasing drugs: a systematic review and meta-analysis: II. Psychotropics</article-title>. <source>J Am Med Dir Assoc</source><year>2018</year>; <volume>19</volume>: <fpage>371.e11</fpage>&#8211;<lpage>371.e17</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jamda.2017.12.098</pub-id><pub-id pub-id-type="pmid">29402652</pub-id></mixed-citation></ref><ref id="bibr11-13872877251371236"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gill</surname><given-names>SS</given-names></name><name name-style="western"><surname>Bronskill</surname><given-names>SE</given-names></name><name name-style="western"><surname>Normand</surname><given-names>SL</given-names></name></person-group>, <etal>et al.</etal><article-title>Antipsychotic drug use and mortality in older adults with dementia</article-title>. <source>Ann Intern Med</source><year>2007</year>; <volume>146</volume>: <fpage>775</fpage>&#8211;<lpage>786</lpage>.<pub-id pub-id-type="pmid">17548409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-146-11-200706050-00006</pub-id></mixed-citation></ref><ref id="bibr12-13872877251371236"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abraha</surname><given-names>I</given-names></name><name name-style="western"><surname>Rimland</surname><given-names>JM</given-names></name><name name-style="western"><surname>Trotta</surname><given-names>FM</given-names></name></person-group>, <etal>et al.</etal><article-title>Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series</article-title>. <source>BMJ Open</source><year>2017</year>; <volume>7</volume>: <comment>e012759</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2016-012759</pub-id><pub-id pub-id-type="pmcid">PMC5372076</pub-id><pub-id pub-id-type="pmid">28302633</pub-id></mixed-citation></ref><ref id="bibr13-13872877251371236"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dyer</surname><given-names>SM</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>SL</given-names></name><name name-style="western"><surname>Laver</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia</article-title>. <source>Int Psychogeriatrics</source><year>2018</year>; <volume>30</volume>: <fpage>295</fpage>&#8211;<lpage>309</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610217002344</pub-id><pub-id pub-id-type="pmid">29143695</pub-id></mixed-citation></ref><ref id="bibr14-13872877251371236"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuiper</surname><given-names>JS</given-names></name><name name-style="western"><surname>Zuidersma</surname><given-names>M</given-names></name><name name-style="western"><surname>Oude Voshaar</surname><given-names>RC</given-names></name></person-group>, <etal>et al.</etal><article-title>Social relationships and risk of dementia: a systematic review and meta-analysis of longitudinal cohort studies</article-title>. <source>Ageing Res Rev</source><year>2015</year>; <volume>22</volume>: <fpage>39</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">25956016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2015.04.006</pub-id></mixed-citation></ref><ref id="bibr15-13872877251371236"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kishita</surname><given-names>N</given-names></name><name name-style="western"><surname>Backhouse</surname><given-names>T</given-names></name><name name-style="western"><surname>Mioshi</surname><given-names>E</given-names></name></person-group>. <article-title>Nonpharmacological interventions to improve depression, anxiety, and quality of life (QoL) in people with dementia: an overview of systematic reviews</article-title>. <source>J Geriatr Psychiatry Neurol</source><year>2020</year>; <volume>33</volume>: <fpage>28</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">31203712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0891988719856690</pub-id></mixed-citation></ref><ref id="bibr16-13872877251371236"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brosch</surname><given-names>T</given-names></name><name name-style="western"><surname>Scherer</surname><given-names>K</given-names></name><name name-style="western"><surname>Grandjean</surname><given-names>D</given-names></name></person-group>, <etal>et al.</etal><article-title>The impact of emotion on perception, attention, memory, and decision-making</article-title>. <source>Swiss Med Wkly</source><year>2013</year>; <volume>143</volume>: <comment>w13786</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4414/smw.2013.13786</pub-id><pub-id pub-id-type="pmid">23740562</pub-id></mixed-citation></ref><ref id="bibr17-13872877251371236"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vuijk</surname><given-names>JGJ</given-names></name><name name-style="western"><surname>Klein Brinke</surname><given-names>J</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>N</given-names></name></person-group>. <article-title>Utilising emotion monitoring for developing music interventions for people with dementia: a state-of-the-art review</article-title>. <source>Sensors (Basel)</source><year>2023</year>; <volume>23</volume>: <fpage>5834</fpage>.<pub-id pub-id-type="pmid">37447684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/s23135834</pub-id><pub-id pub-id-type="pmcid">PMC10347021</pub-id></mixed-citation></ref><ref id="bibr18-13872877251371236"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yanagida</surname><given-names>N</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Matsunari</surname><given-names>Y</given-names></name></person-group>. <article-title>Evaluating the impact of reminiscence therapy on cognitive and emotional outcomes in dementia patients</article-title>. <source>J Pers Med</source><year>2024</year>; <volume>14</volume>: <fpage>629</fpage>.<pub-id pub-id-type="pmid">38929850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm14060629</pub-id><pub-id pub-id-type="pmcid">PMC11204563</pub-id></mixed-citation></ref><ref id="bibr19-13872877251371236"><label>19</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Norris</surname><given-names>A</given-names></name></person-group>. <source>Reminiscence with elderly people</source>. <publisher-loc>London</publisher-loc>: <publisher-name>Winslow Press</publisher-name>, <year>1986</year>.</mixed-citation></ref><ref id="bibr20-13872877251371236"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiernat</surname><given-names>J</given-names></name></person-group>. <article-title>The use of life review activity with confused nursing home residents</article-title>. <source>Am J Occup Ther</source><year>1979</year>; <volume>33</volume>: <fpage>306</fpage>&#8211;<lpage>310</lpage>.<pub-id pub-id-type="pmid">474339</pub-id></mixed-citation></ref><ref id="bibr21-13872877251371236"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woods</surname><given-names>B</given-names></name><name name-style="western"><surname>O&#8217;Philbin</surname><given-names>L</given-names></name><name name-style="western"><surname>Farrell</surname><given-names>EM</given-names></name></person-group>, <etal>et al.</etal><article-title>Reminiscence therapy for dementia</article-title>. <source>Cochrane Database Syst Rev</source><year>2018</year>; <volume>2018</volume>: <comment>CD001120</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD001120.pub3</pub-id><pub-id pub-id-type="pmcid">PMC6494367</pub-id><pub-id pub-id-type="pmid">29493789</pub-id></mixed-citation></ref><ref id="bibr22-13872877251371236"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Sui</surname><given-names>X</given-names></name></person-group>, <etal>et al.</etal><article-title>Effects of group reminiscence interventions on depressive symptoms and life satisfaction in older adults with intact cognition and mild cognitive impairment: a systematic review</article-title>. <source>Arch Gerontol Geriatr</source><year>2023</year>; <volume>114</volume>: <fpage>105103</fpage>.<pub-id pub-id-type="pmid">37354738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.archger.2023.105103</pub-id></mixed-citation></ref><ref id="bibr23-13872877251371236"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>KH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B</given-names></name></person-group>. <article-title>Person-centered care in persons living with dementia: a systematic review and meta-analysis</article-title>. <source>Gerontologist</source><year>2022</year>; <volume>62</volume>: <comment>e253</comment>&#8211;<lpage>e264</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/geront/gnaa207</pub-id><pub-id pub-id-type="pmcid">PMC9019632</pub-id><pub-id pub-id-type="pmid">33326573</pub-id></mixed-citation></ref><ref id="bibr24-13872877251371236"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>B</given-names></name><name name-style="western"><surname>Xv</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name></person-group>, <etal>et al.</etal><article-title>Comparative efficacy and acceptability of treatments for depressive symptoms in cognitive impairment: a systematic review and Bayesian network meta-analysis</article-title>. <source>Front Aging Neurosci</source><year>2022</year>; <volume>14</volume>: <fpage>1037414</fpage>.<pub-id pub-id-type="pmid">36578447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.1037414</pub-id><pub-id pub-id-type="pmcid">PMC9790988</pub-id></mixed-citation></ref><ref id="bibr25-13872877251371236"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#246;k</surname><given-names>N</given-names></name><name name-style="western"><surname>Bademli</surname><given-names>K</given-names></name><name name-style="western"><surname>Sel&#231;uk-Tosun</surname><given-names>A</given-names></name></person-group>. <article-title>The effect of reminiscence therapy on cognitive functions, depression, and quality of life in Alzheimer patients: randomized controlled trial</article-title>. <source>Int J Geriatr Psychiatry</source><year>2019</year>; <volume>34</volume>: <fpage>47</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="pmid">30246408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gps.4980</pub-id></mixed-citation></ref><ref id="bibr26-13872877251371236"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>HC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YT</given-names></name><name name-style="western"><surname>Chen</surname><given-names>PY</given-names></name></person-group>, <etal>et al.</etal><article-title>Reminiscence therapy improves cognitive functions and reduces depressive symptoms in elderly people with dementia: a meta-analysis of randomized controlled trials</article-title>. <source>J Am Med Dir Assoc</source><year>2015</year>; <volume>16</volume>: <fpage>1087</fpage>&#8211;<lpage>1094</lpage>.<pub-id pub-id-type="pmid">26341034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jamda.2015.07.010</pub-id></mixed-citation></ref><ref id="bibr27-13872877251371236"><label>27</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Chapoulie</surname><given-names>E</given-names></name><name name-style="western"><surname>Guerchouche</surname><given-names>R</given-names></name><name name-style="western"><surname>Petit</surname><given-names>PD</given-names></name></person-group>, <etal>et al.</etal><conf-name>Reminiscence therapy using image-based rendering in VR</conf-name>. In: <conf-name>2014 IEEE virtual reality (VR)</conf-name>. <publisher-loc>New York</publisher-loc>: <publisher-name>IEEE</publisher-name>, <year>2014</year>, pp.<fpage>45</fpage>&#8211;<lpage>50</lpage>.</mixed-citation></ref><ref id="bibr28-13872877251371236"><label>28</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Rose</surname><given-names>V</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>I</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>KG</given-names></name></person-group>, <etal>et al.</etal><conf-name>A scoping review exploring the feasibility of virtual reality technology use with individuals living with dementia</conf-name>. In: <conf-name>28th international conference on artificial reality and telexistence, 23rd eurographics symposium on virtual environments</conf-name>, <year>2018</year>, pp.<fpage>131</fpage>&#8211;<lpage>139</lpage>.
<pub-id pub-id-type="doi">10.2312/egve.20181325</pub-id></mixed-citation></ref><ref id="bibr29-13872877251371236"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rose</surname><given-names>V</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>I</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>KG</given-names></name></person-group>, <etal>et al.</etal><article-title>Bringing the outside in: the feasibility of virtual reality with people with dementia in an inpatient psychiatric care setting</article-title>. <source>Dementia</source><year>2021</year>; <volume>20</volume>: <fpage>106</fpage>&#8211;<lpage>129</lpage>.<pub-id pub-id-type="pmid">31510801</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1471301219868036</pub-id></mixed-citation></ref><ref id="bibr30-13872877251371236"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vergara</surname><given-names>D</given-names></name><name name-style="western"><surname>Rubio</surname><given-names>M</given-names></name><name name-style="western"><surname>Lorenzo</surname><given-names>M</given-names></name></person-group>. <article-title>On the design of virtual reality learning environments in engineering</article-title>. <source>Multimodal Technol Interact</source><year>2017</year>; <volume>1</volume>: <fpage>11</fpage>.</mixed-citation></ref><ref id="bibr31-13872877251371236"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>O</given-names></name><name name-style="western"><surname>Pang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name></person-group>. <article-title>The effectiveness of virtual reality for people with mild cognitive impairment or dementia: a meta-analysis</article-title>. <source>BMC Psychiatry</source><year>2019</year>; <volume>19</volume>: <fpage>219</fpage>.<pub-id pub-id-type="pmid">31299921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12888-019-2180-x</pub-id><pub-id pub-id-type="pmcid">PMC6626425</pub-id></mixed-citation></ref><ref id="bibr32-13872877251371236"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Appel</surname><given-names>L</given-names></name><name name-style="western"><surname>Kisonas</surname><given-names>E</given-names></name><name name-style="western"><surname>Appel</surname><given-names>E</given-names></name></person-group>, <etal>et al.</etal><article-title>Administering virtual reality therapy to manage behavioral and psychological symptoms in patients with dementia admitted to an acute care hospital: results of a pilot study</article-title>. <source>JMIR Form Res</source><year>2021</year>; <volume>5</volume>: <comment>e22406</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/22406</pub-id><pub-id pub-id-type="pmcid">PMC7889418</pub-id><pub-id pub-id-type="pmid">33533720</pub-id></mixed-citation></ref><ref id="bibr33-13872877251371236"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>LC</given-names></name><name name-style="western"><surname>Yang</surname><given-names>YH</given-names></name></person-group>. <article-title>The long-term effects of immersive virtual reality reminiscence in people with dementia: longitudinal observational study</article-title>. <source>JMIR Serious Games</source><year>2022</year>; <volume>10</volume>: <comment>e36720</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/36720</pub-id><pub-id pub-id-type="pmcid">PMC9361147</pub-id><pub-id pub-id-type="pmid">35877169</pub-id></mixed-citation></ref><ref id="bibr34-13872877251371236"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saredakis</surname><given-names>D</given-names></name><name name-style="western"><surname>Keage</surname><given-names>HA</given-names></name><name name-style="western"><surname>Corlis</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Using virtual reality to improve apathy in residential aged care: mixed methods study</article-title>. <source>J Med Internet Res</source><year>2020</year>; <volume>22</volume>: <comment>e17632</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/17632</pub-id><pub-id pub-id-type="pmcid">PMC7380990</pub-id><pub-id pub-id-type="pmid">32469314</pub-id></mixed-citation></ref><ref id="bibr35-13872877251371236"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coelho</surname><given-names>T</given-names></name><name name-style="western"><surname>Marques</surname><given-names>C</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>D</given-names></name></person-group>, <etal>et al.</etal><article-title>Promoting reminiscences with virtual reality headsets: a pilot study with people with dementia</article-title>. <source>Int J Environ Res Public Health</source><year>2020</year>; <volume>17</volume>: <fpage>9301</fpage>.<pub-id pub-id-type="pmid">33322679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijerph17249301</pub-id><pub-id pub-id-type="pmcid">PMC7763810</pub-id></mixed-citation></ref><ref id="bibr36-13872877251371236"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Cunha</surname><given-names>NM</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>D</given-names></name><name name-style="western"><surname>Naumovski</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>A mini-review of virtual reality-based interventions to promote well-being for people living with dementia and mild cognitive impairment</article-title>. <source>Gerontology</source><year>2019</year>; <volume>65</volume>: <fpage>430</fpage>&#8211;<lpage>440</lpage>.<pub-id pub-id-type="pmid">31108489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000500040</pub-id></mixed-citation></ref><ref id="bibr37-13872877251371236"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Moussavi</surname><given-names>Z</given-names></name></person-group>. <article-title>Neurocognitive treatment for a patient with Alzheimer&#8217;s disease using a virtual reality navigational environment</article-title>. <source>J Exp Neurosci</source><year>2016</year>; <volume>10</volume>: <fpage>129</fpage>&#8211;<lpage>135</lpage>.<pub-id pub-id-type="pmid">27840579</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4137/JEN.S40827</pub-id><pub-id pub-id-type="pmcid">PMC5102253</pub-id></mixed-citation></ref><ref id="bibr38-13872877251371236"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saredakis</surname><given-names>D</given-names></name><name name-style="western"><surname>Keage</surname><given-names>HA</given-names></name><name name-style="western"><surname>Corlis</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>The effect of reminiscence therapy using virtual reality on apathy in residential aged care: multisite nonrandomized controlled trial</article-title>. <source>J Med Internet Res</source><year>2021</year>; <volume>23</volume>: <comment>e29210</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/29210</pub-id><pub-id pub-id-type="pmcid">PMC8491119</pub-id><pub-id pub-id-type="pmid">34542418</pub-id></mixed-citation></ref><ref id="bibr39-13872877251371236"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khirallah Abd El Fatah</surname><given-names>N</given-names></name><name name-style="western"><surname>Abdelwahab Khedr</surname><given-names>M</given-names></name><name name-style="western"><surname>Alshammari</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Effect of immersive virtual reality reminiscence versus traditional reminiscence therapy on cognitive function and psychological well-being among older adults in assisted living facilities: a randomized controlled trial</article-title>. <source>Geriatr Nurs (Minneap)</source><year>2024</year>; <volume>55</volume>: <fpage>191</fpage>&#8211;<lpage>203</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gerinurse.2023.11.010</pub-id><pub-id pub-id-type="pmid">38007908</pub-id></mixed-citation></ref><ref id="bibr40-13872877251371236"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dwan</surname><given-names>K</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name></person-group>, <etal>et al.</etal><article-title>CONSORT 2010 Statement: extension to randomised crossover trials</article-title>. <source>Br Med J</source><year>2019</year>; <volume>366</volume>: <comment>l4378</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.l4378</pub-id><pub-id pub-id-type="pmcid">PMC6667942</pub-id><pub-id pub-id-type="pmid">31366597</pub-id></mixed-citation></ref><ref id="bibr41-13872877251371236"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holstila</surname><given-names>E</given-names></name><name name-style="western"><surname>Vallittu</surname><given-names>A</given-names></name><name name-style="western"><surname>Ranto</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>World medical association declaration of Helsinki</article-title>. <source>JAMA</source><year>2013</year>; <volume>310</volume>: <fpage>2191</fpage>.<pub-id pub-id-type="pmid">24141714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2013.281053</pub-id></mixed-citation></ref><ref id="bibr42-13872877251371236"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reisberg</surname><given-names>B</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>S</given-names></name><name name-style="western"><surname>De Leon</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>The global deterioration scale for assessment of primary degenerative dementia</article-title>. <source>Am J Psychiatry</source><year>1982</year>; <volume>139</volume>: <fpage>1136</fpage>&#8211;<lpage>1139</lpage>.<pub-id pub-id-type="pmid">7114305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/ajp.139.9.1136</pub-id></mixed-citation></ref><ref id="bibr43-13872877251371236"><label>43</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Barreto</surname><given-names>J</given-names></name><name name-style="western"><surname>Leuschner</surname><given-names>A</given-names></name><name name-style="western"><surname>Santos</surname><given-names>F</given-names></name></person-group>, <etal>et al.</etal><source>Escalas e Testes Na Dem&#234;ncia [Scales and Tests in Dementia]</source>. <edition>2nd ed.</edition><publisher-loc>Condeixa, Coimbra, Portugal</publisher-loc>: <publisher-name>Grupo de Estudos de Envelhecimento Cerebral e Dem&#234;ncias [Study Group on Brain Aging and Dementia]</publisher-name>, <year>2008</year>.</mixed-citation></ref><ref id="bibr44-13872877251371236"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>C</given-names></name><name name-style="western"><surname>Sung</surname><given-names>B</given-names></name><name name-style="western"><surname>Moyle</surname><given-names>W</given-names></name></person-group>. <article-title>Engagement of a person with dementia scale: establishing content validity and psychometric properties</article-title>. <source>J Adv Nurs</source><year>2018</year>; <volume>74</volume>: <fpage>2227</fpage>&#8211;<lpage>2240</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jan.13717</pub-id><pub-id pub-id-type="pmid">29772602</pub-id></mixed-citation></ref><ref id="bibr45-13872877251371236"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jao</surname><given-names>YL</given-names></name><name name-style="western"><surname>Algase</surname><given-names>DL</given-names></name><name name-style="western"><surname>Specht</surname><given-names>JK</given-names></name></person-group>, <etal>et al.</etal><article-title>Developing the person&#8211;environment apathy rating for persons with dementia</article-title>. <source>Aging Ment Health</source><year>2016</year>; <volume>20</volume>: <fpage>861</fpage>&#8211;<lpage>870</lpage>.<pub-id pub-id-type="pmid">25984756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13607863.2015.1043618</pub-id></mixed-citation></ref><ref id="bibr46-13872877251371236"><label>46</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Lawton</surname><given-names>M</given-names></name><name name-style="western"><surname>Van Haitsma</surname><given-names>K</given-names></name><name name-style="western"><surname>Klapper</surname><given-names>J</given-names></name></person-group>. <comment>Observed Emotion Rating Scale, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://abramsonseniorcare.org/media/1199/observed-emotion-rating-scale.pdf" ext-link-type="uri">https://abramsonseniorcare.org/media/1199/observed-emotion-rating-scale.pdf</ext-link></comment> (<year>1999</year>).</mixed-citation></ref><ref id="bibr47-13872877251371236"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mads&#248;</surname><given-names>KG</given-names></name><name name-style="western"><surname>Pachana</surname><given-names>NA</given-names></name><name name-style="western"><surname>Nordhus</surname><given-names>IH</given-names></name></person-group>. <article-title>Development of the observable well-being in living with dementia-scale</article-title>. <source>Am J Alzheimers Dis Other Demen</source><year>2023</year>; <volume>38</volume>: <fpage>15333175231171990</fpage>.<pub-id pub-id-type="pmid">37269060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/15333175231171990</pub-id><pub-id pub-id-type="pmcid">PMC10624086</pub-id></mixed-citation></ref><ref id="bibr48-13872877251371236"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kourtis</surname><given-names>LC</given-names></name><name name-style="western"><surname>Regele</surname><given-names>OB</given-names></name><name name-style="western"><surname>Wright</surname><given-names>JM</given-names></name></person-group>, <etal>et al.</etal><article-title>Digital biomarkers for Alzheimer&#8217;s disease: the mobile/wearable devices opportunity</article-title>. <source>NPJ Digit Med</source><year>2019</year>; <volume>2</volume>: <fpage>9</fpage>.<pub-id pub-id-type="pmid">31119198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-019-0084-2</pub-id><pub-id pub-id-type="pmcid">PMC6526279</pub-id></mixed-citation></ref><ref id="bibr49-13872877251371236"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perna</surname><given-names>G</given-names></name><name name-style="western"><surname>Riva</surname><given-names>A</given-names></name><name name-style="western"><surname>Defillo</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Heart rate variability: can it serve as a marker of mental health resilience?</article-title><source>J Affect Disord</source><year>2020</year>; <volume>263</volume>: <fpage>754</fpage>&#8211;<lpage>761</lpage>.<pub-id pub-id-type="pmid">31630828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2019.10.017</pub-id></mixed-citation></ref><ref id="bibr50-13872877251371236"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaffer</surname><given-names>F</given-names></name><name name-style="western"><surname>Ginsberg</surname><given-names>JP</given-names></name></person-group>. <article-title>An overview of heart rate variability metrics and norms</article-title>. <source>Front Public Health</source><year>2017</year>; <volume>5</volume>: <fpage>258</fpage>.<pub-id pub-id-type="pmid">29034226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpubh.2017.00258</pub-id><pub-id pub-id-type="pmcid">PMC5624990</pub-id></mixed-citation></ref><ref id="bibr51-13872877251371236"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laborde</surname><given-names>S</given-names></name><name name-style="western"><surname>Mosley</surname><given-names>E</given-names></name><name name-style="western"><surname>Thayer</surname><given-names>JF</given-names></name></person-group>. <article-title>Heart rate variability and cardiac vagal tone in psychophysiological research &#8211; recommendations for experiment planning, data analysis, and data reporting</article-title>. <source>Front Psychol</source><year>2017</year>; <volume>8</volume>: <fpage>213</fpage>.<pub-id pub-id-type="pmid">28265249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyg.2017.00213</pub-id><pub-id pub-id-type="pmcid">PMC5316555</pub-id></mixed-citation></ref><ref id="bibr52-13872877251371236"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nayak</surname><given-names>SK</given-names></name><name name-style="western"><surname>Pradhan</surname><given-names>B</given-names></name><name name-style="western"><surname>Mohanty</surname><given-names>B</given-names></name></person-group>, <etal>et al.</etal><article-title>A review of methods and applications for a heart rate variability analysis</article-title>. <source>Algorithms</source><year>2023</year>; <volume>16</volume>: <fpage>433</fpage>.</mixed-citation></ref><ref id="bibr53-13872877251371236"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaffer</surname><given-names>F</given-names></name><name name-style="western"><surname>McCraty</surname><given-names>R</given-names></name><name name-style="western"><surname>Zerr</surname><given-names>CL</given-names></name></person-group>. <article-title>A healthy heart is not a metronome: an integrative review of the heart&#8217;s anatomy and heart rate variability</article-title>. <source>Front Psychol</source><year>2014</year>; <volume>5</volume>: <fpage>1040</fpage>.<pub-id pub-id-type="pmid">25324790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyg.2014.01040</pub-id><pub-id pub-id-type="pmcid">PMC4179748</pub-id></mixed-citation></ref><ref id="bibr54-13872877251371236"><label>54</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Gomes</surname><given-names>P</given-names></name><name name-style="western"><surname>Margaritoff</surname><given-names>P</given-names></name><name name-style="western"><surname>Pl&#225;cido da Silva</surname><given-names>H</given-names></name></person-group>. <conf-name>pyHRV: development and evaluation of an open-source python toolbox for heart rate variability (HRV)</conf-name>. In: <conf-name>Int conf electr electron comput eng</conf-name>, <year>2019</year>, pp.<fpage>822</fpage>&#8211;<lpage>828</lpage>.</mixed-citation></ref><ref id="bibr55-13872877251371236"><label>55</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Gomes</surname><given-names>P</given-names></name></person-group>. <comment>pyHRV &#8211; OpenSource Python Toolbox for Heart Rate Variability Documentation Release 0.4</comment> (<year>2022</year>).</mixed-citation></ref><ref id="bibr56-13872877251371236"><label>56</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Gignac</surname><given-names>G.</given-names></name></person-group><comment><italic toggle="yes">How2statsbook (Online Edition 2)</italic></comment> (<year>2023</year>).</mixed-citation></ref><ref id="bibr57-13872877251371236"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Yan</surname><given-names>W</given-names></name></person-group>, <etal>et al.</etal><article-title>The application of fully immersive virtual reality on reminiscence interventions for older adults: scoping review</article-title>. <source>JMIR Serious Games</source><year>2023</year>; <volume>11</volume>: <comment>e45539</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/45539</pub-id><pub-id pub-id-type="pmcid">PMC10589832</pub-id><pub-id pub-id-type="pmid">37801360</pub-id></mixed-citation></ref><ref id="bibr58-13872877251371236"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendez</surname><given-names>MF</given-names></name><name name-style="western"><surname>Karve</surname><given-names>S</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>E</given-names></name></person-group>. <article-title>Virtual reality for the assessment of frontotemporal dementia, a feasibility study</article-title>. <source>Disabil Rehabil Assist Technol</source><year>2015</year>; <volume>10</volume>: <fpage>160</fpage>&#8211;<lpage>164</lpage>.<pub-id pub-id-type="pmid">24524440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/17483107.2014.889230</pub-id></mixed-citation></ref><ref id="bibr59-13872877251371236"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirk</surname><given-names>M</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>KW</given-names></name><name name-style="western"><surname>Overgaard</surname><given-names>SB</given-names></name></person-group>, <etal>et al.</etal><article-title>Five weeks of immersive reminiscence therapy improves autobiographical memory in Alzheimer&#8217;s disease</article-title>. <source>Memory</source><year>2019</year>; <volume>27</volume>: <fpage>441</fpage>&#8211;<lpage>454</lpage>.<pub-id pub-id-type="pmid">30198380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09658211.2018.1515960</pub-id></mixed-citation></ref><ref id="bibr60-13872877251371236"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akhter</surname><given-names>R</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name><name name-style="western"><surname>Quevedo</surname><given-names>AJU</given-names></name></person-group>, <etal>et al.</etal><article-title>Perceived barriers and solutions identified by healthcare professionals in utilizing web-based reminiscence therapy to support dementia care during the pandemic</article-title>. <source>Aging Clin Exp Res</source><year>2023</year>; <volume>35</volume>: <fpage>2843</fpage>&#8211;<lpage>2846</lpage>.<pub-id pub-id-type="pmid">37581860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40520-023-02520-w</pub-id></mixed-citation></ref><ref id="bibr61-13872877251371236"><label>61</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>A</given-names></name><name name-style="western"><surname>Seals</surname><given-names>CD</given-names></name><name name-style="western"><surname>Garza</surname><given-names>KB</given-names></name></person-group>, <etal>et al.</etal><part-title>Non-immersive vs. immersive: the difference in empathy, user engagement, and user experience when simulating the daily life of rheumatoid arthritis patients</part-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Duffy</surname><given-names>VG</given-names></name></person-group> (ed) <source>Digital human modeling and applications in health, safety, ergonomics and risk management</source>. <comment>HCII 2023. Lecture Notes in Computer Science</comment>, vol. <volume>14029</volume>. <publisher-loc>Cham</publisher-loc>: <publisher-name>Springer</publisher-name>, <year>2023</year>, pp.<fpage>562</fpage>&#8211;<lpage>575</lpage>.</mixed-citation></ref><ref id="bibr62-13872877251371236"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Somarathna</surname><given-names>R</given-names></name><name name-style="western"><surname>Bednarz</surname><given-names>T</given-names></name><name name-style="western"><surname>Mohammadi</surname><given-names>G</given-names></name></person-group>. <article-title>Virtual reality for emotion elicitation &#8211; a review</article-title>. <source>IEEE Trans Affect Comput</source><year>2022</year>; <volume>14</volume>: <fpage>2626</fpage>&#8211;<lpage>2645</lpage>.</mixed-citation></ref><ref id="bibr63-13872877251371236"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>K</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>A systematic review and meta-analysis on the effect of reminiscence therapy for people with dementia</article-title>. <source>Int Psychogeriatrics</source><year>2019</year>; <volume>31</volume>: <fpage>1581</fpage>&#8211;<lpage>1597</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610218002168</pub-id><pub-id pub-id-type="pmid">30712519</pub-id></mixed-citation></ref><ref id="bibr64-13872877251371236"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaze</surname><given-names>F</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>L</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Virtual reality and well-being in older adults: results from a pilot implementation of virtual reality in long-term care</article-title>. <source>J Rehabil Assist Technol Eng</source><year>2022</year>; <volume>9</volume>: <fpage>205566832110723</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/20556683211072384</pub-id><pub-id pub-id-type="pmcid">PMC8832624</pub-id><pub-id pub-id-type="pmid">35154808</pub-id></mixed-citation></ref><ref id="bibr65-13872877251371236"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aganov</surname><given-names>S</given-names></name><name name-style="western"><surname>Nayshtetik</surname><given-names>E</given-names></name><name name-style="western"><surname>Nagibin</surname><given-names>V</given-names></name></person-group>, <etal>et al.</etal><article-title>Pure purr virtual reality technology: measuring heart rate variability and anxiety levels in healthy volunteers affected by moderate stress</article-title>. <source>Arch Med Sci</source><year>2020</year>; <volume>18</volume>: <fpage>336</fpage>&#8211;<lpage>343</lpage>.<pub-id pub-id-type="pmid">35316901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5114/aoms.2020.93239</pub-id><pub-id pub-id-type="pmcid">PMC8924843</pub-id></mixed-citation></ref><ref id="bibr66-13872877251371236"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>CH</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name></person-group>. <article-title>Understanding how virtual reality forest experience promote physiological and psychological health for patients undergoing hemodialysis</article-title>. <source>Front Psychiatry</source><year>2022</year>; <volume>13</volume>: <fpage>1007396</fpage>.<pub-id pub-id-type="pmid">36590601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2022.1007396</pub-id><pub-id pub-id-type="pmcid">PMC9794622</pub-id></mixed-citation></ref><ref id="bibr67-13872877251371236"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Appel</surname><given-names>L</given-names></name><name name-style="western"><surname>Appel</surname><given-names>E</given-names></name><name name-style="western"><surname>Bogler</surname><given-names>O</given-names></name></person-group>, <etal>et al.</etal><article-title>Older adults with cognitive and/or physical impairments can benefit from immersive virtual reality experiences: a feasibility study</article-title>. <source>Front Med (Lausanne)</source><year>2020</year>; <volume>6</volume>: <fpage>329</fpage>.<pub-id pub-id-type="pmid">32010701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2019.00329</pub-id><pub-id pub-id-type="pmcid">PMC6974513</pub-id></mixed-citation></ref><ref id="bibr68-13872877251371236"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saragih</surname><given-names>ID</given-names></name><name name-style="western"><surname>Tonapa</surname><given-names>SI</given-names></name><name name-style="western"><surname>Yao</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Effects of reminiscence therapy in people with dementia: a systematic review and meta-analysis</article-title>. <source>J Psychiatr Ment Health Nurs</source><year>2022</year>; <volume>29</volume>: <fpage>883</fpage>&#8211;<lpage>903</lpage>.<pub-id pub-id-type="pmid">35348260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jpm.12830</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neuroinflammation</journal-id><journal-id journal-id-type="iso-abbrev">J Neuroinflammation</journal-id><journal-id journal-id-type="pmc-domain-id">249</journal-id><journal-id journal-id-type="pmc-domain">jneuro</journal-id><journal-title-group><journal-title>Journal of Neuroinflammation</journal-title></journal-title-group><issn pub-type="epub">1742-2094</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12495855</article-id><article-id pub-id-type="pmcid-ver">PMC12495855.1</article-id><article-id pub-id-type="pmcaid">12495855</article-id><article-id pub-id-type="pmcaiid">12495855</article-id><article-id pub-id-type="pmid">41044568</article-id><article-id pub-id-type="doi">10.1186/s12974-025-03552-x</article-id><article-id pub-id-type="publisher-id">3552</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Cytokine expression profile in the human brain of older adults</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Godoy</surname><given-names initials="JB">Juliana Beker</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vialle</surname><given-names initials="RA">Ricardo A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>dos Santos</surname><given-names initials="L">Loren</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Raittz</surname><given-names initials="RT">Roberto T.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yanling</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Menon</surname><given-names initials="V">Vilas</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>De Jager</surname><given-names initials="PL">Philip L.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schneider</surname><given-names initials="JA">Julie A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tasaki</surname><given-names initials="S">Shinya</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bennett</surname><given-names initials="DA">David A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guizelini</surname><given-names initials="D">Dieval</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>de Paiva Lopes</surname><given-names initials="K">Katia</given-names></name><address><email>Katia_d_Lopes@rush.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05syd6y78</institution-id><institution-id institution-id-type="GRID">grid.20736.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 1941 472X</institution-id><institution>Professional and Technological Education Sector, </institution><institution>Federal University of Paran&#225;, </institution></institution-wrap>Curitiba, Brazil </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01j7c0b24</institution-id><institution-id institution-id-type="GRID">grid.240684.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0705 3621</institution-id><institution>Rush Alzheimer&#8217;s Disease Center, </institution><institution>Rush University Medical Center, </institution></institution-wrap>Chicago, IL USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01esghr10</institution-id><institution-id institution-id-type="GRID">grid.239585.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2285 2675</institution-id><institution>Center for Translational &amp; Computational Neuroimmunology, Department of Neurology and the Taub Institute for Research On Alzheimer&#8217;s Disease and the Aging Brain, </institution><institution>Columbia University Irving Medical Center, </institution></institution-wrap>New York, NY USA </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>22</volume><issue-id pub-id-type="pmc-issue-id">478515</issue-id><elocation-id>224</elocation-id><history><date date-type="received"><day>16</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>3</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 14:25:37.640"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12974_2025_Article_3552.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="preprint" xml:lang="en" xlink:title="research-article" vol="6" elocation-id="2025.06.02.657444" journal-id="bioRxiv" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC12157510"><article-title>Cytokine expression profile in the human brain of older adults</article-title><date><day>4</day><month>6</month><year>2025</year></date><elocation-id>2025.06.02.657444</elocation-id><source>bioRxiv</source><pub-id pub-id-type="pmcid">PMC12157510</pub-id><pub-id pub-id-type="pmid">40501916</pub-id></related-article><abstract id="Abs1"><p id="Par1">Alzheimer&#8217;s disease (AD) is a complex neurodegenerative condition linked to chronic neuroinflammation. This study investigates the cytokine gene expression profile in cortical tissue samples from elderly individuals with and without AD to identify potential biomarkers and enhance our understanding of disease pathogenesis. Utilizing high-depth RNA sequencing data, we identified a set of cytokines whose expression significantly associated with different aspects of the AD phenotype, including measures of neurofibrillary tangles, amyloid-&#946; deposition, and a person-specific rate of cognitive decline. Single-nucleus transcriptomics data facilitated the identification of specific cell types, such as microglia and astrocytes, that significantly contribute to the inflammatory response in AD. Additionally, we observed a correlation between the expression of certain cytokines and genetic risk for the disease. Our findings indicate that cytokine-mediated neuroinflammation may play an important role in neurodegeneration and that modulating the immune response may offer a promising strategy for developing new therapies.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12974-025-03552-x.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alzheimer&#8217;s disease</kwd><kwd>Cytokines</kwd><kwd>Neuroinflammation</kwd><kwd>Single-nuclei RNA-Seq</kwd><kwd>Transcriptomics</kwd><kwd>Biomarkers</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100002322</institution-id><institution>Coordena&#231;&#227;o de Aperfei&#231;oamento de Pessoal de N&#237;vel Superior</institution></institution-wrap></funding-source><award-id>Student fellowship</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>U01AG46152</award-id><award-id>P30AG72975</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Alzheimer&#8217;s disease (AD) is the most common cause of dementia and one of the top ten causes of death worldwide. Even though it is expected to affect 150 million people by 2050, no effective treatment or diagnosis is currently available [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. AD is a neurodegenerative disorder characterized by extracellular amyloid-&#946; plaques and intracellular hyperphosphorylated tau tangles [<xref ref-type="bibr" rid="CR3">3</xref>]. While it typically manifests with memory loss, it can also affect speech, visuospatial skills, and executive functions [<xref ref-type="bibr" rid="CR4">4</xref>]. Cognitive impairment in AD varies, with early signs often appearing as subjective decline despite normal assessments. Mild cognitive impairment (MCI) marks the initial symptomatic stage, featuring slight deficits in one or more cognitive domains while maintaining daily functioning [<xref ref-type="bibr" rid="CR5">5</xref>]. Recent anti-amyloid antibody trials have challenged the notion that amyloid-&#946; accumulation is the sole cause of AD. The findings indicate a more complex disease process involving various interacting factors, where amyloid-&#946; pathology may act as a necessary trigger but is insufficient to drive the disease fully [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par3">For many years, neuroinflammation was considered a secondary response to neuronal death. However, a great number of epidemiological, clinical, and experimental studies now widely recognize neuroinflammation as a central feature of AD, highlighting its role in the disease's pathological process [<xref ref-type="bibr" rid="CR8">8</xref>&#8211;<xref ref-type="bibr" rid="CR10">10</xref>]. Genome-wide association studies (GWAS) have shown that over 51% of AD risk genes are enriched in innate immune system pathways, including in microglia, the myeloid cells of the brain [<xref ref-type="bibr" rid="CR11">11</xref>&#8211;<xref ref-type="bibr" rid="CR13">13</xref>]. Additionally, rare AD risk variants have been identified in genes crucial for immune responses, particularly those involved in microglial activation and phagocytic functions (e.g., <italic toggle="yes">TREM2</italic>, <italic toggle="yes">APOE</italic>) [<xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par4">Building on the understanding that the immune system pathways are crucial to AD risk [<xref ref-type="bibr" rid="CR17">17</xref>], neuroinflammation has emerged as a central aspect of the disease's progression. Neuroinflammation is initiated by activating the brain's innate immune system in response to protein buildup, with cytokines acting as key mediators [<xref ref-type="bibr" rid="CR18">18</xref>]. Produced by activated glial cells and neurons, these signaling molecules include interleukins, chemokines, tumor necrosis factors, interferons, and growth factors. Under healthy conditions, cytokines are crucial to neurodevelopment and regulating cognitive functions like synaptic neurotransmission, brain plasticity, learning, and memory retention [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. On the other hand, cytokines promote inflammation through intercellular communication, accelerating AD progression [<xref ref-type="bibr" rid="CR21">21</xref>]. Previous studies have shown that elderly individuals with amyloid-&#946; neuropathology and cognitive decline exhibit increased brain cytokine expression [<xref ref-type="bibr" rid="CR22">22</xref>]. Here, we extend these findings by leveraging data from two longitudinal cohorts, the Religious Orders Study and the Rush Memory and Aging Project (ROS/MAP) (D. A. [<xref ref-type="bibr" rid="CR23">23</xref>]) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). We investigated cytokine expression in the cortical brain tissue of community-dwelling older adults and its role in AD and related disorders (ADRD). First, we examined the association of these genes with AD pathology and cognitive decline. Next, we explored cell-type-specific expression profiles using single-nucleus RNA sequencing (snRNA-Seq). Then, we evaluated the relationship between AD genetic risk and cytokine expression. Finally, we conducted cell communication analysis to understand the intercellular communication mediated by these inflammatory molecules.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Study design overview. <bold>a</bold> This study analyzed (1) bulk RNA-Seq data (<italic toggle="yes">n</italic>&#8201;=&#8201;1,210) and a subset of (2) snRNA-Seq data (<italic toggle="yes">n</italic>&#8201;=&#8201;424) from the dorsolateral pre-frontal cortex (DLPFC) region of ROSMAP participants. <bold>b</bold> Expression matrices were filtered to retain only cytokine genes, and their associations with selected AD traits were tested using linear and/or logistic regression models. A sex-specific analysis was also included. <bold>c</bold> VariancePartition analysis and AD genetic risk scores (AD-PRS) were used to identify potential expression drivers. <bold>d</bold> Cell&#8211;cell communication analysis among microglial subpopulations revealed cytokine signaling pathways in human-aged brains. Figure created by the author using biorender</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e363" position="float" orientation="portrait" xlink:href="12974_2025_3552_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec2"><title>Results</title><sec id="Sec3"><title>Characteristics of the participants</title><p id="Par5">Transcriptomic data originate from participants of two longitudinal clinical-pathological studies of aging and dementia, the Religious Orders Study (ROS) and the Rush Memory and Aging Project (MAP), commonly referred to as ROSMAP. Both studies were approved by the Institutional Review Board of Rush University Medical Center (Chicago, IL). The participants are older adults who enroll without dementia and agree to longitudinal clinical evaluations and organ donation. To date, ROSMAP has enrolled over 4,000 participants and conducted more than 2,000 brain autopsies. The bulk RNA-Seq data from the dorsolateral pre-frontal cortex (DLPFC) were available for 1,210 participants (Supplementary Table&#160;01&#8211;02), and the snRNA-Seq for a subset of 424 participants. The participants enrolled at a mean age of 80.8 (SD: 7.0) years and died at an average age of 89.5 (SD: 6.6), with 68% being female. At death, 32.9% had no cognitive impairment (NCI), 23.6% had mild cognitive impairment (MCI), and the remaining 43.5% had dementia. At autopsy, 64% had a pathologic AD diagnosis. The characteristics were similar for the participants with snRNA-Seq data (Supplementary Table&#160;03). As expected, the cohorts are mainly composed of volunteers carrying two &#949;3 alleles of the <italic toggle="yes">APOE</italic> gene (60.74%), and at least 25.21% of individuals have one &#949;4 allele in the RNA-Seq data (Supplementary Fig.&#160;1; Supplementary Tables 02&#8211;04).</p></sec><sec id="Sec4"><title>Cytokine expression associated with cognitive decline and neuropathologies</title><p id="Par6">First, we investigated the associations between cytokine expression from bulk RNA-Seq data and seven AD-related traits. These traits included the accumulation of AD pathology measured by PHFtau tangle density and amyloid-&#946; load, global AD pathology capturing the overall burden of AD in the aged brain, the rate of cognitive decline for each participant, a measure of cognitive resilience, and the clinical outcomes represented by Alzheimer's dementia and MCI diagnoses. Overall, 22 out of 42 cytokines (52.4%) were associated with at least one of the tested traits (adj. <italic toggle="yes">p</italic>-value&#8201;&lt;&#8201;0.05) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref> and Supplementary Table&#160;05). Specifically, 15 cytokines were associated with PHFtau tangle density and cognitive decline; 13 with global AD burden; and 11 with amyloid-&#946; load and resilience. The strongest association was observed between <italic toggle="yes">IL15</italic> expression and cognitive decline (estimate: &#8722;0.177, SE: 0.029, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;3.301&#8201;&#215;&#8201;10<sup>&#8211;7</sup>), with <italic toggle="yes">IL15</italic> also associated with increased odds of AD (OR&#8201;=&#8201;1.311, 95% CI: 1.162 to 1.479) and MCI (OR&#8201;=&#8201;1.227, 95% CI: 1.081 to 1.393) diagnoses (Figs.&#160;<xref rid="Fig2" ref-type="fig">2</xref>a-b). As expected, these associations overlapped across traits. For example, 11 cytokines (<italic toggle="yes">CSF1</italic>, <italic toggle="yes">NOG</italic>, <italic toggle="yes">IL15, IL18, CTF1, IL33, SPP1, CCL2, TGFB1, THPO,</italic> and <italic toggle="yes">HGF</italic>) were significantly associated with both cognitive decline and PHFtau tangle density, while 5 cytokines (<italic toggle="yes">TGFB1, CCL2</italic>, <italic toggle="yes">SPP1</italic>, <italic toggle="yes">CTF1</italic>, and <italic toggle="yes">CSF1</italic>) were associated with all the tested traits. Furthermore, 4 cytokines were associated with lower odds of AD diagnosis and MCI (<italic toggle="yes">IGF1, THPO, TNFSF4, IL33</italic>). By contrast, 12 genes were linked with higher odds of these clinical outcomes (<italic toggle="yes">DCN, HGF, FLT3LG, TGFB1, CCL2, SPP1, PSPN, CTF1, IL18, IL15, CSF1,</italic> and <italic toggle="yes">TNFSF12</italic>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Association analysis between brain inflammatory cytokine expression and AD traits. <bold>a</bold> Effects of significant associations between cytokine expression levels in bulk DLPFC data (plot a) and microglia (plot c) with AD-related phenotypes. Results from linear regressions are shown in the heatmap, where color represents the standardized effect sizes. Asterisks indicate the significance based on FDR-adjusted <italic toggle="yes">p</italic>-values (***&#8201;&lt;&#8201;0.001, **&#8201;&lt;&#8201;0.01, *&#8201;&lt;&#8201;0.05,.&#8201;&lt;&#8201;0.1). Numbers inside the cells represent the -log<sub>10</sub>(nominal <italic toggle="yes">p</italic>-value) for results where FDR&#8201;&lt;&#8201;0.05. For logistic regression models, odds ratios (OR) and 95% confidence intervals are shown. AD traits are labelled according to their category: Pathology (global AD pathology burden, PHFtau tangle density, and amyloid-&#946; load) and Cognition (cognitive decline and resilience). All models were adjusted for age, sex, years of education, and postmortem interval (PMI) to control for potential confounding factors. <bold>b</bold> Scatter plot showing the association of <italic toggle="yes">IL15</italic> expression in the bulk DLPFC data and cognitive decline. <bold>d</bold> Scatter plot illustrating the association between <italic toggle="yes">IL15</italic> expression in microglia and global AD pathology burden. In both <bold>b</bold> and <bold>d</bold>, regression lines are shown for participants based on their clinical diagnosis (AD, MCI, or NCI), along with the corresponding Spearman correlation coefficients and <italic toggle="yes">p</italic>-values. <bold>e&#8211;f</bold> Differential expression of <italic toggle="yes">IL15</italic> in bulk tissue (plot <bold>e</bold>) and microglia (plot f) across diagnostic groups: Alzheimer's dementia (AD; red), mild cognitive impairment (MCI; yellow), and no cognitive impairment (NCI; blue). Data are presented as boxplots, with median values shown by the central line and boxes spanning the first to the third quartiles. Pairwise statistically significant differences based on two-sided t-tests (Bonferroni-adjusted <italic toggle="yes">p</italic>-values) are indicated by asterisks (****&#8201;&lt;&#8201;0.0001, ***&#8201;&lt;&#8201;0.001, **&#8201;&lt;&#8201;0.01, *&#8201;&lt;&#8201;0.05)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e486" position="float" orientation="portrait" xlink:href="12974_2025_3552_Fig2_HTML.jpg"/></fig></p><p id="Par7">In the ROSMAP discovery dataset, cytokine genes showed significant associations with multiple AD-related traits. To assess generalizability, we expanded the analysis to two external bulk RNA-Seq datasets for replication: the Mayo Clinic and Mount Sinai Brain Bank (MSBB). In the Mayo Clinic data, 34 of the 44 expressed cytokines (77.3%) were significantly associated with Thal stage, Braak stage, and/or diagnostic status. Consistent with ROSMAP findings, 16 genes (<italic toggle="yes">DCN, HGF, THPO, TGFB1, CCL2, TNFSF4, SPP1, PSPN, C3, EGF, CTF1, IL18, TNFSF13, IL15, IL12A,</italic> and <italic toggle="yes">CSF1</italic>) demonstrated statistically significant associations across both datasets. In the MSBB dataset, 15 of 47 cytokines (31.9%) were associated with Braak stage and/or CDR score, and 10 of these genes (<italic toggle="yes">DCN, IGF1, TGFB1, PSPN, C3, IL33, TNFSF13, IL12A, CSF1,</italic> and <italic toggle="yes">TNFSF12</italic>) also showed significant associations in ROSMAP. Although the AD traits available in the external datasets differ from those in ROSMAP, these results indicate that cytokine genes are consistently associated with AD-related phenotypes across all three analyzed datasets (Supplementary Figs.&#160;2a-b and Supplementary Tables 06&#8211;07).</p></sec><sec id="Sec5"><title>Cytokine expression associated with cognitive decline and neuropathology in specific cell types</title><p id="Par8">Because cytokine production levels vary among different cell types, we investigated their associations with the same AD traits across the seven major cell types in the DLPFC. Cytokines were expressed in all cell types and significantly associated with AD traits, except in endothelial cells (Supplementary Fig.&#160;3 and Supplementary Table&#160;8). We identified 9 cytokines associated with AD traits in astrocytes, 8 in excitatory neurons, 7 in microglia, 3 in oligodendrocytes, 2 in inhibitory neurons, and 1 in oligodendrocyte progenitor cells (OPCs). The strongest association in astrocytes was found between <italic toggle="yes">IL33</italic> and PHFtau tangle density (estimate&#8201;=&#8201;&#8722;0.240, SE&#8201;=&#8201;0.047, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;7.191&#8201;&#215;&#8201;10<sup>&#8211;5</sup>) (Supplementary Fig.&#160;3c). <italic toggle="yes">IL33</italic> was also significantly associated with global AD pathology and cognitive decline. In excitatory neurons, the strongest association was found between <italic toggle="yes">THPO</italic> and cognitive decline (estimate&#8201;=&#8201;0.243, SE&#8201;=&#8201;0.049, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;1.689&#8201;&#215;&#8201;10<sup>&#8211;4</sup>), and <italic toggle="yes">THPO</italic> was also significantly associated with cognitive resilience, PHFtau tangle density and global AD pathology (Supplementary Fig.&#160;3a). Both, <italic toggle="yes">IL33</italic> and <italic toggle="yes">THPO</italic>, were protective for AD (OR&#8201;=&#8201;0.738, 95% CI: 0.599 to 0.909; OR&#8201;=&#8201;0.665, 95% CI: 0.539 to 0.821; respectively).</p><p id="Par9">The strongest association in the snRNA-Seq data was observed in microglia, between global AD burden and <italic toggle="yes">IL15</italic> levels (estimate&#8201;=&#8201;0.343, SE&#8201;=&#8201;0.046, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;7.298&#8201;&#215;&#8201;10<sup>&#8211;11</sup>; Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>c), with greater odds of AD (OR&#8201;=&#8201;1.371, 95% CI: 1.104 to 1.702) and MCI (OR&#8201;=&#8201;1.287, 95% CI: 1.046 to 1.583). Consistently, <italic toggle="yes">IL15</italic> overexpression was positively correlated with higher pathology deposition independent of diagnosis (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>d). We also observed a strong association between <italic toggle="yes">IL15</italic> expression and PHFtau tangle density (estimate&#8201;=&#8201;0.288, SE&#8201;=&#8201;0.046, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;4.071&#8201;&#215;&#8201;10<sup>&#8211;8</sup>) and amyloid-&#946; load (estimate&#8201;=&#8201;0.301, SE&#8201;=&#8201;0.046, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;1.416&#8201;&#215;&#8201;10<sup>&#8211;8</sup>) in microglia. This last association was observed only in this cell type and was not generalizable to the bulk data (adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.075), although both bulk and snRNA-Seq data showed significantly upregulated <italic toggle="yes">IL15</italic> levels in AD participants compared with individuals with NCI (Figs.&#160;<xref rid="Fig2" ref-type="fig">2</xref>e-f).</p><p id="Par10">A comparison of the datasets revealed that <italic toggle="yes">SPP1</italic> levels were significantly associated with all AD tested traits in bulk data but exhibited distinct patterns across cell types. In excitatory neurons, <italic toggle="yes">SPP1</italic> levels were negatively associated with cognitive decline (estimate&#8201;=&#8201;&#8722;0.180, SE&#8201;=&#8201;0.049, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.010) and resilience (estimate&#8201;=&#8201;&#8722;0.166, SE&#8201;=&#8201;0.052, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.022), and positively associated with PHFtau tangle density (estimate&#8201;=&#8201;0.142, SE&#8201;=&#8201;0.047, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.031). <italic toggle="yes">SPP1</italic> was also associated with greater odds of AD (OR&#8201;=&#8201;1.391, 95% CI: 1.126 to 1.718) in this cell type (Supplementary Fig.&#160;3a). In inhibitory neurons, <italic toggle="yes">SPP1</italic> showed significant associations only with cognition traits: cognitive decline (estimate&#8201;=&#8201;&#8722;0.202, SE&#8201;=&#8201;0.049, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.010) and resilience (estimate&#8201;=&#8201;&#8722;0.197, SE&#8201;=&#8201;0.051, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.013), also being associated with greater odds of AD (OR&#8201;=&#8201;1.380, 95% CI: 1.120 to 1.701) and MCI (OR&#8201;=&#8201;1.291, 95% CI: 1.040 to 1.603) (Supplementary Fig.&#160;3b). However, <italic toggle="yes">SPP1</italic> expression in microglia was associated only with global AD burden (estimate&#8201;=&#8201;0.217, SE&#8201;=&#8201;0.047, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;2.414&#8201;&#215;&#8201;10<sup>&#8211;4</sup>) and amyloid-&#946; load (estimate&#8201;=&#8201;0.214, SE&#8201;=&#8201;0.047, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;2.414&#8201;&#215;&#8201;10<sup>&#8211;4</sup>), showing no association with diagnostic traits (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>c).</p><p id="Par11">Some cytokine genes that were not detected in the bulk RNA-Seq but were expressed in the snRNA-Seq exhibited distinct association patterns. The expression of the anti-inflammatory chemokine <italic toggle="yes">CXCL17</italic> was positively associated with cognitive decline (estimate&#8201;=&#8201;0.162, SE&#8201;=&#8201;0.049, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.018) and negatively associated with PHFtau tangle density (estimate&#8201;=&#8201;&#8722;0.134, SE&#8201;=&#8201;0.047, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.042) in excitatory neurons (Supplementary Fig.&#160;3a). Also, <italic toggle="yes">CXCL17</italic> was associated with lower odds of MCI (OR&#8201;=&#8201;0.734, 95% CI: 0.591 to 0.911) in this cell type, suggesting a neuroprotective effect. Similarly, <italic toggle="yes">C5</italic> was not associated with phenotypic data in the bulk data; however, it showed a positive association with PHFtau tangle density in microglia (estimate&#8201;=&#8201;0.155, SE&#8201;=&#8201;0.047, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.015), with greater odds of AD (OR&#8201;=&#8201;1.256, 95% CI: 1.023 to 1.542) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>c). In contrast, <italic toggle="yes">C5</italic> was negatively associated with all pathological traits in astrocytes: PHFtau tangle density (estimate&#8201;=&#8201;&#8722;0.157, SE&#8201;=&#8201;0.047, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.015), amyloid-&#946; load (estimate&#8201;=&#8201;&#8722;0.142, SE&#8201;=&#8201;0.047, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.029), and global AD burden (estimate&#8201;=&#8201;&#8722;0.189, SE&#8201;=&#8201;0.047, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.003), being also associated with lower odds of AD diagnosis (OR&#8201;=&#8201;0.747, 95% CI: 0.609 to 0.916) (Supplementary Fig.&#160;3c). In OPCs, <italic toggle="yes">C5</italic> was the only significant association in this cell type, being negatively associated with cognitive decline (estimate&#8201;=&#8201;&#8722;0.188, SE&#8201;=&#8201;0.049, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.017) and with greater odds of AD (OR&#8201;=&#8201;1.257, 95% CI: 1.026 to 1.539) and MCI (OR&#8201;=&#8201;1.317, 95% CI: 1.070 to 1.622) (Supplementary Fig.&#160;3e). In summary, these findings reveal distinct neuroinflammation patterns across different brain cell types, with varying neuropathologic associations, suggesting that each cell type has a unique relationship with AD.</p></sec><sec id="Sec6"><title>Cytokine functional families and their associations with cognitive decline and neuropathology</title><p id="Par12">Considering that many cytokines exhibit both pro- and anti-inflammatory effects depending on context and expression levels [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR24">24</xref>], we classified them into functional families and investigated how their average expression in bulk and snRNA-Seq datasets could be associated with AD-related traits. In the bulk data, we found that cytokine genes classified as 'other' (e.g., <italic toggle="yes">TGFB1, THPO, PSPN, SPP1</italic>, including hormones and complement system proteins with cytokine-like functions, exhibited significant associations with all the tested AD-related traits and greater odds of AD (OR&#8201;=&#8201;1.318, 95% CI: 1.168 to 1.486 and MCI (OR&#8201;=&#8201;1.250, 95% CI: 1.102 to 1.418 (Supplementary Fig.&#160;4a; Supplementary Table&#160;9. The average expression of superfamily <italic toggle="yes">TNF</italic> was exclusively associated with cognitive decline (estimate&#8201;=&#8201;0.099, SE&#8201;=&#8201;0.029, adj. p-value&#8201;=&#8201;0.005) in bulk data, with lower odds of AD (OR&#8201;=&#8201;0.824, 95% CI: 0.733 to 0.928) and MCI (OR&#8201;=&#8201;0.845, 95% CI: 0.746 to 0.958). In the snRNA-Seq dataset (Supplementary Table&#160;10), &#8216;other&#8217; cytokine genes showed average expression levels associated with amyloid-&#946; load (estimate&#8201;=&#8201;0.208, SE&#8201;=&#8201;0.047, adj. p-value&#8201;=&#8201;3.683&#8201;&#215;&#8201;10<sup>&#8211;4</sup>) and global AD burden (estimate&#8201;=&#8201;0.207, SE&#8201;=&#8201;0.048, adj. p-value&#8201;=&#8201;3.683&#8201;&#215;&#8201;10<sup>&#8211;4</sup>) in microglia (Supplementary Fig. 4&#8201;d), as well as increased odds of AD (OR&#8201;=&#8201;1.237, 95% CI: 1.008 to 1.519). In astrocytes, the growth factor family was associated with all AD tested traits, showing greater odds of AD (OR&#8201;=&#8201;1.374, 95% CI: 1.120 to 1.686) and MCI (OR&#8201;=&#8201;1.268, 95% CI: 1.025 to 1.569) (Supplementary Fig.&#160;4e). Together, these results offer valuable insights into the cytokine function on brain inflammatory gene expression, deepening our understanding of neuroinflammatory mechanisms involved with Alzheimer&#8217;s dementia.</p></sec><sec id="Sec7"><title>Biological factors driving cytokine expression</title><p id="Par13">Next, we sought to investigate how much of the variance in cytokine expression could be explained by biological and AD-related traits (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>; Supplementary Fig.&#160;5). For this analysis, we used a linear mixed model to partition the variance attributable to multiple variables in the data (see <xref rid="Sec12" ref-type="sec">Methods</xref>). The analysis included the same AD traits previously described, age at death, sex, a binary variable indicating whether the participant had at least one allele &#949;4 harboring the <italic toggle="yes">APOE</italic> gene, and a measure of cerebral amyloid angiopathy (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref> and Supplementary Fig.&#160;5). While cytokine gene expression from endothelial cells was not significantly associated with AD traits (Supplementary Fig.&#160;3), variance partitioning analysis revealed that some AD traits still account for a proportion of cytokine expression variability across individuals (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref> and Supplementary Fig.&#160;5). With the bulk RNA-Seq data, we found that age at death was the strongest driver of variance in <italic toggle="yes">C3</italic> expression levels, accounting for 3.29% of the total variance. Cognitive decline was the next strongest factor, explaining 2.87% of the variance in <italic toggle="yes">IL15</italic> levels in bulk data. The global deposition of neurotoxic proteins had a 0.01% influence, while the <italic toggle="yes">APOE</italic> &#949;4 allele did not have a quantified influence on <italic toggle="yes">IL15</italic> expression (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>a and Supplementary Table&#160;11).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Contribution of biological drivers to cytokine expression variation. Distribution of variance explained per cytokine expression for (<bold>a</bold>) bulk RNA-Seq data from 1,210 participants and (<bold>b</bold>, <bold>c</bold>, <bold>d</bold>) from microglia, oligodendrocytes, and astrocytes, respectively. The y-axis represents the percentage of variance explained, while the x-axis shows the variance factors, with medians indicated by horizontal Lines. The box spans the first to third quartiles, and the whiskers extend 1.5 times the interquartile range from the box. Each dot represents one gene, and the top two genes were labeled for each variable tested</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e742" position="float" orientation="portrait" xlink:href="12974_2025_3552_Fig3_HTML.jpg"/></fig></p><p id="Par14">Overall, the max variance explained was between 3% in endothelial cells, 4% and 5% in neurons, and over 8% for the cytokines expressed in microglial cells (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref> and Supplementary Fig.&#160;5). For example, in microglia, amyloid-&#946; load (8.67%) and PHFtau tangle density (6.83%) contributed most to the variance of <italic toggle="yes">IL15</italic> expression levels (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>b and Supplementary Table&#160;12). In oligodendrocytes, cognitive decline (4.45%), PHFtau tangle density (4.49%), and amyloid-&#946; (2.02%) explained part of the total variance in <italic toggle="yes">SPP1</italic> levels (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>c). Amyloid-&#946; load was the strongest driver of <italic toggle="yes">IL7</italic> variance in excitatory neurons (4.67%), inhibitory neurons (4.09%), and OPCs (4.87%) (Supplementary Figs.&#160;5a&#8211;c). PHFtau tangle density contributed to <italic toggle="yes">IL33</italic> variance in both bulk (2.66%) and astrocytes (5.79%), as shown in Figs.&#160;<xref rid="Fig3" ref-type="fig">3</xref>a and 3&#8201;d, respectively. These results show that the percentage of variance explained for cytokines is cell-type dependent. Furthermore, AD-related traits explained a small fraction of the variance in cytokine expression, with cognitive decline, amyloid-&#946; load, and PHFtau tangle density being the most significant contributors.</p></sec><sec id="Sec8"><title>Sex-specific associations of cytokine genes</title><p id="Par15">To measure sex differences, we also evaluate associations between cytokine genes and AD traits in stratified matrices. Due to limitations in sample size, we restricted these analyses to the bulk RNA-Seq data (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). We observed that male volunteers had fewer cytokine genes associated with AD traits, with four genes significantly associated with at least one variable (<italic toggle="yes">THPO, CCL2, IL33,</italic> and <italic toggle="yes">IL15</italic>) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>c;Supplementary Table&#160;13). The strongest association was observed between <italic toggle="yes">THPO</italic> and cognitive decline (estimate&#8201;=&#8201;0.237, SE&#8201;=&#8201;0.051, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.001). Additionally, <italic toggle="yes">THPO</italic> and <italic toggle="yes">IL33</italic> were associated with lower odds of clinical outcomes. In male-stratified data, <italic toggle="yes">IL15</italic> was negatively associated only with cognitive decline (estimate&#8201;=&#8201;&#8722;0.166; SE&#8201;=&#8201;0.051, adj. p-value&#8201;=&#8201;0.046), and the odds ratios for AD and MCI diagnoses were not significant.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Association analysis between brain inflammatory cytokine expression and AD traits in sex-stratified bulk RNA-Seq dataset. <bold>a</bold> Bar plot showing the sex frequency among participants by diagnoses (AD, MCI, and NCI) in the bulk RNA-Seq data. Diagnosis variable available for 1,209 participants. <bold>b</bold> Histogram represents the age at baseline assessment, grouping volunteers by sex. The dashed lines represent the mean age among males (blue) and females (red). Effects of significant associations between cytokine expression levels in males (plot <bold>c</bold>) and females (plot <bold>d</bold>) with AD traits. Results from linear regressions are shown in the heatmap, where color represents the standardized effect sizes. Asterisks indicate the significance based on FDR-adjusted <italic toggle="yes">p</italic>-values (***&#8201;&lt;&#8201;0.001, **&#8201;&lt;&#8201;0.01, *&#8201;&lt;&#8201;0.05,.&#8201;&lt;&#8201;0.1). Numbers inside the cells represent the -log<sub>10</sub>(nominal <italic toggle="yes">p</italic>-value) for results where FDR&#8201;&lt;&#8201;0.05. For logistic regression models, odds ratios (OR) and 95% confidence intervals are shown. The variables are labelled according to their category: Pathology (global AD pathology burden, PHFtau tangle density, and amyloid-&#946; load) and Cognition (cognitive decline and resilience). All models were adjusted for age, years of education, and postmortem interval (PMI) to control for potential confounding factors</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e830" position="float" orientation="portrait" xlink:href="12974_2025_3552_Fig4_HTML.jpg"/></fig></p><p id="Par16">In females, a total of 21 cytokine genes were associated with AD variables, with 19 of them also associated in the full bulk dataset, reflecting a similar overall pattern (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>d; Supplementary Table&#160;14). The strongest association in females was observed between <italic toggle="yes">TGFB1</italic> with cognitive decline (estimate&#8201;=&#8201;&#8722;0.182, SE&#8201;=&#8201;0.035, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;2.656&#8201;&#215;&#8201;10<sup>&#8211;5</sup>). Furthermore, <italic toggle="yes">TGFB1</italic> was associated with greater odds of AD (OR&#8201;=&#8201;1.499, 95% CI: 1.289 to 1.743) and MCI (OR&#8201;=&#8201;1.488, 95% CI: 1.270 to 1.744) in females. <italic toggle="yes">IL15</italic> showed association with cognitive decline (estimate&#8201;=&#8201;&#8722;0.180, SE&#8201;=&#8201;0.035, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;2.656&#8201;&#215;&#8201;10<sup>&#8211;5</sup>), resilience (estimate&#8201;=&#8201;&#8722;0.141, SE&#8201;=&#8201;0.036, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.002), and PHFtau tangle density (estimate&#8201;=&#8201;0.098, SE&#8201;=&#8201;0.035, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.023). Also, <italic toggle="yes">IL15</italic> was associated with greater odds of AD (OR&#8201;=&#8201;1.359, 95% CI: 1.174 to 1.573) and MCI (OR&#8201;=&#8201;1.258, 95% CI: 1.077 to 1.469). <italic toggle="yes">SPP1</italic> showed associations only in females, being significantly associated with all AD tested traits. Furthermore, in this subcluster, a new association was observed between <italic toggle="yes">CX3CL1</italic> and cognitive variables: AD diagnosis (OR&#8201;=&#8201;0.794, 95% CI: 0.688 to 0.917) and MCI (OR&#8201;=&#8201;0.799, 95% CI: 0.684 to 0.932). Taken together, these findings highlight sex differences in cytokine gene association within the human brain of older adults. However, because the sample sizes differed, further analyses are necessary.</p></sec><sec id="Sec9"><title>AD genetic risk is associated with cytokine brain expression in specific cell types</title><p id="Par17">To investigate the influence of genetic variants on cytokine expression in the major cell types of the cortex, we tested the association of cytokine expression with <italic toggle="yes">APOE</italic> &#949;4 and polygenic risk scores for AD (AD-PRS). The PRS was constructed using the GWAS from Bellenguez et al. [<xref ref-type="bibr" rid="CR11">11</xref>] as reference (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>a). The association tests of cytokine expression with <italic toggle="yes">APOE</italic> &#949;4 and AD-PRS were performed using logistic and linear regressions, respectively. All models were controlled for age, sex, years of education, and postmortem interval (PMI). Although all individuals were of European ancestry, we also regressed the top three genotype PCs from the resulting AD-PRS to account for residual population structure. In all results across different cell types, only three cytokines reached statistical significance after multiple testing correction (FDR&#8201;&lt;&#8201;5%) (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>b; Supplementary Tables 15&#8211;16). Among the results, we observed that <italic toggle="yes">SPP1</italic> expression in microglia was positively associated with higher risk scores (estimate&#8201;=&#8201;0.163, SE&#8201;=&#8201;0.049, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.022), and nominally significant when compared with &#949;4 (OR&#8201;=&#8201;1.265, 95% CI: 1.010 to 1.585) (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>c). <italic toggle="yes">IL15</italic> expression, also in microglia, showed a significant association with &#949;4 (OR&#8201;=&#8201;1.516, 95% CI: 1.183 to 1.944) and a nominal association with AD-PRS (estimate&#8201;=&#8201;0.122, SE&#8201;=&#8201;0.049, <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.013) (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>d). Finally, <italic toggle="yes">IL17D</italic> levels in astrocytes were inversely associated with higher AD risk (estimate&#8201;=&#8201;&#8722;0.154, SE&#8201;=&#8201;0.048, adj. <italic toggle="yes">p</italic>-value&#8201;=&#8201;0.039), but not when compared with &#949;4 (OR&#8201;=&#8201;1.078, 95% CI: 0.865 to 1.343) (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>e).<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Cytokine production in distinct cell types was associated with the genetic risk score for AD. <bold>a</bold> Distribution of AD-PRS built for ROSMAP participants with snRNA-Seq (<italic toggle="yes">n</italic>&#8201;=&#8201;424). <bold>b</bold> Cytokines significantly associated (FDR&#8201;&lt;&#8201;0.05, adjusted within cell-type) with AD-PRS and <italic toggle="yes">APOE</italic> &#949;4 alleles. The y-axis shows the -log<sub>10</sub> nominal <italic toggle="yes">p</italic>-value, and the x-axis represents each cytokine grouped by cell types. All models were adjusted for age, sex, years of education, and PMI <bold>c-e</bold> Scatter plots showing the cytokines with significant association with AD-PRS or <italic toggle="yes">APOE</italic> &#949;4. <italic toggle="yes">SPP1</italic> in microglia (<bold>c</bold>), <italic toggle="yes">IL15</italic> in microglia (<bold>d</bold>), and <italic toggle="yes">IL17D</italic> in astrocytes (<bold>e</bold>). Nominal <italic toggle="yes">p</italic>-values estimated from the generalized linear model are shown. In the boxplots, the median values are shown by the central line and boxes spanning the first to the third quartiles. <bold>f</bold> Distribution of mean correlation between AD-PRS and cytokine expression across cell types for 1,000 permutations, with the measured estimate indicated by a red line. Cytokine production in microglia and astrocytes showed a suggestive association with AD-PRS (nominal <italic toggle="yes">p</italic>-value&#8201;&lt;&#8201;0.05)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e979" position="float" orientation="portrait" xlink:href="12974_2025_3552_Fig5_HTML.jpg"/></fig></p><p id="Par18">As an exploratory approach, we investigated whether cell type could explain the heterogeneity in PRS-expression associations. We performed permutation tests by shuffling cell type labels within individuals while preserving the links with PRS and gene expression levels. We found suggestive associations indicating that both microglia- (<italic toggle="yes">p</italic>-value&#8201;=&#8201;0.017) and astrocyte-derived (<italic toggle="yes">p</italic>-value&#8201;=&#8201;0.045) cytokines display, on average, higher correlations with AD-PRS than expected relative to other cell types (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>f). These results suggest that microglia and astrocytes may play roles in mediating cytokine expression and AD genetic risk. However, the correlation coefficients are low, and the significance is only nominal, so further studies with larger sample sizes are necessary for validation.</p></sec><sec id="Sec10"><title>Microglial cell subpopulation-specific cytokine signaling</title><p id="Par19">Following up on our previous results, we investigated the myeloid cells of the brain, microglia. These cells had been previously characterized and annotated into 16 microglia subtypes [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], making them suitable for a systems-level analysis of cell communication. We analyzed intercellular communication networks within these subpopulations by predicting major signaling inputs and outputs using the Cellchat pipeline [<xref ref-type="bibr" rid="CR27">27</xref>]. Full summary statistics are available in Supplementary Tables 17&#8211;18.</p><p id="Par20">Focusing on cytokines, we identified 10 significant ligand-receptor pairs categorized into three key signaling pathway networks: SPP1, TGF&#946;, and Complement. In the inferred cell&#8211;cell SPP1 signaling network, we observed that lipid-associated Mic.13 cells were the dominant source of SPP1 ligands, followed by Mic.15, which is enriched with inflammation, stress signature genes, and disease-associated microglia TREM2-dependent markers (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>a-b). The SPP1 signaling network in microglia was primarily mediated by paracrine signaling; however, Mic.13 (enriched in lipid signatures) and Mic.15 exhibited significant autocrine signaling (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>a). Additionally, in this pathway, Mic. 15 acts as an important receiver and mediator of SPP1 signaling (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>b). The SPP1-(<italic toggle="yes">ITGAV</italic>&#8201;+&#8201;<italic toggle="yes">ITGB1</italic>) ligand-receptor three-way pair was also identified as a potentially key mediator of the microglial communication network, with SPP1-(<italic toggle="yes">ITGAV</italic>&#8201;+&#8201;<italic toggle="yes">ITGB5</italic>) and SPP1-(<italic toggle="yes">ITGA9</italic>&#8201;+&#8201;<italic toggle="yes">ITGB1</italic>) contributing as well (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>c-d). These results indicate that Mic.15 (enriched in inflammatory signatures) may play a pivotal role in the SPP1 signaling pathway, orchestrating and influencing communication among microglial subpopulations in the aged human brain.<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>The cell&#8211;cell interactions among microglial subpopulations in the SPP1 signaling network. <bold>a</bold> Hierarchical plot shows interactions between microglial subpopulations in the inferred SPP1 signaling network. Solid circles indicate sources, while open circles indicate targets within the network. Intercellular interactions are represented by lines, with colors corresponding to the subtype source. The width of the edges reflects the communication probability. <bold>b</bold> Heatmap shows the relative importance of each microglial cluster in the SPP1 signaling network, based on the computed four network centrality measures: sender, receiver, mediator, and influencer. <bold>c</bold> Relative contribution of each ligand-receptor pair to the inferred signaling network. <bold>d</bold> Chord diagram showing significant interactions among microglial subpopulations within the SPP1 signaling network. Inner bar colors represent the target cells, while outer bars correspond to the color-coded microglial sources</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1056" position="float" orientation="portrait" xlink:href="12974_2025_3552_Fig6_HTML.jpg"/></fig></p><p id="Par21">In the inferred TGF&#946; signaling network, Mic.13 emerged as a major contributor in cell&#8211;cell communication. We noted that Mic.13 exhibits high target promiscuity, making it one of the primary targets within this network (Supplementary Fig.&#160;6). By contrast, network centrality analysis showed that Mic.13 primarily acted as a stronger influencer in the inferred Complement signaling network, which is mediated by <italic toggle="yes">C3</italic> levels and <italic toggle="yes">ITGAX</italic>-<italic toggle="yes">ITGB2</italic> receptors (Supplementary Fig.&#160;7). The Mic.12, associated with human amyloid-&#946; deposition [<xref ref-type="bibr" rid="CR28">28</xref>], had moderate involvement in cell&#8211;cell communication, acting mostly as an influencer in the three signaling pathway networks. These findings highlight the distinct roles of cytokines in microglial subpopulations in shaping or participating in intercellular communication networks in the aged human brain, with Mic.13 and Mic.15 emerging as key regulators within the SPP1, TGF&#946;, and Complement signaling pathways.</p></sec></sec><sec id="Sec11"><title>Discussion</title><p id="Par22">In this study, we examined cytokine gene expression in aged human brains using bulk and single-nucleus RNA sequencing (snRNA-Seq) from the ROSMAP cohorts. By applying linear and/or logistic regressions, we identify specific associations between cytokine expression levels and AD-related traits. Next, we noted that these AD traits contribute differently to expression variation, with amyloid-&#946; accumulation driving the highest variance in microglial cells when focusing on cytokines. Our analysis also suggested that AD genetic risk was associated with cytokine production, as high-risk individuals exhibited increased cytokine levels from microglia and astrocytes. Finally, cell communication analysis revealed that amyloid-&#946;-associated (Mic.12/13) and inflammation-related (Mic.15) microglia may regulate SPP1, TGF&#946;, and Complement signaling pathways among microglial cells in the aged human brain.</p><p id="Par23">Neuroinflammation has been suggested to play an independent role from the early stages of AD pathology, with pro- and anti-inflammatory cytokines acting in concert. This occurs not only in AD but also in other neurodegenerative diseases. Their chronic expression may disrupt homeostasis, leading to neuronal damage and cognitive deficits [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Studies suggest that elevated pro-inflammatory IL-15 protein in serum and cerebrospinal fluid is associated with the severity of cognitive decline and increased levels of total and phosphorylated tau [<xref ref-type="bibr" rid="CR29">29</xref>&#8211;<xref ref-type="bibr" rid="CR35">35</xref>]. This evidence indicates a significant role of the expression of <italic toggle="yes">IL15</italic> in the mechanisms underlying AD, highlighting its potential as a biomarker. Although cytokines play a vital role in brain homeostasis, their expression in cortical tissue remains largely unexplored in human-aged brains. Also, the neuroinflammatory complexity and limited temporal-spatial resolution make it difficult to define glial roles in neurodegeneration and their involvement in histopathological changes like protein deposition and neuronal loss [<xref ref-type="bibr" rid="CR36">36</xref>]. A study of 81 brain tissue samples from ROSMAP participants found that individuals with amyloid-&#946; deposition had significantly higher concentrations of specific inflammatory cytokines in cortical tissue [<xref ref-type="bibr" rid="CR22">22</xref>]. More recently, <italic toggle="yes">SPP1</italic> overexpression within the brain parenchyma has been linked with a higher risk of severe neurodegenerative diseases. Furthermore, its expression in specific microglial subgroups (homeostatic/tau-associated Mic.3 and lipid-associated Mic.12 and Mic.13) correlates with increased cognitive decline [<xref ref-type="bibr" rid="CR37">37</xref>]. Our findings linked reduced IL17D expression in astrocytes to high-risk individuals for AD. This gene showed no significant associations with AD traits in the association analysis. The biological role of IL17D remains unclear [<xref ref-type="bibr" rid="CR38">38</xref>], but earlier studies indicate that this cytokine is highly expressed in brain tissue, induces pro-inflammatory responses in endothelial cells [<xref ref-type="bibr" rid="CR39">39</xref>], and helps maintain intestinal homeostasis [<xref ref-type="bibr" rid="CR40">40</xref>]. While these findings provide valuable insights into cytokine activity in Alzheimer&#8217;s dementia, our study builds on this knowledge by utilizing a larger sample size and investigating a broader array of cytokine genes expressed by brain cell types.</p><p id="Par24">Here, we evaluated cytokine gene expression profiles across all major cortical brain cell types and compared the differential expression patterns among individuals based on their clinical diagnoses and protein deposition. As expected, the associations between cytokines and AD traits differed across cell types, with some significant signals being captured only in the snRNA-Seq (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). These results suggest that, at the cellular level, cytokine expression patterns may vary among cells in the brains of older adults. We also found that age at death was the major contributor to the variance in cytokine expression in the bulk data. When examining specific cell groups, pathology deposition and cognitive decline in cortical tissue emerged as important drivers of variance in cytokine expression (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). In the sex-stratified analysis, a new association was observed for <italic toggle="yes">CX3CL1</italic>, also known as Fractalkine, suggesting a protective role of this chemokine in cognitive decline among females (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>).</p><p id="Par25">Another source of variation in cytokine gene expression was the genetic risk for AD. Further supporting the link between AD genetic risk and cytokine expression, we observed that a higher AD-PRS score correlated with increased <italic toggle="yes">SPP1</italic> expression in microglia (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). Microglial subpopulations Mic.12, Mic.13, and Mic.15 (enriched with inflammatory-expressed genes), identified as being linked to pathological AD and neuroinflammation, have a significant influence on <italic toggle="yes">SPP1</italic> signaling in aged brain samples, suggesting their involvement in the molecular mechanisms underlying cognitive decline and pathology deposition. Also, <italic toggle="yes">SPP1</italic> has a strong association with cognitive and pathological outcomes in oligodendrocytes. Previous studies have indicated that microglial subpopulations (e.g., SPP1&#8201;+, M1) may contribute to impaired oligodendrocyte maturation and axonal demyelination in neuroinflammatory conditions [<xref ref-type="bibr" rid="CR41">41</xref>&#8211;<xref ref-type="bibr" rid="CR43">43</xref>]. In AD, oligodendrocytes transition from a homeostatic and myelinating state to focus on immune-related pathways, which may eventually lead to neurodegeneration [<xref ref-type="bibr" rid="CR44">44</xref>]. Reactive astrocytes are another key glial cell type involved in AD, characterized by a loss of homeostatic functions and increased expression of AD-risk genes [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. In this study, astrocytes exhibited the highest number of associations between cytokine genes and AD traits. Moreover, high-risk individuals displayed increased expression of astrocyte-derived cytokines. Overall, these data indicate that microglia, astrocytes, and oligodendrocytes are important players in the progression of neurodegenerative diseases.</p><p id="Par26">Currently, there is no cure for AD, and existing treatments only provide limited symptom relief. In recent years, immunotherapy, particularly monoclonal antibodies targeting amyloid-&#946; plaques, has emerged as a promising alternative to delay clinical progression. At the same time, neuroinflammation has gained attention as a potential target to restore brain homeostasis and modulate disease trajectory [<xref ref-type="bibr" rid="CR47">47</xref>]. Recent studies using NLRP3 inflammasome inhibitors have shown potential in reducing pro-inflammatory cytokine release in neurodegenerative models, thereby decreasing neuronal damage [<xref ref-type="bibr" rid="CR48">48</xref>&#8211;<xref ref-type="bibr" rid="CR50">50</xref>]. Also, evidence suggests that blocking <italic toggle="yes">IL15</italic> activity may inhibit microglial activation and pro-inflammatory cytokine release through the NF&#954;B and MAPK pathways [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. The IL-15 receptor is partly formed by the &#947;c subunit, shared by several interleukin receptors (e.g., IL-2, IL-4, IL-7, IL-9, and IL-21), and mediates pro-inflammatory signaling in microglia. Current evidence from preclinical and clinical studies suggests that inhibiting these pathways may effectively reduce chronic inflammation in AD, with beneficial effects observed at both pathological and clinical levels [<xref ref-type="bibr" rid="CR53">53</xref>]. However, few studies specifically focus on cytokine inhibition, and future work is required to evaluate how <italic toggle="yes">IL15</italic> inhibition could affect neurodegenerative outcomes.</p><p id="Par27">This study has strengths and limitations. A key strength is the integration of bulk and single-nuclei analyses, which provides a comprehensive view of cytokine expression by distinct brain cell types in the human brain. The large sample size and standardized annual clinical assessments, aligned with high follow-up and brain autopsy rates, ensure a well-characterized and deeply phenotyped cohort, enhancing the association between cytokine expression and AD traits. ROSMAP consists of community-based studies where participants were free of dementia at enrollment, minimizing referral bias but also potentially introducing heterogeneity in underlying pathologies. These cytokine patterns likely reflect broader neuroinflammatory processes rather than AD-specific mechanisms, consistent with the presence of mixed pathologies in aging populations. Also, these cohorts are characterized by highly educated individuals with European ancestry. Therefore, these findings cannot be extrapolated to individuals with different social and genetic backgrounds. We also acknowledge the limitations inherent to the observational data. Our findings are based on cross-sectional data and do not imply causality. The convergence of associations, spanning gene expression, AD genetic risk, and established literature, lends robustness to our interpretations. Additionally, we retained cytokine genes expressed at&#8201;&#8805;&#8201;1 CPM in 80% of samples, and we acknowledge that using a less stringent threshold (e.g., expression in 50% of samples) could have included more genes in the analysis, but at the cost of also capturing very lowly expressed genes. Also, further research is needed to better understand cytokine expression patterns across brain regions beyond the DLPFC. The cell-communication analysis was performed within microglia subpopulations to highlight the potential role of these molecules in microglia cells, but future in-depth analysis of other cell types can provide a broader understanding of intercellular signaling dynamics in the brain. Under homeostatic conditions, cytokines play a key role in cognitive function, particularly in hippocampal-dependent learning and memory [<xref ref-type="bibr" rid="CR19">19</xref>]. Given that hippocampal neurodegeneration is a key hallmark of AD [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>], exploring this region may reveal novel or stronger associations between cytokines and AD traits. Additionally, the high mean age of volunteers and the cross-sectional expression data may have influenced these results. Aging has been consistently linked to disruptions in brain homeostasis and an increased expression of inflammatory mediators, which may contribute to chronic low-grade neuroinflammation [<xref ref-type="bibr" rid="CR56">56</xref>&#8211;<xref ref-type="bibr" rid="CR58">58</xref>]. Future research could consider utilizing younger cohorts and expanding the analysis to include a wider array of inflammatory molecules, such as non-coding RNAs, including miRNAs, piRNAs, or circRNAs.</p></sec><sec id="Sec12"><title>Methods</title><sec id="Sec13"><title>Study cohorts: participants and clinical-neuropathological evaluations</title><p id="Par28">Data were obtained from two longitudinal clinical-pathologic cohort studies focused on risk factors for cognitive decline and Alzheimer's disease (AD). The Religious Order Study (ROS) and the Rush Memory and Aging Project (MAP), collectively called ROSMAP, were launched in 1994 and 1997 (D. A. [<xref ref-type="bibr" rid="CR23">23</xref>]). At enrollment, all participants were without known dementia and consented to detailed annual cognitive and clinical assessments. They signed the Anatomical Gift Act for brain donation and provided informed and repository consents. An Institutional Review Board at Rush University Medical Center approved both studies. The phenotypic variables included in this manuscript were defined as follows:</p><sec id="Sec14"><title>Global AD pathology burden, amyloid-&#946; load, and PHFtau tangle density</title><p id="Par29">To quantify amyloid-&#946; deposition and PHFtau tangle density, brain autopsies were conducted by trained staff blinded to age and clinical data. The brains were removed, weighed, and fixed in 4% paraformaldehyde for neuropathological evaluation. Tissue samples were collected from eight distinct brain regions: the angular gyrus, anterior cingulate, calcarine cortex, entorhinal cortex, hippocampus, inferior temporal cortex, midfrontal gyrus, and superior frontal cortex. Immunohistochemical staining with amyloid-&#946; and tau antibodies on 20-micron sections, combined with image analysis and stereology, was employed to assess the neuropathological burden [<xref ref-type="bibr" rid="CR59">59</xref>]. A square root transformation was applied to the data for analysis. For unbiased assessments, examiners were blinded to clinical data during all evaluations. Global AD pathology burden quantifies Alzheimer&#8217;s pathology by aggregating counts of neuritic plaques, diffuse plaques, and neurofibrillary tangles through microscopic examination of silver-stained slides from five regions: midfrontal cortex, mid-temporal cortex, inferior parietal cortex, entorhinal cortex, and hippocampus (D. A. [<xref ref-type="bibr" rid="CR60">60</xref>]).</p></sec><sec id="Sec15"><title>Cognitive decline and resilience</title><p id="Par30">ROSMAP participants completed a series of 21 cognitive performance tests each year, administered by blinded examiners unaware of their earlier performance. The rate of global cognitive decline reflects individual changes in cognition over time. The cognitive examination included 21 tests, 17 of which were used to create a global composite measure of cognitive function. Raw scores for individual tests were standardized using the baseline means and standard deviations of the entire cohort and then averaged across tests to obtain the composite score. This rate was estimated using a linear mixed-effects model, with global cognition as the longitudinal outcome and adjustments made for age at baseline, sex, and years of education [<xref ref-type="bibr" rid="CR61">61</xref>]. To calculate the cognitive resilience variable, linear mixed-effects models measured the slope of global cognition adjusted for the same demographic variables plus all measured neuropathology indices [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]<italic toggle="yes">.</italic></p></sec><sec id="Sec16"><title>Alzheimer&#8217;s dementia and MCI diagnoses</title><p id="Par31">A clinical diagnosis of cognitive status is made by a neurologist with expertise in dementia and a clinician who reviews all clinical data available, both remaining blinded to patient demographic information. A detailed assessment of available clinical data was performed to determine the most likely clinical diagnosis at the time of death, ensuring that the reviewers could not access post-mortem data [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. Diagnosis of MCI and clinical Alzheimer's dementia follows the criteria set by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer&#8217;s Disease and Related Disorders Association (NINCDS/ADRDA). Mild cognitive impairment (MCI) is diagnosed when cognitive impairment is present but does not meet the criteria for dementia. Individuals without dementia or MCI are classified as having no cognitive impairment (NCI) [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR66">66</xref>].</p></sec></sec><sec id="Sec17"><title>Cytokine gene list</title><p id="Par32">To investigate whether abnormal deposition of pathological proteins and cognitive decline were Linked with neuroinflammation, brain cytokine production was assessed using a panel of 147 genes (Supplementary Table&#160;19). A curated List of 147 cytokine genes was generated based on supplementary data from two key studies. These studies provided a comprehensive view of cytokine regulation and immune responses, mapping transcriptional control networks and detailing cell-type-specific cytokine activity at single-cell resolution [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. This list was used as the basis for the subsequent analysis of cytokine gene expression in this manuscript. After filtering bulk and snRNA-Seq data to include only cytokine genes, we evaluate their association with AD phenotype through linear or logistic regressions. Since age, sex, and years of education are important sources of confounders, we adjusted our statistical model to account for them, as in previous publications [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>].</p></sec><sec id="Sec18"><title>Bulk RNA-Seq data: collection and analysis</title><p id="Par33">We utilized previously generated and processed RNA-Seq data from DLPFC tissue, as described in Mostafavi et al. and Tasaki et al. [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. Briefly, the data were obtained using Illumina platforms, aligned to the human genome (GENCODE Release 27 GRCh38) using STAR v2.6, and transcript-level quantification was performed with Kallisto v0.46. The dataset included 17,294 genes detected in over 50% of the samples. Prior normalization procedures included Conditional Quantile Normalization, log&#8322;-transformation of counts per million (CPM), and adjustment for technical confounders. Technical confounders were accounted for using linear regression models that included post-mortem interval, sequencing batch, RNA quality number (RQN), total spliced reads, and metrics derived from Picard and Kallisto.</p></sec><sec id="Sec19"><title>Single-nuclei RNA-Seq data: collection and analysis</title><p id="Par34">Nuclei isolation was originally conducted in 479 brain specimens using available frozen pathological material from the DLPFC, processed via dounce homogenization and centrifugation [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Single-nuclei profile was performed on pooled sample batches to boost Library throughput and reduce batch effects and costs. Each Library construction batch included eight participants, resulting in 60 batches. Even though samples were randomly assigned, they were balanced by clinical, pathological diagnoses, and sex. In each batch, the nuclei suspension from eight donors was combined. Single-nucleus RNA-Seq Libraries were prepared using the 10&#215;&#8201;Genomics 3 Gene Expression kit (v3 chemistry), following the manufacturer&#8217;s protocol. After sequencing, 127 pooled libraries were created. Alignment, noise removal, demultiplexing, normalization, and classification were performed. Low-quality nuclei and doublets were removed using cell-type-specific thresholds. The preprocessing and quality control (QC) steps were extensively described previously [<xref ref-type="bibr" rid="CR26">26</xref>]. In brief, approximately 1.64 million high-quality nuclei profiles were retained from 465 individuals. ElasticNet-regularized logistic regression was performed to annotate cells, resulting in seven major cell types. Our analysis was conducted for all the major cell types: astrocytes (ast), excitatory neurons (ext), inhibitory neurons (inh), microglia (mic), oligodendrocytes (oli), oligodendrocyte progenitor cells (OPCs), and endothelial cells (end). In each cell type, the expression profile of marker genes was identified and categorized using the Seurat <italic toggle="yes">FindAllMarkers</italic> function. The sub-clustering analysis resulted in 96 subpopulations. After preprocessing and QC analyses, 424 participants were retained for the expression analysis [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par35">Pseudo-bulk matrices were created by summing counts per cell for each participant. We retained genes with at least one count per million (CPM) in 80% of the samples. This threshold was chosen to reduce noise from lowly expressed or sample-specific genes, which is especially important in snRNA-Seq data due to its inherent sparsity and dropout effects. The same threshold for expression has been used in previous publications analyzing this dataset [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. Counts were normalized using the trimmed mean of M-values (TMM), as implemented in <italic toggle="yes">edgeR</italic> [<xref ref-type="bibr" rid="CR75">75</xref>], and log-transformed using the voom function from <italic toggle="yes">limma</italic> [<xref ref-type="bibr" rid="CR76">76</xref>]. Finally, batch effects were corrected using the <italic toggle="yes">ComBat</italic> function of <italic toggle="yes">sva</italic> (v.3.42.0) [<xref ref-type="bibr" rid="CR77">77</xref>], as previously performed [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec><sec id="Sec20"><title>Generalization cohorts</title><p id="Par36">For generalization analyses, we selected two external bulk RNA-Seq datasets: the Mayo Clinic and the Mount Sinai Brain Bank (MSBB). The Mayo Clinic dataset includes 597 brain tissue samples isolated from the temporal cortex and cerebellum. Transcriptomic data correspond to 355 unique individuals from the Mayo Brain Bank and the Banner Sun Health Institute [<xref ref-type="bibr" rid="CR78">78</xref>]. The MSBB dataset contains RNA-Seq data from 1,282 samples from multiple brain regions, covering 316 unique individuals [<xref ref-type="bibr" rid="CR79">79</xref>]. Both datasets were uniformly processed through the AMP-AD RNA-Seq Harmonization study (syn21241740). Matrices with conditional quantile normalized (CQN) expression values were obtained for the subsequent analysis (Mayo: syn27024965, and MSBB: syn27068756). We filtered the datasets to include only samples functionally connected to the DLPFC (i.e., 258 temporal cortex samples from Mayo and 304 frontal cortex samples from MSBB). Both datasets were further filtered to include only targeted cytokine genes, and association analyses were performed with the available AD traits. We tested for associations with diagnosis, Braak stage, and Thal score in the Mayo Clinic dataset. In the MSBB dataset, the available variables were CERAD score, Braak stage, Clinical Dementia Rating (CDR), and neuritic plaque density.</p></sec><sec id="Sec21"><title>Statistical methods</title><p id="Par37">To evaluate the association between cytokine expression and AD traits, we used a linear regression model for continuous outcomes and logistic regression for categorical ones. Models were adjusted for age, sex, years of education, and postmortem interval (PMI) to control for potential confounders. The general formula used was: <italic toggle="yes">trait</italic>&#8201;~&#8201;<italic toggle="yes">cytokine_expression</italic>&#8201;+&#8201;<italic toggle="yes">age_at_death</italic>&#8201;+&#8201;<italic toggle="yes">sex</italic>&#8201;+&#8201;<italic toggle="yes">years_of_educ</italic>&#8201;+&#8201;<italic toggle="yes">pmi</italic>. For the sex stratified tests, sex was not included as a covariate. Linear and logistic regression models were implemented using <italic toggle="yes">stats</italic> R functions (<italic toggle="yes">lm</italic>, <italic toggle="yes">glm</italic>), coefficients and confidence intervals were extracted using the <italic toggle="yes">model_parameters</italic> function from the <italic toggle="yes">parameters</italic> package (v0.22.1). In all models, gene expression and trait outcomes were standardized (mean&#8201;=&#8201;0 and standard deviation&#8201;=&#8201;1) to assist in the comparison of effect sizes between different outcomes. To correct for multiple testing within cell type, we applied Benjamini &amp; Hochberg false discovery rate (FDR) correction with declared significance at an &#945; of 0.05. Data visualization was conducted using the <italic toggle="yes">ComplexHeatmap</italic> (v2.18.0), <italic toggle="yes">circlize</italic> (v0.4.16), and <italic toggle="yes">RColorBrewer</italic> (v1.1&#8211;3). We conducted Pearson's and Spearman's correlation analyses using the <italic toggle="yes">cor</italic> R function to examine variable relationships. The differential expression of inflammatory mediators in individuals diagnosed with AD, MCI, and controls (NCI) was assessed using two-tailed Student&#8217;s t-tests for two-group comparisons. Data were presented in boxplots, with the median indicated by a horizontal Line and whiskers representing the 25th and 75th percentiles. All analyses were performed in R version 4.</p><sec id="Sec22"><title>VariancePartition</title><p id="Par38">To identify and quantify sources of biological variation in cytokine expression, we used the variancePartition function in R (v1.32.5). This package applies linear mixed models to quantify the influence of biological and technical factors on gene expression, revealing patterns of variation across datasets [<xref ref-type="bibr" rid="CR80">80</xref>]. The proportions for each covariate are available in Supplementary Tables 11&#8211;12, and the percentage of variance explained is displayed in Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref> and Supplementary Fig.&#160;5.</p></sec><sec id="Sec23"><title>Genetics</title><p id="Par39"> To examine the influence of AD genetic risk on cytokine expression, we constructed polygenic risk scores (AD-PRS) using the GWAS summary statistics from the European Alzheimer &amp; Dementia Biobank (EADB) consortium [<xref ref-type="bibr" rid="CR11">11</xref>] following the procedures previously described [<xref ref-type="bibr" rid="CR81">81</xref>]. Briefly, genotyping was obtained for 424 ROSMAP participants. PRSs were constructed using PRSice-2 v2.3.5, with SNPs pruned for linkage disequilibrium (LD) using an R<sup>2</sup>&#8201;&gt;&#8201;0.1 and a 2,000&#160;kb window. A significance threshold of <italic toggle="yes">P</italic>&#8201;&#8804;&#8201;0.001 was applied. Risk scores were calculated for each individual and PRSs were standardized (z-scored) across participants. To account for population stratification, genotype principal components (PCs) were calculated using PLINK (v.1.90), and the top three PCs were regressed out of the AD-PRS. We assessed the association between cytokine expression and AD-PRS using linear regressions. For comparison, we also measured the association between cytokine expression and <italic toggle="yes">APOE</italic> &#949;4 status (i.e. presence or absence of at least one &#949;4 allele) using logistic regressions. All models were adjusted for age, sex, years of education, and PMI, with p-values corrected within cell types using FDR.</p><p id="Par40">Using Spearman correlation, we assessed the relationship between AD-PRS and the average cytokine expression in each cell cluster. Permutation tests were applied to assess the statistical significance of the associations in each cell type. For this purpose, we followed the permutation shuffling strategy, similar to that implemented in GSEA [<xref ref-type="bibr" rid="CR82">82</xref>], preserving the correlations between genes in the dataset across permutations. Specifically, cell type labels were randomized within each individual, thereby preserving the structure of gene expression and PRS while disrupting cell-type-specific patterns. For each of 1,000 permutations, we computed the average correlation between AD-PRS and cytokine expression using the permuted cell type labels. This approach generates a null distribution of average correlations between AD-PRS and cytokine expressions under the assumption that any observed association is not specific to a given cell type. <italic toggle="yes">P</italic>-values were calculated by comparing the observed correlation with the null distribution for each cell type.</p></sec></sec><sec id="Sec24"><title>Cell communication</title><p id="Par41">Cell&#8211;cell communication analysis was conducted using CellChat v2, an R package designed for inferring, analyzing, and visualizing intercellular interactions from snRNA-Seq data [<xref ref-type="bibr" rid="CR83">83</xref>]. Only microglial subpopulations annotated from snRNA-Seq were included in the analysis. By detecting overexpressed ligands and receptors, Cellchat predicts significant communications and quantifies them with probability values. Ligand&#8211;receptor pairs with a <italic toggle="yes">p</italic>-value of less than 0.05, determined by Cellchat, were considered significant interacting molecules between microglial subpopulations. To focus on cytokine signaling pathways, we further filtered the significant associations to include only those involving cytokine genes. Our analysis followed the official step-by-step protocol. All cell communication graphs were constructed utilizing the built-in functions of the Cellchat package.</p></sec></sec><sec id="Sec25" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12974_2025_3552_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The results published here are in whole or in part based on data obtained from the AD Knowledge Portal (https://adknowledgeportal.org/). We thank all the ROSMAP participants and the investigators, and the staff at the Rush Alzheimer's Disease Center.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>K.P.L supervised the data analysis; K.P.L and D.G conceived and supervised the study; J.B.G curated the cytokine list, ran the regression analysis for both bulk and single-nucleus data, performed exploratory analysis, and created the github pages; R.A.V developed regression functions for the analysis and conducted the genetic association study; L.S ran the cell-communication pipeline; R.T.R supervised the cell communication analysis; Y.W sequenced the bulk RNA-Seq samples; V.M and P.L.D.J provided the single-nucleus dataset; J.A.S supervised the brain pathology quantification; S.T ran the pipelines for bulk RNA-Seq quantification, including normalization and data adjustment; D.A.B built the ROS and MAP cohorts; J.B.G. and K.P.L. wrote the manuscript with feedback from the co-authors.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>ROSMAP is supported by the following grants: P30AG10161, P30AG72975, R01AG15819, R01AG17917, U01AG46152, and U01AG61356. Students fellowship from the Brazilian agency CAPES (Coordena&#231;&#227;o de Aperfei&#231;oamento de Pessoal de N&#237;vel Superior).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Transcriptomic data used in this manuscript are available with the following accession numbers: ROSMAP bulk DLPFC (syn3388564) and snRNA-Seq (syn31512863). The phenotype data can be requested at the RADC Resource Sharing Hub at [www.radc.rush.edu](http:/www.radc.rush.edu) or the AD Knowledge Portal ([https://adknowledgeportal.org](https:/adknowledgeportal.org)). The relevant code generated by this study is available on the GitHub repository&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/RushAlz/Cytokines_public_release">https://github.com/RushAlz/Cytokines_public_release</ext-link>.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par42">Transcriptomic data originate from two longitudinal clinical-pathologic cohort studies of aging and dementia, the Religious Orders Study (ROS) and Rush Memory and Aging Project (MAP). Both studies were approved by the Institutional Review Board of Rush University Medical Center. All participants signed informed and repository consents and the Anatomic Gift Act.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par43">All authors received and approved the manuscript for publication.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par44">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><collab>Alzheimer&#8217;s Association</collab></person-group><article-title>2024 Alzheimer&#8217;s disease facts and figures</article-title><source>Alzheimers Dement</source><year>2024</year><volume>20</volume><issue>5</issue><fpage>3708</fpage><lpage>3821</lpage><pub-id pub-id-type="doi">10.1002/alz.13809</pub-id><pub-id pub-id-type="pmid">38689398</pub-id><pub-id pub-id-type="pmcid">PMC11095490</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Alzheimer&#8217;s Association. 2024 Alzheimer&#8217;s disease facts and figures. Alzheimers Dement. 2024;20(5):3708&#8211;821.<pub-id pub-id-type="pmid">38689398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13809</pub-id><pub-id pub-id-type="pmcid">PMC11095490</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naghavi</surname><given-names>M</given-names></name><name name-style="western"><surname>Ong</surname><given-names>KL</given-names></name><name name-style="western"><surname>Aali</surname><given-names>A</given-names></name><name name-style="western"><surname>Ababneh</surname><given-names>HS</given-names></name><name name-style="western"><surname>Abate</surname><given-names>YH</given-names></name><name name-style="western"><surname>Abbafati</surname><given-names>C</given-names></name><name name-style="western"><surname>Abbasgholizadeh</surname><given-names>R</given-names></name><name name-style="western"><surname>Abbasian</surname><given-names>M</given-names></name><etal/></person-group><article-title>Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990&#8211;2021: a systematic analysis for the Global Burden of Disease Study 2021</article-title><source>Lancet</source><year>2024</year><pub-id pub-id-type="doi">10.1016/S0140-6736(24)00367-2</pub-id><pub-id pub-id-type="pmcid">PMC11126520</pub-id><pub-id pub-id-type="pmid">38582094</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Naghavi M, Ong KL, Aali A, Ababneh HS, Abate YH, Abbafati C, et al. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990&#8211;2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024. 10.1016/S0140-6736(24)00367-2.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(24)00367-2</pub-id><pub-id pub-id-type="pmcid">PMC11126520</pub-id><pub-id pub-id-type="pmid">38582094</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>JM</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></name></person-group><article-title>Alzheimer disease: an update on pathobiology and treatment strategies</article-title><source>Cell</source><year>2019</year><volume>179</volume><issue>2</issue><fpage>312</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.09.001</pub-id><pub-id pub-id-type="pmid">31564456</pub-id><pub-id pub-id-type="pmcid">PMC6778042</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312&#8211;39.<pub-id pub-id-type="pmid">31564456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2019.09.001</pub-id><pub-id pub-id-type="pmcid">PMC6778042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></name><name name-style="western"><surname>Amieva</surname><given-names>H</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name><name name-style="western"><surname>Ch&#233;telat</surname><given-names>G</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>BT</given-names></name><name name-style="western"><surname>Nixon</surname><given-names>RA</given-names></name><name name-style="western"><surname>Jones</surname><given-names>DT</given-names></name></person-group><article-title>Alzheimer disease</article-title><source>Nat Rev Dis Primers</source><year>2021</year><volume>7</volume><issue>1</issue><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1038/s41572-021-00269-y</pub-id><pub-id pub-id-type="pmid">33986301</pub-id><pub-id pub-id-type="pmcid">PMC8574196</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Knopman DS, Amieva H, Petersen RC, Ch&#233;telat G, Holtzman DM, Hyman BT, et al. Alzheimer disease. Nat Rev Dis Primers. 2021;7(1):1&#8211;21.<pub-id pub-id-type="pmid">33986301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-021-00269-y</pub-id><pub-id pub-id-type="pmcid">PMC8574196</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assaf</surname><given-names>G</given-names></name><name name-style="western"><surname>Tanielian</surname><given-names>M</given-names></name></person-group><article-title>Mild cognitive impairment in primary care: a clinical review</article-title><source>Postgrad Med J</source><year>2018</year><volume>94</volume><issue>1117</issue><fpage>647</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1136/postgradmedj-2018-136035</pub-id><pub-id pub-id-type="pmid">30397003</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Assaf G, Tanielian M. Mild cognitive impairment in primary care: a clinical review. Postgrad Med J. 2018;94(1117):647&#8211;52.<pub-id pub-id-type="pmid">30397003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/postgradmedj-2018-136035</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kepp</surname><given-names>KP</given-names></name><name name-style="western"><surname>Robakis</surname><given-names>NK</given-names></name><name name-style="western"><surname>H&#248;ilund-Carlsen</surname><given-names>PF</given-names></name><name name-style="western"><surname>Sensi</surname><given-names>SL</given-names></name><name name-style="western"><surname>Vissel</surname><given-names>B</given-names></name></person-group><article-title>The Amyloid Cascade Hypothesis: An Updated Critical Review</article-title><source>Brain.</source><year>2023</year><volume>146</volume><issue>10</issue><fpage>3969</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1093/brain/awad159</pub-id><pub-id pub-id-type="pmid">37183523</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Kepp KP, Robakis NK, H&#248;ilund-Carlsen PF, Sensi SL, Vissel B. The Amyloid Cascade Hypothesis: An Updated Critical Review. Brain. 2023;146(10):3969&#8211;90.<pub-id pub-id-type="pmid">37183523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awad159</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selkoe</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>J</given-names></name></person-group><article-title>The amyloid hypothesis of Alzheimer&#8217;s disease at 25 years</article-title><source>EMBO Mol Med</source><year>2016</year><pub-id pub-id-type="doi">10.15252/emmm.201606210</pub-id><pub-id pub-id-type="pmid">27025652</pub-id><pub-id pub-id-type="pmcid">PMC4888851</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer&#8217;s disease at 25 years. EMBO Mol Med. 2016. 10.15252/emmm.201606210.<pub-id pub-id-type="pmid">27025652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.201606210</pub-id><pub-id pub-id-type="pmcid">PMC4888851</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castro-Gomez</surname><given-names>S</given-names></name><name name-style="western"><surname>Heneka</surname><given-names>MT</given-names></name></person-group><article-title>Innate immune activation in neurodegenerative diseases</article-title><source>Immunity</source><year>2024</year><volume>57</volume><issue>4</issue><fpage>790</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2024.03.010</pub-id><pub-id pub-id-type="pmid">38599171</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Castro-Gomez S, Heneka MT. Innate immune activation in neurodegenerative diseases. Immunity. 2024;57(4):790&#8211;814.<pub-id pub-id-type="pmid">38599171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2024.03.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heneka</surname><given-names>MT</given-names></name><name name-style="western"><surname>Carson</surname><given-names>MJ</given-names></name><name name-style="western"><surname>El Khoury</surname><given-names>J</given-names></name><name name-style="western"><surname>Landreth</surname><given-names>GE</given-names></name><name name-style="western"><surname>Brosseron</surname><given-names>F</given-names></name><name name-style="western"><surname>Feinstein</surname><given-names>DL</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Neuroinflammation in Alzheimer&#8217;s disease</article-title><source>Lancet Neurol</source><year>2015</year><volume>14</volume><issue>4</issue><fpage>388</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(15)70016-5</pub-id><pub-id pub-id-type="pmid">25792098</pub-id><pub-id pub-id-type="pmcid">PMC5909703</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer&#8217;s disease. Lancet Neurol. 2015;14(4):388&#8211;405.<pub-id pub-id-type="pmid">25792098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(15)70016-5</pub-id><pub-id pub-id-type="pmcid">PMC5909703</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prins</surname><given-names>S</given-names></name><name name-style="western"><surname>de Kam</surname><given-names>ML</given-names></name><name name-style="western"><surname>Teunissen</surname><given-names>CE</given-names></name><name name-style="western"><surname>Groeneveld</surname><given-names>GJ</given-names></name></person-group><article-title>Inflammatory plasma biomarkers in subjects with preclinical Alzheimer&#8217;s disease</article-title><source>Alzheimers Res Ther</source><year>2022</year><volume>14</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/s13195-022-01051-2</pub-id><pub-id pub-id-type="pmid">35922871</pub-id><pub-id pub-id-type="pmcid">PMC9347121</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Prins S, de Kam ML, Teunissen CE, Groeneveld GJ. Inflammatory plasma biomarkers in subjects with preclinical Alzheimer&#8217;s disease. Alzheimers Res Ther. 2022;14(1):1&#8211;9.<pub-id pub-id-type="pmid">35922871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-022-01051-2</pub-id><pub-id pub-id-type="pmcid">PMC9347121</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellenguez</surname><given-names>C</given-names></name><name name-style="western"><surname>K&#252;&#231;&#252;kali</surname><given-names>F</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>IE</given-names></name><name name-style="western"><surname>Kleineidam</surname><given-names>L</given-names></name><name name-style="western"><surname>Moreno-Grau</surname><given-names>S</given-names></name><name name-style="western"><surname>Amin</surname><given-names>N</given-names></name><name name-style="western"><surname>Naj</surname><given-names>AC</given-names></name><etal/></person-group><article-title>New insights into the genetic etiology of Alzheimer&#8217;s disease and related dementias</article-title><source>Nat Genet</source><year>2022</year><volume>54</volume><issue>4</issue><fpage>412</fpage><pub-id pub-id-type="doi">10.1038/s41588-022-01024-z</pub-id><pub-id pub-id-type="pmid">35379992</pub-id><pub-id pub-id-type="pmcid">PMC9005347</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Bellenguez C, K&#252;&#231;&#252;kali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer&#8217;s disease and related dementias. Nat Genet. 2022;54(4):412. 10.1038/s41588-022-01024-z.<pub-id pub-id-type="pmid">35379992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-022-01024-z</pub-id><pub-id pub-id-type="pmcid">PMC9005347</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>IE</given-names></name><name name-style="western"><surname>Savage</surname><given-names>JE</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>K</given-names></name><name name-style="western"><surname>Bryois</surname><given-names>J</given-names></name><name name-style="western"><surname>Williams</surname><given-names>DM</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Sealock</surname><given-names>J</given-names></name><etal/></person-group><article-title>Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#8217;s disease risk</article-title><source>Nat Genet</source><year>2019</year><volume>51</volume><issue>3</issue><fpage>404</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0311-9</pub-id><pub-id pub-id-type="pmid">30617256</pub-id><pub-id pub-id-type="pmcid">PMC6836675</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#8217;s disease risk. Nat Genet. 2019;51(3):404&#8211;13.<pub-id pub-id-type="pmid">30617256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-018-0311-9</pub-id><pub-id pub-id-type="pmcid">PMC6836675</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunkle</surname><given-names>BW</given-names></name><name name-style="western"><surname>Grenier-Boley</surname><given-names>B</given-names></name><name name-style="western"><surname>Sims</surname><given-names>R</given-names></name><name name-style="western"><surname>Bis</surname><given-names>JC</given-names></name><name name-style="western"><surname>Damotte</surname><given-names>V</given-names></name><name name-style="western"><surname>Naj</surname><given-names>AC</given-names></name><name name-style="western"><surname>Boland</surname><given-names>A</given-names></name><etal/></person-group><article-title>Genetic meta-analysis of diagnosed Alzheimer&#8217;s Disease identifies new risk loci and implicates A&#946;, Tau, immunity and lipid processing</article-title><source>Nat Genet</source><year>2019</year><volume>51</volume><issue>3</issue><fpage>414</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/s41588-019-0358-2</pub-id><pub-id pub-id-type="pmid">30820047</pub-id><pub-id pub-id-type="pmcid">PMC6463297</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed Alzheimer&#8217;s Disease identifies new risk loci and implicates A&#946;, Tau, immunity and lipid processing. Nat Genet. 2019;51(3):414&#8211;30.<pub-id pub-id-type="pmid">30820047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-019-0358-2</pub-id><pub-id pub-id-type="pmcid">PMC6463297</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bis</surname><given-names>JC</given-names></name><name name-style="western"><surname>Jian</surname><given-names>X</given-names></name><name name-style="western"><surname>Kunkle</surname><given-names>BW</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hamilton-Nelson</surname><given-names>KL</given-names></name><name name-style="western"><surname>Bush</surname><given-names>WS</given-names></name><name name-style="western"><surname>Salerno</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Whole exome sequencing study identifies novel rare and common Alzheimer&#8217;s-associated variants involved in immune response and transcriptional regulation</article-title><source>Mol Psychiatry</source><year>2020</year><volume>25</volume><issue>8</issue><fpage>1859</fpage><lpage>1875</lpage><pub-id pub-id-type="doi">10.1038/s41380-018-0112-7</pub-id><pub-id pub-id-type="pmid">30108311</pub-id><pub-id pub-id-type="pmcid">PMC6375806</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Bis JC, Jian X, Kunkle BW, Chen Y, Hamilton-Nelson KL, Bush WS, et al. Whole exome sequencing study identifies novel rare and common Alzheimer&#8217;s-associated variants involved in immune response and transcriptional regulation. Mol Psychiatry. 2020;25(8):1859&#8211;75.<pub-id pub-id-type="pmid">30108311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-018-0112-7</pub-id><pub-id pub-id-type="pmcid">PMC6375806</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keren-Shaul</surname><given-names>H</given-names></name><name name-style="western"><surname>Spinrad</surname><given-names>A</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>A</given-names></name><name name-style="western"><surname>Matcovitch-Natan</surname><given-names>O</given-names></name><name name-style="western"><surname>Dvir-Szternfeld</surname><given-names>R</given-names></name><name name-style="western"><surname>Ulland</surname><given-names>TK</given-names></name><name name-style="western"><surname>David</surname><given-names>E</given-names></name><etal/></person-group><article-title>A Unique Microglia Type Associated with Restricting Development of Alzheimer&#8217;s Disease</article-title><source>Cell</source><year>2017</year><volume>169</volume><issue>7</issue><fpage>1276</fpage><lpage>90.e17</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.05.018</pub-id><pub-id pub-id-type="pmid">28602351</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#8217;s Disease. Cell. 2017;169(7):1276-90.e17.<pub-id pub-id-type="pmid">28602351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2017.05.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ray</surname><given-names>NR</given-names></name><name name-style="western"><surname>Kunkle</surname><given-names>BW</given-names></name><name name-style="western"><surname>Hamilton-Nelson</surname><given-names>K</given-names></name><name name-style="western"><surname>Kurup</surname><given-names>JT</given-names></name><name name-style="western"><surname>Rajabli</surname><given-names>F</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>M</given-names></name><name name-style="western"><surname>Vardarajan</surname><given-names>BN</given-names></name><etal/></person-group><article-title>Extended genome-wide association study employing the African Genome Resources Panel identifies novel susceptibility loci for Alzheimer&#8217;s disease in individuals of African ancestry</article-title><source>Alzheimers Dement</source><year>2024</year><volume>20</volume><issue>8</issue><fpage>5247</fpage><lpage>5261</lpage><pub-id pub-id-type="doi">10.1002/alz.13880</pub-id><pub-id pub-id-type="pmid">38958117</pub-id><pub-id pub-id-type="pmcid">PMC11350055</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Ray NR, Kunkle BW, Hamilton-Nelson K, Kurup JT, Rajabli F, Qiao M, et al. Extended genome-wide association study employing the African Genome Resources Panel identifies novel susceptibility loci for Alzheimer&#8217;s disease in individuals of African ancestry. Alzheimers Dement. 2024;20(8):5247&#8211;61.<pub-id pub-id-type="pmid">38958117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13880</pub-id><pub-id pub-id-type="pmcid">PMC11350055</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raj</surname><given-names>T</given-names></name><name name-style="western"><surname>Rothamel</surname><given-names>K</given-names></name><name name-style="western"><surname>Mostafavi</surname><given-names>S</given-names></name><name name-style="western"><surname>Ye</surname><given-names>C</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MN</given-names></name><name name-style="western"><surname>Replogle</surname><given-names>JM</given-names></name><name name-style="western"><surname>Feng</surname><given-names>T</given-names></name><etal/></person-group><article-title>Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes</article-title><source>Science</source><year>2014</year><pub-id pub-id-type="doi">10.1126/science.1249547</pub-id><pub-id pub-id-type="pmid">24786080</pub-id><pub-id pub-id-type="pmcid">PMC4910825</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, Replogle JM, et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science. 2014. 10.1126/science.1249547.<pub-id pub-id-type="pmid">24786080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1249547</pub-id><pub-id pub-id-type="pmcid">PMC4910825</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sobue</surname><given-names>A</given-names></name><name name-style="western"><surname>Komine</surname><given-names>O</given-names></name><name name-style="western"><surname>Yamanaka</surname><given-names>K</given-names></name></person-group><article-title>Neuroinflammation in Alzheimer&#8217;s disease: microglial signature and their relevance to disease</article-title><source>Inflamm Regen</source><year>2023</year><volume>43</volume><issue>1</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1186/s41232-023-00277-3</pub-id><pub-id pub-id-type="pmid">37165437</pub-id><pub-id pub-id-type="pmcid">PMC10170691</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Sobue A, Komine O, Yamanaka K. Neuroinflammation in Alzheimer&#8217;s disease: microglial signature and their relevance to disease. Inflamm Regen. 2023;43(1):1&#8211;6.<pub-id pub-id-type="pmid">37165437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s41232-023-00277-3</pub-id><pub-id pub-id-type="pmcid">PMC10170691</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bourgognon</surname><given-names>J-M</given-names></name><name name-style="western"><surname>Cavanagh</surname><given-names>J</given-names></name></person-group><article-title>The role of cytokines in modulating learning and memory and brain plasticity</article-title><source>Brain Neurosci Adv</source><year>2020</year><pub-id pub-id-type="doi">10.1177/2398212820979802</pub-id><pub-id pub-id-type="pmid">33415308</pub-id><pub-id pub-id-type="pmcid">PMC7750764</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Bourgognon J-M, Cavanagh J. The role of cytokines in modulating learning and memory and brain plasticity. Brain Neurosci Adv. 2020. 10.1177/2398212820979802.<pub-id pub-id-type="pmid">33415308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2398212820979802</pub-id><pub-id pub-id-type="pmcid">PMC7750764</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zipp</surname><given-names>F</given-names></name><name name-style="western"><surname>Bittner</surname><given-names>S</given-names></name><name name-style="western"><surname>Schafer</surname><given-names>DP</given-names></name></person-group><article-title>Cytokines as emerging regulators of central nervous system synapses</article-title><source>Immunity</source><year>2023</year><volume>56</volume><issue>5</issue><fpage>914</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2023.04.011</pub-id><pub-id pub-id-type="pmid">37163992</pub-id><pub-id pub-id-type="pmcid">PMC10233069</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Zipp F, Bittner S, Schafer DP. Cytokines as emerging regulators of central nervous system synapses. Immunity. 2023;56(5):914&#8211;25.<pub-id pub-id-type="pmid">37163992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2023.04.011</pub-id><pub-id pub-id-type="pmcid">PMC10233069</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Balachandran</surname><given-names>YL</given-names></name><name name-style="western"><surname>Chong</surname><given-names>WP</given-names></name><name name-style="western"><surname>Chan</surname><given-names>KWY</given-names></name></person-group><article-title>Roles of cytokines in Alzheimer&#8217;s disease</article-title><source>Int J Mol Sci</source><year>2024</year><pub-id pub-id-type="doi">10.3390/ijms25115803</pub-id><pub-id pub-id-type="pmid">38891990</pub-id><pub-id pub-id-type="pmcid">PMC11171747</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Chen Z, Balachandran YL, Chong WP, Chan KWY. Roles of cytokines in Alzheimer&#8217;s disease. Int J Mol Sci. 2024. 10.3390/ijms25115803.<pub-id pub-id-type="pmid">38891990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25115803</pub-id><pub-id pub-id-type="pmcid">PMC11171747</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flores-Aguilar</surname><given-names>L</given-names></name><name name-style="western"><surname>Iulita</surname><given-names>MF</given-names></name><name name-style="western"><surname>Orciani</surname><given-names>C</given-names></name><name name-style="western"><surname>Tanna</surname><given-names>N</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name><name name-style="western"><surname>Cuello</surname><given-names>AC</given-names></name></person-group><article-title>Cognitive and brain cytokine profile of non-demented individuals with cerebral amyloid-beta deposition</article-title><source>J Neuroinflammation</source><year>2021</year><volume>18</volume><issue>1</issue><fpage>147</fpage><pub-id pub-id-type="doi">10.1186/s12974-021-02169-0</pub-id><pub-id pub-id-type="pmid">34218796</pub-id><pub-id pub-id-type="pmcid">PMC8254948</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Flores-Aguilar L, Iulita MF, Orciani C, Tanna N, Yang J, Bennett DA, et al. Cognitive and brain cytokine profile of non-demented individuals with cerebral amyloid-beta deposition. J Neuroinflammation. 2021;18(1):147. 10.1186/s12974-021-02169-0.<pub-id pub-id-type="pmid">34218796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-021-02169-0</pub-id><pub-id pub-id-type="pmcid">PMC8254948</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name><name name-style="western"><surname>Buchman</surname><given-names>AS</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>PA</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>LL</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></name></person-group><article-title>Religious Orders Study and Rush Memory and Aging Project</article-title><source>Journal of Alzheimer&#8217;s Disease: JAD</source><year>2018</year><volume>64</volume><issue>s1</issue><fpage>S161</fpage><lpage>S189</lpage><pub-id pub-id-type="doi">10.3233/JAD-179939</pub-id><pub-id pub-id-type="pmid">29865057</pub-id><pub-id pub-id-type="pmcid">PMC6380522</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious Orders Study and Rush Memory and Aging Project. Journal of Alzheimer&#8217;s Disease: JAD. 2018;64(s1):S161&#8211;89.<pub-id pub-id-type="pmid">29865057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-179939</pub-id><pub-id pub-id-type="pmcid">PMC6380522</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelhamed</surname><given-names>HG</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>AA</given-names></name><name name-style="western"><surname>Sakraan</surname><given-names>AA</given-names></name><name name-style="western"><surname>Al-Deeb</surname><given-names>RT</given-names></name><name name-style="western"><surname>Mousa</surname><given-names>DM</given-names></name><name name-style="western"><surname>AboulEzz</surname><given-names>HS</given-names></name><name name-style="western"><surname>Noor</surname><given-names>NA</given-names></name><name name-style="western"><surname>Khadrawy</surname><given-names>YA</given-names></name><name name-style="western"><surname>Radwan</surname><given-names>NM</given-names></name></person-group><article-title>Brain Interleukins and Alzheimer&#8217;s Disease</article-title><source>Metabolic Brain Disease.</source><year>2025</year><volume>40</volume><issue>2</issue><fpage>116</fpage><pub-id pub-id-type="doi">10.1007/s11011-025-01538-5</pub-id><pub-id pub-id-type="pmid">39891777</pub-id><pub-id pub-id-type="pmcid">PMC11787210</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Abdelhamed HG, Hassan AA, Sakraan AA, Al-Deeb RT, Mousa DM, AboulEzz HS, et al. Brain Interleukins and Alzheimer&#8217;s Disease. Metabolic Brain Disease. 2025;40(2):116. 10.1007/s11011-025-01538-5.<pub-id pub-id-type="pmid">39891777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11011-025-01538-5</pub-id><pub-id pub-id-type="pmcid">PMC11787210</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujita</surname><given-names>M</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Lu</given-names></name><name name-style="western"><surname>McCabe</surname><given-names>C</given-names></name><name name-style="western"><surname>White</surname><given-names>CC</given-names></name><name name-style="western"><surname>Ng</surname><given-names>B</given-names></name><name name-style="western"><surname>Green</surname><given-names>GS</given-names></name><etal/></person-group><article-title>Cell subtype-specific effects of genetic variation in the Alzheimer&#8217;s disease brain</article-title><source>Nat Genet</source><year>2024</year><volume>56</volume><issue>4</issue><fpage>605</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1038/s41588-024-01685-y</pub-id><pub-id pub-id-type="pmid">38514782</pub-id><pub-id pub-id-type="pmcid">PMC12288883</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Fujita M, Gao Z, Zeng Lu, McCabe C, White CC, Ng B, et al. Cell subtype-specific effects of genetic variation in the Alzheimer&#8217;s disease brain. Nat Genet. 2024;56(4):605&#8211;14.<pub-id pub-id-type="pmid">38514782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-024-01685-y</pub-id><pub-id pub-id-type="pmcid">PMC12288883</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>GS</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H-S</given-names></name><name name-style="western"><surname>Taga</surname><given-names>M</given-names></name><name name-style="western"><surname>Cain</surname><given-names>A</given-names></name><name name-style="western"><surname>McCabe</surname><given-names>C</given-names></name><name name-style="western"><surname>Comandante-Lou</surname><given-names>N</given-names></name><etal/></person-group><article-title>Cellular communities reveal trajectories of brain ageing and Alzheimer&#8217;s disease</article-title><source>Nature</source><year>2024</year><volume>633</volume><issue>8030</issue><fpage>634</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07871-6</pub-id><pub-id pub-id-type="pmid">39198642</pub-id><pub-id pub-id-type="pmcid">PMC11877878</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Green GS, Fujita M, Yang H-S, Taga M, Cain A, McCabe C, et al. Cellular communities reveal trajectories of brain ageing and Alzheimer&#8217;s disease. Nature. 2024;633(8030):634&#8211;45.<pub-id pub-id-type="pmid">39198642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-024-07871-6</pub-id><pub-id pub-id-type="pmcid">PMC11877878</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>S</given-names></name><name name-style="western"><surname>Guerrero-Juarez</surname><given-names>CF</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Chang</surname><given-names>I</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>R</given-names></name><name name-style="western"><surname>Kuan</surname><given-names>C-H</given-names></name><name name-style="western"><surname>Myung</surname><given-names>P</given-names></name><name name-style="western"><surname>Plikus</surname><given-names>MV</given-names></name><name name-style="western"><surname>Nie</surname><given-names>Q</given-names></name></person-group><article-title>Inference and analysis of cell-cell communication using cell chat</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><issue>1</issue><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/s41467-021-21246-9</pub-id><pub-id pub-id-type="pmid">33597522</pub-id><pub-id pub-id-type="pmcid">PMC7889871</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan C-H, et al. Inference and analysis of cell-cell communication using cell chat. Nat Commun. 2021;12(1):1&#8211;20.<pub-id pub-id-type="pmid">33597522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-21246-9</pub-id><pub-id pub-id-type="pmcid">PMC7889871</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerrits</surname><given-names>E</given-names></name><name name-style="western"><surname>Brouwer</surname><given-names>N</given-names></name><name name-style="western"><surname>Kooistra</surname><given-names>SM</given-names></name><name name-style="western"><surname>Woodbury</surname><given-names>ME</given-names></name><name name-style="western"><surname>Vermeiren</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lambourne</surname><given-names>M</given-names></name><name name-style="western"><surname>Mulder</surname><given-names>J</given-names></name><etal/></person-group><article-title>Distinct amyloid-&#946; and tau-associated microglia profiles in Alzheimer&#8217;s disease</article-title><source>Acta Neuropathol</source><year>2021</year><volume>141</volume><issue>5</issue><fpage>681</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1007/s00401-021-02263-w</pub-id><pub-id pub-id-type="pmid">33609158</pub-id><pub-id pub-id-type="pmcid">PMC8043951</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Gerrits E, Brouwer N, Kooistra SM, Woodbury ME, Vermeiren Y, Lambourne M, et al. Distinct amyloid-&#946; and tau-associated microglia profiles in Alzheimer&#8217;s disease. Acta Neuropathol. 2021;141(5):681&#8211;96.<pub-id pub-id-type="pmid">33609158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-021-02263-w</pub-id><pub-id pub-id-type="pmcid">PMC8043951</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bishnoi</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>RF</given-names></name><name name-style="western"><surname>Royall</surname><given-names>DR</given-names></name></person-group><article-title>Serum interleukin (IL)-15 as a biomarker of Alzheimer&#8217;s disease</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><issue>2</issue><fpage>e0117282</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0117282</pub-id><pub-id pub-id-type="pmid">25710473</pub-id><pub-id pub-id-type="pmcid">PMC4339977</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Bishnoi RJ, Palmer RF, Royall DR. Serum interleukin (IL)-15 as a biomarker of Alzheimer&#8217;s disease. PLoS ONE. 2015;10(2):e0117282.<pub-id pub-id-type="pmid">25710473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0117282</pub-id><pub-id pub-id-type="pmcid">PMC4339977</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daniilidou</surname><given-names>M</given-names></name><name name-style="western"><surname>Eroli</surname><given-names>F</given-names></name><name name-style="western"><surname>Alanko</surname><given-names>V</given-names></name><name name-style="western"><surname>Goikolea</surname><given-names>J</given-names></name><name name-style="western"><surname>Latorre-Leal</surname><given-names>M</given-names></name><name name-style="western"><surname>Rodriguez-Rodriguez</surname><given-names>P</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Alzheimer&#8217;s disease biomarker profiling in a memory clinic cohort without common comorbidities</article-title><source>Brain Commun</source><year>2023</year><pub-id pub-id-type="doi">10.1093/braincomms/fcad228</pub-id><pub-id pub-id-type="pmid">37680670</pub-id><pub-id pub-id-type="pmcid">PMC10481253</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Daniilidou M, Eroli F, Alanko V, Goikolea J, Latorre-Leal M, Rodriguez-Rodriguez P, et al. Alzheimer&#8217;s disease biomarker profiling in a memory clinic cohort without common comorbidities. Brain Commun. 2023. 10.1093/braincomms/fcad228.<pub-id pub-id-type="pmid">37680670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcad228</pub-id><pub-id pub-id-type="pmcid">PMC10481253</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></name><name name-style="western"><surname>Mattsson</surname><given-names>N</given-names></name><name name-style="western"><surname>Stomrud</surname><given-names>E</given-names></name><name name-style="western"><surname>Lindberg</surname><given-names>O</given-names></name><name name-style="western"><surname>Palmqvist</surname><given-names>S</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>O</given-names></name></person-group><article-title>CSF Biomarkers of Neuroinflammation and Cerebrovascular Dysfunction in Early Alzheimer Disease</article-title><source>Neurology.</source><year>2018</year><volume>91</volume><issue>9</issue><fpage>e867</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000006082</pub-id><pub-id pub-id-type="pmid">30054439</pub-id><pub-id pub-id-type="pmcid">PMC6133624</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, et al. CSF Biomarkers of Neuroinflammation and Cerebrovascular Dysfunction in Early Alzheimer Disease. Neurology. 2018;91(9):e867-77. 10.1212/WNL.0000000000006082.<pub-id pub-id-type="pmid">30054439</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000006082</pub-id><pub-id pub-id-type="pmcid">PMC6133624</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Popp</surname><given-names>J</given-names></name><name name-style="western"><surname>Oikonomidi</surname><given-names>A</given-names></name><name name-style="western"><surname>Tautvydait&#279;</surname><given-names>D</given-names></name><name name-style="western"><surname>Dayon</surname><given-names>L</given-names></name><name name-style="western"><surname>Bacher</surname><given-names>M</given-names></name><name name-style="western"><surname>Migliavacca</surname><given-names>E</given-names></name><name name-style="western"><surname>Henry</surname><given-names>H</given-names></name><etal/></person-group><article-title>Markers of Neuroinflammation Associated with Alzheimer&#8217;s Disease Pathology in Older Adults</article-title><source>Brain, behavior, and immunity.</source><year>2017</year><volume>1</volume><issue>62</issue><fpage>203</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2017.01.020</pub-id><pub-id pub-id-type="pmid">28161476</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Popp J, Oikonomidi A, Tautvydait&#279; D, Dayon L, Bacher M, Migliavacca E, et al. Markers of Neuroinflammation Associated with Alzheimer&#8217;s Disease Pathology in Older Adults. Brain, behavior, and immunity. 2017;1(62):203&#8211;11. 10.1016/j.bbi.2017.01.020.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2017.01.020</pub-id><pub-id pub-id-type="pmid">28161476</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Rentzos, M., and A. Rombos. &#8220;The Role of IL-15 in Central Nervous System Disorders.&#8221; Acta Neurologica Scandinavica 2012;125 (2). 10.1111/j.1600-0404.2011.01524.x.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0404.2011.01524.x</pub-id><pub-id pub-id-type="pmid">21615353</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rentzos</surname><given-names>M</given-names></name><name name-style="western"><surname>Zoga</surname><given-names>M</given-names></name><name name-style="western"><surname>Paraskevas</surname><given-names>GP</given-names></name><name name-style="western"><surname>Kapaki</surname><given-names>E</given-names></name><name name-style="western"><surname>Rombos</surname><given-names>A</given-names></name><name name-style="western"><surname>Nikolaou</surname><given-names>C</given-names></name><name name-style="western"><surname>Tsoutsou</surname><given-names>A</given-names></name><name name-style="western"><surname>Vassilopoulos</surname><given-names>D</given-names></name></person-group><article-title>IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer&#8217;s disease and frontotemporal dementia</article-title><source>J Geriatr Psychiatry Neurol</source><year>2006</year><pub-id pub-id-type="doi">10.1177/0891988706286226</pub-id><pub-id pub-id-type="pmid">16690997</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Rentzos M, Zoga M, Paraskevas GP, Kapaki E, Rombos A, Nikolaou C, et al. IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer&#8217;s disease and frontotemporal dementia. J Geriatr Psychiatry Neurol. 2006. 10.1177/0891988706286226.<pub-id pub-id-type="pmid">16690997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0891988706286226</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Taipa R, das Neves SP, Sousa AL, Fernandes J, Pinto C, Correia AP, Santos E, et al. Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer's disease and their correlation with cognitive decline. Neurobiology of aging. 2019;76:125-32. 10.1016/j.neurobiolaging.2018.12.019.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2018.12.019</pub-id><pub-id pub-id-type="pmid">30711675</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vidovic</surname><given-names>N</given-names></name><name name-style="western"><surname>Spittau</surname><given-names>B</given-names></name></person-group><article-title>Microglial transforming growth factor-&#946; signaling in Alzheimer&#8217;s disease</article-title><source>Int J Mol Sci</source><year>2024</year><pub-id pub-id-type="doi">10.3390/ijms25063090</pub-id><pub-id pub-id-type="pmid">38542077</pub-id><pub-id pub-id-type="pmcid">PMC10970595</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Vidovic N, Spittau B. Microglial transforming growth factor-&#946; signaling in Alzheimer&#8217;s disease. Int J Mol Sci. 2024. 10.3390/ijms25063090.<pub-id pub-id-type="pmid">38542077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25063090</pub-id><pub-id pub-id-type="pmcid">PMC10970595</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopes</surname><given-names>KdP</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tasaki</surname><given-names>S</given-names></name><name name-style="western"><surname>Iatrou</surname><given-names>A</given-names></name><name name-style="western"><surname>Beeri</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Associations of cortical SPP1 and ITGAX with cognition and common neuropathologies in older adults</article-title><source>Alzheimers Dement</source><year>2024</year><volume>20</volume><issue>1</issue><fpage>525</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1002/alz.13474</pub-id><pub-id pub-id-type="pmid">37727065</pub-id><pub-id pub-id-type="pmcid">PMC10841499</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Lopes KdP, Yu L, Shen X, Qiu Y, Tasaki S, Iatrou A, et al. Associations of cortical SPP1 and ITGAX with cognition and common neuropathologies in older adults. Alzheimers Dement. 2024;20(1):525&#8211;37.<pub-id pub-id-type="pmid">37727065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13474</pub-id><pub-id pub-id-type="pmcid">PMC10841499</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGeachy</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Cua</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Gaffen</surname><given-names>SL</given-names></name></person-group><article-title>The IL-17 Family of Cytokines in Health and Disease</article-title><source>Immunity.</source><year>2019</year><volume>50</volume><issue>4</issue><fpage>892</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.021</pub-id><pub-id pub-id-type="pmid">30995505</pub-id><pub-id pub-id-type="pmcid">PMC6474359</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 Family of Cytokines in Health and Disease. Immunity. 2019;50(4):892&#8211;906. 10.1016/j.immuni.2019.03.021.<pub-id pub-id-type="pmid">30995505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2019.03.021</pub-id><pub-id pub-id-type="pmcid">PMC6474359</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Starnes</surname><given-names>T</given-names></name><name name-style="western"><surname>Broxmeyer</surname><given-names>HE</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Hromas</surname><given-names>R</given-names></name></person-group><article-title>Cutting Edge: IL-17D, a Novel Member of the IL-17 Family, Stimulates Cytokine Production and Inhibits Hemopoiesis</article-title><source>J Immu.</source><year>2002</year><volume>169</volume><issue>2</issue><fpage>642</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.169.2.6421</pub-id><pub-id pub-id-type="pmid">12097364</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Starnes T, Broxmeyer HE, Robertson MJ, Hromas R. Cutting Edge: IL-17D, a Novel Member of the IL-17 Family, Stimulates Cytokine Production and Inhibits Hemopoiesis. J Immu. 2002;169(2):642&#8211;6. 10.4049/jimmunol.169.2.6421.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.169.2.642</pub-id><pub-id pub-id-type="pmid">12097364</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HY</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Han</surname><given-names>J</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Q</given-names></name><name name-style="western"><surname>Shao</surname><given-names>J</given-names></name><name name-style="western"><surname>Ge</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name></person-group><article-title>Interleukin-17D Regulates Group 3 Innate Lymphoid Cell Function Through Its Receptor CD93</article-title><source>Immunity.</source><year>2021</year><volume>54</volume><issue>4</issue><fpage>673</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.03.018</pub-id><pub-id pub-id-type="pmid">33852831</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Huang J, Lee HY, Zhao X, Han J, Su Y, Sun Q, et al. Interleukin-17D Regulates Group 3 Innate Lymphoid Cell Function Through Its Receptor CD93. Immunity. 2021;54(4):673&#8211;86. 10.1016/j.immuni.2021.03.018.<pub-id pub-id-type="pmid">33852831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2021.03.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>M</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Li</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name></person-group><article-title>Inhibiting cyclin B1-treated pontine infarction by suppressing proliferation of SPP1+ microglia</article-title><source>Mol Neurobiol</source><year>2022</year><volume>60</volume><issue>4</issue><fpage>1782</fpage><lpage>1796</lpage><pub-id pub-id-type="doi">10.1007/s12035-022-03183-w</pub-id><pub-id pub-id-type="pmid">36572839</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Luo M, Qiu Z, Tang X, Wu Li, Li S, Zhu J, et al. Inhibiting cyclin B1-treated pontine infarction by suppressing proliferation of SPP1+ microglia. Mol Neurobiol. 2022;60(4):1782&#8211;96. 10.1007/s12035-022-03183-w.<pub-id pub-id-type="pmid">36572839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-022-03183-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miron</surname><given-names>VE</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J-W</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Ruckh</surname><given-names>JM</given-names></name><name name-style="western"><surname>Shadrach</surname><given-names>JL</given-names></name><name name-style="western"><surname>Van Wijngaarden</surname><given-names>P</given-names></name><etal/></person-group><article-title>M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination</article-title><source>Nat Neurosci</source><year>2013</year><volume>16</volume><issue>9</issue><fpage>1211</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1038/nn.3469</pub-id><pub-id pub-id-type="pmid">23872599</pub-id><pub-id pub-id-type="pmcid">PMC3977045</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Miron VE, Boyd A, Zhao J-W, Yuen TJ, Ruckh JM, Shadrach JL, et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci. 2013;16(9):1211&#8211;8. 10.1038/nn.3469.<pub-id pub-id-type="pmid">23872599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.3469</pub-id><pub-id pub-id-type="pmcid">PMC3977045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>C</given-names></name><name name-style="western"><surname>Fan</surname><given-names>W-H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Shang</surname><given-names>Ke</given-names></name><name name-style="western"><surname>Murugan</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L-J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Tian</surname><given-names>D-S</given-names></name></person-group><article-title>Fingolimod protects against ischemic white matter damage by modulating microglia toward M2 polarization via STAT3 pathway</article-title><source>Stroke</source><year>2017</year><volume>48</volume><issue>12</issue><fpage>3336</fpage><lpage>3346</lpage><pub-id pub-id-type="doi">10.1161/strokeaha.117.018505</pub-id><pub-id pub-id-type="pmid">29114096</pub-id><pub-id pub-id-type="pmcid">PMC5728178</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Qin C, Fan W-H, Liu Q, Shang Ke, Murugan M, Wu L-J, et al. Fingolimod protects against ischemic white matter damage by modulating microglia toward M2 polarization via STAT3 pathway. Stroke. 2017;48(12):3336&#8211;46. 10.1161/strokeaha.117.018505.<pub-id pub-id-type="pmid">29114096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.117.018505</pub-id><pub-id pub-id-type="pmcid">PMC5728178</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kedia</surname><given-names>S</given-names></name><name name-style="western"><surname>Simons</surname><given-names>M</given-names></name></person-group><article-title>Oligodendrocytes in Alzheimer&#8217;s disease pathophysiology</article-title><source>Nat Neurosci</source><year>2025</year><pub-id pub-id-type="doi">10.1038/s41593-025-01873-x</pub-id><pub-id pub-id-type="pmid">39881195</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Kedia S, Simons M. Oligodendrocytes in Alzheimer&#8217;s disease pathophysiology. Nat Neurosci. 2025. 10.1038/s41593-025-01873-x.<pub-id pub-id-type="pmid">39881195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-025-01873-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>DL</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>EB</given-names></name></person-group><article-title>Human Alzheimer&#8217;s disease reactive astrocytes exhibit a loss of homeostastic gene expression</article-title><source>Acta neuropathologica communications.</source><year>2023</year><volume>11</volume><issue>1</issue><fpage>127</fpage><pub-id pub-id-type="doi">10.1186/s40478-023-01624-8</pub-id><pub-id pub-id-type="pmid">37533101</pub-id><pub-id pub-id-type="pmcid">PMC10398957</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Dai DL, Li M, Lee EB. Human Alzheimer&#8217;s disease reactive astrocytes exhibit a loss of homeostastic gene expression. Acta neuropathologica communications. 2023;11(1):127. 10.1186/s40478-023-01624-8.<pub-id pub-id-type="pmid">37533101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-023-01624-8</pub-id><pub-id pub-id-type="pmcid">PMC10398957</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>D</given-names></name></person-group><article-title>Astrocytic and Microglial Cells as the Modulators of Neuroinflammation in Alzheimer&#8217;s Disease</article-title><source>J neuroinflammation.</source><year>2022</year><volume>19</volume><issue>1</issue><fpage>206</fpage><pub-id pub-id-type="doi">10.1186/s12974-022-02565-0</pub-id><pub-id pub-id-type="pmid">35978311</pub-id><pub-id pub-id-type="pmcid">PMC9382837</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Singh D. Astrocytic and Microglial Cells as the Modulators of Neuroinflammation in Alzheimer&#8217;s Disease. J neuroinflammation. 2022;19(1):206. 10.1186/s12974-022-02565-0.<pub-id pub-id-type="pmid">35978311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-022-02565-0</pub-id><pub-id pub-id-type="pmcid">PMC9382837</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbott</surname><given-names>V</given-names></name><name name-style="western"><surname>Housden</surname><given-names>BE</given-names></name><name name-style="western"><surname>Houldsworth</surname><given-names>A</given-names></name></person-group><article-title>Could Immunotherapy and Regulatory T Cells Be Used Therapeutically to Slow the Progression of Alzheimer&#8217;s Disease?</article-title><source>Brain Communications.</source><year>2025</year><volume>7</volume><issue>2</issue><fpage>fcaf092</fpage><pub-id pub-id-type="doi">10.1093/braincomms/fcaf092</pub-id><pub-id pub-id-type="pmid">40078868</pub-id><pub-id pub-id-type="pmcid">PMC11896979</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Abbott V, Housden BE, Houldsworth A. Could Immunotherapy and Regulatory T Cells Be Used Therapeutically to Slow the Progression of Alzheimer&#8217;s Disease? Brain Communications. 2025;7(2):fcaf092. 10.1093/braincomms/fcaf092.<pub-id pub-id-type="pmid">40078868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcaf092</pub-id><pub-id pub-id-type="pmcid">PMC11896979</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mustafa</surname><given-names>MA</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>P</given-names></name><name name-style="western"><surname>Pallavi</surname><given-names>MS</given-names></name><name name-style="western"><surname>Panigrahi</surname><given-names>R</given-names></name><name name-style="western"><surname>Nathiya</surname><given-names>D</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Al-Hasnaawei</surname><given-names>S</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>AS</given-names></name><name name-style="western"><surname>Singla</surname><given-names>S</given-names></name></person-group><article-title>Exploring the Role of NLRP3 in Neurodegeneration: Cutting-Edge Therapeutic Strategies and Inhibitors</article-title><source>Developmental Neurobiology.</source><year>2025</year><volume>85</volume><issue>3</issue><fpage>e22982</fpage><pub-id pub-id-type="doi">10.1002/dneu.22982</pub-id><pub-id pub-id-type="pmid">40476303</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Mustafa MA, Bansal P, Pallavi MS, Panigrahi R, Nathiya D, Kumar S, et al. Exploring the Role of NLRP3 in Neurodegeneration: Cutting-Edge Therapeutic Strategies and Inhibitors. Developmental Neurobiology. 2025;85(3):e22982. 10.1002/dneu.22982.<pub-id pub-id-type="pmid">40476303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dneu.22982</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Wahl, Devin, Sydney J. Risen, Shelby C. Osburn, Tobias Emge, Sadhana Sharma, Vincenzo S. Gilberto, Anushree Chatterjee, Prashant Nagpal, Julie A. Moreno, and Thomas J. LaRocca. &#8220;Nanoligomers Targeting NF-&#954;B and NLRP3 Reduce Neuroinflammation and Improve Cognitive Function With Aging and Tauopathy.&#8221; bioRxiv (Cold Spring Harbor Laboratory), 2024. 10.1101/2024.02.03.578493.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-024-03182-9</pub-id><pub-id pub-id-type="pmcid">PMC11283709</pub-id><pub-id pub-id-type="pmid">39068433</pub-id></mixed-citation></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zahid</surname><given-names>A</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Kombe Kombe</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Jin</surname><given-names>T</given-names></name><name name-style="western"><surname>Tao</surname><given-names>J</given-names></name></person-group><article-title>Pharmacological inhibitors of the NLRP3 inflammasome</article-title><source>Front Immunol</source><year>2019</year><pub-id pub-id-type="doi">10.3389/fimmu.2019.02538</pub-id><pub-id pub-id-type="pmid">31749805</pub-id><pub-id pub-id-type="pmcid">PMC6842943</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Zahid A, Li B, Kombe Kombe AJ, Jin T, Tao J. Pharmacological inhibitors of the NLRP3 inflammasome. Front Immunol. 2019. 10.3389/fimmu.2019.02538.<pub-id pub-id-type="pmid">31749805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.02538</pub-id><pub-id pub-id-type="pmcid">PMC6842943</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#243;mez-Nicola</surname><given-names>D</given-names></name><name name-style="western"><surname>Valle-Argos</surname><given-names>B</given-names></name><name name-style="western"><surname>Pita-Thomas</surname><given-names>DW</given-names></name><name name-style="western"><surname>Nieto-Sampedro</surname><given-names>M</given-names></name></person-group><article-title>Interleukin 15 expression in the CNS: blockade of its activity prevents glial activation after an inflammatory injury</article-title><source>Glia</source><year>2008</year><volume>56</volume><issue>5</issue><fpage>494</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1002/glia.20628</pub-id><pub-id pub-id-type="pmid">18240307</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">G&#243;mez-Nicola D, Valle-Argos B, Pita-Thomas DW, Nieto-Sampedro M. Interleukin 15 expression in the CNS: blockade of its activity prevents glial activation after an inflammatory injury. Glia. 2008;56(5):494&#8211;505. 10.1002/glia.20628.<pub-id pub-id-type="pmid">18240307</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/glia.20628</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez-Nicola</surname><given-names>D</given-names></name><name name-style="western"><surname>Valle-Argos</surname><given-names>B</given-names></name><name name-style="western"><surname>Nieto-Sampedro</surname><given-names>M</given-names></name></person-group><article-title>Blockade of IL-15 activity inhibits microglial activation through the NF&#954;B, p38, and ERK1/2 pathways, reducing cytokine and chemokine release</article-title><source>Glia.</source><year>2010</year><volume>58</volume><issue>3</issue><fpage>264</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1002/glia.20920</pub-id><pub-id pub-id-type="pmid">19610094</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Gomez-Nicola D, Valle-Argos B, Nieto-Sampedro M. Blockade of IL-15 activity inhibits microglial activation through the NF&#954;B, p38, and ERK1/2 pathways, reducing cytokine and chemokine release. Glia. 2010;58(3):264&#8211;76. 10.1002/glia.20920.<pub-id pub-id-type="pmid">19610094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/glia.20920</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zuppe</surname><given-names>H</given-names></name><name name-style="western"><surname>Reed</surname><given-names>E</given-names></name></person-group><article-title>Common Cytokine Receptor Gamma Chain Family Cytokines Activate MAPK, PI3K, and JAK/STAT Pathways in Microglia to Influence Alzheimer&#8217;s Disease</article-title><source>Front Mol Neuroscience.</source><year>2024</year><volume>17</volume><fpage>1441691</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2024.1441691</pub-id><pub-id pub-id-type="pmcid">PMC11422389</pub-id><pub-id pub-id-type="pmid">39324116</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Zuppe H, Reed E. Common Cytokine Receptor Gamma Chain Family Cytokines Activate MAPK, PI3K, and JAK/STAT Pathways in Microglia to Influence Alzheimer&#8217;s Disease. Front Mol Neuroscience. 2024;17:1441691. 10.3389/fnmol.2024.1441691.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnmol.2024.1441691</pub-id><pub-id pub-id-type="pmcid">PMC11422389</pub-id><pub-id pub-id-type="pmid">39324116</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pini</surname><given-names>L</given-names></name><name name-style="western"><surname>Pievani</surname><given-names>M</given-names></name><name name-style="western"><surname>Bocchetta</surname><given-names>M</given-names></name><name name-style="western"><surname>Altomare</surname><given-names>D</given-names></name><name name-style="western"><surname>Bosco</surname><given-names>P</given-names></name><name name-style="western"><surname>Cavedo</surname><given-names>E</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>S</given-names></name><name name-style="western"><surname>Marizzoni</surname><given-names>M</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>GB</given-names></name></person-group><article-title>Brain atrophy in Alzheimer&#8217;s disease and aging</article-title><source>Ageing Res Rev</source><year>2016</year><pub-id pub-id-type="doi">10.1016/j.arr.2016.01.002</pub-id><pub-id pub-id-type="pmid">26827786</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Pini L, Pievani M, Bocchetta M, Altomare D, Bosco P, Cavedo E, et al. Brain atrophy in Alzheimer&#8217;s disease and aging. Ageing Res Rev. 2016. 10.1016/j.arr.2016.01.002.<pub-id pub-id-type="pmid">26827786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2016.01.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>YL</given-names></name><name name-style="western"><surname>Ganaraja</surname><given-names>B</given-names></name><name name-style="western"><surname>Murlimanju</surname><given-names>BV</given-names></name><name name-style="western"><surname>Joy</surname><given-names>T</given-names></name><name name-style="western"><surname>Krishnamurthy</surname><given-names>A</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A</given-names></name></person-group><article-title>Hippocampus and its involvement in Alzheimer&#8217;s disease: a review</article-title><source>3 Biotech</source><year>2022</year><pub-id pub-id-type="doi">10.1007/s13205-022-03123-4</pub-id><pub-id pub-id-type="pmid">35116217</pub-id><pub-id pub-id-type="pmcid">PMC8807768</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Rao YL, Ganaraja B, Murlimanju BV, Joy T, Krishnamurthy A, Agrawal A. Hippocampus and its involvement in Alzheimer&#8217;s disease: a review. 3 Biotech. 2022. 10.1007/s13205-022-03123-4.<pub-id pub-id-type="pmid">35116217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13205-022-03123-4</pub-id><pub-id pub-id-type="pmcid">PMC8807768</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cain</surname><given-names>A</given-names></name><name name-style="western"><surname>Taga</surname><given-names>M</given-names></name><name name-style="western"><surname>McCabe</surname><given-names>C</given-names></name><name name-style="western"><surname>Green</surname><given-names>GS</given-names></name><name name-style="western"><surname>Hekselman</surname><given-names>I</given-names></name><name name-style="western"><surname>White</surname><given-names>CC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>DI</given-names></name><name name-style="western"><surname>Gaur</surname><given-names>P</given-names></name><name name-style="western"><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Yeger-Lotem</surname><given-names>E</given-names></name></person-group><article-title>Multicellular Communities Are Perturbed in the Aging Human Brain and Alzheimer&#8217;s Disease</article-title><source>Nature neuroscience.</source><year>2023</year><volume>26</volume><issue>7</issue><fpage>1267</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1038/s41593-023-01356-x</pub-id><pub-id pub-id-type="pmid">37336975</pub-id><pub-id pub-id-type="pmcid">PMC10789499</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Cain A, Taga M, McCabe C, Green GS, Hekselman I, White CC, et al. Multicellular Communities Are Perturbed in the Aging Human Brain and Alzheimer&#8217;s Disease. Nature neuroscience. 2023;26(7):1267&#8211;80. 10.1038/s41593-023-01356-x.<pub-id pub-id-type="pmid">37336975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-023-01356-x</pub-id><pub-id pub-id-type="pmcid">PMC10789499</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>L</given-names></name><name name-style="western"><surname>Di Benedetto</surname><given-names>S</given-names></name></person-group><article-title>Aging brain: exploring the interplay between bone marrow aging, immunosenescence, and neuroinflammation</article-title><source>Front Immunol</source><year>2024</year><pub-id pub-id-type="doi">10.3389/fimmu.2024.1393324</pub-id><pub-id pub-id-type="pmid">38638424</pub-id><pub-id pub-id-type="pmcid">PMC11024322</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">M&#252;ller L, Di Benedetto S. Aging brain: exploring the interplay between bone marrow aging, immunosenescence, and neuroinflammation. Front Immunol. 2024. 10.3389/fimmu.2024.1393324.<pub-id pub-id-type="pmid">38638424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2024.1393324</pub-id><pub-id pub-id-type="pmcid">PMC11024322</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Sun</surname><given-names>HS</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Dumont</surname><given-names>AS</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name></person-group><article-title>Cellular Senescence, DNA Damage, and Neuroinflammation in the Aging Brain</article-title><source>Trends in Neurosciences.</source><year>2024</year><volume>47</volume><issue>6</issue><fpage>461</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2024.04.003</pub-id><pub-id pub-id-type="pmid">38729785</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Zhang W, Sun HS, Wang X, Dumont AS, Liu Q. Cellular Senescence, DNA Damage, and Neuroinflammation in the Aging Brain. Trends in Neurosciences. 2024;47(6):461&#8211;74. 10.1016/j.tins.2024.04.003.<pub-id pub-id-type="pmid">38729785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tins.2024.04.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapasi</surname><given-names>A</given-names></name><name name-style="western"><surname>Poirier</surname><given-names>J</given-names></name><name name-style="western"><surname>Hedayat</surname><given-names>A</given-names></name><name name-style="western"><surname>Scherlek</surname><given-names>A</given-names></name><name name-style="western"><surname>Mondal</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>J</given-names></name><etal/></person-group><article-title>High-throughput digital quantification of Alzheimer disease pathology and associated infrastructure in large autopsy studies</article-title><source>J Neuropathol Exp Neurol</source><year>2023</year><volume>82</volume><issue>12</issue><fpage>976</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1093/jnen/nlad086</pub-id><pub-id pub-id-type="pmid">37944065</pub-id><pub-id pub-id-type="pmcid">PMC11032710</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Kapasi A, Poirier J, Hedayat A, Scherlek A, Mondal S, Wu T, et al. High-throughput digital quantification of Alzheimer disease pathology and associated infrastructure in large autopsy studies. J Neuropathol Exp Neurol. 2023;82(12):976&#8211;86.<pub-id pub-id-type="pmid">37944065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/nlad086</pub-id><pub-id pub-id-type="pmcid">PMC11032710</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><mixed-citation publication-type="other">Bennett, D. A., R. S. Wilson, J. A. Schneider, D. A. Evans, N. T. Aggarwal, S. E. Arnold, E. J. Cochran, E. Berry-Kravis, and J. L. Bienias. 2003. &#8220;Apolipoprotein E epsilon4 Allele, AD Pathology, and the Clinical Expression of Alzheimer&#8217;s Disease.&#8221; Neurology 60 (2). 10.1212/01.wnl.0000042478.08543.f7.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000042478.08543.f7</pub-id><pub-id pub-id-type="pmid">12552039</pub-id></mixed-citation></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>PA</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>LL</given-names></name><name name-style="western"><surname>Sytsma</surname><given-names>J</given-names></name><name name-style="western"><surname>Buchman</surname><given-names>AS</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></name></person-group><article-title>Temporal course and pathologic basis of unawareness of memory loss in dementia</article-title><source>Neurology</source><year>2015</year><volume>85</volume><issue>11</issue><fpage>984</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000001935</pub-id><pub-id pub-id-type="pmid">26311746</pub-id><pub-id pub-id-type="pmcid">PMC4567465</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Wilson RS, Boyle PA, Yu L, Barnes LL, Sytsma J, Buchman AS, et al. Temporal course and pathologic basis of unawareness of memory loss in dementia. Neurology. 2015;85(11):984&#8211;91.<pub-id pub-id-type="pmid">26311746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000001935</pub-id><pub-id pub-id-type="pmcid">PMC4567465</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyle</surname><given-names>PA</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></name><name name-style="western"><surname>Dawe</surname><given-names>R</given-names></name><name name-style="western"><surname>Arfanakis</surname><given-names>K</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name></person-group><article-title>To What Degree Is Late Life Cognitive Decline Driven by Age-Related Neuropathologies?</article-title><source>Brain.</source><year>2021</year><volume>144</volume><issue>7</issue><fpage>2166</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1093/brain/awab092</pub-id><pub-id pub-id-type="pmid">33742668</pub-id><pub-id pub-id-type="pmcid">PMC8370442</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Boyle PA, Wang T, Yu L, Wilson RS, Dawe R, Arfanakis K, et al. To What Degree Is Late Life Cognitive Decline Driven by Age-Related Neuropathologies? Brain. 2021;144(7):2166&#8211;75.<pub-id pub-id-type="pmid">33742668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awab092</pub-id><pub-id pub-id-type="pmcid">PMC8370442</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Tasaki</surname><given-names>S</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></name><name name-style="western"><surname>Arfanakis</surname><given-names>K</given-names></name><name name-style="western"><surname>Duong</surname><given-names>DM</given-names></name><name name-style="western"><surname>Wingo</surname><given-names>AP</given-names></name><name name-style="western"><surname>Wingo</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Cortical proteins associated with cognitive resilience in community-dwelling older persons</article-title><source>JAMA Psychiatr</source><year>2020</year><volume>77</volume><issue>11</issue><fpage>1172</fpage><lpage>1180</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2020.1807</pub-id><pub-id pub-id-type="pmcid">PMC7330835</pub-id><pub-id pub-id-type="pmid">32609320</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Yu L, Tasaki S, Schneider JA, Arfanakis K, Duong DM, Wingo AP, et al. Cortical proteins associated with cognitive resilience in community-dwelling older persons. JAMA Psychiatr. 2020;77(11):1172&#8211;80.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2020.1807</pub-id><pub-id pub-id-type="pmcid">PMC7330835</pub-id><pub-id pub-id-type="pmid">32609320</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>NT</given-names></name><name name-style="western"><surname>Arvanitakis</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shah</surname><given-names>RC</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>JF</given-names></name><name name-style="western"><surname>Fox</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Decision rules guiding the clinical diagnosis of Alzheimer&#8217;s disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study</article-title><source>Neuroepidemiology</source><year>2006</year><volume>27</volume><issue>3</issue><fpage>169</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1159/000096129</pub-id><pub-id pub-id-type="pmid">17035694</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Bennett DA, Schneider JA, Aggarwal NT, Arvanitakis Z, Shah RC, Kelly JF, et al. Decision rules guiding the clinical diagnosis of Alzheimer&#8217;s disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology. 2006;27(3):169&#8211;76.<pub-id pub-id-type="pmid">17035694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000096129</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></name><name name-style="western"><surname>Arvanitakis</surname><given-names>Z</given-names></name><name name-style="western"><surname>Bang</surname><given-names>W</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name></person-group><article-title>Mixed brain pathologies account for most dementia cases in community-dwelling older persons</article-title><source>Neurology</source><year>2007</year><volume>69</volume><issue>24</issue><fpage>2197</fpage><lpage>2204</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000271090.28148.24</pub-id><pub-id pub-id-type="pmid">17568013</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197&#8211;204.<pub-id pub-id-type="pmid">17568013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000271090.28148.24</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></name><name name-style="western"><surname>Evans</surname><given-names>DA</given-names></name><name name-style="western"><surname>Beckett</surname><given-names>LA</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>NT</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>LL</given-names></name><name name-style="western"><surname>Fox</surname><given-names>JH</given-names></name><name name-style="western"><surname>Bach</surname><given-names>J</given-names></name></person-group><article-title>Natural history of mild cognitive impairment in older persons</article-title><source>Neurology</source><year>2002</year><volume>59</volume><issue>2</issue><fpage>198</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1212/WNL.59.2.198</pub-id><pub-id pub-id-type="pmid">12136057</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59(2):198&#8211;205.<pub-id pub-id-type="pmid">12136057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.59.2.198</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>A</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Ma</surname><given-names>A</given-names></name><name name-style="western"><surname>P&#233;rez</surname><given-names>JL</given-names></name><name name-style="western"><surname>Sander</surname><given-names>C</given-names></name><name name-style="western"><surname>Keskin</surname><given-names>DB</given-names></name><name name-style="western"><surname>Wu</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Fraenkel</surname><given-names>E</given-names></name><name name-style="western"><surname>Hacohen</surname><given-names>N</given-names></name></person-group><article-title>Dictionary of immune responses to cytokines at single-cell resolution</article-title><source>Nature</source><year>2023</year><volume>625</volume><issue>7994</issue><fpage>377</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06816-9</pub-id><pub-id pub-id-type="pmid">38057668</pub-id><pub-id pub-id-type="pmcid">PMC10781646</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Cui A, Huang T, Li S, Ma A, P&#233;rez JL, Sander C, et al. Dictionary of immune responses to cytokines at single-cell resolution. Nature. 2023;625(7994):377&#8211;84.<pub-id pub-id-type="pmid">38057668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06816-9</pub-id><pub-id pub-id-type="pmcid">PMC10781646</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santoso</surname><given-names>CS</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lal</surname><given-names>S</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S</given-names></name><name name-style="western"><surname>Gan</surname><given-names>KA</given-names></name><name name-style="western"><surname>Agosto</surname><given-names>LM</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Comprehensive mapping of the human cytokine gene regulatory network</article-title><source>Nucleic Acids Res</source><year>2020</year><volume>48</volume><issue>21</issue><fpage>12055</fpage><lpage>12073</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa1055</pub-id><pub-id pub-id-type="pmid">33179750</pub-id><pub-id pub-id-type="pmcid">PMC7708076</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Santoso CS, Li Z, Lal S, Yuan S, Gan KA, Agosto LM, et al. Comprehensive mapping of the human cytokine gene regulatory network. Nucleic Acids Res. 2020;48(21):12055&#8211;73.<pub-id pub-id-type="pmid">33179750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkaa1055</pub-id><pub-id pub-id-type="pmcid">PMC7708076</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Petyuk</surname><given-names>VA</given-names></name><name name-style="western"><surname>Gaiteri</surname><given-names>C</given-names></name><name name-style="western"><surname>Mostafavi</surname><given-names>S</given-names></name><name name-style="western"><surname>Young-Pearse</surname><given-names>T</given-names></name><name name-style="western"><surname>Shah</surname><given-names>RC</given-names></name><name name-style="western"><surname>Buchman</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Targeted brain proteomics uncover multiple pathways to Alzheimer&#8217;s dementia</article-title><source>Ann Neurol</source><year>2018</year><volume>84</volume><issue>1</issue><fpage>78</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1002/ana.25266</pub-id><pub-id pub-id-type="pmid">29908079</pub-id><pub-id pub-id-type="pmcid">PMC6119500</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Yu L, Petyuk VA, Gaiteri C, Mostafavi S, Young-Pearse T, Shah RC, et al. Targeted brain proteomics uncover multiple pathways to Alzheimer&#8217;s dementia. Ann Neurol. 2018;84(1):78&#8211;88.<pub-id pub-id-type="pmid">29908079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.25266</pub-id><pub-id pub-id-type="pmcid">PMC6119500</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Petyuk</surname><given-names>VA</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>KP</given-names></name><name name-style="western"><surname>Tasaki</surname><given-names>S</given-names></name><name name-style="western"><surname>Menon</surname><given-names>V</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></name><name name-style="western"><surname>De Jager</surname><given-names>PL</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name></person-group><article-title>Associations of VGF with neuropathologies and cognitive health in older adults</article-title><source>Ann Neurol</source><year>2023</year><volume>94</volume><issue>2</issue><fpage>232</fpage><pub-id pub-id-type="doi">10.1002/ana.26676</pub-id><pub-id pub-id-type="pmid">37177846</pub-id><pub-id pub-id-type="pmcid">PMC10524948</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Yu L, Petyuk VA, Lopes KP, Tasaki S, Menon V, Wang Y, et al. Associations of VGF with neuropathologies and cognitive health in older adults. Ann Neurol. 2023;94(2):232. 10.1002/ana.26676.<pub-id pub-id-type="pmid">37177846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26676</pub-id><pub-id pub-id-type="pmcid">PMC10524948</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mostafavi</surname><given-names>S</given-names></name><name name-style="western"><surname>Gaiteri</surname><given-names>C</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>SE</given-names></name><name name-style="western"><surname>White</surname><given-names>CC</given-names></name><name name-style="western"><surname>Tasaki</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Taga</surname><given-names>M</given-names></name><etal/></person-group><article-title>A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer&#8217;s disease</article-title><source>Nat Neurosci</source><year>2018</year><volume>21</volume><issue>6</issue><fpage>811</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1038/s41593-018-0154-9</pub-id><pub-id pub-id-type="pmid">29802388</pub-id><pub-id pub-id-type="pmcid">PMC6599633</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Mostafavi S, Gaiteri C, Sullivan SE, White CC, Tasaki S, Xu J, et al. A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer&#8217;s disease. Nat Neurosci. 2018;21(6):811&#8211;9.<pub-id pub-id-type="pmid">29802388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-018-0154-9</pub-id><pub-id pub-id-type="pmcid">PMC6599633</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tasaki</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Avey</surname><given-names>DR</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>L</given-names></name><name name-style="western"><surname>Petyuk</surname><given-names>VA</given-names></name><name name-style="western"><surname>Dawe</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gaiteri</surname><given-names>C</given-names></name></person-group><article-title>Inferring protein expression changes from mrna in Alzheimer&#8217;s dementia using deep neural networks</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>655</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-28280-1</pub-id><pub-id pub-id-type="pmid">35115553</pub-id><pub-id pub-id-type="pmcid">PMC8814036</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Tasaki S, Xu J, Avey DR, Johnson L, Petyuk VA, Dawe RJ, et al. Inferring protein expression changes from mrna in Alzheimer&#8217;s dementia using deep neural networks. Nat Commun. 2022;13(1):655.<pub-id pub-id-type="pmid">35115553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-28280-1</pub-id><pub-id pub-id-type="pmcid">PMC8814036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Capuano</surname><given-names>AW</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>P</given-names></name><name name-style="western"><surname>Arvanitakis</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>De Jager</surname><given-names>PL</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></name><name name-style="western"><surname>Tasaki</surname><given-names>S</given-names></name><name name-style="western"><surname>de Paiva Lopes</surname><given-names>K</given-names></name><etal/></person-group><article-title>The MIND diet, brain transcriptomic alterations, and dementia</article-title><source>Alzheimers Dement</source><year>2024</year><volume>20</volume><issue>9</issue><fpage>5996</fpage><lpage>6007</lpage><pub-id pub-id-type="doi">10.1002/alz.14062</pub-id><pub-id pub-id-type="pmid">39129336</pub-id><pub-id pub-id-type="pmcid">PMC11497672</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Li J, Capuano AW, Agarwal P, Arvanitakis Z, Wang Y, De Jager PL, et al. The MIND diet, brain transcriptomic alterations, and dementia. Alzheimers Dement. 2024;20(9):5996&#8211;6007. 10.1002/alz.14062.<pub-id pub-id-type="pmid">39129336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14062</pub-id><pub-id pub-id-type="pmcid">PMC11497672</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oveisgharan</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>de Paiva Lopes</surname><given-names>K</given-names></name><etal/></person-group><article-title>G-protein coupled estrogen receptor 1, amyloid-&#946;, and tau tangles in older adults</article-title><source>Commun Biol</source><year>2024</year><volume>7</volume><fpage>569</fpage><pub-id pub-id-type="doi">10.1038/s42003-024-06272-9</pub-id><pub-id pub-id-type="pmid">38750228</pub-id><pub-id pub-id-type="pmcid">PMC11096330</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Oveisgharan S, Yu L, de Paiva Lopes K, et al. G-protein coupled estrogen receptor 1, amyloid-&#946;, and tau tangles in older adults. Commun Biol. 2024;7:569.<pub-id pub-id-type="pmid">38750228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42003-024-06272-9</pub-id><pub-id pub-id-type="pmcid">PMC11096330</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robinson</surname><given-names>MD</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>GK</given-names></name></person-group><article-title>EdgeR: A Bioconductor Package for Differential Expression Analysis of Digital Gene Expression Data</article-title><source>Bioinformatics (Oxford, England)</source><year>2010</year><volume>26</volume><issue>1</issue><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">19910308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btp616</pub-id><pub-id pub-id-type="pmcid">PMC2796818</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Robinson MD, McCarthy DJ, Smyth GK. EdgeR: A Bioconductor Package for Differential Expression Analysis of Digital Gene Expression Data. Bioinformatics (Oxford, England). 2010;26(1):139&#8211;40.<pub-id pub-id-type="pmid">19910308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btp616</pub-id><pub-id pub-id-type="pmcid">PMC2796818</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Law</surname><given-names>CW</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>GK</given-names></name></person-group><article-title>Voom: Precision Weights Unlock Linear Model Analysis Tools for RNA-Seq Read Counts</article-title><source>Genome Biol</source><year>2014</year><volume>15</volume><issue>2</issue><fpage>R29</fpage><pub-id pub-id-type="doi">10.1186/gb-2014-15-2-r29</pub-id><pub-id pub-id-type="pmid">24485249</pub-id><pub-id pub-id-type="pmcid">PMC4053721</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Law CW, Chen Y, Shi W, Smyth GK. Voom: Precision Weights Unlock Linear Model Analysis Tools for RNA-Seq Read Counts. Genome Biol. 2014;15(2):R29.<pub-id pub-id-type="pmid">24485249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/gb-2014-15-2-r29</pub-id><pub-id pub-id-type="pmcid">PMC4053721</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leek</surname><given-names>JT</given-names></name><name name-style="western"><surname>Evan Johnson</surname><given-names>W</given-names></name><name name-style="western"><surname>Parker</surname><given-names>HS</given-names></name><name name-style="western"><surname>Jaffe</surname><given-names>AE</given-names></name><name name-style="western"><surname>Storey</surname><given-names>JD</given-names></name></person-group><article-title>The Sva Package for Removing Batch Effects and Other Unwanted Variation in High-Throughput Experiments</article-title><source>Bioinformatics (Oxford, England)</source><year>2012</year><volume>28</volume><issue>6</issue><fpage>882</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">22257669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/bts034</pub-id><pub-id pub-id-type="pmcid">PMC3307112</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Leek JT, Evan Johnson W, Parker HS, Jaffe AE, Storey JD. The Sva Package for Removing Batch Effects and Other Unwanted Variation in High-Throughput Experiments. Bioinformatics (Oxford, England). 2012;28(6):882&#8211;3.<pub-id pub-id-type="pmid">22257669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/bts034</pub-id><pub-id pub-id-type="pmcid">PMC3307112</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>M</given-names></name><name name-style="western"><surname>Carrasquillo</surname><given-names>MM</given-names></name><name name-style="western"><surname>Funk</surname><given-names>C</given-names></name><name name-style="western"><surname>Heavner</surname><given-names>BD</given-names></name><name name-style="western"><surname>Zou</surname><given-names>F</given-names></name><name name-style="western"><surname>Younkin</surname><given-names>CS</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Human Whole Genome Genotype and Transcriptome Data for Alzheimer&#8217;s and Other Neurodegenerative Diseases</article-title><source>Scientific Data</source><year>2016</year><volume>3</volume><issue>October</issue><fpage>160089</fpage><pub-id pub-id-type="doi">10.1038/sdata.2016.89</pub-id><pub-id pub-id-type="pmid">27727239</pub-id><pub-id pub-id-type="pmcid">PMC5058336</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Allen M, Carrasquillo MM, Funk C, Heavner BD, Zou F, Younkin CS, et al. Human Whole Genome Genotype and Transcriptome Data for Alzheimer&#8217;s and Other Neurodegenerative Diseases. Scientific Data. 2016;3(October):160089.<pub-id pub-id-type="pmid">27727239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sdata.2016.89</pub-id><pub-id pub-id-type="pmcid">PMC5058336</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Beckmann</surname><given-names>ND</given-names></name><name name-style="western"><surname>Roussos</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ming</surname><given-names>C</given-names></name><etal/></person-group><article-title>The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer&#8217;s disease</article-title><source>Sci Data</source><year>2018</year><volume>5</volume><issue>1</issue><fpage>180185</fpage><pub-id pub-id-type="doi">10.1038/sdata.2018.185</pub-id><pub-id pub-id-type="pmid">30204156</pub-id><pub-id pub-id-type="pmcid">PMC6132187</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Wang M, Beckmann ND, Roussos P, Wang E, Zhou X, Wang Q, et al. The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer&#8217;s disease. Sci Data. 2018;5(1):180185.<pub-id pub-id-type="pmid">30204156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sdata.2018.185</pub-id><pub-id pub-id-type="pmcid">PMC6132187</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffman</surname><given-names>GE</given-names></name><name name-style="western"><surname>Schadt</surname><given-names>EE</given-names></name></person-group><article-title>Variancepartition: interpreting drivers of variation in complex gene expression studies</article-title><source>BMC Bioinformatics</source><year>2016</year><volume>17</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1186/s12859-016-1323-z</pub-id><pub-id pub-id-type="pmid">27884101</pub-id><pub-id pub-id-type="pmcid">PMC5123296</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Hoffman GE, Schadt EE. Variancepartition: interpreting drivers of variation in complex gene expression studies. BMC Bioinformatics. 2016;17(1):1&#8211;13.<pub-id pub-id-type="pmid">27884101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12859-016-1323-z</pub-id><pub-id pub-id-type="pmcid">PMC5123296</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tasaki</surname><given-names>S</given-names></name><name name-style="western"><surname>Gaiteri</surname><given-names>C</given-names></name><name name-style="western"><surname>Petyuk</surname><given-names>VA</given-names></name><name name-style="western"><surname>Blizinsky</surname><given-names>KD</given-names></name><name name-style="western"><surname>De Jager</surname><given-names>PL</given-names></name><name name-style="western"><surname>Buchman</surname><given-names>AS</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name></person-group><article-title>Genetic Risk for Alzheimer&#8217;s Dementia Predicts Motor Deficits through Multi-Omic Systems in Older Adults</article-title><source>Transl Psychiatry</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/s41398-019-0577-4</pub-id><pub-id pub-id-type="pmid">31582723</pub-id><pub-id pub-id-type="pmcid">PMC6776503</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Tasaki S, Gaiteri C, Petyuk VA, Blizinsky KD, De Jager PL, Buchman AS, et al. Genetic Risk for Alzheimer&#8217;s Dementia Predicts Motor Deficits through Multi-Omic Systems in Older Adults. Transl Psychiatry. 2019;9(1):1&#8211;11.<pub-id pub-id-type="pmid">31582723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-019-0577-4</pub-id><pub-id pub-id-type="pmcid">PMC6776503</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subramanian</surname><given-names>A</given-names></name><name name-style="western"><surname>Tamayo</surname><given-names>P</given-names></name><name name-style="western"><surname>Mootha</surname><given-names>VK</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S</given-names></name><name name-style="western"><surname>Ebert</surname><given-names>BL</given-names></name><name name-style="western"><surname>Gillette</surname><given-names>MA</given-names></name><name name-style="western"><surname>Paulovich</surname><given-names>A</given-names></name><etal/></person-group><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><issue>43</issue><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id><pub-id pub-id-type="pmcid">PMC1239896</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545&#8211;50.<pub-id pub-id-type="pmid">16199517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmcid">PMC1239896</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>S</given-names></name><name name-style="western"><surname>Plikus</surname><given-names>MV</given-names></name><name name-style="western"><surname>Nie</surname><given-names>Q</given-names></name></person-group><article-title>Cellchat for systematic analysis of cell-cell communication from single-cell transcriptomics</article-title><source>Nat Protoc</source><year>2025</year><volume>20</volume><issue>1</issue><fpage>180</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1038/s41596-024-01045-4</pub-id><pub-id pub-id-type="pmid">39289562</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Jin S, Plikus MV, Nie Q. Cellchat for systematic analysis of cell-cell communication from single-cell transcriptomics. Nat Protoc. 2025;20(1):180&#8211;219.<pub-id pub-id-type="pmid">39289562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41596-024-01045-4</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="editorial" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Sci Monit</journal-id><journal-id journal-id-type="iso-abbrev">Med Sci Monit</journal-id><journal-id journal-id-type="pmc-domain-id">1959</journal-id><journal-id journal-id-type="pmc-domain">medscimon</journal-id><journal-id journal-id-type="publisher-id">Medical Science Monitor</journal-id><journal-title-group><journal-title>Medical Science Monitor: International Medical Journal of Experimental and Clinical Research</journal-title></journal-title-group><issn pub-type="ppub">1234-1010</issn><issn pub-type="epub">1643-3750</issn><publisher><publisher-name>International Scientific Information, Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12499630</article-id><article-id pub-id-type="pmcid-ver">PMC12499630.1</article-id><article-id pub-id-type="pmcaid">12499630</article-id><article-id pub-id-type="pmcaiid">12499630</article-id><article-id pub-id-type="pmid">41030020</article-id><article-id pub-id-type="doi">10.12659/MSM.951655</article-id><article-id pub-id-type="publisher-id">951655</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Editorial: Real-World Outcomes of Disease-Modifying Therapies Highlight the Need for Diagnostic Biomarkers in Early Alzheimer&#8217;s Disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Parums</surname><given-names initials="DV">Dinah V.</given-names></name><degrees>MD PhD</degrees></contrib><aff id="af1-medscimonit-31-e951655">Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA</aff></contrib-group><author-notes><corresp id="c1-medscimonit-31-e951655">e-mail: <email>dinah.v.parums@isi-science.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>01</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="epreprint"><day>25</day><month>9</month><year>2025</year></pub-date><volume>31</volume><issue-id pub-id-type="pmc-issue-id">478681</issue-id><elocation-id>e951655</elocation-id><history><date date-type="received"><day>24</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-07 10:25:20.703"><day>07</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; Med Sci Monit, 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0</ext-link>)</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="medscimonit-31-e951655.pdf"/><abstract><p>The promise of targeted humanized monoclonal antibody therapies to amyloid &#946; and tau protein in Alzheimer&#8217;s disease from clinical trial data has not been realized when put to the test in real-world studies and practice. There have been regulatory approvals for diagnostic blood tests in China, Japan (HISCL A&#946;42/40), and the United Kingdom (UK) (PrecivityAD2). On May 16, 2025, the US FDA approved the Lumipulse G blood test, which utilizes the plasma pTau217/A&#946;1&#8211;42 ratio, for the diagnosis of cerebral amyloid plaques in symptomatic patients of 55 years or more. Biological biomarkers and targets are currently being evaluated in phase 1 to phase 3 clinical trials, to rapidly implement less invasive blood-based assays to detect tau species and neurofilament light (NfL). However, clinical validation of the diagnostic value of identifying blood biomarkers still requires support from amyloid positron emission tomography (PET) brain scans and/or the results of cerebrospinal fluid (CSF) analysis. This editorial aims to identify how real-world outcomes of new disease-modifying therapies highlight the need for diagnostic biomarkers for early Alzheimer&#8217;s disease and the current status of biomarkers identified by blood plasma, CSF, and imaging.</p></abstract><kwd-group><kwd>Alzheimer&#8217;s Disease</kwd><kwd>Disease-Modifying Therapy</kwd><kwd>Real-World Studies</kwd><kwd>Biomarkers</kwd><kwd>Editorial</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Alzheimer&#8217;s disease is the most common type of dementia and represents an increasing global public health challenge as populations are living longer [<xref rid="b1-medscimonit-31-e951655" ref-type="bibr">1</xref>]. Until 2021, the only treatments for patients with Alzheimer&#8217;s disease were symptomatic and aimed to improve cognitive and behavioral symptoms, rather than disease-modifying therapies to delay or slow disease progression [<xref rid="b2-medscimonit-31-e951655" ref-type="bibr">2</xref>]. A recently published systematic review and meta-analysis study by Kusoro and colleagues evaluated 13 cohort studies published up to December 2024 that included more than 30,000 patients with a diagnosis of dementia [<xref rid="b3-medscimonit-31-e951655" ref-type="bibr">3</xref>]. In this analysis, the age of onset of dementia ranged from 54 to 93 years, and the average time to diagnosis was 3.5 years, with younger age at onset and frontotemporal dementia having longer diagnostic delay [<xref rid="b3-medscimonit-31-e951655" ref-type="bibr">3</xref>]. Therefore, timely diagnosis of Alzheimer&#8217;s disease is a major global challenge and a significant factor in outcomes from any disease-modifying therapies that may explain some recent real-world findings [<xref rid="b4-medscimonit-31-e951655" ref-type="bibr">4</xref>].</p><p>The promise of targeted humanized monoclonal antibody therapies to amyloid &#946; and tau protein from clinical trial data has not been realized when put to the test in real-world studies and practice [<xref rid="b4-medscimonit-31-e951655" ref-type="bibr">4</xref>,<xref rid="b5-medscimonit-31-e951655" ref-type="bibr">5</xref>]. For example, in June 2021, the disease-modifying therapy aducanumab, the first humanized recombinant monoclonal antibody targeting amyloid &#946;, received accelerated approval by the US Food and Drug Administration (FDA) to treat Alzheimer&#8217;s disease and mild cognitive impairment [<xref rid="b4-medscimonit-31-e951655" ref-type="bibr">4</xref>, <xref rid="b6-medscimonit-31-e951655" ref-type="bibr">6</xref>]. Clinical trial data showed that one year of monthly intravenous infusion of aducanumab in 165 patients with mild Alzheimer&#8217;s disease reduced brain amyloid &#946; levels in a dose-dependent and time-dependent manner, and positron emission tomography (PET) imaging showed that almost 50% of the patients no longer had cerebral amyloid [<xref rid="b7-medscimonit-31-e951655" ref-type="bibr">7</xref>]. However, 40% of patients experienced amyloid-related imaging abnormalities (ARIA), which included edema (ARIA-E) or micro-hemorrhage (ARIA-H) [<xref rid="b7-medscimonit-31-e951655" ref-type="bibr">7</xref>,<xref rid="b8-medscimonit-31-e951655" ref-type="bibr">8</xref>]. The limitations of screening costs, treatment costs, and side effects resulted in a loss of support from healthcare insurers in the US [<xref rid="b8-medscimonit-31-e951655" ref-type="bibr">8</xref>]. In February 2024, production of aducanumab ceased [<xref rid="b8-medscimonit-31-e951655" ref-type="bibr">8</xref>].</p><p>It is important to recognize that disease-modifying therapies are not a cure for Alzheimer&#8217;s disease. Currently, the two primary disease-modifying monoclonal antibodies in Alzheimer&#8217;s disease are lecanemab and donanemab [<xref rid="b9-medscimonit-31-e951655" ref-type="bibr">9</xref>,<xref rid="b10-medscimonit-31-e951655" ref-type="bibr">10</xref>]. Clinical trial data have shown that when treated in the early stages of the disease, patients may experience delayed disease progression and an increased period of independence [<xref rid="b10-medscimonit-31-e951655" ref-type="bibr">10</xref>,<xref rid="b11-medscimonit-31-e951655" ref-type="bibr">11</xref>]. However, in real-world situations, any benefits of treatment will depend on the diagnosis of Alzheimer&#8217;s disease in the early stages and balance any benefits with increasingly recognized treatment toxicities and recently recognized challenges and inequalities in patient selection [<xref rid="b12-medscimonit-31-e951655" ref-type="bibr">12</xref>].</p><p>The US FDA approved two anti-amyloid therapeutic monoclonal antibodies, lecanemab in 2023 and donanemab in 2024, based on clinical trial data that showed significantly reduced amyloid plaques on brain magnetic resonance imaging (MRI) [<xref rid="b10-medscimonit-31-e951655" ref-type="bibr">10</xref>,<xref rid="b11-medscimonit-31-e951655" ref-type="bibr">11</xref>]. However, in a phase 3 clinical trial, lecanemab slowed cognitive decline by 25% at 18 months, which was only moderately less than placebo after 18 months [<xref rid="b10-medscimonit-31-e951655" ref-type="bibr">10</xref>]. Also, in a phase 3 clinical trial, donanemab slowed Alzheimer&#8217;s disease progression by 22.3% compared with placebo after 76 weeks of treatment [<xref rid="b11-medscimonit-31-e951655" ref-type="bibr">11</xref>]. Additionally, initial clinical trial findings suggested that lecanemab led to fewer amyloid-related imaging abnormalities (ARIA) compared to donanemab [<xref rid="b10-medscimonit-31-e951655" ref-type="bibr">10</xref>,<xref rid="b13-medscimonit-31-e951655" ref-type="bibr">13</xref>]. Notably, the US FDA requires that both disease-modifying therapies have boxed warnings about ARIA, as these imaging findings are usually asymptomatic and should be monitored with magnetic resonance imaging (MRI) scans to detect either bleeding or cerebral edema, and cautions that ARIA can be severe enough to be life-threatening [<xref rid="b14-medscimonit-31-e951655" ref-type="bibr">14</xref>]. Homozygosity for apolipoprotein E4 (APOE4) is a significant genetic risk factor for Alzheimer&#8217;s disease, but it is still unclear whether this is associated with an increased risk for ARIA [<xref rid="b15-medscimonit-31-e951655" ref-type="bibr">15</xref>].</p><p>Donanemab has now been approved in 13 countries, and its approval and launch in Europe are expected in 2025 [<xref rid="b16-medscimonit-31-e951655" ref-type="bibr">16</xref>]. On August 22, 2024 the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved both lecanemab and donanemab for the early stages of Alzheimer&#8217;s disease in adults, but the UK National Institute for Health and Care Excellence (NICE) has not recommended them for routine use, as the benefits of both lecanemab and donanemab for patients without two copies of APOE4 are too small to outweigh the benefits and safety issues [<xref rid="b17-medscimonit-31-e951655" ref-type="bibr">17</xref>]. Investigator-led head-to-head clinical trials of lecanemab and donanemab are required, as well as long-term trials combined with real-world data [<xref rid="b12-medscimonit-31-e951655" ref-type="bibr">12</xref>,<xref rid="b16-medscimonit-31-e951655" ref-type="bibr">16</xref>]. Interpretations and assumptions from the results of controlled clinical trials can be significantly changed when tested in real-world clinical practice, when real-world data are used to support real-world evidence [<xref rid="b5-medscimonit-31-e951655" ref-type="bibr">5</xref>]. Recently approved disease-modifying therapies for Alzheimer&#8217;s disease, which showed such promise in clinical trials, have undergone a recent real-world &#8216;trial by fire&#8217; in Alzheimer&#8217;s disease [<xref rid="b12-medscimonit-31-e951655" ref-type="bibr">12</xref>].</p><p>Phase 3 clinical trial study participants showed major differences from real-world patients as they were selected with minimal comorbidities, unlike patients who can also have stroke, heart failure, endocrine disease, or traumatic brain injury [<xref rid="b12-medscimonit-31-e951655" ref-type="bibr">12</xref>]. There are concerns regarding the duration and mode of treatment, as lecanemab requires an initial infusion every two weeks for 18 months, which is typically administered at infusion centers [<xref rid="b18-medscimonit-31-e951655" ref-type="bibr">18</xref>]. Because the symptoms of dementia can continue even after clearance of amyloid plaque, this supports the need for maintenance therapy [<xref rid="b19-medscimonit-31-e951655" ref-type="bibr">19</xref>]. However, the duration, dosing, and treatment frequency remain to be determined [<xref rid="b19-medscimonit-31-e951655" ref-type="bibr">19</xref>]. The availability and cost of treatment with lecanemab and donanemab result in a disparity in access to these therapies between countries and within countries [<xref rid="b12-medscimonit-31-e951655" ref-type="bibr">12</xref>,<xref rid="b20-medscimonit-31-e951655" ref-type="bibr">20</xref>].</p><p>Any new biomarker associated with Alzheimer&#8217;s disease or other types of dementia is not a disease predictor but is an association that supports early clinical diagnosis [<xref rid="b21-medscimonit-31-e951655" ref-type="bibr">21</xref>]. There is still a lack of public and clinical awareness of the presenting diagnostic features of Alzheimer&#8217;s disease [<xref rid="b21-medscimonit-31-e951655" ref-type="bibr">21</xref>]. The diagnosis of Alzheimer&#8217;s disease has relied on invasive methods in patients who present with symptoms, often at an advanced stage [<xref rid="b1-medscimonit-31-e951655" ref-type="bibr">1</xref>,<xref rid="b22-medscimonit-31-e951655" ref-type="bibr">22</xref>]. Invasive diagnostic procedures, including cerebral positron emission tomography (PET) imaging and analysis of cerebrospinal fluid (CSF), are costly and invasive methods that are not widely accessible [<xref rid="b22-medscimonit-31-e951655" ref-type="bibr">22</xref>]. There is an urgent requirement for early diagnosis and screening for Alzheimer&#8217;s disease, which can then drive a more effective approach to treatment, prevention, and possible screening. In the past year, the challenge for early diagnosis of Alzheimer&#8217;s disease has become realized with several blood biomarkers that may have a future role in diagnosis and screening [<xref rid="b23-medscimonit-31-e951655" ref-type="bibr">23</xref>]. There have been regulatory approvals for diagnostic blood tests in China, Japan (HISCL A&#946;42/40), and the United Kingdom (UK) (PrecivityAD2) [<xref rid="b23-medscimonit-31-e951655" ref-type="bibr">23</xref>]. On May 16, 2025, the US FDA approved the Lumipulse G blood test (Fujirebio Diagnostics), which utilizes the plasma pTau217/A&#946;1&#8211;42 ratio, for the diagnosis of cerebral amyloid plaques in symptomatic patients of 55 years or more [<xref rid="b23-medscimonit-31-e951655" ref-type="bibr">23</xref>]. However, a limitation of blood biomarker tests is the high rate of false positives and false negatives, which are expected in peripheral biomarker tests for conditions that affect the brain [<xref rid="b23-medscimonit-31-e951655" ref-type="bibr">23</xref>]. Therefore, in practice, the clinical validation of the diagnostic value of identifying blood biomarkers still requires support from amyloid PET brain scans and/or the results of CSF analysis [<xref rid="b23-medscimonit-31-e951655" ref-type="bibr">23</xref>].</p><p>Alzheimer&#8217;s disease shares with other neurological diseases, such as Parkinson&#8217;s disease and multiple sclerosis, pathological and physiological changes that occur long before clinical symptoms are seen, which supports research on biomarkers for early disease and screening [<xref rid="b24-medscimonit-31-e951655" ref-type="bibr">24</xref>]. In 2016, the FDA-NIH Biomarker Working Group introduced a classification framework encompassing seven categories of biomarkers and related endpoints [<xref rid="b25-medscimonit-31-e951655" ref-type="bibr">25</xref>]. These include biomarkers for diagnosis, monitoring, prognosis, predictive biomarkers, pharmacodynamic response, safety, and susceptibility (risk) biomarkers [<xref rid="b25-medscimonit-31-e951655" ref-type="bibr">25</xref>]. In 2018 and 2024, the combined National Institute on Aging and the Alzheimer&#8217;s Association (NIA-AA) diagnostic criteria identified a list of diagnostic biomarkers for Alzheimer&#8217;s disease that could be identified by proteomics analysis in plasma and CSF, and brain imaging biomarkers (<xref rid="t1-medscimonit-31-e951655" ref-type="table">Table 1</xref>) [<xref rid="b24-medscimonit-31-e951655" ref-type="bibr">24</xref>,<xref rid="b26-medscimonit-31-e951655" ref-type="bibr">26</xref>]. In Alzheimer&#8217;s disease, amyloid accumulation is followed by tau aggregation, followed by structural changes in the brain that lead to cognitive decline [<xref rid="b26-medscimonit-31-e951655" ref-type="bibr">26</xref>]. The importance of disease biomarkers is highlighted by the fact that biological biomarkers and targets are currently either used or are being investigated in clinical development and in phase 1 to phase 3 clinical trials, with plasma and CSF markers in 26% of trials targeting inflammation and amyloid [<xref rid="b27-medscimonit-31-e951655" ref-type="bibr">27</xref>]. CSF biomarkers for Alzheimer&#8217;s disease, including the FDA-approved A&#946;42/40, phosphorylated tau 181 (pTau181), and total tau tests, and tests for neurofilament light (NfL), are currently used in clinical and trial settings [<xref rid="b23-medscimonit-31-e951655" ref-type="bibr">23</xref>,<xref rid="b27-medscimonit-31-e951655" ref-type="bibr">27</xref>]. The aim is now to move quickly to implementing less invasive blood-based assays to detect tau species and NfL, as demonstrated in the FDA approval of a pTau217/A&#946;42 AD blood test in May 2025 [<xref rid="b23-medscimonit-31-e951655" ref-type="bibr">23</xref>,<xref rid="b27-medscimonit-31-e951655" ref-type="bibr">27</xref>]. Alzheimer&#8217;s disease is now recognized as a heterogeneous condition that may require a more personalized and targeted approach to treatment, which will need refinement in biomarker analysis [<xref rid="b28-medscimonit-31-e951655" ref-type="bibr">28</xref>,<xref rid="b29-medscimonit-31-e951655" ref-type="bibr">29</xref>].</p><sec sec-type="conclusions"><title>Conclusions</title><p>In Alzheimer&#8217;s disease, early detection of pathological changes before clinical symptoms develop remains a significant unmet need, as are biomarkers that can predict and monitor disease progression, and targets for treatment that should be both disease-specific and patient-specific. Drug treatments alone may not provide the solution for prevention or treatment of Alzheimer&#8217;s disease, even if reliable blood biomarkers for early diagnosis do become available. Identifying and controlling risk factors for Alzheimer&#8217;s disease is the third arm in managing this significant global public health problem.</p></sec></body><back><fn-group><fn id="fn1-medscimonit-31-e951655" fn-type="COI-statement"><p><bold>Conflict of interest:</bold> None declared</p></fn></fn-group><ref-list><title>References</title><ref id="b1-medscimonit-31-e951655"><label>1</label><element-citation publication-type="journal"><article-title>Alzheimer&#8217;s disease facts and figures</article-title><source>Alzheimers Dement</source><year>2024</year><volume>20</volume><issue>5</issue><fpage>3708</fpage><lpage>21</lpage><comment>Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pmc.ncbi.nlm.nih.gov/articles/pmid/38689398/" ext-link-type="uri">https://pmc.ncbi.nlm.nih.gov/articles/pmid/38689398/</ext-link></comment><pub-id pub-id-type="pmid">38689398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13809</pub-id><pub-id pub-id-type="pmcid">PMC11095490</pub-id></element-citation></ref><ref id="b2-medscimonit-31-e951655"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parums</surname><given-names>DV</given-names></name></person-group><article-title>Editorial: Targets for disease-modifying therapies in Alzheimer&#8217;s disease, including amyloid &#946; and Tau protein</article-title><source>Med Sci Monit</source><year>2021</year><volume>27</volume><fpage>e934077</fpage><pub-id pub-id-type="pmid">34305135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/MSM.934077</pub-id><pub-id pub-id-type="pmcid">PMC8323472</pub-id></element-citation></ref><ref id="b3-medscimonit-31-e951655"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kusoro</surname><given-names>O</given-names></name><name name-style="western"><surname>Roche</surname><given-names>M</given-names></name><name name-style="western"><surname>Del-Pino-Casado</surname><given-names>R</given-names></name><name name-style="western"><surname>Leung</surname><given-names>P</given-names></name><name name-style="western"><surname>Orgeta</surname><given-names>V</given-names></name></person-group><article-title>Time to diagnosis in dementia: A systematic review with meta-analysis</article-title><source>Int J Geriatr Psychiatry</source><year>2025</year><volume>40</volume><issue>7</issue><fpage>e70129</fpage><pub-id pub-id-type="pmid">40716451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gps.70129</pub-id><pub-id pub-id-type="pmcid">PMC12300619</pub-id></element-citation></ref><ref id="b4-medscimonit-31-e951655"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parums</surname><given-names>DV</given-names></name></person-group><article-title>A review of the current status of disease-modifying therapies and prevention of Alzheimer&#8217;s disease</article-title><source>Med Sci Monit</source><year>2024</year><volume>30</volume><fpage>e945091</fpage><pub-id pub-id-type="pmid">38736218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/MSM.945091</pub-id><pub-id pub-id-type="pmcid">PMC11097689</pub-id></element-citation></ref><ref id="b5-medscimonit-31-e951655"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parums</surname><given-names>DV</given-names></name></person-group><article-title>A Review of the importance and relevance of real-world data and real-world evidence</article-title><source>Med Sci Monit</source><year>2025</year><volume>31</volume><fpage>e951118</fpage><pub-id pub-id-type="pmid">40916614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/MSM.951118</pub-id><pub-id pub-id-type="pmcid">PMC12400973</pub-id></element-citation></ref><ref id="b6-medscimonit-31-e951655"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>GC</given-names></name><name name-style="western"><surname>Emerson</surname><given-names>S</given-names></name><name name-style="western"><surname>Kesselheim</surname><given-names>AS</given-names></name></person-group><article-title>Evaluation of aducanumab for Alzheimer disease: Scientific evidence and regulatory review involving efficacy, safety, and futility</article-title><source>JAMA</source><year>2021</year><volume>325</volume><issue>17</issue><fpage>1717</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">33783469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2021.3854</pub-id></element-citation></ref><ref id="b7-medscimonit-31-e951655"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sevigny</surname><given-names>J</given-names></name><name name-style="western"><surname>Chiao</surname><given-names>P</given-names></name><name name-style="western"><surname>Bussi&#232;re</surname><given-names>T</given-names></name><etal/></person-group><article-title>The antibody aducanumab reduces A&#946; plaques in Alzheimer&#8217;s disease</article-title><source>Nature</source><year>2016</year><volume>537</volume><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">27582220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature19323</pub-id></element-citation></ref><ref id="b8-medscimonit-31-e951655"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dyer</surname><given-names>O</given-names></name></person-group><article-title>Aduhelm: Biogen abandons Alzheimer&#8217;s drug after controversial approval left it unfunded by Medicare</article-title><source>BMJ</source><year>2024</year><volume>384</volume><fpage>q281</fpage><pub-id pub-id-type="pmid">38307520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.q281</pub-id></element-citation></ref><ref id="b9-medscimonit-31-e951655"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belder</surname><given-names>CRS</given-names></name><name name-style="western"><surname>Schott</surname><given-names>JM</given-names></name><name name-style="western"><surname>Fox</surname><given-names>NC</given-names></name></person-group><article-title>Preparing for disease-modifying therapies in Alzheimer&#8217;s disease</article-title><source>Lancet Neurol</source><year>2023</year><volume>22</volume><issue>9</issue><fpage>782</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">37463598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(23)00274-0</pub-id></element-citation></ref><ref id="b10-medscimonit-31-e951655"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Dyck</surname><given-names>CH</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P</given-names></name><etal/></person-group><article-title>Lecanemab in early Alzheimer&#8217;s disease</article-title><source>N Engl J Med</source><year>2023</year><volume>388</volume><issue>1</issue><fpage>9</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">36449413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2212948</pub-id></element-citation></ref><ref id="b11-medscimonit-31-e951655"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sims</surname><given-names>JR</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>JA</given-names></name><name name-style="western"><surname>Evans</surname><given-names>CD</given-names></name><etal/></person-group><collab>TRAILBLAZER-ALZ 2 Investigators</collab><article-title>Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial</article-title><source>JAMA</source><year>2023</year><volume>330</volume><issue>6</issue><fpage>512</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">37459141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2023.13239</pub-id><pub-id pub-id-type="pmcid">PMC10352931</pub-id></element-citation></ref><ref id="b12-medscimonit-31-e951655"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubin</surname><given-names>R</given-names></name></person-group><article-title>Treating Alzheimer disease with antiamyloid therapies-the real-world experience grows</article-title><source>JAMA</source><year>2025</year><month>Aug</month><day>22</day><pub-id pub-id-type="doi">10.1001/jama.2025.14180</pub-id><comment>Epub ahead of print</comment><pub-id pub-id-type="pmid">40844810</pub-id></element-citation></ref><ref id="b13-medscimonit-31-e951655"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Z</given-names></name></person-group><article-title>Re-evaluation of the efficacy and safety of anti-A&#946; monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer&#8217;s disease</article-title><source>Front Pharmacol</source><year>2025</year><volume>16</volume><fpage>1599048</fpage><pub-id pub-id-type="pmid">40308765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2025.1599048</pub-id><pub-id pub-id-type="pmcid">PMC12040886</pub-id></element-citation></ref><ref id="b14-medscimonit-31-e951655"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vukmir</surname><given-names>RB</given-names></name></person-group><article-title>Amyloid-related imaging abnormalities (ARIA): Diagnosis, management, and care in the setting of amyloid-modifying therapy</article-title><source>Ann Clin Transl Neurol</source><year>2024</year><volume>11</volume><issue>7</issue><fpage>1669</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">38939962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acn3.52042</pub-id><pub-id pub-id-type="pmcid">PMC11251480</pub-id></element-citation></ref><ref id="b15-medscimonit-31-e951655"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raulin</surname><given-names>AC</given-names></name><name name-style="western"><surname>Doss</surname><given-names>SV</given-names></name><name name-style="western"><surname>Trottier</surname><given-names>ZA</given-names></name><etal/></person-group><article-title>ApoE in Alzheimer&#8217;s disease: Pathophysiology and therapeutic strategies</article-title><source>Mol Neurodegener</source><year>2022</year><volume>17</volume><issue>1</issue><fpage>72</fpage><pub-id pub-id-type="pmid">36348357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-022-00574-4</pub-id><pub-id pub-id-type="pmcid">PMC9644639</pub-id></element-citation></ref><ref id="b16-medscimonit-31-e951655"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frederiksen</surname><given-names>KS</given-names></name><name name-style="western"><surname>Boada</surname><given-names>M</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>B</given-names></name><etal/></person-group><article-title>Navigating the introduction of anti-amyloid therapy in Europe: A position statement by individual members of the EADC</article-title><source>Alzheimers Res Ther</source><year>2025</year><volume>17</volume><issue>1</issue><fpage>116</fpage><pub-id pub-id-type="pmid">40413561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-025-01766-y</pub-id><pub-id pub-id-type="pmcid">PMC12102950</pub-id></element-citation></ref><ref id="b17-medscimonit-31-e951655"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahase</surname><given-names>E</given-names></name></person-group><article-title>Lecanemab and donanemab: NICE reconsiders controversial Alzheimer&#8217;s drugs</article-title><source>BMJ</source><year>2025</year><volume>388</volume><fpage>r463</fpage><pub-id pub-id-type="pmid">40054859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.r463</pub-id></element-citation></ref><ref id="b18-medscimonit-31-e951655"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bobbins</surname><given-names>A</given-names></name><name name-style="western"><surname>Davies</surname><given-names>M</given-names></name><name name-style="western"><surname>Lynn</surname><given-names>E</given-names></name><name name-style="western"><surname>Roy</surname><given-names>D</given-names></name><etal/></person-group><article-title>Safety and effectiveness of the anti-amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer&#8217;s disease: The pharmacovigilance perspective</article-title><source>Br J Clin Pharmacol</source><year>2025</year><volume>91</volume><issue>5</issue><fpage>1352</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">40051090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bcp.70021</pub-id><pub-id pub-id-type="pmcid">PMC12035590</pub-id></element-citation></ref><ref id="b19-medscimonit-31-e951655"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J</given-names></name><name name-style="western"><surname>Osse</surname><given-names>AML</given-names></name><name name-style="western"><surname>Cammann</surname><given-names>D</given-names></name><etal/></person-group><article-title>Anti-amyloid monoclonal antibodies for the treatment of Alzheimer&#8217;s disease</article-title><source>BioDrugs</source><year>2024</year><volume>38</volume><issue>1</issue><fpage>5</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">37955845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40259-023-00633-2</pub-id><pub-id pub-id-type="pmcid">PMC10789674</pub-id></element-citation></ref><ref id="b20-medscimonit-31-e951655"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aye</surname><given-names>S</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>G</given-names></name><name name-style="western"><surname>Hock</surname><given-names>C</given-names></name><etal/></person-group><article-title>Point of view: Challenges in implementation of new immunotherapies for Alzheimer&#8217;s disease</article-title><source>J Prev Alzheimers Dis</source><year>2025</year><volume>12</volume><issue>1</issue><fpage>100022</fpage><pub-id pub-id-type="pmid">39800469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tjpad.2024.100022</pub-id><pub-id pub-id-type="pmcid">PMC12184012</pub-id></element-citation></ref><ref id="b21-medscimonit-31-e951655"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubois</surname><given-names>B</given-names></name><name name-style="western"><surname>von Arnim</surname><given-names>CAF</given-names></name><name name-style="western"><surname>Burnie</surname><given-names>N</given-names></name><etal/></person-group><article-title>Biomarkers in Alzheimer&#8217;s disease: Role in early and differential diagnosis and recognition of atypical variants</article-title><source>Alzheimers Res Ther</source><year>2023</year><volume>15</volume><issue>1</issue><fpage>175</fpage><pub-id pub-id-type="pmid">37833762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-023-01314-6</pub-id><pub-id pub-id-type="pmcid">PMC10571241</pub-id></element-citation></ref><ref id="b22-medscimonit-31-e951655"><label>22</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Sidhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Lui</surname><given-names>F</given-names></name><etal/></person-group><article-title>Alzheimer disease. [Updated 2024 Feb 12]</article-title><source>StatPearls [Internet]</source><publisher-loc>Treasure Island (FL)</publisher-loc><publisher-name>StatPearls Publishing</publisher-name><year>2025</year><comment>Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK499922/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK499922/</ext-link></comment></element-citation></ref><ref id="b23-medscimonit-31-e951655"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name></person-group><article-title>The pTau217/A&#946;1&#8211;42 plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer&#8217;s disease</article-title><source>Drug Discov Ther</source><year>2025</year><volume>19</volume><issue>3</issue><fpage>208</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">40582836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5582/ddt.2025.01055</pub-id></element-citation></ref><ref id="b24-medscimonit-31-e951655"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sperling</surname><given-names>RA</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>PS</given-names></name><name name-style="western"><surname>Beckett</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Toward defining the preclinical stages of Alzheimer&#8217;s disease: recommendations from the National Institute on Aging-Alzheimer&#8217;s Association workgroups on diagnostic guidelines for Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement</source><year>2011</year><volume>7</volume><issue>3</issue><fpage>280</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">21514248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.03.003</pub-id><pub-id pub-id-type="pmcid">PMC3220946</pub-id></element-citation></ref><ref id="b25-medscimonit-31-e951655"><label>25</label><element-citation publication-type="book"><collab>FDA-NIH Biomarker Working Group</collab><source>BEST (Biomarkers, EndpointS, and other Tools) resource [Internet]</source><publisher-loc>Silver Spring (MD)</publisher-loc><publisher-name>Food and Drug Administration (US)</publisher-name><year>2016</year><comment>Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK326791/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK326791/</ext-link></comment><pub-id pub-id-type="pmid">27010052</pub-id></element-citation></ref><ref id="b26-medscimonit-31-e951655"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Andrews</surname><given-names>JS</given-names></name><name name-style="western"><surname>Beach</surname><given-names>TG</given-names></name><etal/></person-group><article-title>Revised criteria for diagnosis and staging of Alzheimer&#8217;s disease: Alzheimer&#8217;s Association Workgroup</article-title><source>Alzheimers Dement</source><year>2024</year><volume>20</volume><issue>8</issue><fpage>5143</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">38934362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13859</pub-id><pub-id pub-id-type="pmcid">PMC11350039</pub-id></element-citation></ref><ref id="b27-medscimonit-31-e951655"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oosthoek</surname><given-names>M</given-names></name><name name-style="western"><surname>Vermunt</surname><given-names>L</given-names></name><name name-style="western"><surname>de Wilde</surname><given-names>A</given-names></name><etal/></person-group><article-title>Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer&#8217;s disease: A systematic review</article-title><source>Alzheimers Res Ther</source><year>2024</year><volume>16</volume><issue>1</issue><fpage>93</fpage><pub-id pub-id-type="pmid">38678292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-024-01456-1</pub-id><pub-id pub-id-type="pmcid">PMC11055304</pub-id></element-citation></ref><ref id="b28-medscimonit-31-e951655"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jutten</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Sikkes</surname><given-names>SAM</given-names></name><name name-style="western"><surname>van der Flier</surname><given-names>WM</given-names></name><etal/></person-group><collab>Alzheimer&#8217;s Disease Neuroimaging Initiative</collab><article-title>Finding treatment effects in alzheimer trials in the face of disease progression heterogeneity</article-title><source>Neurology</source><year>2021</year><volume>96</volume><issue>22</issue><fpage>e2673</fpage><lpage>e84</lpage><pub-id pub-id-type="pmid">34550903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000012022</pub-id><pub-id pub-id-type="pmcid">PMC8205463</pub-id></element-citation></ref><ref id="b29-medscimonit-31-e951655"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manuello</surname><given-names>J</given-names></name><name name-style="western"><surname>Min</surname><given-names>J</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>P</given-names></name><etal/></person-group><article-title>The effects of genetic and modifiable risk factors on brain regions vulnerable to ageing and disease</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>2576</fpage><pub-id pub-id-type="pmid">38538590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-46344-2</pub-id><pub-id pub-id-type="pmcid">PMC10973379</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="t1-medscimonit-31-e951655" orientation="portrait"><label>Table 1</label><caption><p>Biomarker analysis in Alzheimer&#8217;s disease using imaging, blood plasma, and cerebrospinal fluid (CSF).</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1"/><th valign="middle" align="center" rowspan="1" colspan="1">Imaging</th><th valign="middle" align="center" rowspan="1" colspan="1">Blood plasma</th><th valign="middle" align="center" rowspan="1" colspan="1">Cerebrospinal fluid (CSF)</th></tr></thead><tbody><tr><td colspan="4" valign="top" align="left" rowspan="1">
<bold>Diagnostic biomarkers</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>A:</bold> (A&#946; proteinopathy)<break/><bold>T1:</bold> (phosphorylated and secreted AD tau)</td><td valign="top" align="left" rowspan="1" colspan="1">Amyloid PET<break/>&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;<break/>p-tau217</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;<break/>&#8211;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hybrid ratios</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">%p-tau217</td><td valign="top" align="left" rowspan="1" colspan="1">p-tau181/A&#946;42, t-tau/A&#946;42, A&#946;42/40</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<bold>Staging, prognosis, and treatment response biomarkers</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>A:</bold> (A&#946; proteinopathy)<break/><bold>T1:</bold> (phosphorylated and secreted AD tau)</td><td valign="top" align="left" rowspan="1" colspan="1">Amyloid PET<break/>&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;<break/>&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;<break/>&#8211;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hybrid ratios:</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">%p-tau217</td><td valign="top" align="left" rowspan="1" colspan="1">p-tau 181/A&#223;42, t-tau/A&#946;42, A&#946;42/40</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T2:</bold> (AD tau protein enteropathy)</td><td valign="top" align="left" rowspan="1" colspan="1">Tau PET</td><td valign="top" align="left" rowspan="1" colspan="1">MTBR-tau243, other p-tau forms (e.g., p-tau205)</td><td valign="top" align="left" rowspan="1" colspan="1">MTBR-tau243, other p-tau forms, non-phosphorylated mid-region tau fragments</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>N:</bold> (neutropil injury, dysfunction, or degeneration)</td><td valign="top" align="left" rowspan="1" colspan="1">Anatomic MRI, FDG PET</td><td valign="top" align="left" rowspan="1" colspan="1">NfL</td><td valign="top" align="left" rowspan="1" colspan="1">NfL</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>I:</bold> (inflammation)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">GFAP</td><td valign="top" align="left" rowspan="1" colspan="1">GFAP</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">
<bold>Co-morbid pathology biomarkers</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>N:</bold> (dysfunction, or degeneration of neuropil)</td><td valign="top" align="left" rowspan="1" colspan="1">Anatomic MRI, FDG PET</td><td valign="top" align="left" rowspan="1" colspan="1">NfL</td><td valign="top" align="left" rowspan="1" colspan="1">NfL</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>V:</bold> Vascular brain injury</td><td valign="top" align="left" rowspan="1" colspan="1">Cerebral infarction on MRI or CT</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>S:</bold> a-synuclein</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">aSyn-SAA</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-medscimonit-31-e951655"><p>AD &#8211; Alzheimer&#8217;s disease; CT &#8211; computed tomography; FDG &#8211; fluorodeoxyglucose; GFAP &#8211; glial fibrillary acidic protein; MRI &#8211; magnetic resonance imaging; MTBR &#8211; microtubule binding region of the tau protein; NfL &#8211; neurofilament light chain; PET &#8211; positron emission tomography; SAA &#8211; serum amyloid A. <bold><italic toggle="yes">Adapted from</italic></bold><italic toggle="yes">: The 2024 revised criteria from the Alzheimer&#8217;s Association Workgroup [<xref rid="b26-medscimonit-31-e951655" ref-type="bibr">26</xref>].</italic></p></fn></table-wrap-foot></table-wrap></floats-group></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="ejn70263" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Neurosci</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">EJN</journal-id><journal-title-group><journal-title>The European Journal of Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">0953-816X</issn><issn pub-type="epub">1460-9568</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12495554</article-id><article-id pub-id-type="pmcid-ver">PMC12495554.1</article-id><article-id pub-id-type="pmcaid">12495554</article-id><article-id pub-id-type="pmcaiid">12495554</article-id><article-id pub-id-type="pmid">41045101</article-id><article-id pub-id-type="doi">10.1111/ejn.70263</article-id><article-id pub-id-type="publisher-id">EJN70263</article-id><article-id pub-id-type="other">EJN-2025-04-32684.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Report</subject></subj-group></article-categories><title-group><article-title>Periodic and Aperiodic Alterations of Resting&#8208;State EEG in Schizophrenia Spectrum Disorders: Cognitive and Clinical Insights</article-title></title-group><contrib-group><contrib id="ejn70263-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Hasanaj</surname><given-names initials="G">Genc</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9807-1015</contrib-id><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ejn70263-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ejn70263-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>genc.hasanaj@bkh-augsburg.de</email><email>genc.hasanaj@med.uni-muenchen.de</email></address></contrib><contrib id="ejn70263-cr-0002" contrib-type="author"><name name-style="western"><surname>Jaeger</surname><given-names initials="I">Iris</given-names></name><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ejn70263-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ejn70263-cr-0003" contrib-type="author"><name name-style="western"><surname>Karsli</surname><given-names initials="B">Berkhan</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0763-1078</contrib-id><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ejn70263-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ejn70263-cr-0004" contrib-type="author"><name name-style="western"><surname>Schulz</surname><given-names initials="E">Enrico</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8188-380X</contrib-id><xref rid="ejn70263-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="ejn70263-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="ejn70263-cr-0005" contrib-type="author"><name name-style="western"><surname>Boudriot</surname><given-names initials="E">Emanuel</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6083-6318</contrib-id><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ejn70263-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="ejn70263-cr-0006" contrib-type="author"><name name-style="western"><surname>Roell</surname><given-names initials="L">Lukas</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0284-2290</contrib-id><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ejn70263-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ejn70263-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="ejn70263-cr-0007" contrib-type="author"><name name-style="western"><surname>Korman</surname><given-names initials="M">Maxim</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-7489-8442</contrib-id><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ejn70263-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ejn70263-cr-0008" contrib-type="author"><name name-style="western"><surname>Kallweit</surname><given-names initials="M">Marcel&#160;S.</given-names></name><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ejn70263-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ejn70263-cr-0009" contrib-type="author"><name name-style="western"><surname>Dengl</surname><given-names initials="F">Fanny</given-names></name><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ejn70263-cr-0010" contrib-type="author"><name name-style="western"><surname>Klimas</surname><given-names initials="N">Nicole</given-names></name><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ejn70263-cr-0011" contrib-type="author"><name name-style="western"><surname>Fischer</surname><given-names initials="K">Kristin</given-names></name><xref rid="ejn70263-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ejn70263-cr-0012" contrib-type="author"><name name-style="western"><surname>Hanken</surname><given-names initials="K">Katharina</given-names></name><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ejn70263-cr-0013" contrib-type="author"><name name-style="western"><surname>Meisinger</surname><given-names initials="V">Verena</given-names></name><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ejn70263-cr-0014" contrib-type="author"><name name-style="western"><surname>Moussiopoulou</surname><given-names initials="J">Joanna</given-names></name><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ejn70263-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ejn70263-cr-0015" contrib-type="author"><name name-style="western"><surname>Yakimov</surname><given-names initials="V">Vladislav</given-names></name><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ejn70263-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="ejn70263-cr-0016" contrib-type="author"><name name-style="western"><surname>Karch</surname><given-names initials="S">Susanne</given-names></name><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ejn70263-cr-0017" contrib-type="author"><name name-style="western"><surname>Hasan</surname><given-names initials="A">Alkomiet</given-names></name><xref rid="ejn70263-aff-0008" ref-type="aff">
<sup>8</sup>
</xref><xref rid="ejn70263-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="ejn70263-cr-0018" contrib-type="author"><name name-style="western"><surname>Schmitt</surname><given-names initials="A">Andrea</given-names></name><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ejn70263-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="ejn70263-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="ejn70263-cr-0019" contrib-type="author"><name name-style="western"><surname>Falkai</surname><given-names initials="P">Peter</given-names></name><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ejn70263-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="ejn70263-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="ejn70263-cr-0020" contrib-type="author"><collab collab-type="authors">CDP Working Group</collab><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ejn70263-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ejn70263-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="ejn70263-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="ejn70263-cr-0021" contrib-type="author"><name name-style="western"><surname>Pogarell</surname><given-names initials="O">Oliver</given-names></name><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ejn70263-cr-0022" contrib-type="author"><name name-style="western"><surname>Raabe</surname><given-names initials="F">Florian&#160;J.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8538-0783</contrib-id><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ejn70263-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="ejn70263-cr-0023" contrib-type="author"><name name-style="western"><surname>Wagner</surname><given-names initials="E">Elias</given-names></name><xref rid="ejn70263-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="ejn70263-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="ejn70263-cr-0024" contrib-type="author"><name name-style="western"><surname>Mortazavi</surname><given-names initials="M">Matin</given-names></name><xref rid="ejn70263-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="ejn70263-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="ejn70263-cr-0025" contrib-type="author"><name name-style="western"><surname>Keeser</surname><given-names initials="D">Daniel</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0244-1024</contrib-id><xref rid="ejn70263-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ejn70263-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ejn70263-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib></contrib-group><aff id="ejn70263-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Psychiatry and Psychotherapy</named-content>
<institution>LMU University Hospital, LMU Munich</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff content-type="private-address" id="ejn70263-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>NeuroImaging Core Unit Munich (NICUM), LMU University Hospital, LMU Munich</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="ejn70263-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Evidence&#8208;Based Psychiatry and Psychotherapy, Faculty of Medicine</named-content>
<institution>University of Augsburg</institution>
<city>Augsburg</city>
<country country="DE">Germany</country>
</aff><aff id="ejn70263-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Radiology</named-content>
<institution>LMU University Hospital, Ludwig&#8208;Maximilians&#8208;Universit&#228;t M&#252;nchen</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="ejn70263-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Medical Psychology</named-content>
<institution>Ludwig&#8208;Maximilians&#8208;Universit&#228;t M&#252;nchen</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff content-type="private-address" id="ejn70263-aff-0006">
<label>
<sup>6</sup>
</label>
<institution>Max Planck Institute of Psychiatry</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff content-type="private-address" id="ejn70263-aff-0007">
<label>
<sup>7</sup>
</label>
<institution>International Max Planck Research School for Translational Psychiatry (IMPRS&#8208;TP)</institution>
<country country="DE">Germany</country>
</aff><aff id="ejn70263-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty</named-content>
<institution>University of Augsburg, BKH Augsburg</institution>
<city>Augsburg</city>
<country country="DE">Germany</country>
</aff><aff content-type="private-address" id="ejn70263-aff-0009">
<label>
<sup>9</sup>
</label>
<institution>German Center for Mental Health (DZPG), Partner Site Munich/Augsburg</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="ejn70263-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Laboratory of Neuroscience (LIM27), Institute of Psychiatry</named-content>
<institution>University of S&#227;o Paulo</institution>
<city>S&#227;o Paulo</city>
<country country="BR">Brazil</country>
</aff><aff content-type="private-address" id="ejn70263-aff-0011">
<label>
<sup>11</sup>
</label>
<institution>Munich Center for Neurosciences (MCN), LMU Munich, Planegg</institution>
<city>Martinsried</city>
<country country="DE">Germany</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Genc Hasanaj (<email>genc.hasanaj@bkh-augsburg.de</email>; <email>genc.hasanaj@med.uni-muenchen.de</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>04</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2025</year></pub-date><volume>62</volume><issue seq="80">7</issue><issue-id pub-id-type="pmc-issue-id">498301</issue-id><issue-id pub-id-type="doi">10.1111/ejn.v62.7</issue-id><elocation-id>e70263</elocation-id><history><date date-type="rev-recd"><day>11</day><month>7</month><year>2025</year></date><date date-type="received"><day>08</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>06</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-05 10:25:46.240"><day>05</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">European Journal of Neuroscience</italic> published by Federation of European Neuroscience Societies and John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="EJN-62-0.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:EJN-62-0.pdf"/><abstract><title>ABSTRACT</title><p>Schizophrenia spectrum disorders (SSD) are marked by cognitive deficits and clinical symptoms linked to disrupted neural oscillations. While changes in spectral power are well documented in SSD, many studies have not clearly separated rhythmic (periodic) from the nonrhythmic (aperiodic) brain activity. This study examined both periodic and aperiodic resting&#8208;state EEG components in SSD, recorded from 152 healthy controls and 97 SSD participants. EEG features (periodic power, bandwidth, center frequency; aperiodic exponent and offset) were extracted from global scalp averages and frontoinsular regions, including the dorsal anterior cingulate cortex (dACC), right anterior insula (R&#8208;INS), and left anterior insula (L&#8208;INS). At the scalp level, SSD individuals exhibited a global increase in theta power, along with a decreased alpha center frequency. Aperiodic activity showed increased exponent and offset in SSD. In frontoinsular regions, increased theta power was observed in the dACC, R&#8208;INS, and L&#8208;INS, along with lower alpha center frequency in L&#8208;INS. No significant differences were found for aperiodic activity in these regions. Increased frontoinsular theta power, especially in the dACC, was associated with worse cognitive performance, particularly global cognition and working memory. These findings highlight the importance of separating periodic and aperiodic EEG activity in SSD, suggesting that periodic alterations, particularly in frontoinsular theta oscillations, may underlie cognitive dysfunction in SSD.</p></abstract><abstract abstract-type="graphical"><p>This study examined periodic and aperiodic EEG activity in schizophrenia spectrum disorder (SSD) using FOOOF across scalp and source&#8208;level recordings. SSD patients showed increased theta power and aperiodic components, with dACC theta predicting cognitive impairment. Findings highlight altered excitation&#8211;inhibition dynamics and emphasize the utility of spectral parameterization in SSD.<boxed-text position="anchor" content-type="graphic" id="ejn70263-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="EJN-62-0-g004.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="ejn70263-kwd-0001">aperiodic</kwd><kwd id="ejn70263-kwd-0002">cognition</kwd><kwd id="ejn70263-kwd-0003">EEG</kwd><kwd id="ejn70263-kwd-0004">frontoinsular</kwd><kwd id="ejn70263-kwd-0005">periodic</kwd><kwd id="ejn70263-kwd-0006">schizophrenia spectrum disorders</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>EU HORIZON&#8208;INFRA&#8208;2024&#8208;TECH&#8208;01&#8208;04</institution></institution-wrap></funding-source><award-id>DTRIP4H 101188432</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>DZPG [German Center for Mental Health, Munich, Augsburg]</institution></institution-wrap></funding-source><award-id>01EE2303C</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Bundesministerium f&#252;r Bildung und Forschung [BMBF]</institution></institution-wrap></funding-source><award-id>01EE2303A</award-id><award-id>01EE2303F</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>EraNet project GDNF UpReg</institution></institution-wrap></funding-source><award-id>01EW2206</award-id></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>F&#246;FoLe</institution></institution-wrap></funding-source><award-id>1226/2024</award-id></award-group></funding-group><counts><fig-count count="4"/><table-count count="2"/><page-count count="15"/><word-count count="10600"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:04.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="ejn70263-cit-1001"><string-name name-style="western"><surname>Hasanaj</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Jaeger</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Karsli</surname></string-name>, et al. <year>2025</year>. &#8220;<article-title>Periodic and Aperiodic Alterations of Resting&#8208;State EEG in Schizophrenia Spectrum Disorders: Cognitive and Clinical Insights</article-title>.&#8221; <source>European Journal of Neuroscience</source><volume>62</volume>, no. <issue>7</issue>: <elocation-id>e70263</elocation-id>. <pub-id pub-id-type="doi">10.1111/ejn.70263</pub-id>.</mixed-citation>
</p><fn-group id="ejn70263-ntgp-0001"><fn fn-type="funding" id="ejn70263-note-0001"><p>
<bold>Funding:</bold> This work was supported by EU HORIZON&#8208;INFRA&#8208;2024&#8208;TECH&#8208;01&#8208;04, DTRIP4H 101188432; DZPG [German Center for Mental Health, Munich, Augsburg] 01EE2303C; Bundesministerium f&#252;r Bildung und Forschung [BMBF], 01EE2303A 01EE2303F; EraNet project GDNF UpReg, 01EW2206; F&#246;FoLe, 1226/2024.</p></fn><fn fn-type="equal" id="ejn70263-note-0002"><p>Genc Hasanaj, Iris Jaeger, Matin Mortazavi, and Daniel Keeser contributed equally.</p></fn><fn fn-type="associateEditor" id="ejn70263-note-0003"><p>
<bold>Associate Editor:</bold> Bahar G&#252;ntekin</p></fn></fn-group></notes></front><body id="ejn70263-body-0001"><def-list list-content="abbreviations" id="ejn70263-dl-0001"><title>Abbreviations</title><def-item><term id="ejn70263-li-0001">BACS</term><def id="ejn70263-li-0002"><p>brief assessment of cognition in schizophrenia</p></def></def-item><def-item><term id="ejn70263-li-0003">CPZeq</term><def id="ejn70263-li-0004"><p>chlorpromazine equivalent</p></def></def-item><def-item><term id="ejn70263-li-0005">dACC</term><def id="ejn70263-li-0006"><p>dorsal anterior cingulate cortex</p></def></def-item><def-item><term id="ejn70263-li-0007">EC</term><def id="ejn70263-li-0008"><p>eyes closed</p></def></def-item><def-item><term id="ejn70263-li-0009">EEG</term><def id="ejn70263-li-0010"><p>electroencephalography</p></def></def-item><def-item><term id="ejn70263-li-0011">EO</term><def id="ejn70263-li-0012"><p>eyes open</p></def></def-item><def-item><term id="ejn70263-li-0013">FOOOF</term><def id="ejn70263-li-0014"><p>fitting oscillations and one over F</p></def></def-item><def-item><term id="ejn70263-li-0015">HC</term><def id="ejn70263-li-0016"><p>healthy controls</p></def></def-item><def-item><term id="ejn70263-li-0017">L&#8208;INS</term><def id="ejn70263-li-0018"><p>left anterior insula</p></def></def-item><def-item><term id="ejn70263-li-0019">PANSS</term><def id="ejn70263-li-0020"><p>positive and negative syndrome scale</p></def></def-item><def-item><term id="ejn70263-li-0021">R&#8208;INS</term><def id="ejn70263-li-0022"><p>right anterior insula</p></def></def-item><def-item><term id="ejn70263-li-0023">SSD</term><def id="ejn70263-li-0024"><p>schizophrenia spectrum disorders</p></def></def-item></def-list><sec id="ejn70263-sec-0001"><label>1</label><title>Introduction</title><p>Understanding the neural basis of cognitive and clinical symptoms in schizophrenia spectrum disorders (SSDs) remains one of the most pressing challenges in clinical neuroscience (Kahn et&#160;al.&#160;<xref rid="ejn70263-bib-0030" ref-type="bibr">2015</xref>; McCutcheon, Reis Marques, et&#160;al.&#160;<xref rid="ejn70263-bib-0038" ref-type="bibr">2020</xref>). Cognitive impairments in SSD emerge early and affect multiple aspects of personal and social functioning, with general cognitive performance being 1.5 standard deviations lower compared to a healthy control (HC) population (McCutcheon, Keefe, et&#160;al.&#160;<xref rid="ejn70263-bib-0037" ref-type="bibr">2023</xref>). These impairments are closely linked to structural and functional brain alterations, driving ongoing efforts to identify markers that can offer closer insights into disease status and progression (Gordillo et&#160;al.&#160;<xref rid="ejn70263-bib-0020" ref-type="bibr">2023</xref>; Porter et&#160;al.&#160;<xref rid="ejn70263-bib-0049" ref-type="bibr">2023</xref>).</p><p>There is abundant evidence suggesting widespread structural and functional abnormalities across mental disorders (Dong et&#160;al.&#160;<xref rid="ejn70263-bib-0014" ref-type="bibr">2018</xref>; Pic&#243;&#8208;P&#233;rez et&#160;al.&#160;<xref rid="ejn70263-bib-0048" ref-type="bibr">2022</xref>; Sha et&#160;al.&#160;<xref rid="ejn70263-bib-0058" ref-type="bibr">2019</xref>). Of particular importance, Goodkind et&#160;al.&#160;(<xref rid="ejn70263-bib-0019" ref-type="bibr">2015</xref>) identified the dorsal anterior cingulate cortex (dACC) and bilateral anterior insula as three brain regions commonly affected across both psychotic and nonpsychotic mental illnesses, suggesting that these frontoinsular regions may serve as transdiagnostic vulnerability hubs. More recently, a large&#8208;scale network&#8208;based study reinforced the centrality of these frontoinsular regions, showing that they not only exhibit consistent alterations but also act as disease epicenters in schizophrenia, from which structural and functional pathology appears to propagate (Jiang et&#160;al.&#160;<xref rid="ejn70263-bib-0029" ref-type="bibr">2024</xref>). In contrast to other brain regions (e.g., the hippocampus or temporoparietal regions), which show greater inter&#8208;individual variability, the frontoinsular alterations emerge as consistently altered and spatially central in schizophrenia (Jiang et&#160;al.&#160;<xref rid="ejn70263-bib-0029" ref-type="bibr">2024</xref>). Moreover, altered activity within these regions has been linked to impaired salience processing, which may contribute to the origin and maintenance of cognitive and clinical symptoms in SSD (Menon et&#160;al.&#160;<xref rid="ejn70263-bib-0040" ref-type="bibr">2023</xref>).</p><p>Neural oscillations provide a reliable index of brain functions and play a crucial role in coordinating communication between brain regions (Hirano and Uhlhaas&#160;<xref rid="ejn70263-bib-0027" ref-type="bibr">2021</xref>). Disruptions in these oscillatory mechanisms are increasingly regarded as potential markers of both cognitive and symptomatic impairments in SSD (G&#252;nther and Hanganu&#8208;Opatz&#160;<xref rid="ejn70263-bib-0024" ref-type="bibr">2022</xref>; Phillips and Uhlhaas&#160;<xref rid="ejn70263-bib-0047" ref-type="bibr">2015</xref>). Altered activity across both low&#8208; and high&#8208;frequency bands is widely reported, specifically amplitudes including theta and gamma frequency bands in first&#8208;episode, unmedicated, and chronic schizophrenia individuals during resting&#8208;state EEG (Hirano et&#160;al.&#160;<xref rid="ejn70263-bib-0026" ref-type="bibr">2015</xref>; Hirano and Uhlhaas&#160;<xref rid="ejn70263-bib-0027" ref-type="bibr">2021</xref>). While alpha power differences in SSD are less stable, alpha peak power frequency is notably reduced in SSD and is closely associated with cognitive dysfunctions (Catalano et&#160;al. <xref rid="ejn70263-bib-0075" ref-type="bibr">2024</xref>; Sponheim et&#160;al. <xref rid="ejn70263-bib-0076" ref-type="bibr">2023</xref>).</p><p>Besides oscillatory (periodic) brain activity, the brain also generates nonrhythmic (aperiodic) activity that follows a characteristic 1/f&#8208;like spectral distribution (Donoghue et&#160;al.&#160;<xref rid="ejn70263-bib-0016" ref-type="bibr">2020</xref>; He&#160;<xref rid="ejn70263-bib-0025" ref-type="bibr">2014</xref>). This activity is thought to reflect the brain's excitation and inhibition (E/I) balance, as shown in both in&#160;vivo and in silico models (Gao et&#160;al.&#160;<xref rid="ejn70263-bib-0018" ref-type="bibr">2017</xref>; Wiest et&#160;al.&#160;<xref rid="ejn70263-bib-0068" ref-type="bibr">2023</xref>), and its modulation has been associated with improvements in symptoms and cognition in SSD and major depression (Molina et&#160;al.&#160;<xref rid="ejn70263-bib-0042" ref-type="bibr">2020</xref>; Smith et&#160;al.&#160;<xref rid="ejn70263-bib-0062" ref-type="bibr">2023</xref>). However, findings on group differences between SSD and HC remain mixed, with reports of increased, decreased, or unchanged aperiodic components, potentially due to differences in study design (Donoghue&#160;<xref rid="ejn70263-bib-0015" ref-type="bibr">2024</xref>). The contribution of resting&#8208;state periodic and aperiodic activity to pathophysiology and clinical symptoms still remains unclear, particularly within the epicenters of SSD.</p><p>This study aimed to investigate how periodic and aperiodic resting&#8208;state EEG activities are altered in SSD, both at the scalp level and within frontoinsular regions, and how these alterations relate to cognitive functioning and symptom severity. The existing literature is limited, lacking insight into how these components differ between individuals with SSD and healthy controls, particularly within frontoinsular regions that are central to SSD pathophysiology. Given their transdiagnostic vulnerability, centrality in schizophrenia&#8208;related network pathology, and involvement in salience processing, we selected the bilateral anterior insula and dACC as a priori regions of interest. These regions were chosen to examine whether alterations in oscillatory and aperiodic EEG activity in SSD converge on structurally and functionally critical neural hubs. For anatomical precision, we used ROI masks derived from the original Goodkind et&#160;al.&#160;(<xref rid="ejn70263-bib-0019" ref-type="bibr">2015</xref>) study. We first compared the global scalp&#8208;level periodic activity (power, bandwidth, and center frequency) across theta, alpha, beta, and low&#8208;gamma frequency bands, along with aperiodic activity quantified as exponent and offset, and sought to resolve discrepancies in the literature using a relatively large cohort. We repeated the same analyses for the frontoinsular regions, expecting alterations based on previous evidence of functional and structural changes in these areas. Subsequently, we examined how these alterations relate to cognitive performance as well as symptom severity in SSD.</p></sec><sec sec-type="materials-and-methods" id="ejn70263-sec-0002"><label>2</label><title>Materials and Methods</title><sec id="ejn70263-sec-0003"><label>2.1</label><title>Study Sample and Design</title><p>The sample for this study is part of the Munich Clinical Deep Phenotyping study (Kr&#269;m&#225;&#345; et&#160;al.&#160;<xref rid="ejn70263-bib-0034" ref-type="bibr">2023</xref>), which was approved by the local ethics committee of LMU Munich (approval numbers: 20&#8208;528 and 22&#8208;0035) and registered in the German Clinical Trials Register (DRKS, registration ID: DRKS00024177). Participants included both inpatients and outpatients who were recruited at the Department of Psychiatry and Psychotherapy, LMU University Hospital, Munich, Germany. HC subjects were recruited from the local community by advertising online and in public places. Inclusion criteria for patients were a diagnosis of schizophrenia, schizoaffective disorder, brief psychotic disorder, unspecified schizophrenia spectrum disorder (SSD), and delusional disorder, according to the German version 7.0.2 of the MINI International Neuropsychiatric Interview (Sheehan et&#160;al. <xref rid="ejn70263-bib-0077" ref-type="bibr">1998</xref>). HC participants were screened using the same diagnostic interview and excluded if any current or past mental disorder was suspected.</p><p>All of the participants were assessed with the Positive and Negative Syndrome Scale (PANSS) (Kay et&#160;al.&#160;<xref rid="ejn70263-bib-0031" ref-type="bibr">1987</xref>). Cognitive performance was assessed using the German version of the Brief Assessment of Cognition in Schizophrenia (BACS), with scores standardized as z&#8208;scores using the HC group as reference (Keefe et&#160;al.&#160;<xref rid="ejn70263-bib-0032" ref-type="bibr">2004</xref>; Sachs et&#160;al.&#160;<xref rid="ejn70263-bib-0056" ref-type="bibr">2011</xref>). All clinical interviews and questionnaires were performed by trained personnel. Information about current medication, such as antipsychotic medication and benzodiazepine use, was obtained from medical records and self&#8208;report of the participants. Antipsychotic medications were converted (when applicable) to common chlorpromazine equivalent doses (CPZeq) based on the defined daily doses (DDD) method (Leucht et&#160;al.&#160;<xref rid="ejn70263-bib-0036" ref-type="bibr">2016</xref>).</p></sec><sec id="ejn70263-sec-0004"><label>2.2</label><title>Magnetic Resonance Imaging and Preprocessing</title><p>To increase the precision of EEG source localization, anatomical MRI T1w MPGRAGE and T2w images were recorded to provide individual structural details, enabling a more accurate mapping of electrical activity to specific brain regions (Michel and Brunet&#160;<xref rid="ejn70263-bib-0041" ref-type="bibr">2019</xref>). MRI scans were conducted using the Siemens MAGNETOM Prisma 3&#8201;T scanner (Siemens Healthineers AG) with a 32&#8208;channel head coil at the NeuroImaging Core Unit Munich (NICUM). The T1&#8208;weighted images were obtained through a magnetization&#8208;prepared rapid gradient&#8208;echo sequence. These images featured an isotropic voxel size of 0.8&#8201;mm<sup>3</sup>, encompassing 208 slices. The scanning parameters included a repetition time of 2500&#8201;ms, an echo time of 2.22&#8201;ms, a flip angle of 8&#176;, and a field of view measuring 256&#8201;mm<sup>2</sup>.</p></sec><sec id="ejn70263-sec-0005"><label>2.3</label><title>EEG Recording and Preprocessing</title><p>Resting state EEG was recorded using 32 scalp electrodes (Electro&#8208;Cap International Inc., Eaton, OH, USA) following the International 10&#8211;20 system. The recording was conducted using the BrainAmp amplifier (Brain Products, Martinsried, Germany), at a sampling rate of 1000&#8201;Hz, with Cz used as the reference electrode. Electrode skin impedance was kept below 5&#8201;k&#937;. In total, the recording of the resting state EEG lasted 10&#8201;min, with the first 5&#8201;min recorded during eyes closed (with eyes opening for 3&#8201;s after 120&#8201;s to suppress excessive alpha power) and the last 5&#8201;min of eyes open. Participants were instructed to remain as calm and relaxed as possible throughout the recording.</p><p>The raw data were preprocessed using an automated in&#8208;house preprocessing pipeline implemented in MATLAB (The Mathworks Inc.) using EEGLAB v2022.0 (Delorme and Makeig&#160;<xref rid="ejn70263-bib-0012" ref-type="bibr">2004</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://sccn.ucsd.edu/eeglab/" ext-link-type="uri">https://sccn.ucsd.edu/eeglab/</ext-link>). Each resting&#8208;state condition was preprocessed separately for each participant. All the data were initially re&#8208;referenced to the mastoid electrodes (A1 and A2) and resampled down to 256&#8201;Hz. A bandpass filter (1&#8211;70&#8201;Hz) and a notch filter were applied, and data were segmented into 6&#8208;s epochs.</p><p>Each epoch was further preprocessed to remove linear trends, filtered on low and high&#8208;frequency bands. Channels were rejected based on extreme power spectrum values, kurtosis, and joint probability. Preprocessing included Independent Component Analysis (ICA), and detected artifact components were removed using the Multiple Artifact Rejection Algorithm (MARA) (Winkler et&#160;al.&#160;<xref rid="ejn70263-bib-0069" ref-type="bibr">2011</xref>). After ICA, the data removal and channel rejection are reapplied with minor modifications. The removed channels were interpolated at the final stage of preprocessing (for details, see <xref rid="ejn70263-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>).</p></sec><sec id="ejn70263-sec-0006"><label>2.4</label><title>Source Localization of EEG Activity</title><p>Cortical source activations were estimated using Brainstorm software (version 15&#8208;Nov&#8208;2024), an open&#8208;source brain imaging tool (Tadel et&#160;al.<xref rid="ejn70263-bib-0064" ref-type="bibr">2011</xref>); (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://neuroimage.usc.edu/brainstorm" ext-link-type="uri">http://neuroimage.usc.edu/brainstorm</ext-link>). For each subject, their respective anatomical data were imported, and a three&#8208;layer boundary element method (BEM) was applied to compute the lead field matrix. The head model was computed using the OpenMEEG BEM method, incorporating scalp, skull, and brain conductivities with adaptive integration. Source localization was performed using the Linearly Constrained Minimum Variance (LCMV) beamformer method, with the inverse solution computed for a Pseudoinverse of the Noise&#8208;normalized Average Inverse (PNAI) measure using free orientation and depth weighting. Source localized activity was extracted across three frontoinsular regions of interest: the right anterior insula (R&#8208;INS), the left anterior insula (L&#8208;INS), and the dACC, based on the masks from Goodkind et&#160;al.&#160;(<xref rid="ejn70263-bib-0019" ref-type="bibr">2015</xref>) meta&#8208;analysis (for details of source&#8208;localized parameters see <xref rid="ejn70263-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>).</p></sec><sec id="ejn70263-sec-0007"><label>2.5</label><title>Parameterization of Power Spectrum Density</title><p>The power spectral density (PSD) was calculated using the Welch method, with 6&#8208;s windows and 50% overlap on MNE Python (v1.8.0) (Gramfort et&#160;al.&#160;<xref rid="ejn70263-bib-0021" ref-type="bibr">2014</xref>). PSD was calculated for all electrodes and for the three source&#8208;localized ROIs (R&#8208;INS, L&#8208;INS, dACC). To parameterize the PSD, the <italic toggle="yes">fooof</italic> Python toolbox was used (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://fooof-tools.github.io/fooof/" ext-link-type="uri">https://fooof&#8208;tools.github.io/fooof/</ext-link>) (Donoghue et&#160;al.&#160;<xref rid="ejn70263-bib-0016" ref-type="bibr">2020</xref>). The power spectra were parameterized across a frequency range of 3&#8211;40&#8201;Hz, and the final model parameters included a model with: peak_width_limits&#8201;=&#8201;[1, 10], maximum_n_peak&#8201;=&#8201;8, min_peak_height&#8201;=&#8201;0.1, peak_threshold&#8201;=&#8201;2, and aperiodic_mode&#8201;=&#8201;&#8220;fixed&#8221;. The fooof model demonstrated good fitting performance across both groups and different extractions, as indicated by <italic toggle="yes">R</italic>
<sup>2</sup> values and error in parentheses: Scalp&#8208;level&#8212;HC (0.963&#8201;&#177;&#8201;0.057), SSD (0.967&#8201;&#177;&#8201;0.062); L&#8208;INS&#8212;HC (0.957&#8201;&#177;&#8201;0.054), SSD (0.960&#8201;&#177;&#8201;0.056); R&#8208;INS&#8212;HC (0.958&#8201;&#177;&#8201;0.0544), SSD (0.959&#8201;&#177;&#8201;0.057); dACC&#8212;HC (0.959&#8201;&#177;&#8201;0.055), SSD (0.962&#8201;&#177;&#8201;0.056). All the subsequent analyses in the Result section refer to the aperiodic&#8208;adjusted power, center frequency, and bandwidth.</p><p>The FOOOF algorithm decomposes the PSD into aperiodic and periodic components; it first fits the aperiodic background activity and subtracts it from the original spectrum to isolate residuals that may contain oscillatory peaks (Donoghue et&#160;al.&#160;<xref rid="ejn70263-bib-0016" ref-type="bibr">2020</xref>). These peaks are then identified based on user&#8208;defined thresholds (e.g., minimum peak height and standard deviation threshold) and modeled using Gaussian functions. The final model is constructed by summing the fitted aperiodic component with the&#160;Gaussian functions representing the detected peaks, providing a full parameterization of the power spectrum. Due to the specific detection thresholds applied in this study and the relatively lower power of peaks outside the alpha and beta bands, reliable periodic peaks were less frequently detected in the theta and gamma ranges (see Figures&#160;<xref rid="ejn70263-supitem-0001" ref-type="supplementary-material">S1</xref> and <xref rid="ejn70263-supitem-0001" ref-type="supplementary-material">S2</xref>).</p><p>At scalp level activity, periodic and aperiodic features were averaged across all electrodes. Considering that the FOOOF algorithm's peak detection can result in missing values (NAs) for the signal on which no peak is detected, we set an inclusion/exclusion threshold: if at least 50% of electrodes in a given frequency band exhibited periodic activity, the activity was averaged across all active electrodes. Otherwise, the participants were labeled as missing. At source level, participants were similarly labeled as missing if no periodic activity was detected in a given region (R&#8208;INS, L&#8208;INS, dACC). All statistical analyses were conducted only on available (non&#8208;missing) data.</p></sec><sec id="ejn70263-sec-0008"><label>2.6</label><title>Statistical Analyses</title><p>All the statistical analyses were performed in R, version 4.4.0 (R Core Team&#160;<xref rid="ejn70263-bib-0052" ref-type="bibr">2024</xref>). Fisher's exact test was used to show differences between categorical variables, while Welch's <italic toggle="yes">t</italic>&#8208;test was applied to continuous variables when no covariates were included. To investigate group differences in periodic and aperiodic activity on source and scalp levels, we performed Linear Mixed&#8208;Effects Models (LMM) using the <italic toggle="yes">lmer</italic> function in the lme4 package (Bates et&#160;al.&#160;<xref rid="ejn70263-bib-0007" ref-type="bibr">2015</xref>). The dependent variables were the periodic and aperiodic components, while the primary predictor was group status (HC vs. SSD). To account for potential interactions between condition (eyes closed vs. eyes open) and group status, we included condition as an interaction term (Zhang et&#160;al.&#160;<xref rid="ejn70263-bib-0071" ref-type="bibr">2021</xref>). Sex and age were included as covariates, and participant ID was modeled as a random intercept to account for inter&#8208;individual variability.</p><p>Separate models were run for the scalp&#8208;level activity averaged across all electrodes and three ROI source localized activities (R&#8208;INS, L&#8208;INS, dACC), for three periodic parameters (power, bandwidth, center frequency), five frequency bands (theta: 4&#8211;8&#8201;Hz, alpha: 8&#8211;12&#8201;Hz, beta: 12&#8211;30&#8201;Hz, low&#8208;gamma/gamma1: 30&#8211;40&#8201;Hz), as well as two aperiodic components (exponent and offset). For the scalp level, for each extraction modality (scalp&#8208;level and source&#8208;level), <italic toggle="yes">p</italic> values were adjusted for multiple comparisons using the Benjamini&#8211;Hochberg procedure for all the models run (Benjamini and Hochberg&#160;<xref rid="ejn70263-bib-0008" ref-type="bibr">1995</xref>). The corrected <italic toggle="yes">p</italic> values are further referred to as <italic toggle="yes">q</italic> values.</p><p>Linear regressions are used to examine the relationships between altered EEG components for each condition (eyes closed and eyes open) with cognitive and symptomatic measures while controlling for age, sex, and CPZeq.</p></sec></sec><sec sec-type="results" id="ejn70263-sec-0009"><label>3</label><title>Results</title><sec id="ejn70263-sec-0010"><label>3.1</label><title>Cohort Characteristics</title><p>The sample considered for this study consisted of 97 individuals with SSD (28.9% female, mean age&#8201;=&#8201;38.2&#8201;&#177;&#8201;11.8, PANSS total score&#8201;=&#8201;56.6&#8201;&#177;&#8201;16.7, illness duration (months)&#8201;=&#8201;130.45&#8201;&#177;&#8201;123.51, chlorpromazine equivalents&#8201;=&#8201;329.10&#8201;&#177;&#8201;273.33&#8201;mg, 16.5% benzodiazepine users) and 152 HC (55.9% female, mean age&#8201;=&#8201;34.79&#8201;&#177;&#8201;12.69). The two most prevalent diagnoses in the SSD group were schizophrenia (53.8%) and schizoaffective disorder (27.9%). 38.54% of our SSD sample was in remission according to modified Andreasen criteria without the time criterion (Andreasen et&#160;al.&#160;<xref rid="ejn70263-bib-0003" ref-type="bibr">2005</xref>). Table&#160;<xref rid="ejn70263-tbl-0001" ref-type="table">1</xref> provides more details on the clinical and demographic characteristics of the cohorts.</p><table-wrap position="float" id="ejn70263-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Sample characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1"/><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">SSD</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">HC</th><th align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1"/></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Mean&#8201;&#177;&#8201;SD or <italic toggle="no">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">n</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Mean&#8201;&#177;&#8201;SD or <italic toggle="no">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">n</italic>
</th><th align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">p</italic>
</th></tr></thead><tbody valign="top"><tr><td colspan="6" align="left" valign="top" rowspan="1">Demographic characteristics</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, years</td><td align="center" valign="top" rowspan="1" colspan="1">38.2&#8201;&#177;&#8201;11.8</td><td align="center" valign="top" rowspan="1" colspan="1">97</td><td align="center" valign="top" rowspan="1" colspan="1">34.8&#8201;&#177;&#8201;12.7</td><td align="center" valign="top" rowspan="1" colspan="1">152</td><td align="center" valign="top" rowspan="1" colspan="1">0.004<xref rid="ejn70263-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex, female:male (% female)</td><td align="center" valign="top" rowspan="1" colspan="1">26:68 (28.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">97</td><td align="center" valign="top" rowspan="1" colspan="1">85:67 (55.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">152</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001<xref rid="ejn70263-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI</td><td align="center" valign="top" rowspan="1" colspan="1">27.8&#8201;&#177;&#8201;5.44</td><td align="center" valign="top" rowspan="1" colspan="1">95</td><td align="center" valign="top" rowspan="1" colspan="1">23.4&#8201;&#177;&#8201;3.6</td><td align="center" valign="top" rowspan="1" colspan="1">147</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001<xref rid="ejn70263-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1">Disease characteristics</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Disease duration, months</td><td align="center" valign="top" rowspan="1" colspan="1">130.45&#8201;&#177;&#8201;123.51</td><td align="center" valign="top" rowspan="1" colspan="1">93</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Antipsychotic treatment duration, months</td><td align="center" valign="top" rowspan="1" colspan="1">105.20&#8201;&#177;&#8201;116.18</td><td align="center" valign="top" rowspan="1" colspan="1">89</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Benzodiazepine use, yes:no (% yes)</td><td align="center" valign="top" rowspan="1" colspan="1">16:81 (16.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">97</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CPZeq, mg</td><td align="center" valign="top" rowspan="1" colspan="1">329.10&#8201;&#177;&#8201;273.33</td><td align="center" valign="top" rowspan="1" colspan="1">94</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Remission Andreasen, yes:no (% yes)</td><td align="center" valign="top" rowspan="1" colspan="1">37:59 (38.54%)</td><td align="center" valign="top" rowspan="1" colspan="1">97</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PANSS Positive symptoms</td><td align="center" valign="top" rowspan="1" colspan="1">13.0&#8201;&#177;&#8201;5.09</td><td align="center" valign="top" rowspan="1" colspan="1">96</td><td align="center" valign="top" rowspan="1" colspan="1">7.30&#8201;&#177;&#8201;0.76</td><td align="center" valign="top" rowspan="1" colspan="1">152</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001<xref rid="ejn70263-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PANSS Negative symptoms</td><td align="center" valign="top" rowspan="1" colspan="1">13.8&#8201;&#177;&#8201;5.64</td><td align="center" valign="top" rowspan="1" colspan="1">96</td><td align="center" valign="top" rowspan="1" colspan="1">7.39&#8201;&#177;&#8201;0.88</td><td align="center" valign="top" rowspan="1" colspan="1">152</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001<xref rid="ejn70263-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PANSS General symptoms</td><td align="center" valign="top" rowspan="1" colspan="1">29.80&#8201;&#177;&#8201;8.78</td><td align="center" valign="top" rowspan="1" colspan="1">96</td><td align="center" valign="top" rowspan="1" colspan="1">16.9&#8201;&#177;&#8201;1.43</td><td align="center" valign="top" rowspan="1" colspan="1">152</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001<xref rid="ejn70263-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PANSS Total score</td><td align="center" valign="top" rowspan="1" colspan="1">56.60&#8201;&#177;&#8201;16.70</td><td align="center" valign="top" rowspan="1" colspan="1">96</td><td align="center" valign="top" rowspan="1" colspan="1">31.59&#8201;&#177;&#8201;2.43</td><td align="center" valign="top" rowspan="1" colspan="1">152</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001<xref rid="ejn70263-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GAF</td><td align="center" valign="top" rowspan="1" colspan="1">53.12&#8201;&#177;&#8201;12.83</td><td align="center" valign="top" rowspan="1" colspan="1">97</td><td align="center" valign="top" rowspan="1" colspan="1">89.88&#8201;&#177;&#8201;6.14</td><td align="center" valign="top" rowspan="1" colspan="1">152</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001<xref rid="ejn70263-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BACS Composite z score</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;1.90&#8201;&#177;&#8201;1.42</td><td align="center" valign="top" rowspan="1" colspan="1">91</td><td align="center" valign="top" rowspan="1" colspan="1">0&#8201;&#177;&#8201;1</td><td align="center" valign="top" rowspan="1" colspan="1">148</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001<xref rid="ejn70263-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diagnosis</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Schizophrenia</td><td align="center" valign="top" rowspan="1" colspan="1">56 (57.73%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Schizoaffective disorder</td><td align="center" valign="top" rowspan="1" colspan="1">29 (29.9%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Brief Psychotic disorder</td><td align="center" valign="top" rowspan="1" colspan="1">7 (7.22%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Unspecified schizophrenia</p>
<p>Spectrum disorder</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">3 (3.09%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Delusional disorder</td><td align="center" valign="top" rowspan="1" colspan="1">2 (2.06%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="ejn70263-ntgp-0002"><fn id="ejn70263-note-0004"><p>Abbreviations: BACS&#8201;=&#8201;Brief Assessment of Cognition in Schizophrenia; BMI&#8201;=&#8201;body mass index; CPZeq&#8201;=&#8201;chlorpromazine equivalent dose; GAF&#8201;=&#8201;Global Assessment of Functioning; HC&#8201;=&#8201;healthy control participant; n = number of participants; p = p&#8208;value for the respective test; PANSS&#8201;=&#8201;Positive and Negative Syndrome Scale; SD = standard deviation;&#160;SSD =&#160;schizophrenia spectrum disorder.</p></fn><fn id="ejn70263-note-0005"><label>
<sup>a</sup>
</label><p>Fisher's exact test.</p></fn><fn id="ejn70263-note-0006"><label>
<sup>b</sup>
</label><p>Welch's <italic toggle="yes">t</italic> test.</p></fn></table-wrap-foot></table-wrap></sec><sec id="ejn70263-sec-0011"><label>3.2</label><title>Periodic and Aperiodic Effects on Scalp Level Activity</title><p>To explore whether periodic and aperiodic activity differed between HC and SSD, we applied linear mixed models. At scalp level, for power as a component of periodic activity, we observed an increase in theta power (<italic toggle="yes">b</italic>&#8201;=&#8201;0.108 log (&#956;V<sup>2</sup>), 95% CI [0.029, 0.187]; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.008, <italic toggle="yes">q</italic>&#8201;=&#8201;0.027) in the SSD group compared to HC. Conversely, SSD individuals showed pronounced reductions in the alpha center frequency peak (<italic toggle="yes">b</italic>&#8201;=&#8201;&#8722;0.435&#8201;Hz, 95% CI [&#8722;0.642, &#8722;0.229]; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">q</italic>&#8201;&lt;&#8201;0.001) (see Figure&#160;<xref rid="ejn70263-fig-0001" ref-type="fig">1</xref> and Table&#160;<xref rid="ejn70263-tbl-0002" ref-type="table">2</xref>). In terms of aperiodic activity, the SSD group demonstrated increased exponent (<italic toggle="yes">b</italic>&#8201;=&#8201;0.168&#8201;a.u., 95% CI [0.056, 0.281]; <italic toggle="yes">p</italic>&#8201;=&#8201;0.004, <italic toggle="yes">q</italic>&#8201;=&#8201;0.017) and offset (<italic toggle="yes">b</italic>&#8201;=&#8201;0.272 log (&#956;V<sup>2</sup>/Hz), 95% CI [0.126, 0.418]; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">q</italic>&#8201;=&#8201;0.002) relative to HC (see Figure&#160;<xref rid="ejn70263-fig-0002" ref-type="fig">2</xref> and Table&#160;<xref rid="ejn70263-tbl-0002" ref-type="table">2</xref>).</p><fig position="float" fig-type="FIGURE" id="ejn70263-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Differences in periodic activity at scalp&#8208;level and source&#8208;localized regions. For (A) scalp&#8208;level, (B) left anterior insula, (C) right anterior insula, and (D) dorsal anterior cingulate cortex: The first column visually illustrates the origin of the extracted activity and shows the periodic power spectral density (PSD) for each group; the second column shows power comparisons between HC and SSD across frequency bands; and the third column shows alpha center frequency comparisons between HC and SSD. HC&#8201;=&#8201;healthy controls. SSD&#8201;=&#8201;schizophrenia spectrum disorder. Scalp&#8208;level: averaged activity across electrodes. L&#8208;INS: left anterior insula. R&#8208;INS: right anterior insula. dACC: dorsal anterior cingulate cortex. &#8595;&#8593;: show an increase or decrease in SSD compared to HC. Significance level after FDR correction: *&lt;&#8201;.05, **&lt;&#8201;.01, ***&lt;&#8201;.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="EJN-62-0-g001.jpg"/></fig><table-wrap position="float" id="ejn70263-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Linear Mixed&#8208;Effects models of comparing periodic and aperiodic components between healthy controls and schizophrenia spectrum disorders.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Region</th><th align="center" valign="bottom" rowspan="1" colspan="1">Frequency band</th><th align="center" valign="bottom" rowspan="1" colspan="1">FOOOF parameter</th><th align="center" valign="bottom" rowspan="1" colspan="1">N HC (EC:EO)</th><th align="center" valign="bottom" rowspan="1" colspan="1">N SSD (EC:EO)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Estimates [CI95%: LL, UL]</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">q</italic> (p<sub>FDR</sub>)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">R</italic>
<sup>2</sup> (Marginal)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">R</italic>
<sup>2</sup> (Conditional)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Scalp&#8208;level</td><td align="center" valign="top" rowspan="1" colspan="1">Theta: 4&#8211;8&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Bandwidth</td><td align="center" valign="top" rowspan="1" colspan="1">90 (68:70)</td><td align="center" valign="top" rowspan="1" colspan="1">75 (58:62)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0352 [&#8722;0.1159, 0.1862]</td><td align="center" valign="top" rowspan="1" colspan="1">0.6474</td><td align="center" valign="top" rowspan="1" colspan="1">0.6972</td><td align="center" valign="top" rowspan="1" colspan="1">0.065</td><td align="center" valign="top" rowspan="1" colspan="1">0.3677</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scalp&#8208;level</td><td align="center" valign="top" rowspan="1" colspan="1">Theta: 4&#8211;8&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Power</td><td align="center" valign="top" rowspan="1" colspan="1">90 (68:70)</td><td align="center" valign="top" rowspan="1" colspan="1">75 (58:62)</td><td align="center" valign="top" rowspan="1" colspan="1">0.1083 [0.0292, 0.1874]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0076</td><td align="center" valign="top" rowspan="1" colspan="1">0.0266</td><td align="center" valign="top" rowspan="1" colspan="1">0.1493</td><td align="center" valign="top" rowspan="1" colspan="1">0.8411</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scalp&#8208;level</td><td align="center" valign="top" rowspan="1" colspan="1">Theta: 4&#8211;8&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Center frequency</td><td align="center" valign="top" rowspan="1" colspan="1">90 (68:70)</td><td align="center" valign="top" rowspan="1" colspan="1">75 (58:62)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0877 [&#8722;0.1238, 0.2998]</td><td align="center" valign="top" rowspan="1" colspan="1">0.4156</td><td align="center" valign="top" rowspan="1" colspan="1">0.5818</td><td align="center" valign="top" rowspan="1" colspan="1">0.0461</td><td align="center" valign="top" rowspan="1" colspan="1">0.7682</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scalp&#8208;level</td><td align="center" valign="top" rowspan="1" colspan="1">Low&#8208;gamma: 30&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Bandwidth</td><td align="center" valign="top" rowspan="1" colspan="1">39 (24:35)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (18:20)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.2541 [&#8722;0.9593, 0.4555]</td><td align="center" valign="top" rowspan="1" colspan="1">0.4764</td><td align="center" valign="top" rowspan="1" colspan="1">0.6063</td><td align="center" valign="top" rowspan="1" colspan="1">0.0156</td><td align="center" valign="top" rowspan="1" colspan="1">0.7392</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scalp&#8208;level</td><td align="center" valign="top" rowspan="1" colspan="1">Low&#8208;gamma: 30&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Power</td><td align="center" valign="top" rowspan="1" colspan="1">39 (24:35)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (18:20)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0529 [0.005, 0.1008]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0313</td><td align="center" valign="top" rowspan="1" colspan="1">0.0876</td><td align="center" valign="top" rowspan="1" colspan="1">0.0523</td><td align="center" valign="top" rowspan="1" colspan="1">0.7387</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scalp&#8208;level</td><td align="center" valign="top" rowspan="1" colspan="1">Low&#8208;gamma: 30&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Center frequency</td><td align="center" valign="top" rowspan="1" colspan="1">39 (24:35)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (18:20)</td><td align="center" valign="top" rowspan="1" colspan="1">0.7862 [&#8722;0.5053, 2.0778]</td><td align="center" valign="top" rowspan="1" colspan="1">0.231</td><td align="center" valign="top" rowspan="1" colspan="1">0.5028</td><td align="center" valign="top" rowspan="1" colspan="1">0.0325</td><td align="center" valign="top" rowspan="1" colspan="1">0.7815</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scalp&#8208;level</td><td align="center" valign="top" rowspan="1" colspan="1">Alpha: 8&#8211;12&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Bandwidth</td><td align="center" valign="top" rowspan="1" colspan="1">150 (149:144)</td><td align="center" valign="top" rowspan="1" colspan="1">96 (96:90)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.0299 [&#8722;0.1451, 0.0853]</td><td align="center" valign="top" rowspan="1" colspan="1">0.6107</td><td align="center" valign="top" rowspan="1" colspan="1">0.6972</td><td align="center" valign="top" rowspan="1" colspan="1">0.0701</td><td align="center" valign="top" rowspan="1" colspan="1">0.5333</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scalp&#8208;level</td><td align="center" valign="top" rowspan="1" colspan="1">Alpha: 8&#8211;12&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Power</td><td align="center" valign="top" rowspan="1" colspan="1">150 (149:144)</td><td align="center" valign="top" rowspan="1" colspan="1">96 (96:90)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0423 [&#8722;0.0494, 0.1341]</td><td align="center" valign="top" rowspan="1" colspan="1">0.3652</td><td align="center" valign="top" rowspan="1" colspan="1">0.5681</td><td align="center" valign="top" rowspan="1" colspan="1">0.1755</td><td align="center" valign="top" rowspan="1" colspan="1">0.6255</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scalp&#8208;level</td><td align="center" valign="top" rowspan="1" colspan="1">Alpha: 8&#8211;12&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Center frequency</td><td align="center" valign="top" rowspan="1" colspan="1">150 (149:144)</td><td align="center" valign="top" rowspan="1" colspan="1">96 (96:90)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.4351 [&#8722;0.6416, &#8722;0.2287]</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.0001</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.0001</td><td align="center" valign="top" rowspan="1" colspan="1">0.1132</td><td align="center" valign="top" rowspan="1" colspan="1">0.7259</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scalp&#8208;level</td><td align="center" valign="top" rowspan="1" colspan="1">Beta: 12&#8211;30&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Bandwidth</td><td align="center" valign="top" rowspan="1" colspan="1">152 (152:152)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (97:97)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.1308 [&#8722;0.3978, 0.1362]</td><td align="center" valign="top" rowspan="1" colspan="1">0.3362</td><td align="center" valign="top" rowspan="1" colspan="1">0.5681</td><td align="center" valign="top" rowspan="1" colspan="1">0.0978</td><td align="center" valign="top" rowspan="1" colspan="1">0.6603</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scalp&#8208;level</td><td align="center" valign="top" rowspan="1" colspan="1">Beta: 12&#8211;30&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Power</td><td align="center" valign="top" rowspan="1" colspan="1">152 (152:152)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (97:97)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.0252 [&#8722;0.0683, 0.0179]</td><td align="center" valign="top" rowspan="1" colspan="1">0.2514</td><td align="center" valign="top" rowspan="1" colspan="1">0.5028</td><td align="center" valign="top" rowspan="1" colspan="1">0.1014</td><td align="center" valign="top" rowspan="1" colspan="1">0.7571</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scalp&#8208;level</td><td align="center" valign="top" rowspan="1" colspan="1">Beta: 12&#8211;30&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Center frequency</td><td align="center" valign="top" rowspan="1" colspan="1">152 (152:152)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (97:97)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.1257 [&#8722;0.9075, 0.656]</td><td align="center" valign="top" rowspan="1" colspan="1">0.7521</td><td align="center" valign="top" rowspan="1" colspan="1">0.7521</td><td align="center" valign="top" rowspan="1" colspan="1">0.0189</td><td align="center" valign="top" rowspan="1" colspan="1">0.7799</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scalp&#8208;level</td><td align="center" valign="top" rowspan="1" colspan="1">Aperiodic: 3&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Exponent</td><td align="center" valign="top" rowspan="1" colspan="1">152 (152:152)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (97:97)</td><td align="center" valign="top" rowspan="1" colspan="1">0.1684 [0.0557, 0.2812]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0036</td><td align="center" valign="top" rowspan="1" colspan="1">0.0168</td><td align="center" valign="top" rowspan="1" colspan="1">0.0558</td><td align="center" valign="top" rowspan="1" colspan="1">0.7757</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scalp&#8208;level</td><td align="center" valign="top" rowspan="1" colspan="1">Aperiodic: 3&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Offset</td><td align="center" valign="top" rowspan="1" colspan="1">152 (152:152)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (97:97)</td><td align="center" valign="top" rowspan="1" colspan="1">0.2719 [0.1257, 0.4182]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0003</td><td align="center" valign="top" rowspan="1" colspan="1">0.0021</td><td align="center" valign="top" rowspan="1" colspan="1">0.0677</td><td align="center" valign="top" rowspan="1" colspan="1">0.8708</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Theta: 4&#8211;8&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Bandwidth</td><td align="center" valign="top" rowspan="1" colspan="1">92 (73:68)</td><td align="center" valign="top" rowspan="1" colspan="1">71 (58:48)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.0931 [&#8722;0.4099, 0.2238]</td><td align="center" valign="top" rowspan="1" colspan="1">0.5634</td><td align="center" valign="top" rowspan="1" colspan="1">0.6761</td><td align="center" valign="top" rowspan="1" colspan="1">0.0182</td><td align="center" valign="top" rowspan="1" colspan="1">0.2231</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Theta: 4&#8211;8&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Power</td><td align="center" valign="top" rowspan="1" colspan="1">92 (73:68)</td><td align="center" valign="top" rowspan="1" colspan="1">71 (58:48)</td><td align="center" valign="top" rowspan="1" colspan="1">0.1034 [0.0468, 0.16]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0004</td><td align="center" valign="top" rowspan="1" colspan="1">0.0084</td><td align="center" valign="top" rowspan="1" colspan="1">0.119</td><td align="center" valign="top" rowspan="1" colspan="1">0.734</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Theta: 4&#8211;8&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Center frequency</td><td align="center" valign="top" rowspan="1" colspan="1">92 (73:68)</td><td align="center" valign="top" rowspan="1" colspan="1">71 (58:48)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0418 [&#8722;0.2331, 0.3162]</td><td align="center" valign="top" rowspan="1" colspan="1">0.7647</td><td align="center" valign="top" rowspan="1" colspan="1">0.7647</td><td align="center" valign="top" rowspan="1" colspan="1">0.0464</td><td align="center" valign="top" rowspan="1" colspan="1">0.3538</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Alpha: 8&#8211;12&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Bandwidth</td><td align="center" valign="top" rowspan="1" colspan="1">134 (127:118)</td><td align="center" valign="top" rowspan="1" colspan="1">88 (78:81)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.088 [&#8722;0.3486, 0.1727]</td><td align="center" valign="top" rowspan="1" colspan="1">0.5076</td><td align="center" valign="top" rowspan="1" colspan="1">0.6662</td><td align="center" valign="top" rowspan="1" colspan="1">0.034</td><td align="center" valign="top" rowspan="1" colspan="1">0.1063</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Alpha: 8&#8211;12&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Power</td><td align="center" valign="top" rowspan="1" colspan="1">134 (127:118)</td><td align="center" valign="top" rowspan="1" colspan="1">88 (78:81)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0104 [&#8722;0.0439, 0.0645]</td><td align="center" valign="top" rowspan="1" colspan="1">0.7073</td><td align="center" valign="top" rowspan="1" colspan="1">0.7246</td><td align="center" valign="top" rowspan="1" colspan="1">0.0207</td><td align="center" valign="top" rowspan="1" colspan="1">0.4504</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Alpha: 8&#8211;12&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Center frequency</td><td align="center" valign="top" rowspan="1" colspan="1">134 (127:118)</td><td align="center" valign="top" rowspan="1" colspan="1">88 (78:81)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.4295 [&#8722;0.7191, &#8722;0.1405]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0037</td><td align="center" valign="top" rowspan="1" colspan="1">0.0389</td><td align="center" valign="top" rowspan="1" colspan="1">0.1191</td><td align="center" valign="top" rowspan="1" colspan="1">0.5443</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Beta: 12&#8211;30&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Bandwidth</td><td align="center" valign="top" rowspan="1" colspan="1">152 (151:151)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (97:95)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.4531 [&#8722;0.9285, 0.0224]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0619</td><td align="center" valign="top" rowspan="1" colspan="1">0.2363</td><td align="center" valign="top" rowspan="1" colspan="1">0.0243</td><td align="center" valign="top" rowspan="1" colspan="1">0.2067</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Beta: 12&#8211;30&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Power</td><td align="center" valign="top" rowspan="1" colspan="1">152 (151:151)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (97:95)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.0111 [&#8722;0.0514, 0.0291]</td><td align="center" valign="top" rowspan="1" colspan="1">0.5868</td><td align="center" valign="top" rowspan="1" colspan="1">0.6846</td><td align="center" valign="top" rowspan="1" colspan="1">0.0957</td><td align="center" valign="top" rowspan="1" colspan="1">0.6547</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Beta: 12&#8211;30&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Center frequency</td><td align="center" valign="top" rowspan="1" colspan="1">152 (151:151)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (97:95)</td><td align="center" valign="top" rowspan="1" colspan="1">0.6339 [&#8722;0.5162, 1.784]</td><td align="center" valign="top" rowspan="1" colspan="1">0.2795</td><td align="center" valign="top" rowspan="1" colspan="1">0.5104</td><td align="center" valign="top" rowspan="1" colspan="1">0.018</td><td align="center" valign="top" rowspan="1" colspan="1">0.4985</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Low&#8208;gamma: 30&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Bandwidth</td><td align="center" valign="top" rowspan="1" colspan="1">88 (70:52)</td><td align="center" valign="top" rowspan="1" colspan="1">52 (38:40)</td><td align="center" valign="top" rowspan="1" colspan="1">0.4399 [&#8722;0.3509, 1.2301]</td><td align="center" valign="top" rowspan="1" colspan="1">0.2681</td><td align="center" valign="top" rowspan="1" colspan="1">0.5104</td><td align="center" valign="top" rowspan="1" colspan="1">0.0504</td><td align="center" valign="top" rowspan="1" colspan="1">0.0843</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Low&#8208;Gamma: 30&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Power</td><td align="center" valign="top" rowspan="1" colspan="1">88 (70:52)</td><td align="center" valign="top" rowspan="1" colspan="1">52 (38:40)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0574 [0.0136, 0.1012]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0105</td><td align="center" valign="top" rowspan="1" colspan="1">0.0882</td><td align="center" valign="top" rowspan="1" colspan="1">0.0437</td><td align="center" valign="top" rowspan="1" colspan="1">0.4839</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Low&#8208;gamma: 30&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Center frequency</td><td align="center" valign="top" rowspan="1" colspan="1">88 (70:52)</td><td align="center" valign="top" rowspan="1" colspan="1">52 (38:40)</td><td align="center" valign="top" rowspan="1" colspan="1">0.3319 [&#8722;0.9397, 1.6034]</td><td align="center" valign="top" rowspan="1" colspan="1">0.6078</td><td align="center" valign="top" rowspan="1" colspan="1">0.6899</td><td align="center" valign="top" rowspan="1" colspan="1">0.0073</td><td align="center" valign="top" rowspan="1" colspan="1">0.5068</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Aperiodic: 3&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Exponent</td><td align="center" valign="top" rowspan="1" colspan="1">152 (152:152)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (97:97)</td><td align="center" valign="top" rowspan="1" colspan="1">0.05 [&#8722;0.0264, 0.1264]</td><td align="center" valign="top" rowspan="1" colspan="1">0.1996</td><td align="center" valign="top" rowspan="1" colspan="1">0.4412</td><td align="center" valign="top" rowspan="1" colspan="1">0.0661</td><td align="center" valign="top" rowspan="1" colspan="1">0.5968</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Aperiodic: 3&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Offset</td><td align="center" valign="top" rowspan="1" colspan="1">152 (152:152)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (97:97)</td><td align="center" valign="top" rowspan="1" colspan="1">0.1941 [&#8722;0.0232, 0.4114]</td><td align="center" valign="top" rowspan="1" colspan="1">0.08</td><td align="center" valign="top" rowspan="1" colspan="1">0.2585</td><td align="center" valign="top" rowspan="1" colspan="1">0.0384</td><td align="center" valign="top" rowspan="1" colspan="1">0.4157</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Theta: 4&#8211;8&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Bandwidth</td><td align="center" valign="top" rowspan="1" colspan="1">89 (61:63)</td><td align="center" valign="top" rowspan="1" colspan="1">66 (54:51)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.1197 [&#8722;0.3936, 0.1541]</td><td align="center" valign="top" rowspan="1" colspan="1">0.3905</td><td align="center" valign="top" rowspan="1" colspan="1">0.5656</td><td align="center" valign="top" rowspan="1" colspan="1">0.0154</td><td align="center" valign="top" rowspan="1" colspan="1">0.3644</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Theta: 4&#8211;8&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Power</td><td align="center" valign="top" rowspan="1" colspan="1">89 (61:63)</td><td align="center" valign="top" rowspan="1" colspan="1">66 (54:51)</td><td align="center" valign="top" rowspan="1" colspan="1">0.1013 [0.0351, 0.1675]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0029</td><td align="center" valign="top" rowspan="1" colspan="1">0.0389</td><td align="center" valign="top" rowspan="1" colspan="1">0.1309</td><td align="center" valign="top" rowspan="1" colspan="1">0.6592</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Theta: 4&#8211;8&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Center frequency</td><td align="center" valign="top" rowspan="1" colspan="1">89 (61:63)</td><td align="center" valign="top" rowspan="1" colspan="1">66 (54:51)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0701 [&#8722;0.2354, 0.3759]</td><td align="center" valign="top" rowspan="1" colspan="1">0.652</td><td align="center" valign="top" rowspan="1" colspan="1">0.7166</td><td align="center" valign="top" rowspan="1" colspan="1">0.0529</td><td align="center" valign="top" rowspan="1" colspan="1">0.4071</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Alpha: 8&#8211;12&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Bandwidth</td><td align="center" valign="top" rowspan="1" colspan="1">142 (135:129)</td><td align="center" valign="top" rowspan="1" colspan="1">95 (91:84)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0982 [&#8722;0.1189, 0.3152]</td><td align="center" valign="top" rowspan="1" colspan="1">0.3746</td><td align="center" valign="top" rowspan="1" colspan="1">0.5619</td><td align="center" valign="top" rowspan="1" colspan="1">0.0346</td><td align="center" valign="top" rowspan="1" colspan="1">0.0644</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Alpha: 8&#8211;12&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Power</td><td align="center" valign="top" rowspan="1" colspan="1">142 (135:129)</td><td align="center" valign="top" rowspan="1" colspan="1">95 (91:84)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.0361 [&#8722;0.0909, 0.0187]</td><td align="center" valign="top" rowspan="1" colspan="1">0.1963</td><td align="center" valign="top" rowspan="1" colspan="1">0.4412</td><td align="center" valign="top" rowspan="1" colspan="1">0.047</td><td align="center" valign="top" rowspan="1" colspan="1">0.4658</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Alpha: 8&#8211;12&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Center frequency</td><td align="center" valign="top" rowspan="1" colspan="1">142 (135:129)</td><td align="center" valign="top" rowspan="1" colspan="1">95 (91:84)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.3137 [&#8722;0.591, &#8722;0.0363]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0268</td><td align="center" valign="top" rowspan="1" colspan="1">0.1608</td><td align="center" valign="top" rowspan="1" colspan="1">0.0705</td><td align="center" valign="top" rowspan="1" colspan="1">0.4227</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Beta: 12&#8211;30&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Bandwidth</td><td align="center" valign="top" rowspan="1" colspan="1">152 (152:152)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (96:96)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.1036 [&#8722;0.5735, 0.3664]</td><td align="center" valign="top" rowspan="1" colspan="1">0.6654</td><td align="center" valign="top" rowspan="1" colspan="1">0.7166</td><td align="center" valign="top" rowspan="1" colspan="1">0.048</td><td align="center" valign="top" rowspan="1" colspan="1">0.3714</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Beta: 12&#8211;30&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Power</td><td align="center" valign="top" rowspan="1" colspan="1">152 (152:152)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (96:96)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.0393 [&#8722;0.0804, 0.0018]</td><td align="center" valign="top" rowspan="1" colspan="1">0.061</td><td align="center" valign="top" rowspan="1" colspan="1">0.2363</td><td align="center" valign="top" rowspan="1" colspan="1">0.0805</td><td align="center" valign="top" rowspan="1" colspan="1">0.6717</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Beta: 12&#8211;30&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Center frequency</td><td align="center" valign="top" rowspan="1" colspan="1">152 (152:152)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (96:96)</td><td align="center" valign="top" rowspan="1" colspan="1">0.5418 [&#8722;0.6479, 1.7308]</td><td align="center" valign="top" rowspan="1" colspan="1">0.3713</td><td align="center" valign="top" rowspan="1" colspan="1">0.5619</td><td align="center" valign="top" rowspan="1" colspan="1">0.0192</td><td align="center" valign="top" rowspan="1" colspan="1">0.5435</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Low&#8208;gamma: 30&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Bandwidth</td><td align="center" valign="top" rowspan="1" colspan="1">84 (56:60)</td><td align="center" valign="top" rowspan="1" colspan="1">48 (35:35)</td><td align="center" valign="top" rowspan="1" colspan="1">0.2592 [&#8722;0.5518, 1.0719]</td><td align="center" valign="top" rowspan="1" colspan="1">0.5284</td><td align="center" valign="top" rowspan="1" colspan="1">0.6725</td><td align="center" valign="top" rowspan="1" colspan="1">0.0366</td><td align="center" valign="top" rowspan="1" colspan="1">0.0473</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Low&#8208;gamma: 30&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Power</td><td align="center" valign="top" rowspan="1" colspan="1">84 (56:60)</td><td align="center" valign="top" rowspan="1" colspan="1">48 (35:35)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0214 [&#8722;0.0194, 0.0621]</td><td align="center" valign="top" rowspan="1" colspan="1">0.3004</td><td align="center" valign="top" rowspan="1" colspan="1">0.5257</td><td align="center" valign="top" rowspan="1" colspan="1">0.0627</td><td align="center" valign="top" rowspan="1" colspan="1">0.4297</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Low&#8208;gamma: 30&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Center frequency</td><td align="center" valign="top" rowspan="1" colspan="1">84 (56:60)</td><td align="center" valign="top" rowspan="1" colspan="1">48 (35:35)</td><td align="center" valign="top" rowspan="1" colspan="1">0.7382 [&#8722;0.5279, 2.005]</td><td align="center" valign="top" rowspan="1" colspan="1">0.2521</td><td align="center" valign="top" rowspan="1" colspan="1">0.5104</td><td align="center" valign="top" rowspan="1" colspan="1">0.0206</td><td align="center" valign="top" rowspan="1" colspan="1">0.4627</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Aperiodic: 3&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Exponent</td><td align="center" valign="top" rowspan="1" colspan="1">152 (152:152)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (97:97)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0437 [&#8722;0.0331, 0.1205]</td><td align="center" valign="top" rowspan="1" colspan="1">0.2645</td><td align="center" valign="top" rowspan="1" colspan="1">0.5104</td><td align="center" valign="top" rowspan="1" colspan="1">0.111</td><td align="center" valign="top" rowspan="1" colspan="1">0.6276</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R&#8208;INS</td><td align="center" valign="top" rowspan="1" colspan="1">Aperiodic: 3&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Offset</td><td align="center" valign="top" rowspan="1" colspan="1">152 (152:152)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (97:97)</td><td align="center" valign="top" rowspan="1" colspan="1">0.1665 [&#8722;0.0571, 0.3901]</td><td align="center" valign="top" rowspan="1" colspan="1">0.1443</td><td align="center" valign="top" rowspan="1" colspan="1">0.3565</td><td align="center" valign="top" rowspan="1" colspan="1">0.0289</td><td align="center" valign="top" rowspan="1" colspan="1">0.342</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">dACC</td><td align="center" valign="top" rowspan="1" colspan="1">Theta: 4&#8211;8&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Bandwidth</td><td align="center" valign="top" rowspan="1" colspan="1">98 (80:79)</td><td align="center" valign="top" rowspan="1" colspan="1">75 (61:65)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.2132 [&#8722;0.4824, 0.0564]</td><td align="center" valign="top" rowspan="1" colspan="1">0.1202</td><td align="center" valign="top" rowspan="1" colspan="1">0.3366</td><td align="center" valign="top" rowspan="1" colspan="1">0.0326</td><td align="center" valign="top" rowspan="1" colspan="1">0.276</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">dACC</td><td align="center" valign="top" rowspan="1" colspan="1">Theta: 4&#8211;8&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Power</td><td align="center" valign="top" rowspan="1" colspan="1">98 (80:79)</td><td align="center" valign="top" rowspan="1" colspan="1">75 (61:65)</td><td align="center" valign="top" rowspan="1" colspan="1">0.1145 [0.0611, 0.1678]</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.0001</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.0001</td><td align="center" valign="top" rowspan="1" colspan="1">0.0874</td><td align="center" valign="top" rowspan="1" colspan="1">0.7362</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">dACC</td><td align="center" valign="top" rowspan="1" colspan="1">Theta: 4&#8211;8&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Center frequency</td><td align="center" valign="top" rowspan="1" colspan="1">98 (80:79)</td><td align="center" valign="top" rowspan="1" colspan="1">75 (61:65)</td><td align="center" valign="top" rowspan="1" colspan="1">0.1116 [&#8722;0.1847, 0.4078]</td><td align="center" valign="top" rowspan="1" colspan="1">0.4593</td><td align="center" valign="top" rowspan="1" colspan="1">0.6223</td><td align="center" valign="top" rowspan="1" colspan="1">0.0755</td><td align="center" valign="top" rowspan="1" colspan="1">0.5519</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">dACC</td><td align="center" valign="top" rowspan="1" colspan="1">Alpha: 8&#8211;12&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Bandwidth</td><td align="center" valign="top" rowspan="1" colspan="1">132 (118:113)</td><td align="center" valign="top" rowspan="1" colspan="1">84 (78:73)</td><td align="center" valign="top" rowspan="1" colspan="1">0.2534 [0.0179, 0.489]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0351</td><td align="center" valign="top" rowspan="1" colspan="1">0.1666</td><td align="center" valign="top" rowspan="1" colspan="1">0.0421</td><td align="center" valign="top" rowspan="1" colspan="1">0.1324</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">dACC</td><td align="center" valign="top" rowspan="1" colspan="1">Alpha: 8&#8211;12&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Power</td><td align="center" valign="top" rowspan="1" colspan="1">132 (118:113)</td><td align="center" valign="top" rowspan="1" colspan="1">84 (78:73)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.0108 [&#8722;0.0643, 0.0427]</td><td align="center" valign="top" rowspan="1" colspan="1">0.6925</td><td align="center" valign="top" rowspan="1" colspan="1">0.7246</td><td align="center" valign="top" rowspan="1" colspan="1">0.034</td><td align="center" valign="top" rowspan="1" colspan="1">0.4567</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">dACC</td><td align="center" valign="top" rowspan="1" colspan="1">Alpha: 8&#8211;12&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Center frequency</td><td align="center" valign="top" rowspan="1" colspan="1">132 (118:113)</td><td align="center" valign="top" rowspan="1" colspan="1">84 (78:73)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.368 [&#8722;0.6799, &#8722;0.0563]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0209</td><td align="center" valign="top" rowspan="1" colspan="1">0.1463</td><td align="center" valign="top" rowspan="1" colspan="1">0.041</td><td align="center" valign="top" rowspan="1" colspan="1">0.4003</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">dACC</td><td align="center" valign="top" rowspan="1" colspan="1">Beta: 12&#8211;30&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Bandwidth</td><td align="center" valign="top" rowspan="1" colspan="1">152 (151:152)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (97:96)</td><td align="center" valign="top" rowspan="1" colspan="1">0.2065 [&#8722;0.3009, 0.7138]</td><td align="center" valign="top" rowspan="1" colspan="1">0.4246</td><td align="center" valign="top" rowspan="1" colspan="1">0.5944</td><td align="center" valign="top" rowspan="1" colspan="1">0.0258</td><td align="center" valign="top" rowspan="1" colspan="1">0.2141</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">dACC</td><td align="center" valign="top" rowspan="1" colspan="1">Beta: 12&#8211;30&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Power</td><td align="center" valign="top" rowspan="1" colspan="1">152 (151:152)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (97:96)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0185 [&#8722;0.0213, 0.0582]</td><td align="center" valign="top" rowspan="1" colspan="1">0.3621</td><td align="center" valign="top" rowspan="1" colspan="1">0.5619</td><td align="center" valign="top" rowspan="1" colspan="1">0.1155</td><td align="center" valign="top" rowspan="1" colspan="1">0.7332</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">dACC</td><td align="center" valign="top" rowspan="1" colspan="1">Beta: 12&#8211;30&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Center frequency</td><td align="center" valign="top" rowspan="1" colspan="1">152 (151:152)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (97:96)</td><td align="center" valign="top" rowspan="1" colspan="1">0.3358 [&#8722;0.755, 1.4266]</td><td align="center" valign="top" rowspan="1" colspan="1">0.5456</td><td align="center" valign="top" rowspan="1" colspan="1">0.674</td><td align="center" valign="top" rowspan="1" colspan="1">0.0042</td><td align="center" valign="top" rowspan="1" colspan="1">0.4513</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">dACC</td><td align="center" valign="top" rowspan="1" colspan="1">Low&#8208;gamma: 30&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Bandwidth</td><td align="center" valign="top" rowspan="1" colspan="1">89 (61:62)</td><td align="center" valign="top" rowspan="1" colspan="1">60 (43:46)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.8126 [&#8722;1.5694, &#8722;0.0559]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0357</td><td align="center" valign="top" rowspan="1" colspan="1">0.1666</td><td align="center" valign="top" rowspan="1" colspan="1">0.09</td><td align="center" valign="top" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">dACC</td><td align="center" valign="top" rowspan="1" colspan="1">Low&#8208;gamma: 30&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Power</td><td align="center" valign="top" rowspan="1" colspan="1">89 (61:62)</td><td align="center" valign="top" rowspan="1" colspan="1">60 (43:46)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0349 [&#8722;0.0029, 0.0726]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0704</td><td align="center" valign="top" rowspan="1" colspan="1">0.2464</td><td align="center" valign="top" rowspan="1" colspan="1">0.0376</td><td align="center" valign="top" rowspan="1" colspan="1">0.5157</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">dACC</td><td align="center" valign="top" rowspan="1" colspan="1">Low&#8208;gamma: 30&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Center frequency</td><td align="center" valign="top" rowspan="1" colspan="1">89 (61:62)</td><td align="center" valign="top" rowspan="1" colspan="1">60 (43:46)</td><td align="center" valign="top" rowspan="1" colspan="1">0.8077 [&#8722;0.2398, 1.8588]</td><td align="center" valign="top" rowspan="1" colspan="1">0.1303</td><td align="center" valign="top" rowspan="1" colspan="1">0.342</td><td align="center" valign="top" rowspan="1" colspan="1">0.0314</td><td align="center" valign="top" rowspan="1" colspan="1">0.7475</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">dACC</td><td align="center" valign="top" rowspan="1" colspan="1">Aperiodic: 3&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Exponent</td><td align="center" valign="top" rowspan="1" colspan="1">152 (152:152)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (97:97)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0671 [&#8722;0.0129, 0.1472]</td><td align="center" valign="top" rowspan="1" colspan="1">0.1003</td><td align="center" valign="top" rowspan="1" colspan="1">0.3009</td><td align="center" valign="top" rowspan="1" colspan="1">0.0975</td><td align="center" valign="top" rowspan="1" colspan="1">0.6511</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">dACC</td><td align="center" valign="top" rowspan="1" colspan="1">Aperiodic: 3&#8211;40&#8201;Hz</td><td align="center" valign="top" rowspan="1" colspan="1">Offset</td><td align="center" valign="top" rowspan="1" colspan="1">152 (152:152)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (97:97)</td><td align="center" valign="top" rowspan="1" colspan="1">0.1318 [&#8722;0.1373, 0.401]</td><td align="center" valign="top" rowspan="1" colspan="1">0.3365</td><td align="center" valign="top" rowspan="1" colspan="1">0.5619</td><td align="center" valign="top" rowspan="1" colspan="1">0.0056</td><td align="center" valign="top" rowspan="1" colspan="1">0.4318</td></tr></tbody></table><table-wrap-foot id="ejn70263-ntgp-0003"><fn id="ejn70263-note-0007"><p>
<bold>
<italic toggle="yes">Note:</italic>
</bold>
<italic toggle="yes">Region</italic> refers to either the scalp&#8208;level analysis or specific regions of interest (ROIs): left anterior insula (L&#8208;INS), right anterior insula (R&#8208;INS), and dorsal anterior cingulate cortex (dACC). <italic toggle="yes">Frequency Band</italic> specifies the spectral range analyzed. <italic toggle="yes">FOOOF parameter</italic> refers to the component extracted using the FOOOF algorithm: power, center frequency, bandwidth (periodic), or exponent/offset (aperiodic). <italic toggle="yes">N HC (EC:EO)</italic> and <italic toggle="yes">N SSD (EC:EO)</italic> represent the number of unique participants per group, with the number of recordings from the eyes closed (EC) and eyes open (EO) conditions in parentheses. <italic toggle="yes">Estimates [CI95%: LL, UL]</italic> refer to the model estimate and the lower (LL) and upper (UL) bounds of the 95% confidence interval. <italic toggle="yes">P</italic> indicates the uncorrected <italic toggle="yes">p</italic>&#8208;value; <italic toggle="yes">q</italic> (P<sub>FDR</sub>) indicates the <italic toggle="yes">p</italic>&#8208;value after false discovery rate correction. <italic toggle="yes">R</italic>
<sup>2</sup>
<italic toggle="yes">(marginal)</italic> reflects variance explained by fixed effects; <italic toggle="yes">R</italic>
<sup>2</sup>
<italic toggle="yes">(conditional)</italic> includes both fixed and random effects.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="ejn70263-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Global scalp&#8208;level differences on aperiodic component. (A) Aperiodic components of the power spectrum (bold) averaged across individuals within each diagnostic group. (B) Comparison between HC and SSD for aperiodic exponent and offset shows that these two groups are significantly increased in the SSD group after controlling for age and sex (<italic toggle="no">q</italic>&#8201;&gt;&#8201;0.05). HC&#8201;=&#8201;healthy controls. SSD&#8201;=&#8201;schizophrenia spectrum disorder. Scalp&#8208;level: averaged activity across electrodes. &#8595;&#8593;: show an increase or decrease in the SSD group. Significance level after FDR correction: *&lt;&#8201;.05, **&lt;&#8201;.01, ***&lt;&#8201;.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="EJN-62-0-g003.jpg"/></fig><p>Regarding covariates, we found increased theta power (<italic toggle="yes">b</italic>&#8201;=&#8201;0.075 log (&#956;V<sup>2</sup>), 95% CI [0.036, 0.114]; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">q</italic>&#8201;&lt;&#8201;0.001), as well as a higher exponent (<italic toggle="yes">b</italic>&#8201;=&#8201;0.06&#8201;a.u., 95% CI [0.013, 0.106]; <italic toggle="yes">p</italic>&#8201;=&#8201;0.012, <italic toggle="yes">q</italic>&#8201;=&#8201;0.028), and offset (<italic toggle="yes">b</italic>&#8201;=&#8201;0.147 log (&#956;V<sup>2</sup>/Hz), 95% CI [0.101, 0.193]; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">q</italic>&#8201;&lt;&#8201;0.001) in the eyes closed condition compared to eyes open. Advancing age was associated with higher theta power (<italic toggle="yes">b</italic>&#8201;=&#8201;0.004 log (&#956;V<sup>2</sup>), 95% CI [0.001, 0.007]; <italic toggle="yes">p</italic>&#8201;=&#8201;0.006, <italic toggle="yes">q</italic>&#8201;=&#8201;0.020), and decreased alpha center frequency peak (<italic toggle="yes">b</italic>&#8201;=&#8201;&#8722;0.01&#8201;Hz, 95% CI [&#8722;0.017, &#8722;0.002]; <italic toggle="yes">p</italic>&#8201;=&#8201;0.010, <italic toggle="yes">q</italic>&#8201;=&#8201;0.027). No interactions were found between group and condition for any of the periodic or aperiodic measures (all <italic toggle="yes">q</italic>&#8201;&gt;&#8201;0.05).</p></sec><sec id="ejn70263-sec-0012"><label>3.3</label><title>Periodic and Aperiodic Effects on Source Localized Activity</title><p>Significant differences in periodic activity were present across all regions of interest. The SSD group had higher theta power in the L&#8208;INS (<italic toggle="yes">b</italic>&#8201;=&#8201;0.103 log (&#956;V<sup>2</sup>), 95% CI [0.047&#8211;0.16]; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">q</italic>&#8201;=&#8201;0.008), R&#8208;INS (<italic toggle="yes">b</italic>&#8201;=&#8201;0.101 log (&#956;V<sup>2</sup>), 95% CI [0.035 to 0.168]; <italic toggle="yes">p</italic>&#8201;=&#8201;0.003, <italic toggle="yes">q</italic>&#8201;=&#8201;0.039), and dACC (<italic toggle="yes">b</italic>&#8201;=&#8201;0.114 log (&#956;V<sup>2</sup>), 95% CI [0.061&#8211;0.168]; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <italic toggle="yes">q</italic>&#8201;&lt;&#8201;0.001) compared to HC. In addition to theta power, the SSD group showed a slower alpha center frequency only in L&#8208;INS (<italic toggle="yes">b</italic>&#8201;=&#8201;&#8722;0.43&#8201;Hz, 95% CI [&#8722;0.719 to &#8722;0.141]; <italic toggle="yes">p</italic>&#8201;=&#8201;0.004, <italic toggle="yes">q</italic>&#8201;=&#8201;0.039) (see Figure&#160;<xref rid="ejn70263-fig-0001" ref-type="fig">1</xref> and Table&#160;<xref rid="ejn70263-tbl-0002" ref-type="table">2</xref>). No group differences were observed for either aperiodic exponent or offset in these regions (all <italic toggle="yes">q</italic>&#8201;&gt;&#8201;0.05). Among covariates, advancing age was associated with a lower alpha center frequency in L&#8208;INS (<italic toggle="yes">b</italic>&#8201;=&#8201;&#8722;0.013&#8201;Hz, 95% CI [&#8722;0.023 to &#8722;0.004]; <italic toggle="yes">p</italic>&#8201;=&#8201;0.008, <italic toggle="yes">q</italic>&#8201;=&#8201;0.030). Similarly to scalp level, no interactions were found between group and condition for any of the periodic or aperiodic measures at source (all <italic toggle="yes">q</italic>&#8201;&gt;&#8201;0.05).</p></sec><sec id="ejn70263-sec-0013"><label>3.4</label><title>Medication Effects on Periodic and Aperiodic Activity</title><p>To examine whether medications affect the altered EEG components in SSD, we utilized two different Linear Mixed Models using different predictors: (i) chlorpromazine equivalent (CPZeq; continuous) and (ii) benzodiazepine use (categorical: yes/no). Higher CPZeq dosage is associated with a higher exponent (<italic toggle="yes">b</italic>&#8201;=&#8201;0.128&#8201;a.u., 95% CI [0.041&#8211;0.216]; <italic toggle="yes">p</italic>&#8201;=&#8201;0.005, <italic toggle="yes">q</italic>&#8201;=&#8201;0.019) and a higher offset (<italic toggle="yes">b</italic>&#8201;=&#8201;0.172 log (&#956;V<sup>2</sup>/Hz), 95% CI [0.047&#8211;0.297]; <italic toggle="yes">p</italic>&#8201;=&#8201;0.007, <italic toggle="yes">q</italic>&#8201;=&#8201;0.019). No significant differences were found between benzodiazepine users and non&#8208;users at scalp level and source localized activity (all <italic toggle="yes">q</italic>&#8201;&gt;&#8201;0.05).</p></sec><sec id="ejn70263-sec-0014"><label>3.5</label><title>Follow&#8208;Up Analysis: Associations of Altered EEG Features and Cognitive or Clinical Symptoms in SSD</title><p>After identifying the main altered periodic and aperiodic components in SSD, we further examined whether these components predict cognition and symptom severity in this group using multiple linear regressions. This relationship was investigated separately for the eyes closed and eyes open conditions. Given that increased CPZeq was associated with increased aperiodic exponent and offset, we included CPZeq as an additional covariate alongside age and sex.</p><p>Across both conditions, only two associations survived false discovery rate (FDR) correction. Specifically, increased theta power in the dACC during the eyes&#8208;open condition was negatively associated with two cognitive outcomes: BACS composite score (<italic toggle="yes">b</italic>&#8201;=&#8201;&#8722;0.401, 95% CI [&#8722;0.642, &#8722;0.160], <italic toggle="yes">p</italic>&#8201;=&#8201;0.002, <italic toggle="yes">q</italic>&#8201;=&#8201;0.035) and digit sequencing (<italic toggle="yes">b</italic>&#8201;=&#8201;&#8722;0.429, 95% CI [&#8722;0.680, &#8722;0.178], <italic toggle="yes">p</italic>&#8201;=&#8201;0.001, <italic toggle="yes">q</italic>&#8201;=&#8201;0.035, <italic toggle="yes">N</italic>&#8201;=&#8201;58). These findings suggest that enhanced frontal theta activity during wakeful rest may reflect impairments in cognitive control or working memory among SSD patients (see Figure&#160;<xref rid="ejn70263-fig-0003" ref-type="fig">3</xref>).</p><fig position="float" fig-type="FIGURE" id="ejn70263-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Heatmap of standardized regression estimates depicting the associations between altered EEG components in SSD (predictors) and cognitive performance (BACS) and symptom severity (PANSS) outcomes under eyes&#8208;closed and eyes&#8208;open conditions. All predictor and outcome variables were z&#8208;scored for visualization purposes (refer to the main text for unstandardized estimates). Bolded values indicate results that survived FDR correction. SSD&#8201;=&#8201;Schizophrenia Spectrum Disorder; PW&#8201;=&#8201;Power; CF&#8201;=&#8201;Center Frequency; AP&#8201;=&#8201;Aperiodic. Significance level of the uncorrected <italic toggle="no">p</italic>: * &lt;&#8201;.05, ** &lt;&#8201;.01, *** &lt;&#8201;.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="EJN-62-0-g002.jpg"/></fig><p>In addition, we observed several uncorrected but potentially meaningful associations (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, <italic toggle="yes">q</italic>&#8201;&gt;&#8201;0.05) between EEG features and cognitive or clinical variables. During the eyes&#8208;closed condition, a higher aperiodic exponent at the scalp level was negatively associated with PANSS positive symptoms (<italic toggle="yes">b</italic>&#8201;=&#8201;&#8722;2.474, 95% CI [&#8722;4.47, &#8722;0.477], <italic toggle="yes">p</italic>&#8201;=&#8201;0.016, <italic toggle="yes">q</italic>&#8201;=&#8201;0.536, <italic toggle="yes">N</italic>&#8201;=&#8201;93), as was aperiodic offset (<italic toggle="yes">b</italic>&#8201;=&#8201;&#8722;1.635, 95% CI [&#8722;3.107, &#8722;0.164], <italic toggle="yes">p</italic>&#8201;=&#8201;0.030, <italic toggle="yes">q</italic>&#8201;=&#8201;0.536, <italic toggle="yes">N</italic>&#8201;=&#8201;93). These findings may indicate that stronger aperiodic activity, reflecting greater inhibitory tone or reduced E/I ratio, is linked to a less severe expression of positive symptoms.</p><p>In terms of cognition, alpha center frequency at the scalp during eyes closed was positively associated with token motor performance (<italic toggle="yes">b</italic>&#8201;=&#8201;0.238, 95% CI [0.024, 0.452], <italic toggle="yes">p</italic>&#8201;=&#8201;0.030, <italic toggle="yes">q</italic>&#8201;=&#8201;0.249, <italic toggle="yes">N</italic>&#8201;=&#8201;88) and verbal fluency (<italic toggle="yes">b</italic>&#8201;=&#8201;0.253, 95% CI [0.039, 0.467], <italic toggle="yes">p</italic>&#8201;=&#8201;0.021, <italic toggle="yes">q</italic>&#8201;=&#8201;0.249, <italic toggle="yes">N</italic>&#8201;=&#8201;88). During the eyes&#8208;open condition, alpha CF remained positively associated with composite score (<italic toggle="yes">b</italic>&#8201;=&#8201;0.228, 95% CI [0.01, 0.446], <italic toggle="yes">p</italic>&#8201;=&#8201;0.040, <italic toggle="yes">q</italic>&#8201;=&#8201;0.200, <italic toggle="yes">N</italic>&#8201;=&#8201;82), verbal fluency (<italic toggle="yes">b</italic>&#8201;=&#8201;0.233, 95% CI [0.012, 0.454], <italic toggle="yes">p</italic>&#8201;=&#8201;0.039, <italic toggle="yes">q</italic>&#8201;=&#8201;0.200, <italic toggle="yes">N</italic>&#8201;=&#8201;82), and Tower of London (<italic toggle="yes">b</italic>&#8201;=&#8201;0.277, 95% CI [0.065, 0.488], <italic toggle="yes">p</italic>&#8201;=&#8201;0.011, <italic toggle="yes">q</italic>&#8201;=&#8201;0.099, <italic toggle="yes">N</italic>&#8201;=&#8201;80), suggesting that faster alpha oscillations may support better cognitive functioning in SSD. Additional uncorrected relationships involving source&#8208;level theta power and other cognitive measures are visualized in Figure&#160;<xref rid="ejn70263-fig-0003" ref-type="fig">3</xref> and may warrant further investigation in future studies.</p></sec></sec><sec sec-type="discussion" id="ejn70263-sec-0015"><label>4</label><title>Discussion</title><p>This study reveals significant alterations in both periodic and aperiodic EEG activity in individuals with SSD. At scalp level, the SSD group showed a pronounced increase in theta power, alongside a reduction in alpha center frequency. Additionally, averaged scalp&#8208;level activity showed elevated aperiodic exponent and offset in SSD compared to HC. Furthermore, frontoinsular regions showed a consistent increase of theta power in SSD, as well as decreased alpha center frequency at L&#8208;INS, with no differences in aperiodic activity. In terms of the relationship between altered periodic and aperiodic activity across scalp and frontoinsular regions with cognitive and symptomatic measurements, we only found a significant relationship between the periodic power at dACC during the eyes&#8208;open condition with composite cognition in general and working memory in particular.</p><p>The pronounced increase in theta power in SSD found in this study aligns with the substantial body of research reporting elevated low&#8208;frequency oscillations in this population (Hirano and Uhlhaas&#160;<xref rid="ejn70263-bib-0027" ref-type="bibr">2021</xref>; Newson and Thiagarajan&#160;<xref rid="ejn70263-bib-0044" ref-type="bibr">2018</xref>). Beyond global increases, disturbances of theta power and theta&#8208;band connectivity are particularly reported over frontal regions in SSD (Boutros et&#160;al.&#160;<xref rid="ejn70263-bib-0010" ref-type="bibr">2008</xref>; Kim et&#160;al.&#160;<xref rid="ejn70263-bib-0033" ref-type="bibr">2020</xref>; Shreekantiah Umesh et&#160;al.&#160;<xref rid="ejn70263-bib-0060" ref-type="bibr">2016</xref>). Consistent with these findings, we found elevated theta power to be extended in three frontoinsular regions (dACC, R&#8208;INS, and L&#8208;INS), with the most robust association observed between increased theta power in the dACC and worse working memory, as measured by the digit sequencing task, across both eyes&#8208;closed and eyes&#8208;open conditions, though only the latter survived correction for multiple comparisons. Moreover, elevated dACC theta power was also linked to global cognitive impairment, marked by a lower BACS composite score. Theta power, specifically within the ACC, is considered a key mechanism supporting cognitive control and efficient neural communication of relevant information, which is essential for both working memory and global cognition (Lett et&#160;al.&#160;<xref rid="ejn70263-bib-0035" ref-type="bibr">2014</xref>; McLoughlin et&#160;al.&#160;<xref rid="ejn70263-bib-0039" ref-type="bibr">2022</xref>). Our findings suggest an abnormal increase in dACC theta power during resting&#8208;state EEG may serve as a potential cognitive marker, particularly when spectral power is separated from underlying aperiodic activity.</p><p>In addition to theta power alterations, we did not observe any other differences in periodic power across other frequency bands (alpha, beta, or low&#8208;gamma power). Unlike theta power, which frequently shows elevations in SSD, findings regarding gamma activity are more heterogeneous. Some studies suggest that gamma amplitude measured at resting state decreases as the disorder progresses to chronic stages, proposing it as a potential marker of disease progression (Grent&#8208;'t&#8208;Jong et&#160;al.&#160;<xref rid="ejn70263-bib-0023" ref-type="bibr">2018</xref>), while others report increased gamma power (Baradits et&#160;al.&#160;<xref rid="ejn70263-bib-0006" ref-type="bibr">2019</xref>), or no significant differences at all (Hirano et&#160;al.&#160;<xref rid="ejn70263-bib-0026" ref-type="bibr">2015</xref>). Disturbances in the gamma frequency band are largely attributed to the E/I mechanism, specifically due to disruptions in GABAergic activity. GABAergic interneurons are critical for generating and synchronizing gamma oscillations, as they provide inhibitory control over pyramidal neurons and regulate the timing and synchronization needed for gamma activity (Buzs&#225;ki and Wang&#160;<xref rid="ejn70263-bib-0011" ref-type="bibr">2012</xref>; Shin et&#160;al.&#160;<xref rid="ejn70263-bib-0059" ref-type="bibr">2011</xref>). Dysfunction in GABAergic pathways can disrupt this balance, leading to disorganized and dysregulated gamma oscillations, potentially indicating changes in the E/I balance (Ahmad et&#160;al.&#160;<xref rid="ejn70263-bib-0001" ref-type="bibr">2022</xref>).</p><p>In contrast to all previous studies which did not consider the removal of aperiodic signal from the spectral power, this study was specifically focused on aperiodic&#8208;adjusted low&#8208;gamma power. However, across all frequency bands, gamma power estimates were less reliable, where less than half of the participants showed activity in this range. This is attributed to the small peaks outside the alpha and beta frequency bands that do not pass the algorithm threshold for being detected as true oscillatory activity (Donoghue et&#160;al.&#160;<xref rid="ejn70263-bib-0016" ref-type="bibr">2020</xref>). Taken together, these findings suggest that while gamma abnormalities may reflect underlying disruptions in E/I balance, their inconsistent expression (especially after adjusting for aperiodic components) highlights the need for more refined methodological approaches and caution when interpreting gamma power as a robust biomarker in SSD.</p><p>Another marker often reported in the SSD population, also replicated by our findings, is the decrease of alpha peak frequency (Murphy and &#214;ng&#252;r&#160;<xref rid="ejn70263-bib-0043" ref-type="bibr">2019</xref>; Ramsay et&#160;al.&#160;<xref rid="ejn70263-bib-0055" ref-type="bibr">2021</xref>; Yeum and Kang&#160;<xref rid="ejn70263-bib-0070" ref-type="bibr">2018</xref>). This marker is closely related to global cognition, with disturbances in visual processing being a major contributor (Ramsay et&#160;al.&#160;<xref rid="ejn70263-bib-0055" ref-type="bibr">2021</xref>). In our SSD sample, we observed uncorrected significant associations between slower alpha center frequency and impaired performance in motor tasks, executive functioning, verbal fluency, and overall cognitive performance as captured by global scalp activity. While these findings did not survive correction for multiple comparisons and should be interpreted with caution, they align with previous literature suggesting that alpha slowing might reflect cognitive dysfunction across diagnostic categories. Alpha center frequency is known to be flexible and responsive to stimulation or cognitive load, yet also demonstrates strong test&#8211;retest reliability and trait&#8208;like stability at rest (Ahn et&#160;al.&#160;<xref rid="ejn70263-bib-0002" ref-type="bibr">2019</xref>; Grandy et&#160;al.&#160;<xref rid="ejn70263-bib-0022" ref-type="bibr">2013</xref>; Smit et&#160;al.&#160;<xref rid="ejn70263-bib-0061" ref-type="bibr">2006</xref>). Rather than being a disorder&#8208;specific marker, slowing of alpha center frequency is considered to be a transdiagnostic indicator of cognitive impairment, as it is also observed in cognition&#8208;affected conditions such as dementia, Alzheimer's disease, autism spectrum disorder, and ADHD (Dickinson et&#160;al.&#160;<xref rid="ejn70263-bib-0013" ref-type="bibr">2017</xref>; Puttaert et&#160;al.&#160;<xref rid="ejn70263-bib-0050" ref-type="bibr">2021</xref>; Vollebregt et&#160;al.&#160;<xref rid="ejn70263-bib-0065" ref-type="bibr">2015</xref>). Additionally, age is another independent factor influencing shifts in the alpha center frequency, which, as also shown in this study, decreases with advancing age irrespective of the diagnostic group (Park et&#160;al.&#160;<xref rid="ejn70263-bib-0045" ref-type="bibr">2024</xref>; Scally et&#160;al.&#160;<xref rid="ejn70263-bib-0057" ref-type="bibr">2018</xref>).</p><p>Evidence regarding aperiodic EEG features in schizophrenia remains scarce and inconsistent, in both findings and employed methodology. Among studies conducted in people with SSDs, five studies have reported no difference (Boudewyn et&#160;al.&#160;<xref rid="ejn70263-bib-0009" ref-type="bibr">2025</xref>; Earl et&#160;al.&#160;<xref rid="ejn70263-bib-0017" ref-type="bibr">2024</xref>; Jacob et&#160;al.&#160;<xref rid="ejn70263-bib-0028" ref-type="bibr">2023</xref>; Racz, Farkas, Stylianou, et&#160;al.&#160;<xref rid="ejn70263-bib-0054" ref-type="bibr">2021</xref>; Racz, Farkas, Becske, et&#160;al.&#160;<xref rid="ejn70263-bib-0053" ref-type="bibr">2025</xref>), one reported a decrease (Spencer et&#160;al.&#160;<xref rid="ejn70263-bib-0063" ref-type="bibr">2023</xref>), and two reported an increase in aperiodic exponent in people with SSDs compared to HC samples (Molina et&#160;al.&#160;<xref rid="ejn70263-bib-0042" ref-type="bibr">2020</xref>; Peterson et&#160;al.&#160;<xref rid="ejn70263-bib-0046" ref-type="bibr">2023</xref>). Alterations in aperiodic activity, especially in the aperiodic exponent, are thought to reflect the E/I dynamics of the brain, as demonstrated in both in&#160;vivo and in silico studies, where a steeper exponent indicates greater inhibition, while a flatter exponent suggests increased overall excitation (Gao et&#160;al.&#160;<xref rid="ejn70263-bib-0018" ref-type="bibr">2017</xref>; Wiest et&#160;al.&#160;<xref rid="ejn70263-bib-0068" ref-type="bibr">2023</xref>). Supporting this, inhibitory agents like propofol steepen the exponent, whereas ketamine's excitatory net effects flatten it (Waschke et&#160;al.&#160;<xref rid="ejn70263-bib-0066" ref-type="bibr">2021</xref>).</p><p>Following these studies, the increase in aperiodic exponent observed in our SSD cohort may reflect an overall shift toward inhibitory activity. Moreover, this effect appeared to be modulated by medication dosage, as higher CPZeq levels were associated with steeper exponents. Within the SSD group, we observed uncorrected negative associations (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, but not surviving FDR correction) of both exponent and offset with positive symptoms. The same uncorrected association remained even when controlling for medication dosage, suggesting that medication may influence but does not fully explain the observed patterns. This may indicate that a steeper exponent reflects a compensatory mechanism in SSD, possibly influenced by, but not solely dependent on, medication effects. Increasing inhibitory activity in major depression patients via electroconvulsive therapy led to a steeper aperiodic exponent and reduced symptom severity (Smith et&#160;al.&#160;<xref rid="ejn70263-bib-0062" ref-type="bibr">2023</xref>), suggesting that changes in inhibitory tone may track symptom severity in disorders marked by E/I imbalances. Nonetheless, given the lack of significance after multiple comparison correction, these findings should be regarded as preliminary. Further research with larger samples and longitudinal designs is needed to determine whether aperiodic EEG features serve as reliable markers of excitation/inhibition balance and clinical symptoms in SSD, and whether these relationships are specific to certain diagnostic subgroups within the broader SSD spectrum.</p><sec id="ejn70263-sec-0016"><label>4.1</label><title>Limitations</title><p>Although the signal&#8208;to&#8208;noise ratio of our EEG data was satisfactory, we further tried to enhance our source localization accuracy by providing individual anatomical head models, which are known to improve spatial precision (Michel and Brunet&#160;<xref rid="ejn70263-bib-0041" ref-type="bibr">2019</xref>), and by utilizing a beamforming approach, which enables more accurate source estimation for deeper regions (Backus et&#160;al.&#160;<xref rid="ejn70263-bib-0005" ref-type="bibr">2016</xref>; Quraan et&#160;al.&#160;<xref rid="ejn70263-bib-0051" ref-type="bibr">2011</xref>; Westner et&#160;al.&#160;<xref rid="ejn70263-bib-0067" ref-type="bibr">2022</xref>). However, the use of a 32&#8208;channel EEG system may still limit the spatial precision of source&#8208;localized activity, particularly in deeper regions such as the anterior insula (Asadzadeh et&#160;al.&#160;<xref rid="ejn70263-bib-0004" ref-type="bibr">2020</xref>). Therefore, our source&#8208;level results should be interpreted with caution. We encourage future studies to use high&#8208;density M/EEG to more accurately investigate frontoinsular activity in SSD and to test whether similar source&#8208;level profiles, as well as relationships with cognitive and clinical data, can be replicated.</p><p>At the scalp level, we averaged EEG features across all electrodes (if more than 50% of electrodes showed detectable activity for a given participant) to derive global indices of periodic and aperiodic activity. While this approach provides a summary measure, it inherently limits spatial resolution and prevents region&#8208;specific interpretations. Although the aperiodic activity was relatively uniformly distributed across the scalp (see Figure&#160;<xref rid="ejn70263-supitem-0001" ref-type="supplementary-material">S3</xref>), electrode&#8208;wise variability may still carry topographical relevance that is obscured by averaging.</p><p>Another limitation to be considered is that although our sample size was relatively large, our SSD group represents only a pool of the disease's phenotypic spectrum, reflecting shared mechanisms across psychotic disorders rather than SSD&#8208;specific disease dynamics. Furthermore, while we interpreted some of our results in the framework of E/I imbalances, we acknowledge that the absence of direct neurobiological measures, such as neurotransmitter concentrations or other neurochemical indices, limits the strength of these conclusions. In addition to that, the characterization of frontoinsular regions in this study followed a hypothesis&#8208;driven approach; however, future studies with higher spatial resolution and statistical power should incorporate control anatomical regions in order to capture the complexity of functional alterations in SSD. Future large&#8208;scale multimodal studies integrating M/EEG with other neuroimaging approaches will be crucial to further our understanding of these results and refine their clinical implications.</p></sec></sec><sec sec-type="conclusions" id="ejn70263-sec-0017"><label>5</label><title>Conclusion</title><p>In summary, the present study provides evidence for widespread alterations in both periodic and aperiodic resting&#8208;state EEG activity in individuals with SSD. These alterations are characterized by distinct regional and spectral patterns and show differential associations with cognitive impairment and symptom severity. Periodic activity, particularly theta power, was significantly elevated in SSD compared to HC both globally and across the three frontoinsular regions. Notably, only increased theta power in the dACC was significantly associated with worse overall cognition and lower working memory. In contrast, alpha center frequency was reduced in SSD at global and L&#8208;INS levels, but did not show a significant relationship with cognitive or symptomatic measures. For the aperiodic component, both exponent and offset were higher in SSD at the global level, and their increase was associated with higher CPZeq levels. However, no relationships with cognition or symptom severity survived correction for multiple comparisons. These findings underscore the value of separating periodic and aperiodic components in EEG analyses to better understand the neurophysiological mechanisms underlying SSD. While preliminary, the aperiodic exponent may represent a promising marker of altered excitation&#8211;inhibition dynamics, potentially modulated by antipsychotic medication, and should be explored further in larger, longitudinal studies.</p></sec><sec id="ejn70263-sec-0019"><title>Author Contributions</title><p>
<bold>Genc Hasanaj:</bold> conceptualization, data curation, formal analysis, methodology, visualization, writing &#8211; original draft, writing &#8211; review and editing. <bold>Iris Jaeger:</bold> conceptualization, data curation, methodology, writing &#8211; original draft, writing &#8211; review and editing. <bold>Berkhan Karsli:</bold> formal analysis, methodology, visualization, writing &#8211; original draft, writing &#8211; review and editing. <bold>Enrico Schulz:</bold> methodology, writing &#8211; review and editing. <bold>Emanuel Boudriot:</bold> writing &#8211; review and editing. <bold>Lukas Roell:</bold> writing &#8211; review and editing. <bold>Maxim Korman:</bold> data curation, writing &#8211; review and editing. <bold>Marcel S. Kallweit:</bold> data curation, writing &#8211; review and editing. <bold>Fanny Dengl:</bold> data curation, writing &#8211; review and editing. <bold>Nicole Klimas:</bold> data curation, writing &#8211; review and editing. <bold>Kristin Fischer:</bold> writing &#8211; review and editing. <bold>Katharina Hanken:</bold> data curation, writing &#8211; review and editing. <bold>Verena Meisinger:</bold> data curation, writing &#8211; review and editing. <bold>Joanna Moussiopoulou:</bold> data curation, project administration, writing &#8211; review and editing. <bold>Vladislav Yakimov:</bold> data curation, project administration, writing &#8211; review and editing. <bold>Susanne Karch:</bold> writing &#8211; review and editing. <bold>Alkomiet Hasan:</bold> writing &#8211; review and editing. <bold>Andrea Schmitt:</bold> project administration, resources, writing &#8211; review and editing. <bold>Peter Falkai:</bold> resources, writing &#8211; review and editing. <bold>CDP&#8208;Working Group:</bold> writing &#8211; review and editing. <bold>Oliver Pogarell:</bold> writing &#8211; review and editing. <bold>Florian J. Raabe:</bold> funding acquisition, project administration, resources, writing &#8211; review and editing. <bold>Elias Wagner:</bold> funding acquisition, project administration, resources, writing &#8211; review and editing. <bold>Matin Mortazavi:</bold> conceptualization, formal analysis, investigation, methodology, writing &#8211; original draft, writing &#8211; review and editing. <bold>Daniel Keeser:</bold> funding acquisition, investigation, methodology, project administration, resources, writing &#8211; original draft, writing &#8211; review and editing.</p></sec><sec sec-type="COI-statement" id="ejn70261-sec-0122"><title>Conflicts of Interest</title><p>E.W. was invited to advisory boards from Recordati, Teva, and Boehringer Ingelheim; A.H. was a member of advisory boards of Boehringer Ingelheim, Lundbeck, Janssen, Otsuka, Rovi, and Recordati and received paid speakership by these companies as well as by AbbVie and Advanz. He is the editor of the German schizophrenia guideline; P.F. received paid speakership by Boehringer&#8208;Ingelheim, Janssen, Otsuka, Lundbeck, Recordati, and Richter and was a member of advisory boards of these companies. All other co&#8208;authors report no conflict of interest.</p></sec><sec sec-type="peer-review" id="ejn70263-sec-0021"><title>Peer Review</title><p>The peer review history for this article is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/ejn.70263" ext-link-type="uri">https://www.webofscience.com/api/gateway/wos/peer&#8208;review/10.1111/ejn.70263</ext-link>.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="ejn70263-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S1:</bold> Topographic distribution of periodic activity percentage across theta, alpha, beta, and low&#8208;gamma bands, grouped by resting&#8208;state condition (eyes open vs. eyes closed) and diagnostic status (healthy controls vs. schizophrenia spectrum disorders). Black dots show the position of the electrodes. Notably, periodic activity is most pronounced in the alpha and beta bands across both conditions and groups.</p><p>
<bold>Figure S2:</bold> Barplot showing distribution of periodic EEG activity across three source&#8208;localized regions (L&#8208;INS, R&#8208;INS, dACC) across theta, alpha, beta, and low&#8208;gamma frequency bands, grouped by resting&#8208;state condition (eyes open vs. eyes closed) and diagnostic status (healthy controls vs. schizophrenia spectrum disorders). L&#8208;INS: left anterior insula. R&#8208;INS: right anterior insula. dACC: dorsal anterior cingulate cortex.</p><p>
<bold>Figure S3:</bold> Topographic distribution of the aperiodic activity (exponent and offset parameters) shown across electrodes for each condition (eyes open vs. eyes closed) and diagnostic group (Healthy Controls vs. Schizophrenia Spectrum Disorder) Black dots show the electrode&#8208;placement.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="EJN-62-0-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ejn70263-sec-0018"><title>Acknowledgments</title><p>The procurement of the MRI scanner was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) grant for major research (DFG, INST 86/1739&#8208;1 FUGG). This research was supported by BMBF with the EraNet project GDNF UpReg (01EW2206) to PF, AS, VY, and GH. The study is funded by the EU HORIZON&#8208;INFRA&#8208;2024&#8208;TECH&#8208;01&#8208;04 project DTRIP4H 101188432 to PF, AS, and FR. VY was supported by the Residency/PhD track of the International Max Planck Research School for Translational Psychiatry (IMPRS&#8208;TP). FJR was supported by the Munich Clinician Scientist Program (MCSP) of the Faculty of Medicine, LMU Munich, Munich, Germany (F&#246;FoLe 009/2019), and FJR received funding from the Lisa Oehler&#8208;Stiftung (2022&#8211;2024) and the Pels&#8208;Alzheimer&#8208;Stiftung (2024&#8211;2025). VY is supported by the Faculty of Medicine at LMU Munich (F&#246;FoLe Reg.&#8208;Nr. 1226/2024). The study was endorsed by the Federal Ministry of Education and Research (Bundesministerium f&#252;r Bildung und Forschung [BMBF]) within the initial phase of the German Center for Mental Health (DZPG) (grant: 01EE2303A, 01EE2303F to PF). The study was funded by the supplement to BMBF funding for the German Centre for Mental Health (DZPG) by the Bavarian State Ministry for Science and the Arts with the grant for the research project &#8220;Improving Infrastructures for DZPG and NAKO Cohorts&#8221; to PF, DK, and BK. This work was also supported by the clinical trials infrastructure of the DZPG [German Center for Mental Health, Munich, Augsburg] [FKZ: 01EE2303C to Alkomiet Hasan]. Open Access funding enabled and organized by Projekt DEAL.</p></ack><sec sec-type="data-availability" id="ejn70263-sec-0124"><title>Data Availability Statement</title><p>Data and code used for analysis in this paper will be shared by the lead contact upon request.</p></sec><ref-list content-type="cited-references" id="ejn70263-bibl-0001"><title>References</title><ref id="ejn70263-bib-0001"><mixed-citation publication-type="journal" id="ejn70263-cit-0001"><string-name name-style="western"><surname>Ahmad</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Ellis</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Leech</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>From Mechanisms to Markers: Novel Noninvasive EEG Proxy Markers of the Neural Excitation and Inhibition System in Humans</article-title>.&#8221; <source>Translational Psychiatry</source><volume>12</volume>, no. <issue>1</issue>: <fpage>1</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1038/s41398-022-02218-z</pub-id>.<pub-id pub-id-type="pmid">36344497</pub-id><pub-id pub-id-type="pmcid">PMC9640647</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0002"><mixed-citation publication-type="journal" id="ejn70263-cit-0002"><string-name name-style="western"><surname>Ahn</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Mellin</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Alagapan</surname></string-name>, et&#160;al. <year>2019</year>. &#8220;<article-title>Targeting Reduced Neural Oscillations in Patients With Schizophrenia by Transcranial Alternating Current Stimulation</article-title>.&#8221; <source>NeuroImage</source><volume>186</volume>: <fpage>126</fpage>&#8211;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2018.10.056</pub-id>.<pub-id pub-id-type="pmid">30367952</pub-id><pub-id pub-id-type="pmcid">PMC6338501</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0003"><mixed-citation publication-type="journal" id="ejn70263-cit-0003"><string-name name-style="western"><surname>Andreasen</surname>, <given-names>N. C.</given-names></string-name>, <string-name name-style="western"><given-names>W. T.</given-names><surname>Carpenter</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Kane</surname></string-name>, <string-name name-style="western"><given-names>R. A.</given-names><surname>Lasser</surname></string-name>, <string-name name-style="western"><given-names>S. R.</given-names><surname>Marder</surname></string-name>, and <string-name name-style="western"><given-names>D. R.</given-names><surname>Weinberger</surname></string-name>. <year>2005</year>. &#8220;<article-title>Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus</article-title>.&#8221; <source>American Journal of Psychiatry</source><volume>162</volume>, no. <issue>3</issue>: <fpage>441</fpage>&#8211;<lpage>449</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.162.3.441</pub-id>.<pub-id pub-id-type="pmid">15741458</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0004"><mixed-citation publication-type="journal" id="ejn70263-cit-0004"><string-name name-style="western"><surname>Asadzadeh</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Yousefi Rezaii</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Beheshti</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Delpak</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Meshgini</surname></string-name>. <year>2020</year>. &#8220;<article-title>A Systematic Review of EEG Source Localization Techniques and Their Applications on Diagnosis of Brain Abnormalities</article-title>.&#8221; <source>Journal of Neuroscience Methods</source><volume>339</volume>: <elocation-id>108740</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.jneumeth.2020.108740</pub-id>.<pub-id pub-id-type="pmid">32353472</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0005"><mixed-citation publication-type="journal" id="ejn70263-cit-0005"><string-name name-style="western"><surname>Backus</surname>, <given-names>A. R.</given-names></string-name>, <string-name name-style="western"><given-names>J.&#8208;M.</given-names><surname>Schoffelen</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Szeb&#233;nyi</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Hanslmayr</surname></string-name>, and <string-name name-style="western"><given-names>C. F.</given-names><surname>Doeller</surname></string-name>. <year>2016</year>. &#8220;<article-title>Hippocampal&#8208;Prefrontal Theta Oscillations Support Memory Integration</article-title>.&#8221; <source>Current Biology: CB</source><volume>26</volume>, no. <issue>4</issue>: <fpage>450</fpage>&#8211;<lpage>457</lpage>. <pub-id pub-id-type="doi">10.1016/j.cub.2015.12.048</pub-id>.<pub-id pub-id-type="pmid">26832442</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0006"><mixed-citation publication-type="journal" id="ejn70263-cit-0006"><string-name name-style="western"><surname>Baradits</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Kakuszi</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>B&#225;lint</surname></string-name>, et&#160;al. <year>2019</year>. &#8220;<article-title>Alterations in Resting&#8208;State Gamma Activity in Patients With Schizophrenia: A High&#8208;Density EEG Study</article-title>.&#8221; <source>European Archives of Psychiatry and Clinical Neuroscience</source><volume>269</volume>, no. <issue>4</issue>: <fpage>429</fpage>&#8211;<lpage>437</lpage>. <pub-id pub-id-type="doi">10.1007/s00406-018-0889-z</pub-id>.<pub-id pub-id-type="pmid">29569047</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0007"><mixed-citation publication-type="journal" id="ejn70263-cit-0007"><string-name name-style="western"><surname>Bates</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>M&#228;chler</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Bolker</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Walker</surname></string-name>. <year>2015</year>. &#8220;<article-title>Fitting Linear Mixed&#8208;Effects Models Using lme4</article-title>.&#8221; <source>Journal of Statistical Software</source><volume>67</volume>: <fpage>1</fpage>&#8211;<lpage>48</lpage> 10.18637/jss.v067.i01.</mixed-citation></ref><ref id="ejn70263-bib-0008"><mixed-citation publication-type="journal" id="ejn70263-cit-0008"><string-name name-style="western"><surname>Benjamini</surname>, <given-names>Y.</given-names></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Hochberg</surname></string-name>. <year>1995</year>. &#8220;<article-title>Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing</article-title>.&#8221; <source>Journal of the Royal Statistical Society: Series B: Methodological</source><volume>57</volume>, no. <issue>1</issue>: <fpage>289</fpage>&#8211;<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1111/j.2517-6161.1995.tb02031.x</pub-id>.</mixed-citation></ref><ref id="ejn70263-bib-0009"><mixed-citation publication-type="journal" id="ejn70263-cit-0009"><string-name name-style="western"><surname>Boudewyn</surname>, <given-names>M. A.</given-names></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Erickson</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Winsler</surname></string-name>, et&#160;al. <year>2025</year>. &#8220;<article-title>Assessing Trial&#8208;By&#8208;Trial Electrophysiological and Behavioral Markers of Attentional Control and Sensory Precision in Psychotic and Mood Disorders</article-title>.&#8221; <source>Schizophrenia Bulletin</source><volume>51</volume>, no. <issue>2</issue>: <fpage>543</fpage>&#8211;<lpage>555</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbae038</pub-id>.<pub-id pub-id-type="pmid">38616053</pub-id><pub-id pub-id-type="pmcid">PMC11908867</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0010"><mixed-citation publication-type="journal" id="ejn70263-cit-0010"><string-name name-style="western"><surname>Boutros</surname>, <given-names>N. N.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Arfken</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Galderisi</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Warrick</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Pratt</surname></string-name>, and <string-name name-style="western"><given-names>W.</given-names><surname>Iacono</surname></string-name>. <year>2008</year>. &#8220;<article-title>The Status of Spectral EEG Abnormality as a Diagnostic Test for Schizophrenia</article-title>.&#8221; <source>Schizophrenia Research</source><volume>99</volume>, no. <issue>1&#8211;3</issue>: <fpage>225</fpage>&#8211;<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2007.11.020</pub-id>.<pub-id pub-id-type="pmid">18160260</pub-id><pub-id pub-id-type="pmcid">PMC2288752</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0011"><mixed-citation publication-type="journal" id="ejn70263-cit-0011"><string-name name-style="western"><surname>Buzs&#225;ki</surname>, <given-names>G.</given-names></string-name>, and <string-name name-style="western"><given-names>X. J.</given-names><surname>Wang</surname></string-name>. <year>2012</year>. &#8220;<article-title>Mechanisms of Gamma Oscillations</article-title>.&#8221; <source>Annual Review of Neuroscience</source><volume>35</volume>: <fpage>203</fpage>&#8211;<lpage>225</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-neuro-062111-150444</pub-id>.<pub-id pub-id-type="pmcid">PMC4049541</pub-id><pub-id pub-id-type="pmid">22443509</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0075"><mixed-citation publication-type="journal" id="ejn70263-cit-0075"><string-name name-style="western"><surname>Catalano</surname>, <given-names>L. T.</given-names></string-name>, <string-name name-style="western"><given-names>E. A.</given-names><surname>Reavis</surname></string-name>, <string-name name-style="western"><given-names>J. K.</given-names><surname>Wynn</surname></string-name>, and <string-name name-style="western"><given-names>M. F.</given-names><surname>Green</surname></string-name>. <year>2024</year>. &#8220;<article-title>Peak Alpha Frequency in Schizophrenia, Bipolar Disorder, and Healthy Volunteers: Associations With Visual Information Processing and Cognition</article-title>.&#8221; <source>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</source><volume>9</volume>, no. <issue>11</issue>: <fpage>1132</fpage>&#8211;<lpage>1140</lpage>. <pub-id pub-id-type="doi">10.1016/j.bpsc.2024.06.004</pub-id>.<pub-id pub-id-type="pmid">38909899</pub-id><pub-id pub-id-type="pmcid">PMC11932741</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0012"><mixed-citation publication-type="journal" id="ejn70263-cit-0012"><string-name name-style="western"><surname>Delorme</surname>, <given-names>A.</given-names></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Makeig</surname></string-name>. <year>2004</year>. &#8220;<article-title>EEGLAB: An Open Source Toolbox for Analysis of Single&#8208;Trial EEG Dynamics Including Independent Component Analysis</article-title>.&#8221; <source>Journal of Neuroscience Methods</source><volume>134</volume>, no. <issue>1</issue>: <fpage>9</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneumeth.2003.10.009</pub-id>.<pub-id pub-id-type="pmid">15102499</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0013"><mixed-citation publication-type="journal" id="ejn70263-cit-0013"><string-name name-style="western"><surname>Dickinson</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>DiStefano</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Senturk</surname></string-name>, and <string-name name-style="western"><given-names>S. S.</given-names><surname>Jeste</surname></string-name>. <year>2017</year>. &#8220;<article-title>Peak Alpha Frequency Is a Neural Marker of Cognitive Function Across the Autism Spectrum</article-title>.&#8221; <source>European Journal of Neuroscience</source><volume>47</volume>, no. <issue>6</issue>: <fpage>643</fpage>. <pub-id pub-id-type="doi">10.1111/ejn.13645</pub-id>.<pub-id pub-id-type="pmid">28700096</pub-id><pub-id pub-id-type="pmcid">PMC5766439</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0014"><mixed-citation publication-type="journal" id="ejn70263-cit-0014"><string-name name-style="western"><surname>Dong</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Chang</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Luo</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Yao</surname></string-name>. <year>2018</year>. &#8220;<article-title>Dysfunction of Large&#8208;Scale Brain Networks in Schizophrenia: A Meta&#8208;Analysis of Resting&#8208;State Functional Connectivity</article-title>.&#8221; <source>Schizophrenia Bulletin</source><volume>44</volume>, no. <issue>1</issue>: <fpage>168</fpage>&#8211;<lpage>181</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbx034</pub-id>.<pub-id pub-id-type="pmid">28338943</pub-id><pub-id pub-id-type="pmcid">PMC5767956</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0015"><mixed-citation publication-type="miscellaneous" id="ejn70263-cit-0015"><string-name name-style="western"><surname>Donoghue</surname>, <given-names>T.</given-names></string-name><year>2024</year>. <article-title>A Systematic Review of Aperiodic Neural Activity in Clinical Investigations (2024.10.14.24314925). Medrxiv</article-title>. <pub-id pub-id-type="doi">10.1101/2024.10.14.24314925</pub-id>.</mixed-citation></ref><ref id="ejn70263-bib-0016"><mixed-citation publication-type="journal" id="ejn70263-cit-0016"><string-name name-style="western"><surname>Donoghue</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Haller</surname></string-name>, <string-name name-style="western"><given-names>E. J.</given-names><surname>Peterson</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Parameterizing Neural Power Spectra Into Periodic and Aperiodic Components</article-title>.&#8221; <source>Nature Neuroscience</source><volume>23</volume>, no. <issue>12</issue>: <fpage>1655</fpage>&#8211;<lpage>1665</lpage>. <pub-id pub-id-type="doi">10.1038/s41593-020-00744-x</pub-id>.<pub-id pub-id-type="pmid">33230329</pub-id><pub-id pub-id-type="pmcid">PMC8106550</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0017"><mixed-citation publication-type="journal" id="ejn70263-cit-0017"><string-name name-style="western"><surname>Earl</surname>, <given-names>R. J.</given-names></string-name>, <string-name name-style="western"><given-names>T. C.</given-names><surname>Ford</surname></string-name>, <string-name name-style="western"><given-names>J. A. G.</given-names><surname>Lum</surname></string-name>, <string-name name-style="western"><given-names>P. G.</given-names><surname>Enticott</surname></string-name>, and <string-name name-style="western"><given-names>A. T.</given-names><surname>Hill</surname></string-name>. <year>2024</year>. &#8220;<article-title>Exploring Aperiodic Activity in First Episode Schizophrenia Spectrum Psychosis: A Resting&#8208;State EEG Analysis</article-title>.&#8221; <source>Brain Research</source><volume>1840</volume>: <elocation-id>149052</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.brainres.2024.149052</pub-id>.<pub-id pub-id-type="pmid">38844199</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0018"><mixed-citation publication-type="journal" id="ejn70263-cit-0018"><string-name name-style="western"><surname>Gao</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><given-names>E. J.</given-names><surname>Peterson</surname></string-name>, and <string-name name-style="western"><given-names>B.</given-names><surname>Voytek</surname></string-name>. <year>2017</year>. &#8220;<article-title>Inferring Synaptic Excitation/Inhibition Balance From Field Potentials</article-title>.&#8221; <source>NeuroImage</source><volume>158</volume>: <fpage>70</fpage>&#8211;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2017.06.078</pub-id>.<pub-id pub-id-type="pmid">28676297</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0019"><mixed-citation publication-type="journal" id="ejn70263-cit-0019"><string-name name-style="western"><surname>Goodkind</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>S. B.</given-names><surname>Eickhoff</surname></string-name>, <string-name name-style="western"><given-names>D. J.</given-names><surname>Oathes</surname></string-name>, et&#160;al. <year>2015</year>. &#8220;<article-title>Identification of a Common Neurobiological Substrate for Mental Illness</article-title>.&#8221; <source>JAMA Psychiatry</source><volume>72</volume>, no. <issue>4</issue>: <fpage>305</fpage>&#8211;<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.2206</pub-id>.<pub-id pub-id-type="pmid">25651064</pub-id><pub-id pub-id-type="pmcid">PMC4791058</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0020"><mixed-citation publication-type="journal" id="ejn70263-cit-0020"><string-name name-style="western"><surname>Gordillo</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>da Cruz</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Chkonia</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>The EEG Multiverse of Schizophrenia</article-title>.&#8221; <source>Cerebral Cortex</source><volume>33</volume>, no. <issue>7</issue>: <fpage>3816</fpage>&#8211;<lpage>3826</lpage>. <pub-id pub-id-type="doi">10.1093/cercor/bhac309</pub-id>.<pub-id pub-id-type="pmid">36030389</pub-id><pub-id pub-id-type="pmcid">PMC10068296</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0021"><mixed-citation publication-type="journal" id="ejn70263-cit-0021"><string-name name-style="western"><surname>Gramfort</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Luessi</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Larson</surname></string-name>, et&#160;al. <year>2014</year>. &#8220;<article-title>MNE Software for Processing MEG and EEG Data</article-title>.&#8221; <source>NeuroImage</source><volume>86</volume>: <fpage>446</fpage>&#8211;<lpage>460</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2013.10.027</pub-id>.<pub-id pub-id-type="pmid">24161808</pub-id><pub-id pub-id-type="pmcid">PMC3930851</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0022"><mixed-citation publication-type="journal" id="ejn70263-cit-0022"><string-name name-style="western"><surname>Grandy</surname>, <given-names>T. H.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Werkle&#8208;Bergner</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Chicherio</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>L&#246;vd&#233;n</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Schmiedek</surname></string-name>, and <string-name name-style="western"><given-names>U.</given-names><surname>Lindenberger</surname></string-name>. <year>2013</year>. &#8220;<article-title>Individual Alpha Peak Frequency Is Related to Latent Factors of General Cognitive Abilities</article-title>.&#8221; <source>NeuroImage</source><volume>79</volume>: <fpage>10</fpage>&#8211;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2013.04.059</pub-id>.<pub-id pub-id-type="pmid">23624490</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0023"><mixed-citation publication-type="journal" id="ejn70263-cit-0023"><string-name name-style="western"><surname>Grent&#8208;'t&#8208;Jong</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Gross</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Goense</surname></string-name>, et&#160;al. <year>2018</year>. &#8220;<article-title>Resting&#8208;State Gamma&#8208;Band Power Alterations in Schizophrenia Reveal E/I&#8208;Balance Abnormalities Across Illness&#8208;Stages</article-title>.&#8221; <source>eLife</source><volume>7</volume>: <elocation-id>e37799</elocation-id>. <pub-id pub-id-type="doi">10.7554/eLife.37799</pub-id>.<pub-id pub-id-type="pmid">30260771</pub-id><pub-id pub-id-type="pmcid">PMC6160226</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0024"><mixed-citation publication-type="journal" id="ejn70263-cit-0024"><string-name name-style="western"><surname>G&#252;nther</surname>, <given-names>A.</given-names></string-name>, and <string-name name-style="western"><given-names>I. L.</given-names><surname>Hanganu&#8208;Opatz</surname></string-name>. <year>2022</year>. &#8220;<article-title>Neuronal Oscillations: Early Biomarkers of Psychiatric Disease?</article-title>&#8221; <source>Frontiers in Behavioral Neuroscience</source><volume>16</volume>: <elocation-id>1038981</elocation-id>. <pub-id pub-id-type="doi">10.3389/fnbeh.2022.1038981</pub-id>.<pub-id pub-id-type="pmid">36600993</pub-id><pub-id pub-id-type="pmcid">PMC9806131</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0025"><mixed-citation publication-type="journal" id="ejn70263-cit-0025"><string-name name-style="western"><surname>He</surname>, <given-names>B. J.</given-names></string-name><year>2014</year>. &#8220;<article-title>Scale&#8208;Free Brain Activity: Past, Present, and Future</article-title>.&#8221; <source>Trends in Cognitive Sciences</source><volume>18</volume>, no. <issue>9</issue>: <fpage>480</fpage>&#8211;<lpage>487</lpage>. <pub-id pub-id-type="doi">10.1016/j.tics.2014.04.003</pub-id>.<pub-id pub-id-type="pmid">24788139</pub-id><pub-id pub-id-type="pmcid">PMC4149861</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0026"><mixed-citation publication-type="journal" id="ejn70263-cit-0026"><string-name name-style="western"><surname>Hirano</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Oribe</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Kanba</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Onitsuka</surname></string-name>, <string-name name-style="western"><given-names>P. G.</given-names><surname>Nestor</surname></string-name>, and <string-name name-style="western"><given-names>K. M.</given-names><surname>Spencer</surname></string-name>. <year>2015</year>. &#8220;<article-title>Spontaneous Gamma Activity in Schizophrenia</article-title>.&#8221; <source>JAMA Psychiatry</source><volume>72</volume>, no. <issue>8</issue>: <fpage>813</fpage>&#8211;<lpage>821</lpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.2642</pub-id>.<pub-id pub-id-type="pmid">25587799</pub-id><pub-id pub-id-type="pmcid">PMC4768724</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0027"><mixed-citation publication-type="journal" id="ejn70263-cit-0027"><string-name name-style="western"><surname>Hirano</surname>, <given-names>Y.</given-names></string-name>, and <string-name name-style="western"><given-names>P. J.</given-names><surname>Uhlhaas</surname></string-name>. <year>2021</year>. &#8220;<article-title>Current Findings and Perspectives on Aberrant Neural Oscillations in Schizophrenia</article-title>.&#8221; <source>Psychiatry and Clinical Neurosciences</source><volume>75</volume>, no. <issue>12</issue>: <fpage>358</fpage>&#8211;<lpage>368</lpage>. <pub-id pub-id-type="doi">10.1111/pcn.13300</pub-id>.<pub-id pub-id-type="pmid">34558155</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0028"><mixed-citation publication-type="journal" id="ejn70263-cit-0028"><string-name name-style="western"><surname>Jacob</surname>, <given-names>M. S.</given-names></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Sargent</surname></string-name>, <string-name name-style="western"><given-names>B. J.</given-names><surname>Roach</surname></string-name>, <string-name name-style="western"><given-names>E. A.</given-names><surname>Shamshiri</surname></string-name>, <string-name name-style="western"><given-names>D. H.</given-names><surname>Mathalon</surname></string-name>, and <string-name name-style="western"><given-names>J. M.</given-names><surname>Ford</surname></string-name>. <year>2023</year>. &#8220;<article-title>The Scanner as the Stimulus: Deficient Gamma&#8208;BOLD Coupling in Schizophrenia at Rest</article-title>.&#8221; <source>Schizophrenia Bulletin</source><volume>49</volume>, no. <issue>5</issue>: <fpage>1364</fpage>&#8211;<lpage>1374</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbad014</pub-id>.<pub-id pub-id-type="pmid">37098100</pub-id><pub-id pub-id-type="pmcid">PMC10483456</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0029"><mixed-citation publication-type="journal" id="ejn70263-cit-0029"><string-name name-style="western"><surname>Jiang</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Palaniyappan</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Luo</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Neuroimaging Epicenters as Potential Sites of Onset of the Neuroanatomical Pathology in Schizophrenia. Science</article-title>.&#8221; <source>Advances</source><volume>10</volume>, no. <issue>24</issue>: <elocation-id>eadk6063</elocation-id>. <pub-id pub-id-type="doi">10.1126/sciadv.adk6063</pub-id>.<pub-id pub-id-type="pmcid">PMC11168466</pub-id><pub-id pub-id-type="pmid">38865456</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0030"><mixed-citation publication-type="journal" id="ejn70263-cit-0030"><string-name name-style="western"><surname>Kahn</surname>, <given-names>R. S.</given-names></string-name>, <string-name name-style="western"><given-names>I. E.</given-names><surname>Sommer</surname></string-name>, <string-name name-style="western"><given-names>R. M.</given-names><surname>Murray</surname></string-name>, et&#160;al. <year>2015</year>. &#8220;<article-title>Schizophrenia</article-title>.&#8221; <source>Nature Reviews Disease Primers</source><volume>1</volume>, no. <issue>1</issue>: <fpage>15067</fpage>. <pub-id pub-id-type="doi">10.1038/nrdp.2015.67</pub-id>.<pub-id pub-id-type="pmid">27189524</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0031"><mixed-citation publication-type="journal" id="ejn70263-cit-0031"><string-name name-style="western"><surname>Kay</surname>, <given-names>S. R.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Fiszbein</surname></string-name>, and <string-name name-style="western"><given-names>L. A.</given-names><surname>Opler</surname></string-name>. <year>1987</year>. &#8220;<article-title>The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia</article-title>.&#8221; <source>Schizophrenia Bulletin</source><volume>13</volume>, no. <issue>2</issue>: <fpage>261</fpage>&#8211;<lpage>276</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/13.2.261</pub-id>.<pub-id pub-id-type="pmid">3616518</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0032"><mixed-citation publication-type="journal" id="ejn70263-cit-0032"><string-name name-style="western"><surname>Keefe</surname>, <given-names>R. S. E.</given-names></string-name>, <string-name name-style="western"><given-names>T. E.</given-names><surname>Goldberg</surname></string-name>, <string-name name-style="western"><given-names>P. D.</given-names><surname>Harvey</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Gold</surname></string-name>, <string-name name-style="western"><given-names>M. P.</given-names><surname>Poe</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Coughenour</surname></string-name>. <year>2004</year>. &#8220;<article-title>The Brief Assessment of Cognition in Schizophrenia: Reliability, Sensitivity, and Comparison With a Standard Neurocognitive Battery</article-title>.&#8221; <source>Schizophrenia Research</source><volume>68</volume>, no. <issue>2&#8211;3</issue>: <fpage>283</fpage>&#8211;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2003.09.011</pub-id>.<pub-id pub-id-type="pmid">15099610</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0033"><mixed-citation publication-type="journal" id="ejn70263-cit-0033"><string-name name-style="western"><surname>Kim</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>Y.&#8208;W.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Shim</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Jin</surname></string-name>, <string-name name-style="western"><given-names>C.&#8208;H.</given-names><surname>Im</surname></string-name>, and <string-name name-style="western"><given-names>S.&#8208;H.</given-names><surname>Lee</surname></string-name>. <year>2020</year>. &#8220;<article-title>Altered Cortical Functional Networks in Patients With Schizophrenia and Bipolar Disorder: A Resting&#8208;State Electroencephalographic Study</article-title>.&#8221; <source>Frontiers in Psychiatry</source><volume>11</volume>. <pub-id pub-id-type="doi">10.3389/fpsyt.2020.00661</pub-id>.<pub-id pub-id-type="pmcid">PMC7388793</pub-id><pub-id pub-id-type="pmid">32774308</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0034"><mixed-citation publication-type="journal" id="ejn70263-cit-0034"><string-name name-style="western"><surname>Kr&#269;m&#225;&#345;</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>J&#228;ger</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Boudriot</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>The multimodal Munich Clinical Deep Phenotyping Study to Bridge the Translational Gap in Severe Mental Illness Treatment Research</article-title>.&#8221; <source>Frontiers in Psychiatry</source><volume>14</volume>. <pub-id pub-id-type="doi">10.3389/fpsyt.2023.1179811</pub-id>.<pub-id pub-id-type="pmcid">PMC10196006</pub-id><pub-id pub-id-type="pmid">37215661</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0035"><mixed-citation publication-type="journal" id="ejn70263-cit-0035"><string-name name-style="western"><surname>Lett</surname>, <given-names>T. A.</given-names></string-name>, <string-name name-style="western"><given-names>A. N.</given-names><surname>Voineskos</surname></string-name>, <string-name name-style="western"><given-names>J. L.</given-names><surname>Kennedy</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Levine</surname></string-name>, and <string-name name-style="western"><given-names>Z. J.</given-names><surname>Daskalakis</surname></string-name>. <year>2014</year>. &#8220;<article-title>Treating Working Memory Deficits in Schizophrenia: A Review of the Neurobiology</article-title>.&#8221; <source>Biological Psychiatry</source><volume>75</volume>, no. <issue>5</issue>: <fpage>361</fpage>&#8211;<lpage>370</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2013.07.026</pub-id>.<pub-id pub-id-type="pmid">24011822</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0036"><mixed-citation publication-type="journal" id="ejn70263-cit-0036"><string-name name-style="western"><surname>Leucht</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Samara</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Heres</surname></string-name>, and <string-name name-style="western"><given-names>J. M.</given-names><surname>Davis</surname></string-name>. <year>2016</year>. &#8220;<article-title>Dose Equivalents for Antipsychotic Drugs: The DDD Method</article-title>.&#8221; <source>Schizophrenia Bulletin</source><volume>42</volume>, no. <issue>Suppl 1</issue>: <fpage>S90</fpage>&#8211;<lpage>S94</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbv167</pub-id>.<pub-id pub-id-type="pmid">27460622</pub-id><pub-id pub-id-type="pmcid">PMC4960429</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0037"><mixed-citation publication-type="journal" id="ejn70263-cit-0037"><string-name name-style="western"><surname>McCutcheon</surname>, <given-names>R. A.</given-names></string-name>, <string-name name-style="western"><given-names>R. S. E.</given-names><surname>Keefe</surname></string-name>, and <string-name name-style="western"><given-names>P. K.</given-names><surname>McGuire</surname></string-name>. <year>2023</year>. &#8220;<article-title>Cognitive Impairment in Schizophrenia: Aetiology, Pathophysiology, and Treatment</article-title>.&#8221; <source>Molecular Psychiatry</source><volume>28</volume>, no. <issue>5</issue>: <fpage>1902</fpage>&#8211;<lpage>1918</lpage>. <pub-id pub-id-type="doi">10.1038/s41380-023-01949-9</pub-id>.<pub-id pub-id-type="pmid">36690793</pub-id><pub-id pub-id-type="pmcid">PMC10575791</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0038"><mixed-citation publication-type="journal" id="ejn70263-cit-0038"><string-name name-style="western"><surname>McCutcheon</surname>, <given-names>R. A.</given-names></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Reis Marques</surname></string-name>, and <string-name name-style="western"><given-names>O. D.</given-names><surname>Howes</surname></string-name>. <year>2020</year>. &#8220;<article-title>Schizophrenia&#8212;An Overview</article-title>.&#8221; <source>JAMA Psychiatry</source><volume>77</volume>, no. <issue>2</issue>: <fpage>201</fpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2019.3360</pub-id>.<pub-id pub-id-type="pmid">31664453</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0039"><mixed-citation publication-type="journal" id="ejn70263-cit-0039"><string-name name-style="western"><surname>McLoughlin</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Gyurkovics</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Palmer</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Makeig</surname></string-name>. <year>2022</year>. &#8220;<article-title>Midfrontal Theta Activity in Psychiatric Illness: An Index of Cognitive Vulnerabilities Across Disorders</article-title>.&#8221; <source>Biological Psychiatry</source><volume>91</volume>, no. <issue>2</issue>: <fpage>173</fpage>&#8211;<lpage>182</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2021.08.020</pub-id>.<pub-id pub-id-type="pmid">34756560</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0040"><mixed-citation publication-type="journal" id="ejn70263-cit-0040"><string-name name-style="western"><surname>Menon</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Palaniyappan</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Supekar</surname></string-name>. <year>2023</year>. &#8220;<article-title>Integrative Brain Network and Salience Models of Psychopathology and Cognitive Dysfunction in Schizophrenia</article-title>.&#8221; <source>Biological Psychiatry</source><volume>94</volume>, no. <issue>2</issue>: <fpage>108</fpage>&#8211;<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2022.09.029</pub-id>.<pub-id pub-id-type="pmid">36702660</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0041"><mixed-citation publication-type="journal" id="ejn70263-cit-0041"><string-name name-style="western"><surname>Michel</surname>, <given-names>C. M.</given-names></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Brunet</surname></string-name>. <year>2019</year>. &#8220;<article-title>EEG Source Imaging: A Practical Review of the Analysis Steps</article-title>.&#8221; <source>Frontiers in Neurology</source><volume>10</volume>: <elocation-id>325</elocation-id>. <pub-id pub-id-type="doi">10.3389/fneur.2019.00325</pub-id>.<pub-id pub-id-type="pmid">31019487</pub-id><pub-id pub-id-type="pmcid">PMC6458265</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0042"><mixed-citation publication-type="journal" id="ejn70263-cit-0042"><string-name name-style="western"><surname>Molina</surname>, <given-names>J. L.</given-names></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Voytek</surname></string-name>, <string-name name-style="western"><given-names>M. L.</given-names><surname>Thomas</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Memantine Effects on Electroencephalographic Measures of Putative Excitatory/Inhibitory Balance in Schizophrenia</article-title>.&#8221; <source>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</source><volume>5</volume>, no. <issue>6</issue>: <fpage>562</fpage>&#8211;<lpage>568</lpage>. <pub-id pub-id-type="doi">10.1016/j.bpsc.2020.02.004</pub-id>.<pub-id pub-id-type="pmid">32340927</pub-id><pub-id pub-id-type="pmcid">PMC7286803</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0043"><mixed-citation publication-type="journal" id="ejn70263-cit-0043"><string-name name-style="western"><surname>Murphy</surname>, <given-names>M.</given-names></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>&#214;ng&#252;r</surname></string-name>. <year>2019</year>. &#8220;<article-title>Decreased Peak Alpha Frequency and Impaired Visual Evoked Potentials in First Episode Psychosis</article-title>.&#8221; <source>NeuroImage: Clinical</source><volume>22</volume>: <elocation-id>101693</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.nicl.2019.101693</pub-id>.<pub-id pub-id-type="pmid">30825710</pub-id><pub-id pub-id-type="pmcid">PMC6396327</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0044"><mixed-citation publication-type="journal" id="ejn70263-cit-0044"><string-name name-style="western"><surname>Newson</surname>, <given-names>J. J.</given-names></string-name>, and <string-name name-style="western"><given-names>T. C.</given-names><surname>Thiagarajan</surname></string-name>. <year>2018</year>. &#8220;<article-title>EEG Frequency Bands in Psychiatric Disorders: A Review of Resting State Studies</article-title>.&#8221; <source>Frontiers in Human Neuroscience</source><volume>12</volume>: <elocation-id>521</elocation-id>. <pub-id pub-id-type="doi">10.3389/fnhum.2018.00521</pub-id>.<pub-id pub-id-type="pmid">30687041</pub-id><pub-id pub-id-type="pmcid">PMC6333694</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0045"><mixed-citation publication-type="journal" id="ejn70263-cit-0045"><string-name name-style="western"><surname>Park</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>R. L. M.</given-names><surname>Ho</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>V. Q.</given-names><surname>Nguyen</surname></string-name>, and <string-name name-style="western"><given-names>S. A.</given-names><surname>Coombes</surname></string-name>. <year>2024</year>. &#8220;<article-title>The Effect of Age on Alpha Rhythms in the Human Brain Derived From Source Localized Resting&#8208;State Electroencephalography</article-title>.&#8221; <source>NeuroImage</source><volume>292</volume>: <elocation-id>120614</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2024.120614</pub-id>.<pub-id pub-id-type="pmid">38631618</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0046"><mixed-citation publication-type="journal" id="ejn70263-cit-0046"><string-name name-style="western"><surname>Peterson</surname>, <given-names>E. J.</given-names></string-name>, <string-name name-style="western"><given-names>B. Q.</given-names><surname>Rosen</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Belger</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Voytek</surname></string-name>, and <string-name name-style="western"><given-names>A. M.</given-names><surname>Campbell</surname></string-name>. <year>2023</year>. &#8220;<article-title>Aperiodic Neural Activity is a Better Predictor of Schizophrenia than Neural Oscillations</article-title>.&#8221; <source>Clinical EEG and Neuroscience</source><volume>54</volume>, no. <issue>4</issue>: <fpage>434</fpage>&#8211;<lpage>445</lpage>. <pub-id pub-id-type="doi">10.1177/15500594231165589</pub-id>.<pub-id pub-id-type="pmid">37287239</pub-id><pub-id pub-id-type="pmcid">PMC11905180</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0047"><mixed-citation publication-type="journal" id="ejn70263-cit-0047"><string-name name-style="western"><surname>Phillips</surname>, <given-names>K. G.</given-names></string-name>, and <string-name name-style="western"><given-names>P. J.</given-names><surname>Uhlhaas</surname></string-name>. <year>2015</year>. &#8220;<article-title>Neural Oscillations as a Translational Tool in Schizophrenia Research: Rationale, Paradigms and Challenges</article-title>.&#8221; <source>Journal of Psychopharmacology</source><volume>29</volume>, no. <issue>2</issue>: <fpage>155</fpage>&#8211;<lpage>168</lpage>. <pub-id pub-id-type="doi">10.1177/0269881114562093</pub-id>.<pub-id pub-id-type="pmid">25567552</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0048"><mixed-citation publication-type="journal" id="ejn70263-cit-0048"><string-name name-style="western"><surname>Pic&#243;&#8208;P&#233;rez</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Vieira</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Fern&#225;ndez&#8208;Rodr&#237;guez</surname></string-name>, <string-name name-style="western"><given-names>M. A. P.</given-names><surname>De Barros</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Radua</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Morgado</surname></string-name>. <year>2022</year>. &#8220;<article-title>Multimodal Meta&#8208;Analysis of Structural Gray Matter, Neurocognitive and Social Cognitive fMRI Findings in Schizophrenia Patients</article-title>.&#8221; <source>Psychological Medicine</source><volume>52</volume>, no. <issue>4</issue>: <fpage>614</fpage>&#8211;<lpage>624</lpage>. <pub-id pub-id-type="doi">10.1017/S0033291721005523</pub-id>.<pub-id pub-id-type="pmid">35129109</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0049"><mixed-citation publication-type="journal" id="ejn70263-cit-0049"><string-name name-style="western"><surname>Porter</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Fei</surname></string-name>, <string-name name-style="western"><given-names>K. S. F.</given-names><surname>Damme</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Nusslock</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Gratton</surname></string-name>, and <string-name name-style="western"><given-names>V. A.</given-names><surname>Mittal</surname></string-name>. <year>2023</year>. &#8220;<article-title>A Meta&#8208;Analysis and Systematic Review of Single vs. Multimodal Neuroimaging Techniques in the Classification of Psychosis</article-title>.&#8221; <source>Molecular Psychiatry</source><volume>28</volume>, no. <issue>8</issue>: <fpage>3278</fpage>&#8211;<lpage>3292</lpage>. <pub-id pub-id-type="doi">10.1038/s41380-023-02195-9</pub-id>.<pub-id pub-id-type="pmid">37563277</pub-id><pub-id pub-id-type="pmcid">PMC10618094</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0050"><mixed-citation publication-type="journal" id="ejn70263-cit-0050"><string-name name-style="western"><surname>Puttaert</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Wens</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Fery</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Decreased Alpha Peak Frequency Is Linked to Episodic Memory Impairment in Pathological Aging</article-title>.&#8221; <source>Frontiers in Aging Neuroscience</source><volume>13</volume>. <pub-id pub-id-type="doi">10.3389/fnagi.2021.711375</pub-id>.<pub-id pub-id-type="pmcid">PMC8406997</pub-id><pub-id pub-id-type="pmid">34475819</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0051"><mixed-citation publication-type="journal" id="ejn70263-cit-0051"><string-name name-style="western"><surname>Quraan</surname>, <given-names>M. A.</given-names></string-name>, <string-name name-style="western"><given-names>S. N.</given-names><surname>Moses</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Hung</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Mills</surname></string-name>, and <string-name name-style="western"><given-names>M. J.</given-names><surname>Taylor</surname></string-name>. <year>2011</year>. &#8220;<article-title>Detection and Localization of Hippocampal Activity Using Beamformers With MEG: A Detailed Investigation Using Simulations and Empirical Data</article-title>.&#8221; <source>Human Brain Mapping</source><volume>32</volume>, no. <issue>5</issue>: <fpage>812</fpage>&#8211;<lpage>827</lpage>. <pub-id pub-id-type="doi">10.1002/hbm.21068</pub-id>.<pub-id pub-id-type="pmid">21484951</pub-id><pub-id pub-id-type="pmcid">PMC6870394</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0052"><mixed-citation publication-type="miscellaneous" id="ejn70263-cit-0052"><collab collab-type="authors">R Core Team</collab><year>2024</year>. &#8220;<article-title>R: A Language and Environment for Statistical Computing</article-title>&#8221;. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.R-project.org/" ext-link-type="uri">https://www.R&#8208;project.org/</ext-link>.</mixed-citation></ref><ref id="ejn70263-bib-0053"><mixed-citation publication-type="journal" id="ejn70263-cit-0053"><string-name name-style="western"><surname>Racz</surname>, <given-names>F. S.</given-names></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Farkas</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Becske</surname></string-name>, et&#160;al. <year>2025</year>. &#8220;<article-title>Reduced Temporal Variability of Cortical Excitation/Inhibition Ratio in Schizophrenia</article-title>.&#8221; <source>Schizophrenia</source><volume>11</volume>, no. <issue>1</issue>: <fpage>1</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1038/s41537-025-00568-3</pub-id>.<pub-id pub-id-type="pmid">39966406</pub-id><pub-id pub-id-type="pmcid">PMC11836122</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0054"><mixed-citation publication-type="journal" id="ejn70263-cit-0054"><string-name name-style="western"><surname>Racz</surname>, <given-names>F. S.</given-names></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Farkas</surname></string-name>, <string-name name-style="western"><given-names>O.</given-names><surname>Stylianou</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Separating Scale&#8208;Free and Oscillatory Components of Neural Activity in Schizophrenia</article-title>.&#8221; <source>Brain and Behavior: A Cognitive Neuroscience Perspective</source><volume>11</volume>, no. <issue>5</issue>: <elocation-id>e02047</elocation-id>. <pub-id pub-id-type="doi">10.1002/brb3.2047</pub-id>.<pub-id pub-id-type="pmcid">PMC8119820</pub-id><pub-id pub-id-type="pmid">33538105</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0055"><mixed-citation publication-type="journal" id="ejn70263-cit-0055"><string-name name-style="western"><surname>Ramsay</surname>, <given-names>I. S.</given-names></string-name>, <string-name name-style="western"><given-names>P. A.</given-names><surname>Lynn</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Schermitzler</surname></string-name>, and <string-name name-style="western"><given-names>S. R.</given-names><surname>Sponheim</surname></string-name>. <year>2021</year>. &#8220;<article-title>Individual Alpha Peak Frequency Is Slower in Schizophrenia and Related to Deficits in Visual Perception and Cognition</article-title>.&#8221; <source>Scientific Reports</source><volume>11</volume>, no. <issue>1</issue>: <fpage>17852</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-97303-6</pub-id>.<pub-id pub-id-type="pmid">34497330</pub-id><pub-id pub-id-type="pmcid">PMC8426382</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0056"><mixed-citation publication-type="journal" id="ejn70263-cit-0056"><string-name name-style="western"><surname>Sachs</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Winklbaur</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Jagsch</surname></string-name>, and <string-name name-style="western"><given-names>R. S. E.</given-names><surname>Keefe</surname></string-name>. <year>2011</year>. &#8220;<article-title>Validation of the German Version of the Brief Assessment of Cognition in Schizophrenia (BACS)&#8212;Preliminary Results</article-title>.&#8221; <source>European Psychiatry: The Journal of the Association of European Psychiatrists</source><volume>26</volume>, no. <issue>2</issue>: <fpage>74</fpage>&#8211;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/j.eurpsy.2009.10.006</pub-id>.<pub-id pub-id-type="pmid">20427153</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0057"><mixed-citation publication-type="journal" id="ejn70263-cit-0057"><string-name name-style="western"><surname>Scally</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><given-names>M. R.</given-names><surname>Burke</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Bunce</surname></string-name>, and <string-name name-style="western"><given-names>J.&#8208;F.</given-names><surname>Delvenne</surname></string-name>. <year>2018</year>. &#8220;<article-title>Resting&#8208;State EEG Power and Connectivity Are Associated With Alpha Peak Frequency Slowing in Healthy Aging</article-title>.&#8221; <source>Neurobiology of Aging</source><volume>71</volume>: <fpage>149</fpage>&#8211;<lpage>155</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2018.07.004</pub-id>.<pub-id pub-id-type="pmid">30144647</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0058"><mixed-citation publication-type="journal" id="ejn70263-cit-0058"><string-name name-style="western"><surname>Sha</surname>, <given-names>Z.</given-names></string-name>, <string-name name-style="western"><given-names>T. D.</given-names><surname>Wager</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Mechelli</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>He</surname></string-name>. <year>2019</year>. &#8220;<article-title>Common Dysfunction of Large&#8208;Scale Neurocognitive Networks Across Psychiatric Disorders</article-title>.&#8221; <source>Biological Psychiatry</source><volume>85</volume>, no. <issue>5</issue>: <fpage>379</fpage>&#8211;<lpage>388</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2018.11.011</pub-id>.<pub-id pub-id-type="pmid">30612699</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0077"><mixed-citation publication-type="journal" id="ejn70263-cit-0077"><string-name name-style="western"><surname>Sheehan</surname>, <given-names>D. V.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Lecrubier</surname></string-name>, <string-name name-style="western"><given-names>K. H.</given-names><surname>Sheehan</surname></string-name>, et&#160;al. <year>1998</year>. &#8220;<article-title>The Mini&#8208;International Neuropsychiatric Interview (M.I.N.I.): The Development and Validation of a Structured Diagnostic Psychiatric Interview for DSM&#8208;IV and ICD&#8208;10</article-title>.&#8221; <source>Journal of Clinical Psychiatry</source><volume>59</volume>, no. <issue>Suppl 20</issue>: <fpage>22</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">9881538</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0059"><mixed-citation publication-type="journal" id="ejn70263-cit-0059"><string-name name-style="western"><surname>Shin</surname>, <given-names>Y.&#8208;W.</given-names></string-name>, <string-name name-style="western"><given-names>B. F.</given-names><surname>O'Donnell</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Youn</surname></string-name>, and <string-name name-style="western"><given-names>J. S.</given-names><surname>Kwon</surname></string-name>. <year>2011</year>. &#8220;<article-title>Gamma Oscillation in Schizophrenia</article-title>.&#8221; <source>Psychiatry Investigation</source><volume>8</volume>, no. <issue>4</issue>: <elocation-id>288</elocation-id>. <pub-id pub-id-type="doi">10.4306/pi.2011.8.4.288</pub-id>.<pub-id pub-id-type="pmid">22216037</pub-id><pub-id pub-id-type="pmcid">PMC3246135</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0060"><mixed-citation publication-type="journal" id="ejn70263-cit-0060"><string-name name-style="western"><surname>Shreekantiah Umesh</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>S. K.</given-names><surname>Tikka</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Goyal</surname></string-name>, <string-name name-style="western"><given-names>S. H.</given-names><surname>Nizamie</surname></string-name>, and <string-name name-style="western"><given-names>V. K.</given-names><surname>Sinha</surname></string-name>. <year>2016</year>. &#8220;<article-title>Resting State Theta Band Source Distribution and Functional Connectivity in Remitted Schizophrenia</article-title>.&#8221; <source>Neuroscience Letters</source><volume>630</volume>: <fpage>199</fpage>&#8211;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2016.07.055</pub-id>.<pub-id pub-id-type="pmid">27484634</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0061"><mixed-citation publication-type="journal" id="ejn70263-cit-0061"><string-name name-style="western"><surname>Smit</surname>, <given-names>C. M.</given-names></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Wright</surname></string-name>, <string-name name-style="western"><given-names>N. K.</given-names><surname>Hansell</surname></string-name>, <string-name name-style="western"><given-names>G. M.</given-names><surname>Geffen</surname></string-name>, and <string-name name-style="western"><given-names>N. G.</given-names><surname>Martin</surname></string-name>. <year>2006</year>. &#8220;<article-title>Genetic Variation of Individual Alpha Frequency (IAF) and Alpha Power in a Large Adolescent Twin Sample</article-title>.&#8221; <source>International Journal of Psychophysiology: Official Journal of the International Organization of Psychophysiology</source><volume>61</volume>, no. <issue>2</issue>: <fpage>235</fpage>&#8211;<lpage>243</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpsycho.2005.10.004</pub-id>.<pub-id pub-id-type="pmid">16338015</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0062"><mixed-citation publication-type="journal" id="ejn70263-cit-0062"><string-name name-style="western"><surname>Smith</surname>, <given-names>S. E.</given-names></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Gonzalez</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Clinical EEG Slowing Induced by Electroconvulsive Therapy Is Better Described by Increased Frontal Aperiodic Activity</article-title>.&#8221; <source>Translational Psychiatry</source><volume>13</volume>, no. <issue>1</issue>: <fpage>1</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1038/s41398-023-02634-9</pub-id>.<pub-id pub-id-type="pmid">37968263</pub-id><pub-id pub-id-type="pmcid">PMC10651871</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0063"><mixed-citation publication-type="journal" id="ejn70263-cit-0063"><string-name name-style="western"><surname>Spencer</surname>, <given-names>K. M.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Nakhnikian</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Hirano</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Levin</surname></string-name>. <year>2023</year>. &#8220;<article-title>The Contribution of Gamma Bursting to Spontaneous Gamma Activity in Schizophrenia</article-title>.&#8221; <source>Frontiers in Human Neuroscience</source><volume>17</volume>. <pub-id pub-id-type="doi">10.3389/fnhum.2023.1130897</pub-id>.<pub-id pub-id-type="pmcid">PMC10188978</pub-id><pub-id pub-id-type="pmid">37206313</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0076"><mixed-citation publication-type="journal" id="ejn70263-cit-0076"><string-name name-style="western"><surname>Sponheim</surname>, <given-names>S. R.</given-names></string-name>, <string-name name-style="western"><given-names>J. J.</given-names><surname>Stim</surname></string-name>, <string-name name-style="western"><given-names>S. A.</given-names><surname>Engel</surname></string-name>, and <string-name name-style="western"><given-names>V. J.</given-names><surname>Pokorny</surname></string-name>. <year>2023</year>. &#8220;<article-title>Slowed Alpha Oscillations and Percept Formation in Psychotic Psychopathology</article-title>.&#8221; <source>Frontiers in Psychology</source><volume>14</volume>. <pub-id pub-id-type="doi">10.3389/fpsyg.2023.1144107</pub-id>.<pub-id pub-id-type="pmcid">PMC10322206</pub-id><pub-id pub-id-type="pmid">37416534</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0064"><mixed-citation publication-type="journal" id="ejn70263-cit-0064"><string-name name-style="western"><surname>Tadel</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Baillet</surname></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Mosher</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Pantazis</surname></string-name>, and <string-name name-style="western"><given-names>R. M.</given-names><surname>Leahy</surname></string-name>. <year>2011</year>. &#8220;<article-title>Brainstorm: A User&#8208;Friendly Application for MEG/EEG Analysis</article-title>.&#8221; <source>Computational Intelligence and Neuroscience</source><volume>2011</volume>: <elocation-id>879716</elocation-id>. <pub-id pub-id-type="doi">10.1155/2011/879716</pub-id>.<pub-id pub-id-type="pmid">21584256</pub-id><pub-id pub-id-type="pmcid">PMC3090754</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0065"><mixed-citation publication-type="journal" id="ejn70263-cit-0065"><string-name name-style="western"><surname>Vollebregt</surname>, <given-names>M. A.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>van Dongen&#8208;Boomsma</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Slaats&#8208;Willemse</surname></string-name>, <string-name name-style="western"><given-names>J. K.</given-names><surname>Buitelaar</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Oostenveld</surname></string-name>. <year>2015</year>. &#8220;<article-title>How the Individual Alpha Peak Frequency Helps Unravel the Neurophysiologic Underpinnings of Behavioral Functioning in Children With Attention&#8208;Deficit/Hyperactivity Disorder</article-title>.&#8221; <source>Clinical EEG and Neuroscience</source><volume>46</volume>, no. <issue>4</issue>: <fpage>285</fpage>&#8211;<lpage>291</lpage>. <pub-id pub-id-type="doi">10.1177/1550059414537257</pub-id>.<pub-id pub-id-type="pmid">25392007</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0066"><mixed-citation publication-type="journal" id="ejn70263-cit-0066"><string-name name-style="western"><surname>Waschke</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Donoghue</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Fiedler</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Modality&#8208;Specific Tracking of Attention and Sensory Statistics in the Human Electrophysiological Spectral Exponent</article-title>.&#8221; <source>eLife</source><volume>10</volume>: <elocation-id>e70068</elocation-id>. <pub-id pub-id-type="doi">10.7554/eLife.70068</pub-id>.<pub-id pub-id-type="pmid">34672259</pub-id><pub-id pub-id-type="pmcid">PMC8585481</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0067"><mixed-citation publication-type="journal" id="ejn70263-cit-0067"><string-name name-style="western"><surname>Westner</surname>, <given-names>B. U.</given-names></string-name>, <string-name name-style="western"><given-names>S. S.</given-names><surname>Dalal</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Gramfort</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>A Unified View on Beamformers for M/EEG Source Reconstruction</article-title>.&#8221; <source>NeuroImage</source><volume>246</volume>: <elocation-id>118789</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2021.118789</pub-id>.<pub-id pub-id-type="pmid">34890794</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0068"><mixed-citation publication-type="journal" id="ejn70263-cit-0068"><string-name name-style="western"><surname>Wiest</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Torrecillos</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Pogosyan</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>The Aperiodic Exponent of Subthalamic Field Potentials Reflects Excitation/Inhibition Balance in Parkinsonism</article-title>.&#8221; <source>eLife</source><volume>12</volume>: <elocation-id>e82467</elocation-id>. <pub-id pub-id-type="doi">10.7554/eLife.82467</pub-id>.<pub-id pub-id-type="pmid">36810199</pub-id><pub-id pub-id-type="pmcid">PMC10005762</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0069"><mixed-citation publication-type="journal" id="ejn70263-cit-0069"><string-name name-style="western"><surname>Winkler</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Haufe</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Tangermann</surname></string-name>. <year>2011</year>. &#8220;<article-title>Automatic Classification of Artifactual ICA&#8208;Components for Artifact Removal in EEG Signals</article-title>.&#8221; <source>Behavioral and Brain Functions</source><volume>7</volume>, no. <issue>1</issue>: <elocation-id>30</elocation-id>. <pub-id pub-id-type="doi">10.1186/1744-9081-7-30</pub-id>.<pub-id pub-id-type="pmid">21810266</pub-id><pub-id pub-id-type="pmcid">PMC3175453</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0070"><mixed-citation publication-type="journal" id="ejn70263-cit-0070"><string-name name-style="western"><surname>Yeum</surname>, <given-names>T.&#8208;S.</given-names></string-name>, and <string-name name-style="western"><given-names>U. G.</given-names><surname>Kang</surname></string-name>. <year>2018</year>. &#8220;<article-title>Reduction in Alpha Peak Frequency and Coherence on Quantitative Electroencephalography in Patients With Schizophrenia</article-title>.&#8221; <source>Journal of Korean Medical Science</source><volume>33</volume>, no. <issue>26</issue>: <elocation-id>e179</elocation-id>. <pub-id pub-id-type="doi">10.3346/jkms.2018.33.e179</pub-id>.<pub-id pub-id-type="pmid">29930490</pub-id><pub-id pub-id-type="pmcid">PMC6010743</pub-id></mixed-citation></ref><ref id="ejn70263-bib-0071"><mixed-citation publication-type="journal" id="ejn70263-cit-0071"><string-name name-style="western"><surname>Zhang</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Shi</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Wang</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Reliability of EEG Microstate Analysis at Different Electrode Densities During Propofol&#8208;Induced Transitions of Brain States</article-title>.&#8221; <source>NeuroImage</source><volume>231</volume>: <elocation-id>117861</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2021.117861</pub-id>.<pub-id pub-id-type="pmid">33592245</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">464</journal-id><journal-id journal-id-type="pmc-domain">sageopen</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Journal of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">1387-2877</issn><issn pub-type="epub">1875-8908</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Sage Choice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12495119</article-id><article-id pub-id-type="pmcid-ver">PMC12495119.1</article-id><article-id pub-id-type="pmcaid">12495119</article-id><article-id pub-id-type="pmcaiid">12495119</article-id><article-id pub-id-type="pmid">40899945</article-id><article-id pub-id-type="doi">10.1177/13872877251371240</article-id><article-id pub-id-type="publisher-id">10.1177_13872877251371240</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Reviews</subject></subj-group></article-categories><title-group><article-title>The tale of donanemab: God is in the details</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1970-6903</contrib-id><name name-style="western"><surname>Saido</surname><given-names initials="TC">Takaomi C</given-names></name><xref rid="aff1-13872877251371240" ref-type="aff">1</xref><xref rid="aff2-13872877251371240" ref-type="aff">2</xref><xref rid="corresp1-13872877251371240" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Iwata</surname><given-names initials="N">Nobuhisa</given-names></name><xref rid="aff3-13872877251371240" ref-type="aff">3</xref><xref rid="corresp2-13872877251371240" ref-type="corresp"/></contrib></contrib-group><aff id="aff1-13872877251371240">
<label>1</label>Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Saitama, Japan</aff><aff id="aff2-13872877251371240">
<label>2</label>Department of Neurology, Keio University School of Medicine, Tokyo, Japan</aff><aff id="aff3-13872877251371240">
<label>3</label>Department of Genome-based Drug Discovery and Leading Medical Research Core Unit, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan</aff><author-notes><corresp id="corresp1-13872877251371240">Takaomi C Saido, Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, 2-1 Hirosawa, Saitama, Japan. 
Email: <email>takaomi.saido@riken.jp</email></corresp><corresp id="corresp2-13872877251371240">Nobuhisa Iwata, Department of Genome-based Drug Discovery and Leading Medical Research Core Unit, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan. 
Email: <email>iwata-n@nagasaki-u.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>3</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>107</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">498304</issue-id><fpage>1364</fpage><lpage>1373</lpage><history><date date-type="received"><day>14</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-05 00:26:29.067"><day>05</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_13872877251371240.pdf"/><abstract><p>Alzheimer's disease is a major cause of dementia, that affects approximately 7&#8211;8% of people aged 65 years and older (according to WHO &amp; Alzheimer's Disease International) and thus is a major concern in public health world-wide. This review chronicles the foundational research and translational trajectory leading to the development of donanemab, a monoclonal antibody targeting pyroglutamyl amyloid-&#946; (A&#946;3pE-X) peptides, recently approved for the treatment of early Alzheimer's disease (AD). We trace a 30-year arc from the biochemical identification of A&#946; species to the recognition of A&#946;3pE-42 as a predominant pathological isoform in AD and Down syndrome brains&#8212;a fact still underrecognized among clinicians and researchers. We highlight key breakthroughs in antibody generation, A&#946; peptide biochemistry, and resistance to enzymatic degradation. Mechanistic distinctions between donanemab (Kisunla<sup>&#174;</sup>), and lecanemab (Leqembi<sup>&#174;</sup>) are also explored, along with therapeutic implications for targeting specific A&#946; species at preclinical stages of disease. The review emphasizes how persistent biochemical research, fueled by intellectual curiosity, serendipity, and rigorous experimentation, has culminated in clinical proof-of-concept for the amyloid hypothesis. In addition to its molecular specificity, donanemab's development underscores a critical shift toward precision medicine in Alzheimer's care. Its clinical validation, though limited in scope, reinforces the need for scalable and affordable interventions that can address the growing global burden of dementia. We expect these therapeutic antibodies to contribute to reducing the global burden by ceasing the disease progression in a preclinical stage now that new methods for fluid biomarkers are becoming available. As the global population ages, understanding and addressing AD has become a top priority in neuroscience and public health.</p></abstract><kwd-group><kwd>Alzheimer's disease</kwd><kwd>amyloid-&#946;</kwd><kwd>dementia</kwd><kwd>donanemab</kwd><kwd>lecanemab</kwd><kwd>monoclonal antibody</kwd><kwd>neurodegeneration</kwd><kwd>public health</kwd><kwd>pyroglutamate</kwd><kwd>translational medicine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts19</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>The development trajectory of donanemab&#8212;one of the two disease-modifying monoclonal antibodies now employed in the treatment of early Alzheimer's disease (AD)<sup><xref rid="bibr1-13872877251371240" ref-type="bibr">1</xref>,<xref rid="bibr2-13872877251371240" ref-type="bibr">2</xref></sup>&#8212;can be traced back to 1992, when Selkoe and colleagues identified amyloid-&#946; (A&#946;) 1-40 as the predominant A&#946; species isolated from AD brains.<sup>
<xref rid="bibr3-13872877251371240" ref-type="bibr">3</xref>
</sup> Utilizing advanced two-dimensional reversed-phase high-performance liquid chromatography (HPLC) coupled with mass spectrometry, their study was broadly recognized as a confirmation of earlier findings by Glenner et al., who initially reported the N-terminal sequences of vascular and parenchymal A&#946; peptides from human brain<sup><xref rid="bibr4-13872877251371240" ref-type="bibr">4</xref><xref rid="bibr5-13872877251371240" ref-type="bibr"/>&#8211;<xref rid="bibr6-13872877251371240" ref-type="bibr">6</xref></sup> Notably, Selkoe's team also detected a minor presence of A&#946;3pE-40 (where pE denotes pyroglutamate), a finding that would later prove to be of major importance.</p><p>Driven by scientific intuition, Saido, the late Ihara and colleagues hypothesized that A&#946;3pE-X species might be critically involved in AD pathogenesis. This was grounded in the notion that converting A&#946;1-X to A&#946;3pE-X results in the loss of one positive and two negative charges at the peptide's N-terminus, potentially altering its biochemical behavior (<xref rid="fig1-13872877251371240" ref-type="fig">Figure 1</xref>)<sup><xref rid="bibr7-13872877251371240" ref-type="bibr">7</xref>&#8211;<xref rid="bibr9-13872877251371240" ref-type="bibr">9</xref></sup> To explore this, our team applied a method we had previously developed to generate antibodies against specific protein termini using 5- to 6-mer synthetic peptides (for example, pEFRHD for A&#946;3pE-X, and DAEFR for A&#946;1-X) conjugated via cysteine to keyhole limpet hemocyanin.<sup><xref rid="bibr10-13872877251371240" ref-type="bibr">10</xref>&#8211;<xref rid="bibr15-13872877251371240" ref-type="bibr">15</xref></sup> First, using this approach, we created an antibody selective for A&#946;3pE-X and analyzed aged human brain tissue using immunohistochemistry and Western blotting.<sup>
<xref rid="bibr7-13872877251371240" ref-type="bibr">7</xref>
</sup> We found that A&#946;3pE-X, but not A&#946;1-X, was the dominant species in the cerebral cortex, including in the frontal, temporal, and occipital lobes. The latter was rather quantitatively less significant.</p><fig position="float" id="fig1-13872877251371240" orientation="portrait"><label>Figure 1.</label><caption><p>Possible pathway(s) for generation of A&#946;3pE-42 from a&#946;1-42. DPP: Dipeptidyl peptidase 4; APA: Aminopeptidase A (acidic amino acid); APN: Aminopeptidase N (neutral amino acid); QPCT: glutaminyl-peptide cyclotransferase or glutamyl cyclase; QPCTL: glutaminyl-peptide cyclotransferase-like or glutamyl cyclase-like enzyme. The N3E is the only final precursor for N3pE. The lower panel shows that the conversion of E to pE results in the loss of one positive and one negative charges. Reproduced with minor modifications from Iwata et al. (CC BY 4.0).<sup>
<xref rid="bibr17-13872877251371240" ref-type="bibr">17</xref>
</sup>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251371240-fig1.jpg"/></fig><p>Subsequently, we developed antibodies capable of distinguishing between various N- and C-terminal A&#946; structures each other, confirming that A&#946;3pE-42 is the most abundant form in autopsied brains from AD patients, followed by A&#946;1(iso-D)-42 and A&#946;1(D-Asp)-42 (<xref rid="fig2-13872877251371240" ref-type="fig">Figure 2</xref>)<sup><xref rid="bibr8-13872877251371240" ref-type="bibr">8</xref>,<xref rid="bibr16-13872877251371240" ref-type="bibr">16</xref>,<xref rid="bibr17-13872877251371240" ref-type="bibr">17</xref></sup> The amount of A&#946;3pE-42 correlated better with phospho-tau load in AD and age-matched control brains rather than that of the others.<sup>
<xref rid="bibr18-13872877251371240" ref-type="bibr">18</xref>
</sup> Importantly, phospho-tau pathology correlates well with cognitive impairment as measured by NIA-AA or DSM-5 definitions.<sup><xref rid="bibr19-13872877251371240" ref-type="bibr">19</xref>&#8211;<xref rid="bibr22-13872877251371240" ref-type="bibr">22</xref></sup> Deposition of A&#946;3pE-42 thus appears to be associated with AD pathogenesis. These species exhibit a shared biochemical trait: resistance to major mammalian aminopeptidases. Our findings, along with those of others, confirmed the predominance of A&#946;3pE-42 in both AD and Down syndrome (DS) brains.<sup><xref rid="bibr8-13872877251371240" ref-type="bibr">8</xref>,<xref rid="bibr9-13872877251371240" ref-type="bibr">9</xref>,<xref rid="bibr17-13872877251371240" ref-type="bibr">17</xref>,<xref rid="bibr23-13872877251371240" ref-type="bibr">23</xref>&#8211;<xref rid="bibr26-13872877251371240" ref-type="bibr">26</xref></sup> The resistance of plaque-associated peptides isolated from AD brains in the earlier days to Edman degradation<sup>
<xref rid="bibr27-13872877251371240" ref-type="bibr">27</xref>
</sup> further supports their presence as major pathological forms.</p><fig position="float" id="fig2-13872877251371240" orientation="portrait"><label>Figure 2.</label><caption><p>Quantified terminal structures of A&#946; extracted from AD brain. Western blot analyses of various A&#946; species were performed and quantified using different amounts of corresponding synthetic A&#946; peptides: A&#946;<sub>1(D)-42</sub>, A&#946;1<sub>(isoD)-42</sub>, A&#946;1<sub>(rD)-42</sub>, A&#946;3<sub>(E)-42</sub>, A&#946;3<sub>(pE)-42</sub>, A&#946;<sub>11(pE)-42</sub>, A&#946;<sub>17(L)-42</sub>, A&#946;<sub>1(D)-40</sub>, A&#946;<sub>1(D)-42</sub>, and A&#946;<sub>1(D)-43</sub>. isoD, isoaspartate; rD, rectus (D-form) aspartate; pE, pyroglutamate. These experiments were performed as previously described.<sup><xref rid="bibr7-13872877251371240" ref-type="bibr">7</xref>,<xref rid="bibr16-13872877251371240" ref-type="bibr">16</xref>,<xref rid="bibr17-13872877251371240" ref-type="bibr">17</xref></sup> Samples were obtained from early-onset AD patients (age at death: 45&#8239;&#177;&#8239;1.0 years) and late-onset AD patients (74&#8239;&#177;&#8239;6.6 years). Human brain tissues were kindly provided by Dr. David M. A. Mann (University of Manchester). Reproduced with minor modifications from Iwata et al. (CC BY 4.0).<sup>
<xref rid="bibr17-13872877251371240" ref-type="bibr">17</xref>
</sup>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251371240-fig2.jpg"/></fig><p>Why did the 1992 paper<sup>
<xref rid="bibr3-13872877251371240" ref-type="bibr">3</xref>
</sup> overlook A&#946;3pE-42 or even A&#946;1-42 isoforms in their biochemical analysis? The group led by Younkin gave a partial answer: It was necessary to heat the HPLC column up to 50&#176;C to elute A&#946;1-42.<sup>
<xref rid="bibr28-13872877251371240" ref-type="bibr">28</xref>
</sup> We then found that use of a basic buffer, triethylamine, in combination with a low-molecular-weight detergent, betaine, enables us to fully isolate A&#946;3pE-42 in the process of synthesizing and purifying various forms of the internally radiolabeled A&#946;X-42 peptide (<xref rid="table1-13872877251371240" ref-type="table">Table 1</xref>).<sup><xref rid="bibr8-13872877251371240" ref-type="bibr">8</xref>,<xref rid="bibr17-13872877251371240" ref-type="bibr">17</xref>,<xref rid="bibr29-13872877251371240" ref-type="bibr">29</xref></sup> Satoshi Tsubuki, specialist of analytical and synthetic organic chemistry, Laboratory for Proteolytic Neuroscience, RIKEN CBS, played a major role in determining these conditions. Moreover, we were lucky to have used a high concentration of formic acid to extract A&#946; from human brain tissue as this is the most stringent way to isolate A&#946; from human brain amyloids.<sup><xref rid="bibr4-13872877251371240" ref-type="bibr">4</xref>&#8211;<xref rid="bibr6-13872877251371240" ref-type="bibr">6</xref></sup> If we had not realized such appropriate analytical techniques, we would not have been able to detect A&#946;3pE-42 from human brain tissues constantly. Other groups have also showed observations consistently similar to ours.<sup><xref rid="bibr23-13872877251371240" ref-type="bibr">23</xref>&#8211;<xref rid="bibr26-13872877251371240" ref-type="bibr">26</xref>,<xref rid="bibr30-13872877251371240" ref-type="bibr">30</xref></sup></p><table-wrap position="float" id="table1-13872877251371240" orientation="portrait"><label>Table 1.</label><caption><p>Recovery of various A&#946; variants for elution from reversed phase HPLC under different conditions.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251371240-table1.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">solvent:</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">TFA</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">TFA</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">TEA/betaine</italic>
</th></tr><tr><th align="left" rowspan="1" colspan="1">column temperature:</th><th align="left" rowspan="1" colspan="1">20&#176;C</th><th align="left" rowspan="1" colspan="1">50&#176;C</th><th align="left" rowspan="1" colspan="1">50&#176;C</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">A&#946;1-40</td><td rowspan="1" colspan="1">100%</td><td rowspan="1" colspan="1">100%</td><td rowspan="1" colspan="1">100%</td></tr><tr><td rowspan="1" colspan="1">A&#946;3(pE)-40</td><td rowspan="1" colspan="1">100%</td><td rowspan="1" colspan="1">100%</td><td rowspan="1" colspan="1">100%</td></tr><tr><td rowspan="1" colspan="1">A&#946;1-42</td><td rowspan="1" colspan="1">20&#8211;30%</td><td rowspan="1" colspan="1">100%</td><td rowspan="1" colspan="1">100%</td></tr><tr><td rowspan="1" colspan="1">A&#946;3(pE)-42</td><td rowspan="1" colspan="1">
<bold>0%</bold>
</td><td rowspan="1" colspan="1">
<bold>10&#8211;20%</bold>
</td><td rowspan="1" colspan="1">
<bold>100%</bold>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-13872877251371240"><p>TFA: Trifluoroacetic acid; TEA: Triethyl amine.</p></fn><fn id="table-fn2-13872877251371240"><p>Reproduced with minor modifications from Iwata et al. (CC BY 4.0).<sup>
<xref rid="bibr17-13872877251371240" ref-type="bibr">17</xref>
</sup></p></fn></table-wrap-foot></table-wrap><p>Interestingly, use of guanidine hydrochloride, not formic acid, was sufficient to fully extract A&#946; from the brains of mouse models of A&#946; amyloidosis (such as <italic toggle="yes">App<sup>NL</sup></italic><italic toggle="yes">
<sup>&#8722;F</sup>
</italic>, <italic toggle="yes">App<sup>NL</sup></italic><italic toggle="yes">
<sup>&#8722;G&#8722;F</sup>
</italic> and APP23),<sup><xref rid="bibr31-13872877251371240" ref-type="bibr">31</xref>,<xref rid="bibr32-13872877251371240" ref-type="bibr">32</xref></sup> and the major isoforms therein was A&#946;1-40/42.<sup><xref rid="bibr17-13872877251371240" ref-type="bibr">17</xref>,<xref rid="bibr23-13872877251371240" ref-type="bibr">23</xref>,<xref rid="bibr31-13872877251371240" ref-type="bibr">31</xref></sup> Thus, the physicochemical properties of pathological A&#946; differ between AD and mouse model brains. This difference likely suggests that conversion of A&#946;1-42 to A&#946;3pE-42 takes a long time, probably years to decades, in human brain tissue as A&#946; deposition is known to precede the disease on-set by more than two decades.<sup>
<xref rid="bibr33-13872877251371240" ref-type="bibr">33</xref>
</sup> Consistently, pathological analyses of DS brains demonstrated presence of diffuse plaques and absence of neuritic plaques in the early childhood (before 10 years),<sup>
<xref rid="bibr34-13872877251371240" ref-type="bibr">34</xref>
</sup> and presence of A&#946;1-X and A&#946;3pE-X in small subsets of compacted, neuritic plaques beginning around age 30 and rose with age, the latter isoforms always exceeding the former.<sup>
<xref rid="bibr26-13872877251371240" ref-type="bibr">26</xref>
</sup> Given the short lifespan of mice (typically under three years), it remains challenging to investigate the long-term biochemical conversion of A&#946;1-42 to A&#946;3pE-42 in vivo, by which A&#946;1-42 is converted to A&#946;3pE-42. In fact, no mouse models developed thus far accumulate A&#946;3pE-42 as a major A&#946; isoform to our knowledge. Since glutamine (Q) is much easier to convert to pE than glutamate (E),<sup>
<xref rid="bibr35-13872877251371240" ref-type="bibr">35</xref>
</sup> we made an A&#946; protein precursor (APP) cDNA construct, in which the first two amino acids of A&#946; part are deleted and the third E was converted to Q, and expressed APP<italic toggle="yes">
<sup>&#916;(DA)&#8722;Q&#8722;F</sup>
</italic> in primary neurons, leading to generation of A&#946;3pE-40/42.<sup>
<xref rid="bibr36-13872877251371240" ref-type="bibr">36</xref>
</sup> However, <italic toggle="yes">App</italic> knock-in mice carrying these mutations together with the Beyreuther/Iberian mutation, <italic toggle="yes">Ap</italic><italic toggle="yes">p<sup>&#916;(DA)&#8722;Q&#8722;F</sup></italic>, failed to accumulate A&#946;3pE-42<sup>
<xref rid="bibr17-13872877251371240" ref-type="bibr">17</xref>
</sup> presumably due to the following reasons.</p><p>In general, the selective deposition of A&#946;3pE-42 in human brain is attributed to their high oligomerization/fibrillization/aggregation-prone properties as examined by in vitro paradigms.<sup><xref rid="bibr37-13872877251371240" ref-type="bibr">37</xref>&#8211;<xref rid="bibr42-13872877251371240" ref-type="bibr">42</xref></sup> However, this may not be the only reason because A&#946;11pE-42 and A&#946;17-42 (p3 fragment), more hydrophobic and aggregation-prone than A&#946;1-42 and A&#946;3pE-42,<sup><xref rid="bibr43-13872877251371240" ref-type="bibr">43</xref>&#8211;<xref rid="bibr52-13872877251371240" ref-type="bibr">52</xref></sup> are relatively minor isoforms in aged human and AD brains (<xref rid="fig2-13872877251371240" ref-type="fig">Figure 2</xref>).<sup><xref rid="bibr8-13872877251371240" ref-type="bibr">8</xref>,<xref rid="bibr16-13872877251371240" ref-type="bibr">16</xref>,<xref rid="bibr17-13872877251371240" ref-type="bibr">17</xref>,<xref rid="bibr53-13872877251371240" ref-type="bibr">53</xref></sup> We thus examined the in vivo half-lives of various A&#946;X-42 isoforms in rat hippocampus using internally radiolabeled A&#946;s and found that most A&#946; variants lacking the N-terminal amino acid(s) except A&#946;3pE-42 were more short-lived (half-life: approximately 10&#8197;min) than A&#946;1-42 (half-life: approximately 18&#8197;min). In contrast, the half-life of A&#946;3pE-42 was as long as 90&#8197;min (<xref rid="table2-13872877251371240" ref-type="table">Table 2</xref>).<sup>
<xref rid="bibr17-13872877251371240" ref-type="bibr">17</xref>
</sup> These observations likely explain why A&#946;3Q-42 was quickly proteolyzed before conversion to A&#946;3pE-42 in vivo and why A&#946;3pE-42 dominantly accumulate in aged and AD brains. It is possible that A&#946;3pE-42 aggregated or became associated with some pathological structures such as dystrophic neurites<sup>
<xref rid="bibr54-13872877251371240" ref-type="bibr">54</xref>
</sup> or a complement complex, C1q,<sup><xref rid="bibr55-13872877251371240" ref-type="bibr">55</xref>,<xref rid="bibr56-13872877251371240" ref-type="bibr">56</xref></sup> faster than the other isoforms. The reason for A&#946;11pE-42 and A&#946;17-42 isoforms being relatively minor isoforms in AD brains remains elusive, but we speculate that autophagy followed by endocytosis<sup><xref rid="bibr57-13872877251371240" ref-type="bibr">57</xref>,<xref rid="bibr58-13872877251371240" ref-type="bibr">58</xref></sup> might play a role in their clearance although we have no experimental evidence.</p><table-wrap position="float" id="table2-13872877251371240" orientation="portrait"><label>Table 2.</label><caption><p>In vivo half-lives of various A&#946; species.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251371240-table2.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">A&#946; variants</th><th align="left" rowspan="1" colspan="1">half-life (min)<sup>
<xref rid="table-fn4-13872877251371240" ref-type="table-fn">a</xref>
</sup></th><th align="left" colspan="2" rowspan="1"><italic toggle="yes">p</italic> value against A&#946;1(D)-42<sup>b</sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">A&#946;1(D)-42</td><td rowspan="1" colspan="1">18.08</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">&#12288;</td></tr><tr><td rowspan="1" colspan="1">A&#946;2(A)-42</td><td rowspan="1" colspan="1">10.77</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">significant</td></tr><tr><td rowspan="1" colspan="1">A&#946;3(E)-42</td><td rowspan="1" colspan="1">12.51</td><td rowspan="1" colspan="1">0.016</td><td rowspan="1" colspan="1">significant</td></tr><tr><td rowspan="1" colspan="1">A&#946;4(F)-42</td><td rowspan="1" colspan="1">10.51</td><td rowspan="1" colspan="1">0.005</td><td rowspan="1" colspan="1">significant</td></tr><tr><td rowspan="1" colspan="1">A&#946;3(pE)-42</td><td rowspan="1" colspan="1">90.25</td><td rowspan="1" colspan="1">0.005</td><td rowspan="1" colspan="1">significant</td></tr><tr><td rowspan="1" colspan="1">A&#946;17(L)-42</td><td rowspan="1" colspan="1">34.69</td><td rowspan="1" colspan="1">0.081</td><td rowspan="1" colspan="1">&#12288;</td></tr><tr><td rowspan="1" colspan="1">A&#946;1(AcD)-42</td><td rowspan="1" colspan="1">19.12</td><td rowspan="1" colspan="1">0.816</td><td rowspan="1" colspan="1">&#12288;</td></tr><tr><td rowspan="1" colspan="1">A&#946;1(rD)-42</td><td rowspan="1" colspan="1">20.53</td><td rowspan="1" colspan="1">0.662</td><td rowspan="1" colspan="1">&#12288;</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn3-13872877251371240"><p>A&#946;1(D) designates A&#946; that starts with L-aspartate at position 1; pE: pyroglutamate; isoD: L-isoaspartate; AcD: N-acetyl L-aspartate; rD: rectus (D configuration) aspartate.</p></fn><fn id="table-fn4-13872877251371240"><label>
<sup>a</sup>
</label><p>Calculated using a formula of exponential approximation curve when the y-intercept was 0. <sup>b</sup>Analyzed by two-way ANOVA, followed by <italic toggle="yes">post hoc</italic> test. Reproduced with minor modifications from Iwata et al. (CC BY 4.0).<sup>
<xref rid="bibr17-13872877251371240" ref-type="bibr">17</xref>
</sup></p></fn></table-wrap-foot></table-wrap><p>It is notable that deficiency of neprilysin, a major A&#946;-degrading enzyme mainly presynaptically localized in brain,<sup><xref rid="bibr59-13872877251371240" ref-type="bibr">59</xref>&#8211;<xref rid="bibr61-13872877251371240" ref-type="bibr">61</xref></sup> resulted in a significant increase of A&#946;3pE-40/42 particularly associated with plaque cores in the APP-transgenic mice, APP23, and <italic toggle="yes">App</italic> knock-in mice, <italic toggle="yes">App<sup>NL</sup></italic><italic toggle="yes">
<sup>&#8722;F,</sup>
</italic> as examined by immunohistochemistry, Western blotting, and LC-MS/MS following proteolytic digestion.<sup>
<xref rid="bibr17-13872877251371240" ref-type="bibr">17</xref>
</sup> Presumably, neprilysin-independent pathways are, at least in part, involved in N-terminal truncation of A&#946; and formation of A&#946;3pE-42. Consistently, neprilysin-deficiency increased expression of aminopeptidase N, dipeptidyl peptidase, and glutamyl cyclase-like enzyme in the APP-transgenic mice with aging,<sup>
<xref rid="bibr17-13872877251371240" ref-type="bibr">17</xref>
</sup> all of which may contribute to A&#946;3pE-X formation (<xref rid="fig1-13872877251371240" ref-type="fig">Figure 1</xref>).<sup><xref rid="bibr62-13872877251371240" ref-type="bibr">62</xref>&#8211;<xref rid="bibr70-13872877251371240" ref-type="bibr">70</xref></sup> It is also important that a number of studies consistently demonstrated an aging-dependent or AD-associated decline of neprilysin expression in the human and mouse brains,<sup><xref rid="bibr59-13872877251371240" ref-type="bibr">59</xref>,<xref rid="bibr60-13872877251371240" ref-type="bibr">60</xref>,<xref rid="bibr71-13872877251371240" ref-type="bibr">71</xref>&#8211;<xref rid="bibr76-13872877251371240" ref-type="bibr">76</xref></sup> and that a GWAS-identified mutation in the neprilysin gene, <italic toggle="yes">MME</italic>, associated with an AD risk<sup>
<xref rid="bibr77-13872877251371240" ref-type="bibr">77</xref>
</sup> perturbs neprilysin-dependent extracellular A&#946; degradation (<xref rid="fig3-13872877251371240" ref-type="fig">Figure 3</xref>).<sup>
<xref rid="bibr78-13872877251371240" ref-type="bibr">78</xref>
</sup></p><fig position="float" id="fig3-13872877251371240" orientation="portrait"><label>Figure 3.</label><caption><p>Effect of M8&#8197;V mutation on the action of A&#946;-degrading enzyme, neprilysin, encoded by <italic toggle="yes">MME</italic> gene. The M8&#8197;V mutation is associated with an AD risk.<sup>
<xref rid="bibr77-13872877251371240" ref-type="bibr">77</xref>
</sup> The mutation reduces extracellular A&#946; degradation by suppressing neprilysin expression on cell surface and extracellular vesicles via phosphorylation of S6.<sup>
<xref rid="bibr97-13872877251371240" ref-type="bibr">97</xref>
</sup> MEK: mitogen-activated protein kinase/extracellular signal-regulated kinase.<sup>
<xref rid="bibr105-13872877251371240" ref-type="bibr">105</xref>
</sup>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251371240-fig3.jpg"/></fig><p>In the meantime, Demattos and colleagues, Lilly, USA, created a mouse monoclonal antibody specific to A&#946;3pE-X and showed that administration of this antibody removes A&#946; plaques from APP-transgenic mouse brains<sup>
<xref rid="bibr79-13872877251371240" ref-type="bibr">79</xref>
</sup> The humanized version of this antibody is donanemab.<sup><xref rid="bibr1-13872877251371240" ref-type="bibr">1</xref>,<xref rid="bibr2-13872877251371240" ref-type="bibr">2</xref>,<xref rid="bibr17-13872877251371240" ref-type="bibr">17</xref></sup> In the TRAILBLAZER-ALZ 2 trial,2 donanemab demonstrated a modest slowing (35%) of cognitive and functional decline in early symptomatic AD patients, with amyloid-related imaging abnormalities (ARIA) occurring in approximately 24% of treated individuals (<xref rid="table3-13872877251371240" ref-type="table">Table 3</xref>). (A modified titration protocol (delaying the third 700&#8197;mg vial) reduced ARIA-E rates to &#8764;14%.) These results have led to FDA approval under accelerated pathways, reinforcing the feasibility of amyloid-targeting strategies in clinical settings. Because we observed the A&#946;3pE-positive vascular amyloid in human brain tissue,<sup><xref rid="bibr7-13872877251371240" ref-type="bibr">7</xref>,<xref rid="bibr80-13872877251371240" ref-type="bibr">80</xref></sup> its major side-effect, i.e., ARIA,<sup><xref rid="bibr81-13872877251371240" ref-type="bibr">81</xref>&#8211;<xref rid="bibr84-13872877251371240" ref-type="bibr">84</xref></sup> was predictable. In any case, the success of lecanemab and donanemab in clinical trials (although their effect was limited)<sup><xref rid="bibr1-13872877251371240" ref-type="bibr">1</xref>,<xref rid="bibr2-13872877251371240" ref-type="bibr">2</xref>,<xref rid="bibr85-13872877251371240" ref-type="bibr">85</xref>,<xref rid="bibr86-13872877251371240" ref-type="bibr">86</xref></sup> provided the first clinically evidenced proof-of-concept for the A&#946; hypothesis that had been based on pathological, genetic and experimental observations.<sup><xref rid="bibr87-13872877251371240" ref-type="bibr">87</xref>,<xref rid="bibr88-13872877251371240" ref-type="bibr">88</xref></sup> We believe the reason for these immunotherapies being limited in the treatment of early AD is that it is too late to do so when irreversible neurodegeneration has already taken place<sup>
<xref rid="bibr33-13872877251371240" ref-type="bibr">33</xref>
</sup> as neuronal circuits composed of postmitotic cells (neurons) cannot in principal regenerate after degeneration.<sup>
<xref rid="bibr8-13872877251371240" ref-type="bibr">8</xref>
</sup> Thus, we must target the anti-A&#946; treatment to preclinical AD rather than the later disease stages.<sup><xref rid="bibr8-13872877251371240" ref-type="bibr">8</xref>,<xref rid="bibr89-13872877251371240" ref-type="bibr">89</xref></sup> This would reduce the total number of mild cognitive impairment (MCI) and AD patients and contribute to diminishing the socioeconomical burdens all over the world although the currently approved therapeutics are too expensive to cover the preclinical AD patients that outnumber the MCI and AD patients.<sup><xref rid="bibr90-13872877251371240" ref-type="bibr">90</xref>&#8211;<xref rid="bibr92-13872877251371240" ref-type="bibr">92</xref></sup> This is why we need to develop orally administerable synthetic low-molecular-weight medications that selectively promote neprilysin-dependent A&#946; degradation via activation of somatostatin or dopamine receptors<sup><xref rid="bibr93-13872877251371240" ref-type="bibr">93</xref>&#8211;<xref rid="bibr97-13872877251371240" ref-type="bibr">97</xref></sup> or inhibit aminopeptidases and glutamyl cyclases.<sup>
<xref rid="bibr17-13872877251371240" ref-type="bibr">17</xref>
</sup> We also expect identification of plasma biomarkers such as phospho-tau would accelerate treatment of preclinical AD.</p><table-wrap position="float" id="table3-13872877251371240" orientation="portrait"><label>Table 3.</label><caption><p>Comparison of three therapeutic anti-A&#946; antibodies.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251371240-table3.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Aspect</th><th align="left" rowspan="1" colspan="1">Donanemab</th><th align="left" rowspan="1" colspan="1">Lecanemab</th><th align="left" rowspan="1" colspan="1">Aducanumab</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Epitope Target</td><td rowspan="1" colspan="1">A&#946;3pE-X (pyroglutamate-modified N-terminus)</td><td rowspan="1" colspan="1">Soluble A&#946; protofibrils</td><td rowspan="1" colspan="1">A&#946; residues 3&#8211;7 (Glu-Phe-Arg-His-Asp)</td></tr><tr><td rowspan="1" colspan="1">Mechanism of Action</td><td rowspan="1" colspan="1">Clears plaques by targeting aggregated toxic A&#946;</td><td rowspan="1" colspan="1">Neutralizes protofibrils, clears early aggregates</td><td rowspan="1" colspan="1">Binds to aggregated A&#946; to clear plaques</td></tr><tr><td rowspan="1" colspan="1">Antigen Source</td><td rowspan="1" colspan="1">Plaque core-specific A&#946;</td><td rowspan="1" colspan="1">A&#946; protofibrils</td><td rowspan="1" colspan="1">Derived from human B cells</td></tr><tr><td rowspan="1" colspan="1">Binding to APP Fragments</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes (binds APP/APPs&#945;/CTF&#946; fragments)</td></tr><tr><td rowspan="1" colspan="1">Effect on Amyloid PET</td><td rowspan="1" colspan="1">Yes (robust plaque clearance)</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes (variable results)</td></tr><tr><td rowspan="1" colspan="1">Effect on Tau Pathology</td><td rowspan="1" colspan="1">Modest indirect reduction</td><td rowspan="1" colspan="1">Modest indirect reduction</td><td rowspan="1" colspan="1">Not established</td></tr><tr><td rowspan="1" colspan="1">Clinical Trial Name</td><td rowspan="1" colspan="1">TRAILBLAZER-ALZ 1 &amp; 2</td><td rowspan="1" colspan="1">Clarity AD, Study 201, AHEAD 3&#8211;45</td><td rowspan="1" colspan="1">EMERGE and ENGAGE</td></tr><tr><td rowspan="1" colspan="1">Population (Stage)</td><td rowspan="1" colspan="1">Early symptomatic AD</td><td rowspan="1" colspan="1">Mild cognitive impairment &amp; early AD</td><td rowspan="1" colspan="1">Mild AD (early symptomatic)</td></tr><tr><td rowspan="1" colspan="1">Primary Endpoint Met</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes in one, No in the other</td></tr><tr><td rowspan="1" colspan="1">ARIA Incidence</td><td rowspan="1" colspan="1">ARIA-E: &#8764;24%<sup>
<xref rid="table-fn5-13872877251371240" ref-type="table-fn">a</xref>
</sup></td><td rowspan="1" colspan="1">ARIA-E: &#8764;12%</td><td rowspan="1" colspan="1">ARIA-E: &#8764;35%</td></tr><tr><td rowspan="1" colspan="1">Cognitive Benefit</td><td rowspan="1" colspan="1">Moderate slowing of decline (CDR-SB)</td><td rowspan="1" colspan="1">Statistically significant slowing (CDR-SB)</td><td rowspan="1" colspan="1">Highly debated; clinical significance unclear</td></tr><tr><td rowspan="1" colspan="1">Cognitive Recovery<break/>(CDR-SB)</td><td rowspan="1" colspan="1">35.10%</td><td rowspan="1" colspan="1">27%</td><td rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="1" colspan="1">FDA Approval Status</td><td rowspan="1" colspan="1">Approved (Accelerated)</td><td rowspan="1" colspan="1">Approved (Traditional)</td><td rowspan="1" colspan="1">Approved (Controversially, Accelerated)</td></tr><tr><td rowspan="1" colspan="1">Dosing Frequency</td><td rowspan="1" colspan="1">Monthly IV infusion</td><td rowspan="1" colspan="1">Biweekly IV infusion</td><td rowspan="1" colspan="1">Monthly IV infusion</td></tr><tr><td rowspan="1" colspan="1">Dose per Injection</td><td rowspan="1" colspan="1">700&#8197;mg</td><td rowspan="1" colspan="1">10&#8197;mg/kg (700&#8197;mg/70&#8197;kg)</td><td rowspan="1" colspan="1">10&#8197;mg/kg (700&#8197;mg/70&#8197;kg)</td></tr><tr><td rowspan="1" colspan="1">Developer</td><td rowspan="1" colspan="1">Eli Lilly</td><td rowspan="1" colspan="1">Eisai/Biogen</td><td rowspan="1" colspan="1">Biogen</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn5-13872877251371240"><label>
<sup>a</sup>
</label><p>A modified titration protocol (delaying the third 700&#8239;mg vial) reduced ARIA-E rates to &#8764;14%.</p></fn></table-wrap-foot></table-wrap><p>Incidentally, lecanemab differs from donanemab with soluble A&#946; protofibrils being the original antigen (<xref rid="table3-13872877251371240" ref-type="table">Table 3</xref>).<sup><xref rid="bibr85-13872877251371240" ref-type="bibr">85</xref>,<xref rid="bibr86-13872877251371240" ref-type="bibr">86</xref>,<xref rid="bibr98-13872877251371240" ref-type="bibr">98</xref>&#8211;<xref rid="bibr100-13872877251371240" ref-type="bibr">100</xref></sup> However, treatment of early AD patients reduces A&#946; amyloidosis as examined by amyloid positron emission tomography (PET) accompanying ARIA in some cases.<sup><xref rid="bibr85-13872877251371240" ref-type="bibr">85</xref>,<xref rid="bibr86-13872877251371240" ref-type="bibr">86</xref>,<xref rid="bibr101-13872877251371240" ref-type="bibr">101</xref></sup> This implies that the antibody also binds to parenchymal and vascular A&#946; deposits in vivo. although we tried to immunostain human A&#946; plaques with lecanemab in vain (unpublished observations). Reduction of plasma glial fibrillary acidic protein (GFAP) after lecanemab treatment<sup>
<xref rid="bibr85-13872877251371240" ref-type="bibr">85</xref>
</sup> also implies suppression of the plaque-astrocyte interaction(s). We would like to point out that biological properties of an interaction between a given protein and anything else can drastically differ between the in vitro and in vivo paradigms.<sup><xref rid="bibr17-13872877251371240" ref-type="bibr">17</xref>,<xref rid="bibr29-13872877251371240" ref-type="bibr">29</xref></sup> For instance, neprilysin and insulin-degrading enzyme cleave A&#946; efficiently in a test tube, whereas they preferentially degrade insoluble and soluble A&#946;, respectively, in the mouse brain.<sup>
<xref rid="bibr78-13872877251371240" ref-type="bibr">78</xref>
</sup> Therefore, the mechanisms of action of lecanemab remains unresolved at least in part, but lecanemab and donanemab share one common feature in a manner different from most other therapeutic antibodies including aducanumab.<sup>
<xref rid="bibr102-13872877251371240" ref-type="bibr">102</xref>
</sup> That is, only lecanemab and donanemab avoid binding to A&#946;PP, C-terminal fragment of A&#946;PP developed by &#946;-secretase (A&#946;PP-CTF&#946;), soluble N-terminal fragment of APP generated by &#945;-secretase (sA&#946;PP&#945;), or other non-A&#946; APP fragments physiologically produced and potentially functional in the brain (<xref rid="fig4-13872877251371240" ref-type="fig">Figure 4</xref>).<sup>
<xref rid="bibr8-13872877251371240" ref-type="bibr">8</xref>
</sup> For instance, an antibody raised against the N-terminus of A&#946;PP-CTF&#946;<sup>
<xref rid="bibr13-13872877251371240" ref-type="bibr">13</xref>
</sup> turned out to be one of the best antibodies to immunostain A&#946; plaques in the PD-APP transgenic mice.<sup>
<xref rid="bibr15-13872877251371240" ref-type="bibr">15</xref>
</sup> Binding of these antibodies to non-A&#946; APP fragments may have caused unexpected side-effect(s).</p><fig position="float" id="fig4-13872877251371240" orientation="portrait"><label>Figure 4.</label><caption><p>Binding of anti-A&#946; antibodies to the CTF&#946; fragment of A&#946;PP. Modified from Saido TC.<sup>
<xref rid="bibr8-13872877251371240" ref-type="bibr">8</xref>
</sup> Most antibodies raised against A&#946; bind to A&#946;PP, CTF&#946;, sA&#946;PP&#945;, or other non-A&#946;, A&#946;PP fragments, but donanemab and lecanemab do not. AICD: A&#946;PP intracellular domain.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251371240-fig4.jpg"/></fig><p>We can also predict that combination of lecanemab and donanemab together may result in additive or synergistic effects possibly at lower doses as their epitopes are different, and this could either improve or worsen the side-effects depending on the administration protocols. Generation of mouse models that produce both A&#946;3pE-42 and A&#946; protofibrils in a sufficient quantity or nonhuman primate models of A&#946; amyloidosis<sup><xref rid="bibr30-13872877251371240" ref-type="bibr">30</xref>,<xref rid="bibr103-13872877251371240" ref-type="bibr">103</xref>,<xref rid="bibr104-13872877251371240" ref-type="bibr">104</xref></sup> that live much longer than mice may help address this issue without experimenting on humans.</p><p>In summary, development of donanemab has stemmed from a number of biochemical and immunochemical studies over 30 years since 1992, indicating the importance of basic science based on intellectual curiosity and serendipity. In addition, we would like to point out that the efforts by Ronald Demattos and colleagues to develop monoclonal antibodies to A&#946;3pE-X,<sup>
<xref rid="bibr79-13872877251371240" ref-type="bibr">79</xref>
</sup> together with development of lecanemab by Lars Lannfelt and colleagues,<sup><xref rid="bibr98-13872877251371240" ref-type="bibr">98</xref>,<xref rid="bibr100-13872877251371240" ref-type="bibr">100</xref></sup> made a major break-through for establishing a clinical proof-of-concept for the A&#946; hypothesis in the etiology of AD.<sup><xref rid="bibr87-13872877251371240" ref-type="bibr">87</xref>,<xref rid="bibr88-13872877251371240" ref-type="bibr">88</xref></sup> The God has indeed been in the details.</p></body><back><ack><title>Acknowledgments</title><p>This work was supported by research grants from RIKEN, Special Coordination Funds for promoting Science and Technology of STA, CREST, Ministry of Health and Welfare, Ministry of Education, Science and Technology, Chugai Pharmaceutical Co., Mitsubishi Chemical Co., Takeda Chemical Industries, and AMED under Grant Number JP20dm0207001 (Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS)).</p><p>During the preparation of this work the authors used ChatGPT4 in order to improve the English writing originally created by the author. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.</p></ack><fn-group><fn fn-type="other"><p><bold>ORCID iD:</bold> Takaomi C Saido <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0003-1970-6903" ext-link-type="uri">https://orcid.org/0000-0003-1970-6903</ext-link></p></fn><fn fn-type="financial-disclosure"><p><bold>Author contributions:</bold>
<bold>Takaomi C Saido:</bold> Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing - original draft, Writing - review &amp; editing.</p><p><bold>Nobuhisa Iwata:</bold> Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Validation, Visualization, Writing - review &amp; editing.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> Funding sources are acknowledged in the Acknowledgements section.</p></fn><fn fn-type="COI-statement"><p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-13872877251371240"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mintun</surname><given-names>MA</given-names></name><name name-style="western"><surname>Lo</surname><given-names>AC</given-names></name><name name-style="western"><surname>Duggan Evans</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Donanemab in early Alzheimer's disease</article-title>. <source>N Engl J Med</source><year>2021</year>; <volume>384</volume>: <fpage>1691</fpage>&#8211;<lpage>1704</lpage>.<pub-id pub-id-type="pmid">33720637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2100708</pub-id></mixed-citation></ref><ref id="bibr2-13872877251371240"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sims</surname><given-names>JR</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>JA</given-names></name><name name-style="western"><surname>Evans</surname><given-names>CD</given-names></name></person-group>, <etal>et al.</etal><article-title>Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial</article-title>. <source>JAMA</source><year>2023</year>; <volume>330</volume>: <fpage>512</fpage>&#8211;<lpage>527</lpage>.<pub-id pub-id-type="pmid">37459141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2023.13239</pub-id><pub-id pub-id-type="pmcid">PMC10352931</pub-id></mixed-citation></ref><ref id="bibr3-13872877251371240"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mori</surname><given-names>H</given-names></name><name name-style="western"><surname>Takio</surname><given-names>K</given-names></name><name name-style="western"><surname>Ogawara</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Mass spectrometry of purified amyloid beta protein in Alzheimer's disease</article-title>. <source>J Biol Chem</source><year>1992</year>; <volume>267</volume>: <fpage>17082</fpage>&#8211;<lpage>17086</lpage>.<pub-id pub-id-type="pmid">1512246</pub-id></mixed-citation></ref><ref id="bibr4-13872877251371240"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glenner</surname><given-names>GG</given-names></name><name name-style="western"><surname>Wong</surname><given-names>CW</given-names></name></person-group>. <article-title>Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein</article-title>. <source>Biochem Biophys Res Commun</source><year>1984</year>; <volume>120</volume>: <fpage>885</fpage>&#8211;<lpage>890</lpage>.<pub-id pub-id-type="pmid">6375662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0006-291x(84)80190-4</pub-id></mixed-citation></ref><ref id="bibr5-13872877251371240"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glenner</surname><given-names>GG</given-names></name><name name-style="western"><surname>Wong</surname><given-names>CW</given-names></name></person-group>. <article-title>Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein</article-title>. <source>Biochem Biophys Res Commun</source><year>1984</year>; <volume>122</volume>: <fpage>1131</fpage>&#8211;<lpage>1135</lpage>.<pub-id pub-id-type="pmid">6236805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-291x(84)91209-9</pub-id></mixed-citation></ref><ref id="bibr6-13872877251371240"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>CW</given-names></name><name name-style="western"><surname>Quaranta</surname><given-names>V</given-names></name><name name-style="western"><surname>Glenner</surname><given-names>GG</given-names></name></person-group>. <article-title>Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related</article-title>. <source>Proc Natl Acad Sci U S A</source><year>1985</year>; <volume>82</volume>: <fpage>8729</fpage>&#8211;<lpage>8732</lpage>.<pub-id pub-id-type="pmid">2934737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.82.24.8729</pub-id><pub-id pub-id-type="pmcid">PMC391510</pub-id></mixed-citation></ref><ref id="bibr7-13872877251371240"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saido</surname><given-names>TC</given-names></name><name name-style="western"><surname>Iwatsubo</surname><given-names>T</given-names></name><name name-style="western"><surname>Mann</surname><given-names>DM</given-names></name></person-group>, <etal>et al.</etal><article-title>Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques</article-title>. <source>Neuron</source><year>1995</year>; <volume>14</volume>: <fpage>457</fpage>&#8211;<lpage>466</lpage>.<pub-id pub-id-type="pmid">7857653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0896-6273(95)90301-1</pub-id></mixed-citation></ref><ref id="bibr8-13872877251371240"><label>8</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Saido</surname><given-names>TC</given-names></name></person-group>. <source>Alzheimer's Disease Research Guide: Animal Models for Understanding Mechanisms and Medications</source>. <publisher-loc>Cambridge</publisher-loc>, <publisher-loc>MA</publisher-loc>: <publisher-name>Elsevier Inc</publisher-name>, <year>2024</year>.</mixed-citation></ref><ref id="bibr9-13872877251371240"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosoda</surname><given-names>R</given-names></name><name name-style="western"><surname>Saido</surname><given-names>TC</given-names></name><name name-style="western"><surname>Otvos</surname><given-names>L</given-names><suffix>Jr</suffix></name></person-group>, <etal>et al.</etal><article-title>Quantification of modified amyloid beta peptides in Alzheimer disease and down syndrome brains</article-title>. <source>J Neuropathol Exp Neurol</source><year>1998</year>; <volume>57</volume>: <fpage>1089</fpage>&#8211;<lpage>1095</lpage>.<pub-id pub-id-type="pmid">9825946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00005072-199811000-00012</pub-id></mixed-citation></ref><ref id="bibr10-13872877251371240"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saido</surname><given-names>TC</given-names></name><name name-style="western"><surname>Nagao</surname><given-names>S</given-names></name><name name-style="western"><surname>Shiramine</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Autolytic transition of mu-calpain upon activation as resolved by antibodies distinguishing between the pre- and post-autolysis forms</article-title>. <source>J Biochem</source><year>1992</year>; <volume>111</volume>: <fpage>81</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">1607367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/oxfordjournals.jbchem.a123723</pub-id></mixed-citation></ref><ref id="bibr11-13872877251371240"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saido</surname><given-names>TC</given-names></name><name name-style="western"><surname>Yokota</surname><given-names>M</given-names></name><name name-style="western"><surname>Nagao</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Spatial resolution of fodrin proteolysis in postischemic brain</article-title>. <source>J Biol Chem</source><year>1993</year>; <volume>268</volume>: <fpage>25239</fpage>&#8211;<lpage>25243</lpage>.<pub-id pub-id-type="pmid">8227089</pub-id></mixed-citation></ref><ref id="bibr12-13872877251371240"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saido</surname><given-names>TC</given-names></name><name name-style="western"><surname>Sorimachi</surname><given-names>H</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></name></person-group>. <article-title>Calpain: new perspectives in molecular diversity and physiological-pathological involvement</article-title>. <source>FASEB J</source><year>1994</year>; <volume>8</volume>: <fpage>814</fpage>&#8211;<lpage>822</lpage>.<pub-id pub-id-type="pmid">8070630</pub-id></mixed-citation></ref><ref id="bibr13-13872877251371240"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saido</surname><given-names>TC</given-names></name><name name-style="western"><surname>Yokota</surname><given-names>M</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Spatial resolution of the primary beta-amyloidogenic process induced in postischemic hippocampus</article-title>. <source>J Biol Chem</source><year>1994</year>; <volume>269</volume>: <fpage>15253</fpage>&#8211;<lpage>15257</lpage>.<pub-id pub-id-type="pmid">8195161</pub-id></mixed-citation></ref><ref id="bibr14-13872877251371240"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ono</surname><given-names>Y</given-names></name><name name-style="western"><surname>Saido</surname><given-names>TC</given-names></name><name name-style="western"><surname>Sorimachi</surname><given-names>H</given-names></name></person-group>. <article-title>Calpain research for drug discovery: challenges and potential</article-title>. <source>Nat Rev Drug Discov</source><year>2016</year>; <volume>15</volume>: <fpage>854</fpage>&#8211;<lpage>876</lpage>.<pub-id pub-id-type="pmid">27833121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd.2016.212</pub-id></mixed-citation></ref><ref id="bibr15-13872877251371240"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Games</surname><given-names>D</given-names></name><name name-style="western"><surname>Adams</surname><given-names>D</given-names></name><name name-style="western"><surname>Alessandrini</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein</article-title>. <source>Nature</source><year>1995</year>; <volume>373</volume>: <fpage>523</fpage>&#8211;<lpage>527</lpage>.<pub-id pub-id-type="pmid">7845465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/373523a0</pub-id></mixed-citation></ref><ref id="bibr16-13872877251371240"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saido</surname><given-names>TC</given-names></name><name name-style="western"><surname>Yamao-Harigaya</surname><given-names>W</given-names></name><name name-style="western"><surname>Iwatsubo</surname><given-names>T</given-names></name></person-group>, <etal>et al.</etal><article-title>Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain</article-title>. <source>Neurosci Lett</source><year>1996</year>; <volume>215</volume>: <fpage>173</fpage>&#8211;<lpage>176</lpage>.<pub-id pub-id-type="pmid">8899741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0304-3940(96)12970-0</pub-id></mixed-citation></ref><ref id="bibr17-13872877251371240"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwata</surname><given-names>N</given-names></name><name name-style="western"><surname>Tsubuki</surname><given-names>S</given-names></name><name name-style="western"><surname>Sekiguchi</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Metabolic resistance of A&#946;3pE-42, a target epitope of the anti-Alzheimer therapeutic antibody, donanemab</article-title>. <source>Life Sci Alliance</source><year>2024</year>; <volume>7</volume>: <comment>e202402650</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.26508/lsa.202402650</pub-id><pub-id pub-id-type="pmcid">PMC11443169</pub-id><pub-id pub-id-type="pmid">39348937</pub-id></mixed-citation></ref><ref id="bibr18-13872877251371240"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moro</surname><given-names>ML</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>AS</given-names></name><name name-style="western"><surname>Gaimster</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Pyroglutamate and isoaspartate modified amyloid-Beta in ageing and Alzheimer's disease</article-title>. <source>Acta Neuropathol Commun</source><year>2018</year>; <volume>6</volume>: <fpage>3</fpage>.<pub-id pub-id-type="pmid">29298722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-017-0505-x</pub-id><pub-id pub-id-type="pmcid">PMC5753481</pub-id></mixed-citation></ref><ref id="bibr19-13872877251371240"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braak</surname><given-names>H</given-names></name><name name-style="western"><surname>Braak</surname><given-names>E</given-names></name></person-group>. <article-title>Neuropathological stageing of Alzheimer-related changes</article-title>. <source>Acta Neuropathol</source><year>1991</year>; <volume>82</volume>: <fpage>239</fpage>&#8211;<lpage>259</lpage>.<pub-id pub-id-type="pmid">1759558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00308809</pub-id></mixed-citation></ref><ref id="bibr20-13872877251371240"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>PT</given-names></name><name name-style="western"><surname>Alafuzoff</surname><given-names>I</given-names></name><name name-style="western"><surname>Bigio</surname><given-names>EH</given-names></name></person-group>, <etal>et al.</etal><article-title>Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature</article-title>. <source>J Neuropathol Exp Neurol</source><year>2012</year>; <volume>71</volume>: <fpage>362</fpage>&#8211;<lpage>381</lpage>.<pub-id pub-id-type="pmid">22487856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/NEN.0b013e31825018f7</pub-id><pub-id pub-id-type="pmcid">PMC3560290</pub-id></mixed-citation></ref><ref id="bibr21-13872877251371240"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>NIA-AA Research framework: toward a biological definition of Alzheimer's disease</article-title>. <source>Alzheimers Dement</source><year>2018</year>; <volume>14</volume>: <fpage>535</fpage>&#8211;<lpage>562</lpage>.<pub-id pub-id-type="pmid">29653606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmcid">PMC5958625</pub-id></mixed-citation></ref><ref id="bibr22-13872877251371240"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bejanin</surname><given-names>A</given-names></name><name name-style="western"><surname>Schonhaut</surname><given-names>DR</given-names></name><name name-style="western"><surname>La Joie</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease</article-title>. <source>Brain</source><year>2017</year>; <volume>140</volume>: <fpage>3286</fpage>&#8211;<lpage>3300</lpage>.<pub-id pub-id-type="pmid">29053874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awx243</pub-id><pub-id pub-id-type="pmcid">PMC5841139</pub-id></mixed-citation></ref><ref id="bibr23-13872877251371240"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawarabayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Younkin</surname><given-names>LH</given-names></name><name name-style="western"><surname>Saido</surname><given-names>TC</given-names></name></person-group>, <etal>et al.</etal><article-title>Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease</article-title>. <source>J Neurosci</source><year>2001</year>; <volume>21</volume>: <fpage>372</fpage>&#8211;<lpage>381</lpage>.<pub-id pub-id-type="pmid">11160418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.21-02-00372.2001</pub-id><pub-id pub-id-type="pmcid">PMC6763819</pub-id></mixed-citation></ref><ref id="bibr24-13872877251371240"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>C</given-names></name><name name-style="western"><surname>Saido</surname><given-names>TC</given-names></name><name name-style="western"><surname>DeBusk</surname><given-names>LM</given-names></name></person-group>, <etal>et al.</etal><article-title>Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and down's syndrome brains</article-title>. <source>FEBS Lett</source><year>1997</year>; <volume>409</volume>: <fpage>411</fpage>&#8211;<lpage>416</lpage>.<pub-id pub-id-type="pmid">9224700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0014-5793(97)00564-4</pub-id></mixed-citation></ref><ref id="bibr25-13872877251371240"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>C</given-names></name><name name-style="western"><surname>Schettini</surname><given-names>G</given-names></name><name name-style="western"><surname>Saido</surname><given-names>TC</given-names></name></person-group>, <etal>et al.</etal><article-title>Presenilin-1 mutations in Alzheimer's disease</article-title>. <source>Nature</source><year>2000</year>; <volume>405</volume>: <fpage>531</fpage>&#8211;<lpage>532</lpage>.<pub-id pub-id-type="pmid">10850703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/35014735</pub-id></mixed-citation></ref><ref id="bibr26-13872877251371240"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemere</surname><given-names>CA</given-names></name><name name-style="western"><surname>Blusztajn</surname><given-names>JK</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation</article-title>. <source>Neurobiol Dis</source><year>1996</year>; <volume>3</volume>: <fpage>16</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">9173910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/nbdi.1996.0003</pub-id></mixed-citation></ref><ref id="bibr27-13872877251371240"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selkoe</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>CR</given-names></name><name name-style="western"><surname>Podlisny</surname><given-names>MB</given-names></name></person-group>, <etal>et al.</etal><article-title>Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease</article-title>. <source>J Neurochem</source><year>1986</year>; <volume>46</volume>: <fpage>1820</fpage>&#8211;<lpage>1834</lpage>.<pub-id pub-id-type="pmid">3517233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1471-4159.1986.tb08501.x</pub-id></mixed-citation></ref><ref id="bibr28-13872877251371240"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>N</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>TT</given-names></name><name name-style="western"><surname>Cai</surname><given-names>XD</given-names></name></person-group>, <etal>et al.</etal><article-title>An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants</article-title>. <source>Science</source><year>1994</year>; <volume>264</volume>: <fpage>1336</fpage>&#8211;<lpage>1340</lpage>.<pub-id pub-id-type="pmid">8191290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.8191290</pub-id></mixed-citation></ref><ref id="bibr29-13872877251371240"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwata</surname><given-names>N</given-names></name><name name-style="western"><surname>Tsubuki</surname><given-names>S</given-names></name><name name-style="western"><surname>Takaki</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition</article-title>. <source>Nat Med</source><year>2000</year>; <volume>6</volume>: <fpage>143</fpage>&#8211;<lpage>150</lpage>.<pub-id pub-id-type="pmid">10655101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/72237</pub-id></mixed-citation></ref><ref id="bibr30-13872877251371240"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frost</surname><given-names>JL</given-names></name><name name-style="western"><surname>Le</surname><given-names>KX</given-names></name><name name-style="western"><surname>Cynis</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>Pyroglutamate-3 amyloid-&#946; deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models</article-title>. <source>Am J Pathol</source><year>2013</year>; <volume>183</volume>: <fpage>369</fpage>&#8211;<lpage>381</lpage>.<pub-id pub-id-type="pmid">23747948</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajpath.2013.05.005</pub-id><pub-id pub-id-type="pmcid">PMC3730768</pub-id></mixed-citation></ref><ref id="bibr31-13872877251371240"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>T</given-names></name><name name-style="western"><surname>Matsuba</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mihira</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>Single App knock-in mouse models of Alzheimer's disease</article-title>. <source>Nat Neurosci</source><year>2014</year>; <volume>17</volume>: <fpage>661</fpage>&#8211;<lpage>663</lpage>.<pub-id pub-id-type="pmid">24728269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.3697</pub-id></mixed-citation></ref><ref id="bibr32-13872877251371240"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasaguri</surname><given-names>H</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Watamura</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>Recent advances in the modeling of Alzheimer's disease</article-title>. <source>Front Neurosci</source><year>2022</year>; <volume>16</volume>: <fpage>807473</fpage>.<pub-id pub-id-type="pmid">35431779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2022.807473</pub-id><pub-id pub-id-type="pmcid">PMC9009508</pub-id></mixed-citation></ref><ref id="bibr33-13872877251371240"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bateman</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>C</given-names></name><name name-style="western"><surname>Benzinger</surname><given-names>TL</given-names></name></person-group>, <etal>et al.</etal><article-title>Clinical and biomarker changes in dominantly inherited Alzheimer's disease</article-title>. <source>N Engl J Med</source><year>2012</year>; <volume>367</volume>: <fpage>795</fpage>&#8211;<lpage>804</lpage>.<pub-id pub-id-type="pmid">22784036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1202753</pub-id><pub-id pub-id-type="pmcid">PMC3474597</pub-id></mixed-citation></ref><ref id="bibr34-13872877251371240"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leverenz</surname><given-names>JB</given-names></name><name name-style="western"><surname>Raskind</surname><given-names>MA</given-names></name></person-group>. <article-title>Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis</article-title>. <source>Exp Neurol</source><year>1998</year>; <volume>150</volume>: <fpage>296</fpage>&#8211;<lpage>304</lpage>.<pub-id pub-id-type="pmid">9527899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/exnr.1997.6777</pub-id></mixed-citation></ref><ref id="bibr35-13872877251371240"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abraham</surname><given-names>GN</given-names></name><name name-style="western"><surname>Podell</surname><given-names>DN</given-names></name></person-group>. <article-title>Pyroglutamic acid. Non-metabolic formation, function in proteins and peptides, and characteristics of the enzymes effecting its removal</article-title>. <source>Mol Cell Biochem</source><year>1981</year>; <volume>38 Spec No</volume>: <fpage>181</fpage>&#8211;<lpage>190</lpage>.<pub-id pub-id-type="pmid">6117006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00235695</pub-id></mixed-citation></ref><ref id="bibr36-13872877251371240"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirotani</surname><given-names>K</given-names></name><name name-style="western"><surname>Tsubuki</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name></person-group>, <etal>et al.</etal><article-title>Generation of amyloid beta peptide with pyroglutamate at position 3 in primary cortical neurons</article-title>. <source>Neurosci Lett</source><year>2002</year>; <volume>327</volume>: <fpage>25</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="pmid">12098492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0304-3940(02)00351-8</pub-id></mixed-citation></ref><ref id="bibr37-13872877251371240"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nussbaum</surname><given-names>JM</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>S</given-names></name><name name-style="western"><surname>Cynis</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-&#946;</article-title>. <source>Nature</source><year>2012</year>; <volume>485</volume>: <fpage>651</fpage>&#8211;<lpage>655</lpage>.<pub-id pub-id-type="pmid">22660329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11060</pub-id><pub-id pub-id-type="pmcid">PMC3367389</pub-id></mixed-citation></ref><ref id="bibr38-13872877251371240"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matos</surname><given-names>JO</given-names></name><name name-style="western"><surname>Goldblatt</surname><given-names>G</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Pyroglutamylated amyloid-&#946; peptide reverses cross &#946;-sheets by a prion-like mechanism</article-title>. <source>J Phys Chem B</source><year>2014</year>; <volume>118</volume>: <fpage>5637</fpage>&#8211;<lpage>5643</lpage>.<pub-id pub-id-type="pmid">24802697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jp412743s</pub-id><pub-id pub-id-type="pmcid">PMC4216196</pub-id></mixed-citation></ref><ref id="bibr39-13872877251371240"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldblatt</surname><given-names>G</given-names></name><name name-style="western"><surname>Matos</surname><given-names>JO</given-names></name><name name-style="western"><surname>Gornto</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Isotope-edited FTIR reveals distinct aggregation and structural behaviors of unmodified and pyroglutamylated amyloid &#946; peptides</article-title>. <source>Phys Chem Chem Phys</source><year>2015</year>; <volume>17</volume>: <fpage>32149</fpage>&#8211;<lpage>32160</lpage>.<pub-id pub-id-type="pmid">26214017</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c5cp03343h</pub-id><pub-id pub-id-type="pmcid">PMC4668202</pub-id></mixed-citation></ref><ref id="bibr40-13872877251371240"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wulff</surname><given-names>M</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>M</given-names></name><name name-style="western"><surname>Th&#252;mmler</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Enhanced fibril fragmentation of N-terminally truncated and pyroglutamyl-modified A&#946; peptides</article-title>. <source>Angew Chem Int Ed Engl</source><year>2016</year>; <volume>55</volume>: <fpage>5081</fpage>&#8211;<lpage>5084</lpage>.<pub-id pub-id-type="pmid">26970534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.201511099</pub-id></mixed-citation></ref><ref id="bibr41-13872877251371240"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldblatt</surname><given-names>G</given-names></name><name name-style="western"><surname>Cilenti</surname><given-names>L</given-names></name><name name-style="western"><surname>Matos</surname><given-names>JO</given-names></name></person-group>, <etal>et al.</etal><article-title>Unmodified and pyroglutamylated amyloid &#946; peptides form hypertoxic hetero-oligomers of unique secondary structure</article-title>. <source>FEBS J</source><year>2017</year>; <volume>284</volume>: <fpage>1355</fpage>&#8211;<lpage>1369</lpage>.<pub-id pub-id-type="pmid">28294556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/febs.14058</pub-id></mixed-citation></ref><ref id="bibr42-13872877251371240"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abedin</surname><given-names>F</given-names></name><name name-style="western"><surname>Tatulian</surname><given-names>SA</given-names></name></person-group>. <article-title>Mutual structural effects of unmodified and pyroglutamylated amyloid &#946; peptides during aggregation</article-title>. <source>J Pept Sci</source><year>2021</year>; <volume>27</volume>: <comment>e3312</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psc.3312</pub-id><pub-id pub-id-type="pmid">33631839</pub-id></mixed-citation></ref><ref id="bibr43-13872877251371240"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>N</given-names></name><name name-style="western"><surname>Lyu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name></person-group>, <etal>et al.</etal><article-title>Investigation of the interaction of amyloid &#946; peptide (11-42) oligomers with a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) membrane using molecular dynamics simulation</article-title>. <source>Phys Chem Chem Phys</source><year>2018</year>; <volume>20</volume>: <fpage>6817</fpage>&#8211;<lpage>6829</lpage>.<pub-id pub-id-type="pmid">29299557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c7cp07148e</pub-id></mixed-citation></ref><ref id="bibr44-13872877251371240"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roterman</surname><given-names>I</given-names></name><name name-style="western"><surname>Du&#322;ak</surname><given-names>D</given-names></name><name name-style="western"><surname>Gadza&#322;a</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Structural analysis of the A&#946;(11-42) amyloid fibril based on hydrophobicity distribution</article-title>. <source>J Comput Aided Mol Des</source><year>2019</year>; <volume>33</volume>: <fpage>665</fpage>&#8211;<lpage>675</lpage>.<pub-id pub-id-type="pmid">31292794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10822-019-00209-9</pub-id><pub-id pub-id-type="pmcid">PMC6687686</pub-id></mixed-citation></ref><ref id="bibr45-13872877251371240"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tung</surname><given-names>NT</given-names></name><name name-style="western"><surname>Derreumaux</surname><given-names>P</given-names></name><name name-style="western"><surname>Vu</surname><given-names>VV</given-names></name></person-group>, <etal>et al.</etal><article-title>C-terminal plays as the possible nucleation of the self-aggregation of the S-shape A&#946;(11-42) tetramer in solution: intensive MD study</article-title>. <source>ACS Omega</source><year>2019</year>; <volume>4</volume>: <fpage>11066</fpage>&#8211;<lpage>11073</lpage>.<pub-id pub-id-type="pmid">31460204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsomega.9b00992</pub-id><pub-id pub-id-type="pmcid">PMC6648102</pub-id></mixed-citation></ref><ref id="bibr46-13872877251371240"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gowing</surname><given-names>E</given-names></name><name name-style="western"><surname>Roher</surname><given-names>AE</given-names></name><name name-style="western"><surname>Woods</surname><given-names>AS</given-names></name></person-group>, <etal>et al.</etal><article-title>Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease</article-title>. <source>J Biol Chem</source><year>1994</year>; <volume>269</volume>: <fpage>10987</fpage>&#8211;<lpage>10990</lpage>.<pub-id pub-id-type="pmid">8157623</pub-id></mixed-citation></ref><ref id="bibr47-13872877251371240"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>B</given-names></name><name name-style="western"><surname>Nussinov</surname><given-names>R</given-names></name></person-group>. <article-title>Polymorphism of Alzheimer's Abeta17-42 (p3) oligomers: the importance of the turn location and its conformation</article-title>. <source>Biophys J</source><year>2009</year>; <volume>97</volume>: <fpage>1168</fpage>&#8211;<lpage>1177</lpage>.<pub-id pub-id-type="pmid">19686665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bpj.2009.05.042</pub-id><pub-id pub-id-type="pmcid">PMC2726324</pub-id></mixed-citation></ref><ref id="bibr48-13872877251371240"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>JH</given-names></name><name name-style="western"><surname>Liu</surname><given-names>HL</given-names></name><name name-style="western"><surname>Liu</surname><given-names>YF</given-names></name></person-group>, <etal>et al.</etal><article-title>Molecular dynamics simulations to investigate the aggregation behaviors of the Abeta(17-42) oligomers</article-title>. <source>J Biomol Struct Dyn</source><year>2009</year>; <volume>26</volume>: <fpage>481</fpage>&#8211;<lpage>490</lpage>.<pub-id pub-id-type="pmid">19108587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2009.10507263</pub-id></mixed-citation></ref><ref id="bibr49-13872877251371240"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>W</given-names></name><name name-style="western"><surname>Schulten</surname><given-names>K</given-names></name></person-group>. <article-title>Fibril elongation by A&#946;(17-42): kinetic network analysis of hybrid-resolution molecular dynamics simulations</article-title>. <source>J Am Chem Soc</source><year>2014</year>; <volume>136</volume>: <fpage>12450</fpage>&#8211;<lpage>12460</lpage>.<pub-id pub-id-type="pmid">25134066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ja507002p</pub-id><pub-id pub-id-type="pmcid">PMC4156860</pub-id></mixed-citation></ref><ref id="bibr50-13872877251371240"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khatua</surname><given-names>P</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>SK</given-names></name><name name-style="western"><surname>Bandyopadhyay</surname><given-names>S</given-names></name></person-group>. <article-title>Size-dependent conformational features of A&#946;(17-42) protofilaments from molecular simulation studies</article-title>. <source>J Chem Inf Model</source><year>2017</year>; <volume>57</volume>: <fpage>2378</fpage>&#8211;<lpage>2392</lpage>.<pub-id pub-id-type="pmid">28853902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jcim.7b00407</pub-id></mixed-citation></ref><ref id="bibr51-13872877251371240"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khatua</surname><given-names>P</given-names></name><name name-style="western"><surname>Bandyopadhyay</surname><given-names>S</given-names></name></person-group>. <article-title>Understanding the microscopic origin behind heterogeneous properties of water confined in and around A&#946;(17-42) protofilaments</article-title>. <source>J Chem Phys</source><year>2018</year>; <volume>149</volume>: <fpage>065101</fpage>.<pub-id pub-id-type="pmid">30111136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1063/1.5040672</pub-id></mixed-citation></ref><ref id="bibr52-13872877251371240"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>R&#246;der</surname><given-names>K</given-names></name><name name-style="western"><surname>Wales</surname><given-names>DJ</given-names></name></person-group>. <article-title>Energy landscapes for the aggregation of A&#946;(17-42)</article-title>. <source>J Am Chem Soc</source><year>2018</year>; <volume>140</volume>: <fpage>4018</fpage>&#8211;<lpage>4027</lpage>.<pub-id pub-id-type="pmid">29482324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.7b12896</pub-id></mixed-citation></ref><ref id="bibr53-13872877251371240"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuhn</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Raskatov</surname><given-names>J</given-names></name></person-group>. <article-title>Is the p3 peptide (A&#946;17-40, A&#946;17-42) relevant to the pathology of Alzheimer's disease?</article-title><source>J Alzheimers Dis</source><year>2020</year>; <volume>74</volume>: <fpage>43</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="pmid">32176648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-191201</pub-id><pub-id pub-id-type="pmcid">PMC7443050</pub-id></mixed-citation></ref><ref id="bibr54-13872877251371240"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Z</given-names></name><name name-style="western"><surname>Guo</surname><given-names>JL</given-names></name><name name-style="western"><surname>McBride</surname><given-names>JD</given-names></name></person-group>, <etal>et al.</etal><article-title>Amyloid-beta plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation</article-title>. <source>Nat Med</source><year>2018</year>; <volume>24</volume>: <fpage>29</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="pmid">29200205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.4443</pub-id><pub-id pub-id-type="pmcid">PMC5760353</pub-id></mixed-citation></ref><ref id="bibr55-13872877251371240"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>S</given-names></name><name name-style="western"><surname>Beja-Glasser</surname><given-names>VF</given-names></name><name name-style="western"><surname>Nfonoyim</surname><given-names>BM</given-names></name></person-group>, <etal>et al.</etal><article-title>Complement and microglia mediate early synapse loss in Alzheimer mouse models</article-title>. <source>Science</source><year>2016</year>; <volume>352</volume>: <fpage>712</fpage>&#8211;<lpage>716</lpage>.<pub-id pub-id-type="pmid">27033548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aad8373</pub-id><pub-id pub-id-type="pmcid">PMC5094372</pub-id></mixed-citation></ref><ref id="bibr56-13872877251371240"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liddelow</surname><given-names>SA</given-names></name><name name-style="western"><surname>Guttenplan</surname><given-names>KA</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>LE</given-names></name></person-group>, <etal>et al.</etal><article-title>Neurotoxic reactive astrocytes are induced by activated microglia</article-title>. <source>Nature</source><year>2017</year>; <volume>541</volume>: <fpage>481</fpage>&#8211;<lpage>487</lpage>.<pub-id pub-id-type="pmid">28099414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature21029</pub-id><pub-id pub-id-type="pmcid">PMC5404890</pub-id></mixed-citation></ref><ref id="bibr57-13872877251371240"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nixon</surname><given-names>RA</given-names></name></person-group>. <article-title>Autophagy-lysosomal-associated neuronal death in neurodegenerative disease</article-title>. <source>Acta Neuropathol</source><year>2024</year>; <volume>148</volume>: <fpage>42</fpage>.<pub-id pub-id-type="pmid">39259382</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-024-02799-7</pub-id><pub-id pub-id-type="pmcid">PMC11418399</pub-id></mixed-citation></ref><ref id="bibr58-13872877251371240"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhapola</surname><given-names>R</given-names></name><name name-style="western"><surname>Kumari</surname><given-names>S</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name></person-group>, <etal>et al.</etal><article-title>Advancements in autophagy perturbations in Alzheimer's disease: molecular aspects and therapeutics</article-title>. <source>Brain Res</source><year>2025</year>; <volume>1851</volume>: <fpage>149494</fpage>.<pub-id pub-id-type="pmid">39922409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2025.149494</pub-id></mixed-citation></ref><ref id="bibr59-13872877251371240"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukami</surname><given-names>S</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>K</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>A beta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with A beta pathology</article-title>. <source>Neurosci Res</source><year>2002</year>; <volume>43</volume>: <fpage>39</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">12074840</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0168-0102(02)00015-9</pub-id></mixed-citation></ref><ref id="bibr60-13872877251371240"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwata</surname><given-names>N</given-names></name><name name-style="western"><surname>Takaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fukami</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging</article-title>. <source>J Neurosci Res</source><year>2002</year>; <volume>70</volume>: <fpage>493</fpage>&#8211;<lpage>500</lpage>.<pub-id pub-id-type="pmid">12391610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jnr.10390</pub-id></mixed-citation></ref><ref id="bibr61-13872877251371240"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwata</surname><given-names>N</given-names></name><name name-style="western"><surname>Mizukami</surname><given-names>H</given-names></name><name name-style="western"><surname>Shirotani</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain</article-title>. <source>J Neurosci</source><year>2004</year>; <volume>24</volume>: <fpage>991</fpage>&#8211;<lpage>998</lpage>.<pub-id pub-id-type="pmid">14749444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.4792-03.2004</pub-id><pub-id pub-id-type="pmcid">PMC6729819</pub-id></mixed-citation></ref><ref id="bibr62-13872877251371240"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cynis</surname><given-names>H</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>S</given-names></name><name name-style="western"><surname>Bodn&#225;r</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells</article-title>. <source>Biochim Biophys Acta</source><year>2006</year>; <volume>1764</volume>: <fpage>1618</fpage>&#8211;<lpage>1625</lpage>.<pub-id pub-id-type="pmid">17005457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbapap.2006.08.003</pub-id></mixed-citation></ref><ref id="bibr63-13872877251371240"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cynis</surname><given-names>H</given-names></name><name name-style="western"><surname>Scheel</surname><given-names>E</given-names></name><name name-style="western"><surname>Saido</surname><given-names>TC</given-names></name></person-group>, <etal>et al.</etal><article-title>Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta</article-title>. <source>Biochemistry</source><year>2008</year>; <volume>47</volume>: <fpage>7405</fpage>&#8211;<lpage>7413</lpage>.<pub-id pub-id-type="pmid">18570439</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/bi800250p</pub-id></mixed-citation></ref><ref id="bibr64-13872877251371240"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schilling</surname><given-names>S</given-names></name><name name-style="western"><surname>Zeitschel</surname><given-names>U</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>T</given-names></name></person-group>, <etal>et al.</etal><article-title>Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology</article-title>. <source>Nat Med</source><year>2008</year>; <volume>14</volume>: <fpage>1106</fpage>&#8211;<lpage>1111</lpage>.<pub-id pub-id-type="pmid">18836460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.1872</pub-id></mixed-citation></ref><ref id="bibr65-13872877251371240"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morawski</surname><given-names>M</given-names></name><name name-style="western"><surname>Hartlage-R&#252;bsamen</surname><given-names>M</given-names></name><name name-style="western"><surname>J&#228;ger</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease</article-title>. <source>Acta Neuropathol</source><year>2010</year>; <volume>120</volume>: <fpage>195</fpage>&#8211;<lpage>207</lpage>.<pub-id pub-id-type="pmid">20383514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-010-0685-y</pub-id><pub-id pub-id-type="pmcid">PMC2892616</pub-id></mixed-citation></ref><ref id="bibr66-13872877251371240"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartlage-R&#252;bsamen</surname><given-names>M</given-names></name><name name-style="western"><surname>Morawski</surname><given-names>M</given-names></name><name name-style="western"><surname>Waniek</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-A&#946; deposits in hippocampus via distinct cellular mechanisms</article-title>. <source>Acta Neuropathol</source><year>2011</year>; <volume>121</volume>: <fpage>705</fpage>&#8211;<lpage>719</lpage>.<pub-id pub-id-type="pmid">21301857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-011-0806-2</pub-id><pub-id pub-id-type="pmcid">PMC3098988</pub-id></mixed-citation></ref><ref id="bibr67-13872877251371240"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jawhar</surname><given-names>S</given-names></name><name name-style="western"><surname>Wirths</surname><given-names>O</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice</article-title>. <source>J Biol Chem</source><year>2011</year>; <volume>286</volume>: <fpage>4454</fpage>&#8211;<lpage>4460</lpage>.<pub-id pub-id-type="pmid">21148560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M110.185819</pub-id><pub-id pub-id-type="pmcid">PMC3039372</pub-id></mixed-citation></ref><ref id="bibr68-13872877251371240"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>A</given-names></name><name name-style="western"><surname>Heiser</surname><given-names>U</given-names></name></person-group>, <etal>et al.</etal><article-title>Glutaminyl cyclase inhibitor PQ912 improves cognition in mouse models of Alzheimer's disease-studies on relation to effective target occupancy</article-title>. <source>J Pharmacol Exp Ther</source><year>2017</year>; <volume>362</volume>: <fpage>119</fpage>&#8211;<lpage>130</lpage>.<pub-id pub-id-type="pmid">28446518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.117.240614</pub-id></mixed-citation></ref><ref id="bibr69-13872877251371240"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonyan</surname><given-names>A</given-names></name><name name-style="western"><surname>Schlenzig</surname><given-names>D</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Concerted action of dipeptidyl peptidase IV and glutaminyl cyclase results in formation of pyroglutamate-modified amyloid peptides in vitro</article-title>. <source>Neurochem Int</source><year>2018</year>; <volume>113</volume>: <fpage>112</fpage>&#8211;<lpage>119</lpage>.<pub-id pub-id-type="pmid">29224965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuint.2017.12.001</pub-id></mixed-citation></ref><ref id="bibr70-13872877251371240"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlenzig</surname><given-names>D</given-names></name><name name-style="western"><surname>Cynis</surname><given-names>H</given-names></name><name name-style="western"><surname>Hartlage-R&#252;bsamen</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Dipeptidyl-peptidase activity of meprin &#946; links N-truncation of A&#946; with glutaminyl cyclase-catalyzed pGlu-A&#946; formation</article-title>. <source>J Alzheimers Dis</source><year>2018</year>; <volume>66</volume>: <fpage>359</fpage>&#8211;<lpage>375</lpage>.<pub-id pub-id-type="pmid">30320570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-171183</pub-id></mixed-citation></ref><ref id="bibr71-13872877251371240"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akiyama</surname><given-names>H</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>H</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid beta-protein (Abeta) deposition</article-title>. <source>Brain Res</source><year>2001</year>; <volume>902</volume>: <fpage>277</fpage>&#8211;<lpage>281</lpage>.<pub-id pub-id-type="pmid">11384622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0006-8993(01)02390-3</pub-id></mixed-citation></ref><ref id="bibr72-13872877251371240"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yasojima</surname><given-names>K</given-names></name><name name-style="western"><surname>Akiyama</surname><given-names>H</given-names></name><name name-style="western"><surname>McGeer</surname><given-names>EG</given-names></name></person-group>, <etal>et al.</etal><article-title>Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide</article-title>. <source>Neurosci Lett</source><year>2001</year>; <volume>297</volume>: <fpage>97</fpage>&#8211;<lpage>100</lpage>.<pub-id pub-id-type="pmid">11121879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0304-3940(00)01675-x</pub-id></mixed-citation></ref><ref id="bibr73-13872877251371240"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yasojima</surname><given-names>K</given-names></name><name name-style="western"><surname>McGeer</surname><given-names>EG</given-names></name><name name-style="western"><surname>McGeer</surname><given-names>PL</given-names></name></person-group>. <article-title>Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain</article-title>. <source>Brain Res</source><year>2001</year>; <volume>919</volume>: <fpage>115</fpage>&#8211;<lpage>121</lpage>.<pub-id pub-id-type="pmid">11689168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0006-8993(01)03008-6</pub-id></mixed-citation></ref><ref id="bibr74-13872877251371240"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>DS</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>N</given-names></name><name name-style="western"><surname>Hama</surname><given-names>E</given-names></name></person-group>, <etal>et al.</etal><article-title>Oxidized neprilysin in aging and Alzheimer's disease brains</article-title>. <source>Biochem Biophys Res Commun</source><year>2003</year>; <volume>310</volume>: <fpage>236</fpage>&#8211;<lpage>241</lpage>.<pub-id pub-id-type="pmid">14511676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2003.09.003</pub-id></mixed-citation></ref><ref id="bibr75-13872877251371240"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hellstrom-Lindahl</surname><given-names>E</given-names></name><name name-style="western"><surname>Ravid</surname><given-names>R</given-names></name><name name-style="western"><surname>Nordberg</surname><given-names>A</given-names></name></person-group>. <article-title>Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels</article-title>. <source>Neurobiol Aging</source><year>2008</year>; <volume>29</volume>: <fpage>210</fpage>&#8211;<lpage>221</lpage>.<pub-id pub-id-type="pmid">17098332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2006.10.010</pub-id></mixed-citation></ref><ref id="bibr76-13872877251371240"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maruyama</surname><given-names>M</given-names></name><name name-style="western"><surname>Higuchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Takaki</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease</article-title>. <source>Ann Neurol</source><year>2005</year>; <volume>57</volume>: <fpage>832</fpage>&#8211;<lpage>842</lpage>.<pub-id pub-id-type="pmid">15929037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.20494</pub-id></mixed-citation></ref><ref id="bibr77-13872877251371240"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellenguez</surname><given-names>C</given-names></name><name name-style="western"><surname>K&#252;&#231;&#252;kali</surname><given-names>F</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>IE</given-names></name></person-group>, <etal>et al.</etal><article-title>New insights into the genetic etiology of Alzheimer's disease and related dementias</article-title>. <source>Nat Genet</source><year>2022</year>; <volume>54</volume>: <fpage>412</fpage>&#8211;<lpage>436</lpage>.<pub-id pub-id-type="pmid">35379992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-022-01024-z</pub-id><pub-id pub-id-type="pmcid">PMC9005347</pub-id></mixed-citation></ref><ref id="bibr78-13872877251371240"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morito</surname><given-names>T</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Takamura</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>The role of neprilysin and insulin-degrading enzyme in the etiology of sporadic Alzheimer's disease</article-title>. <source>J Neurosci</source><year>2025</year>; <volume>45</volume>: <comment>e2152242025</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.2152-24.2025</pub-id><pub-id pub-id-type="pmcid">PMC12139590</pub-id><pub-id pub-id-type="pmid">40300834</pub-id></mixed-citation></ref><ref id="bibr79-13872877251371240"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demattos</surname><given-names>RB</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>A plaque-specific antibody clears existing &#946;-amyloid plaques in Alzheimer's disease mice</article-title>. <source>Neuron</source><year>2012</year>; <volume>76</volume>: <fpage>908</fpage>&#8211;<lpage>920</lpage>.<pub-id pub-id-type="pmid">23217740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2012.10.029</pub-id></mixed-citation></ref><ref id="bibr80-13872877251371240"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwatsubo</surname><given-names>T</given-names></name><name name-style="western"><surname>Saido</surname><given-names>TC</given-names></name><name name-style="western"><surname>Mann</surname><given-names>DMA</given-names></name></person-group>, <etal>et al.</etal><article-title>Full-length amyloid-beta(1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques</article-title>. <source>Am J Pathol</source><year>1996</year>; <volume>149</volume>: <fpage>1823</fpage>&#8211;<lpage>1830</lpage>.<pub-id pub-id-type="pmid">8952519</pub-id><pub-id pub-id-type="pmcid">PMC1865366</pub-id></mixed-citation></ref><ref id="bibr81-13872877251371240"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Comparative efficacy and safety of monoclonal antibodies for cognitive decline in patients with Alzheimer's disease: a systematic review and network meta-analysis</article-title>. <source>CNS Drugs</source><year>2024</year>; <volume>38</volume>: <fpage>169</fpage>&#8211;<lpage>192</lpage>.<pub-id pub-id-type="pmid">38429615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40263-024-01067-2</pub-id></mixed-citation></ref><ref id="bibr82-13872877251371240"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Silverglate</surname><given-names>BD</given-names></name></person-group>, <etal>et al.</etal><article-title>Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's</article-title>. <source>Expert Opin Drug Metab Toxicol</source><year>2024</year>; <volume>20</volume>: <fpage>411</fpage>&#8211;<lpage>417</lpage>.<pub-id pub-id-type="pmid">38758223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17425255.2024.2357637</pub-id></mixed-citation></ref><ref id="bibr83-13872877251371240"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cogswell</surname><given-names>PM</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Barakos</surname><given-names>JA</given-names></name></person-group>, <etal>et al.</etal><article-title>Alzheimer disease anti-amyloid immunotherapies: imaging recommendations and practice considerations for monitoring of amyloid-related imaging abnormalities</article-title>. <source>AJNR Am J Neuroradiol</source><year>2025</year>; <volume>46</volume>: <fpage>24</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">39179297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3174/ajnr.A8469</pub-id><pub-id pub-id-type="pmcid">PMC11735439</pub-id></mixed-citation></ref><ref id="bibr84-13872877251371240"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khartabil</surname><given-names>N</given-names></name><name name-style="western"><surname>Awaness</surname><given-names>A</given-names></name></person-group>. <article-title>Targeting amyloid pathology in early Alzheimer's: the promise of donanemab-azbt</article-title>. <source>Pharmacy (Basel)</source><year>2025</year>; <volume>13</volume>: <fpage>23</fpage>.<pub-id pub-id-type="pmid">39998021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmacy13010023</pub-id><pub-id pub-id-type="pmcid">PMC11859624</pub-id></mixed-citation></ref><ref id="bibr85-13872877251371240"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Dyck</surname><given-names>CH</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P</given-names></name></person-group>, <etal>et al.</etal><article-title>Lecanemab in early Alzheimer's disease</article-title>. <source>N Engl J Med</source><year>2023</year>; <volume>388</volume>: <fpage>9</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">36449413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2212948</pub-id></mixed-citation></ref><ref id="bibr86-13872877251371240"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arroyo-Pacheco</surname><given-names>N</given-names></name><name name-style="western"><surname>Sarmiento-Blanco</surname><given-names>S</given-names></name><name name-style="western"><surname>Vergara-Cadavid</surname><given-names>G</given-names></name></person-group>, <etal>et al.</etal><article-title>Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: a systematic review and meta-analysis</article-title>. <source>Ageing Res Rev</source><year>2025</year>; <volume>104</volume>: <fpage>102620</fpage>.<pub-id pub-id-type="pmid">39638097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2024.102620</pub-id></mixed-citation></ref><ref id="bibr87-13872877251371240"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardy</surname><given-names>J</given-names></name><name name-style="western"><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group>. <article-title>The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics</article-title>. <source>Science</source><year>2002</year>; <volume>297</volume>: <fpage>353</fpage>&#8211;<lpage>356</lpage>.<pub-id pub-id-type="pmid">12130773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1072994</pub-id></mixed-citation></ref><ref id="bibr88-13872877251371240"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selkoe</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>J</given-names></name></person-group>. <article-title>The amyloid hypothesis of Alzheimer's disease at 25 years</article-title>. <source>EMBO Mol Med</source><year>2016</year>; <volume>8</volume>: <fpage>595</fpage>&#8211;<lpage>608</lpage>.<pub-id pub-id-type="pmid">27025652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.201606210</pub-id><pub-id pub-id-type="pmcid">PMC4888851</pub-id></mixed-citation></ref><ref id="bibr89-13872877251371240"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jucker</surname><given-names>M</given-names></name><name name-style="western"><surname>Walker</surname><given-names>LC</given-names></name></person-group>. <article-title>Alzheimer's disease: from immunotherapy to immunoprevention</article-title>. <source>Cell</source><year>2023</year>; <volume>186</volume>: <fpage>4260</fpage>&#8211;<lpage>4270</lpage>.<pub-id pub-id-type="pmid">37729908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.08.021</pub-id><pub-id pub-id-type="pmcid">PMC10578497</pub-id></mixed-citation></ref><ref id="bibr90-13872877251371240"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Synnott</surname><given-names>PG</given-names></name><name name-style="western"><surname>Majda</surname><given-names>T</given-names></name><name name-style="western"><surname>Lin</surname><given-names>PJ</given-names></name></person-group>, <etal>et al.</etal><article-title>Modeling the population equity of Alzheimer disease treatments in the US</article-title>. <source>JAMA Netw Open</source><year>2024</year>; <volume>7</volume>: <comment>e2442353</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2024.42353</pub-id><pub-id pub-id-type="pmcid">PMC11528311</pub-id><pub-id pub-id-type="pmid">39480421</pub-id></mixed-citation></ref><ref id="bibr91-13872877251371240"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mudrazija</surname><given-names>S</given-names></name><name name-style="western"><surname>Aranda</surname><given-names>MP</given-names></name><name name-style="western"><surname>Gaskin</surname><given-names>DJ</given-names></name></person-group>, <etal>et al.</etal><article-title>Economic burden of Alzheimer disease and related dementias by race and ethnicity, 2020 to 2060</article-title>. <source>JAMA Netw Open</source><year>2025</year>; <volume>8</volume>: <comment>e2513931</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2025.13931</pub-id><pub-id pub-id-type="pmcid">PMC12142444</pub-id><pub-id pub-id-type="pmid">40471578</pub-id></mixed-citation></ref><ref id="bibr92-13872877251371240"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><name name-style="western"><surname>Rawal</surname><given-names>S</given-names></name><name name-style="western"><surname>Young</surname><given-names>HN</given-names></name></person-group>, <etal>et al.</etal><article-title>Innovation, affordability, access: Alzheimer disease drugs and the Inflation Reduction Act</article-title>. <source>Am J Manag Care</source><year>2024</year>; <volume>30</volume>: <comment>e169</comment>&#8211;<lpage>e171</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.37765/ajmc.2024.89563</pub-id><pub-id pub-id-type="pmid">38912930</pub-id></mixed-citation></ref><ref id="bibr93-13872877251371240"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>T</given-names></name><name name-style="western"><surname>Takaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>Alzheimer's disease, neuropeptides, neuropeptidase, and amyloid-{beta} peptide metabolism</article-title>. <source>Sci Aging Knowledge Environ</source><year>2003</year>; <volume>2003</volume>: <comment>PE1</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sageke.2003.3.pe1</pub-id><pub-id pub-id-type="pmid">12844556</pub-id></mixed-citation></ref><ref id="bibr94-13872877251371240"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>T</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>N</given-names></name><name name-style="western"><surname>Tsubuki</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Somatostatin regulates brain amyloid beta peptide A beta(42) through modulation of proteolytic degradation</article-title>. <source>Nat Med</source><year>2005</year>; <volume>11</volume>: <fpage>434</fpage>&#8211;<lpage>439</lpage>.<pub-id pub-id-type="pmid">15778722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm1206</pub-id></mixed-citation></ref><ref id="bibr95-13872877251371240"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watamura</surname><given-names>N</given-names></name><name name-style="western"><surname>Kakiya</surname><given-names>N</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>P</given-names></name></person-group>, <etal>et al.</etal><article-title>Somatostatin-evoked a&#946; catabolism in the brain: mechanistic involvement of &#945;-endosulfine-K(ATP) channel pathway</article-title>. <source>Mol Psychiatry</source><year>2022</year>; <volume>27</volume>: <fpage>1816</fpage>&#8211;<lpage>1828</lpage>.<pub-id pub-id-type="pmid">34737456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-021-01368-8</pub-id><pub-id pub-id-type="pmcid">PMC9095489</pub-id></mixed-citation></ref><ref id="bibr96-13872877251371240"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watamura</surname><given-names>N</given-names></name><name name-style="western"><surname>Kakiya</surname><given-names>N</given-names></name><name name-style="western"><surname>Fujioka</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>The dopaminergic system promotes neprilysin-mediated degradation of amyloid-&#946; in the brain</article-title>. <source>Sci Signal</source><year>2024</year>; <volume>17</volume>: <comment>eadk1822</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scisignal.adk1822</pub-id><pub-id pub-id-type="pmid">39106321</pub-id></mixed-citation></ref><ref id="bibr97-13872877251371240"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morito</surname><given-names>T</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Takamura</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>The role of neprilysin and insulin-degrading enzyme in the etiology of sporadic Alzheimer's disease</article-title>. <source>J Neurosci</source><year>2025</year>; <volume>45</volume>: <comment>e2152242025</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.2152-24.2025</pub-id><pub-id pub-id-type="pmcid">PMC12139590</pub-id><pub-id pub-id-type="pmid">40300834</pub-id></mixed-citation></ref><ref id="bibr98-13872877251371240"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lannfelt</surname><given-names>L</given-names></name><name name-style="western"><surname>M&#246;ller</surname><given-names>C</given-names></name><name name-style="western"><surname>Basun</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>Perspectives on future Alzheimer therapies: amyloid-&#946; protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease</article-title>. <source>Alzheimers Res Ther</source><year>2014</year>; <volume>6</volume>: <fpage>16</fpage>.<pub-id pub-id-type="pmid">25031633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/alzrt246</pub-id><pub-id pub-id-type="pmcid">PMC4054967</pub-id></mixed-citation></ref><ref id="bibr99-13872877251371240"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tucker</surname><given-names>S</given-names></name><name name-style="western"><surname>M&#246;ller</surname><given-names>C</given-names></name><name name-style="western"><surname>Tegerstedt</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>The murine version of BAN2401 (mAb158) selectively reduces amyloid-&#946; protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice</article-title>. <source>J Alzheimers Dis</source><year>2015</year>; <volume>43</volume>: <fpage>575</fpage>&#8211;<lpage>588</lpage>.<pub-id pub-id-type="pmid">25096615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-140741</pub-id></mixed-citation></ref><ref id="bibr100-13872877251371240"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lord</surname><given-names>A</given-names></name><name name-style="western"><surname>Gumucio</surname><given-names>A</given-names></name><name name-style="western"><surname>Englund</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease</article-title>. <source>Neurobiol Dis</source><year>2009</year>; <volume>36</volume>: <fpage>425</fpage>&#8211;<lpage>434</lpage>.<pub-id pub-id-type="pmid">19703562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2009.08.007</pub-id></mixed-citation></ref><ref id="bibr101-13872877251371240"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name></person-group>, <etal>et al.</etal><article-title>Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials</article-title>. <source>Front Aging Neurosci</source><year>2023</year>; <volume>15</volume>: <fpage>1169499</fpage>.<pub-id pub-id-type="pmid">37213538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2023.1169499</pub-id><pub-id pub-id-type="pmcid">PMC10196238</pub-id></mixed-citation></ref><ref id="bibr102-13872877251371240"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tolar</surname><given-names>M</given-names></name><name name-style="western"><surname>Abushakra</surname><given-names>S</given-names></name><name name-style="western"><surname>Hey</surname><given-names>JA</given-names></name></person-group>, <etal>et al.</etal><article-title>Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval</article-title>. <source>Alzheimers Res Ther</source><year>2020</year>; <volume>12:</volume><fpage>95</fpage>.<pub-id pub-id-type="pmid">32787971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-020-00663-w</pub-id><pub-id pub-id-type="pmcid">PMC7424995</pub-id></mixed-citation></ref><ref id="bibr103-13872877251371240"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>K</given-names></name><name name-style="western"><surname>Sasaguri</surname><given-names>H</given-names></name><name name-style="western"><surname>Kumita</surname><given-names>W</given-names></name></person-group>, <etal>et al.</etal><article-title>Production of a heterozygous exon skipping model of common marmosets using gene-editing technology</article-title>. <source>Lab Anim (NY)</source><year>2024</year>; <volume>53</volume>: <fpage>244</fpage>&#8211;<lpage>251</lpage>.<pub-id pub-id-type="pmid">39215182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41684-024-01424-0</pub-id><pub-id pub-id-type="pmcid">PMC11368816</pub-id></mixed-citation></ref><ref id="bibr104-13872877251371240"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Homanics</surname><given-names>GE</given-names></name><name name-style="western"><surname>Park</surname><given-names>JE</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal><article-title>Early molecular events of autosomal-dominant Alzheimer's disease in marmosets with PSEN1 mutations</article-title>. <source>Alzheimers Dement</source><year>2024</year>; <volume>20</volume>: <fpage>3455</fpage>&#8211;<lpage>3471</lpage>.<pub-id pub-id-type="pmid">38574388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13806</pub-id><pub-id pub-id-type="pmcid">PMC11095452</pub-id></mixed-citation></ref><ref id="bibr105-13872877251371240"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kakiya</surname><given-names>N</given-names></name><name name-style="western"><surname>Saito</surname><given-names>T</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>P</given-names></name></person-group>, <etal>et al.</etal><article-title>Cell surface expression of the major amyloid-beta peptide (A beta)-degrading enzyme, neprilysin, depends on phosphorylation by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) and dephosphorylation by protein phosphatase 1a</article-title>. <source>J Biol Chem</source><year>2012</year>; <volume>287</volume>: <fpage>29362</fpage>&#8211;<lpage>29372</lpage>.<pub-id pub-id-type="pmid">22767595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M112.340372</pub-id><pub-id pub-id-type="pmcid">PMC3436156</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Explor Med</journal-id><journal-id journal-id-type="iso-abbrev">Explor Med</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Exploration of medicine</journal-title></journal-title-group><issn pub-type="epub">2692-3106</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12494297</article-id><article-id pub-id-type="pmcid-ver">PMC12494297.1</article-id><article-id pub-id-type="pmcaid">12494297</article-id><article-id pub-id-type="pmcaiid">12494297</article-id><article-id pub-id-type="manuscript-id">NIHMS2113854</article-id><article-id pub-id-type="pmid">41050829</article-id><article-id pub-id-type="doi">10.37349/emed.2025.1001356</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2113854</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2113854</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Adherence timescale impacts completion rates of high-frequency mobile cognitive assessments among older adults</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0001-5587-7673</contrib-id><name name-style="western"><surname>Christianson</surname><given-names initials="K">Kieffer</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0008-3147-4088</contrib-id><name name-style="western"><surname>Prabhu</surname><given-names initials="M">Meha</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0001-7935-5300</contrib-id><name name-style="western"><surname>Popp</surname><given-names initials="ZT">Zachary T</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0009-5225-3150</contrib-id><name name-style="western"><surname>Rahman</surname><given-names initials="MS">Md Salman</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Drane</surname><given-names initials="J">James</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="M">Marissa</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lathan</surname><given-names initials="C">Corinna</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3043-3942</contrib-id><name name-style="western"><surname>Lin</surname><given-names initials="H">Honghuang</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7742-4491</contrib-id><name name-style="western"><surname>Au</surname><given-names initials="R">Rhoda</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref><xref rid="A7" ref-type="aff">7</xref><xref rid="A8" ref-type="aff">8</xref><xref rid="A9" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6011-8412</contrib-id><name name-style="western"><surname>Sunderaraman</surname><given-names initials="P">Preeti</given-names></name><xref rid="A10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6780-6808</contrib-id><name name-style="western"><surname>Hwang</surname><given-names initials="PH">Phillip H</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Psychology, University of Nevada, Reno, NV 89557, USA</aff><aff id="A2"><label>2</label>Department of Anatomy and Neurobiology, Boston University Chobanian &amp; Avedisian School of Medicine, Boston, MA 02118, USA</aff><aff id="A3"><label>3</label>AnthroTronix, Silver Spring, MD 20910, USA</aff><aff id="A4"><label>4</label>Department of Medicine, UMass Chan Medical School, Worcester, MA 01655, USA</aff><aff id="A5"><label>5</label>The Framingham Heart Study, Boston University Chobanian &amp; Avedisian School of Medicine, Boston, MA 02118, USA</aff><aff id="A6"><label>6</label>Department of Epidemiology, Boston University School of Public Health, Boston, MA 02118, USA</aff><aff id="A7"><label>7</label>Department of Neurology, Boston University Chobanian &amp; Avedisian School of Medicine, Boston, MA 02118, USA</aff><aff id="A8"><label>8</label>Department of Medicine, Boston University Chobanian &amp; Avedisian School of Medicine, Boston, MA 02118, USA</aff><aff id="A9"><label>9</label>Slone Epidemiology Center, Boston University Chobanian &amp; Avedisian School of Medicine, Boston, MA 02118, USA</aff><aff id="A10"><label>10</label>Department of Psychiatry and Human Behavior, Brown University, Providence, RI 02912, USA</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">Author contributions</p><p id="P2">KC: Conceptualization, Investigation, Project administration, Writing&#8212;original draft, Writing&#8212;review &amp; editing. MP: Data curation, Investigation, Project administration. ZTP: Data curation, Formal analysis, Visualization. MSR: Investigation, Project administration. JD: Resources, Software. ML: Resources, Software. CL: Funding acquisition, Resources, Software, Writing&#8212;review &amp; editing. HL: Supervision, Writing&#8212;review &amp; editing. RA: Funding acquisition, Supervision, Writing&#8212;review &amp; editing. PS: Conceptualization, Supervision, Writing&#8212;review &amp; editing. PHH: Conceptualization, Methodology, Supervision, Writing&#8212;review &amp; editing. All authors read and approved the submitted version.</p></fn><corresp id="CR1"><label>*</label><bold>Correspondence:</bold> Kieffer Christianson, Department of Psychology, University of Nevada, Reno, NV 89557, USA. <email>kchristianson@unr.edu</email></corresp></author-notes><pub-date pub-type="ppub"><year>2025</year></pub-date><pub-date pub-type="epub"><day>11</day><month>9</month><year>2025</year></pub-date><volume>6</volume><issue-id pub-id-type="pmc-issue-id">498220</issue-id><elocation-id>10.37349/emed.2025.1001356</elocation-id><pub-history><event event-type="nihms-submitted"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-07 15:25:48.873"><day>07</day><month>10</month><year>2025</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2113854.pdf"/><abstract id="ABS1"><sec id="S1"><title>Aim:</title><p id="P3">Mobile technology enables frequent, remote cognitive assessments, introducing new methodological opportunities and challenges. The study evaluated the feasibility of a high-frequency cognitive assessment schedule among older adults, in terms of total assessments and adherence to a prescribed schedule.</p></sec><sec id="S2"><title>Methods:</title><p id="P4">Thirty-three older adults were recruited from the Boston University Alzheimer&#8217;s Disease Research Center (mean age = 73.5 years; 27.3% cognitively impaired; 57.6% female; 81.8% White, 18.2% Black). Participants downloaded the DANA Brain Vital mobile application on their own mobile devices during a remote study visit, and were provided a schedule with seventeen assessments to complete over one year at varying frequencies. The first segment contained three subsegments to be completed within one week, the second segment consisted of weekly subsegments spanning three weeks, and the third and fourth segments consisted of monthly subsegments spanning five and six months, respectively. Three adherence types were defined to reflect incrementally broader adherence timescales: subsegment adherence (strict adherence to each prescribed assessment period), segment adherence (completing the required number of assessments within each broader segment), and cumulative adherence (completing the total number of assessments irrespective of timing).</p></sec><sec id="S3"><title>Results:</title><p id="P5">Completion rates differed depending on the adherence timescale and corresponding adherence type. Using the strictest adherence definition (subsegment adherence), completion rates declined (from 93.9% to 72.7%, <italic toggle="yes">p</italic> = 0.05) during the fourth segment. However, when a broader adherence timescale was applied, completion rates did not decline. Overall completion rates increased as adherence timescale parameters were broadened from subsegment adherence (60.6%) to segment adherence (78.8%), to cumulative adherence (90.9%).</p></sec><sec id="S4"><title>Conclusions:</title><p id="P6">Older adults, including those with cognitive impairment, are able to complete remote cognitive assessments at a high-frequency, but may not necessarily adhere to prescribed schedules. Future high-frequency studies should consider adherence as a potential behavioral variable to complement cognitive test data, while recognizing the potential influence of adherence timescale on interpreting completion rates.</p></sec></abstract><kwd-group><kwd>remote</kwd><kwd>digital</kwd><kwd>cognitive</kwd><kwd>assessment</kwd><kwd>high-frequency</kwd><kwd>adherence</kwd><kwd>timescale</kwd><kwd>longitudinal</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S5"><title>Introduction</title><p id="P7">Cognitive disorders are now recognized to result from underlying neurodegenerative processes with an insidious onset, beginning with a prodromal phase during which cognitive functioning may remain intact or only subtly impaired [<xref rid="R1" ref-type="bibr">1</xref>&#8211;<xref rid="R3" ref-type="bibr">3</xref>]. Although various biomarker tests may be utilized to inform diagnostic considerations, the traditional approach for characterizing cognitive symptoms consists of a single session of intensive neuropsychological (NP) testing to determine if generalized impairment and/or disorder-specific patterns of dispersion across cognitive domains are observable [<xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R5" ref-type="bibr">5</xref>]. This approach provides reliable estimates of disease at later stages, but does not capture the subtle symptoms that arise sporadically during the early stages of cognitive impairment (CI), in part because standardized NP assessments typically cannot be completed more than once per year and are not structured to detect the subtle cognitive decline inherent to earlier stages of the disease [<xref rid="R6" ref-type="bibr">6</xref>]. The subjective experience or observation of these early-stage symptoms can be the very basis for pursuing a formal cognitive evaluation, which in turn is not structured to detect them [<xref rid="R7" ref-type="bibr">7</xref>]. During these milder stages of CI, it is often family members or other informants who recognize occasional displays of behavior as irregular relative to an individual&#8217;s normative functioning [<xref rid="R8" ref-type="bibr">8</xref>&#8211;<xref rid="R10" ref-type="bibr">10</xref>]. Daily caretaker reports often loosely operationalize behavioral deviations as resulting in an increased frequency of &#8220;bad days&#8221; [<xref rid="R11" ref-type="bibr">11</xref>], although informant reports often do not correspond with an individual&#8217;s self-report [<xref rid="R12" ref-type="bibr">12</xref>]. A bad day interpreted in the context of an otherwise good week can be considered a fluctuation, whereas a steady increase in bad days over the course of a year represents a gradual decline. A single session of NP testing conducted on a bad day may result in a diagnosis of mild CI (MCI), thus resulting in diagnostic bias. Relatedly, a single session of NP testing conducted on a good day could result in a missed or delayed diagnosis. Waiting at least another year before potentially identifying signs of CI will become increasingly consequential as therapeutics to improve symptoms or delay disease progression are likely to become introduced in the future. Depending on the study design, this may also explain why the reversion from MCI to normal is fairly common [<xref rid="R13" ref-type="bibr">13</xref>].</p><p id="P8">To distinguish between fluctuations and true decline, frequent assessment of cognition and behavior is required to avoid relying on data generated from a single session. Remote digital data collection now addresses the juxtaposition between subjective longitudinal observation and objective single session assessment by enabling objective cognitive data to be collected longitudinally and remotely. Mobile device usage among older adults has increased over the last several years, as 84% of USA adults aged 50+ own a smartphone, and 76% report relying on technology to stay connected with friends and family, according to a 2021 survey [<xref rid="R14" ref-type="bibr">14</xref>]. Completing assessments at home, rather than in a formal clinical, setting may also reduce the risk of the &#8220;white-coat effect&#8221;, which explains reduced memory performance in a clinical environment [<xref rid="R15" ref-type="bibr">15</xref>]. Additionally, allowing individuals to complete tasks on their own device as opposed to a study-issued device may contribute to improving the ecological validity of remote assessments [<xref rid="R16" ref-type="bibr">16</xref>].</p><p id="P9">Adherence to the prescribed study schedule consisting of repeated unsupervised assessments represents a novel element of remote study designs, particularly among older adults with CI who may have difficulties remembering to complete assessments according to schedule. Prior studies support the feasibility of cognitively unimpaired adults completing repeated unsupervised assessments via mobile-platform [<xref rid="R6" ref-type="bibr">6</xref>, <xref rid="R17" ref-type="bibr">17</xref>&#8211;<xref rid="R26" ref-type="bibr">26</xref>]. However, evidence as to whether older individuals diagnosed with CI are capable or interested in completing frequent unsupervised mobile assessments remotely is limited [<xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R28" ref-type="bibr">28</xref>]. Furthermore, no published studies that we are aware of have considered how the timescale used to define adherence might impact feasibility outcomes, which represents a novel aspect of evaluating self-administered assessments.</p><p id="P10">The limited research examining adherence and assessment frequency as it relates to cognitive performance may persist for two reasons. The first is that the NP approach traditionally considered cognitive performance to be a relatively stable entity. However, the field now acknowledges that considerable within-person variability may occur when NP tests are repeated over a short period of time [<xref rid="R29" ref-type="bibr">29</xref>]. If cognitive performance is conceptualized as a dynamic process, rather than a stable trait, the timescale of assessment becomes important [<xref rid="R30" ref-type="bibr">30</xref>]. Identifying the appropriate assessment frequency to correspond with the temporal dynamics of behavior has been discussed among other populations [<xref rid="R31" ref-type="bibr">31</xref>], but to our knowledge, it has not been studied in the context of CI. The second possible reason that few studies have examined how assessment frequency impacts cognitive performance could be due to concerns of the ability of older adults with CI to complete unsupervised mobile assessments. Although the feasibility of older adults with CI to complete cognitive assessments at a high-frequency for a period of one-to-two weeks has been demonstrated [<xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R28" ref-type="bibr">28</xref>], no study has assessed whether completion rates remain high when assessments are prescribed continuously over a longer period of time. Therefore, this study aimed to determine the feasibility of self-administered mobile cognitive assessments prescribed at varying frequencies among older adults with and without CI using the DANA Brain Vital application over a period of one year.</p></sec><sec id="S6"><title>Materials and methods</title><sec id="S7"><title>Study sample</title><p id="P11">The study sample consisted of participants who were already enrolled in a parent study at the Boston University Alzheimer&#8217;s Disease Research Center (ADRC). During their regular annual ADRC visits, participants were asked if they were interested in participating in an additional study involving digital technology. Those who expressed interest were then contacted by our study staff by phone or email. The brief screening agreement was completed electronically while on the phone with a study staff member. Inclusion criteria included not meeting criteria for dementia, owning a mobile device (e.g., smartphone, tablet) with access to the internet, speaking English as a primary language, and being over the age of 40 years at the time of enrollment. CI status was assigned to individuals with MCI according to the National Alzheimer&#8217;s Coordinating Center (NACC) Uniform Data Set (UDS) diagnostic criteria version 3 [<xref rid="R32" ref-type="bibr">32</xref>, <xref rid="R33" ref-type="bibr">33</xref>], or who scored one-and-a-half standard deviations below the normative mean on NP testing in the absence of functional impairment. All cognitively impaired participants completed the study without the assistance of a study partner. Among potential participants who were contacted but did not enroll, eleven were uninterested, and two did not meet the inclusion criteria.</p></sec><sec id="S8"><title>DANA brain vital</title><sec id="S9"><title>Application description</title><p id="P12">The DANA Brain Vital tool was utilized as the mobile application in this study. DANA is an FDA-cleared computerized neurocognitive test accessible as a mobile application for iOS and Android devices. Previous work has demonstrated DANA&#8217;s internal consistency and reliability [<xref rid="R34" ref-type="bibr">34</xref>]. The duration of a single assessment session is approximately five minutes and consists of three subtests intended to measure reaction time, executive functioning, and inhibitory control. The subtests are presented in a fixed order, and performance feedback is not provided to the participant. The first subtest, Simple Reaction Time (SRT), measures the latency between when a large target appears on the screen and when the participant taps the target across 40 trials. The second subtest, Procedural Reaction Time (PRT), involves one of four numbers (2, 3, 4, or 5) being displayed for two seconds and requires the participant to tap the corresponding left button (2 or 3) or right button (4 or 5) across 32 trials. The third subtest, Go/NoGo (GNG), requires the participant to either tap or omit a response based on the color of stimuli that appear in varying locations across the screen across 30 trials [<xref rid="R35" ref-type="bibr">35</xref>].</p></sec><sec id="S10"><title>Data quality</title><p id="P13">Data collected from the DANA application is automatically transferred to a secure web portal accessible to the study staff in raw and derived formats. Raw data consists of specific values for each finger tap completed across every trial, whereas summary scores for each subtest within an assessment constitute the derived outcomes that are intended to be readily interpretable. Any subtest with a percentage accuracy of less than 70% is flagged as an indication that the instructions may not have been comprehended or a distraction may have occurred. An additional feature to mitigate extraneous factors influencing test performance is that the application automatically closes if a phone call is received while the application is open. If the application is reopened within three minutes after closing, the assessment may be continued beginning at the subtest that was in progress prior to the interruption. After three minutes of being closed, the data is discarded, and no partial results are recorded.</p></sec></sec><sec id="S11"><title>Remote study design</title><p id="P14">Participants were given the option to complete the remote study visit via Zoom videoconferencing or phone. After obtaining informed consent electronically, participants were directed to download the mobile application to their mobile device and log in using a unique study ID. A practice session using the application was completed to ensure that participants were comfortable completing the assessment tasks. Study staff monitored incoming practice data to confirm that assessment task instructions were followed by participants. Study staff were trained using standardized checklists and ensured all participants completed remote consent procedures, successfully downloaded the mobile application, and completed the initial practice session. Participants were provided contact information for study staff and were encouraged to reach out directly with any technical issues or questions that arose after the initial remote study visit.</p><p id="P15">A self-administered assessment schedule consisting of four segments spanning one year in duration was provided to each participant (<xref rid="F1" ref-type="fig">Figure 1</xref>). Each segment consisted of multiple subsegments, which were defined as specific periods during which individual assessments were expected to be completed. The first segment included three subsegments to be completed within one week; the second segment included weekly subsegments and spanned three weeks; and the third and fourth segments included monthly subsegments spanning five and six months, respectively. Segment durations were varied to inform whether adherence varied as a function of prescribed segment length. A $25 gift card was mailed to participants for each segment completed on time and in its entirety. Participants were only asked to complete the minimum assessment schedule, but were not prevented from completing additional assessments. However, multiple subsegments were not allowed to be completed in one day. Up to three reminders were sent per assessment via text, email, or phone call, depending on participant preference.</p></sec><sec id="S12"><title>Adherence</title><p id="P16">Feasibility was assessed based on adherence to the study schedule, which was objectively measured by task completion rates across a given study period. However, given the variable and longitudinal structure of the schedule, adherence can be defined differently depending on how narrowly or broadly scheduling parameters are applied, a concept referred to here as the timescale of adherence. To illustrate how adherence outcomes depend upon the chosen timescale, three distinct adherence types corresponding to the schedule structure were defined (subsegment, segment, cumulative; <xref rid="F2" ref-type="fig">Figure 2</xref>). Although these specific adherence types were developed for this study, the broader point emphasized is that adherence outcomes fundamentally depend on the timescale selected for evaluation.</p><p id="P17">Subsegment adherence refers to whether the correct number of assessments were completed precisely within the subsegment dates provided to the participant. Based on this definition, an assessment completed one day after a prescribed subsegment period would render the entire segment as non-adherent. Segment adherence only considers the expected number of assessments across the entire segment, disregarding the specific subsegments. For example, a participant who did not complete an assessment during subsegment 2.1, but completed two assessments during subsegment 2.2 the following week, and one assessment during subsegment 2.3 would be considered adherent for segment 2 using the segment adherence definition (three assessments within three weeks), but non-adherent using the more stringent subsegment adherence (one assessment each week for three weeks) definition. Both subsegment and segment adherence were evaluated individually across each segment and collectively across the overall study. To meet the overall criteria within either the subsegment or segment adherence type, segment adherence across each individual segment was required. Finally, cumulative adherence considers the total number of assessments completed during the entire study period, irrespective of specific segment or assessment period deadlines. These different definitions of adherence were examined to determine how the temporal resolution of assessment frequency impacts feasibility. Within the scope of this study, the progressively relaxed definitions for adherence provide different insights as to whether participants completed the total number of scheduled assessments, and whether they adhered to the specific schedule separately.</p></sec><sec id="S13"><title>Analysis</title><p id="P18">Descriptive statistics for the sample demographics were provided as means and standard deviations for continuous variables or counts and percentages for categorical variables. Adherence rates were computed by dividing the number of participants characterized as adherent within each definition by the total number of participants. Cochran&#8217;s Q test was used to evaluate whether there were significant differences in adherence across assessments. Pairwise McNemar&#8217;s chi-squared testing with continuity correction was used for post-hoc testing to compare adherence rates between all segments within the subsegment and segment adherence definitions. Statistical significance was based on two-sided <italic toggle="yes">p</italic> &lt; 0.05. All statistical analyses were conducted in R version 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria) [<xref rid="R36" ref-type="bibr">36</xref>].</p></sec><sec id="S14"><title>Ethics</title><p id="P19">All participants provided informed consent, and the study protocol (H-37474) was approved by the Institutional Review Board of the Boston University Medical Campus. All methods were carried out in accordance with relevant guidelines and regulations. The study was conducted in accordance with the 2024 Declaration of Helsinki.</p></sec></sec><sec id="S15"><title>Results</title><p id="P20">The sample consisted of older adults who were predominantly female (<italic toggle="yes">n</italic> = 19, 57.6%), White (<italic toggle="yes">n</italic> = 27, 81.8%), well-educated (mean 16.9 years), and cognitively unimpaired (<italic toggle="yes">n</italic> = 24, 72.7%) (<xref rid="T1" ref-type="table">Table 1</xref>). Most participants in the study used iPhone mobile devices (<italic toggle="yes">n</italic> = 19, 57.6%) to complete the cognitive assessments in DANA.</p><p id="P21">Utilizing the strict subsegment adherence definition, the completion rate declined during the study (93.9%, 90.9%, 81.8%, and 72.7% for segments 1&#8211;4, respectively). When applying the broader segment adherence definition, the adherence rates remained relatively high across segments (93.9%, 97.0%, 97.0%, and 87.9% for segments 1&#8211;4, respectively). Significant differences were observed across segments when comparing across the subsegment adherence completion rates (<italic toggle="yes">p</italic> = 0.04), but not for the segment adherence completion rates (<italic toggle="yes">p</italic> = 0.35). Within the subsegment adherence definition, the segment 4 adherence rate of 72.7% appears lower than the segment 1 completion rate of 93.9% (<italic toggle="yes">p</italic> = 0.05) (<xref rid="T2" ref-type="table">Table 2</xref>), but did not reach statistical significance which may be attributed to the small sample size. Overall completion rates (<xref rid="T2" ref-type="table">Table 2</xref>) increased as adherence parameters were broadened from subsegment adherence (60.6%), to segment adherence (78.8%), to cumulative adherence (90.9%).</p></sec><sec id="S16"><title>Discussion</title><sec id="S17"><title>Adherence type and completion rates</title><p id="P22">Our study supports the growing literature that older adults, including those with CI, are capable of completing high-frequency, mobile-based cognitive assessments. We observed that the timescale or stringency by which adherence is defined may also influence completion rates in our sample. This is relevant to the emerging practice of self-administered assessments in that individuals have the latitude to choose when to complete assessments at home or in any quiet environment with internet access, rather than during a scheduled time in a clinical environment. This flexibility highlights an important methodological consideration we introduce as adherence timescale, which emphasizes that objectively measured adherence can vary depending on how scheduling parameters are applied.</p><p id="P23">Within this present study, the progressive discrepancy between the overall rates for subsegment adherence, segment adherence, and the cumulative adherence indicates that many individuals completed the total number of prescribed assessments, but that they did not complete them according to specific deadlines. In other words, as adherence criteria were relaxed from using specific subsegment dates to considering broader segment dates or the cumulative study duration, participants continued to complete assessments at a consistent rate over a span of one year. This discrepancy between adherence types provides an initial perspective towards how self-administered completion rates may vary based on frequency, such that individuals were less adherent to the specific study schedule as segment durations lengthened and assessment frequency decreased. Also, the overall subsegment adherence rate as compared to the specific subsegment adherence rates indicates that different participants were non-adherent across different segments, suggesting the phenomenon was not isolated to select individuals.</p><p id="P24">This study supports the feasibility of the high-frequency assessments among older adults, including those with CI, which was previously reported in studies with shorter assessment periods. Among the emerging literature, Nicosia et al., [<xref rid="R28" ref-type="bibr">28</xref>] asked participants to complete up to four brief mobile cognitive assessments per day across three seven-day periods spaced six months apart, and found no difference based on CI status and observed an overall adherence rate of 80.42%. Cerino et al., [<xref rid="R27" ref-type="bibr">27</xref>] included up to six daily assessments for 16 days, and found only a slight difference in adherence based on CI status wherein the mean completion rate for cognitive unimpaired adults was 85.20%, while the rate for adults with MCI was 78.10%. To the best of our knowledge, ours is the first study to span a complete year with continuous assessments and to compare completion rates according to different assessment frequencies and adherence types.</p><p id="P25">It is also important to recognize that adherence in remote cognitive studies depends not only on participants&#8217; motivation and cognitive status, but also on the user experience provided by the application and the availability of technical support. In this study, participants had direct access to research staff for assistance with technical issues, which may have contributed positively to adherence rates. An intuitive application design and readily available technical systems are critical when deploying remote cognitive assessments in both research and clinical contexts.</p></sec><sec id="S18"><title>Enabling process based detection of cognitive impairment</title><p id="P26">The traditional approach to detecting CI relies on identifying intra-individual variability or dispersion (IIV-D) across cognitive domains [<xref rid="R37" ref-type="bibr">37</xref>&#8211;<xref rid="R39" ref-type="bibr">39</xref>]. This approach compresses item-level responses into subtest scores that are then converted into standard scores to decipher whether significant discrepancy (i.e., dispersion) is observed across cognitive domains. The Boston Process Approach (BPA) was introduced decades ago to address these shortcomings by emphasizing process-based scoring (e.g., characterizing cognitive error types to differentiate disease pathology that would otherwise be indistinguishable using traditional NP summary scores) [<xref rid="R40" ref-type="bibr">40</xref>]. Modern adoptions of a process-based approach couple granular digital data with advanced analytics to uncover novel indices of cognitive functioning [<xref rid="R40" ref-type="bibr">40</xref>&#8211;<xref rid="R45" ref-type="bibr">45</xref>]. The enhanced granularity provided by digital assessments enables sensitive detection of disease by capturing fluctuations within individual assessments [<xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R46" ref-type="bibr">46</xref>, <xref rid="R47" ref-type="bibr">47</xref>] and across multiple assessment sessions [<xref rid="R21" ref-type="bibr">21</xref>, <xref rid="R48" ref-type="bibr">48</xref>, <xref rid="R49" ref-type="bibr">49</xref>].</p><p id="P27">These modern process-based approaches to cognitive assessment still rely primarily on active participant engagement. Additionally, clinical identification of CI typically involves actively evaluating everyday functioning (e.g., keeping appointments, effectively using everyday technologies) through questionnaires or interviews with individuals and their family members [<xref rid="R50" ref-type="bibr">50</xref>]. Meanwhile, innovations in digital health increasingly utilize passive measurement of everyday behaviors to indirectly infer cognitive status [<xref rid="R51" ref-type="bibr">51</xref>, <xref rid="R52" ref-type="bibr">52</xref>]. Considering adherence explicitly as a unique variable within high-frequency cognitive assessment protocols could simultaneously yield direct cognitive performance data and indirect insights into participants&#8217; daily functioning. Incorporating adherence could thus conceptually extend the BPA beyond recognizing response patterns alone, to additionally evaluate whether prescribed assessments were completed &#8220;on time&#8221;. It is our hope that the concept of adherence timescale and the adherence type definitions presented here provide clear parameters for future research, encouraging consideration of adherence timescale as an important variable.</p></sec><sec id="S19"><title>Limitations</title><p id="P28">This study provides insight towards future opportunities and challenges associated with remote data collection to assess cognitive functioning, many of which could not be addressed in the study. This study was limited by the small sample size, which affected the interpretations of any statistical comparisons related to feasibility and precluded any comparisons of cognitive performance based on impairment status or other established clinical markers. Furthermore, the generalizability of the results to more diverse populations is restricted as participants were recruited from a clinical research center, consisting mostly of individuals who are White, highly-educated, and inclined towards research participation. It is also acknowledged that the financial compensation received in this study for completing assessments may have influenced adherence. However, the use of financial incentives does not detract from the demonstration that the high-frequency cognitive assessments were feasible. Without financial compensation, it would be difficult to distinguish whether non-adherence reflected inability to complete assessments or lack of motivation. We believe that if high-frequency assessments were integrated into clinical care, individuals may be motivated by potential health benefits rather than external incentives. Assessment reminders provided according to participant preference (i.e., text, email, or phone call) also likely impacted adherence in a fashion that is difficult to directly quantify. However, the relatively homogenous composition of the study sample is likely a reflection of the parent study rather than a function of the study design per se. Conceptually, the remote study design utilized here should enable recruitment of a more representative sample, as has been demonstrated in other literature comparing demographic diversity between in-person and remote research studies [<xref rid="R53" ref-type="bibr">53</xref>]. Future efforts should target a larger and more diverse sample, assess both mean scores and variability in cognitive performance relative to assessment frequency, and collect data related to potential within-person influences on cognitive function, such as sleep, diet, stress, and physical activity. Also, while remote assessment may address certain validity risks related to in-person assessment (e.g., white-coat effect), other unique risks specific to remote environments should be recognized. Additionally, future studies may consider counterbalancing segment frequencies by utilizing a crossover design to account for the possibility that some participants may be more adherent to frequent assessment near the beginning of the study.</p></sec></sec></body><back><ack id="S21"><title>Acknowledgments</title><p id="P30">We would like to thank the individuals who participated in this study, as well as the Boston University Alzheimer&#8217;s Disease Center staff who helped coordinate recruitment.</p><sec id="S22"><title>Funding</title><p id="P31">Support for this work came from NIH/NIA grant [4R44AG063635] and [2P30AG013846] from the National Institute on Aging. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></sec></ack><fn-group><fn fn-type="COI-statement" id="FN2"><p id="P32">Conflicts of interest</p><p id="P33">Rhoda Au is a consultant for Signant Health, Biogen, and the Davos Alzheimer&#8217;s Collaborative, a Swiss foundation and a U.S. not-for-profit. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></fn><fn id="FN3"><p id="P34">Ethical approval</p><p id="P35">The study (H-37474) was approved by the Institutional Review Board of the Boston University Medical Campus.</p></fn><fn id="FN4"><p id="P36">Consent to participate</p><p id="P37">Informed consent to participate in the study was obtained from all participants.</p></fn></fn-group><sec sec-type="data-availability" id="S20"><title>Availability of data and materials</title><p id="P29">Datasets are available on request: the raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.</p></sec><glossary><title>Abbreviations</title><def-list><def-item><term>ADRC</term><def><p id="P38">Alzheimer&#8217;s disease research center</p></def></def-item><def-item><term>BPA</term><def><p id="P39">Boston Process Approach</p></def></def-item><def-item><term>CI</term><def><p id="P40">cognitive impairment</p></def></def-item><def-item><term>MCI</term><def><p id="P41">mild cognitive impairment</p></def></def-item><def-item><term>NP</term><def><p id="P42">neuropsychological</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Price</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Morris</surname><given-names>JC</given-names></name>. <article-title>Tangles and plaques in nondemented aging and &#8220;preclinical&#8221; Alzheimer&#8217;s disease</article-title>. <source>Ann Neurol</source>. <year>1999</year>;<volume>45</volume>:<fpage>358</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">10072051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1531-8249(199903)45:3&lt;358::aid-ana12&gt;3.0.co;2-x</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="book"><name name-style="western"><surname>Soria Lopez</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Gonz&#225;lez</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>L&#233;ger</surname><given-names>GC</given-names></name>. <part-title>Handbook of Clinical Neurology</part-title>. In: <name name-style="western"><surname>Dekosky</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Asthana</surname><given-names>S</given-names></name>, editors. <source>Alzheimer&#8217;s disease</source>. <publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier</publisher-name>; <year>2019</year>. pp. <fpage>23</fpage>&#8211;<lpage>55</lpage>.</mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Katsuno</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sahashi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Iguchi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hashizume</surname><given-names>A</given-names></name>. <article-title>Preclinical progression of neurodegenerative diseases</article-title>. <source>Nagoya J Med Sci</source>. <year>2018</year>;<volume>80</volume>:<fpage>289</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">30214078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18999/nagjms.80.3.289</pub-id><pub-id pub-id-type="pmcid">PMC6125655</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dubois</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Villain</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Frisoni</surname><given-names>GB</given-names></name>, <name name-style="western"><surname>Rabinovici</surname><given-names>GD</given-names></name>, <name name-style="western"><surname>Sabbagh</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cappa</surname><given-names>S</given-names></name>, <etal/><article-title>Clinical diagnosis of Alzheimer&#8217;s disease: recommendations of the International Working Group</article-title>. <source>Lancet Neurol</source>. <year>2021</year>;<volume>20</volume>: <fpage>484</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">33933186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(21)00066-1</pub-id><pub-id pub-id-type="pmcid">PMC8339877</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fellows</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>Schmitter-Edgecombe</surname><given-names>M</given-names></name>. <article-title>Between-domain cognitive dispersion and functional abilities in older adults</article-title>. <source>J Clin Exp Neuropsychol</source>. <year>2015</year>;<volume>37</volume>:<fpage>1013</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">26300441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13803395.2015.1050360</pub-id><pub-id pub-id-type="pmcid">PMC4874189</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jutten</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Sikkes</surname><given-names>SAM</given-names></name>, <name name-style="western"><surname>Maruff</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Molinuevo</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name>, <etal/><article-title>A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimer&#8217;s Disease: Towards a More Continuous Approach</article-title>. <source>J Alzheimers Dis</source>. <year>2022</year>;<volume>86</volume>:<fpage>511</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">35124638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-215098</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jessen</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Amariglio</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>van Boxtel</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Breteler</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ceccaldi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ch&#233;telat</surname><given-names>G</given-names></name>, <etal/>; <article-title>Subjective Cognitive Decline Initiative (SCD-I) Working Group. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer&#8217;s disease</article-title>. <source>Alzheimers Dement</source>. <year>2014</year>;<volume>10</volume>:<fpage>844</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">24798886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2014.01.001</pub-id><pub-id pub-id-type="pmcid">PMC4317324</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Galvin</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Roe</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Xiong</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Morris</surname><given-names>JC</given-names></name>. <article-title>Validity and reliability of the AD8 informant interview in dementia</article-title>. <source>Neurology</source>. <year>2006</year>;<volume>67</volume>:<fpage>1942</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">17159098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000247042.15547.eb</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Geldmacher</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Whitehouse</surname><given-names>PJ</given-names></name>. <article-title>Evaluation of dementia</article-title>. <source>N Engl J Med</source>. <year>1996</year>;<volume>335</volume>:<fpage>330</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">8663868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM199608013350507</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tarawneh</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></name>. <article-title>The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment</article-title>. <source>Cold Spring Harb Perspect Med</source>. <year>2012</year>;<volume>2</volume>:<fpage>a006148</fpage>.<pub-id pub-id-type="pmid">22553492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a006148</pub-id><pub-id pub-id-type="pmcid">PMC3331682</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bradshaw</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Saling</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hopwood</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Brodtmann</surname><given-names>A</given-names></name>. <article-title>Fluctuating cognition in dementia with Lewy bodies and Alzheimer&#8217;s disease is qualitatively distinct</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2004</year>;<volume>75</volume>: <fpage>382</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">14966152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.2002.002576</pub-id><pub-id pub-id-type="pmcid">PMC1738966</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sunderaraman</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Cosentino</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lindgren</surname><given-names>K</given-names></name>, <name name-style="western"><surname>James</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Schultheis</surname><given-names>M</given-names></name>. <article-title>Informant Report of Financial Capacity for Individuals With Chronic Acquired Brain Injury: An Assessment of Informant Accuracy</article-title>. <source>J Head Trauma Rehabil</source>. <year>2018</year>;<volume>33</volume>:<fpage>E85</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">29601341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/HTR.0000000000000382</pub-id><pub-id pub-id-type="pmcid">PMC6163092</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Koepsell</surname><given-names>TD</given-names></name>, <name name-style="western"><surname>Monsell</surname><given-names>SE</given-names></name>. <article-title>Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis</article-title>. <source>Neurology</source>. <year>2012</year>;<volume>79</volume>:<fpage>1591</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">23019264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e31826e26b7</pub-id><pub-id pub-id-type="pmcid">PMC3475624</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="webpage"><source>Older Adults Embrace Tech for Entertainment and Day-to-Day Living [Internet]</source>. <collab>AARP</collab>; [cited <date-in-citation>2022 Mar 17</date-in-citation>]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.aarp.org/pri/topics/technology/internet-media-devices/2022-technology-trends-older-americans/" ext-link-type="uri">https://www.aarp.org/pri/topics/technology/internet-media-devices/2022-technology-trends-older-americans/</ext-link></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Schlemmer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Desrichard</surname><given-names>O</given-names></name>. <article-title>Is Medical Environment Detrimental to Memory? A Test of A White Coat Effect on Older People&#8217;s Memory Performance</article-title>. <source>Clin Gerontol</source>. <year>2018</year>;<volume>41</volume>:<fpage>77</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">28406393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07317115.2017.1307891</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>&#214;hman</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Hassenstab</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Berron</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sch&#246;ll</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Papp</surname><given-names>KV</given-names></name>. <article-title>Current advances in digital cognitive assessment for preclinical Alzheimer&#8217;s disease</article-title>. <source>Alzheimers Dement (Amst)</source>. <year>2021</year>;<volume>13</volume>:<fpage>e12217</fpage>.<pub-id pub-id-type="pmid">34295959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12217</pub-id><pub-id pub-id-type="pmcid">PMC8290833</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hassenstab</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Aschenbrenner</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Balota</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>McDade</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>YY</given-names></name>, <name name-style="western"><surname>Fagan</surname><given-names>AM</given-names></name>, <etal/><article-title>Remote cognitive assessment approaches in the Dominantly Inherited Alzheimer Network (DIAN): Using digital technology to drive clinical innovation in brain-behavior relationships: A new era in neuropsychology</article-title>. <source>Alzheimers Dement</source>. <year>2020</year>;<volume>16</volume>:<fpage>e038144</fpage>.</mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hyun</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sliwinski</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Smyth</surname><given-names>JM</given-names></name>. <article-title>Waking Up on the Wrong Side of the Bed: The Effects of Stress Anticipation on Working Memory in Daily Life</article-title>. <source>J Gerontol B Psychol Sci Soc Sci</source>. <year>2019</year>;<volume>74</volume>:<fpage>38</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">29767767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/geronb/gby042</pub-id><pub-id pub-id-type="pmcid">PMC6294280</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Papp</surname><given-names>KV</given-names></name>, <name name-style="western"><surname>Samaroo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chou</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Buckley</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>OR</given-names></name>, <name name-style="western"><surname>Hsieh</surname><given-names>S</given-names></name>, <etal/><article-title>Unsupervised mobile cognitive testing for use in preclinical Alzheimer&#8217;s disease</article-title>. <source>Alzheimers Dement (Amst)</source>. <year>2021</year>;<volume>13</volume>:<fpage>e12243</fpage>.<pub-id pub-id-type="pmid">34621977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12243</pub-id><pub-id pub-id-type="pmcid">PMC8481881</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rentz</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Dekhtyar</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sherman</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Burnham</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Blacker</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Aghjayan</surname><given-names>SL</given-names></name>, <etal/><article-title>The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials</article-title>. <source>J Prev Alzheimers Dis</source>. <year>2016</year>;<volume>3</volume>:<fpage>8</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">26998469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2015.78</pub-id><pub-id pub-id-type="pmcid">PMC4795477</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Samaroo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Amariglio</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Burnham</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sparks</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Properzi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Schultz</surname><given-names>AP</given-names></name>, <etal/><article-title>Diminished Learning Over Repeated Exposures (LORE) in preclinical Alzheimer&#8217;s disease</article-title>. <source>Alzheimers Dement</source>. <year>2020</year>;<volume>12</volume>: <fpage>1</fpage>&#8211;<lpage>10</lpage>.</mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Schmitter-Edgecombe</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sumida</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cook</surname><given-names>DJ</given-names></name>. <article-title>Bridging the gap between performance-based assessment and self-reported everyday functioning: An ecological momentary assessment approach</article-title>. <source>Clin Neuropsychol</source>. <year>2020</year>;<volume>34</volume>:<fpage>678</fpage>&#8211;<lpage>99</lpage>.<pub-id pub-id-type="pmid">32189568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13854046.2020.1733097</pub-id><pub-id pub-id-type="pmcid">PMC7225027</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Schweitzer</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Husky</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Allard</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Amieva</surname><given-names>H</given-names></name>, <name name-style="western"><surname>P&#233;r&#232;s</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Foubert-Samier</surname><given-names>A</given-names></name>, <etal/><article-title>Feasibility and validity of mobile cognitive testing in the investigation of age-related cognitive decline</article-title>. <source>Int J Methods Psychiatr Res</source>. <year>2017</year>;<volume>26</volume>:<fpage>e1521</fpage>.<pub-id pub-id-type="pmid">27539327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mpr.1521</pub-id><pub-id pub-id-type="pmcid">PMC6877256</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tsoy</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Strom</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Iaccarino</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Erlhoff</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Goode</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Rodriguez</surname><given-names>A</given-names></name>, <etal/><article-title>Detecting Alzheimer&#8217;s disease biomarkers with a brief tablet-based cognitive battery: sensitivity to A&#946; and tau PET</article-title>. <source>Alzheimers Res Ther</source>. <year>2021</year>;<volume>13</volume>:<fpage>36</fpage>.<pub-id pub-id-type="pmid">33557905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-021-00776-w</pub-id><pub-id pub-id-type="pmcid">PMC7871372</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wilks</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Aschenbrenner</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Gordon</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Balota</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Fagan</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Musiek</surname><given-names>E</given-names></name>, <etal/><article-title>Sharper in the morning: Cognitive time of day effects revealed with high-frequency smartphone testing</article-title>. <source>J Clin Exp Neuropsychol</source>. <year>2021</year>;<volume>43</volume>:<fpage>825</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">35037593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13803395.2021.2009447</pub-id><pub-id pub-id-type="pmcid">PMC9116128</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhaoyang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Scott</surname><given-names>SB</given-names></name>, <name name-style="western"><surname>Martire</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Sliwinski</surname><given-names>MJ</given-names></name>. <article-title>Daily social interactions related to daily performance on mobile cognitive tests among older adults</article-title>. <source>PLoS One</source>. <year>2021</year>;<volume>16</volume>:<fpage>e0256583</fpage>.<pub-id pub-id-type="pmid">34437609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0256583</pub-id><pub-id pub-id-type="pmcid">PMC8389411</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cerino</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Katz</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Hyun</surname><given-names>J</given-names></name>, <etal/><article-title>Variability in Cognitive Performance on Mobile Devices Is Sensitive to Mild Cognitive Impairment: Results From the Einstein Aging Study</article-title>. <source>Front Digit Health</source>. <year>2021</year>;<volume>3</volume>:<fpage>758031</fpage>.<pub-id pub-id-type="pmid">34927132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fdgth.2021.758031</pub-id><pub-id pub-id-type="pmcid">PMC8677835</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nicosia</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Aschenbrenner</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Balota</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Sliwinski</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Tahan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Adams</surname><given-names>S</given-names></name>, <etal/><article-title>Unsupervised high-frequency smartphone-based cognitive assessments are reliable, valid, and feasible in older adults at risk for Alzheimer&#8217;s disease</article-title>. <source>J Int Neuropsychol Soc</source>. <year>2023</year>;<volume>29</volume>:<fpage>459</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">36062528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S135561772200042X</pub-id><pub-id pub-id-type="pmcid">PMC9985662</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Salthouse</surname><given-names>TA</given-names></name>. <article-title>Implications of within-person variability in cognitive and neuropsychological functioning for the interpretation of change</article-title>. <source>Neuropsychology</source>. <year>2007</year>;<volume>21</volume>:<fpage>401</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">17605573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/0894-4105.21.4.401</pub-id><pub-id pub-id-type="pmcid">PMC3838958</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>MacDonald</surname><given-names>SWS</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>S</given-names></name>, <name name-style="western"><surname>B&#228;ckman</surname><given-names>L</given-names></name>. <article-title>Neural underpinnings of within-person variability in cognitive functioning</article-title>. <source>Psychol Aging</source>. <year>2009</year>;<volume>24</volume>:<fpage>792</fpage>&#8211;<lpage>808</lpage>.<pub-id pub-id-type="pmid">20025396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/a0017798</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Brinken</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Sch&#252;z</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Ferguson</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Scholz</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Sch&#252;z</surname><given-names>N</given-names></name>. <article-title>Social cognitions and smoking behaviour: Temporal resolution matters</article-title>. <source>Br J Health Psychol</source>. <year>2020</year>;<volume>25</volume>:<fpage>210</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">31814262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjhp.12402</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Albert</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>DeKosky</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Dickson</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Dubois</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Feldman</surname><given-names>HH</given-names></name>, <name name-style="western"><surname>Fox</surname><given-names>NC</given-names></name>, <etal/><article-title>The diagnosis of mild cognitive impairment due to Alzheimer&#8217;s disease: recommendations from the National Institute on Aging-Alzheimer&#8217;s Association workgroups on diagnostic guidelines for Alzheimer&#8217;s disease</article-title>. <source>Alzheimers Dement</source>. <year>2011</year>;<volume>7</volume>:<fpage>270</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21514249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.03.008</pub-id><pub-id pub-id-type="pmcid">PMC3312027</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>McKhann</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Chertkow</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hyman</surname><given-names>BT</given-names></name>, <name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Kawas</surname><given-names>CH</given-names></name>, <etal/><article-title>The diagnosis of dementia due to Alzheimer&#8217;s disease: recommendations from the National Institute on Aging-Alzheimer&#8217;s Association workgroups on diagnostic guidelines for Alzheimer&#8217;s disease</article-title>. <source>Alzheimers Dement</source>. <year>2011</year>;<volume>7</volume>:<fpage>263</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21514250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.03.005</pub-id><pub-id pub-id-type="pmcid">PMC3312024</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Russo</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Lathan</surname><given-names>CE</given-names></name>. <article-title>An Evaluation of the Consistency and Reliability of the Defense Automated Neurocognitive Assessment Tool</article-title>. <source>Appl Psychol Meas</source>. <year>2015</year>;<volume>39</volume>:<fpage>566</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">29881027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0146621615577361</pub-id><pub-id pub-id-type="pmcid">PMC5978515</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lathan</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Spira</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Bleiberg</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Vice</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tsao</surname><given-names>JW</given-names></name>. <article-title>Defense Automated Neurobehavioral Assessment (DANA)-psychometric properties of a new field-deployable neurocognitive assessment tool</article-title>. <source>Mil Med</source>. <year>2013</year>;<volume>178</volume>:<fpage>365</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">23707818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7205/MILMED-D-12-00438</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="webpage"><source>R: A Language and Environment for Statistical Computing [Internet]</source>. <collab>R Foundation for Statistical Computing</collab>; c2021 [cited <date-in-citation>2023 Oct 18</date-in-citation>]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.R-project.org/" ext-link-type="uri">https://www.R-project.org/</ext-link></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bangen</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Weigand</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Delano-Wood</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Clark</surname><given-names>LR</given-names></name>, <name name-style="western"><surname>Eppig</surname><given-names>J</given-names></name>, <etal/><article-title>Cognitive dispersion is a sensitive marker for early neurodegenerative changes and functional decline in nondemented older adults</article-title>. <source>Neuropsychology</source>. <year>2019</year>;<volume>33</volume>:<fpage>599</fpage>&#8211;<lpage>608</lpage>.<pub-id pub-id-type="pmid">30896235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/neu0000532</pub-id><pub-id pub-id-type="pmcid">PMC7380511</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Holtzer</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Verghese</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hall</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Lipton</surname><given-names>RB</given-names></name>. <article-title>Within-person across-neuropsychological test variability and incident dementia</article-title>. <source>JAMA</source>. <year>2008</year>;<volume>300</volume>:<fpage>823</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">18714062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.300.7.823</pub-id><pub-id pub-id-type="pmcid">PMC2736784</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Roalf</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Quarmley</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mechanic-Hamilton</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Wolk</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Arnold</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Moberg</surname><given-names>PJ</given-names></name>; <collab>Alzheimer&#8217;s Disease Neuroimaging Initiative</collab>. <article-title>Within-Individual Variability: An Index for Subtle Change in Neurocognition in Mild Cognitive Impairment</article-title>. <source>J Alzheimers Dis</source>. <year>2016</year>;<volume>54</volume>:<fpage>325</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">27567827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-160259</pub-id><pub-id pub-id-type="pmcid">PMC5238959</pub-id></mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="book"><name name-style="western"><surname>Au</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Devine</surname><given-names>S</given-names></name>. <part-title>The Boston Process Approach to Neuropsychological Assessment: A Practitioner&#8217;s Guide</part-title>. In: <name name-style="western"><surname>Ashendorf</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Swenson</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Libon</surname><given-names>DJ</given-names></name>, editors. <source>Implementing the Boston Process Approach in the Framingham Heart Study: It is possible</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Oxford University Press USA</publisher-name>; <year>2013</year>. pp <fpage>380</fpage>&#8211;<lpage>406</lpage>.</mixed-citation></ref><ref id="R41"><label>41.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Au</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Piers</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Devine</surname><given-names>S</given-names></name>. <article-title>How technology is reshaping cognitive assessment: Lessons from the Framingham Heart Study</article-title>. <source>Neuropsychology</source>. <year>2017</year>;<volume>31</volume>:<fpage>846</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">29376667</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/neu0000411</pub-id><pub-id pub-id-type="pmcid">PMC5791752</pub-id></mixed-citation></ref><ref id="R42"><label>42.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Davoudi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Dion</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Amini</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tighe</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Price</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Libon</surname><given-names>DJ</given-names></name>, <etal/><article-title>Classifying Non-Dementia and Alzheimer&#8217;s Disease/Vascular Dementia Patients Using Kinematic, Time-Based, and Visuospatial Parameters: The Digital Clock Drawing Test</article-title>. <source>J Alzheimers Dis</source>. <year>2021</year>;<volume>82</volume>:<fpage>47</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">34219737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-201129</pub-id><pub-id pub-id-type="pmcid">PMC8283934</pub-id></mixed-citation></ref><ref id="R43"><label>43.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Diaz-Orueta</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Blanco-Campal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lamar</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Libon</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Burke</surname><given-names>T</given-names></name>. <article-title>Marrying Past and Present Neuropsychology: Is the Future of the Process-Based Approach Technology-Based?</article-title><source>Front Psychol</source>. <year>2020</year>;<volume>11</volume>:<fpage>361</fpage>.<pub-id pub-id-type="pmid">32210882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyg.2020.00361</pub-id><pub-id pub-id-type="pmcid">PMC7069278</pub-id></mixed-citation></ref><ref id="R44"><label>44.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Libon</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Swenson</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lamar</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Price</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Baliga</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Pascual-Leone</surname><given-names>A</given-names></name>, <etal/><article-title>The Boston Process Approach and Digital Neuropsychological Assessment: Past Research and Future Directions</article-title>. <source>J Alzheimers Dis</source>. <year>2022</year>;<volume>87</volume>:<fpage>1419</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">35466941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-220096</pub-id></mixed-citation></ref><ref id="R45"><label>45.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lim</surname><given-names>YY</given-names></name>, <name name-style="western"><surname>Baker</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Bruns</surname><given-names>L</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Mills</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fowler</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Fripp</surname><given-names>J</given-names></name>, <etal/><article-title>Association of deficits in short-term learning and A&#946; and hippocampal volume in cognitively normal adults</article-title>. <source>Neurology</source>. <year>2020</year>;<volume>95</volume>: <fpage>e2577</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="pmid">32887774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000010728</pub-id></mixed-citation></ref><ref id="R46"><label>46.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Costa</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Dogan</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Schulz</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Reetz</surname><given-names>K</given-names></name>. <article-title>Going beyond the mean: Intraindividual variability of cognitive performance in prodromal and early neurodegenerative disorders</article-title>. <source>Clin Neuropsychol</source>. <year>2019</year>;<volume>33</volume>: <fpage>369</fpage>&#8211;<lpage>89</lpage>.<pub-id pub-id-type="pmid">30663511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13854046.2018.1533587</pub-id></mixed-citation></ref><ref id="R47"><label>47.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>MacDonald</surname><given-names>SWS</given-names></name>, <name name-style="western"><surname>Stawski</surname><given-names>RS</given-names></name>. <article-title>Longitudinal changes in response time mean and inconsistency exhibit predictive dissociations for risk of cognitive impairment</article-title>. <source>Neuropsychology</source>. <year>2020</year>;<volume>34</volume>:<fpage>264</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">31789567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/neu0000608</pub-id></mixed-citation></ref><ref id="R48"><label>48.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Papp</surname><given-names>KV</given-names></name>, <name name-style="western"><surname>Jutten</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Soberanes</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Weizenbaum</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hsieh</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Molinare</surname><given-names>C</given-names></name>, <etal/><article-title>Early Detection of Amyloid-Related Changes in Memory among Cognitively Unimpaired Older Adults with Daily Digital Testing</article-title>. <source>Ann Neurol</source>. <year>2024</year>;<volume>95</volume>:<fpage>507</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="pmid">37991080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26833</pub-id><pub-id pub-id-type="pmcid">PMC10922126</pub-id></mixed-citation></ref><ref id="R49"><label>49.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Weizenbaum</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Soberanes</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hsieh</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Molinare</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Buckley</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Betensky</surname><given-names>RA</given-names></name>, <etal/><article-title>Capturing learning curves with the multiday Boston Remote Assessment of Neurocognitive Health (BRANCH): Feasibility, reliability, and validity</article-title>. <source>Neuropsychology</source>. <year>2024</year>;<volume>38</volume>:<fpage>198</fpage>&#8211;<lpage>210</lpage>.<pub-id pub-id-type="pmid">37971862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/neu0000933</pub-id><pub-id pub-id-type="pmcid">PMC10841660</pub-id></mixed-citation></ref><ref id="R50"><label>50.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jekel</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Damian</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wattmo</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hausner</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Bullock</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Connelly</surname><given-names>PJ</given-names></name>, <etal/><article-title>Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review</article-title>. <source>Alzheimers Res Ther</source>. <year>2015</year>;<volume>7</volume>:<fpage>17</fpage>.<pub-id pub-id-type="pmid">25815063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-015-0099-0</pub-id><pub-id pub-id-type="pmcid">PMC4374414</pub-id></mixed-citation></ref><ref id="R51"><label>51.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Anda-Duran</surname><given-names>ID</given-names></name>, <name name-style="western"><surname>Hwang</surname><given-names>PH</given-names></name>, <name name-style="western"><surname>Popp</surname><given-names>ZT</given-names></name>, <name name-style="western"><surname>Low</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ding</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>S</given-names></name>, <etal/><article-title>Matching science to reality: how to deploy a participant-driven digital brain health platform</article-title>. <source>Front Dement</source>. <year>2023</year>;<volume>2</volume>:<fpage>1135451</fpage>.<pub-id pub-id-type="pmid">38706716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/frdem.2023.1135451</pub-id><pub-id pub-id-type="pmcid">PMC11067045</pub-id></mixed-citation></ref><ref id="R52"><label>52.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Popp</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Low</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Igwe</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>R</given-names></name>, <etal/><article-title>Shifting From Active to Passive Monitoring of Alzheimer Disease: The State of the Research</article-title>. <source>J Am Heart Assoc</source>. <year>2024</year>;<volume>13</volume>:<fpage>e031247</fpage>.<pub-id pub-id-type="pmid">38226518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.123.031247</pub-id><pub-id pub-id-type="pmcid">PMC10926806</pub-id></mixed-citation></ref><ref id="R53"><label>53.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Stewart</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Krows</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Schaafsma</surname><given-names>TT</given-names></name>, <name name-style="western"><surname>Heller</surname><given-names>KB</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>Boonyaratanakornkit</surname><given-names>J</given-names></name>, <etal/><article-title>Comparison of Racial, Ethnic, and Geographic Location Diversity of Participants Enrolled in Clinic-Based vs 2 Remote COVID-19 Clinical Trials</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>:<fpage>e2148325</fpage>.<pub-id pub-id-type="pmid">35157053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.48325</pub-id><pub-id pub-id-type="pmcid">PMC8844998</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><title>12-Month study schedule.</title><p id="P43">3x: three assessments in one week, each subsegment is completed one time during the first week.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2113854-f0001.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p id="P44">Adherence type definitions.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2113854-f0002.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1.</label><caption><p id="P45">Sample characteristics at study enrollment.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Characteristics</th><th colspan="2" align="left" valign="middle" style="border-bottom: solid 1px" rowspan="1">Sample (<italic toggle="yes">n</italic> = 33)</th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="left" valign="middle" rowspan="1" colspan="1">Mean</th><th align="left" valign="middle" rowspan="1" colspan="1">SD</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age (years)</td><td align="left" valign="middle" rowspan="1" colspan="1">73.5</td><td align="left" valign="middle" rowspan="1" colspan="1">7.0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Education (years)</td><td align="left" valign="middle" rowspan="1" colspan="1">16.9</td><td align="left" valign="middle" rowspan="1" colspan="1">2.1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sex (female)</td><td align="left" valign="middle" rowspan="1" colspan="1">19</td><td align="left" valign="middle" rowspan="1" colspan="1">57.6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Race</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">White</td><td align="left" valign="middle" rowspan="1" colspan="1">27</td><td align="left" valign="middle" rowspan="1" colspan="1">81.8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Black/African American</td><td align="left" valign="middle" rowspan="1" colspan="1">6</td><td align="left" valign="middle" rowspan="1" colspan="1">18.2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Personal mobile device</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">iPhone</td><td align="left" valign="middle" rowspan="1" colspan="1">19</td><td align="left" valign="middle" rowspan="1" colspan="1">57.6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Android</td><td align="left" valign="middle" rowspan="1" colspan="1">11</td><td align="left" valign="middle" rowspan="1" colspan="1">33.3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">iPad</td><td align="left" valign="middle" rowspan="1" colspan="1">3</td><td align="left" valign="middle" rowspan="1" colspan="1">9.1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Cognitive status</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cognitively unimpaired</td><td align="left" valign="middle" rowspan="1" colspan="1">24</td><td align="left" valign="middle" rowspan="1" colspan="1">72.7</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cognitively impaired</td><td align="left" valign="middle" rowspan="1" colspan="1">9</td><td align="left" valign="middle" rowspan="1" colspan="1">27.3</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P46">SD: standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2.</label><caption><p id="P47">Adherence rates across segments and adherence type.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Segment type</th><th align="left" valign="middle" rowspan="1" colspan="1">Subsegment adherence<sup><xref rid="TFN2" ref-type="table-fn">a</xref></sup></th><th align="left" valign="middle" rowspan="1" colspan="1">Segment adherence<sup><xref rid="TFN3" ref-type="table-fn">b</xref></sup></th><th align="left" valign="middle" rowspan="1" colspan="1">Cumulative adherence</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Segment 1</td><td align="left" valign="middle" rowspan="1" colspan="1">31/33 (93.9%)</td><td align="left" valign="middle" rowspan="1" colspan="1">31/33 (93.9%)</td><td align="left" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Segment 2</td><td align="left" valign="middle" rowspan="1" colspan="1">30/33 (90.9%)</td><td align="left" valign="middle" rowspan="1" colspan="1">32/33 (97.0%)</td><td align="left" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Segment 3</td><td align="left" valign="middle" rowspan="1" colspan="1">27/33 (81.8%)</td><td align="left" valign="middle" rowspan="1" colspan="1">32/33 (97.0%)</td><td align="left" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Segment 4</td><td align="left" valign="middle" rowspan="1" colspan="1">24/33 (72.7%)<sup><xref rid="TFN4" ref-type="table-fn">c</xref></sup></td><td align="left" valign="middle" rowspan="1" colspan="1">29/33 (87.9%)</td><td align="left" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Overall</td><td align="left" valign="middle" rowspan="1" colspan="1">20/33 (60.6%)</td><td align="left" valign="middle" rowspan="1" colspan="1">26/33 (78.8%)</td><td align="left" valign="middle" rowspan="1" colspan="1">30/33 (90.9%)</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><label>a:</label><p id="P48">Cochran&#8217;s Q Test, <italic toggle="yes">p</italic> = 0.04;</p></fn><fn id="TFN3"><label>b:</label><p id="P49">Cochran&#8217;s Q Test, <italic toggle="yes">p</italic> = 0.35;</p></fn><fn id="TFN4"><label>c:</label><p id="P50">Pairwise McNemar&#8217;s test for segment 1 and segment 4 comparison, adjusted <italic toggle="yes">p</italic> = 0.05.</p></fn></table-wrap-foot></table-wrap></floats-group></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Epigenetics</journal-id><journal-id journal-id-type="iso-abbrev">Clin Epigenetics</journal-id><journal-id journal-id-type="pmc-domain-id">1699</journal-id><journal-id journal-id-type="pmc-domain">clinepig</journal-id><journal-title-group><journal-title>Clinical Epigenetics</journal-title></journal-title-group><issn pub-type="ppub">1868-7075</issn><issn pub-type="epub">1868-7083</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12495807</article-id><article-id pub-id-type="pmcid-ver">PMC12495807.1</article-id><article-id pub-id-type="pmcaid">12495807</article-id><article-id pub-id-type="pmcaiid">12495807</article-id><article-id pub-id-type="pmid">41044651</article-id><article-id pub-id-type="doi">10.1186/s13148-025-01976-z</article-id><article-id pub-id-type="publisher-id">1976</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Exploring causal relationships between epigenetic age acceleration and Alzheimer&#8217;s disease: a bidirectional Mendelian randomization study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="H">Hongwei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yin</surname><given-names initials="Z">Zhaoxu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="X">Xuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="Z">Zhijun</given-names></name><address><email>13623418033@163.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/040f10867</institution-id><institution-id institution-id-type="GRID">grid.464450.7</institution-id><institution>Department of Neurology, </institution><institution>Taiyuan Central Hospital, </institution></institution-wrap>Taiyuan, Shanxi Province China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0265d1010</institution-id><institution-id institution-id-type="GRID">grid.263452.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 4018</institution-id><institution>Department of Neurology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, </institution><institution>Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, </institution></institution-wrap>No.99, Longcheng Street, Taiyuan, 030000 Shanxi Province China </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">478173</issue-id><elocation-id>164</elocation-id><history><date date-type="received"><day>21</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>2</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-05 10:25:46.240"><day>05</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13148_2025_Article_1976.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Alzheimer&#8217;s disease (AD) is identified by a distinct progression of aging-associated cognitive and functional impairment. Recent advances recognize the DNA methylation-based epigenetic clock as a precise predictor of aging processes and their related health outcomes. However, observational studies exploring this link are often compromised by confounding factors and reverse causality bias. To address the question, our study employs a bidirectional Mendelian randomization (MR) analysis to explore the causal relationship between epigenetic age acceleration (EAA) and AD.</p></sec><sec><title>Methods</title><p id="Par2">Genome-wide association study (GWAS) statistics for epigenetic clocks (GrimAge, PhenoAge, HorvathAge, and HannumAge) were sourced from Edinburgh DataShare and the Alzheimer Disease Genetics Consortium (ADGC). The dataset comprised 63,926 participants, and among them, 21,982 cases were AD patients and 41,944 were controls. The primary analytical method for the MR was the inverse variance weighted (IVW). The potential pleiotropy and heterogeneity among the instrumental variables were evaluated by additional sensitivity analyses.</p></sec><sec><title>Results</title><p id="Par3">Employing the random-effects IVW approach, we found that, as indicated by GrimAge, EAA was associated with an increased risk of AD (Odds Ratio [OR]&#8201;=&#8201;1.025, 95% Confidence Interval [CI]: 1.006&#8211;1.044, <italic toggle="yes">p</italic>&#8201;=&#8201;0.009). Quality control assessments confirmed the reliability and robustness of our findings. However, the evidence did not support a causal relationship between AD and epigenetic aging in the reverse direction.</p></sec><sec><title>Conclusions</title><p id="Par4">Our MR study indicates a positive causal relationship between EAA and AD. Further research is necessary to explore the underlying physiological mechanisms.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13148-025-01976-z.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alzheimer&#8217;s disease</kwd><kwd>Genome wide association study</kwd><kwd>Epigenetic age acceleration</kwd><kwd>Mendelian randomization</kwd><kwd>Epigenetic clocks</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Alzheimer&#8217;s disease (AD) is a progressive neurodegeneration characterized by a gradual deterioration in cognitive function [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref>]. The disease progresses through a continuum, starting from asymptomatic preclinical stages, advancing to mild cognitive impairment due to AD, and eventually progressing through mild, moderate, and severe stages of AD dementia. Aging is a time-dependent decline in physiological function and represents the most significant risk factor for several non-infectious diseases, including AD. Research consistently links aging to AD [<xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref>], noting that AD predominantly affects individuals aged 65 and older (in about 90% of cases) [<xref ref-type="bibr" rid="CR8">8</xref>] with its prevalence doubling every five years, thus showing a time-dependent exponential increase [<xref ref-type="bibr" rid="CR9">9</xref>]. At present, mounting evidence supports the notion that mitophagy activity significantly declines in human brains with aging. Impaired mitophagy and mitochondrial dysfunction have been causally linked to bioenergetic deficiencies, oxidative stress, microglial activation, and chronic inflammation. These factors collectively exacerbate amyloid-beta (A&#946;) and tau pathologies, ultimately leading to neuronal loss in Alzheimer&#8217;s disease (AD) [<xref ref-type="bibr" rid="CR10">10</xref>]. Through comparative and associative studies, Xia X, et al. concluded that accelerated aging is intricately linked to AD through various mechanisms. These mechanisms include genetic factors, DNA methylation, histone modifications, RNA dynamics, as well as neuronal and glial function. The research also highlights the impact of neural stem cell activity, systemic inflammation, and lifestyle factors on the progression of AD [<xref ref-type="bibr" rid="CR11">11</xref>]. However, the current diagnostic techniques for AD and its pharmacological treatments have significant limitations. Patients with AD often exhibit poor compliance with pharmacological treatments, largely due to adverse drug reactions. Therefore, identifying additional risk factors for AD is crucial for optimizing its diagnosis, prevention, and treatment strategies.</p><p id="Par6">Recognized for its precision, the epigenetic clock now stands as the foremost predictor of biological aging, surpassing both chronological age and other traditional age-related biomarkers [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. The epigenetic clock, which derives estimates of age from DNA methylation data, is based on a robust correlation with chronological age. This relationship is established through machine learning algorithms that analyze levels of DNA methylation. Importantly, discrepancies between epigenetic and chronological age have been linked to the severity of the cognitive decline in AD patients [<xref ref-type="bibr" rid="CR14">14</xref>]. It is important to note that DNA methylation profiles associated with AD and brain aging may not directly correspond to those found in the blood methylome. Evidence from studies on CD4&#8201;+&#8201;lymphocytes and the dorsolateral prefrontal cortex indicates that methylation patterns in the blood may not accurately reflect the changes occurring in the brain [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Further investigation is needed to determine whether this observation extends to the entire brain or is specific to certain brain regions. Epigenetic changes in AD seem to function independently of genetic variants, impacting disease risk through interactions with various genetic factors [<xref ref-type="bibr" rid="CR14">14</xref>]. In a study involving monozygotic triplets, where two had developed Alzheimer&#8217;s disease, their epigenetic ages were analyzed using a genome-wide DNA methylation chip. The findings revealed that their epigenetic ages appeared 6&#8211;10&#160;years younger than their actual chronological ages. Conversely, in the triplet with early-onset AD, the DNA methylation age was found to be 9&#160;years older, suggesting a pattern of accelerated aging [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par7">Epigenetic clocks offer an insightful framework for studying AD by elucidating biological aging processes through diverse mechanistic perspectives. Among these, GrimAge stands out as an advanced DNA methylation-based estimator, integrating methylation markers associated with plasma protein biomarkers and cumulative smoking exposure. This unique combination enhances its sensitivity to aging processes driven by inflammation and oxidative stress. With its exceptional predictive accuracy for morbidity and mortality risks, GrimAge has emerged as a robust tool for evaluating lifespan and age-related diseases, including complex neurodegenerative disorders like AD [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. PhenoAge integrates a range of systemic biomarkers, including albumin, glucose, and C-reactive protein, which collectively reflect systemic inflammation and physiological resilience. This integrative approach enables a nuanced assessment of biological age and overall health status, offering a comprehensive framework for understanding age-related physiological changes and associated vulnerabilities [<xref ref-type="bibr" rid="CR19">19</xref>]. PhenoAge&#8217;s focus on systemic inflammation is highly relevant to AD, as chronic inflammatory processes play a pivotal role in driving neurodegenerative progression, positioning it as an insightful tool for AD research [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. HorvathAge, the pioneering multi-tissue epigenetic clock, assesses biological age across diverse tissue types, offering a comprehensive metric for cellular aging [<xref ref-type="bibr" rid="CR22">22</xref>]. Although less targeted to specific diseases, its broad applicability facilitates foundational assessments of biological aging and epigenetic alterations, which are integral to understanding systemic aging processes that may underlie AD pathology [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. HannumAge, which utilizes blood-based DNA methylation profiles, is closely linked to immune aging and inflammation, two central factors in AD&#8217;s pathophysiology. Its heightened sensitivity to hematopoietic aging further underscores its utility in exploring systemic inflammation and its critical role in neurodegeneration. Together, these epigenetic clocks provide a multidimensional approach for investigating epigenetic age acceleration and its relevance to AD. This comprehensive framework offers nuanced insights into aging mechanisms and their contributions to neurodegeneration and cognitive decline in AD [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. However, the associations reported between epigenetic age acceleration (EAA) and AD are primarily observational, yielding inconsistent conclusions. The integrity of these studies is often compromised by confounding factors and reverse causality, making it challenging to establish causal relationships through traditional observational epidemiology. Moreover, the specific impact of EAA on AD, along with the underlying mechanisms, remains poorly understood. Therefore, a tailored approach is crucial to effectively explore the causal relationship between EAA and AD.</p><p id="Par8">Mendelian Randomization (MR) is a robust analytical framework that leverages genetic variants as instrumental variables to infer causal relationships, effectively addressing two major limitations inherent in observational studies: confounding and reverse causality. Confounding arises when an external factor influences both the exposure (EAA) and the outcome (AD), obscuring the causal link between the two. MR minimizes this issue through the principle of Mendelian inheritance, wherein genetic variants are randomly assigned at conception and remain largely unaffected by environmental and behavioral factors. This randomization ensures that genetic variants associated with the exposure are independent of external confounders, enabling clearer interpretations of causal pathways [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. In the context of this study, MR facilitates the evaluation of whether EAA causally influences AD by employing genetic variants linked to EAA. This approach reduces the potential for bias from lifestyle factors, such as smoking or socioeconomic status, and highlights a direct relationship between EAA and AD risk, rather than an indirect association mediated by shared risk factors. Additionally, MR effectively mitigates reverse causality, a frequent challenge in observational research, by relying on genetic variants that are established at conception and remain stable throughout life. This temporal stability establishes a clear sequence between genetic predisposition and disease outcomes, which is particularly valuable for neurodegenerative conditions like AD, where biomarkers often appear as both causes and consequences of the disease [<xref ref-type="bibr" rid="CR28">28</xref>]. Beyond addressing confounding and reverse causality, MR provides insights into biological pathways connecting EAA and AD. For instance, if genetic variants associated with EAA are linked to pathways involving inflammation or cellular aging, this finding could illuminate mechanisms by which EAA contributes to AD progression [<xref ref-type="bibr" rid="CR29">29</xref>]. Furthermore, MR enhances the interpretability and reliability of findings. Observational studies often struggle to disentangle causal relationships from correlations influenced by external factors, but MR strengthens causal inference by positioning EAA as an upstream factor in AD development and a promising candidate for targeted interventions [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. In summary, MR offers a rigorous methodological framework for investigating the causal role of EAA in AD, bolstering confidence in the study&#8217;s conclusions and highlighting EAA as a potential contributor to AD pathology. These insights pave the way for further research and therapeutic strategies aimed at modulating epigenetic aging to reduce AD risk.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p id="Par9">This study was designed in accordance with the guideline of STROBE-MR, ensuring that each stage of the MR analysis was thoroughly conducted [<xref ref-type="bibr" rid="CR32">32</xref>]. The full study design is illustrated in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. A two-sample MR study was conducted to investigate the causal linkage between genetically determined EAA and the risk of AD. This study is pioneering in using MR to analyze the impact of EAA on AD from a genetic perspective. Additionally, our study examined the impact of AD on EAA. MR studies must fulfill three core assumptions for valid causal inference. First, the IVs, such as SNPs, must be associated with the exposure, the epigenetic clocks, strongly. Second, the IVs should be related only to the exposure and not to potential confounders like age, sex, or BMI. Third, the IVs must affect the outcome of AD solely through the exposure pathway (epigenetic clocks), and not via any alternate pathways. Our investigation into the effects of AD on EAA rigorously adheres to these foundational assumptions.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>The process of present Mendelian randomization (MR) analyses is shown in flow chart. Assumption 1: The instrumental variables (IVs) selected for this study should demonstrate a significant association with epigenetic clocks. Assumption 2: The IVs chosen for present study are required to have no significant associations with other potential confounding factors. Assumption 3: The IVs utilized in present study do not have any independent causal pathways leading to Alzheimer&#8217;s disease other than through epigenetic age acceleration. <italic toggle="yes">Abbreviations</italic>: IV, Instrumental variable; SNPs, Single-nucleotide polymorphisms; MR, Mendelian randomization</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="13148_2025_1976_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec4"><title>Selection and data sources for epigenetic clocks in AD analysis</title><p id="Par10">The selection of GrimAge, PhenoAge, HorvathAge, and HannumAge for this study reflects their unique capacities to elucidate various facets of biological aging, offering valuable insights into the pathophysiology of AD. GrimAge and PhenoAge were prioritized for their exceptional predictive accuracy in assessing age-related diseases and mortality risks. GrimAge integrates cumulative smoking exposure and mortality-associated protein biomarkers, while PhenoAge highlights systemic inflammation, both critical in the pathological mechanisms underlying AD. HorvathAge, as a foundational multi-tissue epigenetic clock, provides broad applicability across various tissue types, facilitating a more generalized understanding of biological aging. HannumAge, with its emphasis on immune aging and inflammation, further supports the investigation of neurodegenerative processes. Collectively, these clocks provide a comprehensive, multidimensional framework for exploring EAA and its significance in AD, enabling a detailed examination of aging mechanisms contributing to neurodegeneration.</p><p id="Par11">The data for these epigenetic clocks were derived from a meta-analysis of genome-wide association studies (GWAS), which included 28 cohorts and a total of 34,710 participants of European ancestry, 57.3% of whom were women. This meta-analysis identified 137 loci associated with aging-related DNA biomarkers, which were employed as genetic instruments for the chosen clocks. Additional data on AD were sourced from the Alzheimer Disease Genetics Consortium (ADGC) GWAS, comprising 63,926 participants, including 41,944 cognitively normal controls and 21,982 AD cases [<xref ref-type="bibr" rid="CR33">33</xref>]. These robust datasets provide a strong foundation for investigating the causal associations between EAA and AD, significantly enhancing the depth and rigor of this study.</p></sec><sec id="Sec5"><title>Instrumental variable selection</title><p id="Par12">SNPs that showed significant associations with the exposure (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;5&#8201;&#215;&#8201;10<sup>&#8211;8</sup>) genome-wide were chosen as IVs. For HorvathAge, where initially only four SNPs met this criterion, we relaxed the threshold to 5&#8201;&#215;&#8201;10<sup>&#8211;7</sup> to identify a suitable number of IVs. [<xref ref-type="bibr" rid="CR34">34</xref>] To prevent linkage disequilibrium, we applied criteria of <italic toggle="yes">r</italic><sup>2</sup>&#8201;&lt;&#8201;0.001 and a separation of over 10,000 kilobases (kb) [<xref ref-type="bibr" rid="CR35">35</xref>]. Adhering to the second and third assumptions of Mendelian Randomization, we removed IVs that could proxy for confounders or outcomes, a process validated using the PhenoScannerV2 database. Outlier and palindromic SNPs were also excluded. To improve the statistical analysis, SNPs with an F-statistic greater than 10 were selected [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. calculated by the formula: R<sup>2</sup> &#215; [(N&#8201;&#8722;&#8201;k&#8201;&#8722;&#8201;1)/((1&#8201;&#8722;&#8201;R<sup>2</sup>) &#215; k)], where N indicates sample size for epigenetic clocks, k represents the number of SNPs, and R<sup>2</sup> is the proportion of methylation score variation explained by each SNP. The R<sup>2</sup> value was computed using the formula: 2 &#215; beta<sup>2</sup> &#215; (1-eaf) &#215; eaf, where eaf refers to the allele frequency, and beta is the genetic effect estimate on epigenetic clocks [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR38">38</xref>].</p></sec><sec id="Sec6"><title>Power calculation</title><p id="Par13">To ensure that our study design achieves adequate statistical power, we conducted a power calculation using the online tool available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.mranalysis.cn">www.mranalysis.cn</ext-link>. This analysis was based on key parameters, including the effect size, sample size, and the proportion of variance explained by the instrumental variables (IVs). Specifically, we assumed a hypothetical effect size (e.g., OR&#8201;=&#8201;1.025), a significance level (<italic toggle="yes">&#945;</italic>&#8201;=&#8201;0.05), and a target power of 80% (1-&#946;&#8201;=&#8201;0.80). The inclusion of this power calculation complements our rigorous methodological framework, providing an additional layer of validation for the robustness of our study design. It also allows us to transparently address potential limitations in detecting associations, particularly for exposures characterized by smaller effect sizes or lower variance explained by genetic instruments. By incorporating this step, we aim to strengthen the interpretability and reliability of our findings, even under conditions where sample size constraints may pose challenges to the detection of subtle genetic associations.</p></sec><sec id="Sec7"><title>MR analysis and sensitivity analysis</title><p id="Par14">Programing language R (version 4.3.3) was used for data analysis, and the package, two-Sample MR (version 0.5.6) was installed and applied in this study. MR estimates the causal effect of risk factors on complex diseases by leveraging genetic variation as IVs [<xref ref-type="bibr" rid="CR39">39</xref>]. In this study, the random-effects inverse-variance weighted (IVW) method was used as the main statistical approach [<xref ref-type="bibr" rid="CR40">40</xref>]. To accurately examine causal effects and address the impact of horizontal pleiotropy, multiple complementary MR detection methods were utilized. These included the Weighted Median (WMed), Weighted Mode (WMod), MR Egger (MRE), Simple Mode (SMod), and the MR-pleiotropy residual and outlier method (MR-PRESSO) [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par15">The IVW method is a robust analysis tool that operates under the fundamental premise that all genetic variants used are valid instrumental variables. This method has a strong capacity to reliably detect causal relationships [<xref ref-type="bibr" rid="CR43">43</xref>]. To ensure data consistency, Given the potential heterogeneity arising from variations in experimental conditions, selected populations, and SNPs, this may influence the accuracy of causal effect estimates in two-sample MR analysis. Consequently, heterogeneity tests were performed using the main IVW analysis method and the MRE method. The results, with a <italic toggle="yes">P</italic>-value&#8201;&gt;&#8201;0.05, indicated no significant heterogeneity among the instrumental variables used. A fundamental assumption of MR analysis is that IVs influence outcomes solely through exposure; therefore, tests for horizontal pleiotropy were conducted to validate the causal pathways between the exposure and outcomes [<xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par16">The intercept value in the MRE method serves as an indicator to evaluate pleiotropy. A very close to zero intercept suggests that the MRE regression model closely mirrors the IVW method. Additionally, a lower intercept value indicates a reduced likelihood of horizontal pleiotropy. This suggests that the SNPs are likely associated solely with the exposure rather than with other confounding variables. [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR45">45</xref>] Horizontal pleiotropy was further evaluated using the MR-PRESSO global test, and outlying SNPs that could potentially distort the analysis were identified and excluded based on the MR-PRESSO outlier test [<xref ref-type="bibr" rid="CR46">46</xref>]. We also investigated whether a statistically significant difference exists after removing outlying IVs when compared to the initial analysis. Heterogeneity in the IVW and MRE methods was assessed using Cochran&#8217;s Q statistics and funnel plots [<xref ref-type="bibr" rid="CR47">47</xref>]. Finally, to reveal whether the causal relationship is influenced by a single SNP, several sensitivity analyses were conducted. These included single SNP analysis and leave-one-out analysis [<xref ref-type="bibr" rid="CR42">42</xref>].</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Identification of IVs for MR analysis</title><p id="Par17">First, we screened 8, 9, 11, and 11 IVs based on the GWAS data of GrimAge, PhenoAge, HorvathAge, and HannumAge, respectively. Notably, the F statistics for the selected SNPs exceeded 496, with ranges as follows: GrimAge (977&#8211;1836), PhenoAge (859&#8211;4527), HorvathAge (813&#8211;4462), and HannumAge (496&#8211;1561) (Supplementary Table&#160;<xref rid="MOESM2" ref-type="media">1</xref>). Whereas 21 IVs identified from the GWAS data on AD showed F statistics exceeding 29, ranging from 30 to 962 (Supplementary Table&#160;<xref rid="MOESM2" ref-type="media">2</xref>). In MR analysis, the F-statistic serves as a key indicator for assessing the strength of an instrumental variable, with a value exceeding 10 signifying a robust instrument. Our analysis revealed strong instrument strength, with F-statistics ranging from 496 to 4527 in bidirectional MR analyses, confirming the absence of weak IV bias in our study. Consequently, these instrumental variables provide reliable estimates for assessing the effect of exposure on the outcome.</p></sec><sec id="Sec10"><title>Bidirectional Mendelian randomization results</title><p id="Par18">Significant associations were identified in the summary-level Mendelian randomization analysis between genetically predicted EAA and AD. As plotted in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>, a positive association was noted with GrimAge, showing an OR of 1.025, with a 95%CI of 1.006&#8211;1.044 and a p-value of 0.009 using the IVW method (Power Calculator: 15.9%). However, no causal association between other epigenetic aging-related traits and the likelihood of AD was detected (OR&#8201;=&#8201;1.003, 95%CI: 0.972&#8211;1.035, <italic toggle="yes">p</italic>&#8201;=&#8201;0.860 for PhenoAge by IVW; OR&#8201;=&#8201;1.001, 95%CI: 0.988&#8211;1.015, <italic toggle="yes">p</italic>&#8201;=&#8201;0.840 for HorvathAge by IVW; OR&#8201;=&#8201;1.045, 95%CI: 0.989&#8211;1.104, <italic toggle="yes">p</italic>&#8201;=&#8201;0.116 for HannumAge by IVW). In-depth information regarding the MR analysis examining the causal relationship between EAA and AD is shown in Supplementary Table&#160;<xref rid="MOESM2" ref-type="media">3</xref>. Figure&#160;<xref rid="Fig3" ref-type="fig">3</xref> presents the scatter plots illustrating the outcomes of the five methods. The trend lines depicted in the figure indicated that genetically predicted GrimAge increase was related to a higher risk of AD. Subsequently, we conducted MR analysis with AD as the exposure to explore potential reverse causality effects on EAA. As plotted in Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>, genetic predicted AD was not associated with any epigenetic aging-related traits (OR&#8201;=&#8201;1.384, 95%CI: 0.871&#8211;2.200, <italic toggle="yes">p</italic>&#8201;=&#8201;0.169 for GrimAge by IVW; OR&#8201;=&#8201;0.905, 95%CI: 0.805&#8211;1.017, <italic toggle="yes">p</italic>&#8201;=&#8201;0.093 for PhenoAge by IVW; OR&#8201;=&#8201;1.204, 95%CI: 0.759&#8211;1.911, <italic toggle="yes">p</italic>&#8201;=&#8201;0.431 for HorvathAge by IVW; OR&#8201;=&#8201;0.933, 95%CI: 0.854&#8211;1.020, <italic toggle="yes">p</italic>&#8201;=&#8201;0.126 for HannumAge by IVW). Details of the MR analysis evaluating the causal relationship between EAA and AD are shown in Supplementary Table&#160;<xref rid="MOESM2" ref-type="media">4</xref>. Figure&#160;<xref rid="Fig5" ref-type="fig">5</xref> presents the scatter plots illustrating the outcomes of the five methods.<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Forest plot of estimates for effects of epigenetic age acceleration on Alzheimer&#8217;s disease in Mendelian randomization. Estimates were obtained using the inverse variance weighted, MR Egger, and weighted median. <italic toggle="yes">Abbreviations</italic>: MR, Mendelian randomization; CI, confidence interval; OR, odds ratio; SNPs, single-nucleotide polymorphisms</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="13148_2025_1976_Fig2_HTML.jpg"/></fig><fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Scatter plots of epigenetic age acceleration and Alzheimer&#8217;s disease. GrimAge (<bold>A</bold>), PhenoAge (<bold>B</bold>), HorvathAge (<bold>C</bold>) and HannumAge (<bold>D</bold>) as exposure and Alzheimer&#8217;s disease as outcome. <italic toggle="yes">Abbreviations</italic>: MR, Mendelian randomization; SNPs, single-nucleotide polymorphisms</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="13148_2025_1976_Fig3_HTML.jpg"/></fig><fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Forest plot of estimates for effects of Alzheimer&#8217;s disease on epigenetic age acceleration in Mendelian randomization. Estimates were obtained using the inverse variance weighted, MR Egger, and weighted median. <italic toggle="yes">Abbreviations</italic>: MR, Mendelian randomization; CI, confidence interval; OR, odds ratio; SNPs, single-nucleotide polymorphisms</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="13148_2025_1976_Fig4_HTML.jpg"/></fig><fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Scatter plots of Alzheimer&#8217;s disease and epigenetic age acceleration. Alzheimer&#8217;s disease as exposure, and GrimAge (<bold>A</bold>), PhenoAge (<bold>B</bold>), HorvathAge (<bold>C</bold>) and HannumAge (<bold>D</bold>) as outcome. <italic toggle="yes">Abbreviations</italic>: MR, Mendelian randomization; SNPs, single-nucleotide polymorphisms</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="13148_2025_1976_Fig5_HTML.jpg"/></fig></p></sec><sec id="Sec11"><title>Sensitivity analysis</title><p id="Par19">To examine heterogeneity among the IVs, we employed Cochran&#8217;s Q statistics in conjunction with the IVW and MRE methods. The results showed no significant heterogeneity (all <italic toggle="yes">p</italic>-values&#8201;&gt;&#8201;0.05, Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Additionally, both the MRE intercept and the MR-PRESSO global test revealed that the absence of directional horizontal pleiotropy is not statistically significant (all <italic toggle="yes">p</italic>-values&#8201;&gt;&#8201;0.05, Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Furthermore, we conducted a leave-one-out analysis using the IVW method, systematically removing one SNP at a time to analyze the impact of the remaining SNPs (Supplementary Figs.&#160;<xref rid="MOESM1" ref-type="media">1</xref>, <xref rid="MOESM1" ref-type="media">2</xref>). This analysis confirmed that no individual SNP substantially influenced the overall results, thus affirming their credibility. These sensitivity analyses, including the MRE intercept, Cochran&#8217;s Q statistics, MR-PRESSO global test, and the leave-one-out approach, collectively confirmed the robustness of our two-sample MR study findings.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>The heterogeneity and pleiotropy analysis of the MR study on epigenetic age acceleration and Alzheimer&#8217;s disease</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Exposure</th><th align="left" rowspan="2" colspan="1">Outcome</th><th align="left" colspan="1" rowspan="1">Method</th><th align="left" colspan="1" rowspan="1">Heterogeneity</th><th align="left" colspan="1" rowspan="1">Horizontal pleiotropy</th><th align="left" colspan="4" rowspan="1">MR PRESSO</th></tr><tr><th align="left" colspan="1" rowspan="1">Q</th><th align="left" colspan="1" rowspan="1">Q_<italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">MRE intercept</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">Qutliers</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">Q</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">GrimAge</td><td align="left" rowspan="2" colspan="1">Alzheimer&#8217;s disease</td><td align="left" colspan="1" rowspan="1">MRE</td><td char="." align="char" colspan="1" rowspan="1">2.775</td><td char="." align="char" colspan="1" rowspan="1">0.735</td><td align="left" rowspan="2" colspan="1">0.003</td><td char="." align="char" rowspan="2" colspan="1">0.923</td><td align="left" rowspan="2" colspan="1">0</td><td char="." align="char" rowspan="2" colspan="1">0.876</td></tr><tr><td align="left" colspan="1" rowspan="1">IVW</td><td char="." align="char" colspan="1" rowspan="1">2.786</td><td char="." align="char" colspan="1" rowspan="1">0.835</td></tr><tr><td align="left" rowspan="2" colspan="1">PhenoAge</td><td align="left" rowspan="2" colspan="1">Alzheimer&#8217;s disease</td><td align="left" colspan="1" rowspan="1">MRE</td><td char="." align="char" colspan="1" rowspan="1">5.823</td><td char="." align="char" colspan="1" rowspan="1">0.667</td><td align="left" rowspan="2" colspan="1">&#8722;&#8201;0.008</td><td char="." align="char" rowspan="2" colspan="1">0.595</td><td align="left" rowspan="2" colspan="1">0</td><td char="." align="char" rowspan="2" colspan="1">0.806</td></tr><tr><td align="left" colspan="1" rowspan="1">IVW</td><td char="." align="char" colspan="1" rowspan="1">6.129</td><td char="." align="char" colspan="1" rowspan="1">0.727</td></tr><tr><td align="left" rowspan="2" colspan="1">HorvathAge</td><td align="left" rowspan="2" colspan="1">Alzheimer&#8217;s disease</td><td align="left" colspan="1" rowspan="1">MRE</td><td char="." align="char" colspan="1" rowspan="1">7.660</td><td char="." align="char" colspan="1" rowspan="1">0.364</td><td align="left" rowspan="2" colspan="1">0.004</td><td char="." align="char" rowspan="2" colspan="1">0.869</td><td align="left" rowspan="2" colspan="1">0</td><td char="." align="char" rowspan="2" colspan="1">0.206</td></tr><tr><td align="left" colspan="1" rowspan="1">IVW</td><td char="." align="char" colspan="1" rowspan="1">7.692</td><td char="." align="char" colspan="1" rowspan="1">0.464</td></tr><tr><td align="left" rowspan="2" colspan="1">HannumAge</td><td align="left" rowspan="2" colspan="1">Alzheimer&#8217;s disease</td><td align="left" colspan="1" rowspan="1">MRE</td><td char="." align="char" colspan="1" rowspan="1">1.491</td><td char="." align="char" colspan="1" rowspan="1">0.828</td><td align="left" rowspan="2" colspan="1">&#8722;&#8201;0.060</td><td char="." align="char" rowspan="2" colspan="1">0.111</td><td align="left" rowspan="2" colspan="1">0</td><td char="." align="char" rowspan="2" colspan="1">0.180</td></tr><tr><td align="left" colspan="1" rowspan="1">IVW</td><td char="." align="char" colspan="1" rowspan="1">5.641</td><td char="." align="char" colspan="1" rowspan="1">0.343</td></tr><tr><td align="left" rowspan="2" colspan="1">Alzheimer&#8217;s disease</td><td align="left" rowspan="2" colspan="1">GrimAge</td><td align="left" colspan="1" rowspan="1">MRE</td><td char="." align="char" colspan="1" rowspan="1">8.955</td><td char="." align="char" colspan="1" rowspan="1">0.536</td><td align="left" rowspan="2" colspan="1">0.045</td><td char="." align="char" rowspan="2" colspan="1">0.464</td><td align="left" rowspan="2" colspan="1">0</td><td char="." align="char" rowspan="2" colspan="1">0.594</td></tr><tr><td align="left" colspan="1" rowspan="1">IVW</td><td char="." align="char" colspan="1" rowspan="1">9.533</td><td char="." align="char" colspan="1" rowspan="1">0.573</td></tr><tr><td align="left" rowspan="2" colspan="1">Alzheimer&#8217;s disease</td><td align="left" rowspan="2" colspan="1">PhenoAge</td><td align="left" colspan="1" rowspan="1">MRE</td><td char="." align="char" colspan="1" rowspan="1">6.897</td><td char="." align="char" colspan="1" rowspan="1">0.939</td><td align="left" rowspan="2" colspan="1">&#8722;&#8201;0.009</td><td char="." align="char" rowspan="2" colspan="1">0.620</td><td align="left" rowspan="2" colspan="1">0</td><td char="." align="char" rowspan="2" colspan="1">0.976</td></tr><tr><td align="left" colspan="1" rowspan="1">IVW</td><td char="." align="char" colspan="1" rowspan="1">7.154</td><td char="." align="char" colspan="1" rowspan="1">0.953</td></tr><tr><td align="left" rowspan="2" colspan="1">Alzheimer&#8217;s disease</td><td align="left" rowspan="2" colspan="1">HorvathAge</td><td align="left" colspan="1" rowspan="1">MRE</td><td char="." align="char" colspan="1" rowspan="1">9.460</td><td char="." align="char" colspan="1" rowspan="1">0.489</td><td align="left" rowspan="2" colspan="1">0.029</td><td char="." align="char" rowspan="2" colspan="1">0.635</td><td align="left" rowspan="2" colspan="1">0</td><td char="." align="char" rowspan="2" colspan="1">0.560</td></tr><tr><td align="left" colspan="1" rowspan="1">IVW</td><td char="." align="char" colspan="1" rowspan="1">9.699</td><td char="." align="char" colspan="1" rowspan="1">0.558</td></tr><tr><td align="left" rowspan="2" colspan="1">Alzheimer&#8217;s disease</td><td align="left" rowspan="2" colspan="1">HannumAge</td><td align="left" colspan="1" rowspan="1">MRE</td><td char="." align="char" colspan="1" rowspan="1">4.527</td><td char="." align="char" colspan="1" rowspan="1">0.991</td><td align="left" rowspan="2" colspan="1">&#8722;&#8201;0.012</td><td char="." align="char" rowspan="2" colspan="1">0.392</td><td align="left" rowspan="2" colspan="1">0</td><td char="." align="char" rowspan="2" colspan="1">0.995</td></tr><tr><td align="left" colspan="1" rowspan="1">IVW</td><td char="." align="char" colspan="1" rowspan="1">5.307</td><td char="." align="char" colspan="1" rowspan="1">0.989</td></tr></tbody></table><table-wrap-foot><p>MR, Mendelian randomization; MRE, MR egger; IVW, Inverse variance weighted; Q, Cochran&#8217;s Q test</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par20">To our knowledge, this is the first large-scale MR investigation to uncover and establish bidirectional causal relationships between EAA and AD. Our findings revealed that an increased genetically predicted GrimAge is associated with a higher risk of AD. Conversely, our results do not support a causal relationship between AD and other epigenetic aging-related traits. These outcomes suggest that the EAA of GrimAge may serve as a significant risk factor for AD.</p><p id="Par21">Etiologically, AD manifests as an aging-related neurodegenerative condition, stemming from genetic diversity intertwined with a myriad of life experiences. Pathologically, it is distinguished by the accumulation of cellular and molecular irregularities alongside impairment in neural network functionality. Moreover, AD brains exhibit a decline in normal physiological functions [<xref ref-type="bibr" rid="CR48">48</xref>]. Although the hypothesis that the pathophysiology of aging, as well as aging-related diseases, is related to cellular senescence has been long-standing, direct evidence establishing a causal relationship between senescence and the organ function decline or the aging-associated disease onset in vivo remains elusive.. Recent advancements have only begun to provide evidence for the causal links when investigating the p16-deficient mice model and the use of senolytic drugs [<xref ref-type="bibr" rid="CR49">49</xref>]. Studies have demonstrated an increased p16 expression with age in brain progenitor cells [<xref ref-type="bibr" rid="CR50">50</xref>], a change correlated with a reduced proliferation rate in various mouse brain-derived progenitor cells. Conversely, the absence of the p16INK4a gene, in p16INK4a-deficient mice has been shown to alleviate the age-related decline in the self-renewal capacity of multipotent brain progenitors [<xref ref-type="bibr" rid="CR50">50</xref>]. Together, these results revealed that the age-related rise in p16-positive (senescent) progenitor cells likely contributes to the brain functions decline associated with aging.</p><p id="Par22">In addition to genetic methodologies, pharmacological interventions have been critical in elucidating the contribution of cellular senescence in aging processes. Studies have demonstrated the efficacy of senolytic drugs, such as dasatinib and quercetin, in naturally aged mice and young mice with senescent cell transplantation. The drugs effectively eliminated senescent cells through apoptosis induction. This treatment not only ameliorated physical impairments but also extended post-treatment survival. [<xref ref-type="bibr" rid="CR51">51</xref>] Furthermore, Ogrodnik et al. also revealed that the cognitive function in aged mice was improved following the removal of senescent cells [<xref ref-type="bibr" rid="CR52">52</xref>]. Regarding genetic factors, telomere shortening, which triggers replicative senescence by causing an irreversible halt in the cell cycle, has been heavily linked to the aging process and age-related disorders, particularly AD [<xref ref-type="bibr" rid="CR53">53</xref>&#8211;<xref ref-type="bibr" rid="CR58">58</xref>]. Liu et al. found that in AD patients, particularly in females, the negative correlation between telomere length and age is significantly more pronounced compared to controls [<xref ref-type="bibr" rid="CR58">58</xref>]. Additionally, AD patients who are homozygous for the ApoE&#949;4 allele exhibit notably shorter telomeres than those with heterozygous ApoE&#949;4 alleles, highlighting a genetic influence on aging-related cellular changes. However, overall comparisons show no significant differences in telomere lengths between AD patients and non-dementia elderly controls [<xref ref-type="bibr" rid="CR59">59</xref>]. Inhibiting the initial proliferation of microglia in APP/PS1 mice models impeded the progression of A&#946; accumulation, microglial senescence, and subsequent neuritic and synaptic impairments [<xref ref-type="bibr" rid="CR60">60</xref>]. This suggests that in the AD brain, replicative senescence might be triggered by continual proliferation among microglia. Moreover, hyperphosphorylation of Tau proteins, resulting in neurofibrillary tangles (NFTs), is a pathological hallmark of the AD brain. Employing laser capture microdissection techniques, Musi et al. demonstrated that neurons harboring NFTs, rather than neurons surrounding A<italic toggle="yes">&#946;</italic> plaques, exhibited a phenotype similar to senescence in both AD brain specimens and tau transgenic mice [<xref ref-type="bibr" rid="CR61">61</xref>]. Gaikwad et al. have recently revealed that astrocytes in proximity to pathological tau oligomers exhibit a senescent phenotype within the AD brain [<xref ref-type="bibr" rid="CR62">62</xref>]. Administration of galantamine mitigated the reactive oxygen species (ROS) production, p53 expression, and senescence of U87 cells induced by A&#946;1-40, indicating that ROS serves as a mediator in A&#946;-induced senescence of U87 cells [<xref ref-type="bibr" rid="CR63">63</xref>]. Studies from other groups have shown that A&#946; oligomers can also induce neuron senescence due to ROS production increasing [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. Therefore, these findings derived from animal models and human samples underscore that cellular senescence significantly contributes to aging and aging-related diseases, including AD.</p><p id="Par23">Recent studies have uncovered a significant correlation between DNA methylation and AD. In a research conducted by Breen et al., whole-genome sequencing was performed in 281 blood samples to assess DNA methylation levels across 25,409,826 CpG loci. These samples included 108 individuals diagnosed with AD and 173 individuals whose cognition was not impaired. The study identified 28,038 differentially methylated positions (DMPs) involving 2,707 genes. Notably, 48 out of 75 independent genetic risk loci associated with AD exhibited these DMPs. Furthermore, the researchers observed 1,568 blood-specific enhancers among the DMPs. Importantly, 173 of these enhancers interacted with the promoters of 95 genes that displayed differential expression in blood samples from individuals with and without AD [<xref ref-type="bibr" rid="CR65">65</xref>]. Research indicates that a reduced APOE methylation subsequent to brain death in individuals with AD may imply a link between aberrant epigenetic alterations in APOE and the susceptibility to AD [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. APP plays a role in transcriptional regulation and cell motility in a protein&#8211;protein interaction manner. This activity triggers the activation of protein kinase that is activated by the p38 mitogen, which in turn promotes the internalization of the A&#946; peptide, leading to dysfunction of mitochondria in cultured cortical neurons [<xref ref-type="bibr" rid="CR68">68</xref>]. Existing research underscores the critical role of inflammatory processes in the progression of AD and biological aging, with tumor necrosis factor-alpha (TNF-&#945;) and interleukin-6 (IL-6) emerging as pivotal mechanistic links between EAA and AD. Elevated levels of TNF-&#945; are known to drive chronic inflammation, a hallmark of aging often termed &#8220;inflammaging&#8221;, which exacerbates cellular senescence and accelerates biological aging, leading to neural deterioration and cognitive decline [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. Notably, studies have demonstrated that inflammation is modulated by methylation patterns at specific gene loci, indicating that DNA methylation modifications may regulate the expression of TNF-&#945; and, consequently, influence the inflammatory state of the brain. This epigenetic regulation highlights a potential mechanism by which chronic inflammation contributes to neurodegeneration and cognitive decline, offering insights into the interplay between epigenetic processes and Alzheimer&#8217;s disease pathology [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. In addition, IL-6 plays a dual role as both a pro-inflammatory cytokine and a regulator of epigenetic processes. Research indicates that aberrant methylation at the IL-6 promoter can enhance IL-6 expression, fueling inflammation that further promotes amyloid-beta accumulation and tau hyperphosphorylation, two hallmark AD pathologies [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. This methylation-regulated inflammation suggests a feedback loop where inflammation-induced epigenetic changes contribute to an accelerated epigenetic aging profile. Such findings support the hypothesis that specific methylation signatures associated with TNF-&#945; and IL-6 pathways may serve as biomarkers for EAA and its association with AD risk [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. These findings collectively highlight the dual role of inflammation as both a marker of accelerated biological aging and a driver of AD progression, facilitated through pro-inflammatory methylation patterns. This mechanistic understanding reinforces the potential for therapeutic strategies targeting epigenetic regulators of inflammation to decelerate EAA and mitigate AD risk. Further emphasizing the interplay between epigenetics and AD, studies have demonstrated that methylation at the estrogen receptor-&#945; (ER&#945;) promoter suppresses ER&#945; mRNA expression and transcription. This epigenetic alteration has been associated with impaired cognitive function and diminished quality of life in AD patients, underscoring the pivotal role of hormonal regulation in AD pathophysiology [<xref ref-type="bibr" rid="CR75">75</xref>]. Estrogen signaling, particularly through ER&#945;, is known to modulate cognitive processes such as memory and learning, which are profoundly affected in AD. This link between methylation changes and AD-related cognitive decline underscores the broader impact of epigenetic mechanisms in shaping neurodegenerative processes and highlights the importance of further investigating these pathways for therapeutic opportunities. Supportive studies have shown that over 95% of age-related DNA methylation alterations in the hippocampus are gender-specific. This observation suggests that methylation patterns might have a more pronounced age-related predisposition in women, which correlates with a higher susceptibility to AD. These findings underline the potential role of gender-specific epigenetic mechanisms in the progression and risk factors associated with AD [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. Extensive research has confirmed that DNA methylation is involved in AD progression.</p><p id="Par24">Biological aging encompasses alterations in the fundamental aging hallmarks like epigenetic modifications that are intimately connected with health trajectories and the risk of morbidity and mortality [<xref ref-type="bibr" rid="CR78">78</xref>]. Furthermore, within individuals of identical chronological age, there is significant heterogeneity in physiological functions and the pace of biological aging. [<xref ref-type="bibr" rid="CR79">79</xref>] Epigenetic age, a measurement based on the DNA methylation levels at certain CpG (cytosine-guanine dinucleotide) sites, serves as a unified metric associated with either chronological or phenotypic age. EAA, which represents the residual variance in epigenetic age not explained by chronological age, provides insights into whether individuals are aging faster or slower than their chronological age. An elevated EAA suggests that an individual is aging biologically faster than their chronological age due to a combination of intrinsic and extrinsic factors, while a decreased EAA suggests slower biological aging. Jain P. has unveiled that EAA could serve as a valid biomarker linked with healthy longevity among older women and might be useful for risk stratification and predicting future functional and cognitive aging [<xref ref-type="bibr" rid="CR80">80</xref>]. Polygenic risk score analysis has identified several genetic variants with pleiotropic effects influencing both EAA and AD, suggesting a shared genetic architecture between them. This analysis utilized data from Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) study and mild cognitive impairment (MCI) patients from the National Alzheimer&#8217;s Coordinating Center (NACC) study [<xref ref-type="bibr" rid="CR81">81</xref>]. In the ADNI cohort, none of the variables, including cognitive impairment diagnosis, sex, or the burden of APOE&#949;4 alleles (the most potent genetic risk factor for AD), were found to be associated with EAA, regardless of the specific measures used (such as GrimAge, PhenoAge, intrinsic epigenetic age acceleration-HorvathAge, or HannumAge). However, females exhibited a more pronounced acceleration in epigenetic aging, as indicated by the Skin &amp; Blood clock, during the progression from normal cognitive function to cognitive impairment compared to males. [<xref ref-type="bibr" rid="CR82">82</xref>] Furthermore, HorvathAge was not significantly associated with MCI or AD. These contradictory results may stem from the limited number of cases and the short duration of follow-up. In the present research, we explored the causal association between EAA and AD using MR analysis.</p><p id="Par25">This study makes a meaningful contribution to AD research by highlighting a significant association between EAA, as measured by the GrimAge clock, and an increased likelihood of developing AD. The GrimAge clock, which integrates key markers of aging and health risk, including cumulative smoking exposure and protein biomarkers linked to mortality, emerges as a promising tool in preventive medicine that could enhance clinicians&#8217; ability to assess AD risk. Notably, this investigation stands out for its specific focus on EAA in AD through the lens of GrimAge, thereby addressing a substantial gap in the current literature. However, the observed effect size (OR&#8201;=&#8201;1.025) is modest, warranting cautious interpretation of this association. While statistically significant, this effect size suggests only a slight increase in AD risk with each incremental rise in GrimAge. This nuanced increase may reflect the cumulative, long-term influence of aging processes on AD susceptibility. In the context of complex diseases like AD, modest effect sizes are anticipated, as they often capture the combined influence of multiple, smaller contributing factors. From a clinical perspective, even minor associations can be meaningful over extended timeframes, especially when considering preventive measures or lifestyle interventions to mitigate aging-related risks. Nonetheless, it is important to acknowledge that while MR analysis helps reduce confounding bias, it cannot entirely eliminate it; thus, residual confounding may still partially contribute to this modest effect size. Furthermore, while the power calculation yielded a value (15.9%) below the conventional threshold of 80%, this should not be interpreted as a reflection of the unreliability of our study&#8217;s findings. Multiple factors underpin the robustness of our results, reinforcing the credibility of the observed associations despite the lower statistical power.</p><p id="Par26">Our MR approach aimed to address the inherent biases common in observational studies, particularly confounding and reverse causality. To enhance the reliability of our findings, we exclusively used data from individuals of European descent, ensuring carefully sourced datasets from Edinburgh DataShare and the Alzheimer&#8217;s disease Genetics Consortium to minimize the risk of sample overlap. Additionally, rigorous quality control protocols were applied to strengthen the robustness of our analyses. Nonetheless, despite incorporating sensitivity analyses, including MRMRE, leave-one-out analysis, and MR-PRESSO, certain limitations remain. Further, our reliance on available GWAS data introduced specific constraints. The limited availability of suitable IVs restricted the breadth of exposure assessments, and sample size limitations may have influenced our ability to detect associations accurately. Moreover, as the GWAS summary data were primarily derived from European populations, the generalizability of our findings to populations with different genetic backgrounds is constrained.</p><p id="Par27">Despite these limitations, our study makes valuable contributions as a hypothesis-generating analysis, laying the groundwork for future investigations. The modest associations observed provide preliminary evidence for a potential causal pathway between EAA and AD, warranting further exploration in larger and more diverse cohorts. This foundation allows future research to expand upon these findings, potentially leading to a more comprehensive understanding of EAA&#8217;s role in AD risk across various populations and with additional epigenetic clocks.</p></sec><sec id="Sec13"><title>Conclusion</title><p id="Par28">Our findings provide a foundational platform for researchers to further investigate the potential causal relationship between epigenetic age acceleration, particularly GrimAge, and the risk of AD. Our findings highlight the necessity for further research to validate these associations in diverse populations and using a broader range of epigenetic clocks. Such efforts could contribute to a more thorough understanding of epigenetic age acceleration EAA and its potential role in Alzheimer&#8217;s disease AD risk. Future studies with expanded sample sizes and greater population diversity are likely to clarify the clinical relevance of GrimAge, supporting its integration into a multifaceted approach for AD risk assessment and prevention strategies.</p></sec><sec id="Sec14" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13148_2025_1976_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Additional file 1.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13148_2025_1976_MOESM2_ESM.pdf" position="float" orientation="portrait"><caption><p>Additional file 2.</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Hongwei Liu and Zhaoxu Yin contributed equally to this work and should be considered as co-first authors.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We extend our gratitude to the participants and investigators of the Edinburgh DataShare and the Alzheimer Disease Genetics Consortium study.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors contributed to the conception and design of the study. L.H. and W.Z. conducted material preparation, data collection, and analysis. Y.Z. and W.Z. written the initial draft of the manuscript with all authors providing feedback on earlier versions. L.H. C.X. and W.Z. contributed to the methodology, reviewed manuscript drafts, and approved the final version. All authors have read and endorsed the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The authors acknowledge that no financial support.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par29">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></name><name name-style="western"><surname>De Strooper</surname><given-names>B</given-names></name><name name-style="western"><surname>Kivipelto</surname><given-names>M</given-names></name><etal/></person-group><article-title>Alzheimer&#8217;s disease</article-title><source>Lancet</source><year>2021</year><volume>397</volume><issue>10284</issue><fpage>1577</fpage><lpage>1590</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(20)32205-4</pub-id><pub-id pub-id-type="pmid">33667416</pub-id><pub-id pub-id-type="pmcid">PMC8354300</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer&#8217;s disease. Lancet. 2021;397(10284):1577&#8211;90. 10.1016/s0140-6736(20)32205-4.<pub-id pub-id-type="pmid">33667416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32205-4</pub-id><pub-id pub-id-type="pmcid">PMC8354300</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>S</given-names></name><name name-style="western"><surname>Barve</surname><given-names>KH</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>MS</given-names></name></person-group><article-title>Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer&#8217;s disease</article-title><source>Curr Neuropharmacol</source><year>2020</year><volume>18</volume><issue>11</issue><fpage>1106</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.2174/1570159x18666200528142429</pub-id><pub-id pub-id-type="pmid">32484110</pub-id><pub-id pub-id-type="pmcid">PMC7709159</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Khan S, Barve KH, Kumar MS. Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer&#8217;s disease. Curr Neuropharmacol. 2020;18(11):1106&#8211;25. 10.2174/1570159x18666200528142429.<pub-id pub-id-type="pmid">32484110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1570159X18666200528142429</pub-id><pub-id pub-id-type="pmcid">PMC7709159</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breijyeh</surname><given-names>Z</given-names></name><name name-style="western"><surname>Karaman</surname><given-names>R</given-names></name></person-group><article-title>Comprehensive review on Alzheimer&#8217;s disease: causes and treatment</article-title><source>Molecules</source><year>2020</year><pub-id pub-id-type="doi">10.3390/molecules25245789</pub-id><pub-id pub-id-type="pmid">33302541</pub-id><pub-id pub-id-type="pmcid">PMC7764106</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Breijyeh Z, Karaman R. Comprehensive review on Alzheimer&#8217;s disease: causes and treatment. Molecules. 2020. 10.3390/molecules25245789.<pub-id pub-id-type="pmid">33302541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules25245789</pub-id><pub-id pub-id-type="pmcid">PMC7764106</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>PD</given-names></name><name name-style="western"><surname>Flood</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer&#8217;s disease</article-title><source>Lancet</source><year>1994</year><volume>344</volume><issue>8925</issue><fpage>769</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(94)92338-8</pub-id><pub-id pub-id-type="pmid">7916070</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">West MJ, Coleman PD, Flood DG, et al. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer&#8217;s disease. Lancet. 1994;344(8925):769&#8211;72. 10.1016/s0140-6736(94)92338-8.<pub-id pub-id-type="pmid">7916070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(94)92338-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fjell</surname><given-names>AM</given-names></name><name name-style="western"><surname>McEvoy</surname><given-names>L</given-names></name><name name-style="western"><surname>Holland</surname><given-names>D</given-names></name><etal/></person-group><article-title>What is normal in normal aging? Effects of aging, amyloid and Alzheimer&#8217;s disease on the cerebral cortex and the hippocampus</article-title><source>Prog Neurobiol</source><year>2014</year><volume>117</volume><fpage>20</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2014.02.004</pub-id><pub-id pub-id-type="pmid">24548606</pub-id><pub-id pub-id-type="pmcid">PMC4343307</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Fjell AM, McEvoy L, Holland D, et al. What is normal in normal aging? Effects of aging, amyloid and Alzheimer&#8217;s disease on the cerebral cortex and the hippocampus. Prog Neurobiol. 2014;117:20&#8211;40. 10.1016/j.pneurobio.2014.02.004.<pub-id pub-id-type="pmid">24548606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pneurobio.2014.02.004</pub-id><pub-id pub-id-type="pmcid">PMC4343307</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindemer</surname><given-names>ER</given-names></name><name name-style="western"><surname>Greve</surname><given-names>DN</given-names></name><name name-style="western"><surname>Fischl</surname><given-names>BR</given-names></name><etal/></person-group><article-title>Regional staging of white matter signal abnormalities in aging and Alzheimer&#8217;s disease</article-title><source>NeuroImage Clin</source><year>2017</year><volume>14</volume><fpage>156</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.nicl.2017.01.022</pub-id><pub-id pub-id-type="pmid">28180074</pub-id><pub-id pub-id-type="pmcid">PMC5279704</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Lindemer ER, Greve DN, Fischl BR, et al. Regional staging of white matter signal abnormalities in aging and Alzheimer&#8217;s disease. NeuroImage Clin. 2017;14:156&#8211;65. 10.1016/j.nicl.2017.01.022.<pub-id pub-id-type="pmid">28180074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2017.01.022</pub-id><pub-id pub-id-type="pmcid">PMC5279704</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarantini</surname><given-names>S</given-names></name><name name-style="western"><surname>Tran</surname><given-names>CHT</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Impaired neurovascular coupling in aging and Alzheimer&#8217;s disease: contribution of astrocyte dysfunction and endothelial impairment to cognitive decline</article-title><source>Exp Gerontol</source><year>2017</year><volume>94</volume><fpage>52&#8211;58</fpage><pub-id pub-id-type="doi">10.1016/j.exger.2016.11.004</pub-id><pub-id pub-id-type="pmid">27845201</pub-id><pub-id pub-id-type="pmcid">PMC5429210</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Tarantini S, Tran CHT, Gordon GR, et al. Impaired neurovascular coupling in aging and Alzheimer&#8217;s disease: contribution of astrocyte dysfunction and endothelial impairment to cognitive decline. Exp Gerontol. 2017;94:52&#8211;58. 10.1016/j.exger.2016.11.004.<pub-id pub-id-type="pmid">27845201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.exger.2016.11.004</pub-id><pub-id pub-id-type="pmcid">PMC5429210</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herrup</surname><given-names>K</given-names></name></person-group><article-title>The case for rejecting the amyloid cascade hypothesis</article-title><source>Nat Neurosci</source><year>2015</year><volume>18</volume><issue>6</issue><fpage>794</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1038/nn.4017</pub-id><pub-id pub-id-type="pmid">26007212</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci. 2015;18(6):794&#8211;9. 10.1038/nn.4017.<pub-id pub-id-type="pmid">26007212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.4017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trevisan</surname><given-names>K</given-names></name><name name-style="western"><surname>Cristina-Pereira</surname><given-names>R</given-names></name><name name-style="western"><surname>Silva-Amaral</surname><given-names>D</given-names></name><etal/></person-group><article-title>Theories of aging and the prevalence of Alzheimer&#8217;s disease</article-title><source>Biomed Res Int</source><year>2019</year><volume>2019</volume><fpage>9171424</fpage><pub-id pub-id-type="doi">10.1155/2019/9171424</pub-id><pub-id pub-id-type="pmid">31317043</pub-id><pub-id pub-id-type="pmcid">PMC6601487</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Trevisan K, Cristina-Pereira R, Silva-Amaral D, et al. Theories of aging and the prevalence of Alzheimer&#8217;s disease. Biomed Res Int. 2019;2019:9171424. 10.1155/2019/9171424.<pub-id pub-id-type="pmid">31317043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2019/9171424</pub-id><pub-id pub-id-type="pmcid">PMC6601487</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Song</surname><given-names>F</given-names></name></person-group><article-title>Aging-dependent mitophagy dysfunction in Alzheimer&#8217;s disease</article-title><source>Mol Neurobiol</source><year>2021</year><volume>58</volume><issue>5</issue><fpage>2362</fpage><lpage>2378</lpage><pub-id pub-id-type="doi">10.1007/s12035-020-02248-y</pub-id><pub-id pub-id-type="pmid">33417222</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Song M, Zhao X, Song F. Aging-dependent mitophagy dysfunction in Alzheimer&#8217;s disease. Mol Neurobiol. 2021;58(5):2362&#8211;78. 10.1007/s12035-020-02248-y.<pub-id pub-id-type="pmid">33417222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-020-02248-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>X</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>J</given-names></name><etal/></person-group><article-title>Aging and Alzheimer&#8217;s disease: comparison and associations from molecular to system level</article-title><source>Aging Cell</source><year>2018</year><volume>17</volume><issue>5</issue><fpage>e12802</fpage><pub-id pub-id-type="doi">10.1111/acel.12802</pub-id><pub-id pub-id-type="pmid">29963744</pub-id><pub-id pub-id-type="pmcid">PMC6156542</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Xia X, Jiang Q, McDermott J, et al. Aging and Alzheimer&#8217;s disease: comparison and associations from molecular to system level. Aging Cell. 2018;17(5):e12802. 10.1111/acel.12802.<pub-id pub-id-type="pmid">29963744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.12802</pub-id><pub-id pub-id-type="pmcid">PMC6156542</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horvath</surname><given-names>S</given-names></name><name name-style="western"><surname>Raj</surname><given-names>K</given-names></name></person-group><article-title>DNA methylation-based biomarkers and the epigenetic clock theory of ageing</article-title><source>Nat Rev Genet</source><year>2018</year><volume>19</volume><issue>6</issue><fpage>371</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/s41576-018-0004-3</pub-id><pub-id pub-id-type="pmid">29643443</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet. 2018;19(6):371&#8211;84. 10.1038/s41576-018-0004-3.<pub-id pub-id-type="pmid">29643443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41576-018-0004-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jylh&#228;v&#228;</surname><given-names>J</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>NL</given-names></name><name name-style="western"><surname>H&#228;gg</surname><given-names>S</given-names></name></person-group><article-title>Biological age predictors</article-title><source>EBioMedicine</source><year>2017</year><volume>21</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2017.03.046</pub-id><pub-id pub-id-type="pmid">28396265</pub-id><pub-id pub-id-type="pmcid">PMC5514388</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Jylh&#228;v&#228; J, Pedersen NL, H&#228;gg S. Biological age predictors. EBioMedicine. 2017;21:29&#8211;36. 10.1016/j.ebiom.2017.03.046.<pub-id pub-id-type="pmid">28396265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2017.03.046</pub-id><pub-id pub-id-type="pmcid">PMC5514388</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maity</surname><given-names>S</given-names></name><name name-style="western"><surname>Farrell</surname><given-names>K</given-names></name><name name-style="western"><surname>Navabpour</surname><given-names>S</given-names></name><etal/></person-group><article-title>Epigenetic mechanisms in memory and cognitive decline associated with aging and Alzheimer&#8217;s disease</article-title><source>Int J Mol Sci</source><year>2021</year><pub-id pub-id-type="doi">10.3390/ijms222212280</pub-id><pub-id pub-id-type="pmid">34830163</pub-id><pub-id pub-id-type="pmcid">PMC8618067</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Maity S, Farrell K, Navabpour S, et al. Epigenetic mechanisms in memory and cognitive decline associated with aging and Alzheimer&#8217;s disease. Int J Mol Sci. 2021. 10.3390/ijms222212280.<pub-id pub-id-type="pmid">34830163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms222212280</pub-id><pub-id pub-id-type="pmcid">PMC8618067</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Chibnik</surname><given-names>LB</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Methylation profiles in peripheral blood CD4+ lymphocytes versus brain: the relation to Alzheimer&#8217;s disease pathology</article-title><source>Alzheimers Dement</source><year>2016</year><volume>12</volume><issue>9</issue><fpage>942</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2016.02.009</pub-id><pub-id pub-id-type="pmid">27016692</pub-id><pub-id pub-id-type="pmcid">PMC5014706</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Yu L, Chibnik LB, Yang J, et al. Methylation profiles in peripheral blood CD4+ lymphocytes versus brain: the relation to Alzheimer&#8217;s disease pathology. Alzheimers Dement. 2016;12(9):942&#8211;51. 10.1016/j.jalz.2016.02.009.<pub-id pub-id-type="pmid">27016692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2016.02.009</pub-id><pub-id pub-id-type="pmcid">PMC5014706</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lardenoije</surname><given-names>R</given-names></name><name name-style="western"><surname>Roubroeks</surname><given-names>JAY</given-names></name><name name-style="western"><surname>Pishva</surname><given-names>E</given-names></name><etal/></person-group><article-title>Alzheimer&#8217;s disease-associated (hydroxy)methylomic changes in the brain and blood</article-title><source>Clin Epigenetics</source><year>2019</year><volume>11</volume><issue>1</issue><fpage>164</fpage><pub-id pub-id-type="doi">10.1186/s13148-019-0755-5</pub-id><pub-id pub-id-type="pmid">31775875</pub-id><pub-id pub-id-type="pmcid">PMC6880587</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Lardenoije R, Roubroeks JAY, Pishva E, et al. Alzheimer&#8217;s disease-associated (hydroxy)methylomic changes in the brain and blood. Clin Epigenetics. 2019;11(1):164. 10.1186/s13148-019-0755-5.<pub-id pub-id-type="pmid">31775875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13148-019-0755-5</pub-id><pub-id pub-id-type="pmcid">PMC6880587</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Dilliott</surname><given-names>AA</given-names></name><name name-style="western"><surname>Khallaf</surname><given-names>R</given-names></name><etal/></person-group><article-title>Genetic and epigenetic study of an Alzheimer&#8217;s disease family with monozygotic triplets</article-title><source>Brain</source><year>2019</year><volume>142</volume><issue>11</issue><fpage>3375</fpage><lpage>3381</lpage><pub-id pub-id-type="doi">10.1093/brain/awz289</pub-id><pub-id pub-id-type="pmid">31580390</pub-id><pub-id pub-id-type="pmcid">PMC6821163</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Zhang M, Dilliott AA, Khallaf R, et al. Genetic and epigenetic study of an Alzheimer&#8217;s disease family with monozygotic triplets. Brain. 2019;142(11):3375&#8211;81. 10.1093/brain/awz289.<pub-id pub-id-type="pmid">31580390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awz289</pub-id><pub-id pub-id-type="pmcid">PMC6821163</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>AT</given-names></name><name name-style="western"><surname>Quach</surname><given-names>A</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>JG</given-names></name><etal/></person-group><article-title>DNA methylation grimAge strongly predicts lifespan and healthspan</article-title><source>Aging (Albany NY)</source><year>2019</year><volume>11</volume><issue>2</issue><fpage>303</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.18632/aging.101684</pub-id><pub-id pub-id-type="pmid">30669119</pub-id><pub-id pub-id-type="pmcid">PMC6366976</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Lu AT, Quach A, Wilson JG, et al. DNA methylation grimAge strongly predicts lifespan and healthspan. Aging (Albany NY). 2019;11(2):303&#8211;27. 10.18632/aging.101684.<pub-id pub-id-type="pmid">30669119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.101684</pub-id><pub-id pub-id-type="pmcid">PMC6366976</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levine</surname><given-names>ME</given-names></name><name name-style="western"><surname>Lu</surname><given-names>AT</given-names></name><name name-style="western"><surname>Quach</surname><given-names>A</given-names></name><etal/></person-group><article-title>An epigenetic biomarker of aging for lifespan and healthspan</article-title><source>Aging (Albany NY)</source><year>2018</year><volume>10</volume><issue>4</issue><fpage>573</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.18632/aging.101414</pub-id><pub-id pub-id-type="pmid">29676998</pub-id><pub-id pub-id-type="pmcid">PMC5940111</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018;10(4):573&#8211;91. 10.18632/aging.101414.<pub-id pub-id-type="pmid">29676998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.101414</pub-id><pub-id pub-id-type="pmcid">PMC5940111</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCrory</surname><given-names>C</given-names></name><name name-style="western"><surname>Fiorito</surname><given-names>G</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>B</given-names></name><etal/></person-group><article-title>Grimage outperforms other epigenetic clocks in the prediction of age-related clinical phenotypes and all-cause mortality</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2021</year><volume>76</volume><issue>5</issue><fpage>741</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1093/gerona/glaa286</pub-id><pub-id pub-id-type="pmid">33211845</pub-id><pub-id pub-id-type="pmcid">PMC8087266</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">McCrory C, Fiorito G, Hernandez B, et al. Grimage outperforms other epigenetic clocks in the prediction of age-related clinical phenotypes and all-cause mortality. J Gerontol A Biol Sci Med Sci. 2021;76(5):741&#8211;9. 10.1093/gerona/glaa286.<pub-id pub-id-type="pmid">33211845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/glaa286</pub-id><pub-id pub-id-type="pmcid">PMC8087266</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marioni</surname><given-names>RE</given-names></name><name name-style="western"><surname>Shah</surname><given-names>S</given-names></name><name name-style="western"><surname>McRae</surname><given-names>AF</given-names></name><etal/></person-group><article-title>DNA methylation age of blood predicts all-cause mortality in later life</article-title><source>Genome Biol</source><year>2015</year><volume>16</volume><issue>1</issue><fpage>25</fpage><pub-id pub-id-type="doi">10.1186/s13059-015-0584-6</pub-id><pub-id pub-id-type="pmid">25633388</pub-id><pub-id pub-id-type="pmcid">PMC4350614</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Marioni RE, Shah S, McRae AF, et al. DNA methylation age of blood predicts all-cause mortality in later life. Genome Biol. 2015;16(1):25. 10.1186/s13059-015-0584-6.<pub-id pub-id-type="pmid">25633388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13059-015-0584-6</pub-id><pub-id pub-id-type="pmcid">PMC4350614</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horvath</surname><given-names>S</given-names></name></person-group><article-title>DNA methylation age of human tissues and cell types</article-title><source>Genome Biol</source><year>2013</year><volume>14</volume><issue>10</issue><fpage>R115</fpage><pub-id pub-id-type="doi">10.1186/gb-2013-14-10-r115</pub-id><pub-id pub-id-type="pmid">24138928</pub-id><pub-id pub-id-type="pmcid">PMC4015143</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115. 10.1186/gb-2013-14-10-r115.<pub-id pub-id-type="pmid">24138928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/gb-2013-14-10-r115</pub-id><pub-id pub-id-type="pmcid">PMC4015143</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>BH</given-names></name><name name-style="western"><surname>Marioni</surname><given-names>RE</given-names></name><name name-style="western"><surname>Colicino</surname><given-names>E</given-names></name><etal/></person-group><article-title>DNA methylation-based measures of biological age: meta-analysis predicting time to death</article-title><source>Aging (Albany NY)</source><year>2016</year><volume>8</volume><issue>9</issue><fpage>1844</fpage><lpage>1865</lpage><pub-id pub-id-type="doi">10.18632/aging.101020</pub-id><pub-id pub-id-type="pmid">27690265</pub-id><pub-id pub-id-type="pmcid">PMC5076441</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Chen BH, Marioni RE, Colicino E, et al. DNA methylation-based measures of biological age: meta-analysis predicting time to death. Aging (Albany NY). 2016;8(9):1844&#8211;65. 10.18632/aging.101020.<pub-id pub-id-type="pmid">27690265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.101020</pub-id><pub-id pub-id-type="pmcid">PMC5076441</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Jia</surname><given-names>C</given-names></name><etal/></person-group><article-title>Epigenetic modifications of inflammation in intervertebral disc degeneration</article-title><source>Ageing Res Rev</source><year>2023</year><volume>87</volume><fpage>101902</fpage><pub-id pub-id-type="doi">10.1016/j.arr.2023.101902</pub-id><pub-id pub-id-type="pmid">36871778</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Kang L, Zhang H, Jia C, et al. Epigenetic modifications of inflammation in intervertebral disc degeneration. Ageing Res Rev. 2023;87:101902. 10.1016/j.arr.2023.101902.<pub-id pub-id-type="pmid">36871778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2023.101902</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hannum</surname><given-names>G</given-names></name><name name-style="western"><surname>Guinney</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><etal/></person-group><article-title>Genome-wide methylation profiles reveal quantitative views of human aging rates</article-title><source>Mol Cell</source><year>2013</year><volume>49</volume><issue>2</issue><fpage>359</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2012.10.016</pub-id><pub-id pub-id-type="pmid">23177740</pub-id><pub-id pub-id-type="pmcid">PMC3780611</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Hannum G, Guinney J, Zhao L, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell. 2013;49(2):359&#8211;67. 10.1016/j.molcel.2012.10.016.<pub-id pub-id-type="pmid">23177740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molcel.2012.10.016</pub-id><pub-id pub-id-type="pmcid">PMC3780611</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>NM</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>MV</given-names></name><name name-style="western"><surname>Davey</surname><given-names>SG</given-names></name></person-group><article-title>Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians</article-title><source>BMJ</source><year>2018</year><volume>362</volume><fpage>k601</fpage><pub-id pub-id-type="doi">10.1136/bmj.k601</pub-id><pub-id pub-id-type="pmid">30002074</pub-id><pub-id pub-id-type="pmcid">PMC6041728</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Davies NM, Holmes MV, Davey SG. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601. 10.1136/bmj.k601.<pub-id pub-id-type="pmid">30002074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.k601</pub-id><pub-id pub-id-type="pmcid">PMC6041728</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawlor</surname><given-names>DA</given-names></name><name name-style="western"><surname>Harbord</surname><given-names>RM</given-names></name><name name-style="western"><surname>Sterne</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Mendelian randomization: using genes as instruments for making causal inferences in epidemiology</article-title><source>Stat Med</source><year>2008</year><volume>27</volume><issue>8</issue><fpage>1133</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1002/sim.3034</pub-id><pub-id pub-id-type="pmid">17886233</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Lawlor DA, Harbord RM, Sterne JA, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27(8):1133&#8211;63. 10.1002/sim.3034.<pub-id pub-id-type="pmid">17886233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.3034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowden</surname><given-names>J</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>MV</given-names></name></person-group><article-title>Meta-analysis and Mendelian randomization: a review</article-title><source>Res Synth Methods</source><year>2019</year><volume>10</volume><issue>4</issue><fpage>486</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1002/jrsm.1346</pub-id><pub-id pub-id-type="pmid">30861319</pub-id><pub-id pub-id-type="pmcid">PMC6973275</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: a review. Res Synth Methods. 2019;10(4):486&#8211;96. 10.1002/jrsm.1346.<pub-id pub-id-type="pmid">30861319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jrsm.1346</pub-id><pub-id pub-id-type="pmcid">PMC6973275</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>GD</given-names></name><name name-style="western"><surname>Ebrahim</surname><given-names>S</given-names></name></person-group><article-title>Mendelian randomization: prospects, potentials, and limitations</article-title><source>Int J Epidemiol</source><year>2004</year><volume>33</volume><issue>1</issue><fpage>30</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1093/ije/dyh132</pub-id><pub-id pub-id-type="pmid">15075143</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol. 2004;33(1):30&#8211;42. 10.1093/ije/dyh132.<pub-id pub-id-type="pmid">15075143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyh132</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haycock</surname><given-names>PC</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>S</given-names></name><name name-style="western"><surname>Wade</surname><given-names>KH</given-names></name><etal/></person-group><article-title>Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies</article-title><source>Am J Clin Nutr</source><year>2016</year><volume>103</volume><issue>4</issue><fpage>965</fpage><lpage>978</lpage><pub-id pub-id-type="doi">10.3945/ajcn.115.118216</pub-id><pub-id pub-id-type="pmid">26961927</pub-id><pub-id pub-id-type="pmcid">PMC4807699</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Haycock PC, Burgess S, Wade KH, et al. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. Am J Clin Nutr. 2016;103(4):965&#8211;78. 10.3945/ajcn.115.118216.<pub-id pub-id-type="pmid">26961927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3945/ajcn.115.118216</pub-id><pub-id pub-id-type="pmcid">PMC4807699</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hemani</surname><given-names>G</given-names></name><name name-style="western"><surname>Tilling</surname><given-names>K</given-names></name><name name-style="western"><surname>Davey</surname><given-names>SG</given-names></name></person-group><article-title>Orienting the causal relationship between imprecisely measured traits using GWAS summary data</article-title><source>PLoS Genet</source><year>2017</year><volume>13</volume><issue>11</issue><fpage>e1007081</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1007081</pub-id><pub-id pub-id-type="pmid">29149188</pub-id><pub-id pub-id-type="pmcid">PMC5711033</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Hemani G, Tilling K, Davey SG. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 2017;13(11):e1007081. 10.1371/journal.pgen.1007081.<pub-id pub-id-type="pmid">29149188</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1007081</pub-id><pub-id pub-id-type="pmcid">PMC5711033</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skrivankova</surname><given-names>VW</given-names></name><name name-style="western"><surname>Richmond</surname><given-names>RC</given-names></name><name name-style="western"><surname>Woolf</surname><given-names>BAR</given-names></name><etal/></person-group><article-title>Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR statement</article-title><source>JAMA</source><year>2021</year><volume>326</volume><issue>16</issue><fpage>1614</fpage><lpage>1621</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.18236</pub-id><pub-id pub-id-type="pmid">34698778</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR statement. JAMA. 2021;326(16):1614&#8211;21. 10.1001/jama.2021.18236.<pub-id pub-id-type="pmid">34698778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2021.18236</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunkle</surname><given-names>BW</given-names></name><name name-style="western"><surname>Grenier-Boley</surname><given-names>B</given-names></name><name name-style="western"><surname>Sims</surname><given-names>R</given-names></name><etal/></person-group><article-title>Author correction: genetic meta-analysis of diagnosed Alzheimer&#8217;s disease identifies new risk loci and implicates A&#946;, tau, immunity and lipid processing</article-title><source>Nat Genet</source><year>2019</year><volume>51</volume><issue>9</issue><fpage>1423</fpage><lpage>1424</lpage><pub-id pub-id-type="doi">10.1038/s41588-019-0495-7</pub-id><pub-id pub-id-type="pmid">31417202</pub-id><pub-id pub-id-type="pmcid">PMC7265117</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Kunkle BW, Grenier-Boley B, Sims R, et al. Author correction: genetic meta-analysis of diagnosed Alzheimer&#8217;s disease identifies new risk loci and implicates A&#946;, tau, immunity and lipid processing. Nat Genet. 2019;51(9):1423&#8211;4. 10.1038/s41588-019-0495-7.<pub-id pub-id-type="pmid">31417202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-019-0495-7</pub-id><pub-id pub-id-type="pmcid">PMC7265117</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effects of iron homeostasis on epigenetic age acceleration: a two-sample Mendelian randomization study</article-title><source>Clin Epigenetics</source><year>2023</year><volume>15</volume><issue>1</issue><fpage>159</fpage><pub-id pub-id-type="doi">10.1186/s13148-023-01575-w</pub-id><pub-id pub-id-type="pmid">37805541</pub-id><pub-id pub-id-type="pmcid">PMC10559596</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Wang Z, Liu Y, Zhang S, et al. Effects of iron homeostasis on epigenetic age acceleration: a two-sample Mendelian randomization study. Clin Epigenetics. 2023;15(1):159. 10.1186/s13148-023-01575-w.<pub-id pub-id-type="pmid">37805541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13148-023-01575-w</pub-id><pub-id pub-id-type="pmcid">PMC10559596</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Kong</surname><given-names>J</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J</given-names></name><etal/></person-group><article-title>Kidney damage causally affects the brain cortical structure: a Mendelian randomization study</article-title><source>EBioMedicine</source><year>2021</year><volume>72</volume><fpage>103592</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103592</pub-id><pub-id pub-id-type="pmid">34619639</pub-id><pub-id pub-id-type="pmcid">PMC8498227</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Chen X, Kong J, Pan J, et al. Kidney damage causally affects the brain cortical structure: a Mendelian randomization study. EBioMedicine. 2021;72:103592. 10.1016/j.ebiom.2021.103592.<pub-id pub-id-type="pmid">34619639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2021.103592</pub-id><pub-id pub-id-type="pmcid">PMC8498227</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burgess</surname><given-names>S</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>SG</given-names></name></person-group><article-title>Avoiding bias from weak instruments in Mendelian randomization studies</article-title><source>Int J Epidemiol</source><year>2011</year><volume>40</volume><issue>3</issue><fpage>755</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1093/ije/dyr036</pub-id><pub-id pub-id-type="pmid">21414999</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40(3):755&#8211;64. 10.1093/ije/dyr036.<pub-id pub-id-type="pmid">21414999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyr036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Du</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Causal relationship between multiple sclerosis and cortical structure: a Mendelian randomization study</article-title><source>J Transl Med</source><year>2024</year><volume>22</volume><issue>1</issue><fpage>83</fpage><pub-id pub-id-type="doi">10.1186/s12967-024-04892-7</pub-id><pub-id pub-id-type="pmid">38245759</pub-id><pub-id pub-id-type="pmcid">PMC10800041</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Sun D, Wang R, Du Q, et al. Causal relationship between multiple sclerosis and cortical structure: a Mendelian randomization study. J Transl Med. 2024;22(1):83. 10.1186/s12967-024-04892-7.<pub-id pub-id-type="pmid">38245759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-024-04892-7</pub-id><pub-id pub-id-type="pmcid">PMC10800041</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pierce</surname><given-names>BL</given-names></name><name name-style="western"><surname>Ahsan</surname><given-names>H</given-names></name><name name-style="western"><surname>Vanderweele</surname><given-names>TJ</given-names></name></person-group><article-title>Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants</article-title><source>Int J Epidemiol</source><year>2011</year><volume>40</volume><issue>3</issue><fpage>740</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1093/ije/dyq151</pub-id><pub-id pub-id-type="pmid">20813862</pub-id><pub-id pub-id-type="pmcid">PMC3147064</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol. 2011;40(3):740&#8211;52. 10.1093/ije/dyq151.<pub-id pub-id-type="pmid">20813862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyq151</pub-id><pub-id pub-id-type="pmcid">PMC3147064</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Mendelian randomization with refined instrumental variables from genetic score improves accuracy and reduces bias</article-title><source>Front Genet</source><year>2021</year><volume>12</volume><fpage>618829</fpage><pub-id pub-id-type="doi">10.3389/fgene.2021.618829</pub-id><pub-id pub-id-type="pmid">33868364</pub-id><pub-id pub-id-type="pmcid">PMC8044958</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Lin L, Zhang R, Huang H, et al. Mendelian randomization with refined instrumental variables from genetic score improves accuracy and reduces bias. Front Genet. 2021;12:618829. 10.3389/fgene.2021.618829.<pub-id pub-id-type="pmid">33868364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2021.618829</pub-id><pub-id pub-id-type="pmcid">PMC8044958</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pan</surname><given-names>W</given-names></name></person-group><article-title>Combining the strengths of inverse-variance weighting and Egger regression in Mendelian randomization using a mixture of regressions model</article-title><source>PLoS Genet</source><year>2021</year><volume>17</volume><issue>11</issue><fpage>e1009922</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1009922</pub-id><pub-id pub-id-type="pmid">34793444</pub-id><pub-id pub-id-type="pmcid">PMC8639093</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Lin Z, Deng Y, Pan W. Combining the strengths of inverse-variance weighting and Egger regression in Mendelian randomization using a mixture of regressions model. PLoS Genet. 2021;17(11):e1009922. 10.1371/journal.pgen.1009922.<pub-id pub-id-type="pmid">34793444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1009922</pub-id><pub-id pub-id-type="pmcid">PMC8639093</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verbanck</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CY</given-names></name><name name-style="western"><surname>Neale</surname><given-names>B</given-names></name><etal/></person-group><article-title>Publisher correction: detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases</article-title><source>Nat Genet</source><year>2018</year><volume>50</volume><issue>8</issue><fpage>1196</fpage><pub-id pub-id-type="doi">10.1038/s41588-018-0164-2</pub-id><pub-id pub-id-type="pmid">29967445</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Verbanck M, Chen CY, Neale B, et al. Publisher correction: detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(8):1196. 10.1038/s41588-018-0164-2.<pub-id pub-id-type="pmid">29967445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-018-0164-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burgess</surname><given-names>S</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>SG</given-names></name></person-group><article-title>Interpreting findings from Mendelian randomization using the MR-Egger method</article-title><source>Eur J Epidemiol</source><year>2017</year><volume>32</volume><issue>5</issue><fpage>377</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1007/s10654-017-0255-x</pub-id><pub-id pub-id-type="pmid">28527048</pub-id><pub-id pub-id-type="pmcid">PMC5506233</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32(5):377&#8211;89. 10.1007/s10654-017-0255-x.<pub-id pub-id-type="pmid">28527048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10654-017-0255-x</pub-id><pub-id pub-id-type="pmcid">PMC5506233</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broadbent</surname><given-names>JR</given-names></name><name name-style="western"><surname>Foley</surname><given-names>CN</given-names></name><name name-style="western"><surname>Grant</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Mendelian Randomization v0.5.0: updates to an R package for performing Mendelian randomization analyses using summarized data</article-title><source>Wellcome Open Res</source><year>2020</year><volume>5</volume><fpage>252</fpage><pub-id pub-id-type="doi">10.12688/wellcomeopenres.16374.2</pub-id><pub-id pub-id-type="pmid">33381656</pub-id><pub-id pub-id-type="pmcid">PMC7745186</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Broadbent JR, Foley CN, Grant AJ, et al. Mendelian Randomization v0.5.0: updates to an R package for performing Mendelian randomization analyses using summarized data. Wellcome Open Res. 2020;5:252. 10.12688/wellcomeopenres.16374.2.<pub-id pub-id-type="pmid">33381656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12688/wellcomeopenres.16374.1</pub-id><pub-id pub-id-type="pmcid">PMC7745186</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Kippersluis</surname><given-names>H</given-names></name><name name-style="western"><surname>Rietveld</surname><given-names>CA</given-names></name></person-group><article-title>Pleiotropy-robust Mendelian randomization</article-title><source>Int J Epidemiol</source><year>2018</year><volume>47</volume><issue>4</issue><fpage>1279</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.1093/ije/dyx002</pub-id><pub-id pub-id-type="pmid">28338774</pub-id><pub-id pub-id-type="pmcid">PMC6124631</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">van Kippersluis H, Rietveld CA. Pleiotropy-robust Mendelian randomization. Int J Epidemiol. 2018;47(4):1279&#8211;88. 10.1093/ije/dyx002.<pub-id pub-id-type="pmid">28338774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyx002</pub-id><pub-id pub-id-type="pmcid">PMC6124631</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowden</surname><given-names>J</given-names></name><name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>S</given-names></name></person-group><article-title>Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression</article-title><source>Int J Epidemiol</source><year>2015</year><volume>44</volume><issue>2</issue><fpage>512</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1093/ije/dyv080</pub-id><pub-id pub-id-type="pmid">26050253</pub-id><pub-id pub-id-type="pmcid">PMC4469799</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512&#8211;25. 10.1093/ije/dyv080.<pub-id pub-id-type="pmid">26050253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyv080</pub-id><pub-id pub-id-type="pmcid">PMC4469799</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verbanck</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CY</given-names></name><name name-style="western"><surname>Neale</surname><given-names>B</given-names></name><etal/></person-group><article-title>Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases</article-title><source>Nat Genet</source><year>2018</year><volume>50</volume><issue>5</issue><fpage>693</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0099-7</pub-id><pub-id pub-id-type="pmid">29686387</pub-id><pub-id pub-id-type="pmcid">PMC6083837</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Verbanck M, Chen CY, Neale B, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693&#8211;8. 10.1038/s41588-018-0099-7.<pub-id pub-id-type="pmid">29686387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-018-0099-7</pub-id><pub-id pub-id-type="pmcid">PMC6083837</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowden</surname><given-names>J</given-names></name><name name-style="western"><surname>Spiller</surname><given-names>W</given-names></name><name name-style="western"><surname>Del Greco</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression</article-title><source>Int J Epidemiol</source><year>2018</year><volume>47</volume><issue>4</issue><fpage>1264</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1093/ije/dyy101</pub-id><pub-id pub-id-type="pmid">29961852</pub-id><pub-id pub-id-type="pmcid">PMC6124632</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Bowden J, Spiller W, Del Greco MF, et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression. Int J Epidemiol. 2018;47(4):1264&#8211;78. 10.1093/ije/dyy101.<pub-id pub-id-type="pmid">29961852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyy101</pub-id><pub-id pub-id-type="pmcid">PMC6124632</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name></person-group><article-title>Etiology of Alzheimer&#8217;s disease</article-title><source>Discov Med</source><year>2023</year><volume>35</volume><issue>178</issue><fpage>757</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.24976/Discov.Med.202335178.71</pub-id><pub-id pub-id-type="pmid">37811614</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Zhang C. Etiology of Alzheimer&#8217;s disease. Discov Med. 2023;35(178):757&#8211;76. 10.24976/Discov.Med.202335178.71.<pub-id pub-id-type="pmid">37811614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.24976/Discov.Med.202335178.71</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Wijshake</surname><given-names>T</given-names></name><name name-style="western"><surname>Tchkonia</surname><given-names>T</given-names></name><etal/></person-group><article-title>Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders</article-title><source>Nature</source><year>2011</year><volume>479</volume><issue>7372</issue><fpage>232</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1038/nature10600</pub-id><pub-id pub-id-type="pmid">22048312</pub-id><pub-id pub-id-type="pmcid">PMC3468323</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011;479(7372):232&#8211;6. 10.1038/nature10600.<pub-id pub-id-type="pmid">22048312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature10600</pub-id><pub-id pub-id-type="pmcid">PMC3468323</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molofsky</surname><given-names>AV</given-names></name><name name-style="western"><surname>Slutsky</surname><given-names>SG</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>NM</given-names></name><etal/></person-group><article-title>Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing</article-title><source>Nature</source><year>2006</year><volume>443</volume><issue>7110</issue><fpage>448</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1038/nature05091</pub-id><pub-id pub-id-type="pmid">16957738</pub-id><pub-id pub-id-type="pmcid">PMC2586960</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Molofsky AV, Slutsky SG, Joseph NM, et al. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature. 2006;443(7110):448&#8211;52. 10.1038/nature05091.<pub-id pub-id-type="pmid">16957738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature05091</pub-id><pub-id pub-id-type="pmcid">PMC2586960</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Pirtskhalava</surname><given-names>T</given-names></name><name name-style="western"><surname>Farr</surname><given-names>JN</given-names></name><etal/></person-group><article-title>Senolytics improve physical function and increase lifespan in old age</article-title><source>Nat Med</source><year>2018</year><volume>24</volume><issue>8</issue><fpage>1246</fpage><lpage>1256</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0092-9</pub-id><pub-id pub-id-type="pmid">29988130</pub-id><pub-id pub-id-type="pmcid">PMC6082705</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246&#8211;56. 10.1038/s41591-018-0092-9.<pub-id pub-id-type="pmid">29988130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-018-0092-9</pub-id><pub-id pub-id-type="pmcid">PMC6082705</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogrodnik</surname><given-names>M</given-names></name><name name-style="western"><surname>Evans</surname><given-names>SA</given-names></name><name name-style="western"><surname>Fielder</surname><given-names>E</given-names></name><etal/></person-group><article-title>Whole-body senescent cell clearance alleviates age-related brain inflammation and cognitive impairment in mice</article-title><source>Aging Cell</source><year>2021</year><volume>20</volume><issue>2</issue><fpage>e13296</fpage><pub-id pub-id-type="doi">10.1111/acel.13296</pub-id><pub-id pub-id-type="pmid">33470505</pub-id><pub-id pub-id-type="pmcid">PMC7884042</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Ogrodnik M, Evans SA, Fielder E, et al. Whole-body senescent cell clearance alleviates age-related brain inflammation and cognitive impairment in mice. Aging Cell. 2021;20(2):e13296. 10.1111/acel.13296.<pub-id pub-id-type="pmid">33470505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.13296</pub-id><pub-id pub-id-type="pmcid">PMC7884042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forero</surname><given-names>DA</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Giraldo</surname><given-names>Y</given-names></name><name name-style="western"><surname>L&#243;pez-Quintero</surname><given-names>C</given-names></name><etal/></person-group><article-title>Meta-analysis of telomere length in Alzheimer&#8217;s disease</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2016</year><volume>71</volume><issue>8</issue><fpage>1069</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1093/gerona/glw053</pub-id><pub-id pub-id-type="pmid">27091133</pub-id><pub-id pub-id-type="pmcid">PMC4945891</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Forero DA, Gonz&#225;lez-Giraldo Y, L&#243;pez-Quintero C, et al. Meta-analysis of telomere length in Alzheimer&#8217;s disease. J Gerontol A Biol Sci Med Sci. 2016;71(8):1069&#8211;73. 10.1093/gerona/glw053.<pub-id pub-id-type="pmid">27091133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/glw053</pub-id><pub-id pub-id-type="pmcid">PMC4945891</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name></person-group><article-title>Leukocyte telomere length shortening and Alzheimer&#8217;s disease etiology</article-title><source>J Alzheimers Dis</source><year>2019</year><volume>69</volume><issue>3</issue><fpage>881</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.3233/jad-190134</pub-id><pub-id pub-id-type="pmid">31156167</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Guo Y, Yu H. Leukocyte telomere length shortening and Alzheimer&#8217;s disease etiology. J Alzheimers Dis. 2019;69(3):881&#8211;5. 10.3233/jad-190134.<pub-id pub-id-type="pmid">31156167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-190134</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>F</given-names></name><name name-style="western"><surname>Lv</surname><given-names>X</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Association of leukocyte telomere length with mild cognitive impairment and Alzheimer&#8217;s disease: role of folate and homocysteine</article-title><source>Dement Geriatr Cogn Disord</source><year>2019</year><volume>48</volume><issue>1&#8211;2</issue><fpage>56</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1159/000501958</pub-id><pub-id pub-id-type="pmid">31437841</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Ma F, Lv X, Du Y, et al. Association of leukocyte telomere length with mild cognitive impairment and Alzheimer&#8217;s disease: role of folate and homocysteine. Dement Geriatr Cogn Disord. 2019;48(1&#8211;2):56&#8211;67. 10.1159/000501958.<pub-id pub-id-type="pmid">31437841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000501958</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheller Madrid</surname><given-names>A</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>KL</given-names></name><name name-style="western"><surname>Rode</surname><given-names>L</given-names></name><etal/></person-group><article-title>Observational and genetic studies of short telomeres and Alzheimer&#8217;s disease in 67,000 and 152,000 individuals: a Mendelian randomization study</article-title><source>Eur J Epidemiol</source><year>2020</year><volume>35</volume><issue>2</issue><fpage>147</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1007/s10654-019-00563-w</pub-id><pub-id pub-id-type="pmid">31564046</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Scheller Madrid A, Rasmussen KL, Rode L, et al. Observational and genetic studies of short telomeres and Alzheimer&#8217;s disease in 67,000 and 152,000 individuals: a Mendelian randomization study. Eur J Epidemiol. 2020;35(2):147&#8211;56. 10.1007/s10654-019-00563-w.<pub-id pub-id-type="pmid">31564046</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10654-019-00563-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>EH</given-names></name><name name-style="western"><surname>Han</surname><given-names>MH</given-names></name><name name-style="western"><surname>Ha</surname><given-names>J</given-names></name><etal/></person-group><article-title>Relationship between telomere shortening and age in Korean individuals with mild cognitive impairment and Alzheimer&#8217;s disease compared to that in healthy controls</article-title><source>Aging (Albany NY)</source><year>2020</year><volume>13</volume><issue>2</issue><fpage>2089</fpage><lpage>2100</lpage><pub-id pub-id-type="doi">10.18632/aging.202206</pub-id><pub-id pub-id-type="pmid">33323554</pub-id><pub-id pub-id-type="pmcid">PMC7880372</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Lee EH, Han MH, Ha J, et al. Relationship between telomere shortening and age in Korean individuals with mild cognitive impairment and Alzheimer&#8217;s disease compared to that in healthy controls. Aging (Albany NY). 2020;13(2):2089&#8211;100. 10.18632/aging.202206.<pub-id pub-id-type="pmid">33323554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.202206</pub-id><pub-id pub-id-type="pmcid">PMC7880372</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koh</surname><given-names>SH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>SH</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Telomere shortening reflecting physical aging is associated with cognitive decline and dementia conversion in mild cognitive impairment due to Alzheimer&#8217;s disease</article-title><source>Aging (Albany NY)</source><year>2020</year><volume>12</volume><issue>5</issue><fpage>4407</fpage><lpage>4423</lpage><pub-id pub-id-type="doi">10.18632/aging.102893</pub-id><pub-id pub-id-type="pmid">32126022</pub-id><pub-id pub-id-type="pmcid">PMC7093181</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Koh SH, Choi SH, Jeong JH, et al. Telomere shortening reflecting physical aging is associated with cognitive decline and dementia conversion in mild cognitive impairment due to Alzheimer&#8217;s disease. Aging (Albany NY). 2020;12(5):4407&#8211;23. 10.18632/aging.102893.<pub-id pub-id-type="pmid">32126022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.102893</pub-id><pub-id pub-id-type="pmcid">PMC7093181</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takata</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kikukawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Hanyu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Association between ApoE phenotypes and telomere erosion in Alzheimer&#8217;s disease</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2012</year><volume>67</volume><issue>4</issue><fpage>330</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1093/gerona/glr185</pub-id><pub-id pub-id-type="pmid">22016362</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Takata Y, Kikukawa M, Hanyu H, et al. Association between ApoE phenotypes and telomere erosion in Alzheimer&#8217;s disease. J Gerontol A Biol Sci Med Sci. 2012;67(4):330&#8211;5. 10.1093/gerona/glr185.<pub-id pub-id-type="pmid">22016362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/glr185</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fryatt</surname><given-names>GL</given-names></name><name name-style="western"><surname>Ghorbani</surname><given-names>M</given-names></name><etal/></person-group><article-title>Replicative senescence dictates the emergence of disease-associated microglia and contributes to A&#946; pathology</article-title><source>Cell Rep</source><year>2021</year><volume>35</volume><issue>10</issue><fpage>109228</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109228</pub-id><pub-id pub-id-type="pmid">34107254</pub-id><pub-id pub-id-type="pmcid">PMC8206957</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Hu Y, Fryatt GL, Ghorbani M, et al. Replicative senescence dictates the emergence of disease-associated microglia and contributes to A&#946; pathology. Cell Rep. 2021;35(10):109228. 10.1016/j.celrep.2021.109228.<pub-id pub-id-type="pmid">34107254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2021.109228</pub-id><pub-id pub-id-type="pmcid">PMC8206957</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musi</surname><given-names>N</given-names></name><name name-style="western"><surname>Valentine</surname><given-names>JM</given-names></name><name name-style="western"><surname>Sickora</surname><given-names>KR</given-names></name><etal/></person-group><article-title>Tau protein aggregation is associated with cellular senescence in the brain</article-title><source>Aging Cell</source><year>2018</year><volume>17</volume><issue>6</issue><fpage>e12840</fpage><pub-id pub-id-type="doi">10.1111/acel.12840</pub-id><pub-id pub-id-type="pmid">30126037</pub-id><pub-id pub-id-type="pmcid">PMC6260915</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Musi N, Valentine JM, Sickora KR, et al. Tau protein aggregation is associated with cellular senescence in the brain. Aging Cell. 2018;17(6):e12840. 10.1111/acel.12840.<pub-id pub-id-type="pmid">30126037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.12840</pub-id><pub-id pub-id-type="pmcid">PMC6260915</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><etal/></person-group><article-title>Association between the pattern of mobile phone use and sleep quality in Northeast China college students</article-title><source>Sleep Breath</source><year>2021</year><volume>25</volume><issue>4</issue><fpage>2259</fpage><lpage>2267</lpage><pub-id pub-id-type="doi">10.1007/s11325-021-02295-2</pub-id><pub-id pub-id-type="pmid">33532989</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Meng J, Wang F, Chen R, et al. Association between the pattern of mobile phone use and sleep quality in Northeast China college students. Sleep Breath. 2021;25(4):2259&#8211;67. 10.1007/s11325-021-02295-2.<pub-id pub-id-type="pmid">33532989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11325-021-02295-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Galantamine alleviates senescence of U87 cells induced by beta-amyloid through decreasing ROS production</article-title><source>Neurosci Lett</source><year>2017</year><volume>653</volume><fpage>183</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2017.05.055</pub-id><pub-id pub-id-type="pmid">28554861</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Zhang Y, Zhao L, Wu Z, et al. Galantamine alleviates senescence of U87 cells induced by beta-amyloid through decreasing ROS production. Neurosci Lett. 2017;653:183&#8211;8. 10.1016/j.neulet.2017.05.055.<pub-id pub-id-type="pmid">28554861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2017.05.055</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X</given-names></name><etal/></person-group><article-title>A newly synthesized rhamnoside derivative alleviates Alzheimer&#8217;s amyloid-<italic toggle="yes">&#946;</italic>-induced oxidative stress, mitochondrial dysfunction, and cell senescence through upregulating SIRT3</article-title><source>Oxid Med Cell Longev</source><year>2020</year><volume>2020</volume><fpage>7698560</fpage><pub-id pub-id-type="doi">10.1155/2020/7698560</pub-id><pub-id pub-id-type="pmid">32104538</pub-id><pub-id pub-id-type="pmcid">PMC7040408</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Li Y, Lu J, Cao X, et al. A newly synthesized rhamnoside derivative alleviates Alzheimer&#8217;s amyloid-<italic toggle="yes">&#946;</italic>-induced oxidative stress, mitochondrial dysfunction, and cell senescence through upregulating SIRT3. Oxid Med Cell Longev. 2020;2020:7698560. 10.1155/2020/7698560.<pub-id pub-id-type="pmid">32104538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/7698560</pub-id><pub-id pub-id-type="pmcid">PMC7040408</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Olmesartan prevents oligomerized amyloid &#946; (A&#946;)-induced cellular senescence in neuronal cells</article-title><source>ACS Chem Neurosci</source><year>2021</year><volume>12</volume><issue>7</issue><fpage>1162</fpage><lpage>1169</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.0c00775</pub-id><pub-id pub-id-type="pmid">33710861</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Wang J, Zheng B, Yang S, et al. Olmesartan prevents oligomerized amyloid &#946; (A&#946;)-induced cellular senescence in neuronal cells. ACS Chem Neurosci. 2021;12(7):1162&#8211;9. 10.1021/acschemneuro.0c00775.<pub-id pub-id-type="pmid">33710861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschemneuro.0c00775</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title>ApoE and neurodegenerative diseases in aging</article-title><source>Adv Exp Med Biol</source><year>2018</year><volume>1086</volume><fpage>77</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1007/978-981-13-1117-8_5</pub-id><pub-id pub-id-type="pmid">30232753</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Yin Y, Wang Z. ApoE and neurodegenerative diseases in aging. Adv Exp Med Biol. 2018;1086:77&#8211;92. 10.1007/978-981-13-1117-8_5.<pub-id pub-id-type="pmid">30232753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-981-13-1117-8_5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serrano-Pozo</surname><given-names>A</given-names></name><name name-style="western"><surname>Das</surname><given-names>S</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>BT</given-names></name></person-group><article-title>APOE and Alzheimer&#8217;s disease: advances in genetics, pathophysiology, and therapeutic approaches</article-title><source>Lancet Neurol</source><year>2021</year><volume>20</volume><issue>1</issue><fpage>68</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/s1474-4422(20)30412-9</pub-id><pub-id pub-id-type="pmid">33340485</pub-id><pub-id pub-id-type="pmcid">PMC8096522</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer&#8217;s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021;20(1):68&#8211;80. 10.1016/s1474-4422(20)30412-9.<pub-id pub-id-type="pmid">33340485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(20)30412-9</pub-id><pub-id pub-id-type="pmcid">PMC8096522</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><etal/></person-group><article-title>Modifications and trafficking of APP in the pathogenesis of Alzheimer&#8217;s disease</article-title><source>Front Mol Neurosci</source><year>2017</year><volume>10</volume><fpage>294</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2017.00294</pub-id><pub-id pub-id-type="pmid">28966576</pub-id><pub-id pub-id-type="pmcid">PMC5605621</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Wang X, Zhou X, Li G, et al. Modifications and trafficking of APP in the pathogenesis of Alzheimer&#8217;s disease. Front Mol Neurosci. 2017;10:294. 10.3389/fnmol.2017.00294.<pub-id pub-id-type="pmid">28966576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnmol.2017.00294</pub-id><pub-id pub-id-type="pmcid">PMC5605621</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gri&#241;&#225;n-Ferr&#233;</surname><given-names>C</given-names></name><name name-style="western"><surname>Sarroca</surname><given-names>S</given-names></name><name name-style="western"><surname>Ivanova</surname><given-names>A</given-names></name><etal/></person-group><article-title>Epigenetic mechanisms underlying cognitive impairment and Alzheimer disease hallmarks in 5XFAD mice</article-title><source>Aging (Albany NY)</source><year>2016</year><volume>8</volume><issue>4</issue><fpage>664</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.18632/aging.100906</pub-id><pub-id pub-id-type="pmid">27013617</pub-id><pub-id pub-id-type="pmcid">PMC4925821</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Gri&#241;&#225;n-Ferr&#233; C, Sarroca S, Ivanova A, et al. Epigenetic mechanisms underlying cognitive impairment and Alzheimer disease hallmarks in 5XFAD mice. Aging (Albany NY). 2016;8(4):664&#8211;84. 10.18632/aging.100906.<pub-id pub-id-type="pmid">27013617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.100906</pub-id><pub-id pub-id-type="pmcid">PMC4925821</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franceschi</surname><given-names>C</given-names></name><name name-style="western"><surname>Garagnani</surname><given-names>P</given-names></name><name name-style="western"><surname>Parini</surname><given-names>P</given-names></name><etal/></person-group><article-title>Inflammaging: a new immune-metabolic viewpoint for age-related diseases</article-title><source>Nat Rev Endocrinol</source><year>2018</year><volume>14</volume><issue>10</issue><fpage>576</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1038/s41574-018-0059-4</pub-id><pub-id pub-id-type="pmid">30046148</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Franceschi C, Garagnani P, Parini P, et al. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576&#8211;90. 10.1038/s41574-018-0059-4.<pub-id pub-id-type="pmid">30046148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41574-018-0059-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nadeem</surname><given-names>A</given-names></name><name name-style="western"><surname>Alharbi</surname><given-names>NO</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>SF</given-names></name><etal/></person-group><article-title>Exposure to the plasticizer, Di-(2-ethylhexyl) phthalate during juvenile period exacerbates autism-like behavior in adult BTBR T + tf/J mice due to DNA hypomethylation and enhanced inflammation in brain and systemic immune cells</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2021</year><volume>109</volume><fpage>110249</fpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2021.110249</pub-id><pub-id pub-id-type="pmid">33497755</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Nadeem A, Alharbi NO, Ahmad SF, et al. Exposure to the plasticizer, Di-(2-ethylhexyl) phthalate during juvenile period exacerbates autism-like behavior in adult BTBR T + tf/J mice due to DNA hypomethylation and enhanced inflammation in brain and systemic immune cells. Prog Neuropsychopharmacol Biol Psychiatry. 2021;109:110249. 10.1016/j.pnpbp.2021.110249.<pub-id pub-id-type="pmid">33497755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pnpbp.2021.110249</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irvin</surname><given-names>MR</given-names></name><name name-style="western"><surname>Aslibekyan</surname><given-names>S</given-names></name><name name-style="western"><surname>Do</surname><given-names>A</given-names></name><etal/></person-group><article-title>Metabolic and inflammatory biomarkers are associated with epigenetic aging acceleration estimates in the GOLDN study</article-title><source>Clin Epigenetics</source><year>2018</year><volume>10</volume><fpage>56</fpage><pub-id pub-id-type="doi">10.1186/s13148-018-0481-4</pub-id><pub-id pub-id-type="pmid">29713391</pub-id><pub-id pub-id-type="pmcid">PMC5907301</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Irvin MR, Aslibekyan S, Do A, et al. Metabolic and inflammatory biomarkers are associated with epigenetic aging acceleration estimates in the GOLDN study. Clin Epigenetics. 2018;10:56. 10.1186/s13148-018-0481-4.<pub-id pub-id-type="pmid">29713391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13148-018-0481-4</pub-id><pub-id pub-id-type="pmcid">PMC5907301</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daily</surname><given-names>KP</given-names></name><name name-style="western"><surname>Badr</surname><given-names>A</given-names></name><name name-style="western"><surname>Eltobgy</surname><given-names>M</given-names></name><etal/></person-group><article-title>DNA hypomethylation promotes the expression of CASPASE-4 which exacerbates inflammation and amyloid-<italic toggle="yes">&#946;</italic> deposition in Alzheimer&#8217;s disease</article-title><source>Alzheimers Res Ther</source><year>2024</year><volume>16</volume><issue>1</issue><fpage>29</fpage><pub-id pub-id-type="doi">10.1186/s13195-024-01390-2</pub-id><pub-id pub-id-type="pmid">38326859</pub-id><pub-id pub-id-type="pmcid">PMC10851453</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Daily KP, Badr A, Eltobgy M, et al. DNA hypomethylation promotes the expression of CASPASE-4 which exacerbates inflammation and amyloid-<italic toggle="yes">&#946;</italic> deposition in Alzheimer&#8217;s disease. Alzheimers Res Ther. 2024;16(1):29. 10.1186/s13195-024-01390-2.<pub-id pub-id-type="pmid">38326859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-024-01390-2</pub-id><pub-id pub-id-type="pmcid">PMC10851453</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sawkulycz</surname><given-names>X</given-names></name><name name-style="western"><surname>Bradburn</surname><given-names>S</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Regulation of interleukin 6 by a polymorphic CpG within the frontal cortex in Alzheimer&#8217;s disease</article-title><source>Neurobiol Aging</source><year>2020</year><volume>92</volume><fpage>75</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2020.04.008</pub-id><pub-id pub-id-type="pmid">32408055</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Sawkulycz X, Bradburn S, Robinson A, et al. Regulation of interleukin 6 by a polymorphic CpG within the frontal cortex in Alzheimer&#8217;s disease. Neurobiol Aging. 2020;92:75&#8211;81. 10.1016/j.neurobiolaging.2020.04.008.<pub-id pub-id-type="pmid">32408055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2020.04.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>KX</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wei</surname><given-names>LL</given-names></name><etal/></person-group><article-title>ER<italic toggle="yes">&#945;</italic> gene promoter methylation in cognitive function and quality of life of patients with Alzheimer&#8217;s disease</article-title><source>J Geriatr Psychiatry Neurol</source><year>2019</year><volume>32</volume><issue>4</issue><fpage>221</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1177/0891988719835325</pub-id><pub-id pub-id-type="pmid">30947592</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Li KX, Sun Q, Wei LL, et al. ER<italic toggle="yes">&#945;</italic> gene promoter methylation in cognitive function and quality of life of patients with Alzheimer&#8217;s disease. J Geriatr Psychiatry Neurol. 2019;32(4):221&#8211;8. 10.1177/0891988719835325.<pub-id pub-id-type="pmid">30947592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0891988719835325</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Unnikrishnan</surname><given-names>A</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>WM</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>J</given-names></name><etal/></person-group><article-title>The role of DNA methylation in epigenetics of aging</article-title><source>Pharmacol Ther</source><year>2019</year><volume>195</volume><fpage>172&#8211;185</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2018.11.001</pub-id><pub-id pub-id-type="pmid">30419258</pub-id><pub-id pub-id-type="pmcid">PMC6397707</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Unnikrishnan A, Freeman WM, Jackson J, et al. The role of DNA methylation in epigenetics of aging. Pharmacol Ther. 2019;195:172&#8211;185. 10.1016/j.pharmthera.2018.11.001.<pub-id pub-id-type="pmid">30419258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2018.11.001</pub-id><pub-id pub-id-type="pmcid">PMC6397707</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Young</surname><given-names>JI</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>L</given-names></name><etal/></person-group><article-title>Sex-specific DNA methylation differences in Alzheimer&#8217;s disease pathology</article-title><source>Acta Neuropathol Commun</source><year>2021</year><volume>9</volume><issue>1</issue><fpage>77</fpage><pub-id pub-id-type="doi">10.1186/s40478-021-01177-8</pub-id><pub-id pub-id-type="pmid">33902726</pub-id><pub-id pub-id-type="pmcid">PMC8074512</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Zhang L, Young JI, Gomez L, et al. Sex-specific DNA methylation differences in Alzheimer&#8217;s disease pathology. Acta Neuropathol Commun. 2021;9(1):77. 10.1186/s40478-021-01177-8.<pub-id pub-id-type="pmid">33902726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-021-01177-8</pub-id><pub-id pub-id-type="pmcid">PMC8074512</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrucci</surname><given-names>L</given-names></name><name name-style="western"><surname>Gonzalez-Freire</surname><given-names>M</given-names></name><name name-style="western"><surname>Fabbri</surname><given-names>E</given-names></name><etal/></person-group><article-title>Measuring biological aging in humans: a quest</article-title><source>Aging Cell</source><year>2020</year><volume>19</volume><issue>2</issue><fpage>e13080</fpage><pub-id pub-id-type="doi">10.1111/acel.13080</pub-id><pub-id pub-id-type="pmid">31833194</pub-id><pub-id pub-id-type="pmcid">PMC6996955</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Ferrucci L, Gonzalez-Freire M, Fabbri E, et al. Measuring biological aging in humans: a quest. Aging Cell. 2020;19(2):e13080. 10.1111/acel.13080.<pub-id pub-id-type="pmid">31833194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.13080</pub-id><pub-id pub-id-type="pmcid">PMC6996955</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>KH</given-names></name><name name-style="western"><surname>Cameron-Smith</surname><given-names>D</given-names></name><name name-style="western"><surname>Wessner</surname><given-names>B</given-names></name><etal/></person-group><article-title>Biomarkers of aging: from function to molecular biology</article-title><source>Nutrients</source><year>2016</year><pub-id pub-id-type="doi">10.3390/nu8060338</pub-id><pub-id pub-id-type="pmid">27271660</pub-id><pub-id pub-id-type="pmcid">PMC4924179</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Wagner KH, Cameron-Smith D, Wessner B, et al. Biomarkers of aging: from function to molecular biology. Nutrients. 2016. 10.3390/nu8060338.<pub-id pub-id-type="pmid">27271660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu8060338</pub-id><pub-id pub-id-type="pmcid">PMC4924179</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>P</given-names></name><name name-style="western"><surname>Binder</surname><given-names>AM</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><etal/></person-group><article-title>Analysis of epigenetic age acceleration and healthy longevity among older US women</article-title><source>JAMA Netw Open</source><year>2022</year><volume>5</volume><issue>7</issue><fpage>e2223285</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.23285</pub-id><pub-id pub-id-type="pmid">35895062</pub-id><pub-id pub-id-type="pmcid">PMC9331104</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Jain P, Binder AM, Chen B, et al. Analysis of epigenetic age acceleration and healthy longevity among older US women. JAMA Netw Open. 2022;5(7):e2223285. 10.1001/jamanetworkopen.2022.23285.<pub-id pub-id-type="pmid">35895062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.23285</pub-id><pub-id pub-id-type="pmcid">PMC9331104</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Lutz</surname><given-names>M</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S</given-names></name></person-group><article-title>Genetic association between epigenetic aging-acceleration and the progression of mild cognitive impairment to Alzheimer&#8217;s disease</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2022</year><volume>77</volume><issue>9</issue><fpage>1734</fpage><lpage>1742</lpage><pub-id pub-id-type="doi">10.1093/gerona/glac138</pub-id><pub-id pub-id-type="pmid">35797594</pub-id><pub-id pub-id-type="pmcid">PMC9434458</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Liu H, Lutz M, Luo S. Genetic association between epigenetic aging-acceleration and the progression of mild cognitive impairment to Alzheimer&#8217;s disease. J Gerontol A Biol Sci Med Sci. 2022;77(9):1734&#8211;42. 10.1093/gerona/glac138.<pub-id pub-id-type="pmid">35797594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/glac138</pub-id><pub-id pub-id-type="pmcid">PMC9434458</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inkster</surname><given-names>AM</given-names></name><name name-style="western"><surname>Duarte-Guterman</surname><given-names>P</given-names></name><name name-style="western"><surname>Albert</surname><given-names>AY</given-names></name><etal/></person-group><article-title>Are sex differences in cognitive impairment reflected in epigenetic age acceleration metrics?</article-title><source>Neurobiol Aging</source><year>2022</year><volume>109</volume><fpage>192</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2021.09.022</pub-id><pub-id pub-id-type="pmid">34775209</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Inkster AM, Duarte-Guterman P, Albert AY, et al. Are sex differences in cognitive impairment reflected in epigenetic age acceleration metrics? Neurobiol Aging. 2022;109:192&#8211;4. 10.1016/j.neurobiolaging.2021.09.022.<pub-id pub-id-type="pmid">34775209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2021.09.022</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">464</journal-id><journal-id journal-id-type="pmc-domain">sageopen</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Journal of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">1387-2877</issn><issn pub-type="epub">1875-8908</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Sage Choice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12495115</article-id><article-id pub-id-type="pmcid-ver">PMC12495115.1</article-id><article-id pub-id-type="pmcaid">12495115</article-id><article-id pub-id-type="pmcaiid">12495115</article-id><article-id pub-id-type="pmid">40938625</article-id><article-id pub-id-type="doi">10.1177/13872877251372566</article-id><article-id pub-id-type="publisher-id">10.1177_13872877251372566</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>The cross-sectional associations between enlarged perivascular spaces and mild behavioral impairment in dementia-free older adults</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0005-7691-5703</contrib-id><name name-style="western"><surname>Mudalige</surname><given-names initials="D">Dinithi</given-names></name><xref rid="aff1-13872877251372566" ref-type="aff">1</xref><xref rid="aff2-13872877251372566" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guan</surname><given-names initials="DX">Dylan X</given-names></name><xref rid="aff1-13872877251372566" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McLeod</surname><given-names initials="GA">Graham A</given-names></name><xref rid="aff3-13872877251372566" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Smith</surname><given-names initials="EE">Eric E</given-names></name><xref rid="aff1-13872877251372566" ref-type="aff">1</xref><xref rid="aff3-13872877251372566" ref-type="aff">3</xref><xref rid="aff4-13872877251372566" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ganesh</surname><given-names initials="A">Aravind</given-names></name><xref rid="aff1-13872877251372566" ref-type="aff">1</xref><xref rid="aff3-13872877251372566" ref-type="aff">3</xref><xref rid="aff4-13872877251372566" ref-type="aff">4</xref><xref rid="aff5-13872877251372566" ref-type="aff">5</xref><xref rid="fn1-13872877251372566" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5529-3731</contrib-id><name name-style="western"><surname>Ismail</surname><given-names initials="Z">Zahinoor</given-names></name><xref rid="aff1-13872877251372566" ref-type="aff">1</xref><xref rid="aff3-13872877251372566" ref-type="aff">3</xref><xref rid="aff4-13872877251372566" ref-type="aff">4</xref><xref rid="aff5-13872877251372566" ref-type="aff">5</xref><xref rid="aff6-13872877251372566" ref-type="aff">6</xref><xref rid="aff7-13872877251372566" ref-type="aff">7</xref><xref rid="aff8-13872877251372566" ref-type="aff">8</xref><xref rid="fn1-13872877251372566" ref-type="author-notes">#</xref><xref rid="corresp1-13872877251372566" ref-type="corresp"/></contrib></contrib-group><aff id="aff1-13872877251372566">
<label>1</label>Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada</aff><aff id="aff2-13872877251372566">
<label>2</label>Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada</aff><aff id="aff3-13872877251372566">
<label>3</label>Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada</aff><aff id="aff4-13872877251372566">
<label>4</label>Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada</aff><aff id="aff5-13872877251372566">
<label>5</label>O&#8217;Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada</aff><aff id="aff6-13872877251372566">
<label>6</label>Department of Psychiatry, University of Calgary, Calgary, AB, Canada</aff><aff id="aff7-13872877251372566">
<label>7</label>Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK</aff><aff id="aff8-13872877251372566">
<label>8</label>Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada</aff><author-notes><fn fn-type="other" id="fn1-13872877251372566"><label>
<sup>#</sup>
</label><p>These authors contributed to the manuscript as co-senior authors.</p></fn><corresp id="corresp1-13872877251372566">Zahinoor Ismail, MD, 3280 Hospital Dr NW, Calgary, AB T2N 4Z6, Canada. Email: <email>ismailz@ucalgary.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>107</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">498304</issue-id><fpage>1682</fpage><lpage>1692</lpage><history><date date-type="received"><day>3</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-05 00:26:29.067"><day>05</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_13872877251372566.pdf"/><abstract><sec><title>Background</title><p>Enlarged perivascular spaces (EPVS) and mild behavioral impairment (MBI) are associated with greater dementia risk.</p></sec><sec><title>Objective</title><p>We investigated cross-sectional associations between EPVS burden and MBI presence and symptom severity.</p></sec><sec><title>Methods</title><p>Participants were dementia-free older adults in the Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS-ND) study. EPVS were assessed using a validated visual rating scale applied to T2-weighted magnetic resonance imaging. MBI was measured using the informant-reported MBI Checklist (MBI-C) with a cut-point of &gt;5 for MBI presence. Multivariable logistic and zero-inflated negative binomial regressions modelled EPVS associations with MBI presence and symptom severity, respectively, adjusting for age, education, Montreal Cognitive Assessment score, and presence of hypertension with an EPVS*sex interaction term.</p></sec><sec><title>Results</title><p>Among 363 participants (52.9% female), every 1-point rise in total EPVS score was associated with 1.28-fold greater odds of having MBI (95%CI:1.06&#8211;1.53, p&#8201;=&#8201;0.009). When examining regional EPVS burden, those with higher centrum semiovale scores had greater odds of MBI (aOR&#8201;=&#8201;1.47, 95%CI:1.08&#8211;2.00, p&#8201;=&#8201;0.01), but this association was not significant for the basal ganglia (aOR&#8201;=&#8201;1.37, 95%CI:0.95&#8211;1.97, p&#8201;=&#8201;0.09) or midbrain (aOR&#8201;=&#8201;1.49, 95%CI:0.80&#8211;2.79, p&#8201;=&#8201;0.21). Total and regional EPVS scores were not associated with MBI symptom severity. None of the associations were moderated by sex.</p></sec><sec><title>Conclusions</title><p>Older adults with greater global and centrum semiovale EPVS burden are more likely to have MBI. These findings suggest that early microvascular pathology may contribute to later-life emergent and persistent behavioral symptoms, although longitudinal data are required, along with other indicators of vascular pathology.</p></sec></abstract><kwd-group><kwd>Alzheimer's disease</kwd><kwd>cerebral small vessel disease</kwd><kwd>dementia</kwd><kwd>enlarged perivascular spaces</kwd><kwd>mild behavioral impairment</kwd><kwd>neuropsychiatric symptoms</kwd><kwd>vascular disease</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts19</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section1-13872877251372566"><title>Introduction</title><p>Dementia is characterized by cognitive and behavioral impairment severe enough to affect daily life. While Alzheimer disease (AD) is the most common cause of dementia in older adults, there is a significant role of vascular factors in the trajectory of dementia.<sup>
<xref rid="bibr1-13872877251372566" ref-type="bibr">1</xref>
</sup> Cerebrovascular risk factors and related diseases among older adults affect nearly one-third of patients with dementia.<sup>
<xref rid="bibr2-13872877251372566" ref-type="bibr">2</xref>
</sup> Brain infarcts, arterial lipid deposits, or arteriolar wall thickening have been found in many patients diagnosed with AD in autopsy studies, indicating comorbid vascular pathology.<sup>
<xref rid="bibr3-13872877251372566" ref-type="bibr">3</xref>
</sup> Studies also implicate vascular disease in over 90% of cases of probable AD and mixed AD pathology.<sup>
<xref rid="bibr4-13872877251372566" ref-type="bibr">4</xref>
</sup></p><p>Cerebral small vessel disease (CSVD) is the most common vascular pathology in dementia. CSVD is a chronic and progressive vascular disease that affects arterioles, capillaries, and small veins of the brain.<sup>
<xref rid="bibr5-13872877251372566" ref-type="bibr">5</xref>
</sup> Several longitudinal studies have investigated the coexistence of CSVD with AD pathology in those with dementia, with some indicating an additive relationship and others illustrating a synergistic contribution to cognitive impairment.<sup><xref rid="bibr6-13872877251372566" ref-type="bibr">6</xref><xref rid="bibr7-13872877251372566" ref-type="bibr"/><xref rid="bibr8-13872877251372566" ref-type="bibr"/>&#8211;<xref rid="bibr9-13872877251372566" ref-type="bibr">9</xref></sup> Neuroimaging features of CSVD are associated with a greater risk of AD.<sup>
<xref rid="bibr10-13872877251372566" ref-type="bibr">10</xref>
</sup></p><p>Enlarged perivascular spaces (EPVS) are a neuroimaging feature of CSVD, alongside other markers such as white matter hyperintensities (WMHs) and lacunes.<sup>
<xref rid="bibr11-13872877251372566" ref-type="bibr">11</xref>
</sup> EPVS has been reported to increase in number on magnetic resonance imaging (MRI) with age, along with other brain features of CSVD.<sup><xref rid="bibr12-13872877251372566" ref-type="bibr">12</xref>,<xref rid="bibr13-13872877251372566" ref-type="bibr">13</xref></sup> Similar to other CSVD features,<sup><xref rid="bibr13-13872877251372566" ref-type="bibr">13</xref>,<xref rid="bibr14-13872877251372566" ref-type="bibr">14</xref></sup> high EPVS burden predicts future risk of dementia.<sup>
<xref rid="bibr15-13872877251372566" ref-type="bibr">15</xref>
</sup> EPVS burden in the centrum semiovale is associated with a greater risk of incident cognitive decline and dementia, independent of other vascular risks, total brain volume, WMHs, and covert infarcts.<sup>
<xref rid="bibr16-13872877251372566" ref-type="bibr">16</xref>
</sup> Hence, EPVS may be a useful subclinical MRI marker to identify individuals who are at higher risk of developing dementia.</p><p>While behavioral symptoms are core features of dementia, these symptoms can also emerge in advance of dementia.<sup><xref rid="bibr17-13872877251372566" ref-type="bibr">17</xref>,<xref rid="bibr18-13872877251372566" ref-type="bibr">18</xref></sup> These behavioral changes have been incorporated into a validated clinical construct called mild behavioral impairment (MBI).<sup>
<xref rid="bibr17-13872877251372566" ref-type="bibr">17</xref>
</sup> MBI is characterized by the later-life onset of persistent neuropsychiatric symptoms (NPS) that represent change from longstanding behaviors, as an indicator of dementia risk. Numerous studies have supported MBI, whether concurrently presenting with mild cognitive impairment (MCI) or absent objective cognitive impairment in persons with subjective cognitive decline (SCD) or normal cognition, as a clinical marker of risk for incident dementia.<sup><xref rid="bibr18-13872877251372566" ref-type="bibr">18</xref><xref rid="bibr19-13872877251372566" ref-type="bibr"/><xref rid="bibr20-13872877251372566" ref-type="bibr"/><xref rid="bibr21-13872877251372566" ref-type="bibr"/>&#8211;<xref rid="bibr22-13872877251372566" ref-type="bibr">22</xref></sup></p><p>The link between MBI and specific neurodegenerative etiologies of dementia has been explored primarily with AD biomarkers, including amyloid-&#946; (A&#946;) and phosphorylated tau (p-tau), AD genetic risk factors like Apolipoprotein E, and AD patterns of brain atrophy or neurodegeneration.<sup><xref rid="bibr23-13872877251372566" ref-type="bibr">23</xref><xref rid="bibr24-13872877251372566" ref-type="bibr"/><xref rid="bibr25-13872877251372566" ref-type="bibr"/><xref rid="bibr26-13872877251372566" ref-type="bibr"/><xref rid="bibr27-13872877251372566" ref-type="bibr"/><xref rid="bibr28-13872877251372566" ref-type="bibr"/><xref rid="bibr29-13872877251372566" ref-type="bibr"/><xref rid="bibr30-13872877251372566" ref-type="bibr"/><xref rid="bibr31-13872877251372566" ref-type="bibr"/><xref rid="bibr32-13872877251372566" ref-type="bibr"/>&#8211;<xref rid="bibr33-13872877251372566" ref-type="bibr">33</xref></sup> However, other brain pathologies and atrophy patterns may contribute to later-life emergent and persistent behavioral symptoms.<sup><xref rid="bibr34-13872877251372566" ref-type="bibr">34</xref>,<xref rid="bibr35-13872877251372566" ref-type="bibr">35</xref></sup> There is some evidence supporting the association between cerebrovascular pathologies and behavioral impairment. Recent findings show that NPS are common in cerebral amyloid angiopathy (CAA), with severity linked to greater white matter hyperintensity volume.<sup>
<xref rid="bibr36-13872877251372566" ref-type="bibr">36</xref>
</sup> Postmortem studies also reported associations between NPS and cerebrovascular disease.<sup>
<xref rid="bibr37-13872877251372566" ref-type="bibr">37</xref>
</sup> Cardiovascular risk factors, like diabetes, hypertension, and stroke, additionally accelerate cognitive decline and exacerbate the presence of NPS, such as depression and apathy.<sup><xref rid="bibr38-13872877251372566" ref-type="bibr">38</xref>,<xref rid="bibr39-13872877251372566" ref-type="bibr">39</xref></sup> More recently, studies have found an association between greater burden of vascular risk factors (e.g., hypertension, diabetes, dyslipidemia, high body mass index) and MBI.<sup><xref rid="bibr40-13872877251372566" ref-type="bibr">40</xref><xref rid="bibr41-13872877251372566" ref-type="bibr"/>&#8211;<xref rid="bibr42-13872877251372566" ref-type="bibr">42</xref></sup></p><p>However, the association between CSVD markers and MBI remains poorly characterized, and EPVS burden has not been studied in this regard. Therefore, we aimed to investigate cross-sectional associations between EPVS burden and MBI presence (i.e., MBI&#8201;+&#8201;status) and symptom severity. Given that EPVS in different regions may reflect different underlying CSVD pathology, a secondary analysis examined associations involving regional EPVS burden in the basal ganglia, centrum semiovale, and midbrain EPVS.<sup>
<xref rid="bibr43-13872877251372566" ref-type="bibr">43</xref>
</sup> Due to the high prevalence of cerebrovascular disease in older adults with dementia and the association between MBI and WMH volume,<sup>
<xref rid="bibr44-13872877251372566" ref-type="bibr">44</xref>
</sup> we hypothesized that older adults with greater EPVS burden would be more likely to have MBI and exhibit greater MBI symptom severity.</p></sec><sec sec-type="methods" id="section2-13872877251372566"><title>Method</title><sec id="section2A-13872877251372566"><title>Study design</title><p>Data were from the Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS-ND), a Canada-wide prospective cohort study aiming to investigate several causes of neurodegeneration and their interactions (ClinicalTrials.gov <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03402919">NCT03402919</ext-link>).<sup><xref rid="bibr45-13872877251372566" ref-type="bibr">45</xref>,<xref rid="bibr46-13872877251372566" ref-type="bibr">46</xref></sup> COMPASS-ND participants included older adults with dementia, MCI, SCD, and cognitively normal individuals (CN). For this study, we defined CN as those who performed in the normal range on neuropsychological testing, which includes those who were CN and had SCD. Data collected included sociodemographic information, clinical and cognitive data, structural brain imaging, biomarkers, and measures of sensory function. Extensive descriptions of COMPASS-ND recruitment and data collection procedures have been published elsewhere.<sup>
<xref rid="bibr45-13872877251372566" ref-type="bibr">45</xref>
</sup> The COMPASS-ND study was approved by the Jewish General Research Ethics Board.<sup>
<xref rid="bibr45-13872877251372566" ref-type="bibr">45</xref>
</sup> Data were downloaded on October 2, 2023. Data were collected with ethical approval by institutional review boards at each of the 13 study sites affiliated with the study, with written informed consent provided by participants.<sup>
<xref rid="bibr47-13872877251372566" ref-type="bibr">47</xref>
</sup></p></sec><sec id="section2B-13872877251372566"><title>Participants</title><p>The complete sample from COMPASS-ND consisted of 1284 participants. However, the Mild Behavioral Impairment Checklist (MBI-C) was only introduced into the study about two years after its initial launch.<sup><xref rid="bibr48-13872877251372566" ref-type="bibr">48</xref>,<xref rid="bibr49-13872877251372566" ref-type="bibr">49</xref></sup> Therefore, only participants enrolled thereafter were administered the MBI-C (n&#8201;=&#8201;531). From this subset of participants, further exclusions were made if participants (1) had a diagnosis of dementia, indicating that they no longer met criteria for MBI (n&#8201;=&#8201;115)<sup>
<xref rid="bibr17-13872877251372566" ref-type="bibr">17</xref>
</sup>; (2) were missing T2 MRI scans (n&#8201;=&#8201;36); (3) had poor quality T2 scans, where EPVS severity could not be accurately assessed (n&#8201;=&#8201;15); and (4) were missing data for covariates such as sex, education, or Montreal Cognitive Assessment (MoCA) score (n&#8201;=&#8201;2). The final sample size was 363 (<xref rid="fig1-13872877251372566" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="fig1-13872877251372566" orientation="portrait"><label>Figure 1.</label><caption><p>Participant flow-diagram. Demographics included age, sex, education, and MoCA score. COMPASS-ND: Comprehensive Assessment of Neurodegeneration and Dementia; MBI-C: Mild Behavioral Impairment Checklist; MRI: magnetic resonance image; EPVS: enlarged perivascular spaces; MoCA: Montreal Cognitive Assessment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251372566-fig1.jpg"/></fig></sec><sec id="section2C-13872877251372566"><title>MRI acquisition</title><p>Brain MRIs were acquired using the previously validated Canadian Dementia Imaging Protocol (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.cdip-pcid.ca)" ext-link-type="uri">http://www.cdip-pcid.ca)</ext-link>.<sup><xref rid="bibr50-13872877251372566" ref-type="bibr">50</xref>,<xref rid="bibr51-13872877251372566" ref-type="bibr">51</xref></sup> Across data collection sites, participants underwent MRI scanning on a 3&#8197;T magnet machine.<sup>
<xref rid="bibr45-13872877251372566" ref-type="bibr">45</xref>
</sup> The sequences used included three-dimensional T1, proton density/T2, fluid-attenuated inversion recovery, gradient echo, resting-state functional MRI, and diffusion tensor imaging.</p><p>For this study, data on EPVS were collected from T2-weighted MRI scans which allow for more accurate detection of EPVS due to the high contrast between EPVS and the white matter.<sup>
<xref rid="bibr52-13872877251372566" ref-type="bibr">52</xref>
</sup> Three-dimensional inversion-prepared T2-weighted images were acquired using the following parameters: repetition time (TR)/echo time (TE)&#8201;=&#8201;650/20&#8197;ms, flip angle&#8201;=&#8201;20&#176;, voxel size&#8201;=&#8201;0.94&#8201;&#215;&#8201;0.94&#8201;&#215;&#8201;3.0&#8197;mm3, field of view (FOV)&#8201;=&#8201;240&#8201;&#215;&#8201;240&#8197;mm, resolution&#8201;=&#8201;0.94&#8201;&#215;&#8201;0.94&#8201;&#215;&#8201;3.0&#8197;mm.<sup><xref rid="bibr50-13872877251372566" ref-type="bibr">50</xref>,<xref rid="bibr51-13872877251372566" ref-type="bibr">51</xref></sup></p></sec><sec id="section2D-13872877251372566"><title>Enlarged perivascular spaces rating</title><p>EPVS were assessed by three raters (DG, AG, GM) using a validated visual rating scale, which evaluates the number of EPVS in the basal ganglia and centrum semiovale, as well as the presence/absence of EPVS in the midbrain.<sup>
<xref rid="bibr53-13872877251372566" ref-type="bibr">53</xref>
</sup> This scale was used in this study as it incorporates all relevant EPVS sites and allows the rating of all grades of EPVS severity on standard structural brain MRI.<sup>
<xref rid="bibr53-13872877251372566" ref-type="bibr">53</xref>
</sup> EPVS severity is rated from 0&#8211;4 in the basal ganglia and centrum semiovale. A rating of 0 indicates no EPVS, 1 indicates 1&#8211;10 EPVS, 2 indicates 11&#8211;20 EPVS, 3 indicates 21&#8211;40 EPVS, and 4 indicates more than 40 EPVS. For the midbrain, only presence or absence is recorded, with a maximum score of 1. For each rating, both hemispheres and all relevant slices are assessed; however, only the slice and hemisphere with the highest number of EPVS are used for the rating. The total EPVS score is obtained from the sum of the three regional ratings.</p><p>Inter-rater reliability was established through a training program wherein AG (neurologist with 10 years of experience in neuroimaging research) trained DG and GM on EPVS ratings using 20 training cases graded in person. All three raters then independently rated 20 unseen testing cases. Gwet's agreement coefficient (AC, particularly suitable for samples with greater frequencies of certain values, e.g., 0&#8211;1) and percentage agreement with AG were calculated, with Gwet's AC&#8201;&gt;&#8201;0.6 and agreement &gt;70% set <italic toggle="yes">a priori</italic> as thresholds for DG and GM to attain in order to proceed with independent ratings.<sup>
<xref rid="bibr54-13872877251372566" ref-type="bibr">54</xref>
</sup></p></sec><sec id="section2E-13872877251372566"><title>Mild behavioral impairment</title><p>MBI was measured using the informant-reported MBI-C.<sup>
<xref rid="bibr48-13872877251372566" ref-type="bibr">48</xref>
</sup> The MBI-C comprises five domains assessed by 34 items: decreased motivation (6 questions), emotional dysregulation (6 questions), impulse dyscontrol (12 questions), social inappropriateness (5 questions), and abnormal perceptions (5 questions). Each question assesses the severity of symptoms and can be answered on a scale from 0&#8211;3, with 0 indicating no symptoms and 3 indicating severe symptoms. The full MBI-C is available for free at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mbitest.org/" ext-link-type="uri">https://www.mbitest.org/</ext-link>. MBI presence was ascertained based on an MBI-C total score &gt;5, as this cut-off can effectively distinguish between participants with and without MBI in CN and mixed CN and MCI samples.<sup><xref rid="bibr55-13872877251372566" ref-type="bibr">55</xref>,<xref rid="bibr56-13872877251372566" ref-type="bibr">56</xref></sup> The MBI total score, ranging from 0&#8211;102, was calculated by summing the scores for each item, with higher scores indicating more severe symptoms.</p></sec><sec id="section2F-13872877251372566"><title>Statistical analyses</title><p>Multivariable logistic regressions modelled the cross-sectional associations between total, basal ganglia, centrum semiovale, and midbrain EPVS scores (predictors) and MBI presence (outcome). Multivariable zero-inflated negative binomial regression modelled the cross-sectional associations between total, basal ganglia, centrum semiovale, and midbrain EPVS scores (predictors) and MBI symptom severity (outcome). This model was used because the distribution of MBI-C scores resembled an overdispersed (variance&#8201;&gt;&#8201;mean and variance increases quadratically) Poisson distribution with an excess of zeroes. Raw coefficients, which are in the natural logarithmic scale, were exponentiated to facilitate interpretation along the original MBI-C scale of measurement. The corresponding coefficients reported in this paper represent the adjusted multiplicative change in the MBI-C total score for each one-unit rise in EPVS score.</p><p>The analyses were controlled for age, sex, education, MoCA score, and presence of hypertension; sex was explored as a moderator for all associations as per the COMPASS-ND publications and data access policy. R version 4.4.0 was used to conduct all statistical analyses.<sup>
<xref rid="bibr57-13872877251372566" ref-type="bibr">57</xref>
</sup></p></sec></sec><sec sec-type="results" id="section3-13872877251372566"><title>Results</title><sec id="section3A-13872877251372566"><title>Participant characteristics</title><p>Participant characteristics for all analyses are summarized in <xref rid="table1-13872877251372566" ref-type="table">Table 1</xref>. Of the total sample (n&#8201;=&#8201;363), the mean age was 74.6 (SD&#8201;=&#8201;7.2, range&#8201;=&#8201;54.8&#8211;95.1), 192 (52.9%) were females, and mean years of education was 15.7 (SD&#8201;=&#8201;3.4, range&#8201;=&#8201;5.0&#8211;30.0). Regarding cognition, 180 (49.6%) participants had MCI, and 183 (50.4%) were CN, with a mean MoCA score of 25.3 (SD&#8201;=&#8201;3.6, range&#8201;=&#8201;13.0&#8211;30.0). There were no significant differences in vascular risk factor presence between the MBI presence and absence groups with the exception of hypertension, which was more common in the MBI group. The median EPVS score was 5.0 (IQR&#8201;=&#8201;4.0&#8211;6.0), with a median basal ganglia EPVS score of 2.0 (IQR&#8201;=&#8201;1.0&#8211;2.0), centrum semiovale EPVS score of 2.0 (IQR&#8201;=&#8201;2.0&#8211;3.0), and midbrain EPVS score of 1.0 (IQR&#8201;=&#8201;1.0&#8211;1.0). Lastly, the median MBI-C score was 2.0 (0&#8211;8.0); 125 (34.4%) participants were MBI&#8201;+&#8201;based on the MBI-C total score cut-off &gt;5.</p><table-wrap position="float" id="table1-13872877251372566" orientation="portrait"><label>Table 1.</label><caption><p>Participant demographics.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251372566-table1.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Total</th><th align="left" rowspan="1" colspan="1">MBI Present</th><th align="left" rowspan="1" colspan="1">MBI Absent</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">n</td><td rowspan="1" colspan="1">363</td><td rowspan="1" colspan="1">125</td><td rowspan="1" colspan="1">238</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Age (y)</td><td rowspan="1" colspan="1">74.6 (7.2), 54.8&#8211;95.1</td><td rowspan="1" colspan="1">75.0 (8.1), 54.8&#8211;94.2</td><td rowspan="1" colspan="1">74.4 (6.6), 58.4&#8211;95.1</td><td rowspan="1" colspan="1">0.30<sup>w</sup></td></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&lt;0.001<sup>c</sup></td></tr><tr><td rowspan="1" colspan="1">&#8195;Female</td><td rowspan="1" colspan="1">192 (52.9%)</td><td rowspan="1" colspan="1">51 (40.8%)</td><td rowspan="1" colspan="1">141 (59.2%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Male</td><td rowspan="1" colspan="1">171 (47.1%)</td><td rowspan="1" colspan="1">74 (59.2%)</td><td rowspan="1" colspan="1">97 (40.8%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Education (Years)</td><td rowspan="1" colspan="1">15.7 (3.4), 5.0&#8211;30.0</td><td rowspan="1" colspan="1">15.3 (3.5), 7.0&#8211;25.0</td><td rowspan="1" colspan="1">15.9 (3.4), 5.0&#8211;30.0</td><td rowspan="1" colspan="1">0.057<sup>w</sup></td></tr><tr><td rowspan="1" colspan="1">MoCA Score</td><td rowspan="1" colspan="1">25.3 (3.6), 13.0&#8211;30.0</td><td rowspan="1" colspan="1">24.1 (3.9), 13.0&#8211;30.0</td><td rowspan="1" colspan="1">25.9 (3.3), 14.0&#8211;30.0</td><td rowspan="1" colspan="1">&lt;0.001<sup>w</sup></td></tr><tr><td rowspan="1" colspan="1">Cognitive Diagnosis</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&lt;0.001<sup>c</sup></td></tr><tr><td rowspan="1" colspan="1">&#8195;MCI</td><td rowspan="1" colspan="1">180 (49.6%)</td><td rowspan="1" colspan="1">85 (68.0%)</td><td rowspan="1" colspan="1">95 (39.9%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;CN</td><td rowspan="1" colspan="1">183 (50.4%)</td><td rowspan="1" colspan="1">40 (32.0%)</td><td rowspan="1" colspan="1">143 (60.1%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Vascular Risk Factors</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Hypertension Present</td><td rowspan="1" colspan="1">122 (33.6%)</td><td rowspan="1" colspan="1">52 (41.6%)</td><td rowspan="1" colspan="1">70 (29.4%)</td><td rowspan="1" colspan="1">0.02<sup>c</sup></td></tr><tr><td rowspan="1" colspan="1">&#8195;Hyperlipidemia Present</td><td rowspan="1" colspan="1">152 (41.9%)</td><td rowspan="1" colspan="1">54 (43.2%)</td><td rowspan="1" colspan="1">98 (41.2%)</td><td rowspan="1" colspan="1">0.73<sup>c</sup></td></tr><tr><td rowspan="1" colspan="1">&#8195;Type I Diabetes Present</td><td rowspan="1" colspan="1">4 (1.1%)</td><td rowspan="1" colspan="1">2 (1.6%)</td><td rowspan="1" colspan="1">2 (0.8%)</td><td rowspan="1" colspan="1">0.51<sup>c</sup></td></tr><tr><td rowspan="1" colspan="1">&#8195;Type 2 Diabetes Present</td><td rowspan="1" colspan="1">40 (11.0%)</td><td rowspan="1" colspan="1">19 (15.2%)</td><td rowspan="1" colspan="1">21 (8.8%)</td><td rowspan="1" colspan="1">0.06<sup>c</sup></td></tr><tr><td rowspan="1" colspan="1">MBI-C Score</td><td rowspan="1" colspan="1">2.0 (0&#8211;8.0)</td><td rowspan="1" colspan="1">12.0 (8.0&#8211;20.0)</td><td rowspan="1" colspan="1">0 (0&#8211;1.0)</td><td rowspan="1" colspan="1">&lt;0.001<sup>w</sup></td></tr><tr><td rowspan="1" colspan="1">Total EPVS Score</td><td rowspan="1" colspan="1">5.0 (4.0&#8211;6.0)</td><td rowspan="1" colspan="1">5.0 (4.0&#8211;6.0)</td><td rowspan="1" colspan="1">4.5 (4.0&#8211;6.0)</td><td rowspan="1" colspan="1">0.001<sup>w</sup></td></tr><tr><td rowspan="1" colspan="1">&#8195;Basal Ganglia Score</td><td rowspan="1" colspan="1">2.0 (1.0&#8211;2.0)</td><td rowspan="1" colspan="1">2.0 (1.0&#8211;2.0)</td><td rowspan="1" colspan="1">1.0 (1.0&#8211;2.0)</td><td rowspan="1" colspan="1">0.011<sup>w</sup></td></tr><tr><td rowspan="1" colspan="1">&#8195;Centrum Semiovale Score</td><td rowspan="1" colspan="1">2.0 (2.0&#8211;3.0)</td><td rowspan="1" colspan="1">3.0 (2.0&#8211;3.0)</td><td rowspan="1" colspan="1">2.0 (2.0&#8211;3.0)</td><td rowspan="1" colspan="1">0.004<sup>w</sup></td></tr><tr><td rowspan="1" colspan="1">&#8195;Midbrain Score</td><td rowspan="1" colspan="1">1.0 (1.0&#8211;1.0)</td><td rowspan="1" colspan="1">1.0 (1.0&#8211;1.0)</td><td rowspan="1" colspan="1">1.0 (1.0&#8211;1.0)</td><td rowspan="1" colspan="1">0.18<sup>w</sup></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-13872877251372566"><p>Values for continuous variables are shown in mean (SD), range, except for MBI and EPVS scores, which are indicated in median (IQR). Values were rounded to one decimal place where appropriate. Categorical variables are shown as n (%). Five participants were missing data for the vascular risk factors: hyperlipidemia (n&#8201;=&#8201;1), type I diabetes (n&#8201;=&#8201;2), type II diabetes (n&#8201;=&#8201;2). MBI presence was defined as an MBI total score of &gt;5. MBI: mild behavioral impairment; MoCA: Montreal Cognitive Assessment; MCI: mild cognitive impairment; CN: cognitively normal; EPVS: enlarged perivascular space. <sup>w</sup>Wilcoxon Rank Sum (Mann-Whitney) Test; <sup>c</sup>Chi-Squared Test</p></fn></table-wrap-foot></table-wrap></sec><sec id="section3B-13872877251372566"><title>Inter-rater reliability of EPVS ratings</title><p>Compared to the senior expert rater, each rater attained the pre-set thresholds of Gwet's AC&#8201;&gt;&#8201;0.60 and agreement&#8201;&gt;&#8201;70% based on 20 independently rated test cases from the dataset. Specifically, Gwet's AC and percentage agreement were, respectively, 0.76&#8211;0.80 and 85.0&#8211;85.7% for midbrain ratings, 0.74&#8211;0.94 and 80.0&#8211;95.2% for the basal ganglia, and 0.72&#8211;0.79 and 81.0&#8211;85.0% for the centrum semiovale.</p></sec><sec id="section3C-13872877251372566"><title>The association between EPVS score and MBI status</title><p>As shown in <xref rid="table2-13872877251372566" ref-type="table">Table 2</xref> and <xref rid="fig2-13872877251372566" ref-type="fig">Figure 2</xref>, for every 1-point rise in EPVS total score, the odds of having MBI increased by a factor of 1.28 (95%CI:1.06&#8211;1.53, p&#8201;=&#8201;0.009). When examining subregion EPVS scores, those with higher centrum semiovale scores had greater odds of MBI (aOR&#8201;=&#8201;1.47, 95%CI:1.08&#8211;2.00, p&#8201;=&#8201;0.01). However, this association was not observed for the basal ganglia (aOR&#8201;=&#8201;1.37, 95%CI:0.95&#8211;1.97, p&#8201;=&#8201;0.09) or midbrain (aOR&#8201;=&#8201;1.49, 95%CI:0.80&#8211;2.79, p&#8201;=&#8201;0.21). The associations between total and subregion EPVS and MBI status were not dependent on sex, based on our moderation analyses (EPVS total*sex aOR&#8201;=&#8201;0.83, 95%CI:0.58&#8211;1.17, p&#8201;=&#8201;0.29; EPVS basal ganglia*sex aOR&#8201;=&#8201;0.73, 95%CI:0.37&#8211;1.46, p&#8201;=&#8201;0.38; EPVS centrum semiovale*sex aOR&#8201;=&#8201;0.80, 95%:0.44&#8211;1.48, p&#8201;=&#8201;0.48; EPVS midbrain*sex aOR&#8201;=&#8201;0.88, 95%CI:0.25&#8211;3.08, p&#8201;=&#8201;0.84).</p><fig position="float" id="fig2-13872877251372566" orientation="portrait"><label>Figure 2.</label><caption><p>Violin plots for the distribution of the total EPVS score, basal ganglia EPVS score, centrum semiovale EPVS score, and midbrain EPVS score for participants with MBI absence and presence. MBI presence was determined using an MBI-C total score cut-off of &gt;5. The white line indicates the interquartile range. Data points were jittered randomly by up to 0.4 units along the x-axis and 0.3 units along the y-axis to reduce overlap. Wilcoxon rank-sum test p-values are provided above each plot representing the difference between the MBI absence and presence distributions. EPVS: enlarged perivascular spaces; MBI: mild behavioral impairment; MBI-C: mild behavioral impairment checklist (n&#8201;=&#8201;363).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251372566-fig2.jpg"/></fig><table-wrap position="float" id="table2-13872877251372566" orientation="portrait"><label>Table 2.</label><caption><p>Multivariable regression model outputs for the association between MBI presence, MBI total score, and EPVS ratings.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251372566-table2.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="&#x2013;" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Exposure Variable</th><th align="left" rowspan="1" colspan="1">Outcome Variable</th><th align="left" rowspan="1" colspan="1">aOR</th><th align="left" rowspan="1" colspan="1">95%CI</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Total EPVS</td><td rowspan="1" colspan="1">MBI Presence</td><td rowspan="1" colspan="1">1.28</td><td rowspan="1" colspan="1">1.06&#8211;1.53</td><td rowspan="1" colspan="1">0.009*</td></tr><tr><td rowspan="1" colspan="1">Basal Ganglia EPVS</td><td rowspan="1" colspan="1">MBI Presence</td><td rowspan="1" colspan="1">1.37</td><td rowspan="1" colspan="1">0.95&#8211;1.97</td><td rowspan="1" colspan="1">0.09</td></tr><tr><td rowspan="1" colspan="1">Centrum Semiovale EPVS</td><td rowspan="1" colspan="1">MBI Presence</td><td rowspan="1" colspan="1"> 1.47</td><td rowspan="1" colspan="1">1.08&#8211;2.00</td><td rowspan="1" colspan="1">0.01*</td></tr><tr><td rowspan="1" colspan="1">Midbrain EPVS</td><td rowspan="1" colspan="1">MBI Presence</td><td rowspan="1" colspan="1">1.49</td><td rowspan="1" colspan="1">0.80&#8211;2.79</td><td rowspan="1" colspan="1">0.21</td></tr></tbody></table><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="&#x2013;" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Exposure Variable</th><th rowspan="1" colspan="1">Outcome Variable</th><th rowspan="1" colspan="1">b</th><th rowspan="1" colspan="1">95%CI</th><th rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Total EPVS</td><td rowspan="1" colspan="1">MBI Total Score</td><td rowspan="1" colspan="1">1.08</td><td rowspan="1" colspan="1">0.94&#8211;1.24</td><td rowspan="1" colspan="1">0.28</td></tr><tr><td rowspan="1" colspan="1">Basal Ganglia EPVS</td><td rowspan="1" colspan="1">MBI Total Score</td><td rowspan="1" colspan="1">1.06</td><td rowspan="1" colspan="1">0.79&#8211;1.41</td><td rowspan="1" colspan="1">0.71</td></tr><tr><td rowspan="1" colspan="1">Centrum Semiovale EPVS</td><td rowspan="1" colspan="1">MBI Total Score</td><td rowspan="1" colspan="1">1.13</td><td rowspan="1" colspan="1">0.89&#8211;1.44</td><td rowspan="1" colspan="1">0.31</td></tr><tr><td rowspan="1" colspan="1">Midbrain EPVS</td><td rowspan="1" colspan="1">MBI Total Score</td><td rowspan="1" colspan="1">1.30</td><td rowspan="1" colspan="1">0.81&#8211;2.08</td><td rowspan="1" colspan="1">0.28</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn2-13872877251372566"><p>For the associations between EPVS (total, basal ganglia, centrum semiovale, and midbrain) and MBI presence multivariable logistic regressions were used. For the associations between EPVS (total, basal ganglia, centrum semiovale, and midbrain) and MBI total score multivariable zero-inflated negative binomial models were used. Coefficients for MBI total score (b) are exponentiated to reflect the original scale (n&#8201;=&#8201;363). aOR: adjusted odds ratio; CI: confidence interval; EPVS: enlarged perivascular spaces; MBI: mild behavioral impairment.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section3D-13872877251372566"><title>The association between EPVS score and MBI symptom severity</title><p>As shown in <xref rid="table2-13872877251372566" ref-type="table">Table 2</xref> and <xref rid="fig3-13872877251372566" ref-type="fig">Figure 3</xref>, the total EPVS score was not associated with MBI-C total score (b&#8201;=&#8201;1.08, 95%CI:0.94&#8211;1.24, p&#8201;=&#8201;0.28). Additionally, none of the basal ganglia (b&#8201;=&#8201;1.06, 95%CI:0.79&#8211;1.41, p&#8201;=&#8201;0.71), centrum semiovale (b&#8201;=&#8201;1.13, 95%CI:0.89&#8211;1.44, p&#8201;=&#8201;0.31), or midbrain (b&#8201;=&#8201;1.30, 95%CI:0.81&#8211;2.08, p&#8201;=&#8201;0.28) EPVS scores were associated with MBI-C total score. The associations between total and subregion EPVS and MBI symptom severity were not dependent on sex, based on our moderation analyses (EPVS total*sex b&#8201;=&#8201;0.89, 95%CI:0.68&#8211;1.17, p&#8201;=&#8201;0.41; EPVS basal ganglia*sex b&#8201;=&#8201;0.70, 95%CI:0.41&#8211;1.21, p&#8201;=&#8201;0.21; EPVS centrum semiovale*sex b&#8201;=&#8201;0.88, 95%:0.55&#8211;1.42, p&#8201;=&#8201;0.60; EPVS midbrain*sex b&#8201;=&#8201;1.05, 95%CI:0.40&#8211;2.74, p&#8201;=&#8201;0.92).</p><fig position="float" id="fig3-13872877251372566" orientation="portrait"><label>Figure 3.</label><caption><p>Boxplot for the distribution of the EPVS score quartiles as a function of the total MBI-C score. Kruskal-Wallis test p-value represents differences between quartiles. EPVS: enlarged perivascular spaces; MBI-C: Mild Behavioral Impairment Checklist (n&#8201;=&#8201;363).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251372566-fig3.jpg"/></fig></sec></sec><sec sec-type="discussion" id="section4-13872877251372566"><title>Discussion</title><p>This study examined the cross-sectional associations between EPVS burden and MBI presence and severity to understand the relationship between these dementia risk markers. We found that participants with greater total and centrum semiovale EPVS burden had greater odds of having MBI.</p><p>Our exploration of the relationship between EPVS and MBI adds to the previous literature on the association of cerebrovascular pathology with neuropsychiatric symptoms. First, there is a link between NPS preceding dementia and vascular disease.<sup>
<xref rid="bibr58-13872877251372566" ref-type="bibr">58</xref>
</sup> For instance, the worsening of NPS is a clinical indicator of CSVD progression and progression in NPS and CSVD are associated with cognitive decline.<sup>
<xref rid="bibr59-13872877251372566" ref-type="bibr">59</xref>
</sup> Postmortem studies have found an overlap between the presence of NPS and cerebrovascular disease in non-dementia populations.<sup>
<xref rid="bibr37-13872877251372566" ref-type="bibr">37</xref>
</sup> Studies have also found that the number of vascular comorbidities, like arterial hypertension, diabetes, and dyslipidemia, were positively associated with MBI-C scores greater than 6.5.<sup>
<xref rid="bibr40-13872877251372566" ref-type="bibr">40</xref>
</sup> In memory clinic patients with MCI, patients with MBI had a 9.3% greater WMH volume.<sup>
<xref rid="bibr44-13872877251372566" ref-type="bibr">44</xref>
</sup> NPS are also common in CAA, where their severity is linked to white matter hyperintensity, suggesting white matter damage as a contributing factor.<sup>
<xref rid="bibr36-13872877251372566" ref-type="bibr">36</xref>
</sup> However, no previous studies, to our knowledge, investigate the relationship between EPVS and MBI.</p><p>There may be several mechanisms underlying this association between global EPVS burden and the presence of MBI. First, PVS are involved in several pathways that aid in clearing brain waste, like the perivascular,<sup>
<xref rid="bibr60-13872877251372566" ref-type="bibr">60</xref>
</sup> glymphatic,<sup>
<xref rid="bibr61-13872877251372566" ref-type="bibr">61</xref>
</sup> and intermural periarterial drainage pathways.<sup>
<xref rid="bibr62-13872877251372566" ref-type="bibr">62</xref>
</sup> Enlargement of PVS is a marker of dysfunction in these drainage pathways.<sup>
<xref rid="bibr63-13872877251372566" ref-type="bibr">63</xref>
</sup> Thus, impaired clearance, as indicated by EPVS, could lead to the accumulation of toxic metabolites such as A&#946;, increasing dementia risk. Given the association between MBI and A&#946;,<sup>
<xref rid="bibr26-13872877251372566" ref-type="bibr">26</xref>
</sup> MBI might be a clinical marker of poor A&#946; clearance. Additionally, EPVS are associated with neuroinflammation, possibly due to reduced clearance of pro-inflammatory cytokines and increased blood-brain barrier (BBB) permeability.<sup><xref rid="bibr64-13872877251372566" ref-type="bibr">64</xref>,<xref rid="bibr65-13872877251372566" ref-type="bibr">65</xref></sup> Dysfunctions of glymphatic clearance may exacerbate neuroinflammation by impairing the clearance of pro-inflammatory cytokines.<sup>
<xref rid="bibr66-13872877251372566" ref-type="bibr">66</xref>
</sup> Because the BBB is the internal boundary of the PVS,<sup>
<xref rid="bibr67-13872877251372566" ref-type="bibr">67</xref>
</sup> inflammation in the PVS can disrupt the BBB, leading to the infiltration of other immune cells and furthering neuroinflammation. NPS have also been shown to have associations with neuroinflammation and oxidative stress,<sup><xref rid="bibr68-13872877251372566" ref-type="bibr">68</xref><xref rid="bibr69-13872877251372566" ref-type="bibr"/><xref rid="bibr70-13872877251372566" ref-type="bibr"/>&#8211;<xref rid="bibr71-13872877251372566" ref-type="bibr">71</xref></sup> suggesting that EPVS and MBI may both be markers of neuroinflammation.</p><p>This study also found that the EPVS scores in the centrum semiovale were associated with MBI status. However, EPVS scores in basal ganglia and midbrain were neither associated with MBI presence nor its severity. This finding may relate to the fact that EPVS in different regions have different underlying etiologies. For instance, EPVS in the basal ganglia are associated with hypertensive angiopathy.<sup><xref rid="bibr72-13872877251372566" ref-type="bibr">72</xref><xref rid="bibr73-13872877251372566" ref-type="bibr"/>&#8211;<xref rid="bibr74-13872877251372566" ref-type="bibr">74</xref></sup> In contrast, EPVS in the centrum semiovale are associated with advanced age and cerebral amyloid angiopathy,<sup>
<xref rid="bibr75-13872877251372566" ref-type="bibr">75</xref>
</sup> which is frequently associated with AD,<sup><xref rid="bibr76-13872877251372566" ref-type="bibr">76</xref><xref rid="bibr77-13872877251372566" ref-type="bibr"/><xref rid="bibr78-13872877251372566" ref-type="bibr"/>&#8211;<xref rid="bibr79-13872877251372566" ref-type="bibr">79</xref></sup> and has shown associations with MBI.<sup>
<xref rid="bibr36-13872877251372566" ref-type="bibr">36</xref>
</sup> Thus, it is possible that MBI is more strongly associated with amyloid deposition, including vascular amyloid, than other vascular disease, as only centrum semiovale EPVS were significantly associated with MBI in this study.</p><p>On the other hand, EPVS score was not associated with the severity of MBI, as reflected by the MBI-C total score. Considering the fact that EPVS are one of the earliest markers of CSVD, preceding vascular pathologies like lacunes, cerebral microbleeds,<sup>
<xref rid="bibr63-13872877251372566" ref-type="bibr">63</xref>
</sup> and WMHs,<sup><xref rid="bibr11-13872877251372566" ref-type="bibr">11</xref>,<xref rid="bibr80-13872877251372566" ref-type="bibr">80</xref></sup> these early signs of EPVS alone may not be associated with severe MBI symptoms. However, this finding was unexpected, and future studies may seek to study the relationship of MBI symptom severity with more granular assessments of EPVS with emerging technology, such as automated quantification of EPVS numbers or of combining EPVS with other markers of CSVD. Additionally, it may be worth studying the relationship between EPVS and MBI symptom severity in populations with more severe CSVD burden.</p><p>This study is not without limitations. First, these are cross-sectional data, so no causal associations can be inferred. Future studies should investigate the longitudinal relationships between these markers to monitor changes in MBI over time as a function of EPVS severity. Second, the rating of EPVS severity is subject to human error and may not reflect the precise extent of vascular pathology in the participants. However, we used a rigorous system of training and testing of inter-rater reliability to ensure a high quality of our EPVS ratings. Lastly, cerebrospinal fluid (CSF) data were only available in a limited number of participants, and thus information about AD biomarkers such as amyloid-&#946; 42, phosphorylated tau, and total tau were not included in the models. Exploring AD biomarkers in the context of EPVS is another avenue for future studies.</p></sec><sec id="section5-13872877251372566"><title>Conclusion</title><p>This study explored the relationship between EPVS severity and MBI presence and severity. We hypothesized that a greater EPVS burden would be associated with greater odds of MBI presence and increased MBI symptom severity. We found that greater global and centrum semiovale EPVS burdens were associated with MBI presence; however, we found no associations between EPVS burden and MBI symptom severity or between basal ganglia and midbrain EPVS scores and MBI presence or severity. These findings suggest that EPVS may contribute to later-life emergent and persistent behavioral symptoms, consistent with known associations between EPVS and cognition, and merit further validation in longitudinal studies. Future studies should investigate MBI associations with other CSVD markers.</p></sec></body><back><ack><title>Acknowledgements</title><p>Eric E. Smith and Aravind Ganesh are members of Team 7 and Zahinoor Ismail is a member of Team 11, which are a part of the Canadian Consortium on Neurodegeneration in Aging (CCNA).</p></ack><fn-group><fn fn-type="other"><p><bold>Ethical considerations:</bold> The COMPASS-ND study was approved by the Jewish General Research Ethics Board.<sup>
<xref rid="bibr45-13872877251372566" ref-type="bibr">45</xref>
</sup> Data were collected with ethical approval by institutional review boards at each of the 13 study sites affiliated with the study, with written informed consent provided by participants.<sup>
<xref rid="bibr47-13872877251372566" ref-type="bibr">47</xref>
</sup></p></fn><fn fn-type="other"><p><bold>Consent to participate:</bold> All participants and their study partners provided written informed consent at the start of the COMPASS-ND study.</p></fn><fn fn-type="other"><p><bold>Consent for publication:</bold> Not applicable</p></fn><fn fn-type="other"><p><bold>Author contributions:</bold>
<bold>Dinithi Mudalige:</bold> Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Writing &#8211; original draft.</p><p><bold>Dylan Guan:</bold> Conceptualization; Methodology; Supervision; Writing &#8211; review &amp; editing.</p><p><bold>Graham McLeod:</bold> Data curation; Methodology; Writing &#8211; review &amp; editing.</p><p><bold>Eric Smith:</bold> Conceptualization; Writing &#8211; review &amp; editing.</p><p><bold>Aravind Ganesh:</bold> Conceptualization; Methodology; Supervision; Writing &#8211; review &amp; editing.</p><p><bold>Zahinoor Ismail:</bold> Conceptualization; Resources; Supervision; Writing &#8211; review &amp; editing.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Canadian Consortium on Neurodegeneration in Aging is supported by a grant from the Canadian Institutes of Health Research with funding from several partners. ZI is supported by CIHR (Grant BCA 527734) and the NIHR UK Exeter Biomedical Research Centre.</p></fn><fn fn-type="COI-statement"><p>The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: EES reported consulting (unpaid) for Alnylam Pharmaceuticals and Eli Lilly, and an advisory board (unpaid) for Eisai. ZI has served as an advisor/consultant to CADTH, EISAI, Lilly, Lundbeck/Otsuka, Novo Nordisk, and Roche. ZI is an Editorial Board Member of this journal but was not involved in the peer-review process of this article nor had access to any information regarding its peer-review. The remaining authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn><fn fn-type="other"><p><bold>Data availability statement:</bold> The data used in this study were obtained from CCNA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ccna-ccnv.ca" ext-link-type="uri">https://ccna-ccnv.ca</ext-link>). Data are available free of charge to bona fide researchers who submit a research proposal.</p></fn><fn fn-type="other"><p><bold>ORCID iDs:</bold> Dinithi Mudalige <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0009-0005-7691-5703" ext-link-type="uri">https://orcid.org/0009-0005-7691-5703</ext-link></p><p>Zahinoor Ismail <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-5529-3731" ext-link-type="uri">https://orcid.org/0000-0002-5529-3731</ext-link></p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-13872877251372566"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deckers</surname><given-names>K</given-names></name><name name-style="western"><surname>van Boxtel</surname><given-names>MP</given-names></name><name name-style="western"><surname>Schiepers</surname><given-names>OJ</given-names></name></person-group>, <etal>et al.</etal><article-title>Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies</article-title>. <source>Int J Geriatr Psychiatry</source><year>2015</year>; <volume>30</volume>: <fpage>234</fpage>&#8211;<lpage>246</lpage>.<pub-id pub-id-type="pmid">25504093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gps.4245</pub-id></mixed-citation></ref><ref id="bibr2-13872877251372566"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Power</surname><given-names>MC</given-names></name><name name-style="western"><surname>Mormino</surname><given-names>E</given-names></name><name name-style="western"><surname>Soldan</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Combined neuropathological pathways account for age-related risk of dementia</article-title>. <source>Ann Neurol</source><year>2018</year>; <volume>84</volume>: <fpage>10</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">29944741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.25246</pub-id><pub-id pub-id-type="pmcid">PMC6119518</pub-id></mixed-citation></ref><ref id="bibr3-13872877251372566"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyle</surname><given-names>PA</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Leurgans</surname><given-names>SE</given-names></name></person-group>, <etal>et al.</etal><article-title>Attributable risk of Alzheimer's dementia attributed to age-related neuropathologies</article-title>. <source>Ann Neurol</source><year>2019</year>; <volume>85</volume>: <fpage>114</fpage>&#8211;<lpage>124</lpage>.<pub-id pub-id-type="pmid">30421454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.25380</pub-id><pub-id pub-id-type="pmcid">PMC10128614</pub-id></mixed-citation></ref><ref id="bibr4-13872877251372566"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapasi</surname><given-names>A</given-names></name><name name-style="western"><surname>DeCarli</surname><given-names>C</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></name></person-group>. <article-title>Impact of multiple pathologies on the threshold for clinically overt dementia</article-title>. <source>Acta Neuropathol</source><year>2017</year>; <volume>134</volume>: <fpage>171</fpage>&#8211;<lpage>186</lpage>.<pub-id pub-id-type="pmid">28488154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-017-1717-7</pub-id><pub-id pub-id-type="pmcid">PMC5663642</pub-id></mixed-citation></ref><ref id="bibr5-13872877251372566"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chojdak-&#321;ukasiewicz</surname><given-names>J</given-names></name><name name-style="western"><surname>Dziadkowiak</surname><given-names>E</given-names></name><name name-style="western"><surname>Zimny</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Cerebral small vessel disease: a review</article-title>. <source>Adv Clin Exp Med</source><year>2021</year>; <volume>30</volume>: <fpage>349</fpage>&#8211;<lpage>356</lpage>.<pub-id pub-id-type="pmid">33768739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17219/acem/131216</pub-id></mixed-citation></ref><ref id="bibr6-13872877251372566"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akoudad</surname><given-names>S</given-names></name><name name-style="western"><surname>Wolters</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Viswanathan</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Association of cerebral microbleeds with cognitive decline and dementia</article-title>. <source>JAMA Neurol</source><year>2016</year>; <volume>73</volume>: <fpage>934</fpage>&#8211;<lpage>943</lpage>.<pub-id pub-id-type="pmid">27271785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2016.1017</pub-id><pub-id pub-id-type="pmcid">PMC5966721</pub-id></mixed-citation></ref><ref id="bibr7-13872877251372566"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jellinger</surname><given-names>KA</given-names></name><name name-style="western"><surname>Attems</surname><given-names>J</given-names></name></person-group>. <article-title>Neuropathology and general autopsy findings in nondemented aged subjects</article-title>. <source>Clin Neuropathol</source><year>2012</year>; <volume>31</volume>: <fpage>87</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">22385790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5414/np300418</pub-id></mixed-citation></ref><ref id="bibr8-13872877251372566"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name></person-group>. <article-title>Where vascular meets neurodegenerative disease</article-title>. <source>Stroke</source><year>2010</year>; <volume>41</volume>: <comment>S144</comment>&#8211;<lpage>S146</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.110.598326</pub-id><pub-id pub-id-type="pmcid">PMC2967303</pub-id><pub-id pub-id-type="pmid">20876491</pub-id></mixed-citation></ref><ref id="bibr9-13872877251372566"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>LR</given-names></name><name name-style="western"><surname>Edland</surname><given-names>SD</given-names></name><name name-style="western"><surname>Hemmy</surname><given-names>LS</given-names></name></person-group>, <etal>et al.</etal><article-title>Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia aging studies</article-title>. <source>Neurology</source><year>2016</year>; <volume>86</volume>: <fpage>1000</fpage>&#8211;<lpage>1008</lpage>.<pub-id pub-id-type="pmid">26888993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000002480</pub-id><pub-id pub-id-type="pmcid">PMC4799714</pub-id></mixed-citation></ref><ref id="bibr10-13872877251372566"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M</given-names></name><name name-style="western"><surname>Lu</surname><given-names>P</given-names></name></person-group>, <etal>et al.</etal><article-title>Cerebrolysin alleviates cognitive deficits induced by chronic cerebral hypoperfusion by increasing the levels of plasticity-related proteins and decreasing the levels of apoptosis-related proteins in the rat hippocampus</article-title>. <source>Neurosci Lett</source><year>2017</year>; <volume>651</volume>: <fpage>72</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">28458021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2017.04.022</pub-id></mixed-citation></ref><ref id="bibr11-13872877251372566"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duering</surname><given-names>M</given-names></name><name name-style="western"><surname>Biessels</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Brodtmann</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Neuroimaging standards for research into small vessel disease&#8212;advances since 2013</article-title>. <source>Lancet Neurol</source><year>2023</year>; <volume>22</volume>: <fpage>602</fpage>&#8211;<lpage>618</lpage>.<pub-id pub-id-type="pmid">37236211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(23)00131-X</pub-id></mixed-citation></ref><ref id="bibr12-13872877251372566"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wardlaw</surname><given-names>JM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>EE</given-names></name><name name-style="western"><surname>Biessels</surname><given-names>GJ</given-names></name></person-group>, <etal>et al.</etal><article-title>Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration</article-title>. <source>Lancet Neurol</source><year>2013</year>; <volume>12</volume>: <fpage>822</fpage>&#8211;<lpage>838</lpage>.<pub-id pub-id-type="pmid">23867200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(13)70124-8</pub-id><pub-id pub-id-type="pmcid">PMC3714437</pub-id></mixed-citation></ref><ref id="bibr13-13872877251372566"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Francis</surname><given-names>F</given-names></name><name name-style="western"><surname>Ballerini</surname><given-names>L</given-names></name><name name-style="western"><surname>Wardlaw</surname><given-names>JM</given-names></name></person-group>. <article-title>Perivascular spaces and their associations with risk factors, clinical disorders and neuroimaging features: a systematic review and meta-analysis</article-title>. <source>Int J Stroke</source><year>2019</year>; <volume>14</volume>: <fpage>359</fpage>&#8211;<lpage>371</lpage>.<pub-id pub-id-type="pmid">30762496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1747493019830321</pub-id></mixed-citation></ref><ref id="bibr14-13872877251372566"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Debette</surname><given-names>S</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>S</given-names></name><name name-style="western"><surname>Duperron</surname><given-names>M-G</given-names></name></person-group>, <etal>et al.</etal><article-title>Clinical significance of magnetic resonance imaging markers of vascular brain injury: a systematic review and meta-analysis</article-title>. <source>JAMA Neurol</source><year>2019</year>; <volume>76</volume>: <fpage>81</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">30422209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2018.3122</pub-id><pub-id pub-id-type="pmcid">PMC6439887</pub-id></mixed-citation></ref><ref id="bibr15-13872877251372566"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smeijer</surname><given-names>D</given-names></name><name name-style="western"><surname>Ikram</surname><given-names>MK</given-names></name><name name-style="western"><surname>Hilal</surname><given-names>S</given-names></name></person-group>. <article-title>Enlarged perivascular spaces and dementia: a systematic review</article-title>. <source>J Alzheimers Dis</source><year>2019</year>; <volume>72</volume>: <fpage>247</fpage>&#8211;<lpage>256</lpage>.<pub-id pub-id-type="pmid">31561362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-190527</pub-id><pub-id pub-id-type="pmcid">PMC6839481</pub-id></mixed-citation></ref><ref id="bibr16-13872877251372566"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jose</surname><given-names>RR</given-names></name><name name-style="western"><surname>Adlin</surname><given-names>P</given-names></name><name name-style="western"><surname>Hugo</surname><given-names>JA</given-names></name></person-group>, <etal>et al.</etal><article-title>MRI-visible perivascular spaces and risk of incident dementia</article-title>. <source>Neurology</source><year>2022</year>; <volume>99</volume>: <comment>e2561</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000201293</pub-id><pub-id pub-id-type="pmcid">PMC9754649</pub-id><pub-id pub-id-type="pmid">36175148</pub-id></mixed-citation></ref><ref id="bibr17-13872877251372566"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>Z</given-names></name><name name-style="western"><surname>Smith</surname><given-names>EE</given-names></name><name name-style="western"><surname>Geda</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment</article-title>. <source>Alzheimers Dement</source><year>2016</year>; <volume>12</volume>: <fpage>195</fpage>&#8211;<lpage>202</lpage>.<pub-id pub-id-type="pmid">26096665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2015.05.017</pub-id><pub-id pub-id-type="pmcid">PMC4684483</pub-id></mixed-citation></ref><ref id="bibr18-13872877251372566"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wise</surname><given-names>EA</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>PB</given-names></name><name name-style="western"><surname>Lyketsos</surname><given-names>CG</given-names></name></person-group>, <etal>et al.</etal><article-title>Time course of neuropsychiatric symptoms and cognitive diagnosis in national Alzheimer's coordinating centers volunteers</article-title>. <source>Alzheimers Dement (Amst)</source><year>2019</year>; <volume>11</volume>: <fpage>333</fpage>&#8211;<lpage>339</lpage>.<pub-id pub-id-type="pmid">31024987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dadm.2019.02.006</pub-id><pub-id pub-id-type="pmcid">PMC6476801</pub-id></mixed-citation></ref><ref id="bibr19-13872877251372566"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuoka</surname><given-names>T</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>Z</given-names></name><name name-style="western"><surname>Narumoto</surname><given-names>J</given-names></name></person-group>. <article-title>Prevalence of mild behavioral impairment and risk of dementia in a psychiatric outpatient clinic</article-title>. <source>J Alzheimers Dis</source><year>2019</year>; <volume>70</volume>: <fpage>505</fpage>&#8211;<lpage>513</lpage>.<pub-id pub-id-type="pmid">31177229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-190278</pub-id><pub-id pub-id-type="pmcid">PMC6700628</pub-id></mixed-citation></ref><ref id="bibr20-13872877251372566"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>Z</given-names></name><name name-style="western"><surname>McGirr</surname><given-names>A</given-names></name><name name-style="western"><surname>Gill</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Mild behavioral impairment and subjective cognitive decline predict cognitive and functional decline</article-title>. <source>J Alzheimers Dis</source><year>2021</year>; <volume>80</volume>: <fpage>459</fpage>&#8211;<lpage>469</lpage>.<pub-id pub-id-type="pmid">33554909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-201184</pub-id><pub-id pub-id-type="pmcid">PMC8075401</pub-id></mixed-citation></ref><ref id="bibr21-13872877251372566"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGirr</surname><given-names>A</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>S</given-names></name><name name-style="western"><surname>Ghahremani</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Progression to dementia or reversion to normal cognition in mild cognitive impairment as a function of late-onset neuropsychiatric symptoms</article-title>. <source>Neurology</source><year>2022</year>; <volume>98</volume>: <comment>e2132</comment>&#8211;<lpage>e2139</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000200256</pub-id><pub-id pub-id-type="pmcid">PMC9169943</pub-id><pub-id pub-id-type="pmid">35351783</pub-id></mixed-citation></ref><ref id="bibr22-13872877251372566"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghahremani</surname><given-names>M</given-names></name><name name-style="western"><surname>Smith</surname><given-names>EE</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>Z</given-names></name></person-group>. <article-title>Improving dementia prognostication in cognitively normal older adults: conventional versus novel approaches to modelling risk associated with neuropsychiatric symptoms</article-title>. <source>Br J Psychiatry</source><year>2025</year>; <volume>226</volume>: <fpage>129</fpage>&#8211;<lpage>136</lpage>.<pub-id pub-id-type="pmid">39679452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1192/bjp.2024.136</pub-id></mixed-citation></ref><ref id="bibr23-13872877251372566"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johansson</surname><given-names>M</given-names></name><name name-style="western"><surname>Stomrud</surname><given-names>E</given-names></name><name name-style="western"><surname>Insel</surname><given-names>PS</given-names></name></person-group>, <etal>et al.</etal><article-title>Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer&#8217;s disease</article-title>. <source>Transl Psychiatry</source><year>2021</year>; <volume>11</volume>: <fpage>76</fpage>.<pub-id pub-id-type="pmid">33500386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-021-01206-z</pub-id><pub-id pub-id-type="pmcid">PMC7838407</pub-id></mixed-citation></ref><ref id="bibr24-13872877251372566"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lussier</surname><given-names>FZ</given-names></name><name name-style="western"><surname>Pascoal</surname><given-names>TA</given-names></name><name name-style="western"><surname>Chamoun</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Mild behavioral impairment is associated with &#946;-amyloid but not tau or neurodegeneration in cognitively intact elderly individuals</article-title>. <source>Alzheimers Dement</source><year>2020</year>; <volume>16</volume>: <fpage>192</fpage>&#8211;<lpage>199</lpage>.<pub-id pub-id-type="pmid">31914223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12007</pub-id><pub-id pub-id-type="pmcid">PMC7041633</pub-id></mixed-citation></ref><ref id="bibr25-13872877251372566"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Creese</surname><given-names>B</given-names></name><name name-style="western"><surname>Arathimos</surname><given-names>R</given-names></name><name name-style="western"><surname>Brooker</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>Genetic risk for Alzheimer's disease, cognition, and mild behavioral impairment in healthy older adults</article-title>. <source>Alzheimers Dement (Amst)</source><year>2021</year>; <volume>13</volume>: <comment>e12164</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12164</pub-id><pub-id pub-id-type="pmcid">PMC7968121</pub-id><pub-id pub-id-type="pmid">33748395</pub-id></mixed-citation></ref><ref id="bibr26-13872877251372566"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>Z</given-names></name><name name-style="western"><surname>Leon</surname><given-names>R</given-names></name><name name-style="western"><surname>Creese</surname><given-names>B</given-names></name></person-group>, <etal>et al.</etal><article-title>Optimizing detection of Alzheimer&#8217;s disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO</article-title>. <source>Mol Neurodegener</source><year>2023</year>; <volume>18</volume>: <fpage>50</fpage>.<pub-id pub-id-type="pmid">37516848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-023-00631-6</pub-id><pub-id pub-id-type="pmcid">PMC10386685</pub-id></mixed-citation></ref><ref id="bibr27-13872877251372566"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>R</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H-Y</given-names></name><name name-style="western"><surname>Gill</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Plasma &#946;-amyloid in mild behavioural impairment &#8211; neuropsychiatric symptoms on the Alzheimer&#8217;s continuum</article-title>. <source>J Geriatr Psychiatry Neurol</source><year>2021</year>; <volume>35</volume>: <fpage>434</fpage>&#8211;<lpage>441</lpage>.<pub-id pub-id-type="pmid">34036829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/08919887211016068</pub-id></mixed-citation></ref><ref id="bibr28-13872877251372566"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghahremani</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>HY</given-names></name></person-group>, <etal>et al.</etal><article-title>Plasma phosphorylated tau at threonine 181 and neuropsychiatric symptoms in preclinical and prodromal Alzheimer disease</article-title>. <source>Neurology</source><year>2023</year>; <volume>100</volume>: <comment>e683</comment>&#8211;<lpage>e693</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000201517</pub-id><pub-id pub-id-type="pmcid">PMC9969916</pub-id><pub-id pub-id-type="pmid">36323521</pub-id></mixed-citation></ref><ref id="bibr29-13872877251372566"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naude</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Leon</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Tau-PET in early cortical Alzheimer brain regions in relation to mild behavioral impairment in older adults with either normal cognition or mild cognitive impairment</article-title>. <source>Neurobiol Aging</source><year>2024</year>; <volume>138</volume>: <fpage>19</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">38490074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2024.02.006</pub-id></mixed-citation></ref><ref id="bibr30-13872877251372566"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuoka</surname><given-names>T</given-names></name><name name-style="western"><surname>Imai</surname><given-names>A</given-names></name><name name-style="western"><surname>Narumoto</surname><given-names>J</given-names></name></person-group>. <article-title>Neuroimaging of mild behavioral impairment: a systematic review</article-title>. <source>PCN Rep</source><year>2023</year>; <volume>2</volume>: <comment>e81</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pcn5.81</pub-id><pub-id pub-id-type="pmcid">PMC11114318</pub-id><pub-id pub-id-type="pmid">38868411</pub-id></mixed-citation></ref><ref id="bibr31-13872877251372566"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>DX</given-names></name><name name-style="western"><surname>Rehman</surname><given-names>T</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Neuropsychiatric symptoms: risk factor or disease marker? A study of structural imaging biomarkers of Alzheimer's disease and incident cognitive decline</article-title>. <source>Hum Brain Mapp</source><year>2024</year>; <volume>45</volume>: <comment>e70016</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.70016</pub-id><pub-id pub-id-type="pmcid">PMC11386326</pub-id><pub-id pub-id-type="pmid">39254167</pub-id></mixed-citation></ref><ref id="bibr32-13872877251372566"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharif</surname><given-names>SF</given-names></name><name name-style="western"><surname>Guan</surname><given-names>DX</given-names></name><name name-style="western"><surname>Bodnar</surname><given-names>T</given-names></name></person-group>, <etal>et al.</etal><article-title>Neuropsychiatric symptoms and progression to pathologically confirmed Alzheimer's disease</article-title>. <source>Brain</source><year>2025</year>: <fpage>1</fpage>&#8211;<lpage>15</lpage>. <comment>Epub ahead of print 25 April 2025</comment>. DOI: <pub-id pub-id-type="doi">10.1093/brain/awaf156</pub-id>.<pub-id pub-id-type="pmid">40279515</pub-id><pub-id pub-id-type="pmcid">PMC12493056</pub-id></mixed-citation></ref><ref id="bibr33-13872877251372566"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghahremani</surname><given-names>M</given-names></name><name name-style="western"><surname>Leon</surname><given-names>R</given-names></name><name name-style="western"><surname>Smith</surname><given-names>EE</given-names></name></person-group>, <etal>et al.</etal><article-title>Exploring the association between mild behavioral impairment and plasma p-tau217: implications for early detection of Alzheimer's disease</article-title>. <source>Alzheimers Dement (Amst)</source><year>2025</year>; <volume>17</volume>: <comment>e70119</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.70119</pub-id><pub-id pub-id-type="pmcid">PMC12094880</pub-id><pub-id pub-id-type="pmid">40406748</pub-id></mixed-citation></ref><ref id="bibr34-13872877251372566"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuoka</surname><given-names>T</given-names></name><name name-style="western"><surname>Narumoto</surname><given-names>J</given-names></name><name name-style="western"><surname>Morii-Kitani</surname><given-names>F</given-names></name></person-group>, <etal>et al.</etal><article-title>Contribution of amyloid and putative Lewy body pathologies in neuropsychiatric symptoms</article-title>. <source>Int J Geriatr Psychiatry</source><year>2023</year>; <volume>38</volume>: <comment>e5993</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gps.5993</pub-id><pub-id pub-id-type="pmid">37655505</pub-id></mixed-citation></ref><ref id="bibr35-13872877251372566"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orso</surname><given-names>B</given-names></name><name name-style="western"><surname>Mattei</surname><given-names>C</given-names></name><name name-style="western"><surname>Arnaldi</surname><given-names>D</given-names></name></person-group>, <etal>et al.</etal><article-title>Clinical and MRI predictors of conversion from mild behavioural impairment to dementia</article-title>. <source>Am J Geriatr Psychiatry</source><year>2020</year>; <volume>28</volume>: <fpage>755</fpage>&#8211;<lpage>763</lpage>.<pub-id pub-id-type="pmid">31928846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jagp.2019.12.007</pub-id></mixed-citation></ref><ref id="bibr36-13872877251372566"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>EE</given-names></name><name name-style="western"><surname>Crites</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Cerebral amyloid angiopathy is associated with emotional dysregulation, impulse dyscontrol, and apathy</article-title>. <source>J Am Heart Assoc</source><year>2021</year>; <volume>10</volume>: <comment>e022089</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.121.022089</pub-id><pub-id pub-id-type="pmcid">PMC8751932</pub-id><pub-id pub-id-type="pmid">34755541</pub-id></mixed-citation></ref><ref id="bibr37-13872877251372566"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>QL</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>Association of cerebral small vessel disease burden with neuropsychiatric symptoms in non-demented elderly: a longitudinal study</article-title>. <source>J Alzheimers Dis</source><year>2022</year>; <volume>89</volume>: <fpage>583</fpage>&#8211;<lpage>592</lpage>.<pub-id pub-id-type="pmid">35912738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-220128</pub-id></mixed-citation></ref><ref id="bibr38-13872877251372566"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhar</surname><given-names>AK</given-names></name><name name-style="western"><surname>Barton</surname><given-names>DA</given-names></name></person-group>. <article-title>Depression and the link with cardiovascular disease</article-title>. <source>Front Psychiatry</source><year>2016</year>; <volume>7</volume>: <fpage>33</fpage>.<pub-id pub-id-type="pmid">27047396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2016.00033</pub-id><pub-id pub-id-type="pmcid">PMC4800172</pub-id></mixed-citation></ref><ref id="bibr39-13872877251372566"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eurelings</surname><given-names>LS</given-names></name><name name-style="western"><surname>Jaccard</surname><given-names>J</given-names></name><name name-style="western"><surname>Moll van Charante</surname><given-names>EP</given-names></name></person-group>, <etal>et al.</etal><article-title>The mediating role of cardiovascular risk factors in the relationship between symptoms of apathy and incident cardiovascular disease in community-dwelling older individuals</article-title>. <source>Int Psychogeriatr</source><year>2016</year>; <volume>28</volume>: <fpage>669</fpage>&#8211;<lpage>679</lpage>.<pub-id pub-id-type="pmid">26542880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610215001751</pub-id></mixed-citation></ref><ref id="bibr40-13872877251372566"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stella</surname><given-names>F</given-names></name><name name-style="western"><surname>Pais</surname><given-names>MV</given-names></name><name name-style="western"><surname>Loureiro</surname><given-names>JC</given-names></name></person-group>, <etal>et al.</etal><article-title>Neuropsychiatric symptoms and cerebrovascular risk in non-demented elders: cross-sectional study using the mild behavioural impairment checklist (MBI-C)</article-title>. <source>Psychogeriatrics</source><year>2022</year>; <volume>22</volume>: <fpage>55</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="pmid">34704636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/psyg.12776</pub-id></mixed-citation></ref><ref id="bibr41-13872877251372566"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>DX</given-names></name><name name-style="western"><surname>Aundhakar</surname><given-names>A</given-names></name><name name-style="western"><surname>Tomaszewski Farias</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Vascular risk factor associations with subjective cognitive decline and mild behavioural impairment</article-title>. <source>Brain Commun</source><year>2025</year>; <volume>7</volume>: <comment>fcaf163</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcaf163</pub-id><pub-id pub-id-type="pmcid">PMC12077299</pub-id><pub-id pub-id-type="pmid">40370691</pub-id></mixed-citation></ref><ref id="bibr42-13872877251372566"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soo</surname><given-names>SA</given-names></name><name name-style="western"><surname>Ng</surname><given-names>KP</given-names></name><name name-style="western"><surname>Wong</surname><given-names>F</given-names></name></person-group>, <etal>et al.</etal><article-title>The association between diabetes mellitus and mild behavioral impairment among mild cognitive impairment: findings from Singapore</article-title>. <source>J Alzheimers Dis</source><year>2021</year>; <volume>82</volume>: <fpage>411</fpage>&#8211;<lpage>420</lpage>.<pub-id pub-id-type="pmid">34024829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-210037</pub-id></mixed-citation></ref><ref id="bibr43-13872877251372566"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trolli</surname><given-names>F</given-names></name><name name-style="western"><surname>Cipollini</surname><given-names>V</given-names></name><name name-style="western"><surname>Moci</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Perivascular unit: this must be the place. The anatomical crossroad between the immune, vascular and nervous system</article-title>. <source>Front Neuroanat</source><year>2020</year>; <volume>14</volume>: <fpage>17</fpage>.<pub-id pub-id-type="pmid">32372921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnana.2020.00017</pub-id><pub-id pub-id-type="pmcid">PMC7177187</pub-id></mixed-citation></ref><ref id="bibr44-13872877251372566"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>R</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H-Y</given-names></name><name name-style="western"><surname>Robert</surname><given-names>P</given-names></name></person-group>, <etal>et al.</etal><article-title>White matter hyperintensities and mild behavioral impairment: findings from the MEMENTO cohort study</article-title>. <source>Cereb Circ Cogn Behav</source><year>2021</year>; <volume>2</volume>: <fpage>100028</fpage>.<pub-id pub-id-type="pmid">36324720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cccb.2021.100028</pub-id><pub-id pub-id-type="pmcid">PMC9616384</pub-id></mixed-citation></ref><ref id="bibr45-13872877251372566"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chertkow</surname><given-names>H</given-names></name><name name-style="western"><surname>Borrie</surname><given-names>M</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>V</given-names></name></person-group>, <etal>et al.</etal><article-title>The comprehensive assessment of neurodegeneration and dementia: Canadian cohort study</article-title>. <source>Can J Neurol Sci</source><year>2019</year>; <volume>46</volume>: <fpage>499</fpage>&#8211;<lpage>511</lpage>.<pub-id pub-id-type="pmid">31309917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/cjn.2019.27</pub-id></mixed-citation></ref><ref id="bibr46-13872877251372566"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohaddes</surname><given-names>Z</given-names></name><name name-style="western"><surname>Das</surname><given-names>S</given-names></name><name name-style="western"><surname>Abou-Haidar</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>National neuroinformatics framework for Canadian consortium on neurodegeneration in aging (CCNA)</article-title>. <source>Front Neuroinform</source><year>2018</year>; <volume>12</volume>: <fpage>85</fpage>.<pub-id pub-id-type="pmid">30622468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fninf.2018.00085</pub-id><pub-id pub-id-type="pmcid">PMC6308193</pub-id></mixed-citation></ref><ref id="bibr47-13872877251372566"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>EE</given-names></name><name name-style="western"><surname>Duchesne</surname><given-names>S</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F</given-names></name></person-group>, <etal>et al.</etal><article-title>Vascular contributions to neurodegeneration: protocol of the COMPASS-ND study</article-title>. <source>Can J Neurol Sci</source><year>2021</year>; <volume>48</volume>: <fpage>799</fpage>&#8211;<lpage>806</lpage>.<pub-id pub-id-type="pmid">33504400</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/cjn.2021.19</pub-id></mixed-citation></ref><ref id="bibr48-13872877251372566"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ag&#252;era-Ortiz</surname><given-names>L</given-names></name><name name-style="western"><surname>Brodaty</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>The mild behavioral impairment checklist (MBI-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations</article-title>. <source>J Alzheimers Dis</source><year>2017</year>; <volume>56</volume>: <fpage>929</fpage>&#8211;<lpage>938</lpage>.<pub-id pub-id-type="pmid">28059789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-160979</pub-id><pub-id pub-id-type="pmcid">PMC5652315</pub-id></mixed-citation></ref><ref id="bibr49-13872877251372566"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>S</given-names></name><name name-style="western"><surname>Patten</surname><given-names>S</given-names></name><name name-style="western"><surname>Charlton</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Validating the mild behavioral impairment checklist in a cognitive clinic: comparisons with the neuropsychiatric inventory questionnaire</article-title>. <source>J Geriatr Psychiatry Neurol</source><year>2023</year>; <volume>36</volume>: <fpage>107</fpage>&#8211;<lpage>120</lpage>.<pub-id pub-id-type="pmid">35430902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/08919887221093353</pub-id><pub-id pub-id-type="pmcid">PMC9941652</pub-id></mixed-citation></ref><ref id="bibr50-13872877251372566"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duchesne</surname><given-names>S</given-names></name><name name-style="western"><surname>Chouinard</surname><given-names>I</given-names></name><name name-style="western"><surname>Potvin</surname><given-names>O</given-names></name></person-group>, <etal>et al.</etal><article-title>The Canadian dementia imaging protocol: harmonizing national cohorts</article-title>. <source>J Magn Reson Imaging</source><year>2019</year>; <volume>49</volume>: <fpage>456</fpage>&#8211;<lpage>465</lpage>.<pub-id pub-id-type="pmid">30635988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmri.26197</pub-id></mixed-citation></ref><ref id="bibr51-13872877251372566"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>E</given-names></name><name name-style="western"><surname>Duchesne</surname><given-names>S</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F</given-names></name></person-group>, <etal>et al.</etal><article-title>Vascular contributions to neurodegeneration: protocol of the COMPASS-ND study</article-title>. <source>Can J Neurol Sci</source><year>2021</year>; <volume>48</volume>: <fpage>799</fpage>&#8211;<lpage>806</lpage>.<pub-id pub-id-type="pmid">33504400</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/cjn.2021.19</pub-id></mixed-citation></ref><ref id="bibr52-13872877251372566"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barisano</surname><given-names>G</given-names></name><name name-style="western"><surname>Law</surname><given-names>M</given-names></name><name name-style="western"><surname>Custer</surname><given-names>RM</given-names></name></person-group>, <etal>et al.</etal><article-title>Perivascular space imaging at ultrahigh field MR imaging</article-title>. <source>Magn Reson Imaging Clin N Am</source><year>2021</year>; <volume>29</volume>: <fpage>67</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">33237016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mric.2020.09.005</pub-id><pub-id pub-id-type="pmcid">PMC7694884</pub-id></mixed-citation></ref><ref id="bibr53-13872877251372566"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Potter</surname><given-names>GM</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>FM</given-names></name><name name-style="western"><surname>Morris</surname><given-names>Z</given-names></name></person-group>, <etal>et al.</etal><article-title>Cerebral perivascular spaces visible on magnetic resonance imaging: development of a qualitative rating scale and its observer reliability</article-title>. <source>Cerebrovasc Dis</source><year>2015</year>; <volume>39</volume>: <fpage>224</fpage>&#8211;<lpage>231</lpage>.<pub-id pub-id-type="pmid">25823458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000375153</pub-id><pub-id pub-id-type="pmcid">PMC4386144</pub-id></mixed-citation></ref><ref id="bibr54-13872877251372566"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gwet</surname><given-names>KL</given-names></name></person-group>. <article-title>Computing inter-rater reliability and its variance in the presence of high agreement</article-title>. <source>Br J Math Stat Psychol</source><year>2008</year>; <volume>61</volume>: <fpage>29</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="pmid">18482474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1348/000711006X126600</pub-id></mixed-citation></ref><ref id="bibr55-13872877251372566"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kassam</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Nosheny</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Cognitive profile of people with mild behavioral impairment in brain health registry participants</article-title>. <source>Int Psychogeriatr</source><year>2023</year>; <volume>35</volume>: <fpage>643</fpage>&#8211;<lpage>652</lpage>.<pub-id pub-id-type="pmid">35130991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610221002878</pub-id><pub-id pub-id-type="pmcid">PMC10063171</pub-id></mixed-citation></ref><ref id="bibr56-13872877251372566"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghahremani</surname><given-names>M</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>S</given-names></name><name name-style="western"><surname>Smith</surname><given-names>EE</given-names></name></person-group>, <etal>et al.</etal><article-title>Functional connectivity and mild behavioral impairment in dementia-free elderly</article-title>. <source>Alzheimers Dement (N Y)</source><year>2023</year>; <volume>9</volume>: <comment>e12371</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/trc2.12371</pub-id><pub-id pub-id-type="pmcid">PMC9847513</pub-id><pub-id pub-id-type="pmid">36698771</pub-id></mixed-citation></ref><ref id="bibr57-13872877251372566"><label>57</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>R Core Team</collab></person-group>. <source>R: A Language and Environment for Statistical Computing</source>. <publisher-loc>Austria</publisher-loc>: <publisher-name>R Foundation for Statistical Computing</publisher-name>, <year>2022</year>.</mixed-citation></ref><ref id="bibr58-13872877251372566"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clancy</surname><given-names>U</given-names></name><name name-style="western"><surname>Gilmartin</surname><given-names>D</given-names></name><name name-style="western"><surname>Jochems</surname><given-names>AC</given-names></name></person-group>, <etal>et al.</etal><article-title>Neuropsychiatric symptoms associated with cerebral small vessel disease: a systematic review and meta-analysis</article-title>. <source>Lancet Psychiatry</source><year>2021</year>; <volume>8</volume>: <fpage>225</fpage>&#8211;<lpage>236</lpage>.<pub-id pub-id-type="pmid">33539776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(20)30431-4</pub-id></mixed-citation></ref><ref id="bibr59-13872877251372566"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kan</surname><given-names>CN</given-names></name><name name-style="western"><surname>Gyanwali</surname><given-names>B</given-names></name><name name-style="western"><surname>Hilal</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Neuropsychiatric correlates of small vessel disease progression in incident cognitive decline: independent and interactive effects</article-title>. <source>J Alzheimers Dis</source><year>2020</year>; <volume>73</volume>: <fpage>1053</fpage>&#8211;<lpage>1062</lpage>.<pub-id pub-id-type="pmid">31884482</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-190999</pub-id></mixed-citation></ref><ref id="bibr60-13872877251372566"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rennels</surname><given-names>ML</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>TF</given-names></name><name name-style="western"><surname>Blaumanis</surname><given-names>OR</given-names></name></person-group>, <etal>et al.</etal><article-title>Evidence for a &#8216;paravascular&#8217; fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space</article-title>. <source>Brain Res</source><year>1985</year>; <volume>326</volume>: <fpage>47</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">3971148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-8993(85)91383-6</pub-id></mixed-citation></ref><ref id="bibr61-13872877251372566"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iliff</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid &#946;</article-title>. <source>Sci Transl Med</source><year>2012</year>; <volume>4</volume>: <fpage>147ra111</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3003748</pub-id><pub-id pub-id-type="pmcid">PMC3551275</pub-id><pub-id pub-id-type="pmid">22896675</pub-id></mixed-citation></ref><ref id="bibr62-13872877251372566"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diem</surname><given-names>AK</given-names></name><name name-style="western"><surname>MacGregor Sharp</surname><given-names>M</given-names></name><name name-style="western"><surname>Gatherer</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Arterial pulsations cannot drive intramural periarterial drainage: significance for A&#946; drainage</article-title>. <source>Front Neurosci</source><year>2017</year>; <volume>11</volume>: <fpage>274820</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2017.00475</pub-id><pub-id pub-id-type="pmcid">PMC5574214</pub-id><pub-id pub-id-type="pmid">28883786</pub-id></mixed-citation></ref><ref id="bibr63-13872877251372566"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wardlaw</surname><given-names>JM</given-names></name><name name-style="western"><surname>Benveniste</surname><given-names>H</given-names></name><name name-style="western"><surname>Nedergaard</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Perivascular spaces in the brain: anatomy, physiology and pathology</article-title>. <source>Nat Rev Neurol</source><year>2020</year>; <volume>16</volume>: <fpage>137</fpage>&#8211;<lpage>153</lpage>.<pub-id pub-id-type="pmid">32094487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-020-0312-z</pub-id></mixed-citation></ref><ref id="bibr64-13872877251372566"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ineichen</surname><given-names>BV</given-names></name><name name-style="western"><surname>Okar</surname><given-names>SV</given-names></name><name name-style="western"><surname>Proulx</surname><given-names>ST</given-names></name></person-group>, <etal>et al.</etal><article-title>Perivascular spaces and their role in neuroinflammation</article-title>. <source>Neuron</source><year>2022</year>; <volume>110</volume>: <fpage>3566</fpage>&#8211;<lpage>3581</lpage>.<pub-id pub-id-type="pmid">36327898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2022.10.024</pub-id><pub-id pub-id-type="pmcid">PMC9905791</pub-id></mixed-citation></ref><ref id="bibr65-13872877251372566"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>XY</given-names></name><name name-style="western"><surname>Gao</surname><given-names>MC</given-names></name><name name-style="western"><surname>Bai</surname><given-names>SW</given-names></name></person-group>, <etal>et al.</etal><article-title>Enlarged perivascular spaces, neuroinflammation and neurological dysfunction in NMOSD patients</article-title>. <source>Front Immunol</source><year>2022</year>; <volume>13</volume>: <fpage>966781</fpage>.<pub-id pub-id-type="pmid">36248814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.966781</pub-id><pub-id pub-id-type="pmcid">PMC9557144</pub-id></mixed-citation></ref><ref id="bibr66-13872877251372566"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filiano</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Gadani</surname><given-names>SP</given-names></name><name name-style="western"><surname>Kipnis</surname><given-names>J</given-names></name></person-group>. <article-title>How and why do T cells and their derived cytokines affect the injured and healthy brain?</article-title><source>Nat Rev Neurosci</source><year>2017</year>; <volume>18</volume>: <fpage>375</fpage>&#8211;<lpage>384</lpage>.<pub-id pub-id-type="pmid">28446786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn.2017.39</pub-id><pub-id pub-id-type="pmcid">PMC5823005</pub-id></mixed-citation></ref><ref id="bibr67-13872877251372566"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gouveia-Freitas</surname><given-names>K</given-names></name><name name-style="western"><surname>Bastos-Leite</surname><given-names>AJ</given-names></name></person-group>. <article-title>Perivascular spaces and brain waste clearance systems: relevance for neurodegenerative and cerebrovascular pathology</article-title>. <source>Neuroradiology</source><year>2021</year>; <volume>63</volume>: <fpage>1581</fpage>&#8211;<lpage>1597</lpage>.<pub-id pub-id-type="pmid">34019111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00234-021-02718-7</pub-id><pub-id pub-id-type="pmcid">PMC8460534</pub-id></mixed-citation></ref><ref id="bibr68-13872877251372566"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esch</surname><given-names>T</given-names></name><name name-style="western"><surname>Stefano</surname><given-names>G</given-names></name></person-group>. <article-title>Proinflammation: a common denominator or initiator of different pathophysiological disease processes</article-title>. <source>Signature</source><year>2002</year>; <volume>8</volume>: <fpage>9</fpage>.<pub-id pub-id-type="pmid">12011758</pub-id></mixed-citation></ref><ref id="bibr69-13872877251372566"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esch</surname><given-names>T</given-names></name><name name-style="western"><surname>Stefano</surname><given-names>GB</given-names></name><name name-style="western"><surname>Fricchione</surname><given-names>GL</given-names></name></person-group>, <etal>et al.</etal><article-title>The role of stress in neurodegenerative diseases and mental disorders</article-title>. <source>Neuro Endocrinol Lett</source><year>2002</year>; <volume>23</volume>: <fpage>199</fpage>&#8211;<lpage>208</lpage>.<pub-id pub-id-type="pmid">12080279</pub-id></mixed-citation></ref><ref id="bibr70-13872877251372566"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#252;ttiker</surname><given-names>P</given-names></name><name name-style="western"><surname>Weissenberger</surname><given-names>S</given-names></name><name name-style="western"><surname>Esch</surname><given-names>T</given-names></name></person-group>, <etal>et al.</etal><article-title>Dysfunctional mitochondrial processes contribute to energy perturbations in the brain and neuropsychiatric symptoms</article-title>. <source>Front Pharmacol</source><year>2023</year>; <volume>13</volume>: <fpage>1095923</fpage>.<pub-id pub-id-type="pmid">36686690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.1095923</pub-id><pub-id pub-id-type="pmcid">PMC9849387</pub-id></mixed-citation></ref><ref id="bibr71-13872877251372566"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>C</given-names></name><name name-style="western"><surname>Richiardi</surname><given-names>J</given-names></name><name name-style="western"><surname>Mar&#233;chal</surname><given-names>B</given-names></name></person-group>, <etal>et al.</etal><article-title>Systemic and central nervous system neuroinflammatory signatures of neuropsychiatric symptoms and related cognitive decline in older people</article-title>. <source>J Neuroinflammation</source><year>2022</year>; <volume>19</volume>: <fpage>127</fpage>.<pub-id pub-id-type="pmid">35643540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-022-02473-3</pub-id><pub-id pub-id-type="pmcid">PMC9148517</pub-id></mixed-citation></ref><ref id="bibr72-13872877251372566"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>TP</given-names></name><name name-style="western"><surname>Cain</surname><given-names>J</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>O</given-names></name></person-group>, <etal>et al.</etal><article-title>Dilated perivascular spaces in the Basal Ganglia are a biomarker of small-vessel disease in a very elderly population with dementia</article-title>. <source>AJNR Am J Neuroradiol</source><year>2015</year>; <volume>36</volume>: <fpage>893</fpage>&#8211;<lpage>898</lpage>.<pub-id pub-id-type="pmid">25698626</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3174/ajnr.A4237</pub-id><pub-id pub-id-type="pmcid">PMC7990588</pub-id></mixed-citation></ref><ref id="bibr73-13872877251372566"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhuo</surname><given-names>W</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>The correlation between enlarged perivascular spaces and cognitive impairment in Parkinson&#8217;s disease and vascular parkinsonism</article-title>. <source>BMC Neurol</source><year>2022</year>; <volume>22</volume>: <fpage>282</fpage>.<pub-id pub-id-type="pmid">35906550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12883-022-02819-7</pub-id><pub-id pub-id-type="pmcid">PMC9336003</pub-id></mixed-citation></ref><ref id="bibr74-13872877251372566"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamasaki</surname><given-names>T</given-names></name><name name-style="western"><surname>Ikawa</surname><given-names>F</given-names></name><name name-style="western"><surname>Ichihara</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>Factors associated with the location of perivascular space enlargement in middle-aged individuals undergoing brain screening in Japan</article-title>. <source>Clin Neurol Neurosurg</source><year>2022</year>; <volume>223</volume>: <fpage>107497</fpage>.<pub-id pub-id-type="pmid">36356441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clineuro.2022.107497</pub-id></mixed-citation></ref><ref id="bibr75-13872877251372566"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charidimou</surname><given-names>A</given-names></name><name name-style="western"><surname>Meegahage</surname><given-names>R</given-names></name><name name-style="western"><surname>Fox</surname><given-names>Z</given-names></name></person-group>, <etal>et al.</etal><article-title>Enlarged perivascular spaces as a marker of underlying arteriopathy in intracerebral haemorrhage: a multicentre MRI cohort study</article-title>. <source>J Neurol Neurosurg Psychiatry</source><year>2013</year>; <volume>84</volume>: <fpage>624</fpage>&#8211;<lpage>629</lpage>.<pub-id pub-id-type="pmid">23412074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2012-304434</pub-id><pub-id pub-id-type="pmcid">PMC3905629</pub-id></mixed-citation></ref><ref id="bibr76-13872877251372566"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charidimou</surname><given-names>A</given-names></name><name name-style="western"><surname>Hong</surname><given-names>YT</given-names></name><name name-style="western"><surname>J&#228;ger</surname><given-names>HR</given-names></name></person-group>, <etal>et al.</etal><article-title>White matter perivascular spaces on magnetic resonance imaging</article-title>. <source>Stroke</source><year>2015</year>; <volume>46</volume>: <fpage>1707</fpage>&#8211;<lpage>1709</lpage>.<pub-id pub-id-type="pmid">25908461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.115.009090</pub-id></mixed-citation></ref><ref id="bibr77-13872877251372566"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charidimou</surname><given-names>A</given-names></name><name name-style="western"><surname>Boulouis</surname><given-names>G</given-names></name><name name-style="western"><surname>Pasi</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>MRI-visible perivascular spaces in cerebral amyloid angiopathy and hypertensive arteriopathy</article-title>. <source>Neurology</source><year>2017</year>; <volume>88</volume>: <fpage>1157</fpage>&#8211;<lpage>1164</lpage>.<pub-id pub-id-type="pmid">28228568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000003746</pub-id><pub-id pub-id-type="pmcid">PMC5373782</pub-id></mixed-citation></ref><ref id="bibr78-13872877251372566"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>G</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Fox</surname><given-names>Z</given-names></name></person-group>, <etal>et al.</etal><article-title>MRI-visible perivascular space location is associated with Alzheimer's disease independently of amyloid burden</article-title>. <source>Brain</source><year>2017</year>; <volume>140</volume>: <fpage>1107</fpage>&#8211;<lpage>1116</lpage>.<pub-id pub-id-type="pmid">28335021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awx003</pub-id></mixed-citation></ref><ref id="bibr79-13872877251372566"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>SH</given-names></name><name name-style="western"><surname>Cha</surname><given-names>J</given-names></name><name name-style="western"><surname>Park</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Association of enlarged perivascular spaces with amyloid burden and cognitive decline in Alzheimer disease continuum</article-title>. <source>Neurology</source><year>2022</year>; <volume>99</volume>: <comment>e1791</comment>&#8211;<lpage>e1802</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000200989</pub-id><pub-id pub-id-type="pmid">35985826</pub-id></mixed-citation></ref><ref id="bibr80-13872877251372566"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>A</given-names></name><name name-style="western"><surname>Ballerini</surname><given-names>L</given-names></name><name name-style="western"><surname>Vald&#233;s Hern&#225;ndez</surname><given-names>MdC</given-names></name></person-group>, <etal>et al.</etal><article-title>Topological relationships between perivascular spaces and progression of white matter hyperintensities: a pilot study in a sample of the lothian birth cohort 1936</article-title>. <source>Front Neurol</source><year>2022</year>; <volume>13</volume>: <fpage>889884</fpage>.<pub-id pub-id-type="pmid">36090857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2022.889884</pub-id><pub-id pub-id-type="pmcid">PMC9449650</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="pmc-domain-id">2786</journal-id><journal-id journal-id-type="pmc-domain">medicine</journal-id><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12499664</article-id><article-id pub-id-type="pmcid-ver">PMC12499664.1</article-id><article-id pub-id-type="pmcaid">12499664</article-id><article-id pub-id-type="pmcaiid">12499664</article-id><article-id pub-id-type="pmid">41054159</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000044785</article-id><article-id pub-id-type="publisher-id">MD-D-25-05204</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>3900</subject></subj-group><subj-group><subject>Research Article</subject><subject>Observational Study</subject></subj-group></article-categories><title-group><article-title>Association of blood nardilysin and neurogranin levels with early outcomes in transient ischemic attack: A prospective cohort study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5879-7858</contrib-id><name name-style="western"><surname>Orun</surname><given-names initials="S">Serhat</given-names></name><degrees>MD</degrees><email>serhatorun@gmail.com</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="c1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0299-1691</contrib-id><name name-style="western"><surname>Guru</surname><given-names initials="S">Selahattin</given-names></name><degrees>MD</degrees><email>selahattinguru@gmail.com</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8147-5379</contrib-id><name name-style="western"><surname>Firat Oguz</surname><given-names initials="E">Esra</given-names></name><degrees>MD</degrees><email>dr_esrafirat@hotmail.com</email><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9261-2669</contrib-id><name name-style="western"><surname>Ozensoy</surname><given-names initials="HS">Habibe Selmin</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><aff id="aff1"><label>a</label>Department of Emergency Medicine, Tekirda&#287; Namik Kemal University, Tekirdag, Turkey</aff><aff id="aff2"><label>b</label>Department of Emergency Medicine, Ankara Bilkent City Hospital, Ankara, Turkey</aff><aff id="aff3"><label>c</label>Department of Medical Biochemistry, Ankara Bilkent City Hospital, Ankara, Turkey.</aff></contrib-group><author-notes><corresp id="c1"><label>*</label>Correspondence: Serhat Orun, Department of Emergency Medicine, Tekirda&#287; Namik Kemal University, Tekirdag, Turkey (e-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="serhatorun@gmail.com">serhatorun@gmail.com</email>).</corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><day>03</day><month>10</month><year>2025</year></pub-date><volume>104</volume><issue>40</issue><issue-id pub-id-type="pmc-issue-id">498401</issue-id><elocation-id>e44785</elocation-id><history><date date-type="received"><day>20</day><month>5</month><year>2025</year></date><date date-type="rev-recd"><day>26</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>03</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC)</ext-link>, where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="medi-104-e44785.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="medi-104-e44785.pdf"/><abstract><p>Transient ischemic attack (TIA) is a brief neurological dysfunction without acute infarction, often preceding ischemic stroke. Although tools like the ABCD2 score aid early risk stratification, their predictive reliability is limited in emergency settings, creating a demand for new biomarkers. Nardilysin (NRDC) and neurogranin (Ng) have emerged as promising candidates due to their involvement in axonal maturation, synaptic plasticity, and neurorepair. However, their diagnostic utility in early TIA remains unclear. This prospective cohort study aimed to evaluate the association between serum NRDC and Ng levels and early outcomes in TIA. We hypothesized that these biomarkers, particularly NRDC due to its neurovascular repair function, could serve as early indicators in patients at risk. A total of 33 TIA patients (20 males; mean age: 65.97&#8197;&#177;&#8197;15.99) and 48 healthy controls (23 males; mean age: 66.85&#8197;&#177;&#8197;9.53) were recruited from the emergency department of a university-affiliated tertiary hospital in Ankara, T&#252;rkiye, between June and December 2022. Groups were similar in age, sex, and body mass index. The control group had no known comorbidities such as hypertension or diabetes. Blood samples were collected within 6 hours of symptom onset and analyzed using ELISA. Clinical variables, ABCD2 scores, and outcomes (e.g., admission, discharge, 1-month mortality) were recorded. Statistical analysis included <italic toggle="yes">t</italic>-tests, chi-square, Mann&#8211;Whitney <italic toggle="yes">U</italic>, and receiver operating characteristic analysis using SPSS and Analyse-it. NRDC levels were significantly lower in TIA patients (4.65&#8197;&#177;&#8197;2.01 pg/mL) than in controls (6.39&#8197;&#177;&#8197;2.32 pg/mL, <italic toggle="yes">P</italic>&#8197;=&#8197;.001), showing moderate diagnostic accuracy (AUC&#8197;=&#8197;0.720). Ng levels did not significantly differ between groups (<italic toggle="yes">P</italic>&#8197;=&#8197;.5), and ABCD<sup>2</sup> scores showed no correlation with either biomarker. NRDC may be a promising early blood-based biomarker for TIA, particularly when imaging is inconclusive. Further studies are needed to validate these findings and clarify Ng&#8217;s role.</p></abstract><kwd-group><kwd>biochemistry</kwd><kwd>biomarkers</kwd><kwd>emergency medical services</kwd><kwd>ischemic attack</kwd><kwd>neurogranin</kwd><kwd>transient</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>1. Introduction</title><p>Transient ischemic attack (TIA) is an acute neurovascular syndrome in which the neurological symptoms regress entirely, and there is no tissue infarction detectable by diffusion-weighted magnetic resonance imaging (MRI). If neurological symptoms have not regressed, this should be considered as a clinical stroke, even in cases where no infarction can be detected by MRI.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> TIA has been considered a predisposing risk factor for a subsequent ischemic stroke since the 1950s.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> After TIA, the risk of stroke is 1.2% on the 2nd day and 7.4% on the 90th day.<sup>[<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref>]</sup> When ischemic stroke cases are considered, it is known that a previous TIA occurs in approximately 20% of ischemic strokes.<sup>[<xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref>]</sup> Due to this predisposition to ischemic stroke, elimination of risky TIAs became a concern, and the California score was developed and introduced in 2000 and the ABCD score in 2005.<sup>[<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref>]</sup> The California score is a simple clinical tool that uses age, symptom duration, and specific clinical signs to estimate the short-term risk of stroke, especially within 7 days. The ABCD score, and later the refined ABCD<sup>2</sup> version, incorporate additional parameters such as blood pressure and diabetes to offer more nuanced risk stratification. Both scores aim to support rapid decision-making in emergency settings by quantifying early stroke risk after TIA, despite variability in their long-term predictive accuracy.<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> In 2007, California and ABCD scores were studied, and the ABCD<sup>2</sup> score was developed, in which the presence of a history of diabetes mellitus is also questioned and scored. Using ABCD<sup>2</sup>, prognostic predictions on the first 2, first 7, and first 90-day risk of ischemic stroke are based simply on the patient&#8217;s age, blood pressure, the presence of specific clinical features, and the duration of symptoms.<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> When it was introduced, all components of ABCD<sup>2</sup> successfully predicted the 90-day ischemic stroke risk, similar to the predictions on the 2nd and 7th days.<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> In the following years, various validation studies reached different results. Although some reported it as valid,<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup> according to some other reports, ABCD<sup>2</sup> is still considered controversial in predicting ischemic stroke risk.<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref>]</sup> It has even been reported that ABCD<sup>2</sup> is less successful when used by emergency department (ED) physicians than by neurologists.<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup> Considering all these reports and that cases are primarily evaluated in the ED, different methods and comprehensive studies are needed to evaluate and identify the potential relationships of TIA in the ED setting. While scoring systems like the California score<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> and the ABCD2 score<sup>[<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref>]</sup> provide practical tools for estimating the short-term risk of ischemic stroke following TIA, their predictive accuracy remains limited, especially in the ED setting. This highlights the ongoing need for objective and reliable biomarkers that can support clinical decision-making and improve early risk stratification in patients presenting with TIA.</p><p>N-arginine dibasic convertase (nardilysin &#8211; NRDC) protein is a metallopeptidase from the M16 family.<sup>[<xref rid="R11" ref-type="bibr">11</xref>&#8211;<xref rid="R14" ref-type="bibr">14</xref>]</sup> The extracellular area facilitates the ectodomain shedding of various membrane proteins, such as heparin-binding epidermal growth factor and tumor necrosing factor-&#945;.<sup>[<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref>]</sup> It is also a transcriptional regulator of the nucleus that acts as a shuttle between the cytosol and the nucleus.<sup>[<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R17" ref-type="bibr">17</xref>]</sup> NRDC is a positive regulator of axonal maturation and myelination on central and peripheral neurons. It has a dose-dependent effect on myelin thickness experimentally in vivo, and this can be considered a futuristic pharmacological target for demyelinating diseases such as multiple sclerosis. NRDC also has a function in the repair of injured axons.<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> NRDC also has preventive activity against amyloid plaque formation in Alzheimer disease, according to evidence-based on in vivo mouse models.<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup> All these experimental data point to the role of NRDC in a wide range of neurological disorders.<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> Given its role in axonal repair, NRDC may contribute to reducing the risk of progression from TIA to ischemic stroke by supporting neuronal recovery in the acute phase.</p><p>Neurogranin (Ng) is a small protein of 78 amino acids found in pyramidal cells with a granule-like structure in the hippocampus and cortex.<sup>[<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref>]</sup> It plays a key role in synaptic plasticity, neuronal regeneration, and long-term potentiation.<sup>[<xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref>]</sup> Its postsynaptic function has led researchers to propose it as a promising biomarker in various neurological and neurodegenerative disorders. This protein has been associated with Alzheimer disease, Parkinson disease, ischemic stroke, frontotemporal dementia, and schizophrenia, reflecting synaptic dysfunction and cognitive decline.<sup>[<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R23" ref-type="bibr">23</xref>]</sup> Compared to cerebrospinal fluid, which requires a more invasive and painful lumbar puncture, Ng can be measured more easily and noninvasively in blood samples, supporting its potential clinical utility as a practical biomarker.<sup>[<xref rid="R19" ref-type="bibr">19</xref>]</sup> Given that neurodegenerative conditions like Parkinson disease increase ischemic stroke risk through vascular and inflammatory pathways,<sup>[<xref rid="R24" ref-type="bibr">24</xref>]</sup> evaluating this marker in TIA patients may help reveal shared pathological mechanisms. It may thus serve as a molecular indicator for stroke risk stratification in individuals with neurodegenerative vulnerability.</p><p>This study aimed to investigate the potential of NRDC and Ng levels in early blood serum samples for identifying relationships in TIA patients diagnosed in the ED, with a particular focus on their possible utility as early biomarkers for increased risk of ischemic stroke. Unlike conventional scoring systems whose accuracy varies in emergency settings, serum biomarkers may offer more objective and pathophysiologically grounded indicators of stroke risk. NRDC has shown promise in neural repair and myelination, while Ng has been linked to synaptic integrity and is elevated in several neurodegenerative diseases that themselves increase the risk of ischemic stroke. Exploring these markers in TIA patients could therefore provide novel insights into biological mechanisms underlying stroke progression and help identify high-risk individuals beyond what clinical scoring systems currently offer.</p></sec><sec sec-type="methods"><title>2. Materials and methods</title><sec><title>2.1. Ethical approval and informed consent process</title><p>Ethical approval for this study was obtained from the Ankara Bilkent City Hospital&#8217;s Non-Invasive Clinical Research Ethics Committee (registration number &#8211; E2-23-4179). Signed informed consent was obtained from all patients, their legal guardians, and healthy volunteers who agreed to participate.</p></sec><sec sec-type="subjects"><title>2.2. Study design, setting, and participant selection</title><p>This study was conducted at a high-capacity tertiary hospital affiliated with 2 universities that provide medical education and specialization training in neurology and emergency medicine. This hospital&#8217;s ED and neurology clinics serve as a referral center for stroke cases, receiving patients via ground and air ambulances (fixed-wing and helicopters) on specific days each month as determined by the provincial health directorate. This center is fully equipped to manage stroke cases, including performing embolization through interventional radiology.</p><p>Individuals aged 18 and above who arrived at the ED with any complaint between June 15, 2022, and December 15, 2022, and were diagnosed with TIA were included in the study. Patients presenting to the ED with a neurological deficit but without evidence of ischemic tissue on cranial imaging and whose neurological deficits did not persist and regressed, as well as those presenting due to a previous neurological deficit or whose neurological deficit completely resolved during ED follow-up, were considered to have TIA by definition. Patients meeting this definition and whose care plans were established accordingly were included in the study, and their previously collected serum samples were stored for NRDC and Ng analyses. The Glasgow Coma Scores of the patients, their outcomes from the ED (admission to regular service, intensive care, discharge, refusal of treatment, referral), and 1-month mortality were determined and recorded in a case form specifically designed for this study. All patients&#8217; demographic characteristics, body mass index (BMI), physical examination findings, comorbidities, CRP levels, and high-sensitive troponin levels were collected and recorded in case report forms. The control group consisted of healthy volunteers without any known comorbidities, including hypertension, diabetes, or chronic diseases, to ensure a clear comparison with the TIA group.</p><p>To protect patient data, all information was recorded without including personally identifiable information such as names or other distinguishing details. Demographic data such as age and gender, physical examination findings, laboratory results, and imaging outcomes were recorded in a de-identified format. These records are securely stored on the researchers&#8217; computers, with restricted access to ensure confidentiality and compliance with ethical standards.</p><p>Patients who were pregnant had a history of malignancy, experienced a head injury, had acute or previous cardiovascular disease, had a chronic neurological condition (such as myasthenia gravis or depression), showed any findings on computed tomography (CT) or MRI suggestive of acute cerebrovascular hemorrhage, or required cardiopulmonary resuscitation were excluded from the sampling.</p><p>To reduce selection bias, consecutive patient enrollment and strict inclusion/exclusion criteria were used. Laboratory personnel and clinical assessors were blinded to biomarker levels to minimize measurement bias.</p><p>This study follows the STROBE reporting guidelines, and the STROBE checklist was completed accordingly.</p></sec><sec sec-type="methods"><title>2.3. Laboratory procedures for NRDC and Ng level measurement</title><p>Upon diagnosis of TIA, a 5&#8201;mL venous blood sample was collected within 6 hours of symptom onset, using standard phlebotomy technique and placed into red-capped tubes. The samples were immediately centrifuged at 1300&#8197;&#215;&#8197;g for 10 minutes. The separated sera were aliquoted into Eppendorf tubes and stored at&#8211;80 &#176;C until analysis. NRDC and Ngn levels were measured using commercially available Enzyme-Linked Immuno Sorbent Assay (ELISA) kits. According to the manual of the kits, it was recommended to dilute the human samples with sample dilution buffer before testing and the samples were diluted 2-fold (1/2) with recommended dilution buffer before testing process. Human NRDC levels were quantified using an ELISA kit (Fine Test, Wuhan, China; catalog no: EH10653; lot no: H10653H085 E) employing a quantitative sandwich enzyme immunoassay technique. The 96-well plate was precoated with Anti NRD1 antibody. The standards prepared according to the instructions of the kit manual Standard solutions and samples were added to the wells. After incubation process, unbound conjugates were removed by wash buffer. The biotin conjugated anti NRD1 antibody was used as the detection antibody, after washing procedure biotinylated detection antibody was added to bind with NRD1 conjugated on coated antibody. After incubation, the plate was washed again to remove unbound conjugates, HRP-Streptavidin solution was added. After the last step of washing procedure, TMB substrates were added to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that turned yellow after adding a stop solution. The optical density (OD) measured spectrophotometrically at 450nm in a microplate reader. The concentration of NRD1 in the sample was determined by drawing a standard curve. The concentration of the target substance is proportional to the OD450 value. The detection range for NRDC was 0.313 to 20&#8201;ng/mL, with intra- and inter-assay precision being &lt;8% and 10%, respectively. The sensitivity of the kit was 0,188&#8201;ng/mL.</p><p>Similarly, Human NRG levels were measured using an ELISA kit (Fine Test, Wuhan, China; catalog no: EH2396; lot no: H2396H085 E). The kit was based on sandwich enzyme-linked immune-sorbent assay technology. Anti NRG antibody was precoated onto the 96-well plate. The standards prepared according to the instructions and human samples were added to the wells subsequently. After incubation, unbound conjugates were removed by wash buffer. Then, biotinylated detection antibody was added to bind with NRG conjugated on coated antibody. The biotin conjugated anti NRG antibody was used as the detection antibody. After incubation, the plate was washed to remove unbound conjugates, then HRP-Streptavidin solution was added. After the last step of washing, TMB substrates were added to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that turned yellow after adding a stop solution. The OD measured spectrophotometrically at 450nm in a microplate reader. The concentration of NRG in the sample was determined by drawing a standard curve. The concentration of the target substance is proportional to the OD450 value. The detection range of NRG was 78.125 to 5000 pg/mL, with intra- and inter-assay precision of &lt;8% and 10%, respectively. The sensitivity of the kit was 46,875 pg/mL.</p><p>The laboratory technician who measured NRDC and Ng was not informed about the patients&#8217; definitive diagnosis, clinical findings, and imaging test results. The physician assigned to diagnose patients in the ED and evaluate the imaging tests did not have information about NRDC and Ng levels, which had not yet been studied.</p><p>To optimally evaluate NRDC and Ng activity, blood samples taken from patients diagnosed with TIA were compared with healthy volunteers of similar age and gender who had no active complaints, no head trauma, and no acute or chronic neurological disease. No patient&#8217;s planned treatment was changed or postponed during the study.</p></sec><sec><title>2.4. Imaging modalities used in the ED</title><p>All CT scans were conducted utilizing a 128-slice multidetector scanner (GE Revolution EVO 128 Slice CT Scanner, GE Medical Systems, Milwaukee). Noncontrast CT (NCCT) was the primary modality used for initial evaluation of all patients. CT angiography (CTA) and CT perfusion (CTP) were not performed as part of the diagnostic workup in this study. The acquisition parameters for NCCT included a slice thickness of 2&#8201;mm, tube voltage of 120 kVp, tube current of 200 mAs, and coverage from the skull base to the vertex. No contrast agents were administered during CT scanning. MRI scans were obtained using a 1.5 T MR scanner (Signa Explorer, GE Medical System, Milwaukee) equipped with an 8-channel head coil.</p></sec><sec><title>2.5. ABCD<sup>2</sup> scoring: calculating methodology and risk stratification</title><p>In calculating the ABCD<sup>2</sup> score, Cases aged 60 and over receive 1 point each; those received 1 point each if blood pressure was 140/90&#8201;mm Hg and above; those with unilateral weakness receive 2 points each; those with speech impairment without weakness receive 1 point each; those with a symptom duration of at least 10 minutes to 59 minutes receive 1 point, and those with a symptom duration of 60 minutes or more receive 2 points; those with a history of diabetes mellitus also received 1 point each. According to this calculation, those with 0 to 3 points were scored as low risk, those with 4 or 5 points were scored as medium, and those with 6 or 7 points were scored as high risk.</p></sec><sec><title>2.6. Primary and secondary outcome measures</title><p>The study&#8217;s patient group consisted of TIA patients and a control group of healthy volunteers. The primary distinction between the 2 groups was the diagnosis of TIA. Demographic data and laboratory results were compared between both groups to provide context for interpreting the comparison results. NRDC and Ng values were compared between the patient and control groups. Additionally, ABCD<sup>2</sup> scores were calculated for the patients, and their NRDC and Ng values were compared according to their high, medium, or low-risk categories.</p></sec><sec sec-type="methods"><title>2.7. Statistical analysis methods</title><p>Statistical analyses were performed using Statistical Program for the Social Sciences (SPSS) version 18.0 (IBM Inc.) and Analyse-it (Analyse-it Software Ltd). The Kolmogorov&#8211;Smirnov test was used to assess the normality of distribution of the NRDC and Ng levels and TIA parameters, and the Student <italic toggle="yes">t</italic> test was used to compare the TIA and control groups. Pearson chi-squared test was used to determine the relationship between gender, TIA variables, and age and TIA variables. Continuous variables were expressed as either mean&#8197;&#177;&#8197;standard deviation or median (min&#8211;max), and the Mann&#8211;Whitney U test was used to determine relationships between them. Categorical values were expressed as absolute numbers and percentages. A <italic toggle="yes">P</italic>-value of&#8197;&lt;&#8197;.05 was considered statistically significant. Receiver operating characteristic (ROC) analysis was specified with a 95% confidence interval (95% CI) and area under curve (AUC) values. Cutoff was determined according to the highest likelihood ratio. Additionally the power analysis of the study was performed again in the G-Power program at the end of the study. When 33 cases were included in the TIA group and 48 cases in the control group and the alpha error was accepted as 0.05, the calculated effect size was 0.7503854, and the power of the study was determined as 95%.</p></sec></sec><sec sec-type="results"><title>3. Results</title><sec><title>3.1. Baseline demographics and key laboratory findings</title><p>Within the scope of the study, 33 cases with TIA and 48 cases in the control group were examined. In the TIA group, 13 were female, and 20 were male. In the control group, there were 25 females and 23 males. The age in the TIA group was 65.97&#8197;&#177;&#8197;15.99 years, while the age of control cases was 66.85&#8197;&#177;&#8197;9.53 years. BMI was 24.58&#8197;&#177;&#8197;1.92 in the TIA group and 24.04&#8197;&#177;&#8197;2.18 in the control group. The groups were similar in gender, age, and BMI (<italic toggle="yes">P</italic>&#8197;=&#8197;.26, <italic toggle="yes">P</italic>&#8197;=&#8197;.77, and <italic toggle="yes">P</italic>&#8197;=&#8197;.26, respectively). Although there were statistically significant differences in WBC, lymphocyte, and platelet counts between the TIA and control groups, these 3 values were within the reference ranges (<italic toggle="yes">P</italic>&#8197;=&#8197;.04, <italic toggle="yes">P</italic>&#8197;=&#8197;.03, <italic toggle="yes">P</italic>&#8197;=&#8197;.002). The groups were also statistically similar regarding other laboratory values (Table <xref rid="T1" ref-type="table">1</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Comparison of descriptive characteristics and some laboratory values of patients diagnosed with TIA in the emergency department and control groups of healthy volunteers.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">TIA</th><th align="center" rowspan="1" colspan="1">Control group</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">Gender</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Female</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">.26</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Male</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (Mean)</td><td align="center" rowspan="1" colspan="1">65.97&#8197;&#177;&#8197;15.99</td><td align="center" rowspan="1" colspan="1">66.85&#8197;&#177;&#8197;9.53</td><td align="center" rowspan="1" colspan="1">.77</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">24.58&#8197;&#177;&#8197;1.92</td><td align="center" rowspan="1" colspan="1">24.04&#8197;&#177;&#8197;2.18</td><td align="center" rowspan="1" colspan="1">.26</td></tr><tr><td align="left" rowspan="1" colspan="1">AST (U/L)</td><td align="center" rowspan="1" colspan="1">25.33&#8197;&#177;&#8197;12.35</td><td align="center" rowspan="1" colspan="1">25.58&#8197;&#177;&#8197;7.98</td><td align="center" rowspan="1" colspan="1">.9</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT (U/L)</td><td align="center" rowspan="1" colspan="1">21.27&#8197;&#177;&#8197;12.27</td><td align="center" rowspan="1" colspan="1">23.08&#8197;&#177;&#8197;9.26</td><td align="center" rowspan="1" colspan="1">.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Urea (mg/dL)</td><td align="center" rowspan="1" colspan="1">39.18&#8197;&#177;&#8197;13.17</td><td align="center" rowspan="1" colspan="1">36.14&#8197;&#177;&#8197;14.51</td><td align="center" rowspan="1" colspan="1">.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatine (mg/dL)</td><td align="center" rowspan="1" colspan="1">0.89&#8197;&#177;&#8197;0.26</td><td align="center" rowspan="1" colspan="1">0.86&#8197;&#177;&#8197;0.22</td><td align="center" rowspan="1" colspan="1">.5</td></tr><tr><td align="left" rowspan="1" colspan="1">WBC (&#215;10<sup>9</sup>/L)</td><td align="center" rowspan="1" colspan="1">7072&#8197;&#177;&#8197;2963</td><td align="center" rowspan="1" colspan="1">8323&#8197;&#177;&#8197;2603</td><td align="center" rowspan="1" colspan="1">
<bold>.04</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Hg (g/dL)</td><td align="center" rowspan="1" colspan="1">13,3&#8197;&#177;&#8197;1,5</td><td align="center" rowspan="1" colspan="1">13,1&#8197;&#177;&#8197;1,8</td><td align="center" rowspan="1" colspan="1">.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Neutrophil (&#215;10<sup>9</sup>/L)</td><td align="center" rowspan="1" colspan="1">5028&#8197;&#177;&#8197;2253</td><td align="center" rowspan="1" colspan="1">5333&#8197;&#177;&#8197;2340</td><td align="center" rowspan="1" colspan="1">.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphocyte (&#215;10<sup>9</sup>/L)</td><td align="center" rowspan="1" colspan="1">1782&#8197;&#177;&#8197;745</td><td align="center" rowspan="1" colspan="1">2157&#8197;&#177;&#8197;787</td><td align="center" rowspan="1" colspan="1">
<bold>.03</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Plt (&#215;10<sup>9</sup>/L)</td><td align="center" rowspan="1" colspan="1">225,393&#8197;&#177;&#8197;40,458</td><td align="center" rowspan="1" colspan="1">269,854&#8197;&#177;&#8197;71,815</td><td align="center" rowspan="1" colspan="1">
<bold>.002</bold>
</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Bold values indicate statistical significance at <italic toggle="yes">P</italic> &lt; .05.</p></fn><fn fn-type="other"><p>ALT = alanine aminotransferase, AST = aspartate aminotransferase, BMI = body mass index, Hg = hemoglobin, Plt = platelet, TIA = transient ischemic attack, WBC = white blood cell.</p></fn></table-wrap-foot></table-wrap><p>In the TIA group, dysarthria was the most common complaint, observed in 17 patients, followed by left-sided motor strength loss, detected in 12 patients.</p></sec><sec sec-type="results"><title>3.2. Biomarker results and clinical correlations</title><p>The ROC curve demonstrates the diagnostic performance of NRDC levels in distinguishing TIA patients from healthy controls, based on measurements obtained through ELISA. The AUC was 0.720 (95% CI: 0.605&#8211;0.836), indicating moderate diagnostic accuracy. ROC analysis identified an optimal NRDC cutoff value of 5.05 pg/mL, selected due to the absence of a standardized reference for this biomarker. At this cutoff, the test achieved a sensitivity of 72% and a specificity of 63%, with an odds ratio of 2, supporting its potential as an early diagnostic tool for TIA (Fig. <xref rid="F1" ref-type="fig">1</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>Receiver operating characteristic (ROC) curve for nardilysin (NRDC) levels in differentiating transient ischemic attack patients from healthy controls in the emergency department (blue curve). 95% CI, AUC: 0.720 (0.605&#8211;0.836). AUC = area under the curve.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-104-e44785-g001.jpg"/></fig><p>The NRDC and Ng values showed a normal distribution concerning TIA diagnosis. The mean NRDC value for the case group was 4.65&#8197;&#177;&#8197;2.01, whereas the control group had an average NRDC value of 6.39&#8197;&#177;&#8197;2.32. This difference in NRDC levels between the case and control groups was statistically significant (<italic toggle="yes">P</italic>&#8197;=&#8197;.001). The average Ng value for the patient group was 284.57&#8197;&#177;&#8197;78.81, compared to 298.84&#8197;&#177;&#8197;131.19 for the control group. There was no statistically significant difference in Ng values between the 2 groups (<italic toggle="yes">P</italic>&#8197;=&#8197;.5) (Table <xref rid="T2" ref-type="table">2</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Comparison of nardilysin and neurogranin values of patients diagnosed with TIA in the emergency department and control groups of healthy volunteers.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">TIA</th><th align="center" rowspan="1" colspan="1">Control</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">NRDC (ng/mL)</td><td align="center" rowspan="1" colspan="1">4.65&#8197;&#177;&#8197;2.01</td><td align="center" rowspan="1" colspan="1">6.39&#8197;&#177;&#8197;2.32</td><td align="center" rowspan="1" colspan="1">
<bold>.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Ng (pg/mL)</td><td align="center" rowspan="1" colspan="1">284.57&#8197;&#177;&#8197;78.81</td><td align="center" rowspan="1" colspan="1">298.84&#8197;&#177;&#8197;131.19</td><td align="center" rowspan="1" colspan="1">.5</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Bold value indicates statistical significance at <italic toggle="yes">P</italic> &lt; .05.</p></fn><fn fn-type="other"><p>Ng = neurogranin, NRDC = nardilysin, TIA = transient ischemic attack.</p></fn></table-wrap-foot></table-wrap><p>According to the ABCD<sup>2</sup> scoring system, 17 patients in the TIA group were classified as low risk, while 16 patients were classified as medium risk. The mean NRDC value for the low-risk group was 4.7&#8197;&#177;&#8197;1.8, and for the medium-risk group, it was 4.52&#8197;&#177;&#8197;2.2. This difference between the 2 groups was not statistically significant (<italic toggle="yes">P</italic>&#8197;=&#8197;.7). Similarly, when comparing the mean Ng values of the cases in the low- and medium-risk TIA groups, no significant difference was detected, similar to that of NRDC. The mean Ng value for the low-risk group was 272.64, and for the medium-risk group, it was 297.26 (<italic toggle="yes">P</italic>&#8197;=&#8197;.378).</p></sec></sec><sec sec-type="discussion"><title>4. Discussion</title><p>This study provides critical insights into the potential relationship of NRDC and Ng levels with outcomes for TIA patients in an ED setting. Our findings indicated that NRDC levels could significantly differentiate between TIA patients and healthy controls, suggesting its potential utility as a biomarker for early identification in TIA. In contrast, Ng levels did not significantly differ between the 2 groups.</p><p>Various studies support the role of NRDC in neurological conditions. NRDC has been implicated in numerous neural processes, including axonal maturation, myelination, and neuronal repair, making it a critical factor in neurovascular health and recovery.<sup>[<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R15" ref-type="bibr">15</xref>&#8211;<xref rid="R17" ref-type="bibr">17</xref>]</sup> Recent studies have also highlighted NRDC&#8217;s involvement in demyelinating diseases and its potential as a pharmacological target for multiple sclerosis.<sup>[<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R15" ref-type="bibr">15</xref>]</sup> In Alzheimer disease models, NRDC has shown preventive activity against amyloid plaque formation, indicating its broad neurological relevance.<sup>[<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R25" ref-type="bibr">25</xref>]</sup> Our finding of a significant difference in NRDC levels between TIA patients and controls aligns with these studies, suggesting that NRDC could be a valuable biomarker for acute neurovascular events.</p><p>Ng has been extensively studied for its role in synaptic plasticity and long-term potentiation, with implications for various neurological disorders, including Alzheimer disease and schizophrenia.<sup>[<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R26" ref-type="bibr">26</xref>]</sup> Recent studies have focused on Ng as a biomarker for neurodegenerative diseases, where it has shown promise in reflecting synaptic loss and dysfunction.<sup>[<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R27" ref-type="bibr">27</xref>]</sup> However, its effectiveness as a biomarker for TIA appears limited based on our findings. This aligns with some studies showing mixed results regarding Ng levels in acute neurological events.<sup>[<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref>]</sup> The lack of significant difference in Ng levels between TIA patients and controls in our study suggests that while Ng is crucial for synaptic function, it may not be as sensitive or specific for early TIA identification or as an indicator of related outcomes.</p><p>Nevertheless, in our previous study investigating Ng and NRDC in acute IS patients,<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup> we demonstrated that serum Ng levels were significantly elevated in IS patients compared to healthy controls and were associated with increased severity, as reflected by higher values in patients requiring intensive care. In contrast, NRDC showed no significant association in the IS cohort. These findings suggest that Ng may be released in larger quantities following more severe neuronal injury, as occurs in stroke, but not necessarily in milder ischemic episodes such as TIA. This discrepancy may indicate that NRDC plays a more prominent role in transient ischemic events, where neuronal repair and myelination processes are rapidly activated, whereas in established ischemic stroke the extensive and irreversible neuronal damage may overshadow its contribution and limit its detectability.</p><p>Using NRDC as a biomarker in the ED setting could enhance early diagnostic accuracy for TIA, allowing for timely and targeted interventions. This is particularly crucial given the high risk of subsequent ischemic stroke following a TIA.<sup>[<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref>]</sup> Our ROC analysis indicated a cutoff value of 5.05 pg/mL for NRDC, with a sensitivity of 72% and specificity of 63%. These results emphasize NRDC&#8217;s potential to complement existing clinical scoring systems, particularly in situations where imaging results are inconclusive or clinical risk stratification remains uncertain.<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref>]</sup></p><p>The ABCD<sup>2</sup> score has been widely used for risk stratification in TIA patients, but its predictive power has been debated. Some studies have validated its effectiveness, while others have highlighted limitations, particularly in the ED setting, where it might be less accurate compared to specialist settings.<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup> Our study found no significant correlation between the ABCD2 score and NRDC or Ng levels. Specifically, the mean NRDC and Ng values did not differ significantly between low- and medium-risk groups classified by the ABCD2 score. This lack of correlation suggests that while the ABCD<sup>2</sup> score is valuable for stratifying stroke risk, incorporating NRDC and Ng does not enhance its predictive utility in this context. However, future multicenter studies with larger sample sizes may clarify whether these biomarkers could provide additive prognostic value beyond current scoring systems.</p><p>The potential of NRDC and Ng as biomarkers fits within a broader context of biomarker research in stroke and TIA. Recent systematic reviews and meta-analyses have emphasized the need for reliable biomarkers to enhance clinical risk scores&#8217; predictive accuracy and guide therapeutic decisions.<sup>[<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref>]</sup> NRDC&#8217;s role in neuronal health and repair makes it a promising candidate. Ng, although not diagnostically useful in our TIA cohort, remains of scientific interest because of its established role in synaptic integrity and its demonstrated association with disease severity in ischemic stroke.</p><p>This study has several limitations, including the relatively small sample size and the single-center design, which may limit the generalizability of our findings. Further multicenter studies with larger cohorts are needed to validate the role of NRDC and Ng for TIA. Additionally, longitudinal studies examining the relationship between NRDC/Ng levels and long-term outcomes in TIA patients would provide deeper insights into their predictive value. Future research should also explore the molecular mechanisms underlying NRDC&#8217;s contribution to neurorepair following transient ischemic events, as well as the pathophysiological thresholds at which Ng release becomes detectable in cerebrovascular disease.</p></sec><sec sec-type="conclusions"><title>5. Conclusions</title><p>Our study demonstrates that NRDC levels significantly differ between TIA patients and healthy controls, highlighting its potential as a biomarker for early TIA identification in the ED. In contrast, Ng levels did not significantly differ, suggesting limited utility in this context. These findings underscore the need for further research to validate and expand upon our results, with the ultimate goal of improving clinical approaches for TIA patients through enhanced tools for early identification and management.</p></sec><sec><title>Author contributions</title><p><bold>Conceptualization:</bold> Serhat Orun, Selahattin Guru.</p><p><bold>Data curation:</bold> Selahattin Guru, Esra Firat Oguz.</p><p><bold>Investigation:</bold> Esra Firat Oguz, Habibe Selmin Ozensoy.</p><p><bold>Methodology:</bold> Serhat Orun, Selahattin Guru, Esra Firat Oguz.</p><p><bold>Project administration:</bold> Serhat Orun.</p><p><bold>Resources:</bold> Serhat Orun.</p><p><bold>Software:</bold> Serhat Orun.</p><p><bold>Validation:</bold> Serhat Orun, Selahattin Guru, Habibe Selmin Ozensoy.</p><p><bold>Writing &#8211; original draft:</bold> Serhat Orun, Selahattin Guru, Esra Firat Oguz, Habibe Selmin Ozensoy.</p><p><bold>Writing &#8211; review &amp; editing:</bold> Serhat Orun, Selahattin Guru, Habibe Selmin Ozensoy.</p></sec></body><back><fn-group><fn fn-type="abbr"><p>
<def-list><title>Abbreviations:</title><def-item><term>ABCD</term><def><p>age, blood pressure, clinical features, duration of symptoms, diabetes (stroke risk scoring system)</p></def></def-item><def-item><term>ALT</term><def><p>alanine aminotransferase</p></def></def-item><def-item><term>AST</term><def><p>aspartate aminotransferase</p></def></def-item><def-item><term>AUC</term><def><p>area under the curve</p></def></def-item><def-item><term>BMI</term><def><p>body mass index</p></def></def-item><def-item><term>BUN</term><def><p>blood urea nitrogen</p></def></def-item><def-item><term>CSF</term><def><p>cerebrospinal fluid</p></def></def-item><def-item><term>CT</term><def><p>computed tomography</p></def></def-item><def-item><term>ED</term><def><p>emergency department</p></def></def-item><def-item><term>ELISA</term><def><p>enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>Hb</term><def><p>hemoglobin</p></def></def-item><def-item><term>Hct</term><def><p>hematocrit</p></def></def-item><def-item><term>HRP</term><def><p>horseradish peroxidase</p></def></def-item><def-item><term>ICU</term><def><p>intensive care unit</p></def></def-item><def-item><term>IS</term><def><p>ischemic stroke</p></def></def-item><def-item><term>MRI</term><def><p>magnetic resonance imaging</p></def></def-item><def-item><term>Ng</term><def><p>neurogranin</p></def></def-item><def-item><term>NRDC</term><def><p>nardilysin</p></def></def-item><def-item><term>OD</term><def><p>optical density</p></def></def-item><def-item><term>PLT</term><def><p>platelet</p></def></def-item><def-item><term>RBC</term><def><p>red blood cell</p></def></def-item><def-item><term>ROC</term><def><p>receiver operating characteristic</p></def></def-item><def-item><term>TIA</term><def><p>transient ischemic attack</p></def></def-item><def-item><term>TMB</term><def><p>tetramethylbenzidine</p></def></def-item><def-item><term>WBC</term><def><p>white blood cell</p></def></def-item></def-list>
</p></fn></fn-group><fn-group><fn fn-type="COI-statement"><p>The authors have no funding and conflicts of interest to disclose.</p></fn><fn fn-type="other"><p>The datasets generated during and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request.</p></fn><fn fn-type="other"><p>How to cite this article: Orun S, Guru S, Firat Oguz E, Ozensoy HS. Association of blood nardilysin and neurogranin levels with early outcomes in transient ischemic attack: A prospective cohort study. Medicine 2025;104:40(e44785).</p></fn><fn fn-type="other"><p>The work was done at Department of Emergency Medicine and Department of Medical Biochemistry, Ankara Bilkent City Hospital.</p></fn><fn fn-type="other"><p>All figures submitted have been created by the authors, who confirm that the images are original, duplicate-free, and have not been previously published in whole or in part.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amin</surname><given-names>HP</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>TE</given-names></name><name name-style="western"><surname>Bravata</surname><given-names>DM</given-names></name><etal/></person-group>; <collab>American Heart Association Emergency Neurovascular Care Committee of the Stroke Council and Council on Peripheral Vascular Disease</collab>. <article-title>Diagnosis, workup, risk reduction of transient ischemic attack in the emergency department setting: a scientific statement from the American Heart Association.</article-title><source>Stroke</source>. <year>2023</year>;<volume>54</volume>:<fpage>e109</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">36655570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STR.0000000000000418</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsao</surname><given-names>CW</given-names></name><name name-style="western"><surname>Aday</surname><given-names>AW</given-names></name><name name-style="western"><surname>Almarzooq</surname><given-names>ZI</given-names></name><etal/></person-group>; <collab>American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee</collab>. <article-title>Heart disease and stroke statistics-2023 update: a report from the American Heart Association.</article-title><source>Circulation</source>. <year>2023</year>;<volume>147</volume>:<fpage>e93</fpage>&#8211;<lpage>e621</lpage>.<pub-id pub-id-type="pmid">36695182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIR.0000000000001123</pub-id><pub-id pub-id-type="pmcid">PMC12135016</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Najib</surname><given-names>N</given-names></name><name name-style="western"><surname>Magin</surname><given-names>P</given-names></name><name name-style="western"><surname>Lasserson</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Contemporary prognosis of transient ischemic attack patients: a systematic review and meta-analysis.</article-title><source>Int J Stroke</source>. <year>2019</year>;<volume>14</volume>:<fpage>460</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">30632953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1747493018823568</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nizar</surname><given-names>D</given-names></name><name name-style="western"><surname>Amine</surname><given-names>MM</given-names></name><name name-style="western"><surname>Aissi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>External validations of the ABCD2 score in prediction of stroke risk after transient ischemic attack. A Tunisian hospital-based cohort study.</article-title><source>Int J Neurosci</source>. <year>2023</year>;<volume>133</volume>:<fpage>1218</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">33059508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00207454.2020.1835897</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoshino</surname><given-names>T</given-names></name><name name-style="western"><surname>Mizuno</surname><given-names>S</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>S</given-names></name><name name-style="western"><surname>Uchiyama</surname><given-names>S</given-names></name></person-group>. <article-title>Clinical features and functional outcome of stroke after transient ischemic attack.</article-title><source>J Stroke Cerebrovasc Dis</source>. <year>2013</year>;<volume>22</volume>:<fpage>260</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">22005036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jstrokecerebrovasdis.2011.08.010</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>SC</given-names></name><name name-style="western"><surname>Gress</surname><given-names>DR</given-names></name><name name-style="western"><surname>Browner</surname><given-names>WS</given-names></name><name name-style="western"><surname>Sidney</surname><given-names>S</given-names></name></person-group>. <article-title>Short-term prognosis after emergency department diagnosis of TIA.</article-title><source>JAMA</source>. <year>2000</year>;<volume>284</volume>:<fpage>2901</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">11147987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.284.22.2901</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rothwell</surname><given-names>PM</given-names></name><name name-style="western"><surname>Giles</surname><given-names>MF</given-names></name><name name-style="western"><surname>Flossmann</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack.</article-title><source>Lancet</source>. <year>2005</year>;<volume>366</volume>:<fpage>29</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">15993230</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(05)66702-5</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>SC</given-names></name><name name-style="western"><surname>Rothwell</surname><given-names>PM</given-names></name><name name-style="western"><surname>Nguyen-Huynh</surname><given-names>MN</given-names></name><etal/></person-group>. <article-title>Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack.</article-title><source>Lancet</source>. <year>2007</year>;<volume>369</volume>:<fpage>283</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">17258668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(07)60150-0</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perry</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>M</given-names></name><name name-style="western"><surname>Sivilotti</surname><given-names>ML</given-names></name><etal/></person-group>. <article-title>Prospective validation of the ABCD2 score for patients in the emergency department with transient ischemic attack.</article-title><source>CMAJ</source>. <year>2011</year>;<volume>183</volume>:<fpage>1137</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="pmid">21646462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1503/cmaj.101668</pub-id><pub-id pub-id-type="pmcid">PMC3134721</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Shah</surname><given-names>K</given-names></name></person-group>. <article-title>In patients presenting with transient ischemic attack, does the ABCD(2) clinical prediction rule provide adequate risk stratification for clinical decision making in the emergency department?</article-title><source>Ann Emerg Med</source>. <year>2013</year>;<volume>62</volume>:<fpage>14</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">23842051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annemergmed.2013.02.007</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishi</surname><given-names>E</given-names></name><name name-style="western"><surname>Prat</surname><given-names>A</given-names></name><name name-style="western"><surname>Hospital</surname><given-names>V</given-names></name><name name-style="western"><surname>Elenius</surname><given-names>K</given-names></name><name name-style="western"><surname>Klagsbrun</surname><given-names>M</given-names></name></person-group>. <article-title>N&#8208;arginine dibasic convertase is a specific receptor for heparin&#8208;binding EGF&#8208;like growth factor that mediates cell migration.</article-title><source>EMBO J</source>. <year>2001</year>;<volume>20</volume>:<fpage>3342</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">11432822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/emboj/20.13.3342</pub-id><pub-id pub-id-type="pmcid">PMC125525</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batbaatar</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kinoshita</surname><given-names>T</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Nardilysin in vascular smooth muscle cells controls blood pressure via the regulation of calcium dynamics.</article-title><source>Biochem Biophys Res Commun</source>. <year>2024</year>;<volume>712-713</volume>:<fpage>149961</fpage>.<pub-id pub-id-type="pmid">38648679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2024.149961</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hospital</surname><given-names>V</given-names></name><name name-style="western"><surname>Prat</surname><given-names>A</given-names></name></person-group>. <article-title>Nardilysin, a basic residues specific metallopeptidase that mediates cell migration and proliferation.</article-title><source>Protein Pept Lett</source>. <year>2004</year>;<volume>11</volume>:<fpage>501</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">15544571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0929866043406508</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernstein</surname><given-names>HG</given-names></name><name name-style="western"><surname>Stricker</surname><given-names>R</given-names></name><name name-style="western"><surname>Dobrowolny</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Nardilysin in human brain diseases: both friend and foe.</article-title><source>Amino Acids</source>. <year>2013</year>;<volume>45</volume>:<fpage>269</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">23604405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00726-013-1499-8</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohno</surname><given-names>M</given-names></name><name name-style="western"><surname>Hiraoka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Nardilysin regulates axonal maturation and myelination in the central and peripheral nervous system.</article-title><source>Nat Neurosci</source>. <year>2009</year>;<volume>12</volume>:<fpage>1506</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">19935654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.2438</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hiraoka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>K</given-names></name><name name-style="western"><surname>Ohno</surname><given-names>M</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>T</given-names></name><name name-style="western"><surname>Kita</surname><given-names>T</given-names></name><name name-style="western"><surname>Nishi</surname><given-names>E</given-names></name></person-group>. <article-title>Ectodomain shedding of TNF-&#945; is enhanced by nardilysin via activation of ADAM proteases.</article-title><source>Biochem Biophys Res Commun</source>. <year>2008</year>;<volume>370</volume>:<fpage>154</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18355445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2008.03.050</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hiraoka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>T</given-names></name><name name-style="western"><surname>Ohno</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Critical roles of nardilysin in the maintenance of body temperature homoeostasis.</article-title><source>Nat Commun</source>. <year>2014</year>;<volume>5</volume>:<fpage>3224</fpage>.<pub-id pub-id-type="pmid">24492630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms4224</pub-id><pub-id pub-id-type="pmcid">PMC3926010</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohno</surname><given-names>M</given-names></name><name name-style="western"><surname>Hiraoka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lichtenthaler</surname><given-names>SF</given-names></name><etal/></person-group>. <article-title>Nardilysin prevents amyloid plaque formation by enhancing &#945;-secretase activity in an Alzheimer&#8217;s disease mouse model.</article-title><source>Neurobiol Aging</source>. <year>2014</year>;<volume>35</volume>:<fpage>213</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">23954170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2013.07.014</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xin</surname><given-names>J</given-names></name><name name-style="western"><surname>Le</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name></person-group>. <article-title>Neurogranin: a potential biomarker of neurological and mental diseases.</article-title><source>Front Aging Neurosci</source>. <year>2020</year>;<volume>12</volume>:<fpage>584743</fpage>.<pub-id pub-id-type="pmid">33132903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2020.584743</pub-id><pub-id pub-id-type="pmcid">PMC7573493</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watson</surname><given-names>JB</given-names></name><name name-style="western"><surname>Battenberg</surname><given-names>EF</given-names></name><name name-style="western"><surname>Wong</surname><given-names>KK</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>FE</given-names></name><name name-style="western"><surname>Sutcliffe</surname><given-names>JG</given-names></name></person-group>. <article-title>Subtractive cDNA cloning of RC3, a rodent cortex-enriched mRNA encoding a novel 78 residue protein.</article-title><source>J Neurosci Res</source>. <year>1990</year>;<volume>26</volume>:<fpage>397</fpage>&#8211;<lpage>408</lpage>.<pub-id pub-id-type="pmid">2231781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jnr.490260402</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Represa</surname><given-names>A</given-names></name><name name-style="western"><surname>Deloulme</surname><given-names>JC</given-names></name><name name-style="western"><surname>Sensenbrenner</surname><given-names>M</given-names></name><name name-style="western"><surname>Ben-Ari</surname><given-names>Y</given-names></name><name name-style="western"><surname>Baudier</surname><given-names>J</given-names></name></person-group>. <article-title>Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate.</article-title><source>J Neurosci</source>. <year>1990</year>;<volume>10</volume>:<fpage>3782</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">2269883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.10-12-03782.1990</pub-id><pub-id pub-id-type="pmcid">PMC6570038</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mavroudis</surname><given-names>IA</given-names></name><name name-style="western"><surname>Petridis</surname><given-names>F</given-names></name><name name-style="western"><surname>Chatzikonstantinou</surname><given-names>S</given-names></name><name name-style="western"><surname>Kazis</surname><given-names>D</given-names></name></person-group>. <article-title>A meta-analysis on CSF neurogranin levels for the diagnosis of Alzheimer&#8217;s disease and mild cognitive impairment.</article-title><source>Aging Clin Exp Res</source>. <year>2020</year>;<volume>32</volume>:<fpage>1639</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">31463927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40520-019-01326-z</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saunders</surname><given-names>T</given-names></name><name name-style="western"><surname>Gunn</surname><given-names>C</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Neurogranin in Alzheimer&#8217;s disease and ageing: a human post-mortem study.</article-title><source>Neurobiol Dis</source>. <year>2023</year>;<volume>177</volume>:<fpage>105991</fpage>.<pub-id pub-id-type="pmid">36623608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2023.105991</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elfil</surname><given-names>M</given-names></name><name name-style="western"><surname>Bayoumi</surname><given-names>A</given-names></name><name name-style="western"><surname>Sayed</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Stroke in Parkinson&#8217;s disease: a review of epidemiological studies and potential pathophysiological mechanisms.</article-title><source>Acta Neurol Belg</source>. <year>2023</year>;<volume>123</volume>:<fpage>773</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="pmid">36710306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13760-023-02202-4</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernstein</surname><given-names>HG</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>J</given-names></name><name name-style="western"><surname>Bogerts</surname><given-names>B</given-names></name><name name-style="western"><surname>Stricker</surname><given-names>R</given-names></name><name name-style="western"><surname>Reiser</surname><given-names>G</given-names></name></person-group>. <article-title>Nardilysin, ADAM10, and Alzheimer&#8217;s disease: of mice and men.</article-title><source>Neurobiol Aging</source>. <year>2014</year>;<volume>35</volume>:<fpage>e1</fpage>.<pub-id pub-id-type="pmid">24099785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2013.08.028</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pereira</surname><given-names>JB</given-names></name><name name-style="western"><surname>Westman</surname><given-names>E</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>O</given-names></name></person-group>; <collab>Alzheimer's Disease Neuroimaging Initiative</collab>. <article-title>Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer&#8217;s disease.</article-title><source>Neurobiol Aging</source>. <year>2017</year>;<volume>58</volume>:<fpage>14</fpage>&#8211;<lpage>29</lpage>.<pub-id pub-id-type="pmid">28692877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2017.06.002</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaleka</surname><given-names>KS</given-names></name><name name-style="western"><surname>Gerges</surname><given-names>NZ</given-names></name></person-group>. <article-title>Neurogranin restores amyloid &#946;-mediated synaptic transmission and long-term potentiation deficits.</article-title><source>Exp Neurol</source>. <year>2016</year>;<volume>277</volume>:<fpage>115</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">26721336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.expneurol.2015.12.013</pub-id></mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolmans</surname><given-names>LS</given-names></name><name name-style="western"><surname>Rutten</surname><given-names>FH</given-names></name><name name-style="western"><surname>Koenen</surname><given-names>NCT</given-names></name><etal/></person-group>. <article-title>Candidate biomarkers for the diagnosis of transient ischemic attack: a systematic review.</article-title><source>Cerebrovasc Dis</source>. <year>2019</year>;<volume>47</volume>:<fpage>207</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">31473737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000502449</pub-id><pub-id pub-id-type="pmcid">PMC6878855</pub-id></mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foschi</surname><given-names>M</given-names></name><name name-style="western"><surname>Padroni</surname><given-names>M</given-names></name><name name-style="western"><surname>Abu-Rumeileh</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Diagnostic and prognostic blood biomarkers in transient ischemic attack and minor ischemic stroke: an up-to-date narrative review.</article-title><source>J Stroke Cerebrovasc Dis</source>. <year>2022</year>;<volume>31</volume>:<fpage>106292</fpage>.<pub-id pub-id-type="pmid">35026496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jstrokecerebrovasdis.2021.106292</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozensoy</surname><given-names>HS</given-names></name><name name-style="western"><surname>&#214;r&#252;n</surname><given-names>S</given-names></name><name name-style="western"><surname>G&#252;r&#252;</surname><given-names>S</given-names></name><name name-style="western"><surname>Firat Oguz</surname><given-names>E</given-names></name></person-group>. <article-title>Exploring the association between serum Neurogranin, Nardilysin, and ischemic stroke: a case-control study conducted in the emergency department.</article-title><source>Med Sci Monit</source>. <year>2025</year>;<volume>31</volume>:<fpage>e947703</fpage>.<pub-id pub-id-type="pmid">40108794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/MSM.947703</pub-id><pub-id pub-id-type="pmcid">PMC11934785</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12494955</article-id><article-id pub-id-type="pmcid-ver">PMC12494955.1</article-id><article-id pub-id-type="pmcaid">12494955</article-id><article-id pub-id-type="pmcaiid">12494955</article-id><article-id pub-id-type="pmid">41044395</article-id><article-id pub-id-type="doi">10.1038/s41598-025-18073-z</article-id><article-id pub-id-type="publisher-id">18073</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Estimation of reference curves for brain atrophy and analysis of robustness to machine effects</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Piot</surname><given-names initials="E">Elodie</given-names></name><address><email>elodie.piot@univ-grenoble-alpes.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Renard</surname><given-names initials="F">F&#233;lix</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Atty&#233;</surname><given-names initials="A">Arnaud</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Krainik</surname><given-names initials="A">Alexandre</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><on-behalf-of>for the Alzheimer&#8217;s Disease Neuroimaging Initiative</on-behalf-of><on-behalf-of>For the Frontotemporal Lobar Degeneration Neuroimaging Initiative</on-behalf-of><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04as3rk94</institution-id><institution-id institution-id-type="GRID">grid.462307.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0429 3736</institution-id><institution>Functional neuroimaging and cerebral perfusion laboratory, </institution><institution>Grenoble Institute of Neurosciences (GIN, Grenoble Alpes University), </institution></institution-wrap>Grenoble, France </aff><aff id="Aff2"><label>2</label>GeodAIsics, Grenoble, France </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02rx3b187</institution-id><institution-id institution-id-type="GRID">grid.450307.5</institution-id><institution>University Grenoble Alps, </institution></institution-wrap>38000 Grenoble, France </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02vjkv261</institution-id><institution-id institution-id-type="GRID">grid.7429.8</institution-id><institution-id institution-id-type="ISNI">0000000121866389</institution-id><institution>University Grenoble Alpes, Inserm, CHU Grenoble Alpes, CNRS, IRMaGe, </institution></institution-wrap>38000 Grenoble, France </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/041rhpw39</institution-id><institution-id institution-id-type="GRID">grid.410529.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 0792 4829</institution-id><institution>Department of neuroradiology, </institution><institution>University Hospital of Grenoble, </institution></institution-wrap>38000 Grenoble, France </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043mz5j54</institution-id><institution-id institution-id-type="GRID">grid.266102.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2297 6811</institution-id><institution>UC San Francisco, </institution></institution-wrap>San Francisco, CA 94107 USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0168r3w48</institution-id><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution>UC San Diego, </institution></institution-wrap>La Jolla, CA 92093 USA </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02qp3tb03</institution-id><institution-id institution-id-type="GRID">grid.66875.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0459 167X</institution-id><institution>Mayo Clinic, </institution></institution-wrap>Rochester, Mn USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01an7q238</institution-id><institution-id institution-id-type="GRID">grid.47840.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2181 7878</institution-id><institution>UC Berkeley, </institution></institution-wrap>Berkeley, San Francisco, USA </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00b30xv10</institution-id><institution-id institution-id-type="GRID">grid.25879.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8972</institution-id><institution>University of Pennsylvania, </institution></institution-wrap>Philadelphia, PA 19104 USA </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03taz7m60</institution-id><institution-id institution-id-type="GRID">grid.42505.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 2156 6853</institution-id><institution>USC, </institution></institution-wrap>Los Angeles, CA 90032 USA </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05rrcem69</institution-id><institution-id institution-id-type="GRID">grid.27860.3b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9684</institution-id><institution>UC Davis, </institution></institution-wrap>Sacramento, CA USA </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04b6nzv94</institution-id><institution-id institution-id-type="GRID">grid.62560.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8294</institution-id><institution>Brigham and Women&#8217;s Hospital/Harvard Medical School, </institution></institution-wrap>Boston, MA 02215 USA </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02k40bc56</institution-id><institution-id institution-id-type="GRID">grid.411377.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0790 959X</institution-id><institution>Indiana University, </institution></institution-wrap>Bloomington, IN 47405 USA </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01yc7t268</institution-id><institution-id institution-id-type="GRID">grid.4367.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9350</institution-id><institution>Washington University St. Louis, </institution></institution-wrap>St. Louis, MO 63110 USA </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04as4jd41</institution-id><institution-id institution-id-type="GRID">grid.468171.d</institution-id><institution>Prevent Alzheimer&#8217;s Disease 2020, </institution></institution-wrap>Rockville, MD 20850 USA </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/059mq0909</institution-id><institution-id institution-id-type="GRID">grid.5406.7</institution-id><institution-id institution-id-type="ISNI">000000012178835X</institution-id><institution>Siemens, </institution></institution-wrap>Erlangen, Germany </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0375f4d26</institution-id><institution-id institution-id-type="GRID">grid.422384.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0614 7003</institution-id><institution>Alzheimer&#8217;s Association, </institution></institution-wrap>Chicago, IL 60631 USA </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01an3r305</institution-id><institution-id institution-id-type="GRID">grid.21925.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9000</institution-id><institution>University of Pittsburgh, </institution></institution-wrap>Pittsburgh, PA 15213 USA </aff><aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05bnh6r87</institution-id><institution-id institution-id-type="GRID">grid.5386.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 877X</institution-id><institution>Cornell University, </institution></institution-wrap>Ithaca, NY 14853 USA </aff><aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05cf8a891</institution-id><institution-id institution-id-type="GRID">grid.251993.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2179 1997</institution-id><institution>Albert Einstein College of Medicine of Yeshiva University, </institution></institution-wrap>Bronx, NY 10461 USA </aff><aff id="Aff22"><label>22</label>AD Drug Discovery Foundation, New York, NY 10019 USA </aff><aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05pvq8q22</institution-id><institution-id institution-id-type="GRID">grid.427650.2</institution-id><institution>Acumen Pharmaceuticals, </institution></institution-wrap>Livermore, CA 94551 USA </aff><aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/000e0be47</institution-id><institution-id institution-id-type="GRID">grid.16753.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 2299 3507</institution-id><institution>Northwestern University, </institution></institution-wrap>Chicago, IL 60611 USA </aff><aff id="Aff25"><label>25</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04xeg9z08</institution-id><institution-id institution-id-type="GRID">grid.416868.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0464 0574</institution-id><institution>National Institute of Mental Health, </institution></institution-wrap>Bethesda, MD 20892 USA </aff><aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05gq02987</institution-id><institution-id institution-id-type="GRID">grid.40263.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9094</institution-id><institution>Brown University, </institution></institution-wrap>Providence, RI 02912 USA </aff><aff id="Aff27"><label>27</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00cvxb145</institution-id><institution-id institution-id-type="GRID">grid.34477.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2298 6657</institution-id><institution>University of Washington, </institution></institution-wrap>Seattle, WA 98195 USA </aff><aff id="Aff28"><label>28</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04cw6st05</institution-id><institution-id institution-id-type="GRID">grid.4464.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2161 2573</institution-id><institution>University of London, </institution></institution-wrap>London, UK </aff><aff id="Aff29"><label>29</label>UC LA, Torrance, CA 90509 USA </aff><aff id="Aff30"><label>30</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00jmfr291</institution-id><institution-id institution-id-type="GRID">grid.214458.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7347</institution-id><institution>University of Michigan, </institution></institution-wrap>Ann Arbor, MI 48109-2800 USA </aff><aff id="Aff31"><label>31</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03r0ha626</institution-id><institution-id institution-id-type="GRID">grid.223827.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2193 0096</institution-id><institution>University of Utah, </institution></institution-wrap>Salt Lake City, UT 84112 USA </aff><aff id="Aff32"><label>32</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/023jwkg52</institution-id><institution>Banner Alzheimer&#8217;s Institute, </institution></institution-wrap>Phoenix, AZ 85006 USA </aff><aff id="Aff33"><label>33</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04gyf1771</institution-id><institution-id institution-id-type="GRID">grid.266093.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 0668 7243</institution-id><institution>UUC Irvine, </institution></institution-wrap>Orange, CA 92868 USA </aff><aff id="Aff34"><label>34</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00za53h95</institution-id><institution-id institution-id-type="GRID">grid.21107.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9311</institution-id><institution>Johns Hopkins University, </institution></institution-wrap>Baltimore, MD 21205 USA </aff><aff id="Aff35"><label>35</label>Richard Frank Consulting, Consulting, New York, USA </aff><aff id="Aff36"><label>36</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/049v75w11</institution-id><institution-id institution-id-type="GRID">grid.419475.a</institution-id><institution-id institution-id-type="ISNI">0000 0000 9372 4913</institution-id><institution>National Institute on Aging, </institution></institution-wrap>Baltimore, Maryland USA </aff><aff id="Aff37"><label>37</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/009avj582</institution-id><institution-id institution-id-type="GRID">grid.5288.7</institution-id><institution-id institution-id-type="ISNI">0000 0000 9758 5690</institution-id><institution>Oregon Health and Science University, </institution></institution-wrap>Portland, OR 97239 USA </aff><aff id="Aff38"><label>38</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03xrrjk67</institution-id><institution-id institution-id-type="GRID">grid.411015.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0727 7545</institution-id><institution>University of Alabama, </institution></institution-wrap>Birmingham, AL USA </aff><aff id="Aff39"><label>39</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04a9tmd77</institution-id><institution-id institution-id-type="GRID">grid.59734.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0670 2351</institution-id><institution>Mount Sinai School of Medicine, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff40"><label>40</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01j7c0b24</institution-id><institution-id institution-id-type="GRID">grid.240684.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0705 3621</institution-id><institution>Rush University Medical Center, </institution></institution-wrap>Chicago, IL 60612 USA </aff><aff id="Aff41"><label>41</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02pttbw34</institution-id><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2160 926X</institution-id><institution>Baylor College of Medicine, </institution></institution-wrap>Houston, TX USA </aff><aff id="Aff42"><label>42</label>Wien Center, Miami Beach, FL 33140 USA </aff><aff id="Aff43"><label>43</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01esghr10</institution-id><institution-id institution-id-type="GRID">grid.239585.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2285 2675</institution-id><institution>Columbia University Medical Center, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff44"><label>44</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0190ak572</institution-id><institution-id institution-id-type="GRID">grid.137628.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8753</institution-id><institution>New York University, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff45"><label>45</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05byvp690</institution-id><institution-id institution-id-type="GRID">grid.267313.2</institution-id><institution-id institution-id-type="ISNI">0000 0000 9482 7121</institution-id><institution>University of Texas Southwestern Medical School, </institution></institution-wrap>Galveston, TX 77555 USA </aff><aff id="Aff46"><label>46</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04bct7p84</institution-id><institution-id institution-id-type="GRID">grid.189509.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0024 1216</institution-id><institution>Duke University Medical Center, </institution></institution-wrap>Durham, NC USA </aff><aff id="Aff47"><label>47</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03czfpz43</institution-id><institution-id institution-id-type="GRID">grid.189967.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7398</institution-id><institution>Emory University, </institution></institution-wrap>Atlanta, GA 30307 USA </aff><aff id="Aff48"><label>48</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/036c9yv20</institution-id><institution-id institution-id-type="GRID">grid.412016.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2177 6375</institution-id><institution>University of Kansas Medical Center, </institution></institution-wrap>Kansas City, Kansas USA </aff><aff id="Aff49"><label>49</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02k3smh20</institution-id><institution-id institution-id-type="GRID">grid.266539.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8438</institution-id><institution>University of Kentucky, </institution></institution-wrap>Lexington, KY USA </aff><aff id="Aff50"><label>50</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02qp3tb03</institution-id><institution-id institution-id-type="GRID">grid.66875.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0459 167X</institution-id><institution>Mayo Clinic, </institution></institution-wrap>Jacksonville, Florida USA </aff><aff id="Aff51"><label>51</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00trqv719</institution-id><institution-id institution-id-type="GRID">grid.412750.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9166</institution-id><institution>University of Rochester Medical Center, </institution></institution-wrap>Rochester, NY 14642 USA </aff><aff id="Aff52"><label>52</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03v76x132</institution-id><institution-id institution-id-type="GRID">grid.47100.32</institution-id><institution-id institution-id-type="ISNI">0000000419368710</institution-id><institution>Yale University School of Medicine, </institution></institution-wrap>New Haven, ct USA </aff><aff id="Aff53"><label>53</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/056jjra10</institution-id><institution-id institution-id-type="GRID">grid.414980.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9401 2774</institution-id><institution>McGill Univ. Montreal-Jewish General Hospital, </institution></institution-wrap>Montreal, PQ H3A 2A7 Canada </aff><aff id="Aff54"><label>54</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03wefcv03</institution-id><institution-id institution-id-type="GRID">grid.413104.3</institution-id><institution-id institution-id-type="ISNI">0000 0000 9743 1587</institution-id><institution>Sunnybrook Health Sciences, </institution></institution-wrap>Toronto, On Canada </aff><aff id="Aff55"><label>55</label>U.B.C. Clinic for AD and Related Disorders, Vancouver, BC Canada </aff><aff id="Aff56"><label>56</label>Cognitive Neurology - St. Joseph&#8217;s, London, ON Canada </aff><aff id="Aff57"><label>57</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03xjacd83</institution-id><institution-id institution-id-type="GRID">grid.239578.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0675 4725</institution-id><institution>Cleveland Clinic Lou Ruvo Center for Brain Health, </institution></institution-wrap>Las Vegas, NV 89106 USA </aff><aff id="Aff58"><label>58</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02z2kxd64</institution-id><institution-id institution-id-type="GRID">grid.477769.c</institution-id><institution>Premiere Research Inst (Palm Beach Neurology), </institution></institution-wrap>W Palm Beach, FL USA </aff><aff id="Aff59"><label>59</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00hjz7x27</institution-id><institution-id institution-id-type="GRID">grid.411667.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2186 0438</institution-id><institution>Georgetown University Medical Center, </institution></institution-wrap>Washington, DC, 20007 USA </aff><aff id="Aff60"><label>60</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f54p054</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8956</institution-id><institution>Stanford University, </institution></institution-wrap>Stanford, CA 94305 USA </aff><aff id="Aff61"><label>61</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05qwgg493</institution-id><institution-id institution-id-type="GRID">grid.189504.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7558</institution-id><institution>Boston University, </institution></institution-wrap>Boston, Massachusetts USA </aff><aff id="Aff62"><label>62</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05gt1vc06</institution-id><institution-id institution-id-type="GRID">grid.257127.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 0547 4545</institution-id><institution>Howard University, </institution></institution-wrap>Washington, DC 20059 USA </aff><aff id="Aff63"><label>63</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/051fd9666</institution-id><institution-id institution-id-type="GRID">grid.67105.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 2164 3847</institution-id><institution>Case Western Reserve University, </institution></institution-wrap>Cleveland, OH 44106 USA </aff><aff id="Aff64"><label>64</label>Neurological Care of CNY, Liverpool, NY 13088 USA </aff><aff id="Aff65"><label>65</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05rj7xr73</institution-id><institution-id institution-id-type="GRID">grid.416448.b</institution-id><institution-id institution-id-type="ISNI">0000 0000 9674 4717</institution-id><institution>St. Joseph&#8217;s Health Care, </institution></institution-wrap>London, ON N6A 4H1 Canada </aff><aff id="Aff66"><label>66</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0106aa564</institution-id><institution-id institution-id-type="GRID">grid.417854.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0430 9339</institution-id><institution>Dent Neurologic Institute, </institution></institution-wrap>Amherst, NY 14226 USA </aff><aff id="Aff67"><label>67</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00rs6vg23</institution-id><institution-id institution-id-type="GRID">grid.261331.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2285 7943</institution-id><institution>Ohio State University, </institution></institution-wrap>Columbus, OH 43210 USA </aff><aff id="Aff68"><label>68</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0307crw42</institution-id><institution-id institution-id-type="GRID">grid.413558.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0427 8745</institution-id><institution>Albany Medical College, </institution></institution-wrap>Albany, NY 12208 USA </aff><aff id="Aff69"><label>69</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00gt5xe03</institution-id><institution-id institution-id-type="GRID">grid.277313.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0626 2712</institution-id><institution>Hartford Hospital Olin Neuropsychiatry Research Center, </institution></institution-wrap>Hartford, CT 06114 USA </aff><aff id="Aff70"><label>70</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00d1dhh09</institution-id><institution-id institution-id-type="GRID">grid.413480.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0440 749X</institution-id><institution>Dartmouth-Hitchcock Medical Center, </institution></institution-wrap>Lebanon, NH USA </aff><aff id="Aff71"><label>71</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04v8djg66</institution-id><institution-id institution-id-type="GRID">grid.412860.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0459 1231</institution-id><institution>Wake Forest University Health Sciences, </institution></institution-wrap>Winston-Salem, NC USA </aff><aff id="Aff72"><label>72</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/012jban78</institution-id><institution-id institution-id-type="GRID">grid.259828.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2189 3475</institution-id><institution>Medical University South Carolina, </institution></institution-wrap>Charleston, SC 29425 USA </aff><aff id="Aff73"><label>73</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01s434164</institution-id><institution-id institution-id-type="GRID">grid.250263.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2189 4777</institution-id><institution>Nathan Kline Institute, </institution></institution-wrap>Orangeburg, NY USA </aff><aff id="Aff74"><label>74</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/036jqmy94</institution-id><institution-id institution-id-type="GRID">grid.214572.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8294</institution-id><institution>University of Iowa College of Medicine, </institution></institution-wrap>Iowa City, IA 52242 USA </aff><aff id="Aff75"><label>75</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/032db5x82</institution-id><institution-id institution-id-type="GRID">grid.170693.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2353 285X</institution-id><institution>University of South Florida, USF Health Byrd Alzheimer&#8217;s Institute, </institution></institution-wrap>Tampa, FL 33613 USA </aff><aff id="Aff76"><label>76</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043mz5j54</institution-id><institution-id institution-id-type="GRID">grid.266102.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2297 6811</institution-id><institution>University of California, </institution></institution-wrap>San Francisco, USA </aff><aff id="Aff77"><label>77</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/002pd6e78</institution-id><institution-id institution-id-type="GRID">grid.32224.35</institution-id><institution-id institution-id-type="ISNI">0000 0004 0386 9924</institution-id><institution>Harvard Medical School and Massachusetts General Hospital, </institution></institution-wrap>Boston, USA </aff><aff id="Aff78"><label>78</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00cvxb145</institution-id><institution-id institution-id-type="GRID">grid.34477.33</institution-id><institution-id institution-id-type="ISNI">0000000122986657</institution-id><institution>University of Washington School of Medicine, </institution></institution-wrap>Seattle, USA </aff><aff id="Aff79"><label>79</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02qp3tb03</institution-id><institution-id institution-id-type="GRID">grid.66875.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0459 167X</institution-id><institution>Mayo Clinic, </institution></institution-wrap>Rochester, USA </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>34585</elocation-id><history><date date-type="received"><day>22</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>29</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 08:25:43.467"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2025_Article_18073.pdf"/><abstract id="Abs1"><p id="Par1">Neurodegenerative diseases like Alzheimer&#8217;s are difficult to diagnose due to brain complexity and imaging variability. However, volumetric analysis tools, using reference curves, help detect abnormal brain atrophy and support diagnosis and monitoring. This study evaluates the robustness of three segmentation algorithms, AssemblyNet, FastSurfer and FreeSurfer, in constructing brain volume reference curves and detecting hippocampal atrophy. Using data from 3,730 cognitively normal subjects, we built reference curves and assessed robustness to magnetic field strength (1.5T vs. 3T) using four error metrics (sMAPE, sMSPE, wMAPE, sMdAPE) with bootstrap validation. We evaluated classification performance using hippocampal atrophy rates and HAVAs scores&#160;(Hippocampal-Amygdalo-Ventricular Atrophy scores). AssemblyNet shows the lowest errors across all robustness metrics. In contrast, FastSurfer and FreeSurfer exhibit greater deviations, indicating higher sensitivity to field strength variability. AssemblyNet provides consistent hippocampal atrophy rates across all reference models, despite slightly lower sensitivity, while FastSurfer and FreeSurfer display greater variability. Specificity ranges from 0.87 to 0.91 for AssemblyNet, compared to 0.76-0.93 for FastSurfer and 0.86-0.93 for FreeSurfer. Using the HAVAs score, all methods detect high atrophy rates in Alzheimer&#8217;s patients. FastSurfer achieves the highest sensitivity (0.98), while AssemblyNet reaches the best specificity (0.95) and the highest balanced accuracy (0.91). This study underscores the importance of algorithm choice for reliable brain volumetric analysis in heterogeneous imaging environments. Among the methods tested, AssemblyNet stands out as both sensitive to Alzheimer&#8217;s-related atrophy and robust to acquisition variability, making it a strong candidate when analyzing hippocampal volumes in large, multi-site datasets.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Reference curves</kwd><kwd>AssemblyNet</kwd><kwd>FastSurfer</kwd><kwd>FreeSurfer</kwd><kwd>Robustness</kwd><kwd>Atrophy</kwd><kwd>Sensitivity</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Learning algorithms</kwd><kwd>Nervous system</kwd><kwd>Neurodegeneration</kwd><kwd>Diagnostic markers</kwd><kwd>Dementia</kwd><kwd>Neurodegeneration</kwd><kwd>Neurodegenerative diseases</kwd><kwd>Biomedical engineering</kwd><kwd>Scientific data</kwd><kwd>Software</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100003032</institution-id><institution>Association Nationale de la Recherche et de la Technologie</institution></institution-wrap></funding-source><award-id>CIFRE No. 2022/0918</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Neurodegenerative diseases cause accelerated neuronal death, leading to varying levels of cerebral atrophy<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. The spatial pattern of atrophy provides critical insights for differential diagnosis and disease staging<sup><xref ref-type="bibr" rid="CR2">2</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. To better quantify and interpret such patterns, normative modeling tools have emerged as valuable resources. These tools rely on reference curves that represent healthy age-related variation in brain structure, allowing for the identification of individual deviations from typical trajectories<sup><xref ref-type="bibr" rid="CR4">4</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR5">5</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. By comparing an individual&#8217;s brain volumes to these normative models, deviations indicative of abnormal atrophy can be detected. In the context of neurodegenerative disease, atrophy is typically defined when regional volumes fall below the lower bounds of these normative distributions, providing a standardized and interpretable framework for assessing structural brain changes<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>.</p><p id="Par3">However, the increasing use of large, diverse datasets has introduced additional challenges. Modern research relies on databases of unprecedented size, incorporating data from a wide variety of sources (Coupe et al., (2023)<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>: 40,944 subjects pooled across 24 databases). This diversity increases the prevalence of the &#8220;machine effects&#8221;, where differences in MRI acquisition parameters<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>, scanner hardware<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>, and processing pipelines<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> may lead to biases in volumetric measurements. Such variability can mask subtle disease-related changes, as differences in MRI acquisition parameters alone can alter volume measures by up to 4.8%<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>, comparable to early disease-related brain volume changes<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>.</p><p id="Par5">Tools for volume-based diagnostics enable clinicians to monitor disease progression and evaluate severity, with atrophy serving as a reliable biomarker<sup><xref ref-type="bibr" rid="CR14">14</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. However, the impact of the machine effects underscores the need for robust algorithms. Commercial tools for volume-based diagnostics have emerged to meet increasing demand<sup><xref ref-type="bibr" rid="CR16">16</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR17">17</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR18">18</xref></sup>, yet most lack thorough validation: of 17 identified products, only 4 underwent clinical validation in dementia populations<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Moreover, normative datasets vary widely (100-8,000 subjects), raising concerns about reliability and generalizability<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Further validation is essential for their full potential in neurodegenerative disease diagnosis and monitoring.</p><p id="Par6">Several studies propose reference curves with divergent trajectories for cortical and subcortical structures, sometimes described as linear, U-shaped, or complex polynomial curves, highlighting a lack of consensus in the field<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. This variability has led to inconsistent findings<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> and, in some cases, may even alter the observed differences between control and pathological groups<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. As explained by Coupe et al., (2017)<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>, several factors contribute to these inconsistencies: the use of data covering only restricted age ranges, which biases the construction of reference curves, limited scanner diversity within certain age groups<sup><xref ref-type="bibr" rid="CR19">19</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR23">23</xref></sup>, non-harmonized acquisition protocols<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>, differences in curve modeling approaches and segmentation tools<sup><xref ref-type="bibr" rid="CR20">20</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR23">23</xref></sup> and the use of heterogeneous volumetric measures (e.g., absolute volumes, normalized volumes, or z-scores)<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>.</p><p id="Par7">Selecting a model for normative curves is challenging, requiring a balance between flexibility and overfitting (where the model becomes too tailored to the training data and fails to generalize to new data)<sup><xref ref-type="bibr" rid="CR23">23</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Options range from linear models<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> to advanced methods like GAMLSS<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. This study uses Generalized Additive Models (GAMs) to test segmentation reproducibility with a standard approach. GAMs extend generalized linear models, offering flexibility and controlling overfitting through constraints<sup><xref ref-type="bibr" rid="CR28">28</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR29">29</xref></sup>.</p><p id="Par8">Normative curve robustness is as crucial as model selection. Liu et al., (2024)<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> show that identical models yield different curves across datasets. Sample size, age representation, and intracranial volume normalization further impact results<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Temporal dependencies and machine effects also challenge reproducibility, underscoring the need for robust methods.</p><p id="Par9">Several methods exist for comparing reference curves. Summing pairwise distances is simple but prone to error cancellation. Advanced time series metrics (please refer to Supplementary Section S1) provide a more robust assessment by capturing trajectory alignment. These metrics, available in classical, symmetrized, and sometimes weighted forms, were chosen for their interpretability, consistency, scale invariance, and balanced handling of over- and under-predictions.</p><p id="Par10">The first objective of this study is to investigate the robustness of AssemblyNet, FastSurfer and FreeSurfer in generating reference curves and evaluating brain atrophy using GAMs. The second objective is to develop a methodology for comparing reference curves estimated from volumetric data of 3,730 healthy subjects. These curves, generated by three segmentation algorithms, that extract brain volumes, are evaluated for robustness across magnetic field strengths. To our knowledge, no study has used GAMs to build reference curves for AssemblyNet, FastSurfer, and FreeSurfer, quantified segmentation algorithm impact, or assessed robustness to machine effects. The third objective is to assess segmentation algorithms&#8217; sensitivity and stability by measuring the proportion of Alzheimer&#8217;s patients (AD) with hippocampal atrophy<sup><xref ref-type="bibr" rid="CR30">30</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR31">31</xref></sup> and HAVAs scores<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>&#160;(Hippocampal-Amygdalo-Ventricular Atrophy scores); and comparing results with the literature. The Scheltens scale<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> is commonly used but observer-dependent<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. While visual assessment detects cerebrospinal fluid enlargement, it only indirectly reflects gray or white matter loss. Automated segmentation directly targets gray matter, overcoming this limitation. To our knowledge, the impact of machine effects on atrophy assessment using GAMs remains unexplored. For an overview of this study, please refer to Fig. <xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Study overview.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="41598_2025_18073_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Data</title><sec id="Sec4"><title>Data used to construct reference curves</title><p id="Par11">To build our reference curves, we segmented 3730 T1-weighted MRI scans of healthy subjects from 11 open-access datasets: ABIDE<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> (n=469), ICBM<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> (n=294), IXI (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://brain-development.org/ixi-dataset/">https://brain-development.org/ixi-dataset/</ext-link>) (n=549), ADNI<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> (n=373), OASIS1<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> (n=298), PPMI<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> (n=166), UCLA<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> (n=125), DLBS (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://sites.utdallas.edu/dlbs/">https://sites.utdallas.edu/dlbs/</ext-link>) (n=315), SALD<sup><xref ref-type="bibr" rid="CR41">41</xref></sup> (n=494), NIFD (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://memory.ucsf.edu/research/studies/nifd">http://memory.ucsf.edu/research/studies/nifd</ext-link>) (n=114), and SLIM (https://fcon_1000.projects.nitrc.org/indi/retro/southwestuni_qiu_index.html) (n=580).</p><p id="Par12">Figure <xref rid="Fig2" ref-type="fig">2</xref> illustrates the distribution by age and study. Table <xref rid="Tab1" ref-type="table">1</xref> show a summary of the key characteristics of the 11 datasets presented.</p><p id="Par13">Part of the data for this work were sourced from the International Consortium for Brain Mapping (ICBM) dataset (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.loni.usc.edu/">https://www.loni.usc.edu/</ext-link>). Then, part of the data utilized in this study were sourced from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) dataset (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://adni.loni.usc.edu">adni.loni.usc.edu</ext-link>). Established in 2003 as a public-private partnership and led by Principal Investigator Michael W. Weiner, MD, ADNI&#8217;s primary objective is to evaluate whether the combination of serial MRI, positron emission tomography (PET), various biological markers, and clinical and neuropsychological assessments can track the progression of mild cognitive impairment (MCI) and early Alzheimer&#8217;s disease (AD). For the most recent updates, please visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.adni-info.org">www.adni-info.org</ext-link>. In addition, we used data from the Open Access Series of Imaging Studies (OASIS) OASIS1, which provides cross-sectional MRI data in young, middle-aged, nondemented, and demented older adults. Finally, NIFD is the abbreviation for the frontotemporal lobar degeneration neuroimaging initiative (FTLDNI).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Datasets used to construct our reference curves: distribution by age and study.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="41598_2025_18073_Fig2_HTML.jpg"/></fig><table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Main characteristics of the datasets used to construct the reference curves. N_sub: number of subjects; min/max/mean/std: age statistics; F/M: number of females/males; 1.5T/3T: number of scans acquired at each field strength.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"><bold>Dataset</bold></th><th align="left" rowspan="2" colspan="1"><bold>N</bold>_<bold>sub</bold></th><th align="left" colspan="4" rowspan="1"><bold>Age</bold></th><th align="left" colspan="2" rowspan="1"><bold>Sex</bold></th><th align="left" colspan="3" rowspan="1"><bold>Acquisition and Field Strength</bold></th></tr><tr><th align="left" colspan="1" rowspan="1">Min</th><th align="left" colspan="1" rowspan="1">Max</th><th align="left" colspan="1" rowspan="1">Mean</th><th align="left" colspan="1" rowspan="1">Std</th><th align="left" colspan="1" rowspan="1">F</th><th align="left" colspan="1" rowspan="1">M</th><th align="left" colspan="1" rowspan="1">Manufacturer</th><th align="left" colspan="1" rowspan="1">1.5T</th><th align="left" colspan="1" rowspan="1">3T</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">ABIDE</td><td align="left" colspan="1" rowspan="1">448</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">56</td><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">7.7</td><td align="left" colspan="1" rowspan="1">18.5%</td><td align="left" colspan="1" rowspan="1">81.5%</td><td align="left" colspan="1" rowspan="1">GE/Philips/Siemens</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">448</td></tr><tr><td align="left" colspan="1" rowspan="1">ICBM</td><td align="left" colspan="1" rowspan="1">294</td><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">80</td><td align="left" colspan="1" rowspan="1">34</td><td align="left" colspan="1" rowspan="1">14.3</td><td align="left" colspan="1" rowspan="1">48.3%</td><td align="left" colspan="1" rowspan="1">51.7%</td><td align="left" colspan="1" rowspan="1">Philips/Siemens</td><td align="left" colspan="1" rowspan="1">278</td><td align="left" colspan="1" rowspan="1">16</td></tr><tr><td align="left" colspan="1" rowspan="1">IXI</td><td align="left" colspan="1" rowspan="1">549</td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">86</td><td align="left" colspan="1" rowspan="1">48</td><td align="left" colspan="1" rowspan="1">16.5</td><td align="left" colspan="1" rowspan="1">55.9%</td><td align="left" colspan="1" rowspan="1">44.1%</td><td align="left" colspan="1" rowspan="1">Philips/GE</td><td align="left" colspan="1" rowspan="1">371</td><td align="left" colspan="1" rowspan="1">178</td></tr><tr><td align="left" colspan="1" rowspan="1">ADNI</td><td align="left" colspan="1" rowspan="1">372</td><td align="left" colspan="1" rowspan="1">56</td><td align="left" colspan="1" rowspan="1">90</td><td align="left" colspan="1" rowspan="1">75</td><td align="left" colspan="1" rowspan="1">5.9</td><td align="left" colspan="1" rowspan="1">51.6%</td><td align="left" colspan="1" rowspan="1">48.4%</td><td align="left" colspan="1" rowspan="1">GE/Philips/Siemens</td><td align="left" colspan="1" rowspan="1">193</td><td align="left" colspan="1" rowspan="1">179</td></tr><tr><td align="left" colspan="1" rowspan="1">OASIS</td><td align="left" colspan="1" rowspan="1">298</td><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">94</td><td align="left" colspan="1" rowspan="1">45</td><td align="left" colspan="1" rowspan="1">23.8</td><td align="left" colspan="1" rowspan="1">62.8%</td><td align="left" colspan="1" rowspan="1">37.2%</td><td align="left" colspan="1" rowspan="1">Siemens</td><td align="left" colspan="1" rowspan="1">298</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">PPMI</td><td align="left" colspan="1" rowspan="1">150</td><td align="left" colspan="1" rowspan="1">31</td><td align="left" colspan="1" rowspan="1">83</td><td align="left" colspan="1" rowspan="1">60</td><td align="left" colspan="1" rowspan="1">11.5</td><td align="left" colspan="1" rowspan="1">34.7%</td><td align="left" colspan="1" rowspan="1">65.3%</td><td align="left" colspan="1" rowspan="1">GE/Philips/Siemens</td><td align="left" colspan="1" rowspan="1">38</td><td align="left" colspan="1" rowspan="1">112</td></tr><tr><td align="left" colspan="1" rowspan="1">UCLA</td><td align="left" colspan="1" rowspan="1">125</td><td align="left" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">32</td><td align="left" colspan="1" rowspan="1">8.8</td><td align="left" colspan="1" rowspan="1">47.2%</td><td align="left" colspan="1" rowspan="1">52.8%</td><td align="left" colspan="1" rowspan="1">Siemens</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">125</td></tr><tr><td align="left" colspan="1" rowspan="1">DLBS</td><td align="left" colspan="1" rowspan="1">314</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">89</td><td align="left" colspan="1" rowspan="1">54</td><td align="left" colspan="1" rowspan="1">20.0</td><td align="left" colspan="1" rowspan="1">62.7%</td><td align="left" colspan="1" rowspan="1">37.3%</td><td align="left" colspan="1" rowspan="1">Philips</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">314</td></tr><tr><td align="left" colspan="1" rowspan="1">SALD</td><td align="left" colspan="1" rowspan="1">494</td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">80</td><td align="left" colspan="1" rowspan="1">45</td><td align="left" colspan="1" rowspan="1">17.4</td><td align="left" colspan="1" rowspan="1">62.1%</td><td align="left" colspan="1" rowspan="1">37.4%</td><td align="left" colspan="1" rowspan="1">Siemens</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">494</td></tr><tr><td align="left" colspan="1" rowspan="1">NIFD</td><td align="left" colspan="1" rowspan="1">112</td><td align="left" colspan="1" rowspan="1">47</td><td align="left" colspan="1" rowspan="1">81</td><td align="left" colspan="1" rowspan="1">63</td><td align="left" colspan="1" rowspan="1">7.2</td><td align="left" colspan="1" rowspan="1">55.4%</td><td align="left" colspan="1" rowspan="1">44.6%</td><td align="left" colspan="1" rowspan="1">Siemens</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">112</td></tr><tr><td align="left" colspan="1" rowspan="1">SLIM</td><td align="left" colspan="1" rowspan="1">574</td><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">1.3</td><td align="left" colspan="1" rowspan="1">55.7%</td><td align="left" colspan="1" rowspan="1">44.3%</td><td align="left" colspan="1" rowspan="1">Siemens</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">574</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Total</bold></td><td align="left" colspan="1" rowspan="1"><bold>3730</bold></td><td align="left" colspan="1" rowspan="1"><bold>7</bold></td><td align="left" colspan="1" rowspan="1"><bold>94</bold></td><td align="left" colspan="1" rowspan="1">44</td><td align="left" colspan="1" rowspan="1">12.2</td><td align="left" colspan="1" rowspan="1">51.2%</td><td align="left" colspan="1" rowspan="1">48.8%</td><td align="left" colspan="1" rowspan="1">GE/Philips/Siemens</td><td align="left" colspan="1" rowspan="1"><bold>1178</bold></td><td align="left" colspan="1" rowspan="1"><bold>2552</bold></td></tr></tbody></table></table-wrap><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Main characteristics of the datasets used for sensitivity and stability analysis. N_sub: number of subjects; min/max/mean/std: age statistics; F/M: number of females/males; 1.5T/3T: number of scans acquired at each field strength; CN: controls subjects; AD: Alzheimer&#8217;s patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"><bold>Dataset</bold></th><th align="left" rowspan="2" colspan="1"><bold>N</bold>_<bold>sub</bold></th><th align="left" colspan="4" rowspan="1"><bold>Age</bold></th><th align="left" colspan="2" rowspan="1"><bold>Sex</bold></th><th align="left" colspan="2" rowspan="1"><bold>Field Strength</bold></th><th align="left" rowspan="2" colspan="1"><bold>Analysis</bold></th></tr><tr><th align="left" colspan="1" rowspan="1">Min</th><th align="left" colspan="1" rowspan="1">Max</th><th align="left" colspan="1" rowspan="1">Mean</th><th align="left" colspan="1" rowspan="1">Std</th><th align="left" colspan="1" rowspan="1">F</th><th align="left" colspan="1" rowspan="1">M</th><th align="left" colspan="1" rowspan="1">1.5T</th><th align="left" colspan="1" rowspan="1">3T</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">ADNI AD</td><td align="left" colspan="1" rowspan="1">219</td><td align="left" colspan="1" rowspan="1">65</td><td align="left" colspan="1" rowspan="1">80</td><td align="left" colspan="1" rowspan="1">74.1</td><td align="left" colspan="1" rowspan="1">4.0</td><td align="left" colspan="1" rowspan="1">48.9%</td><td align="left" colspan="1" rowspan="1">51.1%</td><td align="left" colspan="1" rowspan="1">102</td><td align="left" colspan="1" rowspan="1">117</td><td align="left" colspan="1" rowspan="1">Sensitivity</td></tr><tr><td align="left" colspan="1" rowspan="1">ADNI CN</td><td align="left" colspan="1" rowspan="1">255</td><td align="left" colspan="1" rowspan="1">65</td><td align="left" colspan="1" rowspan="1">80</td><td align="left" colspan="1" rowspan="1">71.7</td><td align="left" colspan="1" rowspan="1">4.2</td><td align="left" colspan="1" rowspan="1">58.8%</td><td align="left" colspan="1" rowspan="1">41.2%</td><td align="left" colspan="1" rowspan="1">24</td><td align="left" colspan="1" rowspan="1">231</td><td align="left" colspan="1" rowspan="1">Sensitivity</td></tr><tr><td align="left" colspan="1" rowspan="1">MIRIAD AD</td><td align="left" colspan="1" rowspan="1">46</td><td align="left" colspan="1" rowspan="1">55</td><td align="left" colspan="1" rowspan="1">85</td><td align="left" colspan="1" rowspan="1">68.7</td><td align="left" colspan="1" rowspan="1">7.1</td><td align="left" colspan="1" rowspan="1">58.7%</td><td align="left" colspan="1" rowspan="1">41.3%</td><td align="left" colspan="1" rowspan="1">46</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">Stability</td></tr><tr><td align="left" colspan="1" rowspan="1">MIRIAD CN</td><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">58</td><td align="left" colspan="1" rowspan="1">85</td><td align="left" colspan="1" rowspan="1">68.9</td><td align="left" colspan="1" rowspan="1">7.2</td><td align="left" colspan="1" rowspan="1">50%</td><td align="left" colspan="1" rowspan="1">50%</td><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">Stability</td></tr><tr><td align="left" colspan="1" rowspan="1">SRPBS</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">24</td><td align="left" colspan="1" rowspan="1">32</td><td align="left" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">2.6</td><td align="left" colspan="1" rowspan="1">0%</td><td align="left" colspan="1" rowspan="1">100%</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Stability</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec5"><title>Data for sensitivity and stability analysis</title><p id="Par14">To evaluate the sensitivity of segmentation algorithms, we segmented images of 219 AD subjects and 255 controls subjects from ADNI (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://adni.loni.usc.edu/">https://adni.loni.usc.edu/</ext-link>). The subjects are all between 65 and 80 years of age.</p><p id="Par15">For the stability analysis, we used the data of 46 patients with &#8220;mild-moderate Alzheimer&#8217;s disease&#8221; and 22 age-matched healthy subjects from Malone et al., (2013)<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> (MIRIAD). They have been scanned 8 times (2, 6, 14, 26, 38 and 52 weeks, 18 and 24 months from baseline) on the same 1.5 T scanner. Additionally, stability was assessed using the data of 9 healthy traveling subjects from Tanaka et al., (2021)<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> (SRPBS). They have been scanned at 12 different imaging centers within a 30-day period, making up a total of 156 exams. Three MRI manufacturers, and seven MRI scanner types were used (3T only). Table <xref rid="Tab2" ref-type="table">2</xref> presents the dataset used for the sensitivity and stability analysis of segmentation algorithms.</p></sec></sec><sec id="Sec6"><title>Pipeline analysis</title><sec id="Sec7"><title>Segmentation algorithms</title><p id="Par16">The data were segmented using AssemblyNet (version 1.0.0), a segmentation algorithm based on a large ensemble of Convolutional Neural Networks (CNNs)<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. Segmentation was then performed using 250 deep learning models through a multiscale framework.</p><p id="Par17">We compared our results with FreeSurfer, one of the most widely used segmentation software packages in neuroimaging<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. All data was processed using FreeSurfer version 7.3.1. We segmented each subject using the automated &#8220;recon-all&#8221; pipeline with the default parameters. For FreeSurfer, because of the time required for segmentation (around 15&#8201;h per subject), the FreeSurfer segmentations were calculated on the VIP platform, which provides substantial computing resources<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>.</p><p id="Par18">FastSurfer<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>(version 2.4.2) builds upon FreeSurfer and incorporates technologies similar to those used in AssemblyNet (Deep Learning), enabling segmentation in approximately ten minutes. FastSurfer utilizes three Fully Convolutional Neural Networks (F-CNNs), each responsible for segmenting 2D slices in the coronal, axial, and sagittal planes. The three segmentations are then aggregated.</p></sec><sec id="Sec8"><title>GAM and constraints</title><p id="Par19">Reference curves were estimated using a Generalized Additive Models (GAM) model<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>(pyGAM (ExpectileGAM)&#160;version 0.9.1). This model generates a curve fitting a set of points using a flexible combination of smooth functions, and captures linear relationships between points. GAM&#8217;s model extends generalized linear models resulting in a highly flexible model, in which it is easy to control overfitting.</p><p id="Par20">To prevent overfitting and avoid &#8220;non-physical&#8221; behaviors, such as abrupt variations in the variable over short periods throughout life, we applied convex or concave smoothing techniques. Overfitting can result from excessive learning from data, leading to a strong influence from specific studies rather than generalizable patterns. By applying appropriate smoothing methods, we ensure a more physiologically plausible representation of changes over time. Supplementary Section S2, Fig. S1 illustrates smoothing effects.</p></sec></sec><sec id="Sec9"><title>Curve stability assessment</title><sec id="Sec10"><title>Methods for comparing reference curves across magnetic field strengths</title><p id="Par21">Results in the &#8220;Assessment of curves stability&#8221; section include visual and quantitative analyses: the former offers a graphical comparison, while the latter quantifies visual differences using different methods. We assessed the robustness of segmentation algorithms to magnetic field strength variations by comparing reference curves derived from 1.5T data with those from 3T data. For this analysis, we compared the lower, mean, and upper bound curves using metrics designed to quantify differences between curve pairs.</p><p id="Par22">
<bold>Measure of errors between curves</bold>
</p><p id="Par23">We aimed to compare reference curves that depict volume evolution over a lifespan. To achieve this, we explored metrics for time series analysis and forecasting that calculate errors between these curves. Given the nature of our data, the selected metrics had to meet specific requirements: 1) Interpretability: the metrics should be easy to interpret, for example, by being on the same scale as the data or presented as a percentage. 2) Independence from error sign: the metric should not cancel out positive and negative errors. This means the metric should not differentiate between the direction of the error. 3) Scale-independence/invariance: the metric should remain consistent regardless of data scaling, allowing comparisons between different algorithms. 4) Treat over-predictions and under-predictions equally.</p><p id="Par24">Based on the literature, we selected 18 error metrics for evaluating the reference curves. An overview of these metrics is provided in Supplementary Section S1, where we define each metric, and discuss its strengths and limitations. We summarized the characteristics of the 18 metrics in relation to the selection criteria in Supplementary Section S1, Table S1. This table supports our selection of 5 key metrics for the comparison of reference curves: the symmetric Mean Squared Percentage Error (sMSPE<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>, sktime version 0.34.0), the Mean Absolute Scaled Error (MASE<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>, sklearn 1.4.1), the symmetric Mean Absolute Percentage Error (sMAPE<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>), the weighted Mean Absolute Percentage Error (wMAPE<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>) and the symmetric Median Absolute Percentage Error (sMdAPE<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>, sktime version 0.34.0). Since these are error metrics, the ideal value for all of them is 0, indicating no difference between reference curves.</p><p id="Par25">Each metric has specific characteristics and relevance to our analysis, as described below: sMSPE amplifies larger errors by squaring the percentage differences, providing insight into the presence of significant deviations. sMAPE quantifies the percentage difference between predicted and reference values, taking into account both over- and under-predictions. A lower sMAPE indicates higher agreement between the predicted and reference values. wMAPE evaluates the absolute percentage errors while weighting them by the magnitude of the observed (reference) values. wMAPE accounts for errors weighted by volume size, making it crucial for datasets with a wide range of volumes. Since wMAPE accounts for volume size, this metric is particularly useful in applications where larger volumes might dominate the error. sMdAPE focuses on the median of absolute percentage differences, making it less sensitive to outliers.</p><p id="Par26">
<bold>Method for identifying biases related to magnetic field strength: bootstrapping</bold>
</p><p id="Par27">To evaluate the presence of bias related to the magnetic field strength, we compared the metric values (sMSPE, MASE, sMAPE, wMAPE and sMdAPE) obtained using the true labels with the distributions generated through bootstrapping<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>. We applied bootstrapping to evaluate the variability of error metrics under different configurations of shuffled labels. This approach helps to identify biases in the results.</p><p id="Par28">Initially, we constructed two types of reference curves 1) using data from 1.5T MRI scans and 2) using data from 3T MRI scans. For each curve boundary, we calculated the metrics to compare the 1.5T curves against the 3T curves. Then, we performed a bootstrapping procedure<sup><xref ref-type="bibr" rid="CR52">52</xref></sup> involving 10,000 iterations. In each iteration, we shuffled the labels of the data, effectively randomizing the assignment of MRI scan data to the &#8220;1.5T&#8221; and &#8220;3T&#8221; groups. Using these shuffled labels, we reconstructed the reference curves for both groups and recalculated the metrics (sMSPE, MASE, sMAPE, wMAPE and sMdAPE) between the new curves. This allowed us to assess the variability in the metrics under random label assignments. The 5th percentile and 95th percentile were computed to characterize the range of variability.</p><p id="Par29">To assess magnetic field bias, we compared the true-label metric values to the bootstrapped distributions. A significant bias was considered present if the true-label metric values fell outside the 5th-95th percentile range of the bootstrapped distributions. This would indicate that the observed differences between 1.5T and 3T data are not due to random variability but are likely influenced by differences related to magnetic field strength.</p></sec></sec><sec id="Sec11"><title>Atrophy assessment</title><p id="Par30">While reproducibility is crucial for a segmentation algorithm, it is ineffective if it cannot detect pathological variations. So, we examined how segmentation algorithms affect atrophy assessment by studying the sensitivity and stability of results across different magnetic field strengths.</p><sec id="Sec12"><title>Sensitivity analysis</title><p id="Par31">To assess sensitivity, two complementary approaches were used. First, hippocampal atrophy percentages were computed for both AD patients and cognitively normal (CN) subjects. Second, we implemented the HAVAs method, from Coupe et al., (2022)<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. In this method, hippocampal, amygdalar, and inferior lateral ventricle volumes were first normalized by intracranial volume<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>, then converted into z-scores using the mean and standard deviation from a reference set of 3730 CN subjects covering the full lifespan. This double normalization accounts for inter-individual and inter-structural variability<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. The HAVAs score was then computed as the sum of the hippocampal and amygdalar z-scores, from which the z-scores of the inferior lateral ventricle is subtracted, based on the observation that AD is associated with atrophy in the hippocampus and amygdala and enlargement of the ventricle. Left and right HAVAs scores were also z-normalized using the same reference population.</p></sec><sec id="Sec13"><title>Performance metrics</title><p id="Par32">To evaluate the effectiveness of each segmentation method in distinguishing between AD and CN subjects, we computed standard classification metrics. These include sensitivity (or true positive rate), specificity (or true negative rate), balanced accuracy (the average of sensitivity and specificity), and the area under the ROC curve (AUC). A higher AUC indicates better discrimination between the two groups (AD vs. CN). Values closer to 1 reflect excellent performance, while values near 0.5 indicate performance close to chance. AUC values above 0.80 are typically considered clinically meaningful<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. These metrics provide insight into the algorithm&#8217;s ability to correctly classify both group.</p></sec></sec></sec><sec id="Sec14"><title>Results</title><p id="Par33">This study presents results with volumes normalized by the intracranial volume (ICV).</p><sec id="Sec15"><title>Curve stability assessment</title><p id="Par34">The first row of Fig. <xref rid="Fig3" ref-type="fig">3</xref> presents reference curves for the left hippocampus, with curves for other regions available on <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://gitlab.com/geodaisics1/Estimation_of_reference_curves_for_brain_atrophy_and_analysis_of_robustness_to_machine_effects">https://gitlab.com/geodaisics1/ Estimation_of_reference_curves_for_brain_atrophy_and _analysis_of_ro bustness_to_machine_effects</ext-link>. The differences in FastSurfer&#8217;s reference curves compared to AssemblyNet and FreeSurfer suggest that using FastSurfer may yield varying results, potentially providing different information and influencing final diagnoses.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Reference curves for the left hippocampus (using concave smoothing), computed using data from different magnetic field strengths: 1.5T + 3T combined (first row: points colored by study; second row: points colored by field strength), only 1.5T (third row), and only 3T (fourth row). Each column corresponds to one of the three segmentation algorithms evaluated in the study. Each dot represents one subject. The 5th (red), 50th (green), and 95th (red) expectiles were computed to characterize the range of variability. AssemblyNet appears less sensitive to magnetic field strength variations compared to FastSurfer and FreeSurfer.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="41598_2025_18073_Fig3_HTML.jpg"/></fig></p><sec id="Sec16"><title>Evaluation of the consistency of reference curves across magnetic field strengths</title><p id="Par35"><bold>Preliminary results</bold> We calculated the median percentage volume difference of 3730 subjects segmented by AssemblyNet, FastSurfer, and FreeSurfer, both with and without normalization by ICV (Supplementary Section S3, Fig. S2). For non-normalized volumes, the median percentage differences were 2.53% for AssemblyNet, 5.60% for FastSurfer, and 6.15% for FreeSurfer. The median percentage differences were 2.54% for AssemblyNet, 10.38% for FastSurfer, and 9.05% for FreeSurfer when normalized by the ICV.</p><p id="Par36"><bold>Visual analysis</bold> Observing the points in the first row of Fig. <xref rid="Fig3" ref-type="fig">3</xref>, we noticed a greater dispersion of data for FastSurfer compared to the other two algorithms. To analyze the organization of these dots, especially for FastSurfer, and to determine if their positions are influenced by an acquisition parameter, we therefore repeated the first row of Fig. <xref rid="Fig3" ref-type="fig">3</xref> but color-coding the points according to the magnetic field strength of the MRI machine in which the images were acquired. This is shown in the first line of Fig. <xref rid="Fig3" ref-type="fig">3</xref>. We then built additional reference curves using only the data from images acquired at 1.5T, shown in the second line of Fig. <xref rid="Fig3" ref-type="fig">3</xref>, and only the images acquired at 3T, shown in the third line of the same figure, for all three segmentation algorithms in the study. Visually, a slight study effect can be observed for all three algorithms, indicating minor variations in segmentation results across different studies. However, this effect is considerably weaker than the influence of magnetic field strength, which remains the primary source of variability in our Figures. Moreover, assessing the impact of study-related differences is not the focus of this article, especially since the number of subjects from different studies within each age range is insufficient to robustly evaluate this effect. Additional sources of variability such as sex and scanner effects are also considered: please refer to Supplementary Section S4, Fig. S3 and Discussion for the sex effect, and Supplementary Section S5, Figs. S4 and Fig. S5 and Discussion for the scanner effect. Please refer to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://gitlab.com/geodaisics1/Estimation_of_reference_curves_for_brain_atrophy_and_analysis_of_robustness_to_machine_effects">https://gitlab.com/geodaisics1/ Estimation_of_reference_curves_for_brain _atrophy_and _analysis_of_robustness_to_machine_effects</ext-link> to view those curves for other regions. The visual differences in reference curves as a function of training data indicate that FastSurfer is not robust to magnetic field intensity.</p><p id="Par37">
<bold>Measure of errors between curves</bold>
</p><p id="Par38">In this section, we assess the performance of segmentation algorithms by directly comparing reference curves calculated with data from 3T MRI scans to curves predicted using data from 1.5T MRI scans (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). This approach enables us to evaluate how each algorithm performs when applied across datasets with differing MRI field strengths, reflecting the variability introduced by different MRI field strengths. The robustness of the segmentation algorithms is assessed based on their ability to maintain reference values despite changes in the magnetic field strength.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Values of different error metrics: (<bold>a</bold>) sMSPE (symmetric Mean Squared Percentage Error), (<bold>b</bold>) sMAPE (Symmetric Mean Absolute Percentage Error), (<bold>c</bold>) wMAPE (Weighted Mean Absolute Percentage Error), and (<bold>d</bold>) sMdAPE (Symmetric Median Absolute Percentage Error); for the three algorithms (AssemblyNet, FastSurfer, and FreeSurfer). The errors were calculated between the reference curves constructed with data from 1.5T MRI scans and the reference curves predicted using data from 3T MRI scans. AssemblyNet consistently shows lower error metric values compared to FastSurfer and FreeSurfer for all bounds and metrics.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="41598_2025_18073_Fig4_HTML.jpg"/></fig></p><p id="Par39">AssemblyNet achieves the lowest sMSPE for all bounds. Since sMSPE emphasizes larger errors, the smaller values for AssemblyNet indicate that its predictions are consistently closer to the reference curves with fewer large errors. AssemblyNet consistently on sMAPE values outperforms FastSurfer and FreeSurfer across all bounds with lower sMAPE values. A lower sMAPE indicates that AssemblyNet is more robust to magnetic field strength. The lower wMAPE for AssemblyNet indicates that it can maintain high accuracy across different volume sizes, making it more reliable when the data has a wide range of volumes. AssemblyNet achieves the lowest sMdAPE for all bounds. The results for the MASE metric are available in Supplementary Section S6, Fig. S6, and will be discussed in the Discussion section. In conclusion, AssemblyNet consistently outperforms FastSurfer and FreeSurfer in terms of robustness. AssemblyNet&#8217;s superior performance across these metrics, especially sMAPE, sMSPE, and wMAPE, indicates that it is more capable of providing reliable volume predictions, even when faced with the variability introduced by different MRI field strengths.</p><p id="Par40">
<bold>Method for identifying biases related to magnetic field strength: bootstrapping</bold>
</p><p id="Par41">The evaluation of bias related to the magnetic field strength, comparing 1.5T and 3T MRI reference curves using bootstrapping, reveals distinct patterns across the three algorithms (Fig. <xref rid="Fig5" ref-type="fig">5</xref> illustrates sMAPE values; for other metrics and views, please refer to Supplementary Section S7, Fig. S7 (sMdAPE), Fig. S8 (sMSPE) and Fig. S9 (wMAPE)).<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Histograms showing the distribution of sMAPE (symmetric Mean Absolute Percentage Error) values across 10,000 bootstrap iterations with randomized field strength labels. Columns correspond to segmentation algorithms (AssemblyNet, FastSurfer and FreeSurfer), while rows represent boundary conditions (lower, mean and upper bounds). The red line indicates the observed/true label value (&#8220;Obs&#8221;), i.e., the error metric calculated between the 1.5T and 3T reference curves using the true field strength labels, and the black lines mark the 5th and 95th percentiles. The histogram represents the distribution (y) of metric values (x) obtained from 10,000 bootstrap iterations with randomized field strength labels. This distribution estimates the range of metric variability expected by chance. If the observed value (red line, the true metric value) falls outside the 5th-95th percentile of the bootstrap distribution, it indicates a statistically significant bias likely driven by magnetic field strength rather than random variability. AssemblyNet exhibits fewer true-label values outside the 5th-95th percentiles compared to FastSurfer and FreeSurfer, indicating it is less biased by differences related to magnetic field strength.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="41598_2025_18073_Fig5_HTML.jpg"/></fig></p><p id="Par42">For AssemblyNet, the true-label values of the sMAPE, sMdAPE and wMAPE fall within the bootstrapped bounds for the lower bound but are slightly outside the 95th percentile for the mean and upper bound indicating a slight magnetic field-related bias. Conversely, sMSPE values for AssemblyNet consistently fall within the bootstrapped bounds across all bounds. In contrast, FastSurfer shows significant deviations for all metrics across configurations, indicating a pronounced bias likely driven by magnetic field effects. Similar trends are observed for sMdAPE and wMAPE. The substantial distances highlight that FastSurfer metrics are heavily influenced by magnetic field strength. FreeSurfer displays similar trends, with marked deviations across metrics, again reflecting strong magnetic field-related effects. In summary, while AssemblyNet exhibits minor deviations, FastSurfer and FreeSurfer demonstrate significant biases across all metrics. These findings suggest that FastSurfer and FreeSurfer are more sensitive to magnetic field differences, while AssemblyNet provides relatively stable results.</p></sec></sec><sec id="Sec17"><title>Atrophy assessment</title><sec id="Sec18"><title>Hippocampal atrophy sensitivity analysis</title><p id="Par43">Table <xref rid="Tab3" ref-type="table">3</xref> shows the percentage of subjects with left/right hippocampal atrophy. For the control group, the percentages of subjects showing hippocampal atrophy according to AssemblyNet are notably consistent across all reference curves. In contrast, FastSurfer exhibits variability. FreeSurfer also shows some variability, though it is more stable compared to FastSurfer. For the pathological group, the percentage of Alzheimer&#8217;s patients with hippocampal atrophy is very stable with AssemblyNet, while FastSurfer shows more variability than FreeSurfer. There is a significant difference (McNemar test, p &lt; 0.05)(R version 4.5.0) in the atrophy percentage between AssemblyNet and FreeSurfer, and between FastSurfer and FreeSurfer, across all models.<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Percentage of control and AD subjects showing left/right hippocampal atrophy (for each cell: value1: left/value2: right), according to algorithms (columns) and reference curves used (rows) (concave smoothing). Controls: controls subjects; AD: Alzheimer&#8217;s patients. For both groups, AssemblyNet shows a stable percentage of subjects with hippocampal atrophy, while FastSurfer exhibits more variability than FreeSurfer.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"><bold>Reference curves</bold></th><th align="left" colspan="3" rowspan="1"><bold>Controls</bold></th><th align="left" colspan="3" rowspan="1"><bold>AD patients</bold></th></tr><tr><th align="left" colspan="1" rowspan="1"><bold>AN</bold></th><th align="left" colspan="1" rowspan="1"><bold>Fast</bold></th><th align="left" colspan="1" rowspan="1"><bold>Free</bold></th><th align="left" colspan="1" rowspan="1"><bold>AN</bold></th><th align="left" colspan="1" rowspan="1"><bold>Fast</bold></th><th align="left" colspan="1" rowspan="1"><bold>Free</bold></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1.5T+3T data</td><td align="left" colspan="1" rowspan="1">11.76/8.24</td><td align="left" colspan="1" rowspan="1">12.94/12.55</td><td align="left" colspan="1" rowspan="1">9.41/9.02</td><td align="left" colspan="1" rowspan="1">77.17/67.58</td><td align="left" colspan="1" rowspan="1">84.47/80.82</td><td align="left" colspan="1" rowspan="1">81.74/76.26</td></tr><tr><td align="left" colspan="1" rowspan="1">1.5T data</td><td align="left" colspan="1" rowspan="1">10.59/8.24</td><td align="left" colspan="1" rowspan="1">7.45/7.06</td><td align="left" colspan="1" rowspan="1">5.10/4.31</td><td align="left" colspan="1" rowspan="1">77.17/68.04</td><td align="left" colspan="1" rowspan="1">80.37/73.52</td><td align="left" colspan="1" rowspan="1">70.78/67.58</td></tr><tr><td align="left" colspan="1" rowspan="1"> 3T data</td><td align="left" colspan="1" rowspan="1">12.6/8.24</td><td align="left" colspan="1" rowspan="1">22.75/19.61</td><td align="left" colspan="1" rowspan="1">12.16/12.94</td><td align="left" colspan="1" rowspan="1">78.54/67.12</td><td align="left" colspan="1" rowspan="1">89.50/85.84</td><td align="left" colspan="1" rowspan="1">86.30/79.91</td></tr></tbody></table></table-wrap><table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Classification scores related to the left/right hippocampus (for each cell: value1: left/value2: right), with rows corresponding to models and columns to segmentation algorithms.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"><bold>Metrics</bold></th><th align="left" colspan="1" rowspan="1"><bold>References</bold></th><th align="left" colspan="1" rowspan="1"><bold>AssemblyNet</bold></th><th align="left" colspan="1" rowspan="1"><bold>FastSurfer</bold></th><th align="left" colspan="1" rowspan="1"><bold>FreeSurfer</bold></th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">Sensitivity</td><td align="left" colspan="1" rowspan="1">1.5T and 3T</td><td align="left" colspan="1" rowspan="1">0.77/0.68</td><td align="left" colspan="1" rowspan="1">0.85/0.81</td><td align="left" colspan="1" rowspan="1">0.82/0.76</td></tr><tr><td align="left" colspan="1" rowspan="1">1.5T</td><td align="left" colspan="1" rowspan="1">0.78/0.68</td><td align="left" colspan="1" rowspan="1">0.81/0.74</td><td align="left" colspan="1" rowspan="1">0.75/0.71</td></tr><tr><td align="left" colspan="1" rowspan="1">3T</td><td align="left" colspan="1" rowspan="1">0.79/0.68</td><td align="left" colspan="1" rowspan="1">0.89/0.86</td><td align="left" colspan="1" rowspan="1">0.87/0.81</td></tr><tr><td align="left" rowspan="3" colspan="1">Specificity</td><td align="left" colspan="1" rowspan="1">1.5T and 3T</td><td align="left" colspan="1" rowspan="1">0.87/0.91</td><td align="left" colspan="1" rowspan="1">0.86/0.87</td><td align="left" colspan="1" rowspan="1">0.90/0.91</td></tr><tr><td align="left" colspan="1" rowspan="1">1.5T</td><td align="left" colspan="1" rowspan="1">0.89/0.91</td><td align="left" colspan="1" rowspan="1">0.92/0.93</td><td align="left" colspan="1" rowspan="1">0.93/0.93</td></tr><tr><td align="left" colspan="1" rowspan="1">3T</td><td align="left" colspan="1" rowspan="1">0.87/0.91</td><td align="left" colspan="1" rowspan="1">0.76/0.80</td><td align="left" colspan="1" rowspan="1">0.87/0.86</td></tr><tr><td align="left" rowspan="3" colspan="1">Balanced Accuracy</td><td align="left" colspan="1" rowspan="1">1.5T and 3T</td><td align="left" colspan="1" rowspan="1">0.82/0.80</td><td align="left" colspan="1" rowspan="1">0.86/0.84</td><td align="left" colspan="1" rowspan="1">0.86/0.84</td></tr><tr><td align="left" colspan="1" rowspan="1">1.5T</td><td align="left" colspan="1" rowspan="1">0.83/0.80</td><td align="left" colspan="1" rowspan="1">0.86/0.84</td><td align="left" colspan="1" rowspan="1">0.84/0.82</td></tr><tr><td align="left" colspan="1" rowspan="1">3T</td><td align="left" colspan="1" rowspan="1">0.83/0.79</td><td align="left" colspan="1" rowspan="1">0.83/0.83</td><td align="left" colspan="1" rowspan="1">0.87/0.84</td></tr><tr><td align="left" rowspan="3" colspan="1">Area under the ROC curve</td><td align="left" colspan="1" rowspan="1">1.5T and 3T</td><td align="left" colspan="1" rowspan="1">0.85/0.81</td><td align="left" colspan="1" rowspan="1">0.90/0.88</td><td align="left" colspan="1" rowspan="1">0.88/0.86</td></tr><tr><td align="left" colspan="1" rowspan="1">1.5T</td><td align="left" colspan="1" rowspan="1">0.85/0.81</td><td align="left" colspan="1" rowspan="1">0.88/0.85</td><td align="left" colspan="1" rowspan="1">0.85/0.83</td></tr><tr><td align="left" colspan="1" rowspan="1">3T</td><td align="left" colspan="1" rowspan="1">0.86/0.81</td><td align="left" colspan="1" rowspan="1">0.91/0.89</td><td align="left" colspan="1" rowspan="1">0.91/0.87</td></tr></tbody></table></table-wrap></p><p id="Par44">Table <xref rid="Tab4" ref-type="table">4</xref> provides the classification performance scores for the detection of left hippocampal atrophy across segmentation algorithms and reference curves. Supplementary Section S8, Fig. S10 shows ROC curves for the left hippocampus. Although AssemblyNet shows slightly lower classification metrics than FastSurfer and FreeSurfer, it consistently demonstrates greater stability across all reference models. In contrast, FastSurfer and FreeSurfer exhibit more variability, with performance scores fluctuating significantly depending on magnetic field strength. For example, regarding specificity, AssemblyNet ranges between 0.87 and 0.91 (considering both left and right hippocampus and all models), while FastSurfer ranges from 0.76 to 0.93, and FreeSurfer from 0.86 to 0.93. This supports the earlier observation that AssemblyNet is more robust to acquisition differences compared to the other segmentation tools.</p></sec><sec id="Sec19"><title>HAVAs results</title><p id="Par45">Supplementary Section S9, Fig. S11 presents the reference curves for the hippocampus, amygdala, and inferior lateral ventricle, across segmentation algorithms. A sensitivity to magnetic field strength is observed for FastSurfer and FreeSurfer, particularly for the hippocampus and amygdala, as indicated by the distribution of colored points according to field strength. However, as shown in Supplementary Section S9, Fig. S12, the HAVAs score appears to reduce this sensitivity to magnetic field strength, likely due to the two-step z-score normalization applied during its computation.</p><p id="Par46">Table <xref rid="Tab5" ref-type="table">5</xref> presents the percentages of HAVAs scores considered pathological (i.e., scores falling below the 5th percentile of the reference curve) across CN subjects and AD patients, for each model and segmentation algorithms. In CN subjects, AssemblyNet yields overall lower atrophy percentages compared to FastSurfer and FreeSurfer (with a maximum value of 21.96% for AssemblyNet, versus 40.39% for FastSurfer and 33.73% for FreeSurfer). Moreover, AssemblyNet shows a narrower range of atrophy percentages (5.10% to 14.12%), while FastSurfer and FreeSurfer exhibit wider ranges (16.08% to 40.39% and 14.51% to 33.73%, respectively). In AD patients, the percentage of pathological scores is higher, as expected. AssemblyNet again shows slightly lower values (ranging from 82.19% to 94.98%) compared to FastSurfer (87.21% to 97.71%) and FreeSurfer (84.02% to 96.35%).<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Percentages of abnormally low (i.e., scores falling below the 5th percentile of the reference curve) left/right HAVAs scores (for each cell: value1: left/value2: right) in cognitively normal subjects (CN) and Alzheimer&#8217;s disease (AD) patients, for each model considered.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">References</th><th align="left" colspan="3" rowspan="1"><bold>CN</bold></th><th align="left" colspan="3" rowspan="1"><bold>AD</bold></th></tr><tr><th align="left" colspan="1" rowspan="1">AN</th><th align="left" colspan="1" rowspan="1">FastSurfer</th><th align="left" colspan="1" rowspan="1">FreeSurfer</th><th align="left" colspan="1" rowspan="1">AN</th><th align="left" colspan="1" rowspan="1">FastSurfer</th><th align="left" colspan="1" rowspan="1">FreeSurfer</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1.5T and 3T</td><td align="left" colspan="1" rowspan="1">9.41/12.55</td><td align="left" colspan="1" rowspan="1">19.61/18.43</td><td align="left" colspan="1" rowspan="1">16.86/14.12</td><td align="left" colspan="1" rowspan="1">89.04/86.30</td><td align="left" colspan="1" rowspan="1">95.43/92.24</td><td align="left" colspan="1" rowspan="1">93.15/91.78</td></tr><tr><td align="left" colspan="1" rowspan="1">1.5T</td><td align="left" colspan="1" rowspan="1">14.12/21.96</td><td align="left" colspan="1" rowspan="1">40.39/34.51</td><td align="left" colspan="1" rowspan="1">33.73/32.94</td><td align="left" colspan="1" rowspan="1">94.98/93.15</td><td align="left" colspan="1" rowspan="1">97.71/95.43</td><td align="left" colspan="1" rowspan="1">96.35/94.98</td></tr><tr><td align="left" colspan="1" rowspan="1">3T</td><td align="left" colspan="1" rowspan="1">5.10/9.02</td><td align="left" colspan="1" rowspan="1">16.08/18.04</td><td align="left" colspan="1" rowspan="1">14.51/15.69</td><td align="left" colspan="1" rowspan="1">87.67/82.19</td><td align="left" colspan="1" rowspan="1">87.21/87.21</td><td align="left" colspan="1" rowspan="1">84.02/87.67</td></tr></tbody></table></table-wrap></p><p id="Par47">Table <xref rid="Tab6" ref-type="table">6</xref> presents the classification scores between AD patients and CN subjects obtained using the HAVAs method, across the different models and algorithms. Supplementary Section S9, Fig. S13 shows the ROC curves for the left HAVAs. When comparing the models derived from 1.5T and 3T data (HAVAs left), FastSurfer and FreeSurfer stand out with higher sensitivity (0.95 and 0.93 respectively), compared to 0.89 for AssemblyNet. However, AssemblyNet achieves both the highest specificity (0.91 vs. 0.80 for FastSurfer and 0.83 for FreeSurfer) and the highest balanced accuracy (0.90 vs. 0.88 for FastSurfer and FreeSurfer). Expanding the analysis to all three models (1.5T-only, 3T-only, and combined)(HAVAs left), we observe that the specificity of FastSurfer and FreeSurfer drops significantly compared to AssemblyNet, with minimum values of 0.60 and 0.66, respectively, versus 0.86 for AssemblyNet. These results suggest that FastSurfer, due to its higher sensitivity, may be more effective at detecting Alzheimer&#8217;s cases. However, AssemblyNet, with its superior specificity and balanced accuracy, provides a better trade-off between correctly identifying both AD patients and healthy controls.<table-wrap id="Tab6" position="float" orientation="portrait"><label>Table 6</label><caption><p>Classification scores obtained with the left/right HAVAs scores (for each cell: value1: left/value2: right), organized by model (rows) and segmentation algorithm (columns).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"><bold>Metrics</bold></th><th align="left" colspan="1" rowspan="1"><bold>References</bold></th><th align="left" colspan="1" rowspan="1"><bold>AssemblyNet</bold></th><th align="left" colspan="1" rowspan="1"><bold>FastSurfer</bold></th><th align="left" colspan="1" rowspan="1"><bold>FreeSurfer</bold></th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">Sensitivity</td><td align="left" colspan="1" rowspan="1">1.5T and 3T</td><td align="left" colspan="1" rowspan="1">0.89/0.86</td><td align="left" colspan="1" rowspan="1">0.95/0.92</td><td align="left" colspan="1" rowspan="1">0.93/0.92</td></tr><tr><td align="left" colspan="1" rowspan="1">1.5T</td><td align="left" colspan="1" rowspan="1">0.95/0.93</td><td align="left" colspan="1" rowspan="1">0.98/0.95</td><td align="left" colspan="1" rowspan="1">0.96/0.95</td></tr><tr><td align="left" colspan="1" rowspan="1">3T</td><td align="left" colspan="1" rowspan="1">0.88/0.82</td><td align="left" colspan="1" rowspan="1">0.87/0.87</td><td align="left" colspan="1" rowspan="1">0.84/0.88</td></tr><tr><td align="left" rowspan="3" colspan="1">Specificity</td><td align="left" colspan="1" rowspan="1">1.5T and 3T</td><td align="left" colspan="1" rowspan="1">0.91/0.87</td><td align="left" colspan="1" rowspan="1">0.80/0.82</td><td align="left" colspan="1" rowspan="1">0.83/0.86</td></tr><tr><td align="left" colspan="1" rowspan="1">1.5T</td><td align="left" colspan="1" rowspan="1">0.86/0.78</td><td align="left" colspan="1" rowspan="1">0.60/0.65</td><td align="left" colspan="1" rowspan="1">0.66/0.67</td></tr><tr><td align="left" colspan="1" rowspan="1">3T</td><td align="left" colspan="1" rowspan="1">0.95/0.91</td><td align="left" colspan="1" rowspan="1">0.84/0.82</td><td align="left" colspan="1" rowspan="1">0.85/0.84</td></tr><tr><td align="left" rowspan="3" colspan="1">Balanced Accuracy</td><td align="left" colspan="1" rowspan="1">1.5T and 3T</td><td align="left" colspan="1" rowspan="1">0.90/0.87</td><td align="left" colspan="1" rowspan="1">0.88/0.87</td><td align="left" colspan="1" rowspan="1">0.88/0.89&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">1.5T</td><td align="left" colspan="1" rowspan="1">0.90/0.86</td><td align="left" colspan="1" rowspan="1">0.79/0.80</td><td align="left" colspan="1" rowspan="1">0.81/0.81</td></tr><tr><td align="left" colspan="1" rowspan="1">3T</td><td align="left" colspan="1" rowspan="1">0.91/0.87</td><td align="left" colspan="1" rowspan="1">0.86/0.85</td><td align="left" colspan="1" rowspan="1">0.85/0.86</td></tr><tr><td align="left" rowspan="3" colspan="1">Area under the ROC curve</td><td align="left" colspan="1" rowspan="1">1.5T and 3T</td><td align="left" colspan="1" rowspan="1">0.93/0.90</td><td align="left" colspan="1" rowspan="1">0.94/0.93</td><td align="left" colspan="1" rowspan="1">0.93/0.94</td></tr><tr><td align="left" colspan="1" rowspan="1">1.5T</td><td align="left" colspan="1" rowspan="1">0.95/0.93</td><td align="left" colspan="1" rowspan="1">0.92/0.91</td><td align="left" colspan="1" rowspan="1">0.92/0.92</td></tr><tr><td align="left" colspan="1" rowspan="1">3T</td><td align="left" colspan="1" rowspan="1">0.93/0.89</td><td align="left" colspan="1" rowspan="1">0.89/0.89</td><td align="left" colspan="1" rowspan="1">0.88/0.90</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec20"><title>Atrophy stability analysis</title><p id="Par48">
<bold>Longitudinal analysis</bold>
</p><p id="Par49">Supplementary Section S10, Fig. S14, Fig. S15 and Fig. S16 shows left hippocampal volumes of control and AD subjects from the MIRIAD dataset, acquired during follow-ups, overlaid with reference curves from the three algorithms (using 1.5T and 3T data). This comparison enabled us to assess the consistency and reliability of each algorithm in detecting atrophy over time. For the healthy subjects, most subjects showed no signs of atrophy across all algorithms, indicating that the algorithms generally agree when there is no pathological change. However, discrepancies were observed in some cases. For instance, subject 230 was consistently atrophied, with important variations specifically in FreeSurfer&#8217;s results. Subject 231 showed no atrophy with AssemblyNet, consistent atrophy with FastSurfer, and fluctuating results with FreeSurfer. In the AD subjects, the majority were consistently identified as atrophied across all algorithms, which aligns with the expected progression of AD. However, there were notable exceptions, such as subject 191, where FreeSurfer and FastSurfer detected atrophy consistently, but AssemblyNet did not until the penultimate session. Overall, these findings suggest that while all three algorithms can reliably detect atrophy, there are differences in sensitivity and stability, particularly in borderline.</p><p id="Par50">
<bold>Inter-sites analysis</bold>
</p><p id="Par51">In this study, we used MRI data from the SRPBS traveling subjects. Brain volumes extracted from scans acquired at different sites were projected onto the reference curves for evaluation. Details of this analysis are provided in the Supplementary Section S11, Fig. S17. Supplementary Section S11, Table S2 summarizes the atrophy assessments obtained for SRPBS subjects using the three segmentation algorithms. Overall, FastSurfer exhibits greater variability across sites compared to AssemblyNet and FreeSurfer, suggesting reduced robustness in multi-site settings.</p></sec></sec></sec><sec id="Sec21"><title>Discussion</title><p id="Par52">The objectives of this study were to evaluate the robustness and sensitivity of three MRI segmentation algorithms in constructing reference curves for brain atrophy assessment in neurodegenerative diseases, with a focus on hippocampal volumes. The study aimed to determine which algorithm produces the most stable reference curves under varying magnetic field conditions and which algorithm provides the most consistent detection of hippocampal atrophy, a key marker in Alzheimer&#8217;s disease. Evaluating the impact of the machine effect and sensitivity is essential, as variability in MRI acquisition parameters and algorithm performance can compromise the reliability and the conclusion of study of reference curves.</p><p id="Par53">Our results indicate that AssemblyNet is the most robust algorithm, consistently generating stable reference curves with minimal impact from variations in magnetic field strength. This robustness is particularly valuable in industrial settings, where data often come from heterogeneous sources, including varying MRI field strengths and different scanner models. In such contexts, covariates like magnetic field strength may not be correctable. Therefore, segmentation methods that are intrinsically robust to these variations are highly advantageous for large-scale deployment. In contrast, FastSurfer displays significant instability, with notable differences in reference curves depending on the MRI field strength. This lack of stability suggests that FastSurfer may not be the optimal choice when consistency across different imaging environments is required. Additionally, AssemblyNet also provides more consistent estimates of hippocampal atrophy and HAVAs scores compared to the other algorithms, though the atrophy percentages were generally lower.</p><sec id="Sec22"><title>Reference modeling: addressing confounding factors including imaging variability</title><sec id="Sec23"><title>Accounting for confounders in normative modeling</title><p id="Par54">Confounding variables such as age, sex, scanners effects and MRI field strength can influence brain volumetric measurements and impact the construction of normative models. Addressing these confounders is essential for building accurate and generalizable lifespan trajectories. A review<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> found that, among 13 normative modeling studies, 7 included only age as a covariate, 4 included both age and sex. Only one study<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> accounted for field strength, but without justifying this choice.</p><p id="Par55">In our approach, age is directly modeled through GAMs, while sex-related differences are addressed via ICV normalization<sup><xref ref-type="bibr" rid="CR56">56</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR57">57</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR58">58</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. This approach is widely used to compensate for head size differences, a major source of inter-individual variability in brain volume measurements. Without ICV correction, differences in regional volumes may reflect cranial size rather than meaningful biological effects. For instance, part of the apparent sex difference in brain volumes is explained by ICV disparities and applying normalization substantially reduces or eliminates these differences<sup><xref ref-type="bibr" rid="CR59">59</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR60">60</xref></sup>. ICV normalization is particularly important for assessing regional volume changes relative to maximum brain size, which is critical in studies of atrophy<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>. It also improves statistical sensitivity, enabling group comparisons with smaller sample sizes, especially in hippocampal studies<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>. Furthermore, ICV normalization contributes to reducing scanner-related variability, thereby enhancing comparability across MRI platforms<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Previous work using AssemblyNet has shown that, without normalization, males consistently exhibit larger brain volumes than females across most structures<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. However, after ICV normalization, these differences largely disappear, suggesting that explicit inclusion of sex as a covariate may not be necessary. Our findings support this interpretation: without normalization, small sex effects were observed across all algorithms, with males generally showing higher hippocampal volumes. After normalization, these effects became very small for AssemblyNet, while FastSurfer and FreeSurfer exhibited persistent differences (please refer to Supplementary Section S4, Fig. S3).</p><p id="Par56">In summary, our modeling framework accounts for age via GAMs and sex through ICV normalization. Field strength was not included as a formal covariate, but its influence was assessed post hoc. Scanner-related effects are discussed in more detail in Section <xref rid="Sec24" ref-type="sec">4.1</xref>.</p></sec><sec id="Sec24"><title>Magnetic field strength and scanner model effects: considerations and limitations</title><p id="Par57">Machine effects are complex and multifactorial, as reported in numerous studies<sup><xref ref-type="bibr" rid="CR63">63</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR9">9</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR64">64</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR65">65</xref></sup>. The variability observed in data can indeed arise from multiple sources, including not only magnetic field strength<sup><xref ref-type="bibr" rid="CR66">66</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR67">67</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR63">63</xref></sup>, but also vendor<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>, model<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>, software version<sup><xref ref-type="bibr" rid="CR68">68</xref></sup>, sequence parameters<sup><xref ref-type="bibr" rid="CR8">8</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR65">65</xref></sup> or gradient non-linearities<sup><xref ref-type="bibr" rid="CR69">69</xref></sup>. Although some studies report minimal effects of magnetic field strength on volumetric estimates, especially for global measures<sup><xref ref-type="bibr" rid="CR66">66</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR63">63</xref></sup>, others have shown regional differences, particularly in areas with low contrast or complex anatomy<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>. Moreover, Marchewka et al., (2014)<sup><xref ref-type="bibr" rid="CR70">70</xref></sup> did not observe significant differences in hippocampal or amygdalar volumes between field strengths in epilepsy cohorts, especially when using high-quality standardized protocols such as those from ADNI. However, Marchewka et al., (2014)<sup><xref ref-type="bibr" rid="CR70">70</xref></sup> also reported magnetic field strength-related differences in gray matter volume in the cerebellum, precentral cortex, and thalamus, regions known to be sensitive to scanner parameters and segmentation challenges. These regional effects are consistent with several previous studies<sup><xref ref-type="bibr" rid="CR71">71</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR72">72</xref></sup>, and segmentation accuracy has been shown to improve at 3T in difficult regions due to better contrast-to-noise ratio<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>. In parallel, scanner model effects are also documented. For example, Yang et al., (2016)<sup><xref ref-type="bibr" rid="CR64">64</xref></sup> found significant variability across models in over 12% of brain regions using FreeSurfer.</p><p id="Par58">In this work, we chose to focus specifically on the magnetic field strength (1.5T vs. 3T) as a proxy of machine-related variability for several reasons. First, as shown in the Supplementary Section S5, Fig. S5, within a given scanner model (Intera), volumetric differences between 1.5T and 3T scans were greater than those observed between different scanner models operating at the same field strength. This suggests that, in our dataset, magnetic field strength exerts a more dominant effect than vendor or model. Second, scanner models were not evenly distributed across age groups, limiting our ability to disentangle model and vendor effects independently of age (please refer to Supplementary Section S5, Fig. S4). Such an analysis would require well-balanced subgroups across all age bins and scanner types, which is not achievable with the current data. Given these considerations, magnetic field strength was selected as the most interpretable and impactful axis of variability for this robustness study. We acknowledge that more granular investigations of vendor, model, and sequence-related effects would be valuable.</p></sec><sec id="Sec25"><title>The &#8220;gold standard&#8221; issue</title><p id="Par59">Manual segmentation is traditionally used as the reference, often termed the &#8220;gold standard&#8221;, for evaluating automated brain segmentation methods. However, this designation is increasingly questioned, as manual labeling suffers from limited reproducibility, with intra-rater agreement frequently falling below 80%. For example, using the BrainCOLOR protocol, intra-rater Dice scores (i.e., between repeated manual segmentations) were estimated at 76.8%<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. This level of agreement is comparable to the consistency observed between manual and automated segmentations: 75.8% for AssemblyNet using the same protocol, and approximately 80% for FastSurfer (80.19% subcortical, 80.65% cortical) on the Mindboggle-101 dataset<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. Moreover, Coupe et al., (2020)<sup><xref ref-type="bibr" rid="CR44">44</xref></sup> reported intra-method Dice scores of 92.8% for AssemblyNet (i.e., between scan and rescan automatic segmentations), again surpassing the manual intra-rater reproducibility. These results suggest that automated methods can be as consistent as human experts. These findings challenge the conventional use of manual segmentation as a gold standard.</p><p id="Par60">Although manual segmentations can serve as a reference for partial evaluation, this approach has important limitations. Both human raters and algorithms may exhibit similar biases, particularly in regions with ill-defined anatomical boundaries. This issue also applies to many automated methods: recent deep learning models such as FastSurfer, SynthSeg, and LOD-Brain are often trained on labels generated by FreeSurfer, thereby inheriting its structural biases, for example with hippocampal segmentation, as shown by Valabregue et al., (2024)<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>. These factors make it inherently difficult to determine how close a segmentation truly approximates the underlying anatomical ground truth.</p></sec><sec id="Sec26"><title>Median percentage volume differences between 1.5T and 3T and data</title><p id="Par61">To compare our volumes between 1.5T and 3T and data, we refer to Lee et al., (2024)<sup><xref ref-type="bibr" rid="CR74">74</xref></sup>, who assessed the reliability of FreeSurfer at 1.5T and 3T. They reported the following median volume differences for the left hippocampus: 3.63 cm&#179; for 1.5T and 3.70 cm&#179; for 3T, resulting in a 1.89% volume variation between the two field strengths (non-normalized analysis). For FreeSurfer, the higher variation observed for our study (6.15%) could be attributed to the larger and more diverse dataset of 3730 subjects (from 11 different datasets), as opposed to Lee et al., (2024)<sup><xref ref-type="bibr" rid="CR74">74</xref></sup>&#8217;s dataset of 101 patients (from 3 datasets). The larger sample size and the inclusion of multiple datasets likely contributed to the increased variability in segmentation results, particularly for FreeSurfer and FastSurfer.</p></sec></sec><sec id="Sec27"><title>Comparing modeling strategies for reference curves construction</title><sec id="Sec28"><title>Mean Absolute Scaled Error (MASE) evaluation</title><p id="Par62">The Mean Absolute Scaled Error (MASE) metric meets all inclusion criteria for our study. However, we observed that its value varied a lot depending on the number of points selected (please refer to Supplementary Section S6, Fig. S6). We hypothesize that this variation is due to the fact that our data follow very regular trends, where small errors can lead to elevated MASE values. This is in contrast to the findings of Liu et al., (2024)<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>, who reported MASE values between 0 and 0.15 when comparing reference curves with different datasets. In our case, we observe much higher MASE values, even when selecting only one point out of eight from our reference curves.</p></sec><sec id="Sec29"><title>Comparison of GAM-based curves with existing literature</title><p id="Par63">We compared our GAM-based reference curves to those published in Coupe et al., (2017)<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>, focusing on hippocampal atrophy percentages in both AD and CN subjects (please refer to Supplementary Section S12, Fig. S18 and Fig. S19). The results Supplementary Section S12, Table S3 show that AssemblyNet, when used with our GAM-based models, yields higher atrophy detection rates in AD patients (77.17% left/67.58% right) compared to the reference curves from Coupe et al., (2017)<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> (63.01%/59.36%). However, for CN subjects, our GAM curves detect a slightly higher percentage of atrophy (11.76%/8.24%) than those of Coupe et al., (2017)<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> (6.27%/4.31%). This trend is consistent across FastSurfer and FreeSurfer, where GAM-based curves yield both higher detection in AD and slightly elevated atrophy rates in controls. These findings suggest that while the GAM framework may offer improved sensitivity for detecting pathological deviations, it may also slightly increase atrophy detection in CN individuals. This trade-off is further discussed in Section <xref rid="Sec36" ref-type="sec">4.3</xref>.</p></sec><sec id="Sec30"><title>Limitations of reference curves and potential of manifold learning for complex analysis</title><p id="Par64">Reference curves are valuable for region-by-region analysis but face limitations in capturing the complexity of high-dimensional MRI data, which often exhibit correlations between brain regions due to the brain&#8217;s closed system. This challenge is further compounded by the lack of tools to effectively evaluate the robustness of these curves, particularly in the context of temporal data. In our case, the dataset includes brain volumes from approximately a hundred regions, adding to the analytical complexity. While reference curves are useful for localized assessments, they may fall short in capturing the global dynamics and intricate interdependencies among brain regions. Manifold learning algorithms offer a promising complementary approach by accounting for the interdependence between variables and revealing complex, non-linear relationships within high-dimensional datasets. These methods provide a more integrated and robust framework, enabling a deeper understanding of the global structure and intricate interactions within brain data<sup><xref ref-type="bibr" rid="CR75">75</xref></sup>.</p></sec></sec><sec id="Sec31"><title>Atrophy detection across acquisition conditions</title><sec id="Sec32"><title>Early atrophy detection considerations</title><p id="Par65">Our normative lifespan curves suggest that hippocampal volume decline begins at different ages depending on the segmentation algorithm: around 35 years for FastSurfer, 50 years for FreeSurfer, and approximately 55 years for AssemblyNet. However, prior studies indicate that hippocampal atrophy may begin earlier than these estimates suggest<sup><xref ref-type="bibr" rid="CR76">76</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR77">77</xref></sup>. It is important to note that volume trajectories are influenced not only by segmentation accuracy but also by the modeling strategy used to estimate them. In our case, the use of GAMs likely contributes to delay visible inflection points as earlier work using AssemblyNet on larger datasets has shown divergence between AD and normative hippocampal trajectories before the age of 40<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>, suggesting that AssemblyNet is indeed capable of detecting early pathological changes. Therefore, the later onset of decline observed in our curves likely reflects modeling limitations rather than segmentation constraints.</p><p id="Par66">More fundamentally, it is important to recognize that hippocampal atrophy visible on structural MRI occurs relatively late in the pathological cascade of AD. Alzheimer&#8217;s disease is characterized by the abnormal accumulation of proteins, including amyloid plaques and neurofibrillary tangles composed of tau. These anomalies disrupt neuronal function and trigger a cascade of toxic mechanisms. Neurons are progressively damaged, lose their connections, and ultimately die<sup><xref ref-type="bibr" rid="CR79">79</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR14">14</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR80">80</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR81">81</xref></sup>. The ATN framework<sup><xref ref-type="bibr" rid="CR82">82</xref></sup>, recently revisited in 2024<sup><xref ref-type="bibr" rid="CR83">83</xref></sup>, offers a biological staging system based on three biomarker categories: A for amyloid accumulation, T for tau pathology, and N for neurodegeneration. CSF biomarkers, measurable through lumbar puncture, can detect amyloid and tau abnormalities up to 15 years before clinical symptom onset<sup><xref ref-type="bibr" rid="CR84">84</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR85">85</xref></sup>. In contrast, neurodegeneration (N), as measured by structural MRI, reflects macroscopic neuronal loss and thus appears later in the disease process. In this context, although MRI remains a valuable tool for assessing neurodegeneration, it inherently captures late-stage processes. As such, efforts to improve early detection of AD may need to focus more on upstream biomarkers (A and T), while MRI-based approaches like ours are better suited for staging and differential diagnosis once neurodegeneration is established. Recent advances in blood-based diagnostics support this shift: improvements in mass spectrometry and antibody-based detection methods have enabled precise quantification of amyloid-<inline-formula id="IEq1"><alternatives><tex-math id="d33e4467">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\beta$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_18073_Article_IEq1.gif"/></alternatives></inline-formula> and various forms of tau in plasma, paving the way for faster, cheaper, and more accessible detection strategies<sup><xref ref-type="bibr" rid="CR86">86</xref></sup>.</p></sec><sec id="Sec33"><title>Reasons for robustness to magnetic field strength</title><p id="Par67">MRI field strength (1.5T vs. 3T) impacts tissue contrast and signal-to-noise ratio, which can significantly influence segmentation accuracy, especially for methods relying heavily on voxel intensity. Previous studies have shown that higher field strength generally improves segmentation accuracy, particularly in challenging anatomical regions due to better contrast-to-noise ratios<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>. Our results consistently show that AssemblyNet is more robust to magnetic field strength variations compared to FastSurfer and FreeSurfer. This robustness can be attributed to several key aspects of its segmentation architecture and design.</p><p id="Par68">First, AssemblyNet relies on a multiscale 3D deep learning framework composed of 250 U-Net models distributed across two levels of resolution. The first level performs coarse segmentation on overlapping 3D regions (2x2x2 mm3), each independently processed by a dedicated U-Net. A majority voting scheme aggregates the overlapping outputs, effectively introducing spatial redundancy that enhances robustness to contrast variability. The overlap of at least 50% between adjacent regions reinforces this effect by ensuring that the same anatomical region is processed by multiple models. Then, in a second stage, the coarse segmentation is refined using a finer resolution (1x1x1 mm3), improving anatomical boundary delineation. This multi-resolution approach substantially increases the number of learnable parameters (by nearly a factor of ten) allowing more precise modeling of tissue boundaries. According to Coupe et al., (2019)<sup><xref ref-type="bibr" rid="CR87">87</xref></sup>, this two-stage cascade was specifically designed to improve robustness. In addition, the model incorporates a novel nearest-neighbor transfer learning scheme: the weights from a trained U-Net are propagated to adjacent U-Nets processing overlapping regions. This design enables local anatomical knowledge to be shared across the network, which likely further contributes to stable performance across diverse imaging conditions.</p><p id="Par69">In contrast, FastSurfer uses a 2D neural network that segments each slice independently. While this architecture is computationally efficient, it does not exploit the 3D context across slices. As a result, it is more susceptible to slice-wise intensity variations. This likely contributes to its greater sensitivity to field strength variability.</p><p id="Par70">FreeSurfer, on the other hand, employs atlas-based and intensity-driven methods. Subcortical segmentation is based on voxel-wise probabilistic atlases and intensity priors<sup><xref ref-type="bibr" rid="CR88">88</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR89">89</xref></sup>, while cortical surfaces are reconstructed through sulcal and gyral pattern extraction using mesh smoothing and spherical registration<sup><xref ref-type="bibr" rid="CR90">90</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR91">91</xref></sup>. This reliance on local contrast and intensity features makes FreeSurfer vulnerable to variability in MRI contrast and signal quality (contrast-to-noise ratio). This limitation also affects SPM, which, like FreeSurfer, relies on strong anatomical priors (SPM uses voxel intensities and tissue probability maps)<sup><xref ref-type="bibr" rid="CR92">92</xref></sup>.</p><p id="Par71">In summary, the superior robustness of AssemblyNet likely stems from its 3D patch-based architecture, redundant spatial encoding, and multi-resolution refinement, which provide enhanced tolerance to contrast variability. In contrast, FastSurfer&#8217;s 2D architecture and FreeSurfer&#8217;s reliance on contrast-dependent features make them more susceptible to changes in magnetic field strength.</p></sec><sec id="Sec34"><title>Sensitivity of algorithms to hippocampal atrophy</title><p id="Par72">We assessed the sensitivity of AssemblyNet, FastSurfer, and FreeSurfer in detecting pathological changes, such as hippocampal atrophy. All three segmentation algorithms of our study have demonstrated their capability to detect pathological variations in brain imaging. FreeSurfer has been validated by Fellhauer et al., (2015)<sup><xref ref-type="bibr" rid="CR93">93</xref></sup>, showing its effectiveness in identifying increased brain atrophy in conditions such as AD and mild cognitive impairment. Both FastSurfer and FreeSurfer can detect differences in cortical areas associated with disease progression<sup><xref ref-type="bibr" rid="CR94">94</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. AssemblyNet further extends this ability, as demonstrated by Coupe et al., (2022)<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>, where AssemblyNet, combined with classification-based approaches using lifespan models, showed very accurate detection of AD (AUC <inline-formula id="IEq2"><alternatives><tex-math id="d33e4537">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\ge$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_18073_Article_IEq2.gif"/></alternatives></inline-formula> 94%) compared to control subjects. Additionally, it was able to accurately discriminate between progressive MCI and stable MCI (AUC = 78%) during a 3-year follow-up.</p><p id="Par73">Our analysis shows that AssemblyNet not only provides stable reference curves but also offers consistent estimates of hippocampal atrophy. In contrast, FastSurfer and FreeSurfer showed greater variability in atrophy detection. This variability could lead to important differences in the interpretation of atrophy, highlighting the need for careful consideration when selecting segmentation algorithms for atrophy assessment.</p><p id="Par74">Although AssemblyNet tends to report lower atrophy percentages, these results are in line with De et al., (1997)<sup><xref ref-type="bibr" rid="CR95">95</xref></sup>, but only for the left hippocampus. This study uses the Scheltens scale as a method of determining whether a hippocampus is atrophied: it&#8217;s a visual scale. This study includes mild AD patients and patients with moderate to severe AD. The study found frequencies of hippocampal atrophy ranged from 78% in the mild AD patients group to 96% in the advanced AD group. In comparison, the analysis using AssemblyNet (Table <xref rid="Tab3" ref-type="table">3</xref>), using reference curves with both 1.5T and 3T data, revealed an atrophy rate of 77% (left) and 68% (right) (FastSurfer: 84%/81%; FreeSurfer: 82%/76%).</p><p id="Par75">Besides, for all algorithms, there is a disparity in percentages between the left and right hippocampus. This aligns with multiple studies<sup><xref ref-type="bibr" rid="CR96">96</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR97">97</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR98">98</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR99">99</xref></sup> demonstrating that AD is associated with greater atrophy in the left hippocampus compared to the right.</p><p id="Par76">In addition, De et al., (1997)<sup><xref ref-type="bibr" rid="CR95">95</xref></sup> found hippocampal atrophy in 15% of the normal elderly group between 60-75 years of age. In our case, the analysis revealed the following percentages of hippocampal atrophy in the control group: AssemblyNet detected 12% atrophy in the left hippocampus and 8% in the right. FastSurfer identified 13% atrophy in both the left and right hippocampus, while FreeSurfer showed 9% atrophy for both sides (MIRIAD: 22 controls; 69 years+/- 16).</p><p id="Par77">We found two other interesting studies on this subject, but neither can be used for comparative analysis as they both use FreeSurfer as their segmentation algorithm. First, in the study by Byun et al<sup><xref ref-type="bibr" rid="CR100">100</xref></sup>, 77.9% of the 163 AD subjects from ADNI are considered to have hippocampal atrophy. Then, in the study Lowe et al<sup><xref ref-type="bibr" rid="CR101">101</xref></sup>, 76% of the 92 AD subjects from ADNI are considered to have hippocampal atrophy.</p></sec><sec id="Sec35"><title>Sensitivity with HAVAs method</title><p id="Par78">As demonstrated by Coupe et al., (2022)<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>, the HAVAs methods offers superior classification performance compared to individual brain regions taken independently, reinforcing its relevance for distinguishing AD patients from CN subjects. When comparing our results to those reported in Coupe et al., (2022)<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>, we observe higher balanced accuracy scores. Specifically, Coupe et al., (2022)<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> reported a balanced accuracy of 0.81, whereas our current study achieved 0.90 with AssemblyNet, and 0.88 with both FastSurfer and FreeSurfer using reference curves built from combined 1.5T and 3T data. Although the HAVAs method and the segmentation algorithm are the same, several factors explain this discrepancy: the test datasets differ (AIBL in their studies vs. ADNI in ours), the reference models are not the same (GAMs vs. hybrid models), and the training datasets also vary.</p></sec><sec id="Sec36"><title>Trade-off between sensitivity and robustness: bias-variance balance</title><p id="Par79">Our results highlight a classic bias-variance trade-off across segmentation algorithms when applied to AD detection. FastSurfer and FreeSurfer demonstrate higher sensitivity, making them more effective at detecting hippocampal atrophy. This is evidenced in both the direct hippocampal atrophy analysis and the HAVAs-based classification results. However, this increased sensitivity comes at the cost of greater variability and reduced robustness, particularly with respect to acquisition differences. In CN subjects, FastSurfer and FreeSurfer showed broader and less consistent ranges of atrophy percentages (up to 40.39% for FastSurfer), whereas AssemblyNet maintained lower and more stable values (maximum of 21.96%). Across all reference models and field strengths, classification metrics fluctuated more for FastSurfer and FreeSurfer, dropping as low as 0.60 and 0.66 (specificity, HAVAs method), while AssemblyNet consistently maintained higher specificity (0.86-0.95) and balanced accuracy (0.90-0.91)(left HAVAs. These results suggest that AssemblyNet favors a lower-variance strategy, yielding slightly lower sensitivity but offering a more robust and stable performance across different magnetic field strength. While it may miss a few pathological cases, it is more reliable for consistently distinguishing AD patients from healthy individuals without overfitting to magnetic field strength-specific noise.</p><p id="Par80">From an industrial standpoint, robustness is often more desirable than maximal sensitivity. In fact, in a real-world setting, MRI data come from a wide range of machines, models, and sequences. Correction methods such as ComBat<sup><xref ref-type="bibr" rid="CR102">102</xref></sup> are not always applicable due to insufficient sample size. These harmonization techniques typically require large and balanced datasets, often 20-30 subjects per scanner, per sequence<sup><xref ref-type="bibr" rid="CR102">102</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="CR103">103</xref></sup>, which are rarely available in industrial settings<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. Moreover, such harmonization algorithms can introduce additional variability<sup><xref ref-type="bibr" rid="CR104">104</xref></sup> and may even degrade data quality<sup><xref ref-type="bibr" rid="CR105">105</xref></sup>. Notably, none of the harmonization algorithms evaluated in Gebre et al., (2023)<sup><xref ref-type="bibr" rid="CR106">106</xref></sup>improved intraclass correlation coefficients in longitudinal designs<sup><xref ref-type="bibr" rid="CR69">69</xref></sup>. Thus, a robust algorithm that handles acquisition heterogeneity gracefully is preferable, especially in large-scale screening or multi-site contexts where harmonization is not feasible.</p></sec></sec></sec><sec id="Sec37"><title>Conclusion</title><p id="Par81">This study highlights the critical role of algorithm selection in constructing reference curves and assessing brain atrophy in neurodegenerative diseases. We observed that AssemblyNet produces very stable reference curves with respect to magnetic field variations, unlike FastSurfer, which is not robust to this parameter. Significant differences in trends are noted between reference curves constructed with data acquired at 1.5T + 3T, only at 1.5T, and only at 3T. When considering the different reference curves calculated, the percentages of hippocampal atrophy and the HAVAs score in AD patients are more stable with AssemblyNet, though they are lower compared to FastSurfer and FreeSurfer.</p><p id="Par82">In conclusion, AssemblyNet stands out as the most robust and reliable choice, offering stability across varying MRI conditions and consistent atrophy detection. In contrast, FastSurfer and FreeSurfer require further refinement to reduce their sensitivity to magnetic field strength and improve their consistency in atrophy assessment. These findings underscore the importance of segmentation algorithm selection, as the choice of segmentation method can significantly impact the consistency and accuracy of atrophy assessments in neurodegenerative diseases like Alzheimer&#8217;s.</p></sec><sec id="Sec38" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_18073_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Information.</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>List of authors and their affiliations appear at the end of the paper.</p></fn></fn-group><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-18073-z.</p></sec><ack><title>Acknowledgements</title><p><italic toggle="yes">Virtual Imaging Platform: VIP</italic> Part of the results presented in this work were achieved using the Neuroimaging (FreeSurfer-Recon-all) application through the Virtual Imaging Platform<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>, which uses the resources provided by the biomed virtual organisation of the EGI infrastructure. <italic toggle="yes">Autism Brain Imaging Data Exchange: ABIDE</italic> The ABIDE<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> data used in the preparation of this article were supported by ABIDE funding resources listed at https://fcon_1000.projects.nitrc.org/indi/abide/. <italic toggle="yes">International Consortium for Brain Mapping: ICBM</italic> The International Consortium for Brain Mapping (ICBM), under the leadership of Principal Investigator John Mazziotta, MD, PhD, provided the data collection and sharing for this project. The National Institute of Biomedical Imaging and BioEngineering funded the ICBM. The Laboratory of Neuro Imaging at the University of Southern California distributes the ICBM data<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. <italic toggle="yes">Information eXtraction from Images: IXI</italic> Data collected as part of the project EPSRC GR/S21533/02 were obtained from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://brain-development.org/ixi-dataset/">https://brain-development.org/ixi-dataset/</ext-link>. <italic toggle="yes">Alzheimer&#8217;s Disease Neuroimaging Initiative: ADNI</italic> The Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) data collection and sharing are funded by the National Institute on Aging (National Institutes of Health Grant U19 AG024904), with the Northern California Institute for Research and Education serving as the grantee organization. ADNI has also received past funding from the National Institute of Biomedical Imaging and Bioengineering, the Canadian Institutes of Health Research, and private sector contributions through the Foundation for the National Institutes of Health (FNIH). Generous contributions have been made by numerous organizations, including AbbVie, the Alzheimer&#8217;s Association, the Alzheimer&#8217;s Drug Discovery Foundation, Araclon Biotech, BioClinica, Inc., Biogen, Bristol-Myers Squibb Company, CereSpir, Inc., Cogstate, Eisai Inc., Elan Pharmaceuticals, Inc., Eli Lilly and Company, EuroImmun, F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc., Fujirebio, GE Healthcare, IXICO Ltd., Janssen Alzheimer Immunotherapy Research and Development, LLC, Johnson and Johnson Pharmaceutical Research and Development LLC, Lumosity, Lundbeck, Merck and Co., Inc., Meso Scale Diagnostics, LLC, NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals Corporation, Pfizer Inc., Piramal Imaging, Servier, Takeda Pharmaceutical Company, and Transition Therapeutics<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. <italic toggle="yes">Open Access Series of Imaging Studies: OASIS</italic> The data were provided by OASIS-1: Cross-Sectional, with Principal Investigators D. Marcus, R. Buckner, J. Csernansky, and J. Morris. Funding support includes grants P50 AG05681, P01 AG03991, P01 AG026276, R01 AG021910, P20 MH071616, and U24 RR021382<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. <italic toggle="yes">Parkinson&#8217;s Progression Markers Initiative: PPMI</italic> Data used in the preparation of this article was obtained on 2023-10-23 from the Parkinson&#8217;s Progression Markers Initiative (PPMI) database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ppmi-info.org/access-data-specimens/download-data">https://www.ppmi-info.org/access-data-specimens/download-data</ext-link>), RRID:SCR_006431. For up-to-date information on the study, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ppmi-info.org">www.ppmi-info.org</ext-link>. PPMI - a public-private partnership - is funded by the Michael J. Fox Foundation for Parkinson&#8217;s Research and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson&#8217;s, AskBio, Avid Radiopharmaceuticals, BIAL, BioArctic, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol-Myers Squibb, Calico Labs, Capsida Biotherapeutics, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Jazz Pharmaceuticals, Johnson and Johnson Innovative Medicine, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Neuron23, Neuropore, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation and Yumanity Therapeutics. <italic toggle="yes">UCLA Consortium for Neuropsychiatric Phenomics LA5c Study: UCLA</italic> Data used in the preparation of this article were obtained from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://openneuro.org/datasets/ds000030/versions/00016">https://openneuro.org/datasets/ds000030/versions/00016</ext-link>. Its accession number is ds000030<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. <italic toggle="yes">Dallas Lifespan Brain Study: DLBS</italic> Data used in the preparation of this article were obtained from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nitrc.org/ir/app/template/XDATScreen_report_xnat_projectData.vm/search_element/xnat:projectData/search_field/xnat:projectData.ID/search_value/dlbs">https://www.nitrc.org/ir/app/template/XDATScreen_report_xnat_projectData.vm/search_element/xnat:project Data/search_field/xnat:projectData.ID/search _value/dlbs</ext-link> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://sites.utdallas.edu/dlbs/">https://sites.utdallas.edu/dlbs/</ext-link>). <italic toggle="yes">Southwest University Adult Lifespan Dataset: SALD</italic><sup><xref ref-type="bibr" rid="CR41">41</xref></sup> Data used in the preparation of this article were obtained from https://fcon_1000.projects.nitrc.org/indi/retro/sald.html. <italic toggle="yes">Frontotemporal lobar degeneration neuroimaging initiative: NIFD</italic> NIFD is the abbreviation for the frontotemporal lobar degeneration neuroimaging initiative (FTLDNI, AG032306) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://memory.ucsf.edu/research/studies/nifd">http://memory.ucsf.edu/ research/studies/ nifd</ext-link>). This project&#8217;s data collection and sharing were funded by the Frontotemporal Lobar Degeneration Neuroimaging Initiative (National Institutes of Health Grant R01 AG032306). The study is coordinated by the Memory and Aging Center at the University of California, San Francisco, and the data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. <italic toggle="yes">Southwest University Longitudinal Imaging Multimodal: SLIM</italic> Data used in the preparation of this article were obtained from https://fcon_1000.projects.nitrc.org/indi/retro/southwestuni_qiu_index.html. <italic toggle="yes">Minimal Interval Resonance Imaging in Alzheimer&#8217;s Disease (MIRIAD):</italic> Data used in the preparation of this article were obtained from the MIRIAD dataset<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. The MIRIAD investigators did not participate in analysis or writing of this report. The MIRIAD dataset is made available through the support of the UK Alzheimer&#8217;s Society (Grant RF116). The original data collection was funded through an unrestricted educational grant from GlaxoSmithKline (Grant 6GKC). <italic toggle="yes">SRPBS Traveling Subject MRI Dataset:</italic><sup><xref ref-type="bibr" rid="CR43">43</xref></sup> Data used in the preparation of this article were obtained from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.synapse.org/#%21Synapse:syn22317082">https://www.synapse.org/#!Synapse:syn22317082</ext-link>.&#160;Data used in preparation of this article were obtained from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) dataset (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://adni.loni.usc.edu">adni.loni.usc.edu</ext-link>). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf">http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf</ext-link>. A comprehensive list of consortium members appears at the end of the paper.&#160;Data used in preparation of this article were obtained from the Frontotemporal Lobar Degeneration Neuroimaging Initiative (FTLDNI) dataset. The investigators at NIFD/FTLDNI contributed to the design and implementation of FTLDNI and/or provided data, but did not participate in analysis or writing of this report (unless otherwise listed). A comprehensive list of consortium members appears at the end of the paper.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>F. R., A. K. and A.A. designed the study; E. P. performed the analysis; all authors discussed the results; E. P. wrote the main manuscript text; All authors reviewed the manuscript; &#8220;For Alzheimer&#8217;s Disease Neuroimaging Initiative&#8221; and &#8220;For the Frontotemporal Lobar Degeneration Neuroimaging Initiative&#8221; generate part of the data used.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the Association Nationale de la Recherche et de la Technologie (CIFRE No. 2022/0918).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Reference curves associated with this study are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://gitlab.com/geodaisics1/Estimation_of_reference_curves_for_brain_atrophy_and_analysis_of_robustness_to_machine_effects">https://gitlab.com/geodaisics1/Estimation_of_ reference_curves_for_brain_atrophy_and_analysis_of_robustness_to_machine_effects</ext-link>. Reference curves, stored as Excel files, provide the lower, middle, and upper bounds for brain regions, computed for three segmentation algorithms (AssemblyNet, FastSurfer, FreeSurfer) using different MRI field strengths (1.5T, 3T, or both) and smoothing methods (none, concave, convex). Visualizations show the effects of MRI field strength, displaying reference curves with training points color-coded by the field strength. Additional images provide general and consistent visualizations of reference curves, ensuring comparability across algorithms and regions. Concatenated figures summarize multi-algorithm and multi-region comparisons, showing the impact of smoothing and MRI datasets on reference curve generation. These data offer a comprehensive overview of the methods and analyses performed in the study. Links to open-access datasets are also provided. Access to the MRI datasets aggregated here is subject to application procedures individually managed at the discretion of each primary study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par83">Four authors have a potential conflict of interest: Arnaud Atty&#233; and F&#233;lix Renard are co-founders of GeodAIsics, A. Krainik is a consultant at GeodAIsics and E. Piot is a PhD student at GeodAIsics. &#8220;For Alzheimer&#8217;s Disease Neuroimaging Initiative&#8221; and &#8220;For the Frontotemporal Lobar Degeneration Neuroimaging Initiative&#8221; have no conflict of interest as they only generate part of the data used.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Risacher, S.&#160;L. &amp; Saykin, A.&#160;J. Neuroimaging biomarkers of neurodegenerative diseases and dementia. In <italic toggle="yes">Seminars in neurology</italic>, vol.&#160;33, 386&#8211;416 (Thieme Medical Publishers, 2013).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0033-1359312</pub-id><pub-id pub-id-type="pmcid">PMC3975244</pub-id><pub-id pub-id-type="pmid">24234359</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Besson</surname><given-names>FL</given-names></name><etal/></person-group><article-title>Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical alzheimer&#8217;s disease</article-title><source>Journal of Neuroscience</source><year>2015</year><volume>35</volume><fpage>10402</fpage><lpage>10411</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0150-15.2015</pub-id><pub-id pub-id-type="pmid">26203136</pub-id><pub-id pub-id-type="pmcid">PMC6605120</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Besson, F. L. et al. Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical alzheimer&#8217;s disease. <italic toggle="yes">Journal of Neuroscience</italic><bold>35</bold>, 10402&#8211;10411 (2015).<pub-id pub-id-type="pmid">26203136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.0150-15.2015</pub-id><pub-id pub-id-type="pmcid">PMC6605120</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartos</surname><given-names>A</given-names></name><name name-style="western"><surname>Gregus</surname><given-names>D</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>I</given-names></name><name name-style="western"><surname>Tint&#283;ra</surname><given-names>J</given-names></name></person-group><article-title>Brain volumes and their ratios in alzheimer s disease on magnetic resonance imaging segmented using freesurfer 6.0</article-title><source>Psychiatry Research: Neuroimaging</source><year>2019</year><volume>287</volume><fpage>70</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.pscychresns.2019.01.014</pub-id><pub-id pub-id-type="pmid">31003044</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Bartos, A., Gregus, D., Ibrahim, I. &amp; Tint&#283;ra, J. Brain volumes and their ratios in alzheimer s disease on magnetic resonance imaging segmented using freesurfer 6.0. <italic toggle="yes">Psychiatry Research: Neuroimaging</italic><bold>287</bold>, 70&#8211;74 (2019).<pub-id pub-id-type="pmid">31003044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pscychresns.2019.01.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Coupe, P. <italic toggle="yes">et al.</italic> Lifespan neurodegeneration of the human brain in multiple sclerosis. <italic toggle="yes">bioRxiv</italic> 2023&#8211;03 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.26464</pub-id><pub-id pub-id-type="pmcid">PMC10619394</pub-id><pub-id pub-id-type="pmid">37615064</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marquand</surname><given-names>AF</given-names></name><etal/></person-group><article-title>Conceptualizing mental disorders as deviations from normative functioning</article-title><source>Molecular psychiatry</source><year>2019</year><volume>24</volume><fpage>1415</fpage><lpage>1424</lpage><pub-id pub-id-type="doi">10.1038/s41380-019-0441-1</pub-id><pub-id pub-id-type="pmid">31201374</pub-id><pub-id pub-id-type="pmcid">PMC6756106</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Marquand, A. F. et al. Conceptualizing mental disorders as deviations from normative functioning. <italic toggle="yes">Molecular psychiatry</italic><bold>24</bold>, 1415&#8211;1424 (2019).<pub-id pub-id-type="pmid">31201374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-019-0441-1</pub-id><pub-id pub-id-type="pmcid">PMC6756106</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolfers</surname><given-names>T</given-names></name><etal/></person-group><article-title>Individual differences v. the average patient: mapping the heterogeneity in adhd using normative models</article-title><source>Psychological Medicine</source><year>2020</year><volume>50</volume><fpage>314</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1017/S0033291719000084</pub-id><pub-id pub-id-type="pmid">30782224</pub-id><pub-id pub-id-type="pmcid">PMC7083555</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Wolfers, T. et al. Individual differences v. the average patient: mapping the heterogeneity in adhd using normative models. <italic toggle="yes">Psychological Medicine</italic><bold>50</bold>, 314&#8211;323 (2020).<pub-id pub-id-type="pmid">30782224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0033291719000084</pub-id><pub-id pub-id-type="pmcid">PMC7083555</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Warrington, S. <italic toggle="yes">et al.</italic> A resource for development and comparison of multi-modal brain 3t mri harmonisation approaches. <italic toggle="yes">bioRxiv</italic> 2023&#8211;06 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1162/imag_a_00042</pub-id><pub-id pub-id-type="pmcid">PMC12007558</pub-id><pub-id pub-id-type="pmid">40799694</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hedges</surname><given-names>EP</given-names></name><etal/></person-group><article-title>Reliability of structural mri measurements: The effects of scan session, head tilt, inter-scan interval, acquisition sequence, freesurfer version and processing stream</article-title><source>Neuroimage</source><year>2022</year><volume>246</volume><fpage>118751</fpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2021.118751</pub-id><pub-id pub-id-type="pmid">34848299</pub-id><pub-id pub-id-type="pmcid">PMC8784825</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Hedges, E. P. et al. Reliability of structural mri measurements: The effects of scan session, head tilt, inter-scan interval, acquisition sequence, freesurfer version and processing stream. <italic toggle="yes">Neuroimage</italic><bold>246</bold>, 118751 (2022).<pub-id pub-id-type="pmid">34848299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2021.118751</pub-id><pub-id pub-id-type="pmcid">PMC8784825</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>C</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>D</given-names></name><name name-style="western"><surname>Fink</surname><given-names>K</given-names></name><name name-style="western"><surname>Westman</surname><given-names>E</given-names></name><name name-style="western"><surname>Granberg</surname><given-names>T</given-names></name></person-group><article-title>Repeatability and reproducibility of freesurfer, fsl-sienax and spm brain volumetric measurements and the effect of lesion filling in multiple sclerosis</article-title><source>European radiology</source><year>2019</year><volume>29</volume><fpage>1355</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1007/s00330-018-5710-x</pub-id><pub-id pub-id-type="pmid">30242503</pub-id><pub-id pub-id-type="pmcid">PMC6510869</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Guo, C., Ferreira, D., Fink, K., Westman, E. &amp; Granberg, T. Repeatability and reproducibility of freesurfer, fsl-sienax and spm brain volumetric measurements and the effect of lesion filling in multiple sclerosis. <italic toggle="yes">European radiology</italic><bold>29</bold>, 1355&#8211;1364 (2019).<pub-id pub-id-type="pmid">30242503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-018-5710-x</pub-id><pub-id pub-id-type="pmcid">PMC6510869</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srinivasan</surname><given-names>D</given-names></name><etal/></person-group><article-title>A comparison of freesurfer and multi-atlas muse for brain anatomy segmentation: Findings about size and age bias, and inter-scanner stability in multi-site aging studies</article-title><source>Neuroimage</source><year>2020</year><volume>223</volume><fpage>117248</fpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2020.117248</pub-id><pub-id pub-id-type="pmid">32860881</pub-id><pub-id pub-id-type="pmcid">PMC8382092</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Srinivasan, D. et al. A comparison of freesurfer and multi-atlas muse for brain anatomy segmentation: Findings about size and age bias, and inter-scanner stability in multi-site aging studies. <italic toggle="yes">Neuroimage</italic><bold>223</bold>, 117248 (2020).<pub-id pub-id-type="pmid">32860881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2020.117248</pub-id><pub-id pub-id-type="pmcid">PMC8382092</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Rebsamen, M. <italic toggle="yes">et al.</italic> Growing importance of brain morphometry analysis in the clinical routine: The hidden impact of mr sequence parameters. <italic toggle="yes">Journal of neuroradiology</italic> (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurad.2023.04.003</pub-id><pub-id pub-id-type="pmid">37116782</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Obrien</surname><given-names>J</given-names></name></person-group><article-title>Role of imaging techniques in the diagnosis of dementia</article-title><source>The British journal of radiology</source><year>2007</year><volume>80</volume><fpage>S71</fpage><lpage>S77</lpage><pub-id pub-id-type="doi">10.1259/bjr/33117326</pub-id><pub-id pub-id-type="pmid">18445747</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Obrien, J. Role of imaging techniques in the diagnosis of dementia. <italic toggle="yes">The British journal of radiology</italic><bold>80</bold>, S71&#8211;S77 (2007).<pub-id pub-id-type="pmid">18445747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1259/bjr/33117326</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klunk</surname><given-names>WE</given-names></name><etal/></person-group><article-title>The centiloid project: standardizing quantitative amyloid plaque estimation by pet</article-title><source>Alzheimer&#8217;s &amp; dementia</source><year>2015</year><volume>11</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2014.07.003</pub-id><pub-id pub-id-type="pmcid">PMC4300247</pub-id><pub-id pub-id-type="pmid">25443857</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Klunk, W. E. et al. The centiloid project: standardizing quantitative amyloid plaque estimation by pet. <italic toggle="yes">Alzheimer&#8217;s &amp; dementia</italic><bold>11</bold>, 1&#8211;15 (2015).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2014.07.003</pub-id><pub-id pub-id-type="pmcid">PMC4300247</pub-id><pub-id pub-id-type="pmid">25443857</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Engels-Dom&#237;nguez, N. <italic toggle="yes">et al.</italic> State-of-the-art imaging of neuromodulatory subcortical systems in aging and alzheimer&#8217;s disease: challenges and opportunities. <italic toggle="yes">Neuroscience &amp; Biobehavioral Reviews</italic> 104998 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2022.104998</pub-id><pub-id pub-id-type="pmcid">PMC9805533</pub-id><pub-id pub-id-type="pmid">36526031</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huynh</surname><given-names>K</given-names></name><etal/></person-group><article-title>Clinical and biological correlates of white matter hyperintensities in patients with behavioral-variant frontotemporal dementia and alzheimer disease</article-title><source>Neurology</source><year>2021</year><volume>96</volume><fpage>e1743</fpage><lpage>e1754</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000011638</pub-id><pub-id pub-id-type="pmid">33597290</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Huynh, K. et al. Clinical and biological correlates of white matter hyperintensities in patients with behavioral-variant frontotemporal dementia and alzheimer disease. <italic toggle="yes">Neurology</italic><bold>96</bold>, e1743&#8211;e1754 (2021).<pub-id pub-id-type="pmid">33597290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000011638</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calloni</surname><given-names>SF</given-names></name><etal/></person-group><article-title>Combining semi-quantitative rating and automated brain volumetry in mri evaluation of patients with probable behavioural variant of fronto-temporal dementia: an added value for clinical practise?</article-title><source>Neuroradiology</source><year>2023</year><volume>65</volume><fpage>1025</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.1007/s00234-023-03133-w</pub-id><pub-id pub-id-type="pmid">36867204</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Calloni, S. F. et al. Combining semi-quantitative rating and automated brain volumetry in mri evaluation of patients with probable behavioural variant of fronto-temporal dementia: an added value for clinical practise?. <italic toggle="yes">Neuroradiology</italic><bold>65</bold>, 1025&#8211;1035 (2023).<pub-id pub-id-type="pmid">36867204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00234-023-03133-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavedo</surname><given-names>E</given-names></name><etal/></person-group><article-title>Validation of an automatic tool for the measurement of brain atrophy and white matter hyperintensity in clinical routine: Qyscore&#174;: Neuroimaging/optimal neuroimaging measures for early detection</article-title><source>Alzheimer&#8217;s &amp; Dementia</source><year>2020</year><volume>16</volume><fpage>e040259</fpage><pub-id pub-id-type="doi">10.1002/alz.040259</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Cavedo, E. et al. Validation of an automatic tool for the measurement of brain atrophy and white matter hyperintensity in clinical routine: Qyscore&#174;: Neuroimaging/optimal neuroimaging measures for early detection. <italic toggle="yes">Alzheimer&#8217;s &amp; Dementia</italic><bold>16</bold>, e040259 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#228;nninen</surname><given-names>K</given-names></name><etal/></person-group><article-title>Thalamic atrophy predicts 5-year disability progression in multiple sclerosis</article-title><source>Frontiers in Neurology</source><year>2020</year><volume>11</volume><fpage>606</fpage><pub-id pub-id-type="doi">10.3389/fneur.2020.00606</pub-id><pub-id pub-id-type="pmid">32760339</pub-id><pub-id pub-id-type="pmcid">PMC7373757</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">H&#228;nninen, K. et al. Thalamic atrophy predicts 5-year disability progression in multiple sclerosis. <italic toggle="yes">Frontiers in Neurology</italic><bold>11</bold>, 606 (2020).<pub-id pub-id-type="pmid">32760339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2020.00606</pub-id><pub-id pub-id-type="pmcid">PMC7373757</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pemberton</surname><given-names>HG</given-names></name><etal/></person-group><article-title>Technical and clinical validation of commercial automated volumetric mri tools for dementia diagnosis&#8212;a systematic review</article-title><source>Neuroradiology</source><year>2021</year><volume>63</volume><fpage>1773</fpage><lpage>1789</lpage><pub-id pub-id-type="doi">10.1007/s00234-021-02746-3</pub-id><pub-id pub-id-type="pmid">34476511</pub-id><pub-id pub-id-type="pmcid">PMC8528755</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Pemberton, H. G. et al. Technical and clinical validation of commercial automated volumetric mri tools for dementia diagnosis&#8212;a systematic review. <italic toggle="yes">Neuroradiology</italic><bold>63</bold>, 1773&#8211;1789 (2021).<pub-id pub-id-type="pmid">34476511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00234-021-02746-3</pub-id><pub-id pub-id-type="pmcid">PMC8528755</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coup&#233;</surname><given-names>P</given-names></name><name name-style="western"><surname>Catheline</surname><given-names>G</given-names></name><name name-style="western"><surname>Lanuza</surname><given-names>E</given-names></name><name name-style="western"><surname>Manj&#243;n</surname><given-names>JV</given-names></name><name name-style="western"><surname>Initiative</surname><given-names>ADN</given-names></name></person-group><article-title>Towards a unified analysis of brain maturation and aging across the entire lifespan: A mri analysis</article-title><source>Human brain mapping</source><year>2017</year><volume>38</volume><fpage>5501</fpage><lpage>5518</lpage><pub-id pub-id-type="doi">10.1002/hbm.23743</pub-id><pub-id pub-id-type="pmid">28737295</pub-id><pub-id pub-id-type="pmcid">PMC6866824</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Coup&#233;, P., Catheline, G., Lanuza, E., Manj&#243;n, J. V. &amp; Initiative, A. D. N. Towards a unified analysis of brain maturation and aging across the entire lifespan: A mri analysis. <italic toggle="yes">Human brain mapping</italic><bold>38</bold>, 5501&#8211;5518 (2017).<pub-id pub-id-type="pmid">28737295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.23743</pub-id><pub-id pub-id-type="pmcid">PMC6866824</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajagopalan</surname><given-names>V</given-names></name><name name-style="western"><surname>Yue</surname><given-names>GH</given-names></name><name name-style="western"><surname>Pioro</surname><given-names>EP</given-names></name></person-group><article-title>Do preprocessing algorithms and statistical models influence voxel-based morphometry (vbm) results in amyotrophic lateral sclerosis patients? a systematic comparison of popular vbm analytical methods</article-title><source>Journal of Magnetic Resonance Imaging</source><year>2014</year><volume>40</volume><fpage>662</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1002/jmri.24415</pub-id><pub-id pub-id-type="pmid">24470336</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Rajagopalan, V., Yue, G. H. &amp; Pioro, E. P. Do preprocessing algorithms and statistical models influence voxel-based morphometry (vbm) results in amyotrophic lateral sclerosis patients? a systematic comparison of popular vbm analytical methods. <italic toggle="yes">Journal of Magnetic Resonance Imaging</italic><bold>40</bold>, 662&#8211;667 (2014).<pub-id pub-id-type="pmid">24470336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmri.24415</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katuwal</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>Inter-method discrepancies in brain volume estimation may drive inconsistent findings in autism</article-title><source>Frontiers in neuroscience</source><year>2016</year><volume>10</volume><fpage>439</fpage><pub-id pub-id-type="doi">10.3389/fnins.2016.00439</pub-id><pub-id pub-id-type="pmid">27746713</pub-id><pub-id pub-id-type="pmcid">PMC5043189</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Katuwal, G. J. et al. Inter-method discrepancies in brain volume estimation may drive inconsistent findings in autism. <italic toggle="yes">Frontiers in neuroscience</italic><bold>10</bold>, 439 (2016).<pub-id pub-id-type="pmid">27746713</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2016.00439</pub-id><pub-id pub-id-type="pmcid">PMC5043189</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bozek</surname><given-names>J</given-names></name><name name-style="western"><surname>Griffanti</surname><given-names>L</given-names></name><name name-style="western"><surname>Lau</surname><given-names>S</given-names></name><name name-style="western"><surname>Jenkinson</surname><given-names>M</given-names></name></person-group><article-title>Normative models for neuroimaging markers: Impact of model selection, sample size and evaluation criteria</article-title><source>NeuroImage</source><year>2023</year><volume>268</volume><fpage>119864</fpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2023.119864</pub-id><pub-id pub-id-type="pmid">36621581</pub-id><pub-id pub-id-type="pmcid">PMC11636675</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Bozek, J., Griffanti, L., Lau, S. &amp; Jenkinson, M. Normative models for neuroimaging markers: Impact of model selection, sample size and evaluation criteria. <italic toggle="yes">NeuroImage</italic><bold>268</bold>, 119864 (2023).<pub-id pub-id-type="pmid">36621581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2023.119864</pub-id><pub-id pub-id-type="pmcid">PMC11636675</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Liu, Y. <italic toggle="yes">et al.</italic> Quantifying individualized deviations of brain structure in patients with multiple neurological diseases from normative references. <italic toggle="yes">Under review on researchsquare.com</italic> (2024).</mixed-citation></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mills</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Structural brain development between childhood and adulthood: Convergence across four longitudinal samples</article-title><source>Neuroimage</source><year>2016</year><volume>141</volume><fpage>273</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2016.07.044</pub-id><pub-id pub-id-type="pmid">27453157</pub-id><pub-id pub-id-type="pmcid">PMC5035135</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Mills, K. L. et al. Structural brain development between childhood and adulthood: Convergence across four longitudinal samples. <italic toggle="yes">Neuroimage</italic><bold>141</bold>, 273&#8211;281 (2016).<pub-id pub-id-type="pmid">27453157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2016.07.044</pub-id><pub-id pub-id-type="pmcid">PMC5035135</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borghi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Construction of the world health organization child growth standards: selection of methods for attained growth curves</article-title><source>Statistics in medicine</source><year>2006</year><volume>25</volume><fpage>247</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1002/sim.2227</pub-id><pub-id pub-id-type="pmid">16143968</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Borghi, E. et al. Construction of the world health organization child growth standards: selection of methods for attained growth curves. <italic toggle="yes">Statistics in medicine</italic><bold>25</bold>, 247&#8211;265 (2006).<pub-id pub-id-type="pmid">16143968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.2227</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bethlehem</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Brain charts for the human lifespan</article-title><source>Nature</source><year>2022</year><volume>604</volume><fpage>525</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04554-y</pub-id><pub-id pub-id-type="pmid">35388223</pub-id><pub-id pub-id-type="pmcid">PMC9021021</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Bethlehem, R. A. et al. Brain charts for the human lifespan. <italic toggle="yes">Nature</italic><bold>604</bold>, 525&#8211;533 (2022).<pub-id pub-id-type="pmid">35388223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-04554-y</pub-id><pub-id pub-id-type="pmcid">PMC9021021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pomponio</surname><given-names>R</given-names></name><etal/></person-group><article-title>Harmonization of large mri datasets for the analysis of brain imaging patterns throughout the lifespan</article-title><source>NeuroImage</source><year>2020</year><volume>208</volume><fpage>116450</fpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2019.116450</pub-id><pub-id pub-id-type="pmid">31821869</pub-id><pub-id pub-id-type="pmcid">PMC6980790</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Pomponio, R. et al. Harmonization of large mri datasets for the analysis of brain imaging patterns throughout the lifespan. <italic toggle="yes">NeuroImage</italic><bold>208</bold>, 116450 (2020).<pub-id pub-id-type="pmid">31821869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2019.116450</pub-id><pub-id pub-id-type="pmcid">PMC6980790</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Satterthwaite</surname><given-names>TD</given-names></name><etal/></person-group><article-title>Impact of puberty on the evolution of cerebral perfusion during adolescence</article-title><source>Proceedings of the National Academy of Sciences</source><year>2014</year><volume>111</volume><fpage>8643</fpage><lpage>8648</lpage><pub-id pub-id-type="doi">10.1073/pnas.1400178111</pub-id><pub-id pub-id-type="pmcid">PMC4060665</pub-id><pub-id pub-id-type="pmid">24912164</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Satterthwaite, T. D. et al. Impact of puberty on the evolution of cerebral perfusion during adolescence. <italic toggle="yes">Proceedings of the National Academy of Sciences</italic><bold>111</bold>, 8643&#8211;8648 (2014).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1400178111</pub-id><pub-id pub-id-type="pmcid">PMC4060665</pub-id><pub-id pub-id-type="pmid">24912164</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanpitukpongse</surname><given-names>TP</given-names></name><name name-style="western"><surname>Mazurowski</surname><given-names>MA</given-names></name><name name-style="western"><surname>Ikhena</surname><given-names>J</given-names></name><name name-style="western"><surname>Petrella</surname><given-names>JR</given-names></name></person-group><article-title>Predictive utility of marketed volumetric software tools in subjects at risk for alzheimer disease: do regions outside the hippocampus matter?</article-title><source>American Journal of Neuroradiology</source><year>2017</year><volume>38</volume><fpage>546</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.3174/ajnr.A5061</pub-id><pub-id pub-id-type="pmid">28057634</pub-id><pub-id pub-id-type="pmcid">PMC5352470</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Tanpitukpongse, T. P., Mazurowski, M. A., Ikhena, J. &amp; Petrella, J. R. Predictive utility of marketed volumetric software tools in subjects at risk for alzheimer disease: do regions outside the hippocampus matter?. <italic toggle="yes">American Journal of Neuroradiology</italic><bold>38</bold>, 546&#8211;552 (2017).<pub-id pub-id-type="pmid">28057634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3174/ajnr.A5061</pub-id><pub-id pub-id-type="pmcid">PMC5352470</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eckerstr&#246;m</surname><given-names>C</given-names></name><etal/></person-group><article-title>Small baseline volume of left hippocampus is associated with subsequent conversion of mci into dementia: the g&#246;teborg mci study</article-title><source>Journal of the neurological sciences</source><year>2008</year><volume>272</volume><fpage>48</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2008.04.024</pub-id><pub-id pub-id-type="pmid">18571674</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Eckerstr&#246;m, C. et al. Small baseline volume of left hippocampus is associated with subsequent conversion of mci into dementia: the g&#246;teborg mci study. <italic toggle="yes">Journal of the neurological sciences</italic><bold>272</bold>, 48&#8211;59 (2008).<pub-id pub-id-type="pmid">18571674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jns.2008.04.024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coup&#233;</surname><given-names>P</given-names></name><etal/></person-group><article-title>Hippocampal-amygdalo-ventricular atrophy score: Alzheimer disease detection using normative and pathological lifespan models</article-title><source>Human Brain Mapping</source><year>2022</year><volume>43</volume><fpage>3270</fpage><lpage>3282</lpage><pub-id pub-id-type="doi">10.1002/hbm.25850</pub-id><pub-id pub-id-type="pmid">35388950</pub-id><pub-id pub-id-type="pmcid">PMC9188974</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Coup&#233;, P. et al. Hippocampal-amygdalo-ventricular atrophy score: Alzheimer disease detection using normative and pathological lifespan models. <italic toggle="yes">Human Brain Mapping</italic><bold>43</bold>, 3270&#8211;3282 (2022).<pub-id pub-id-type="pmid">35388950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.25850</pub-id><pub-id pub-id-type="pmcid">PMC9188974</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></name><name name-style="western"><surname>De Carli</surname><given-names>C</given-names></name></person-group><article-title>Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion</article-title><source>The Lancet Neurology</source><year>2002</year><volume>1</volume><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(02)00002-9</pub-id><pub-id pub-id-type="pmid">12849541</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Scheltens, P., Fox, N., Barkhof, F. &amp; De Carli, C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. <italic toggle="yes">The Lancet Neurology</italic><bold>1</bold>, 13&#8211;21 (2002).<pub-id pub-id-type="pmid">12849541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1474-4422(02)00002-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chapuis</surname><given-names>P</given-names></name><etal/></person-group><article-title>Morphologic and neuropsychological patterns in patients suffering from alzheimer&#8217;s disease</article-title><source>Neuroradiology</source><year>2016</year><volume>58</volume><fpage>459</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1007/s00234-016-1659-0</pub-id><pub-id pub-id-type="pmid">26879914</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Chapuis, P. et al. Morphologic and neuropsychological patterns in patients suffering from alzheimer&#8217;s disease. <italic toggle="yes">Neuroradiology</italic><bold>58</bold>, 459&#8211;466 (2016).<pub-id pub-id-type="pmid">26879914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00234-016-1659-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Craddock</surname><given-names>C</given-names></name><etal/></person-group><article-title>The neuro bureau preprocessing initiative: open sharing of preprocessed neuroimaging data and derivatives</article-title><source>Frontiers in Neuroinformatics</source><year>2013</year><volume>7</volume><fpage>5</fpage></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Craddock, C. et al. The neuro bureau preprocessing initiative: open sharing of preprocessed neuroimaging data and derivatives. <italic toggle="yes">Frontiers in Neuroinformatics</italic><bold>7</bold>, 5 (2013).23658544
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Mazziotta, J.&#160;C. <italic toggle="yes">et al.</italic> A probabilistic approach for mapping the human brain: the international consortium for brain mapping (icbm). In <italic toggle="yes">Brain mapping: the systems</italic>, 141&#8211;156 (Elsevier, 2000).</mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Alzheimer&#8217;s disease neuroimaging initiative (adni): clinical characterization</article-title><source>Neurology</source><year>2010</year><volume>74</volume><fpage>201</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181cb3e25</pub-id><pub-id pub-id-type="pmid">20042704</pub-id><pub-id pub-id-type="pmcid">PMC2809036</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Petersen, R. C. et al. Alzheimer&#8217;s disease neuroimaging initiative (adni): clinical characterization. <italic toggle="yes">Neurology</italic><bold>74</bold>, 201&#8211;209 (2010).<pub-id pub-id-type="pmid">20042704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3181cb3e25</pub-id><pub-id pub-id-type="pmcid">PMC2809036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marcus</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Open access series of imaging studies (oasis): cross-sectional mri data in young, middle aged, nondemented, and demented older adults</article-title><source>Journal of cognitive neuroscience</source><year>2007</year><volume>19</volume><fpage>1498</fpage><lpage>1507</lpage><pub-id pub-id-type="doi">10.1162/jocn.2007.19.9.1498</pub-id><pub-id pub-id-type="pmid">17714011</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Marcus, D. S. et al. Open access series of imaging studies (oasis): cross-sectional mri data in young, middle aged, nondemented, and demented older adults. <italic toggle="yes">Journal of cognitive neuroscience</italic><bold>19</bold>, 1498&#8211;1507 (2007).<pub-id pub-id-type="pmid">17714011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1162/jocn.2007.19.9.1498</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marek</surname><given-names>K</given-names></name><etal/></person-group><article-title>The parkinson&#8217;s progression markers initiative (ppmi)-establishing a pd biomarker cohort</article-title><source>Annals of clinical and translational neurology</source><year>2018</year><volume>5</volume><fpage>1460</fpage><lpage>1477</lpage><pub-id pub-id-type="doi">10.1002/acn3.644</pub-id><pub-id pub-id-type="pmid">30564614</pub-id><pub-id pub-id-type="pmcid">PMC6292383</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Marek, K. et al. The parkinson&#8217;s progression markers initiative (ppmi)-establishing a pd biomarker cohort. <italic toggle="yes">Annals of clinical and translational neurology</italic><bold>5</bold>, 1460&#8211;1477 (2018).<pub-id pub-id-type="pmid">30564614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acn3.644</pub-id><pub-id pub-id-type="pmcid">PMC6292383</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poldrack</surname><given-names>RA</given-names></name><etal/></person-group><article-title>A phenome-wide examination of neural and cognitive function</article-title><source>Scientific data</source><year>2016</year><volume>3</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/sdata.2016.110</pub-id><pub-id pub-id-type="pmcid">PMC5139672</pub-id><pub-id pub-id-type="pmid">27922632</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Poldrack, R. A. et al. A phenome-wide examination of neural and cognitive function. <italic toggle="yes">Scientific data</italic><bold>3</bold>, 1&#8211;12 (2016).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sdata.2016.110</pub-id><pub-id pub-id-type="pmcid">PMC5139672</pub-id><pub-id pub-id-type="pmid">27922632</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Wei, D. <italic toggle="yes">et al.</italic> Structural and functional mri from a cross-sectional southwest university adult lifespan dataset (sald). <italic toggle="yes">bioRxiv</italic> 177279 (2017).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sdata.2018.134</pub-id><pub-id pub-id-type="pmcid">PMC6049036</pub-id><pub-id pub-id-type="pmid">30015807</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malone</surname><given-names>IB</given-names></name><etal/></person-group><article-title>Miriad&#8212;public release of a multiple time point alzheimer&#8217;s mr imaging dataset</article-title><source>NeuroImage</source><year>2013</year><volume>70</volume><fpage>33</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2012.12.044</pub-id><pub-id pub-id-type="pmid">23274184</pub-id><pub-id pub-id-type="pmcid">PMC3809512</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Malone, I. B. et al. Miriad&#8212;public release of a multiple time point alzheimer&#8217;s mr imaging dataset. <italic toggle="yes">NeuroImage</italic><bold>70</bold>, 33&#8211;36 (2013).<pub-id pub-id-type="pmid">23274184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2012.12.044</pub-id><pub-id pub-id-type="pmcid">PMC3809512</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>SC</given-names></name><etal/></person-group><article-title>A multi-site, multi-disorder resting-state magnetic resonance image database</article-title><source>Scientific data</source><year>2021</year><volume>8</volume><fpage>227</fpage><pub-id pub-id-type="doi">10.1038/s41597-021-01004-8</pub-id><pub-id pub-id-type="pmid">34462444</pub-id><pub-id pub-id-type="pmcid">PMC8405782</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Tanaka, S. C. et al. A multi-site, multi-disorder resting-state magnetic resonance image database. <italic toggle="yes">Scientific data</italic><bold>8</bold>, 227 (2021).<pub-id pub-id-type="pmid">34462444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41597-021-01004-8</pub-id><pub-id pub-id-type="pmcid">PMC8405782</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coup&#233;</surname><given-names>P</given-names></name><etal/></person-group><article-title>Assemblynet: A large ensemble of cnns for 3d whole brain mri segmentation</article-title><source>NeuroImage</source><year>2020</year><volume>219</volume><fpage>117026</fpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2020.117026</pub-id><pub-id pub-id-type="pmid">32522665</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Coup&#233;, P. et al. Assemblynet: A large ensemble of cnns for 3d whole brain mri segmentation. <italic toggle="yes">NeuroImage</italic><bold>219</bold>, 117026 (2020).<pub-id pub-id-type="pmid">32522665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2020.117026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischl</surname><given-names>B</given-names></name></person-group><article-title>Freesurfer</article-title><source>Neuroimage</source><year>2012</year><volume>62</volume><fpage>774</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2012.01.021</pub-id><pub-id pub-id-type="pmid">22248573</pub-id><pub-id pub-id-type="pmcid">PMC3685476</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Fischl, B. Freesurfer. <italic toggle="yes">Neuroimage</italic><bold>62</bold>, 774&#8211;781 (2012).<pub-id pub-id-type="pmid">22248573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2012.01.021</pub-id><pub-id pub-id-type="pmcid">PMC3685476</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glatard</surname><given-names>T</given-names></name><etal/></person-group><article-title>A virtual imaging platform for multi-modality medical image simulation</article-title><source>IEEE transactions on medical imaging</source><year>2012</year><volume>32</volume><fpage>110</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1109/TMI.2012.2220154</pub-id><pub-id pub-id-type="pmid">23014715</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Glatard, T. et al. A virtual imaging platform for multi-modality medical image simulation. <italic toggle="yes">IEEE transactions on medical imaging</italic><bold>32</bold>, 110&#8211;118 (2012).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TMI.2012.2220154</pub-id><pub-id pub-id-type="pmid">23014715</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henschel</surname><given-names>L</given-names></name><etal/></person-group><article-title>Fastsurfer-a fast and accurate deep learning based neuroimaging pipeline</article-title><source>NeuroImage</source><year>2020</year><volume>219</volume><fpage>117012</fpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2020.117012</pub-id><pub-id pub-id-type="pmid">32526386</pub-id><pub-id pub-id-type="pmcid">PMC7898243</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Henschel, L. et al. Fastsurfer-a fast and accurate deep learning based neuroimaging pipeline. <italic toggle="yes">NeuroImage</italic><bold>219</bold>, 117012 (2020).<pub-id pub-id-type="pmid">32526386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2020.117012</pub-id><pub-id pub-id-type="pmcid">PMC7898243</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsen</surname><given-names>K</given-names></name></person-group><article-title>Gam: the predictive modeling silver bullet</article-title><source>Multithreaded. Stitch Fix</source><year>2015</year><volume>30</volume><fpage>1</fpage><lpage>27</lpage></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Larsen, K. Gam: the predictive modeling silver bullet. <italic toggle="yes">Multithreaded. Stitch Fix</italic><bold>30</bold>, 1&#8211;27 (2015).</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hyndman</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Koehler</surname><given-names>AB</given-names></name></person-group><article-title>Another look at measures of forecast accuracy</article-title><source>International journal of forecasting</source><year>2006</year><volume>22</volume><fpage>679</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1016/j.ijforecast.2006.03.001</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Hyndman, R. J. &amp; Koehler, A. B. Another look at measures of forecast accuracy. <italic toggle="yes">International journal of forecasting</italic><bold>22</bold>, 679&#8211;688 (2006).</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="other">Kreinovich, V., Nguyen, H.&#160;T. &amp; Ouncharoen, R. How to estimate forecasting quality: A system-motivated derivation of symmetric mean absolute percentage error (smape) and other similar characteristics. <italic toggle="yes">Departmental Technical Reports (CS). 865</italic> (2014).</mixed-citation></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="other">Wang, X., Peng, Y. &amp; Ma, W. An end-to-end smart predict-then-optimize framework for vehicle relocation problems in large-scale vehicle crowd sensing. <italic toggle="yes">arXiv preprint</italic><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://arxiv.org/abs/2411.18432">arXiv:2411.18432</ext-link> (2024).</mixed-citation></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tibshirani</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Efron</surname><given-names>B</given-names></name></person-group><article-title>An introduction to the bootstrap</article-title><source>Monographs on statistics and applied probability</source><year>1993</year><volume>57</volume><fpage>1</fpage><lpage>436</lpage></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Tibshirani, R. J. &amp; Efron, B. An introduction to the bootstrap. <italic toggle="yes">Monographs on statistics and applied probability</italic><bold>57</bold>, 1&#8211;436 (1993).</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manj&#243;n</surname><given-names>JV</given-names></name><etal/></person-group><article-title>Nonlocal intracranial cavity extraction</article-title><source>International journal of biomedical imaging</source><year>2014</year><volume>2014</volume><fpage>820205</fpage><pub-id pub-id-type="doi">10.1155/2014/820205</pub-id><pub-id pub-id-type="pmid">25328511</pub-id><pub-id pub-id-type="pmcid">PMC4195262</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Manj&#243;n, J. V. et al. Nonlocal intracranial cavity extraction. <italic toggle="yes">International journal of biomedical imaging</italic><bold>2014</bold>, 820205 (2014).<pub-id pub-id-type="pmid">25328511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2014/820205</pub-id><pub-id pub-id-type="pmcid">PMC4195262</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#199;orbac&#305;o&#287;lu</surname><given-names>&#350;K</given-names></name><name name-style="western"><surname>Aksel</surname><given-names>G</given-names></name></person-group><article-title>Receiver operating characteristic curve analysis in diagnostic accuracy studies: A guide to interpreting the area under the curve value</article-title><source>Turkish journal of emergency medicine</source><year>2023</year><volume>23</volume><fpage>195</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.4103/tjem.tjem_182_23</pub-id><pub-id pub-id-type="pmid">38024184</pub-id><pub-id pub-id-type="pmcid">PMC10664195</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">&#199;orbac&#305;o&#287;lu, &#350;K. &amp; Aksel, G. Receiver operating characteristic curve analysis in diagnostic accuracy studies: A guide to interpreting the area under the curve value. <italic toggle="yes">Turkish journal of emergency medicine</italic><bold>23</bold>, 195&#8211;198 (2023).<pub-id pub-id-type="pmid">38024184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/tjem.tjem_182_23</pub-id><pub-id pub-id-type="pmcid">PMC10664195</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ziegler</surname><given-names>G</given-names></name><etal/></person-group><article-title>Individualized gaussian process-based prediction and detection of local and global gray matter abnormalities in elderly subjects</article-title><source>NeuroImage</source><year>2014</year><volume>97</volume><fpage>333</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2014.04.018</pub-id><pub-id pub-id-type="pmid">24742919</pub-id><pub-id pub-id-type="pmcid">PMC4077633</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Ziegler, G. et al. Individualized gaussian process-based prediction and detection of local and global gray matter abnormalities in elderly subjects. <italic toggle="yes">NeuroImage</italic><bold>97</bold>, 333&#8211;348 (2014).<pub-id pub-id-type="pmid">24742919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2014.04.018</pub-id><pub-id pub-id-type="pmcid">PMC4077633</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathalon</surname><given-names>DH</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>EV</given-names></name><name name-style="western"><surname>Rawles</surname><given-names>JM</given-names></name><name name-style="western"><surname>Pfefferbaum</surname><given-names>A</given-names></name></person-group><article-title>Correction for head size in brain-imaging measurements</article-title><source>Psychiatry Research: Neuroimaging</source><year>1993</year><volume>50</volume><fpage>121</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/0925-4927(93)90016-B</pub-id><pub-id pub-id-type="pmid">8378488</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Mathalon, D. H., Sullivan, E. V., Rawles, J. M. &amp; Pfefferbaum, A. Correction for head size in brain-imaging measurements. <italic toggle="yes">Psychiatry Research: Neuroimaging</italic><bold>50</bold>, 121&#8211;139 (1993).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0925-4927(93)90016-b</pub-id><pub-id pub-id-type="pmid">8378488</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yaakub</surname><given-names>SN</given-names></name><etal/></person-group><article-title>On brain atlas choice and automatic segmentation methods: a comparison of maper &amp; freesurfer using three atlas databases</article-title><source>Scientific Reports</source><year>2020</year><volume>10</volume><fpage>2837</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-57951-6</pub-id><pub-id pub-id-type="pmid">32071355</pub-id><pub-id pub-id-type="pmcid">PMC7028906</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Yaakub, S. N. et al. On brain atlas choice and automatic segmentation methods: a comparison of maper &amp; freesurfer using three atlas databases. <italic toggle="yes">Scientific Reports</italic><bold>10</bold>, 2837 (2020).<pub-id pub-id-type="pmid">32071355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-57951-6</pub-id><pub-id pub-id-type="pmcid">PMC7028906</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kijonka</surname><given-names>M</given-names></name><etal/></person-group><article-title>Whole brain and cranial size adjustments in volumetric brain analyses of sex-and age-related trends</article-title><source>Frontiers in neuroscience</source><year>2020</year><volume>14</volume><fpage>278</fpage><pub-id pub-id-type="doi">10.3389/fnins.2020.00278</pub-id><pub-id pub-id-type="pmid">32317915</pub-id><pub-id pub-id-type="pmcid">PMC7147247</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Kijonka, M. et al. Whole brain and cranial size adjustments in volumetric brain analyses of sex-and age-related trends. <italic toggle="yes">Frontiers in neuroscience</italic><bold>14</bold>, 278 (2020).<pub-id pub-id-type="pmid">32317915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2020.00278</pub-id><pub-id pub-id-type="pmcid">PMC7147247</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malone</surname><given-names>IB</given-names></name><etal/></person-group><article-title>Accurate automatic estimation of total intracranial volume: a nuisance variable with less nuisance</article-title><source>Neuroimage</source><year>2015</year><volume>104</volume><fpage>366</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2014.09.034</pub-id><pub-id pub-id-type="pmid">25255942</pub-id><pub-id pub-id-type="pmcid">PMC4265726</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Malone, I. B. et al. Accurate automatic estimation of total intracranial volume: a nuisance variable with less nuisance. <italic toggle="yes">Neuroimage</italic><bold>104</bold>, 366&#8211;372 (2015).<pub-id pub-id-type="pmid">25255942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2014.09.034</pub-id><pub-id pub-id-type="pmcid">PMC4265726</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pintzka</surname><given-names>CW</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>TI</given-names></name><name name-style="western"><surname>Evensmoen</surname><given-names>HR</given-names></name><name name-style="western"><surname>H&#229;berg</surname><given-names>AK</given-names></name></person-group><article-title>Marked effects of intracranial volume correction methods on sex differences in neuroanatomical structures: a hunt mri study</article-title><source>Frontiers in neuroscience</source><year>2015</year><volume>9</volume><fpage>238</fpage><pub-id pub-id-type="doi">10.3389/fnins.2015.00238</pub-id><pub-id pub-id-type="pmid">26217172</pub-id><pub-id pub-id-type="pmcid">PMC4496575</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Pintzka, C. W., Hansen, T. I., Evensmoen, H. R. &amp; H&#229;berg, A. K. Marked effects of intracranial volume correction methods on sex differences in neuroanatomical structures: a hunt mri study. <italic toggle="yes">Frontiers in neuroscience</italic><bold>9</bold>, 238 (2015).<pub-id pub-id-type="pmid">26217172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2015.00238</pub-id><pub-id pub-id-type="pmcid">PMC4496575</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Brien</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Statistical adjustments for brain size in volumetric neuroimaging studies: some practical implications in methods</article-title><source>Psychiatry Research: Neuroimaging</source><year>2011</year><volume>193</volume><fpage>113</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.pscychresns.2011.01.007</pub-id><pub-id pub-id-type="pmcid">PMC3510982</pub-id><pub-id pub-id-type="pmid">21684724</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">O&#8217;Brien, L. M. et al. Statistical adjustments for brain size in volumetric neuroimaging studies: some practical implications in methods. <italic toggle="yes">Psychiatry Research: Neuroimaging</italic><bold>193</bold>, 113&#8211;122 (2011).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pscychresns.2011.01.007</pub-id><pub-id pub-id-type="pmcid">PMC3510982</pub-id><pub-id pub-id-type="pmid">21684724</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klasson</surname><given-names>N</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>E</given-names></name><name name-style="western"><surname>Eckerstr&#246;m</surname><given-names>C</given-names></name><name name-style="western"><surname>Malmgren</surname><given-names>H</given-names></name><name name-style="western"><surname>Wallin</surname><given-names>A</given-names></name></person-group><article-title>Estimated intracranial volume from freesurfer is biased by total brain volume</article-title><source>European Radiology Experimental</source><year>2018</year><volume>2</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1186/s41747-018-0055-4</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Klasson, N., Olsson, E., Eckerstr&#246;m, C., Malmgren, H. &amp; Wallin, A. Estimated intracranial volume from freesurfer is biased by total brain volume. <italic toggle="yes">European Radiology Experimental</italic><bold>2</bold>, 1&#8211;6 (2018).29708215
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jovicich</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mri-derived measurements of human subcortical, ventricular and intracranial brain volumes: reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths</article-title><source>Neuroimage</source><year>2009</year><volume>46</volume><fpage>177</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2009.02.010</pub-id><pub-id pub-id-type="pmid">19233293</pub-id><pub-id pub-id-type="pmcid">PMC2866077</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Jovicich, J. et al. Mri-derived measurements of human subcortical, ventricular and intracranial brain volumes: reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. <italic toggle="yes">Neuroimage</italic><bold>46</bold>, 177&#8211;192 (2009).<pub-id pub-id-type="pmid">19233293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2009.02.010</pub-id><pub-id pub-id-type="pmcid">PMC2866077</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C-Y</given-names></name><etal/></person-group><article-title>Reproducibility of brain morphometry from short-term repeat clinical mri examinations: a retrospective study</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><fpage>e0146913</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0146913</pub-id><pub-id pub-id-type="pmid">26812647</pub-id><pub-id pub-id-type="pmcid">PMC4727912</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Yang, C.-Y. et al. Reproducibility of brain morphometry from short-term repeat clinical mri examinations: a retrospective study. <italic toggle="yes">PLoS One</italic><bold>11</bold>, e0146913 (2016).<pub-id pub-id-type="pmid">26812647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0146913</pub-id><pub-id pub-id-type="pmcid">PMC4727912</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rebsamen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Growing importance of brain morphometry analysis in the clinical routine: The hidden impact of mr sequence parameters</article-title><source>Journal of Neuroradiology</source><year>2024</year><volume>51</volume><fpage>5</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.neurad.2023.04.003</pub-id><pub-id pub-id-type="pmid">37116782</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Rebsamen, M. et al. Growing importance of brain morphometry analysis in the clinical routine: The hidden impact of mr sequence parameters. <italic toggle="yes">Journal of Neuroradiology</italic><bold>51</bold>, 5&#8211;9 (2024).<pub-id pub-id-type="pmid">37116782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurad.2023.04.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heinen</surname><given-names>R</given-names></name><etal/></person-group><article-title>Robustness of automated methods for brain volume measurements across different mri field strengths</article-title><source>PloS one</source><year>2016</year><volume>11</volume><fpage>e0165719</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0165719</pub-id><pub-id pub-id-type="pmid">27798694</pub-id><pub-id pub-id-type="pmcid">PMC5087903</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Heinen, R. et al. Robustness of automated methods for brain volume measurements across different mri field strengths. <italic toggle="yes">PloS one</italic><bold>11</bold>, e0165719 (2016).<pub-id pub-id-type="pmid">27798694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0165719</pub-id><pub-id pub-id-type="pmcid">PMC5087903</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keihaninejad</surname><given-names>S</given-names></name><etal/></person-group><article-title>A robust method to estimate the intracranial volume across mri field strengths (1.5 t and 3t)</article-title><source>Neuroimage</source><year>2010</year><volume>50</volume><fpage>1427</fpage><lpage>1437</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.01.064</pub-id><pub-id pub-id-type="pmid">20114082</pub-id><pub-id pub-id-type="pmcid">PMC2883144</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Keihaninejad, S. et al. A robust method to estimate the intracranial volume across mri field strengths (1.5 t and 3t). <italic toggle="yes">Neuroimage</italic><bold>50</bold>, 1427&#8211;1437 (2010).<pub-id pub-id-type="pmid">20114082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2010.01.064</pub-id><pub-id pub-id-type="pmcid">PMC2883144</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Potvin</surname><given-names>O</given-names></name><etal/></person-group><article-title>Measurement variability following mri system upgrade</article-title><source>Frontiers in neurology</source><year>2019</year><volume>10</volume><fpage>726</fpage><pub-id pub-id-type="doi">10.3389/fneur.2019.00726</pub-id><pub-id pub-id-type="pmid">31379704</pub-id><pub-id pub-id-type="pmcid">PMC6648007</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Potvin, O. et al. Measurement variability following mri system upgrade. <italic toggle="yes">Frontiers in neurology</italic><bold>10</bold>, 726 (2019).<pub-id pub-id-type="pmid">31379704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2019.00726</pub-id><pub-id pub-id-type="pmcid">PMC6648007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jovicich</surname><given-names>J</given-names></name><etal/></person-group><article-title>Reliability in multi-site structural mri studies: effects of gradient non-linearity correction on phantom and human data</article-title><source>Neuroimage</source><year>2006</year><volume>30</volume><fpage>436</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2005.09.046</pub-id><pub-id pub-id-type="pmid">16300968</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Jovicich, J. et al. Reliability in multi-site structural mri studies: effects of gradient non-linearity correction on phantom and human data. <italic toggle="yes">Neuroimage</italic><bold>30</bold>, 436&#8211;443 (2006).<pub-id pub-id-type="pmid">16300968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2005.09.046</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchewka</surname><given-names>A</given-names></name><etal/></person-group><article-title>Influence of magnetic field strength and image registration strategy on voxel-based morphometry in a study of alzheimer&#8217;s disease</article-title><source>Human brain mapping</source><year>2014</year><volume>35</volume><fpage>1865</fpage><lpage>1874</lpage><pub-id pub-id-type="doi">10.1002/hbm.22297</pub-id><pub-id pub-id-type="pmid">23723177</pub-id><pub-id pub-id-type="pmcid">PMC6869431</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Marchewka, A. et al. Influence of magnetic field strength and image registration strategy on voxel-based morphometry in a study of alzheimer&#8217;s disease. <italic toggle="yes">Human brain mapping</italic><bold>35</bold>, 1865&#8211;1874 (2014).<pub-id pub-id-type="pmid">23723177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.22297</pub-id><pub-id pub-id-type="pmcid">PMC6869431</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodro</surname><given-names>M</given-names></name><name name-style="western"><surname>Sameti</surname><given-names>M</given-names></name><name name-style="western"><surname>Patenaude</surname><given-names>B</given-names></name><name name-style="western"><surname>Fein</surname><given-names>G</given-names></name></person-group><article-title>Age effect on subcortical structures in healthy adults</article-title><source>Psychiatry Research: Neuroimaging</source><year>2012</year><volume>203</volume><fpage>38</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.pscychresns.2011.09.014</pub-id><pub-id pub-id-type="pmcid">PMC3444666</pub-id><pub-id pub-id-type="pmid">22863654</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Goodro, M., Sameti, M., Patenaude, B. &amp; Fein, G. Age effect on subcortical structures in healthy adults. <italic toggle="yes">Psychiatry Research: Neuroimaging</italic><bold>203</bold>, 38&#8211;45 (2012).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pscychresns.2011.09.014</pub-id><pub-id pub-id-type="pmcid">PMC3444666</pub-id><pub-id pub-id-type="pmid">22863654</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfefferbaum</surname><given-names>A</given-names></name><name name-style="western"><surname>Rohlfing</surname><given-names>T</given-names></name><name name-style="western"><surname>Rosenbloom</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>EV</given-names></name></person-group><article-title>Combining atlas-based parcellation of regional brain data acquired across scanners at 1.5 t and 3.0 t field strengths</article-title><source>Neuroimage</source><year>2012</year><volume>60</volume><fpage>940</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2012.01.092</pub-id><pub-id pub-id-type="pmid">22297204</pub-id><pub-id pub-id-type="pmcid">PMC3303927</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Pfefferbaum, A., Rohlfing, T., Rosenbloom, M. J. &amp; Sullivan, E. V. Combining atlas-based parcellation of regional brain data acquired across scanners at 1.5 t and 3.0 t field strengths. <italic toggle="yes">Neuroimage</italic><bold>60</bold>, 940&#8211;951 (2012).<pub-id pub-id-type="pmid">22297204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2012.01.092</pub-id><pub-id pub-id-type="pmcid">PMC3303927</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><mixed-citation publication-type="other">Valabregue, R., Khemir, I., Auzias, G., Rousseau, F. &amp; Ounissi, M. Unraveling systematic biases in brain segmentation: Insights from synthetic training. In <italic toggle="yes">MIDL 2024-Medical Imaging with Deep Learning</italic> (2024).</mixed-citation></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><etal/></person-group><article-title>Evaluating brain volume segmentation accuracy and reliability of freesurfer and neurophet aqua at variations in mri magnetic field strengths</article-title><source>Scientific Reports</source><year>2024</year><volume>14</volume><fpage>24513</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-74622-y</pub-id><pub-id pub-id-type="pmid">39424856</pub-id><pub-id pub-id-type="pmcid">PMC11489576</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Lee, H. et al. Evaluating brain volume segmentation accuracy and reliability of freesurfer and neurophet aqua at variations in mri magnetic field strengths. <italic toggle="yes">Scientific Reports</italic><bold>14</bold>, 24513 (2024).<pub-id pub-id-type="pmid">39424856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-74622-y</pub-id><pub-id pub-id-type="pmcid">PMC11489576</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atty&#233;</surname><given-names>A</given-names></name><etal/></person-group><article-title>Data-driven normative values based on generative manifold learning for quantitative mri</article-title><source>Scientific Reports</source><year>2024</year><volume>14</volume><fpage>7563</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-58141-4</pub-id><pub-id pub-id-type="pmid">38555415</pub-id><pub-id pub-id-type="pmcid">PMC10981723</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Atty&#233;, A. et al. Data-driven normative values based on generative manifold learning for quantitative mri. <italic toggle="yes">Scientific Reports</italic><bold>14</bold>, 7563 (2024).<pub-id pub-id-type="pmid">38555415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-58141-4</pub-id><pub-id pub-id-type="pmcid">PMC10981723</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiely</surname><given-names>M</given-names></name><etal/></person-group><article-title>Insights into human cerebral white matter maturation and degeneration across the adult lifespan</article-title><source>Neuroimage</source><year>2022</year><volume>247</volume><fpage>118727</fpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2021.118727</pub-id><pub-id pub-id-type="pmid">34813969</pub-id><pub-id pub-id-type="pmcid">PMC8792239</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Kiely, M. et al. Insights into human cerebral white matter maturation and degeneration across the adult lifespan. <italic toggle="yes">Neuroimage</italic><bold>247</bold>, 118727 (2022).<pub-id pub-id-type="pmid">34813969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2021.118727</pub-id><pub-id pub-id-type="pmcid">PMC8792239</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hedman</surname><given-names>AM</given-names></name><name name-style="western"><surname>van Haren</surname><given-names>NE</given-names></name><name name-style="western"><surname>Schnack</surname><given-names>HG</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>RS</given-names></name><name name-style="western"><surname>Hulshoff Pol</surname><given-names>HE</given-names></name></person-group><article-title>Human brain changes across the life span: a review of 56 longitudinal magnetic resonance imaging studies</article-title><source>Human brain mapping</source><year>2012</year><volume>33</volume><fpage>1987</fpage><lpage>2002</lpage><pub-id pub-id-type="doi">10.1002/hbm.21334</pub-id><pub-id pub-id-type="pmid">21915942</pub-id><pub-id pub-id-type="pmcid">PMC6870052</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Hedman, A. M., van Haren, N. E., Schnack, H. G., Kahn, R. S. &amp; Hulshoff Pol, H. E. Human brain changes across the life span: a review of 56 longitudinal magnetic resonance imaging studies. <italic toggle="yes">Human brain mapping</italic><bold>33</bold>, 1987&#8211;2002 (2012).<pub-id pub-id-type="pmid">21915942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.21334</pub-id><pub-id pub-id-type="pmcid">PMC6870052</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coup&#233;</surname><given-names>P</given-names></name><name name-style="western"><surname>Manj&#243;n</surname><given-names>JV</given-names></name><name name-style="western"><surname>Lanuza</surname><given-names>E</given-names></name><name name-style="western"><surname>Catheline</surname><given-names>G</given-names></name></person-group><article-title>Lifespan changes of the human brain in alzheimer&#8217;s disease</article-title><source>Scientific reports</source><year>2019</year><volume>9</volume><fpage>3998</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-39809-8</pub-id><pub-id pub-id-type="pmid">30850617</pub-id><pub-id pub-id-type="pmcid">PMC6408544</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Coup&#233;, P., Manj&#243;n, J. V., Lanuza, E. &amp; Catheline, G. Lifespan changes of the human brain in alzheimer&#8217;s disease. <italic toggle="yes">Scientific reports</italic><bold>9</bold>, 3998 (2019).<pub-id pub-id-type="pmid">30850617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-39809-8</pub-id><pub-id pub-id-type="pmcid">PMC6408544</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breijyeh</surname><given-names>Z</given-names></name><name name-style="western"><surname>Karaman</surname><given-names>R</given-names></name></person-group><article-title>Comprehensive review on alzheimer&#8217;s disease: causes and treatment</article-title><source>Molecules</source><year>2020</year><volume>25</volume><fpage>5789</fpage><pub-id pub-id-type="doi">10.3390/molecules25245789</pub-id><pub-id pub-id-type="pmid">33302541</pub-id><pub-id pub-id-type="pmcid">PMC7764106</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Breijyeh, Z. &amp; Karaman, R. Comprehensive review on alzheimer&#8217;s disease: causes and treatment. <italic toggle="yes">Molecules</italic><bold>25</bold>, 5789 (2020).<pub-id pub-id-type="pmid">33302541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules25245789</pub-id><pub-id pub-id-type="pmcid">PMC7764106</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhogal</surname><given-names>P</given-names></name><etal/></person-group><article-title>The common dementias: a pictorial review</article-title><source>European radiology</source><year>2013</year><volume>23</volume><fpage>3405</fpage><lpage>3417</lpage><pub-id pub-id-type="doi">10.1007/s00330-013-3005-9</pub-id><pub-id pub-id-type="pmid">24081643</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Bhogal, P. et al. The common dementias: a pictorial review. <italic toggle="yes">European radiology</italic><bold>23</bold>, 3405&#8211;3417 (2013).<pub-id pub-id-type="pmid">24081643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-013-3005-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><mixed-citation publication-type="other">Bansode, P., Chivte, V. &amp; Nikalje, A.&#160;P. A brief review on parkinson&#8217;s disease. <italic toggle="yes">EC Pharmacology &amp; Toxicology&#8211;Review Article, Maharshtra, published: June</italic><bold>15</bold> (2018).</mixed-citation></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>A/t/n: An unbiased descriptive classification scheme for alzheimer disease biomarkers</article-title><source>Neurology</source><year>2016</year><volume>87</volume><fpage>539</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000002923</pub-id><pub-id pub-id-type="pmid">27371494</pub-id><pub-id pub-id-type="pmcid">PMC4970664</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Jack, C. R. Jr. et al. A/t/n: An unbiased descriptive classification scheme for alzheimer disease biomarkers. <italic toggle="yes">Neurology</italic><bold>87</bold>, 539&#8211;547 (2016).<pub-id pub-id-type="pmid">27371494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000002923</pub-id><pub-id pub-id-type="pmcid">PMC4970664</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Altmann</surname><given-names>A</given-names></name><etal/></person-group><article-title>Towards cascading genetic risk in alzheimer&#8217;s disease</article-title><source>Brain</source><year>2024</year><volume>147</volume><fpage>2680</fpage><lpage>2690</lpage><pub-id pub-id-type="doi">10.1093/brain/awae176</pub-id><pub-id pub-id-type="pmid">38820112</pub-id><pub-id pub-id-type="pmcid">PMC11292901</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Altmann, A. et al. Towards cascading genetic risk in alzheimer&#8217;s disease. <italic toggle="yes">Brain</italic><bold>147</bold>, 2680&#8211;2690 (2024).<pub-id pub-id-type="pmid">38820112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awae176</pub-id><pub-id pub-id-type="pmcid">PMC11292901</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bateman</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Clinical and biomarker changes in dominantly inherited alzheimer&#8217;s disease</article-title><source>New England Journal of Medicine</source><year>2012</year><volume>367</volume><fpage>795</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1202753</pub-id><pub-id pub-id-type="pmid">22784036</pub-id><pub-id pub-id-type="pmcid">PMC3474597</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited alzheimer&#8217;s disease. <italic toggle="yes">New England Journal of Medicine</italic><bold>367</bold>, 795&#8211;804 (2012).<pub-id pub-id-type="pmid">22784036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1202753</pub-id><pub-id pub-id-type="pmcid">PMC3474597</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fagan</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Longitudinal change in csf biomarkers in autosomal-dominant alzheimer&#8217;s disease</article-title><source>Science translational medicine</source><year>2014</year><volume>6</volume><fpage>226ra30</fpage><lpage>226ra30</lpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3007901</pub-id><pub-id pub-id-type="pmid">24598588</pub-id><pub-id pub-id-type="pmcid">PMC4038930</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Fagan, A. M. et al. Longitudinal change in csf biomarkers in autosomal-dominant alzheimer&#8217;s disease. <italic toggle="yes">Science translational medicine</italic><bold>6</bold>, 226ra30-226ra30 (2014).<pub-id pub-id-type="pmid">24598588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3007901</pub-id><pub-id pub-id-type="pmcid">PMC4038930</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolgin</surname><given-names>E</given-names></name></person-group><article-title>Faster, cheaper, better: the rise of blood tests for alzheimer&#8217;s</article-title><source>Nature</source><year>2025</year><volume>640</volume><fpage>S11</fpage><lpage>S13</lpage><pub-id pub-id-type="doi">10.1038/d41586-025-01105-z</pub-id><pub-id pub-id-type="pmid">40240848</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Dolgin, E. Faster, cheaper, better: the rise of blood tests for alzheimer&#8217;s. <italic toggle="yes">Nature</italic><bold>640</bold>, S11&#8211;S13 (2025).<pub-id pub-id-type="pmid">40240848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-025-01105-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><mixed-citation publication-type="other">Coup&#233;, P. <italic toggle="yes">et al.</italic> Assemblynet: a novel deep decision-making process for whole brain mri segmentation. In <italic toggle="yes">Medical Image Computing and Computer Assisted Intervention&#8211;MICCAI 2019: 22nd International Conference, Shenzhen, China, October 13&#8211;17, 2019, Proceedings, Part III 22</italic>, 466&#8211;474 (Springer, 2019).</mixed-citation></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischl</surname><given-names>B</given-names></name><etal/></person-group><article-title>Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain</article-title><source>Neuron</source><year>2002</year><volume>33</volume><fpage>341</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(02)00569-X</pub-id><pub-id pub-id-type="pmid">11832223</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Fischl, B. et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. <italic toggle="yes">Neuron</italic><bold>33</bold>, 341&#8211;355 (2002).<pub-id pub-id-type="pmid">11832223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0896-6273(02)00569-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischl</surname><given-names>B</given-names></name><etal/></person-group><article-title>Sequence-independent segmentation of magnetic resonance images</article-title><source>Neuroimage</source><year>2004</year><volume>23</volume><fpage>S69</fpage><lpage>S84</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2004.07.016</pub-id><pub-id pub-id-type="pmid">15501102</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Fischl, B. et al. Sequence-independent segmentation of magnetic resonance images. <italic toggle="yes">Neuroimage</italic><bold>23</bold>, S69&#8211;S84 (2004).<pub-id pub-id-type="pmid">15501102</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2004.07.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischl</surname><given-names>B</given-names></name><name name-style="western"><surname>Sereno</surname><given-names>MI</given-names></name><name name-style="western"><surname>Dale</surname><given-names>AM</given-names></name></person-group><article-title>Cortical surface-based analysis: Ii: inflation, flattening, and a surface-based coordinate system</article-title><source>Neuroimage</source><year>1999</year><volume>9</volume><fpage>195</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1006/nimg.1998.0396</pub-id><pub-id pub-id-type="pmid">9931269</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Fischl, B., Sereno, M. I. &amp; Dale, A. M. Cortical surface-based analysis: Ii: inflation, flattening, and a surface-based coordinate system. <italic toggle="yes">Neuroimage</italic><bold>9</bold>, 195&#8211;207 (1999).<pub-id pub-id-type="pmid">9931269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/nimg.1998.0396</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desikan</surname><given-names>RS</given-names></name><etal/></person-group><article-title>An automated labeling system for subdividing the human cerebral cortex on mri scans into gyral based regions of interest</article-title><source>Neuroimage</source><year>2006</year><volume>31</volume><fpage>968</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2006.01.021</pub-id><pub-id pub-id-type="pmid">16530430</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Desikan, R. S. et al. An automated labeling system for subdividing the human cerebral cortex on mri scans into gyral based regions of interest. <italic toggle="yes">Neuroimage</italic><bold>31</bold>, 968&#8211;980 (2006).<pub-id pub-id-type="pmid">16530430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2006.01.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kazemi</surname><given-names>K</given-names></name><name name-style="western"><surname>Noorizadeh</surname><given-names>N</given-names></name></person-group><article-title>Quantitative comparison of spm, fsl, and brainsuite for brain mr image segmentation</article-title><source>Journal of biomedical physics &amp; engineering</source><year>2014</year><volume>4</volume><fpage>13</fpage><pub-id pub-id-type="pmid">25505764</pub-id><pub-id pub-id-type="pmcid">PMC4258855</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Kazemi, K. &amp; Noorizadeh, N. Quantitative comparison of spm, fsl, and brainsuite for brain mr image segmentation. <italic toggle="yes">Journal of biomedical physics &amp; engineering</italic><bold>4</bold>, 13 (2014).<pub-id pub-id-type="pmid">25505764</pub-id><pub-id pub-id-type="pmcid">PMC4258855</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fellhauer</surname><given-names>I</given-names></name><etal/></person-group><article-title>Comparison of automated brain segmentation using a brain phantom and patients with early alzheimer&#8217;s dementia or mild cognitive impairment</article-title><source>Psychiatry Research: Neuroimaging</source><year>2015</year><volume>233</volume><fpage>299</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1016/j.pscychresns.2015.07.011</pub-id><pub-id pub-id-type="pmid">26211622</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Fellhauer, I. et al. Comparison of automated brain segmentation using a brain phantom and patients with early alzheimer&#8217;s dementia or mild cognitive impairment. <italic toggle="yes">Psychiatry Research: Neuroimaging</italic><bold>233</bold>, 299&#8211;305 (2015).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pscychresns.2015.07.011</pub-id><pub-id pub-id-type="pmid">26211622</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poulin</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Amygdala atrophy is prominent in early alzheimer&#8217;s disease and relates to symptom severity</article-title><source>Psychiatry Research: Neuroimaging</source><year>2011</year><volume>194</volume><fpage>7</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.pscychresns.2011.06.014</pub-id><pub-id pub-id-type="pmcid">PMC3185127</pub-id><pub-id pub-id-type="pmid">21920712</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Poulin, S. P. et al. Amygdala atrophy is prominent in early alzheimer&#8217;s disease and relates to symptom severity. <italic toggle="yes">Psychiatry Research: Neuroimaging</italic><bold>194</bold>, 7&#8211;13 (2011).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pscychresns.2011.06.014</pub-id><pub-id pub-id-type="pmcid">PMC3185127</pub-id><pub-id pub-id-type="pmid">21920712</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Leon</surname><given-names>M</given-names></name><etal/></person-group><article-title>Frequency of hippocampal formation atrophy in normal aging and alzheimer&#8217;s disease</article-title><source>Neurobiology of aging</source><year>1997</year><volume>18</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/S0197-4580(96)00213-8</pub-id><pub-id pub-id-type="pmid">8983027</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">De Leon, M. et al. Frequency of hippocampal formation atrophy in normal aging and alzheimer&#8217;s disease. <italic toggle="yes">Neurobiology of aging</italic><bold>18</bold>, 1&#8211;11 (1997).<pub-id pub-id-type="pmid">8983027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0197-4580(96)00213-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><mixed-citation publication-type="other">Shi, F., Liu, B., Zhou, Y., Yu, C. &amp; Jiang, T. Hippocampal volume and asymmetry in mild cognitive impairment and alzheimer&#8217;s disease: Meta-analyses of mri studies (2009).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hipo.20573</pub-id><pub-id pub-id-type="pmid">19309039</pub-id></mixed-citation></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhikav</surname><given-names>V</given-names></name><name name-style="western"><surname>Duraisamy</surname><given-names>S</given-names></name><name name-style="western"><surname>Anand</surname><given-names>KS</given-names></name><name name-style="western"><surname>Garga</surname><given-names>UC</given-names></name></person-group><article-title>Hippocampal volumes among older indian adults: Comparison with alzheimer&#8217;s disease and mild cognitive impairment</article-title><source>Annals of Indian Academy of Neurology</source><year>2016</year><volume>19</volume><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.4103/0972-2327.176863</pub-id><pub-id pub-id-type="pmid">27293329</pub-id><pub-id pub-id-type="pmcid">PMC4888681</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Dhikav, V., Duraisamy, S., Anand, K. S. &amp; Garga, U. C. Hippocampal volumes among older indian adults: Comparison with alzheimer&#8217;s disease and mild cognitive impairment. <italic toggle="yes">Annals of Indian Academy of Neurology</italic><bold>19</bold>, 195&#8211;200 (2016).<pub-id pub-id-type="pmid">27293329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0972-2327.176863</pub-id><pub-id pub-id-type="pmcid">PMC4888681</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ezzati</surname><given-names>A</given-names></name><etal/></person-group><article-title>Differential association of left and right hippocampal volumes with verbal episodic and spatial memory in older adults</article-title><source>Neuropsychologia</source><year>2016</year><volume>93</volume><fpage>380</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1016/j.neuropsychologia.2016.08.016</pub-id><pub-id pub-id-type="pmid">27542320</pub-id><pub-id pub-id-type="pmcid">PMC5154822</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Ezzati, A. et al. Differential association of left and right hippocampal volumes with verbal episodic and spatial memory in older adults. <italic toggle="yes">Neuropsychologia</italic><bold>93</bold>, 380&#8211;385 (2016).<pub-id pub-id-type="pmid">27542320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropsychologia.2016.08.016</pub-id><pub-id pub-id-type="pmcid">PMC5154822</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Hippocampal subfield volumetry in patients with subcortical vascular mild cognitive impairment</article-title><source>Scientific reports</source><year>2016</year><volume>6</volume><fpage>20873</fpage><pub-id pub-id-type="doi">10.1038/srep20873</pub-id><pub-id pub-id-type="pmid">26876151</pub-id><pub-id pub-id-type="pmcid">PMC4753487</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Li, X. et al. Hippocampal subfield volumetry in patients with subcortical vascular mild cognitive impairment. <italic toggle="yes">Scientific reports</italic><bold>6</bold>, 20873 (2016).<pub-id pub-id-type="pmid">26876151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep20873</pub-id><pub-id pub-id-type="pmcid">PMC4753487</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byun</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Heterogeneity of regional brain atrophy patterns associated with distinct progression rates in alzheimer&#8217;s disease</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0142756</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0142756</pub-id><pub-id pub-id-type="pmid">26618360</pub-id><pub-id pub-id-type="pmcid">PMC4664412</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Byun, M. S. et al. Heterogeneity of regional brain atrophy patterns associated with distinct progression rates in alzheimer&#8217;s disease. <italic toggle="yes">PLoS One</italic><bold>10</bold>, e0142756 (2015).<pub-id pub-id-type="pmid">26618360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0142756</pub-id><pub-id pub-id-type="pmcid">PMC4664412</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lowe</surname><given-names>VJ</given-names></name><etal/></person-group><article-title>Application of the national institute on aging-alzheimer&#8217;s association ad criteria to adni</article-title><source>Neurology</source><year>2013</year><volume>80</volume><fpage>2130</fpage><lpage>2137</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e318295d6cf</pub-id><pub-id pub-id-type="pmid">23645596</pub-id><pub-id pub-id-type="pmcid">PMC3716359</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Lowe, V. J. et al. Application of the national institute on aging-alzheimer&#8217;s association ad criteria to adni. <italic toggle="yes">Neurology</italic><bold>80</bold>, 2130&#8211;2137 (2013).<pub-id pub-id-type="pmid">23645596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e318295d6cf</pub-id><pub-id pub-id-type="pmcid">PMC3716359</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orlhac</surname><given-names>F</given-names></name><etal/></person-group><article-title>A guide to combat harmonization of imaging biomarkers in multicenter studies</article-title><source>Journal of Nuclear Medicine</source><year>2022</year><volume>63</volume><fpage>172</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.2967/jnumed.121.262464</pub-id><pub-id pub-id-type="pmid">34531263</pub-id><pub-id pub-id-type="pmcid">PMC8805779</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Orlhac, F. et al. A guide to combat harmonization of imaging biomarkers in multicenter studies. <italic toggle="yes">Journal of Nuclear Medicine</italic><bold>63</bold>, 172&#8211;179 (2022).<pub-id pub-id-type="pmid">34531263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.121.262464</pub-id><pub-id pub-id-type="pmcid">PMC8805779</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinto</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Harmonization of brain diffusion mri: Concepts and methods</article-title><source>Frontiers in Neuroscience</source><year>2020</year><volume>14</volume><fpage>396</fpage><pub-id pub-id-type="doi">10.3389/fnins.2020.00396</pub-id><pub-id pub-id-type="pmid">32435181</pub-id><pub-id pub-id-type="pmcid">PMC7218137</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Pinto, M. S. et al. Harmonization of brain diffusion mri: Concepts and methods. <italic toggle="yes">Frontiers in Neuroscience</italic><bold>14</bold>, 396 (2020).<pub-id pub-id-type="pmid">32435181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2020.00396</pub-id><pub-id pub-id-type="pmcid">PMC7218137</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orlhac</surname><given-names>F</given-names></name><etal/></person-group><article-title>A postreconstruction harmonization method for multicenter radiomic studies in pet</article-title><source>Journal of Nuclear Medicine</source><year>2018</year><volume>59</volume><fpage>1321</fpage><lpage>1328</lpage><pub-id pub-id-type="doi">10.2967/jnumed.117.199935</pub-id><pub-id pub-id-type="pmid">29301932</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Orlhac, F. et al. A postreconstruction harmonization method for multicenter radiomic studies in pet. <italic toggle="yes">Journal of Nuclear Medicine</italic><bold>59</bold>, 1321&#8211;1328 (2018).<pub-id pub-id-type="pmid">29301932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.117.199935</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bayer</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Accommodating site variation in neuroimaging data using normative and hierarchical bayesian models</article-title><source>Neuroimage</source><year>2022</year><volume>264</volume><fpage>119699</fpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2022.119699</pub-id><pub-id pub-id-type="pmid">36272672</pub-id><pub-id pub-id-type="pmcid">PMC7614761</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Bayer, J. M. et al. Accommodating site variation in neuroimaging data using normative and hierarchical bayesian models. <italic toggle="yes">Neuroimage</italic><bold>264</bold>, 119699 (2022).<pub-id pub-id-type="pmid">36272672</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/2021.02.09.430363</pub-id><pub-id pub-id-type="pmcid">PMC7614761</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gebre</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Cross-scanner harmonization methods for structural mri may need further work: A comparison study</article-title><source>NeuroImage</source><year>2023</year><volume>269</volume><fpage>119912</fpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2023.119912</pub-id><pub-id pub-id-type="pmid">36731814</pub-id><pub-id pub-id-type="pmcid">PMC10170652</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Gebre, R. K. et al. Cross-scanner harmonization methods for structural mri may need further work: A comparison study. <italic toggle="yes">NeuroImage</italic><bold>269</bold>, 119912 (2023).<pub-id pub-id-type="pmid">36731814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2023.119912</pub-id><pub-id pub-id-type="pmcid">PMC10170652</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Redox Biol</journal-id><journal-id journal-id-type="iso-abbrev">Redox Biol</journal-id><journal-id journal-id-type="pmc-domain-id">2171</journal-id><journal-id journal-id-type="pmc-domain">redox</journal-id><journal-title-group><journal-title>Redox Biology</journal-title></journal-title-group><issn pub-type="epub">2213-2317</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12495055</article-id><article-id pub-id-type="pmcid-ver">PMC12495055.1</article-id><article-id pub-id-type="pmcaid">12495055</article-id><article-id pub-id-type="pmcaiid">12495055</article-id><article-id pub-id-type="pmid">40992081</article-id><article-id pub-id-type="doi">10.1016/j.redox.2025.103872</article-id><article-id pub-id-type="pii">S2213-2317(25)00385-4</article-id><article-id pub-id-type="publisher-id">103872</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Copper overload worsens the inflammatory response of microglia to amyloid beta (A&#946;) by impairing phagocytosis and promoting mitochondrial DNA-mediated NLRP3 inflammasome activation</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Zubillaga</surname><given-names initials="M">Marlene</given-names></name><email>marlene.zubillaga@iibb.csic.es</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Abadin</surname><given-names initials="X">Xenia</given-names></name><email>xenia.abadin@iibb.csic.es</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Ivars</surname><given-names initials="E">Elia</given-names></name><email>elia.ivars@iibb.csic.es</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Puigr&#242;s</surname><given-names initials="M">Margalida</given-names></name><email>margalida.puigros@iibb.csic.es</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Trullas</surname><given-names initials="R">Ramon</given-names></name><email>ramon.trullas@iibb.csic.es</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Bellini</surname><given-names initials="MJ">M. Jos&#233;</given-names></name><email>mariajosebellini@med.unlp.edu.ar</email><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Arnal</surname><given-names initials="N">Nathalie</given-names></name><email>narnal@med.unlp.edu.ar</email><xref rid="aff5" ref-type="aff">e</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Colell</surname><given-names initials="A">Anna</given-names></name><email>a.colell@csic.es</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor2" ref-type="corresp">&#8270;&#8270;</xref></contrib><aff id="aff1"><label>a</label>Department of Molecular and Cellular Biomedicine, Institut d&#8217;Investigacions Biom&#232;diques de Barcelona (IIBB), Consejo Superior de Investigaciones Cient&#237;ficas (CSIC), Institut d&#8217;Investigacions Biom&#232;diques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain</aff><aff id="aff2"><label>b</label>Centro de Investigaci&#243;n Biom&#233;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28029, Madrid, Spain</aff><aff id="aff3"><label>c</label>Programa de doctorat, Facultat de Medicina, Universitat de Barcelona, 08036, Barcelona, Spain</aff><aff id="aff4"><label>d</label>Laboratory of neurobiology and cognition in aging and neurodegenerative diseases, Institute of Biochemical Research of La Plata &#8220;Prof. Dr. Rodolfo R. Brenner&#8221; (INIBIOLP), National Scientific and Technical Research Council (CONICET), The National University of La Plata (UNLP), 1900, La Plata, Argentina</aff><aff id="aff5"><label>e</label>Laboratory of neurobiology of lipids and metals in Alzheimer's disease, Institute of Biochemical Research of La Plata &#8220;Prof. Dr. Rodolfo R. Brenner&#8221; (INIBIOLP), National Scientific and Technical Research Council (CONICET), The National University of La Plata (UNLP), 1900, La Plata, Argentina</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. Laboratory of neurobiology of lipids and metals in Alzheimer's disease (INIBIOLP),CONICET,-UNLP Calle 60 y 120, 1900, La Plata, Argentina. <email>narnal@med.unlp.edu.ar</email></corresp><corresp id="cor2"><label>&#8270;&#8270;</label>Corresponding author. Department of Molecular and Cellular Biomedicine, IIBB-CSIC, Rossell&#243; 161, 08034, Barcelona, Spain <email>a.colell@csic.es</email></corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>17</day><month>9</month><year>2025</year></pub-date><volume>87</volume><issue-id pub-id-type="pmc-issue-id">497696</issue-id><elocation-id>103872</elocation-id><history><date date-type="received"><day>31</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>14</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-05 05:25:37.723"><day>05</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>Microglia play a significant role in the development and progression of Alzheimer's disease (AD). These brain-resident immune cells efficiently clear neurotoxic amyloid beta (A&#946;) peptides; however, chronic activation may overwhelm their protective abilities, resulting in persistent neuroinflammation. The causes of aberrant microglial activation in AD remain elusive. Emerging evidence indicates that copper (Cu) accumulation, which can arise from prolonged exposure to various environmental sources, modifies the innate immune response in AD. Here, we sought to explore the mechanisms by which Cu overload regulates the microglial phenotype when exposed to A&#946;. Our findings showed that exposure to sublethal doses of Cu led to the accumulation of this transition metal in the mitochondria. Elevated mitochondrial Cu (mtCu) levels were accompanied by reduced mitochondrial glutathione (mtGSH) and high oxidative stress, leading to A&#946;-induced inflammasome activation through the release of oxidized mitochondrial DNA (ox-mtDNA). Moreover, increased intracellular Cu levels enhanced cholesterol biosynthesis and facilitated its transport to mitochondria. The combination of elevated cholesterol and mitochondrial oxidative stress hindered the ability of microglia to phagocytose A&#946; effectively. As expected, conditioned medium from Cu-activated microglia reduced neuronal viability. The neurotoxicity caused by Cu-overloaded microglia was prevented by inhibiting inflammasome activation and restoring mtGSH levels. In conclusion, our study outlines a mechanistic pathway by which chronic exposure to environmental Cu may lead to neuroinflammation and A&#946; accumulation in AD, underscoring the crucial role of mitochondrial oxidative stress.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p><fig id="undfig1" position="anchor" orientation="portrait"><alt-text id="alttext0010">Image 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ga1.jpg"/></fig></p></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#8226;</label><p id="p0010">Sub-toxic copper Cu exposure disrupts microglial function by promoting mitochondrial Cu buildup and oxidative stress.</p></list-item><list-item id="u0015"><label>&#8226;</label><p id="p0015">Mitochondrial oxidative stress activates the NLRP3 inflammasome via ox-mtDNA release, amplifying A&#946; inflammation response.</p></list-item><list-item id="u0020"><label>&#8226;</label><p id="p0020">Cholesterol biosynthesis and mitochondrial transport are increased in microglia after Cu overload.</p></list-item><list-item id="u0025"><label>&#8226;</label><p id="p0025">Altered cholesterol metabolism downregulates ABCA7 levels, impairing microglial A&#946; clearance and promoting neurotoxicity.</p></list-item><list-item id="u0030"><label>&#8226;</label><p id="p0030">mtGSH recovery and inflammasome inhibition counteract Cu neurotoxicity, revealing potential therapeutic targets for AD.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Alzheimer's disease</kwd><kwd>Neuroinflammation</kwd><kwd>Mitochondrial oxidative stress</kwd><kwd>ABCA7</kwd><kwd>Cholesterol</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="nomen0010"><title>Abbreviations</title><def-list><def-item><term id="d0010">A&#946;</term><def><p id="p0040">amyloid-beta</p></def></def-item><def-item><term id="d0015">ABCA7</term><def><p id="p0045">ATP-binding cassette subfamily A member 7</p></def></def-item><def-item><term id="d0020">AIF-1/IBA1</term><def><p id="p0050">allograft inflammatory factor 1</p></def></def-item><def-item><term id="d0025">APP</term><def><p id="p0055">amyloid precursor protein</p></def></def-item><def-item><term id="d0030">ASC</term><def><p id="p0060">apoptosis-associated speck-like protein containing a CARD</p></def></def-item><def-item><term id="d0035">CASP-1</term><def><p id="p0065">caspase-1</p></def></def-item><def-item><term id="d0040">cGAS-STING</term><def><p id="p0070">cyclic GMP-AMP synthase - stimulating interferon gene</p></def></def-item><def-item><term id="d0045">CMPK2</term><def><p id="p0075">UMP-CMP kinase 2</p></def></def-item><def-item><term id="d0050">COX-1</term><def><p id="p0080">cytochrome <italic toggle="yes">c</italic> oxidase subunit I</p></def></def-item><def-item><term id="d0055">DAMPs</term><def><p id="p0085">damage-associated molecular patterns</p></def></def-item><def-item><term id="d0060">DAPI</term><def><p id="p0090">4&#8242;,6-diamidino-2-phenylindole, dihydrochloride</p></def></def-item><def-item><term id="d0065">DCFH2-DA</term><def><p id="p0095">2&#8242;,7&#8242;-dichlorodihydrofluorescein diacetate</p></def></def-item><def-item><term id="d0070">ddC</term><def><p id="p0100">2&#8242;,3&#8242;-dideoxycytidine</p></def></def-item><def-item><term id="d0075">DHE</term><def><p id="p0105">dihydroethidium</p></def></def-item><def-item><term id="d0080">ER</term><def><p id="p0110">endoplasmic reticulum</p></def></def-item><def-item><term id="d0085">EV</term><def><p id="p0115">extracellular vesicles</p></def></def-item><def-item><term id="d0090">GSHee</term><def><p id="p0120">glutathione reduced ethyl ester</p></def></def-item><def-item><term id="d0095">GST-PFO</term><def><p id="p0125">glutathione-S-transferase perfringolysin O</p></def></def-item><def-item><term id="d0100">HP-&#946;-CD</term><def><p id="p0130">2-hydroxypropyl-&#946;-cyclodextrin</p></def></def-item><def-item><term id="d0105">IL-1&#946;</term><def><p id="p0135">interleukin-1&#946;</p></def></def-item><def-item><term id="d0110">IL-18</term><def><p id="p0140">interleukin-18</p></def></def-item><def-item><term id="d0115">IRF3</term><def><p id="p0145">interferon regulatory factor 3</p></def></def-item><def-item><term id="d0120">LPS</term><def><p id="p0150">lipopolysaccharide</p></def></def-item><def-item><term id="d0125">LRP1</term><def><p id="p0155">low-density lipoprotein receptor-related protein 1</p></def></def-item><def-item><term id="d0130">mtTFA</term><def><p id="p0160">mitochondrial transcription factor A</p></def></def-item><def-item><term id="d0135">MDP</term><def><p id="p0165">muramyl dipeptide</p></def></def-item><def-item><term id="d0140">NLRP3</term><def><p id="p0170">NACHT, LRR and PYD domains-containing protein 3</p></def></def-item><def-item><term id="d0145">NF-&#954;B</term><def><p id="p0175">nuclear factor NF-kappa-B</p></def></def-item><def-item><term id="d0150">proIL-1&#946;</term><def><p id="p0180">pro-interleukin-1&#946;</p></def></def-item><def-item><term id="d0155">proIL-18</term><def><p id="p0185">pro-interleukin-18</p></def></def-item><def-item><term id="d0160">PRRs</term><def><p id="p0190">pattern-recognition receptors</p></def></def-item><def-item><term id="d0165">PSEN1</term><def><p id="p0195">presenilin-1</p></def></def-item><def-item><term id="d0170">ROS</term><def><p id="p0200">reactive oxygen species</p></def></def-item><def-item><term id="d0175">SDHA</term><def><p id="p0205">succinate dehydrogenase complex flavoprotein subunit A</p></def></def-item><def-item><term id="d0180">SIM-A9</term><def><p id="p0210">spontaneously immortalized microglia-9</p></def></def-item><def-item><term id="d0185">SLC25A3</term><def><p id="p0215">solute carrier family 25 member 3</p></def></def-item><def-item><term id="d0190">SREBF2</term><def><p id="p0220">sterol regulatory element-binding transcription factor 2</p></def></def-item><def-item><term id="d0195">STAR</term><def><p id="p0225">steroidogenic acute regulatory protein</p></def></def-item><def-item><term id="d0200">STARD3</term><def><p id="p0230">transporter stAR-related lipid transfer domain containing 3</p></def></def-item><def-item><term id="d0205">TSPO</term><def><p id="p0235">translocator protein</p></def></def-item></def-list></sec><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0240">Copper (Cu) is an essential trace element that acts as a cofactor for cuproproteins involved in mitochondrial energy generation and antioxidant defense [<xref rid="bib1" ref-type="bibr">1</xref>]. It also plays key roles in redox reactions, iron balance regulation, and neurotransmitter metabolism, processes particularly relevant for proper brain development and function. Cu dyshomeostasis is closely associated with the onset and progression of different neurodegenerative disorders [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib3" ref-type="bibr">3</xref>]. Genetic loss-of-function mutations in Cu transporters, specifically ATPase Cu transporting alpha (ATP7A) and beta (ATP7B), cause Menkes disease (Cu deficiency) and Wilson disease (Cu overload), respectively [<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib5" ref-type="bibr">5</xref>]. Besides genetic factors, Cu accumulation can result from chronic environmental exposure, including pollution, Cu pipes in water systems, and Cu-containing dietary supplements [<xref rid="bib6" ref-type="bibr">[6]</xref>, <xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib8" ref-type="bibr">[8]</xref>]. Currently, there is a consensus that eukaryotic cells essentially have no free Cu available, as all Cu ions are bound to proteins or low-molecular-weight ligands like reduced glutathione (GSH) [<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib10" ref-type="bibr">10</xref>]. However, excess Cu can be released into its free form, catalyzing the formation of highly reactive hydroxyl radicals and inducing oxidative damage [<xref rid="bib11" ref-type="bibr">11</xref>]. Additionally, studies primarily conducted in non-cellular systems show that Cu complexed with GSH retains its capacity to interact with molecular oxygen and generate superoxide radicals [<xref rid="bib12" ref-type="bibr">12</xref>]. In this regard, our previous research revealed elevated levels of this redox-active Cu form and oxidative stress biomarkers in women using Cu intrauterine devices and in agricultural workers exposed to Cu-based pesticides [<xref rid="bib13" ref-type="bibr">13</xref>,<xref rid="bib14" ref-type="bibr">14</xref>].</p><p id="p0245">Chronic exposure to Cu is considered a potential environmental risk factor for Alzheimer's disease (AD). High levels of free (non-ceruloplasmin-bound) Cu have been detected in the blood of individuals with AD and correlate with a decline in cognitive performance [<xref rid="bib15" ref-type="bibr">15</xref>,<xref rid="bib16" ref-type="bibr">16</xref>]. In AD brains, although total Cu content is decreased [<xref rid="bib17" ref-type="bibr">17</xref>], a pool of redox-active labile Cu linked to increased oxidative injury has been identified [<xref rid="bib18" ref-type="bibr">18</xref>], particularly enriched in amyloid-beta (A&#946;) plaques and tau aggregates [<xref rid="bib19" ref-type="bibr">19</xref>,<xref rid="bib20" ref-type="bibr">20</xref>]. The link between Cu and AD is further supported by preclinical studies in AD rabbit and mouse models, which show that excess dietary Cu exacerbates the pathological hallmarks of AD [<xref rid="bib21" ref-type="bibr">21</xref>,<xref rid="bib22" ref-type="bibr">22</xref>]. Remarkably, cognitive decline is accelerated when high Cu intake is combined with a high-fat diet [<xref rid="bib23" ref-type="bibr">23</xref>]. At the molecular level, Cu interacts with both amyloid precursor protein (APP) and A&#946;, stimulating amyloidogenesis, A&#946; aggregation, and oxidative damage [<xref rid="bib24" ref-type="bibr">[24]</xref>, <xref rid="bib25" ref-type="bibr">[25]</xref>, <xref rid="bib26" ref-type="bibr">[26]</xref>]. Treatment with selective Cu chelators favors the nonamyloidogenic processing of APP and significantly preserves cognitive function [<xref rid="bib3" ref-type="bibr">3</xref>,<xref rid="bib27" ref-type="bibr">27</xref>]. Beyond A&#946; and tau pathology, chronic Cu exposure may interact with different inflammatory pathways [<xref rid="bib28" ref-type="bibr">28</xref>], driving microglia activation and neuroinflammation, which are considered directly responsible for cognitive impairment in AD [<xref rid="bib29" ref-type="bibr">29</xref>]. Cu overload exacerbates A&#946;-induced microglial activation, promoting a shift toward pro-degenerative gene expression signatures [<xref rid="bib30" ref-type="bibr">30</xref>]. Oxidative stress and dysfunctional mitochondria have been proposed to be involved [<xref rid="bib31" ref-type="bibr">[31]</xref>, <xref rid="bib32" ref-type="bibr">[32]</xref>, <xref rid="bib33" ref-type="bibr">[33]</xref>]; however, the molecular pathways linking Cu to neuroinflammation in AD remain incompletely defined.</p><p id="p0250">Key players in the innate immune response are inflammasomes, multimeric protein complexes containing pattern-recognition receptors (PRRs), such as NACHT, LRR and PYD domains-containing protein 3 (NLRP3), which sense both pathogen-associated patterns (PAMPs) and damage-associated molecular patterns (DAMPs) released during tissue damage [<xref rid="bib34" ref-type="bibr">34</xref>]. Once assembled, the functional complex activates caspase-1 (CASP-1), which cleaves the pro-inflammatory cytokines pro-interleukin-1&#946; (proIL-1&#946;) and pro-interleukin-18 (proIL-18) into their mature, biologically active forms [<xref rid="bib34" ref-type="bibr">34</xref>]. Active NLRP3 inflammasomes have been reported in human and mouse brains with AD, suggesting a contributory role in the onset of neuroinflammation and neurodegeneration [<xref rid="bib35" ref-type="bibr">[35]</xref>, <xref rid="bib36" ref-type="bibr">[36]</xref>, <xref rid="bib37" ref-type="bibr">[37]</xref>]. In agreement with these findings, genetic or pharmacological ablation of NLRP3 rescues the neuroprotective phenotype of microglia, reduces A&#946; deposits, and alleviates AD-related pathological features [<xref rid="bib35" ref-type="bibr">35</xref>,<xref rid="bib36" ref-type="bibr">36</xref>]. NLRP3 inflammasome activation relies on two functionally distinct steps [<xref rid="bib34" ref-type="bibr">34</xref>]. The priming step involves the activation of nuclear factor-&#954;B (NF-&#954;B), which stimulates proIL-1&#946; and NLRP3 expression. On the other hand, mitochondrial dysfunction&#8212;an early event in the neurodegenerative process [<xref rid="bib38" ref-type="bibr">38</xref>]&#8212;has been reported essential for the activation step, facilitating the assembly of the NLRP3 complex [<xref rid="bib39" ref-type="bibr">39</xref>]. Recently, we demonstrated that changes in mitochondrial antioxidant capacity, related to increased intracellular cholesterol levels, regulate the inflammasome-mediated inflammatory response elicited by A&#946;, differentially in microglia and neuronal cells [<xref rid="bib40" ref-type="bibr">40</xref>]. Evidence also suggests a connection between Cu and inflammasome activation. Deigendesch et al. described a Cu-dependent regulatory mechanism for NLRP3 inflammasome assembly in macrophages directly linked to maintaining an adequate redox milieu [<xref rid="bib41" ref-type="bibr">41</xref>]. Furthermore, blocking NLRP3 inflammasome activation has been shown to prevent Cu-induced neuropathology in a mouse model of Wilson disease [<xref rid="bib42" ref-type="bibr">42</xref>]. However, the specific role of Cu in inflammasome-driven neuroinflammation in AD has not been fully characterized. Herein, we investigated how Cu overload modulates microglial response to A&#946; exposure. We showed that the immunogenic properties of Cu are linked to its capacity to induce mitochondrial oxidative damage. Excessive Cu promotes NLRP3 inflammasome activation and proinflammatory cytokine secretion in A&#946;-activated cells by facilitating the cytosolic release of oxidized mitochondrial DNA (ox-mtDNA). Furthermore, we observed that elevated Cu levels increase cholesterol biosynthesis, which downregulates ABCA7 expression and diminishes the ability of microglia to phagocytose A&#946;. Our results provide new insights into how chronic environmental Cu exposure may contribute to neuroinflammation and impaired A&#946; clearance in AD.</p></sec><sec id="sec2"><label>2</label><title>Methods</title><sec id="sec2.1"><label><bold>2.1</bold></label><title>Mice</title><p id="p0255">Breeding pairs of B6C3-Tg (APPswe, PSEN1dE9)85Dbo/J (APP-PSEN1; MMRRC stock 34,829) [<xref rid="bib43" ref-type="bibr">43</xref>] and B6; SJL-Tg (rPEPCKSREBF2)788Reh/J (SREBF2; JAX stock 003311) [<xref rid="bib44" ref-type="bibr">44</xref>] mice were purchased from The Jackson Laboratory. APP-PSEN1 mice express a chimeric mouse/human APP (isoform 695) with the Swedish mutation (Mo/HuAPP695swe) and mutant human presenilin 1 (PSEN1dE9), both of which are directed to neurons by the mouse PRNP (prion protein) promoter. Sterol regulatory element-binding transcription factor 2 (SREBF2) mice express a transgenic construct containing a human <italic toggle="yes">SREBF2</italic> cDNA fragment (amino acids 1&#8211;468) under the control of the rat phosphoenolpyruvate carboxykinase (<italic toggle="yes">PEPCK</italic>) promoter. APP-PSEN1-SREBF2 mice were generated by crossing and backcrossing &#8805;10 generations into the B6SJL background; genotype was confirmed by PCR at weaning (21 days). All procedures involving animals and their care were ethics-approved by the University of Barcelona in compliance with institutional, national, and international guidelines.</p></sec><sec id="sec2.2"><label>2.2</label><title>Cell culture and treatments</title><p id="p0260">The mouse spontaneously immortalized microglia-9 (SIM-A9) cell line (ATCC-CRL-3265) was cultured in DMEM/F-12 (Gibco&#8482;) supplemented with GlutaMAX&#8482;, 10&#160;% fetal bovine serum (Thermo Fisher Sci., 10565018 and 16140071), 5&#160;&#956;g/ml plasmocin&#8482; (InvivoGen, ant-mpt), and 5&#160;% horse serum (Sigma-Aldrich, H1270). Embryonic cortical-hippocampal neurons were isolated from mice at gestational days 16&#8211;17 using a standard trypsin digestion protocol [<xref rid="bib45" ref-type="bibr">45</xref>]. Dissociated cells were cultured in Neurobasal&#8482; medium with 2.5&#160;% (v/v) B27 supplement (Thermo Fisher Sci., 21103049 and 17504001), 0.5&#160;mM&#8201;<sc>l</sc>-glutamine (Sigma-Aldrich, G7513), and 5&#160;&#956;g/ml plasmocin&#8482;. Cells were seeded on poly-<sc>d</sc>-lysine (Sigma-Aldrich, P6407) coated plates at a density of 2&#160;&#215;&#160;10<sup>5</sup>&#160;cells/cm<sup>2</sup>. Half-medium changes every 3&#8211;4&#8201;days. Neuronal purity (&gt;95&#160;%) was confirmed by immunocytochemistry using mature neuron markers such as microtubule-associated protein 2 (MAP2) and synaptophysin. Experiments were conducted at 7&#8211;10&#8201;days in vitro (DIV), as previously described [<xref rid="bib46" ref-type="bibr">46</xref>].</p><p id="p0265">Cells were exposed to CuSO<sub>4</sub>&#183; 5H<sub>2</sub>O (Sigma-Aldrich, C3036) at the indicated doses for 24&#160;h. Preincubation with 1&#160;mM reduced GSH ethyl ester (GSHee; Sigma-Aldrich, G1404) or with the mitochondria-targeted antioxidants mitoquinone mesylate (MitoQ, 1&#160;&#956;M; MedChemExpress, HY-100116A) and triphenylphosphonium chloride (Mito-TEMPO, 5&#160;&#956;M; Sigma-Aldrich, SML0737) was performed 30&#160;min before treatment when indicated. In some cases, cells were incubated with 2-hydroxypropyl-&#946;-cyclodextrin (HP-&#946;-CD, 300&#160;&#956;M; Thermo Fisher Sci., 15414047), wortmannin (5&#160;&#956;M; Santa Cruz Biotech, sc-3505), or MCC950 (10&#160;mM; Sigma-Aldrich, CP-456773) for 24&#160;h. To induce phagocytosis, cells were treated with 10&#160;&#956;g/ml lipopolysaccharide (LPS) from Escherichia coli O111:B4 (Sigma-Aldrich, L4391) and 10&#160;&#956;g/ml N-acetylmuramyl-L-alanyl-<sc>d</sc>-isoglutamine hydrate (also known as muramyl dipeptide, MDP; Sigma-Aldrich, A9519) for 16&#160;h mtDNA depletion was achieved by incubating the cells with 2&#8242;,3&#8242;-dideoxycytidine (ddC,150&#160;&#956;M; Thermo Fisher Sci., <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="L10619">L10619</ext-link>.MF) for the specified time.</p></sec><sec id="sec2.3"><label>2.3</label><title>Preparation of A&#946; peptides</title><p id="p0270">Human A&#946; (1&#8211;42) hydrochloride salt (Bachem, H-6466) was dissolved to 1&#160;mM in hexafluoroisopropanol (HFIP; Sigma-Aldrich, 10522&#8211;8), aliquoted, and stored at&#160;&#8722;&#160;20&#160;&#176;C after HFIP evaporation. For oligomeric assembly, concentrated peptides were resuspended at 5&#160;mM in DMSO by sonication, then diluted to 100&#160;&#956;M in phenol red-free DMEM and incubated at 4&#160;&#176;C for 24&#160;h [<xref rid="bib47" ref-type="bibr">47</xref>]. Oligomerization was confirmed as previously described [<xref rid="bib46" ref-type="bibr">46</xref>].</p></sec><sec id="sec2.4"><label>2.4</label><title>Preparation of conditioned media</title><p id="p0275">SIM-A9 conditioned media was passed through 4&#160;% Chelex-100 resin (1&#160;h, 37&#160;&#176;C) to remove excess Cu and supplemented with CaCl<sub>2</sub> (107.3&#160;mg/L), ZnSO<sub>4</sub>&#183;7H<sub>2</sub>O (0.39&#160;mg/L), MgCl<sub>2</sub> (26.35&#160;mg/L), MgSO<sub>4</sub> (45&#160;mg/L), FeSO<sub>4</sub> (4.5&#160;mM), and CuCl<sub>2</sub> (0.01&#160;mM) [<xref rid="bib48" ref-type="bibr">48</xref>], before supplying to neuronal cultures.</p></sec><sec id="sec2.5"><label>2.5</label><title>Cell viability</title><p id="p0280">SIM-A9 cell viability was assessed by MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Thermo Fisher Sci., M6494). Primary neuronal culture viability was measured using the Live and Dead Cell Assay Kit (Calcein AM, 7-AAD; Abcam, ab270789) following the manufacturer's instructions. Fluorescence images were captured using an Olympus inverted microscope TH4-200, and cell viability was calculated as the ratio of total cells to those stained with the exclusion dye 7-AAD.</p></sec><sec id="sec2.6"><label>2.6</label><title>Reactive oxygen species (ROS) determination</title><p id="p0285">Oxidative stress was determined by using the cell-permeant fluorogenic dyes dihydroethidium (DHE; Thermo Fisher Sci., M6494) and 2&#8242;,7&#8242;-dichlorodihydrofluorescein diacetate (DCFH2-DA; Sigma-Aldrich, D6883). Cells were incubated with 10&#160;&#956;M DHE or 10&#160;&#956;M DCFH2-DA in Live Cell Imaging Solution (Thermo Fisher Sci., A14291DJ) at 37&#160;&#176;C for 30&#160;min in the dark. After rinsing, the oxidized products 2-hydroxy ethidium (Ex 490&#160;nm, Em 580&#160;nm) and dichlorofluorescein (DCF, Ex 488, Em 525) were detected by fluorimetry.</p></sec><sec id="sec2.7"><label>2.7</label><title>Cholesterol and GSH measurements</title><p id="p0290">Mitochondria from SIM-A9 cells were isolated by digitonin fractionation as described previously [<xref rid="bib49" ref-type="bibr">49</xref>]. Cholesterol levels were quantified in whole cells (0.5&#160;&#215;&#160;10<sup>5</sup>&#160;cells) and mitochondrial fractions (2&#160;&#215;&#160;10<sup>6</sup>&#160;cells) using the Amplex Red Cholesterol Assay Kit (Thermo Fisher Sci., A12216). Briefly, samples were extracted with chloroform:isopropanol:IGEPAL CA-630 (7:11:0.1) and centrifuged at 13,000&#160;<italic toggle="yes">g</italic> for 10&#160;min to remove insoluble material. The organic phase was then dried under vacuum, reconstituted in 1&#160;&#215;&#160;cholesterol reaction buffer, and analyzed according to the guidelines provided by the supplier. The mitochondrial GSH/GSSG ratio was assessed in mitochondrial extracts (4&#160;&#215;&#160;10<sup>6</sup>&#160;cells) using the glutathione GSH/GSSG Assay Kit (Sigma-Aldrich, MAK440), following the manufacturer's instructions. In some experiments, total mGSH content was quantified from mitochondrial fractions prepared as described previously [<xref rid="bib50" ref-type="bibr">50</xref>].</p></sec><sec id="sec2.8"><label>2.8</label><title>Colorimetric assays</title><p id="p0295">Aconitase activity was measured in mitochondrial extracts (2&#160;&#215;&#160;10<sup>6</sup>&#160;cells) by detecting the isocitrate produced, using the Aconitase Activity Assay Kit (Sigma-Aldrich, MAK337) and following the manufacturer's instructions. The Protein Carbonyl Content Assay kit (Abcam, ab12687) was used to determine the carbonyl levels in mitochondrial extracts (2&#160;&#215;&#160;10<sup>7</sup>&#160;cells).</p></sec><sec id="sec2.9"><label>2.9</label><title>ATP measurement</title><p id="p0300">Cellular ATP levels were determined using the ATP Determination kit (Thermo Fisher Sci., A22066). Briefly, 0.1&#160;&#215;&#160;10<sup>6</sup>&#160;cells were solubilized in 50&#160;&#956;l of Somatic Cell ATP Release Agent. Then, 10&#160;&#956;l of the sample was added to 90&#160;&#956;l of the reaction solution in black plates, and luminescence was measured using an Orion Microplate Luminometer (Berthold Detection Systems).</p></sec><sec id="sec2.10"><label>2.10</label><title>Determination of metal concentration (Cu, Fe, Zn, mg, and ca)</title><p id="p0305">Culture media and mitochondrial fractions (0.4&#160;&#215;&#160;10<sup>5</sup>&#160;cells) were treated with 10&#160;% trichloroacetic acid (TCA), vortexed for 20&#160;min, and centrifuged at 1500&#160;rpm for 15&#160;min. Supernatants were then transferred to trace metal-free tubes and stored at 4&#160;&#176;C until analysis. Samples were digested by first heating them in nitric acid and then adding 30&#160;% hydrogen peroxide. Mg and Ca concentrations were determined by inductively coupled plasma atomic emission spectrometry (ICP-AES; Agilent 5800 system, Agilent Technologies). Quantification of Cu, Fe, and Zn was assessed by ICP mass spectrometry (ICP-MS; Agilent 7500ce system, Agilent Technologies).</p></sec><sec id="sec2.11"><label>2.11</label><title>Immunofluorescence and laser confocal imaging</title><p id="p0310">The cells were seeded either on &#956;-Slide 8 Ibidi&#174; chamber slides (Thermo Fisher Sci., 177402) or on 12&#160;mm glass coverslips (Marienfeld Superior&#8482;, 0117520). After treatment, cells were fixed with 4&#160;% paraformaldehyde (PFA) for 15&#160;min before permeabilization with 0.1&#160;% saponin in blocking buffer (1&#160;% fatty acid-free BSA, 20&#160;mM glycine in PBS) for 15&#160;min at room temperature. Samples were incubated overnight at 4&#160;&#176;C with the antibodies listed in <xref rid="appsec1" ref-type="sec">Supplementary Table S1</xref>, diluted in antibody diluent buffer (Agilent Technologies, S302283-2) with 0.05&#160;% saponin. After washing with PBS, the immunoreaction was visualized using the following secondary antibodies: anti-rabbit Alexa Fluor&#8482; 555 (1:300; Thermo Fisher Sci., <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="A27039">A27039</ext-link>; RRID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2536100" id="intref0010">AB_2536100</ext-link>), anti-rabbit Alexa Fluor&#8482; 488 (1:300; Thermo Fisher Sci., A21206; RRID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2535792" id="intref0015">AB_2535792</ext-link>), anti-mouse Alexa Fluor&#8482; 555 (1:300; Thermo Fisher Sci., <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="A31570">A31570</ext-link>; RRID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2536180" id="intref0020">AB_2536180</ext-link>), and anti-mouse Alexa Fluor&#8482; 488 (1:300; Thermo Fisher Sci., A21202; RRID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_141607" id="intref0025">AB_141607</ext-link>).</p><p id="p0315">To assess the intracellular distribution of cholesterol, we used recombinant perfringolysin O (PFO), a bacterial toxin produced by <italic toggle="yes">Clostridium perfringens</italic> that specifically binds cholesterol, fused with glutathione-S-transferase (GST-PFO), as previously described [<xref rid="bib51" ref-type="bibr">51</xref>,<xref rid="bib52" ref-type="bibr">52</xref>]. The pGEX4T plasmid vector containing the coding DNA sequence for GST-PFO was kindly provided by Dr. Kwiatkowska [<xref rid="bib51" ref-type="bibr">51</xref>]. The cells were fixed in 4&#160;% PFA for 20&#160;min at room temperature. After triple washing, they were incubated with 20&#160;&#956;g/ml GST-PFO in antibody diluent buffer (Agilent Technologies, S302283-2) for 45&#160;min before immunostaining.</p><p id="p0320">To evaluate the presence of apoptosis-associated speck-like protein containing a CARD (ASC) oligomers, cells were transfected with the pLEX-MSC-ASC-GFP plasmid, which was generously provided by Christian Stehlik (Addgene plasmid #73957; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://n2t.net/addgene:73957" id="intref0030">http://n2t.net/addgene:73957</ext-link>; RRID: Addgene_73957) [<xref rid="bib53" ref-type="bibr">53</xref>]. Transfections were conducted using Lipofectamine P300 (Invitrogen, L3000-008) in Opti-MEM medium. 48 h post-transfection, cells were subjected to the designated treatment. The formation of ASC specks was assessed as the formation of reticulated structures.</p><p id="p0325">Plasma membrane/cytosol and nuclei were labelled with CellMask&#8482; Orange (1:20,000; Thermo Fisher Sci., <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="C10045">C10045</ext-link>) and DAPI (4&#8242;,6-diamidino-2-phenylindole, dihydrochloride, 1:1000; Thermo Fisher Sci., D1306), respectively, for 5&#160;min. From each well, three non-overlapping images were randomly captured at the top, middle, and bottom areas using either an Andor Dragonfly spinning disk confocal microscope (Zyla 4.2&#215;PLUS sCMOS camera, 63&#215; oil objective, 1 Airy unit pinhole) or a Leica STELLARIS 8 spectral confocal microscope (Power HyD S detector, 63x/1,40 oil objective). ImageJ software [<xref rid="bib54" ref-type="bibr">54</xref>] was used to calculate the colocalization coefficient and manually count the number of speck-positive cells.</p></sec><sec id="sec2.12"><label>2.12</label><title>Mitophagy</title><p id="p0330">Mitophagy was analyzed using the Mitophagy Detection Kit (Dojindo Molecular Technologies, MD01-10) for live cells following the manufacturer's instructions. Briefly, 0.1&#160;&#215;&#160;10<sup>6</sup>&#160;cells were plated in a 35&#160;mm Petri FluoroDish&#8482; and incubated with Mtphagy Dye (100&#160;nM) and MitoTracker&#8482; Deep Red FM Dye (Thermo Fisher Sci., M46753) in Live Cell Imaging solution (Thermo Fisher Sci., A59688DJ) at 37&#160;&#176;C for 30&#160;min. After treatment with mitophagy inducers, cells were incubated with Lyso Dye (1&#160;&#956;M) for 30&#160;min. Confocal images were acquired as described in Section <xref rid="sec2.9" ref-type="sec">2.9</xref>.</p></sec><sec id="sec2.13"><label>2.13</label><title>CASP-1 inflammasome assay</title><p id="p0335">CASP-1 activity was assessed using the Caspase-Glo&#174; 1 kit (Promega, G9951) according to the manufacturer's instructions. In brief, 100&#160;&#956;L of Caspase-Glo&#174; 1 reagent was added to each well with or without the CASP-1 inhibitor YVAD-CHO. Samples were shaken at 300&#8211;500&#160;rpm for 30&#160;s and incubated at room temperature for 90&#160;min. Luminescence was measured using an Orion Microplate Luminometer (Berthold Detection Systems).</p></sec><sec id="sec2.14"><label>2.14</label><title>Cytokines quantification by enzyme-linked immunosorbent assay (ELISA) and antibody array</title><p id="p0340">Cell supernatants (0.1&#160;&#215;&#160;10<sup>6</sup>&#160;cells) were centrifuged at 3000&#160;<italic toggle="yes">g</italic> for 10&#160;min and concentrated using Corning&#174; Spin-X&#174; UF centrifugal concentrators (Corning Life Sciences, 431,482). A mouse IL-1&#946; ELISA kit (Abcam, ab229440) was used to quantify the IL-1&#946; levels in the culture media, following the manufacturer's protocol. To determine the amount of IL-1&#946; encapsulated in extracellular vesicles (EVs), supernatants were treated with Triton X-100 (final concentration 1&#160;%) and incubated for 10&#160;min at room temperature prior to cytokine quantification. The global cytokine profile was assessed using the RayBio&#174; C-Series Mouse Cytokine Antibody Array 1 Kit (RayBiotech, AAM-CYT-1-2). Samples were hybridized according to the manufacturer's instructions and analyzed using an InnoScan 710 laser scanner (Innopsys) for glass slides, and Mapix 9.0.0 software was used for quantifications.</p></sec><sec id="sec2.15"><label>2.15</label><title>Phagocytosis assay</title><p id="p0345">Phagocytosis was assessed in microglia by quantifying the degree of internalization of fluorescent yellow-green beads (0.01&#160;%; Sigma-Aldrich, L4655) for 20&#160;min and HiLyte Fluor 488-labelled A&#946;1-42 peptides (1&#160;&#956;M; AnaSpec, AS-60479-01) for 4&#160;h. Cells were immunostained following the protocol described in Section <xref rid="sec2.9" ref-type="sec">2.9</xref>. ImageJ software was used to calculate the number of phagocytosed microspheres per individual cell and to measure fluorescence intensity. Corrected total cell fluorescence (CTCF) was calculated using the following formula: CTCF&#8201;=&#8201;Integrated Density&#160;&#8722;&#160;(Area of selected cell&#160;&#215;&#160;Mean fluorescence of background readings).</p></sec><sec id="sec2.16"><label>2.16</label><title>Immunoblotting</title><p id="p0350">Cells were lysed in RIPA lysis buffer with phenylmethylsulphonyl fluoride (PMSF, 2&#160;mM), sodium orthovanadate (1&#160;mM), and protease inhibitor cocktail (Santa Cruz Biotech., sc-24948) for 30&#160;min at 4&#160;&#176;C. Lysates were centrifuged at 16,000&#160;<italic toggle="yes">g</italic> for 15&#160;min and protein content was quantified using the Pierce&#8482; BCA Protein Assay Kit (Thermo Fisher Sci., 23227). Samples (25&#8211;50&#160;&#956;g protein/well) were resolved by SDS-PAGE using precast 4&#8211;15&#160;% Criterion&#8482; TGX Stain-Free&#8482; gels (Bio-Rad, 5678084). Proteins were transferred onto either nitrocellulose membranes (Bio-Rad, V1704271) or Amersham Hybond&#8482; PVDF membranes (GE Healthcare, 10600021), depending on the target protein and downstream detection sensitivity requirements. Membranes were incubated with the primary antibodies listed in <xref rid="appsec1" ref-type="sec">Supplementary Table S1</xref>. After overnight incubation at 4&#160;&#176;C, membranes were incubated with anti-rabbit (1:10,000) or anti-mouse (1:20,000) IgG horseradish peroxidase-coupled secondary antibodies (Sigma-Aldrich, A8275 and GENA931, respectively). Detection was performed using Clarity&#8482; Western ECL substrate (Bio-Rad, 1,705,061) or Clarity&#8482; Max ECL substrate (Bio-Rad, 1,705,062) for low-abundance proteins. Uncropped scans of representative immunoblots are shown in <xref rid="appsec1" ref-type="sec">Supplementary Fig. S6 and Fig. S7</xref>.</p></sec><sec id="sec2.17"><label>2.17</label><title>Selfie reverse transcription qPCR (RT-qPCR)</title><p id="p0355">Absolute quantification of gene expression was performed using the Selfie RT-qPCR method, as previously described by Podlesniy and Trullas [<xref rid="bib55" ref-type="bibr">55</xref>]. Briefly, the cells were extracted and diluted in 100ST reagent (DireCtQuant, DCQ100ST) according to the manufacturer's instructions. For each target, 2&#160;&#956;l of lysate was mixed with 2&#160;&#956;l of 2.5&#160;&#956;M reverse primer at 70&#160;&#176;C for 5&#160;min. Next, the reaction mixture containing 1&#160;mM dNTP mixture, 10 U of the RiboLock RNase Inhibitor (Thermo Fisher Sci., EO0381), and 200 U of Maxima H Minus Reverse Transcriptase (Thermo Fisher Sci., EP0751) or 50&#160;% glycerol was retrotranscribed for 30&#160;min at 60&#160;&#176;C, followed by 5&#160;min at 85&#160;&#176;C. Finally, 2.5&#160;&#956;M of the corresponding forward primer was added to each reaction. Amplification was performed by conventional RT-qPCR using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad, 1725271) under the following cycling conditions: initial denaturation at 95&#160;&#176;C for 5&#160;min, followed by 49 cycles of 15&#160;s at 95&#160;&#176;C, 25&#160;s at 60&#160;&#176;C, and 25&#160;s at 72&#160;&#176;C. The number of transcripts per encoding gene was calculated as the fold change after subtracting the Ct values derived from the glycerol-containing sample. The sequence of the primers used is listed in <xref rid="appsec1" ref-type="sec">Supplementary Table S2</xref>.</p></sec><sec id="sec2.18"><label>2.18</label><title>Measurement of mtDNA copy number, mtDNA deletions, and nuclear genomes by digital PCR (dPCR)</title><p id="p0360">The mtDNA copy number and deletion ratio were quantified in a multiplex dPCR assay using two different primer pairs as previously [<xref rid="bib56" ref-type="bibr">56</xref>]. The sequence of the mtDNA primers used are listed in <xref rid="appsec1" ref-type="sec">Supplementary Table S2</xref>.</p><p id="p0365">Samples were solubilized using 100ST reagent (DireCtQuant, DCQ100ST) and incubated at 90&#160;&#176;C for 3&#160;min at 750&#160;rpm following the manufacturer's instructions. mtDNA and diploid genomes were quantified by digital PCR (dPCR) without previous nucleic acid purification. Before quantification, samples were diluted according to their concentration. Briefly, 8&#160;&#956;l of the diluted sample was mixed with 10&#160;&#956;l of 2x QX200 ddPCR EvaGreen Supermix (Bio-Rad, 1864033), 1&#160;&#956;l of primer mix (mmt86-ND1 120&#160;nM and mmt71-ND4 80&#160;nM, final concentration), and 1&#160;&#956;l of the restriction enzyme <italic toggle="yes">Alu</italic>I (Thermo Fisher Sci., FD0014). To quantify the number of diploid genomes, the mBax-72 amplicon (100&#160;nM, final concentration) was used with the SaqA1 and <italic toggle="yes">Hae</italic>III restriction enzymes (Thermo Fisher Sci., FD2174 and FD0154). Restriction enzyme digestion was performed at&#8201;37&#160;&#176;C for 15&#160;min before partitioning into droplets (QX200&#8482; Droplet generator; BioRad, 1864002, RRID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_019707" id="intref0035">SCR_019707</ext-link>) [<xref rid="bib57" ref-type="bibr">57</xref>]. The PCR amplification programme was as follows: 95&#160;&#176;C for 5&#160;min, followed by 40 cycles of 95&#160;&#176;C for 30&#160;s and 57&#160;&#176;C (mtDNA) or 60&#160;&#176;C (genomic DNA) for 1&#160;min, then 4&#160;&#176;C for 5&#160;min and 90&#160;&#176;C for 5&#160;min. Finally, amplified PCR products were quantified using a QX200 Droplet Reader (BioRad, 1864003, RRID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_019707" id="intref0040">SCR_019707</ext-link>). Results were analyzed with QuantaSoft&#8482; Analysis Pro software. Based on the positive-to-total droplets ratio, the software estimates the concentration of target molecules per reaction, which is used to calculate the absolute number of target molecules per sample volume analyzed. To calculate mtDNA copy number per diploid genome, the number of copies of mtDNA was divided by the number of copies of the single-copy <italic toggle="yes">Bax</italic> gene present in the sample. All samples were analyzed using four independent measures of the same sample as technical replicates.</p></sec><sec id="sec2.19"><label>2.19</label><title>Statistical analyses</title><p id="p0370">Results are shown as the mean&#160;&#177;&#160;standard deviation (SD). Data were initially assessed for normality using the Shapiro-Wilk test and subsequently analyzed by the unpaired, two-tailed <italic toggle="yes">t</italic>-test or one-way analysis of variance (ANOVA) followed by Tukey's test for multiple comparisons, performed using the GraphPad Prism 9 software. Pearson's correlation coefficient was determined as a statistic for quantifying colocalization using the FIJI ImageJ plugin Coloc 2, with ROI selection of interest in some cases. A value of <italic toggle="yes">P</italic>&#160;&lt;&#160;0.05 was considered statistically significant.</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title>Cu overload accumulates in mitochondria and promotes A&#946;-induced mitochondrial oxidative stress</title><p id="p0375">First, we analyzed the effect of Cu overload on mitochondria from microglia. We used spontaneously immortalized SIM-A9 microglia, which express macrophage/microglia-specific proteins such as CD68 and allograft inflammatory factor 1 (AIF-1, also known as IBA1) and show complete responsiveness to exogenous inflammatory stimulation [<xref rid="bib58" ref-type="bibr">58</xref>]. Cells were exposed to sublethal doses of Cu<sup>2+</sup> for 24&#160;h. Our data confirmed that cell viability was not significantly affected at the indicated concentrations (<xref rid="fig1" ref-type="fig">Fig. 1</xref>A). We isolated the mitochondrial fraction, with minimal contamination from cytosol and other organelles such as the endoplasmic reticulum (ER), endosomes, and lysosomes (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S1A</xref>). Cu treatment resulted in a dose-dependent rise of mitochondrial Cu (mtCu) levels (<xref rid="fig1" ref-type="fig">Fig. 1</xref>B), associated with a marked depletion of mitochondrial GSH (mtGSH) content (<xref rid="fig1" ref-type="fig">Fig. 1</xref>C. We assessed the expression levels of solute carrier family 25 member 3 (SLC25A3), responsible for transporting Cu across the mitochondrial inner membrane into the matrix compartment [<xref rid="bib59" ref-type="bibr">59</xref>]. No significant changes were observed in Cu-treated cells compared to control cells (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S1B</xref>). Next, we analyzed superoxide generation using the cell-permeable fluorescent dye DHE (<xref rid="fig1" ref-type="fig">Fig. 1</xref>D). As shown, ROS formation increased proportionally to the Cu dose. Oxidative stress was further enhanced when Cu was combined with A&#946; (5&#160;&#956;M) (<xref rid="fig1" ref-type="fig">Fig. 1</xref>D), leading to a significant loss of viability (<xref rid="fig1" ref-type="fig">Fig. 1</xref>A). Cell viability remained unaffected after exposure to A&#946; alone (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S2</xref>). mtGSH is the primary line of defense for maintaining a suitable mitochondrial redox environment [<xref rid="bib60" ref-type="bibr">60</xref>]. To restore the compromised pool of mtGSH in Cu-treated cells, we used the cell-permeable derivative GSHee. As expected, GSHee treatment (1&#160;mM) partially recovered mtGSH levels (<xref rid="fig1" ref-type="fig">Fig. 1</xref>C) and counteracted the generation of ROS induced by Cu and A&#946; (<xref rid="fig1" ref-type="fig">Fig. 1</xref>D). Similar results were obtained when cells were incubated with mitochondria-targeted antioxidants such as the superoxide scavenger Mito-TEMPO (5&#160;&#956;M) [<xref rid="bib61" ref-type="bibr">61</xref>] and MitoQ (1&#160;&#956;M) [<xref rid="bib62" ref-type="bibr">62</xref>]. In both cases, the increased synthesis of superoxide after Cu exposure was significantly blunted (<xref rid="fig1" ref-type="fig">Fig. 1</xref>E), thus confirming that Cu-induced oxidative stress originates mainly in mitochondria. Oxidative stress was also measured using the fluorogenic probe DCFH2-DA (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S3</xref>). Originally devised as a marker for H<sub>2</sub>O<sub>2</sub> generation, it is now known that DCFH2 does not react directly with superoxide or H<sub>2</sub>O<sub>2</sub> [<xref rid="bib63" ref-type="bibr">63</xref>]; however, it can be indirectly oxidized by hydroxyl radicals generated from redox-active metals [<xref rid="bib64" ref-type="bibr">64</xref>]. Consistent with this, cells incubated with Cu showed increased DCF fluorescence, which was reduced by treatment with MitoQ.<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p><bold>Sublethal doses of Cu enhance A&#946;-mediated mitochondrial oxidative stress in a dose-dependent manner.</bold> SIM-A9 cells were exposed to increasing doses of Cu with and without A&#946; (5&#160;&#956;M) treatment for 24&#160;h. <bold>(A)</bold> Cell viability assessed by MTT assay. Results are expressed as % relative to control (CTRL) cells. <bold>(B)</bold> Mitochondrial Cu (mtCu) levels analyzed in the mitochondrial fraction and expressed as fold-change relative to CTRL values. <bold>(C)</bold> Total mitochondrial glutathione (mtGSH) levels in control and Cu-loaded cells with and without GSH ethyl ester (GSHee) treatment. <bold>(D)</bold> Spectrofluorimetric measurements of dihydroethidium (DHE) fluorescence, indicating a Cu dose-dependent generation of reactive oxidative species (ROS), which is enhanced by exposure to A&#946; (5&#160;&#956;M) and inhibited by GSHee (1&#160;mM) treatment. Tert-butyl-hydroperoxide (tBHP, 500&#160;&#956;M) was used as a positive control. <bold>(E)</bold> Spectrofluorimetric measurements of DHE fluorescence showing a significant reduction of Cu-induced ROS after treatment with the mitochondria-targeted antioxidants MitoQ (1&#160;&#956;M) and MitoTEMPO (5&#160;&#956;M). (<bold>F&#8211;H</bold>) The mitochondrial fraction was isolated from control and Cu-loaded cells with and without MitoQ (1&#160;&#956;M) or Ab (5&#160;&#956;M) treatment. (<bold>F</bold>) Reduced levels of glutathione (GSH) and its oxidized form (GSSG). The GSH/GSSG ratio was calculated as an indicator of redox status. (<bold>G</bold>) Protein carbonyl content. (<bold>H</bold>) Aconitase activity assessed by the rate of isocitrate formation. (<bold>I</bold>) ATP levels. Data are shown as mean&#160;&#177;&#160;SD (<italic toggle="yes">n</italic>&#160;=&#160;3&#8211;6 independent experiments performed in triplicate). Unpaired <italic toggle="yes">t</italic>-test (A) and one-way ANOVA followed by Tukey's test (B&#8211;E) were applied to calculate statistical significance (&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.05, &#8727;&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.01, &#8727;&#8727;&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.001).</p></caption><alt-text id="alttext0020">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0380">To better understand the impact of high Cu levels on mitochondrial function, we subsequently evaluated various markers related to oxidative damage. The findings revealed a decline in the GSH/GSSG ratio in mitochondria from Cu-overloaded cells (<xref rid="fig1" ref-type="fig">Fig. 1</xref>F), along with elevated protein carbonyl content (<xref rid="fig1" ref-type="fig">Fig. 1</xref>G). The mitochondrial damage linked to high Cu levels was further evidenced by the loss of catalytic activity of mitochondrial aconitase (<xref rid="fig1" ref-type="fig">Fig. 1</xref>H), a TCA cycle enzyme containing an iron&#8211;sulfur cluster that is highly sensitive to oxidative modifications [<xref rid="bib65" ref-type="bibr">65</xref>] and a direct target of Cu toxicity [<xref rid="bib66" ref-type="bibr">66</xref>]. The deleterious effect of Cu on mitochondrial function was amplified by A&#946; exposure, showing an enhanced inhibitory effect on aconitase activity and lower ATP levels (<xref rid="fig1" ref-type="fig">Fig. 1</xref>H and I). In contrast, treatment with the mitochondrial antioxidant MitoQ significantly reduced GSSG levels (<xref rid="fig1" ref-type="fig">Fig. 1</xref>F). The recovery of GSH redox balance by MitoQ was accompanied by decreased protein carbonyl formation and full aconitase reactivation (<xref rid="fig1" ref-type="fig">Fig. 1</xref>G and H), which led to partial restoration of ATP levels (<xref rid="fig1" ref-type="fig">Fig. 1</xref>I).</p></sec><sec id="sec3.2"><label>3.2</label><title>A&#946;-induced mitochondrial impairment, exacerbated by high Cu levels, activates mitochondrial quality control mechanisms that affect the mtDNA content</title><p id="p0385">Mitochondrial damage initiates a selective autophagy-mediated clearance, known as mitophagy, which prevents the buildup of dysfunctional mitochondria [<xref rid="bib67" ref-type="bibr">67</xref>]. To assess whether Cu-mediated oxidative stress induces mitophagy, cells were stained with the fluorophore Mtphagy alongside fluorescent probes specific for mitochondria (MitoTraker Deep Red) and lysosomes (Lyso dye) (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A). The Mtphagy dye, which remains stable in healthy mitochondria, emits bright fluorescence when phagosomes containing mitochondria fuse with lysosomes [<xref rid="bib68" ref-type="bibr">68</xref>]. As shown, Cu exposure (100&#160;&#956;M) activated mitophagy (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A and B), which was inhibited by GSHee treatment (1&#160;mM) or the autophagy inhibitor wortmannin (5&#160;&#956;M). A&#946;-treated cells showed enhanced Mtphagy fluorescence, indicative of an increased mitophagy rate; however, this increase was markedly attenuated when microglia were subjected to Cu overload (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A and B). Next, we evaluated the mtDNA copy number as a measure of the mitochondrial content (<xref rid="fig2" ref-type="fig">Fig. 2</xref>C). We performed a multiplex dPCR assay using two different primer pairs targeting opposing regions of mtDNA: one region with a low frequency of deletions (mmt86-ND1) and another with a high frequency of deletions (mmt71-ND4), enabling simultaneous assessment of the deletion rate. Remarkably, despite the activation of mitophagy, Cu-overloaded cells showed elevated mtDNA copy number (<xref rid="fig2" ref-type="fig">Fig. 2</xref>C). The rise in mtDNA content caused by high Cu levels was more pronounced in cells subjected to A&#946; (5&#160;&#956;M) and was prevented by MitoQ administration. These findings suggest that a compensatory response is triggered to counteract mitochondrial oxidative stress caused by mtCu enrichment, enhancing mtDNA synthesis. Additionally, we calculated the mmt71-ND4/mmt86-ND1 ratio to determine the proportion of mtDNA molecules with deletions. In all the cases, the ratio approached one (<xref rid="fig2" ref-type="fig">Fig. 2</xref>C), signifying a lack of deletions.<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p><bold>Cu overload stimulates mitophagy and mitochondrial biogenesis.</bold> SIM-A9 cells were exposed to Cu (100&#160;&#956;M) with and without A&#946; (5&#160;&#956;M) treatment for 24&#160;h. In some cases, cells were pre-treated with the antioxidants GSH ethyl ester (GSHee, 1&#160;mM) and MitoQ (1&#160;&#956;M) for 30&#160;min before Cu exposure. <bold>(A</bold> and <bold>B)</bold> Mitophagy flux assay using Mtphagy dye. <bold>(A)</bold> Representative confocal images showing colocalization of Mtphagy dye (red) with lysosomes (Lyso dye, green). An increase in Mtphagy dye fluorescence intensity indicates the recruitment of mitochondria to lysosomes. Mitochondria were labelled using MitoTracker Deep Red (MTK; magenta). To inhibit autophagy, cells were incubated with wortmannin (Wn, 5&#160;&#956;M) for 24&#160;h. Scale bar: 25&#160;&#956;m. <bold>(B)</bold> Mitophagy quantification assessed as the relative fluorescence intensity of Mtphagy dye divided by the relative fluorescence intensity of MTK. Three non-overlapping images randomly captured from the upper, middle, and lower areas were analyzed (<italic toggle="yes">n</italic>&#160;=&#160;3 independent experiments). <bold>(C)</bold> Quantification of mtDNA copies by multiplex dPCR assay using two different primer pairs (mmt86-ND1 and mmt71-ND4). The right histogram shows the mtDNA deletion ratio (mmt71-ND4/mmt86-ND1) (<italic toggle="yes">n</italic>&#160;=&#160;5&#8211;6 independent experiments). <bold>(D)</bold> Immunoblots displaying the relative levels of mtTFA in cell extracts (<italic toggle="yes">n</italic>&#160;=&#160;3 independent experiments). <bold>(E)</bold> Immunoblot analysis of the respiratory chain proteins SDHA (nuclear-encoded) and COX-1 (mitochondria-encoded) in cell extracts. The COX-1/SDHA ratio was calculated as an indicator of mitobiogenesis (<italic toggle="yes">n</italic>&#160;=&#160;3 independent experiments). In immunoblots, &#946;-actin was used as a loading control, and the optical density values of the bands representing specific protein immunoreactivity were normalized to &#946;-actin. Data are shown as mean&#160;&#177;&#160;SD. One-way ANOVA followed by Tukey's test was applied to calculate statistical significance (&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.05, &#8727;&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.01, &#8727;&#8727;&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.001). See <xref rid="appsec1" ref-type="sec">Supplementary Fig. S6</xref> for uncropped blots.</p></caption><alt-text id="alttext0025">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0390">A key regulatory factor for the mitochondrial genome is the mitochondrial transcription factor A (mtTFA), which is essential for both mtDNA replication and transcription. mtTFA also maintains mtDNA integrity and provides structural stability by compacting the genome into nucleoid structures, reducing its vulnerability to damage from mitochondrial ROS (mtROS) [<xref rid="bib69" ref-type="bibr">69</xref>,<xref rid="bib70" ref-type="bibr">70</xref>]. Consistent with the elevated mtDNA levels, we observed that Cu exposure upregulated mtTFA expression (<xref rid="fig2" ref-type="fig">Fig. 2</xref>D). The effect was more pronounced after A&#946; co-incubation (<xref rid="fig2" ref-type="fig">Fig. 2</xref>D). Interestingly, mtTFA immunoblottings from Cu-treated cell extracts revealed smaller bands (<xref rid="fig2" ref-type="fig">Fig. 2</xref>D), indicating the presence of short mtTFA isoforms, which are described as less stable but capable of stimulating mitochondrial transcription [<xref rid="bib71" ref-type="bibr">71</xref>]. The physiological significance of enriching these isoforms with increased Cu levels is unknown and requires further investigation.</p><p id="p0395">In parallel, as a readout of mitochondrial transcription, we determined the protein levels of the mitochondrially encoded cytochrome <italic toggle="yes">c</italic> oxidase subunit I (COX-1) together with the expression of the nuclear DNA-encoded succinate dehydrogenase complex flavoprotein subunit A (SDHA). While the SDHA levels remained unchanged across all the conditions (<xref rid="fig2" ref-type="fig">Fig. 2</xref>E), we observed a Cu-dependent increase in the levels of COX-1. Furthermore, Cu exposure markedly elevated the COX-1/SDHA protein ratio in A&#946;-treated cells (<xref rid="fig2" ref-type="fig">Fig. 2</xref>E). The high levels of COX-1 and mtTFA in Cu-enriched cells were not modified by GSHee treatment (<xref rid="fig2" ref-type="fig">Fig. 2</xref>D and E), suggesting that Cu overload may upregulate mitochondrial transcriptional pathways independently of mtROS signaling.</p></sec><sec id="sec3.3"><label>3.3</label><title>Cu overload promotes an NLRP3 inflammasome-mediated inflammatory response</title><p id="p0400">Next, we analyzed how changes in mitochondrial homeostasis caused by sublethal doses of Cu might influence the inflammatory response of microglia to A&#946;. We observed that the activation of SIM-A9 cells by A&#946; (5&#160;&#956;M), assessed by the upregulation of AIF-1/IBA1 levels, was stimulated after Cu overload (100&#160;&#956;M) (<xref rid="fig3" ref-type="fig">Fig. 3</xref>A). Furthermore, the activated phenotype exhibited by the Cu-treated cells was prevented following GSHee treatment (1&#160;mM) (<xref rid="fig3" ref-type="fig">Fig. 3</xref>A). In parallel, as an indicator of NF-&#954;B activation, we evaluated the nuclear presence of the p65 subunit by immunofluorescence microscopy (<xref rid="fig3" ref-type="fig">Fig. 3</xref>B). As shown, Cu exposure promoted the nuclear translocation of NF-&#954;B, whereas in untreated cells, p65 NF-&#954;B remained in the cytosol. A similar nuclear translocation was observed in A&#946;-treated cells, which was markedly enhanced after Cu overload (<xref rid="fig3" ref-type="fig">Fig. 3</xref>B). NF-&#954;B activation in Cu-treated cells was completely blocked by GSHee and MitoQ treatment (<xref rid="fig3" ref-type="fig">Fig. 3</xref>B). Our findings point to the involvement of mitochondrial oxidative stress in the induction of the NF-&#954;B pathway elicited by high Cu levels, corroborating previous reports [<xref rid="bib31" ref-type="bibr">31</xref>].<fig id="fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p><bold>Cu enrichment induces NLRP3 inflammasome activation leading to a pro-inflammatory microglial profile.</bold> SIM-A9 cells were exposed to Cu (100&#160;&#956;M) with and without A&#946; (5&#160;&#956;M) treatment for 24&#160;h. In some cases, cells were pre-treated with the antioxidants GSH ethyl ester (GSHee, 1&#160;mM) and MitoQ (1&#160;&#956;M) for 30&#160;min before Cu exposure. <bold>(A)</bold> Immunoblot analysis of AIF-1/IBA1 in cell extracts (<italic toggle="yes">n</italic>&#160;=&#160;3 independent experiments). <bold>(B)</bold> Representative fluorescence micrographs of NF-kb p65 expression and localization. Nuclei were stained with 1&#160;&#956;g/ml Hoechst 33342 (H, blue). Scale bar: 25&#160;&#956;m. The histogram shows mean fluorescence intensities of nuclear NF-&#954;B staining. A total of 50&#160;cells were analyzed per condition; A.U., arbitrary units. <bold>(C)</bold><italic toggle="yes">Nlrp3</italic> and <italic toggle="yes">Il1b</italic> mRNA expression levels analyzed by selfie qRT-PCR. Transcript copies were normalized to total genomic DNA and reported as relative levels referred to the expression in control (CTRL) cells (<italic toggle="yes">n</italic>&#160;=&#160;3 independent experiments). <bold>(D</bold> and <bold>E)</bold> Representative immunoblots of NLRP3 and IL-1&#946; (37&#160;kDa proform and 17&#160;kDa mature form) in cell extracts (n&#160;=&#160;3 independent experiments). <bold>(F)</bold> Representative confocal images of oligomeric ASC (white arrows) from 3 independent experiments. Cells were transfected with a plasmid encoding an ASC:GFP fusion protein and treated as indicated. Cells were counterstained with CellMask (CM, cytosol/plasma membrane, red). Scale bar: 25&#160;&#956;m. <bold>(G)</bold> Caspase-1 (CASP-1) activity in cell lysates measured using a pro-bioluminescent substrate (<italic toggle="yes">n</italic>&#160;=&#160;4 independent experiments). A.U., arbitrary units. <bold>(H)</bold> Levels of IL-1&#946; in cell culture supernatants. In some cases, to assess the presence of IL-1&#946; encapsulated in extracellular vesicles, supernatants were incubated with 1&#160;% Triton X-100 (<italic toggle="yes">n</italic>&#160;=&#160;3 independent experiments). <bold>(I)</bold> Heat map representation of the cytokine expression profiles. Mouse Cytokine Array was hybridized with cell culture supernatants from CTRL and treated cells and quantified using Mapix software (<italic toggle="yes">n</italic>&#160;=&#160;3 independent experiments). In immunoblots, &#946;-actin was used as a loading control, and the optical density values of the bands representing specific protein immunoreactivity were normalized to &#946;-actin. Data are shown as mean&#160;&#177;&#160;SD. One-way ANOVA followed by Tukey's test was applied to calculate statistical significance (&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.05, &#8727;&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.01, &#8727;&#8727;&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.001). See <xref rid="appsec1" ref-type="sec">Supplementary Fig. S6</xref> for uncropped blots.</p></caption><alt-text id="alttext0030">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0405">Different mitochondrial components, including mtROS, ox-mtDNA, and externalized cardiolipin under mitochondrial stress, have been shown to trigger NLRP3 inflammasome induction [<xref rid="bib39" ref-type="bibr">39</xref>,<xref rid="bib72" ref-type="bibr">72</xref>,<xref rid="bib73" ref-type="bibr">73</xref>]. We evaluated whether mtCu enrichment (<xref rid="fig1" ref-type="fig">Fig. 1</xref>B) and subsequent oxidative stress (<xref rid="fig1" ref-type="fig">Fig. 1</xref>D and E) can promote the NLRP3 inflammasome activation in A&#946;-treated cells. We confirmed the transcriptional upregulation of both the <italic toggle="yes">Il1b</italic> and <italic toggle="yes">Nlrp3</italic> genes in SIM-A9 cells exposed to high Cu levels through RT-PCR (<xref rid="fig3" ref-type="fig">Fig. 3</xref>C), which led to an increase in the corresponding protein levels, assessed by immunoblotting (<xref rid="fig3" ref-type="fig">Fig. 3</xref>D and E). Consistent with the nuclear presence of p65 NF-&#954;B, a slight rise in <italic toggle="yes">Nlrp3</italic> and <italic toggle="yes">Il1b</italic> mRNA levels was also observed in A&#946;-treated cells (<xref rid="fig3" ref-type="fig">Fig. 3</xref>C), which was significantly enhanced after Cu loading and translated into elevated protein levels (<xref rid="fig3" ref-type="fig">Fig. 3</xref>D and E). We determined inflammasome assembly using green fluorescent protein (GFP)- tagged ASC (ASC-GFP). Under normal conditions, the conjugate is evenly distributed in the cytosol; however, it appears as condensed specks when it associates with PRRs such as NLRP3. As shown, Cu enrichment stimulated ASC oligomerization in both control and A&#946;-activated cells (<xref rid="fig3" ref-type="fig">Fig. 3</xref>F). In parallel, as a direct indicator of inflammasome function, we monitored CASP-1 activity in live cells using the specific Z-WEHD-amino luciferin substrate coupled with a bioluminescence assay. Mirroring the inflammasome assembly, Cu exposure significantly enhanced CASP-1 activity in control and A&#946;-treated cells (<xref rid="fig3" ref-type="fig">Fig. 3</xref>G). Accordingly, in response to CASP-1 activation, cells incubated with Cu showed increased IL-1&#946; processing (<xref rid="fig3" ref-type="fig">Fig. 3</xref>E) and subsequent release of mature IL-1&#946; into the culture media, quantified by ELISA (<xref rid="fig3" ref-type="fig">Fig. 3</xref>H). Bioactive cytokines can be secreted within EVs [<xref rid="bib74" ref-type="bibr">74</xref>,<xref rid="bib75" ref-type="bibr">75</xref>], a process influenced by cell activation [<xref rid="bib74" ref-type="bibr">74</xref>]. Due to the inability of cell-free cytokine assays, such as ELISA, to detect cytokines within EVs, we treated the supernatants with 1&#160;% Triton X-100 for 10&#160;min. The resulting detergent-treated media from microglia exposed to Cu showed increased IL-1&#946; levels (<xref rid="fig3" ref-type="fig">Fig. 3</xref>H), indicating that Cu enrichment promotes the release of EV-encapsulated IL-1&#946;. Additionally, downregulation of Cu-induced oxidative stress through GSHee or the mitochondria-targeted MitoQ inhibited inflammasome activation (<xref rid="fig3" ref-type="fig">Fig. 3</xref>F and G) and significantly decreased IL-1&#946; processing and secretion of both free and EV-associated forms (<xref rid="fig3" ref-type="fig">Fig. 3</xref>E and H), in agreement with earlier studies that connect mitochondrial dysfunction to NLRP3 inflammasome engagement [<xref rid="bib39" ref-type="bibr">39</xref>,<xref rid="bib76" ref-type="bibr">76</xref>]. To gain a comprehensive understanding of the inflammatory response triggered by Cu, we conducted a cytokine multiplex assay (<xref rid="fig3" ref-type="fig">Fig. 3</xref>I). The 24-h conditioned media from Cu-treated cells exhibited elevated levels of proinflammatory cytokines, whereas the levels of anti-inflammatory cytokines remained unchanged (IL-4 and IL-13) or decreased (IL-10). This proinflammatory profile was attenuated by GSHee and MitoQ co-incubation (<xref rid="fig3" ref-type="fig">Fig. 3</xref>I). Once again, Cu overload amplified the inflammatory response of microglia in the presence of A&#946; (<xref rid="fig3" ref-type="fig">Fig. 3</xref>I). These findings indicate that the altered mitochondrial redox balance elicited by high mtCu levels promotes NLRP3 inflammasome activation, which may contribute to perpetuating the pro-inflammatory state of microglia exposed to A&#946;.</p></sec><sec id="sec3.4"><label>3.4</label><title>mtDNA oxidation caused by Cu overload triggers NLRP3 inflammasome activation</title><p id="p0410">Previous studies have reported that mtDNA can be released into the cytosol as part of a cell death program and bind to the NLRP3 inflammasome when it becomes oxidized [<xref rid="bib77" ref-type="bibr">77</xref>]. The requirement of ox-mtDNA for NLRP3 inflammasome activation was further confirmed by Zhong et al. [<xref rid="bib72" ref-type="bibr">72</xref>], showing that the release of ox-mtDNA is triggered by mtROS and is preceded by the induction of mtDNA <italic toggle="yes">de novo</italic> synthesis. Given that mitochondrial oxidative stress elicited by Cu overload was accompanied by increased mtDNA copy number (<xref rid="fig2" ref-type="fig">Fig. 2</xref>C), we next sought to evaluate whether mtDNA was involved in the Cu-mediated induction of the NLRP3 inflammasome. First, we analyzed the cytosolic presence of mtDNA under Cu-overloaded conditions using SYBR Gold dye, which preferentially labels mitochondrial nucleoids at high dilutions [<xref rid="bib78" ref-type="bibr">78</xref>]. As expected, confocal micrographs showed SYBR Gold staining localized mainly in mitochondria, and no remarkable increase in cytosolic mtDNA was observed with Cu enrichment (<xref rid="fig4" ref-type="fig">Fig. 4</xref>A). The release of mtDNA into the cytosol was also quantified by dPCR, confirming comparable low levels of cytosolic mtDNA regardless of Cu treatment (<xref rid="fig4" ref-type="fig">Fig. 4</xref>B). Interestingly, unlike control cells, mitochondria from Cu-exposed cells showed high levels of ox-mtDNA, assessed by immunostaining with anti-8-oxyhydrodioxyguanosine (8-OHdG), a marker of DNA oxidative damage (<xref rid="fig4" ref-type="fig">Fig. 4</xref>C). GSHee pre-treatment completely blocked ox-mtDNA generation, thereby corroborating the involvement of oxidative stress. In contrast, the induction of mtDNA oxidation by Cu loading was enhanced in A&#946;-treated cells, which displayed an increased mitochondrial size, likely due to swelling and cristae disruption evoked by the cytotoxic peptide itself, as reported previously [<xref rid="bib79" ref-type="bibr">79</xref>]. Furthermore, the lack of colocalization between some of the 8-OHdG immunostaining spots and mitochondria in Cu-overloaded cells suggested a cytosolic leakage of ox-mtDNA (<xref rid="fig4" ref-type="fig">Fig. 4</xref>C, see insets). Additionally, we evaluated the levels of mitochondrial UMP-CMP kinase 2 (CMPK2), the rate-limiting enzyme responsible for providing deoxyribonucleotides for mtDNA synthesis, which was reported to be essential for producing ox-mtDNA fragments [<xref rid="bib72" ref-type="bibr">72</xref>]. As shown, Cu exposure increased CMPK2 levels, which were even higher in A&#946;-activated cells (<xref rid="fig4" ref-type="fig">Fig. 4</xref>D). In contrast, treatment with GSHee inhibited Cu-mediated increase of the CMPK2 levels (<xref rid="fig4" ref-type="fig">Fig. 4</xref>D). Next, to study the relationship between Cu-induced ox-mtDNA generation and NLRP3 inflammasome activation, we used SIM-A9 cells depleted of mtDNA. The cells were treated with ddC, an analog of the cellular DNA precursor 2&#8242;-deoxycytidine-5&#8242;-triphosphate (dCTP) that inhibits mitochondrial DNA polymerase (POLG) [<xref rid="bib80" ref-type="bibr">80</xref>]. As shown, mtDNA copy number declined progressively by up to 75&#8211;80&#160;% after 6 days of ddC treatment (<xref rid="fig4" ref-type="fig">Fig. 4</xref>E), with almost undetectable presence of cytosolic mtDNA at 3 days of treatment (<xref rid="fig4" ref-type="fig">Fig. 4</xref>F). Remarkably, depletion of mtDNA content led to reduced CASP-1 activation, indicating that Cu-induced inflammasome activation was inhibited in both control and A&#946;-activated microglia (<xref rid="fig4" ref-type="fig">Fig. 4</xref>G). Cells lacking mtDNA also exhibited reduced IL-1&#946; secretion after Cu treatment (<xref rid="fig4" ref-type="fig">Fig. 4</xref>H). A complete inhibition of inflammasome induction was achieved when mtDNA downregulation was combined with GSHee treatment (<xref rid="fig4" ref-type="fig">Fig. 4</xref>G and H). These findings suggest the participation of cytosolic ox-mtDNA in NLRP3 activation and the enhanced inflammatory response evoked by high Cu levels in A&#946;-activated microglia.<fig id="fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p><bold>The release of oxidized mtDNA (ox-mtDNA) by high Cu levels contributes to NLRP3 inflammasome activation.</bold> SIM-A9 cells were exposed to Cu (100&#160;&#956;M) with and without A&#946; (5&#160;&#956;M) treatment for 24&#160;h. In some cases, cells were pre-treated with the antioxidant GSH ethyl ester (GSHee, 1&#160;mM) for 30&#160;min before Cu exposure. <bold>(A)</bold> Representative confocal photomicrographs showing DNA immunoreactivity (green) in mitochondria labelled with Mitotracker Deep Red (MTK; red). Scale bar: 10&#160;&#956;m. Insets show a 3-fold magnification of the indicated regions. <bold>(B)</bold> Quantification of mtDNA copies in the cytosolic fraction by multiplex dPCR assay using two different primer pairs (mmt86-ND1 and mmt71-ND4). Values were normalized to total protein levels (<italic toggle="yes">n</italic>&#160;=&#160;5&#8211;6 independent experiments). <bold>(C)</bold> Representative confocal photomicrographs showing 8-hydroxy-2&#8242;-deoxyguanosine (8-OHdG) immunoreactivity (green) in mitochondria labelled with Mitotracker Deep Red (MTK; red). Scale bar: 10&#160;&#956;m. Insets show a 5-fold magnification of the indicated region. <bold>(D)</bold> Immunoblot showing the relative levels of cytidine/uridine monophosphate kinase 2 (CMPK2) in cell extracts. &#946;-actin was used as a loading control, and the optical density values of the band corresponding to CMPK2 immunoreactivity were normalized to &#946;-actin (<italic toggle="yes">n</italic>&#160;=&#160;3 independent experiments). <bold>(E</bold>&#8211;<bold>H)</bold> Cells were treated with the POLG inhibitor mtDNA 2&#8242;,3&#8242;-dideoxycytidine (ddC,150&#160;&#956;M) for the indicated period of time. <bold>(E)</bold> Quantification of mtDNA copies after ddC treatment by multiplex dPCR (n&#160;=&#160;3 independent experiments). <bold>(F)</bold> mtDNA copy number in the cytosolic fraction of untreated (NT) and ddC-treated cells for 6 days, with or without Cu exposure. Values were normalized to total protein levels (<italic toggle="yes">n</italic>&#160;=&#160;3&#8211;5 independent experiments). <bold>(G)</bold> Caspase-1 (CASP-1) activity in cell lysates measured using a pro-bioluminescent substrate (<italic toggle="yes">n</italic>&#160;=&#160;4 independent experiments). A.U., arbitrary units. <bold>(H)</bold> Levels of IL-1&#946; in cell culture supernatants (<italic toggle="yes">n</italic>&#160;=&#160;3 independent experiments). Data are shown as mean&#160;&#177;&#160;SD. Unpaired <italic toggle="yes">t</italic>-test (F) and one-way ANOVA followed by Tukey's test (B-E, G, H) were applied to calculate statistical significance (&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.05, &#8727;&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.01, &#8727;&#8727;&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.001). See <xref rid="appsec1" ref-type="sec">Supplementary Fig. S6</xref> for uncropped blots.</p></caption><alt-text id="alttext0035">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec><sec id="sec3.5"><label>3.5</label><title>High Cu levels impair microglial A&#946; clearance by downregulating ABCA7 levels and phagocytosis</title><p id="p0415">Cu exposure has been reported to influence phagocytosis and reduce A&#946; disposal in BV-2 microglial cells [<xref rid="bib81" ref-type="bibr">81</xref>]. We found a similar effect in SIM-A9 cells. The cells were incubated with fluorescent microbeads for 20&#160;min, and the internalization was analyzed using confocal microscopy. Microglia exhibited basal internalization of fluorescent beads (nonspecific phagocytosis), which was significantly reduced after Cu enrichment (<xref rid="fig5" ref-type="fig">Fig. 5</xref>A). A similar inhibitory effect of Cu was observed when cells were activated by A&#946; (5&#160;&#956;M) or exposed to bacterial endotoxins, such as LPS (10&#160;&#956;g/ml) and MDP (10&#160;&#956;g/ml), a classical inflammasome inducer (<xref rid="fig5" ref-type="fig">Fig. 5</xref>A). In parallel, to evaluate whether Cu exposure affects A&#946; clearance, the cells were incubated with fibrilized HiLyte Fluor 488-labelled A&#946; for 4&#160;h. Phagocytosis was assessed by confocal microscopy (<xref rid="fig5" ref-type="fig">Fig. 5</xref>B). Micrographs revealed a significant downregulation in the amount of fluorescent A&#946; phagocytosed when the cells were exposed to Cu. Furthermore, the enhanced A&#946; intake displayed by bacterial endotoxin-activated microglia was significantly blunted after Cu enrichment (<xref rid="fig5" ref-type="fig">Fig. 5</xref>B). Treatment with GSHee and the mitochondrial antioxidant MitoQ partially mitigated the inhibitory effects of Cu on both nonspecific and A&#946;-specific phagocytosis (<xref rid="fig5" ref-type="fig">Fig. 5</xref>A and B), suggesting the involvement of mitochondrial oxidative stress.<fig id="fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p><bold>Exposure to high Cu levels impairs the phagocytic clearance of A&#946; mediated by ABCA7.</bold> SIM-A9 cells were exposed to Cu (100&#160;&#956;M) with and without A&#946; (5&#160;&#956;M) treatment for 24&#160;h. In some cases, cells were pre-treated with the antioxidants GSH ethyl ester (GSHee, 1&#160;mM) and MitoQ (1&#160;&#956;M) for 30&#160;min before Cu exposure. To reduce intracellular cholesterol levels, Cu-enriched cells were co-incubated with the cholesterol-lowering compound 2-hydroxypropyl-&#946;-cyclodextrin (HP-&#946;-CD, 300&#160;&#956;M). <bold>(A</bold> and <bold>B)</bold> Representative confocal micrographs from 3 independent experiments showing phagocytosis of yellow-green fluorescent microspheres <bold>(A)</bold> and HiLyte Fluor 488-labelled A&#946; <bold>(B)</bold>. Cells were counterstained with CellMask (CM, cytosol/plasma membrane, red) and Hoechst 33342 (nuclei, blue). To induce phagocytosis cells were stimulated with LPS (10&#160;&#956;g/ml) plus MDP (10&#160;&#956;g/ml) for 16&#160;h. Scale bar: 25&#160;&#956;m. Plots represent phagocytosed beads or A&#946; per cell, quantified as the corrected total cell fluorescence (CTCF) of the green channel (<italic toggle="yes">n</italic>&#160;=&#160;10 non-overlapping images). <bold>(C)</bold> Immunoblots showing the relative levels of ABCA7 and CD36 in cell extracts (<italic toggle="yes">n</italic>&#160;=&#160;3 independent experiments). <bold>(D)</bold> Representative confocal micrographs from 3 independent experiments showing ABCA7 (green) expression and distribution. Cells were counterstained with CellMask (CM, cytosol/plasma membrane, red) and DAPI (nuclei, blue). Scale bar: 25&#160;&#956;m. <bold>(E)</bold> Representative confocal images of CTRL and Cu-treated cells immunostained for ABCA7 (red) and incubated with HiLyte Fluor 488-labelled A&#946; (green). Scale bar: 25&#160;&#956;m. The Pearson correlation coefficient was used as a measure of colocalization of HiLyte fluor 488 signal (A&#946;) with Alexa fluor 555 signal (ABCA7). Three non-overlapping images randomly captured from the upper, middle, and lower areas were analyzed (<italic toggle="yes">n</italic>&#160;=&#160;3 independent experiments). <bold>(F)</bold> Representative photomicrographs of CTRL and Cu-treated cells labelled with anti-LRP1 (green) and counterstained with CellMask (CM, red) and DAPI (blue). Scale bar: 25&#160;&#956;m. <bold>(G)</bold> Immunoblot analysis of LRP1 in cytosolic and nuclear fractions (<italic toggle="yes">n</italic>&#160;=&#160;3 independent experiments). In immunoblots, b-actin and LSD1 were used as loading controls for cytosol/cell extracts and nuclear extracts, respectively, and optical density values of the bands representing specific protein immunoreactivity were normalized to b-actin (cytosol/cell extracts) or LSD1 (nuclear extracts). Data are shown as mean&#160;&#177;&#160;SD. Unpaired <italic toggle="yes">t</italic>-test (E, G) and one-way ANOVA followed by Tukey's test (A&#8211;C) were applied to calculate statistical significance (&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.05, &#8727;&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.01, &#8727;&#8727;&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.001). See <xref rid="appsec1" ref-type="sec">Supplementary Fig. S7</xref> for uncropped blots.</p></caption><alt-text id="alttext0040">Fig. 5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p><p id="p0420">Next, we investigated the Cu-dependent mechanism underlying the inefficient removal of A&#946;. To this end, we determined the expression levels of the transmembrane glycoprotein receptor CD36 (also known as platelet glycoprotein 4) and the ATP-binding cassette subfamily A member 7 (ABCA7) transporter protein. Both proteins have been reported to mediate microglial A&#946; phagocytosis [<xref rid="bib82" ref-type="bibr">[82]</xref>, <xref rid="bib83" ref-type="bibr">[83]</xref>, <xref rid="bib84" ref-type="bibr">[84]</xref>, <xref rid="bib85" ref-type="bibr">[85]</xref>, <xref rid="bib86" ref-type="bibr">[86]</xref>]. Deficient A&#946; phagocytosis has been linked to impaired recycling of CD36 [<xref rid="bib84" ref-type="bibr">84</xref>]. Similarly, the loss of ABCA7 function has been shown to promote A&#946; accumulation and accelerate pathology in AD mouse models [<xref rid="bib85" ref-type="bibr">85</xref>,<xref rid="bib86" ref-type="bibr">86</xref>]. We observed that while CD36 remained unchanged, ABCA7 levels decreased following Cu exposure (<xref rid="fig5" ref-type="fig">Fig. 5</xref>C). We confirmed the lower ABCA7 content in Cu-exposed cells by immunofluorescence staining (<xref rid="fig5" ref-type="fig">Fig. 5</xref>D). The blockage of oxidative stress by GSHee treatment was sufficient to recover ABCA7 levels in Cu-enriched cells (<xref rid="fig5" ref-type="fig">Fig. 5</xref>C and D). Micrographs revealed that, in nonreactive microglia, intracellular ABCA7 mainly accumulated at the cell edge (<xref rid="fig5" ref-type="fig">Fig. 5</xref>D), likely within endosomal compartments, supporting its role in the vesicular transport of phospholipids and cholesterol [<xref rid="bib87" ref-type="bibr">87</xref>]. Notably, upon A&#946; stimulation, ABCA7 translocates to the plasma membrane, enabling efficient phagocytosis as evidenced by colocalization with fluorescently labelled A&#946; peptides (<xref rid="fig5" ref-type="fig">Fig. 5</xref>E). Conversely, Cu-enriched cells displaying impaired phagocytic activity showed minimal colocalization of ABCA7 and A&#946; (<xref rid="fig5" ref-type="fig">Fig. 5</xref>E).</p><p id="p0425">Low-density lipoprotein receptor-related protein 1 (LRP1) has been described to participate in ABCA7-mediated phagocytosis of apoptotic cells and colocalizes with ABCA7 within the phagocytic cup after macrophage activation [<xref rid="bib88" ref-type="bibr">88</xref>]. Intriguingly, we found that Cu exposure increased the levels of LRP1; however, unlike in the control cells, the protein appeared restricted to the nucleus (<xref rid="fig5" ref-type="fig">Fig. 5</xref>F and G). LRP1 is a heterodimer consisting of a 515&#160;kDa &#945; chain (LRP1&#945;) and an 85&#160;kDa membrane-anchored cytoplasmic &#946; chain (LRP1&#946;). It has been reported that the subunit LRP1&#946; can be processed by &#947;-secretase and translocate to the nucleus [<xref rid="bib89" ref-type="bibr">89</xref>,<xref rid="bib90" ref-type="bibr">90</xref>], where it inhibits transcriptional regulators involved in different inflammatory signaling pathways, such as interferon regulatory factor 3 (IRF3) and poly(ADP-ribose) polymerase 1 (PARP1). Further investigation will be needed to assess how LRP1 nuclear translocation and related transcriptional changes affect the microglial inflammatory response after Cu exposure, beyond its impact on phagocytosis.</p></sec><sec id="sec3.6"><label>3.6</label><title>Upregulation of intracellular cholesterol levels caused by Cu overload influences phagocytosis and the immune response of SIM-A9 cells</title><p id="p0430">ABCA7 levels and &#947;-secretase activity, which is also responsible for amyloidogenic processing [<xref rid="bib91" ref-type="bibr">91</xref>], are both regulated by cholesterol levels. Active &#947;-secretase resides in cholesterol-rich membrane microdomains, and membrane cholesterol depletion significantly reduces its enzymatic activity [<xref rid="bib92" ref-type="bibr">92</xref>]. Likewise, cholesterol-lowering therapies have been shown to raise ABCA7 levels and boost phagocytosis [<xref rid="bib93" ref-type="bibr">93</xref>,<xref rid="bib94" ref-type="bibr">94</xref>]. Remarkably, a close relationship has been reported between Cu dysregulation and changes in cholesterol metabolism, although sometimes with contradictory conclusions likely due to tissue- and species-specific differences [<xref rid="bib95" ref-type="bibr">95</xref>]. We previously showed that sublethal Cu doses stimulate cholesterol synthesis in astrocytes and immature neurons, resulting in cholesterol enrichment in membrane rafts and increased amyloidogenesis [<xref rid="bib96" ref-type="bibr">96</xref>,<xref rid="bib97" ref-type="bibr">97</xref>]. In this study, we aimed to analyze the mechanistic link between Cu-mediated cholesterol rise and the induction of a pro-inflammatory microglia profile. As shown, SIM-A9 cells exposed to Cu exhibited a 50&#8211;60&#160;% increase in total cholesterol content (<xref rid="fig6" ref-type="fig">Fig. 6</xref>A). We also found high mRNA levels of genes related to cholesterol synthesis and transport, such as <italic toggle="yes">Srf2</italic>, <italic toggle="yes">ApoE</italic> (apolipoprotein E), and <italic toggle="yes">Hmgcr</italic>, after Cu overloading regardless of A&#946; insult (<xref rid="fig6" ref-type="fig">Fig. 6</xref>C). These changes in cholesterol homeostasis were accompanied by increased levels of ER stress response proteins, such as the chaperone BiP and phosphorylated eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3, also known as PERK) (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S4</xref>), which have been reported to activate the cholesterol biosynthetic pathway [<xref rid="bib98" ref-type="bibr">98</xref>]. Paralleling total cholesterol rise, the mitochondrial fraction from Cu-overloaded cells showed increased cholesterol levels (<xref rid="fig6" ref-type="fig">Fig. 6</xref>A), as confirmed by confocal microscopy (<xref rid="fig6" ref-type="fig">Fig. 6</xref>B). We analyzed the intracellular distribution of cholesterol using recombinant perfringolysin O, a cholesterol-binding bacterial toxin fused with glutathione S-transferase (GST-FPO) [<xref rid="bib51" ref-type="bibr">51</xref>]. In Cu-treated cells, GST-PFO immunostaining partially colocalized with the mitochondrial import receptor subunit TOM20 homolog (TOM20) (<xref rid="fig6" ref-type="fig">Fig. 6</xref>B). Furthermore, pre-treatment with GSHee and MitoQ, which significantly reduced the ER stress response (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S4</xref>), resulted in decreased intracellular cholesterol levels and low colocalization with the mitochondrial marker (<xref rid="fig6" ref-type="fig">Fig. 6</xref>B). Additionally, we studied different lipid transfer proteins known to transport cholesterol to the mitochondria. We assessed the expression levels of the endosome-bound transporter stAR-related lipid transfer domain containing 3 (STARD3) [<xref rid="bib99" ref-type="bibr">99</xref>], as well as the levels of the translocator protein (TSPO) and the steroidogenic acute regulatory protein (STAR), which cooperate to mobilize cholesterol to the mitochondrial inner membrane [<xref rid="bib100" ref-type="bibr">100</xref>]. As shown, Cu treatment increased the levels of STARD3 and TSPO, while the content of STAR remained unchanged (<xref rid="fig6" ref-type="fig">Fig. 6</xref>D). Compared with those in control cells, the levels of STARD3 and TSPO were also elevated in A&#946;-activated cells, and Cu exposure further stimulated TSPO expression (<xref rid="fig6" ref-type="fig">Fig. 6</xref>D), suggesting that these lipid transfer proteins are responsible for the increase in mitochondrial cholesterol elicited by Cu. To analyze how elevated cholesterol influences the microglial immune response and phagocytosis, Cu-enriched cells were treated with the cholesterol-sequestering compound 2-hydroxypropyl-&#946;-cyclodextrin (HP-&#946;-CD, 300&#160;&#956;M). Cyclodextrin treatment normalized cholesterol levels (<xref rid="fig6" ref-type="fig">Fig. 6</xref>E) without affecting cell viability (<xref rid="fig6" ref-type="fig">Fig. 6</xref>F). The activation of CASP-1 and subsequent release of IL-1&#946;, induced by high levels of Cu, were significantly diminished following HP-&#946;-CD treatment (<xref rid="fig6" ref-type="fig">Fig. 6</xref>G and H). Furthermore, HP-&#946;-CD incubation prevented the depletion of ABCA7 in Cu-treated cells (<xref rid="fig6" ref-type="fig">Fig. 6</xref>I) and improved the phagocytic capacity of these cells, increasing A&#946; intake (<xref rid="fig5" ref-type="fig">Fig. 5</xref>A and B). Our findings indicate that upregulation of intracellular cholesterol levels plays a key role in the microglia phenotypic alterations linked to excess Cu.<fig id="fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p><bold>Cu-induced intracellular cholesterol accumulation alters cholesterol trafficking and impairs the immune response in microglial cells.</bold> SIM-A9 cells were exposed to Cu (100&#160;&#956;M) with and without A&#946; (5&#160;&#956;M) treatment for 24&#160;h. In some cases, cells were pre-treated with the antioxidant MitoQ (1&#160;&#956;M) for 30&#160;min before Cu exposure. <bold>(A)</bold> Total cholesterol (CHO) levels in mitochondria-enriched fractions (Mito) and whole-cell homogenates (Cell) (<italic toggle="yes">n</italic>&#160;=&#160;5 independent experiments). <bold>(B)</bold> Representative confocal photomicrograph of double immunofluorescence for GST-PFO (red) and TOMM20 (green). Scale bar: 50&#160;&#956;m. Line-scan fluorescence intensity profiles of GST-PFO were generated along selected mitochondrial regions. Fluorescence intensity (A.U.) was plotted against the linear distance (&#956;m) to visualise cholesterol distribution within mitochondria. <bold>(C)</bold> Relative mRNA expression levels of <italic toggle="yes">Srebf2</italic>, <italic toggle="yes">Apoe</italic>, and <italic toggle="yes">Hmgcr</italic> were quantified by selfie qRT-PCR. Transcript copies were normalized to total genomic DNA and reported as relative levels referred to the expression in control (CTRL) cells (<italic toggle="yes">n</italic>&#160;=&#160;3 independent experiments). <bold>(D)</bold> Immunoblot showing the relative levels of TSPO, STAR, and STARD3 in cell extracts (<italic toggle="yes">n</italic>&#160;=&#160;3 independent experiments). <bold>(E</bold>&#8211;<bold>I)</bold> To reduce the intracellular cholesterol levels, Cu-enriched cells were co-incubated with the cholesterol-lowering compound 2-hydroxypropyl-&#946;-cyclodextrin (HP-&#946;-CD, 300&#160;&#956;M) (<italic toggle="yes">n</italic>&#160;=&#160;3 independent experiments). <bold>(E)</bold> Total cholesterol (CHO) content in mitochondria-enriched fractions (Mito) and whole-cell homogenates (Cell). <bold>(F)</bold> Cell viability assessed by MTT assay. Results are expressed as % relative to control (CTRL) cells. <bold>(G)</bold> Caspase-1 (CASP-1) activity in cell lysates measured using a pro-bioluminescent substrate. <bold>(H)</bold> Levels of IL-1&#946; in cell culture supernatants quantified by ELISA. In some cases, to assess the presence of IL-1&#946; encapsulated in extracellular vesicles, supernatants were incubated with 1&#160;% Triton X-100. <bold>(I)</bold> Immunoblot analysis of ABCA7 in cell extracts (<italic toggle="yes">n</italic>&#160;=&#160;3 independent experiments). In immunoblots, &#946;-actin was used as a loading control, and the optical density values of the bands representing specific protein immunoreactivity were normalized to &#946;-actin. Data are shown as mean&#160;&#177;&#160;SD. Unpaired <italic toggle="yes">t</italic>-test (A) and one-way ANOVA followed by Tukey's test (C&#8211;I) were applied to calculate statistical significance (&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.05, &#8727;&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.01, &#8727;&#8727;&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.001). See <xref rid="appsec1" ref-type="sec">Supplementary Fig. S7</xref> for uncropped blots.</p></caption><alt-text id="alttext0045">Fig. 6</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p></sec><sec id="sec3.7"><label>3.7</label><title>SREBF2 overexpression sensitizes APP-PSEN1 neurons to the cytotoxic effects of conditioned media from Cu-treated SIM-A9 cells</title><p id="p0435">Finally, we analyzed the impact of the intensified inflammatory response evoked by Cu overload on neuronal viability. We previously demonstrated that cholesterol enrichment sensitizes neurons to mitochondrial insults, such as A&#946; [<xref rid="bib46" ref-type="bibr">46</xref>]. Additionally, AD mice that overexpress both the mutant APP and PSEN1 genes, together with the cholesterol-related transcription factor SREBF2, exhibit accelerated cognitive deficits and enhanced pathological features, including neuroinflammation [<xref rid="bib101" ref-type="bibr">101</xref>]. These data prompted us to investigate whether high intracellular cholesterol levels could modify the susceptibility of neuronal cells to Cu-induced reactive microglia (<xref rid="fig7" ref-type="fig">Fig. 7</xref>). Embryonic cortical-hippocampal neurons isolated from WT and APP-PSEN1 transgenic mice, with and without SREBF2 overexpression, were exposed to 24-h conditioned media from control and Cu-treated SIM-A9 cells for 16&#160;h. Conditioned media were treated with Chelex before use in neuronal cultures [<xref rid="bib48" ref-type="bibr">48</xref>], which significantly lowered Cu levels (<xref rid="appsec1" ref-type="sec">Supplementary Table S3</xref>). After treatment with the ion-exchange resin, the metal-depleted medium was replenished with a specific mixture of metals to restore its growth potential (<xref rid="appsec1" ref-type="sec">Supplementary Table S3</xref>). We observed a significant reduction in neuronal viability when conditioned media from Cu-treated cells were administered (<xref rid="fig7" ref-type="fig">Fig. 7</xref>). The cytotoxic effect was more significant in APP-PSEN1 mutant neurons and was amplified by cholesterol enrichment in APP-PSEN1-SERBF2 cells (<xref rid="fig7" ref-type="fig">Fig. 7</xref>). Conversely, viability was maintained, except for in APP-PSEN1-SERBF2 cells, when neuronal cultures were exposed to conditioned media from Cu-overloaded microglia treated with GSHee, which showed a reduced inflammatory profile (<xref rid="fig3" ref-type="fig">Fig. 3</xref>H). To confirm the involvement of the NLRP3 inflammasome, SIM-A9 cells were treated with the selective NLRP3 inhibitor MCC950 30&#160;min before exposure to Cu. Treatment with MCC950 significantly reduced Cu-induced CASP-1 activation and IL-1&#946; release in SIM-A9 cells (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S5A and Fig. S5B</xref>). MCC950-mediated inflammasome inhibition prevented the cytotoxic effects of conditioned media from Cu-treated cells when these media were transferred to WT and all mutant cultures (<xref rid="fig7" ref-type="fig">Fig. 7</xref>). Our findings suggest that the inflammatory response of microglia evoked by excess Cu levels can contribute to neuronal death in AD. Furthermore, the fact that changes in intracellular cholesterol levels influence neuronal resilience to the neurotoxic factors released by microglia further supports a key role of cholesterol in controlling neuron-immune cell communications, as we previously reported [<xref rid="bib40" ref-type="bibr">40</xref>].<fig id="fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p><bold>Neurotoxic effect of conditioned media from SIM-A9 cells exposed to Cu overload on primary neuronal cultures.</bold> Conditioned media (CM) were obtained from SIM-A9 cells exposed to Cu (100&#160;&#956;M) with and without A&#946; (5&#160;&#956;M) treatment for 24&#160;h. In some cases, cells were pre-treated with the antioxidant GSH ethyl ester (GSHee, 1&#160;mM) or the NLRP3 inhibitor MCC950 (10&#160;mM) for 30&#160;min before Cu exposure. Primary neuronal cultures from WT and APP-PSEN1 mice with and without SREBF2 overexpression were incubated with conditioned media for 16&#160;h, and cell viability was evaluated by calcein and 7-amino-actinomycin D (7-AAD) double labelling. Representative fluorescence micrographs from three independent experiments are shown, where metabolically active cells are marked by calcein staining (green) and membrane-compromised cells are labelled with 7-AAD (red). Scale bar: 200&#160;&#956;m. The ratio of green (live cells) to red (dead cells) fluorescence was calculated as an indicator of cell viability and expressed as the percentage relative to control (CTRL) values (<italic toggle="yes">n</italic>&#160;=&#160;6 independent experiments). Data are shown as mean&#160;&#177;&#160;SD. One-way ANOVA followed by Tukey's test was applied to calculate statistical significance (&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.05, &#8727;&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.01, &#8727;&#8727;&#8727;<italic toggle="yes">P</italic>&#160;&lt;&#160;0.001).</p></caption><alt-text id="alttext0050">Fig. 7</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr7.jpg"/></fig></p></sec></sec><sec id="sec4"><label>4</label><title>Discussion</title><p id="p0440">Alzheimer's disease is the most prevalent neurodegenerative disorder worldwide, with age being the leading risk factor for its development. Initially, the amyloid and tau hypotheses sought to explain the disease neuropathology. However, given the limited success of therapies targeting A&#946; and tau, alternative hypotheses have emerged. Among them, the amyloid cascade-inflammatory hypothesis [<xref rid="bib102" ref-type="bibr">102</xref>] suggests that A&#946; alone is not sufficient to trigger AD onset, emphasizing instead the role of the immune system and persistent neuroinflammation. This has been further supported by recent genome-wide association studies (GWAS), showing that many of the identified AD risk genes encode factors that regulate immune responses and are enriched in microglia [<xref rid="bib103" ref-type="bibr">103</xref>,<xref rid="bib104" ref-type="bibr">104</xref>].</p><p id="p0445">In the present study, we systematically illustrate the impact of Cu overload on sustaining a proinflammatory microglial phenotype in AD. We show that sublethal doses of Cu exert a dual effect on microglia, increasing mtROS and cholesterol levels, which potentiates A&#946;-induced cytotoxicity and inflammation and impairs A&#946; phagocytosis.</p><p id="p0450">Cu homeostasis is strictly regulated by metallothioneins, which play a crucial role in neutralizing cytosolic Cu [<xref rid="bib105" ref-type="bibr">105</xref>]. Besides these protective mechanisms, excess intracellular Cu is transported into the mitochondrial matrix for storage [<xref rid="bib106" ref-type="bibr">106</xref>]. Mitochondria are a primary site for Cu use but are also a key target of harmful Cu overload, especially brain mitochondria, which display lower mtGSH content compared to mitochondria from other tissues [<xref rid="bib107" ref-type="bibr">107</xref>]. Studies in liver cells and animal models of Wilson disease indicate that mitochondrial structural alterations occur prior to deficits in oxidative phosphorylation and the onset of oxidative damage [<xref rid="bib108" ref-type="bibr">108</xref>,<xref rid="bib109" ref-type="bibr">109</xref>]. In these models, elevated mitochondrial ROS appear as a late manifestation, arising only after irreversible mitochondrial damage and cell death. Emerging evidence suggests that Cu cytotoxicity is closely linked to Cu-induced protein conformational changes and proteotoxic stress [<xref rid="bib110" ref-type="bibr">110</xref>,<xref rid="bib111" ref-type="bibr">111</xref>], challenging the traditional view of Cu toxicity based on Fenton chemistry and ROS generation. Intriguingly, unlike these previous studies, we observed a dose-dependent increase in mtCu and a simultaneous depletion of mtGSH upon Cu exposure, which led to elevated ROS production and mitochondrial dysfunction without compromising cell viability. Cell-type-specific differences in mtCu handling may explain these seemingly conflicting findings. Within the mitochondrial matrix, most Cu forms non-protein complexes that exceed the requirements for metalloprotein assembly and can accumulate further before functional collapse ensues [<xref rid="bib106" ref-type="bibr">106</xref>,<xref rid="bib108" ref-type="bibr">108</xref>,<xref rid="bib109" ref-type="bibr">109</xref>]. Our findings are consistent with previous work showing that mitochondria from Cu-loaded glioblastoma cells, unlike those from neuronal cells, can sustain markedly elevated Cu levels&#8212;up to 40-fold higher than controls&#8212; while exhibiting increased ROS production without major structural alterations [<xref rid="bib107" ref-type="bibr">107</xref>]. The rise in protein carbonyl content, elevated levels of oxidized GSH, and reduced aconitase activity&#8212;effects that were all prevented by MitoQ&#8212;collectively suggest that oxidative stress is the main driver of mitochondrial damage triggered by Cu overload in microglial cells. In line with this mitochondrial dysfunction, we detected a marked reduction in ATP levels. Notably, MitoQ treatment partially restored ATP content, implying that, in addition to oxidative injury, Cu may exert a direct toxic action on specific mitochondrial protein residues, further contributing to mitochondrial impairment.</p><p id="p0455">Cu-induced mitochondrial oxidative stress favored the NLRP3 inflammasome activation through the release of ox-mtDNA, potentiating the inflammatory response elicited by A&#946;. MtCu accumulation has also been reported in activated monocyte-derived macrophages. In these cells, the increase of ionic Cu<sup>2+</sup> in mitochondria triggers the oxidation of NADH to NAD<sup>+</sup>, which contributes to metabolic reprogramming toward a proinflammatory state [<xref rid="bib112" ref-type="bibr">112</xref>]. The link between mtCu enrichment and neuroinflammation in AD is further substantiated by a recent study showing that lead (Pb) exposure activates microglia and worsens AD pathology by promoting Cu translocation to mitochondria, which leads to enhanced ROS generation and inflammatory cytokine release [<xref rid="bib113" ref-type="bibr">113</xref>].</p><p id="p0460">We show that mitochondrial oxidative damage linked to Cu overload triggers mitophagy, a protective response to mitochondrial damage. This clearance process is typically upregulated under moderate stress conditions, such as those exerted by sublethal Cu or A&#946; doses. Conversely, impaired mitophagy has been reported when Cu is chronically administered or combined with the presence of other neuronal insults, such as &#945;-synuclein, the pathogenic hallmark of Parkinson's disease [<xref rid="bib114" ref-type="bibr">114</xref>,<xref rid="bib115" ref-type="bibr">115</xref>]. In line with these findings, mitophagy was significantly blunted in Cu-enriched cells after A&#946; treatment. Parallel to the induction of mitophagy, Cu-overloaded cells exhibited an increased mtDNA copy number, together with elevated expression of mtTFA and the mitochondrial-encoded COX-1 protein, indicating the activation of mitobiogenesis signaling pathways. Notably, transcriptional inducers of mtTFA, such as peroxisome proliferator-activated receptor gamma coactivator 1&#945; (PGC-1&#945;) and nuclear respiratory factors 1/2 (NRF-1/-2), are sensitive to redox changes and have been reported to increase following Cu exposure [<xref rid="bib116" ref-type="bibr">[116]</xref>, <xref rid="bib117" ref-type="bibr">[117]</xref>, <xref rid="bib118" ref-type="bibr">[118]</xref>]. Significantly, we found a higher content of mtDNA in Cu-enriched cells exposed to A&#946;, which was accompanied by increased levels of the mitochondrial nucleotide kinase CMPK2. Emerging evidence highlights the critical role of CMPK2 in mitochondria-mediated control of innate immunity [<xref rid="bib119" ref-type="bibr">119</xref>], which modulates the inflammatory response of monocytes/macrophages and microglia under various pathological conditions, such as ischemic stroke or viral infection [<xref rid="bib120" ref-type="bibr">120</xref>,<xref rid="bib121" ref-type="bibr">121</xref>]. Mechanistically, CMPK2-dependent mtDNA synthesis seems to be required for the production of oxidized mtDNA fragments [<xref rid="bib72" ref-type="bibr">72</xref>]. Ox-mtDNA fragments exit mitochondria via the mitochondrial permeability transition pore (mPTP) and voltage-dependent anion channels (VDAC) and can bind NLRP3, unlike unoxidized mtDNA that more readily triggers the activation of other inflammasome sensors, such as AIM2 [<xref rid="bib72" ref-type="bibr">72</xref>,<xref rid="bib122" ref-type="bibr">122</xref>,<xref rid="bib123" ref-type="bibr">123</xref>]. In agreement with these former studies, Cu-overloaded cells showed ox-mtDNA in mitochondria, accompanied by abnormal mitochondrial morphology, most likely swollen mitochondria, when Cu exposure was combined with A&#946;. Ox-mtDNA was partially released into the cytosol, as indicated by the lack of colocalization with the mitochondrial marker at some spots, examined by confocal microscopy. Furthermore, the reduction of active CASP-1 and IL-1&#946; maturation after mtDNA depletion confirmed the involvement of the mitochondrial genome in the induction of the NLRP3 inflammasome.</p><p id="p0465">Ox-mtDNA fragments can also activate the cyclic GMP-AMP synthase - stimulating interferon gene (cGAS-STING) signaling pathway [<xref rid="bib122" ref-type="bibr">122</xref>]. In this regard, mtDNA release and cGAS-STING activation have been reported in chicken hepatocytes after Cu overload under mTFA deficiency [<xref rid="bib124" ref-type="bibr">124</xref>]. Similarly, in astrocytes, leakage of mtDNA into the cytoplasm caused by Cu exposure has been shown to activate cGAS-STING signaling, which, in cooperation with NLRP3 inflammasome, leads to pyroptotic cell death [<xref rid="bib125" ref-type="bibr">125</xref>]. Recent studies indicate that STING promotes NLRP3 localization in the ER and facilitates NLRP3 deubiquitination to activate the inflammasome [<xref rid="bib126" ref-type="bibr">126</xref>]. Thus, further studies are warranted to evaluate the induction of the cGAS-STING pathway and its crosstalk with NLRP3 inflammasome as part of the Cu-mediated inflammatory responses in microglia cells.</p><p id="p0470">Our findings demonstrate that Cu exposure activates the cholesterol biosynthesis pathway and promotes cholesterol accumulation in mitochondria by increasing the expression of lipid transfer proteins, including TSPO and STARD3. In neuronal cells, we have linked these changes in cholesterol metabolism to an ER stress response triggered by A&#946; [<xref rid="bib127" ref-type="bibr">127</xref>]. Our current data also support the induction of ER stress as the mechanism behind cholesterol upregulation by Cu, highlighting mitochondrial oxidative stress as a contributing factor, consistent with the redox regulation of the ER stress response [<xref rid="bib128" ref-type="bibr">128</xref>].</p><p id="p0475">Results using the cholesterol-lowering compound HP-&#946;-CD indicate that changes in cholesterol synthesis and distribution after Cu loading play a key role in the activation of the NLRP3 inflammasome. Our earlier studies revealed that mitochondrial cholesterol enrichment in neuronal cells hampers mitochondrial GSH transport, reducing antioxidant buffering against A&#946;-induced mitochondrial ROS [<xref rid="bib46" ref-type="bibr">46</xref>]. Therefore, it is likely that elevated mitochondrial cholesterol levels in Cu-overloaded microglial cells contribute to ROS-mediated NLRP3 inflammasome activation, partly by compromising the mitochondrial antioxidant defense. Moreover, cholesterol enrichment and subsequent changes in the fluidity of the inner mitochondrial membrane have been shown to affect the efficiency of the respiratory chain, leading to increased mtROS production [<xref rid="bib129" ref-type="bibr">129</xref>]. Besides raising mitochondrial ROS, cholesterol levels in the ER and the cholesterol-associated SCAP-SREBF2 complex&#8212;serving as a scaffold for NLRP3 translocation from the ER to the Golgi&#8212;are also reported to induce inflammasome activation [<xref rid="bib130" ref-type="bibr">130</xref>,<xref rid="bib131" ref-type="bibr">131</xref>], further emphasizing the mechanistic connection between cholesterol regulation and innate immune signaling. Interestingly, in Cu-enriched cells, some of the IL-1&#946; released upon NLRP3 activation is protected within EVs. Both cholesterol depletion by HP-&#946;-CD and MitoQ treatment not only decreased IL-1&#946; release but also prevented EV encapsulation. EV-encapsulated cytokines are biologically active and more resistant to degradation [<xref rid="bib74" ref-type="bibr">74</xref>]. The packaging of IL-1&#946; within EVs triggered by Cu overload may facilitate cytokine delivery to target cells while also shielding microglia from autocrine effects.</p><p id="p0480">We have previously demonstrated that intracellular cholesterol enrichment&#8212;assessed by incubation with a soluble cholesterol complex&#8212;regulates the inflammasome pathway induced by classical stimuli, such as pathogen-associated molecules, differentially in microglia and neuronal cells [<xref rid="bib40" ref-type="bibr">40</xref>]. In SH-SY5Y neuronal cells, the activation of the NLRP3 inflammasome is linked to mitochondrial oxidative stress and leads to pyroptotic death. In contrast, inflammasome induction under high cholesterol levels in microglial cells promotes a shift toward a neuroprotective phenotype, with upregulated phagocytosis [<xref rid="bib40" ref-type="bibr">40</xref>]. Intriguingly, unlike Cu-overloaded cells, mtGSH remains unchanged when microglia are externally loaded with cholesterol [<xref rid="bib40" ref-type="bibr">40</xref>]. Borchard et al. have shown that SH-SY5Y neuronal cells with lower mtGSH levels are more susceptible to Cu damage than glia cells [<xref rid="bib107" ref-type="bibr">107</xref>]. The study suggests that mtGSH content determines mitochondrial resilience against oxidative damage induced by mitochondria-targeted insults, such as Cu, and may explain the mixed outcomes after inflammasome induction, depending on cell type and cholesterol-loading pathway.</p><p id="p0485">Consistent with a proinflammatory phenotype, microglia cells displayed a significant reduction in the phagocytic capacity following Cu exposure, linked to cholesterol-mediated downregulation of ABCA7 expression. An inverse relationship has been described between ABCA7 levels and cholesterol [<xref rid="bib87" ref-type="bibr">87</xref>,<xref rid="bib94" ref-type="bibr">94</xref>]. Intriguingly, ABCA7 levels and phagocytosis normalized in Cu-overloaded cells following treatment with antioxidants, suggesting a potential role for redox regulation, as reported for ABCA1 [<xref rid="bib132" ref-type="bibr">132</xref>]. Notably, several genetic polymorphisms leading to protein loss-of-function or decreased ABCA7 expression have been identified in samples from AD patients [<xref rid="bib133" ref-type="bibr">133</xref>]. Furthermore, consistent with the ABCA7 role in A&#946; phagocytosis, these AD risk variants are associated with increased A&#946; deposition at early disease stages [<xref rid="bib134" ref-type="bibr">134</xref>]. Interestingly, recent studies have shown that neuronal-specific ABCA7 deficiency in an AD mouse model markedly affects mitochondrial function, exacerbating A&#946; pathology and neuronal damage [<xref rid="bib135" ref-type="bibr">135</xref>]. Whether low ABCA7 levels also affect mitochondrial function in Cu-enriched microglia and how this might contribute to creating a mtROS-mediated inhibitory feedback loop of ABCA7 expression would need further investigation.</p><p id="p0490">Along with decreased ABCA7 levels, the presence of LRP1 at the plasma membrane remained low in Cu-overloaded cells, which may contribute to impairing microglia phagocytosis. Chronic administration of low doses of Cu has been shown to promote proteasomal degradation of LRP1 in endothelial cells, thereby impairing LRP1-dependent A&#946; transcytosis [<xref rid="bib81" ref-type="bibr">81</xref>,<xref rid="bib136" ref-type="bibr">136</xref>]. Moreover, LRP1 knockdown has been reported to stimulate NF-&#954;B/MAPK-mediated pro-inflammatory signaling pathways in glia cells exposed to A&#946; [<xref rid="bib137" ref-type="bibr">137</xref>]. Unlike these previous studies, we found an abnormal accumulation of LRP1, most likely C-terminal fragments, in the nuclei after Cu loading. Interestingly, nuclear LRP1 forms have been shown to facilitate the nuclear export of inflammatory transcription factors such as the interferon-regulated factor 3 (IRF3), thereby inhibiting the transcriptional activity of inflammatory genes linked to cGAS-STING signaling [<xref rid="bib90" ref-type="bibr">90</xref>]. Thus, the relocalization of LRP1 in response to Cu overload may play a dual role by regulating both A&#946; clearance and Cu-induced inflammatory signaling pathways.</p><p id="p0495">Finally, we showed that conditioned media from Cu-treated microglia cells significantly impacted neuronal viability. Notably, the neurotoxic effect was amplified in APP/PSEN1 neurons overexpressing SREBF2, underscoring the increased vulnerability of cholesterol-enriched neurons to various cellular stressors, as reported in previous studies [<xref rid="bib40" ref-type="bibr">40</xref>,<xref rid="bib46" ref-type="bibr">46</xref>]. The neurotoxicity of microglia-conditioned media was completely abolished when NLRP3 activity was selectively inhibited, thus confirming the involvement of the NLRP3 inflammasome. The detrimental effects of sustained proinflammatory cytokine release and their role in neurodegeneration have been extensively documented [<xref rid="bib138" ref-type="bibr">138</xref>]. More recently, ASC specks have been detected extracellularly and linked to the spread of inflammation [<xref rid="bib139" ref-type="bibr">139</xref>]. In AD, the release of microglia-derived ASC specks has been implicated in A&#946; seeding [<xref rid="bib140" ref-type="bibr">140</xref>] and proposed as a reliable fluid biomarker of inflammation [<xref rid="bib141" ref-type="bibr">141</xref>]. It remains to be determined whether Cu-induced microglial proinflammatory profile is accompanied by the release of ASC specks, which, together with impaired phagocytosis, may favor A&#946; deposition.</p></sec><sec id="sec5"><label>5</label><title>Conclusion</title><p id="p0500">Our findings outline the abnormal accumulation of Cu in mitochondria and subsequent mitochondrial oxidative damage as a key factor in regulating microglial behavior in response to immunogenic insults, such as A&#946;, supporting the growing evidence that chronic environmental exposure to sub-toxic Cu levels contributes to neuroinflammation and <funding-source id="gs11"><institution-wrap><institution-id institution-id-type="doi">10.13039/100020014</institution-id><institution>AD</institution></institution-wrap></funding-source> progression. From a therapeutic standpoint, the systematic analysis of the underlying mechanisms behind the inflammatory response triggered by Cu overload may open novel therapeutic interventions. In this regard, using different mouse models of acute inflammation, Solier et al. [<xref rid="bib112" ref-type="bibr">112</xref>] have shown that macrophage activation linked to excess mtCu can be mitigated by administering supformin (LCC-12), a metformin derivative that selectively binds Cu<sup>2+</sup> without affecting other divalent metals. Similar approaches aimed at normalizing mtCu levels, combined with other mitochondria-targeted drugs that prevent mitochondrial ROS and ox-mtDNA release, may be a strategy to consider for counteracting metal-driven inflammation and preserving microglial capacity in neurodegenerative diseases.</p></sec><sec id="sec6"><title>CRediT authorship contribution statement</title><p id="p0505"><bold>Marlene Zubillaga:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Methodology, Formal analysis, Data curation, Conceptualization. <bold>Xenia Abadin:</bold> Methodology, Formal analysis. <bold>Elia Ivars:</bold> Methodology, Formal analysis. <bold>Margalida Puigr&#242;s:</bold> Methodology, Formal analysis. <bold>Ramon Trullas:</bold> Writing &#8211; review &amp; editing, Resources, Methodology, Funding acquisition, Formal analysis. <bold>M. Jos&#233; Bellini:</bold> Writing &#8211; review &amp; editing. <bold>Nathalie Arnal:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Resources, Methodology, Funding acquisition, Formal analysis, Conceptualization. <bold>Anna Colell:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Resources, Methodology, Funding acquisition, Formal analysis, Data curation, Conceptualization.</p></sec><sec id="sec7"><title>Funding sources</title><p id="p0510">This work was funded by the <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004837</institution-id><institution>MCIN</institution></institution-wrap></funding-source>/AEI/<award-id award-type="grant" rid="gs3">10.13039</award-id>/501100011033, co-funded by <funding-source id="gs4">NextGenerationEU/PRTR</funding-source>, and by &#8220;ERDF A way of making Europe&#8221;, grants <award-id award-type="grant" rid="gs4">PID2022-143279OB-100</award-id> (A.C.), PID2023-153168OB-100 (R.T.) and RED2024-154130-T (A.C. and R.T.); by the Instituto de Salud Carlos III (ISCIII) and European Union NextGenerationEU/PRTR, grants PMP22/00100 (R&#160;T. and A.C.); by the CSIC, grant COOPA20476 (A&#160;C. and N.A.), by the <funding-source id="gs5"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100003030</institution-id><institution>AGAUR</institution></institution-wrap></funding-source>, Generalitat de Catalunya, grant <award-id award-type="grant" rid="gs5">2021-SGR00490</award-id> (A.C.)</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of competing interest</title><p id="p0515">None.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Tsang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Brady</surname><given-names>D.C.</given-names></name></person-group><article-title>Copper biology</article-title><source>Curr. Biol.</source><volume>31</volume><year>2021</year><fpage>R421</fpage><lpage>R427</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2021.03.054</pub-id><pub-id pub-id-type="pmid">33974864</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Cherny</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Atwood</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Xilinas</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>McLean</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Barnham</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Volitakis</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>F.W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Moir</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Beyreuther</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tanzi</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Masters</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Bush</surname><given-names>A.I.</given-names></name></person-group><article-title>Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice</article-title><source>Neuron</source><volume>30</volume><year>2001</year><fpage>665</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1016/s0896-6273(01)00317-8</pub-id><pub-id pub-id-type="pmid">11430801</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Gromadzka</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tarnacka</surname><given-names>B.</given-names></name><name name-style="western"><surname>Flaga</surname><given-names>A.</given-names></name><name name-style="western"><surname>Adamczyk</surname><given-names>A.</given-names></name></person-group><article-title>Copper dyshomeostasis in neurodegenerative diseases-therapeutic implications</article-title><source>Int. J. Mol. Sci.</source><volume>21</volume><year>2020</year><fpage>9259</fpage><pub-id pub-id-type="doi">10.3390/ijms21239259</pub-id><pub-id pub-id-type="pmid">33291628</pub-id><pub-id pub-id-type="pmcid">PMC7730516</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Cz&#322;onkowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Litwin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dusek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ferenci</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lutsenko</surname><given-names>S.</given-names></name><name name-style="western"><surname>Medici</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rybakowski</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Schilsky</surname><given-names>M.L.</given-names></name></person-group><article-title>Wilson disease</article-title><source>Nat. Rev. Dis. Primers</source><volume>4</volume><year>2018</year><fpage>21</fpage><pub-id pub-id-type="doi">10.1038/s41572-018-0018-3</pub-id><pub-id pub-id-type="pmid">30190489</pub-id><pub-id pub-id-type="pmcid">PMC6416051</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>T&#252;mer</surname><given-names>Z.</given-names></name><name name-style="western"><surname>M&#248;ller</surname><given-names>L.B.</given-names></name></person-group><article-title>Menkes disease</article-title><source>Eur. J. Hum. Genet.</source><volume>18</volume><year>2010</year><fpage>511</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2009.187</pub-id><pub-id pub-id-type="pmid">19888294</pub-id><pub-id pub-id-type="pmcid">PMC2987322</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lopez-Roldan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cortina</surname><given-names>J.-L.</given-names></name></person-group><article-title>Presence of metals in drinking water distribution networks due to pipe material leaching: a review</article-title><source>Toxicol. Environ. Chem.</source><volume>95</volume><year>2013</year><fpage>870</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1080/02772248.2013.840372</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Mursu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Robien</surname><given-names>K.</given-names></name><name name-style="western"><surname>Harnack</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>D.R.</given-names></name></person-group><article-title>Dietary supplements and mortality rate in older women: the Iowa Women's Health Study</article-title><source>Arch. Intern. Med.</source><volume>171</volume><year>2011</year><fpage>1625</fpage><lpage>1633</lpage><pub-id pub-id-type="doi">10.1001/archinternmed.2011.445</pub-id><pub-id pub-id-type="pmid">21987192</pub-id><pub-id pub-id-type="pmcid">PMC4114071</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Brewer</surname><given-names>G.J.</given-names></name></person-group><article-title>Copper-2 Hypothesis for causation of the Current alzheimer's disease epidemic together with dietary changes that enhance the epidemic</article-title><source>Chem. Res. Toxicol.</source><volume>30</volume><year>2017</year><fpage>763</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrestox.6b00373</pub-id><pub-id pub-id-type="pmid">28161940</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Finney</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>O'Halloran</surname><given-names>T.V.</given-names></name></person-group><article-title>Transition metal speciation in the cell: insights from the chemistry of metal ion receptors</article-title><source>Science</source><volume>300</volume><year>2003</year><fpage>931</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1126/science.1085049</pub-id><pub-id pub-id-type="pmid">12738850</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Rae</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Pufahl</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Culotta</surname><given-names>V.C.</given-names></name><name name-style="western"><surname>O'Halloran</surname><given-names>T.V.</given-names></name></person-group><article-title>Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase</article-title><source>Science</source><volume>284</volume><year>1999</year><fpage>805</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1126/science.284.5415.805</pub-id><pub-id pub-id-type="pmid">10221913</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Bremner</surname><given-names>I.</given-names></name></person-group><article-title>Manifestations of copper excess</article-title><source>Am. J. Clin. Nutr.</source><volume>67</volume><year>1998</year><fpage>1069S</fpage><lpage>1073S</lpage><pub-id pub-id-type="doi">10.1093/ajcn/67.5.1069S</pub-id><pub-id pub-id-type="pmid">9587154</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Aliaga</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>L&#243;pez-Alarc&#243;n</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bridi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Speisky</surname><given-names>H.</given-names></name></person-group><article-title>Redox-implications associated with the formation of complexes between copper ions and reduced or oxidized glutathione</article-title><source>J. Inorg. Biochem.</source><volume>154</volume><year>2016</year><fpage>78</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2015.08.005</pub-id><pub-id pub-id-type="pmid">26277412</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Arnal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Astiz</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Alaniz</surname><given-names>M.J.T.</given-names></name><name name-style="western"><surname>Marra</surname><given-names>C.A.</given-names></name></person-group><article-title>Clinical parameters and biomarkers of oxidative stress in agricultural workers who applied copper-based pesticides</article-title><source>Ecotoxicol. Environ. Saf.</source><volume>74</volume><year>2011</year><fpage>1779</fpage><lpage>1786</lpage><pub-id pub-id-type="doi">10.1016/j.ecoenv.2011.05.018</pub-id><pub-id pub-id-type="pmid">21700338</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Arnal</surname><given-names>N.</given-names></name><name name-style="western"><surname>de Alaniz</surname><given-names>M.J.T.</given-names></name><name name-style="western"><surname>Marra</surname><given-names>C.A.</given-names></name></person-group><article-title>Alterations in copper homeostasis and oxidative stress biomarkers in women using the intrauterine device TCu380A</article-title><source>Toxicol. Lett.</source><volume>192</volume><year>2010</year><fpage>373</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2009.11.012</pub-id><pub-id pub-id-type="pmid">19931365</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Squitti</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ghidoni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Scrascia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Benussi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Panetta</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pasqualetti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moffa</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bernardini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ventriglia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Binetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rossini</surname><given-names>P.M.</given-names></name></person-group><article-title>Free copper distinguishes mild cognitive impairment subjects from healthy elderly individuals</article-title><source>J Alzheimers Dis</source><volume>23</volume><year>2011</year><fpage>239</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.3233/JAD-2010-101098</pub-id><pub-id pub-id-type="pmid">20930297</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Arnal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cristalli</surname><given-names>D.O.</given-names></name><name name-style="western"><surname>de Alaniz</surname><given-names>M.J.T.</given-names></name><name name-style="western"><surname>Marra</surname><given-names>C.A.</given-names></name></person-group><article-title>Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives</article-title><source>Brain Res.</source><volume>1319</volume><year>2010</year><fpage>118</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2009.11.085</pub-id><pub-id pub-id-type="pmid">20026314</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Church</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Patassini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Begley</surname><given-names>P.</given-names></name><name name-style="western"><surname>Waldvogel</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Faull</surname><given-names>R.L.M.</given-names></name><name name-style="western"><surname>Unwin</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>G.J.S.</given-names></name></person-group><article-title>Evidence for widespread, severe brain copper deficiency in Alzheimer's dementia</article-title><source>Metallomics</source><volume>9</volume><year>2017</year><fpage>1106</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1039/c7mt00074j</pub-id><pub-id pub-id-type="pmid">28654115</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>James</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Volitakis</surname><given-names>I.</given-names></name><name name-style="western"><surname>Adlard</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Duce</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Masters</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Cherny</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Bush</surname><given-names>A.I.</given-names></name></person-group><article-title>Elevated labile Cu is associated with oxidative pathology in Alzheimer disease</article-title><source>Free Radic. Biol. Med.</source><volume>52</volume><year>2012</year><fpage>298</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2011.10.446</pub-id><pub-id pub-id-type="pmid">22080049</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Telivala</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Lanzirotti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miklossy</surname><given-names>J.</given-names></name></person-group><article-title>Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease</article-title><source>J. Struct. Biol.</source><volume>155</volume><year>2006</year><fpage>30</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.jsb.2005.09.004</pub-id><pub-id pub-id-type="pmid">16325427</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Sayre</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>G.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Schubert</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M.A.</given-names></name></person-group><article-title>In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals</article-title><source>J. Neurochem.</source><volume>74</volume><year>2000</year><fpage>270</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2000.0740270.x</pub-id><pub-id pub-id-type="pmid">10617129</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Sparks</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Schreurs</surname><given-names>B.G.</given-names></name></person-group><article-title>Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>100</volume><year>2003</year><fpage>11065</fpage><lpage>11069</lpage><pub-id pub-id-type="doi">10.1073/pnas.1832769100</pub-id><pub-id pub-id-type="pmid">12920183</pub-id><pub-id pub-id-type="pmcid">PMC196927</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Voss</surname><given-names>K.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ralle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Murchison</surname><given-names>C.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>J.F.</given-names></name></person-group><article-title>Modulation of tau phosphorylation by environmental copper</article-title><source>Transl. Neurodegener.</source><volume>3</volume><year>2014</year><fpage>24</fpage><pub-id pub-id-type="doi">10.1186/2047-9158-3-24</pub-id><pub-id pub-id-type="pmid">25671100</pub-id><pub-id pub-id-type="pmcid">PMC4322670</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Tangney</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Bienias</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Scherr</surname><given-names>P.A.</given-names></name></person-group><article-title>Dietary copper and high saturated and trans fat intakes associated with cognitive decline</article-title><source>Arch. Neurol.</source><volume>63</volume><year>2006</year><fpage>1085</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1001/archneur.63.8.1085</pub-id><pub-id pub-id-type="pmid">16908733</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Noda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Asada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kubota</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maesako</surname><given-names>M.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Uemura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kihara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shimohama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kinoshita</surname><given-names>A.</given-names></name><name name-style="western"><surname>Uemura</surname><given-names>K.</given-names></name></person-group><article-title>Copper enhances APP dimerization and promotes A&#946; production</article-title><source>Neurosci. Lett.</source><volume>547</volume><year>2013</year><fpage>10</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2013.04.057</pub-id><pub-id pub-id-type="pmid">23669644</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Role of copper and the copper-related protein CUTA in mediating APP processing and A&#946; generation</article-title><source>Neurobiol. Aging</source><volume>36</volume><year>2015</year><fpage>1310</fpage><lpage>1315</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.12.005</pub-id><pub-id pub-id-type="pmid">25557959</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Sarell</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Viles</surname><given-names>J.H.</given-names></name></person-group><article-title>Substoichiometric levels of Cu2+ ions accelerate the kinetics of fiber formation and promote cell toxicity of amyloid-{beta} from Alzheimer disease</article-title><source>J. Biol. Chem.</source><volume>285</volume><year>2010</year><fpage>41533</fpage><lpage>41540</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.171355</pub-id><pub-id pub-id-type="pmid">20974842</pub-id><pub-id pub-id-type="pmcid">PMC3009880</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.-L.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>M.-L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T.-T.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>R.-F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N.-N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.-D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.-Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P.</given-names></name></person-group><article-title>Copper chelators promote nonamyloidogenic processing of A&#946;PP via MT1/2/CREB-dependent signaling pathways in A&#946;PP/PS1 transgenic mice</article-title><source>J. Pineal Res.</source><volume>65</volume><year>2018</year><object-id pub-id-type="publisher-id">e12502</object-id><pub-id pub-id-type="doi">10.1111/jpi.12502</pub-id><pub-id pub-id-type="pmid">29710396</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name></person-group><article-title>The dysregulation of inflammatory pathways triggered by copper exposure</article-title><source>Biol. Trace Elem. Res.</source><volume>201</volume><year>2023</year><fpage>539</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1007/s12011-022-03171-0</pub-id><pub-id pub-id-type="pmid">35312958</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Leng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hinz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gentleman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hampshire</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Edison</surname><given-names>P.</given-names></name></person-group><article-title>Neuroinflammation is independently associated with brain network dysfunction in Alzheimer's disease</article-title><source>Mol. Psychiatr.</source><volume>28</volume><year>2023</year><fpage>1303</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1038/s41380-022-01878-z</pub-id><pub-id pub-id-type="pmcid">PMC10005956</pub-id><pub-id pub-id-type="pmid">36474000</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Rodriguez-Ortiz</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>H.-W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zumkehr</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kilian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vidal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ayata</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kitazawa</surname><given-names>M.</given-names></name></person-group><article-title>Chronic copper exposure directs microglia towards degenerative expression signatures in wild-type and J20 mouse model of Alzheimer's disease</article-title><source>J. Trace Elem. Med. Biol.</source><volume>62</volume><year>2020</year><object-id pub-id-type="publisher-id">126578</object-id><pub-id pub-id-type="doi">10.1016/j.jtemb.2020.126578</pub-id><pub-id pub-id-type="pmcid">PMC7655674</pub-id><pub-id pub-id-type="pmid">32599538</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>Cu(II) enhances the effect of Alzheimer's amyloid-&#946; peptide on microglial activation</article-title><source>J. Neuroinflammation</source><volume>12</volume><year>2015</year><fpage>122</fpage><pub-id pub-id-type="doi">10.1186/s12974-015-0343-3</pub-id><pub-id pub-id-type="pmid">26104799</pub-id><pub-id pub-id-type="pmcid">PMC4490619</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Behzadfar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Abdollahi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sabzevari</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Salimi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Naserzadeh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sharifzadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pourahmad</surname><given-names>J.</given-names></name></person-group><article-title>Potentiating role of copper on spatial memory deficit induced by beta amyloid and evaluation of mitochondrial function markers in the hippocampus of rats</article-title><source>Metallomics</source><volume>9</volume><year>2017</year><fpage>969</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1039/c7mt00075h</pub-id><pub-id pub-id-type="pmid">28644490</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name></person-group><article-title>Subneurotoxic copper(II)-induced NF-&#954;B-dependent microglial activation is associated with mitochondrial ROS</article-title><source>Toxicol. Appl. Pharmacol.</source><volume>276</volume><year>2014</year><fpage>95</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.taap.2014.01.020</pub-id><pub-id pub-id-type="pmid">24530511</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Deets</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Vance</surname><given-names>R.E.</given-names></name></person-group><article-title>Inflammasomes and adaptive immune responses</article-title><source>Nat. Immunol.</source><volume>22</volume><year>2021</year><fpage>412</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-00869-6</pub-id><pub-id pub-id-type="pmid">33603227</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Heneka</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Kummer</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Stutz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Delekate</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vieira-Saecker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Griep</surname><given-names>A.</given-names></name><name name-style="western"><surname>Axt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Remus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tzeng</surname><given-names>T.-C.</given-names></name><name name-style="western"><surname>Gelpi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Halle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Korte</surname><given-names>M.</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Golenbock</surname><given-names>D.T.</given-names></name></person-group><article-title>NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice</article-title><source>Nature</source><volume>493</volume><year>2013</year><fpage>674</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1038/nature11729</pub-id><pub-id pub-id-type="pmid">23254930</pub-id><pub-id pub-id-type="pmcid">PMC3812809</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Halle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hornung</surname><given-names>V.</given-names></name><name name-style="western"><surname>Petzold</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Monks</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Reinheckel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Golenbock</surname><given-names>D.T.</given-names></name></person-group><article-title>The NALP3 inflammasome is involved in the innate immune response to amyloid-beta</article-title><source>Nat. Immunol.</source><volume>9</volume><year>2008</year><fpage>857</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1038/ni.1636</pub-id><pub-id pub-id-type="pmid">18604209</pub-id><pub-id pub-id-type="pmcid">PMC3101478</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Vontell</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>de Rivero Vaccari</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gultekin</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Bramlett</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Keane</surname><given-names>R.W.</given-names></name></person-group><article-title>Identification of inflammasome signaling proteins in neurons and microglia in early and intermediate stages of Alzheimer's disease</article-title><source>Brain Pathol.</source><volume>33</volume><year>2023</year><object-id pub-id-type="publisher-id">e13142</object-id><pub-id pub-id-type="doi">10.1111/bpa.13142</pub-id><pub-id pub-id-type="pmcid">PMC10307529</pub-id><pub-id pub-id-type="pmid">36579934</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Terada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Obi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bunai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsudaira</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yoshikawa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ando</surname><given-names>I.</given-names></name><name name-style="western"><surname>Futatsubashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsukada</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ouchi</surname><given-names>Y.</given-names></name></person-group><article-title>In vivo mitochondrial and glycolytic impairments in patients with Alzheimer disease</article-title><source>Neurol.</source><volume>94</volume><year>2020</year><fpage>e1592</fpage><lpage>e1604</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000009249</pub-id><pub-id pub-id-type="pmid">32139504</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yazdi</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Menu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tschopp</surname><given-names>J.</given-names></name></person-group><article-title>A role for mitochondria in NLRP3 inflammasome activation</article-title><source>Nature</source><volume>469</volume><year>2011</year><fpage>221</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1038/nature09663</pub-id><pub-id pub-id-type="pmid">21124315</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>de Dios</surname><given-names>C.</given-names></name><name name-style="western"><surname>Abadin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Roca-Agujetas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Jimenez-Martinez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morales</surname><given-names>A.</given-names></name><name name-style="western"><surname>Trullas</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Colell</surname><given-names>A.</given-names></name></person-group><article-title>Inflammasome activation under high cholesterol load triggers a protective microglial phenotype while promoting neuronal pyroptosis</article-title><source>Transl. Neurodegener.</source><volume>12</volume><year>2023</year><fpage>10</fpage><pub-id pub-id-type="doi">10.1186/s40035-023-00343-3</pub-id><pub-id pub-id-type="pmid">36895045</pub-id><pub-id pub-id-type="pmcid">PMC9996936</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Deigendesch</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zychlinsky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meissner</surname><given-names>F.</given-names></name></person-group><article-title>Copper regulates the canonical NLRP3 inflammasome</article-title><source>J. Immunol.</source><volume>200</volume><year>2018</year><fpage>1607</fpage><lpage>1617</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1700712</pub-id><pub-id pub-id-type="pmid">29358279</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>N.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name></person-group><article-title>Inhibiting NLRP3 inflammasome activation prevents copper-induced neuropathology in a murine model of Wilson's disease</article-title><source>Cell Death Dis.</source><volume>12</volume><year>2021</year><fpage>87</fpage><pub-id pub-id-type="doi">10.1038/s41419-021-03397-1</pub-id><pub-id pub-id-type="pmid">33462188</pub-id><pub-id pub-id-type="pmcid">PMC7813851</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Horton</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Shimomura</surname><given-names>I.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Hammer</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Shimano</surname><given-names>H.</given-names></name></person-group><article-title>Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2</article-title><source>J. Clin. Investig.</source><volume>101</volume><year>1998</year><fpage>2331</fpage><lpage>2339</lpage><pub-id pub-id-type="doi">10.1172/JCI2961</pub-id><pub-id pub-id-type="pmid">9616204</pub-id><pub-id pub-id-type="pmcid">PMC508822</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Jankowsky</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Fadale</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Gonzales</surname><given-names>V.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Copeland</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Younkin</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Younkin</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Borchelt</surname><given-names>D.R.</given-names></name></person-group><article-title>Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase</article-title><source>Hum. Mol. Genet.</source><volume>13</volume><year>2004</year><fpage>159</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddh019</pub-id><pub-id pub-id-type="pmid">14645205</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Kaech</surname><given-names>S.</given-names></name><name name-style="western"><surname>Banker</surname><given-names>G.</given-names></name></person-group><article-title>Culturing hippocampal neurons</article-title><source>Nat. Protoc.</source><volume>1</volume><year>2006</year><fpage>2406</fpage><lpage>2415</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.356</pub-id><pub-id pub-id-type="pmid">17406484</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Llacuna</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Checa</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Colell</surname><given-names>A.</given-names></name></person-group><article-title>Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity</article-title><source>J. Neurosci.</source><volume>29</volume><year>2009</year><fpage>6394</fpage><lpage>6405</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4909-08.2009</pub-id><pub-id pub-id-type="pmid">19458211</pub-id><pub-id pub-id-type="pmcid">PMC2740839</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Stine</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Dahlgren</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Krafft</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>LaDu</surname><given-names>M.J.</given-names></name></person-group><article-title>In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis</article-title><source>J. Biol. Chem.</source><volume>278</volume><year>2003</year><fpage>11612</fpage><lpage>11622</lpage><pub-id pub-id-type="doi">10.1074/jbc.M210207200</pub-id><pub-id pub-id-type="pmid">12499373</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Rayner</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K.T.</given-names></name></person-group><article-title>A simple and effective method for the removal of trace metal cations from a mammalian culture medium supplemented with 10% fetal calf serum</article-title><source>Biometals</source><volume>8</volume><year>1995</year><fpage>188</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1007/BF00143374</pub-id><pub-id pub-id-type="pmid">7647515</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Dixit</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vanhoozer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Anti</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>O'Connor</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Boominathan</surname><given-names>A.</given-names></name></person-group><article-title>Rapid enrichment of mitochondria from mammalian cell cultures using digitonin</article-title><source>MethodsX</source><volume>8</volume><year>2021</year><object-id pub-id-type="publisher-id">101197</object-id><pub-id pub-id-type="doi">10.1016/j.mex.2020.101197</pub-id><pub-id pub-id-type="pmcid">PMC8374178</pub-id><pub-id pub-id-type="pmid">34434723</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez-Checa</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Ookhtens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kaplowitz</surname><given-names>N.</given-names></name></person-group><article-title>Effect of chronic ethanol feeding on rat hepatocytic glutathione. Compartmentation, efflux, and response to incubation with ethanol</article-title><source>J. Clin. Investig.</source><volume>80</volume><year>1987</year><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1172/JCI113063</pub-id><pub-id pub-id-type="pmid">2885343</pub-id><pub-id pub-id-type="pmcid">PMC442201</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Kwiatkowska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Marsza&#322;ek-Sadowska</surname><given-names>E.</given-names></name><name name-style="western"><surname>Traczyk</surname><given-names>G.</given-names></name><name name-style="western"><surname>Koprowski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Musielak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lugowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kulma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grzelczyk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sobota</surname><given-names>A.</given-names></name></person-group><article-title>Visualization of cholesterol deposits in lysosomes of Niemann-Pick type C fibroblasts using recombinant perfringolysin O</article-title><source>Orphanet J. Rare Dis.</source><volume>9</volume><year>2014</year><fpage>64</fpage><pub-id pub-id-type="doi">10.1186/1750-1172-9-64</pub-id><pub-id pub-id-type="pmid">24775609</pub-id><pub-id pub-id-type="pmcid">PMC4005833</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Roca-Agujetas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Barbero-Camps</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Dios</surname><given-names>C.</given-names></name><name name-style="western"><surname>Podlesniy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Abadin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Morales</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mar&#237;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Trull&#224;s</surname><given-names>R.</given-names></name><name name-style="western"><surname>Colell</surname><given-names>A.</given-names></name></person-group><article-title>Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimer's disease</article-title><source>Mol. Neurodegener.</source><volume>16</volume><year>2021</year><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/s13024-021-00435-6</pub-id><pub-id pub-id-type="pmid">33685483</pub-id><pub-id pub-id-type="pmcid">PMC7941983</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>de Almeida</surname><given-names>L.</given-names></name><name name-style="western"><surname>Khare</surname><given-names>S.</given-names></name><name name-style="western"><surname>Misharin</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ratsimandresy</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Wallin</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Greaves</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Dorfleutner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stehlik</surname><given-names>C.</given-names></name></person-group><article-title>The PYRIN Domain-only Protein POP1 inhibits inflammasome assembly and ameliorates inflammatory disease</article-title><source>Immunity</source><volume>43</volume><year>2015</year><fpage>264</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.07.018</pub-id><pub-id pub-id-type="pmid">26275995</pub-id><pub-id pub-id-type="pmcid">PMC4666005</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Schindelin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arganda-Carreras</surname><given-names>I.</given-names></name><name name-style="western"><surname>Frise</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kaynig</surname><given-names>V.</given-names></name><name name-style="western"><surname>Longair</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pietzsch</surname><given-names>T.</given-names></name><name name-style="western"><surname>Preibisch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rueden</surname><given-names>C.</given-names></name><name name-style="western"><surname>Saalfeld</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tinevez</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>White</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Hartenstein</surname><given-names>V.</given-names></name><name name-style="western"><surname>Eliceiri</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tomancak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cardona</surname><given-names>A.</given-names></name></person-group><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nat. Methods</source><volume>9</volume><year>2012</year><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id><pub-id pub-id-type="pmcid">PMC3855844</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Podlesniy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Trullas</surname><given-names>R.</given-names></name></person-group><article-title>Absolute measurement of gene transcripts with Selfie-digital PCR</article-title><source>Sci. Rep.</source><volume>7</volume><year>2017</year><fpage>8328</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-08270-w</pub-id><pub-id pub-id-type="pmid">28827685</pub-id><pub-id pub-id-type="pmcid">PMC5566441</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Puigr&#242;s</surname><given-names>M.</given-names></name><name name-style="western"><surname>Calderon</surname><given-names>A.</given-names></name><name name-style="western"><surname>P&#233;rez-Soriano</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Dios</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Colell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mart&#237;</surname><given-names>M.-J.</given-names></name><name name-style="western"><surname>Tolosa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Trullas</surname><given-names>R.</given-names></name></person-group><article-title>Cell-free mitochondrial DNA deletions in idiopathic, but not LRRK2, Parkinson's disease</article-title><source>Neurobiol. Dis.</source><volume>174</volume><year>2022</year><object-id pub-id-type="publisher-id">105885</object-id><pub-id pub-id-type="doi">10.1016/j.nbd.2022.105885</pub-id><pub-id pub-id-type="pmid">36208866</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Parfenov</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gorham</surname><given-names>J.M.</given-names></name></person-group><article-title>Droplet digital PCR with EvaGreen assay: confirmational analysis of structural variants</article-title><source>Curr Protoc Hum Genet</source><volume>97</volume><year>2018</year><fpage>e58</fpage><pub-id pub-id-type="doi">10.1002/cphg.58</pub-id><pub-id pub-id-type="pmid">30040209</pub-id><pub-id pub-id-type="pmcid">PMC7001142</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Nagamoto-Combs</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kulas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Combs</surname><given-names>C.K.</given-names></name></person-group><article-title>A novel cell line from spontaneously immortalized murine microglia</article-title><source>J. Neurosci. Methods</source><volume>233</volume><year>2014</year><fpage>187</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.jneumeth.2014.05.021</pub-id><pub-id pub-id-type="pmid">24975292</pub-id><pub-id pub-id-type="pmcid">PMC4140094</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Boulet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vest</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Maynard</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Gammon</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Mathews</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Kwong</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>Dodani</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Leary</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Cobine</surname><given-names>P.A.</given-names></name></person-group><article-title>The mammalian phosphate carrier SLC25A3 is a mitochondrial copper transporter required for cytochrome c oxidase biogenesis</article-title><source>J. Biol. Chem.</source><volume>293</volume><year>2018</year><fpage>1887</fpage><lpage>1896</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA117.000265</pub-id><pub-id pub-id-type="pmid">29237729</pub-id><pub-id pub-id-type="pmcid">PMC5808751</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Mar&#237;</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Gregorio</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Dios</surname><given-names>C.</given-names></name><name name-style="western"><surname>Roca-Agujetas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cucarull</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tutusaus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Morales</surname><given-names>A.</given-names></name><name name-style="western"><surname>Colell</surname><given-names>A.</given-names></name></person-group><article-title>Mitochondrial glutathione: recent insights and role in disease</article-title><source>Antioxidants</source><volume>9</volume><year>2020</year><fpage>909</fpage><pub-id pub-id-type="doi">10.3390/antiox9100909</pub-id><pub-id pub-id-type="pmid">32987701</pub-id><pub-id pub-id-type="pmcid">PMC7598719</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Ni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>G.-C.</given-names></name><name name-style="western"><surname>Lacefield</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Le Tissier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>T.</given-names></name></person-group><article-title>Therapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces diabetic cardiomyopathy</article-title><source>Free Radic. Biol. Med.</source><volume>90</volume><year>2016</year><fpage>12</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.11.013</pub-id><pub-id pub-id-type="pmid">26577173</pub-id><pub-id pub-id-type="pmcid">PMC5066872</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R.A.J.</given-names></name></person-group><article-title>Targeting antioxidants to mitochondria by conjugation to lipophilic cations</article-title><source>Annu. Rev. Pharmacol. Toxicol.</source><volume>47</volume><year>2007</year><fpage>629</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.47.120505.105110</pub-id><pub-id pub-id-type="pmid">17014364</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Wardman</surname><given-names>P.</given-names></name></person-group><article-title>Fluorescent and luminescent probes for measurement of oxidative and nitrosative species in cells and tissues: progress, pitfalls, and prospects</article-title><source>Free Radic. Biol. Med.</source><volume>43</volume><year>2007</year><fpage>995</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2007.06.026</pub-id><pub-id pub-id-type="pmid">17761297</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez</surname><given-names>T.</given-names></name><name name-style="western"><surname>Peiretti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Defoort</surname><given-names>C.</given-names></name><name name-style="western"><surname>Borel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Govers</surname><given-names>R.</given-names></name></person-group><article-title>2&#8217;,7&#8217;-dichlorofluorescin-based analysis of Fenton chemistry reveals auto-amplification of probe fluorescence and albumin as catalyst for the detection of hydrogen peroxide</article-title><source>Biochem. J.</source><year>2020</year><pub-id pub-id-type="doi">10.1042/BCJ20200602</pub-id><comment>BCJ20200602</comment><pub-id pub-id-type="pmid">33216850</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Gardner</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>White</surname><given-names>C.W.</given-names></name></person-group><article-title>Aconitase is a sensitive and critical target of oxygen poisoning in cultured mammalian cells and in rat lungs</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>91</volume><year>1994</year><fpage>12248</fpage><lpage>12252</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.25.12248</pub-id><pub-id pub-id-type="pmid">7991614</pub-id><pub-id pub-id-type="pmcid">PMC45414</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Macomber</surname><given-names>L.</given-names></name><name name-style="western"><surname>Imlay</surname><given-names>J.A.</given-names></name></person-group><article-title>The iron-sulfur clusters of dehydratases are primary intracellular targets of copper toxicity</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>106</volume><year>2009</year><fpage>8344</fpage><lpage>8349</lpage><pub-id pub-id-type="doi">10.1073/pnas.0812808106</pub-id><pub-id pub-id-type="pmid">19416816</pub-id><pub-id pub-id-type="pmcid">PMC2688863</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Long</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.-W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name></person-group><article-title>The mitophagy pathway and its implications in human diseases</article-title><source>Signal Transduct. Targeted Ther.</source><volume>8</volume><year>2023</year><fpage>304</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01503-7</pub-id><pub-id pub-id-type="pmcid">PMC10427715</pub-id><pub-id pub-id-type="pmid">37582956</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Iwashita</surname><given-names>H.</given-names></name><name name-style="western"><surname>Torii</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nagahora</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ishiyama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shioji</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sasamoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okuma</surname><given-names>K.</given-names></name></person-group><article-title>Live cell imaging of mitochondrial autophagy with a novel fluorescent small molecule</article-title><source>ACS Chem. Biol.</source><volume>12</volume><year>2017</year><fpage>2546</fpage><lpage>2551</lpage><pub-id pub-id-type="doi">10.1021/acschembio.7b00647</pub-id><pub-id pub-id-type="pmid">28925688</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Gustafsson</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Falkenberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>N.-G.</given-names></name></person-group><article-title>Maintenance and expression of Mammalian mitochondrial DNA</article-title><source>Annu. Rev. Biochem.</source><volume>85</volume><year>2016</year><fpage>133</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060815-014402</pub-id><pub-id pub-id-type="pmid">27023847</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Al&#225;n</surname><given-names>L.</given-names></name><name name-style="western"><surname>&#352;pa&#269;ek</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pajuelo Reguera</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jab&#367;rek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Je&#382;ek</surname><given-names>P.</given-names></name></person-group><article-title>Mitochondrial nucleoid clusters protect newly synthesized mtDNA during Doxorubicin- and Ethidium Bromide-induced mitochondrial stress</article-title><source>Toxicol. Appl. Pharmacol.</source><volume>302</volume><year>2016</year><fpage>31</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.taap.2016.04.011</pub-id><pub-id pub-id-type="pmid">27102948</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>De Virgilio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pousis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gadaleta</surname><given-names>G.</given-names></name></person-group><article-title>New isoforms of human mitochondrial transcription factor A detected in normal and tumoral cells</article-title><source>Mitochondrion</source><volume>11</volume><year>2011</year><fpage>287</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.mito.2010.10.009</pub-id><pub-id pub-id-type="pmid">21081181</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sanchez-Lopez</surname><given-names>E.</given-names></name><name name-style="western"><surname>He</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shalapour</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.-J.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>S.</given-names></name><name name-style="western"><surname>Seki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schnabl</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hevener</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Kisseleva</surname><given-names>T.</given-names></name><name name-style="western"><surname>Karin</surname><given-names>M.</given-names></name></person-group><article-title>New mitochondrial DNA synthesis enables NLRP3 inflammasome activation</article-title><source>Nature</source><volume>560</volume><year>2018</year><fpage>198</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0372-z</pub-id><pub-id pub-id-type="pmid">30046112</pub-id><pub-id pub-id-type="pmcid">PMC6329306</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Iyer</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Janczy</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Olivier</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Sadler</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Knepper-Adrian</surname><given-names>V.</given-names></name><name name-style="western"><surname>Han</surname><given-names>R.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Eisenbarth</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Nauseef</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Cassel</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Sutterwala</surname><given-names>F.S.</given-names></name></person-group><article-title>Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation</article-title><source>Immunity</source><volume>39</volume><year>2013</year><fpage>311</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.08.001</pub-id><pub-id pub-id-type="pmid">23954133</pub-id><pub-id pub-id-type="pmcid">PMC3779285</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Fitzgerald</surname><given-names>W.</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Lederman</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Vasilieva</surname><given-names>E.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>R.</given-names></name><name name-style="western"><surname>Margolis</surname><given-names>L.</given-names></name></person-group><article-title>A System of cytokines encapsulated in ExtraCellular vesicles</article-title><source>Sci. Rep.</source><volume>8</volume><year>2018</year><fpage>8973</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-27190-x</pub-id><pub-id pub-id-type="pmid">29895824</pub-id><pub-id pub-id-type="pmcid">PMC5997670</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>MacKenzie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Kiss-Toth</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dower</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>North</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Surprenant</surname><given-names>A.</given-names></name></person-group><article-title>Rapid secretion of interleukin-1beta by microvesicle shedding</article-title><source>Immunity</source><volume>15</volume><year>2001</year><fpage>825</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(01)00229-1</pub-id><pub-id pub-id-type="pmid">11728343</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Saller</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>W&#246;hrle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dufossez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ingerl</surname><given-names>I.L.</given-names></name><name name-style="western"><surname>Kessler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mateo-Tortola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gorka</surname><given-names>O.</given-names></name><name name-style="western"><surname>Lange</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Neuwirt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Marada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koentges</surname><given-names>C.</given-names></name><name name-style="western"><surname>Urban</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aktories</surname><given-names>P.</given-names></name><name name-style="western"><surname>Reuther</surname><given-names>P.</given-names></name><name name-style="western"><surname>Giese</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kirschnek</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pilic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Falquez-Medina</surname><given-names>H.</given-names></name><name name-style="western"><surname>Oelgeklaus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Deepagan</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Shojaee</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Crois</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ciminski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Peyronnet</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brandenburg</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Baumeister</surname><given-names>R.</given-names></name><name name-style="western"><surname>Heimbucher</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rizzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Riedel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Helmst&#228;dter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Buescher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Misgeld</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kerschensteiner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walentek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kreutz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Maurer</surname><given-names>U.</given-names></name><name name-style="western"><surname>Rambold</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Vince</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Edlich</surname><given-names>F.</given-names></name><name name-style="western"><surname>Malli</surname><given-names>R.</given-names></name><name name-style="western"><surname>H&#228;cker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kierdorf</surname><given-names>K.</given-names></name><name name-style="western"><surname>Meisinger</surname><given-names>C.</given-names></name><name name-style="western"><surname>K&#246;ttgen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jakobs</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>A.N.R.</given-names></name><name name-style="western"><surname>Schwemmle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gro&#223;</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Gro&#223;</surname><given-names>O.</given-names></name></person-group><article-title>Acute suppression of mitochondrial ATP production prevents apoptosis and provides an essential signal for NLRP3 inflammasome activation</article-title><source>Immunity</source><volume>58</volume><year>2025</year><fpage>90</fpage><lpage>107.e11</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2024.10.012</pub-id><pub-id pub-id-type="pmid">39571574</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Shimada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Crother</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Karlin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dagvadorj</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chiba</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ramanujan</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Vergnes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ojcius</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Rentsendorj</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vargas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guerrero</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Underhill</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Town</surname><given-names>T.</given-names></name><name name-style="western"><surname>Arditi</surname><given-names>M.</given-names></name></person-group><article-title>Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis</article-title><source>Immunity</source><volume>36</volume><year>2012</year><fpage>401</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.01.009</pub-id><pub-id pub-id-type="pmid">22342844</pub-id><pub-id pub-id-type="pmcid">PMC3312986</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Jevtic</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kindle</surname><given-names>P.</given-names></name><name name-style="western"><surname>Avilov</surname><given-names>S.V.</given-names></name></person-group><article-title>SYBR Gold dye enables preferential labelling of mitochondrial nucleoids and their time-lapse imaging by structured illumination microscopy</article-title><source>PLoS One</source><volume>13</volume><year>2018</year><object-id pub-id-type="publisher-id">e0203956</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0203956</pub-id><pub-id pub-id-type="pmcid">PMC6143240</pub-id><pub-id pub-id-type="pmid">30226899</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>Cha</surname><given-names>M.-Y.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Son</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>H.-S.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Byun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mook-Jung</surname><given-names>I.</given-names></name></person-group><article-title>Mitochondria-specific accumulation of amyloid &#946; induces mitochondrial dysfunction leading to apoptotic cell death</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><object-id pub-id-type="publisher-id">e34929</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0034929</pub-id><pub-id pub-id-type="pmcid">PMC3325919</pub-id><pub-id pub-id-type="pmid">22514691</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Zsurka</surname><given-names>G.</given-names></name><name name-style="western"><surname>Trombly</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sch&#246;ler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Blei</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kunz</surname><given-names>W.S.</given-names></name></person-group><article-title>Functional assessment of mitochondrial DNA maintenance by depletion and repopulation using 2&#8217;,3&#8217;-Dideoxycytidine in cultured cells</article-title><source>Methods Mol. Biol.</source><volume>2615</volume><year>2023</year><fpage>229</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-2922-2_17</pub-id><pub-id pub-id-type="pmid">36807796</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Kitazawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>H.-W.</given-names></name><name name-style="western"><surname>Medeiros</surname><given-names>R.</given-names></name></person-group><article-title>Copper exposure perturbs brain inflammatory responses and impairs clearance of amyloid-beta</article-title><source>Toxicol. Sci.</source><volume>152</volume><year>2016</year><fpage>194</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfw081</pub-id><pub-id pub-id-type="pmid">27122238</pub-id><pub-id pub-id-type="pmcid">PMC4922545</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Yamanaka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Griep</surname><given-names>A.</given-names></name><name name-style="western"><surname>Axt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kummer</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Heneka</surname><given-names>M.T.</given-names></name></person-group><article-title>PPAR&#947;/RXR&#945;-induced and CD36-mediated microglial amyloid-&#946; phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice</article-title><source>J. Neurosci.</source><volume>32</volume><year>2012</year><fpage>17321</fpage><lpage>17331</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1569-12.2012</pub-id><pub-id pub-id-type="pmid">23197723</pub-id><pub-id pub-id-type="pmcid">PMC6621845</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>J.-H.T.</given-names></name><name name-style="western"><surname>Paxinos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Halliday</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>W.S.</given-names></name></person-group><article-title>ABCA7 mediates phagocytic clearance of Amyloid-&#946; in the brain</article-title><source>J Alzheimers Dis</source><volume>54</volume><year>2016</year><fpage>569</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.3233/JAD-160456</pub-id><pub-id pub-id-type="pmid">27472885</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Lucin</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>O'Brien</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Bieri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Czirr</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mosher</surname><given-names>K.I.</given-names></name><name name-style="western"><surname>Abbey</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Mastroeni</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>J.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Masliah</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wyss-Coray</surname><given-names>T.</given-names></name></person-group><article-title>Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer's disease</article-title><source>Neuron</source><volume>79</volume><year>2013</year><fpage>873</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2013.06.046</pub-id><pub-id pub-id-type="pmid">24012002</pub-id><pub-id pub-id-type="pmcid">PMC3779465</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Aikawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tachibana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Martens</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Holm</surname><given-names>M.-L.</given-names></name><name name-style="western"><surname>Asmann</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>T.</given-names></name><name name-style="western"><surname>Saido</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kanekiyo</surname><given-names>T.</given-names></name></person-group><article-title>ABCA7 haplodeficiency disturbs microglial immune responses in the mouse brain</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>116</volume><year>2019</year><fpage>23790</fpage><lpage>23796</lpage><pub-id pub-id-type="doi">10.1073/pnas.1908529116</pub-id><pub-id pub-id-type="pmid">31690660</pub-id><pub-id pub-id-type="pmcid">PMC6876254</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Sakae</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.-C.</given-names></name><name name-style="western"><surname>Shinohara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frisch-Daiello</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tachibana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Younkin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kurti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carrasquillo</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sevlever</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bisceglio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fol</surname><given-names>R.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fryer</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Ohyagi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Younkin</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kanekiyo</surname><given-names>T.</given-names></name></person-group><article-title>ABCA7 deficiency accelerates Amyloid-&#946; Generation and alzheimer's neuronal pathology</article-title><source>J. Neurosci.</source><volume>36</volume><year>2016</year><fpage>3848</fpage><lpage>3859</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3757-15.2016</pub-id><pub-id pub-id-type="pmid">27030769</pub-id><pub-id pub-id-type="pmcid">PMC4812140</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Dib</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pahnke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gosselet</surname><given-names>F.</given-names></name></person-group><article-title>Role of ABCA7 in human health and in alzheimer's disease</article-title><source>Int. J. Mol. Sci.</source><volume>22</volume><year>2021</year><fpage>4603</fpage><pub-id pub-id-type="doi">10.3390/ijms22094603</pub-id><pub-id pub-id-type="pmid">33925691</pub-id><pub-id pub-id-type="pmcid">PMC8124837</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Jehle</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Gardai</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Linsel-Nitschke</surname><given-names>P.</given-names></name><name name-style="western"><surname>Morimoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Vandivier</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dale</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Henson</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Tall</surname><given-names>A.R.</given-names></name></person-group><article-title>ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages</article-title><source>J. Cell Biol.</source><volume>174</volume><year>2006</year><fpage>547</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1083/jcb.200601030</pub-id><pub-id pub-id-type="pmid">16908670</pub-id><pub-id pub-id-type="pmcid">PMC2064260</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lockyer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Townley-Tilson</surname><given-names>W.H.D.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pi</surname><given-names>X.</given-names></name></person-group><article-title>LRP1 regulates retinal angiogenesis by inhibiting PARP-1 activity and endothelial cell proliferation</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><volume>36</volume><year>2016</year><fpage>350</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.115.306713</pub-id><pub-id pub-id-type="pmid">26634655</pub-id><pub-id pub-id-type="pmcid">PMC4732907</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Zurhove</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>C.</given-names></name><name name-style="western"><surname>Herz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bock</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>May</surname><given-names>P.</given-names></name></person-group><article-title>Gamma-secretase limits the inflammatory response through the processing of LRP1</article-title><source>Sci. Signal.</source><volume>1</volume><year>2008</year><fpage>ra15</fpage><pub-id pub-id-type="doi">10.1126/scisignal.1164263</pub-id><pub-id pub-id-type="pmid">19036715</pub-id><pub-id pub-id-type="pmcid">PMC2694618</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>Hur</surname><given-names>J.-Y.</given-names></name></person-group><article-title>&#947;-Secretase in Alzheimer's disease</article-title><source>Exp. Mol. Med.</source><volume>54</volume><year>2022</year><fpage>433</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1038/s12276-022-00754-8</pub-id><pub-id pub-id-type="pmid">35396575</pub-id><pub-id pub-id-type="pmcid">PMC9076685</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Wahrle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Das</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nyborg</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>McLendon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shoji</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kawarabayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Younkin</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Younkin</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Golde</surname><given-names>T.E.</given-names></name></person-group><article-title>Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains</article-title><source>Neurobiol. Dis.</source><volume>9</volume><year>2002</year><fpage>11</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1006/nbdi.2001.0470</pub-id><pub-id pub-id-type="pmid">11848681</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Iwamoto</surname><given-names>N.</given-names></name><name name-style="western"><surname>Abe-Dohmae</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yokoyama</surname><given-names>S.</given-names></name></person-group><article-title>ABCA7 expression is regulated by cellular cholesterol through the SREBP2 pathway and associated with phagocytosis</article-title><source>J. Lipid Res.</source><volume>47</volume><year>2006</year><fpage>1915</fpage><lpage>1927</lpage><pub-id pub-id-type="doi">10.1194/jlr.M600127-JLR200</pub-id><pub-id pub-id-type="pmid">16788211</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Abe-Dohmae</surname><given-names>S.</given-names></name><name name-style="western"><surname>Iwamoto</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Yokoyama</surname><given-names>S.</given-names></name></person-group><article-title>HMG-CoA reductase inhibitors enhance phagocytosis by upregulating ATP-binding cassette transporter A7</article-title><source>Atherosclerosis</source><volume>217</volume><year>2011</year><fpage>407</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2011.06.031</pub-id><pub-id pub-id-type="pmid">21762915</pub-id><pub-id pub-id-type="pmcid">PMC3150192</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Bush</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>La Fontaine</surname><given-names>S.</given-names></name></person-group><article-title>Links between copper and cholesterol in Alzheimer's disease</article-title><source>Front. Physiol.</source><volume>4</volume><year>2013</year><fpage>111</fpage><pub-id pub-id-type="doi">10.3389/fphys.2013.00111</pub-id><pub-id pub-id-type="pmid">23720634</pub-id><pub-id pub-id-type="pmcid">PMC3655288</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name name-style="western"><surname>Zubillaga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Astiz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tricerri</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Arnal</surname><given-names>N.</given-names></name></person-group><article-title>Effect of Sublethal Copper Overload on Cholesterol De Novo Synthesis in Undifferentiated Neuronal Cells</article-title><source>ACS Omega</source><volume>7</volume><year>2022</year><fpage>25022</fpage><lpage>25030</lpage><pub-id pub-id-type="doi">10.1021/acsomega.2c00703</pub-id><pub-id pub-id-type="pmid">35910134</pub-id><pub-id pub-id-type="pmcid">PMC9330139</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Zubillaga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bellini</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Arnal</surname><given-names>N.</given-names></name></person-group><article-title>Sex-dependent effect of sublethal copper concentrations on de novo cholesterol synthesis in astrocytes and their possible links to variations in cholesterol and amyloid precursor protein levels in neuronal membranes</article-title><source>Biol. Sex Differ.</source><volume>15</volume><year>2024</year><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/s13293-023-00578-9</pub-id><pub-id pub-id-type="pmid">38191520</pub-id><pub-id pub-id-type="pmcid">PMC10775608</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>Moncan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mnich</surname><given-names>K.</given-names></name><name name-style="western"><surname>Blomme</surname><given-names>A.</given-names></name><name name-style="western"><surname>Almanza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Samali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gorman</surname><given-names>A.M.</given-names></name></person-group><article-title>Regulation of lipid metabolism by the unfolded protein response</article-title><source>J. Cell Mol. Med.</source><volume>25</volume><year>2021</year><fpage>1359</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.1111/jcmm.16255</pub-id><pub-id pub-id-type="pmid">33398919</pub-id><pub-id pub-id-type="pmcid">PMC7875919</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Charman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Osborne</surname><given-names>N.</given-names></name><name name-style="western"><surname>Karten</surname><given-names>B.</given-names></name></person-group><article-title>MLN64 mediates egress of cholesterol from endosomes to mitochondria in the absence of functional Niemann-Pick Type C1 protein</article-title><source>J. Lipid Res.</source><volume>51</volume><year>2010</year><fpage>1023</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1194/jlr.M002345</pub-id><pub-id pub-id-type="pmid">19965586</pub-id><pub-id pub-id-type="pmcid">PMC2853429</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name name-style="western"><surname>Rone</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Midzak</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Issop</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rammouz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jagannathan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>X.</given-names></name><name name-style="western"><surname>Blonder</surname><given-names>J.</given-names></name><name name-style="western"><surname>Veenstra</surname><given-names>T.</given-names></name><name name-style="western"><surname>Papadopoulos</surname><given-names>V.</given-names></name></person-group><article-title>Identification of a dynamic mitochondrial protein complex driving cholesterol import, trafficking, and metabolism to steroid hormones</article-title><source>Mol. Endocrinol.</source><volume>26</volume><year>2012</year><fpage>1868</fpage><lpage>1882</lpage><pub-id pub-id-type="doi">10.1210/me.2012-1159</pub-id><pub-id pub-id-type="pmid">22973050</pub-id><pub-id pub-id-type="pmcid">PMC5416962</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>Barbero-Camps</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Checa</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Colell</surname><given-names>A.</given-names></name></person-group><article-title>APP/PS1 mice overexpressing SREBP-2 exhibit combined A&#946; accumulation and tau pathology underlying Alzheimer's disease</article-title><source>Hum. Mol. Genet.</source><volume>22</volume><year>2013</year><fpage>3460</fpage><lpage>3476</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddt201</pub-id><pub-id pub-id-type="pmid">23648430</pub-id><pub-id pub-id-type="pmcid">PMC3736868</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>McGeer</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>McGeer</surname><given-names>E.G.</given-names></name></person-group><article-title>The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy</article-title><source>Acta Neuropathol.</source><volume>126</volume><year>2013</year><fpage>479</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1007/s00401-013-1177-7</pub-id><pub-id pub-id-type="pmid">24052108</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name name-style="western"><surname>Bis</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Jian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kunkle</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hamilton-Nelson</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Bush</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Salerno</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Lancour</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Renton</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Marcora</surname><given-names>E.</given-names></name><name name-style="western"><surname>Farrell</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Amin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Amouyel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Beecham</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Below</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Campion</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cantwell</surname><given-names>L.</given-names></name><name name-style="western"><surname>Charbonnier</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Crane</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Cruchaga</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cupples</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Dartigues</surname><given-names>J.-F.</given-names></name><name name-style="western"><surname>Debette</surname><given-names>S.</given-names></name><name name-style="western"><surname>Deleuze</surname><given-names>J.-F.</given-names></name><name name-style="western"><surname>Fulton</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gabriel</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Genin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Goate</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grenier-Boley</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>N.</given-names></name><name name-style="western"><surname>Haines</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Havulinna</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Helisalmi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hiltunen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Howrigan</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Ikram</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Kaprio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Konrad</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kuzma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lander</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Lathrop</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lehtim&#228;ki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mattila</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mayeux</surname><given-names>R.</given-names></name><name name-style="western"><surname>Muzny</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Nasser</surname><given-names>W.</given-names></name><name name-style="western"><surname>Neale</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nho</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nicolas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pericak-Vance</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Perola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Psaty</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Quenez</surname><given-names>O.</given-names></name><name name-style="western"><surname>Rajabli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Redon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reitz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Remes</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Salomaa</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sarnowski</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Soininen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thornton</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Tosto</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tzourio</surname><given-names>C.</given-names></name><name name-style="western"><surname>van der Lee</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>van Duijn</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Valladares</surname><given-names>O.</given-names></name><name name-style="western"><surname>Vardarajan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.-S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wijsman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Witten</surname><given-names>D.</given-names></name><name name-style="western"><surname>Worley</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><collab>Alzheimer&#8217;s Disease Sequencing Project</collab><name name-style="western"><surname>Bellenguez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>J.-C.</given-names></name><name name-style="western"><surname>Kurki</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Palotie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Daly</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boerwinkle</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lunetta</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Destefano</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Dupuis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Schellenberg</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Seshadri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Naj</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Fornage</surname><given-names>M.</given-names></name><name name-style="western"><surname>Farrer</surname><given-names>L.A.</given-names></name></person-group><article-title>Whole exome sequencing study identifies novel rare and common Alzheimer&#8217;s-Associated variants involved in immune response and transcriptional regulation</article-title><source>Mol. Psychiatr.</source><volume>25</volume><year>2020</year><fpage>1859</fpage><lpage>1875</lpage><pub-id pub-id-type="doi">10.1038/s41380-018-0112-7</pub-id><pub-id pub-id-type="pmcid">PMC6375806</pub-id><pub-id pub-id-type="pmid">30108311</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Laws</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Miles</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Wiley</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Masters</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>B.J.</given-names></name></person-group><article-title>Genomics of Alzheimer's disease implicates the innate and adaptive immune systems</article-title><source>Cell. Mol. Life Sci.</source><volume>78</volume><year>2021</year><fpage>7397</fpage><lpage>7426</lpage><pub-id pub-id-type="doi">10.1007/s00018-021-03986-5</pub-id><pub-id pub-id-type="pmid">34708251</pub-id><pub-id pub-id-type="pmcid">PMC11073066</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name name-style="western"><surname>Tapia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Ag&#252;ero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cisternas</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Suazo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cambiazo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Uauy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>M.</given-names></name></person-group><article-title>Metallothionein is crucial for safe intracellular copper storage and cell survival at normal and supra-physiological exposure levels</article-title><source>Biochem. J.</source><volume>378</volume><year>2004</year><fpage>617</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1042/BJ20031174</pub-id><pub-id pub-id-type="pmid">14627437</pub-id><pub-id pub-id-type="pmcid">PMC1223976</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name name-style="western"><surname>Cobine</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Leary</surname><given-names>S.C.</given-names></name></person-group><article-title>Getting out what you put in: copper in mitochondria and its impacts on human disease</article-title><source>Biochim. Biophys. Acta Mol. Cell Res.</source><volume>1868</volume><year>2021</year><object-id pub-id-type="publisher-id">118867</object-id><pub-id pub-id-type="doi">10.1016/j.bbamcr.2020.118867</pub-id><pub-id pub-id-type="pmcid">PMC7680424</pub-id><pub-id pub-id-type="pmid">32979421</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name name-style="western"><surname>Borchard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bork</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rieder</surname><given-names>T.</given-names></name><name name-style="western"><surname>Eberhagen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Popper</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lichtmannegger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Adamski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Klingenspor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>K.-H.</given-names></name><name name-style="western"><surname>Zischka</surname><given-names>H.</given-names></name></person-group><article-title>The exceptional sensitivity of brain mitochondria to copper</article-title><source>Toxicol. Vitro</source><volume>51</volume><year>2018</year><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.tiv.2018.04.012</pub-id><pub-id pub-id-type="pmid">29715505</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name name-style="western"><surname>Zischka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lichtmannegger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>S.</given-names></name><name name-style="western"><surname>J&#228;gemann</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wartini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jennen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rust</surname><given-names>C.</given-names></name><name name-style="western"><surname>Larochette</surname><given-names>N.</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chajes</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bandow</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gilles</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>DiSpirito</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>I.</given-names></name><name name-style="western"><surname>Goettlicher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Summer</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name></person-group><article-title>Liver mitochondrial membrane crosslinking and destruction in a rat model of Wilson disease</article-title><source>J. Clin. Investig.</source><volume>121</volume><year>2011</year><fpage>1508</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.1172/JCI45401</pub-id><pub-id pub-id-type="pmid">21364284</pub-id><pub-id pub-id-type="pmcid">PMC3068979</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name name-style="western"><surname>Lichtmannegger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leitzinger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wimmer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kabiri</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Eberhagen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rieder</surname><given-names>T.</given-names></name><name name-style="western"><surname>Janik</surname><given-names>D.</given-names></name><name name-style="western"><surname>Neff</surname><given-names>F.</given-names></name><name name-style="western"><surname>Straub</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Schirmacher</surname><given-names>P.</given-names></name><name name-style="western"><surname>DiSpirito</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Bandow</surname><given-names>N.</given-names></name><name name-style="western"><surname>Baral</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Flatley</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kremmer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Denk</surname><given-names>G.</given-names></name><name name-style="western"><surname>Reiter</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Hohenester</surname><given-names>S.</given-names></name><name name-style="western"><surname>Eckardt-Schupp</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dencher</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Adamski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sauer</surname><given-names>V.</given-names></name><name name-style="western"><surname>Niemietz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>H.H.J.</given-names></name><name name-style="western"><surname>Merle</surname><given-names>U.</given-names></name><name name-style="western"><surname>Gotthardt</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Zischka</surname><given-names>H.</given-names></name></person-group><article-title>Methanobactin reverses acute liver failure in a rat model of Wilson disease</article-title><source>J. Clin. Investig.</source><volume>126</volume><year>2016</year><fpage>2721</fpage><lpage>2735</lpage><pub-id pub-id-type="doi">10.1172/JCI85226</pub-id><pub-id pub-id-type="pmid">27322060</pub-id><pub-id pub-id-type="pmcid">PMC4922707</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name name-style="western"><surname>Tsvetkov</surname><given-names>P.</given-names></name><name name-style="western"><surname>Coy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Petrova</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dreishpoon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abdusamad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rossen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Joesch-Cohen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Humeidi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Spangler</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Eaton</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Frenkel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kocak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Corsello</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lutsenko</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kanarek</surname><given-names>N.</given-names></name><name name-style="western"><surname>Santagata</surname><given-names>S.</given-names></name><name name-style="western"><surname>Golub</surname><given-names>T.R.</given-names></name></person-group><article-title>Copper induces cell death by targeting lipoylated TCA cycle proteins</article-title><source>Science</source><volume>375</volume><year>2022</year><fpage>1254</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1126/science.abf0529</pub-id><pub-id pub-id-type="pmid">35298263</pub-id><pub-id pub-id-type="pmcid">PMC9273333</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name name-style="western"><surname>Saporito-Magri&#241;&#225;</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Musacco-Sebio</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Andrieux</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kook</surname><given-names>L.</given-names></name><name name-style="western"><surname>Orrego</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Tuttolomondo</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Desimone</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Boerries</surname><given-names>M.</given-names></name><name name-style="western"><surname>Borner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Repetto</surname><given-names>M.G.</given-names></name></person-group><article-title>Copper-induced cell death and the protective role of glutathione: the implication of impaired protein folding rather than oxidative stress</article-title><source>Metallomics</source><volume>10</volume><year>2018</year><fpage>1743</fpage><lpage>1754</lpage><pub-id pub-id-type="doi">10.1039/c8mt00182k</pub-id><pub-id pub-id-type="pmid">30311620</pub-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name name-style="western"><surname>Solier</surname><given-names>S.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ca&#241;eque</surname><given-names>T.</given-names></name><name name-style="western"><surname>Versini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mansart</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sindikubwabo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Baron</surname><given-names>L.</given-names></name><name name-style="western"><surname>Emam</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gestraud</surname><given-names>P.</given-names></name><name name-style="western"><surname>Panto&#351;</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Gandon</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gaillet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.-D.</given-names></name><name name-style="western"><surname>Dingli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Loew</surname><given-names>D.</given-names></name><name name-style="western"><surname>Baulande</surname><given-names>S.</given-names></name><name name-style="western"><surname>Durand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sencio</surname><given-names>V.</given-names></name><name name-style="western"><surname>Robil</surname><given-names>C.</given-names></name><name name-style="western"><surname>Trottein</surname><given-names>F.</given-names></name><name name-style="western"><surname>P&#233;ricat</surname><given-names>D.</given-names></name><name name-style="western"><surname>N&#228;ser</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cougoule</surname><given-names>C.</given-names></name><name name-style="western"><surname>Meunier</surname><given-names>E.</given-names></name><name name-style="western"><surname>B&#232;gue</surname><given-names>A.-L.</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Manel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Puisieux</surname><given-names>A.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Servant</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Annane</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>R.</given-names></name></person-group><article-title>A druggable copper-signalling pathway that drives inflammation</article-title><source>Nature</source><volume>617</volume><year>2023</year><fpage>386</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06017-4</pub-id><pub-id pub-id-type="pmid">37100912</pub-id><pub-id pub-id-type="pmcid">PMC10131557</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X.</given-names></name></person-group><article-title>Lead aggravates Alzheimer's disease pathology via mitochondrial copper accumulation regulated by COX17</article-title><source>Redox Biol.</source><volume>69</volume><year>2024</year><object-id pub-id-type="publisher-id">102990</object-id><pub-id pub-id-type="doi">10.1016/j.redox.2023.102990</pub-id><pub-id pub-id-type="pmcid">PMC10716782</pub-id><pub-id pub-id-type="pmid">38091880</pub-id></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z.</given-names></name></person-group><article-title>Long-term oral tribasic copper chloride exposure impedes cognitive function and disrupts mitochondrial metabolism by inhibiting mitophagy in rats</article-title><source>Environ. Pollut.</source><volume>336</volume><year>2023</year><object-id pub-id-type="publisher-id">122474</object-id><pub-id pub-id-type="doi">10.1016/j.envpol.2023.122474</pub-id><pub-id pub-id-type="pmid">37652230</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>He</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>Low-dose Cu exposure enhanced &#945;-synuclein accumulation associates with mitochondrial impairments in mice model of Parkinson's disease</article-title><source>Toxicol. Lett.</source><volume>387</volume><year>2023</year><fpage>14</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2023.09.004</pub-id><pub-id pub-id-type="pmid">37717680</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>C.</given-names></name><name name-style="western"><surname>O'Moore</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Dickman</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>L.L.</given-names></name></person-group><article-title>Exercise activation of muscle peroxisome proliferator-activated receptor-gamma coactivator-1alpha signaling is redox sensitive</article-title><source>Free Radic. Biol. Med.</source><volume>47</volume><year>2009</year><fpage>1394</fpage><lpage>1400</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2009.08.007</pub-id><pub-id pub-id-type="pmid">19686839</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name name-style="western"><surname>Aloysius Dhivya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aberami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nikhalashree</surname><given-names>S.</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Irudayaraj</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sulochana</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Coral</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bharathi Devi</surname><given-names>S.R.</given-names></name></person-group><article-title>Copper mediates mitochondrial biogenesis in retinal pigment epithelial cells</article-title><source>Biochim. Biophys. Acta Mol. Basis Dis.</source><volume>1866</volume><year>2020</year><object-id pub-id-type="publisher-id">165843</object-id><pub-id pub-id-type="doi">10.1016/j.bbadis.2020.165843</pub-id><pub-id pub-id-type="pmid">32454166</pub-id></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Mattie</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>J.H.</given-names></name></person-group><article-title>The role of Nrf1 and Nrf2 in the regulation of copper-responsive transcription</article-title><source>Exp. Cell Res.</source><volume>322</volume><year>2014</year><fpage>39</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2014.01.013</pub-id><pub-id pub-id-type="pmid">24462598</pub-id><pub-id pub-id-type="pmcid">PMC3964198</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name name-style="western"><surname>Arumugam</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rajeev</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bisht</surname><given-names>K.</given-names></name><name name-style="western"><surname>Madan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shankaran</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ramalingam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gandotra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>V.</given-names></name></person-group><article-title>The mitochondrial gene-CMPK2 functions as a rheostat for macrophage homeostasis</article-title><source>Front. Immunol.</source><volume>13</volume><year>2022</year><object-id pub-id-type="publisher-id">935710</object-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.935710</pub-id><pub-id pub-id-type="pmcid">PMC9702992</pub-id><pub-id pub-id-type="pmid">36451821</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>T.</given-names></name></person-group><article-title>Microglial CMPK2 promotes neuroinflammation and brain injury after ischemic stroke</article-title><source>Cell Rep. Med.</source><volume>5</volume><year>2024</year><object-id pub-id-type="publisher-id">101522</object-id><pub-id pub-id-type="doi">10.1016/j.xcrm.2024.101522</pub-id><pub-id pub-id-type="pmcid">PMC11148565</pub-id><pub-id pub-id-type="pmid">38701781</pub-id></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D.-W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>L.-F.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.-Y.</given-names></name><name name-style="western"><surname>Ka</surname><given-names>S.-M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Z.-F.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>L.-J.</given-names></name></person-group><article-title>Mitochondrial CMPK2 mediates immunomodulatory and antiviral activities through IFN-dependent and IFN-independent pathways</article-title><source>iScience</source><volume>24</volume><year>2021</year><object-id pub-id-type="publisher-id">102498</object-id><pub-id pub-id-type="doi">10.1016/j.isci.2021.102498</pub-id><pub-id pub-id-type="pmcid">PMC8188380</pub-id><pub-id pub-id-type="pmid">34142025</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name name-style="western"><surname>Xian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Watari</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sanchez-Lopez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Offenberger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Onyuru</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sampath</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Shadel</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Karin</surname><given-names>M.</given-names></name></person-group><article-title>Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels to activate NLRP3 inflammasome and interferon signaling</article-title><source>Immunity</source><volume>55</volume><year>2022</year><fpage>1370</fpage><lpage>1385.e8</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2022.06.007</pub-id><pub-id pub-id-type="pmid">35835107</pub-id><pub-id pub-id-type="pmcid">PMC9378606</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name name-style="western"><surname>Cabral</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cabral</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nikbakht</surname><given-names>D.</given-names></name><name name-style="western"><surname>Corona</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>McNulty</surname><given-names>R.</given-names></name></person-group><article-title>Differential Binding of NLRP3 to non-oxidized and Ox-mtDNA mediates NLRP3 Inflammasome Activation</article-title><source>Commun. Biol.</source><volume>6</volume><year>2023</year><fpage>578</fpage><pub-id pub-id-type="doi">10.1038/s42003-023-04817-y</pub-id><pub-id pub-id-type="pmid">37253813</pub-id><pub-id pub-id-type="pmcid">PMC10229695</pub-id></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z.</given-names></name></person-group><article-title>Mitochondrial DNA release mediated by TFAM deficiency promotes copper-induced mitochondrial innate immune response via cGAS-STING signalling in chicken hepatocytes</article-title><source>Sci. Total Environ.</source><volume>905</volume><year>2023</year><object-id pub-id-type="publisher-id">167315</object-id><pub-id pub-id-type="doi">10.1016/j.scitotenv.2023.167315</pub-id><pub-id pub-id-type="pmid">37742962</pub-id></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>L.</given-names></name></person-group><article-title>Copper induced cytosolic escape of mitochondrial DNA and activation of cGAS-STING-NLRP3 pathway-dependent pyroptosis in C8-D1A cells</article-title><source>Ecotoxicol. Environ. Saf.</source><volume>285</volume><year>2024</year><object-id pub-id-type="publisher-id">117085</object-id><pub-id pub-id-type="doi">10.1016/j.ecoenv.2024.117085</pub-id><pub-id pub-id-type="pmid">39321529</pub-id></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Shereen</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name></person-group><article-title>STING promotes NLRP3 localization in ER and facilitates NLRP3 deubiquitination to activate the inflammasome upon HSV-1 infection</article-title><source>PLoS Pathog.</source><volume>16</volume><year>2020</year><object-id pub-id-type="publisher-id">e1008335</object-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008335</pub-id><pub-id pub-id-type="pmcid">PMC7080238</pub-id><pub-id pub-id-type="pmid">32187211</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name name-style="western"><surname>Barbero-Camps</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baulies</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Checa</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Colell</surname><given-names>A.</given-names></name></person-group><article-title>Endoplasmic reticulum stress mediates amyloid &#946; neurotoxicity via mitochondrial cholesterol trafficking</article-title><source>Am. J. Pathol.</source><volume>184</volume><year>2014</year><fpage>2066</fpage><lpage>2081</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2014.03.014</pub-id><pub-id pub-id-type="pmid">24815354</pub-id><pub-id pub-id-type="pmcid">PMC4076561</pub-id></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name name-style="western"><surname>Eletto</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chevet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Argon</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Appenzeller-Herzog</surname><given-names>C.</given-names></name></person-group><article-title>Redox controls UPR to control redox</article-title><source>J. Cell Sci.</source><volume>127</volume><year>2014</year><fpage>3649</fpage><lpage>3658</lpage><pub-id pub-id-type="doi">10.1242/jcs.153643</pub-id><pub-id pub-id-type="pmid">25107370</pub-id></element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name name-style="western"><surname>Bosch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mar&#237;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Herms</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fajardo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kassan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giralt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Colell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Balgoma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Barbero</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Moreno</surname><given-names>E.</given-names></name><name name-style="western"><surname>Matias</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tebar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Balsinde</surname><given-names>J.</given-names></name><name name-style="western"><surname>Camps</surname><given-names>M.</given-names></name><name name-style="western"><surname>Enrich</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Garc&#237;a-Ruiz</surname><given-names>C.</given-names></name><name name-style="western"><surname>P&#233;rez-Navarro</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Checa</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Pol</surname><given-names>A.</given-names></name></person-group><article-title>Caveolin-1 deficiency causes cholesterol-dependent mitochondrial dysfunction and apoptotic susceptibility</article-title><source>Curr. Biol.</source><volume>21</volume><year>2011</year><fpage>681</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2011.03.030</pub-id><pub-id pub-id-type="pmid">21497090</pub-id><pub-id pub-id-type="pmcid">PMC3409647</pub-id></element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name name-style="western"><surname>de la Roche</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mortensen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jeyaprakash</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Anand</surname><given-names>P.K.</given-names></name></person-group><article-title>Trafficking of cholesterol to the ER is required for NLRP3 inflammasome activation</article-title><source>J. Cell Biol.</source><volume>217</volume><year>2018</year><fpage>3560</fpage><lpage>3576</lpage><pub-id pub-id-type="doi">10.1083/jcb.201709057</pub-id><pub-id pub-id-type="pmid">30054450</pub-id><pub-id pub-id-type="pmcid">PMC6168277</pub-id></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>B.-L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name></person-group><article-title>Cholesterol homeostatic regulator SCAP-SREBP2 integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling in macrophages</article-title><source>Immunity</source><volume>49</volume><year>2018</year><fpage>842</fpage><lpage>856.e7</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.08.021</pub-id><pub-id pub-id-type="pmid">30366764</pub-id></element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>ROS and NF-kappaB but not LXR mediate IL-1beta signaling for the downregulation of ATP-binding cassette transporter A1</article-title><source>Am. J. Physiol. Cell Physiol.</source><volume>292</volume><year>2007</year><fpage>C1493</fpage><lpage>C1501</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00016.2006</pub-id><pub-id pub-id-type="pmid">17135302</pub-id></element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name name-style="western"><surname>De Roeck</surname><given-names>A.</given-names></name><name name-style="western"><surname>Van Broeckhoven</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sleegers</surname><given-names>K.</given-names></name></person-group><article-title>The role of ABCA7 in Alzheimer's disease: evidence from genomics, transcriptomics and methylomics</article-title><source>Acta Neuropathol.</source><volume>138</volume><year>2019</year><fpage>201</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1007/s00401-019-01994-1</pub-id><pub-id pub-id-type="pmid">30903345</pub-id><pub-id pub-id-type="pmcid">PMC6660495</pub-id></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name name-style="western"><surname>Apostolova</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Risacher</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Duran</surname><given-names>T.</given-names></name><name name-style="western"><surname>Stage</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Goukasian</surname><given-names>N.</given-names></name><name name-style="western"><surname>West</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Do</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Grotts</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wilhalme</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nho</surname><given-names>K.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>M.</given-names></name><name name-style="western"><surname>Elashoff</surname><given-names>D.</given-names></name><name name-style="western"><surname>Saykin</surname><given-names>A.J.</given-names></name></person-group><article-title>Alzheimer's disease neuroimaging initiative, associations of the top 20 alzheimer disease risk variants with brain amyloidosis</article-title><source>JAMA Neurol.</source><volume>75</volume><year>2018</year><fpage>328</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2017.4198</pub-id><pub-id pub-id-type="pmid">29340569</pub-id><pub-id pub-id-type="pmcid">PMC5885860</pub-id></element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Starling</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Haskell</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Quintero</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Kawatani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shue</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Aikawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Martens</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Kurti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Perkerson</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Raulin</surname><given-names>A.-C.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Y.</given-names></name><name name-style="western"><surname>DeTure</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kanekiyo</surname><given-names>T.</given-names></name></person-group><article-title>Neuronal ABCA7 deficiency aggravates mitochondrial dysfunction and neurodegeneration in Alzheimer's disease</article-title><source>Alzheimer's Dement.</source><volume>21</volume><year>2025</year><object-id pub-id-type="publisher-id">e70112</object-id><pub-id pub-id-type="doi">10.1002/alz.70112</pub-id><pub-id pub-id-type="pmcid">PMC11947734</pub-id><pub-id pub-id-type="pmid">40145325</pub-id></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sagare</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Coma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Perlmutter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gelein</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Deane</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>E.</given-names></name><name name-style="western"><surname>Parisi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ciszewski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kasper</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Deane</surname><given-names>R.</given-names></name></person-group><article-title>Low levels of copper disrupt brain amyloid-&#946; homeostasis by altering its production and clearance</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>110</volume><year>2013</year><fpage>14771</fpage><lpage>14776</lpage><pub-id pub-id-type="doi">10.1073/pnas.1302212110</pub-id><pub-id pub-id-type="pmid">23959870</pub-id><pub-id pub-id-type="pmcid">PMC3767519</pub-id></element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ruganzu</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name></person-group><article-title>LRP1 knockdown aggravates A&#946;1-42-stimulated microglial and astrocytic neuroinflammatory responses by modulating TLR4/NF-&#954;B/MAPKs signaling pathways</article-title><source>Exp. Cell Res.</source><volume>394</volume><year>2020</year><object-id pub-id-type="publisher-id">112166</object-id><pub-id pub-id-type="doi">10.1016/j.yexcr.2020.112166</pub-id><pub-id pub-id-type="pmid">32645395</pub-id></element-citation></ref><ref id="bib138"><label>138</label><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>H.</given-names></name></person-group><article-title>Role of neuroinflammation in neurodegeneration development</article-title><source>Signal Transduct. Targeted Ther.</source><volume>8</volume><year>2023</year><fpage>267</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01486-5</pub-id><pub-id pub-id-type="pmcid">PMC10336149</pub-id><pub-id pub-id-type="pmid">37433768</pub-id></element-citation></ref><ref id="bib139"><label>139</label><element-citation publication-type="journal" id="sref139"><person-group person-group-type="author"><name name-style="western"><surname>Franklin</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Bossaller</surname><given-names>L.</given-names></name><name name-style="western"><surname>De Nardo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ratter</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Stutz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Engels</surname><given-names>G.</given-names></name><name name-style="western"><surname>Brenker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nordhoff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mirandola</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Al-Amoudi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mangan</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Monks</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Fricke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Espevik</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jarnicki</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Hansbro</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Busto</surname><given-names>P.</given-names></name><name name-style="western"><surname>Marshak-Rothstein</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hornemann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aguzzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kastenm&#252;ller</surname><given-names>W.</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E.</given-names></name></person-group><article-title>The adaptor ASC has extracellular and &#8220;prionoid&#8221; activities that propagate inflammation</article-title><source>Nat. Immunol.</source><volume>15</volume><year>2014</year><fpage>727</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1038/ni.2913</pub-id><pub-id pub-id-type="pmid">24952505</pub-id><pub-id pub-id-type="pmcid">PMC4116676</pub-id></element-citation></ref><ref id="bib140"><label>140</label><element-citation publication-type="journal" id="sref140"><person-group person-group-type="author"><name name-style="western"><surname>Venegas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Franklin</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Dierkes</surname><given-names>T.</given-names></name><name name-style="western"><surname>Brinkschulte</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tejera</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vieira-Saecker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Santarelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kummer</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Griep</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gelpi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Beilharz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Riedel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Golenbock</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Geyer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Heneka</surname><given-names>M.T.</given-names></name></person-group><article-title>Microglia-derived ASC specks cross-seed amyloid-&#946; in Alzheimer's disease</article-title><source>Nature</source><volume>552</volume><year>2017</year><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1038/nature25158</pub-id><pub-id pub-id-type="pmid">29293211</pub-id></element-citation></ref><ref id="bib141"><label>141</label><element-citation publication-type="journal" id="sref141"><person-group person-group-type="author"><name name-style="western"><surname>Lobanova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Emin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brelstaff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kahanawita</surname><given-names>L.</given-names></name><name name-style="western"><surname>Malpetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Quaegebeur</surname><given-names>A.</given-names></name><name name-style="western"><surname>Triantafilou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Triantafilou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Williams-Gray</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Bryant</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Klenerman</surname><given-names>D.</given-names></name></person-group><article-title>ASC specks as a single-molecule fluid biomarker of inflammation in neurodegenerative diseases</article-title><source>Nat. Commun.</source><volume>15</volume><year>2024</year><fpage>9690</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-53547-0</pub-id><pub-id pub-id-type="pmid">39528447</pub-id><pub-id pub-id-type="pmcid">PMC11555386</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0525">The following is the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Multimedia component 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.pdf" position="float" orientation="portrait"><alt-text>Multimedia component 1</alt-text></media></supplementary-material></p></sec><sec sec-type="data-availability" id="da0010"><title>Data availability</title><p id="p0035">No data was used for the research described in the article.</p></sec><ack id="ack0010"><title>Acknowledgements</title><p id="p0520">The authors acknowledge the support of the <funding-source id="gs1">Microscopy Service at IIBB&#8208;CSIC</funding-source>, the Geochemistry Laboratory at IGME-CSIC for ICP-AES and ICP-MS analyses, and the Animal Experimentation Unit from the Scientific and Technological Centers (CCiTUB), Universitat de Barcelona, for their support with <funding-source id="gs2">mouse care</funding-source>.</p></ack><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0530">Supplementary data to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.redox.2025.103872" id="intref0045">https://doi.org/10.1016/j.redox.2025.103872</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Angew Chem Int Ed Engl</journal-id><journal-id journal-id-type="iso-abbrev">Angew Chem Int Ed Engl</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Angewandte Chemie (International ed. in English)</journal-title></journal-title-group><issn pub-type="ppub">1433-7851</issn><issn pub-type="epub">1521-3773</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12498309</article-id><article-id pub-id-type="pmcid-ver">PMC12498309.1</article-id><article-id pub-id-type="pmcaid">12498309</article-id><article-id pub-id-type="pmcaiid">12498309</article-id><article-id pub-id-type="manuscript-id">NIHMS2114125</article-id><article-id pub-id-type="pmid">38407551</article-id><article-id pub-id-type="doi">10.1002/anie.202402007</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2114125</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2114125</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Functional Selection of Tau Oligomerization-Inhibiting Aptamers</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="B">Bang</given-names></name><xref rid="FN1" ref-type="author-notes">+</xref><aff id="A1">Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611 (USA)</aff><aff id="A2">Foundation for Applied Molecular Evolution, Firebird Biomolecular Sciences LLC, 13709 Progress Boulevard, No. 7, Alachua, FL 32615, (USA)</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pan</surname><given-names initials="X">Xiaoshu</given-names></name><xref rid="FN1" ref-type="author-notes">+</xref><aff id="A3">Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611 (USA)</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Teng</surname><given-names initials="IT">I-Ting</given-names></name><aff id="A4">Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611 (USA)</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="X">Xiaowei</given-names></name><aff id="A5">Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611 (USA)</aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5008-6944</contrib-id><name name-style="western"><surname>Kobeissy</surname><given-names initials="F">Firas</given-names></name><aff id="A6">Center for Neurotrauma, Multiomics &amp; Biomarkers, Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310&#8211;1458, (USA).</aff><aff id="A7">Department of Emergency Medicine, McKnight Brain Institute, University of Florida, Gainesville, FL 32611(USA)</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="ZY">Zo-Yu</given-names></name><aff id="A8">Center for Neurotrauma, Multiomics &amp; Biomarkers, Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310&#8211;1458, (USA).</aff><aff id="A9">Department of Emergency Medicine, McKnight Brain Institute, University of Florida, Gainesville, FL 32611(USA)</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="J">Jiepei</given-names></name><aff id="A10">Center for Neurotrauma, Multiomics &amp; Biomarkers, Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310&#8211;1458, (USA).</aff><aff id="A11">Department of Emergency Medicine, McKnight Brain Institute, University of Florida, Gainesville, FL 32611(USA)</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cai</surname><given-names initials="G">Guangzheng</given-names></name><aff id="A12">Center for Neurotrauma, Multiomics &amp; Biomarkers, Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310&#8211;1458, (USA).</aff><aff id="A13">Department of Emergency Medicine, McKnight Brain Institute, University of Florida, Gainesville, FL 32611(USA)</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yan</surname><given-names initials="H">He</given-names></name><aff id="A14">Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611 (USA)</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yan</surname><given-names initials="X">Xin</given-names></name><aff id="A15">Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611 (USA)</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liang</surname><given-names initials="M">Mingwei</given-names></name><aff id="A16">Department of Biochemistry and Molecular Biology, UF Health Cancer Center, College of Medicine, University of Florida Gainesville, FL 32610 (USA)</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yu</surname><given-names initials="F">Fahong</given-names></name><aff id="A17">Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611 (USA)</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lu</surname><given-names initials="J">Jianrong</given-names></name><aff id="A18">Department of Biochemistry and Molecular Biology, UF Health Cancer Center, College of Medicine, University of Florida Gainesville, FL 32610 (USA)</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="Z">Zunyi</given-names></name><aff id="A19">Foundation for Applied Molecular Evolution, Firebird Biomolecular Sciences LLC, 13709 Progress Boulevard, No. 7, Alachua, FL 32615, (USA)</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Biondi</surname><given-names initials="E">Elisa</given-names></name><aff id="A20">Foundation for Applied Molecular Evolution, Firebird Biomolecular Sciences LLC, 13709 Progress Boulevard, No. 7, Alachua, FL 32615, (USA)</aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7972-2142</contrib-id><name name-style="western"><surname>Haskins</surname><given-names initials="W">William</given-names></name><aff id="A21">Gryphon Bio, Inc., 611 Gateway Blvd. Suite 120 #253, South San Francisco, CA 94080&#8211;7066, (USA)</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cao</surname><given-names initials="YC">Y. Charles</given-names></name><aff id="A22">Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611 (USA)</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Benner</surname><given-names initials="SA">Steven A.</given-names></name><xref rid="CR1" ref-type="corresp">*</xref><aff id="A23">Foundation for Applied Molecular Evolution, Firebird Biomolecular Sciences LLC, 13709 Progress Boulevard, No. 7, Alachua, FL 32615, (USA)</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tan</surname><given-names initials="W">Weihong</given-names></name><xref rid="CR1" ref-type="corresp">*</xref><aff id="A24">Department of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611 (USA)</aff><aff id="A25">Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, Hunan 410082, (China);</aff><aff id="A26">Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, (China)</aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9343-6473</contrib-id><name name-style="western"><surname>Wang</surname><given-names initials="KK">Kevin K.</given-names></name><xref rid="CR1" ref-type="corresp">*</xref><aff id="A27">Center for Neurotrauma, Multiomics &amp; Biomarkers, Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310&#8211;1458, (USA).</aff><aff id="A28">Department of Emergency Medicine, McKnight Brain Institute, University of Florida, Gainesville, FL 32611(USA)</aff><aff id="A29">Gryphon Bio, Inc., 611 Gateway Blvd. Suite 120 #253, South San Francisco, CA 94080&#8211;7066, (USA)</aff><aff id="A30">Brain Rehabilitation Research Center, Malcom Randall VA Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL 32608 (USA)</aff></contrib></contrib-group><author-notes><fn fn-type="equal" id="FN1"><label>[+]</label><p id="P1">These authors contributed equally to this work.</p></fn><corresp id="CR1"><label>[*]</label><email>sbenner@ffame.org</email>, <email>tan@hnu.edu.cn</email>, <email>kwang@msm.edu</email></corresp></author-notes><pub-date pub-type="ppub"><day>24</day><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>14</day><month>3</month><year>2024</year></pub-date><volume>63</volume><issue>18</issue><issue-id pub-id-type="pmc-issue-id">498359</issue-id><fpage>e202402007</fpage><lpage>e202402007</lpage><pub-history><event event-type="nihms-submitted"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>06</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-07 10:25:20.703"><day>07</day><month>10</month><year>2025</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the Creative Commons Attribution Non-Commercial NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2114125.pdf"/><abstract id="ABS1"><p id="P2">Pathological hyperphosphorylation and aggregation of microtubule-associated Tau protein contribute to Alzheimer&#8217;s Disease (AD) and other related tauopathies. Currently, no cure exists for Alzheimer&#8217;s Disease. Aptamers offer significant potential as next-generation therapeutics in biotechnology and the treatment of neurological disorders. Traditional aptamer selection methods for Tau protein focus on binding affinity rather than interference with pathological Tau. In this study, we developed a new selection strategy to enrich DNA aptamers that bind to surviving monomeric Tau protein under conditions that would typically promote Tau aggregation. Employing this approach, we identified a set of aptamer candidates. Notably, BW1c demonstrates a high binding affinity (<italic toggle="yes">K</italic><sub>d</sub> = 6.6 nM) to Tau protein and effectively inhibits arachidonic acid (AA)-induced Tau protein oligomerization and aggregation. Additionally, it inhibits GSK3&#946;-mediated Tau hyperphosphorylation in cell-free systems and okadaic acid-mediated Tau hyperphosphorylation in cellular milieu. Lastly, retro-orbital injection of BW1c tau aptamer shows the ability to cross the blood brain barrier and gain access to neuronal cell body. Through further refinement and development, these Tau aptamers may pave the way for a first-in-class neurotherapeutic to mitigate tauopathy-associated neurodegenerative disorders.</p></abstract><abstract id="ABS2" abstract-type="graphical"><title>Graphical Abstract</title><p id="P3">
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="nihms-2114125-f0001.jpg"/>
</p><p id="P4">A novel aptamer selection method (Functional Selection) has identified a DNA aptamer, BW1c, with high specificity and affinity binding to Tau protein, representing a new avenue for inhibiting Tau protein aggregation. This strategy shows a &#8220;fit-for-purpose&#8221; selection workflow for discovery of aptamers with desired functionality.</p></abstract><kwd-group><kwd>Functional Selection</kwd><kwd>Tauopathy</kwd><kwd>Aptamer</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S1"><title>Introduction</title><p id="P5">Tau is a primary microtubule-associated protein in normal mature neurons, where it stabilizes microtubule networks.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> Pathologically, hyperphosphorylated tau detaches from microtubules, leading to improper accumulation and oligomerization, which are hallmarks in the etiology of tauopathy-associated neurodegenerative diseases such as Alzheimer&#8217;s disease<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup> (AD), Pick&#8217;s disease,<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> and chronic traumatic encephalopathy<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup> (CTE).</p><p id="P6">Oligomer Tau (Oligo-Tau) further promotes polymerization into paired helical filaments, resulting in neurofibrillary tangles. Consequently, tauopathy is presumed to originate from the phosphorylation and oligomerization of Tau, or in other words, the pathological gain-of-function propensity of Tau. Developing functional molecules to specifically inhibit tau aggregation is a crucial strategy for treating neurodegenerative diseases.</p><p id="P7">DNA or RNA, due to their repetitive backbone charges, allow them to maintain solubility throughout their sequence spaces. They are considered promising platforms for laboratory in vitro evolution (LIVE) to create functional biopolymers and potentially treat various diseases. In particular, the Darwinian selection of aptamers, which are artificial single-stranded oligonucleotides, has been widely employed in laboratories to create molecules that bind to diverse targets, owing to their specific binding capacity and high affinity.<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup> These techniques have been implemented in the fields of biomarker discovery, early disease diagnosis, and therapeutic applications.<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup></p><p id="P8">Numerous methods related to selection techniques,<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup> aptamer chemistry,<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> and bioinformatics<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup> have been developed to enhance aptamer quality (affinity, specificity, and stability) as well as selection efficiency, automation, and high throughput.<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup> Recently, researchers also reported the use of mirror-image DNA polymerase for the selection of highly biostable L-DNA aptamers<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup> and AI-assisted aptamer screening.<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup> These exciting results are driving the iterative development of aptamers. Currently, most selection strategies focus on target binding, leading to aptamers potential with various unpredictable functional abilities.<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup> Few efforts have directly contributed to functional discoveries, such as reaction catalysis,<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup> synthetic ribozymes,<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> and DNAzymes,<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup> during the aptamer selection process. This challenge also extends to protein functional selection,<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup> where designing or selecting a molecule from first principles that meets the performance standards required for various biological scenarios proves to be difficult.</p><p id="P9">To target tauopathy-associated neurodegenerative diseases, we utilized the laboratory in vitro evolution (LIVE) method to further evolve aptamers that bind Tau or Tau epitopes in our group<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup> or in other laboratories.<sup>[<xref rid="R19" ref-type="bibr">19</xref>]</sup> Previously selected DNA or RNA Tau aptamers exhibited high affinities against the target but did not guarantee optimal inhibition or modulation of Tau oligomerization/ aggregation. For instance, these binding events may occur at protein epitopes not involved in aggregation or hyperphosphorylation. Actually, the detailed physiological mechanisms regulating tau interaction and aggregation are not yet fully understood.<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup> Therefore, to select aptamers that prevent Tau pathology, we first developed a modified functional selection strategy (<xref rid="F1" ref-type="fig">Figure 1A</xref>) to evolve aptamers that exhibit oligomerization/aggregation inhibitory function (<xref rid="F1" ref-type="fig">Figure 1B</xref>).</p><p id="P10">This new strategy comprises two steps. In the first step, we perform three rounds of gel electrophoresis (GE) selection using the classic gel shift strategy<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup> to enrich the DNA pool of Tau-binding candidates. In the second selection step (13 rounds), we preferentially enrich DNA aptamer molecules that bind only Tau monomers, not Tau oligomers, in the presence of an aggregation inducer. We hypothesized that only aptamers surviving this selection would prevent Tau from forming oligomers. Consequently, this built-in &#8220;counter-selection&#8221; eliminates aptamer candidates that bind oligo-Tau but fail to inhibit Tau pathology. Indeed, our evolved aptamers not only bind Tau with high affinity but also inhibit Tau oligomerization/aggregation in vitro. Furthermore, the discovered aptamers inhibit Tau hyperphosphorylation in both cell-free and cellular environments.</p></sec><sec id="S2"><title>Results and Discussion</title><sec id="S3"><title>Enriching the DNA pool using GE-Selection.</title><p id="P11">The initial GE-selection aims to identify binders within a DNA library pool of single-stranded DNA (76 nucleotides) (<xref rid="SD1" ref-type="supplementary-material">Figure S1A</xref>). Native non-denatured PAGE is initially employed to analyze the DNA library after incubation with monomeric Tau441 protein (441 amino acids long) (<xref rid="F2" ref-type="fig">Figure 2A</xref>). The unbound DNA pool, which exhibits nonspecific or weak binding, is separated from tightly bound complexes during electrophoresis. Flow cytometry is used to further validate the selection progress. In this process, the FAM-labeled random library and the DNA pools after rounds 1, 2, and 3 selections are incubated with Tau (His-tag Tau) and Ni-NTA resin beads for flow cytometry analysis. The Tau protein alone and the DNA pool after round 1 alone are also assessed as controls. The flow cytometry shift, in comparison with the controls, indicates that the R1 (Round 1), R2, and R3 DNA pools already contain DNA aptamers with strong affinity for Tau (<xref rid="F2" ref-type="fig">Figure 2B</xref>).</p></sec><sec id="S4"><title>Functional Selection.</title><p id="P12">The selection was then performed with the preselected and enriched Tau binding DNA pool from the third round of GE-Selection as starting library. To generate Tau aggregates in cell-free conditions, we first attempted to use arachidonic acid (AA)<sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup> and heparin<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup> to induce tau aggregation. AA was found to be a robust inducer of Tau oligomerization/aggregation since it promoted Tau aggregation in a dose-dependent manner (50&#8211;100 &#956;M), as shown by denaturing SDS-PAGE (<xref rid="F2" ref-type="fig">Figure 2C</xref>). After the assessment of aggregation inducers, the selection was performed by incubating Tau441 monomers with the GE-Selection-enriched Tau-binding DNA pool in oligomerization buffer (30 min at 37&#176;C, followed by additional incubation with AA for 12 h at 37&#176;C). Tau441 monomers, along with their bound aptamers, were then separated from Oligo-Tau by non-denaturing PAGE, the increase in AA would lead to a decrease in the ratio of mon-Tau. (<xref rid="SD1" ref-type="supplementary-material">Figure S2</xref>). The bands corresponding to Tau441 monomers and aptamers in the gel were excised. The surviving candidates were subjected to PCR amplification for the next round of selection. During this functional selection, we interspersed 2 rounds of regular Tau binding GE-Selection. Functional selection was performed for a total of 15 cycles, with the DNA pools examined at rounds 1, 4, 7, 9, 11, 13, and 15 for their ability to reduce the levels of AA-induced Tau oligomerization (<xref rid="F2" ref-type="fig">Figure 2D</xref>).</p><p id="P13"><xref rid="F2" ref-type="fig">Figure 2E</xref> shows the ratio of Oligo-Tau versus Mono-Tau after incubation with aptamer pools from rounds 1, 4, 7, 9, 11, 13, and 15 and induced aggregation with AA. From the first round through the ninth round, the inhibitory ability of the selected pool showed a stable state with increasing rounds of selection. After nine rounds of selection, the oligomer/monomer ratio decreased dramatically, reaching a minimum at the 13<sup>th</sup> round. However, after two more rounds of selection (15<sup>th</sup>), No further improving was observed. Based on these data, DNA pools from the 13<sup>th</sup> round were cloned and sequenced. The sequence data on the most abundant 20 aptamer candidates are summarized in <xref rid="SD1" ref-type="supplementary-material">Table S3</xref>. The ten most abundant sequences were re-synthesized for more testing. <xref rid="SD1" ref-type="supplementary-material">Figure S3</xref> shows the predicted secondary structures of BW1 to BW7 aptamers using mFold software and the IDT website software.</p></sec><sec id="S5"><title>Binding and Specificity of the Best Tau Aptamers Against Tau441 Protein.</title><p id="P14">The binding of the ten most-represented sequences (BW1 to BW10) to Tau441 was validated by flow cytometry. Among the best aptamer candidates, BW1 exhibited the largest shift in fluorescence intensity (green, <xref rid="F3" ref-type="fig">Figure 3A</xref>). Furthermore, the binding specificity of the selected Tau aptamers to full-length Tau441 protein was confirmed by dot blotting. Each of the FAM-labeled aptamers was incubated with nitrocellulose membranes to which had been immobilized either target Tau441 protein or a set of non-target proteins (<xref rid="F3" ref-type="fig">Figure 3B</xref>).</p><p id="P15">Each of the Tau aptamers (BW2-BW10) displayed only one main band at the native Tau position. Aptamer BW1 showed one strong band at the Tau441 position and a weaker band at P-Tau (pre-phosphorylated by DYRKA kinase, SignalChem Inc.). This means that BW1 is also capable of binding to P-Tau. No cross-reactivity was observed between the aptamers and nontarget proteins, including &#945; casein+&#946; casein, BSA (bovine serum albumin), and IgG (Immunoglobulin G).</p></sec><sec id="S6"><title>Inhibition of Tau Aggregation <italic toggle="yes">In Vitro</italic> Antibody assay.</title><p id="P16">To examine the inhibitory effects of aptamer candidates on the arachidonic acid-induced Tau oligomerization in vitro, Tau protein was incubated with each aptamer candidate or random DNA pool (as a control) for 30 min followed by treatment with AA for 12 h to induce the formation of Tau oligomers. The products were analyzed by SDS-PAGE (<xref rid="F4" ref-type="fig">Figure 4A</xref>), which was then immunoblotted with polyclonal total Tau antibody (DA9<sup>[<xref rid="R23" ref-type="bibr">23</xref>]</sup>). In the absence of AA in PBS buffer, Tau441 was detected in monomeric form (~Mr 68 K) (lane 1) with only a trace of Oligo-Tau observed. However, slightly more Oligo-Tau was formed in the binding buffer (lane 12). The addition of AA caused the formation of large amounts of high molecular weight oligomeric Tau (lane 14). All the tested aptamers (BW1 to BW10) markedly inhibited AA-induced Tau oligomerization (lanes 2 through 11). In contrast, a random sequence DNA library did not. As shown in <xref rid="F4" ref-type="fig">Figure 4B</xref>, BW1 showed the most robust inhibition of oligomeric Tau formation. In a separate experiment, we incubated Tau441 (2 &#956;M) with BW1 at increasing concentrations (2 &#956;M, 4 &#956;M, 6 &#956;M) for 30 min and then performed the oligomerization study with AA followed by western blotting with DA9 antibody. The formation of Tau oligomers was again shown to be inhibited by the aptamer in a dose-dependent manner (<xref rid="SD1" ref-type="supplementary-material">Figure S15</xref>).</p></sec><sec id="S7"><title>Sequence Truncation and Modification of the BW1 Aptamer.</title><p id="P17">The aptamers identified are full-length sequences evolved from the initial library, which contain a fixed primer-binding region on each end required for PCR amplification. However, full-length aptamers can often be truncated, removing part or all the primer-binding regions, to give shorter sequences without compromising binding affinity towards their targets. This truncation was performed here with the BW1 aptamer, as it exhibited the best binding ability and Tau aggregation inhibitory ability.</p><p id="P18">Two truncated versions of BW1 (BW1a and BW1b) were created based on secondary structures predicted by RNAfold (<xref rid="F5" ref-type="fig">Figure 5A</xref>). These truncations retained the predicted core fold of BW1. BW1c was further modified from BW1b by replacing a G:T pair with an A:T pair in the stem structure, presuming that this would potentially enhance the stability of the aptamer. All the engineered aptamers maintained their binding and specificity to Tau441 by the dot blotting assay (<xref rid="F5" ref-type="fig">Figure 5B</xref>).</p><p id="P19">For the kinetics study of these aptamers, biotin-labeled Tau441 protein was immobilized on the surface of a bio-layer interferometry instrument (BLI), and various concentrations of aptamer candidates were presented to the target in the solution phase. The binding interaction between Tau protein and ligand was measured in real-time, as recorded from signal changes at the sensor surface. The equilibrium dissociation constants (<italic toggle="yes">K</italic><sub>d</sub>), kinetic on-rate constant (<italic toggle="yes">K</italic><sub>on</sub>) and off-rate constant (<italic toggle="yes">K</italic><sub>off</sub>) were measured and summarized in <xref rid="F5" ref-type="fig">Figure 5C</xref>, <xref rid="SD1" ref-type="supplementary-material">Table S4</xref> and <xref rid="SD1" ref-type="supplementary-material">Figure S17</xref>. However, after truncation, BW1a and BW1b showed weaker band intensity and higher <italic toggle="yes">K</italic><sub>d</sub> value, as reflected by the decreased binding affinity to Tau 441. Importantly, BW1c had a stronger binding affinity than either BW1a or BW1b, and it bound even better than BW1. Therefore, we speculated that the stem structure of the aptamers had substantial importance in the binding affinity, likely by stabilizing the active folding of the target binding portion of the molecule. We also suggest that several 3D folds may coexist in equilibrium in solution based on the Watson&#8211;Crick base-pair analysis. A relatively stable fold would dominate and maintain the 3D structure, making distinct contributions to the binding process. Because the modified position in BW1c is in the primer region (<xref rid="F5" ref-type="fig">Figure 5D</xref>), it is worth noting that a similar modification may guide future primer design in selection research and aptamer discovery. Though it may not be a general rule for guiding aptamer mutations in the modification.</p></sec><sec id="S8"><title>Inhibiting <italic toggle="yes">In Vitro</italic> Tau Aggregation by Aptamers Exhibited by ThT Binding Assay.</title><p id="P20">After the successful truncation and modification of the BW1 aptamer to obtain the BW1c aptamer with higher affinity, we asked whether the resulting aptamer would retain its inhibitory function which had previously guided the functional selection process. Therefore, we investigated the inhibitory ability of BW1c, together with BW1 and a previously discovered Tau aptamer, IT2a (from our previous work based on Tau-epitope binding Selection<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup>), to compare the inhibitory ability of aptamers developed from binding-criteria-based selection <italic toggle="yes">vs</italic>. functional selection. Thioflavin-T (ThT<sup>[<xref rid="R24" ref-type="bibr">24</xref>]</sup>) intercalates directly with &#946;-sheet structures in self-assembled, multimeric proteins. Once bound, ThT emits fluorescence signals in proportion to the amount bound, which is a measure of aggregation. This was used as an indicator of Tau aggregation (<xref rid="F6" ref-type="fig">Figure 6A</xref>). The increasing fluorescence showed that AA greatly induces the aggregation of Tau. With prolonged incubation time, fluorescence continuously increased until reaching a plateau, indicating aggregation saturation. A similar increasing trend was also observed with Tau, AA, and random DNA sequences. This indicated no inhibitory effects of random DNA on Tau aggregation.</p><p id="P21">However, In the presence of each of the three Tau aptamers (BW1c, BW1, or IT2a), AA-induced Tau aggregation and ThT fluorescence increased more slowly and yielded a weaker saturation intensity. This confirmed that AA-induced formation of Tau aggregates is significantly inhibited by BW1c, BW1, or IT2a aptamers (<xref rid="F6" ref-type="fig">Figure 6B</xref>). Consistent with our hypothesis, BW1 and BW1c exhibited stronger inhibition of both AA and heparin-induced Tau aggregation compared to IT2a (<xref rid="F6" ref-type="fig">Figure 6C</xref>). When the inducer was AA, it is noteworthy that BW1 and BW1c showed similar inhibition of Tau aggregation, even though BW1c had a higher affinity. With heparin, BW1c exhibited better inhibition than BW1 in the early stage of incubation, but the inhibition tended to be the same after longer incubation time up to 12 hr. Altogether, the data provided reliable evidence that BW1 and BW1c obtained from functional selection exhibited more robust and desirable inhibition of Tau aggregation induced by two molecules (AA and heparin) than IT2a, which was obtained by traditional binding-driven selection.</p></sec><sec id="S9"><title>Cell-free Tau phosphorylation assay and effects of Tau aptamers.</title><p id="P22">While other functional features of Tau were not directly targeted in functional selection, we were interested in determining if the aptamers also inhibited them. For example, we asked whether the aptamers could inhibit the phosphorylation of Tau catalyzed by GSK3&#946; kinase. This was tested by pre-incubating Tau441 (2 &#956;M) with BW1c, BW1, and IT2a for 30 min, adding GSK3&#946; kinase with ATP in an MgCl<sub>2</sub>-containing buffer, and further incubating for 24 hours. High-affinity Tau-antibody (6 &#956;M, mouse DA9 monoclonal antibody)<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup> replaced the aptamers as a positive control. Samples were then analyzed by SDS-PAGE/western blotting with Tau antibody (DAKO A0024, rabbit polyclonal antibody) for non-phospho-Tau and phospho-Tau quantification. <xref rid="F6" ref-type="fig">Figure 6D</xref> shows that a lower band was assigned as non-phosphorylated Tau (blue label). The upper bands were phospho-Tau species induced with GSK3&#946; phosphorylation in vitro. GSK3&#946; phosphorylation increases in slower migrating P-Tau species, while decreasing the signal for the non-phospho-Tau parent species (quantified in <xref rid="F6" ref-type="fig">Figure 6E</xref>). The aptamers and the antibody both inhibited GSK3&#946; phosphorylation in the order of Mab DA9 &gt; BW1c &#8776; BW1 (<xref rid="F6" ref-type="fig">Figure 6D</xref>,<xref rid="F6" ref-type="fig">E</xref>). IT2a was relatively ineffective in preventing GSK3b-mediated Tau phosphorylation under the same conditions.</p></sec><sec id="S10"><title>Investigation of Tau Binding to Microtubules in the Presence of Aptamers.</title><p id="P23">A key physiological function of Tau is its ability to bind to microtubule (MT) proteins. Therefore, an MT-binding protein spin-down assay<sup>[<xref rid="R26" ref-type="bibr">26</xref>]</sup> was used to investigate whether the binding of Tau to microtubules (preformed from tubulin) was affected by the presence of the selected aptamers. In the first set of steps, the spin-down assay was validated by the manufacturer&#8217;s instructions (<xref rid="SD1" ref-type="supplementary-material">Figure S19</xref>). To measure the binding of Tau, Tau-bound microtubules were recovered by ultracentrifugation. Then the pellet and supernatant fractions were analyzed by SDS-PAGE, followed by silver staining. As a negative control, bovine serum albumin (BSA), which has no affinity for MTs, was also used in the spin-down assay and remained in the supernatant fraction. As a positive control, microtubule-associated protein fraction (MAP) was used in the spin-down assay and was found in the pellet after centrifugation. We confirmed that Tau441, like the MAP positive control, was also bound to MTs and was found in the pellet fractions after ultracentrifugation.</p><p id="P24">To learn whether the binding between Tau and MTs would be inhibited by Tau aptamer, three experiments were performed (<xref rid="SD1" ref-type="supplementary-material">Figure S20</xref>). In the control Group 1 experiments, Tau441 alone was incubated with microtubules. Here, Tau was found almost exclusively in the microtubule pellet fraction. In Group 2 experiments, Tau441 was first incubated with microtubule proteins for 30 min. Then a stoichiometric excess of BW1c was added to the mixture and incubated for another 30 min. Here, only a trace amount of Tau was found in the supernatant, indicating that Tau aptamer BW1c does not cause Tau to be released from microtubules. Last, in Group 3 experiments, Tau441 was first incubated with BW1c aptamer for 30 min, mixed with MTs, and further incubated for 30 min. In this case, a small amount of Tau441 was found in the pellet fraction compared with Groups 1 and 2. This indicates that the soluble Tau441 pre-complexed with BW1c does not bind to MT as efficiently or as tightly as non-complexed Tau441.</p></sec><sec id="S11"><title>Inhibitory Effects of Tauopathy in Cell Models.</title><p id="P25">Following these characterizations in vitro, we asked whether a similar impact would be observed intracellularly. Specifically, we investigated the ability of Tau aptamers to inhibit Tau aggregation in intact neural cells. To accomplish this, we used neural N2a cells, a murine neuroblastoma cell line that expresses Tau protein, as our model. N2a cells were incubated with BW1c aptamers (25 nM&#8211;400 nM) pre-mixed with Lipofectamine 2000 (0.2% v/v). Cell viability against Lipofectamine 2000 and aptamers was measured with the MTS cytotoxicity assay.<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup>
<xref rid="SD1" ref-type="supplementary-material">Figure S16</xref> shows that N2a incubation with BW1c did not produce neurotoxic effects. Next, confocal microscopy was used to show that Cy5-labeled BW1c efficiently entered the cytoplasm of N2a cells in the presence of Lipofectamine 2000 (<xref rid="F7" ref-type="fig">Figure 7A</xref>). Our laboratory and others have used okadaic acid (OA) to develop cell models of tauopathy.<sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup> OA inhibits the dephosphorylation of P-Tau catalyzed by protein phosphatase 1 and 2A (PP1/PP2A). By not allowing P-Tau to be dephosphorylated, OA enhances Tau hyperphosphorylation as a pathological state in cell culture, including N2a cells.<sup>[<xref rid="R28" ref-type="bibr">28</xref>&#8211;<xref rid="R29" ref-type="bibr">29</xref>]</sup> OA treatment in wild-type mice causes tauopathy-related abnormalities in different regions of the brain.<sup>[<xref rid="R29" ref-type="bibr">29a</xref>]</sup> In our neural cell model of tauopathy, N2a cells were treated with OA (100 nM) for 24 h to induce Tau hyperphosphorylation and oligomerization, thus mimicking a tauopathy-relevant condition. Following OA-treatment of N2a cells, total cellular proteins extracted from cells were analyzed by using western blotting with DA9 antibody, which recognizes Monomeric-Tau (Mono-Tau, 46 kDa), P-Tau (50&#8211;70 kDa) and Oligomeric Tau (Oligo-Tau 90&#8211;160 kDa), and in-house monoclonal antibody 4E7&#8211;1, which recognizes P-Tau (Ser396/S404) (<xref rid="F7" ref-type="fig">Figure 7B</xref>, middle). Here, cells treated with OA and either with or without BW1c and lipofectamine were recovered, lysed, and analyzed. Total Tau immunoblot (DA9) showed that OA induced marked reduction of monomeric tau, while increasing oligomeric tau species. These effects were reversed by the presence of BW1c dose-dependently (50&#8211;200 nM), while random sequence DNA was ineffective (<xref rid="F7" ref-type="fig">Figure 7B</xref>, top).</p><p id="P26">We also suspected that these OA-induced high molecular weight oligomeric forms of Tau contained predominantly phospho-Tau. Using immunoblotting with P-Tau (Ser396/S404)-specific mouse monoclonal antibody (4E7&#8211;1, made in house), we further confirmed that OA treatment did, indeed, produce multiple bands of P-Tau MAb-positive monomeric and high molecular weight Tau oligomers (<xref rid="F7" ref-type="fig">Figure 7B</xref> middle, D). Importantly, BW1c effectively reduced overall P-Tau band signals to near baseline levels, while random sequence DNA did not. The P-Tau antibody did not detect significant presence of P-Tau (<xref rid="F7" ref-type="fig">Figure 7D</xref>).</p></sec><sec id="S12"><title>Synthesis and Characterization of Circular Bi-specific Transferrin Receptor-Tau aptamer (TfR-Tau-Aptamer).</title><p id="P27">Next, we wanted to conduct some blood and brain exposure study for this new BW1c Tau aptamer series. Based on our previous study,<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup> it was possible to synthesize circular bispecific aptamer that contains a transferrin receptor binding aptamer moiety in order to potentially improve plasma stability as well as enhance transcytosis across the blood brain barrier (BBB)-gating brain vascular endothelial cells. <xref rid="SD1" ref-type="supplementary-material">Figure S21</xref> show schematic workflow of the synthesis of circular bi-specific BW1c-TfR-Cy5.5 derivatives of BW1c.</p></sec><sec id="S13"><title>Subjecting mice to exposure of mono-specific BW1C-Cy5.5 (BW) and bispecific BW1c-TfR-Cy5.5 (BWT) Tau aptamer.</title><p id="P28">Mice, both na&#239;ve and subjected to controlled cortical impact (CCI),<sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup> were exposed to BW aptamer and BWT aptamer. We injected 8.6 nmol of either the BW1c aptamer labeled with Cy5 (BW) or the circular bispecific BW1c-TfR aptamer labeled with Cy5.5 (BWT) (10 &#956;L in phosphate-buffered saline) via the retro-orbital intravenous route. <xref rid="F8" ref-type="fig">Figure 8</xref> displays representative composite Cy5.5 fluorescence visualizations, indicating the brain residency of BW and BWT aptamers in both na&#239;ve mice and mice one hour post-CCI. Five hours post-aptamer administration, the animals were perfused first with phosphate-buffered saline (PBS), then with paraformaldehyde-fixed PBS. Consequently, the 2 &#956;m thick brain sections&#8217; Cy5.5 signals denote the penetration and residency of BW and BWT in the brain. Consistent with the Cy5.5 signal quantification in brain homogenates (<xref rid="SD1" ref-type="supplementary-material">Figure S22</xref>), both BW and BWT demonstrated substantial brain penetration and cellular residency in the cortex and hippocampus regions of both na&#239;ve mice (panels A &amp; B, <xref rid="F8" ref-type="fig">Figure 8</xref>) and CCI-affected mice (panels C&amp;D).</p><p id="P29">The staining patterns in the hippocampus distinctly reveal predominant labeling of CA3 neurons, characterized by weakly DAPI-stained nuclei, in contrast to the fewer Cy5.5-aptamer positive cells observed in the nucleus-rich bands of CA1 and DG (images b,d,e,f). Upon closer examination at higher magnification, it becomes evident that within the CA3 region, the aptamers are located in a punctate form within the neuronal cytosolic compartment, distinct from the DAPI-stained nuclei (image i). We also attempted to identify if the Tau aptamers are also located to long axons (e.g. in the CA2 region), but we did not found strong presence of them in long axons (<xref rid="F8" ref-type="fig">Figure 8A</xref>&#8211;<xref rid="F8" ref-type="fig">D</xref>, panel a,b; <italic toggle="yes">magnified images not shown</italic>). Taken together, these data suggest that BW and BWT are in the cell body compartment of neurons, likely including those inside endosomes and engaging in complexing to its target tau within the cell body.</p><p id="P30">We also note that pathologic tau has been demonstrated to reside more dominantly in the cell body rather than in long axons, thus it is encouraging that the tau aptamers appear to be in the proper cell compartment (cell body) to engage tau monomers to prevent them from forming tau oligomers or aggregate. Intriguingly, in the vicinity of the CA3 band, we also observed cytosolic punctate-BW and BWT staining in cells with small nuclei, indicative of either interneurons or other brain cell types, such as astrocytes. In the cortex, similar dominant Cy5.5-aptamer signals were observed (images b,c). At enhanced magnification, both BW and BWT exhibit punctate staining patterns, again external to the nuclei, consistent with cytosolic localization.</p><p id="P31">Given the limited presence of astrocytes in the mouse cortex, particularly in na&#239;ve animals, the substantial number of Cy5.5-positive cells (panels A and B, images a, b) is indicative not solely of astrocytes, but also of cortical neurons. Additionally, the identification of micro vessels in the cortex (image g) revealed that perivascular cells also exhibit BW and BWT staining. The morphological characteristics and perivascular positioning of these cells suggest they are either astrocytes and/or pericytes.</p><p id="P32"><xref rid="SD1" ref-type="supplementary-material">Figure S22A</xref> presents the computed total plasma concentrations of BW1c (BW) and BW1c-TfR (BWT) aptamers, with peak levels observed at 15 min post-injection, followed by a decrease at 1 h and a further decline at 5 h. The plasma half-life was determined to be between 1&#8211;2 h. No significant differences were observed between BW and BWT in either na&#239;ve or CCI groups. However, the concentrations of BW and BWT were lower in CCI groups, despite administering equal aptamer amounts. <xref rid="SD1" ref-type="supplementary-material">Figure S22B</xref> displays the calculated whole brain concentrations of BW and BWT at the 5 h terminal time point. Notably, overall brain exposure levels were comparable in both na&#239;ve and CCI groups subjected to either aptamer. Additionally, <xref rid="SD1" ref-type="supplementary-material">Figure S22C</xref> presents the average brain-to-plasma ratio (as %) for BW and BWT, calculated using their 15 min peak plasma levels and 5 h brain levels for estimation. BW and BWT displayed 0.60 &#177; 0.09% and 0.77 &#177; 0.02% (mean &#177; SEM) distribution to the brain compartment, respectively. In contrast, their BW and BWT counterparts in the CCI mouse groups exhibited higher % brain distribution at 1.19 &#177; 0.27% and 2.68 &#177;0.37%, respectively (p &lt; 0.05). Consequently, post-CCI environment-induced blood&#8211;brain barrier (BBB) alterations may facilitate greater exposure to the tau aptamers. Although 0.60 to 2.68% represents only a small fraction of the total plasma pool of both aptamers, it does indicate their partial ability to cross the BBB, despite their relatively high molecular weight (18,856 Da for BW and 26,781 Da for BWT).</p><p id="P33">In summary, this in vivo dataset elucidates the capability of both the circular BW1c aptamer with Cy5.5 label (BW) and the circular bispecific BW1c-TfR aptamer with Cy5.5 label (BWT) to traverse the blood&#8211;brain barrier and to infiltrate the cytosolic compartment of neurons and other cell types in both na&#239;ve mice and those with a history of traumatic brain injury.</p><p id="P34">Tauopathy-related neurological diseases may be caused by cumulative tau gene mutations, brain injuries and metabolic syndrome. In clinical settings, these factors are characterized by long duration and phenotypic heterogeneity. From the molecular pathological perspective, intracellular Tau protein and its hyperphosphorylated forms are reported to be prone to oligomerization, given the right pathophysiological conditions.<sup>[<xref rid="R32" ref-type="bibr">32</xref>]</sup> Over time, the Tau oligomers further form large protein aggregates, which become neurotoxic by interfering with normal cellular functions. Thus, inhibiting abnormal hyperphosphorylation and/or aggregation of Tau offers a promising therapeutic target for Alzheimer&#8217;s disease and related tauopathies.</p><p id="P35">Accordingly, therapeutic antibodies that may mediate tauopathy by this mechanism have been widely pursued in biomedical research and drug development. However, this Tau-targeted immunotherapy is limited by immunogenicity, cost, availability of antibody, and other factors influencing antibody effectiveness.<sup>[<xref rid="R33" ref-type="bibr">33</xref>]</sup> Thus, despite several major clinical trials, anti-Tau immunotherapy has thus far shown no clinical efficacy against any of the known tauopathy-linked diseases, suggesting that there are still technical challenges to overcome.<sup>[<xref rid="R34" ref-type="bibr">34</xref>]</sup></p><p id="P36">Aptamers, known as chemical antibodies, are promising therapeutic agents having several key advantages over antibodies.<sup>[<xref rid="R35" ref-type="bibr">35</xref>]</sup> In fact, aptamers may allow rapid screening from a random library, benefiting from the strong reproducibility of PCR and proven DNA sequencing techniques. Thousands of proteins, including Tau, have been selected as targets for aptamer selection. However, the obtained tau aptamers lock or have weak critical function.</p><p id="P37">We thus devised a &#8220;Functional selection&#8221; (<xref rid="F1" ref-type="fig">Figure 1</xref>). After successful selection and analysis of sequencing results, we discovered that BW1, was the most abundant among the 10 top aptamer candidates. Interestingly, BW1 was the only aptamer that could also bind to P-Tau, though with a weaker affinity (<xref rid="F4" ref-type="fig">Figure 4</xref>). BW1 also prevents oligomerization into Oligo-Tau. It is also possible that binding to the aptamer impairs Tau monomer ability to seed and propagate into high molecular weight oligomers. Subsequently, we conducted three-dimensional conformational modeling of BW1 based on the predicted secondary structures to guide us for aptamer truncation. The 3D modeling of BW1 led to successful affinity improvement of about 11-fold (comparing BW1c with BW1b) (<xref rid="F6" ref-type="fig">Figure 6</xref>). However, further structural improvement would be needed to enhance the therapeutic ability of the tau aptamer candidates.</p><p id="P38">Importantly, BW1c can enter the cells with help from Lipofectamine 2000 and exert its biological activity there. We found that Tau aptamer BW1c in N2a cells strongly suppressed OA-induced phosphorylation of Tau, as well as its associated oligomerization. This raises the possibility that Tau aptamers like BW1c could serve as building blocks for a new kind of therapeutics to mitigate tauopathy-associated neurodegenerative disorders. Based on our preliminary animal study data, both circular BW1c-TfR aptamer (BWT) and the linear BW1c Tau aptamer (BW) are capable of entering the brain especially under experimental TBI condition and able to enter cell body of neurons (<xref rid="F8" ref-type="fig">Figure 8</xref>). Somewhat surprisingly, the presence of functional TfR aptamer portion, however, does not seem to enhance brain distribution or penetration. Yet, the fact that these mid-size aptamers (18&#8211;26 kDa) can partially partition into the brain is promising in terms of their therapeutic potentials. One significant challenge is that both BW and BWT still have relatively short plasma half-life (1&#8211;2 h). Thus, further optimization of its delivery to the brain and/or significantly improved stability in circulation through further chemical modifications or other formulation strategies will need to be addressed. Then, one could explore the potentials of this Tau oligomerization-inhibiting aptamer series as a possible anti-tauopathy biologic therapeutic.</p></sec></sec><sec id="S14"><title>Conclusion</title><p id="P39">Taken together, our results showed proof-of-principle feasibility for applying the &#8220;Functional selection&#8221; strategy to select useful aptamers using Tau oligomerization as an example. We submit that the functional properties of other proteins may be exploited in a similar context. These include protein oligomerization, such as that seen, for example, in anthrax toxins, aggregation, binding to cell surfaces, catalytic self-modification (as in many kinases), binding to a partner molecule/protein, post-translational modifications, or conformational changes, upon binding to an endogenous ligand or ions. The results reported here provide a framework for enabling function-based enrichment of aptamer candidates targeting a wide range of cellular biological molecules that undergo critical conformational changes or modifications. Therefore, depending on the specific function of a protein, a &#8220;fit-for-purpose&#8221; functional selection workflow could be designed to successfully optimize the selection/enrichment process of aptamer candidates.</p></sec><sec id="S15"><title>Experimental Section</title><p id="P40">Detailed experimental procedures, materials sources, DNA sequences, predicted secondary structure of DNA were summarized in <xref rid="SD1" ref-type="supplementary-material">Supporting Information</xref>.</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><label>supporting information</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS2114125-supplement-supporting_information.pdf" id="d67e790" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><ack id="S17"><title>Acknowledgements</title><p id="P42">This work was supported by the Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, through the Defense Health Program, Congressionally Directed Medical Research Programs, Peer Reviewed Alzheimer&#8217;s Research Program, Convergence Science Research Award, Funding Opportunity Number W81XWH-18-PRARP-CSRA under Award No. W81XWH1910860 (Gryphon Bio PI: WEH, UF Subaward PI: KKW). And (1R01GM141391-01A1 to SAB). We thank for Bharat N. Gawande (FfAME), Michael E. Harris (UF), Jeffrey D. Rudolf (UF) for the kind support and discussion.</p></ack><fn-group><fn fn-type="COI-statement" id="FN2"><p id="P43">Conflict of Interest</p><p id="P44">WH and KW are shareholders of Gryphon Bio. Inc. and Owls Therapeutics.</p></fn></fn-group><sec sec-type="data-availability" id="S16"><title>Data Availability Statement</title><p id="P41">The data that support the findings of this study are available in the <xref rid="SD1" ref-type="supplementary-material">supplementary material</xref> of this article.</p></sec><ref-list><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal" id="mixed-citation1"><label>a)</label><name name-style="western"><surname>Weingarten</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Lockwood</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Hwo</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Kirschner</surname><given-names>MW</given-names></name>, <source>Proc. Natl. Acad. Sci. USA</source><year>1975</year>, <volume>72</volume>, <fpage>1858</fpage>&#8211;<lpage>1862</lpage>;<pub-id pub-id-type="pmid">1057175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.72.5.1858</pub-id><pub-id pub-id-type="pmcid">PMC432646</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation2"><label>b)</label><name name-style="western"><surname>Mandelkow</surname><given-names>E-M</given-names></name>, <name name-style="western"><surname>Biernat</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Drewes</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Gustke</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Trinczek</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Mandelkow</surname><given-names>E</given-names></name>, <source>Neurobiol. Aging</source><year>1995</year>, <volume>16</volume>, <fpage>355</fpage>&#8211;<lpage>362</lpage>.<pub-id pub-id-type="pmid">7566345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0197-4580(95)00025-a</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Maccioni</surname><given-names>RB</given-names></name>, <name name-style="western"><surname>Far&#237;as</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Morales</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Navarrete</surname><given-names>L</given-names></name>, <source>Arch. Med. Res</source><year>2010</year>, <volume>41</volume>, <fpage>226</fpage>&#8211;<lpage>231</lpage>.<pub-id pub-id-type="pmid">20682182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arcmed.2010.03.007</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Falcon</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Murzin</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Murshudov</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Garringer</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Vidal</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Crowther</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Ghetti</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Scheres</surname><given-names>SHW</given-names></name>, <name name-style="western"><surname>Goedert</surname><given-names>M</given-names></name>, <source>Nature</source>. <year>2018</year>, <volume>561</volume>, <fpage>137</fpage>&#8211;<lpage>140</lpage>.<pub-id pub-id-type="pmid">30158706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-018-0454-y</pub-id><pub-id pub-id-type="pmcid">PMC6204212</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>McKee</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Cantu</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Nowinski</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Hedley-Whyte</surname><given-names>ET</given-names></name>, <name name-style="western"><surname>Gavett</surname><given-names>BE</given-names></name>, <name name-style="western"><surname>Budson</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Santini</surname><given-names>VE</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>H-S</given-names></name>, <name name-style="western"><surname>Kubilus</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Stern</surname><given-names>RA</given-names></name>, <source>J. Neuropathol. Exp. Neurol</source><year>2009</year>, <volume>68</volume>, <fpage>709</fpage>&#8211;<lpage>735</lpage>.<pub-id pub-id-type="pmid">19535999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/NEN.0b013e3181a9d503</pub-id><pub-id pub-id-type="pmcid">PMC2945234</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal" id="mixed-citation6"><label>a)</label><name name-style="western"><surname>Ellington</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Szostak</surname><given-names>JW</given-names></name>, <source>Nature</source>. <year>1990</year>, <volume>346</volume>, <fpage>818</fpage>&#8211;<lpage>822</lpage>;<pub-id pub-id-type="pmid">1697402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/346818a0</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation7"><label>b)</label><name name-style="western"><surname>Tuerk</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gold</surname><given-names>L</given-names></name>, <source>Science</source>. <year>1990</year>, <volume>249</volume>, <fpage>505</fpage>&#8211;<lpage>510</lpage>;<pub-id pub-id-type="pmid">2200121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.2200121</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation8"><label>c)</label><name name-style="western"><surname>Robertson</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Joyce</surname><given-names>GF</given-names></name>, <source>Nature</source>. <year>1990</year>, <volume>344</volume>, <fpage>467</fpage>&#8211;<lpage>468</lpage>.<pub-id pub-id-type="pmid">1690861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/344467a0</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal" id="mixed-citation9"><label>a)</label><name name-style="western"><surname>Dunn</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Jimenez</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Chaput</surname><given-names>JC</given-names></name>, <source>Nat. Chem. Rev</source><year>2017</year>, <volume>1</volume>, <fpage>1</fpage>&#8211;<lpage>16</lpage>;</mixed-citation><mixed-citation publication-type="journal" id="mixed-citation10"><label>b)</label><name name-style="western"><surname>Banerjee</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Nilsen-Hamilton</surname><given-names>M</given-names></name>, <source>J. Mol. Med</source><year>2013</year>, <volume>91</volume>, <fpage>1333</fpage>&#8211;<lpage>1342</lpage>;<pub-id pub-id-type="pmid">24045702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00109-013-1085-2</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation11"><label>c)</label><name name-style="western"><surname>Fang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>W</given-names></name>, <source>Acc. Chem. Res</source><year>2010</year>, <volume>43</volume>, <fpage>48</fpage>&#8211;<lpage>57</lpage>;<pub-id pub-id-type="pmid">19751057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ar900101s</pub-id><pub-id pub-id-type="pmcid">PMC2808443</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation12"><label>d)</label><name name-style="western"><surname>Zheng</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Seferos</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Giljohann</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Mirkin</surname><given-names>CA</given-names></name>, <source>Nano Lett</source>. <year>2009</year>, <volume>9</volume>, <fpage>3258</fpage>&#8211;<lpage>3261</lpage>.<pub-id pub-id-type="pmid">19645478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/nl901517b</pub-id><pub-id pub-id-type="pmcid">PMC3200529</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal" id="mixed-citation13"><label>a)</label><name name-style="western"><surname>Ozer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pagano</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Lis</surname><given-names>JT</given-names></name>, <source>Mol. Ther. Nucleic Acids</source><year>2014</year>, <volume>3</volume>, <fpage>e183</fpage>;<pub-id pub-id-type="pmid">25093707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mtna.2014.34</pub-id><pub-id pub-id-type="pmcid">PMC4221594</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation14"><label>b)</label><name name-style="western"><surname>Yang</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Barbu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Halim</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pallavi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kolpashchikov</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Pecic</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Worgall</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Stojanovic</surname><given-names>MN</given-names></name>, <source>Nat. Chem</source><year>2014</year>, <volume>6</volume>, <fpage>1003</fpage>&#8211;<lpage>1008</lpage>.<pub-id pub-id-type="pmid">25343606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nchem.2058</pub-id><pub-id pub-id-type="pmcid">PMC4339820</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal" id="mixed-citation15"><label>a)</label><name name-style="western"><surname>Sefah</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Bradley</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Hoshika</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jim&#233;nez</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Shanker</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Turek</surname><given-names>D</given-names></name>, <source>Proc. Natl. Acad. Sci. USA</source><year>2014</year>, <volume>111</volume>, <fpage>1449</fpage>&#8211;<lpage>1454</lpage>;<pub-id pub-id-type="pmid">24379378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1311778111</pub-id><pub-id pub-id-type="pmcid">PMC3910645</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation16"><label>b)</label><name name-style="western"><surname>Kimoto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yamashige</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Matsunaga</surname><given-names>K.-i.</given-names></name>, <name name-style="western"><surname>Yokoyama</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hirao</surname><given-names>I</given-names></name>, <source>Nat. Biotechnol</source><year>2013</year>, <volume>31</volume>, <fpage>453</fpage>&#8211;<lpage>457</lpage>;<pub-id pub-id-type="pmid">23563318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.2556</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation17"><label>c)</label><name name-style="western"><surname>Gold</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ayers</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bertino</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bock</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Bock</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Brody</surname><given-names>EN</given-names></name>, <name name-style="western"><surname>Carter</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Dalby</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Eaton</surname><given-names>BE</given-names></name>, <name name-style="western"><surname>Fitzwater</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Flather</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Forbes</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Foreman</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Fowler</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gawande</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Goss</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gunn</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Halladay</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Heil</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Heilig</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hicke</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Husar</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Janjic</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Jarvis</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Jennings</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Katilius</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Keeney</surname><given-names>TR</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Koch</surname><given-names>TH</given-names></name>, <name name-style="western"><surname>Kraemer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kroiss</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Le</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Levine</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lindsey</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Lollo</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Mayfield</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Mehan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mehler</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nieuwlandt</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Nikrad</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ochsner</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Ostroff</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Otis</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Parker</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Pietrasiewicz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Resnicow</surname><given-names>DI</given-names></name>, <name name-style="western"><surname>Rohloff</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sanders</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Sattin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Singer</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Stanton</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sterkel</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Stewart</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Stratford</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Vaught</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Vrkljan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Watrobka</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Waugh</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Weiss</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wilcox</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Wolfson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wolk</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Zichi</surname><given-names>D</given-names></name>, <source>PLoS One</source>. <year>2010</year>, <volume>5</volume>, <fpage>e15004</fpage>.<pub-id pub-id-type="pmid">21165148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0015004</pub-id><pub-id pub-id-type="pmcid">PMC3000457</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kinghorn</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Fraser</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Shiu</surname><given-names>SC-C</given-names></name>, <name name-style="western"><surname>Tanner</surname><given-names>JA</given-names></name>, <source>Int. J. Mol. Sci</source><year>2017</year>, <volume>18</volume>, <fpage>2516</fpage>.<pub-id pub-id-type="pmid">29186809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms18122516</pub-id><pub-id pub-id-type="pmcid">PMC5751119</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal" id="mixed-citation19"><label>a)</label><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gong</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Maheshwari</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Eisenstein</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Arcila</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Kosik</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Soh</surname><given-names>HT</given-names></name>, <source>Angew. Chem. Int. Ed</source><year>2014</year>, <volume>53</volume>, <fpage>4796</fpage>&#8211;<lpage>4801</lpage>; <italic toggle="yes">Angew. Chem</italic>. <bold>2014</bold>, 126, <fpage>4896</fpage>&#8211;<lpage>4901</lpage>;<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.201309334</pub-id><pub-id pub-id-type="pmcid">PMC4065591</pub-id><pub-id pub-id-type="pmid">24644057</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation20"><label>b)</label><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>McDermott</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Scott</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vukovich</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lagrois</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Gong</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Greenleaf</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Eisenstein</surname><given-names>M</given-names></name>, <source>Angew. Chem. Int. Ed</source><year>2017</year>, <volume>56</volume>, <fpage>744</fpage>&#8211;<lpage>747</lpage>; <italic toggle="yes">Angew. Chem</italic>. <bold>2017</bold>, 129, <fpage>762</fpage>&#8211;<lpage>765</lpage>;<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.201608880</pub-id><pub-id pub-id-type="pmcid">PMC5225111</pub-id><pub-id pub-id-type="pmid">27933702</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation21"><label>c)</label><name name-style="western"><surname>Zhuo</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name>, <source>Int. J. Mol. Sci</source><year>2017</year>, <volume>18</volume>, <fpage>2142</fpage>.<pub-id pub-id-type="pmid">29036890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms18102142</pub-id><pub-id pub-id-type="pmcid">PMC5666824</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="other"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>TF</given-names></name>, <source>Nat. Biotechnol</source><year>2022</year>, <fpage>1</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">35668324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41587-022-01337-8</pub-id><pub-id pub-id-type="pmcid">PMC9646512</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal" id="mixed-citation23"><label>a)</label><name name-style="western"><surname>Bashir</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hoyer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chou</surname><given-names>W</given-names></name>, <name name-style="western"><surname>McLean</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Davis</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Gong</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Armstrong</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Jang</surname><given-names>J</given-names></name>, <source>Nat. Commun</source><year>2021</year>, <volume>12</volume>, <fpage>1</fpage>&#8211;<lpage>11</lpage>;<pub-id pub-id-type="pmid">33888692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-22555-9</pub-id><pub-id pub-id-type="pmcid">PMC8062585</pub-id></mixed-citation><mixed-citation publication-type="other" id="mixed-citation24"><label>b)</label><name name-style="western"><surname>Iwano</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Adachi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Aoki</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Nakamura</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hamada</surname><given-names>M</given-names></name>, <source>Nat. Comput. Sci</source><year>2022</year>, <fpage>1</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">38177576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43588-022-00249-6</pub-id><pub-id pub-id-type="pmcid">PMC10766510</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kahsai</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Wisler</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ahn</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Cahill III</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Dennison</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Staus</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Thomsen</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Anasti</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Pani</surname><given-names>B</given-names></name>, <source>Nat. Chem. Biol</source><year>2016</year>, <volume>12</volume>, <fpage>709</fpage>&#8211;<lpage>716</lpage>.<pub-id pub-id-type="pmid">27398998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nchembio.2126</pub-id><pub-id pub-id-type="pmcid">PMC4990464</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal" id="mixed-citation26"><label>a)</label><name name-style="western"><surname>Scheitl</surname><given-names>CPM</given-names></name>, <name name-style="western"><surname>Ghaem Maghami</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lenz</surname><given-names>A-K</given-names></name>, <name name-style="western"><surname>H&#246;bartner</surname><given-names>C</given-names></name>, <source>Nature</source>. <year>2020</year>, <volume>587</volume>, <fpage>663</fpage>&#8211;<lpage>667</lpage>;<pub-id pub-id-type="pmid">33116304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2854-z</pub-id><pub-id pub-id-type="pmcid">PMC7116789</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation27"><label>b)</label><name name-style="western"><surname>Silverman</surname><given-names>SK</given-names></name>, <source>Trends Biochem. Sci</source><year>2016</year>, <volume>41</volume>, <fpage>595</fpage>&#8211;<lpage>609</lpage>;<pub-id pub-id-type="pmid">27236301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tibs.2016.04.010</pub-id><pub-id pub-id-type="pmcid">PMC4930396</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation28"><label>c)</label><name name-style="western"><surname>Jerome</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Hoshika</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bradley</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Benner</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Biondi</surname><given-names>E</given-names></name>, <source>Proc. Natl. Acad. Sci. USA</source><year>2022</year>, <volume>119</volume>, e2208261119.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2208261119</pub-id><pub-id pub-id-type="pmcid">PMC9636917</pub-id><pub-id pub-id-type="pmid">36279447</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bartel</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Szostak</surname><given-names>JW</given-names></name>, <source>Science</source><year>1993</year>, <volume>261</volume>, <fpage>1411</fpage>&#8211;<lpage>1418</lpage>.<pub-id pub-id-type="pmid">7690155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.7690155</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Torabi</surname><given-names>S-F</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>P</given-names></name>, <name name-style="western"><surname>McGhee</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Hwang</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name>, <source>Proc. Natl. Acad. Sci. USA</source><year>2015</year>, <volume>112</volume>, <fpage>5903</fpage>&#8211;<lpage>5908</lpage>.<pub-id pub-id-type="pmid">25918425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1420361112</pub-id><pub-id pub-id-type="pmcid">PMC4434688</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lopez</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Mustafa</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>KB</given-names></name>, <name name-style="western"><surname>Ramirez</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Benitez</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Ji</surname><given-names>R-R</given-names></name>, <name name-style="western"><surname>Ge</surname><given-names>X</given-names></name>, <source>Proc. Natl. Acad. Sci. USA</source><year>2019</year>, <volume>116</volume>, <fpage>16314</fpage>&#8211;<lpage>16319</lpage>.<pub-id pub-id-type="pmid">31363054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1903330116</pub-id><pub-id pub-id-type="pmcid">PMC6697876</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Teng</surname><given-names>I-T</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Yadikar</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lyu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>W</given-names></name>, <source>J. Am. Chem. Soc</source><year>2018</year>, <volume>140</volume>, <fpage>14314</fpage>&#8211;<lpage>14323</lpage>.<pub-id pub-id-type="pmid">30277395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.8b08645</pub-id><pub-id pub-id-type="pmcid">PMC6442731</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal" id="mixed-citation33"><label>a)</label><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>WH</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>D-E</given-names></name>, <name name-style="western"><surname>Suh</surname><given-names>YH</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>MJ</given-names></name>, <source>Mol. Pharm</source><year>2016</year>, <volume>13</volume>, <fpage>2039</fpage>&#8211;<lpage>2048</lpage>;<pub-id pub-id-type="pmid">27120117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.6b00165</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation34"><label>b)</label><name name-style="western"><surname>Lisi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fiore</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Scarano</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pascale</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Boehman</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ducong&#233;</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Chierici</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Minunni</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Peyrin</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ravelet</surname><given-names>C</given-names></name>, <source>Anal. Chim. Acta</source><year>2018</year>, <volume>1038</volume>, <fpage>173</fpage>&#8211;<lpage>181</lpage>.<pub-id pub-id-type="pmid">30278900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.aca.2018.07.029</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Iqbal</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Gong</surname><given-names>C-X</given-names></name>, <source>Nat. Rev. Neurol</source><year>2016</year>, <volume>12</volume>, <fpage>15</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">26635213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneurol.2015.225</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal" id="mixed-citation36"><label>a)</label><name name-style="western"><surname>Tsai</surname><given-names>RY</given-names></name>, <name name-style="western"><surname>Reed</surname><given-names>RR</given-names></name>, <source>Mol. Cell. Biol</source><year>1998</year>, <volume>18</volume>, <fpage>6447</fpage>&#8211;<lpage>6456</lpage>;<pub-id pub-id-type="pmid">9774661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mcb.18.11.6447</pub-id><pub-id pub-id-type="pmcid">PMC109231</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation37"><label>b)</label><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhuang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>JS</given-names></name>, <source>Journal of Biological Engineering</source>. <year>2020</year>, <volume>14</volume>, <fpage>1</fpage>;<pub-id pub-id-type="pmid">31956340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13036-019-0223-y</pub-id><pub-id pub-id-type="pmcid">PMC6956507</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation38"><label>c)</label><name name-style="western"><surname>Alves Ferreira-Bravo</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Cozens</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Holliger</surname><given-names>P</given-names></name>, <name name-style="western"><surname>DeStefano</surname><given-names>JJ</given-names></name>, <source>Nucleic Acids Res</source>. <year>2015</year>, <volume>43</volume>, <fpage>9587</fpage>&#8211;<lpage>9599</lpage>.<pub-id pub-id-type="pmid">26476448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkv1057</pub-id><pub-id pub-id-type="pmcid">PMC4751925</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Patterson</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Remmers</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Brooker</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kanaan</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Vana</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ward</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Reyes</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Philibert</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Glucksman</surname><given-names>MJ</given-names></name>, <source>J. Biol. Chem</source><year>2011</year>, <volume>286</volume>, <fpage>23063</fpage>&#8211;<lpage>23076</lpage>.<pub-id pub-id-type="pmid">21550980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M111.237974</pub-id><pub-id pub-id-type="pmcid">PMC3123074</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="book"><name name-style="western"><surname>Davies</surname><given-names>P</given-names></name>, in <source>Alzheimer&#8217;s Disease: Methods and Protocols</source> (Ed.: <name name-style="western"><surname>Hooper</surname><given-names>NM</given-names></name>), <publisher-name>Humana Press</publisher-name>, <publisher-loc>Totowa, NJ</publisher-loc><year>2000</year>, pp. <fpage>361</fpage>&#8211;<lpage>373</lpage>.</mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Groenning</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Olsen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>van de Weert</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Flink</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Frokjaer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>J&#248;rgensen</surname><given-names>FS</given-names></name>, <source>J. Struct. Biol</source><year>2007</year>, <volume>158</volume>, <fpage>358</fpage>&#8211;<lpage>369</lpage>.<pub-id pub-id-type="pmid">17289401</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsb.2006.12.010</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>d&#8217;Abramo</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Acker</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Schachter</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Terracina</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Forest</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Davies</surname><given-names>P</given-names></name>, <source>Neurobiol. Aging</source><year>2016</year>, <volume>37</volume>, <fpage>58</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">26508157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2015.09.017</pub-id><pub-id pub-id-type="pmcid">PMC4688074</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cho</surname><given-names>HP</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gomez</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dunlap</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tyers</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <source>Mol. Cell. Biol</source><year>2005</year>, <volume>25</volume>, <fpage>4541</fpage>&#8211;<lpage>4551</lpage>.<pub-id pub-id-type="pmid">15899858</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/MCB.25.11.4541-4551.2005</pub-id><pub-id pub-id-type="pmcid">PMC1140622</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Malich</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Markovic</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Winder</surname><given-names>C</given-names></name>, <source>Toxicology</source>. <year>1997</year>, <volume>124</volume>, <fpage>179</fpage>&#8211;<lpage>192</lpage>.<pub-id pub-id-type="pmid">9482120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0300-483x(97)00151-0</pub-id></mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yadikar</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Torres</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Aiello</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kurup</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Kobeissy</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Yost</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>KK</given-names></name>, <source>PLoS One</source><year>2020</year>, <volume>15</volume>, <fpage>e0224952</fpage>.<pub-id pub-id-type="pmid">32692785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0224952</pub-id><pub-id pub-id-type="pmcid">PMC7373298</pub-id></mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal" id="mixed-citation46"><label>a)</label><name name-style="western"><surname>Zhou</surname><given-names>X-W</given-names></name>, <name name-style="western"><surname>Gustafsson</surname><given-names>J-&#197;</given-names></name>, <name name-style="western"><surname>Tanila</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Bjorkdahl</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Winblad</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Pei</surname><given-names>J-J</given-names></name>, <source>Neurobiol. Dis</source><year>2008</year>, <volume>31</volume>, <fpage>386</fpage>&#8211;<lpage>394</lpage>;<pub-id pub-id-type="pmid">18586097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2008.05.013</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation47"><label>b)</label><name name-style="western"><surname>Xu</surname><given-names>YF</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>JZ</given-names></name>, <source>Cell Stress Chaperones</source><year>2004</year>, <volume>9</volume>, <fpage>304</fpage>&#8211;<lpage>312</lpage>.<pub-id pub-id-type="pmid">15544168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1379/CSC-23R1.1</pub-id><pub-id pub-id-type="pmcid">PMC1065289</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>W</given-names></name>, <source>J. Am. Chem. Soc</source><year>2020</year>, <volume>142</volume>, <fpage>3862</fpage>&#8211;<lpage>3872</lpage>.<pub-id pub-id-type="pmid">31991082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.9b11490</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Arja</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Sarkis</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Patterson</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Romo</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Rathore</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Moghieb</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Abbatiello</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Robertson</surname><given-names>CS</given-names></name>, <source>Int. J. Mol. Sci</source><year>2022</year>, <volume>23</volume>, <fpage>8960</fpage>.<pub-id pub-id-type="pmid">36012232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23168960</pub-id><pub-id pub-id-type="pmcid">PMC9409281</pub-id></mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal" id="mixed-citation50"><label>a)</label><name name-style="western"><surname>Iqbal</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Gong</surname><given-names>C-X</given-names></name>, <name name-style="western"><surname>Grundke-Iqbal</surname><given-names>I</given-names></name>, <source>Curr. Alzheimer Res</source><year>2010</year>, <volume>7</volume>, <fpage>656</fpage>&#8211;<lpage>664</lpage>;<pub-id pub-id-type="pmid">20678074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/156720510793611592</pub-id><pub-id pub-id-type="pmcid">PMC3090074</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation51"><label>b)</label><name name-style="western"><surname>Lee</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Leugers</surname><given-names>CJ</given-names></name>, <source>Prog. Mol. Biol. Transl. Sci</source><year>2012</year>, <volume>107</volume>, <fpage>263</fpage>&#8211;<lpage>293</lpage>;<pub-id pub-id-type="pmid">22482453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-385883-2.00004-7</pub-id><pub-id pub-id-type="pmcid">PMC3614411</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation52"><label>c)</label><name name-style="western"><surname>Stoothoff</surname><given-names>WH</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>GV</given-names></name>, <source>Biochim. Biophys. Acta</source><year>2005</year>, <volume>1739</volume>, <fpage>280</fpage>&#8211;<lpage>297</lpage>.<pub-id pub-id-type="pmid">15615646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2004.06.017</pub-id></mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal" id="mixed-citation53"><label>a)</label><name name-style="western"><surname>Novak</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kontsekova</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Zilka</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Novak</surname><given-names>M</given-names></name>, <source>Front. Neurol. Neurosci</source><year>2018</year>, <volume>12</volume>, <fpage>798</fpage>;<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2018.00798</pub-id><pub-id pub-id-type="pmcid">PMC6224648</pub-id><pub-id pub-id-type="pmid">30450030</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation54"><label>b)</label><name name-style="western"><surname>Bittar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bhatt</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kayed</surname><given-names>R</given-names></name>, <source>Neurobiol. Dis</source><year>2020</year>, <volume>134</volume>, <fpage>104707</fpage>;<pub-id pub-id-type="pmid">31841678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2019.104707</pub-id><pub-id pub-id-type="pmcid">PMC6980703</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation55"><label>c)</label><name name-style="western"><surname>Sigurdsson</surname><given-names>EM</given-names></name>, <source>Curr. Alzheimer Res</source><year>2009</year>, <volume>6</volume>, <fpage>446</fpage>&#8211;<lpage>450</lpage>.<pub-id pub-id-type="pmid">19874269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/156720509789207930</pub-id><pub-id pub-id-type="pmcid">PMC2891148</pub-id></mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lee</surname><given-names>HE</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Pae</surname><given-names>AN</given-names></name>, <source>Future Med. Chem</source><year>2019</year>, <volume>11</volume>, <fpage>1845</fpage>&#8211;<lpage>1848</lpage>.<pub-id pub-id-type="pmid">31517533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4155/fmc-2019-0151</pub-id></mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal" id="mixed-citation57"><label>a)</label><name name-style="western"><surname>Thiviyanathan</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Gorenstein</surname><given-names>DG</given-names></name>, <source>Proteomics Clin. Appl</source><year>2012</year>, <volume>6</volume>, <fpage>563</fpage>&#8211;<lpage>573</lpage>;<pub-id pub-id-type="pmid">23090891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/prca.201200042</pub-id><pub-id pub-id-type="pmcid">PMC4021847</pub-id></mixed-citation><mixed-citation publication-type="journal" id="mixed-citation58"><label>b)</label><name name-style="western"><surname>Tian</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Ding</surname><given-names>B</given-names></name>, <source>Aggregate</source>. <year>2021</year>, <volume>2</volume>, <fpage>133</fpage>&#8211;<lpage>144</lpage>.</mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p id="P45">Functional Tau aptamer discovered by laboratory in vitro evolution workflow. (A) Schematic illustration of gel electrophoresis (GE) Selection and Arachidonic acid (AA)-induced Tau aggregation-guided Functional Selection. (B) Formation of Tauopathy and Tau aptamer inhibits Tau protein oligomerization/ aggregation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2114125-f0002.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p id="P46">Aptamer selection results. (A) Gel-shift of FAM-labeled aptamers binding to Tau in native nondenaturing PAGE. Aptamers that form binding complexes with Tau show slower migration. (B) Flow cytometry monitoring the results of GE-Selection. (C) A series of concentrations of arachidonic acid (AA) induces Tau protein aggregation analysis by SDS PAGE stained with Coomassie blue. (D) western blot monitoring each round of DNA pool inhibits Tau aggregation in vitro. (E) The normalized value of Oligomeric Tau (Oligo-Tau)/Monomeric Tau under each selected pool&#8217;s inhibitory effects. Error bars represent standard deviation, n &#8805; 3. Note: Uncropped gel images are provided in the <xref rid="SD1" ref-type="supplementary-material">Supporting Information</xref>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2114125-f0003.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p id="P47">Analysis of evolved Tau aptamers. (A) Primary binding analysis of aptamers BW1 through BW10 to Tau441 by flow cytometry. (B) Aptamer binding specificity by dot blot assay. BSA: Bovine Serum Albumin; Casein: &#945;+&#946; casein mixture; IgG: immunoglobulin G; P-Tau: phosphorylated Tau. Note: Uncropped dot images are provided in the <xref rid="SD1" ref-type="supplementary-material">Supporting Information</xref>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2114125-f0004.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><p id="P48">Inhibitory effects of Tau aptamers on the aggregation of Tau441 in vitro. (A) Tau oligomerization assay was performed by incubating Tau441 (2 &#956;M) with aptamers (6 &#956;M) for 30 min, followed by incubation with Arachidonic acid (50 &#956;M). Samples were analyzed by SDS-PAGE, followed by western blotting with Tau antibody (DA9 Mab). (B) Quantification of levels of oligomeric Tau/ monomeric Tau in each lane. ****p &lt; 0.0001 (<italic toggle="yes">n</italic> = 3, two-way ANOVA). Note: Uncropped gel image is provided in the <xref rid="SD1" ref-type="supplementary-material">Supporting Information</xref>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2114125-f0005.jpg"/></fig><fig position="float" id="F5" orientation="portrait"><label>Figure 5.</label><caption><p id="P49">Maturation of Tau aptamer BW1 by truncation and nucleotide replacement. (A) Secondary structures of BW1 serial aptamers were predicted by mFold. BW1a and BW1b were truncated from BW1. BW1c was modified from BW1b by replacing a G : T pair by A : T. (B) Primary binding analysis between aptamer candidates and Tau protein by dot blotting assay. Every membrane contains two dots (0.1 ug protein per dot), which correspond to two parallel experiments. Aptamers were labeled with Cy5 at the 5&#8217;-end. Dots were scanned simultaneously by the Typhoon Imaging System (Amersham Biosciences). Note: Uncropped dot images are provided in the <xref rid="SD1" ref-type="supplementary-material">Supporting Information</xref>. (C) Data parameters of BW1 serial aptamers. (D) The sequences of BW1 serial aptamers.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2114125-f0006.jpg"/></fig><fig position="float" id="F6" orientation="portrait"><label>Figure 6.</label><caption><p id="P50">Effects of Tau aptamers on Tau aggregation and Tau phosphorylation. (A) Schematic representation of the thioflavin-T (ThT) assay monitoring the process of Tau aggregation with the inducer (arachidonic acid or heparin), and western blot analysis to detect Tau protein phosphorylation induced with GSK3&#946; phosphorylation in vitro. (B) (C) AA- or heparin- induced Tau441 aggregation monitored in 384 well microplate format by ThT fluorescence. (D) In vitro Tau phosphorylation assay was performed by western blotting with Tau antibody (DAKO A0024 rabbit Ab). The lower band is the non-phosphorylated Tau (blue arrow label), and the upper bands are phospho-Tau species (red label) induced with GSK3&#946; phosphorylation in vitro. Note: Uncropped blot images are provided in the <xref rid="SD1" ref-type="supplementary-material">Supporting Information</xref>. (E) Quantification of the non-phospho-Tau band (blue bars) and phospho-Tau bands (gray bars) (expressed as % of total). GSK3&#946; phosphorylation-induced reduction of non-phospho-Tau was reversed most effectively by DA9 Tau monoclonal antibody (Mab) and Tau Aptamers BW1 and BW1c. Error bars are SD, n &#8804; 3.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2114125-f0007.jpg"/></fig><fig position="float" id="F7" orientation="portrait"><label>Figure 7.</label><caption><p id="P51">Neural cell-based characterization of functional Tau aptamer BW1c. (A) Confocal microscopy analysis of the internalization of 5&#8217;-Cy5-labeled BW1c in N2a cells with Lipofectamine 2000 added to facilitate aptamer-cell uptake, followed by incubation for 6 h and 24 h. (B) Cells were treated with okadaic acid (OA 100 nM) for 24 h after the internalization of aptamer 30 min. Immunoblots of N2a cells extracted protein (20 &#956;g) using total Tau Mab: DA9 (Targets Total Tau) and P-Tau Mab HL2576 4E7&#8211;1 (targets P-Tau S396/S404). The blue bracket presents monomeric P-Tau and oligomeric P-Tau. Black arrows show the non-phosphorylated Tau monomer band (46 kDa). (C) Immunoblot quantification of DA9 Mab for total Tau. (D) Immunoblot quantification of 4E7&#8211;1 for P-Tau. All data are normalized to &#946;-actin and are expressed as a percentage of control. ***p &lt; 0.001 and ****p &lt; 0.0001 (<italic toggle="yes">n</italic> = 3, two-way ANOVA). Note: Uncropped gel images are provided in the <xref rid="SD1" ref-type="supplementary-material">Supporting Information</xref>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2114125-f0008.jpg"/></fig><fig position="float" id="F8" orientation="portrait"><label>Figure 8.</label><caption><p id="P52">Illustrates Cy5.5 fluorescence microscopy images of mouse brain sections obtained 5 hours&#8217; post-intravenous injection of tau aptamer BW or BWT. The images represent both na&#239;ve and controlled cortical impact (CCI) groups, focusing on the hippocampus and cortex regions at various magnifications (Scale bars: 100, 20, and 5 &#956;m, as indicated). Panel (<bold>A</bold>) BW administration in a naive mouse, (<bold>B</bold>) BWT administration in a naive mouse, (<bold>C</bold>) BW administration in a mouse one hour post-CCI, (<bold>D</bold>) BWT administration in a mouse one hour post-CCI. Image (a) Cy5-aptamer fluorescence alone, (b) Cy5 and nuclei stain DAPI double staining. Origin of image C, D,E&amp;F are shown with red letters, (c), Cortex: hippocampus, (d) dentate gyrus (DG). (e) CA1 nuclear layer. (f) CA3 layer. Origin of image h and i are shown with red letters. Panel (g) shows cortical perivascular cells stained positive with BW/BWT. (i) Magnified CA3 region showing cytosolic staining of large BW/BWT in CA3 neuronal cell body that is non-overlapping with nuclear DAPI staining (blue). (h) Magnified region near CA3 nuclear band showing cytosolic staining of BW/BWT cells with small nuclear (interneurons or astrocytes).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2114125-f0009.jpg"/></fig></floats-group></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Radiol Adv</journal-id><journal-id journal-id-type="iso-abbrev">Radiol Adv</journal-id><journal-id journal-id-type="pmc-domain-id">4788</journal-id><journal-id journal-id-type="pmc-domain">radadv</journal-id><journal-id journal-id-type="publisher-id">radadv</journal-id><journal-title-group><journal-title>Radiology Advances</journal-title></journal-title-group><issn pub-type="epub">2976-9337</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12429239</article-id><article-id pub-id-type="pmcid-ver">PMC12429239.1</article-id><article-id pub-id-type="pmcaid">12429239</article-id><article-id pub-id-type="pmcaiid">12429239</article-id><article-id pub-id-type="pmid">41058864</article-id><article-id pub-id-type="doi">10.1093/radadv/umae021</article-id><article-id pub-id-type="publisher-id">umae021</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="category-toc-heading"><subject>Neuroradiology</subject></subj-group></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00870</subject></subj-group></article-categories><title-group><article-title><sup>18</sup>F-FDG-PET-based deep learning for predicting cognitive decline in non-demented elderly across the Alzheimer&#8217;s disease clinical spectrum</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6765-8056</contrib-id><name name-style="western"><surname>Sohn</surname><given-names initials="B">Beomseok</given-names></name><degrees>MD, PhD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft">Writing - original draft</role><aff><institution>Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine</institution>, Seoul, 06351, <country country="KR">Korea</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chung</surname><given-names initials="SJ">Seok Jong</given-names></name><degrees>MD, PhD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft">Writing - original draft</role><aff><institution>Department of Neurology, Yonsei University College of Medicine</institution>, Seoul, 03722, <country country="KR">Korea</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="JR">Jeong Ryong</given-names></name><degrees>BSc</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff><institution>Medical Artificial Intelligence Lab, School of Electrical and Electronic Engineering, Yonsei University</institution>, Seoul, 03722, <country country="KR">Korea</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hwang</surname><given-names initials="D">Dosik</given-names></name><degrees>PhD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff><institution>Medical Artificial Intelligence Lab, School of Electrical and Electronic Engineering, Yonsei University</institution>, Seoul, 03722, <country country="KR">Korea</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xie</surname><given-names initials="W">Wanying</given-names></name><degrees>MBBS</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff><institution>Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital</institution>, Singapore, 169608, <country country="SG">Singapore</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7603-7334</contrib-id><name name-style="western"><surname>Chan</surname><given-names initials="LL">Ling Ling</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff><institution>Department of Diagnostic Radiology, Singapore General Hospital</institution>, Singapore, 169608, <country country="SG">Singapore</country></aff><aff><institution>Duke-NUS Medical School</institution>, Singapore, 169857, <country country="SG">Singapore</country></aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6034-9912</contrib-id><name name-style="western"><surname>Choi</surname><given-names initials="YS">Yoon Seong</given-names></name><degrees>MD, PhD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff><institution>Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore</institution>, Singapore, 117597, <country country="SG">Singapore</country></aff><aff><institution>Clinical Imaging Research Centre, Yong Loo Lin School of Medicine, National University of Singapore</institution>, Singapore, 117597, <country country="SG">Singapore</country></aff><xref rid="umae021-cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><collab>Harvard Brain Imaging Study</collab><xref rid="umae021-FM1" ref-type="author-notes"/></contrib><contrib contrib-type="author"><collab>Japanese Alzheimer&#8217;s Disease Neuroimaging Initiative</collab><xref rid="umae021-FM1" ref-type="author-notes"/></contrib><contrib contrib-type="author"><collab> Alzheimer&#8217;s Disease Neuroimaging Initiative</collab><xref rid="umae021-FM1" ref-type="author-notes"/></contrib></contrib-group><author-notes><corresp id="umae021-cor1">Corresponding author: Yoon S. Choi, MD, PhD, Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074, Singapore (<email>yoonseong.choi07@gmail.com</email>)</corresp><fn id="umae021-FM1"><p>Data used in preparation of this article were obtained from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) database, the Japanese Alzheimer&#8217;s Disease Neuroimaging Initiative (J-ADNI) database deposited in the National Bioscience Database Center Human Database, Japan (Research ID: hum0043.v1, 2016), and Harvard Aging Brain Study (HABS). As such, the investigators of ADNI, J-ADNI and HABS provided data but did not participate in analysis or writing of this report. A complete listing of ADNI, J-ADNI, and HABS investigators can be found at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf" ext-link-type="uri">http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf</ext-link> (ADNI), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://humandbs.biosciencedbc.jp/en/hum0043-j-adni-authors" ext-link-type="uri">https://humandbs.biosciencedbc.jp/en/hum0043-j-adni-authors</ext-link> (J-ADNI), and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://habs.mgh.harvard.edu/" ext-link-type="uri">https://habs.mgh.harvard.edu/</ext-link> (HABS).</p></fn></author-notes><pub-date pub-type="collection"><month>9</month><year>2024</year></pub-date><pub-date pub-type="epub" iso-8601-date="2024-08-10"><day>10</day><month>8</month><year>2024</year></pub-date><volume>1</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">496785</issue-id><elocation-id>umae021</elocation-id><history><date date-type="received"><day>26</day><month>4</month><year>2024</year></date><date date-type="rev-recd"><day>15</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>02</day><month>8</month><year>2024</year></date><date date-type="corrected-typeset"><day>13</day><month>9</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>08</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024. Published by Oxford University Press on behalf of the Radiological Society of North America.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="umae021.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="umae021.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>With disease-modifying treatments for Alzheimer's disease (AD), prognostic tools for the pre-dementia stage are needed. This study aimed to evaluate the prognostic value of an <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography (<sup>18</sup>F-FDG-PET)-based deep-learning (DL) model in the pre-dementia stage of mild cognitive impairment (MCI) and normal cognition (NC).</p></sec><sec id="s2"><title>Materials and Methods</title><p>A <sup>18</sup>F-FDG-PET-based DL model was developed to classify diagnosis of AD-dementia vs NC using AD Neuroimaging Initiative (ADNI) and Japanese-ADNI (J-ADNI) datasets (<italic toggle="yes">n</italic>&#8201;=&#8201;756), which provided the degree of similarity to AD-dementia. The prognostic value of the DL output for cognitive decline was assessed in the ADNI MCI (<italic toggle="yes">n</italic>&#8201;=&#8201;663), J-ADNI MCI (<italic toggle="yes">n</italic>&#8201;=&#8201;129), and Harvard Aging Brain Study (HABS) NC (<italic toggle="yes">n</italic>&#8201;=&#8201;274) participants using Cox regression and calculating the integrated area under the time-dependent ROC curves (iAUC), along with clinical information and <sup>18</sup>F-FDG-PET standardized uptake value ratio (SUVR). Subgroup analysis in the amyloid-positive ADNI MCI participants was performed using Cox regression and calculating the area under the time-dependent ROC (tdAUC) curves at 4-year follow-up to assess prognostic value of DL output over clinical information, <sup>18</sup>F-FDG-PET SUVR, and amyloid PET Centiloids.</p></sec><sec id="s3"><title>Results</title><p>DL output remained independently prognostic among other factors in all three datasets (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;.05 for all by Cox regression). By adding DL output to other prognostic factors, prediction significantly improved in ADNI-MCI (iAUC differences 0.020 [0.007-0.034] before and after adding DL output) and improved without statistical significance in J-ADNI (0.020 [&#8722;0.005 to 0.044], and HABS-NC sets (0.059 [&#8722;0.003 to 0.126]). DL output showed independent (<italic toggle="yes">P</italic>&#8201;=&#8201;.002 by Cox regression) and significant added prognostic value (tdROC difference 0.019 [&lt;0.001-0.036]) over clinical information, <sup>18</sup>F-FDG-PET SUVR, and Centiloids in the amyloid-positive ADNI MCI participants.</p></sec><sec id="s4"><title>Conclusion</title><p>The <sup>18</sup>F-FDG-PET-based DL model demonstrated the potential to improve cognitive decline prediction beyond clinical information, and conventional measures from <sup>18</sup>F-FDG-PET and amyloid PET and may prove useful for clinical trial recruitment and individualized management.</p></sec></abstract><kwd-group><kwd>Alzheimer&#8217;s disease</kwd><kwd>cognitive decline</kwd><kwd>deep learning</kwd><kwd>dementia</kwd><kwd><sup>18</sup>F-FDG-PET</kwd><kwd>prognosis</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Samsung Research Funding Center of Samsung Electronics</institution></institution-wrap></funding-source><award-id>SRFC-TF2103-01</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>National Research Foundation of Korea</institution><institution-id institution-id-type="DOI">10.13039/501100003725</institution-id></institution-wrap></funding-source><award-id>MSIT, 2022-31-0220</award-id></award-group></funding-group><counts><page-count count="10"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="umae021-BOX1" position="float" orientation="portrait"><label>Abbreviations</label><p><sup>18</sup>F-FDG = <sup>18</sup>F-fluorodeoxyglucose; AD = Alzheimer&#8217;s disease; ADNI = Alzheimer&#8217;s Disease Neuroimaging Initiative; APOE4 = apolipoprotein E4; AUC = area under the receiver operating characteristic curve; DL = deep learning; FAQ = Functional Activities Questionnaire; HABS = Harvard Aging Brain Study; iAUC = integrated area under the time-dependent receiver operating characteristic curve; J-ADNI = Japanese Alzheimer&#8217;s Disease Neuroimaging Initiative; MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination; NC = normal cognition; PACC = Preclinical Alzheimer's Cognitive Composite; PET = positron emission tomography; ROC = receiver operating characteristic; SUV = standardized uptake value; SUVR = standardized uptake value ratio; T1W1 = T1-weighted; tdAUC = area under the time-dependent receiver operating characteristic curve</p><p>
<bold>Summary</bold>
</p><p><sup>18</sup>F-FDG-PET-based deep learning model may help improve the prediction of cognitive decline in non-demented elderly individuals beyond conventional <sup>18</sup>F-FDG-PET measures as well as clinical characteristics.</p><p>
<bold>Key Results</bold>
</p><list list-type="bullet"><list-item><p>A deep learning (DL) model captured the hypometabolic patterns related to Alzheimer&#8217;s disease (AD) on <sup>18</sup>F-FDG-PET images and provided the degree of similarity to AD-dementia.</p></list-item><list-item><p>The DL output showed independent and added prognostic value over clinical characteristics and conventional <sup>18</sup>F-FDG-PET for predicting cognitive decline in non-demented elderly.</p></list-item><list-item><p>The DL output also showed independent and added prognostic value in the amyloid-positive subgroup even beyond amyloid PET measures.</p></list-item></list></boxed-text><sec sec-type="intro"><title>Introduction</title><p>Alzheimer&#8217;s disease (AD) is the leading cause of dementia in the elderly. The introduction of the ATN (amyloid, tau, neurodegeneration) biomarker-driven diagnosis of AD, coupled with recent FDA-approved treatments and clinical trials targeting early stages of AD, underscores the importance of identifying individuals with pre-dementia stages of mild cognitive impairment (MCI) or normal cognition (NC) before the onset of overt dementia symptoms.<xref rid="umae021-B1" ref-type="bibr"><sup>1&#8211;3</sup></xref> However, due to the heterogeneous prognosis of the non-demented elderly, with only 10%-15% of individuals with MCI progressing to AD-dementia,<xref rid="umae021-B4" ref-type="bibr"><sup>4</sup></xref> there is a critical need for accurate prognostic tools to identify potential treatment beneficiaries and to aid in the interpretation of ongoing AD clinical trials.<xref rid="umae021-B5" ref-type="bibr"><sup>5&#8211;8</sup></xref></p><p><sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG)-positron emission tomography (PET), used as a measure of N (neurodegeneration) in ATN, provides earlier detection of neuronal degeneration than MRI changes.<xref rid="umae021-B9" ref-type="bibr"><sup>9</sup></xref> Although conventional metrics such as standardized uptake value (SUV) ratio (SUVR) of <sup>18</sup>F-FDG PET have been evaluated for prognostic prediction in AD, their accuracy remains variable.<xref rid="umae021-B10" ref-type="bibr"><sup>10&#8211;14</sup></xref></p><p>Deep learning (DL) is capable of extracting relevant features directly from images, outperforming human visual cognition and conventional imaging measures.<xref rid="umae021-B15" ref-type="bibr"><sup>15</sup></xref> Previous studies have applied DL to <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography (<sup>18</sup>F-FDG-PET) for cross-sectional diagnosis, such as differentiating between NC and AD-dementia.<xref rid="umae021-B16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="umae021-B17" ref-type="bibr"><sup>17</sup></xref> However, the prognostic potential of such DL models for predicting future cognitive decline remains unexplored. Several studies have used FDG-PET-based machine learning for prognosis,<xref rid="umae021-B18" ref-type="bibr"><sup>18&#8211;20</sup></xref> but they mainly trained models on MCI subjects only. This approach did not take into account the broader, continuous disease trajectory from NC to AD-dementia, thereby limiting its utility to MCI subjects alone. In addition, previous studies faced challenges including small sample sizes, limited ethnic diversity, and lack of integration of conventional imaging measures such as SUVR.</p><p>We hypothesized that a DL model trained on NC and AD-dementia, originally designed to discriminate AD-dementia from NC, could be repurposed to predict cognitive trajectories in the pre-dementia stages, providing insight into where predementia individuals are on the spectrum of cognitive decline from NC to AD-dementia. In this study, we attempted to assess the prognostic potential of <sup>18</sup>F-FDG-PET-based DL in a clinical context. We predicted cognitive decline in non-demented elderly individuals of different stages and ethnicities in the presence of conventional <sup>18</sup>F-FDG-PET measures (ie, SUVR) and clinical information for the entire follow-up period. We also assessed our DL within the biomarker-based AD framework in a subgroup where amyloid burden was considered. Cognitive decline in our study was defined as either conversion from MCI to AD-dementia or conversion from NC to MCI. Our aim was to develop and test the prognostic value of an <sup>18</sup>F-FDG-PET-based DL model for the prediction of cognitive decline in elderly individuals with MCI and NC.</p></sec><sec><title>Materials and methods</title><sec><title>Study population</title><p>The patient enrollment process is shown in <xref rid="umae021-F1" ref-type="fig">Figure&#160;1</xref>. Data used in this study were obtained from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://adni.loni.usc.edu" ext-link-type="uri">https://adni.loni.usc.edu</ext-link>), the Japanese ADNI (J-ADNI, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.j-adni.org" ext-link-type="uri">https://www.j-adni.org</ext-link>)<xref rid="umae021-B20" ref-type="bibr"><sup>20</sup></xref> studies, and the Harvard Aging Brain Study (HABS, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://habs.mgh.harvard.edu/" ext-link-type="uri">https://habs.mgh.harvard.edu/</ext-link>).<xref rid="umae021-B21" ref-type="bibr"><sup>21</sup></xref> The details of ADNI, J-ADNI, and HABS are described in <xref rid="sup1" ref-type="supplementary-material">Supplementary Material</xref>. Additionally, the inclusion criteria for the three datasets and the number of individuals included in the analysis are detailed in <xref rid="umae021-F1" ref-type="fig">Figure&#160;1</xref> and the <xref rid="sup1" ref-type="supplementary-material">Supplementary Material</xref>.</p><fig position="float" id="umae021-F1" orientation="portrait"><label>Figure 1.</label><caption><p>Participant enrollment flowchart. Abbreviations: <sup>18</sup>F-FDG = <sup>18</sup>F-fluorodeoxyglucose; AD = Alzheimer&#8217;s disease; ADNI = Alzheimer&#8217;s disease neuroimaging initiative; HABS = Harvard Aging Brain Study; J-ADNI = Japanese-Alzheimer&#8217;s Disease Neuroimaging Initiative; MCI = mild cognitive impairment; NC = normal cognition; PET = positron emission tomography.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="umae021f1.jpg"/></fig><p>For prognostic value assessment, follow-up duration and time to cognitive decline (ie, conversion from MCI to AD-dementia in the ADNI and J-ADNI MCI groups and from NC to MCI in the HABS NC group) were recorded in the ADNI MCI, J-ADNI MCI, and HABS NC groups. As the number of individuals progressing from MCI to AD-dementia decreases sharply after 9&#8201;years of follow-up (<xref rid="sup1" ref-type="supplementary-material">Figure S1</xref>), we used the first 9&#8201;years of follow-up data for the ADNI MCI group. In addition, amyloid PET quantification (Centiloid) and amyloid-positivity information of the ADNI MCI group were recorded from the ADNI website for the subgroup analysis.</p><p>The characteristics of the AD-dementia/NC groups from the ADNI and J-ADNI datasets are detailed in <xref rid="sup1" ref-type="supplementary-material">Table S1</xref>; the number of participants was 281/279 and 105/91, respectively. <xref rid="umae021-T1" ref-type="table">Table&#160;1</xref> summarizes the characteristics of the ADNI MCI (<italic toggle="yes">n</italic>&#8201;=&#8201;663), J-ADNI MCI (<italic toggle="yes">n</italic>&#8201;=&#8201;129) and HABS NC (<italic toggle="yes">n</italic>&#8201;=&#8201;274) groups.</p><table-wrap position="float" id="umae021-T1" orientation="portrait"><label>Table 1.</label><caption><p>Study population characteristics.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Characteristic</th><th rowspan="1" colspan="1">ADNI MCI</th><th rowspan="1" colspan="1">J-ADNI MCI</th><th rowspan="1" colspan="1">HABS NC</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>Baseline diagnosis</bold>
</td><td rowspan="1" colspan="1">MCI</td><td rowspan="1" colspan="1">MCI</td><td rowspan="1" colspan="1">NC</td></tr><tr><td rowspan="1" colspan="1">
<bold>Number of subjects</bold>
</td><td rowspan="1" colspan="1">663</td><td rowspan="1" colspan="1">129</td><td rowspan="1" colspan="1">274</td></tr><tr><td rowspan="1" colspan="1"><bold>Age in years (mean</bold>&#8201;<bold>&#177;</bold>&#8201;<bold>SD)</bold></td><td rowspan="1" colspan="1">72.6&#8201;&#177;&#8201;7.5</td><td rowspan="1" colspan="1">72.4&#8201;&#177;&#8201;5.6</td><td rowspan="1" colspan="1">73.7&#8201;&#177;&#8201;6.1</td></tr><tr><td rowspan="1" colspan="1">
<bold>Gender, number (%)</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;Female</bold>
</td><td rowspan="1" colspan="1">272 (41.0%)</td><td rowspan="1" colspan="1">66 (51.2%)</td><td rowspan="1" colspan="1">164 (59.9%)</td></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;Male</bold>
</td><td rowspan="1" colspan="1">391 (59.0%)</td><td rowspan="1" colspan="1">63 (48.8%)</td><td rowspan="1" colspan="1">110 (40.1%)</td></tr><tr><td rowspan="1" colspan="1"><bold>Education in years (mean</bold>&#8201;<bold>&#177;</bold>&#8201;<bold>SD)</bold></td><td rowspan="1" colspan="1">16.1&#8201;&#177;&#8201;2.7</td><td rowspan="1" colspan="1">13.3&#8201;&#177;&#8201;2.9</td><td rowspan="1" colspan="1">15.9&#8201;&#177;&#8201;3.0</td></tr><tr><td rowspan="1" colspan="1">
<bold>APOE4 allele</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;0</bold>
</td><td rowspan="1" colspan="1">340 (51.3%)</td><td rowspan="1" colspan="1">59 (45.7%)</td><td rowspan="1" colspan="1">196 (71.5%)</td></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;1</bold>
</td><td rowspan="1" colspan="1">252 (38.0%)</td><td rowspan="1" colspan="1">62 (48.1%)</td><td rowspan="1" colspan="1">74 (27.0%)</td></tr><tr><td rowspan="1" colspan="1">
<bold>&#8195;2</bold>
</td><td rowspan="1" colspan="1">71 (10.7%)</td><td rowspan="1" colspan="1">8 (6.2%)</td><td rowspan="1" colspan="1">4 (1.5%)</td></tr><tr><td rowspan="1" colspan="1"><bold>FAQ (mean</bold>&#8201;<bold>&#177;</bold>&#8201;<bold>SD)</bold></td><td rowspan="1" colspan="1">2.9&#8201;&#177;&#8201;3.8</td><td rowspan="1" colspan="1">3.9&#8201;&#177;&#8201;4.3</td><td rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="1" colspan="1"><bold>MMSE (mean</bold>&#8201;<bold>&#177;</bold>&#8201;<bold>SD)</bold></td><td rowspan="1" colspan="1">27.8&#8201;&#177;&#8201;1.8</td><td rowspan="1" colspan="1">26.4&#8201;&#177;&#8201;1.7</td><td rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="1" colspan="1"><bold>PACC (mean</bold>&#8201;<bold>&#177;</bold>&#8201;<bold>SD)</bold></td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">&#8722;0.1&#8201;&#177;&#8201;0.7</td></tr><tr><td rowspan="1" colspan="1">
<bold>Follow-up time (quartiles in years)</bold>
</td><td rowspan="1" colspan="1">2.5-7.0</td><td rowspan="1" colspan="1">2.9-3.0</td><td rowspan="1" colspan="1">4.5-5.2</td></tr><tr><td rowspan="1" colspan="1">
<bold>Progressors</bold>
</td><td rowspan="1" colspan="1">224 (33.8%)</td><td rowspan="1" colspan="1">66 (51.2%)</td><td rowspan="1" colspan="1">22 (8.0%)</td></tr><tr><td rowspan="1" colspan="1">
<bold>Time to progression (quartiles in years)</bold>
</td><td rowspan="1" colspan="1">1.0-4.0</td><td rowspan="1" colspan="1">0.6-2.0</td><td rowspan="1" colspan="1">3.0-5.1</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>Abbreviations: ADNI = Alzheimer&#8217;s disease neuroimaging initiative; APOE4 = Apolipoprotein E4; FAQ = functional activities questionnaire; HABS = Harvard Aging Brain Study; J-ADNI = Japanese-Alzheimer&#8217;s disease neuroimaging initiative; MCI = mild cognitive impairment; MMSE = mini-mental state examination; NC = normal cognition; PACC = Preclinical Alzheimer's Cognitive Composite.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Study design</title><p>The study design is shown in <xref rid="umae021-F1" ref-type="fig">Figure&#160;1</xref>. First, a DL model for classifying AD-dementia vs NC was developed, which provided the degree of similarity to AD-dementia from <sup>18</sup>F-FDG-PET images (<xref rid="sup1" ref-type="supplementary-material">Figure S2</xref>). The ADNI AD-dementia/NC set was divided into the development (<italic toggle="yes">n</italic>&#8201;=&#8201;487) and test sets (<italic toggle="yes">n&#8201;</italic>=&#8201;73) with stratification for the AD-dementia/NC ratio. The DL model was developed using the ADNI AD-dementia/NC development set and tested on the ADNI AD-dementia/NC test set, and externally tested on the J-ADNI AD-dementia/NC set to assess the diagnostic performance on an Asian population. Saliency maps were generated and averaged from the ADNI AD-dementia/NC test set using layer-wise relevance propagation, calculating relevance in each anatomical area.<xref rid="umae021-B22" ref-type="bibr"><sup>22</sup></xref> The DL model development and saliency maps are detailed in the <xref rid="sup1" ref-type="supplementary-material">Supplementary Material</xref>.</p><p>Second, after the DL model development, the prognostic value of DL output for cognitive decline was evaluated in conjunction with clinical features and <sup>18</sup>F-FDG-PET SUVR in the ADNI MCI, J-ADNI MCI, and HABS NC sets. The prognostic value of DL output was assessed in the three different datasets to assess the applicability of our model across different ethnicities and baseline diagnoses. In addition, the subgroup analysis for amyloid-positive participants from the ADNI MCI was performed to assess the applicability of our model in the biomarker-based framework of AD.</p></sec><sec><title>Image processing</title><p>The T1WI and <sup>18</sup>F-FDG-PET images were downloaded from the ADNI, J-ADNI, and HABS data inventory. The image processing for the DL model included registration of <sup>18</sup>F-FDG-PET images to T1WI and MNI standard space by using FSL FLIRT, background cropping, resampling to a 72 &#215; 72 &#215; 72 matrix, and min&#8211;max normalization of voxel values, where the normalized voxel value is calculated as voxel<sub>normalized</sub> = (voxel<sub>original</sub>&#8201;&#8722;&#8201;voxel<sub>min</sub>)/(voxel<sub>max</sub>&#8201;&#8722;&#8201;voxel<sub>min</sub>), where voxel<sub>min</sub> and voxel<sub>max</sub> represent the minimum and maximum values of the <sup>18</sup>F-FDG-PET voxel values.</p><p><sup>18</sup>F-FDG-PET SUVR values of the ADNI MCI set were provided by the ADNI.<xref rid="umae021-B23" ref-type="bibr"><sup>23</sup></xref> For the J-ADNI MCI and HABS NC sets, SUVRs were calculated by the author using the posterior cingulate and precuneus as targets and the pons as a reference.<xref rid="umae021-B24" ref-type="bibr"><sup>24</sup></xref> The J-ADNI MCI T1WIs were segmented with FreeSurfer, and <sup>18</sup>F-FDG-PET images were registered to T1WI for SUVR calculations, while HABS provided SUVRs of each anatomical region to calculate the SUVRs. Amyloid positivity information and Centiloid values of the ADNI MCI set were provided by the ADNI side, as described elsewhere (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://adni.loni.usc.edu/updated-uc-berkeley-amyloid-pet-methods/" ext-link-type="uri">https://adni.loni.usc.edu/updated-uc-berkeley-amyloid-pet-methods/</ext-link>), which was used for the subgroup analysis as detailed later.</p></sec><sec><title>Statistical analysis</title><p>Statistical tests were performed in R, version 4.2.1 (R Foundation for Statistical Computing). Performance of the DL output in classifying AD-dementia vs NC was assessed using the area under the receiver operating characteristic (ROC) curve (AUC) and accuracy. DL-ADprob prediction of &#8805;0.5 was classified as AD-dementia, while values below 0.5 were considered NC for calculating accuracy.</p><p>In assessing the prognostic value of the DL output, the main outcome was conversion from MCI to AD-dementia in the ADNI MCI and J-ADNI MCI sets, and from NC to MCI in the HABS NC set. The prognostic value of the DL output was assessed in three ways: First, the ADNI and J-ADNI MCI sets were divided into three groups based on the DL output tertiles, while the HABS NC set was divided into two groups based on the DL output median (low-risk: DL output &lt; the median, high-risk: DL output &#8805; the median) due to the small number of progressors (<xref rid="umae021-T1" ref-type="table">Table&#160;1</xref>). The prognosis was compared between different risk groups using the log-rank test. Additionally, the SUVR median value was used to divide the ADNI MCI, J-ADNI MCI, and HABS NC sets into two risk groups (low-risk: SUVR &#8805; the median, high-risk: SUVR &lt; the median). If the SUVR median-based risk groups significantly stratified prognosis, individuals were further stratified into four different risk groups based on the median values of both SUVR and DL output, with various combinations of low and high-risk groups based on SUVR and DL output. Specifically, the prognosis was compared between the two subgroups belonging to discordant risk groups of SUVR and DL output by log-rank test. Second, the independent prognostic value of DL output was assessed by Cox regression analysis with DL output along with clinical features (ie age, gender, education, APOE4, FAQ, and MMSE for the ADNI MCI and J-ADNI MCI sets, and age, gender, education, APOE4 and PACC for the HABS NC set) and SUVR. Third, the added prognostic value of DL output over clinical features and SUVR was assessed by calculating the integrated area under the time-dependent ROC curves (iAUC) for Cox regression models with clinical features and SUVR only (Model 1) and with DL output added (Model 2). The iAUC measures prediction accuracy over time, with an iAUC of 1 indicating perfect prediction and 0.5 indicating no better than random guessing.<xref rid="umae021-B25" ref-type="bibr"><sup>25</sup></xref> The iAUC values were compared between Model 1 and 2 through 1000 resampling iterations. Statistical significance was determined if the 95% CI of iAUC difference did not include zero.</p><p>A subgroup analysis of ADNI MCI participants who were amyloid-positive on baseline amyloid PET scans was performed. Similarly, Kaplan-Meier curves were plotted for risk groups based on DL output (low risk: DL power &lt; median, high risk: DL power &#8805; median), and prognoses were compared using the log-rank test. The independent prognostic value of DL output was assessed by Cox regression analysis. Clinical features, <sup>18</sup>F-FDG-PET SUVR, and amyloid PET Centiloids were included as covariates. Additionally, the added prognostic value of DL output was assessed by calculating the area under the time-dependent ROC curves at 4-year follow-up (tdAUC). The tdAUCs of Cox regression models before (Model 1) and after adding DL output (Model 2) to clinical features, <sup>18</sup>F-FDG-PET SUVR and Centiloids were compared by 1000 resampling iterations.</p></sec><sec><title>Deep learning model availability</title><p>The trained model is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/yoonchoi-neuro/FDG-PET_AD" ext-link-type="uri">https://github.com/yoonchoi-neuro/FDG-PET_AD</ext-link>. All the data used in this study are available through the respective portals.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Performance of the DL in classification of AD-dementia vs NC</title><p><sup>18</sup>F-FDG-PET-based DL could distinguish between AD-dementia and NC with AUCs of 0.97 and 0.98, and accuracies of 91.8% and 90.8% on the ADNI AD-dementia/NC test set and the J-ADNI AD-dementia/NC set, respectively. On the saliency map (<xref rid="umae021-F2" ref-type="fig">Figure&#160;2A and B</xref>), the precuneus cortex (37.5%) was the most relevant, followed by the posterior cingulate cortex (21.4%), intracalcarine cortex (11.3%), and cuneal cortex (10.6%).</p><fig position="float" id="umae021-F2" orientation="portrait"><label>Figure 2.</label><caption><p>Saliency map of the <sup>18</sup>F-FDG-PET-based deep learning model for Alzheimer&#8217;s dementia.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="umae021f2.jpg"/></fig></sec><sec><title>Prognostic value of the DL output</title><p>The DL output-based risk groups significantly stratified the prognosis of the ADNI MCI, J-ADNI MCI, and HABS NC sets (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001 for the ADNI and J-ADNI MCI sets, and <italic toggle="yes">P</italic>&#8201;=&#8201;.034 for the HABS NC set by log-rank test, <xref rid="umae021-F3" ref-type="fig">Figure&#160;3</xref>). In contrast, the SUVR-based risk groups significantly stratified prognosis only in the ADNI MCI set only (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001 by log-rank test), but not in the J-ADNI MCI and HABS NC sets (<italic toggle="yes">P</italic>&#8201;=&#8201;.072 and .340 by log-rank test, respectively, <xref rid="sup1" ref-type="supplementary-material">Figure S3</xref>). In the ADNI MCI set, the four risk groups split by the medians of SUVR and DL output significantly stratified prognoses (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001 by log-rank test, <xref rid="umae021-F3" ref-type="fig">Figure&#160;3B</xref>). Among the two groups with discordant risk from SUVR and DL output, the group with DL output-based high-risk and SUVR-based low-risk tended to have a worse prognosis than the group with DL output-based low-risk and SUVR-based high-risk, despite lower risk based on SUVR (<italic toggle="yes">P</italic>&#8201;=&#8201;.095 by log-rank test, <xref rid="umae021-F3" ref-type="fig">Figure&#160;3B</xref>). The representative PET images of the four groups in the ADNI MCI set are shown in <xref rid="umae021-F4" ref-type="fig">Figure&#160;4A-D</xref>.</p><fig position="float" id="umae021-F3" orientation="portrait"><label>Figure 3.</label><caption><p>Kaplan-Meier curves showing the cumulative incidence of cognitive decline in the ADNI (A and B), J-ADNI (C), and HABS (D) data, stratified by DL tertiles (A and C), DL median (D) and the median of DL and <sup>18</sup>F-FDG-PET SUVR (B). Abbreviations: ADNI = Alzheimer&#8217;s disease neuroimaging initiative; DL = deep-learning model for classification of AD-dementia vs NC; HABS = Harvard Aging Brain Study; J-ADNI = Japanese-Alzheimer&#8217;s Disease Neuroimaging Initiative; SUVR = standardized uptake value ratio.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="umae021f3.jpg"/></fig><fig position="float" id="umae021-F4" orientation="portrait"><label>Figure 4.</label><caption><p>Representative brain PET images of the four groups in the ADNI MCI set, categorized by combinations of DL and SUVR high- and low-risk predictions. (A) DL low risk &amp; SUVR low risk, no progression during 7.98&#8201;years of follow-up. (B) DL low risk &amp; SUVR high risk, no progression within 8.19&#8201;years of follow-up. (C) DL high risk and SUVR low risk, progression at 1.00&#8201;years of follow-up. (D) DL high risk &amp; SUVR high risk, progression at 0.99&#8201;years of follow-up. Abbreviations: SUVR = standardized uptake value ratio; ADNI = Alzheimer&#8217;s disease neuroimaging initiative; MCI = mild cognitive impairment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="umae021f4.jpg"/></fig><p>In Cox regression analyses, the DL output remained independently prognostic among clinical features and SUVR in all datasets (HR 3.45 [2.39-4.98], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001 for the ADNI-MCI; HR 2.28 [1.16-4.46], <italic toggle="yes">P</italic>&#8201;=&#8201;.016 for the J-ADNI MCI; and HR 4.57 [1.52-13.75], <italic toggle="yes">P</italic>&#8201;=&#8201;.007 for the HABS NC sets, <xref rid="umae021-T2" ref-type="table">Table&#160;2</xref>). The performance of the Cox regression models before and after adding DL output is shown in <xref rid="umae021-T3" ref-type="table">Table&#160;3</xref>. The addition of DL output to clinical features and SUVR significantly improved the prognosis prediction in the ADNI MCI set (iAUC 0.768 [0.744-0.791] and 0.787 [0.766-0.811] for Model 1 and 2, respectively, iAUC difference 0.020 [0.007-0.034]), while it increased prognostic performance without statistical significance in the J-ADNI MCI (iAUC 0.694 [0.639-0.752] and 0.716 [0.657-0.772] for Model 1 and 2, respectively, iAUC difference 0.020 [&#8722;0.005 to 0.044]) and HABS NC sets (iAUC 0.817 [0.692-0.909] and 0.902 [0.751-0.951] for Model 1 and 2, respectively, iAUC difference 0.059 [&#8722;0.003 to 0.126]).</p><table-wrap position="float" id="umae021-T2" orientation="portrait"><label>Table 2.</label><caption><p>Cox regression model of cognitive decline with DL model output, clinical features, and <sup>18</sup>F-FDG-PET in the ADNI MCI, J-ADNI MCI, and HABS NC sets.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="char" char="(" span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="char" char="(" span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="char" char="(" span="1"/><col valign="top" align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th colspan="2" rowspan="1">ADNI MCI<hr/></th><th colspan="2" rowspan="1">J-ADNI MCI<hr/></th><th colspan="2" rowspan="1">HABS NC<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">
<bold>Hazard ratio (95% CI)</bold>
</th><th rowspan="1" colspan="1">
<bold><italic toggle="yes">P</italic> value</bold>
</th><th rowspan="1" colspan="1">
<bold>Hazard ratio (95% CI)</bold>
</th><th rowspan="1" colspan="1">
<bold><italic toggle="yes">P</italic> value</bold>
</th><th rowspan="1" colspan="1">
<bold>Hazard ratio (95% CI)</bold>
</th><th rowspan="1" colspan="1">
<bold><italic toggle="yes">P</italic> value</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>Age (years)</bold>
</td><td rowspan="1" colspan="1">1.01 (0.99-1.03)</td><td rowspan="1" colspan="1">.227</td><td rowspan="1" colspan="1">1.01 (0.96-1.06)</td><td rowspan="1" colspan="1">.786</td><td rowspan="1" colspan="1">1.09 (1.00-1.20)</td><td rowspan="1" colspan="1">.053</td></tr><tr><td rowspan="1" colspan="1">
<bold>Gender (male vs female)</bold>
</td><td rowspan="1" colspan="1">0.85 (0.65-1.12)</td><td rowspan="1" colspan="1">.254</td><td rowspan="1" colspan="1">1.07 (0.59-1.94)</td><td rowspan="1" colspan="1">.818</td><td rowspan="1" colspan="1">0.20 (0.06-0.62)</td><td rowspan="1" colspan="1">.006</td></tr><tr><td rowspan="1" colspan="1">
<bold>Education (years)</bold>
</td><td rowspan="1" colspan="1">1.01 (0.96-1.06)</td><td rowspan="1" colspan="1">.666</td><td rowspan="1" colspan="1">0.99 (0.89-1.09)&#160;</td><td rowspan="1" colspan="1">.772</td><td rowspan="1" colspan="1">1.30 (1.07-1.59)</td><td rowspan="1" colspan="1">.010</td></tr><tr><td rowspan="1" colspan="1">
<bold>APOE4 status</bold>
</td><td rowspan="1" colspan="1">1.72 (1.42-2.08)</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">1.31 (0.85-2.03)</td><td rowspan="1" colspan="1">.219</td><td rowspan="1" colspan="1">1.92 (0.95-3.87)</td><td rowspan="1" colspan="1">.070</td></tr><tr><td rowspan="1" colspan="1">
<bold>MMSE</bold>
</td><td rowspan="1" colspan="1">0.90 (0.84-0.98)</td><td rowspan="1" colspan="1">.013</td><td rowspan="1" colspan="1">0.91 (0.77-1.07)</td><td rowspan="1" colspan="1">.245</td><td colspan="2" align="left" rowspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">
<bold>FAQ</bold>
</td><td rowspan="1" colspan="1">1.12 (1.09-1.15)</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">1.15 (1.08-1.23)</td><td rowspan="1" colspan="1">&lt;.001</td><td colspan="2" align="left" rowspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">
<bold>PACC</bold>
</td><td colspan="2" align="left" rowspan="1">NA</td><td colspan="2" align="left" rowspan="1">NA</td><td rowspan="1" colspan="1">0.19 (0.08-0.45)</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">
<bold>SUVR</bold>
</td><td rowspan="1" colspan="1">0.04 (0.01-0.14)</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">1.62 (0.13-20.22)&#160;</td><td rowspan="1" colspan="1">.706</td><td rowspan="1" colspan="1">2.30 (0.07-73.95)</td><td rowspan="1" colspan="1">.639</td></tr><tr><td rowspan="1" colspan="1">
<bold>DL</bold>
</td><td rowspan="1" colspan="1">3.45 (2.39-4.98)</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">2.28 (1.16-4.46)</td><td rowspan="1" colspan="1">.016</td><td rowspan="1" colspan="1">4.57 (1.52-13.75)</td><td rowspan="1" colspan="1">.007</td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><p>Abbreviations: ADNI = Alzheimer&#8217;s disease neuroimaging initiative; APOE4. apolipoprotein E4; DL = deep-learning model for classification of AD-dementia vs NC; FAQ = Functional Activities Questionnaire; J-ADNI = Japanese-Alzheimer&#8217;s disease neuroimaging initiative; HABS = Harvard Aging Brain Study; MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination; NC = normal cognition; PACC = Preclinical Alzheimer's Cognitive Composite; SUVR = standardized uptake value ratio.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="umae021-T3" orientation="portrait"><label>Table 3.</label><caption><p>Performance of Cox regression models in the prediction of cognitive decline.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="char" char="(" span="1"/><col valign="top" align="char" char="(" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Dataset</th><th rowspan="1" colspan="1">Predictors</th><th rowspan="1" colspan="1">iAUC (95% CI)</th><th rowspan="1" colspan="1">
<bold>iAUC difference</bold>
<break/>
<bold>(95% CI)</bold>
</th></tr></thead><tbody><tr><td rowspan="2" colspan="1">ADNI MCI</td><td rowspan="1" colspan="1">Clinical features<sup>a</sup> + SUVR</td><td rowspan="1" colspan="1">0.768 (0.744-0.791)</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Clinical features + SUVR + DL<sup>b</sup></td><td rowspan="1" colspan="1">0.787 (0.766-0.811)</td><td rowspan="1" colspan="1">0.020 (0.007-0.034)</td></tr><tr><td rowspan="2" colspan="1">J-ADNI MCI</td><td rowspan="1" colspan="1">Clinical features + SUVR</td><td rowspan="1" colspan="1">0.694 (0.639-0.752)</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Clinical features + SUVR + DL</td><td rowspan="1" colspan="1">0.716 (0.657-0.772)</td><td rowspan="1" colspan="1">0.020 (&#8722;0.005 to 0.044)</td></tr><tr><td rowspan="2" colspan="1">HABS NC</td><td rowspan="1" colspan="1">Clinical features + SUVR</td><td rowspan="1" colspan="1">0.817 (0.692-0.909)</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Clinical features + SUVR + DL</td><td rowspan="1" colspan="1">0.902 (0.751-0.951)</td><td rowspan="1" colspan="1">0.059 (&#8722;0.003 to 0.126)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn3"><label>a</label><p>Clinical features consisted of age, gender, years of education, APOE4 allele, FAQ and MMSE scores for the ADNI and J-ADNI data, and age, gender, years of education, APOE4 allele, and PACC score for HABS data.</p></fn><fn id="tblfn4"><label>b</label><p>The DL output obtained from the <sup>18</sup>F-FDG-PET images.</p></fn><fn id="tblfn5"><p>Abbreviations: ADNI = Alzheimer&#8217;s disease neuroimaging initiative; DL = deep-learning model for classification of AD-dementia vs NC; HABS = Harvard Aging Brain Study; iAUC integrated area under the time-dependent receiver operating characteristic curve J-ADNI = Japanese-Alzheimer&#8217;s disease neuroimaging initiative; MCI = mild cognitive impairment; NC = normal cognition; SUVR = standardized uptake value ratio.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Subgroup analysis in the amyloid-positive participants</title><p>In the ADNI MCI group, 486 out of 663 participants had a baseline amyloid PET scan, of whom 258 were amyloid positive. Of the 258 amyloid-positive participants, 144 and 92 participants had progressed to AD-dementia during the entire follow-up period and at 4&#8201;years, respectively. The DL output-based risk groups significantly stratified prognosis of cognitive decline in the ADNI MCI set (<italic toggle="yes">P</italic>&#8201;=&#8201;.001 by log-rank test, <xref rid="umae021-F5" ref-type="fig">Figure&#160;5A</xref>). The DL output was independently prognostic in the presence of clinical features, <sup>18</sup>F-FDG-PET SUVR and Centiloids (HR 2.60 [1.40-4.80], <italic toggle="yes">P</italic>&#8201;=&#8201;.002 by Cox regression, <xref rid="umae021-T4" ref-type="table">Table&#160;4</xref>). The addition of DL output to clinical information, <sup>18</sup>F-FDG-PET SUVR and Centiloids significantly improved the prediction of cognitive decline at 4-year follow-up in the amyloid-positive participants from the ADNI MCI set (tdAUC 0.720 [0.678-0.760] and 0.739 [0.691-0.783] for Model 1 and 2, respectively, tdAUC difference 0.019 [&lt;0.001-0.036]), <xref rid="umae021-F5" ref-type="fig">Figure&#160;5B</xref>.</p><fig position="float" id="umae021-F5" orientation="portrait"><label>Figure 5.</label><caption><p>Cox regression models for predicting cognitive decline in the amyloid-positive participants from the ADNI MCI set. (A) Kaplan-Meier curves stratified by the DL tertiles, (B) time-dependent ROC curve at 4-year follow-up before (Model 1) and after (Model 2) addling DL output to clinical features, <sup>18</sup>F-FDG-PET SUVR, and amyloid PET Centiloids. Abbreviations: AUC = area under the receiver operating characteristic curve; DL = deep-learning model for classification of AD-dementia vs NC.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="umae021f5.jpg"/></fig><table-wrap position="float" id="umae021-T4" orientation="portrait"><label>Table 4.</label><caption><p>Cox regression models of cognitive decline in the amyloid-positive participants from the ADNI MCI set with deep learning output, clinical features, <sup>18</sup>F-FDG-PET, and amyloid PET.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="char" char="(" span="1"/><col valign="top" align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Hazard ratio (95% CI)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>Age (years)</bold>
</td><td rowspan="1" colspan="1">1.01 (0.98-1.04)</td><td rowspan="1" colspan="1">.538</td></tr><tr><td rowspan="1" colspan="1">
<bold>Gender</bold>
</td><td rowspan="1" colspan="1">0.89 (0.59-1.34)</td><td rowspan="1" colspan="1">.568</td></tr><tr><td rowspan="1" colspan="1">
<bold>Education (years)</bold>
</td><td rowspan="1" colspan="1">1.02 (0.94-1.10)</td><td rowspan="1" colspan="1">.668</td></tr><tr><td rowspan="1" colspan="1">
<bold>APOE4 status</bold>
</td><td rowspan="1" colspan="1">1.31 (0.97-1.77)</td><td rowspan="1" colspan="1">.082</td></tr><tr><td rowspan="1" colspan="1">
<bold>MMSE</bold>
</td><td rowspan="1" colspan="1">0.94 (0.83-1.05)</td><td rowspan="1" colspan="1">.264</td></tr><tr><td rowspan="1" colspan="1">
<bold>FAQ</bold>
</td><td rowspan="1" colspan="1">1.15 (1.10-1.20)</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">
<bold><sup>18</sup>F-FDG-PET SUVR</bold>
</td><td rowspan="1" colspan="1">0.02 (0.00-0.18)</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">
<bold>Amyloid PET Centiloids</bold>
</td><td rowspan="1" colspan="1">1.01 (1.00-1.01)</td><td rowspan="1" colspan="1">.005</td></tr><tr><td rowspan="1" colspan="1">
<bold>DL</bold>
</td><td rowspan="1" colspan="1">2.60 (1.40-4.80)</td><td rowspan="1" colspan="1">.002</td></tr></tbody></table><table-wrap-foot><fn id="tblfn6"><p>Abbreviations: <sup>18</sup>F-FDG = <sup>18</sup>F-fluorodeoxyglucose; APOE4 = apolipoprotein E4; DL = deep-learning model for classification of AD-dementia vs NC; FAQ = Functional Activities Questionnaire; MMSE = Mini-Mental State Examination; PET = positron emission tomography; SUVR = standardized uptake value ratio.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>We investigated the prognostic value of the <sup>18</sup>F-FDG-PET-based DL model, initially developed for AD-dementia diagnosis. In the predementia stage of MCI and NC, the DL output provided prognostic information, beyond 18F-FDG-PET SUVR as well as clinical information. Moreover, the DL output showed prognostic potential even beyond amyloid PET measures.</p><p>Previous studies reported excellent diagnostic performance of <sup>18</sup>F-FDG-PET-based DL for AD-dementia; one study reported AUCs of 0.92-0.98 for diagnosing AD-dementia.<xref rid="umae021-B16" ref-type="bibr"><sup>16</sup></xref> However, such DL models have been tested only for diagnostic purposes, and their prognostic ability remains largely unexplored. While some research has evaluated the prognostic value of <sup>18</sup>F-FDG-PET-based machine learning such as DL-based radiomic features<xref rid="umae021-B19" ref-type="bibr"><sup>19</sup></xref> or principal component analysis,<xref rid="umae021-B14" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="umae021-B26" ref-type="bibr"><sup>26</sup></xref> their model training was typically based on classification of stable vs progressive MCI based on a single follow-up time, which may not adequately capture the continuous and progressive nature of AD as it may provide limited insights by grouping MCI subjects with heterogeneous prognosis into the same group, limiting the model application to MCI subjects only. In this study, we hypothesized that a DL model trained on NC and AD-dementia could be repurposed to predict cognitive trajectories in the predementia stages, providing insight into where predementia individuals are on the broader spectrum of cognitive decline from NC to AD-dementia, benefiting both NC and MCI predementia stages. For practicality, we integrated <sup>18</sup>F-FDG PET SUVR, clinical information, and amyloid PET measures, and used various datasets spanning different countries and ethnicities.</p><p>The excellent diagnostic performance of our model indicates its ability to detect AD-dementia-related patterns in <sup>18</sup>F-FDG PET images across ethnicities. The saliency map is consistent with previously reported hypometabolic patterns of AD on <sup>18</sup>F-FDG-PET, with the precuneus and posterior cingulate gyrus being one of the earliest areas of hypometabolic change.<xref rid="umae021-B27" ref-type="bibr"><sup>27</sup></xref> In the assessment of prognostic value, DL output maintained its independent prognostic value among SUVR and clinical information in all datasets. However, there were variances in the hazard ratios of DL output and in the improvement in prognostic performance by adding DL output between datasets. Differences in sample size, follow-up duration, and number of progressions are one possible explanation for such variance; the J-ADNI MCI set has the smallest sample size and shortest follow-up duration, and the HABS NC set has the smallest number of progressors, making it more difficult to show statistically significant improvement than the ADNI MCI set. Other explanations may include race-specific intrinsic differences in AD biomarkers,<xref rid="umae021-B28" ref-type="bibr"><sup>28</sup></xref> and extrinsic differences between different countries and cognitive stages, such as follow-up intervals.<xref rid="umae021-B29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="umae021-B30" ref-type="bibr"><sup>30</sup></xref> Nevertheless, despite the excellent diagnostic performance in the external J-ADNI dataset, we cannot completely exclude the possibility of limited generalizability to datasets other than the ADNI. Although our model is applicable across a broad range of predementia stages, further research is needed to account for this inevitable diversity in the clinical settings.</p><p>A notable finding from our study is the stronger stratification by DL output than <sup>18</sup>F-FDG-PET SUVR in the groups with discordant risk between DL output and SUVR in the ADNI MCI set. In addition, the DL output showed the potential to improve prediction of cognitive decline even beyond amyloid PET measures in the amyloid-positive participants. This suggests that DL output may provide neurodegeneration-related insight beyond <sup>18</sup>F-FDG PET SUVR which also works within the ATN framework.</p><p>Our study has limitations. First, we used only <sup>18</sup>F-FDG-PET images and amyloid PET for subgroup analysis, not including MRI and tau PET. A more comprehensive approach with diverse imaging modalities may be needed. Second, although we attempted to address the ethnic imbalance in the ADNI and HABS data by including the J-ADNI dataset, future studies are needed to generalize to broader ethnic groups. Third, although a substantial number of NC participants were enrolled from the HABS dataset, there were a relatively small number of progressors to MCI among them, resulting in less robust validation for NC subjects compared to MCI subjects. Future research is needed with larger sample size and longer follow-up.</p><p>In conclusion, our study developed an <sup>18</sup>F-FDG-PET-based deep learning model that outputs the degree of similarity to AD-dementia and tested its prognostic value. The DL output showed independent and added prognostic value over clinical information, <sup>18</sup>F-FDG-PET SUVR, and amyloid PET measures, suggesting the potential to aid effective clinical trial recruitment and individualized treatment in clinical practice.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>umae021_Supplementary_Data</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="umae021_Supplementary_Data.zip" position="float" orientation="portrait"/></supplementary-material></sec></body><back><sec><title>Author contributions</title><p>Beomseok Sohn (Data curation, Investigation, Resources, Visualization, Writing&#8212;original draft), Seok J. Chung (Data curation, Writing&#8212;original draft), Jeong R. Lee (Visualization, Writing&#8212;review &amp; editing), Dosik Hwang (Funding acquisition, Visualization, Writing&#8212;review &amp; editing), Wanying Xie (Writing&#8212;review &amp; editing), Ling L. Chan (Writing&#8212;review &amp; editing), Yoon S. Choi (Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Writing&#8212;review &amp; editing)</p></sec><sec><title>Supplementary material</title><p><xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref> is available at <italic toggle="yes">Radiology Advances</italic> online.</p></sec><sec><title>Funding</title><p>This study was supported by Samsung Research Funding Center of Samsung Electronics (SRFC-TF2103-01), the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT, 2022-31-0220), and Start-up Grant funded by National University of Singapore, Yong Loo Lin School of Medicine (A-0009827-01-00).</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest</title><p>Please see ICMJE form(s) for author conflicts of interest. These have been provided as <xref rid="sup1" ref-type="supplementary-material">supplementary materials</xref>. There is no conflict of interest.</p></sec><sec sec-type="data-availability"><title>Data availability</title><p>The data used in this study are available in the Alzheimer's Disease Initiative, Japanese Alzheimer&#8217;s Disease Initiative, and HABS databases, where the data can be obtained upon request.</p></sec><ref-list id="ref1"><title>References</title><ref id="umae021-B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sevigny</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chiao</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bussiere</surname><given-names>T</given-names></string-name></person-group>, <etal>et al</etal><article-title>The antibody aducanumab reduces Abeta plaques in Alzheimer's disease</article-title>. <source>Nature</source>. <year>2016</year>;<volume>537</volume>(<issue>7618</issue>):<fpage>50</fpage>-<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1038/nature19323</pub-id><pub-id pub-id-type="pmid">27582220</pub-id></mixed-citation></ref><ref id="umae021-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Salloway</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chalkias</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></string-name></person-group>, <etal>et al</etal><article-title>Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease</article-title>. <source>JAMA Neurol</source>. <year>2022</year>;<volume>79</volume>(<issue>1</issue>):<fpage>13</fpage>-<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2021.4161</pub-id><pub-id pub-id-type="pmid">34807243</pub-id><pub-id pub-id-type="pmcid">PMC8609465</pub-id></mixed-citation></ref><ref id="umae021-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cummings</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Apostolova</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Atri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Salloway</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Weiner</surname><given-names>M.</given-names></string-name></person-group><article-title>Aducanumab: appropriate use recommendations</article-title>. <source>J Prev Alzheimers Dis</source>. <year>2021</year>;<volume>8</volume>(<issue>4</issue>):<fpage>398</fpage>-<lpage>410</lpage>. <pub-id pub-id-type="doi">10.14283/jpad.2021.41</pub-id><pub-id pub-id-type="pmid">34585212</pub-id><pub-id pub-id-type="pmcid">PMC8835345</pub-id></mixed-citation></ref><ref id="umae021-B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Parnetti</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chipi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Salvadori</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>D'Andrea</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Eusebi</surname><given-names>P.</given-names></string-name></person-group><article-title>Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis</article-title>. <source>Alzheimers Res Ther</source>. <year>2019</year>;<volume>11</volume>(<issue>1</issue>):<fpage>7</fpage>. <pub-id pub-id-type="doi">10.1186/s13195-018-0459-7</pub-id><pub-id pub-id-type="pmid">30646955</pub-id><pub-id pub-id-type="pmcid">PMC6334406</pub-id></mixed-citation></ref><ref id="umae021-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Farias</surname><given-names>ST</given-names></string-name>, <string-name name-style="western"><surname>Mungas</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Reed</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Harvey</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>DeCarli</surname><given-names>C.</given-names></string-name></person-group><article-title>Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts</article-title>. <source>Arch Neurol</source>. <year>2009</year>;<volume>66</volume>(<issue>9</issue>):<fpage>1151</fpage>-<lpage>1157</lpage>. <pub-id pub-id-type="doi">10.1001/archneurol.2009.106</pub-id><pub-id pub-id-type="pmid">19752306</pub-id><pub-id pub-id-type="pmcid">PMC2863139</pub-id></mixed-citation></ref><ref id="umae021-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dubois</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Villain</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Frisoni</surname><given-names>GB</given-names></string-name></person-group>, <etal>et al</etal><article-title>Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group</article-title>. <source>Lancet Neurol</source>. <year>2021</year>;<volume>20</volume>(<issue>6</issue>):<fpage>484</fpage>-<lpage>496</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(21)00066-1</pub-id><pub-id pub-id-type="pmid">33933186</pub-id><pub-id pub-id-type="pmcid">PMC8339877</pub-id></mixed-citation></ref><ref id="umae021-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schneider</surname><given-names>LS</given-names></string-name>, <string-name name-style="western"><surname>Mangialasche</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Andreasen</surname><given-names>N</given-names></string-name></person-group>, <etal>et al</etal><article-title>Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014</article-title>. <source>J Intern Med</source>. <year>2014</year>;<volume>275</volume>(<issue>3</issue>):<fpage>251</fpage>-<lpage>283</lpage>. <pub-id pub-id-type="doi">10.1111/joim.12191</pub-id><pub-id pub-id-type="pmid">24605808</pub-id><pub-id pub-id-type="pmcid">PMC3956752</pub-id></mixed-citation></ref><ref id="umae021-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ezzati</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Abdulkadir</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></string-name></person-group>, <etal>et al</etal><article-title>Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer's disease dementia</article-title>. <source>Alzheimers Dement</source>. <year>2021</year>;<volume>17</volume>(<issue>11</issue>):<fpage>1855</fpage>-<lpage>1867</lpage>. <pub-id pub-id-type="doi">10.1002/alz.12491</pub-id><pub-id pub-id-type="pmid">34870371</pub-id><pub-id pub-id-type="pmcid">PMC8842842</pub-id></mixed-citation></ref><ref id="umae021-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zimmer</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Parent</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Souza</surname><given-names>DG</given-names></string-name></person-group>, <etal>et al</etal> [<article-title><sup>18</sup>F]FDG PET signal is driven by astroglial glutamate transport</article-title>. <source>Nat Neurosci</source>. <year>2017</year>;<volume>20</volume>(<issue>3</issue>):<fpage>393</fpage>-<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1038/nn.4492</pub-id><pub-id pub-id-type="pmid">28135241</pub-id><pub-id pub-id-type="pmcid">PMC5378483</pub-id></mixed-citation></ref><ref id="umae021-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Trzepacz</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal><article-title>Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia</article-title>. <source>Neurobiol Aging</source>. <year>2014</year>;<volume>35</volume>(<issue>1</issue>):<fpage>143</fpage>-<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.06.018</pub-id><pub-id pub-id-type="pmid">23954175</pub-id></mixed-citation></ref><ref id="umae021-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grimmer</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Wutz</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Alexopoulos</surname><given-names>P</given-names></string-name></person-group>, <etal>et al</etal><article-title>Visual versus fully automated analyses of 18F-FDG and amyloid PET for prediction of dementia due to Alzheimer disease in mild cognitive impairment</article-title>. <source>J Nucl Med</source>. <year>2016</year>;<volume>57</volume>(<issue>2</issue>):<fpage>204</fpage>-<lpage>207</lpage>. <pub-id pub-id-type="doi">10.2967/jnumed.115.163717</pub-id><pub-id pub-id-type="pmid">26585056</pub-id></mixed-citation></ref><ref id="umae021-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Frings</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hellwig</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bormann</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Spehl</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Buchert</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Meyer</surname><given-names>PT.</given-names></string-name></person-group><article-title>Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. <year>2018</year>;<volume>45</volume>(<issue>8</issue>):<fpage>1442</fpage>-<lpage>1448</lpage>. <pub-id pub-id-type="doi">10.1007/s00259-018-3983-6</pub-id><pub-id pub-id-type="pmid">29546632</pub-id></mixed-citation></ref><ref id="umae021-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Smailagic</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lafortune</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kelly</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hyde</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Brayne</surname><given-names>C.</given-names></string-name></person-group><article-title><sup>18</sup>F-FDG PET for prediction of conversion to Alzheimer's disease dementia in people with mild cognitive impairment: an updated systematic review of test accuracy</article-title>. <source>J Alzheimers Dis</source>. <year>2018</year>;<volume>64</volume>(<issue>4</issue>):<fpage>1175</fpage>-<lpage>1194</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-171125</pub-id><pub-id pub-id-type="pmid">30010119</pub-id><pub-id pub-id-type="pmcid">PMC6218118</pub-id></mixed-citation></ref><ref id="umae021-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Blazhenets</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sorensen</surname><given-names>A</given-names></string-name></person-group>, <etal>et al</etal><article-title>Predictive value of (18)F-Florbetapir and (18)F-FDG PET for conversion from mild cognitive impairment to Alzheimer dementia</article-title>. <source>J Nucl Med</source>. <year>2020</year>;<volume>61</volume>(<issue>4</issue>):<fpage>597</fpage>-<lpage>603</lpage>. <pub-id pub-id-type="doi">10.2967/jnumed.119.230797</pub-id><pub-id pub-id-type="pmid">31628215</pub-id><pub-id pub-id-type="pmcid">PMC7198373</pub-id></mixed-citation></ref><ref id="umae021-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>LeCun</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Bengio</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hinton</surname><given-names>G.</given-names></string-name></person-group><article-title>Deep learning</article-title>. <source>Nature</source>. <year>2015</year>;<volume>521</volume>(<issue>7553</issue>):<fpage>436</fpage>-<lpage>444</lpage>. <pub-id pub-id-type="doi">10.1038/nature14539</pub-id><pub-id pub-id-type="pmid">26017442</pub-id></mixed-citation></ref><ref id="umae021-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ding</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sohn</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Kawczynski</surname><given-names>MG</given-names></string-name></person-group>, <etal>et al</etal><article-title>A deep learning model to predict a diagnosis of Alzheimer disease by using (18)F-FDG PET of the brain</article-title>. <source>Radiology</source>. <year>2019</year>;<volume>290</volume>(<issue>2</issue>):<fpage>456</fpage>-<lpage>464</lpage>. <pub-id pub-id-type="doi">10.1148/radiol.2018180958</pub-id><pub-id pub-id-type="pmid">30398430</pub-id><pub-id pub-id-type="pmcid">PMC6358051</pub-id></mixed-citation></ref><ref id="umae021-B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Duan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>CLP.</given-names></string-name></person-group><article-title>Broad learning for early diagnosis of Alzheimer's disease using FDG-PET of the brain</article-title>. <source>Front Neurosci</source>. <year>2023</year>;<volume>17</volume>:<fpage>1137567</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2023.1137567</pub-id><pub-id pub-id-type="pmid">36992851</pub-id><pub-id pub-id-type="pmcid">PMC10040750</pub-id></mixed-citation></ref><ref id="umae021-B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>T</given-names></string-name></person-group>, <etal>et al</etal><article-title>Deep learning with 18F-fluorodeoxyglucose-PET gives valid diagnoses for the uncertain cases in memory impairment of Alzheimer's disease</article-title>. <source>Front Aging Neurosci</source>. <year>2021</year>;<volume>13</volume>:<fpage>764272</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2021.764272</pub-id><pub-id pub-id-type="pmid">34975455</pub-id><pub-id pub-id-type="pmcid">PMC8715958</pub-id></mixed-citation></ref><ref id="umae021-B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name></person-group>, <etal>et al</etal><article-title>Deep-learning radiomics for discrimination conversion of Alzheimer's disease in patients with mild cognitive impairment: a study based on (18)F-FDG PET imaging</article-title>. <source>Front Aging Neurosci</source>. <year>2021</year>;<volume>13</volume>:<fpage>764872</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2021.764872</pub-id><pub-id pub-id-type="pmid">34764864</pub-id><pub-id pub-id-type="pmcid">PMC8576572</pub-id></mixed-citation></ref><ref id="umae021-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Iwatsubo</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Iwata</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></string-name></person-group>, <etal>et al</etal><article-title>Japanese and North American Alzheimer's disease neuroimaging initiative studies: harmonization for international trials</article-title>. <source>Alzheimers Dement</source>. <year>2018</year>;<volume>14</volume>(<issue>8</issue>):<fpage>1077</fpage>-<lpage>1087</lpage>. <pub-id pub-id-type="doi">10.1016/j.jalz.2018.03.009</pub-id><pub-id pub-id-type="pmid">29753531</pub-id></mixed-citation></ref><ref id="umae021-B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dagley</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>LaPoint</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Huijbers</surname><given-names>W</given-names></string-name></person-group>, <etal>et al</etal><article-title>Harvard aging brain study: dataset and accessibility</article-title>. <source>Neuroimage</source>. <year>2017</year>;<volume>144</volume>(<issue>Pt B</issue>):<fpage>255</fpage>-<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2015.03.069</pub-id><pub-id pub-id-type="pmid">25843019</pub-id><pub-id pub-id-type="pmcid">PMC4592689</pub-id></mixed-citation></ref><ref id="umae021-B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bach</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Binder</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Montavon</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Klauschen</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>M&#252;ller</surname><given-names>K-R</given-names></string-name>, <string-name name-style="western"><surname>Samek</surname><given-names>W.</given-names></string-name></person-group><article-title>On pixel-wise explanations for non-linear classifier decisions by layer-wise relevance propagation</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>7</issue>):<fpage>e0130140</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0130140</pub-id><pub-id pub-id-type="pmid">26161953</pub-id><pub-id pub-id-type="pmcid">PMC4498753</pub-id></mixed-citation></ref><ref id="umae021-B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Landau</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Harvey</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Madison</surname><given-names>CM</given-names></string-name></person-group>, <etal>et al</etal><article-title>Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI</article-title>. <source>Neurobiol Aging</source>. <year>2011</year>;<volume>32</volume>(<issue>7</issue>):<fpage>1207</fpage>-<lpage>1218</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2009.07.002</pub-id><pub-id pub-id-type="pmid">19660834</pub-id><pub-id pub-id-type="pmcid">PMC2891865</pub-id></mixed-citation></ref><ref id="umae021-B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nugent</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Croteau</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Potvin</surname><given-names>O</given-names></string-name></person-group>, <etal>et al</etal><article-title>Selection of the optimal intensity normalization region for FDG-PET studies of normal aging and Alzheimer's disease</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>9261</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-65957-3</pub-id><pub-id pub-id-type="pmid">32518360</pub-id><pub-id pub-id-type="pmcid">PMC7283334</pub-id></mixed-citation></ref><ref id="umae021-B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chambless</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Diao</surname><given-names>G.</given-names></string-name></person-group><article-title>Estimation of time-dependent area under the ROC curve for long-term risk prediction</article-title>. <source>Stat Med</source>. <year>2006</year>;<volume>25</volume>(<issue>20</issue>):<fpage>3474</fpage>-<lpage>3486</lpage>. <pub-id pub-id-type="doi">10.1002/sim.2299</pub-id><pub-id pub-id-type="pmid">16220486</pub-id></mixed-citation></ref><ref id="umae021-B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Blazhenets</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sorensen</surname><given-names>A</given-names></string-name></person-group>, <etal>et al</etal><article-title>Principal components analysis of brain metabolism predicts development of Alzheimer dementia</article-title>. <source>J Nucl Med</source>. <year>2019</year>;<volume>60</volume>(<issue>6</issue>):<fpage>837</fpage>-<lpage>843</lpage>. <pub-id pub-id-type="doi">10.2967/jnumed.118.219097</pub-id><pub-id pub-id-type="pmid">30389825</pub-id></mixed-citation></ref><ref id="umae021-B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brown</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Bohnen</surname><given-names>NI</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Minoshima</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Frey</surname><given-names>KA.</given-names></string-name></person-group><article-title>Brain PET in suspected dementia: patterns of altered FDG metabolism</article-title>. <source>Radiographics</source>. <year>2014</year>;<volume>34</volume>(<issue>3</issue>):<fpage>684</fpage>-<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1148/rg.343135065</pub-id><pub-id pub-id-type="pmid">24819789</pub-id></mixed-citation></ref><ref id="umae021-B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morris</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Schindler</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>McCue</surname><given-names>LM</given-names></string-name></person-group>, <etal>et al</etal><article-title>Assessment of racial disparities in biomarkers for Alzheimer disease</article-title>. <source>JAMA Neurol</source>. <year>2019</year>;<volume>76</volume>(<issue>3</issue>):<fpage>264</fpage>-<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2018.4249</pub-id><pub-id pub-id-type="pmid">30615028</pub-id><pub-id pub-id-type="pmcid">PMC6439726</pub-id></mixed-citation></ref><ref id="umae021-B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wammes</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Nakanishi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>van der Steen</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>MacNeil Vroomen</surname><given-names>JL.</given-names></string-name></person-group><article-title>Japanese national dementia plan is associated with a small shift in location of death: an interrupted time series analysis</article-title>. <source>J Alzheimers Dis</source>. <year>2021</year>;<volume>83</volume>(<issue>2</issue>):<fpage>791</fpage>-<lpage>797</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-210521</pub-id><pub-id pub-id-type="pmid">34366352</pub-id><pub-id pub-id-type="pmcid">PMC8543253</pub-id></mixed-citation></ref><ref id="umae021-B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fortinsky</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Downs</surname><given-names>M.</given-names></string-name></person-group><article-title>Optimizing person-centered transitions in the dementia journey: a comparison of national dementia strategies</article-title>. <source>Health Aff (Millwood)</source>. <year>2014</year>;<volume>33</volume>(<issue>4</issue>):<fpage>566</fpage>-<lpage>573</lpage>. <pub-id pub-id-type="doi">10.1377/hlthaff.2013.1304</pub-id><pub-id pub-id-type="pmid">24711316</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">464</journal-id><journal-id journal-id-type="pmc-domain">sageopen</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Journal of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">1387-2877</issn><issn pub-type="epub">1875-8908</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Sage Choice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12495109</article-id><article-id pub-id-type="pmcid-ver">PMC12495109.1</article-id><article-id pub-id-type="pmcaid">12495109</article-id><article-id pub-id-type="pmcaiid">12495109</article-id><article-id pub-id-type="pmid">40899946</article-id><article-id pub-id-type="doi">10.1177/13872877251372641</article-id><article-id pub-id-type="publisher-id">10.1177_13872877251372641</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>Arteriosclerosis in the heart-brain axis and Alzheimer's disease plasma markers in the Rotterdam Study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-9369-2297</contrib-id><name name-style="western"><surname>Streiber</surname><given-names initials="AM">Anna M</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="aff1-13872877251372641" ref-type="aff">1</xref><xref rid="aff2-13872877251372641" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5739-466X</contrib-id><name name-style="western"><surname>Neitzel</surname><given-names initials="J">Julia</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff1-13872877251372641" ref-type="aff">1</xref><xref rid="aff2-13872877251372641" ref-type="aff">2</xref><xref rid="aff3-13872877251372641" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3579-8054</contrib-id><name name-style="western"><surname>Yaqub</surname><given-names initials="A">Amber</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff2-13872877251372641" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4658-2176</contrib-id><name name-style="western"><surname>Vernooij</surname><given-names initials="MW">Meike W</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff1-13872877251372641" ref-type="aff">1</xref><xref rid="aff2-13872877251372641" ref-type="aff">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8979-2603</contrib-id><name name-style="western"><surname>Bos</surname><given-names initials="D">Daniel</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff1-13872877251372641" ref-type="aff">1</xref><xref rid="aff2-13872877251372641" ref-type="aff">2</xref><xref rid="aff3-13872877251372641" ref-type="aff">3</xref><xref rid="corresp1-13872877251372641" ref-type="corresp"/></contrib></contrib-group><aff id="aff1-13872877251372641">
<label>1</label>Department of Radiology and Nuclear Medicine, <institution-wrap><institution-id institution-id-type="Ringgold">6993</institution-id><institution content-type="university">Erasmus MC</institution></institution-wrap>, Rotterdam, the Netherlands</aff><aff id="aff2-13872877251372641">
<label>2</label>Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands</aff><aff id="aff3-13872877251372641">
<label>3</label>Department of Epidemiology, <institution-wrap><institution-id institution-id-type="Ringgold">1857</institution-id><institution content-type="university">Harvard T.H. Chan School of Public Health</institution></institution-wrap>, Boston, MA, USA</aff><author-notes><corresp id="corresp1-13872877251372641">Daniel Bos, MD, PhD, Department of Radiology and Nuclear Medicine, Department of Epidemiology, Erasmus MC, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands. Email: <email>d.bos@erasmusmc.nl</email></corresp><fn fn-type="other" id="fn1-13872877251372641"><p><bold>Handling Associate Editor:</bold> Peiyu Huang</p></fn></author-notes><pub-date pub-type="epub"><day>3</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>107</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">498304</issue-id><fpage>1741</fpage><lpage>1750</lpage><history><date date-type="received"><day>5</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-05 00:26:29.067"><day>05</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_13872877251372641.pdf"/><abstract><sec><title>Background</title><p>Arteriosclerosis in the heart-brain axis has emerged as an important area of study in Alzheimer's disease (AD) dementia research. While previous research primarily focused on structural brain changes, the relationship between arteriosclerosis and blood-based markers for AD dementia remains understudied.</p></sec><sec><title>Objective</title><p>To comprehensively assess arteriosclerosis in the heart-brain axis and investigate its link to AD dementia plasma markers.</p></sec><sec><title>Methods</title><p>Analyses are based on 2238 community-dwelling elderly from the population-based Rotterdam Study (52% female, mean age 69.5&#8201;&#177;&#8201;6.8 years) who underwent a non-contrast CT scan to quantify arteriosclerosis in the heart-brain axis. Coronary artery calcification, aortic arch calcification, extracranial carotid artery calcification, intracranial carotid artery calcification, and vertebrobasilar artery calcification were measured as proxies for arteriosclerosis. Participants had available total tau, neurofilament light chain (NfL), and amyloid-&#946; (A&#946;<sub>40</sub>, A&#946;<sub>42</sub>, and A&#946;<sub>42/40</sub> ratio) plasma measures (median time difference between CT scan and plasma measurement 3.2 months). Using linear regression, we studied the relationship of calcification presence and burden in the abovementioned arteries with plasma markers.</p></sec><sec><title>Results</title><p>A higher arteriosclerosis burden correlated with higher plasma marker concentrations, especially for NfL (e.g., &#946;<sub>intracranial carotid</sub>: 0.15, [95% Confidence interval (CI): 0.04, 0.26]) and A&#946;<sub>40</sub> (e.g., &#946;<sub>intracranial carotid</sub>: 0.18, [95% CI: 0.05, 0.30]). Additionally, vertebrobasilar artery calcification was most consistently associated with elevated levels of AD dementia plasma markers (e.g., total tau; &#946;: 0.06. [95% CI: 0.01, 0.10]).</p></sec><sec><title>Conclusions</title><p>Our findings emphasize the critical role of vascular health in neurodegenerative processes and underscore the importance of monitoring and managing arteriosclerosis.</p></sec></abstract><kwd-group><kwd>Alzheimer's disease</kwd><kwd>arteriosclerosis</kwd><kwd>biomarkers</kwd><kwd>cohort studies</kwd><kwd>neuroimaging</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="award1-13872877251372641"><funding-source id="funding1-13872877251372641"><institution-wrap><institution>Alzheimer's Association</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000957</institution-id></institution-wrap></funding-source><award-id rid="funding1-13872877251372641">AARG -21-846504</award-id><award-id rid="funding1-13872877251372641">AARG-22-972229</award-id></award-group><award-group id="award2-13872877251372641"><funding-source id="funding2-13872877251372641"><institution-wrap><institution>Cure Alzheimer's Fund</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100007625</institution-id></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts19</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="section1-13872877251372641"><title>Introduction</title><p>Alzheimer's disease (AD) dementia exerts a significant burden on global health care systems, which is estimated to increase even further in the upcoming years.<sup><xref rid="bibr1-13872877251372641" ref-type="bibr">1</xref>,<xref rid="bibr2-13872877251372641" ref-type="bibr">2</xref></sup> While the clinical symptoms of AD dementia are well documented, the underlying etiology requires further investigation.<sup>
<xref rid="bibr3-13872877251372641" ref-type="bibr">3</xref>
</sup> In this context, the heart-brain axis has emerged as a crucial area of study.<sup>
<xref rid="bibr4-13872877251372641" ref-type="bibr">4</xref>
</sup> Recent evidence suggests that arteriosclerosis within the heart-brain axis is associated with cognitive decline, smaller brain tissue volume, and cerebral small vessel disease.<sup><xref rid="bibr5-13872877251372641" ref-type="bibr">5</xref><xref rid="bibr6-13872877251372641" ref-type="bibr"/><xref rid="bibr7-13872877251372641" ref-type="bibr"/>&#8211;<xref rid="bibr8-13872877251372641" ref-type="bibr">8</xref></sup> These pathological changes are hypothesized to be caused by impaired cerebral blood flow, inflammation, and endothelial dysfunction.</p><p>While much of the current research focuses on structural brain changes (e.g.,<sup>
<xref rid="bibr7-13872877251372641" ref-type="bibr">7</xref>
</sup>), the relationship between arteriosclerosis and blood-based markers of AD dementia remains understudied. The development of blood-based biomarkers may eventually help to diagnose AD dementia in a non-invasive, cost-efficient manner.<sup>
<xref rid="bibr9-13872877251372641" ref-type="bibr">9</xref>
</sup> Beyond diagnosis, they also capture pathology earlier and more specifically than structural markers such as MRI, allowing researchers to explore the underlying etiology more comprehensively. Although some previous studies have investigated the link between subclinical atherosclerosis and selected plasma markers of neurodegeneration,<sup><xref rid="bibr10-13872877251372641" ref-type="bibr">10</xref>,<xref rid="bibr11-13872877251372641" ref-type="bibr">11</xref></sup> no earlier study has comprehensively assessed arteriosclerosis throughout the heart-brain axis and, subsequently, linked it to multiple AD dementia plasma markers.</p><p>The current study aims to further elucidate the association between arteriosclerosis in the heart-brain axis and AD dementia plasma markers within the population-based Rotterdam Study. By investigating the relationship between vascular health and AD dementia biomarkers in a population-based setting, we hope to identify etiological factors underlying neurodegeneration that improve prevention of AD dementia. In this study, we will investigate the link between arteriosclerosis in five major arteries between the heart and the brain and plasma concentrations of total tau, neurofilament light chain (NfL), and amyloid-&#946; peptides (A&#946;<sub>40</sub>, A&#946;<sub>42</sub>, and the A&#946;<sub>42/40</sub> ratio). All of these plasma markers have been previously linked to AD dementia and cognitive decline.<sup><xref rid="bibr12-13872877251372641" ref-type="bibr">12</xref>,<xref rid="bibr13-13872877251372641" ref-type="bibr">13</xref></sup> While the A&#946;<sub>42/40</sub> ratio has been shown to predict AD dementia,<sup>
<xref rid="bibr14-13872877251372641" ref-type="bibr">14</xref>
</sup> its interpretation in an etiological context remains challenging.<sup>
<xref rid="bibr15-13872877251372641" ref-type="bibr">15</xref>
</sup> To provide a more nuanced overview, we also included A&#946;<sub>40</sub> and A&#946;<sub>42</sub> as separate measures.</p></sec><sec id="section2-13872877251372641"><title>Methods</title><sec id="section2A-13872877251372641"><title>Setting and study sample</title><p>The Rotterdam Study is a prospective cohort study that was implemented in 1990 to assess the prevalence and determinants of age-related diseases within the Ommoord district in the city of Rotterdam in The Netherlands.<sup>
<xref rid="bibr16-13872877251372641" ref-type="bibr">16</xref>
</sup> The Rotterdam Study is divided in four sub cohorts (RS-I, RS-II, RS-III, and RS-IV). At study entry, all participants receive a baseline measurement including a home interview followed by clinical examinations and plasma sampling at the research center. Every three to five years, participants are re-invited for a follow-up visit. Between 2003 and 2006, participants from the first and second study cohort were invited to undergo a non-contrast multidetector computed tomography (MDCT) scan to visualize extra- and intracranial arterial calcification. In total, 2524 participants (response rate 78%) were included of which 140 participants had to be excluded due to incomplete imaging data or imaging artifacts. Out of the participants who underwent the MDCT scan, 2156 had available tau measures, 2204 had complete NfL measures, 2124 had complete A&#946;<sub>40</sub> measures, 2123 had complete A&#946;<sub>42</sub> measures, and 2055 had complete A&#946;<sub>42/40</sub> ratio measures. A detailed overview of the sample selection is provided in <xref rid="fig1-13872877251372641" ref-type="fig">Figure 1</xref>.</p><fig position="float" id="fig1-13872877251372641" orientation="portrait"><label>Figure 1.</label><caption><p>Flow chart showing the sample composition for this study. CV: coefficient variation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251372641-fig1.jpg"/></fig></sec><sec id="section2B-13872877251372641"><title>Assessment of arterial calcification and plasma markers</title><p><italic toggle="yes">Calcification assessment.</italic> As a hallmark of arteriosclerosis, we measured arterial calcification in five major arteries in the heart-brain axis, using non-contrast 16-slice or 64-slice MDCT scans (Somatom Sensation 16 or 64; Siemens, Forchheim, Germany). The field-of-view was optimized for visualization of blood vessels. The exact imaging parameters have been described elsewhere.<sup>
<xref rid="bibr17-13872877251372641" ref-type="bibr">17</xref>
</sup> We quantified coronary artery calcification, aortic arch calcification, and extracranial carotid artery calcification using commercially available software (Syngo CalciumScoring; Siemens). Intracranial carotid artery calcification and vertebrobasilar artery calcification were closely located to the scull base and, therefore, assessed employing a validated semi-automated scoring method.<sup>
<xref rid="bibr18-13872877251372641" ref-type="bibr">18</xref>
</sup> First, trained raters manually delineated arterial calcification from adjacent bone. Thereafter, calcification volume was calculated by multiplying the pixel number above the calcification threshold of 130 Hounsfield units with the pixel size and slice increment. The details of this scoring method have been extensively described previously.<sup><xref rid="bibr19-13872877251372641" ref-type="bibr">19</xref>,<xref rid="bibr20-13872877251372641" ref-type="bibr">20</xref></sup></p><p><italic toggle="yes">Plasma marker assessment.</italic> According to standard procedures, ethylenediamine tetra-acetic-treated plasma samples were collected between 2002 and 2005 and subsequently aliquoted and frozen at &#8722;80&#176;C. Measurements (5094 samples) were obtained in two separate batches at Quanterix on a single molecule array (SiMoA<sup>&#174;</sup>) HD-1 analyzer platform.<sup>
<xref rid="bibr21-13872877251372641" ref-type="bibr">21</xref>
</sup> The initial batch comprised 2000 samples, randomly chosen from 1000 participants of the fourth visit in RS-I and 1000 participants of the second visit in RS-II. The second batch consisted of 3094 samples, gathered from the remaining participants of these two study cohorts. NfL levels were quantified using the SiMoA NF-light<sup>&#174;</sup> advantage kit.<sup><xref rid="bibr22-13872877251372641" ref-type="bibr">22</xref>,<xref rid="bibr23-13872877251372641" ref-type="bibr">23</xref></sup> To determine the concentrations of total tau, A&#946;<sub>40</sub>, and A&#946;<sub>42</sub>, the SiMoA Human Neurology 3-Plex A assay (N3PA) was used.<sup>
<xref rid="bibr24-13872877251372641" ref-type="bibr">24</xref>
</sup> Each sample was analyzed in duplicate and two quality control samples for each analyte were included on every plate. Plasma measures were excluded from the analyses if duplicates or individual measurements were missing, if the coefficient of variation for concentrations exceeded 20%, or if control samples fell outside the acceptable range.<sup>
<xref rid="bibr12-13872877251372641" ref-type="bibr">12</xref>
</sup></p></sec><sec id="section2C-13872877251372641"><title>Assessment of covariables</title><p>Covariables included age, sex, kidney function, <italic toggle="yes">APOE</italic> carriership (&#949;2, &#949;3, &#949;4), body mass index (BMI), hypertension, diabetes, dyslipidemia, smoking status (never, current, former), and alcohol intake (grams/day). Kidney function was assessed using estimated glomerular filtration rate (eGFR) measures, which are based on plasma creatinine.<sup>
<xref rid="bibr25-13872877251372641" ref-type="bibr">25</xref>
</sup> Kidney function was included as a covariate as it may affect the clearance of circulating proteins and the burden of arteriosclerosis.<sup><xref rid="bibr26-13872877251372641" ref-type="bibr">26</xref>,<xref rid="bibr27-13872877251372641" ref-type="bibr">27</xref></sup> BMI was measured as weight (in kg)/height<sup>2</sup> (in m). Hypertension was classified as present if one or more of the following characteristics were met: systolic blood pressure&#8201;&#8805;&#8201;140&#8197;mmHg, diastolic blood pressure&#8201;&#8805;&#8201;90&#8197;mmHg, use of antihypertensive medication. Participants were rated as diabetic if fasting serum glucose levels were &#8805;7&#8197;mmol/L and/or if they were using antidiabetic medication. Dyslipidemia was defined as using lipid-lowering medication and/or having a total cholesterol concentration of at least 6.2&#8197;mmol/L.</p></sec><sec id="section2D-13872877251372641"><title>Data analysis and statistics</title><p>All analyses were carried out using R version 4.2.2.<sup>
<xref rid="bibr28-13872877251372641" ref-type="bibr">28</xref>
</sup> Missing covariate data were imputed using multivariate imputation by chained equations<sup>
<xref rid="bibr29-13872877251372641" ref-type="bibr">29</xref>
</sup> with 30 imputations and 60 iterations. In the current RS round, eGFR was only assessed in a subset of participants (n&#8201;=&#8201;965, 43.1%). Due to the large proportion of missing data, we used eGFR measures from the previous research visit as an auxiliary variable in the imputation model.</p><p>Determinants of plasma marker concentrations were calcification presence and calcification burden. Calcification data across all arteries were zero-inflated and, therefore, strongly skewed. To compute the calcification burden per individual, we temporarily excluded participants without calcification and assigned tertiles, representing low, medium, and high calcification, to the remaining participants. Subsequently, participants without calcification were added back to the dataset and received a score of zero. Importantly, these categories are data-driven and specific to the calcification distribution in our Rotterdam Study sample and should not be interpreted as clinical thresholds. Plasma data were log<sub>2</sub>-transformed to approximate a normal distribution and to reduce skewness. Subsequently, we standardized plasma data to improve comparability between the plasma markers, as they have inherently different ranges. A&#946;<sub>42/40</sub> ratio measures were only standardized and not log<sub>2</sub>-transformed, as the data followed a normal distribution.</p><p>In our main analyses, we first applied multiple linear regression to determine a relationship between calcification presence and standardized log<sub>2</sub>-transformed plasma biomarker concentrations. Subsequently, we studied the relationship between calcification burden (tertiles compared to no calcification) and plasma biomarker concentrations. Analyses were carried out for all possible combinations of arteries and plasma markers. All analyses were initially adjusted for age, sex, eGFR, and cohort (model 1). In a second step, we additionally adjusted for APOE genotype and cardiovascular risk factors (BMI, hypertension, diabetes, dyslipidemia, smoking status, alcohol intake; model 2). Regression estimates reflect the change in standardized plasma marker concentrations in log<sub>2</sub> pg/mL based on calcification presence and burden compared to calcification absence. Due to the large number of missing eGFR data, we performed a sensitivity analysis excluding participants with incomplete eGFR assessments.</p></sec><sec id="section2E-13872877251372641"><title>Ethics statement</title><p>The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-PG). The Rotterdam Study Personal Registration Data collection is filed with the Erasmus MC Data Protection Officer under registration number EMC1712001. The Rotterdam Study has been entered into the Netherlands National Trial Register (NTR; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.trialregister.nl" ext-link-type="uri">www.trialregister.nl</ext-link>) and into the WHO International Clinical Trials Registry Platform (ICTRP; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://apps.who.int/trialsearch/" ext-link-type="uri">https://apps.who.int/trialsearch/</ext-link>) under shared catalogue number NL6645 / NTR6831. All participants provided written informed consent to participate in the study and to have their information obtained from treating physicians.</p></sec></sec><sec id="section3-13872877251372641"><title>Results</title><sec id="section3A-13872877251372641"><title>Descriptives and demographics</title><p>Approximately 52% of the participants were female and the mean age was 69.5 (<italic toggle="yes">SD</italic>&#8201;<italic toggle="yes">=</italic>&#8201;6.8). The prevalence of coronary artery calcification, aortic arch calcification, as well as intra- and extracranial carotid artery calcification ranged primarily from 73.1% to 92.5%. The prevalence of vertebrobasilar calcification was notably lower, at 20.1%. A descriptive overview of sample characteristics is summarized in <xref rid="table1-13872877251372641" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="table1-13872877251372641" orientation="portrait"><label>Table 1.</label><caption><p>Descriptive sample characteristics.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251372641-table1.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="(" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">N&#8201;=&#8201;2238</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Cohort</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> 1</td><td rowspan="1" colspan="1">674 (30.1%)</td></tr><tr><td rowspan="1" colspan="1"> 2</td><td rowspan="1" colspan="1">1564 (69.9%)</td></tr><tr><td rowspan="1" colspan="1">Sex (female)</td><td rowspan="1" colspan="1">1168 (52.2%)</td></tr><tr><td rowspan="1" colspan="1">Age (y)</td><td rowspan="1" colspan="1">69.5(6.8)</td></tr><tr><td rowspan="1" colspan="1">Self-reported ethnic background</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> North-West European</td><td rowspan="1" colspan="1">2015 (90.0%)</td></tr><tr><td rowspan="1" colspan="1"> Other ethnic background</td><td rowspan="1" colspan="1">65 (2.9%)</td></tr><tr><td rowspan="1" colspan="1"> Missing</td><td rowspan="1" colspan="1">158 (7.1%)</td></tr><tr><td rowspan="1" colspan="1">Time difference between CT scan and plasma measures (months)<sup>
<xref rid="table-fn2-13872877251372641" ref-type="table-fn">a</xref>
</sup></td><td rowspan="1" colspan="1">3.2 (0.1, 30.7)</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m&#178;)</td><td rowspan="1" colspan="1">27.6 (4.0)</td></tr><tr><td rowspan="1" colspan="1"> Missing</td><td rowspan="1" colspan="1">5 (0.2%)</td></tr><tr><td rowspan="1" colspan="1">Hypertension (yes)</td><td rowspan="1" colspan="1">1651 (73.8%)</td></tr><tr><td rowspan="1" colspan="1"> Missing</td><td rowspan="1" colspan="1">2 (0.1%)</td></tr><tr><td rowspan="1" colspan="1">Dyslipidemia (yes)</td><td rowspan="1" colspan="1">648 (29.0%)</td></tr><tr><td rowspan="1" colspan="1"> Missing</td><td rowspan="1" colspan="1">2 (0.1%)</td></tr><tr><td rowspan="1" colspan="1">Diabetes (yes)</td><td rowspan="1" colspan="1">202 (9.0%)</td></tr><tr><td rowspan="1" colspan="1"> Missing</td><td rowspan="1" colspan="1">2 (0.1%)</td></tr><tr><td rowspan="1" colspan="1">Smoking</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> Never</td><td rowspan="1" colspan="1">674 (30.1%)</td></tr><tr><td rowspan="1" colspan="1"> Former</td><td rowspan="1" colspan="1">1222 (54.6%)</td></tr><tr><td rowspan="1" colspan="1"> Current</td><td rowspan="1" colspan="1">284 (12.7%)</td></tr><tr><td rowspan="1" colspan="1"> Missing</td><td rowspan="1" colspan="1">58 (2.6%)</td></tr><tr><td rowspan="1" colspan="1">Alcohol consumption (gr/day)</td><td rowspan="1" colspan="1">13.2 (15.2)</td></tr><tr><td rowspan="1" colspan="1"> Missing</td><td rowspan="1" colspan="1">58 (2.6%)</td></tr><tr><td rowspan="1" colspan="1">eGFR</td><td rowspan="1" colspan="1">77.2 (14.4)</td></tr><tr><td rowspan="1" colspan="1"> Missing</td><td rowspan="1" colspan="1">1273 (56.9%)</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">APOE</italic> Alleles</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;<italic toggle="yes">APOE</italic> &#949;3</td><td rowspan="1" colspan="1">1255 (56.1%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;<italic toggle="yes">APOE</italic> &#949;2</td><td rowspan="1" colspan="1">272 (12.2%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;<italic toggle="yes">APOE</italic> &#949;4</td><td rowspan="1" colspan="1">585 (26.1%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Missing</td><td rowspan="1" colspan="1">126 (5.6%)</td></tr><tr><td rowspan="1" colspan="1">Total tau<sup>
<xref rid="table-fn3-13872877251372641" ref-type="table-fn">b</xref>
</sup></td><td rowspan="1" colspan="1">2.4 (1.0)</td></tr><tr><td rowspan="1" colspan="1">NfL<sup>
<xref rid="table-fn3-13872877251372641" ref-type="table-fn">b</xref>
</sup></td><td rowspan="1" colspan="1">11.7 (6.6)</td></tr><tr><td rowspan="1" colspan="1">A&#946;<sub>40</sub><sup>
<xref rid="table-fn3-13872877251372641" ref-type="table-fn">b</xref>
</sup></td><td rowspan="1" colspan="1">249.5 (57.4)</td></tr><tr><td rowspan="1" colspan="1">A&#946;<sub>42</sub><sup>
<xref rid="table-fn3-13872877251372641" ref-type="table-fn">b</xref>
</sup></td><td rowspan="1" colspan="1">10.1 (2.9)</td></tr><tr><td rowspan="1" colspan="1">A&#946;<sub>42/40</sub></td><td rowspan="1" colspan="1">0.04 (0.01)</td></tr><tr><td rowspan="1" colspan="1">Coronary artery calcification prevalence</td><td rowspan="1" colspan="1">1832 (81.9%)</td></tr><tr><td rowspan="1" colspan="1">Coronary artery calcification volume<sup>
<xref rid="table-fn3-13872877251372641" ref-type="table-fn">b</xref>
</sup></td><td rowspan="1" colspan="1">49.5 (269.2)</td></tr><tr><td rowspan="1" colspan="1">Aortic arch calcification prevalence</td><td rowspan="1" colspan="1">2070 (92.5%)</td></tr><tr><td rowspan="1" colspan="1">Aortic arch calcification volume<sup>
<xref rid="table-fn3-13872877251372641" ref-type="table-fn">b</xref>
</sup></td><td rowspan="1" colspan="1">250 (783.5)</td></tr><tr><td rowspan="1" colspan="1">Extracranial carotid artery calcification prevalence</td><td rowspan="1" colspan="1">1635 (73.1%)</td></tr><tr><td rowspan="1" colspan="1">Extracranial carotid artery calcification volume<sup>
<xref rid="table-fn3-13872877251372641" ref-type="table-fn">b</xref>
</sup></td><td rowspan="1" colspan="1">22.1 (114.9)</td></tr><tr><td rowspan="1" colspan="1">Intracranial carotid artery calcification prevalence</td><td rowspan="1" colspan="1">1822 (81.4%)</td></tr><tr><td rowspan="1" colspan="1">Intracranial carotid artery calcification volume<sup>
<xref rid="table-fn3-13872877251372641" ref-type="table-fn">b</xref>
</sup></td><td rowspan="1" colspan="1">41.8 (129.7)</td></tr><tr><td rowspan="1" colspan="1">Vertebrobasilar artery calcification prevalence</td><td rowspan="1" colspan="1">450 (20.1%)</td></tr><tr><td rowspan="1" colspan="1">Vertebrobasilar artery calcification volume<sup>
<xref rid="table-fn4-13872877251372641" ref-type="table-fn">c</xref>
</sup></td><td rowspan="1" colspan="1">0, 598</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-13872877251372641"><p>Continuous values are reported as mean (SD). Categorical variables are reported as n (%).</p></fn><fn id="table-fn2-13872877251372641"><label>
<sup>a</sup>
</label><p>Values are reported as median (minimum, maximum). There were 109 participants with a gap of more than 12 months between the CT and the plasma assessment.</p></fn><fn id="table-fn3-13872877251372641"><label>
<sup>b</sup>
</label><p>Values are reported as median (IQR).</p></fn><fn id="table-fn4-13872877251372641"><label>
<sup>c</sup>
</label><p>Values are reported as minimum, maximum.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section3B-13872877251372641"><title>Relationship between calcification and plasma markers</title><p>The results of the fully adjusted regression analyses investigating the relationship of calcification presence and calcification burden with AD dementia plasma markers are presented in <xref rid="fig2-13872877251372641" ref-type="fig">Figure 2</xref> and <xref rid="fig3-13872877251372641" ref-type="fig">Figure 3</xref>, respectively. The results of model 1 adjusted for age, sex, eGFR, and cohort are provided in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/13872877251372641" ext-link-type="uri">Supplemental Table 1</ext-link>.</p><fig position="float" id="fig2-13872877251372641" orientation="portrait"><label>Figure 2.</label><caption><p>Forest plots showing linear regression estimates and associated 95% confidence intervals for the association between calcification presence and plasma marker concentrations. Beta reflects the change in standardized plasma marker concentrations (in log<sub>2</sub> pg/mL) in participants with prevalent arterial calcification compared to participants without arterial calcification. VBAC: vertebrobasilar artery calcification; ICAC: intracranial carotid artery calcification; ECAC: extracranial carotid artery calcification; CAC: coronary artery calcification; AAC: aortic arch calcification.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251372641-fig2.jpg"/></fig><fig position="float" id="fig3-13872877251372641" orientation="portrait"><label>Figure 3.</label><caption><p>Forest plots showing linear regression estimates and associated 95% confidence intervals for the association between calcification burden (in tertiles) and plasma marker concentrations. Beta reflects the change in standardized plasma marker concentrations (in log<sub>2</sub> pg/mL) in participants with a low (tertile 1), medium (tertile 2), and high (tertile 3) arterial calcification burden compared to participants without arterial calcification. VBAC: vertebrobasilar artery calcification; ICAC: intracranial carotid artery calcification; ECAC: extracranial carotid artery calcification; CAC: coronary artery calcification; AAC: aortic arch calcification.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251372641-fig3.jpg"/></fig><p>Vertebrobasilar artery calcification presence was most consistently associated with higher plasma concentrations of AD dementia markers. More specifically, it was associated with higher total tau (&#946;: 0.06 [95% confidence interval (CI): 0.01&#8211;0.10]), higher NfL (&#946;: 0.09 [95% CI: 0.00&#8211;0.17]), and higher A&#946;<sub>40</sub> concentrations (&#946;: 0.17 [95% CI: 0.07&#8211;0.27]). Similarly, a higher vertebrobasilar artery calcification burden was linked to higher NFL (&#946;<sub>Tertile 2</sub>: 0.14 [95% CI: 0.00&#8211;0.28]; &#946;<sub>Tertile 3</sub>: 0.20 [95% CI: 0.06&#8211;0.34]), total tau (&#946;<sub>Tertile 3</sub>: 0.08 [95% CI: 0.00&#8211;0.16]) and A&#946;<sub>40</sub> (&#946;<sub>Tertile 2</sub>: 0.17 [95% CI: 0.02&#8211;0.33]; &#946;<sub>Tertile 3</sub>: 0.26 [95% CI: 0.10&#8211;0.42]) concentrations.</p><p>While intracranial carotid artery calcification presence was solely associated with elevated A&#946;<sub>40</sub> concentrations (&#946;: 0.10 [95% CI: 0.00&#8211;0.20]), a higher burden was associated with both higher A&#946;<sub>40</sub> (&#946;<sub>Tertile 3</sub>: 0.18 [95% CI: 0.05&#8211;0.30]) and higher NfL concentrations (&#946;<sub>Tertile 3</sub>: 0.15 [95% CI: 0.04&#8211;0.26]).</p><p>Presence of extracranial carotid artery calcification was associated with elevated NfL (&#946;: 0.10 [95% CI: 0.03&#8211;0.18]) and A&#946;<sub>40</sub> (&#946;: 0.11 [95% CI: 0.02&#8211;0.19]). The analyses focusing on extracranial carotid artery calcification burden indicated that a higher burden was associated with higher NfL (&#946;<sub>Tertile3</sub>: 0.19 [95% CI: 0.09&#8211;0.30]), higher A&#946;<sub>40</sub> (&#946;<sub>Tertile 3</sub>: 0.19 [95% CI: 0.08&#8211;0.31]), and higher A&#946;<sub>42</sub> concentrations (&#946;<sub>Tertile 3</sub>: 0.17 [95% CI: 0.04&#8211;0.29]).</p><p>Presence of aortic arch calcification was not associated with higher biomarker concentrations across all plasma markers. However, a high aortic arch calcification burden was associated with higher A&#946;<sub>40</sub> concentrations (&#946;<sub>Tertile</sub> 3: 0.19 [95% CI: 0.03&#8211;0.35]).</p><p>Overall, coronary artery calcification presence was predominantly associated with elevated A&#946;<sub>40</sub> (&#946;<sub>presence</sub>: 0.19 [95% CI: 0.09&#8211;0.29]) and A&#946;<sub>42</sub> concentrations (&#946;<sub>presence</sub>: 0.19 [95% CI: 0.08&#8211;0.30]). This association remained for a low, medium, and high coronary artery calcification burden for both A&#946;<sub>42</sub> (&#946;<sub>Tertile1</sub>: 0.22 [95% CI: 0.09&#8211;0.34]; &#946;<sub>Tertile2</sub>: 0.14 [95% CI: 0.02&#8211;0.27]; &#946;<sub>Tertile3</sub>: 0.19 [95% CI: 0.05&#8211;0.33]) and A&#946;<sub>40</sub> (&#946;<sub>Tertile1</sub>: 0.18 [95% CI: 0.06&#8211;0.29]; &#946;<sub>Tertile2</sub>: 0.19 [95% CI: 0.08&#8211;0.31]; &#946;<sub>Tertile3</sub>: 0.31 [95% CI: 0.18&#8211;0.44]). Additionally, a high CAC burden was associated with higher NfL concentrations (&#946;<sub>Tertile 3</sub>: 0.19 [95% CI: 0.07&#8211;0.30]).</p><p>To ensure that the imputation of the large number of missing eGFR values did not influence our results, we compared all clinical and demographic characteristics of participants with and without available eGFR measures. Subsequently, we repeated our regression analyses only in participants with complete eGFR data. The participant characteristics are presented in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/13872877251372641" ext-link-type="uri">Supplemental Table 2</ext-link>, and the regression results are presented <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/13872877251372641" ext-link-type="uri">Supplemental Tables 3 and 4</ext-link>. Overall, the results were consistent between our study sample and the subgroup of participants with complete eGFR measures.</p></sec></sec><sec id="section4-13872877251372641"><title>Discussion</title><p>In this study among community-dwelling individuals, we assessed the relationship between arteriosclerosis in the heart-brain axis and AD dementia plasma markers. The prevalence of arteriosclerosis in this sample is comparable to earlier studies.<sup><xref rid="bibr30-13872877251372641" ref-type="bibr">30</xref><xref rid="bibr31-13872877251372641" ref-type="bibr"/>&#8211;<xref rid="bibr32-13872877251372641" ref-type="bibr">32</xref></sup> Overall, a higher calcification burden along the heart-brain axis was associated with higher plasma marker concentrations, specifically NfL and A&#946;<sub>40</sub>. Among the examined arteries, vertebrobasilar artery calcification presence and burden were specifically associated with elevated total tau, NfL, and A&#946;<sub>40</sub>.</p><p>The association of vertebrobasilar artery calcification with various neurodegeneration markers could be partly explained by hemodynamic changes. Previous research indicates that intracranial arteriosclerosis is associated with changes in cerebral perfusion, including blood flow velocity and pulsatility.<sup>
<xref rid="bibr33-13872877251372641" ref-type="bibr">33</xref>
</sup> Furthermore, potential hypoperfusion injury resulting from these changes may promote the accumulation of misfolded proteins and axonal injury.<sup><xref rid="bibr34-13872877251372641" ref-type="bibr">34</xref>,<xref rid="bibr35-13872877251372641" ref-type="bibr">35</xref></sup> It is hypothesized that vascular lesions, in combination with cerebral hemodynamic changes, may impair glucose metabolism and enhance &#946;-secretase expression, consequently enhancing tau and A&#946; pathology.<sup>
<xref rid="bibr36-13872877251372641" ref-type="bibr">36</xref>
</sup> Notably, the vertebrobasilar arteries supply critical deep brain structures, including the thalamus, which may upregulate NfL release in response to lower perfusion.<sup>
<xref rid="bibr37-13872877251372641" ref-type="bibr">37</xref>
</sup> This posterior circulation-dependent vulnerability might explain the specific link between vertebrobasilar artery calcification and both NfL and tau.</p><p>Beyond the vertebrobasilar system, a medium and high arteriosclerosis burden were associated with higher NfL concentrations in all arteries except the aortic arch. Earlier work from the Rotterdam study showed that a higher intracranial arteriosclerosis burden accelerates the development of small vessel disease,<sup>
<xref rid="bibr7-13872877251372641" ref-type="bibr">7</xref>
</sup> which is, in turn, associated with higher plasma NfL concentrations.<sup>
<xref rid="bibr38-13872877251372641" ref-type="bibr">38</xref>
</sup> Moreover, coronary artery calcification may trigger inflammatory cascades,<sup>
<xref rid="bibr39-13872877251372641" ref-type="bibr">39</xref>
</sup> possibly contributing to an upregulation of cytokines and further axonal injury.<sup>
<xref rid="bibr40-13872877251372641" ref-type="bibr">40</xref>
</sup> Taken together, these findings point to a broader vascular pathway linking systemic arteriosclerosis to neurodegeneration.</p><p>Besides its relationship to NfL, arteriosclerosis across the heart-brain axis was consistently associated with higher plasma A&#946;<sub>40</sub> but not A&#946;<sub>42</sub> concentrations. Both A&#946;<sub>40</sub> and A&#946;<sub>42</sub> are misfolded proteins that result from dysfunctional cleavage of the amyloid-&#946; protein precursor.<sup>
<xref rid="bibr41-13872877251372641" ref-type="bibr">41</xref>
</sup> While A&#946;<sub>42</sub> tends to form extracellular plaques in the brain parenchyma, A&#946;<sub>40</sub> is more strongly associated with cerebrovascular pathology.<sup>
<xref rid="bibr42-13872877251372641" ref-type="bibr">42</xref>
</sup> Previous studies have demonstrated that A&#946;<sub>40</sub> is associated with vascular aging through its pro-inflammatory and pro-atherosclerotic properties,<sup>
<xref rid="bibr43-13872877251372641" ref-type="bibr">43</xref>
</sup> which are expressed in both the heart and the brain. Although A&#946;<sub>40</sub> is not a core pathological hallmark of AD dementia, previous studies (e.g.,<sup>
<xref rid="bibr44-13872877251372641" ref-type="bibr">44</xref>
</sup>) propose that it may act as a risk-modifying factor, influencing AD dementia pathology indirectly rather than serving as a primary etiological factor. Thus, the observed association between arteriosclerosis and A&#946;<sub>40</sub> suggests an interplay between arteriosclerosis and A&#946;<sub>40</sub> that may influence AD dementia vulnerability.</p><p>In contrast to A&#946;<sub>40</sub> concentrations, A&#946;<sub>42</sub> plasma levels were almost exclusively associated with coronary artery calcification presence, irrespective of the arteriosclerosis burden. Cerebral A&#946;<sub>42</sub> has been previously linked to AD dementia pathogenesis, yet its link to cardiovascular disease remains unclear.<sup>
<xref rid="bibr41-13872877251372641" ref-type="bibr">41</xref>
</sup> Recent studies indicate no direct causal relationship between coronary heart disease and cerebral amyloid deposition,<sup>
<xref rid="bibr45-13872877251372641" ref-type="bibr">45</xref>
</sup> implying that other shared mechanisms, such as inflammation, oxidative stress, or lipid metabolism may explain this overlap.<sup>
<xref rid="bibr4-13872877251372641" ref-type="bibr">4</xref>
</sup> Thus, future studies are needed to understand these potential mediators and to provide insights into the complex interplay between cardiovascular health and AD dementia.</p><p>In contrast to individual A&#946;<sub>40</sub> and A&#946;<sub>42</sub> peptides, there was no association between arteriosclerosis in any of the arteries in the heart-brain axis and the A&#946;<sub>42/40</sub> ratio. The A&#946;<sub>42/40</sub> ratio is a recognized marker for cerebral amyloid accumulation.<sup>
<xref rid="bibr46-13872877251372641" ref-type="bibr">46</xref>
</sup> Our findings of associations with both A&#946;<sub>40</sub> and A&#946;<sub>42</sub> individually suggest that arteriosclerosis may influence the processing or clearance of these peptides. Yet, the absence of an association with the A&#946;<sub>42/40</sub> ratio points to a limited role in amyloidogenic processes specific to AD dementia. This is in line with prior findings from the Rotterdam Study and the Atherosclerosis Risk in Communities Study, both of which found no association between arteriosclerosis and cerebral amyloid accumulation.<sup><xref rid="bibr47-13872877251372641" ref-type="bibr">47</xref>,<xref rid="bibr48-13872877251372641" ref-type="bibr">48</xref></sup> Taken together, these findings suggest that arteriosclerosis may not drive cerebral amyloid accumulation per se, but may contribute to AD dementia through alternative pathways, such as those involving A&#946;<sub>40</sub> and NfL.</p><p>Overall, the effects of arteriosclerosis on A&#946;<sub>40</sub> and NfL were most pronounced in individuals within the highest calcification tertiles, suggesting a dose&#8211;response relationship in which greater calcification volume is associated with stronger effects on AD dementia plasma markers. These findings imply that in individuals who already exhibit arteriosclerosis, further progression may still be clinically relevant and potentially modifiable. Intervening to slow or halt the progression of arteriosclerosis could, therefore, help mitigate possible downstream effects on neurodegenerative processes, especially if implemented before extensive calcification has occurred. While direct evidence linking vascular interventions to improvements in AD dementia plasma markers is limited, studies have demonstrated that addressing vascular risk factors can reduce cognitive decline and dementia risk.<sup>
<xref rid="bibr49-13872877251372641" ref-type="bibr">49</xref>
</sup> These findings support the notion that targeting arteriosclerosis may not only benefit cardiovascular health but could also delay or reduce neurodegenerative changes.</p><sec id="section4A-13872877251372641"><title>Strengths and limitations</title><p>Strengths of our study include the comprehensive investigation of arteriosclerosis in the heart-brain axis and the population-based design, which allows for the identification of etiological mechanisms underlying AD dementia. However, potential limitations of our study need to be addressed. First, previous research indicates that, compared to total tau, phosphorylated tau has higher prognostic utility regarding clinical outcomes of AD dementia.<sup><xref rid="bibr50-13872877251372641" ref-type="bibr">50</xref>,<xref rid="bibr51-13872877251372641" ref-type="bibr">51</xref></sup> Total tau is a rather broad, aspecific marker that is not exclusively associated with dementia.<sup>
<xref rid="bibr52-13872877251372641" ref-type="bibr">52</xref>
</sup> At the time of biomarker assessment, tau assessments were not yet widely implemented<sup>
<xref rid="bibr53-13872877251372641" ref-type="bibr">53</xref>
</sup> and only recently, the research focus shifted to more dementia-specific phosphorylated tau markers.<sup>
<xref rid="bibr54-13872877251372641" ref-type="bibr">54</xref>
</sup> Nonetheless, studies indicate that total tau can still provide added prognostic value, especially if combined with other biomarkers.<sup>
<xref rid="bibr55-13872877251372641" ref-type="bibr">55</xref>
</sup></p><p>Second, our study offers preliminary evidence on the relationship between arteriosclerosis and AD dementia plasma markers, yet it does not allow to establish a causal relationship. In order to establish causality in cross-sectional etiological studies, it is important to capture the time window in which relevant etiological changes occur.<sup>
<xref rid="bibr56-13872877251372641" ref-type="bibr">56</xref>
</sup> However, this time window may span decades and still remains incompletely understood,<sup>
<xref rid="bibr57-13872877251372641" ref-type="bibr">57</xref>
</sup> making it challenging to assess in our study. We explored the feasibility of applying causal inference methods, such as Mendelian randomization. However, this approach was not suitable due to sample overlap between our dataset and available genome-wide association studies,<sup>
<xref rid="bibr58-13872877251372641" ref-type="bibr">58</xref>
</sup> which could introduce bias. Moreover, many of our exposures and outcomes share common genetic loci, challenging the assumption of no horizontal pleiotropy. Given these limitations, we conclude that longitudinal studies are needed to unravel the temporal dynamics of these markers, facilitating causal research in the future.</p><p>Third, we cannot rule out residual confounding. For example, we were unable to adjust for physical activity, an established factor associated with both arteriosclerosis and neurodegeneration,<sup>
<xref rid="bibr59-13872877251372641" ref-type="bibr">59</xref>
</sup> due to data unavailability in the current sample. Nonetheless, we accounted for a broad range of relevant confounders, strengthening the internal validity of our findings. Future studies should consider incorporating measures of physical activity to further refine the robustness of the findings. Finally, dividing the calcification data into tertiles resulted in relatively small subgroups for our analyses, particularly for vertebrobasilar artery calcification, which had a low prevalence. This small sample size may have resulted in a lack of statistical power and, hence, an underestimation of the true effects associated with calcification tertiles.</p></sec><sec id="section4B-13872877251372641"><title>Conclusion</title><p>Our study indicates distinct pathways through which arteriosclerosis may contribute to the development of AD dementia. First, systemic arteriosclerosis (i.e., within the heart and brain) was associated with upregulated NfL, indicating that it may contribute to AD dementia through axonal damage. Second, intracranial arteriosclerosis in the vertebrobasilar arteries was additionally associated with higher total tau accumulation, suggesting a separate, posterior circulation-dependent mechanism. Third, we observed consistent associations between arteriosclerosis and plasma A&#946;<sub>40</sub> levels, indicating a vascular contribution to systemic amyloid dysregulation, which may serve as a risk factor for AD dementia. These findings highlight the importance of vascular health in multiple neurodegenerative processes relevant to AD dementia. Ultimately, targeted interventions on cardiovascular risk factors may offer a promising strategy to reduce the risk of AD dementia-related pathology.</p></sec></sec><sec sec-type="supplementary-material" id="section5-13872877251372641"><title>Supplemental Material</title><supplementary-material id="suppl1-13872877251372641" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-docx-1-alz-10.1177_13872877251372641 - Supplemental material for Arteriosclerosis in the heart-brain axis and Alzheimer's disease plasma markers in the Rotterdam Study</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-docx-1-alz-10.1177_13872877251372641.docx" position="float" orientation="portrait"/><p>Supplemental material, sj-docx-1-alz-10.1177_13872877251372641 for Arteriosclerosis in the heart-brain axis and Alzheimer's disease plasma markers in the Rotterdam Study by Anna M Streiber, Julia Neitzel, Amber Yaqub, Meike W Vernooij and Daniel Bos in Journal of Alzheimer's Disease</p></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>We acknowledge the immense contribution of the data management team of the Rotterdam Study, with Jolande Verkroost-van Heemst in particular, and the Imaging Trialbureau. Lastly, we thank our study participants for their contribution.</p></ack><fn-group><fn fn-type="other"><p><bold>ORCID iDs:</bold> Anna M Streiber <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0009-0006-9369-2297" ext-link-type="uri">https://orcid.org/0009-0006-9369-2297</ext-link></p><p>Julia Neitzel <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0001-5739-466X" ext-link-type="uri">https://orcid.org/0000-0001-5739-466X</ext-link></p><p>Amber Yaqub <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-3579-8054" ext-link-type="uri">https://orcid.org/0000-0002-3579-8054</ext-link></p><p>Meike W Vernooij <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0003-4658-2176" ext-link-type="uri">https://orcid.org/0000-0003-4658-2176</ext-link></p><p>Daniel Bos <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0001-8979-2603" ext-link-type="uri">https://orcid.org/0000-0001-8979-2603</ext-link></p></fn><fn fn-type="other"><p><bold>Ethical considerations:</bold> The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-PG). The Rotterdam Study Personal Registration Data collection is filed with the Erasmus MC Data Protection Officer under registration number EMC1712001. The Rotterdam Study has been entered into the Netherlands National Trial Register (NTR; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.trialregister.nl" ext-link-type="uri">www.trialregister.nl</ext-link>) and into the WHO International Clinical Trials Registry Platform (ICTRP; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://apps.who.int/trialsearch/" ext-link-type="uri">https://apps.who.int/trialsearch/</ext-link>) under shared catalogue number NL6645 / NTR6831.</p></fn><fn fn-type="other"><p><bold>Consent to participate:</bold> All participants provided written informed consent to participate in the study.</p></fn><fn fn-type="other"><p><bold>Consent for publication:</bold> Not applicable.</p></fn><fn fn-type="con"><p><bold>Author contributions:</bold>
<bold>Anna M Streiber:</bold> Conceptualization; Formal analysis; Methodology; Visualization; Writing &#8211; original draft.</p><p><bold>Julia Neitzel:</bold> Conceptualization; Methodology; Supervision; Writing &#8211; review &amp; editing.</p><p><bold>Amber Yaqub:</bold> Conceptualization; Methodology; Writing &#8211; review &amp; editing.</p><p><bold>Meike W Vernooij:</bold> Conceptualization; Formal analysis; Supervision; Writing &#8211; review &amp; editing.</p><p><bold>Daniel Bos:</bold> Conceptualization; Formal analysis; Methodology; Resources; Supervision; Writing &#8211; review &amp; editing.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by the Cure Alzheimer's Fund (DB, MWV, JN), and the Alzheimer's Association (DB, AARG -21-846504; MWV and JN, AARG-22-972229). The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam.</p></fn><fn fn-type="COI-statement"><p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn><fn fn-type="COI-statement"><p>Data can be obtained upon request. Requests should be directed towards the management team of the Rotterdam Study (datamanagement.ergo@erasmusmc.nl), which has a protocol for approving data requests. Because of restrictions based on privacy regulations and informed consent of the participants, data cannot be made freely available in a public repository.</p></fn><fn fn-type="other"><p><bold>Supplemental material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-13872877251372641"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Br&#252;ck</surname><given-names>CC</given-names></name><name name-style="western"><surname>Wolters</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Ikram</surname><given-names>MA</given-names></name></person-group>, <etal>et al.</etal><article-title>Projections of costs and quality adjusted life years lost due to dementia from 2020 to 2050: a population-based microsimulation study</article-title>. <source>Alzheimers Dement</source><year>2023</year>; <volume>19</volume>: <fpage>4532</fpage>&#8211;<lpage>4541</lpage>.<pub-id pub-id-type="pmid">36916447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13019</pub-id></mixed-citation></ref><ref id="bibr2-13872877251372641"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tahami Monfared</surname><given-names>AA</given-names></name><name name-style="western"><surname>Byrnes</surname><given-names>MJ</given-names></name><name name-style="western"><surname>White</surname><given-names>LA</given-names></name></person-group>, <etal>et al.</etal><article-title>The humanistic and economic burden of Alzheimer's disease</article-title>. <source>Neurol Ther</source><year>2022</year>; <volume>11</volume>: <fpage>525</fpage>&#8211;<lpage>551</lpage>.<pub-id pub-id-type="pmid">35192176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40120-022-00335-x</pub-id><pub-id pub-id-type="pmcid">PMC9095804</pub-id></mixed-citation></ref><ref id="bibr3-13872877251372641"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gouilly</surname><given-names>D</given-names></name><name name-style="western"><surname>Rafiq</surname><given-names>M</given-names></name><name name-style="western"><surname>Nogueira</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal><article-title>Beyond the amyloid cascade: an update of Alzheimer's disease pathophysiology</article-title>. <source>Rev Neurol (Paris)</source><year>2023</year>; <volume>179</volume>: <fpage>812</fpage>&#8211;<lpage>830</lpage>.<pub-id pub-id-type="pmid">36906457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurol.2022.12.006</pub-id></mixed-citation></ref><ref id="bibr4-13872877251372641"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saeed</surname><given-names>A</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>O</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Cardiovascular disease and Alzheimer's disease: the heart-brain axis</article-title>. <source>J Am Heart Assoc</source><year>2023</year>; <volume>12</volume>: <comment>e030780</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.123.030780</pub-id><pub-id pub-id-type="pmcid">PMC10727398</pub-id><pub-id pub-id-type="pmid">37929715</pub-id></mixed-citation></ref><ref id="bibr5-13872877251372641"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bos</surname><given-names>D</given-names></name><name name-style="western"><surname>Vernooij</surname><given-names>MW</given-names></name><name name-style="western"><surname>de Bruijn</surname><given-names>RF</given-names></name></person-group>, <etal>et al.</etal><article-title>Atherosclerotic calcification is related to a higher risk of dementia and cognitive decline</article-title>. <source>Alzheimers Dement</source><year>2015</year>; <volume>11</volume>: <fpage>639</fpage>&#8211;<lpage>647</lpage> e631.<pub-id pub-id-type="pmid">25150731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2014.05.1758</pub-id></mixed-citation></ref><ref id="bibr6-13872877251372641"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bos</surname><given-names>D</given-names></name><name name-style="western"><surname>Vernooij</surname><given-names>MW</given-names></name><name name-style="western"><surname>Elias-Smale</surname><given-names>SE</given-names></name></person-group>, <etal>et al.</etal><article-title>Atherosclerotic calcification relates to cognitive function and to brain changes on magnetic resonance imaging</article-title>. <source>Alzheimers Dement</source><year>2012</year>; <volume>8</volume>: <comment>S104</comment>&#8211;<lpage>S111</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2012.01.008</pub-id><pub-id pub-id-type="pmid">22537801</pub-id></mixed-citation></ref><ref id="bibr7-13872877251372641"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vinke</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Yilmaz</surname><given-names>P</given-names></name><name name-style="western"><surname>van der Toorn</surname><given-names>JE</given-names></name></person-group>, <etal>et al.</etal><article-title>Intracranial arteriosclerosis is related to cerebral small vessel disease: a prospective cohort study</article-title>. <source>Neurobiol Aging</source><year>2021</year>; <volume>105</volume>: <fpage>16</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">34004492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2021.04.005</pub-id></mixed-citation></ref><ref id="bibr8-13872877251372641"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Streiber</surname><given-names>AM</given-names></name><name name-style="western"><surname>van den Beukel</surname><given-names>TC</given-names></name><name name-style="western"><surname>Vom Hofe</surname><given-names>I</given-names></name></person-group>, <etal>et al.</etal><article-title>Arterial calcification in the heart&#8211;brain axis and cognitive performance over time</article-title>. <source>Alzheimers Dement</source><year>2025</year>; <volume>21</volume>: <comment>e14374</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14374</pub-id><pub-id pub-id-type="pmcid">PMC11782186</pub-id><pub-id pub-id-type="pmid">39625064</pub-id></mixed-citation></ref><ref id="bibr9-13872877251372641"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teunissen</surname><given-names>CE</given-names></name><name name-style="western"><surname>Verberk</surname><given-names>IMW</given-names></name><name name-style="western"><surname>Thijssen</surname><given-names>EH</given-names></name></person-group>, <etal>et al.</etal><article-title>Blood-based biomarkers for Alzheimer's disease: towards clinical implementation</article-title>. <source>Lancet Neurol</source><year>2022</year>; <volume>21</volume>: <fpage>66</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="pmid">34838239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(21)00361-6</pub-id></mixed-citation></ref><ref id="bibr10-13872877251372641"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolters</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Hilal</surname><given-names>S</given-names></name><name name-style="western"><surname>Leening</surname><given-names>MJG</given-names></name></person-group>, <etal>et al.</etal><article-title>Plasma amyloid-&#946;40 in relation to subclinical atherosclerosis and cardiovascular disease: a population-based study</article-title>. <source>Atherosclerosis</source><year>2022</year>; <volume>348</volume>: <fpage>44</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">35452865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2022.03.025</pub-id></mixed-citation></ref><ref id="bibr11-13872877251372641"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>D</given-names></name><name name-style="western"><surname>Cherian</surname><given-names>L</given-names></name><name name-style="western"><surname>Arfanakis</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Intracranial atherosclerotic disease and neurodegeneration: a narrative review and plausible mechanisms</article-title>. <source>J Stroke Cerebrovasc Dis</source><year>2024</year>; <volume>33</volume>: <fpage>108015</fpage>.<pub-id pub-id-type="pmid">39303868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jstrokecerebrovasdis.2024.108015</pub-id><pub-id pub-id-type="pmcid">PMC11570339</pub-id></mixed-citation></ref><ref id="bibr12-13872877251372641"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Wolf</surname><given-names>F</given-names></name><name name-style="western"><surname>Ghanbari</surname><given-names>M</given-names></name><name name-style="western"><surname>Licher</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Plasma tau, neurofilament light chain and amyloid-&#946; levels and risk of dementia; a population-based cohort study</article-title>. <source>Brain</source><year>2020</year>; <volume>143</volume>: <fpage>1220</fpage>&#8211;<lpage>1232</lpage>.<pub-id pub-id-type="pmid">32206776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awaa054</pub-id><pub-id pub-id-type="pmcid">PMC7174054</pub-id></mixed-citation></ref><ref id="bibr13-13872877251372641"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mielke</surname><given-names>MM</given-names></name><name name-style="western"><surname>Hagen</surname><given-names>CE</given-names></name><name name-style="western"><surname>Wennberg</surname><given-names>AMV</given-names></name></person-group>, <etal>et al.</etal><article-title>Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the mayo clinic study on aging</article-title>. <source>JAMA Neurol</source><year>2017</year>; <volume>74</volume>: <fpage>1073</fpage>&#8211;<lpage>1080</lpage>.<pub-id pub-id-type="pmid">28692710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2017.1359</pub-id><pub-id pub-id-type="pmcid">PMC5710182</pub-id></mixed-citation></ref><ref id="bibr14-13872877251372641"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koyama</surname><given-names>A</given-names></name><name name-style="western"><surname>Okereke</surname><given-names>OI</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T</given-names></name></person-group>, <etal>et al.</etal><article-title>Plasma amyloid-&#946; as a predictor of dementia and cognitive decline: a systematic review and meta-analysis</article-title>. <source>Arch Neurol</source><year>2012</year>; <volume>69</volume>: <fpage>824</fpage>&#8211;<lpage>831</lpage>.<pub-id pub-id-type="pmid">22451159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneurol.2011.1841</pub-id><pub-id pub-id-type="pmcid">PMC3772635</pub-id></mixed-citation></ref><ref id="bibr15-13872877251372641"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mooldijk</surname><given-names>SS</given-names></name><name name-style="western"><surname>Labrecque</surname><given-names>JA</given-names></name><name name-style="western"><surname>Ikram</surname><given-names>MA</given-names></name></person-group>, <etal>et al.</etal><article-title>Ratios in regression analyses with causal questions</article-title>. <source>Am J Epidemiol</source><year>2024</year>; <volume>194</volume>: <fpage>311</fpage>&#8211;<lpage>313</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/aje/kwae162</pub-id><pub-id pub-id-type="pmcid">PMC11735960</pub-id><pub-id pub-id-type="pmid">38932568</pub-id></mixed-citation></ref><ref id="bibr16-13872877251372641"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ikram</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kieboom</surname><given-names>BCT</given-names></name><name name-style="western"><surname>Brouwer</surname><given-names>WP</given-names></name></person-group>, <etal>et al.</etal><article-title>The Rotterdam Study. Design update and major findings between 2020 and 2024</article-title>. <source>Eur J Epidemiol</source><year>2024</year>; <volume>39</volume>: <fpage>183</fpage>&#8211;<lpage>206</lpage>.<pub-id pub-id-type="pmid">38324224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10654-023-01094-1</pub-id></mixed-citation></ref><ref id="bibr17-13872877251372641"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Odink</surname><given-names>AE</given-names></name><name name-style="western"><surname>van der Lugt</surname><given-names>A</given-names></name><name name-style="western"><surname>Hofman</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Association between calcification in the coronary arteries, aortic arch and carotid arteries: the Rotterdam study</article-title>. <source>Atherosclerosis</source><year>2007</year>; <volume>193</volume>: <fpage>408</fpage>&#8211;<lpage>413</lpage>.<pub-id pub-id-type="pmid">16919637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2006.07.007</pub-id></mixed-citation></ref><ref id="bibr18-13872877251372641"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bos</surname><given-names>D</given-names></name><name name-style="western"><surname>Ikram</surname><given-names>MA</given-names></name><name name-style="western"><surname>Elias-Smale</surname><given-names>SE</given-names></name></person-group>, <etal>et al.</etal><article-title>Calcification in major vessel beds relates to vascular brain disease</article-title>. <source>Arterioscler Thromb Vasc Biol</source><year>2011</year>; <volume>31</volume>: <fpage>2331</fpage>&#8211;<lpage>2337</lpage>.<pub-id pub-id-type="pmid">21868705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/ATVBAHA.111.232728</pub-id></mixed-citation></ref><ref id="bibr19-13872877251372641"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agatston</surname><given-names>AS</given-names></name><name name-style="western"><surname>Janowitz</surname><given-names>WR</given-names></name><name name-style="western"><surname>Hildner</surname><given-names>FJ</given-names></name></person-group>, <etal>et al.</etal><article-title>Quantification of coronary artery calcium using ultrafast computed tomography</article-title>. <source>J Am Coll Cardiol</source><year>1990</year>; <volume>15</volume>: <fpage>827</fpage>&#8211;<lpage>832</lpage>.<pub-id pub-id-type="pmid">2407762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0735-1097(90)90282-t</pub-id></mixed-citation></ref><ref id="bibr20-13872877251372641"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Weert</surname><given-names>TT</given-names></name><name name-style="western"><surname>Cakir</surname><given-names>H</given-names></name><name name-style="western"><surname>Rozie</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Intracranial internal carotid artery calcifications: association with vascular risk factors and ischemic cerebrovascular disease</article-title>. <source>AJNR Am J Neuroradiol</source><year>2009</year>; <volume>30</volume>: <fpage>177</fpage>&#8211;<lpage>184</lpage>.<pub-id pub-id-type="pmid">18842764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3174/ajnr.A1301</pub-id><pub-id pub-id-type="pmcid">PMC7051707</pub-id></mixed-citation></ref><ref id="bibr21-13872877251372641"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rissin</surname><given-names>DM</given-names></name><name name-style="western"><surname>Kan</surname><given-names>CW</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>TG</given-names></name></person-group>, <etal>et al.</etal><article-title>Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations</article-title>. <source>Nat Biotechnol</source><year>2010</year>; <volume>28</volume>: <fpage>595</fpage>&#8211;<lpage>599</lpage>.<pub-id pub-id-type="pmid">20495550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.1641</pub-id><pub-id pub-id-type="pmcid">PMC2919230</pub-id></mixed-citation></ref><ref id="bibr22-13872877251372641"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russ</surname><given-names>KA</given-names></name><name name-style="western"><surname>Stecker</surname><given-names>M</given-names></name><name name-style="western"><surname>Olson</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Implementation of blood-based biomarker assays to deliver consistent and comparable data</article-title>. <source>Alzheimers Dement</source><year>2022</year>; <volume>18</volume>: <comment>e065790</comment>.</mixed-citation></ref><ref id="bibr23-13872877251372641"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Truffi</surname><given-names>M</given-names></name><name name-style="western"><surname>Garofalo</surname><given-names>M</given-names></name><name name-style="western"><surname>Ricciardi</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Neurofilament-light chain quantification by Simoa and Ella in plasma from patients with dementia: a comparative study</article-title>. <source>Sci Rep</source><year>2023</year>; <volume>13</volume>: <fpage>4041</fpage>.<pub-id pub-id-type="pmid">36899015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-29704-8</pub-id><pub-id pub-id-type="pmcid">PMC10006166</pub-id></mixed-citation></ref><ref id="bibr24-13872877251372641"><label>24</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>L</given-names></name><name name-style="western"><surname>Shan</surname><given-names>D</given-names></name><name name-style="western"><surname>Wickman</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>SimoA human neurology 3-plex A (N3PA) immunoassay measures amyloid beta 1-42, amyloid beta 1-40 and tau in blood and CSF samples simultaneously</article-title>. In: <comment><italic toggle="yes">Alzheimer&#8217;s Association International Conference</italic></comment>, <conf-date>2017</conf-date>.</mixed-citation></ref><ref id="bibr25-13872877251372641"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inker</surname><given-names>LA</given-names></name><name name-style="western"><surname>Eneanya</surname><given-names>ND</given-names></name><name name-style="western"><surname>Coresh</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>New creatinine-and cystatin C&#8211;based equations to estimate GFR without race</article-title>. <source>N Engl J Med</source><year>2021</year>; <volume>385</volume>: <fpage>1737</fpage>&#8211;<lpage>1749</lpage>.<pub-id pub-id-type="pmid">34554658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2102953</pub-id><pub-id pub-id-type="pmcid">PMC8822996</pub-id></mixed-citation></ref><ref id="bibr26-13872877251372641"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sedaghat</surname><given-names>S</given-names></name><name name-style="western"><surname>Mattace-Raso</surname><given-names>FUS</given-names></name><name name-style="western"><surname>Hoorn</surname><given-names>EJ</given-names></name></person-group>, <etal>et al.</etal><article-title>Arterial stiffness and decline in kidney function</article-title>. <source>Clin J Am Soc Nephrol</source><year>2015</year>; <volume>10</volume>: <fpage>2190</fpage>&#8211;<lpage>2197</lpage>.<pub-id pub-id-type="pmid">26563380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.03000315</pub-id><pub-id pub-id-type="pmcid">PMC4670762</pub-id></mixed-citation></ref><ref id="bibr27-13872877251372641"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sedaghat</surname><given-names>S</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>TM</given-names></name></person-group>, <etal>et al.</etal><article-title>The association of kidney function with plasma amyloid-&#946; levels and brain amyloid deposition</article-title>. <source>J Alzheimers Dis</source><year>2023</year>; <volume>92</volume>: <fpage>229</fpage>&#8211;<lpage>239</lpage>.<pub-id pub-id-type="pmid">36710673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-220765</pub-id><pub-id pub-id-type="pmcid">PMC10124796</pub-id></mixed-citation></ref><ref id="bibr28-13872877251372641"><label>28</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>R Core Team</collab></person-group>. <source>R: A language and environment for statistical computing</source>. <publisher-loc>Vienna</publisher-loc>, <publisher-loc>Austria</publisher-loc>: <publisher-name>R Foundation for Statistical Computing</publisher-name>, <year>2022</year>.</mixed-citation></ref><ref id="bibr29-13872877251372641"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Buuren</surname><given-names>S</given-names></name><name name-style="western"><surname>Groothuis-Oudshoorn</surname><given-names>K</given-names></name></person-group>. <article-title>Mice: multivariate imputation by chained equations in R</article-title>. <source>J Stat Softw</source><year>2011</year>; <volume>45</volume>: <fpage>1</fpage>&#8211;<lpage>67</lpage>.</mixed-citation></ref><ref id="bibr30-13872877251372641"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Beukel</surname><given-names>TC</given-names></name><name name-style="western"><surname>Lucci</surname><given-names>C</given-names></name><name name-style="western"><surname>Hendrikse</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Risk factors for calcification of the vertebrobasilar arteries in cardiovascular patients referred for a head CT, the SMART study</article-title>. <source>J Neuroradiol</source><year>2021</year>; <volume>48</volume>: <fpage>248</fpage>&#8211;<lpage>253</lpage>.<pub-id pub-id-type="pmid">32169469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurad.2020.02.004</pub-id></mixed-citation></ref><ref id="bibr31-13872877251372641"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergstr&#246;m</surname><given-names>G</given-names></name><name name-style="western"><surname>Persson</surname><given-names>M</given-names></name><name name-style="western"><surname>Adiels</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Prevalence of subclinical coronary artery atherosclerosis in the general population</article-title>. <source>Circulation</source><year>2021</year>; <volume>144</volume>: <fpage>916</fpage>&#8211;<lpage>929</lpage>.<pub-id pub-id-type="pmid">34543072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.121.055340</pub-id><pub-id pub-id-type="pmcid">PMC8448414</pub-id></mixed-citation></ref><ref id="bibr32-13872877251372641"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jayalath</surname><given-names>RW</given-names></name><name name-style="western"><surname>Mangan</surname><given-names>SH</given-names></name><name name-style="western"><surname>Golledge</surname><given-names>J</given-names></name></person-group>. <article-title>Aortic calcification</article-title>. <source>Eur J Vasc Endovasc Surg</source><year>2005</year>; <volume>30</volume>: <fpage>476</fpage>&#8211;<lpage>488</lpage>.<pub-id pub-id-type="pmid">15963738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejvs.2005.04.030</pub-id></mixed-citation></ref><ref id="bibr33-13872877251372641"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Impact of intracranial artery calcification on cerebral hemodynamic changes</article-title>. <source>Neuroradiology</source><year>2018</year>; <volume>60</volume>: <fpage>357</fpage>&#8211;<lpage>363</lpage>.<pub-id pub-id-type="pmid">29426978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00234-018-1988-2</pub-id></mixed-citation></ref><ref id="bibr34-13872877251372641"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Altered expression of neurofilament 200 and amyloid-&#946; peptide (1-40) in a rat model of chronic cerebral hypoperfusion</article-title>. <source>Neurol Sci</source><year>2015</year>; <volume>36</volume>: <fpage>707</fpage>&#8211;<lpage>712</lpage>.<pub-id pub-id-type="pmid">25452168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10072-014-2014-z</pub-id></mixed-citation></ref><ref id="bibr35-13872877251372641"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laing</surname><given-names>KK</given-names></name><name name-style="western"><surname>Simoes</surname><given-names>S</given-names></name><name name-style="western"><surname>Baena-Caldas</surname><given-names>GP</given-names></name></person-group>, <etal>et al.</etal><article-title>Cerebrovascular disease promotes tau pathology in Alzheimer&#8217;s disease</article-title>. <source>Brain Commun</source><year>2020</year>; <volume>2</volume>: <comment>fcaa132</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcaa132</pub-id><pub-id pub-id-type="pmcid">PMC7660042</pub-id><pub-id pub-id-type="pmid">33215083</pub-id></mixed-citation></ref><ref id="bibr36-13872877251372641"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gong</surname><given-names>CX</given-names></name></person-group>. <article-title>From chronic cerebral hypoperfusion to Alzheimer-like brain pathology and neurodegeneration</article-title>. <source>Cell Mol Neurobiol</source><year>2015</year>; <volume>35</volume>: <fpage>101</fpage>&#8211;<lpage>110</lpage>.<pub-id pub-id-type="pmid">25352419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10571-014-0127-9</pub-id><pub-id pub-id-type="pmcid">PMC11486181</pub-id></mixed-citation></ref><ref id="bibr37-13872877251372641"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jakimovski</surname><given-names>D</given-names></name><name name-style="western"><surname>Gibney</surname><given-names>BL</given-names></name><name name-style="western"><surname>Marr</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Lower cerebral arterial blood flow is associated with greater serum neurofilament light chain levels in multiple sclerosis patients</article-title>. <source>Eur J Neurol</source><year>2022</year>; <volume>29</volume>: <fpage>2299</fpage>&#8211;<lpage>2308</lpage>.<pub-id pub-id-type="pmid">35474598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.15374</pub-id></mixed-citation></ref><ref id="bibr38-13872877251372641"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tan</surname><given-names>C-C</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X-N</given-names></name></person-group>, <etal>et al.</etal><article-title>Association of plasma neurofilament light with small vessel disease burden in nondemented elderly: a longitudinal study</article-title>. <source>Stroke</source><year>2021</year>; <volume>52</volume>: <fpage>896</fpage>&#8211;<lpage>904</lpage>.<pub-id pub-id-type="pmid">33517704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.120.030302</pub-id></mixed-citation></ref><ref id="bibr39-13872877251372641"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alfaddagh</surname><given-names>A</given-names></name><name name-style="western"><surname>Martin</surname><given-names>SS</given-names></name><name name-style="western"><surname>Leucker</surname><given-names>TM</given-names></name></person-group>, <etal>et al.</etal><article-title>Inflammation and cardiovascular disease: from mechanisms to therapeutics</article-title>. <source>Am J Prev Cardiol</source><year>2020</year>; <volume>4</volume>: <fpage>100130</fpage>.<pub-id pub-id-type="pmid">34327481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajpc.2020.100130</pub-id><pub-id pub-id-type="pmcid">PMC8315628</pub-id></mixed-citation></ref><ref id="bibr40-13872877251372641"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno</surname><given-names>B</given-names></name><name name-style="western"><surname>Jukes</surname><given-names>JP</given-names></name><name name-style="western"><surname>Vergara-Irigaray</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>Systemic inflammation induces axon injury during brain inflammation</article-title>. <source>Ann Neurol</source><year>2011</year>; <volume>70</volume>: <fpage>932</fpage>&#8211;<lpage>942</lpage>.<pub-id pub-id-type="pmid">22190366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.22550</pub-id></mixed-citation></ref><ref id="bibr41-13872877251372641"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>G-f</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T-h</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>Amyloid beta: structure, biology and structure-based therapeutic development</article-title>. <source>Acta Pharmacol Sin</source><year>2017</year>; <volume>38</volume>: <fpage>1205</fpage>&#8211;<lpage>1235</lpage>.<pub-id pub-id-type="pmid">28713158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/aps.2017.28</pub-id><pub-id pub-id-type="pmcid">PMC5589967</pub-id></mixed-citation></ref><ref id="bibr42-13872877251372641"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ap&#225;tiga-P&#233;rez</surname><given-names>R</given-names></name><name name-style="western"><surname>Soto-Rojas</surname><given-names>LO</given-names></name><name name-style="western"><surname>Campa-C&#243;rdoba</surname><given-names>BB</given-names></name></person-group>, <etal>et al.</etal><article-title>Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer's disease</article-title>. <source>Metab Brain Dis</source><year>2022</year>; <volume>37</volume>: <fpage>39</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">34406560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11011-021-00814-4</pub-id></mixed-citation></ref><ref id="bibr43-13872877251372641"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stamatelopoulos</surname><given-names>K</given-names></name><name name-style="western"><surname>Pol</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Ayers</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Amyloid-Beta (1-40) peptide and subclinical cardiovascular disease</article-title>. <source>J Am Coll Cardiol</source><year>2018</year>; <volume>72</volume>: <fpage>1060</fpage>&#8211;<lpage>1061</lpage>.<pub-id pub-id-type="pmid">30139434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2018.06.027</pub-id><pub-id pub-id-type="pmcid">PMC6467498</pub-id></mixed-citation></ref><ref id="bibr44-13872877251372641"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lehmann</surname><given-names>S</given-names></name><name name-style="western"><surname>Dumurgier</surname><given-names>J</given-names></name><name name-style="western"><surname>Ayrignac</surname><given-names>X</given-names></name></person-group>, <etal>et al.</etal><article-title>Cerebrospinal fluid A beta 1&#8211;40 peptides increase in Alzheimer&#8217;s disease and are highly correlated with phospho-tau in control individuals</article-title>. <source>Alzheimers Res Ther</source><year>2020</year>; <volume>12</volume>: <fpage>123</fpage>.<pub-id pub-id-type="pmid">33008460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-020-00696-1</pub-id><pub-id pub-id-type="pmcid">PMC7532565</pub-id></mixed-citation></ref><ref id="bibr45-13872877251372641"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Starmans</surname><given-names>NLP</given-names></name><name name-style="western"><surname>Leeuwis</surname><given-names>AE</given-names></name><name name-style="western"><surname>Biessels</surname><given-names>GJ</given-names></name></person-group>, <etal>et al.</etal><article-title>Cerebral amyloid-&#946; deposition in patients with heart disease or carotid occlusive disease: a systematic review and meta-analysis</article-title>. <source>J Neurol Sci</source><year>2023</year>; <volume>445</volume>: <fpage>120551</fpage>.<pub-id pub-id-type="pmid">36669349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jns.2023.120551</pub-id></mixed-citation></ref><ref id="bibr46-13872877251372641"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Risacher</surname><given-names>SL</given-names></name><name name-style="western"><surname>Fandos</surname><given-names>N</given-names></name><name name-style="western"><surname>Romero</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition</article-title>. <source>Alzheimers Dement (Amst)</source><year>2019</year>; <volume>11</volume>: <fpage>510</fpage>&#8211;<lpage>519</lpage>.<pub-id pub-id-type="pmid">31384662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dadm.2019.05.007</pub-id><pub-id pub-id-type="pmcid">PMC6661419</pub-id></mixed-citation></ref><ref id="bibr47-13872877251372641"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Streiber</surname><given-names>AM</given-names></name><name name-style="western"><surname>Neitzel</surname><given-names>J</given-names></name><name name-style="western"><surname>Nguyen Ho</surname><given-names>PT</given-names></name></person-group>, <etal>et al.</etal><article-title>Intracranial arteriosclerosis is not associated with cerebral amyloid deposition</article-title>. <source>Alzheimers Dement (Amst)</source><year>2024</year>; <volume>16</volume>: <comment>e70005</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.70005</pub-id><pub-id pub-id-type="pmcid">PMC11444050</pub-id><pub-id pub-id-type="pmid">39360005</pub-id></mixed-citation></ref><ref id="bibr48-13872877251372641"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottesman</surname><given-names>RF</given-names></name><name name-style="western"><surname>Mosley</surname><given-names>TH</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></name></person-group>, <etal>et al.</etal><article-title>Association of intracranial atherosclerotic disease with brain &#946;-amyloid deposition: secondary analysis of the ARIC study</article-title>. <source>JAMA Neurol</source><year>2020</year>; <volume>77</volume>: <fpage>350</fpage>&#8211;<lpage>357</lpage>.<pub-id pub-id-type="pmid">31860001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2019.4339</pub-id><pub-id pub-id-type="pmcid">PMC6990749</pub-id></mixed-citation></ref><ref id="bibr49-13872877251372641"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>A</given-names></name><name name-style="western"><surname>Mangialasche</surname><given-names>F</given-names></name><name name-style="western"><surname>Ngandu</surname><given-names>T</given-names></name></person-group>, <etal>et al.</etal><article-title>Multidomain interventions to prevent cognitive impairment, Alzheimer's disease, and dementia: from FINGER to world-wide FINGERS</article-title>. <source>J Prev Alzheimers Dis</source><year>2020</year>; <volume>7</volume>: <fpage>29</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">32010923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2019.41</pub-id><pub-id pub-id-type="pmcid">PMC7222931</pub-id></mixed-citation></ref><ref id="bibr50-13872877251372641"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Brum</surname><given-names>WS</given-names></name><name name-style="western"><surname>Di Molfetta</surname><given-names>G</given-names></name></person-group>, <etal>et al.</etal><article-title>Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology</article-title>. <source>JAMA Neurol</source><year>2024</year>; <volume>81</volume>: <fpage>255</fpage>&#8211;<lpage>263</lpage>.<pub-id pub-id-type="pmid">38252443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2023.5319</pub-id><pub-id pub-id-type="pmcid">PMC10804282</pub-id></mixed-citation></ref><ref id="bibr51-13872877251372641"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karikari</surname><given-names>TK</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Brinkmalm</surname><given-names>G</given-names></name></person-group>, <etal>et al.</etal><article-title>Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility</article-title>. <source>Nat Rev Neurol</source><year>2022</year>; <volume>18</volume>: <fpage>400</fpage>&#8211;<lpage>418</lpage>.<pub-id pub-id-type="pmid">35585226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-022-00665-2</pub-id></mixed-citation></ref><ref id="bibr52-13872877251372641"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubenstein</surname><given-names>R</given-names></name><name name-style="western"><surname>Chang</surname><given-names>B</given-names></name><name name-style="western"><surname>Yue</surname><given-names>JK</given-names></name></person-group>, <etal>et al.</etal><article-title>Comparing plasma phospho tau, total tau, and phospho tau&#8211;total tau ratio as acute and chronic traumatic brain injury biomarkers</article-title>. <source>JAMA Neurol</source><year>2017</year>; <volume>74</volume>: <fpage>1063</fpage>&#8211;<lpage>1072</lpage>.<pub-id pub-id-type="pmid">28738126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2017.0655</pub-id><pub-id pub-id-type="pmcid">PMC5710183</pub-id></mixed-citation></ref><ref id="bibr53-13872877251372641"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hampel</surname><given-names>H</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>LM</given-names></name></person-group>, <etal>et al.</etal><article-title>Total and phosphorylated tau protein as biological markers of Alzheimer's disease</article-title>. <source>Exp Gerontol</source><year>2010</year>; <volume>45</volume>: <fpage>30</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">19853650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.exger.2009.10.010</pub-id><pub-id pub-id-type="pmcid">PMC2815003</pub-id></mixed-citation></ref><ref id="bibr54-13872877251372641"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bayoumy</surname><given-names>S</given-names></name><name name-style="western"><surname>Verberk</surname><given-names>IMW</given-names></name><name name-style="western"><surname>den Dulk</surname><given-names>B</given-names></name></person-group>, <etal>et al.</etal><article-title>Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231</article-title>. <source>Alzheimers Res Ther</source><year>2021</year>; <volume>13</volume>: <fpage>198</fpage>.<pub-id pub-id-type="pmid">34863295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-021-00939-9</pub-id><pub-id pub-id-type="pmcid">PMC8645090</pub-id></mixed-citation></ref><ref id="bibr55-13872877251372641"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shim</surname><given-names>KH</given-names></name><name name-style="western"><surname>Kang</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Suh</surname><given-names>JW</given-names></name></person-group>, <etal>et al.</etal><article-title>CSF Total tau/&#945;-synuclein ratio improved the diagnostic performance for Alzheimer&#8217;s disease as an indicator of tau phosphorylation</article-title>. <source>Alzheimers Res Ther</source><year>2020</year>; <volume>12</volume>: <fpage>83</fpage>.<pub-id pub-id-type="pmid">32660565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-020-00648-9</pub-id><pub-id pub-id-type="pmcid">PMC7359621</pub-id></mixed-citation></ref><ref id="bibr56-13872877251372641"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savitz</surname><given-names>DA</given-names></name><name name-style="western"><surname>Wellenius</surname><given-names>GA</given-names></name></person-group>. <article-title>Can cross-sectional studies contribute to causal inference? It depends</article-title>. <source>Am J Epidemiol</source><year>2023</year>; <volume>192</volume>: <fpage>514</fpage>&#8211;<lpage>516</lpage>.<pub-id pub-id-type="pmid">35231933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/aje/kwac037</pub-id></mixed-citation></ref><ref id="bibr57-13872877251372641"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X-N</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H-F</given-names></name></person-group>, <etal>et al.</etal><article-title>The dynamics of plasma biomarkers across the Alzheimer&#8217;s continuum</article-title>. <source>Alzheimers Res Ther</source><year>2023</year>; <volume>15</volume>: <fpage>31</fpage>.<pub-id pub-id-type="pmid">36750875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-023-01174-0</pub-id><pub-id pub-id-type="pmcid">PMC9906840</pub-id></mixed-citation></ref><ref id="bibr58-13872877251372641"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>HHH</given-names></name><name name-style="western"><surname>Ikram</surname><given-names>MA</given-names></name><name name-style="western"><surname>Vernooij</surname><given-names>MW</given-names></name></person-group>, <etal>et al.</etal><article-title>Heritability and genome-wide association analyses of intracranial carotid artery calcification</article-title>. <source>Stroke</source><year>2016</year>; <volume>47</volume>: <fpage>912</fpage>&#8211;<lpage>917</lpage>.<pub-id pub-id-type="pmid">26965845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.115.012248</pub-id></mixed-citation></ref><ref id="bibr59-13872877251372641"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamer</surname><given-names>M</given-names></name><name name-style="western"><surname>Chida</surname><given-names>Y</given-names></name></person-group>. <article-title>Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence</article-title>. <source>Psychol Med</source><year>2009</year>; <volume>39</volume>: <fpage>3</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">18570697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0033291708003681</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12494874</article-id><article-id pub-id-type="pmcid-ver">PMC12494874.1</article-id><article-id pub-id-type="pmcaid">12494874</article-id><article-id pub-id-type="pmcaiid">12494874</article-id><article-id pub-id-type="pmid">41044176</article-id><article-id pub-id-type="doi">10.1038/s41598-025-22025-y</article-id><article-id pub-id-type="publisher-id">22025</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>An ensemble model based on transfer learning for the early detection of Alzheimer&#8217;s disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Varzaneh</surname><given-names initials="ZA">Zahra Asghari</given-names></name><address><email>Zahra.asghari-varzaneh@mau.se</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Mousavi</surname><given-names initials="SM">Seyyed Mohammad</given-names></name><address><email>mr.mousavi.khj@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khoshkangini</surname><given-names initials="R">Reza</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moosavi Khaliji</surname><given-names initials="SM">Sayyed Mostafa</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05wp7an13</institution-id><institution-id institution-id-type="GRID">grid.32995.34</institution-id><institution-id institution-id-type="ISNI">0000 0000 9961 9487</institution-id><institution>Department of Computer Science and Media Technology, Sustainable Digitalisation Research Center, </institution><institution>Malm&#246; University, </institution></institution-wrap>Malm&#246;, Sweden </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02kxbqc24</institution-id><institution-id institution-id-type="GRID">grid.412105.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2092 9755</institution-id><institution>Health Information Sciences Department, Faculty of Management and Medical Information Sciences, </institution><institution>Kerman University of Medical Sciences, </institution></institution-wrap>Kerman, Iran </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04r58gt57</institution-id><institution-id institution-id-type="GRID">grid.444911.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0619 1231</institution-id><institution>Department of Research and Technology Activities Support of Kerman Provincial Unit, </institution><institution>University of Applied Science and Technology, </institution></institution-wrap>Tehran, Iran </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>34634</elocation-id><history><date date-type="received"><day>1</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 07:25:25.147"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2025_Article_22025.pdf"/><abstract id="Abs1"><p id="Par1">Alzheimer&#8217;s disease (AD) is a progressive neurodegenerative disorder characterized by the gradual decline in cognitive functions, particularly memory and reasoning. Early detection, especially during cognitive impairment (MCI) stage, is crucial for timely intervention and management. Enhanced diagnostic methods are essential for facilitating early identification and improving patient outcomes. This study presents a robust deep learning framework for the early detection of Alzheimer&#8217;s disease. It employs transfer learning and hyperparameter-tuning of InceptionResnetV2, InceptionV3, Xception architectures to enhance feature extraction by leveraging their pre-trained capabilities. An ensemble voting mechanism has been integrated to combine predictions from different models, optimizing both accuracy and robustness. The proposed ensemble voting approach demonstrated exceptional performance, achieving 98.96% accuracy and 100% precision for predicting classes Mildly Demented and Moderately Demented. It outperformed baseline and state-of-the-art models, highlighting its potential as a reliable tool for early diagnosis and intervention.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alzheimer&#8217;s disease</kwd><kwd>Convolutional neural network</kwd><kwd>Transfer learning</kwd><kwd>Medical imaging</kwd><kwd>Ensemble learning</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Neuroscience</kwd><kwd>Diseases</kwd><kwd>Medical research</kwd></kwd-group><funding-group><award-group><funding-source><institution>Malm&#246; University</institution></funding-source></award-group><open-access><p>Open access funding provided by Malm&#246; University.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4"> Alzheimer&#8217;s disease (AD) is the most common form of dementia, a term that refers to the decline in memory and other cognitive abilities, which can significantly impact a person&#8217;s daily life<sup><xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR4">4</xref></sup>. Typically, Alzheimer&#8217;s begins with mild cognitive impairment (MCI), which progressively worsens over time<sup><xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref></sup>. Individuals with MCI are at a higher risk of developing AD compared to the general population. AD is a complex and progressive neurological disorder that leads to the gradual deterioration of brain cells, ultimately affecting a person&#8217;s memory, thinking skills, and cognitive functions<sup><xref ref-type="bibr" rid="CR8">8</xref>&#8211;<xref ref-type="bibr" rid="CR10">10</xref></sup>. In the advanced stages of the disease, patients may experience severe weaknesses and a decline in the functionality of vital bodily systems. This decline can lead to secondary complications over time, ultimately resulting in mortality<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>.</p><p id="Par5">Currently, the most reliable method for diagnosing Alzheimer&#8217;s dementia involves monitoring individuals with MCI and evaluating their cognitive changes over the years<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup>. Magnetic resonance imaging (MRI) can detect alterations in brain structures that indicate the onset of AD. Early diagnosis of MCI due to Alzheimer&#8217;s is crucial, as individuals may benefit from early interventions aimed at preventing or delaying cognitive decline<sup><xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref></sup>. Typically, a neurologist will ask about the patient&#8217;s symptoms and medical history, as well as that of their immediate family, while also evaluating for other neurological disorders. To confirm a diagnosis of dementia, a series of diagnostic tests is required. These may include brain imaging to rule out other similar conditions, CT scans and MRIs to assess brain issues related to strokes or tumors, and PET scans for a more detailed examination of brain activity<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Early identification of AD, along with preventive measures, can help slow the progression of the disease and improve the quality of life for those affected<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>.</p><p id="Par6">Early detection of AD is essential for effective treatment and improved patient outcomes. Traditional diagnostic methods typically rely on neuropsychological assessments and clinical evaluations, which can often be time-consuming. In recent years, the integration of artificial intelligence (AI) algorithms, particularly machine learning (ML) and deep learning (DL) techniques, has transformed disease diagnosis, providing greater accuracy and efficiency<sup><xref ref-type="bibr" rid="CR20">20</xref>&#8211;<xref ref-type="bibr" rid="CR23">23</xref></sup>. AI algorithms have shown significant promise in analyzing complex medical data. While machine learning models have been widely adopted, deep learning models, especially convolutional neural networks (CNNs), have demonstrated superior performance in various medical applications<sup><xref ref-type="bibr" rid="CR24">24</xref>&#8211;<xref ref-type="bibr" rid="CR27">27</xref></sup>. These models excel at automatically extracting hierarchical features from raw data, minimizing the need for extensive manual preprocessing. In the field of medical imaging, deep learning techniques have significantly enhanced the analysis of images, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans. CNNs are particularly valuable because they can identify patterns and structures within these images, aiding in the diagnosis of numerous medical conditions<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup>. In the context of Alzheimer&#8217;s disease, CNNs can extract critical features from MRI scans to help identify early signs of neurodegeneration by analyzing brain structures, including the hippocampus<sup><xref ref-type="bibr" rid="CR30">30</xref>&#8211;<xref ref-type="bibr" rid="CR34">34</xref></sup>. As research progresses, the potential applications of AI in medical diagnosis will continue to grow, paving the way for more effective healthcare solutions.</p><p id="Par7">Venugopalan et al.<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> classified patients into three groups: control (CN), mild cognitive impairment (MCI), and AD. They did this by analyzing several sorts of data using deep learning algorithms. They applied 3D-CNN to the imaging data and stacked denoising autoencoders to the clinical and genetic datasets for feature extraction. They also presented a novel method for interpreting data that uses perturbation analysis and clustering to identify the best characteristics found by deep learning models. Results show that deep learning models perform noticeably better than conventional shallow models. Helaly et al.<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> introduced a comprehensive method for early AD identification that makes use of CNNs and deep learning. The first approach used both 2D and 3D convolutional approaches to process 2D and 3D structural brain scans from the ADNI dataset using simple CNN architectures. In order to use pretrained models, such VGG19, for medical picture classification, the second technique used transfer learning. Lin et al.<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> employed the method of coupling a pre-trained 2D CNN for transfer learning with a reliable relational vector machine for the regression approach, rather than a 3D CNN. Feature transfer learning, 3D feature concatenation, and dimensionality reduction are important techniques used in this study. To estimate brain age, sMRI data is used to train the model. They proposed a pre-trained AlexNet for feature extraction, which achieved superior performance for older adults.</p><p id="Par8">In order to identify AD and dementia, Buvaneswari et al.<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> proposed a deep learning technique that uses SegNet to segregate brain features from structural MRI. The method improves the classification of AD, moderate cognitive impairment, and cognitive normal by detecting small morphological alterations. ResNet-101 classifier trained using features taken from 240 sMRI scans makes automated AD diagnosis possible. Goyal et al.<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> diagnosed Alzheimer&#8217;s using LSTM and transfer-learned AlexNet. Their multi-layer system was used to classify MRIs into binary and multiclass categories. To improve the classification results, the authors discovered that their model needed a larger training dataset. They used a GAN to enhance the training dataset in order to address this issue. Their framework performed better than other models, according to a comparison examination.</p><p id="Par9">Kadri et al.<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> proposed two innovative methods for diagnosing AD. The first method combined a Swin transformer with an improved version of EfficientNet, which includes a Depthwise Over-Parameterized Convolutional Layer (DO-Conv) and multi-head attention. The second method integrated inverted residual blocks and incorporated ECA-Net into the CoAtNet network. Evaluations were conducted using the OASIS and ADNI datasets, while Gradient-based Localization (Grad-CAM) was employed for analysis.</p><p id="Par10">Shah et al.<sup><xref ref-type="bibr" rid="CR41">41</xref></sup> introduced the Bi-Vision Transformer (BiViT) architecture for classifying various stages of AD and other cognitive disorders using 2D MRI imaging data. To improve feature learning, the BiViT model employs a dual strategy that combines concurrent coupled encoding and mutual latent fusion. Arafa et al.<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> implemented two methods for analyzing AD. A basic CNN architecture was used in the first approach, while a pre-trained VGG16 model that had been refined by transfer learning on several datasets was used in the second. With fewer labeled training samples and less domain knowledge needed, the suggested method shows mastery of AD analysis and produces notable performance improvements in all diagnostic groups during the experiments. EL-Geneedy et al.<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> developed a deep learning-based pipeline for the accurate diagnosis and stratification of AD stages. The pipeline provides a quick and accurate AD diagnostic module by using 2D T1-weighted MRI brain images with a shallow CNN architecture. It offers both local classification, which tackles the difficult problem of classifying mild cognitive impairment into Very Mild Dementia, Mild Dementia, and Moderate Dementia as prodromal phases of AD, and global classification (normal vs. Mild Cognitive Impairment vs. AD). In addition to MRI and CT image data taken from the brain, EEG signals are also used to diagnose Alzheimer&#8217;s disease. Sercek et al.<sup><xref ref-type="bibr" rid="CR44">44</xref></sup> introduced a novel graph theoretic, and quantum inspired approach to feature extraction, contributing an innovative perspective to Alzheimer&#8217;s diagnosis. In<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>, also the authors have employed biologically inspired EEG analysis, offering a promising noninvasive model grounded in primate brain activity patterns.</p><p id="Par11">This study presents a practical deep-learning approach for predicting Alzheimer&#8217;s Disease (AD) using transfer learning and ensemble learning techniques. We fine-tuned three advanced pre-trained models&#8212;InceptionResNetV2, InceptionV3, and Xception&#8212;for multi-class classification. The final layers of each model were adapted to classify MRI images into four categories: Non-Demented, Very Mildly Demented, Mildly Demented, and Moderately Demented. To improve the prediction performance, we applied an ensemble learning strategy. Each model was trained independently, and their outputs were combined using a majority voting method. This ensemble approach increases the robustness and accuracy of the classification, providing more stable and reliable results than using a single model.</p><p id="Par12">The main contributions of this study are summarized as follows:</p><p id="Par13">
<list list-type="bullet"><list-item><p id="Par14">Introducing a robust ensemble framework that combines transfer learning with a majority voting mechanism for accurate classification of Alzheimer&#8217;s disease stages.</p></list-item><list-item><p id="Par15">Utilizing transfer learning to extract optimal features for multi-class prediction of Alzheimer&#8217;s disease by adapting pre-trained models, including InceptionResNetV2, InceptionV3, and Xception.</p></list-item><list-item><p id="Par16">Adjusting the final layers of models to improve performance for task-specific classification through fine-tuning.</p></list-item><list-item><p id="Par17">Enhancing the model&#8217;s efficiency for early prediction of 4-class Alzheimer&#8217;s disease, focusing on improvements in accuracy and precision.</p></list-item></list>
</p></sec><sec id="Sec2"><title>Dataset description</title><p id="Par18">In this study, we utilize the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) dataset, which contains 6,735 images categorized into four different cognitive classes: Non-Demented, Very Mildly Demented, Mildly Demented, and Moderately Demented<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. The ADNI dataset is a comprehensive, multimodal collection that includes not only MRI images but also cerebrospinal fluid (CSF) biomarkers, blood tests, RNA, urine tests, and omics data (encompassing genomics, proteomics, metabolomics, and lipidomic). However, the scope of this study is specifically focused on diagnosing Alzheimer&#8217;s disease stages using structural MRI data, and thus, other modalities were not incorporated. Figure <xref rid="Fig1" ref-type="fig">1</xref> shows the distribution of samples across these classes.</p><p id="Par19">Non-Demented class includes 2,067 samples of individuals who exhibit normal cognitive function without any discernible impairment. This group&#8217;s participants act as a control population, which is crucial for creating benchmarks that other classes can be measured against. Neuroimaging tests in this group show healthy brain architecture and functions, and they usually don&#8217;t exhibit any indicators of cognitive deterioration. Very Mildly Demented consists of 1,495 samples. Participants in this category exhibit early signs of cognitive decline, often characterized by mild memory issues that do not significantly disrupt their daily functioning. Neuroimaging may show subtle changes in brain structure or function, indicating the beginning of neurodegeneration.</p><p id="Par20">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Distribution of samples across classes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e380" position="float" orientation="portrait" xlink:href="41598_2025_22025_Fig1_HTML.jpg"/></fig>
</p><p id="Par21">The Mildly Demented class includes 1,749 samples. Individuals in this group display more noticeable cognitive impairments but still retain some level of independence, even though these impairments impact their daily tasks. Common complaints in this category include increased memory loss and difficulties with complex tasks. This group is crucial for studying the progression of AD, as neuroimaging often reveals more apparent atrophy in specific brain regions, such as the hippocampus, which is associated with memory and learning. The Moderately Demented class includes 1,424 samples of individuals with moderate cognitive decline, which significantly impacts their ability to perform daily activities. Participants may experience confusion, memory loss, and difficulty recognizing familiar faces. Neuroimaging data often reveal changes in functional connectivity and significant brain atrophy. To understand the later phases of Alzheimer&#8217;s disease and the associated neurobiological changes, it is essential to study this group of individuals. Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref> shows sample images from each of the four data classes.</p><p id="Par22">After preprocessing and balancing the data, as well as applying data augmentation techniques, the dataset is divided into three sets: 70% for training, 20% for testing, and 10% for validation. This method enables a thorough analysis of cognitive decline and the progression of AD. Our deep learning model supports known biomarkers, established in prior research, by detecting structural patterns in MRI images. This capability aids in understanding neurobiological changes associated with each class and can facilitate early disease diagnosis.</p><p id="Par23">Our focus was on extracting structural features using convolutional neural network (CNN) models, and thus, demographic data such as age and sex were not included, as they would require a multimodal approach beyond the scope of this research.</p><p id="Par24">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Sample MRI images from the four cognitive classes of the ADNI dataset.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e399" position="float" orientation="portrait" xlink:href="41598_2025_22025_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec3"><title>Background</title><p id="Par25">In this study, three models&#8212; Inception ResNetV2, InceptionV3, and Xception &#8212;were employed to detect Alzheimer&#8217;s disease using MRI images. These images provide detailed information and complex features that are crucial for accurately diagnosing this disease. All three models incorporate advanced blocks, such as Inception Modules and Residual Connections. These models possess a more sophisticated architecture than basic deep learning models, enabling them to extract both low-level features, like edges, and high-level features, such as complex shapes, from images simultaneously. This ability enhances their effectiveness in detecting changes in brain structure associated with Alzheimer&#8217;s disease.</p><p id="Par26">Another reason for utilizing these models is their low risk of overfitting, due to the presence of mechanisms such as Batch Normalization and Dropout in these models. The architecture of these models is described in more detail below.</p><sec id="Sec4"><title>Inception ResNetV2</title><p id="Par27">In order to increase accuracy and decrease training time, Szegedy introduced this architecture at Google in 2016, which was trained on over a million images from the ImageNet database<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. It combines two cutting-edge deep neural network techniques, the Inception and ResNet designs. The architecture consists of Inception blocks that use short ResNet connections. This combination allows the network to efficiently extract features simultaneously and avoid the learning problems of deep networks. The general scheme of this architecture is shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>, which includes the following components<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>:</p><p id="Par28">
<list list-type="bullet"><list-item><p id="Par29"><italic toggle="yes">Stem</italic>: This section is positioned at the beginning of the network and is responsible for preparing the inputs for further processing. It includes the initial layers that help effectively distribute features and enable the network to quickly extract information.</p></list-item><list-item><p id="Par30"><italic toggle="yes">Inception ResNet A</italic>,<italic toggle="yes"> B</italic>,<italic toggle="yes"> and C</italic>: These three sections contain Inception blocks that utilize ResNet skip connections, which assist in identifying features in the initial, middle, and final layers.</p></list-item><list-item><p id="Par31"><italic toggle="yes">Reduction A</italic>: This section is tasked with reducing the dimensionality of features. This section includes layers that facilitate down-sampling of the input size while maintaining important features. As a result, the network may go deeper without losing important data.</p></list-item><list-item><p id="Par32"><italic toggle="yes">Reduction B</italic>: It works like Reduction A, but is used in the later stages of the network. It is designed to reduce dimensionality while preserving features, enabling the network to extract additional features in the final stages.</p></list-item></list>
</p><p id="Par33">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Inception ResNetV2 architecture, featuring Stem (input preprocessing), Inception ResNet blocks (feature extraction), and Reduction modules (dimensionality reduction).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e460" position="float" orientation="portrait" xlink:href="41598_2025_22025_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec5"><title>InceptionV3</title><p id="Par34">The InceptionV3 model, developed by Google, features multiple parallel Inception blocks. As the third version of the Inception models, Google developed the InceptionV3 architecture, which is made up of multiple parallel Inception blocks<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>.</p><p id="Par35">
<list list-type="bullet"><list-item><p id="Par36">Inception A: Contains parallel <inline-formula id="IEq1"><alternatives><tex-math id="d33e476">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:1\times\:1$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq1.gif"/></alternatives></inline-formula> and 3<inline-formula id="IEq2"><alternatives><tex-math id="d33e482">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\times\:3$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq2.gif"/></alternatives></inline-formula> kernels.</p></list-item><list-item><p id="Par37">Inception B: Uses <inline-formula id="IEq3"><alternatives><tex-math id="d33e491">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:1\times\:1$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq1.gif"/></alternatives></inline-formula>, 3<inline-formula id="IEq4"><alternatives><tex-math id="d33e497">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\times\:3$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq2.gif"/></alternatives></inline-formula> and 5<inline-formula id="IEq5"><alternatives><tex-math id="d33e503">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\times\:5$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq5.gif"/></alternatives></inline-formula> kernels. To improve extraction of more complex features.</p></list-item><list-item><p id="Par38">Designed for use in later network stages, this concept is comparable to Inception B.</p></list-item></list>
</p><p id="Par39">InceptionV3 also includes down-sampling layers that help reduce the size of features and preserve important information. Additionally, normalization layers aid in increasing learning speed and training stability, which enables the model to train more quickly and precisely<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>.</p></sec><sec id="Sec6"><title>Xception</title><p id="Par40">Xception, introduced by Francois Chollet at Google, is a deep learning model that extends and complements Inception<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. In Xception, inception modules are replaced with depthwise separable convolution layers, and the model has a total of 36 layers. Comparing the Xception model with the Inception V3 model, the model performs better on the ImageNet dataset, however, on a larger dataset consisting of 350 million images, Xception performs significantly better. Depthwise separable convolutions comprise the core of the Xception model. In this approach, depthwise convolution is performed first, followed by pointwise convolution. The Xception model employs various <inline-formula id="IEq6"><alternatives><tex-math id="d33e527">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:n\times\:n\:$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq6.gif"/></alternatives></inline-formula>filters for depthwise convolution, which occurs after the initial pointwise convolution (<inline-formula id="IEq7"><alternatives><tex-math id="d33e533">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:1\times\:1$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq1.gif"/></alternatives></inline-formula>). Figure <xref rid="Fig4" ref-type="fig">4</xref> depicts the Xception model&#8217;s architecture and different layers. According to this image, the Xception architecture has three primary components: the entry flow, the middle flow, and the exit flow, with skip connections around the 36 layers<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>.</p><p id="Par41">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Xception architecture.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e554" position="float" orientation="portrait" xlink:href="41598_2025_22025_Fig4_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec7"><title>Proposed approach</title><p id="Par42">In this study, we emphasize the critical importance of early diagnosis of Alzheimer&#8217;s disease, as it can significantly reduce the challenges associated with its progression. Timely intervention can lead to better symptom management and improve quality of life.</p><p id="Par43">Our Proposed solution consists of several key steps. First, we gather the relevant data on Alzheimer&#8217;s disease and then preprocess it to ensure it is suitable for analysis. We apply data augmentation techniques to increase the dataset&#8217;s diversity, which enhances the model&#8217;s robustness. For classification, we employ the InceptionResnetV2, InceptionV3, and Xception architectures as backbone, known for its improved accuracy and efficiency due to its optimized depth and width. This approach allows us to systematically categorize Alzheimer&#8217;s data into four distinct classes. Finally, we thoroughly evaluate the results to assess the effectiveness of our proposed methodology. Figure&#160;<xref rid="Fig5" ref-type="fig">5</xref> illustrates an overview of the proposed model.</p><p id="Par44">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>An Overview of the proposed model for early Alzheimer&#8217;s diagnosis, featuring preprocessing, training using pre-trained CNN models (InceptionResNetV2, InceptionV3, Xception), hyperparameter tuning and ensemble learning with voting method.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e573" position="float" orientation="portrait" xlink:href="41598_2025_22025_Fig5_HTML.jpg"/></fig>
</p><sec id="Sec8"><title>Preprocessing</title><p id="Par45">In this study, we utilized the ADNI dataset, which consists of 6,735 samples. To prepare this data for more effective analysis, we implemented a series of preprocessing steps. Initially, each image <bold><italic toggle="yes">I</italic></bold> were resized to a uniform dimension of 299&#8201;&#215;&#8201;299 pixels as indicated in Eq.&#160;<xref rid="Equ1" ref-type="disp-formula">1</xref>. This standardization is crucial for ensuring compatibility with the InceptionResnetV2, InceptionV3, and Xception architectures.<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="d33e585">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{I}_{resized}=Resize\:(I,\:(\text{299,299}\left)\right)$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_22025_Article_Equ1.gif"/></alternatives></disp-formula></p><p id="Par46">To tackle data imbalance, we enhanced the dataset using techniques like horizontal flipping with a 90% probability (see Eq.&#160;<xref rid="Equ2" ref-type="disp-formula">2</xref>) and zooming within &#177;&#8201;20 degrees (see Eq.&#160;<xref rid="Equ3" ref-type="disp-formula">3</xref>).<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="d33e599">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{I}_{flipped}=RandomHorizontalFlip\:\left(I,\:p\right)\:\:\:\:\:where,\:p\:=\:0.9$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_22025_Article_Equ2.gif"/></alternatives></disp-formula><disp-formula id="Equ3"><label>3</label><alternatives><tex-math id="d33e605">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{I}_{Zoomed}=Zoom\:\left(I,\:\theta\:\right)\:\:\:\:\:\:\:\:\:\:\:\:\:\:where,\:\theta\:\:=\:20$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_22025_Article_Equ3.gif"/></alternatives></disp-formula></p><p id="Par47">The <inline-formula id="IEq8"><alternatives><tex-math id="d33e613">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\text{s}\text{h}\text{e}\text{a}\text{r}\_\text{r}\text{a}\text{n}\text{g}\text{e}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq8.gif"/></alternatives></inline-formula> was set to 0.2, where the transformation is defined as:<disp-formula id="Equ4"><label>4</label><alternatives><tex-math id="d33e619">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\left[\begin{array}{c}x{\prime\:}\\\:y{\prime\:}\end{array}\right]=\:\left[\begin{array}{cc}1&amp;\:shear\_x\\\:shear\_y&amp;\:1\end{array}\right]\left[\begin{array}{c}x\\\:y\end{array}\right]$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_22025_Article_Equ4.gif"/></alternatives></disp-formula></p><p id="Par48">with <inline-formula id="IEq9"><alternatives><tex-math id="d33e627">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\text{s}\text{h}\text{e}\text{a}\text{r}\_\text{x}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq9.gif"/></alternatives></inline-formula> and <inline-formula id="IEq10"><alternatives><tex-math id="d33e633">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\text{s}\text{h}\text{e}\text{a}\text{r}\_\text{y}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq10.gif"/></alternatives></inline-formula> randomly selected in the range [&#8722;&#8201;0.2,0.2]. The variables <inline-formula id="IEq11"><alternatives><tex-math id="d33e639">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:x$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq11.gif"/></alternatives></inline-formula> and <inline-formula id="IEq12"><alternatives><tex-math id="d33e645">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:y$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq12.gif"/></alternatives></inline-formula> denote the original pixel coordinates in the image, while <inline-formula id="IEq13"><alternatives><tex-math id="d33e651">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:x{\prime\:}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq13.gif"/></alternatives></inline-formula> and <inline-formula id="IEq14"><alternatives><tex-math id="d33e658">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:y{\prime\:}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq14.gif"/></alternatives></inline-formula> indicate the new pixel coordinates after the shear transformation is applied. Images were also randomly shifted by up to 5% of their width and height to introduce spatial variability and improve model robustness.</p><p id="Par49">Data augmentation not only increases the diversity of the training samples but also improves the model&#8217;s ability to generalize unseen data, helping to mitigate the overfitting problem. Figure&#160;<xref rid="Fig6" ref-type="fig">6</xref> shows some images created by augmentation techniques.</p><p id="Par50">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Data augmentation methods applied on an image.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e677" position="float" orientation="portrait" xlink:href="41598_2025_22025_Fig6_HTML.jpg"/></fig>
</p><p id="Par51">Additionally, all images were converted from color (RGB with three channels) to grayscale (single channel) as shown in Eq.&#160;<xref rid="Equ5" ref-type="disp-formula">5</xref>. This conversion aimed to simplify the model and reduce complexity while retaining essential features. After converting to grayscale, pixel values were normalized from a range of 0-255 to 0&#8211;1, following Eq.&#160;<xref rid="Equ6" ref-type="disp-formula">6</xref>. This normalization aligns the data with the input requirements of the pre-trained InceptionResnetV2, InceptionV3, and Xception architectures, ensuring consistent and high-quality input for accurate classification.<disp-formula id="Equ5"><label>5</label><alternatives><tex-math id="d33e687">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$I\,=\,0.{\text{299}} \times R\,+\,0.{\text{587}} \times G\,+\,0.{\text{114}} \times B$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_22025_Article_Equ5.gif"/></alternatives></disp-formula><disp-formula id="Equ6"><label>6</label><alternatives><tex-math id="d33e693">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{I}_{norm}=I/255\:\:$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_22025_Article_Equ6.gif"/></alternatives></disp-formula></p></sec><sec id="Sec9"><title>Architecture</title><p id="Par52">The proposed architecture combines the strengths of the three architectures mentioned above along with transfer learning and layer customization for the last layers. All three models were originally trained on the large ImageNet dataset, which helps them learn general image features. In our approach, the base layers of each model are kept frozen, and only the final classification layers are trained on the Alzheimer&#8217;s dataset. This helps the models focus on learning task-specific patterns without losing the powerful feature extraction abilities from the pre-trained layers. This approach effectively combines transfer learning and hyperparameter tuning, employing the general feature extraction capabilities of pre-trained models along with task-specific adjustments made through hyperparameter tuning.</p><p id="Par53">All three architectures begin with a 2D convolution layer to preprocess the input data, followed by the model seen from the pre-training. GlobalAveragePooling2D and Flatten layers were added to reduce the spatial dimension and transform the multi-dimensional features into a 1D vector, respectively. Fully connected (Dense) layers with ReLU activation functions are incorporated to enhance the model&#8217;s ability to learn complex patterns. Dropout layers are added to mitigate overfitting. Finally, a Dense layer with four units and a softmax activation function is included to generate the output probabilities for the four target classes. The key parameters and configurations utilized in our proposed architecture are presented in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par54">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Overview of main parameters for the base and proposed models used in alzheimer&#8217;s diagnosis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameter</th><th align="left" colspan="1" rowspan="1">Value/configuration</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Base Models</td><td align="left" colspan="1" rowspan="1">InceptionResNetV2, Xception, InceptionV3</td></tr><tr><td align="left" colspan="1" rowspan="1">Input Shape</td><td align="left" colspan="1" rowspan="1">(229, 229, 3)</td></tr><tr><td align="left" colspan="1" rowspan="1">Dropout Rate</td><td align="left" colspan="1" rowspan="1">0.3</td></tr><tr><td align="left" colspan="1" rowspan="1">Learning Rate</td><td align="left" colspan="1" rowspan="1">0.003</td></tr><tr><td align="left" colspan="1" rowspan="1">Optimizer</td><td align="left" colspan="1" rowspan="1">Adam</td></tr><tr><td align="left" colspan="1" rowspan="1">Epochs</td><td align="left" colspan="1" rowspan="1">30</td></tr><tr><td align="left" colspan="1" rowspan="1">Batch size</td><td align="left" colspan="1" rowspan="1">16</td></tr><tr><td align="left" colspan="1" rowspan="1">Loss Function</td><td align="left" colspan="1" rowspan="1">Sparse categorical cross entropy</td></tr><tr><td align="left" colspan="1" rowspan="1">Evaluation Metric</td><td align="left" colspan="1" rowspan="1">Accuracy</td></tr></tbody></table></table-wrap>
</p><p id="Par55">To enhance the efficiency of the proposed models, we employed an ensemble learning approach that combines the predictions from three different architectures using a voting mechanism. Figure&#160;<xref rid="Fig7" ref-type="fig">7</xref> illustrates the overall method of weighted ensemble learning. This method not only strengthens the model&#8217;s performance but also minimizes the risk of overfitting and improves generalization. In general, ensemble learning uses the strategy of effectively combining different individual learners. Each individual learner is generated from training data by existing learning algorithms. Using individual learners of the same type is called homogeneous ensemble learning, and using various individual learners is called heterogeneous ensemble learning. In this research, homogeneous ensemble learning is used by combining CNN networks including InceptionV3, Xception, InceptionResNetV2.</p><p id="Par56">There are three strategies for combining models, which include voting, averaging, and stacking. In this research, the voting method is used. This method assumes that there are <italic toggle="yes">T</italic> different classifiers including &#8462;<sub>1</sub>, &#8462;<sub>2</sub>, &#8230;, &#8462;<sub>T</sub>. The objective is to use the classifier&#8217;s output to forecast the final category from the category markers <italic toggle="yes">c</italic><sub>1</sub>, <italic toggle="yes">c</italic><sub>2</sub>, &#8230;.<italic toggle="yes">c</italic><sub><italic toggle="yes">l</italic></sub>. The output result of the classifier &#8462;<sub>i</sub> for a sample <italic toggle="yes">x</italic> is usually a one-dimensional label vector <inline-formula id="IEq15"><alternatives><tex-math id="d33e807">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{({h}_{i}^{1}\left(x\right),{h}_{i}^{2}\left(x\right),\dots\:,{h}_{i}^{l}\left(x\right))}^{T}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq15.gif"/></alternatives></inline-formula>, where <inline-formula id="IEq16"><alternatives><tex-math id="d33e814">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{h}_{i}^{j}\left(x\right)$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq16.gif"/></alternatives></inline-formula> is the prediction output of the &#8462;<sub><italic toggle="yes">i</italic></sub> classifier on the class <italic toggle="yes">c</italic><sub><italic toggle="yes">j</italic></sub> label.</p><p id="Par57">The proposed ensemble learning method assigns a weight to each network based on its performance. If a classifier performs better, it is assigned a higher weight. First, the weights are scaled to values between 0 and 1. Then, for each weight vector, the combination of weights that has the highest accuracy in predicting the disease stages is selected. These optimized weights are applied in the final stage of the ensemble learning method. The weighted ensemble learning formula is given in Eq.&#160;(<xref rid="Equ7" ref-type="disp-formula">7</xref>):<disp-formula id="Equ7"><label>7</label><alternatives><tex-math id="d33e835">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:H\left(x\right)=\:{c}_{{arg}_{j}max}\:\sum\:_{i=1}^{T}{w}_{i}{h}_{i}^{j}\left(x\right),\:$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_22025_Article_Equ7.gif"/></alternatives></disp-formula></p><p id="Par58">where the weight of classifier &#8462;<sub><italic toggle="yes">i</italic></sub> is represented by <inline-formula id="IEq17"><alternatives><tex-math id="d33e847">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{w}_{i}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq17.gif"/></alternatives></inline-formula>. In real-world applications, the weight coefficients are frequently normalized and restricted by <inline-formula id="IEq18"><alternatives><tex-math id="d33e853">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{w}_{i}\ge\:$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq18.gif"/></alternatives></inline-formula> 0 and <inline-formula id="IEq19"><alternatives><tex-math id="d33e859">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\sum\:_{i=1}^{T}{w}_{i}=1$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_22025_Article_IEq19.gif"/></alternatives></inline-formula>, much like in the weighted average approach. Selecting the appropriate weight is crucial. Selecting the appropriate weights for classifiers is crucial and should align with the performance of each individual classifier, provided that the output of each classifier operates independently from the others.</p><p id="Par59">
<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>Weighted ensemble learning method for classifying Alzheimer&#8217;s disease, combining votes from InceptionV3, Xception, and InceptionResNetV2 with weights based on performance.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e873" position="float" orientation="portrait" xlink:href="41598_2025_22025_Fig7_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec10"><title>Experimental results and model evaluation</title><p id="Par60">The experiments were conducted to implement the models in a Google Colab environment, utilizing a system with an Intel Core i7 processor, 16 GB of RAM, and running on Windows 11.</p><p id="Par61">We compared the performance of three transfer learning models InceptionResNetV2, InceptionV3, and Xception for Alzheimer&#8217;s disease classification across four categories. Following this, we benchmarked these models against the proposed ensemble learning model to evaluate its effectiveness in improving diagnostic accuracy. This comparative analysis enables us to assess the advantages of using these models in the context of Alzheimer&#8217;s disease classification. For the evaluation of these models, we employed several metrics to provide a thorough assessment of their performance<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. The key evaluation criteria include Accuracy, Precision, Recall, and F1-Score. In addition, the confusion matrix offers a detailed view of model performance, allowing for a detailed analysis of classification errors<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>.</p><sec id="Sec11"><title>Model evaluation</title><p id="Par62">The results presented in this subsection were obtained by evaluating the proposed deep learning model on the test split of the ADNI dataset. The model was trained on all four classes (Non-Demented, Very Mildly Demented, Mildly Demented, and Moderately Demented) and evaluated on a separate test set, comprising 20% of the data. Training curves, including learning curves, demonstrate the model&#8217;s stable performance and absence of overfitting, confirming the validity of the results.</p><p id="Par63">Table&#160;<xref rid="Tab2" ref-type="table">2</xref> presents a performance comparison of the proposed methods, focusing on overall evaluation metrics. This table displays the average accuracy, precision, recall, and F-score across all classes. As shown, Inception ResNetV2 and Ensemble Voting are the top-performing models, followed closely by Xception, which ranks third. InceptionV3 also shows good results, although it performs slightly weaker than the other models. Table&#160;<xref rid="Tab3" ref-type="table">3</xref> presents the performance of the models according to various evaluation criteria, including Accuracy, Precision, Recall, and F-Score, across different data classes: Non-Demented, Very Mildly Demented, Mildly Demented, and Moderately Demented. All models demonstrated high accuracy in diagnosing Alzheimer&#8217;s disease; however, Inception ResNetV2 model proposed in this study exhibited the highest accuracy as well as Ensemble voting. In the Non-Demented category, both Inception ResNetV2 and Ensemble voting outperformed other models in terms of all metrics. Notably, the Recall criterion for the Ensemble voting model was also superior to that of the other models, achieving a value of 0.98 and the precision criterion for the Inception ResNetV2 model was also superior to that of the other models, achieving a value of 0.97.</p><p id="Par64">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Performance comparison of the proposed methods in terms of evaluation metrics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Architecture</th><th align="left" colspan="1" rowspan="1">Accuracy</th><th align="left" colspan="1" rowspan="1">Precision</th><th align="left" colspan="1" rowspan="1">Recall</th><th align="left" colspan="1" rowspan="1">F-score</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Inception ResNetV2</td><td char="." align="char" colspan="1" rowspan="1">0.96</td><td char="." align="char" colspan="1" rowspan="1">0.97</td><td char="." align="char" colspan="1" rowspan="1">0.96</td><td char="." align="char" colspan="1" rowspan="1">0.96</td></tr><tr><td align="left" colspan="1" rowspan="1">InceptionV3</td><td char="." align="char" colspan="1" rowspan="1">86.46</td><td char="." align="char" colspan="1" rowspan="1">0.88</td><td char="." align="char" colspan="1" rowspan="1">0.86</td><td char="." align="char" colspan="1" rowspan="1">0.86</td></tr><tr><td align="left" colspan="1" rowspan="1">Xception</td><td char="." align="char" colspan="1" rowspan="1">0.93</td><td char="." align="char" colspan="1" rowspan="1">0.93</td><td char="." align="char" colspan="1" rowspan="1">0.93</td><td char="." align="char" colspan="1" rowspan="1">0.93</td></tr><tr><td align="left" colspan="1" rowspan="1">Ensemble voting</td><td char="." align="char" colspan="1" rowspan="1">0.98</td><td char="." align="char" colspan="1" rowspan="1">0.98</td><td char="." align="char" colspan="1" rowspan="1">0.98</td><td char="." align="char" colspan="1" rowspan="1">0.98</td></tr></tbody></table></table-wrap>
</p><p id="Par65">All models performed exceptionally well in diagnosing Mildly Demented patients, with a Recall criterion of 1.00, but Xception model with 0.99. Among these models, Inception ResNetV2 and Ensemble voting were identified as the top-performing options. In general, all models showed slightly reduced performance in detecting the Very Mildly Demented class compared to the other classes, with Inception ResNetV2 being the least effective. However, the Ensemble voting model excelled in this area, achieving a Precision of 0.97 and a Recall of 0.95. On the other hand, all models performed exceptionally well in identifying the Moderately Demented class, with Precision, Recall, and F-Score metrics all reaching 1.00 for each model.</p><p id="Par66">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Class-wise performance comparison of each class for the proposed methods in terms of evaluation metrics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Class</th><th align="left" colspan="1" rowspan="1">Architecture</th><th align="left" colspan="1" rowspan="1">Precision</th><th align="left" colspan="1" rowspan="1">Recall</th><th align="left" colspan="1" rowspan="1">F-Score</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Non-demented</td><td align="left" colspan="1" rowspan="1">Inception ResNetV2</td><td char="." align="char" colspan="1" rowspan="1">0.97</td><td char="." align="char" colspan="1" rowspan="1">0.97</td><td char="." align="char" colspan="1" rowspan="1">0.97</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">InceptionV3</td><td char="." align="char" colspan="1" rowspan="1">0.93</td><td char="." align="char" colspan="1" rowspan="1">0.69</td><td char="." align="char" colspan="1" rowspan="1">0.79</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Xception</td><td char="." align="char" colspan="1" rowspan="1">0.91</td><td char="." align="char" colspan="1" rowspan="1">0.89</td><td char="." align="char" colspan="1" rowspan="1">0.90</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Ensemble voting</td><td char="." align="char" colspan="1" rowspan="1">0.96</td><td char="." align="char" colspan="1" rowspan="1">0.98</td><td char="." align="char" colspan="1" rowspan="1">0.97</td></tr><tr><td align="left" colspan="1" rowspan="1">Mildly demented</td><td align="left" colspan="1" rowspan="1">Inception ResNetV2</td><td char="." align="char" colspan="1" rowspan="1">1.00</td><td char="." align="char" colspan="1" rowspan="1">1.00</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">InceptionV3</td><td char="." align="char" colspan="1" rowspan="1">0.87</td><td char="." align="char" colspan="1" rowspan="1">1.00</td><td char="." align="char" colspan="1" rowspan="1">0.93</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Xception</td><td char="." align="char" colspan="1" rowspan="1">0.97</td><td char="." align="char" colspan="1" rowspan="1">0.99</td><td char="." align="char" colspan="1" rowspan="1">0.98</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Ensemble voting</td><td char="." align="char" colspan="1" rowspan="1">1.00</td><td char="." align="char" colspan="1" rowspan="1">1.00</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1">Very mildly demented</td><td align="left" colspan="1" rowspan="1">Inception ResNetV2</td><td char="." align="char" colspan="1" rowspan="1">0.96</td><td char="." align="char" colspan="1" rowspan="1">0.95</td><td char="." align="char" colspan="1" rowspan="1">0.95</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">InceptionV3</td><td char="." align="char" colspan="1" rowspan="1">0.69</td><td char="." align="char" colspan="1" rowspan="1">0.82</td><td char="." align="char" colspan="1" rowspan="1">0.75</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Xception</td><td char="." align="char" colspan="1" rowspan="1">0.86</td><td char="." align="char" colspan="1" rowspan="1">0.85</td><td char="." align="char" colspan="1" rowspan="1">0.85</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Ensemble voting</td><td char="." align="char" colspan="1" rowspan="1">0.97</td><td char="." align="char" colspan="1" rowspan="1">0.95</td><td char="." align="char" colspan="1" rowspan="1">0.96</td></tr><tr><td align="left" colspan="1" rowspan="1">Moderately demented</td><td align="left" colspan="1" rowspan="1">Inception ResNetV2</td><td char="." align="char" colspan="1" rowspan="1">1.00</td><td char="." align="char" colspan="1" rowspan="1">1.00</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">InceptionV3</td><td char="." align="char" colspan="1" rowspan="1">1.00</td><td char="." align="char" colspan="1" rowspan="1">1.00</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Xception</td><td char="." align="char" colspan="1" rowspan="1">1.00</td><td char="." align="char" colspan="1" rowspan="1">1.00</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Ensemble voting</td><td char="." align="char" colspan="1" rowspan="1">1.00</td><td char="." align="char" colspan="1" rowspan="1">1.00</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr></tbody></table></table-wrap>
</p><p id="Par67">Subsequently, the four proposed models were compared using their confusion matrices, as illustrated in Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>.</p><p id="Par68">The Xception model demonstrated perfect classification accuracy for the moderated demented class, with zero misclassifications. However, its primary errors occurred in the nondemented group. It identified 38 samples related to the very mildly demented class as nondemented and also incorrectly classified 45 samples that were nondemented into other categories. The Inception ResNetV2 model also has the highest error in detecting nondemented. In contrast, InceptionV3 as the most week model has the highest misclassification of very demented samples as nondemented to 21 instances and incorrectly classified 128 samples that were nondemented into other categories. Notably, the ensemble learning model achieved superior performance across all classes, committing only 9 misclassifications of very demented samples as nondemented&#8212;the lowest among all evaluated architectures. A consistent pattern across all models was the misclassification of very demented samples into the nondemented category. Misclassifications between control (Non-Demented) and Very Demented samples in Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>, though surprising, can occur in deep learning models, particularly for complex tasks like Alzheimer&#8217;s disease diagnosis. These errors may stem from factors such as slight class imbalance (e.g., fewer Very Demented samples compared to Non-Demented in the ADNI dataset), noise in MRI data, or limitations in the model&#8217;s ability to distinguish subtle features in early disease stages.</p><p id="Par69">
<fig id="Fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><p>Confusion matrix of the base and proposed ensemble models for classifying four Alzheimer&#8217;s classes (Non-Demented, Very Mildly, Mildly, Moderately) with ADNI MRI images.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1184" position="float" orientation="portrait" xlink:href="41598_2025_22025_Fig8_HTML.jpg"/></fig>
</p><p id="Par70">Overall, the numerical results, along with confusion matrix plots, indicate good performance of the models. Additionally, the classification performance of the ensemble learning method was generally superior to that of the individual transfer learning methods. The proposed model was finally compared with four other state-of-the-art methods concerning accuracy metric. The results of this comparison are presented in Table <xref rid="Tab4" ref-type="table">4</xref>. Saratxaga et al.<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> employed three different models&#8212;ResNet18, BrainNet2D, and BrainNet3D&#8212;to predict Alzheimer&#8217;s disease based on brain MRI data. However, the accuracy of these models was lower than other competitors. Jabason et al.<sup><xref ref-type="bibr" rid="CR56">56</xref></sup> utilized a hybrid ensemble model to classify Alzheimer&#8217;s disease from MRI data, achieving an accuracy of 0.95. Sarraf and Tofighi<sup><xref ref-type="bibr" rid="CR57">57</xref></sup> used the LeNet-5 model for this classification, which yielded an acceptable accuracy of approximately 0.96. Cui et al.<sup><xref ref-type="bibr" rid="CR58">58</xref></sup> developed an enhanced inception network based on brain MRI to diagnose Alzheimer&#8217;s disease, achieving an accuracy of 0.85. In contrast, our proposed method outperformed all other models, achieving an accuracy of 0.98.</p><p id="Par71">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Accuracy comparison of the proposed ensemble voting model with other state-of-the-art models.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Reference</th><th align="left" colspan="1" rowspan="1">Data type</th><th align="left" colspan="2" rowspan="1">Model</th><th align="left" colspan="1" rowspan="1">Accuracy</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">Saratxaga et al.<sup><xref ref-type="bibr" rid="CR55">55</xref></sup></td><td align="left" rowspan="3" colspan="2">MRI</td><td align="left" colspan="1" rowspan="1">ResNet18</td><td align="left" colspan="1" rowspan="1">0.88</td></tr><tr><td align="left" colspan="1" rowspan="1">BrainNet2D</td><td align="left" colspan="1" rowspan="1">0.85</td></tr><tr><td align="left" colspan="1" rowspan="1">BrainNet3D</td><td align="left" colspan="1" rowspan="1">0.77</td></tr><tr><td align="left" colspan="1" rowspan="1">Jabason et al.<sup><xref ref-type="bibr" rid="CR56">56</xref></sup></td><td align="left" colspan="2" rowspan="1">MRI</td><td align="left" colspan="1" rowspan="1">Hybrid deep learning</td><td align="left" colspan="1" rowspan="1">0.95</td></tr><tr><td align="left" colspan="1" rowspan="1">Sarraf and Tofighi<sup><xref ref-type="bibr" rid="CR57">57</xref></sup></td><td align="left" colspan="2" rowspan="1">FMRI</td><td align="left" colspan="1" rowspan="1">LeNet-5</td><td align="left" colspan="1" rowspan="1">0.96</td></tr><tr><td align="left" colspan="1" rowspan="1">Cui et al.<sup><xref ref-type="bibr" rid="CR58">58</xref></sup></td><td align="left" colspan="2" rowspan="1">MRI</td><td align="left" colspan="1" rowspan="1">InceptionV3</td><td align="left" colspan="1" rowspan="1">0.85</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Proposed model</bold>
</td><td align="left" colspan="2" rowspan="1">
<bold>MRI</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>Ensemble voting</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>0.98</bold>
</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec12"><title>Ablation study</title><p id="Par72">To thoroughly evaluate the effectiveness of our proposed ensemble framework, we conducted an ablation study to evaluate the individual contributions of each base model (InceptionResNetV2, InceptionV3, and Xception) and their combinations. This analysis helps isolate the impact of different architectural choices and ensemble strategies on the overall performance. Table&#160;<xref rid="Tab5" ref-type="table">5</xref> shows the performance of different ensemble models with respect to the Precision, Recall, F-Score, and Accuracy metrics.</p><p id="Par73">
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Performance comparison of different ensemble methods in terms of evaluation metrics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Architecture</th><th align="left" colspan="1" rowspan="1">Accuracy</th><th align="left" colspan="1" rowspan="1">Precision</th><th align="left" colspan="1" rowspan="1">Recall</th><th align="left" colspan="1" rowspan="1">F-score</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Inception ResNetV2 &amp; InceptionV3</td><td align="left" colspan="1" rowspan="1">0.96</td><td align="left" colspan="1" rowspan="1">0.96</td><td align="left" colspan="1" rowspan="1">0.96</td><td align="left" colspan="1" rowspan="1">0.96</td></tr><tr><td align="left" colspan="1" rowspan="1">Inception ResNetV2 &amp; Xception</td><td align="left" colspan="1" rowspan="1">0.97</td><td align="left" colspan="1" rowspan="1">0.97</td><td align="left" colspan="1" rowspan="1">0.97</td><td align="left" colspan="1" rowspan="1">0.97</td></tr><tr><td align="left" colspan="1" rowspan="1">InceptionV3 &amp; Xception</td><td align="left" colspan="1" rowspan="1">0.93</td><td align="left" colspan="1" rowspan="1">0.93</td><td align="left" colspan="1" rowspan="1">0.93</td><td align="left" colspan="1" rowspan="1">0.93</td></tr><tr><td align="left" colspan="1" rowspan="1">All models</td><td align="left" colspan="1" rowspan="1">0.98</td><td align="left" colspan="1" rowspan="1">0.98</td><td align="left" colspan="1" rowspan="1">0.98</td><td align="left" colspan="1" rowspan="1">0.98</td></tr></tbody></table></table-wrap>
</p><p id="Par74">As you can see in the table of results of ensemble different models, better results are obtained when all three architectures are combined. After that, the combination of Inception ResNetV2 &amp; Xception performs better than the others. Since the InceptionV3 model performs much weaker than the others, ensemble can well have a positive and significant impact on its performance, as it performs much better after combining with Xception.</p></sec></sec><sec id="Sec13"><title>Limitations and future work</title><p id="Par75">Although our proposed deep learning framework demonstrates promising results for the early and accurate classification of Alzheimer&#8217;s disease stages, several limitations must be acknowledged to contextualize its findings. The dataset used in this study, although standardized and collected with high accuracy, has limitations that could limit the model&#8217;s ability to generalize across the full spectrum of disease variability. In addition, variations in MRI imaging protocols, such as differences in scanner types, imaging parameters, or imaging resolution across institutions, may introduce biases that affect the consistency of image quality and, consequently, model performance. Demographic factors, including age, ethnicity, sex, or socioeconomic status, may also contribute to biases if the training data lacks adequate representation of diverse populations. The model should also be validated in real-world clinical settings, which are crucial to ensure its applicability in routine medical settings. Finally, the inherent lack of interpretability in deep learning models may reduce clinician confidence, as the decision-making process remains ambiguous without explicit links to neuroanatomical or pathological correlates.</p><p id="Par76">To address these limitations, future research should prioritize model validation on larger and more diverse datasets collected from multiple institutions to increase generalizability and reduce biases due to imaging variations or population imbalances. Standardization of MRI imaging protocols or application of advanced data augmentation techniques could further improve the robustness of the model to image quality inconsistencies. Furthermore, the inclusion of multimodal data, such as clinical assessments and genetic markers, could provide a more comprehensive approach to Alzheimer&#8217;s diagnosis and potentially improve predictive accuracy and clinical relevance. Prospective validation studies in real-world clinical settings, along with user studies involving neurologists to assess model usability and interpretation, are essential to bridge the gap between research and clinical practice. Techniques from explainable AI (XAI), such as attention maps or saliency visualizations, should be incorporated to highlight disease-relevant regions and align model outputs with clinical understanding.</p></sec><sec id="Sec14"><title>Conclusion</title><p id="Par77">In this study, an advanced CNN framework for the early and accurate multi-class classification of Alzheimer&#8217;s disease was proposed. This framework leveraged transfer learning, hyperparameter tuning, and ensemble voting to address the challenges of diagnosing AD across its progressive stages. By adapting state-of-the-art architectures&#8212;InceptionResNetV2, InceptionV3, and Xception&#8212;and optimizing their final layers to predict four categories: Non-Demented, Very Mildly Demented, Mildly Demented, and Moderately Demented, we achieved significant improvements in diagnostic performance. Outperforming all individual baseline models, the ensemble voting mechanism, which included predictions from various models, showed remarkable robustness, attaining 98.96% accuracy and 100% precision for crucial classes (Mildly and Moderately Demented). Additionally, the InceptionV3 model emerged as a strong candidate for standalone classification. Overall, the results of this research have the potential to assist doctors in diagnosing Alzheimer&#8217;s disease at an early stage and help patients to the disease&#8217;s progression. However, there are still many challenges and ongoing studies that need to be addressed in future research. Incorporating multimodal data and considering other clinical and genetic factors in patients could lead to more precise and robust predictions.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors contributed to the study&#8217;s conception and design, provided feedback on earlier versions of the manuscript, and approved the final version.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by Malm&#246; University.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The dataset analyzed during the current study are available in the https://www.kaggle.com/datasets/praneshkumarm/multidiseasedataset.</p></notes><notes notes-type="data-availability"><title>Code availability</title><p>The source codes of the current study are available in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/muhammadmo/Alzheimer_Classification_MRI">https://github.com/muhammadmo/Alzheimer_Classification_MRI</ext-link>.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par78">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karantzoulis</surname><given-names>S</given-names></name><name name-style="western"><surname>Galvin</surname><given-names>JE</given-names></name></person-group><article-title>Distinguishing Alzheimer&#8217;s disease from other major forms of dementia</article-title><source>Expert Rev. Neurother.</source><year>2011</year><volume>11</volume><issue>11</issue><fpage>1579</fpage><lpage>1591</lpage><pub-id pub-id-type="doi">10.1586/ern.11.155</pub-id><pub-id pub-id-type="pmid">22014137</pub-id><pub-id pub-id-type="pmcid">PMC3225285</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Karantzoulis, S. &amp; Galvin, J. E. Distinguishing Alzheimer&#8217;s disease from other major forms of dementia. <italic toggle="yes">Expert Rev. Neurother.</italic><bold>11</bold> (11), 1579&#8211;1591 (2011).<pub-id pub-id-type="pmid">22014137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/ern.11.155</pub-id><pub-id pub-id-type="pmcid">PMC3225285</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rom&#225;n</surname><given-names>GC</given-names></name></person-group><article-title>Vascular dementia may be the most common form of dementia in the elderly</article-title><source>J. Neurol. Sci.</source><year>2002</year><volume>203</volume><fpage>7</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/S0022-510X(02)00252-6</pub-id><pub-id pub-id-type="pmid">12417349</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Rom&#225;n, G. C. Vascular dementia may be the most common form of dementia in the elderly. <italic toggle="yes">J. Neurol. Sci.</italic><bold>203</bold>, 7&#8211;10 (2002).<pub-id pub-id-type="pmid">12417349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0022-510x(02)00252-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Rizzi, L., Rosset, I. &amp; Roriz-Cruz, M. Global epidemiology of dementia: Alzheimer&#8217;s and vascular types. <italic toggle="yes">BioMed. Res. Int.</italic><bold>1</bold>, 908915 (2014).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2014/908915</pub-id><pub-id pub-id-type="pmcid">PMC4095986</pub-id><pub-id pub-id-type="pmid">25089278</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name><name name-style="western"><surname>de Leon</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name></person-group><article-title>Alzheimer&#8217;s disease</article-title><source>Lancet</source><year>2006</year><volume>368</volume><issue>9533</issue><fpage>387</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(06)69113-7</pub-id><pub-id pub-id-type="pmid">16876668</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Blennow, K., de Leon, M. J. &amp; Zetterberg, H. Alzheimer&#8217;s disease. <italic toggle="yes">Lancet</italic><bold>368</bold> (9533), 387&#8211;403 (2006).<pub-id pub-id-type="pmid">16876668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(06)69113-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reisberg</surname><given-names>B</given-names></name><etal/></person-group><article-title>Mild cognitive impairment (MCI): a historical perspective</article-title><source>Int. Psychogeriatr.</source><year>2008</year><volume>20</volume><issue>1</issue><fpage>18</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1017/S1041610207006394</pub-id><pub-id pub-id-type="pmid">18031593</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Reisberg, B. et al. Mild cognitive impairment (MCI): a historical perspective. <italic toggle="yes">Int. Psychogeriatr.</italic><bold>20</bold> (1), 18&#8211;31 (2008).<pub-id pub-id-type="pmid">18031593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610207006394</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Almkvist, O. et al. <italic toggle="yes">Mild Cognitive Impairment&#8212;An Early Stage of Alzheimer&#8217;s Disease?</italic> (Springer, 1998).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-7091-7508-8_3</pub-id><pub-id pub-id-type="pmid">9850912</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name></person-group><article-title>Early diagnosis of alzheimer&#8217;s disease: is MCI too late?</article-title><source>Curr. Alzheimer Res.</source><year>2009</year><volume>6</volume><issue>4</issue><fpage>324</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.2174/156720509788929237</pub-id><pub-id pub-id-type="pmid">19689230</pub-id><pub-id pub-id-type="pmcid">PMC3098139</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Petersen, R. C. Early diagnosis of alzheimer&#8217;s disease: is MCI too late? <italic toggle="yes">Curr. Alzheimer Res.</italic><bold>6</bold> (4), 324&#8211;330 (2009).<pub-id pub-id-type="pmid">19689230</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/156720509788929237</pub-id><pub-id pub-id-type="pmcid">PMC3098139</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Breijyeh, Z. &amp; Karaman, R. Comprehensive review on Alzheimer&#8217;s disease: Causes and treatment. <italic toggle="yes">Molecules</italic><bold>25</bold>(24), 5789 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules25245789</pub-id><pub-id pub-id-type="pmcid">PMC7764106</pub-id><pub-id pub-id-type="pmid">33302541</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Association</surname><given-names>A</given-names></name></person-group><article-title>2019 alzheimer&#8217;s disease facts and figures</article-title><source>Alzheimer&#8217;s Dement.</source><year>2019</year><volume>15</volume><issue>3</issue><fpage>321</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2019.01.010</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Association, A. 2019 alzheimer&#8217;s disease facts and figures. <italic toggle="yes">Alzheimer&#8217;s Dement.</italic><bold>15</bold> (3), 321&#8211;387 (2019).</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Cummings, J. L., Vinters, H. V., Cole, G. M. &amp; Khachaturian, Z. S. Alzheimer&#8217;s disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities. <italic toggle="yes">Neurology</italic><bold>51</bold>(1_suppl_1), S2-S17 (1998).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.51.1_suppl_1.s2</pub-id><pub-id pub-id-type="pmid">9674758</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Post, S. G. <italic toggle="yes">The Moral Challenge of Alzheimer Disease: Ethical Issues from Diagnosis to Dying</italic> (JHU, 2002).</mixed-citation></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liss</surname><given-names>J</given-names></name><etal/></person-group><article-title>Practical recommendations for timely, accurate diagnosis of symptomatic alzheimer&#8217;s disease (MCI and dementia) in primary care: a review and synthesis</article-title><source>J. Intern. Med.</source><year>2021</year><volume>290</volume><issue>2</issue><fpage>310</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1111/joim.13244</pub-id><pub-id pub-id-type="pmid">33458891</pub-id><pub-id pub-id-type="pmcid">PMC8359937</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Liss, J. et al. Practical recommendations for timely, accurate diagnosis of symptomatic alzheimer&#8217;s disease (MCI and dementia) in primary care: a review and synthesis. <italic toggle="yes">J. Intern. Med.</italic><bold>290</bold> (2), 310&#8211;334 (2021).<pub-id pub-id-type="pmid">33458891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/joim.13244</pub-id><pub-id pub-id-type="pmcid">PMC8359937</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>LG</given-names></name><name name-style="western"><surname>Loewenstein</surname><given-names>DA</given-names></name></person-group><article-title>Assessing the progression of mild cognitive impairment to alzheimer&#8217;s disease: current trends and future directions</article-title><source>Alzheimers Res. Ther.</source><year>2010</year><volume>2</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/alzrt52</pub-id><pub-id pub-id-type="pmid">20920147</pub-id><pub-id pub-id-type="pmcid">PMC2983437</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Brooks, L. G. &amp; Loewenstein, D. A. Assessing the progression of mild cognitive impairment to alzheimer&#8217;s disease: current trends and future directions. <italic toggle="yes">Alzheimers Res. Ther.</italic><bold>2</bold>, 1&#8211;9 (2010).<pub-id pub-id-type="pmid">20920147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/alzrt52</pub-id><pub-id pub-id-type="pmcid">PMC2983437</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ries</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Magnetic resonance imaging characterization of brain structure and function in mild cognitive impairment: a review</article-title><source>J. Am. Geriatr. Soc.</source><year>2008</year><volume>56</volume><issue>5</issue><fpage>920</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2008.01684.x</pub-id><pub-id pub-id-type="pmid">18410325</pub-id><pub-id pub-id-type="pmcid">PMC2668820</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Ries, M. L. et al. Magnetic resonance imaging characterization of brain structure and function in mild cognitive impairment: a review. <italic toggle="yes">J. Am. Geriatr. Soc.</italic><bold>56</bold> (5), 920&#8211;934 (2008).<pub-id pub-id-type="pmid">18410325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1532-5415.2008.01684.x</pub-id><pub-id pub-id-type="pmcid">PMC2668820</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Smith, C. et al. Brain structural alterations before mild cognitive impairment. <italic toggle="yes">Neurology</italic><bold>68</bold>(16), 1268&#8211;1273 (2007).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000259542.54830.34</pub-id><pub-id pub-id-type="pmid">17438217</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dijkhuizen</surname><given-names>RM</given-names></name><name name-style="western"><surname>Nicolay</surname><given-names>K</given-names></name></person-group><article-title>Magnetic resonance imaging in experimental models of brain disorders</article-title><source>J. Cereb. Blood Flow. Metabolism</source><year>2003</year><volume>23</volume><issue>12</issue><fpage>1383</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1097/01.WCB.0000100341.78607.EB</pub-id><pub-id pub-id-type="pmid">14663334</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Dijkhuizen, R. M. &amp; Nicolay, K. Magnetic resonance imaging in experimental models of brain disorders. <italic toggle="yes">J. Cereb. Blood Flow. Metabolism</italic>. <bold>23</bold> (12), 1383&#8211;1402 (2003).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.WCB.0000100341.78607.EB</pub-id><pub-id pub-id-type="pmid">14663334</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fink</surname><given-names>JR</given-names></name><name name-style="western"><surname>Muzi</surname><given-names>M</given-names></name><name name-style="western"><surname>Peck</surname><given-names>M</given-names></name><name name-style="western"><surname>Krohn</surname><given-names>KA</given-names></name></person-group><article-title>Multimodality brain tumor imaging: MR imaging, PET, and PET/MR imaging</article-title><source>J. Nucl. Med.</source><year>2015</year><volume>56</volume><issue>10</issue><fpage>1554</fpage><lpage>1561</lpage><pub-id pub-id-type="doi">10.2967/jnumed.113.131516</pub-id><pub-id pub-id-type="pmid">26294301</pub-id><pub-id pub-id-type="pmcid">PMC4592410</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Fink, J. R., Muzi, M., Peck, M. &amp; Krohn, K. A. Multimodality brain tumor imaging: MR imaging, PET, and PET/MR imaging. <italic toggle="yes">J. Nucl. Med.</italic><bold>56</bold> (10), 1554&#8211;1561 (2015).<pub-id pub-id-type="pmid">26294301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.113.131516</pub-id><pub-id pub-id-type="pmcid">PMC4592410</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Rasmussen, J. &amp; Langerman, H. Alzheimer&#8217;s disease&#8211;why we need early diagnosis. <italic toggle="yes">Degener. Neurol. Neuromuscul. Dis.</italic> 123&#8211;130 (2019).<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DNND.S228939</pub-id><pub-id pub-id-type="pmcid">PMC6935598</pub-id><pub-id pub-id-type="pmid">31920420</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alberdi</surname><given-names>A</given-names></name><name name-style="western"><surname>Aztiria</surname><given-names>A</given-names></name><name name-style="western"><surname>Basarab</surname><given-names>A</given-names></name></person-group><article-title>On the early diagnosis of Alzheimer&#8217;s disease from multimodal signals: A survey</article-title><source>Artif. Intell. Med.</source><year>2016</year><volume>71</volume><fpage>1</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.artmed.2016.06.003</pub-id><pub-id pub-id-type="pmid">27506128</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Alberdi, A., Aztiria, A. &amp; Basarab, A. On the early diagnosis of Alzheimer&#8217;s disease from multimodal signals: A survey. <italic toggle="yes">Artif. Intell. Med.</italic><bold>71</bold>, 1&#8211;29 (2016).<pub-id pub-id-type="pmid">27506128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.artmed.2016.06.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varzaneh</surname><given-names>ZA</given-names></name><name name-style="western"><surname>Orooji</surname><given-names>A</given-names></name><name name-style="western"><surname>Erfannia</surname><given-names>L</given-names></name><name name-style="western"><surname>Shanbehzadeh</surname><given-names>M</given-names></name></person-group><article-title>A new COVID-19 intubation prediction strategy using an intelligent feature selection and K-NN method</article-title><source>Inf. Med. Unlocked</source><year>2022</year><volume>28</volume><fpage>100825</fpage><pub-id pub-id-type="doi">10.1016/j.imu.2021.100825</pub-id><pub-id pub-id-type="pmcid">PMC8712462</pub-id><pub-id pub-id-type="pmid">34977330</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Varzaneh, Z. A., Orooji, A., Erfannia, L. &amp; Shanbehzadeh, M. A new COVID-19 intubation prediction strategy using an intelligent feature selection and K-NN method. <italic toggle="yes">Inf. Med. Unlocked</italic>. <bold>28</bold>, 100825 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.imu.2021.100825</pub-id><pub-id pub-id-type="pmcid">PMC8712462</pub-id><pub-id pub-id-type="pmid">34977330</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asghari Varzaneh</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shanbehzadeh</surname><given-names>M</given-names></name><name name-style="western"><surname>Kazemi-Arpanahi</surname><given-names>H</given-names></name></person-group><article-title>Prediction of successful aging using ensemble machine learning algorithms</article-title><source>BMC Med. Inf. Decis. Mak.</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>258</fpage><pub-id pub-id-type="doi">10.1186/s12911-022-02001-6</pub-id><pub-id pub-id-type="pmcid">PMC9527392</pub-id><pub-id pub-id-type="pmid">36192713</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Asghari Varzaneh, Z., Shanbehzadeh, M. &amp; Kazemi-Arpanahi, H. Prediction of successful aging using ensemble machine learning algorithms. <italic toggle="yes">BMC Med. Inf. Decis. Mak.</italic><bold>22</bold> (1), 258 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12911-022-02001-6</pub-id><pub-id pub-id-type="pmcid">PMC9527392</pub-id><pub-id pub-id-type="pmid">36192713</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mousavi</surname><given-names>M</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>S</given-names></name></person-group><article-title>A deep convolutional neural network approach using medical image classification</article-title><source>BMC Med. Inf. Decis. Mak.</source><year>2024</year><volume>24</volume><issue>1</issue><fpage>239</fpage><pub-id pub-id-type="doi">10.1186/s12911-024-02646-5</pub-id><pub-id pub-id-type="pmcid">PMC11360845</pub-id><pub-id pub-id-type="pmid">39210320</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Mousavi, M. &amp; Hosseini, S. A deep convolutional neural network approach using medical image classification. <italic toggle="yes">BMC Med. Inf. Decis. Mak.</italic><bold>24</bold> (1), 239 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12911-024-02646-5</pub-id><pub-id pub-id-type="pmcid">PMC11360845</pub-id><pub-id pub-id-type="pmid">39210320</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asghari Varzaneh</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hemmatipour</surname><given-names>A</given-names></name><name name-style="western"><surname>Kazemi-Arpanahi</surname><given-names>H</given-names></name></person-group><article-title>Comparing the effect of pre-anesthesia clonidine and tranexamic acid on intraoperative bleeding volume in rhinoplasty: a machine learning approach</article-title><source>Sci. Rep.</source><year>2025</year><volume>15</volume><issue>1</issue><fpage>30062</fpage><pub-id pub-id-type="doi">10.1038/s41598-025-07450-3</pub-id><pub-id pub-id-type="pmid">40820015</pub-id><pub-id pub-id-type="pmcid">PMC12358529</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Asghari Varzaneh, Z., Hemmatipour, A. &amp; Kazemi-Arpanahi, H. Comparing the effect of pre-anesthesia clonidine and tranexamic acid on intraoperative bleeding volume in rhinoplasty: a machine learning approach. <italic toggle="yes">Sci. Rep.</italic><bold>15</bold> (1), 30062 (2025).<pub-id pub-id-type="pmid">40820015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-025-07450-3</pub-id><pub-id pub-id-type="pmcid">PMC12358529</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mousavi</surname><given-names>SM</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>S</given-names></name></person-group><article-title>A convolutional neural network model for detection of COVID-19 disease and pneumonia</article-title><source>J. Health Biomedical Inf.</source><year>2023</year><volume>10</volume><issue>1</issue><fpage>41</fpage><lpage>56</lpage></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Mousavi, S. M. &amp; Hosseini, S. A convolutional neural network model for detection of COVID-19 disease and pneumonia. <italic toggle="yes">J. Health Biomedical Inf.</italic><bold>10</bold> (1), 41&#8211;56 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anwar</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Medical image analysis using convolutional neural networks: a review</article-title><source>J. Med. Syst.</source><year>2018</year><volume>42</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1007/s10916-018-1088-1</pub-id><pub-id pub-id-type="pmid">30298337</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Anwar, S. M. et al. Medical image analysis using convolutional neural networks: a review. <italic toggle="yes">J. Med. Syst.</italic><bold>42</bold>, 1&#8211;13 (2018).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10916-018-1088-1</pub-id><pub-id pub-id-type="pmid">30298337</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarvamangala</surname><given-names>D</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>RV</given-names></name></person-group><article-title>Convolutional neural networks in medical image understanding: a survey</article-title><source>Evol. Intel.</source><year>2022</year><volume>15</volume><issue>1</issue><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1007/s12065-020-00540-3</pub-id><pub-id pub-id-type="pmcid">PMC7778711</pub-id><pub-id pub-id-type="pmid">33425040</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Sarvamangala, D. &amp; Kulkarni, R. V. Convolutional neural networks in medical image understanding: a survey. <italic toggle="yes">Evol. Intel.</italic><bold>15</bold> (1), 1&#8211;22 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12065-020-00540-3</pub-id><pub-id pub-id-type="pmcid">PMC7778711</pub-id><pub-id pub-id-type="pmid">33425040</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baydili</surname><given-names>&#304;</given-names></name><name name-style="western"><surname>Tasci</surname><given-names>B</given-names></name><name name-style="western"><surname>Tasci</surname><given-names>G</given-names></name></person-group><article-title>Deep learning-based detection of depression and suicidal tendencies in social media data with feature selection</article-title><source>Behav. Sci.</source><year>2025</year><volume>15</volume><issue>3</issue><fpage>352</fpage><pub-id pub-id-type="doi">10.3390/bs15030352</pub-id><pub-id pub-id-type="pmid">40150247</pub-id><pub-id pub-id-type="pmcid">PMC11939175</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Baydili, &#304;., Tasci, B. &amp; Tasci, G. Deep learning-based detection of depression and suicidal tendencies in social media data with feature selection. <italic toggle="yes">Behav. Sci.</italic><bold>15</bold> (3), 352 (2025).<pub-id pub-id-type="pmid">40150247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/bs15030352</pub-id><pub-id pub-id-type="pmcid">PMC11939175</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Rawat, W. &amp; Wang, Z. Deep convolutional neural networks for image classification: A comprehensive review. <italic toggle="yes">Neural Comput.</italic><bold>29</bold>(9), 2352&#8211;2449 (2017).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1162/NECO_a_00990</pub-id><pub-id pub-id-type="pmid">28599112</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Xu, L., Ren, J. S., Liu, C. &amp; Jia, J. Deep convolutional neural network for image deconvolution. <italic toggle="yes">Adv. Neural Inform. Process. Syst.</italic><bold>27</bold> (2014).</mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Miah, A. S. M. et al. Alzheimer&#8217;s disease detection using CNN based on effective dimensionality reduction approach. In <italic toggle="yes">Intelligent Computing and Optimization: Proceedings of the 3rd International Conference on Intelligent Computing and Optimization 2020 (ICO 2020)</italic>. 801&#8211;811. (Springer, 2021).</mixed-citation></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nawaz</surname><given-names>H</given-names></name><etal/></person-group><article-title>A deep feature-based real-time system for Alzheimer disease stage detection</article-title><source>Multimedia Tools Appl.</source><year>2021</year><volume>80</volume><fpage>35789</fpage><lpage>35807</lpage><pub-id pub-id-type="doi">10.1007/s11042-020-09087-y</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Nawaz, H. et al. A deep feature-based real-time system for Alzheimer disease stage detection. <italic toggle="yes">Multimedia Tools Appl.</italic><bold>80</bold>, 35789&#8211;35807 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">AlSaeed, D. &amp; Omar, S. F. Brain MRI analysis for Alzheimer&#8217;s disease diagnosis using CNN-based feature extraction and machine learning, <italic toggle="yes">Sensors</italic><bold>22</bold>(8), 2911 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/s22082911</pub-id><pub-id pub-id-type="pmcid">PMC9025443</pub-id><pub-id pub-id-type="pmid">35458896</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Amini, M., Pedram, M. M., Moradi, A. &amp; Ouchani, M. Diagnosis of Alzheimer&#8217;s disease severity with fMRI images using robust multitask feature extraction method and convolutional neural network (CNN). In <italic toggle="yes">Computational and Mathematical Methods in Medicine</italic>. Vol. 1. 5514839 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/5514839</pub-id><pub-id pub-id-type="pmcid">PMC8100410</pub-id><pub-id pub-id-type="pmid">34007305</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Silva, I. R., Silva, G. S., de Souza, R. G., dos Santos, W. P. &amp; Fagundes, R. A. Model based on deep feature extraction for diagnosis of Alzheimer&#8217;s disease. In <italic toggle="yes">International Joint Conference on Neural Networks (IJCNN)</italic>. 1&#8211;7. (IEEE, 2019).</mixed-citation></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venugopalan</surname><given-names>J</given-names></name><name name-style="western"><surname>Tong</surname><given-names>L</given-names></name><name name-style="western"><surname>Hassanzadeh</surname><given-names>HR</given-names></name><name name-style="western"><surname>Wang</surname><given-names>MD</given-names></name></person-group><article-title>Multimodal deep learning models for early detection of Alzheimer&#8217;s disease stage</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><issue>1</issue><fpage>3254</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-74399-w</pub-id><pub-id pub-id-type="pmid">33547343</pub-id><pub-id pub-id-type="pmcid">PMC7864942</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Venugopalan, J., Tong, L., Hassanzadeh, H. R. &amp; Wang, M. D. Multimodal deep learning models for early detection of Alzheimer&#8217;s disease stage. <italic toggle="yes">Sci. Rep.</italic><bold>11</bold> (1), 3254 (2021).<pub-id pub-id-type="pmid">33547343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-74399-w</pub-id><pub-id pub-id-type="pmcid">PMC7864942</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Helaly</surname><given-names>HA</given-names></name><name name-style="western"><surname>Badawy</surname><given-names>M</given-names></name><name name-style="western"><surname>Haikal</surname><given-names>AY</given-names></name></person-group><article-title>Deep learning approach for early detection of Alzheimer&#8217;s disease</article-title><source>Cogn. Comput.</source><year>2022</year><volume>14</volume><issue>5</issue><fpage>1711</fpage><lpage>1727</lpage><pub-id pub-id-type="doi">10.1007/s12559-021-09946-2</pub-id><pub-id pub-id-type="pmcid">PMC8563360</pub-id><pub-id pub-id-type="pmid">34745371</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Helaly, H. A., Badawy, M. &amp; Haikal, A. Y. Deep learning approach for early detection of Alzheimer&#8217;s disease. <italic toggle="yes">Cogn. Comput.</italic><bold>14</bold> (5), 1711&#8211;1727 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12559-021-09946-2</pub-id><pub-id pub-id-type="pmcid">PMC8563360</pub-id><pub-id pub-id-type="pmid">34745371</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Tian</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name></person-group><article-title>Utilizing transfer learning of pre-trained AlexNet and relevance vector machine for regression for predicting healthy older adult&#8217;s brain age from structural MRI</article-title><source>Multimedia Tools Appl.</source><year>2021</year><volume>80</volume><issue>16</issue><fpage>24719</fpage><lpage>24735</lpage><pub-id pub-id-type="doi">10.1007/s11042-020-10377-8</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Lin, L., Zhang, G., Wang, J., Tian, M. &amp; Wu, S. Utilizing transfer learning of pre-trained AlexNet and relevance vector machine for regression for predicting healthy older adult&#8217;s brain age from structural MRI. <italic toggle="yes">Multimedia Tools Appl.</italic><bold>80</bold> (16), 24719&#8211;24735 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buvaneswari</surname><given-names>P</given-names></name><name name-style="western"><surname>Gayathri</surname><given-names>R</given-names></name></person-group><article-title>Deep learning-based segmentation in classification of Alzheimer&#8217;s disease</article-title><source>Arab. J. Sci. Eng.</source><year>2021</year><volume>46</volume><issue>6</issue><fpage>5373</fpage><lpage>5383</lpage><pub-id pub-id-type="doi">10.1007/s13369-020-05193-z</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Buvaneswari, P. &amp; Gayathri, R. Deep learning-based segmentation in classification of Alzheimer&#8217;s disease. <italic toggle="yes">Arab. J. Sci. Eng.</italic><bold>46</bold> (6), 5373&#8211;5383 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goyal</surname><given-names>P</given-names></name><name name-style="western"><surname>Rani</surname><given-names>R</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K</given-names></name></person-group><article-title>A multilayered framework for diagnosis and classification of Alzheimer&#8217;s disease using transfer learned Alexnet and LSTM</article-title><source>Neural Comput. Appl.</source><year>2024</year><volume>36</volume><issue>7</issue><fpage>3777</fpage><lpage>3801</lpage><pub-id pub-id-type="doi">10.1007/s00521-023-09301-6</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Goyal, P., Rani, R. &amp; Singh, K. A multilayered framework for diagnosis and classification of Alzheimer&#8217;s disease using transfer learned Alexnet and LSTM. <italic toggle="yes">Neural Comput. Appl.</italic><bold>36</bold> (7), 3777&#8211;3801 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kadri</surname><given-names>R</given-names></name><name name-style="western"><surname>Bouaziz</surname><given-names>B</given-names></name><name name-style="western"><surname>Tmar</surname><given-names>M</given-names></name><name name-style="western"><surname>Gargouri</surname><given-names>F</given-names></name></person-group><article-title>Efficient multimodel method based on transformers and CoAtNet for Alzheimer&#8217;s diagnosis</article-title><source>Digit. Signal Proc.</source><year>2023</year><volume>143</volume><fpage>104229</fpage><pub-id pub-id-type="doi">10.1016/j.dsp.2023.104229</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Kadri, R., Bouaziz, B., Tmar, M. &amp; Gargouri, F. Efficient multimodel method based on transformers and CoAtNet for Alzheimer&#8217;s diagnosis. <italic toggle="yes">Digit. Signal Proc.</italic><bold>143</bold>, 104229 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>SMAH</given-names></name><etal/></person-group><article-title>Computer-aided diagnosis of Alzheimer&#8217;s disease and neurocognitive disorders with multimodal Bi-Vision transformer (BiViT)</article-title><source>Pattern Anal. Appl.</source><year>2024</year><volume>27</volume><issue>3</issue><fpage>76</fpage><pub-id pub-id-type="doi">10.1007/s10044-024-01297-6</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Shah, S. M. A. H. et al. Computer-aided diagnosis of Alzheimer&#8217;s disease and neurocognitive disorders with multimodal Bi-Vision transformer (BiViT). <italic toggle="yes">Pattern Anal. Appl.</italic><bold>27</bold> (3), 76 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arafa</surname><given-names>DA</given-names></name><name name-style="western"><surname>Moustafa</surname><given-names>HED</given-names></name><name name-style="western"><surname>Ali</surname><given-names>HA</given-names></name><name name-style="western"><surname>Ali-Eldin</surname><given-names>AM</given-names></name><name name-style="western"><surname>Saraya</surname><given-names>SF</given-names></name></person-group><article-title>A deep learning framework for early diagnosis of Alzheimer&#8217;s disease on MRI images</article-title><source>Multimedia Tools Appl.</source><year>2024</year><volume>83</volume><issue>2</issue><fpage>3767</fpage><lpage>3799</lpage><pub-id pub-id-type="doi">10.1007/s11042-023-15738-7</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Arafa, D. A., Moustafa, H. E. D., Ali, H. A., Ali-Eldin, A. M. &amp; Saraya, S. F. A deep learning framework for early diagnosis of Alzheimer&#8217;s disease on MRI images. <italic toggle="yes">Multimedia Tools Appl.</italic><bold>83</bold> (2), 3767&#8211;3799 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marwa</surname><given-names>EG</given-names></name><name name-style="western"><surname>Moustafa</surname><given-names>HED</given-names></name><name name-style="western"><surname>Khalifa</surname><given-names>F</given-names></name><name name-style="western"><surname>Khater</surname><given-names>H</given-names></name><name name-style="western"><surname>AbdElhalim</surname><given-names>E</given-names></name></person-group><article-title>An MRI-based deep learning approach for accurate detection of Alzheimer&#8217;s disease</article-title><source>Alexandria Eng. J.</source><year>2023</year><volume>63</volume><fpage>211</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.aej.2022.07.062</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Marwa, E. G., Moustafa, H. E. D., Khalifa, F., Khater, H. &amp; AbdElhalim, E. An MRI-based deep learning approach for accurate detection of Alzheimer&#8217;s disease. <italic toggle="yes">Alexandria Eng. J.</italic><bold>63</bold>, 211&#8211;221 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sercek</surname><given-names>I</given-names></name><etal/></person-group><article-title>A new quantum-inspired pattern based on Goldner-Harary graph for automated Alzheimer&#8217;s disease detection</article-title><source>Cogn. Neurodyn.</source><year>2025</year><volume>19</volume><issue>1</issue><fpage>71</fpage><pub-id pub-id-type="doi">10.1007/s11571-025-10249-7</pub-id><pub-id pub-id-type="pmid">40351570</pub-id><pub-id pub-id-type="pmcid">PMC12065701</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Sercek, I. et al. A new quantum-inspired pattern based on Goldner-Harary graph for automated Alzheimer&#8217;s disease detection. <italic toggle="yes">Cogn. Neurodyn.</italic><bold>19</bold> (1), 71 (2025).<pub-id pub-id-type="pmid">40351570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11571-025-10249-7</pub-id><pub-id pub-id-type="pmcid">PMC12065701</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dogan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Primate brain pattern-based automated Alzheimer&#8217;s disease detection model using EEG signals</article-title><source>Cogn. Neurodyn.</source><year>2023</year><volume>17</volume><issue>3</issue><fpage>647</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1007/s11571-022-09859-2</pub-id><pub-id pub-id-type="pmid">37265658</pub-id><pub-id pub-id-type="pmcid">PMC10229526</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Dogan, S. et al. Primate brain pattern-based automated Alzheimer&#8217;s disease detection model using EEG signals. <italic toggle="yes">Cogn. Neurodyn.</italic><bold>17</bold> (3), 647&#8211;659 (2023).<pub-id pub-id-type="pmid">37265658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11571-022-09859-2</pub-id><pub-id pub-id-type="pmcid">PMC10229526</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">ADNI|About. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://adni.loni.usc.edu/about/">https://adni.loni.usc.edu/about/</ext-link>.</mixed-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">Szegedy, C., Ioffe, S., Vanhoucke, V. &amp; Alemi, A. Inception-v4, inception-resnet and the impact of residual connections on learning. In <italic toggle="yes">Proceedings of the AAAI Conference on Artificial Intelligence</italic>. Vol. 31(1). (2017).</mixed-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">Aruna Sri, P. &amp; Santhi, V. Enhanced land use and land cover classification using modified CNN in uppal Earth region. <italic toggle="yes">Multimed. Tools Appl.</italic>. 1&#8211;24 (2024).</mixed-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Szegedy, C., Vanhoucke, V., Ioffe, S., Shlens, J. &amp; Wojna, Z. Rethinking the inception architecture for computer vision. In <italic toggle="yes">Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition</italic>. 2818&#8211;2826 (2016).</mixed-citation></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Pulmonary image classification based on inception-v3 transfer learning model</article-title><source>IEEE Access.</source><year>2019</year><volume>7</volume><fpage>146533</fpage><lpage>146541</lpage><pub-id pub-id-type="doi">10.1109/ACCESS.2019.2946000</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Wang, C. et al. Pulmonary image classification based on inception-v3 transfer learning model. <italic toggle="yes">IEEE Access.</italic><bold>7</bold>, 146533&#8211;146541 (2019).</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="other">Chollet, F. Xception: Deep learning with depthwise separable convolutions. In <italic toggle="yes">Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition</italic>. 1251&#8211;1258 (2017).</mixed-citation></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Wu, X., Liu, R., Yang, H. &amp; Chen, Z. An xception based convolutional neural network for scene image classification with transfer learning. In <italic toggle="yes">2nd International Conference on Information Technology and Computer Application (ITCA)</italic>. 262&#8211;267. (IEEE, 2020).</mixed-citation></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hossin</surname><given-names>M</given-names></name><name name-style="western"><surname>Sulaiman</surname><given-names>MN</given-names></name></person-group><article-title>A review on evaluation metrics for data classification evaluations</article-title><source>Int. J. Data Min. Knowl. Manage. process.</source><year>2015</year><volume>5</volume><issue>2</issue><fpage>1</fpage><pub-id pub-id-type="doi">10.5121/ijdkp.2015.5201</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Hossin, M. &amp; Sulaiman, M. N. A review on evaluation metrics for data classification evaluations. <italic toggle="yes">Int. J. Data Min. Knowl. Manage. process.</italic><bold>5</bold> (2), 1 (2015).</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Townsend</surname><given-names>JT</given-names></name></person-group><article-title>Theoretical analysis of an alphabetic confusion matrix</article-title><source>Percept. Psychophys.</source><year>1971</year><volume>9</volume><fpage>40</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.3758/BF03213026</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Townsend, J. T. Theoretical analysis of an alphabetic confusion matrix. <italic toggle="yes">Percept. Psychophys.</italic><bold>9</bold>, 40&#8211;50 (1971).</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saratxaga</surname><given-names>CL</given-names></name><etal/></person-group><article-title>MRI deep learning-based solution for alzheimer&#8217;s disease prediction</article-title><source>J. Personalized Med.</source><year>2021</year><volume>11</volume><issue>9</issue><fpage>902</fpage><pub-id pub-id-type="doi">10.3390/jpm11090902</pub-id><pub-id pub-id-type="pmcid">PMC8466762</pub-id><pub-id pub-id-type="pmid">34575679</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Saratxaga, C. L. et al. MRI deep learning-based solution for alzheimer&#8217;s disease prediction. <italic toggle="yes">J. Personalized Med.</italic><bold>11</bold> (9), 902 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm11090902</pub-id><pub-id pub-id-type="pmcid">PMC8466762</pub-id><pub-id pub-id-type="pmid">34575679</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="other">Jabason, E., Ahmad, M. O. &amp; Swamy, M. Classification of Alzheimer&#8217;s disease from MRI data using an ensemble of hybrid deep convolutional neural networks. In <italic toggle="yes">2019 IEEE 62nd International Midwest Symposium on Circuits and Systems (MWSCAS)</italic>. 481&#8211;484. (IEEE, 2019).</mixed-citation></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="other">Sarraf, S. &amp; Tofighi, G. Classification of Alzheimer&#8217;s disease using fmri data and deep learning convolutional neural networks. arXiv preprint arXiv:1603.08631 (2016).</mixed-citation></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Cui, Z. et al. Alzheimer&#8217;s disease diagnosis using enhanced inception network based on brain magnetic resonance image. In <italic toggle="yes">IEEE International Conference on Bioinformatics and Biomedicine (BIBM)</italic>. 2324&#8211;2330. (IEEE, 2019).</mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Physiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Physiol</journal-id><journal-id journal-id-type="pmc-domain-id">1464</journal-id><journal-id journal-id-type="pmc-domain">frontphysiol</journal-id><journal-id journal-id-type="publisher-id">Front. Physiol.</journal-id><journal-title-group><journal-title>Frontiers in Physiology</journal-title></journal-title-group><issn pub-type="epub">1664-042X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12497739</article-id><article-id pub-id-type="pmcid-ver">PMC12497739.1</article-id><article-id pub-id-type="pmcaid">12497739</article-id><article-id pub-id-type="pmcaiid">12497739</article-id><article-id pub-id-type="pmid">41059494</article-id><article-id pub-id-type="doi">10.3389/fphys.2025.1606267</article-id><article-id pub-id-type="publisher-id">1606267</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Physiology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Resisting decline: the neuroprotective role of resistance exercise in supporting cerebrovascular function and brain health in aging</article-title><alt-title alt-title-type="left-running-head">Allison et al.</alt-title><alt-title alt-title-type="right-running-head"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.3389/fphys.2025.1606267" ext-link-type="uri">10.3389/fphys.2025.1606267</ext-link></alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Allison</surname><given-names initials="EY">Elric Y.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3089193/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bedi</surname><given-names initials="AM">Anjali M.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3026931/overview"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rourke</surname><given-names initials="AJ">Aedan J.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3027019/overview"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mizzi</surname><given-names initials="V">Vanessa</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3031506/overview"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Walsh</surname><given-names initials="JJ">Jeremy J.</given-names></name><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/458366/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Heisz</surname><given-names initials="JJ">Jennifer J.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/30748/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Al-Khazraji</surname><given-names initials="BK">Baraa K.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1224826/overview"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Kinesiology, Faculty of Science, McMaster University</institution>, <addr-line>Hamilton</addr-line>, <addr-line>ON</addr-line>, <country>Canada</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Department of Biomedical engineering, McMaster University </institution>, <addr-line>Hamilton</addr-line>, <addr-line>ON</addr-line>, <country>Canada</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/514063/overview" ext-link-type="uri">Giovanna D'Arcangelo</ext-link>, University of Rome Tor Vergata, Italy</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/170928/overview" ext-link-type="uri">Blake Graeme Perry</ext-link>, Massey University, New Zealand</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/827056/overview" ext-link-type="uri">Bruce Rogers</ext-link>, University of Central Florida, United States</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1857554/overview" ext-link-type="uri">Kang Chen</ext-link>, Tianjin University of Sport, China</p></fn><corresp id="c001">*Correspondence: Baraa K. Al-Khazraji, <email>alkhazrb@mcmaster.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">480575</issue-id><elocation-id>1606267</elocation-id><history><date date-type="received"><day>05</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>02</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 09:25:15.110"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Allison, Bedi, Rourke, Mizzi, Walsh, Heisz and Al-Khazraji.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Allison, Bedi, Rourke, Mizzi, Walsh, Heisz and Al-Khazraji</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fphys-16-1606267.pdf"/><abstract><p>Reduced cerebral blood flow (CBF) and cerebrovascular function are critical early-stage biomarkers preceding changes in brain function and structure observed in normal aging and during the onset and progression of Alzheimer&#8217;s Disease and related dementias (ADRD). Though several interventions attempt to curb the effects of aging and brain neurodegeneration, exercise and lifestyle habits remain one of the most impactful and easily modifiable factors for preserving brain health. Although the effects of aerobic exercise on cerebrovascular function and brain health are well established, resistance training (RT) is rapidly increasing in popularity across all age demographics due to its numerous health benefits. Despite the clear physiological benefits of resistance exercise, its potential efficacy for preserving or improving cerebrovascular and overall brain health remains understudied to date. The aim of this review is to examine the literature pertaining to ways in which resistance exercise may reduce the risk of ADRD and slow age-related decline of brain structures and functions. Additionally, this review seeks to highlight key considerations and challenges regarding the feasibility, adoption, and adherence to resistance exercise in the context of normal aging, mild cognitive impairment, and ADRD.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><p>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="FPHYS_fphys-2025-1606267_wc_abs.jpg"><alt-text content-type="machine-generated">Illustration depicting the relationship between exercise, brain health, and effective training programs. On the left, a brain shows various functions improved by exercise, including endothelial function, cognitive function, and reduced inflammation. Along with reduced risks of sarcopenia, systemic cardiovascular, and cerebrovascular issues. On the right, factors for effective resistance training programs include adoption, adherence, and feasibility, with emphasis on self-efficacy, social support, timing, program types, and sustainability. Increased muscle strength is associated with lower Alzheimer&#8217;s and dementia risks, along with reduced risks of sarcopenia and cardiovascular issues.</alt-text></graphic>
</p></abstract><kwd-group><kwd>resistance exercise</kwd><kwd>cerebral blood flow (CBF)</kwd><kwd>Alzheimer&#8217;s disease related dementias</kwd><kwd>brain health</kwd><kwd>cerebrovascular</kwd><kwd>neurodegeneration</kwd><kwd>aging</kwd><kwd>resistance training (RT)</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Natural Sciences and Engineering Research Council of Canada
</institution><institution-id institution-id-type="doi">10.13039/501100000038</institution-id></institution-wrap></funding-source></award-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. Funding sources include Natural Sciences and Engineering Research Council (NSERC) Discovery Grant (held by BKA) and NSERC Canada Graduate Scholarship (held by EYA).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Exercise Physiology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>As the global population ages, neurodegenerative conditions like Alzheimer&#8217;s disease and related dementias (ADRD) are becoming increasingly prevalent (<xref rid="B246" ref-type="bibr">Rajan et al., 2021</xref>). These conditions involve a progressive decline of cognitive function, significant deterioration of neural structures, and widespread metabolic dysfunction throughout the brain (<xref rid="B133" ref-type="bibr">Hoyer et al., 1988</xref>; <xref rid="B230" ref-type="bibr">O&#8217;Brien J et al., 2020</xref>; <xref rid="B316" ref-type="bibr">Zhang B. et al., 2021</xref>). Pathological processes such as inflammation, oxidative stress, and cerebrovascular dysfunction emerge in early stages of disease progression (<xref rid="B154" ref-type="bibr">Kinney et al., 2018</xref>; <xref rid="B134" ref-type="bibr">Huang et al., 2016</xref>; <xref rid="B219" ref-type="bibr">Nelson et al., 2016</xref>), long before clinical symptoms like memory loss appear, presenting a significant challenge for the timing and efficacy of targeted pharmaceutical interventions (<xref rid="B139" ref-type="bibr">Iturria-Medina et al., 2016</xref>).</p><p>Physical inactivity is an important modifiable risk factor for cognitive decline and progression of ADRD. Aerobic exercise is associated with beneficial effects on brain health such that increased physical activity is associated with attenuated rate of age-related cortical atrophy (<xref rid="B58" ref-type="bibr">Colcombe et al., 2003</xref>), hippocampal growth (<xref rid="B84" ref-type="bibr">Erickson et al., 2011</xref>; <xref rid="B278" ref-type="bibr">ten Brinke et al., 2015</xref>), and improved cognitive function (<xref rid="B216" ref-type="bibr">Nagamatsu et al., 2013</xref>). Much of the available literature has focused on the protective effects of aerobic exercise and cardiorespiratory fitness in reducing the onset and progression of ADRD (<xref rid="B58" ref-type="bibr">Colcombe et al., 2003</xref>; <xref rid="B83" ref-type="bibr">Erickson and Kramer, 2009</xref>; <xref rid="B15" ref-type="bibr">Baker et al., 2010</xref>; <xref rid="B5" ref-type="bibr">Alty et al., 2020</xref>). These neuroprotective and cerebrovascular benefits of aerobic exercise may be partly explained by its ability to reduced systemic inflammation (<xref rid="B112" ref-type="bibr">Gleeson et al., 2011</xref>), improved antioxidant defense systems (<xref rid="B74" ref-type="bibr">de Sousa et al., 2017</xref>), and improved vascular health and function (<xref rid="B23" ref-type="bibr">Bliss et al., 2021</xref>). Converging evidence suggests that reductions in cerebral blood flow (CBF) and cerebrovascular dysfunction may precede structural and functional deficits associated with neurodegeneration, representing one of the earliest indicators of ADRD risk (<xref rid="B141" ref-type="bibr">Jack et al., 2010</xref>), and therefore, cerebrovascular dysfunction may serve as an ideal early-stage biomarker that is receptive to aerobic exercise interventions (<xref rid="B156" ref-type="bibr">Kleinloog et al., 2019</xref>; <xref rid="B283" ref-type="bibr">Tomoto et al., 2022</xref>; <xref rid="B281" ref-type="bibr">Thomas et al., 2020</xref>).</p><p>Improved skeletal muscle strength is another exercise-induced effect associated with improvements in cognitive function (<xref rid="B290" ref-type="bibr">Van Dam et al., 2018</xref>; <xref rid="B108" ref-type="bibr">Frith and Loprinzi, 2018</xref>), maintenance of brain structure (<xref rid="B187" ref-type="bibr">Lu et al., 2024</xref>; <xref rid="B210" ref-type="bibr">Moon et al., 2019</xref>), and reduced risk for onset and progression of ADRD (<xref rid="B27" ref-type="bibr">Boyle et al., 2009</xref>; <xref rid="B86" ref-type="bibr">Esteban-Cornejo et al., 2022</xref>). Resistance training (RT) has gained popularity, particularly among those prescribing exercise to the elderly, due to its positive effects on muscle strength, metabolism, bone density, and mobility, as well as its potential to reduce the risk and progression of osteoporosis, sarcopenia, frailty, and cardiovascular disease (<xref rid="B302" ref-type="bibr">Westcott, 2012</xref>). Likely due to the high magnitude and rapid oscillatory blood pressure responses associated with resistance exercise, the effects of RT on peripheral vascular and cerebrovascular function appear to be distinct from those of aerobic exercise (<xref rid="B282" ref-type="bibr">Thomas et al., 2021</xref>). Despite the numerous physiological benefits of RT, its impact on brain health in older adults, particularly those at risk for or living with ADRD, requires further exploration.</p><p>Thus, the purpose of this paper is to synthesize the current literature related to the effects of RT on brain health with a specific focus on cerebrovascular function, brain structure, and cognition. This review will first highlight the pathophysiological mechanisms underlying the onset and progression of ADRD. We will also explore mechanisms related to cerebrovascular and neurological adaptations to RT, and their interactions with age- and disease-related changes in cerebrovascular function and brain health. Additionally, this review will identify research gaps and propose future directions throughout for the study of RT and its effects on brain health and ADRD risk and progression. Finally, this review will summarize challenges of prescribing RT interventions (i.e., feasibility, adoption, adherence) in healthy and older adults at risk for ADRD and provide recommendations to overcome these challenges.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2-1"><title>Inclusion and exclusion criteria</title><p>The population of interest for this review included humans (both male and female) described as middle- or older-aged in the studies, of any health status. We also included mechanistic evidence from young healthy adults and animal studies to help support and interpret findings from human studies when available and appropriate. Studies of any study design were included in this review if they examined the effects of RT. Throughout the manuscript studies involving training interventions refer to the exercise stimulus as RT, whereas acute exercise is referred to as resistance exercise. Acute resistance exercise responses were considered to provide mechanistic background for longer-term adaptations to chronic RT. No limitations related to resistance exercise program design were placed, including factors of intensity, volume, frequency, duration, type of muscular contractions (i.e., concentric, eccentric, isometric), or type of resistance exercise performed. Outcomes of interest for this review included cellular factors such as neurotrophins (i.e., brain derived neurotrophic factor (BDNF), insulin-like growth factor-1 (IGF-1)) and inflammatory markers, hemodynamic and functional measures for any cerebral conduit arteries (e.g., neck artery compliance/stiffness, blood flow, reactivity) and cerebral arteries (e.g., cerebral hemodynamics, blood flow, reactivity, autoregulation), brain structure (regional grey matter integrity, white matter lesions, diffusion tensor images, blood-brain barrier (BBB) integrity), clinical neurodegenerative measures (amyloid deposition, tau neurofibrillary tangles, inflammatory markers), functional connectivity (functional magnetic resonance imaging (fMRI) indices), and cognitive function. Studies were excluded from this review if they did not examine effects of resistance training on any outcomes mentioned above. Additional studies from outside our search including review papers and findings from animal studies are cited for interpretation and speculation of mechanisms underlying effects of resistance exercise on the above-mentioned outcomes.</p></sec><sec id="s2-2"><title>Search strategy and screening</title><p>Though this review is not a systematic review, we aimed to conduct best research practices and facilitate reproducibility in our search strategy. Our literature search was conducted in 3 databases: MEDLINE, EMBASE, and Web of Science with no date restrictions up to October 2024 (range of publication date for studies: 1985-2024). The search strategy was developed with assistance from a research librarian. For our search we used keywords related to cerebrovascular structure and function, resistance exercise and training, cerebral hemodynamics, cognitive function, brain structure, neurodegeneration, and dementia subtypes. Following the database search, authors (EYA, AMB, AR) screened papers for inclusion eligibility based on the inclusion and exclusion criteria mentioned above. Our search across three databases yielded N = 7275 papers. After screening titles and abstracts for eligibility, there were N = 313 papers for full-text screening. After completion of full-text screening, we had a final pool of N = 172 papers. Because this is not a systematic review, not all 172 of these papers were reviewed comprehensively. Instead, we have used this pool of 172 papers as well as supplementing with articles from outside our search to narratively summarize and review overall trends, relationships, and underlying mechanisms behind the potential efficacy of RT and brain health in older adults and those vulnerable for the onset and progression of vascular dementia and Alzheimer&#8217;s disease.</p></sec></sec><sec id="s3"><title>Metabolic and vascular contributions to ADRD</title><p>It is important to recognize that the etiology of ADRD is multifactorial and heterogeneous (<xref rid="B139" ref-type="bibr">Iturria-Medina et al., 2016</xref>; <xref rid="B141" ref-type="bibr">Jack et al., 2010</xref>; <xref rid="B300" ref-type="bibr">Wang et al., 2017</xref>; <xref rid="B120" ref-type="bibr">Habes et al., 2020</xref>). In any given case, the onset and progression of ADRD may be driven by one or several interacting mechanisms discussed below, including inflammation and oxidative stress, alterations in cerebral metabolism, cerebral perfusion, systemic and cerebrovascular structure and function, and blood-brain barrier integrity. Moreover, this list is not exhaustive, and ongoing research continues to uncover additional contributors to neurodegeneration, emphasizing the complexity of ADRD pathophysiology and the need for specific prevention and intervention strategies.</p><sec id="s3-1"><title>Cerebral metabolism</title><p>The brain has limited energy stores and a near exclusive reliance on glucose to support cerebral metabolism that is required to support its extensive energy requirements (<xref rid="B268" ref-type="bibr">Sims-Robinson et al., 2015</xref>). Normal aging is accompanied by a decline in cerebral metabolism, driven by impaired mitochondrial ATP production, increased reactive oxygen species (ROS), and decreased antioxidant defenses (<xref rid="B191" ref-type="bibr">Maldonado et al., 2023</xref>), and these deficits are amplified in ADRD compared to cognitively normal older adults (<xref rid="B235" ref-type="bibr">Patro et al., 2021</xref>; <xref rid="B137" ref-type="bibr">Ionescu-Tucker and Cotman, 2021</xref>). Mitochondrial dysfunction, oxidative stress, inflammation, and impaired ATP production occur in a feedforward cycle, serving as both consequences and causes of the marked reduction in glucose metabolism in the brain across the spectrum of ADRD development (<xref rid="B300" ref-type="bibr">Wang et al., 2017</xref>). Disrupted glucose metabolism in ADRD is closely linked with an inflammatory and neurotoxic milieu, as increased presence of ROS and pro-inflammatory cytokines reduce expression of glucose transporters, disrupt insulin signalling, and reduce mitochondrial efficiency and function, resulting in impaired transport, uptake, and metabolism of glucose (<xref rid="B252" ref-type="bibr">Rojas&#8208;Gutierrez et al., 2017</xref>; <xref rid="B313" ref-type="bibr">Yin et al., 2016</xref>). Indeed, glucose hypometabolism is present in both early and advanced stages of ADRD with greater impairments in metabolism coinciding with worsening neurodegeneration (<xref rid="B76" ref-type="bibr">Desgranges et al., 1998</xref>; <xref rid="B126" ref-type="bibr">Herholz et al., 2002</xref>). Furthermore, impaired cerebral metabolism appears to be an early-stage biomarker for ADRD, as several studies have shown reduced glucose metabolism in the hippocampus and posterior cingulate prior to observation of overt clinical symptoms (i.e., cognitive impairment) (<xref rid="B166" ref-type="bibr">Kumar et al., 2022</xref>; <xref rid="B243" ref-type="bibr">Protas et al., 2013</xref>; <xref rid="B91" ref-type="bibr">Ferrari et al., 2019</xref>; <xref rid="B45" ref-type="bibr">Chen et al., 2021</xref>).</p></sec><sec id="s3-2"><title>Cerebral perfusion</title><p>Converging evidence strongly supports the notion that changes in CBF precede structural and functional deficits associated with neurodegeneration, and may be amongst the earliest indicators of ADRD risk (<xref rid="B141" ref-type="bibr">Jack et al., 2010</xref>). In healthy individuals, CBF is tightly coupled to the metabolic demands of neurons (<xref rid="B53" ref-type="bibr">Claassen et al., 2021</xref>), however, it is unclear whether reduced CBF in ADRD is a cause or consequence of cerebral hypometabolism. It remains unclear whether the observed cerebral hypoperfusion in those at risk for development of ADRD is primarily a consequence of impairments in systemic vascular health or a result of reductions in in cerebral metabolism. Nonetheless, evidence supports the marked reductions in global CBF in early stages of MCI compared to age-matched controls with normal cognition, and further reduction in CBF as individuals progress from MCI into ADRD (<xref rid="B317" ref-type="bibr">Zhang H. et al., 2021</xref>). In people with MCI, the pattern of brain regions with reduced CBF aligns with regions impacted early in the ADRD pathophysiological cascade (posterior cingulate, parietal, temporal, and hippocampal regions (<xref rid="B317" ref-type="bibr">Zhang H. et al., 2021</xref>), supporting a role for cerebral hypoperfusion in the MCI-ADRD progression.</p><p>Cardiovascular disease is also associated with development of neurodegenerative conditions, driven by both cardiac insufficiency-related hypoperfusion as well as damage to cerebral microvasculature, similarly reducing blood flow to cerebral tissues (<xref rid="B220" ref-type="bibr">Newman et al., 2005</xref>; <xref rid="B271" ref-type="bibr">Stefanidis et al., 2018</xref>; <xref rid="B157" ref-type="bibr">KNOPMAN, 2007</xref>). The consequences of the cardiovascular disease-related reductions in CBF include accelerated reduction in frontal, parietal, and temporal grey matter volumes (<xref rid="B10" ref-type="bibr">Anazodo et al., 2013</xref>), greater white matter hyperintensity burden (<xref rid="B212" ref-type="bibr">Moroni et al., 2018</xref>), cognitive deficits (<xref rid="B147" ref-type="bibr">Jiang et al., 2023</xref>), and increased risk of ADRD (<xref rid="B28" ref-type="bibr">Brain et al., 2023</xref>). Given the role of CBF in supporting neuronal function, cardiovascular disease appears to exacerbate the feed-forward processes in neurodegeneration by contributing to chronic hypoperfusion and metabolic stress in these vulnerable regions. In the context of ADRD risk, cerebral hypoperfusion also appears to precede Amyloid-&#946; (A&#946;) and hyperphosphorylated tau accumulation in the ADRD pathophysiological cascade (<xref rid="B139" ref-type="bibr">Iturria-Medina et al., 2016</xref>), particularly in regions vulnerable to early pathology (entorhinal cortex, hippocampus, inferior parietal cortex, inferior temporal cortex) (<xref rid="B196" ref-type="bibr">Mattsson et al., 2014</xref>). Increased A&#946; and neurofibrillary tangle deposition in the brain subsequently promote further cerebrovascular dysfunction via increased ROS production and inflammation (<xref rid="B2" ref-type="bibr">Alavi Naini and Soussi-Yanicostas, 2015</xref>; <xref rid="B42" ref-type="bibr">Cheignon et al., 2018</xref>). Thus, the literature related to the chronology of ADRD pathophysiology implicates CBF as a critical early-stage target for attenuating neurodegenerative cascades prior to symptomatic changes in brain function.</p></sec><sec id="s3-3"><title>Systemic vascular structure and function</title><p>Though it remains unclear whether reductions in CBF or cerebral metabolism occurs first in the ADRD cascade, mechanical factors such as systemic and cerebral arterial stiffening are additional early stage vascular markers implicated in cerebral hypoperfusion in older adulthood beyond the typical effects of aging (<xref rid="B204" ref-type="bibr">Mitchell, 2011</xref>; <xref rid="B146" ref-type="bibr">Jefferson et al., 2018</xref>; <xref rid="B214" ref-type="bibr">Muhire et al., 2019</xref>). The processes leading to increased arterial stiffness are related to structural remodelling such as increased collagen and decreased elastin in the vessel wall, as well as higher resting vascular tone, endothelial dysfunction, and reduced nitric oxide bioavailability (<xref rid="B188" ref-type="bibr">Lyle and Raaz, 2017</xref>). Other cellular factors such as oxidative stress and inflammation can also negatively impact systemic and cerebral endothelial function by damaging endothelial cells (<xref rid="B263" ref-type="bibr">Shaito et al., 2022</xref>) and reducing nitric oxide bioavailability (<xref rid="B117" ref-type="bibr">Gryglewski et al., 1986</xref>). Long-term consequences of arterial stiffening include negative impacts on brain function, BBB breakdown (<xref rid="B165" ref-type="bibr">Krizbai et al., 2005</xref>), reduced CBF, and blunted cerebrovascular reactivity (<xref rid="B185" ref-type="bibr">Louren&#231;o et al., 2017</xref>). Increased arterial stiffness in cerebral conduit arteries impairs their ability to dampen blood flow ejected from the heart, leading to transmission of high pressure and pulsatile blood flow to the cerebral microvasculature and neuronal tissue. This increased transmission of pulsatile and high-pressure blood flow into the cerebral circulation is associated with cerebral microvascular damage, which contributes to chronic reductions in CBF seen with aging and disease (<xref rid="B274" ref-type="bibr">Suri et al., 2020</xref>). Cerebrovascular pulsatility is elevated in ADRD compared to healthy controls (<xref rid="B48" ref-type="bibr">Chung et al., 2017</xref>; <xref rid="B251" ref-type="bibr">Roher et al., 2011</xref>). Previous work from our group supports the importance of arterial stiffness as an early-stage biomarker for future decrements in brain structure by showing that high levels of arterial stiffness in midlife, but not age-related arterial stiffening, are predictive of lower grey matter volume and greater white matter hyperintensity burden in a 10-year follow-up (<xref rid="B3" ref-type="bibr">Allison and Al-Khazraji, 2024a</xref>). Bown et al similarly showed strong predictive effects of baseline arterial stiffness on occipital and hippocampal volume and temporal lobe white matter hyperintensity volume in a 5-year follow up (<xref rid="B26" ref-type="bibr">Bown et al., 2021</xref>), all of which are brain regions that are highly vulnerable to neurodegeneration (<xref rid="B101" ref-type="bibr">Fjell et al., 2014</xref>). These findings emphasize the importance of systemic vascular function and mechanics on long term brain health, likely mediated by damage and mechanical stress on cerebral microvasculature.</p></sec><sec id="s3-4"><title>Cerebrovascular function</title><p>Optimal function of cerebral conduit arteries is another critical factor in ensuring CBF matches the metabolic demands for brain function and maintain long-term brain health. Several techniques can be used to assess cerebral arterial function, including measures of perfusion (middle cerebral artery blood velocity; MCAv, CBF), cerebrovascular reactivity, cerebrovascular conductance, cerebrovascular resistance, cerebrovascular pulsatility, cerebral autoregulation, and neurovascular coupling (<xref rid="B229" ref-type="bibr">Ozturk and Tan, 2018</xref>). MCAv begins to decrease in early midlife (<xref rid="B7" ref-type="bibr">Alwatban et al., 2021</xref>), aligning with the reductions in global CBF observed with aging (<xref rid="B44" ref-type="bibr">Chen et al., 2011</xref>). Compared to healthy older adults, MCAv is lower in age-matched individuals with MCI and ADRD, worsening along the neurodegenerative spectrum (<xref rid="B317" ref-type="bibr">Zhang H. et al., 2021</xref>; <xref rid="B257" ref-type="bibr">Sabayan et al., 2012</xref>). Cerebrovascular resistance can also provide information on cerebrovascular function in ADRD. Greater cerebrovascular resistance is indicative of constricted downstream vessels (higher vascular tone) in the cerebral circulation, restricting perfusion into cerebral tissues (<xref rid="B53" ref-type="bibr">Claassen et al., 2021</xref>). Compared to cognitively normal older adults, cerebrovascular resistance is higher in individuals with MCI and ADRD, and has been associated with greater A&#946; burden, cortical atrophy, and risk of progression to ADRD (<xref rid="B312" ref-type="bibr">Yew and Nation, 2017</xref>). Additionally, increased cerebrovascular resistance has been suggested to precede observable reductions in regional CBF (<xref rid="B312" ref-type="bibr">Yew and Nation, 2017</xref>). Higher resting cerebrovascular tone may occur due to endothelial dysfunction (<xref rid="B25" ref-type="bibr">Bolduc et al., 2013</xref>) or chronic overactivity of the sympathetic nervous system (<xref rid="B305" ref-type="bibr">Willie et al., 2014</xref>), as seen in cardiovascular disease (<xref rid="B144" ref-type="bibr">Jay Widmer and Lerman, 2014</xref>; <xref rid="B192" ref-type="bibr">Malpas, 2010</xref>) and diabetes (<xref rid="B32" ref-type="bibr">Calles-Escandon and Cipolla, 2001</xref>; <xref rid="B85" ref-type="bibr">Esler et al., 2001</xref>), conditions which contribute to ADRD risk.</p><p>Cerebrovascular resistance serves as the foundational basis other indices of cerebrovascular function and health. Cerebrovascular reactivity is a frequently used measure to provide insight into the health and function of the cerebral vasculature, and is dictated by changes in cerebral vascular tone in response to a given stimuli (<xref rid="B53" ref-type="bibr">Claassen et al., 2021</xref>). Assessing changes in either large cerebral artery cross-sectional area and CBF (MRI) or cerebral hemodynamics (MCAv) in response to a vasoactive stimuli, such as carbon dioxide (CO<sub>2</sub>), forms the basis of cerebrovascular reactivity (<xref rid="B301" ref-type="bibr">Wang et al., 2023</xref>). CO<sub>2</sub> is a potent regulator of CBF, as elevated CO<sub>2</sub> and the accompanying pH change causes healthy cerebral arterioles to dilate, subsequently increasing conductance and CBF (<xref rid="B131" ref-type="bibr">Hoiland et al., 2019</xref>). Crucially, individuals in ADRD demonstrate marked impairments in cerebrovascular reactivity to CO<sub>2</sub> compared to controls (<xref rid="B113" ref-type="bibr">Glodzik et al., 2013</xref>; <xref rid="B6" ref-type="bibr">Alwatban et al., 2019</xref>; <xref rid="B111" ref-type="bibr">Gao et al., 2013</xref>; <xref rid="B296" ref-type="bibr">Vicenzini et al., 2007</xref>). Based on these associations, cerebrovascular reactivity may relate to early cerebrovascular dysfunction associated with neurodegenerative diseases like ADRD. Another key regulator of CBF is neuronal activity, mediated through the process of neurovascular coupling (<xref rid="B241" ref-type="bibr">Phillips et al., 2016</xref>). Briefly, neurovascular coupling describes the change in cerebral oxygen extraction or blood flow delivery to meet the metabolic demands of active neurons (<xref rid="B241" ref-type="bibr">Phillips et al., 2016</xref>). Similar to cerebrovascular reactivity, impaired neurovascular coupling is attenuated with advanced age (<xref rid="B237" ref-type="bibr">Peng et al., 2018</xref>), MCI and ADRD (<xref rid="B241" ref-type="bibr">Phillips et al., 2016</xref>; <xref rid="B237" ref-type="bibr">Peng et al., 2018</xref>; <xref rid="B221" ref-type="bibr">Nicolakakis and Hamel, 2011</xref>). Factors associated with impaired cerebrovascular reactivity and neurovascular coupling include cerebral microvascular dysfunction, insulin-like growth factor 1 (IGF-1) deficiency, and oxidative stress-related inhibition of neuronal and astrocytic vasodilators (<xref rid="B241" ref-type="bibr">Phillips et al., 2016</xref>; <xref rid="B324" ref-type="bibr">Zlokovic, 2005</xref>). The importance of these cerebrovascular functional measures are supported by the graded relationship between impairment in cerebrovascular reactivity to CO<sub>2</sub> (<xref rid="B153" ref-type="bibr">Kim et al., 2021</xref>; <xref rid="B267" ref-type="bibr">Silvestrini et al., 2006</xref>) and neurovascular coupling responses and severity of cognitive impairment in individuals with MCI and ADRD (<xref rid="B291" ref-type="bibr">van Dijk et al., 2024</xref>). Overall, these findings emphasize the importance of cerebral vasoreactivity as a marker of cerebrovascular and overall brain health.</p></sec><sec id="s3-5"><title>Cerebral autoregulation</title><p>The responsiveness of cerebral vasculature to stimuli also underlies cerebral autoregulation. The concept of cerebral autoregulation describes the ability of the cerebral vasculature to regulate CBF during oscillations in cerebral perfusion pressure (<xref rid="B53" ref-type="bibr">Claassen et al., 2021</xref>). Currently the data suggests that autoregulatory function remains intact in individuals across the spectrum of ADRD progression (<xref rid="B53" ref-type="bibr">Claassen et al., 2021</xref>; <xref rid="B52" ref-type="bibr">Claassen and Zhang, 2011</xref>; <xref rid="B68" ref-type="bibr">de Heus et al., 2018</xref>; <xref rid="B69" ref-type="bibr">de Jong et al., 2019</xref>). Increased resting cerebrovascular tone in individuals along the ADRD progression spectrum (<xref rid="B312" ref-type="bibr">Yew and Nation, 2017</xref>) is likely to restrict transient increases in blood pressure into the cerebral circulation. Thus, an absence of a change in CBF during increases in blood pressure due to increased resting cerebrovascular resistance in neurodegenerative models may mask differences in autoregulatory function. Whether blood pressure oscillation direction (increases vs. decreases) affects interpretation of data pertaining to autoregulatory function in cognitive decline, vascular dementia, and ADRD remains unclear.</p></sec><sec id="s3-6"><title>Blood-brain barrier (BBB)</title><p>The structural and functional integrity of the BBB is emerging as another early-stage biomarker for neurodegenerative conditions. A critical neuroprotective structure, the BBB&#8217;s primary role is regulating the transport of compounds into (influx) and out of (efflux) the parenchyma (<xref rid="B213" ref-type="bibr">Moyaert et al., 2023</xref>). A key characteristic of the BBB compared to peripheral vasculature is the arrangement of endothelial cells, which include tightly sealed cell-to-cell contacts called tight junctions (<xref rid="B213" ref-type="bibr">Moyaert et al., 2023</xref>). The BBB, similar to the peripheral vasculature, is susceptible to degradation and dysfunction of endothelial cells through oxidative stress, inflammation, and mechanical hemodynamic stress (i.e., high systolic pressures and pulsatility) (<xref rid="B213" ref-type="bibr">Moyaert et al., 2023</xref>; <xref rid="B71" ref-type="bibr">de Montgolfier et al., 2019</xref>). Damage to the tight endothelial junctions results in increased BBB permeability, leading to the entry of immune cells and inflammatory cytokines into the parenchyma, as well as impaired clearance of metabolic waste and neurotoxic compounds (<xref rid="B323" ref-type="bibr">Zlokovic, 2004</xref>; <xref rid="B67" ref-type="bibr">De Boer and Gaillard, 2006</xref>). One of the most vulnerable brain regions to normal age-related and disease related alterations in BBB permeability is the hippocampus (<xref rid="B275" ref-type="bibr">Sweeney et al., 2018a</xref>; <xref rid="B276" ref-type="bibr">Sweeney et al., 2018b</xref>). The disruption in BBB in the hippocampus is accelerated with MCI and ADRD progression compared to normal aging (<xref rid="B276" ref-type="bibr">Sweeney et al., 2018b</xref>). BBB dysregulation precedes A&#946; and tau protein deposition, cognitive decline, and structural changes in brain tissue (<xref rid="B139" ref-type="bibr">Iturria-Medina et al., 2016</xref>). The role of the BBB in the progression of ADRD is further supported by evidence showing that disrupted BBB function impairs efflux of A&#946; from the parenchyma (<xref rid="B300" ref-type="bibr">Wang et al., 2017</xref>; <xref rid="B323" ref-type="bibr">Zlokovic, 2004</xref>; <xref rid="B276" ref-type="bibr">Sweeney et al., 2018b</xref>). However, with continued accumulation of A&#946; plaques, the inflammatory and neurotoxic parenchymal environment can progress to further damage the BBB (<xref rid="B82" ref-type="bibr">Erickson and Banks, 2013</xref>). This cycle of A&#946; accumulation causing BBB damage, leading to further impairments in A&#946; efflux and thus greater accumulation is a major process underlying the severe and rapid loss of function in AD. Thus, the BBB may represent a viable therapeutic target to prevent or attenuate progression of ADRD prior to histopathological, structural, or functional changes in the brain.</p></sec></sec><sec id="s4"><title>Why resistance exercise?</title><sec id="s4-1"><title>Muscle strength as a risk factor for ADRD</title><p>Muscle weakness and the associated frailty are associated with MCI and ADRD severity (<xref rid="B210" ref-type="bibr">Moon et al., 2019</xref>; <xref rid="B27" ref-type="bibr">Boyle et al., 2009</xref>; <xref rid="B97" ref-type="bibr">Filardi et al., 2022</xref>; <xref rid="B81" ref-type="bibr">Dost et al., 2023</xref>). Sarcopenia and the accompanying loss in muscle strength and balance leads to frailty, decreased independence, lower rates of physical activity, and increased sedentary time (<xref rid="B183" ref-type="bibr">Loprinzi, 2016</xref>). Importantly, patterns of age-related muscle loss appear to be different between sexes, with men demonstrating a greater rate of relative loss in muscle mass with age and females having a greater prevalence for sarcopenia&#8211;likely due to males having a higher muscular reserve compared to females (<xref rid="B70" ref-type="bibr">de Jong et al., 2023</xref>). The relationship between sex and prevalence of sarcopenia may partially be explained by longer life expectancy in females&#8211;as it is primarily an aging related disorder. Nonetheless, the greater likelihood of sarcopenia in females aligns with epidemiological studies that point to females comprising two thirds of all ADRD diagnoses (<xref rid="B202" ref-type="bibr">Mielke, 2018</xref>; <xref rid="B8" ref-type="bibr">Alzheimer&#8217;s Association, 2019</xref>). Improving skeletal muscle mass and quality via RT may therefore be a critical non-pharmacological approach to attenuate systemic inflammation and ROS production associated with sarcopenia sedentarism (<xref rid="B200" ref-type="bibr">Meng and Yu, 2010</xref>; <xref rid="B65" ref-type="bibr">Dalle et al., 2017</xref>; <xref rid="B233" ref-type="bibr">Pan et al., 2021</xref>; <xref rid="B170" ref-type="bibr">Laufs et al., 2005</xref>; <xref rid="B115" ref-type="bibr">Gratas-Delamarche et al., 2014</xref>), and slow the rate of age and disease-related neurodegeneration. Given its beneficial effects on muscle size and quality (<xref rid="B302" ref-type="bibr">Westcott, 2012</xref>), and improved metabolic function (i.e., improved glucose metabolism, insulin sensitivity) (<xref rid="B321" ref-type="bibr">Zhou et al., 2022</xref>), partaking in regular RT is a promising behaviour to attenuate cellular and behavioural risk factors for neurodegenerative processes.</p></sec><sec id="s4-2"><title>Resistance exercise and sleep</title><p>Sleep duration and quality are important factors in the development and progression of ADRD (<xref rid="B129" ref-type="bibr">Himali et al., 2023</xref>). The glymphatic system, most active during slow-wave or restorative sleep, is essential for facilitating clearance of metabolic waste (<xref rid="B250" ref-type="bibr">Reddy and van der Werf, 2020</xref>; <xref rid="B307" ref-type="bibr">Xie et al., 2013</xref>). This process of glymphatic clearance during sleep includes the efflux of A&#946; and tau proteins out of the parenchyma (<xref rid="B307" ref-type="bibr">Xie et al., 2013</xref>; <xref rid="B132" ref-type="bibr">Holth et al., 2019</xref>; <xref rid="B149" ref-type="bibr">Kang et al., 2009</xref>). Beyond the two primary proteins of focus in ADRD progression, glymphatic clearance also helps support removal of inflammatory markers to maintain the parenchymal environment and reduce neurotoxic load on neurons (<xref rid="B208" ref-type="bibr">Mogensen et al., 2021</xref>). Meta-analyses have shown that habitual participation in RT is associated with improved sleep quality (<xref rid="B161" ref-type="bibr">Kovacevic et al., 2018</xref>). Further, in older sarcopenic adults, a 12-week RT program (3 times per week of full body RT at 75% 1RM) was shown to reduce sleep latency (shorter time necessary to fall asleep) as well as increase time spent in slow-wave sleep, when a large proportion of glymphatic drainage and restorative processes occur (<xref rid="B73" ref-type="bibr">De S&#225; Souza et al., 2022</xref>). While more work is needed to determine the optimal parameters of RT programs for improving sleep, it is nonetheless important to recognize the role of RT, and exercise in general, as a non-pharmacological strategy to support brain health. RT may help improve sleep, which could mitigate the accumulation of metabolic waste, inflammatory markers, and neurotoxic proteins, ultimately lowering the risk for the onset and progression of ADRD.</p></sec><sec id="s4-3"><title>Resistance exercise as a unique hemodynamic stressor</title><p>From a vascular perspective, the hemodynamic stimulus associated with resistance exercise, particularly at high intensities is unique, characterized by high magnitude and rapid oscillations in blood pressure (<xref rid="B240" ref-type="bibr">Perry and Lucas, 2021</xref>). These oscillations in blood pressure involve a transition between hyper- and hypotension (corresponding to concentric and eccentric muscular contractions) within each repetition cycle (<xref rid="B240" ref-type="bibr">Perry and Lucas, 2021</xref>). While more research is necessary, repeated exposure to oscillatory hemodynamic stress and the associated patterns of shear stress on the endothelium may prime the vasculature to better handle both surges and sudden drops in systemic blood pressure, potentially leading to better maintenance and regulation of CBF during pressure challenges. Improved regulation of CBF in response to both transient hyper- and hypotension subsequently protects cerebral microvasculature from hyperperfusive injury and damage as well as ensuring cerebral perfusion is able to match metabolic demand during periods of reduced driving pressures (i.e., orthostatic stress) (<xref rid="B53" ref-type="bibr">Claassen et al., 2021</xref>). Indeed, recent cross-sectional evidence supports enhanced pressure regulation in the brain in resistance-trained individuals (<xref rid="B160" ref-type="bibr">Korad et al., 2024</xref>; <xref rid="B255" ref-type="bibr">Roy et al., 2022</xref>). Thus, the rationale for RT interventions to mitigate neurodegenerative processes is strengthened by the distinct vascular and cerebrovascular adaptations (<xref rid="B4" ref-type="bibr">Allison and Al-Khazraji, 2024b</xref>; <xref rid="B318" ref-type="bibr">Zhang Y. et al., 2021</xref>), as well as the apparent neuroanatomical and cognitive benefits that will be discussed in subsequent sections of this review.</p></sec><sec id="s4-4"><title>Resistance exercise as a cognitive stimulus</title><p>Resistance exercise involves multiple aspects that require attention and focus. These aspects include neuronal adaptations centered around synchronized recruitment of motor neurons in several different muscle groups, matching muscle fibre recruitment to exercise intensity, learning new motor patterns involving multiple muscle groups or muscles in isolation (<xref rid="B37" ref-type="bibr">Carroll et al., 2001</xref>; <xref rid="B110" ref-type="bibr">Gabriel et al., 2006</xref>), keeping track of repetitions and sets completed, and use of intentional breathing techniques such as the Valsalva Maneuver (<xref rid="B102" ref-type="bibr">Forte et al., 2013</xref>; <xref rid="B174" ref-type="bibr">Lepley and Hatzel, 2010</xref>). Indeed, motor task complexity has been linked to neuroplasticity (<xref rid="B35" ref-type="bibr">Carey et al., 2005</xref>). Thus, while significantly more research is necessary, the novelty and complexity of resistance exercises may be an important factor underlying its pro-cognitive effects and efficacy in driving neuroplasticity. Nonetheless, resistance exercise is a unique model, likely eliciting different neuronal and physiological adaptations related to improved brain health and function compared to other forms of exercise. The mechanisms underlying protective effects of RT on the brain and its role in reducing risk of neurodegeneration are discussed herein.</p><p>An important concept to define prior to synthesis of literature is progressive RT. Briefly, progressive RT relies on a fundamental principle of resistance exercise prescription&#8211;progressive overload in which intensities, reps, or sets may start lower but increase gradually over the duration of the intervention (<xref rid="B163" ref-type="bibr">Kraemer et al., 2002</xref>). The fundamental principles of progressive overload are rooted in facilitating continued strength gains; however, given the relationship between muscular strength and overall brain health, there may be potential application of these principles in improving brain health. Progressive overload is applied in both human and animal research and will be referred to as progressive RT herein.</p></sec></sec><sec id="s5"><title>Effects of resistance training on brain-related outcomes</title><p>The issue of maintaining and promoting brain health is highly complex. However, multiple factors, including inflammation (<xref rid="B1" ref-type="bibr">Ahmad et al., 2022</xref>) and cerebral perfusion (<xref rid="B306" ref-type="bibr">Wolters et al., 2017</xref>) have been supported as early-stage biomarkers for neurodegenerative processes that are receptive to intervention prior to onset of clinically relevant loss in brain function. Additionally, neurotrophic factors such as IGF-1 and BDNF are critical targets for facilitating slower rates of structural and functional decline in the brain with advancing age&#8211;as both promote neurogenesis (<xref rid="B234" ref-type="bibr">Park and Poo, 2013</xref>; <xref rid="B11" ref-type="bibr">Anderson et al., 2002</xref>), as well as neuronal plasticity (<xref rid="B315" ref-type="bibr">Zagrebelsky and Korte, 2014</xref>) and survival (<xref rid="B234" ref-type="bibr">Park and Poo, 2013</xref>; <xref rid="B222" ref-type="bibr">Nieto-Bona et al., 1997</xref>). While the factors underlying brain health and longevity discussed below are not exhaustive, they represent what appear to be the most quantifiable and targetable factors underlying neurodegenerative processes along the MCI-ADRD continuum. Below we discuss the effects of resistance exercise on both humans and in animal models. Though findings from animal models provide an important basis for future research in humans, the findings from studies using animal models need to be interpreted with caution and as hypothesis generating, rather than definitive evidence of the neuroprotective effects of RT. Nonetheless, for completeness and interpretive purposes, studies using animal models are included in this review and are explicitly described as such herein.</p><sec id="s5-1"><title>Effects of resistance exercise training on oxidative stress and inflammation</title><p>Chronically elevated oxidative stress and diminished antioxidant defenses causes neuronal damage and mitochondrial dysfunction, which play key roles in neurodegenerative pathologies (<xref rid="B118" ref-type="bibr">Guo et al., 2013</xref>). The brain is particularly susceptible to oxidative stress given its limited antioxidant enzymatic capacity to counteract reactive oxygen species production (<xref rid="B92" ref-type="bibr">Ferreira et al., 2015</xref>). Despite a well-established relationship between acute resistance exercise and increased oxidative stress (<xref rid="B100" ref-type="bibr">Fisher-Wellman and Bloomer, 2009</xref>), habitual RT has been associated with a reduction in markers of oxidative stress at rest, with the bulk of evidence coming from animal models. 6 weeks of progressive ladder-climbing RT (8 climbs, progression from 50% to 100% maximal carrying load (MCL), 3 times per week) mitigates the rise in reactive oxygen species production, as represented by lipid peroxidation/malondialdehyde levels in the brain tissue of an AD rodent model (<xref rid="B228" ref-type="bibr">&#214;zbeyli et al., 2017</xref>). The RT intervention also improved antioxidant defence capabilities, as represented by glutathione levels (<xref rid="B228" ref-type="bibr">&#214;zbeyli et al., 2017</xref>). Interestingly, the same results were not observed in healthy age-matched mice, as 6 weeks of progressive ladder-climbing RT (3 climbs, progression from 50% to 100%MCL, 5 times per week) decreased lipid peroxidation in the cerebral cortex but increased lipid peroxidation in the hippocampus (<xref rid="B94" ref-type="bibr">Feter et al., 2019</xref>). It is possible that RT in healthy mice may initially act on antioxidant defence capacity, rather than mitigating reactive oxygen species production directly. The benefits of RT on oxidative stress in rodent models of AD do appear to persist beyond 6 weeks, as another trial found that 8 weeks of ladder-climbing RT (8 climbs, 2 repetitions at 50%, 75%, 90%, and 100% MCL, 3 times per week) prevented a rise in lipid peroxidation (<xref rid="B261" ref-type="bibr">Schimidt et al., 2019</xref>). This evidence suggests that RT may be more effective at reducing oxidative stress in situations where ROS and antioxidant balance is compromised, as observed along the continuum of neurodegenerative disease progression or with aging. Indeed, 24 weeks of moderate intensity RT (3 sets of 8&#8211;12 reps with progression to 12-16 reps at 65%&#8211;75% 1RM, 2 times per week) in combination with cognitive stimulation and aerobic exercise in older adults with MCI reduced plasma markers of lipid peroxidation (<xref rid="B253" ref-type="bibr">Rond&#227;o et al., 2022</xref>). Similarly, 6 months of resistance training improved numerous blood indices of oxidative stress including reduced oxidative damage, ameliorated antioxidant defence and DNA stability in older adults (<xref rid="B106" ref-type="bibr">Franzke et al., 2018</xref>). Thus, current evidence suggests that RT protocols are beneficial for mitigating rises in oxidative stress that occur along the development of neurodegenerative diseases and aging. Future work is required to determine if this training modality can bolster antioxidant defenses and mitigate excess oxidative stress in healthy human populations.</p><p>Inflammation and oxidative stress are closely interconnected, as the cellular damage imposed by increases in oxidative stress prompts immune inflammatory responses which contribute to the development and severity of neurodegeneration (<xref rid="B125" ref-type="bibr">Heneka et al., 2015</xref>). Despite acute physical exercise transiently increasing inflammatory responses, longer-term RT lowers circulating levels and cellular concentrations of anti-inflammatory cytokines. Acute long duration resistance exercise (180 min of bilateral knee extensions at 55% 1RM) in elderly populations is typically accompanied by an acute inflammatory immune response characterized by the release of interleukin-6 (IL-6) into the circulation (<xref rid="B270" ref-type="bibr">Steensberg et al., 2002</xref>). Whereas, 4 weeks of progressive ladder-climbing RT (2 climbs per session at 75%, 90%, and 100% MCL) 5 times per week in a mouse model of AD lowered circulating IL-6 to levels comparable to healthy controls (<xref rid="B123" ref-type="bibr">Hashiguchi et al., 2020</xref>). Similarly, 12 weeks of progressive full body RT 3 times per week (3 sets of 10 reps, progression from 50%&#8211;80% 1RM), in older humans lowers basal IL-6 levels, which may represent an adaptation to the exercise (<xref rid="B103" ref-type="bibr">Forti et al., 2014</xref>). Though IL-6 has pro-inflammatory functions, it can also stimulate the release of IL-10 (<xref rid="B227" ref-type="bibr">Ostrowski et al., 1999</xref>) which in turn inhibits the production of inflammatory cytokines such as IL-1&#946;, and tumour necrosis factor-&#945; (TNF-&#945;) (<xref rid="B38" ref-type="bibr">Cassatella et al., 1993</xref>). Indeed, progressive RT (15 climbs, progression from 15%&#8211;75% of MCL over 4 weeks) performed on alternating days attenuated neuroinflammation in the frontal cortex and hippocampus of mice by reducing mRNA expression of TNF-&#945; and protein concentrations of IL-1&#946; (<xref rid="B179" ref-type="bibr">Liu et al., 2020</xref>). In contrast to these findings, 8 weeks of progressive RT (3 sets of 8&#8211;12 climbs, 50%&#8211;100% of MCL) on alternating days in aging rats observed increased hippocampal protein expression of TNF-&#945; and IL-1&#946; (<xref rid="B297" ref-type="bibr">Vilela et al., 2017</xref>). However, given that this study did not measure IL-6 or IL-10, it is unclear where there was also a concomitant increase in anti-inflammatory molecular factors to counteract this response. Overall, current research presents substantial evidence for the therapeutic potential of RT to mitigate oxidative stress and inflammation, which are crucial pathophysiological factors underlying neurodegenerative disease pathogenesis (<xref rid="B298" ref-type="bibr">Vints et al., 2024</xref>).</p></sec><sec id="s5-2"><title>Effects of resistance exercise training on ADRD biomarkers</title><p>For the last 2 decades, the discourse related to the underlying mechanism for development of AD specifically has largely focused on the amyloid hypothesis, attributing the transition from MCI to AD to the accelerated rate of A&#946; plaque deposition and subsequent neurofibrillary tangle formation (<xref rid="B122" ref-type="bibr">Hardy and Higgins, 1992</xref>). ROS production and inflammation are the assumed to be the primary drivers of accelerated A&#946; plaque deposition and neurofibrillary tangle formation (<xref rid="B134" ref-type="bibr">Huang et al., 2016</xref>; <xref rid="B137" ref-type="bibr">Ionescu-Tucker and Cotman, 2021</xref>; <xref rid="B42" ref-type="bibr">Cheignon et al., 2018</xref>). Several animal studies have shown proof-of-concept for alleviation of amyloid burden with RT interventions. In AD animal models, 3 days of progressive ladder-climbing RT (6&#8211;11 climbs progressing from 75%&#8211;100% MCL) on alternating days for 4 weeks resulted in significant reductions in A&#946; levels and significant reductions in IL-1, IL-4, IL-6, and no differences in IL-10 between exercising and AD non-exercising controls (<xref rid="B123" ref-type="bibr">Hashiguchi et al., 2020</xref>). The mechanisms for reduced A&#946; are hypothesized to be related to restoration of the BBB, facilitating efflux of A&#946; from the parenchyma (<xref rid="B323" ref-type="bibr">Zlokovic, 2004</xref>). A separate study from the same research group, using the same exercise protocol similarly showed significant reductions in A&#946; levels and increased microglia in the hippocampus in AD mice (<xref rid="B33" ref-type="bibr">Campos et al., 2023</xref>). These findings are supported by work from Liu et al who similarly observed increased expression of synaptic signalling proteins in the hippocampus, and reductions in A&#946; and tau burden in the frontal cortex and hippocampus of AD mice with 4-week progressive ladder-climbing RT (15 climbs, progression from 15%&#8211;75% MCL) (<xref rid="B179" ref-type="bibr">Liu et al., 2020</xref>).</p><p>&#214;zbeyli et al showed that 3 days of progressive ladder-climbing RT (50%&#8211;100% MCL) per week for 6 weeks significantly reduced amyloid burden in AD mice compared to sedentary and aerobic trained AD mice (<xref rid="B228" ref-type="bibr">&#214;zbeyli et al., 2017</xref>). In animal models of AD, RT has shown efficacy for mitigating accumulation of A&#946; plaques, with fewer studies showing positive effects on neurofibrillary tangles. Exercise related attenuations in A&#946; production is a critical consideration as well. Work from Marko et al demonstrated that treatment of human neuronal cells with post-exercise serum, albeit aerobic, was associated with decreased expression of amyloid processing enzyme &#946;-secretase linked to production of A&#946; and increased expression of non-amyloidogenic enzyme &#945;-secretase, producing the soluble amyloid proteins that have not been implicated in neurodegeneration (<xref rid="B193" ref-type="bibr">Marko et al., 2022</xref>). The implications of the work from Marko et al should not be understated, as it provides critical insight into the effectiveness of even a single bout of exercise on reducing A&#946; production and plaque accumulation. Future studies should aim to extend these results to determine whether RT would have similar anti-amyloidogenic effects on the amyloid precursor protein processing. In addition to acute effects, future studies should also aim to investigate the effects of RT interventions on biomarkers of ADRD in humans to continue to build understanding on how exercise can attenuate or potentially reverse ADRD pathology.</p></sec><sec id="s5-3"><title>Effects of resistance exercise training on circulating neurotrophins</title><p>Acute and chronic changes in circulating neurotrophic growth factors following RT have been extensively studied as potential mechanisms that contribute to the structural and functional improvements in brain health with RT. Although RT increases several circulating growth factors that are important for brain health, this review will primarily focus on BDNF and IGF-1, given their prominent role in modulating brain plasticity. BDNF is a member of the neurotrophin family that contributes to a myriad of functions including synaptic plasticity (<xref rid="B315" ref-type="bibr">Zagrebelsky and Korte, 2014</xref>), neuronal growth, survival, and repair (<xref rid="B234" ref-type="bibr">Park and Poo, 2013</xref>), and is essential for facilitating learning and memory (<xref rid="B51" ref-type="bibr">Cirulli et al., 2004</xref>; <xref rid="B186" ref-type="bibr">Lu et al., 2014</xref>). In particular, BDNF has been identified as a prominent contributor to exercise-induced changes in brain health. Evidence from murine models demonstrate that hippocampal and cortical BDNF mRNA expression remains elevated for up to 24 h post-exercise, supporting the role of BDNF in facilitating changes in brain function well beyond the cessation of exercise (<xref rid="B249" ref-type="bibr">Rasmussen et al., 2009</xref>). Further research has also provided evidence of increased hippocampal BDNF following both acute resistance exercise in insulin-resistant rats (<xref rid="B20" ref-type="bibr">Berbert-Gomes et al., 2024</xref>) and increases in basal BDNF concentrations following 8 weeks of progressive ladder-climbing RT (8 climbs, 2 repetitions for each load of 50%, 75%, 90%, and 100% MCL, 3 times per week) in a rodent model of AD (<xref rid="B142" ref-type="bibr">Jafarzadeh et al., 2021</xref>). Collectively, this evidence suggests that BDNF concentrations are rapidly increased following acute resistance exercise and performing repeated bouts of resistance exercise (i.e., RT) may lead to sustained increases in resting BDNF over time.</p><p>Given that blood BDNF concentrations decline with aging (<xref rid="B181" ref-type="bibr">Lommatzsch et al., 2005</xref>; <xref rid="B322" ref-type="bibr">Ziegenhorn et al., 2007</xref>), extensive research has aimed to assess whether RT is an effective lifestyle intervention to help mitigate these reductions in humans. Research assessing exercise-induced BDNF responses in humans are limited to only measuring peripheral concentrations of blood BDNF, unlike in animal models where brain BDNF expression and/or concentrations can be directly measured. As a result, it is difficult to precisely localize potential changes in brain function arising from exercise-induced increases in BDNF. Nonetheless, there is evidence to suggest that peripheral BDNF may cross the BBB into the brain parenchyma (<xref rid="B232" ref-type="bibr">Pan et al., 1998</xref>) and circulating concentrations closely mirror BDNF content in the brain (<xref rid="B155" ref-type="bibr">Klein et al., 2011</xref>; <xref rid="B260" ref-type="bibr">Sartorius et al., 2009</xref>), suggesting that peripheral BDNF concentrations may be a viable surrogate for brain BDNF concentrations. Numerous research groups have shown that acute resistance exercise robustly increases circulating BDNF in humans, albeit transiently (<xref rid="B311" ref-type="bibr">Yarrow et al., 2010</xref>; <xref rid="B299" ref-type="bibr">Walsh et al., 2015</xref>; <xref rid="B194" ref-type="bibr">Marston et al., 2017</xref>; <xref rid="B50" ref-type="bibr">Church et al., 2016</xref>), while other studies have demonstrated no such change in circulating BDNF following acute resistance exercise (<xref rid="B61" ref-type="bibr">Correia et al., 2010</xref>; <xref rid="B114" ref-type="bibr">Goekint et al., 2010</xref>). Though the circulating BDNF response to acute resistance exercise is transient, Walsh et al demonstrated that post-exercise BDNF release persists, but did not increase as a result of 8 weeks of RT (3 exercises, 4 sets, 8-12 repetitions, progression from 60%&#8211;80% 1RM, 3 times per week (<xref rid="B299" ref-type="bibr">Walsh et al., 2015</xref>). In contrast, Church et al, who found that independent of training structure (high volume-low intensity [10&#8211;12 reps; 70% 1RM] vs. high intensity-low volume [3-5 reps; 90% 1RM], 4 days per week for 8 weeks) the magnitude of post-exercise BDNF release was increased compared to pre-training levels (<xref rid="B50" ref-type="bibr">Church et al., 2016</xref>), suggesting that each bout of resistance exercise session independent of training status provides a &#8220;dose&#8221; of BDNF to the brain, and the release of BDNF can be increased with habitual RT. These acute increases in circulating BDNF from resistance exercise may be an important stimulus for longer-term adaptations to brain health, given the plethora of evidence supporting the beneficial effects of RT on cognitive function, especially executive function (<xref rid="B180" ref-type="bibr">Liu-Ambrose et al., 2010</xref>; <xref rid="B168" ref-type="bibr">Landrigan et al., 2020</xref>). The neurocognitive effects of repeated acute BDNF doses via RT requires further research, as much of the current evidence aside from the work conducted by Church et al suggests that RT does not increase basal blood BDNF levels. Progressive RT interventions in middle-aged to older adults for 8 weeks (<xref rid="B299" ref-type="bibr">Walsh et al., 2015</xref>; <xref rid="B256" ref-type="bibr">Ruiz et al., 2015</xref>), 12 weeks (<xref rid="B103" ref-type="bibr">Forti et al., 2014</xref>), and as long as 9 months in individuals with type 2 diabetes (<xref rid="B277" ref-type="bibr">Swift et al., 2012</xref>) have not been shown to change basal serum BDNF. Previous work has also demonstrated that 8 weeks of combined aerobic and RT (full body RT; 3 sets of 8&#8211;15 reps to failure, 3 times per week) does not change basal plasma BDNF levels in individuals with Type 2 Diabetes (<xref rid="B266" ref-type="bibr">Silveira-Rodrigues et al., 2023</xref>) and 24 weeks of multicomponent exercise decreases basal plasma BDNF in older adults with MCI (<xref rid="B253" ref-type="bibr">Rond&#227;o et al., 2022</xref>). Contrarily, other work has shown that 10 weeks of RT (1-3 sets of 8 repetitions at 75% 1RM, 3 times per week) (<xref rid="B54" ref-type="bibr">Coelho et al., 2012</xref>; <xref rid="B238" ref-type="bibr">Pereira et al., 2013</xref>) and 16 weeks of a multicomponent exercise paradigm (2 sets of 6-8 repetitions, 2 times per week) (<xref rid="B292" ref-type="bibr">Vaughan et al., 2014</xref>) were both sufficient to increase basal plasma BDNF in otherwise healthy elderly adults. In summary, a single bout of resistance exercise likely leads to robust and transient increases in circulating BDNF, which may be leveraged in chronic RT interventions with repeated bouts to improve and/or protect brain health with aging. Furthermore, the literature related to the effects of RT on basal BDNF remain mixed and requires further investigation to clarify this relationship, with an emphasis on delineating these findings based on populations (i.e., young vs. older adults, healthy vs. chronic health conditions such as diabetes, ADRD) and exercise parameters (i.e., multicomponent vs. RT alone, intensity, frequency, duration of training).</p><p>Liver-derived IGF-1 is another neurotrophic growth factor implicated in long-term brain health. Similar to BDNF, IGF-1 modulates exercise-induced neurogenesis (<xref rid="B11" ref-type="bibr">Anderson et al., 2002</xref>), synaptic density and plasticity (<xref rid="B222" ref-type="bibr">Nieto-Bona et al., 1997</xref>), and hippocampal expression of BDNF (<xref rid="B78" ref-type="bibr">Ding et al., 2006</xref>). Furthermore, IGF-1 may regulate A&#946; plaque concentrations, as lower circulating IGF-1 have been associated with A&#946; plaque accumulation in the rodent brain (<xref rid="B36" ref-type="bibr">Carro et al., 2002</xref>). IGF-1 deficiencies are also implicated in the development of neurodegenerative diseases such as AD (<xref rid="B303" ref-type="bibr">Westwood et al., 2014</xref>), while excess levels of IGF-1 are associated with aberrant cellular growth (i.e., cancers) (<xref rid="B245" ref-type="bibr">Qian and Huo, 2020</xref>). The focus of this section is to review evidence related the impacts of RT-induced IGF-1 on brain health and not to imply that more circulating IGF-1 is better. Indeed, in normal physiological circumstances, basal circulating IGF-1 is tightly regulated by the cerebral spinal fluid (CSF) and any changes in circulating IGF-1 due to a single bout of resistance exercise are transient. Limited evidence of basal changes in IGF-1 following a period of RT training are likely due to corrections of a deficit, rather than an increase in IGF-1 per se. Evidence from animal models suggest that improvements in spatial memory following an acute bout of resistance exercise may be mediated via IGF-1, however the relationship between IGF-1 and short term cognitive performance in humans remains unclear (<xref rid="B40" ref-type="bibr">Cassilhas et al., 2012</xref>). Findings from human trials showed that a single bout of isometric knee extension resistance exercise (40% and 110% of maximal effort) (<xref rid="B294" ref-type="bibr">Vega et al., 2010</xref>) elicits an increase in circulating serum IGF-1 in young adults, similar to both moderate (50% 1RM) and high-intensity (80% 1RM) resistance exercise (<xref rid="B285" ref-type="bibr">Tsai et al., 2014</xref>). The improvement in serum IGF-1 with resistance exercise (two sets of 10 repetitions at 75% 1RM) is also present in older adults with MCI, though these changes in IGF-1 were not associated with improvements in cognition (<xref rid="B286" ref-type="bibr">Tsai et al., 2018</xref>). The vast majority of IGF-1 is secreted by the liver (<xref rid="B169" ref-type="bibr">Laron, 2001</xref>) with tissues like skeletal muscle also contributing to IGF-1 release during resistance exercise (<xref rid="B239" ref-type="bibr">Perrone et al., 1995</xref>). Despite the exercise-induced increase in IGF-1, this increase has not been shown to be associated improvements in executive function in young (<xref rid="B285" ref-type="bibr">Tsai et al., 2014</xref>) or older adults with MCI (<xref rid="B286" ref-type="bibr">Tsai et al., 2018</xref>). The absence of a relationship between increases in IGF-1 and improvements in cognition following resistance exercise may be attributed to the transient nature of the circulating IGF-1 response, as levels remain elevated for only &#8764;20 min (<xref rid="B285" ref-type="bibr">Tsai et al., 2014</xref>). IGF-1 is tonically regulated and in excess quantities is taken up by CSF. Therefore, a potential reason for the rapid return to baseline of IGF-1 post-exercise could be uptake into the brain via CSF (<xref rid="B244" ref-type="bibr">Pulford and Ishii, 2001</xref>). Despite the transient nature of resistance exercise-induced IGF-1 release, there is some evidence suggesting RT interventions may influence basal levels of IGF-1. The same work by &#214;zbeyli et al mentioned in previous sections also demonstrated that 6 weeks of ladder-climbing RT improved basal serum IGF-1 levels in a rodent model of Alzheimer&#8217;s disease (<xref rid="B228" ref-type="bibr">&#214;zbeyli et al., 2017</xref>). In humans, 2 years of progressive RT (full body RT; 2 sets of 2-8 repetitions with progression from 30%&#8211;55% 1RM, 2 times per week) increased basal levels of plasma IGF-1 in older women, with changes in IGF-1 concentration being associated with improvements in global cognition (<xref rid="B209" ref-type="bibr">Molina-Sotomayor et al., 2020</xref>). In contrast, 8 weeks of lower-limb RT (Walsh et al; exercise parameters highlighted in BDNF section) did not change basal serum IGF-1 (<xref rid="B299" ref-type="bibr">Walsh et al., 2015</xref>). Thus, it is possible that longer-term interventions are needed to elicit a change in basal serum IGF-1 concentrations in humans. Collectively, there is limited evidence to demonstrate that chronic RT may be improving cognitive function and protecting brain health through augmenting circulating IGF-1. The inconsistent results regarding IGF-1 responses to RT further suggests that the relationship between exercise and molecular factors underlying the neurocognitive benefits of exercise are complex and extend beyond IGF-1 and BDNF alone. Additional research is needed to clarify our current understanding, especially considering circulating IGF-1 responses to acute resistance exercise and RT have been understudied relative to BDNF.</p></sec><sec id="s5-4"><title>Effects of resistance exercise training on cerebrovascular health and function</title><p>Our group has previously reviewed the effects of habitual RT on cerebrovascular function across the lifespan (<xref rid="B4" ref-type="bibr">Allison and Al-Khazraji, 2024b</xref>). Habitual RT is associated with improved endothelial function (<xref rid="B265" ref-type="bibr">Silva et al., 2021</xref>), nitric oxide bioavailability (<xref rid="B119" ref-type="bibr">G&#252;zel et al., 2007</xref>), resting arterial diameter (<xref rid="B325" ref-type="bibr">Zoeller et al., 2009</xref>), improved cerebral autoregulatory function (<xref rid="B255" ref-type="bibr">Roy et al., 2022</xref>), and importantly improved global (<xref rid="B308" ref-type="bibr">Xu et al., 2014</xref>) and regional CBF (<xref rid="B189" ref-type="bibr">Macaulay et al., 2022</xref>). Despite the clear associations between habitual participation in RT and improved vascular and cerebrovascular function, the mechanisms as they relate to neurodegenerative disease such as ADRD have not been discussed. Increased oxidative stress and inflammation ultimately disrupts proper endothelial function (<xref rid="B117" ref-type="bibr">Gryglewski et al., 1986</xref>), leading to impaired BBB integrity and cerebrovascular dysfunction (<xref rid="B165" ref-type="bibr">Krizbai et al., 2005</xref>), neurovascular coupling (<xref rid="B185" ref-type="bibr">Louren&#231;o et al., 2017</xref>), and cerebrovascular reactivity (<xref rid="B198" ref-type="bibr">Mayhan et al., 2008</xref>). There are limited data related to effects of RT on cerebrovascular function in the elderly or in neurodegenerative conditions. Despite the paucity of data in older adults, findings from young healthy individuals may provide a fundamental backdrop for future study considerations. RT and its effects on arterial stiffness remain a topic of debate (<xref rid="B206" ref-type="bibr">Miyachi, 2013</xref>). Meta-analyses suggest that RT interventions increase aortic and carotid artery stiffness in healthy young men in an intensity dependent manner&#8211;such that higher intensities (75%&#8211;80% of 1RM) yield greater increases in central arterial stiffness (<xref rid="B150" ref-type="bibr">Kawano et al., 2006</xref>; <xref rid="B207" ref-type="bibr">Miyachi et al., 2004</xref>; <xref rid="B226" ref-type="bibr">Okamoto et al., 2009</xref>; <xref rid="B225" ref-type="bibr">Okamoto et al., 2006</xref>), but no such evidence has been observed in healthy young women (<xref rid="B211" ref-type="bibr">Morgan et al., 2023</xref>; <xref rid="B254" ref-type="bibr">Rossow et al., 2014</xref>), or older adults (<xref rid="B254" ref-type="bibr">Rossow et al., 2014</xref>; <xref rid="B63" ref-type="bibr">Cortez-Cooper et al., 2008</xref>; <xref rid="B247" ref-type="bibr">Ram&#237;rez-V&#233;lez et al., 2020</xref>; <xref rid="B145" ref-type="bibr">Jefferson, 2014</xref>). Acutely, high intensity resistance exercise (80%&#8211;100% 1RM) has been reported to increase carotid artery stiffness for up to 30 min post-exercise (<xref rid="B173" ref-type="bibr">Lefferts et al., 2014</xref>), MCAv for at least 1-min post exercise, and MCA pulsatility index in the immediate (&#8764;30s) post-exercise period (<xref rid="B158" ref-type="bibr">Koch et al., 2005</xref>). The increase in MCAv and MCA pulsatility index is likely a compensatory response to counter the drop in blood pressure following resistance exercise and maintain adequate cerebral perfusion (<xref rid="B173" ref-type="bibr">Lefferts et al., 2014</xref>; <xref rid="B158" ref-type="bibr">Koch et al., 2005</xref>). Indeed, the magnitude of post-exercise hypotension is commensurate with the pressure challenge during exercise (<xref rid="B43" ref-type="bibr">Chen and Bonham, 2010</xref>). On the surface, increased arterial stiffness in young men with habitual RT may raise concern due to its associations with hypertension (<xref rid="B258" ref-type="bibr">Safar, 2018</xref>), cardiovascular diseases (<xref rid="B205" ref-type="bibr">Mitchell et al., 2010</xref>), and cerebral microvascular damage (<xref rid="B13" ref-type="bibr">Badji et al., 2019</xref>; <xref rid="B287" ref-type="bibr">Tsao et al., 2013</xref>; <xref rid="B269" ref-type="bibr">Singer et al., 2014</xref>; <xref rid="B203" ref-type="bibr">Mitchell, 1985</xref>). However, the relationship between RT and arterial stiffness may need recontextualization and in our opinion should not be interpreted in the same lense as disease related arterial stiffening. There is evidence of chronic RT-induced adaptations supporting improved pulsatile dampening in the cerebral vasculature&#8211;in turn reducing pulsatile burden on the cerebral microvasculature in trained individuals (<xref rid="B217" ref-type="bibr">Nakamura et al., 2021</xref>). Perhaps the structural remodelling of arteries with RT is a compensatory adaptation to reduce arterial distension during high-grade resistance exercise-induced oscillations in blood pressure. Additional work is necessary to understand the broader cerebrovascular and neurological implications of RT-related arterial stiffening. Nonetheless, there is currently no evidence that RT is associated with negative effects on the cerebral vasculature despite the theoretical link between RT-induced arterial stiffness and microvascular damage.</p><p>Cross-sectionally, young healthy resistance-trained individuals (&gt;6 months) have elevated cerebrovascular resistance and reduced cerebrovascular pulsatility during high intensity exercise. The cerebrovascular adaptations to RT are supported by work from Thomas et al, who conducted 12 weeks of progressive RT (progression from 60%&#8211;90% 1RM with repetitions lowering as intensity increases, 3 times per week) in healthy young adults and similarly observed increased cerebrovascular resistance and decreased pulsatility at rest. These findings are unique to RT, as Thomas et al observed no such changes in the age-matched aerobically trained group (<xref rid="B282" ref-type="bibr">Thomas et al., 2021</xref>). Further research is required to better understand cerebrovascular adaptations to RT, as increased resting cerebrovascular resistance is typically a sign of negative alterations in cerebrovascular function (<xref rid="B312" ref-type="bibr">Yew and Nation, 2017</xref>). As mentioned previously, increased cerebrovascular resistance at rest, whether it be related to aging or disease, is typically a negative change in cerebrovascular function and is a sign of greater flow impedance&#8211;ultimately leading to reductions in CBF (<xref rid="B53" ref-type="bibr">Claassen et al., 2021</xref>). In the work from Thomas et al, they observed a significant but relatively minor increase in resting mean arterial pressure (&#8764;3 mmHg) and a reduction in resting MCAv (&#8764;3 cm/s) after 12 weeks of RT. This is an important finding related to cerebrovascular function, as cerebrovascular resistance is an index measure calculated as mean arterial pressure divided by MCAv (<xref rid="B282" ref-type="bibr">Thomas et al., 2021</xref>). Therefore, even slight increases in resting mean arterial pressure alongside reductions in MCAv would lead to significant increases in cerebrovascular resistance. Elevated mean arterial pressure with RT reported in this study is of note due to the more frequently reported blood pressure lowering effects of RT reported across the literature, particularly in hypertensive individuals (<xref rid="B62" ref-type="bibr">Correia et al., 2023</xref>). Considering the positive effects of RT on blood pressure in older and hypertensive adults, it is unlikely that the &#8764;3 mmHg rise in resting blood pressure observed by Thomas et al is of clinical concern. Importantly, the authors of this work similarly did not interpret their findings related to cerebrovascular resistance as negative adaptations to RT, but instead consider the increase to be a protective response to reduce the effects of increased mean arterial pressure on the cerebral circulation - where hyperperfusion can damage the microvasculature (<xref rid="B282" ref-type="bibr">Thomas et al., 2021</xref>). Indeed, despite the increase in cerebrovascular resistance with 12 weeks of RT, the authors also observed a significant reduction in MCA pulsatility index&#8211;suggestive of improved pulsatile damping despite the increase in mean arterial pressure. Thus, in alignment with the interpretation from Thomas et al, perhaps changes in cerebrovascular resistance observed in RT are to be separated from vascular pathology and recontextualized as a favourable adaptation, as increased resistance may suppress transmission of pulsatile blood flow into the cerebral circulation during- and post-resistance exercise (<xref rid="B158" ref-type="bibr">Koch et al., 2005</xref>). Reduced cerebrovascular pulsatility with RT could also be interpreted as improved capacity for cerebral arteries to dampen pressure waves ejected from the heart. Nonetheless, more work is necessary to better understand the effects of RT on cerebrovascular structure and function, particularly in elderly and diseased populations.</p><p>As it relates to cerebral autoregulatory function, Koch et al demonstrated that acute resistance exercise (low load &#8764;20 repetitions at 50%&#8211;60% 1RM; high load &#8764;8 repetitions at 80%&#8211;90% 1RM) has been shown to significantly impair the cerebral autoregulation immediately post-exercise, demonstrating a stark increase in MCAv relative to blood pressure (autoregulatory gain) (<xref rid="B158" ref-type="bibr">Koch et al., 2005</xref>). Impaired cerebral autoregulation and the other metrics of cerebral hemodynamics reported by Koch et al (rapid rise in MCA pulsatility, drop in cerebrovascular resistance index) in the immediate post-exercise period align well with the phenomenon of <italic toggle="yes">weightlifter&#8217;s blackout</italic>&#8211;in which individuals may experience syncope or pre-syncope immediately following high intensity resistance exercise, particularly when in the upright standing position due to the sudden pressure drop upon release of the external load (<xref rid="B60" ref-type="bibr">Compton et al., 1973</xref>). However, the work from Koch et al is suggestive of a compensatory response to the sudden drop in blood pressure. Given that blood pressure drops dramatically following resistance exercise, an increase in pulsatility, a drop in resistance, and an overall increase in MCAv (and likely cerebral perfusion) are indicative of an emergency protective response to avoid pre-syncope and syncope (<xref rid="B158" ref-type="bibr">Koch et al., 2005</xref>). Thus, while metrics of cerebral autoregulation appear to be impaired immediately following resistance exercise, increased autoregulatory gain (change in MCAv relative to change in blood pressure) should not be misinterpreted as damaging but instead as oppositional to <italic toggle="yes">weightlifter&#8217;s blackout</italic>.</p><p>In untrained individuals, the cerebral circulation exhibits greater sensitivity to reductions (than increases) in mean arterial pressure, demonstrating a greater change in MCAv (and assumingly CBF) during a hypotensive stimulus compared to a hypertensive stimulus (<xref rid="B255" ref-type="bibr">Roy et al., 2022</xref>; <xref rid="B4" ref-type="bibr">Allison and Al-Khazraji, 2024b</xref>). Interestingly, based on cross-sectional studies, it appears that sensitivity to reductions and increases in mean arterial pressure are handled similarly by the cerebral vasculature in resistance-trained adults (<xref rid="B255" ref-type="bibr">Roy et al., 2022</xref>). Furthermore, recent work from Korad et al. suggests improved pressure-buffering capacity of the cerebral circulation in resistance-trained adults, in which trained participants exhibited a similar change in MCAv to controls during unilateral knee extension resistance exercise despite a greater systemic blood pressure response (<xref rid="B160" ref-type="bibr">Korad et al., 2024</xref>). While they did not investigate the directional sensitivity of the cerebral circulation in this study, their findings do support adaptation in the inherent directional sensitivity of the cerebral pressure-flow relationship. While longer-term interventional work is necessary to understand how RT directly influences directional sensitivity of the cerebral pressure-flow relationship, the findings from Korad et al and Roy et al do indeed suggest that frequent exposure to oscillatory pressure challenges via resistance exercise may habituate the arteries to better handle both elevations and drops in mean arterial pressure and avoid hyperperfusion and pre-syncopal and syncopal responses, respectively (<xref rid="B160" ref-type="bibr">Korad et al., 2024</xref>; <xref rid="B255" ref-type="bibr">Roy et al., 2022</xref>).</p><p>In cross-sectional work from Xu et al, higher global CBF was observed in older individuals who frequently participating in RT (<xref rid="B308" ref-type="bibr">Xu et al., 2014</xref>). One of the few training studies in older adults from Macaulay et al, reported increased regional CBF in the hippocampus, anterior cingulate, posterior cingulate, putamen, insula, occipital lobe, and temporal lobe following high-intensity (70%&#8211;85% 1RM) RT 3 times per week for 12 weeks (<xref rid="B189" ref-type="bibr">Macaulay et al., 2022</xref>). Though the effect size was small (attributed to short duration of the exercise intervention by authors), the &#8764;4% increase in temporal lobe CBF is of clinical interest due to the region&#8217;s relationship with memory and ADRD. Furthermore, Macaulay et al also observed significant increases in the fMRI-derived fraction of low frequency fluctuations in the cerebellum, right middle temporal gyrus, and bilateral inferior parietal lobes, representing greater functional neuronal integrity and connectivity between brain regions (<xref rid="B189" ref-type="bibr">Macaulay et al., 2022</xref>). Reduced fraction of low frequency fluctuations has been reported in MCI and ADRD (<xref rid="B310" ref-type="bibr">Yang et al., 2018</xref>), suggesting that RT may support regional neuronal activity and functional integrity. Considering the critical importance of CBF delivery in maintaining neuronal health and function, these findings alone warrant further interventional investigations on how long-term RT affects cerebrovascular function in older adults across the cognitive and neurodegenerative spectrum.</p><p>Many of the positive vascular and cerebrovascular adaptations to RT can be linked back to reduced ROS production, improved antioxidant defenses, and reduced inflammation. These adaptations underlie the improvements in endothelial function via habitual RT which are well established (<xref rid="B265" ref-type="bibr">Silva et al., 2021</xref>) and likely driving the beneficial effects on CBF and improved regulation of CBF with changes in arterial blood pressure that have been observed to date. However, the implications of these improvements on BBB permeability and function are an emerging area of study. Recent work from Cho et al in women aged 65&#8211;84 showed improvements in BBB integrity with 12 weeks of 3 times per week moderate intensity (10-14/20 RPE) resistance band-based RT. Importantly, alongside the observed improvement in BBB function was an enhancement of antioxidant capacity, increased vascular endothelial growth factor and BDNF signalling (<xref rid="B47" ref-type="bibr">Cho and Roh, 2022</xref>). The neurotrophic responses to RT alongside upregulation of endothelial growth factors, improved endothelial function, and reduced inflammation and oxidative damage together implicate a role of RT in restoration of BBB function. However, additional research is needed to establish protective effects of RT on the BBB.</p></sec><sec id="s5-5"><title>Effects of resistance exercise training on brain structure</title><p>Given the importance of brain structure as a predictive biomarker for neurological health (<xref rid="B279" ref-type="bibr">Ten Kate et al., 2018</xref>; <xref rid="B242" ref-type="bibr">Planche et al., 2019</xref>; <xref rid="B90" ref-type="bibr">Fein et al., 2000</xref>; <xref rid="B77" ref-type="bibr">Dicks et al., 2020</xref>), and its chronology in the neurodegenerative cascade (preceded by inflammation, oxidative stress, vascular dysregulation, and A&#946; deposition) (<xref rid="B139" ref-type="bibr">Iturria-Medina et al., 2016</xref>), measures of brain structure can provide tangible insight into whether exercise as a therapeutic intervention is efficacious for slowing the rate of atrophy with age and neurodegenerative disease.</p><p>Most literature reports overall positive effects of RT on regional grey matter brain structure, but effects of RT on global brain structure are less clear. One study from Liu-Ambrose et al observed significant reductions in global brain volume following 1 year of high-intensity progressive RT (2 sets of 6-8 repetitions at 70%&#8211;85% of 1RM, either once or twice weekly) in older women free from MCI (<xref rid="B180" ref-type="bibr">Liu-Ambrose et al., 2010</xref>). Despite a reduction in whole brain volume with RT, there was a clear improvement in cognitive function following the RT intervention. The reduction in brain volume with RT has been observed in pharmaceutical trials for AD, and is hypothesized to be related to reduction in A&#946; load (<xref rid="B104" ref-type="bibr">Fox et al., 2005</xref>). The authors use this rationale cautiously to reconcile the mismatch between improved cognition and reduced brain volume, stating A&#946; clearance and subsequent shifts in cerebrospinal fluid may therefore have also partially explained their findings. Improvements in BBB function (in particular efflux of metabolic waste), and reduced A&#946; burden have been reported with RT in animal models (<xref rid="B123" ref-type="bibr">Hashiguchi et al., 2020</xref>).</p><p>More research is necessary to elucidate underlying causes for reductions in brain volume in response to exercise in older adults, including specific measurement of A&#946; and neurofibrillary tangles. In work from Best et al, there was no evidence of attenuated global grey matter atrophy with 1 year of high-intensity progressive RT (2 sets of 6-8 repetitions at 70%&#8211;85% of 1RM, either once or twice weekly) in 155 older women (<xref rid="B21" ref-type="bibr">Best et al., 2015</xref>). Though Best et al reported no change in grey matter atrophy rates, they did observe clear improvements in memory (<xref rid="B21" ref-type="bibr">Best et al., 2015</xref>). These findings suggest that positive effects of RT on brain function may occur without changes in total brain volume and grey matter volume.</p><p>Increases in global brain volume in response to exercise is not well supported; however, there is support that while exercise may not reverse age-related cortical decline, it does appear to reduce the rate of cortical decline compared to normal aging (<xref rid="B58" ref-type="bibr">Colcombe et al., 2003</xref>). Additionally, while the changes in global brain structure may be negligible, evidence does suggest that certain brain regions are particularly responsive to exercise effects. In cardiac rehab settings, 3 days per week of moderate-intensity aerobic exercise for a total of 6 months was associated with improved regional grey matter volume in the superior frontal gyrus, superior temporal gyrus, posterior cerebellum, and supplementary motor area (<xref rid="B10" ref-type="bibr">Anazodo et al., 2013</xref>). While these findings were in response to aerobic exercise training, they support the notion that not all regions of the brain are structurally responsive to the benefits of exercise. As it relates to RT interventions, importantly, the hippocampus and related subfields appear to be highly responsive to RT interventions (<xref rid="B29" ref-type="bibr">Broadhouse et al., 2020</xref>; <xref rid="B93" ref-type="bibr">Feter et al., 2018</xref>). Broadhouse et al demonstrated a clear protection of the left hippocampus with 6 months of high-intensity RT (3 sets of 8 repetitions at 80% 1RM, two or three times per week) compared to sham&#8211;an effect that persisted 1-year post-intervention in the 200 older adults studied (<xref rid="B29" ref-type="bibr">Broadhouse et al., 2020</xref>). In particular, there was a clear neuroprotective effect on the left CA1, dentate gyrus, and subiculum regions of the hippocampus, all showing a reduced atrophy rate compared to sham controls (<xref rid="B29" ref-type="bibr">Broadhouse et al., 2020</xref>). The CA1, dentate gyrus, and subiculum regions are of particular interest in the context of ADRD, as they are associated with autobiographical memory (<xref rid="B17" ref-type="bibr">Bartsch et al., 2011</xref>), encoding and retrieval of episodic memories (<xref rid="B121" ref-type="bibr">Hainmueller and Bartos, 2020</xref>), and hippocampal synaptic relay (<xref rid="B18" ref-type="bibr">Baset and Fengwen, 2024</xref>), respectively. Protection of these hippocampal subfields is critical in maintaining memory function with advanced age.</p><p>The benefits of RT on hippocampal subfields are further supported by recent work from Vints et al, demonstrating that even 12 weeks of progressive RT peaking at 85% of 1RM was sufficient in improving CA1, CA4, subiculum, and dentate gyrus volume in 70 older men and women (<xref rid="B298" ref-type="bibr">Vints et al., 2024</xref>). In contrast, a study investigating the effects of 6-month of either high intensity aerobic training or lower limb progressive RT (3 sets of 6&#8211;10 repetitions with intensity progression from 70%&#8211;85% 1RM, 2 times per week) on hippocampal volumes in 29 older women with probable MCI demonstrated a 5.6% and 2.5% increase in the left and right hippocampus, respectively, in response to aerobic exercise training&#8211;but observed no such positive effects of RT on hippocampal volumes (<xref rid="B278" ref-type="bibr">ten Brinke et al., 2015</xref>). Considering the small sample size in the RT group (N = 8), further study is necessary to determine the effects of RT on hippocampal volumes. The responsiveness of the hippocampus and its subfields to exercise are well supported by molecular mechanisms&#8211;as these brain regions exhibit elevated levels of neurotrophic factors (IGF-1; BDNF expression) with RT (<xref rid="B20" ref-type="bibr">Berbert-Gomes et al., 2024</xref>). Taken alongside the reported increases in regional CBF discussed previously, increased expression of neurotrophic factors in response to RT may facilitate neurogenesis and synaptic plasticity in the hippocampus and its subfields.</p><p>The improved brain structure in older adults after RT may also be related to increased cerebral glucose metabolism. Hippocampal atrophy has been shown to be strongly linked to cerebral glucose hypometabolism in older adults with AD (<xref rid="B309" ref-type="bibr">Yamaguchi et al., 1997</xref>). Though there are limited studies investigating the effects of RT on cerebral glucose metabolism, studies looking at the effects of 16 weeks of combined exercise interventions (aerobic and RT) reported significant improvements in glucose metabolism in the sensorimotor cortex in 172 elderly adults (<xref rid="B262" ref-type="bibr">Shah et al., 2014</xref>). 12 weeks of moderate-intensity RT (3 sets of 10&#8211;13 repetitions at 45%&#8211;65% 1RM, 3 times per week) has also been shown to improve systemic glucose metabolism in older adults with metabolic syndrome (<xref rid="B321" ref-type="bibr">Zhou et al., 2022</xref>). Indeed, decreased insulin sensitivity and impaired glucose metabolism systemically are linked to the progression of neurodegenerative diseases (<xref rid="B87" ref-type="bibr">Farooqui et al., 2012</xref>). Though the direct effects of RT on cerebral glucose metabolism across the cognitive spectrum remain unclear, the mechanistic rationale is sufficient to warrant future investigations on mechanisms underlying improved brain structure with habitual RT.</p><p>RT interventions have also been demonstrated to improve measures of white matter integrity. One year of high-intensity RT (2 sets of 6-8 repetitions at 70%&#8211;85% of 1RM) twice per week in 54 older women (65&#8211;75 years) reduced white matter hyperintensity progression compared to balance and toning controls. However there was no difference between controls and individuals who did the RT protocol only once per week&#8211;indicating a training frequency threshold of 2 times per week on neuroprotective effects, in line with current physical activity guidelines (<xref rid="B24" ref-type="bibr">Bolandzadeh et al., 2015</xref>). In a separate research article from the same cohort and intervention, 1 year of RT was associated with reductions in white matter hyperintensity related disruptions in the sensorimotor network, and dorsal and ventral attention networks (<xref rid="B64" ref-type="bibr">Crockett et al., 2022</xref>). Similarly, 4-month of thrice-weekly RT (3 sets of 8&#8211;15 repetitions at 50%&#8211;80% of 1RM) improved white matter density in 37 frail older women (<xref rid="B30" ref-type="bibr">Bucci et al., 2023</xref>). The observed effects in this study were also observed with physical phenotype, as frail women who were born to lean and normal-weight mothers conferred greater RT-related white matter benefits compared to those born to obese mothers. The underlying cause of these observations are likely to be multi-factorial, receiving contributions from metabolic, inflammatory, and vascular factors. In a previously mentioned study primarily investigating regional changes in CBF in response to RT, a reversal of the progression of white matter lesion volume - indicative of improved white matter perfusion - was also reported following 12 weeks of RT (<xref rid="B189" ref-type="bibr">Macaulay et al., 2022</xref>). Best et al similarly reported positive effects of RT on white matter structure, demonstrating a reduced rate of white matter atrophy in individuals in the RT group compared to controls after the 1-year training intervention as well as 1 year post-intervention (<xref rid="B21" ref-type="bibr">Best et al., 2015</xref>). These findings also align well with the work from Broadhouse et al, in which improvements in brain structure are maintained up to 1-year after cessation of training (<xref rid="B29" ref-type="bibr">Broadhouse et al., 2020</xref>). It is unclear whether these benefits in the RT groups compared to controls are related to residual physiological effects of training or whether they are a result of habit-forming related to the 1-year exercise intervention. Future works should consider collecting questionnaire or physical fitness data to determine the underlying cause of the long-term benefits of RT.</p></sec><sec id="s5-6"><title>Effects of resistance exercise training on cognitive function</title><p>The effects of acute and habitual exercise of any type on cognitive function are well established, with multiple quality reviews highlighting the effectiveness of resistance exercise on improved cognition across multiple domains (<xref rid="B168" ref-type="bibr">Landrigan et al., 2020</xref>; <xref rid="B41" ref-type="bibr">Chang et al., 2012</xref>; <xref rid="B127" ref-type="bibr">Herold et al., 2019</xref>; <xref rid="B46" ref-type="bibr">Cheng et al., 2022</xref>; <xref rid="B57" ref-type="bibr">Coelho-Junior et al., 2022</xref>). Acutely, it appears that low-to-moderate resistance exercise is effective in improving global cognition, as well as multiple aspects of executive function, cognitive flexibility, and processing speed, with inconsistent findings as it relates to memory function (<xref rid="B184" ref-type="bibr">Loprinzi et al., 2018</xref>). For the purposes of this review, memory will be the primary domain of interest due to its intimate relationship with MCI and ADRD. Cognitive performance in subdomains of memory also track well with brain regions most vulnerable to age- and disease-related atrophy (<xref rid="B101" ref-type="bibr">Fjell et al., 2014</xref>). In contrast to the equivocal effects of resistance exercise, other studies show strong associations between acute bouts of aerobic exercise and improved memory performance (<xref rid="B34" ref-type="bibr">Cantelon and Giles, 2021</xref>). It is unclear whether the discrepant impacts of resistance versus aerobic exercise on memory-related tasks in humans results from activation of different physiological pathways, individual differences in response to exercise, or different cognitive testing approaches used across studies.</p><p>The literature widely reports benefits of RT on global cognition (<xref rid="B273" ref-type="bibr">Suo et al., 2016</xref>; <xref rid="B56" ref-type="bibr">Coelho-J&#250;nior et al., 2020</xref>; <xref rid="B96" ref-type="bibr">Fiatarone Singh et al., 2014</xref>; <xref rid="B49" ref-type="bibr">Chupel et al., 2017</xref>; <xref rid="B197" ref-type="bibr">Mavros et al., 2017</xref>) and executive function (<xref rid="B224" ref-type="bibr">Nouchi et al., 2014</xref>; <xref rid="B72" ref-type="bibr">de Oliveira Silva et al., 2019</xref>; <xref rid="B124" ref-type="bibr">Helmes and Harris, 2017</xref>) in older adults across the neurocognitive spectrum (cognitively normal and MCI) but free from diagnosed ADRD. Though acute effects of resistance exercise on memory function are contentious at best, it is reasonable to assume habitual RT would be more efficacious in improving memory given the associations between muscular strength and both memory (<xref rid="B264" ref-type="bibr">Shaughnessy et al., 2020</xref>; <xref rid="B176" ref-type="bibr">Liao et al., 2024</xref>; <xref rid="B31" ref-type="bibr">Cai et al., 2023</xref>) and hippocampal volume (<xref rid="B151" ref-type="bibr">Kim YS. et al., 2017</xref>; <xref rid="B98" ref-type="bibr">Firth et al., 2020</xref>; <xref rid="B201" ref-type="bibr">Meysami et al., 2023</xref>). Greater muscle strength in older adults is inversely related to the development of sarcopenia and frailty (<xref rid="B293" ref-type="bibr">Veen et al., 2021</xref>). Maintaining muscle strength and mass is critical for promoting higher functional capacity and physical independence with aging (<xref rid="B80" ref-type="bibr">dos Santos et al., 2017</xref>). The positive adaptations observed in both global and regional measures of perfusion and brain structure to RT detailed in the sections above also support reported benefits of RT on memory function. A study investigating the effects of thrice-weekly moderate intensity resistance-band RT with self-directed intensity progression in over 200 community dwelling older adults demonstrated marked improvements in working memory (<xref rid="B167" ref-type="bibr">Lachman et al., 2006</xref>). Furthermore, the magnitude of cognitive benefits of RT were associated with the strength gains made over 6 months&#8211;suggesting a dose-response relationship between increased muscular strength and memory function (<xref rid="B167" ref-type="bibr">Lachman et al., 2006</xref>). A study from Mavros et al reported that muscle gains via RT (3 sets of 8 repetitions at 80%&#8211;90% 1RM, 2-3 times per week), but not improvements in aerobic fitness over 6-month were related to improved memory performance in 100 community dwelling adults diagnosed with MCI (<xref rid="B197" ref-type="bibr">Mavros et al., 2017</xref>). Additionally, a 1-year training study in 155 older women demonstrated that not only was a single day of high intensity RT (2 sets of 6-8 repetitions at 70%&#8211;85% of 1RM) per week sufficient to improve memory at the cessation of the study compared to pre-training, but these cognitive benefits persisted for 1 year after training compared to balance-and-toning controls (<xref rid="B21" ref-type="bibr">Best et al., 2015</xref>). The relationship between exercise intensity and neurocognitive effects of RT is supported by work from Feter et al, who showed improvements in cognition over 12-week of high velocity RT (1&#8211;3 sets of 8&#8211;10 repetitions at 40%&#8211;60% 1RM, 2 times per week) were statistically mediated by the improvements in lower body strength, power, and muscle thickness (<xref rid="B95" ref-type="bibr">Feter et al., 2023</xref>), though they did not find any effects of the RT intervention on memory-related domains. The null findings on memory reported by Feter et al may be related to exercise intensity&#8211;as increases in muscle mass are not necessarily intensity dependent (<xref rid="B199" ref-type="bibr">Mcleod et al., 2024</xref>), but evidence does support that intensity mediates exercise-related neurogenesis and neuroplasticity in interval and aerobic exercise models (<xref rid="B193" ref-type="bibr">Marko et al., 2022</xref>; <xref rid="B107" ref-type="bibr">Freitas et al., 2018</xref>; <xref rid="B130" ref-type="bibr">Hoffmann et al., 2016</xref>; <xref rid="B162" ref-type="bibr">Kovacevic et al., 2020</xref>; <xref rid="B215" ref-type="bibr">Murawska-Cia&#322;owicz et al., 2021</xref>). Another large-scale trial (N = 1335) similarly found no clear benefits of low-to-moderate intensity RT (2 sets of 15 repetitions at 60% 1RM, 5 times per week) on memory function in 2 years of training, further suggesting the importance of intensity in maximizing pro-cognitive effects of RT (<xref rid="B159" ref-type="bibr">Komulainen et al., 2010</xref>). It is important to note that in an investigation from Cassilhas et al directly comparing the effects of different intensities of RT (2 sets of 8 repetitions at 50% 1RM vs. 80% 1RM, both conducted 3 times per week), there appeared to be no differences in cognitive benefits (<xref rid="B39" ref-type="bibr">Cassilhas et al., 2007</xref>). The underlying factors for absence of differences in the work from Cassilhas et al despite clear mechanistic rationale and evidence for intensity-mediated neurocognitive benefits of RT remains unclear and warrants further study. Nonetheless, the literature does suggest that moderate-to-high intensities of RT is associated with significant improvements on memory function (<xref rid="B21" ref-type="bibr">Best et al., 2015</xref>; <xref rid="B55" ref-type="bibr">Coelho-J&#250;nior and Uchida, 2021</xref>; <xref rid="B195" ref-type="bibr">Marston et al., 2019</xref>).</p><p>The cognitive benefits of RT may also be related to the inherent complexity of resistance exercise itself. As mentioned previously, resistance exercise requires individuals to remember exercises, machine settings, and training protocols, synchronize movements between several muscle different groups, and recruit the appropriate amount of muscle fibres to meet exercise demands. Thus, resistance exercise may act as a cognitive stimulus in and of itself (<xref rid="B102" ref-type="bibr">Forte et al., 2013</xref>). Furthermore, dual-task exercises that combine RT with simultaneous cognitive tasks may provide additional challenges, potentially enhancing cognitive outcomes. This idea is supported by Baek et al, who reported improved cognitive performance in older adults with cognitive impairment that completed 6-week of dual-task resistance band-based RT (3 sets of 10 repetitions, 3 times per week), which involved cognitively stimulating tasks simultaneously during RT (<xref rid="B14" ref-type="bibr">Baek et al., 2024</xref>). Several studies have demonstrated that resistance exercise, across varying intensities, improves psychological wellbeing without measurable changes in neurocognitive performance from pre to post-intervention (<xref rid="B288" ref-type="bibr">Tsutsumi et al., 1997</xref>; <xref rid="B236" ref-type="bibr">Peig-Chiello et al., 1998</xref>). The absence of improvements in neurocognitive performance may be due to limitations in study duration or the specific cognitive domains assessed. However, qualitative analyses of participants&#8217; experiences in RT programs highlight perceived improvements in psychological wellbeing, which suggest enhanced self-efficacy&#8212;a critical factor for long-term adherence (<xref rid="B79" ref-type="bibr">Dionigi, 2007</xref>).</p></sec></sec><sec id="s6"><title>Practical considerations for resistance training in older adults at risk of ADRD</title><sec id="s6-1"><title>Adherence, adoption, and feasibility of resistance training interventions</title><p>Adherence to exercise programs, particularly RT, is a multifactorial challenge influenced by biopsychosocial factors. Barriers to adherence can be broadly categorized under the concept of self-efficacy, which refers to an individual&#8217;s confidence in their ability to succeed in specific tasks, including both physical and psychological aspects. Additionally, social support plays a critical role in overcoming these barriers (<xref rid="B79" ref-type="bibr">Dionigi, 2007</xref>). Effective programs must address both the initial adoption of exercise and the sustained maintenance of participation over time. A study by Furlano and Nagamatsu demonstrated that longer-term RT (2 sets of 6-8 repetitions at 70%&#8211;85% of 1RM, 3 times per week for 26 weeks) is generally feasible for older adults at risk of type 2 diabetes, a population often experiencing deficits in cognitive functioning and at elevated risk for AD (<xref rid="B109" ref-type="bibr">Furlano and Nagamatsu, 2021</xref>). Although recruitment posed challenges, the study achieved high retention (100%) and adherence (85.5%) rates within the RT group. Notably, 90% of participants reported enjoying the program, with many citing social interaction and increased feelings of strength, mobility, and fitness as their favorite aspects. Key factors influencing adherence included program characteristics such as session timing and location, social connectivity, enjoyment, perceived safety, and delivery by trained healthcare professionals (<xref rid="B109" ref-type="bibr">Furlano and Nagamatsu, 2021</xref>). These findings underscore the critical role of socialization and perceived physical benefits in driving adherence, suggesting that similar strategies could be applied across diverse populations with chronic health conditions. However, recruitment challenges highlight potential barriers to scaling similar interventions, particularly in populations with varying degrees of health or cognitive impairment. These studies highlight the importance of self-efficacy, social interaction, and program characteristics in promoting adherence, aligning with biopsychosocial models of adherence that emphasize the interplay between individual motivations, environmental factors, and perceived outcomes (<xref rid="B79" ref-type="bibr">Dionigi, 2007</xref>).</p><p>Personalized exercise prescriptions that cater to the unique needs of older adults are essential. Individualized program design, including adjustments to intensity and duration, is crucial for optimizing outcomes. RT programs can be adapted to various settings, including community centers, homes, and online platforms, increasing accessibility for a diverse population. For example, online RT programs demonstrate increased accessibility with high adherence levels and improved psychological wellbeing. In addition to being accessible and feasible, RT is cost-effective compared to balance and toning exercises, offering significant health and cognitive benefits. For instance, Davis et al found that 6 months of RT (2 sets of 6-8 repetitions at 70%&#8211;85% of 1RM, 2 times per week) in older adults with MCI led to greater cognitive improvements compared to the balance and toning group (<xref rid="B66" ref-type="bibr">Davis et al., 2013</xref>). Moreover, resistance training classes were more cost-effective for achieving each unit of Stroop test performance compared to balance and toning classes. These findings suggest that RT is a feasible, affordable, and effective option for individuals of varying health statuses, potentially promoting greater adherence after initial adoption. It is important to consider the role of total training load on exercise adherence in older adults, as training overload in older adults may lead to dropout. This is of particular concern in interventions using a multimodal approach of both aerobic and resistance exercise. Current recommendations suggest &#8764;150 min of moderate intensity aerobic exercise per week alongside moderate intensity RT at least twice per week (<xref rid="B218" ref-type="bibr">Nelson et al., 2007</xref>). While multimodal exercise has potential to negatively influence adherence by increasing total training volume, studies have demonstrated that multimodal or circuit-based exercise protocols are not only feasible but well-tolerated in older adults. A single session each of aerobic and resistance exercise per week (two total exercise sessions) was shown to elicit significant improvements in muscular strength and aerobic fitness similar in magnitude to twice and thrice weekly over the course of the 16-week intervention&#8211;though this study did not include cognitive of brain related measures (<xref rid="B99" ref-type="bibr">Fisher et al., 2013</xref>). Furthermore, all three groups (1 aerobic/week, 1 RT/week; 2 aerobic/week, 2 RT/week; 3 aerobic/week, 3 RT/week) had adherence rates of &gt;88% over the duration of the 16-week protocol (<xref rid="B99" ref-type="bibr">Fisher et al., 2013</xref>). These findings suggest that combination exercise, particularly in older adults may be effective without necessarily needing to increase exercise frequency. Indeed, other work has demonstrated that RT twice weekly has been shown to improve cognitive performance (<xref rid="B24" ref-type="bibr">Bolandzadeh et al., 2015</xref>), and taken alongside low-moderate intensity aerobic exercise such as walking (<xref rid="B172" ref-type="bibr">Lee et al., 2025</xref>), is likely to be well received by older adults - particularly if there is a social element integrated into the program (<xref rid="B79" ref-type="bibr">Dionigi, 2007</xref>). Despite the numerous factors mentioned above, further research is still needed to explore long-term adherence and its determinants. Strategies to improve adherence include clear communication, addressing motivation and self-efficacy, and fostering social interactions while balancing exercise load and physical fatigue (<xref rid="B79" ref-type="bibr">Dionigi, 2007</xref>; <xref rid="B109" ref-type="bibr">Furlano and Nagamatsu, 2021</xref>). A biopsychosocial approach to program design can better address diverse health statuses and contribute to sustained engagement to ensure that participating individuals experience the psychological and physiological benefits of RT.</p></sec><sec id="s6-2"><title>Additional considerations in resistance training approaches</title><p>The combined effects of protein supplementation and resistance training on muscle mass, strength, and cognition in older adults remain a complex and debated area of research. RT is a well-established intervention for mitigating age-related muscle loss and weakness, and as discussed earlier, has demonstrated potential for improving cognitive functioning. However, the additional benefits of protein supplementation are less definitive, with studies reporting mixed outcomes (<xref rid="B116" ref-type="bibr">Griffen et al., 2024</xref>; <xref rid="B9" ref-type="bibr">Amasene et al., 2019</xref>). Some research suggests a synergistic relationship between protein intake and resistance exercise, noting that protein ingestion close to the time of exercise may enhance specific domains of cognitive functioning, like executive function, processing speed, memory, and reaction time (<xref rid="B116" ref-type="bibr">Griffen et al., 2024</xref>). However, many studies involving older adults have failed to demonstrate consistent added benefits of protein supplementation, potentially due to variations in the protein dosage and RT protocol itself. Amasene et al found that 12 weeks of RT (2 sets of individualized repetitions, progression of intensity from 50%&#8211;75% 1RM, 2 times per week) alone increased physical function, with no additional benefit from leucine-enriched whey protein supplementation (<xref rid="B9" ref-type="bibr">Amasene et al., 2019</xref>). In this study, authors noted that the dosage of protein after RT sessions may have been inadequate and suggested that participants may have required higher supplementation levels. Griffen et al aimed to address insufficient protein supplementation by examining how increasing protein intake, in isolation and with RT, in older adults would impact cognitive outcomes (<xref rid="B116" ref-type="bibr">Griffen et al., 2024</xref>). Their study found that whey protein supplementation at approximately 1.6 g/kg/day resulted in statistically significant improvements in executive function compared to the control group and the RT-only group. However, this improvement appeared domain-specific, as no significant differences were observed in working memory. Interestingly, RT (3 sets of 8&#8211;12 repetitions progressing from 50%&#8211;80% 1RM, 2 times per week) alone did not improve cognitive function in this study, nor did it exhibit synergistic effects with protein supplementation (<xref rid="B116" ref-type="bibr">Griffen et al., 2024</xref>). In addition to an underpowered analysis for the synergistic effects of protein and RT, Griffen et al noted that after final progressions to 80% 1RM, their RT protocol involved a &#8764;10% higher intensity than those examined in previous studies, potentially influencing the cognitive outcomes (<xref rid="B116" ref-type="bibr">Griffen et al., 2024</xref>). These discrepancies underscore the mixed results regarding the effects of protein supplementation and its interaction with RT. Future research should aim to disentangle these inconsistencies by carefully examining the specific health outcomes being measured (e.g., physical function versus cognitive function), the type and dosage of protein used, individual differences in protein intake, characteristics of the target population, and the design of RT protocols. A more nuanced understanding of these variables will help clarify the potential benefits of combining protein supplementation with RT in older adults.</p><p>Innovative approaches are essential for enhancing RT programs for older adults by addressing diverse needs and barriers. Various modalities of RT such as elastic bands (<xref rid="B314" ref-type="bibr">Yoon et al., 2017</xref>) and isometric exercise training (<xref rid="B128" ref-type="bibr">Hess and Smart, 2017</xref>), as well as different RT set structures, have shown efficacy in improving levels of critical neuronal growth factors, cognitive and physical function, and vascular and mental health. Other RT prescription structures, such as drop-set RT (several sets to failure with descending loads with each consecutive set), have also shown significant improvements in BDNF and nerve growth factor levels in middle-aged Korean women with obesity (<xref rid="B16" ref-type="bibr">Bang, 2023</xref>). This highlights the potential of drop-set RT for targeting populations with specific metabolic or health challenges, though its high intensity and tempo may limit broader applicability. Compared to RT alone, which was shown to improve psychological wellbeing and physical functioning in older adults with cognitive impairment, dual-task exercises (exercise plus cognitive stimulation) were shown to also improve cognitive functioning (<xref rid="B14" ref-type="bibr">Baek et al., 2024</xref>). This suggests that a dual-task exercise, which requires both cognitive and physical effort, may be a more potent stimulus that allows older adults to maximize the benefits from RT.</p><p>Blood flow restriction exercise is also a promising avenue for improving functional capacity in older adults where exercise with high external loads may not be well tolerated (<xref rid="B284" ref-type="bibr">T&#246;rpel et al., 2018</xref>). RT with blood flow restriction is an ideal alternative to RT alone for older adults facing physical barriers as it is a safer and more efficient approach to elicit improvements in muscle strength and hypertrophy while minimizing the risk of injury (<xref rid="B248" ref-type="bibr">Ramos-Campo et al., 2018</xref>). Importantly, acute blood flow restriction exercise using an occlusive cuff in the upper or lower limbs has been shown to elicit similar improvements in cognitive flexibility compared to traditional RT despite working with significantly lower loads (30% of 1RM in blood flow restricted RT vs. 70% of 1RM in traditional RT) (<xref rid="B19" ref-type="bibr">Batman et al., 2024</xref>). In addition to its muscle and strength building qualities despite a lower relative load, blood flow restriction exercise with low loads has been shown to have no adverse effects on vascular function or blood flow in older adults (<xref rid="B182" ref-type="bibr">Lopes et al., 2022</xref>; <xref rid="B152" ref-type="bibr">Kim J. et al., 2017</xref>). Furthermore, recent meta-analyses of 12 randomized control trials demonstrated that blood flow restriction exercise is associated with improved arterial endothelial function (as assessed via brachial artery flow mediated dilation test) (<xref rid="B319" ref-type="bibr">Zhang et al., 2022</xref>). As mentioned in previous sections, strength gains have been associated with cognitive improvements in response to exercise interventions (<xref rid="B197" ref-type="bibr">Mavros et al., 2017</xref>; <xref rid="B167" ref-type="bibr">Lachman et al., 2006</xref>; <xref rid="B95" ref-type="bibr">Feter et al., 2023</xref>). While the direct neuroprotective effects of blood flow restriction exercise remain unclear (<xref rid="B284" ref-type="bibr">T&#246;rpel et al., 2018</xref>), exercise of any form are suggested to have positive effects on brain function. Blood flow restriction both increases the efficiency of RT (from a strength and hypertrophy perspective) while simultaneously lowering the barrier to entry, thus making it an exciting focus for future research with implications on exercise prescription in older adults with physical limitations.</p><p>Alternative approaches leveraging technology&#8212;such as online platforms, mobile apps, and wearable devices&#8212;can improve adherence and streamline program delivery (<xref rid="B59" ref-type="bibr">Coletta et al., 2024</xref>; <xref rid="B171" ref-type="bibr">Lee et al., 2024</xref>). However, accessibility issues, such as technological literacy and cost, may limit their reach in underserved populations. One solution could be community-based programs, which combine cognitive and physical training with health education lectures. Indeed, these programs have been shown to improve both physical and cognitive function among community-dwelling older adults (<xref rid="B223" ref-type="bibr">Nose et al., 2023</xref>). Emerging approaches like Electrical Muscle Stimulation (EMS) combined with RT may also offer additive benefits. Thapa et al demonstrated that EMS combined with RT enhanced strength, physical performance, and cognitive outcomes in middle-aged and older women compared to RT alone. While these findings highlight the potential of EMS as a complementary strategy, future research could explore its application in clinical populations with limited physical capacity, where traditional RT may be less feasible (<xref rid="B280" ref-type="bibr">Thapa et al., 2023</xref>). These innovations underscore the importance of tailoring RT programs to individual needs through holistic approaches that address physical, psychological, and social factors (<xref rid="B140" ref-type="bibr">Iuliano et al., 2015</xref>). Future research should investigate long-term outcomes, cost-effectiveness, and the comparative benefits of these methods relative to traditional RT. Additionally, exploring how these approaches can be integrated with other interventions, such as dietary strategies, may further optimize overall health outcomes (<xref rid="B140" ref-type="bibr">Iuliano et al., 2015</xref>).</p></sec><sec id="s6-3"><title>Safety of resistance training in older adults and clinical populations</title><p>Despite the benefits of RT on multiple physiological systems, particularly related to muscle mass and reducing the risk of frailty and loss of independence, as of 2018 only 19% of older adults report participating in muscle strengthening activities of any kind (<xref rid="B136" ref-type="bibr">Hyde et al., 2021</xref>). The hesitancy for participation in RT in older adults can be largely attributed to safety concerns&#8211;a topic that has been debated in recent years (<xref rid="B105" ref-type="bibr">Fragala et al., 2019</xref>). These concerns are a valid barrier to entry, as RT-na&#239;ve older adults may very well incur injury without proper program design (i.e., exercise intensity, volume), technique, and supervision (<xref rid="B105" ref-type="bibr">Fragala et al., 2019</xref>). Additionally, resistance exercise has traditionally been considered hazardous (<xref rid="B259" ref-type="bibr">Sagiv, 2009</xref>) for individuals with cardiovascular dysfunction due to exaggerated blood pressure responses. However, with appropriate exercise prescription beginning at lower intensities and coupled with incremental progression, these effects are of less concern (<xref rid="B105" ref-type="bibr">Fragala et al., 2019</xref>). Importantly older adults participating in RT should be coached on proper breathing techniques, specifically to avoid the Valsalva maneuver during exercise to reduce the likelihood of problematic increases in blood pressure. With coached breathing and appropriate supervision, RT at low-to-moderate intensities are unlikely to elicit Valsalva maneuver related spikes in blood pressure, as the Valsalva maneuver is only involuntary at intensities &gt;80% of 1RM (<xref rid="B190" ref-type="bibr">MacDougall et al., 1992</xref>). To further ensure safety during RT in older adults, prescribing machine-based exercise early on in programming as opposed to free-weights is an ideal alternative that typically will protect the lower back by avoiding spinal loading and compensatory movements through the back, and allow for greater control and balance during exercise with external load (<xref rid="B89" ref-type="bibr">Feigenbaum and Pollock, 1999</xref>). Thus, for promotion of participation in RT in older adults, lower intensity, machine-based exercise led by qualified exercise professionals is critical for safe implementation of RT (<xref rid="B105" ref-type="bibr">Fragala et al., 2019</xref>). Ultimately, while safety concerns related to participation in RT are valid, when exercise is prescribed and monitored appropriately, the benefits of RT outweigh the risks and have potential to dramatically improve quality of life and independence in older adults (<xref rid="B175" ref-type="bibr">Levinger et al., 2007</xref>).</p><p>Similar to otherwise healthy older adults, individuals living with chronic health conditions stand to greatly benefit from participation in RT. The positive effects of RT are well-documented, improving glycemic control in healthy adults (<xref rid="B12" ref-type="bibr">Ashton et al., 2020</xref>) and type-2 diabetics (<xref rid="B138" ref-type="bibr">Ishiguro et al., 2016</xref>; <xref rid="B143" ref-type="bibr">Jansson et al., 2022</xref>), reducing resting and ambulatory blood pressure in individuals with hypertension (<xref rid="B62" ref-type="bibr">Correia et al., 2023</xref>), enhancing muscular strength and function in sarcopenia (<xref rid="B320" ref-type="bibr">Zhao et al., 2022</xref>) and osteoarthritis (<xref rid="B178" ref-type="bibr">Lim et al., 2024</xref>), and positively influencing vascular health in those with cardiovascular disease (<xref rid="B231" ref-type="bibr">Paluch et al., 2024</xref>; <xref rid="B88" ref-type="bibr">Fecchio et al., 2021</xref>). Despite its effectiveness, several key considerations must be addressed when prescribing RT to ensure safety, adherence, and efficacy.</p><p>Medical clearance from a physician and individualized risk assessment are essential by certified healthcare and exercise professionals (<xref rid="B177" ref-type="bibr">Liguori and American College of Sports Medicine, 2020</xref>). In individuals with diabetes, careful attention to glycemic control is necessary, including monitoring blood glucose levels before and after training sessions and timing exercise to avoid periods of peak insulin activity (<xref rid="B148" ref-type="bibr">KANALEY et al., 2022</xref>). In hypertensive individuals, while RT can lower resting blood pressure over time, acute hypertensive responses during high-intensity or isometric lifts warrant caution (<xref rid="B295" ref-type="bibr">Vermeer et al., 1997</xref>; <xref rid="B75" ref-type="bibr">de Souza Nery et al., 2010</xref>). Submaximal loads and avoidance of the Valsalva maneuver via controlled breathing are recommended (<xref rid="B304" ref-type="bibr">Williams et al., 2007</xref>). Indeed, while progressive overload remains foundational to resistance training, but initial intensities should typically be low to moderate (e.g., 40%&#8211;60% of 1RM) with gradual increases to minimize injury risk (<xref rid="B231" ref-type="bibr">Paluch et al., 2024</xref>). For individuals with cardiovascular disease or stroke, factors such as impaired autonomic regulation, cerebrovascular function, and potential motor or balance deficits need to be considered and monitored during exercise sessions (<xref rid="B22" ref-type="bibr">Billinger et al., 2014</xref>). As such, programming may need to begin with machine-based or seated exercises, with gradual progression as physical function improves. When tailored appropriately to the individual&#8217;s clinical status, capacity, and goals, RT serves as an important element alongside aerobic exercise for management of chronic disease.</p></sec><sec id="s6-4"><title>Female-specific considerations in administration of resistance exercise</title><p>The feasibility and practical considerations discussed above apply to both males and females, but it is also important to acknowledge sex-specific barriers to RT&#8211;particularly as it pertains to older females. While in recent years the dogma of RT being inherently &#8220;masculine&#8221; has fallen out of favour, older adults may still possess pre-conceived notions about the concept of weightlifting. Though participation in RT has increased in females in recent years (<xref rid="B164" ref-type="bibr">Kraemer et al., 2025</xref>), many older females still report hesitancy, citing a lack of education and beliefs that any heavy lifting should be avoided (<xref rid="B135" ref-type="bibr">Hurst et al., 2023</xref>). The pre-conceived notion that RT needs to be done with heavy external loads is damaging and plays into the stereotype that there is no clear access point for RT-na&#239;ve older adults, and older females in particular. A lack of education and resources, taken alongside a generally lower level of baseline strength in older females compared to males, may deter females from initiating participation in RT programs and further promote the age-related loss in muscle and physical independence that disproportionately affects older females (<xref rid="B70" ref-type="bibr">de Jong et al., 2023</xref>). Hurst et al reported that although awareness and understanding of RT is low in older females, there is open mindedness towards resistance exercise as a modality so long as adequate peer and healthcare professional support is provided (<xref rid="B135" ref-type="bibr">Hurst et al., 2023</xref>). While participation in RT in older adulthood is key for females to combat age-related muscle loss, adoption of RT in females in midlife is of critical importance. Promotion of RT to maintain and build muscular strength in midlife greatly reduces the onset and progression of sarcopenia in older age (<xref rid="B289" ref-type="bibr">Vaishya et al., 2024</xref>). The primary barrier for participation in RT in midlife cited by females is related to time constraints and shifting life transitions, which include taking on primary caregiver roles to not only children but potentially aging parents as well (<xref rid="B272" ref-type="bibr">Stimson et al., 2024</xref>). Providing education on short duration resistance exercise provides an accessible and feasible approach to facilitate participation and adherence to RT and greatly reduces risk of frailty in older adulthood. In summary, addressing misconceptions, improving access to female-focused programming, and promoting time-efficient, low-barrier approaches to RT are critical to improving participation in older females.</p></sec><sec id="s6-5"><title>Summary</title><p>The neuroprotective effects of RT are multi-factorial and have direct effects on ADRD pathophysiological cascades. Initial benefits of RT primarily begin at the molecular level, as even an acute bout of resistance exercise reduces inflammation and increases antioxidant defenses (<xref rid="B228" ref-type="bibr">&#214;zbeyli et al., 2017</xref>; <xref rid="B94" ref-type="bibr">Feter et al., 2019</xref>; <xref rid="B261" ref-type="bibr">Schimidt et al., 2019</xref>; <xref rid="B253" ref-type="bibr">Rond&#227;o et al., 2022</xref>; <xref rid="B106" ref-type="bibr">Franzke et al., 2018</xref>; <xref rid="B125" ref-type="bibr">Heneka et al., 2015</xref>; <xref rid="B270" ref-type="bibr">Steensberg et al., 2002</xref>; <xref rid="B123" ref-type="bibr">Hashiguchi et al., 2020</xref>; <xref rid="B103" ref-type="bibr">Forti et al., 2014</xref>; <xref rid="B227" ref-type="bibr">Ostrowski et al., 1999</xref>; <xref rid="B38" ref-type="bibr">Cassatella et al., 1993</xref>; <xref rid="B179" ref-type="bibr">Liu et al., 2020</xref>; <xref rid="B297" ref-type="bibr">Vilela et al., 2017</xref>; <xref rid="B298" ref-type="bibr">Vints et al., 2024</xref>), promotes expression of neurotrophic factors such as IGF-1 (<xref rid="B228" ref-type="bibr">&#214;zbeyli et al., 2017</xref>; <xref rid="B40" ref-type="bibr">Cassilhas et al., 2012</xref>; <xref rid="B294" ref-type="bibr">Vega et al., 2010</xref>; <xref rid="B285" ref-type="bibr">Tsai et al., 2014</xref>; <xref rid="B209" ref-type="bibr">Molina-Sotomayor et al., 2020</xref>) and BDNF (<xref rid="B20" ref-type="bibr">Berbert-Gomes et al., 2024</xref>; <xref rid="B142" ref-type="bibr">Jafarzadeh et al., 2021</xref>; <xref rid="B311" ref-type="bibr">Yarrow et al., 2010</xref>; <xref rid="B299" ref-type="bibr">Walsh et al., 2015</xref>; <xref rid="B194" ref-type="bibr">Marston et al., 2017</xref>; <xref rid="B54" ref-type="bibr">Coelho et al., 2012</xref>; <xref rid="B238" ref-type="bibr">Pereira et al., 2013</xref>; <xref rid="B292" ref-type="bibr">Vaughan et al., 2014</xref>) in brain regions vulnerable to neurodegeneration (i.e., hippocampus). While reduction in inflammation and ROS production may not be sufficient to reverse A&#946; and neurofibrillary tangle deposition; there is reason to believe that the production and accumulation of neurotoxic compounds in the parenchyma is attenuated with habitual RT, potentially preventing further accumulation. Furthermore, habitual RT is associated with improvements in endothelial function (<xref rid="B265" ref-type="bibr">Silva et al., 2021</xref>), cerebral perfusion (<xref rid="B308" ref-type="bibr">Xu et al., 2014</xref>; <xref rid="B189" ref-type="bibr">Macaulay et al., 2022</xref>), and glucose uptake in the brain (<xref rid="B309" ref-type="bibr">Yamaguchi et al., 1997</xref>; <xref rid="B262" ref-type="bibr">Shah et al., 2014</xref>), resulting in a better matching between neuronal metabolic supply and demand. The improved endothelial function reported with RT may also have implications on BBB function and integrity. In both animal and human studies, RT interventions have been shown to improve BBB structure and function (<xref rid="B123" ref-type="bibr">Hashiguchi et al., 2020</xref>; <xref rid="B47" ref-type="bibr">Cho and Roh, 2022</xref>), and likely underlie findings related to A&#946; clear-out with habitual RT. Given that neuronal atrophy is largely driven by cerebral hypoperfusion and hypometabolism, a restoration in CBF via exercise has been shown to reverse or attenuate the rate of white matter damage (<xref rid="B189" ref-type="bibr">Macaulay et al., 2022</xref>; <xref rid="B21" ref-type="bibr">Best et al., 2015</xref>; <xref rid="B29" ref-type="bibr">Broadhouse et al., 2020</xref>; <xref rid="B24" ref-type="bibr">Bolandzadeh et al., 2015</xref>; <xref rid="B64" ref-type="bibr">Crockett et al., 2022</xref>; <xref rid="B30" ref-type="bibr">Bucci et al., 2023</xref>) and improve or attenuate age-related reductions in grey matter volumes, particularly in the hippocampus and its related subfields (<xref rid="B298" ref-type="bibr">Vints et al., 2024</xref>; <xref rid="B29" ref-type="bibr">Broadhouse et al., 2020</xref>; <xref rid="B93" ref-type="bibr">Feter et al., 2018</xref>). Restoration of cerebral tissues, increased expression of neurotrophic factors promoting neuroplasticity and neurogenesis, and improved efflux of neurotoxic A&#946; with RT are likely to drive the subsequent improvements in cognition observed across the literature in several domains, particularly memory function (<xref rid="B110" ref-type="bibr">Gabriel et al., 2006</xref>; <xref rid="B21" ref-type="bibr">Best et al., 2015</xref>; <xref rid="B167" ref-type="bibr">Lachman et al., 2006</xref>; <xref rid="B55" ref-type="bibr">Coelho-J&#250;nior and Uchida, 2021</xref>; <xref rid="B195" ref-type="bibr">Marston et al., 2019</xref>).</p><p>Ultimately, the neuroprotective cascade via habitual participation in resistance exercise hold promise for reducing risk of onset and reducing the rate of progression of ADRD. RT programs for older adults are most effective when they address adoption, adherence, and feasibility concerns, by integrating dietary strategies and innovative approaches to enhance outcomes (<xref rid="B79" ref-type="bibr">Dionigi, 2007</xref>; <xref rid="B66" ref-type="bibr">Davis et al., 2013</xref>; <xref rid="B116" ref-type="bibr">Griffen et al., 2024</xref>; <xref rid="B9" ref-type="bibr">Amasene et al., 2019</xref>; <xref rid="B171" ref-type="bibr">Lee et al., 2024</xref>). Employing methods such as dual-task training, community-based programs, and technology-based delivery, can improve cognitive and physical health while ensuring long-term engagement and accessibility (<xref rid="B14" ref-type="bibr">Baek et al., 2024</xref>; <xref rid="B59" ref-type="bibr">Coletta et al., 2024</xref>; <xref rid="B171" ref-type="bibr">Lee et al., 2024</xref>; <xref rid="B223" ref-type="bibr">Nose et al., 2023</xref>). Investigators should continue to prioritize conducting well-controlled randomized control trials to gain greater insight into the effects of multiple types of RT, multi-modal training, and community-based RT programs on brain health outcomes across the lifespan in both healthy and clinical populations. There should also be a priority to investigate whether RT has differential effects on males and females as it relates to cerebrovascular and brain health&#8211;as sexual dimorphism in exercise-related reduction in ADRD risk remains poorly understood. Future research should also consider personalized interventions, include measures of psychological and behavioral factors, and examine the combined effects of exercise and dietary interventions in a more nuanced manner, alongside the role of vascular health.</p></sec></sec></body><back><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>EA: Writing &#8211; original draft, Visualization, Writing &#8211; review and editing, Methodology, Project administration, Conceptualization. AB: Writing &#8211; review and editing, Writing &#8211; original draft, Methodology. AR: Methodology, Writing &#8211; original draft, Writing &#8211; review and editing. VM: Visualization, Writing &#8211; review and editing. JW: Conceptualization, Methodology, Writing &#8211; original draft, Writing &#8211; review and editing. JH: Writing &#8211; original draft, Methodology, Conceptualization, Writing &#8211; review and editing. BA-K: Writing &#8211; review and editing, Conceptualization, Funding acquisition, Supervision, Methodology, Writing &#8211; original draft.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s10"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Kareem</surname><given-names>O.</given-names></name><name name-style="western"><surname>Khushtar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Akbar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haque</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Iqubal</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Neuroinflammation: a potential risk for dementia</article-title>. <source>Int. J. Mol. Sci.</source><volume>23</volume> (<issue>2</issue>), <fpage>616</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23020616</pub-id><pub-id pub-id-type="pmid">35054805</pub-id><pub-id pub-id-type="pmcid">PMC8775769</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alavi Naini</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Soussi-Yanicostas</surname><given-names>N.</given-names></name></person-group> (<year>2015</year>). <article-title>Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies?</article-title><source>Oxidative Med. Cell. Longev.</source><volume>2015</volume> (<issue>1</issue>), <fpage>151979</fpage>. <pub-id pub-id-type="doi">10.1155/2015/151979</pub-id><pub-id pub-id-type="pmid">26576216</pub-id><pub-id pub-id-type="pmcid">PMC4630413</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allison</surname><given-names>E. Y.</given-names></name><name name-style="western"><surname>Al-Khazraji</surname><given-names>B. K.</given-names></name></person-group> (<year>2024a</year>). <article-title>Association of arterial stiffness index and brain structure in the UK biobank: a 10-year retrospective analysis</article-title>. <source>Aging Dis.</source><volume>15</volume> (<issue>4</issue>), <fpage>1872</fpage>&#8211;<lpage>1884</lpage>. <pub-id pub-id-type="doi">10.14336/AD.2023.0419</pub-id><pub-id pub-id-type="pmid">37307821</pub-id><pub-id pub-id-type="pmcid">PMC11272205</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allison</surname><given-names>E. Y.</given-names></name><name name-style="western"><surname>Al-Khazraji</surname><given-names>B. K.</given-names></name></person-group> (<year>2024b</year>). <article-title>Cerebrovascular adaptations to habitual resistance exercise with aging</article-title>. <source>Am. J. Physiology-Heart Circulatory Physiology</source><volume>326</volume> (<issue>3</issue>), <fpage>H772</fpage>&#8211;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.00625.2023</pub-id><pub-id pub-id-type="pmid">38214906</pub-id><pub-id pub-id-type="pmcid">PMC11221804</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alty</surname><given-names>J.</given-names></name><name name-style="western"><surname>Farrow</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lawler</surname><given-names>K.</given-names></name></person-group> (<year>2020</year>). <article-title>Exercise and dementia prevention</article-title>. <source>Pract. Neurol.</source><volume>20</volume> (<issue>3</issue>), <fpage>234</fpage>&#8211;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1136/practneurol-2019-002335</pub-id><pub-id pub-id-type="pmid">31964800</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alwatban</surname><given-names>M.</given-names></name><name name-style="western"><surname>Murman</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Bashford</surname><given-names>G.</given-names></name></person-group> (<year>2019</year>). <article-title>Cerebrovascular reactivity impairment in preclinical alzheimer&#8217;s disease</article-title>. <source>J. Neuroimaging</source><volume>29</volume> (<issue>4</issue>), <fpage>493</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/jon.12606</pub-id><pub-id pub-id-type="pmid">30748053</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alwatban</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Aaron</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>J. N.</given-names></name><name name-style="western"><surname>Brassard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>J. L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Effects of age and sex on middle cerebral artery blood velocity and flow pulsatility index across the adult lifespan</article-title>. <source>J. Appl. Physiol.</source><volume>130</volume> (<issue>6</issue>), <fpage>1675</fpage>&#8211;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1152/japplphysiol.00926.2020</pub-id><pub-id pub-id-type="pmid">33703940</pub-id><pub-id pub-id-type="pmcid">PMC8285608</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><collab>Alzheimer&#8217;s Association</collab> (<year>2019</year>). <article-title>Alzheimer&#8217;s disease facts and figures</article-title>. <source>Alzheimer&#8217;s and dementia</source><volume>15</volume> (<issue>3</issue>), <fpage>321</fpage>&#8211;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1016/j.jalz.2019.01.010</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amasene</surname><given-names>M.</given-names></name><name name-style="western"><surname>Besga</surname><given-names>A.</given-names></name><name name-style="western"><surname>Echeverria</surname><given-names>I.</given-names></name><name name-style="western"><surname>Urquiza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Rodriguez-Larrad</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Effects of leucine-enriched whey protein supplementation on physical function in post-hospitalized older adults participating in 12-Weeks of resistance training program: a randomized controlled trial</article-title>. <source>Nutrients</source><volume>11</volume> (<issue>10</issue>), <fpage>2337</fpage>. <pub-id pub-id-type="doi">10.3390/nu11102337</pub-id><pub-id pub-id-type="pmid">31581591</pub-id><pub-id pub-id-type="pmcid">PMC6835698</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anazodo</surname><given-names>U. C.</given-names></name><name name-style="western"><surname>Shoemaker</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Suskin</surname><given-names>N.</given-names></name><name name-style="western"><surname>St. Lawrence</surname><given-names>K. S.</given-names></name></person-group> (<year>2013</year>). <article-title>An investigation of changes in regional gray matter volume in cardiovascular disease patients, pre and post cardiovascular rehabilitation</article-title>. <source>NeuroImage Clin.</source><volume>3</volume>, <fpage>388</fpage>&#8211;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/j.nicl.2013.09.011</pub-id><pub-id pub-id-type="pmid">24273722</pub-id><pub-id pub-id-type="pmcid">PMC3814972</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>&#197;berg</surname><given-names>M. A. I.</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eriksson</surname><given-names>P. S.</given-names></name></person-group> (<year>2002</year>). <article-title>Insulin-like growth factor-I and neurogenesis in the adult mammalian brain</article-title>. <source>Dev. Brain Res.</source><volume>134</volume> (<issue>1&#8211;2</issue>), <fpage>115</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/s0165-3806(02)00277-8</pub-id><pub-id pub-id-type="pmid">11947942</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashton</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Tew</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Aning</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Saxton</surname><given-names>J. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Effects of short-term, medium-term and long-term resistance exercise training on cardiometabolic health outcomes in adults: systematic review with meta-analysis</article-title>. <source>Br. J. sports Med.</source><volume>54</volume> (<issue>6</issue>), <fpage>341</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1136/bjsports-2017-098970</pub-id><pub-id pub-id-type="pmid">29934430</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badji</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sabra</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bherer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cohen-Adad</surname><given-names>J.</given-names></name><name name-style="western"><surname>Girouard</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>C. J.</given-names></name></person-group> (<year>2019</year>). <article-title>Arterial stiffness and brain integrity: a review of MRI findings</article-title>. <source>Ageing Res. Rev.</source><volume>53</volume>, <fpage>100907</fpage>. <pub-id pub-id-type="doi">10.1016/j.arr.2019.05.001</pub-id><pub-id pub-id-type="pmid">31063866</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baek</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Hyeon</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>H. young</given-names></name><name name-style="western"><surname>Hahm</surname><given-names>S. C.</given-names></name></person-group> (<year>2024</year>). <article-title>Effects of dual-task resistance exercise on cognition, mood, depression, functional fitness, and activities of daily living in older adults with cognitive impairment: a single-blinded, randomized controlled trial</article-title>. <source>BMC Geriatr.</source><volume>24</volume> (<issue>1</issue>), <fpage>369</fpage>. <pub-id pub-id-type="doi">10.1186/s12877-024-04942-1</pub-id><pub-id pub-id-type="pmid">38658827</pub-id><pub-id pub-id-type="pmcid">PMC11044356</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>L. L.</given-names></name><name name-style="western"><surname>Foster-Schubert</surname><given-names>K.</given-names></name><name name-style="western"><surname>Green</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>C. W.</given-names></name><name name-style="western"><surname>McTiernan</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer&#8217;s disease</article-title>. <source>J. Alzheimer&#8217;s Dis.</source><volume>22</volume> (<issue>2</issue>), <fpage>569</fpage>&#8211;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-2010-100768</pub-id><pub-id pub-id-type="pmid">20847403</pub-id><pub-id pub-id-type="pmcid">PMC3049111</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bang</surname><given-names>H. S.</given-names></name></person-group> (<year>2023</year>). <article-title>Effect of resistance training with different set structures on neurotrophic factors and obesity-related biomarkers in middle-aged Korean women with obesity</article-title>. <source>J. Clin. Med.</source><volume>12</volume> (<issue>9</issue>), <fpage>3135</fpage>. <pub-id pub-id-type="doi">10.3390/jcm12093135</pub-id><pub-id pub-id-type="pmid">37176576</pub-id><pub-id pub-id-type="pmcid">PMC10179607</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartsch</surname><given-names>T.</given-names></name><name name-style="western"><surname>D&#246;hring</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rohr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Deuschl</surname><given-names>G.</given-names></name></person-group> (<year>2011</year>). <article-title>CA1 neurons in the human hippocampus are critical for autobiographical memory, mental time travel, and autonoetic consciousness</article-title>. <source>Proc. Natl. Acad. Sci.</source><volume>108</volume> (<issue>42</issue>), <fpage>17562</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1110266108</pub-id><pub-id pub-id-type="pmid">21987814</pub-id><pub-id pub-id-type="pmcid">PMC3198338</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baset</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fengwen</surname><given-names>H.</given-names></name></person-group> (<year>2024</year>). <article-title>Shedding light on subiculum&#8217;s role in human brain disorders</article-title>. <source>Brain Res. Bull.</source><volume>214</volume>, <fpage>110993</fpage>. <pub-id pub-id-type="doi">10.1016/j.brainresbull.2024.110993</pub-id><pub-id pub-id-type="pmid">38825254</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batman</surname><given-names>G. B.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Traylor</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Ransom</surname><given-names>K. V.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>E. C.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>B. D.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Various modalities of resistance exercise promote similar acute cognitive improvements and hemodynamic increases in young, healthy adults</article-title>. <source>Cereb. Circulation - Cognition Behav.</source><volume>7</volume>, <fpage>100363</fpage>. <pub-id pub-id-type="doi">10.1016/j.cccb.2024.100363</pub-id><pub-id pub-id-type="pmid">39252851</pub-id><pub-id pub-id-type="pmcid">PMC11381452</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berbert-Gomes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Silveira-Rodrigues</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Leite</surname><given-names>D. M. M.</given-names></name><name name-style="western"><surname>Melo</surname><given-names>B. P.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>D. D.</given-names></name></person-group> (<year>2024</year>). <article-title>An acute bout of resistance exercise increases BDNF in hippocampus and restores the long-term memory of insulin-resistant rats</article-title>. <source>Exp. Brain Res.</source><volume>242</volume> (<issue>4</issue>), <fpage>901</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1007/s00221-024-06795-x</pub-id><pub-id pub-id-type="pmid">38453752</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Best</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>B. K.</given-names></name><name name-style="western"><surname>Liang Hsu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nagamatsu</surname><given-names>L. S.</given-names></name><name name-style="western"><surname>Liu-Ambrose</surname><given-names>T.</given-names></name></person-group> (<year>2015</year>). <article-title>Long-Term effects of resistance exercise training on cognition and brain volume in older women: results from a randomized controlled trial</article-title>. <source>J. Int. Neuropsychological Soc.</source><volume>21</volume> (<issue>10</issue>), <fpage>745</fpage>&#8211;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1017/S1355617715000673</pub-id><pub-id pub-id-type="pmid">26581787</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Billinger</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Arena</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bernhardt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eng</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Franklin</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>C. M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Physical activity and exercise recommendations for stroke survivors: a statement for healthcare professionals from the American Heart association/American stroke association</article-title>. <source>Stroke</source><volume>45</volume> (<issue>8</issue>), <fpage>2532</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1161/STR.0000000000000022</pub-id><pub-id pub-id-type="pmid">24846875</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bliss</surname><given-names>E. S.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>R. H. X.</given-names></name><name name-style="western"><surname>Howe</surname><given-names>P. R. C.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>D. E.</given-names></name></person-group> (<year>2021</year>). <article-title>Benefits of exercise training on cerebrovascular and cognitive function in ageing</article-title>. <source>J. Cereb. Blood Flow. Metab.</source><volume>41</volume> (<issue>3</issue>), <fpage>447</fpage>&#8211;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1177/0271678X20957807</pub-id><pub-id pub-id-type="pmid">32954902</pub-id><pub-id pub-id-type="pmcid">PMC7907999</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolandzadeh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>R.</given-names></name><name name-style="western"><surname>Handy</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Nagamatsu</surname><given-names>L. S.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J. C.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Resistance training and white matter lesion progression in older women: exploratory analysis of a 12-Month randomized controlled trial</article-title>. <source>J. Am. Geriatrics Soc.</source><volume>63</volume> (<issue>10</issue>), <fpage>2052</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1111/jgs.13644</pub-id><pub-id pub-id-type="pmid">26456233</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolduc</surname><given-names>V.</given-names></name><name name-style="western"><surname>Thorin-Trescases</surname><given-names>N.</given-names></name><name name-style="western"><surname>Thorin</surname><given-names>E.</given-names></name></person-group> (<year>2013</year>). <article-title>Endothelium-dependent control of cerebrovascular functions through age: exercise for healthy cerebrovascular aging</article-title>. <source>Am. J. Physiology-Heart Circulatory Physiology</source><volume>305</volume> (<issue>5</issue>), <fpage>H620</fpage>&#8211;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.00624.2012</pub-id><pub-id pub-id-type="pmid">23792680</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bown</surname><given-names>C. W.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>O. A.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>E. E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pechman</surname><given-names>K. R.</given-names></name><name name-style="western"><surname>Cambronero</surname><given-names>F. E.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Elevated aortic pulse wave velocity relates to longitudinal gray and white matter changes</article-title>. <source>Arteriosclerosis, Thrombosis, Vasc. Biol.</source><volume>41</volume> (<issue>12</issue>), <fpage>3015</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.121.316477</pub-id><pub-id pub-id-type="pmid">34706559</pub-id><pub-id pub-id-type="pmcid">PMC8627676</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyle</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Buchman</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Leurgans</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D. A.</given-names></name></person-group> (<year>2009</year>). <article-title>Association of muscle strength with the risk of alzheimer disease and the rate of cognitive decline in community-dwelling older persons</article-title>. <source>Archives Neurology</source><volume>66</volume> (<issue>11</issue>), <fpage>1339</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1001/archneurol.2009.240</pub-id><pub-id pub-id-type="pmid">19901164</pub-id><pub-id pub-id-type="pmcid">PMC2838435</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brain</surname><given-names>J.</given-names></name><name name-style="western"><surname>Greene</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>E. Y. H.</given-names></name><name name-style="western"><surname>Louise</surname><given-names>J.</given-names></name><name name-style="western"><surname>Salter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Beach</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Cardiovascular disease, associated risk factors, and risk of dementia: an umbrella review of meta-analyses</article-title>. <source>Front. Epidemiol.</source><volume>3</volume>, <fpage>1095236</fpage>. <pub-id pub-id-type="doi">10.3389/fepid.2023.1095236</pub-id><pub-id pub-id-type="pmid">38455934</pub-id><pub-id pub-id-type="pmcid">PMC10910908</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broadhouse</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Suo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gates</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Brodaty</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Hippocampal plasticity underpins long-term cognitive gains from resistance exercise in MCI</article-title>. <source>NeuroImage Clin.</source><volume>25</volume>, <fpage>102182</fpage>. <pub-id pub-id-type="doi">10.1016/j.nicl.2020.102182</pub-id><pub-id pub-id-type="pmid">31978826</pub-id><pub-id pub-id-type="pmcid">PMC6974789</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bucci</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iozzo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Merisaari</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huovinen</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lipponen</surname><given-names>H.</given-names></name><name name-style="western"><surname>R&#228;ikk&#246;nen</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Resistance training increases white matter density in frail elderly women</article-title>. <source>J. Clin. Med.</source><volume>12</volume> (<issue>7</issue>), <fpage>2684</fpage>. <pub-id pub-id-type="doi">10.3390/jcm12072684</pub-id><pub-id pub-id-type="pmid">37048767</pub-id><pub-id pub-id-type="pmcid">PMC10094827</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name></person-group> (<year>2023</year>). <article-title>Does muscle strength predict working memory? A cross-sectional fNIRS study in older adults</article-title>. <source>Front. Aging Neurosci.</source><volume>15</volume>, <fpage>1243283</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2023.1243283</pub-id><pub-id pub-id-type="pmid">37876877</pub-id><pub-id pub-id-type="pmcid">PMC10590893</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calles-Escandon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cipolla</surname><given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>Diabetes and endothelial dysfunction: a clinical perspective</article-title>. <source>Endocr. Rev.</source><volume>22</volume> (<issue>1</issue>), <fpage>36</fpage>&#8211;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1210/edrv.22.1.0417</pub-id><pub-id pub-id-type="pmid">11159815</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campos</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Hashiguchi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Glaser</surname><given-names>T.</given-names></name><name name-style="western"><surname>Milanis</surname><given-names>M. da S.</given-names></name><name name-style="western"><surname>Gimenes</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Neuroprotective effects of resistance physical exercise on the APP/PS1 mouse model of Alzheimer&#8217;s disease</article-title>. <source>Front. Neurosci.</source>, <fpage>17</fpage>&#8211;<lpage>2023</lpage>. <pub-id pub-id-type="doi">10.3389/fnins.2023.1132825</pub-id><pub-id pub-id-type="pmid">37090809</pub-id><pub-id pub-id-type="pmcid">PMC10116002</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cantelon</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Giles</surname><given-names>G. E.</given-names></name></person-group> (<year>2021</year>). <article-title>A review of cognitive changes during acute aerobic exercise</article-title>. <source>Front. Psychol.</source><volume>12</volume>, <fpage>653158</fpage>. <pub-id pub-id-type="doi">10.3389/fpsyg.2021.653158</pub-id><pub-id pub-id-type="pmid">34975602</pub-id><pub-id pub-id-type="pmcid">PMC8716584</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carey</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nagpal</surname><given-names>A.</given-names></name></person-group> (<year>2005</year>). <article-title>Neuroplasticity promoted by task complexity</article-title>. <source>Exerc. sport Sci. Rev.</source><volume>33</volume> (<issue>1</issue>), <fpage>24</fpage>&#8211;<lpage>31</lpage>.
<pub-id pub-id-type="pmid">15640717</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carro</surname><given-names>E.</given-names></name><name name-style="western"><surname>Trejo</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Gomez-Isla</surname><given-names>T.</given-names></name><name name-style="western"><surname>LeRoith</surname><given-names>D.</given-names></name><name name-style="western"><surname>Torres-Aleman</surname><given-names>I.</given-names></name></person-group> (<year>2002</year>). <article-title>Serum insulin-like growth factor I regulates brain amyloid-&#946; levels</article-title>. <source>Nat. Med.</source><volume>8</volume> (<issue>12</issue>), <fpage>1390</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nm1202-793</pub-id><pub-id pub-id-type="pmid">12415260</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Riek</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carson</surname><given-names>R. G.</given-names></name></person-group> (<year>2001</year>). <article-title>Neural adaptations to resistance training: implications for movement control</article-title>. <source>Sports Med.</source><volume>31</volume>, <fpage>829</fpage>&#8211;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.2165/00007256-200131120-00001</pub-id><pub-id pub-id-type="pmid">11665911</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassatella</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Meda</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bonora</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ceska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Constantin</surname><given-names>G.</given-names></name></person-group> (<year>1993</year>). <article-title>Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide</article-title>. <source>J. Exp. Med.</source><volume>178</volume> (<issue>6</issue>), <fpage>2207</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1084/jem.178.6.2207</pub-id><pub-id pub-id-type="pmid">8245792</pub-id><pub-id pub-id-type="pmcid">PMC2191270</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassilhas</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Viana</surname><given-names>V. A.</given-names></name><name name-style="western"><surname>Grassmann</surname><given-names>V.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>R. T.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>R. F.</given-names></name><name name-style="western"><surname>Tufik</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>The impact of resistance exercise on the cognitive function of the elderly</article-title>. <source>Med. and Sci. Sports and Exerc.</source><volume>39</volume> (<issue>8</issue>), <fpage>1401</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1249/mss.0b013e318060111f</pub-id><pub-id pub-id-type="pmid">17762374</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassilhas</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>M. G. M. de</given-names></name><name name-style="western"><surname>Tufik</surname><given-names>S.</given-names></name><name name-style="western"><surname>Meeusen</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Spatial memory is improved by aerobic and resistance exercise through divergent molecular mechanisms</article-title>. <source>Neuroscience</source><volume>202</volume>, <fpage>309</fpage>&#8211;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2011.11.029</pub-id><pub-id pub-id-type="pmid">22155655</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>Y. K.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F. T.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C. C.</given-names></name></person-group> (<year>2012</year>). <article-title>Effect of resistance-exercise training on cognitive function in healthy older adults: a review</article-title>. <source>J. Aging Phys. Activity</source><volume>20</volume> (<issue>4</issue>), <fpage>497</fpage>&#8211;<lpage>517</lpage>. <pub-id pub-id-type="doi">10.1123/japa.20.4.497</pub-id><pub-id pub-id-type="pmid">22186664</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheignon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tomas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bonnefont-Rousselot</surname><given-names>D.</given-names></name><name name-style="western"><surname>Faller</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hureau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Collin</surname><given-names>F.</given-names></name></person-group> (<year>2018</year>). <article-title>Oxidative stress and the amyloid beta peptide in Alzheimer&#8217;s disease</article-title>. <source>Redox Biol.</source><volume>14</volume>, <fpage>450</fpage>&#8211;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2017.10.014</pub-id><pub-id pub-id-type="pmid">29080524</pub-id><pub-id pub-id-type="pmcid">PMC5680523</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Bonham</surname><given-names>A. C.</given-names></name></person-group> (<year>2010</year>). <article-title>Postexercise hypotension: central mechanisms</article-title>. <source>Exerc. Sport Sci. Rev.</source><volume>38</volume> (<issue>3</issue>), <fpage>122</fpage>&#8211;<lpage>127</lpage>. <pub-id pub-id-type="doi">10.1097/JES.0b013e3181e372b5</pub-id><pub-id pub-id-type="pmid">20577060</pub-id><pub-id pub-id-type="pmcid">PMC2936915</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Rosas</surname><given-names>H. D.</given-names></name><name name-style="western"><surname>Salat</surname><given-names>D. H.</given-names></name></person-group> (<year>2011</year>). <article-title>Age-associated reductions in cerebral blood flow are independent from regional atrophy</article-title>. <source>NeuroImage.</source><volume>55</volume> (<issue>2</issue>), <fpage>468</fpage>&#8211;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.12.032</pub-id><pub-id pub-id-type="pmid">21167947</pub-id><pub-id pub-id-type="pmcid">PMC3435846</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Reduced cerebral glucose uptake in an Alzheimer&#8217;s rat model with glucose-weighted chemical exchange saturation transfer imaging</article-title>. <source>Front. Aging Neurosci.</source><volume>13</volume>, <fpage>618690</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2021.618690</pub-id><pub-id pub-id-type="pmid">33815088</pub-id><pub-id pub-id-type="pmcid">PMC8010663</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name></person-group> (<year>2022</year>). <article-title>The physiological mechanism and effect of resistance exercise on cognitive function in the elderly people</article-title>. <source>Front. public health</source><volume>10</volume> (<issue>101616579</issue>), <fpage>1013734</fpage>. <pub-id pub-id-type="doi">10.3389/fpubh.2022.1013734</pub-id><pub-id pub-id-type="pmid">36483263</pub-id><pub-id pub-id-type="pmcid">PMC9723356</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Roh</surname><given-names>H. T.</given-names></name></person-group> (<year>2022</year>). <article-title>Effects of exercise training on neurotrophic factors and blood&#8211;brain barrier permeability in young-old and old-old women</article-title>. <source>Int. J. Environ. Res. Public Health</source><volume>19</volume> (<issue>24</issue>), <fpage>16896</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph192416896</pub-id><pub-id pub-id-type="pmid">36554777</pub-id><pub-id pub-id-type="pmcid">PMC9778715</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H. Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P. N.</given-names></name></person-group> (<year>2017</year>). <article-title>Cerebral artery pulsatility is associated with cognitive impairment and predicts dementia in individuals with subjective memory decline or mild cognitive impairment</article-title>. <source>J. Alzheimer&#8217;s Dis.</source><volume>60</volume> (<issue>2</issue>), <fpage>625</fpage>&#8211;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-170349</pub-id><pub-id pub-id-type="pmid">28826186</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chupel</surname><given-names>M. U.</given-names></name><name name-style="western"><surname>Direito</surname><given-names>F.</given-names></name><name name-style="western"><surname>Furtado</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>Minuzzi</surname><given-names>L. G.</given-names></name><name name-style="western"><surname>Pedrosa</surname><given-names>F. M.</given-names></name><name name-style="western"><surname>Colado</surname><given-names>J. C.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Strength training decreases inflammation and increases cognition and physical fitness in older women with cognitive impairment</article-title>. <source>Front. physiology</source><volume>8</volume>, <fpage>377</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2017.00377</pub-id><pub-id pub-id-type="pmid">28659812</pub-id><pub-id pub-id-type="pmcid">PMC5467003</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Church</surname><given-names>D. D.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Mangine</surname><given-names>G. T.</given-names></name><name name-style="western"><surname>Jajtner</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Townsend</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Beyer</surname><given-names>K. S.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Comparison of high-intensity vs. high-volume resistance training on the BDNF response to exercise</article-title>. <source>J. Appl. Physiology</source><volume>121</volume> (<issue>1</issue>), <fpage>123</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1152/japplphysiol.00233.2016</pub-id><pub-id pub-id-type="pmid">27231312</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cirulli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Berry</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chiarotti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Alleva</surname><given-names>E.</given-names></name></person-group> (<year>2004</year>). <article-title>Intrahippocampal administration of BDNF in adult rats affects short-term behavioral plasticity in the morris water maze and performance in the elevated plus-maze</article-title>. <source>Hippocampus</source><volume>14</volume> (<issue>7</issue>), <fpage>802</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/hipo.10220</pub-id><pub-id pub-id-type="pmid">15382250</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Claassen</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name></person-group> (<year>2011</year>). <article-title>Cerebral autoregulation in Alzheimer&#8217;s disease</article-title>. <source>J. Cereb. Blood Flow and Metabolism</source><volume>31</volume> (<issue>7</issue>), <fpage>1572</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2011.69</pub-id><pub-id pub-id-type="pmid">21540872</pub-id><pub-id pub-id-type="pmcid">PMC3137479</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Claassen</surname><given-names>JAHR</given-names></name><name name-style="western"><surname>Thijssen</surname><given-names>D. H. J.</given-names></name><name name-style="western"><surname>Panerai</surname><given-names>R. B.</given-names></name><name name-style="western"><surname>Faraci</surname><given-names>F. M.</given-names></name></person-group> (<year>2021</year>). <article-title>Regulation of cerebral blood flow in humans: physiology and clinical implications of autoregulation</article-title>. <source>Physiol. Rev.</source><volume>101</volume> (<issue>4</issue>), <fpage>1487</fpage>&#8211;<lpage>559</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00022.2020</pub-id><pub-id pub-id-type="pmid">33769101</pub-id><pub-id pub-id-type="pmcid">PMC8576366</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coelho</surname><given-names>F. M.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Lustosa</surname><given-names>L. P.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>J. M. D.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>R. C. D.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Physical therapy intervention (PTI) increases plasma brain-derived neurotrophic factor (BDNF) levels in non-frail and pre-frail elderly women</article-title>. <source>Archives gerontology geriatrics</source><volume>54</volume> (<issue>3</issue>), <fpage>415</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.archger.2011.05.014</pub-id><pub-id pub-id-type="pmid">21684022</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coelho-J&#250;nior</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>M. C.</given-names></name></person-group> (<year>2021</year>). <article-title>Effects of low-speed and high-speed resistance training programs on frailty status, physical performance, cognitive function, and blood pressure in prefrail and frail older adults</article-title>. <source>Front. Med.</source><volume>8</volume>, <fpage>702436</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2021.702436</pub-id><pub-id pub-id-type="pmid">34381802</pub-id><pub-id pub-id-type="pmcid">PMC8350041</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coelho-J&#250;nior</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Oliveira Gon&#231;alves</surname><given-names>I. D.</given-names></name><name name-style="western"><surname>Sampaio</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Sampaio</surname><given-names>P. Y.</given-names></name><name name-style="western"><surname>Lusa Cadore</surname><given-names>E.</given-names></name><name name-style="western"><surname>Calvani</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Effects of combined resistance and power training on cognitive function in older women: a randomized controlled trial</article-title>. <source>Int. J. Environ. Res. Public Health</source><volume>17</volume> (<issue>10</issue>), <fpage>3435</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph17103435</pub-id><pub-id pub-id-type="pmid">32423126</pub-id><pub-id pub-id-type="pmcid">PMC7277751</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coelho-Junior</surname><given-names>H.</given-names></name><name name-style="western"><surname>Marzetti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Calvani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Picca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>M.</given-names></name></person-group> (<year>2022</year>). <article-title>Resistance training improves cognitive function in older adults with different cognitive status: a systematic review and meta-analysis</article-title>. <source>Aging and Ment. Health</source><volume>26</volume> (<issue>2</issue>), <fpage>213</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1080/13607863.2020.1857691</pub-id><pub-id pub-id-type="pmid">33325273</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colcombe</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Erickson</surname><given-names>K. I.</given-names></name><name name-style="western"><surname>Raz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Webb</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>N. J.</given-names></name><name name-style="western"><surname>McAuley</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Aerobic fitness reduces brain tissue loss in aging humans</article-title>. <source>Journals Gerontology Ser. A Biol. Sci. Med. Sci.</source><volume>58</volume> (<issue>2</issue>), <fpage>M176</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1093/gerona/58.2.m176</pub-id><pub-id pub-id-type="pmid">12586857</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coletta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Noguchi</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Beaudoin</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>McQuarrie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>A live online exercise program for older adults improves depression and life-space mobility: a mixed-methods pilot randomized controlled trial</article-title>. <source>PLOS ONE</source><volume>19</volume> (<issue>11</issue>), <fpage>e0312992</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0312992</pub-id><pub-id pub-id-type="pmid">39527532</pub-id><pub-id pub-id-type="pmcid">PMC11554215</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Compton</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Sinclair</surname><given-names>J. D.</given-names></name></person-group> (<year>1973</year>). <article-title>WEIGHT-LIFTERS&#8217; BLACKOUT</article-title>. <source>Lancet</source><volume>302</volume> (<issue>7840</issue>), <fpage>1234</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(73)90974-4</pub-id><pub-id pub-id-type="pmid">4128562</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Correia</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Pansani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Machado</surname><given-names>F.</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>M.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Scorza</surname><given-names>F. A.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Acute strength exercise and the involvement of small or large muscle mass on plasma brain-derived neurotrophic factor levels</article-title>. <source>Clinics</source><volume>65</volume> (<issue>11</issue>), <fpage>1123</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1590/s1807-59322010001100012</pub-id><pub-id pub-id-type="pmid">21243284</pub-id><pub-id pub-id-type="pmcid">PMC2999707</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Correia</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Veras</surname><given-names>A. S. C.</given-names></name><name name-style="western"><surname>Tebar</surname><given-names>W. R.</given-names></name><name name-style="western"><surname>Rufino</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Batista</surname><given-names>V. R. G.</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>G. R.</given-names></name></person-group> (<year>2023</year>). <article-title>Strength training for arterial hypertension treatment: a systematic review and meta-analysis of randomized clinical trials</article-title>. <source>Sci. Rep.</source><volume>13</volume> (<issue>1</issue>), <fpage>201</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-022-26583-3</pub-id><pub-id pub-id-type="pmid">36604479</pub-id><pub-id pub-id-type="pmcid">PMC9814600</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cortez-Cooper</surname><given-names>M. Y.</given-names></name><name name-style="western"><surname>Anton</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Devan</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Neidre</surname><given-names>D. B.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>J. N.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>H.</given-names></name></person-group> (<year>2008</year>). <article-title>The effects of strength training on central arterial compliance in middle-aged and older adults</article-title>. <source>Eur. J. Cardiovasc Prev. Rehabil.</source><volume>15</volume> (<issue>2</issue>), <fpage>149</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1097/HJR.0b013e3282f02fe2</pub-id><pub-id pub-id-type="pmid">18391640</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crockett</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Dao</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>R.</given-names></name><name name-style="western"><surname>Eng</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Handy</surname><given-names>T. C.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Weight for it: resistance training mitigates white matter hyperintensity-related disruption to functional networks in older females</article-title>. <source>J. Alzheimer&#8217;s Dis.</source><volume>90</volume> (<issue>2</issue>), <fpage>553</fpage>&#8211;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-220142</pub-id><pub-id pub-id-type="pmid">36155502</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dalle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rossmeislova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Koppo</surname><given-names>K.</given-names></name></person-group> (<year>2017</year>). <article-title>The role of inflammation in age-related sarcopenia</article-title>. <source>Front. physiology</source><volume>8</volume>, <fpage>1045</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2017.01045</pub-id><pub-id pub-id-type="pmid">29311975</pub-id><pub-id pub-id-type="pmcid">PMC5733049</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Bryan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marra</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Beattie</surname><given-names>B. L.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>An economic evaluation of resistance training and aerobic training <italic toggle="yes">versus</italic> balance and toning exercises in older adults with mild cognitive impairment</article-title>. <source>PLOS ONE</source><volume>8</volume> (<issue>5</issue>), <fpage>e63031</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0063031</pub-id><pub-id pub-id-type="pmid">23690976</pub-id><pub-id pub-id-type="pmcid">PMC3653911</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Boer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gaillard</surname><given-names>P.</given-names></name></person-group> (<year>2006</year>). <article-title>Blood&#8211;brain barrier dysfunction and recovery</article-title>. <source>J. Neural Transm.</source><volume>113</volume>, <fpage>455</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1007/s00702-005-0375-4</pub-id><pub-id pub-id-type="pmid">16550324</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Heus</surname><given-names>R. A. A.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>D. L. K.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>van Spijker</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Oudegeest-Sander</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Hopman</surname><given-names>M. T.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Dynamic regulation of cerebral blood flow in patients with alzheimer disease</article-title>. <source>Hypertension</source><volume>72</volume> (<issue>1</issue>), <fpage>139</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.118.10900</pub-id><pub-id pub-id-type="pmid">29844143</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Jong</surname><given-names>D. L. K.</given-names></name><name name-style="western"><surname>de Heus</surname><given-names>R. A. A.</given-names></name><name name-style="western"><surname>Rijpma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Donders</surname><given-names>R.</given-names></name><name name-style="western"><surname>Olde Rikkert</surname><given-names>M. G. M.</given-names></name><name name-style="western"><surname>G&#252;nther</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Effects of nilvadipine on cerebral blood flow in patients with alzheimer disease</article-title>. <source>Hypertension</source><volume>74</volume> (<issue>2</issue>), <fpage>413</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.119.12892</pub-id><pub-id pub-id-type="pmid">31203725</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Jong</surname><given-names>JCBC</given-names></name><name name-style="western"><surname>Attema</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>van der Hoek</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Verschuren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Caspers</surname><given-names>M. P. M.</given-names></name><name name-style="western"><surname>Kleemann</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Sex differences in skeletal muscle-aging trajectory: same processes, but with a different ranking</article-title>. <source>GeroScience</source><volume>45</volume> (<issue>4</issue>), <fpage>2367</fpage>&#8211;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1007/s11357-023-00750-4</pub-id><pub-id pub-id-type="pmid">36820956</pub-id><pub-id pub-id-type="pmcid">PMC10651666</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Montgolfier</surname><given-names>O.</given-names></name><name name-style="western"><surname>Pin&#231;on</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pouliot</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gillis</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sled</surname><given-names>J. G.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>High systolic blood pressure induces cerebral microvascular endothelial dysfunction, neurovascular unit damage, and cognitive decline in mice</article-title>. <source>Hypertension</source><volume>73</volume> (<issue>1</issue>), <fpage>217</fpage>&#8211;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.118.12048</pub-id><pub-id pub-id-type="pmid">30571552</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Oliveira Silva</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>J. V.</given-names></name><name name-style="western"><surname>Pl&#225;cido</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sant&#8217;Anna</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ara&#250;jo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marinho</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Three months of multimodal training contributes to mobility and executive function in elderly individuals with mild cognitive impairment, but not in those with Alzheimer&#8217;s disease: a randomized controlled trial</article-title>. <source>Maturitas</source><volume>126</volume>, <fpage>28</fpage>&#8211;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.maturitas.2019.04.217</pub-id><pub-id pub-id-type="pmid">31239114</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De S&#225; Souza</surname><given-names>H.</given-names></name><name name-style="western"><surname>de Melo</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Piovezan</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Miranda</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Carneiro-Junior</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>B. M.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Resistance training improves sleep and anti-inflammatory parameters in sarcopenic older adults: a randomized controlled trial</article-title>. <source>Int. J. Environ. Res. Public Health</source><volume>19</volume> (<issue>23</issue>), <fpage>16322</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph192316322</pub-id><pub-id pub-id-type="pmid">36498393</pub-id><pub-id pub-id-type="pmcid">PMC9736460</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Sousa</surname><given-names>C. V.</given-names></name><name name-style="western"><surname>Sales</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>T. S.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>de Andrade</surname><given-names>R. V.</given-names></name><name name-style="western"><surname>Sim&#245;es</surname><given-names>H. G.</given-names></name></person-group> (<year>2017</year>). <article-title>The antioxidant effect of exercise: a systematic review and meta-analysis</article-title>. <source>Sports Med.</source><volume>47</volume>, <fpage>277</fpage>&#8211;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1007/s40279-016-0566-1</pub-id><pub-id pub-id-type="pmid">27260682</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Souza Nery</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gomides</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>G. V. da</given-names></name><name name-style="western"><surname>de Moraes Forjaz</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Mion</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tinucci</surname><given-names>T.</given-names></name></person-group> (<year>2010</year>). <article-title>Intra-Arterial blood pressure response in hypertensive subjects during Low- and high-intensity resistance exercise</article-title>. <source>Clinics</source><volume>65</volume> (<issue>3</issue>), <fpage>271</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1590/S1807-59322010000300006</pub-id><pub-id pub-id-type="pmid">20360917</pub-id><pub-id pub-id-type="pmcid">PMC2845767</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desgranges</surname><given-names>B.</given-names></name><name name-style="western"><surname>Baron</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>de la Sayette</surname><given-names>V.</given-names></name><name name-style="western"><surname>Petit-Tabou&#233;</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Benali</surname><given-names>K.</given-names></name><name name-style="western"><surname>Landeau</surname><given-names>B.</given-names></name><etal/></person-group> (<year>1998</year>). <article-title>The neural substrates of memory systems impairment in Alzheimer&#8217;s disease. A PET study of resting brain glucose utilization</article-title>. <source>Brain a J. neurology</source><volume>121</volume> (<issue>4</issue>), <fpage>611</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1093/brain/121.4.611</pub-id><pub-id pub-id-type="pmid">9577389</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dicks</surname><given-names>E.</given-names></name><name name-style="western"><surname>van der Flier</surname><given-names>W. M.</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tijms</surname><given-names>B. M.</given-names></name></person-group><collab>Alzheimer's Disease Neuroimaging Initiative</collab> (<year>2020</year>). <article-title>Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease</article-title>. <source>Neurobiol. Aging</source><volume>94</volume>, <fpage>71</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2020.05.008</pub-id><pub-id pub-id-type="pmid">32585492</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Vaynman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Akhavan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gomez-Pinilla</surname><given-names>F.</given-names></name></person-group> (<year>2006</year>). <article-title>Insulin-like growth factor I interfaces with brain-derived neurotrophic factor-mediated synaptic plasticity to modulate aspects of exercise-induced cognitive function</article-title>. <source>Neuroscience</source><volume>140</volume> (<issue>3</issue>), <fpage>823</fpage>&#8211;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2006.02.084</pub-id><pub-id pub-id-type="pmid">16650607</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dionigi</surname><given-names>R.</given-names></name></person-group> (<year>2007</year>). <article-title>Resistance training and older adults&#8217; beliefs about psychological benefits: the importance of self-efficacy and social interaction</article-title>. <source>J. Sport Exerc. Psychol.</source><volume>29</volume> (<issue>6</issue>), <fpage>723</fpage>&#8211;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1123/jsep.29.6.723</pub-id><pub-id pub-id-type="pmid">18089901</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>dos Santos</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cyrino</surname><given-names>E. S.</given-names></name><name name-style="western"><surname>Antunes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Sardinha</surname><given-names>L. B.</given-names></name></person-group> (<year>2017</year>). <article-title>Sarcopenia and physical independence in older adults: the independent and synergic role of muscle mass and muscle function</article-title>. <source>J. Cachexia, Sarcopenia Muscle</source><volume>8</volume> (<issue>2</issue>), <fpage>245</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1002/jcsm.12160</pub-id><pub-id pub-id-type="pmid">27897417</pub-id><pub-id pub-id-type="pmcid">PMC5377449</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dost</surname><given-names>F. S.</given-names></name><name name-style="western"><surname>Erken</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ontan</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Ates Bulut</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kaya</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kocyigit</surname><given-names>S. E.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Muscle strength seems to be related to the functional status and severity of dementia in older adults with Alzheimer&#8217;s disease</article-title>. <source>Curr. Aging Sci.</source><volume>16</volume> (<issue>1</issue>), <fpage>75</fpage>&#8211;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.2174/1573411018666220616114641</pub-id><pub-id pub-id-type="pmid">35726809</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erickson</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Banks</surname><given-names>W. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Blood&#8211;brain barrier dysfunction as a cause and consequence of Alzheimer&#8217;s disease</article-title>. <source>J. Cereb. Blood Flow and Metabolism</source><volume>33</volume> (<issue>10</issue>), <fpage>1500</fpage>&#8211;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2013.135</pub-id><pub-id pub-id-type="pmid">23921899</pub-id><pub-id pub-id-type="pmcid">PMC3790938</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erickson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>A. F.</given-names></name></person-group> (<year>2009</year>). <article-title>Aerobic exercise effects on cognitive and neural plasticity in older adults</article-title>. <source>Br. J. sports Med.</source><volume>43</volume> (<issue>1</issue>), <fpage>22</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1136/bjsm.2008.052498</pub-id><pub-id pub-id-type="pmid">18927158</pub-id><pub-id pub-id-type="pmcid">PMC2853472</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erickson</surname><given-names>K. I.</given-names></name><name name-style="western"><surname>Voss</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>Prakash</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Basak</surname><given-names>C.</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chaddock</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Exercise training increases size of hippocampus and improves memory</article-title>. <source>Proc. Natl. Acad. Sci.</source><volume>108</volume> (<issue>7</issue>), <fpage>3017</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1015950108</pub-id><pub-id pub-id-type="pmid">21282661</pub-id><pub-id pub-id-type="pmcid">PMC3041121</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rumantir</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wiesner</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hastings</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>G.</given-names></name></person-group> (<year>2001</year>). <article-title>Sympathetic nervous system and insulin resistance: from obesity to diabetes</article-title>. <source>Am. J. Hypertens.</source><volume>14</volume> (<issue>S7</issue>), <fpage>304S-309S</fpage>&#8211;<lpage>309S</lpage>. <pub-id pub-id-type="doi">10.1016/s0895-7061(01)02236-1</pub-id><pub-id pub-id-type="pmid">11721888</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esteban-Cornejo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>F. K.</given-names></name><name name-style="western"><surname>Petermann-Rocha</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lyall</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Martinez-Gomez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cabanas-S&#225;nchez</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Handgrip strength and all-cause dementia incidence and mortality: findings from the UK Biobank prospective cohort study</article-title>. <source>J. Cachexia, Sarcopenia Muscle</source><volume>13</volume> (<issue>3</issue>), <fpage>1514</fpage>&#8211;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1002/jcsm.12857</pub-id><pub-id pub-id-type="pmid">35445560</pub-id><pub-id pub-id-type="pmcid">PMC9178163</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farooqui</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Farooqui</surname><given-names>T.</given-names></name><name name-style="western"><surname>Panza</surname><given-names>F.</given-names></name><name name-style="western"><surname>Frisardi</surname><given-names>V.</given-names></name></person-group> (<year>2012</year>). <article-title>Metabolic syndrome as a risk factor for neurological disorders</article-title>. <source>Cell. Mol. Life Sci.</source><volume>69</volume> (<issue>5</issue>), <fpage>741</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-011-0840-1</pub-id><pub-id pub-id-type="pmid">21997383</pub-id><pub-id pub-id-type="pmcid">PMC11115054</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fecchio</surname><given-names>R. Y.</given-names></name><name name-style="western"><surname>Brito</surname><given-names>L. C.</given-names></name><name name-style="western"><surname>Pecanha</surname><given-names>T.</given-names></name><name name-style="western"><surname>de Moraes Forjaz</surname><given-names>C. L.</given-names></name></person-group> (<year>2021</year>). <article-title>Potential mechanisms behind the blood pressure&#8211;lowering effect of dynamic resistance training</article-title>. <source>Curr. Hypertens. Rep.</source><volume>23</volume> (<issue>6</issue>), <fpage>35</fpage>. <pub-id pub-id-type="doi">10.1007/s11906-021-01154-5</pub-id><pub-id pub-id-type="pmid">34152491</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feigenbaum</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Pollock</surname><given-names>M. L.</given-names></name></person-group> (<year>1999</year>). <article-title>Prescription of resistance training for health and disease</article-title>. <source>Med. and Sci. Sports and Exerc.</source><volume>31</volume> (<issue>1</issue>), <fpage>38</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1097/00005768-199901000-00008</pub-id><pub-id pub-id-type="pmid">9927008</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fein</surname><given-names>G.</given-names></name><name name-style="western"><surname>Di Sclafani</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tanabe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cardenas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease</article-title>. <source>Neurology</source><volume>55</volume> (<issue>11</issue>), <fpage>1626</fpage>&#8211;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1212/wnl.55.11.1626</pub-id><pub-id pub-id-type="pmid">11113215</pub-id><pub-id pub-id-type="pmcid">PMC2733356</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrari</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Neto</surname><given-names>G. de C. C.</given-names></name><name name-style="western"><surname>Nucci</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Mamani</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Lacerda</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Fel&#237;cio</surname><given-names>A. C.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>The accuracy of hippocampal volumetry and glucose metabolism for the diagnosis of patients with suspected Alzheimer&#8217;s disease, using automatic quantitative clinical tools</article-title>. <source>Medicine</source><volume>98</volume> (<issue>45</issue>), <fpage>e17824</fpage>. <pub-id pub-id-type="doi">10.1097/MD.0000000000017824</pub-id><pub-id pub-id-type="pmid">31702636</pub-id><pub-id pub-id-type="pmcid">PMC6855664</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>M. E. S.</given-names></name><name name-style="western"><surname>de Vasconcelos</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>da Costa Vilhena</surname><given-names>T.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>T. L.</given-names></name><name name-style="western"><surname>da Silva Barbosa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>A. R. Q.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Oxidative stress in Alzheimer&#8217;s disease: should we keep trying antioxidant therapies?</article-title><source>Cell. Mol. Neurobiol.</source><volume>35</volume>, <fpage>595</fpage>&#8211;<lpage>614</lpage>. <pub-id pub-id-type="doi">10.1007/s10571-015-0157-y</pub-id><pub-id pub-id-type="pmid">25616523</pub-id><pub-id pub-id-type="pmcid">PMC11486210</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feter</surname><given-names>N.</given-names></name><name name-style="western"><surname>Penny</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Freitas</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Rombaldi</surname><given-names>A. J.</given-names></name></person-group> (<year>2018</year>). <article-title>Effect of physical exercise on hippocampal volume in adults: systematic review and meta-analysis</article-title>. <source>Sci. and Sports</source><volume>33</volume> (<issue>6</issue>), <fpage>327</fpage>&#8211;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.scispo.2018.02.011</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feter</surname><given-names>N.</given-names></name><name name-style="western"><surname>Spanevello</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>M. S. P.</given-names></name><name name-style="western"><surname>Spohr</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pedra</surname><given-names>N. S.</given-names></name><name name-style="western"><surname>Bona</surname><given-names>N. P.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>How does physical activity and different models of exercise training affect oxidative parameters and memory?</article-title><source>Physiology Behav.</source><volume>201</volume>, <fpage>42</fpage>&#8211;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.physbeh.2018.12.002</pub-id><pub-id pub-id-type="pmid">30552921</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feter</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schaun</surname><given-names>G. Z.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>E. C.</given-names></name><name name-style="western"><surname>Cassuriaga</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Redig</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>High-velocity resistance training improves executive function in mobility-limited older adults</article-title>. <source>Archives Gerontology Geriatrics</source><volume>114</volume>, <fpage>105081</fpage>. <pub-id pub-id-type="doi">10.1016/j.archger.2023.105081</pub-id><pub-id pub-id-type="pmid">37269697</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiatarone Singh</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Gates</surname><given-names>N.</given-names></name><name name-style="western"><surname>Saigal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>G. C.</given-names></name><name name-style="western"><surname>Meiklejohn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brodaty</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>The study of mental and resistance training (SMART) Study&#8212;resistance training And/Or cognitive training in mild cognitive impairment: a randomized, double-blind, double-sham controlled trial</article-title>. <source>J. Am. Med. Dir. Assoc.</source><volume>15</volume> (<issue>12</issue>), <fpage>873</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.jamda.2014.09.010</pub-id><pub-id pub-id-type="pmid">25444575</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filardi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barone</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bramato</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nigro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tafuri</surname><given-names>B.</given-names></name><name name-style="western"><surname>Frisullo</surname><given-names>M. E.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>The relationship between muscle strength and cognitive performance across Alzheimer&#8217;s disease clinical continuum</article-title>. <source>Front. Neurology</source><volume>13</volume>, <fpage>833087</fpage>. <pub-id pub-id-type="doi">10.3389/fneur.2022.833087</pub-id><pub-id pub-id-type="pmid">35645971</pub-id><pub-id pub-id-type="pmcid">PMC9133788</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Firth</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sarris</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vancampfort</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schuch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>A. F.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Handgrip strength is associated with hippocampal volume and white matter hyperintensities in major depression and healthy controls: a UK biobank study</article-title>. <source>Biopsychosoc. Sci. Med.</source><volume>82</volume> (<issue>1</issue>), <fpage>39</fpage>&#8211;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1097/PSY.0000000000000753</pub-id><pub-id pub-id-type="pmid">31702599</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>G.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Zuckerman</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Bryan</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Bickel</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>G. R.</given-names></name></person-group> (<year>2013</year>). <article-title>Frequency of combined resistance and aerobic training in older women</article-title>. <source>J. Strength and Cond. Res.</source><volume>27</volume> (<issue>7</issue>), <fpage>1868</fpage>&#8211;<lpage>1876</lpage>. <pub-id pub-id-type="doi">10.1519/JSC.0b013e31827367e0</pub-id><pub-id pub-id-type="pmid">22996024</pub-id><pub-id pub-id-type="pmcid">PMC4066209</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher-Wellman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bloomer</surname><given-names>R. J.</given-names></name></person-group> (<year>2009</year>). <article-title>Acute exercise and oxidative stress: a 30 year history</article-title>. <source>Dyn. Med.</source><volume>8</volume> (<issue>1</issue>), <fpage>1</fpage>. <pub-id pub-id-type="doi">10.1186/1476-5918-8-1</pub-id><pub-id pub-id-type="pmid">19144121</pub-id><pub-id pub-id-type="pmcid">PMC2642810</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fjell</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>McEvoy</surname><given-names>L.</given-names></name><name name-style="western"><surname>Holland</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dale</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Walhovd</surname><given-names>K. B.</given-names></name></person-group><collab>Alzheimer&#8217;s Disease Neuroimaging Initiative</collab> (<year>2014</year>). <article-title>What is normal in normal aging? Effects of aging, amyloid and Alzheimer&#8217;s disease on the cerebral cortex and the hippocampus</article-title>. <source>Prog. Neurobiol.</source><volume>117</volume>, <fpage>20</fpage>&#8211;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.pneurobio.2014.02.004</pub-id><pub-id pub-id-type="pmid">24548606</pub-id><pub-id pub-id-type="pmcid">PMC4343307</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forte</surname><given-names>R.</given-names></name><name name-style="western"><surname>Boreham</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Leite</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>De Vito</surname><given-names>G.</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gibney</surname><given-names>E. R.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Enhancing cognitive functioning in the elderly: multicomponent vs resistance training</article-title>. <source>Clin. Interventions Aging</source><volume>8</volume> (<issue>null</issue>), <fpage>19</fpage>&#8211;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.2147/CIA.S36514</pub-id><pub-id pub-id-type="pmid">23341738</pub-id><pub-id pub-id-type="pmcid">PMC3546758</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forti</surname><given-names>L. N.</given-names></name><name name-style="western"><surname>Njemini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Beyer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Eelbode</surname><given-names>E.</given-names></name><name name-style="western"><surname>Meeusen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mets</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Strength training reduces circulating interleukin-6 but not brain-derived neurotrophic factor in community-dwelling elderly individuals</article-title>. <source>Age</source><volume>36</volume> (<issue>5</issue>), <fpage>9704</fpage>. <pub-id pub-id-type="doi">10.1007/s11357-014-9704-6</pub-id><pub-id pub-id-type="pmid">25128203</pub-id><pub-id pub-id-type="pmcid">PMC4453935</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fox</surname><given-names>N.</given-names></name><name name-style="western"><surname>Black</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gilman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rossor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Griffith</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Effects of abeta immunization (AN1792) on MRI measures of cerebral volume in alzheimer disease</article-title>. <source>Neurology</source><volume>64</volume> (<issue>9</issue>), <fpage>1563</fpage>&#8211;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1212/01.WNL.0000159743.08996.99</pub-id><pub-id pub-id-type="pmid">15883317</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fragala</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Cadore</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Dorgo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Izquierdo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kraemer</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>M. D.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Resistance training for older adults: position statement from the national strength and conditioning association</article-title>. <source>J. Strength and Cond. Res.</source><volume>33</volume> (<issue>8</issue>), <fpage>2019</fpage>&#8211;<lpage>2052</lpage>. <pub-id pub-id-type="doi">10.1519/JSC.0000000000003230</pub-id><pub-id pub-id-type="pmid">31343601</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franzke</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schober-Halper</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hofmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oesen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tosevska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Henriksen</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Age and the effect of exercise, nutrition and cognitive training on oxidative stress &#8211; the vienna active aging study (VAAS), a randomized controlled trial</article-title>. <source>Free Radic. Biol. Med.</source><volume>121</volume>, <fpage>69</fpage>&#8211;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2018.04.565</pub-id><pub-id pub-id-type="pmid">29698742</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freitas</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Nonato</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Martins</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Mendon&#231;a</surname><given-names>V. A.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>High intensity interval training modulates hippocampal oxidative stress, BDNF and inflammatory mediators in rats</article-title>. <source>Physiology and Behav.</source><volume>184</volume>, <fpage>6</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.physbeh.2017.10.027</pub-id><pub-id pub-id-type="pmid">29111230</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frith</surname><given-names>E.</given-names></name><name name-style="western"><surname>Loprinzi</surname><given-names>P. D.</given-names></name></person-group> (<year>2018</year>). <article-title>The association between lower extremity muscular strength and cognitive function in a national sample of older adults</article-title>. <source>J. lifestyle Med.</source><volume>8</volume> (<issue>2</issue>), <fpage>99</fpage>&#8211;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.15280/jlm.2018.8.2.99</pub-id><pub-id pub-id-type="pmid">30474005</pub-id><pub-id pub-id-type="pmcid">PMC6239135</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furlano</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Nagamatsu</surname><given-names>L. S.</given-names></name></person-group> (<year>2021</year>). <article-title>Feasibility of a 26-Week exercise program to improve brain health in older adults at risk for type 2 diabetes: a pilot study</article-title>. <source>Can. J. Diabetes</source><volume>45</volume> (<issue>6</issue>), <fpage>546</fpage>&#8211;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcjd.2020.11.001</pub-id><pub-id pub-id-type="pmid">33358932</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gabriel</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Kamen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Frost</surname><given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>Neural adaptations to resistive exercise: mechanisms and recommendations for training practices</article-title>. <source>Sports Med.</source><volume>36</volume>, <fpage>133</fpage>&#8211;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.2165/00007256-200636020-00004</pub-id><pub-id pub-id-type="pmid">16464122</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Y. Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G. Y.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Regional cerebral blood flow and cerebrovascular reactivity in Alzheimer&#8217;s disease and vascular dementia assessed by arterial spinlabeling magnetic resonance imaging</article-title>. <source>Curr. neurovascular Res.</source><volume>10</volume> (<issue>1</issue>), <fpage>49</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.2174/156720213804806016</pub-id><pub-id pub-id-type="pmid">23151075</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gleeson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Stensel</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Lindley</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Mastana</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Nimmo</surname><given-names>M. A.</given-names></name></person-group> (<year>2011</year>). <article-title>The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease</article-title>. <source>Nat. Rev. Immunol.</source><volume>11</volume> (<issue>9</issue>), <fpage>607</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1038/nri3041</pub-id><pub-id pub-id-type="pmid">21818123</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glodzik</surname><given-names>L.</given-names></name><name name-style="western"><surname>Randall</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rusinek</surname><given-names>H.</given-names></name><name name-style="western"><surname>de Leon</surname><given-names>M. J.</given-names></name></person-group> (<year>2013</year>). <article-title>Cerebrovascular reactivity to carbon dioxide in Alzheimer&#8217;s disease</article-title>. <source>J. Alzheimer&#8217;s Dis.</source><volume>35</volume> (<issue>3</issue>), <fpage>427</fpage>&#8211;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-122011</pub-id><pub-id pub-id-type="pmid">23478306</pub-id><pub-id pub-id-type="pmcid">PMC3776495</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goekint</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Pauw</surname><given-names>K.</given-names></name><name name-style="western"><surname>Roelands</surname><given-names>B.</given-names></name><name name-style="western"><surname>Njemini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bautmans</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mets</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Strength training does not influence serum brain-derived neurotrophic factor</article-title>. <source>Eur. J. Appl. physiology</source><volume>110</volume>, <fpage>285</fpage>&#8211;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1007/s00421-010-1461-3</pub-id><pub-id pub-id-type="pmid">20467874</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gratas-Delamarche</surname><given-names>A.</given-names></name><name name-style="western"><surname>Derbr&#233;</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cillard</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Physical inactivity, insulin resistance, and the oxidative-inflammatory loop</article-title>. <source>Free Radic. Res.</source><volume>48</volume> (<issue>1</issue>), <fpage>93</fpage>&#8211;<lpage>108</lpage>. <pub-id pub-id-type="doi">10.3109/10715762.2013.847528</pub-id><pub-id pub-id-type="pmid">24060092</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griffen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hattersley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weickert</surname><given-names>M. O.</given-names></name><name name-style="western"><surname>Dallaway</surname><given-names>A.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Effects of resistance exercise and whey protein supplementation on cognitive function in older men: secondary analysis of a randomised, double-blind, placebo-controlled trial</article-title>. <source>Exp. Gerontol.</source><volume>193</volume>, <fpage>112477</fpage>. <pub-id pub-id-type="doi">10.1016/j.exger.2024.112477</pub-id><pub-id pub-id-type="pmid">38844183</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gryglewski</surname><given-names>R.</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Moncada</surname><given-names>S.</given-names></name></person-group> (<year>1986</year>). <article-title>Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor</article-title>. <source>Nature</source><volume>320</volume> (<issue>6061</issue>), <fpage>454</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/320454a0</pub-id><pub-id pub-id-type="pmid">3007998</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name></person-group> (<year>2013</year>). <article-title>Oxidative stress, mitochondrial damage and neurodegenerative diseases</article-title>. <source>Neural Regen. Res.</source><volume>8</volume> (<issue>21</issue>), <fpage>2003</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.3969/j.issn.1673-5374.2013.21.009</pub-id><pub-id pub-id-type="pmid">25206509</pub-id><pub-id pub-id-type="pmcid">PMC4145906</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#252;zel</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Hazar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Erbas</surname><given-names>D.</given-names></name></person-group> (<year>2007</year>). <article-title>Effects of different resistance exercise protocols on nitric oxide, lipid peroxidation and creatine kinase activity in sedentary males</article-title>. <source>J. sports Sci. and Med.</source><volume>6</volume> (<issue>4</issue>), <fpage>417</fpage>&#8211;<lpage>422</lpage>.
<pub-id pub-id-type="pmid">24149472</pub-id><pub-id pub-id-type="pmcid">PMC3794479</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Habes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grothe</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Tunc</surname><given-names>B.</given-names></name><name name-style="western"><surname>McMillan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wolk</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Davatzikos</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>Disentangling heterogeneity in alzheimer&#8217;s disease and related dementias using data-driven methods</article-title>. <source>Biol. Psychiatry</source><volume>88</volume> (<issue>1</issue>), <fpage>70</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2020.01.016</pub-id><pub-id pub-id-type="pmid">32201044</pub-id><pub-id pub-id-type="pmcid">PMC7305953</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hainmueller</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bartos</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Dentate gyrus circuits for encoding, retrieval and discrimination of episodic memories</article-title>. <source>Nat. Rev. Neurosci.</source><volume>21</volume> (<issue>3</issue>), <fpage>153</fpage>&#8211;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1038/s41583-019-0260-z</pub-id><pub-id pub-id-type="pmid">32042144</pub-id><pub-id pub-id-type="pmcid">PMC7115869</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardy</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>G. A.</given-names></name></person-group> (<year>1992</year>). <article-title>Alzheimer&#8217;s disease: the amyloid Cascade hypothesis</article-title>. <source>Science</source><volume>256</volume> (<issue>5054</issue>), <fpage>184</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1126/science.1566067</pub-id><pub-id pub-id-type="pmid">1566067</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hashiguchi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Campos</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Wuo-Silva</surname><given-names>R.</given-names></name><name name-style="western"><surname>Faber</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gomes da Silva</surname><given-names>S.</given-names></name><name name-style="western"><surname>Coppi</surname><given-names>A. A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Resistance exercise decreases amyloid load and modulates inflammatory responses in the APP/PS1 mouse model for Alzheimer&#8217;s disease</article-title>. <source>J. Alzheimer&#8217;s Dis.</source><volume>73</volume> (<issue>4</issue>), <fpage>1525</fpage>&#8211;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-190729</pub-id><pub-id pub-id-type="pmid">31958083</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Helmes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Exercise and executive functioning in older women</article-title>. <source>J. Women and Aging</source><volume>29</volume> (<issue>5</issue>), <fpage>376</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1080/08952841.2016.1256736</pub-id><pub-id pub-id-type="pmid">28027014</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heneka</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Carson</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>El Khoury</surname><given-names>J.</given-names></name><name name-style="western"><surname>Landreth</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>Brosseron</surname><given-names>F.</given-names></name><name name-style="western"><surname>Feinstein</surname><given-names>D. L.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Neuroinflammation in Alzheimer&#8217;s disease</article-title>. <source>Lancet Neurology</source><volume>14</volume> (<issue>4</issue>), <fpage>388</fpage>&#8211;<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(15)70016-5</pub-id><pub-id pub-id-type="pmid">25792098</pub-id><pub-id pub-id-type="pmcid">PMC5909703</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herholz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Perani</surname><given-names>D.</given-names></name><name name-style="western"><surname>Baron</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Holthoff</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fr&#246;lich</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Discrimination between alzheimer dementia and controls by automated analysis of multicenter FDG PET</article-title>. <source>Neuroimage.</source><volume>17</volume> (<issue>1</issue>), <fpage>302</fpage>&#8211;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1006/nimg.2002.1208</pub-id><pub-id pub-id-type="pmid">12482085</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herold</surname><given-names>F.</given-names></name><name name-style="western"><surname>T&#246;rpel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schega</surname><given-names>L.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>N. G.</given-names></name></person-group> (<year>2019</year>). <article-title>Functional and/or structural brain changes in response to resistance exercises and resistance training lead to cognitive improvements &#8211; a systematic review</article-title>. <source>Eur. Rev. Aging Phys. Activity</source><volume>16</volume> (<issue>1</issue>), <fpage>10</fpage>. <pub-id pub-id-type="doi">10.1186/s11556-019-0217-2</pub-id><pub-id pub-id-type="pmid">31333805</pub-id><pub-id pub-id-type="pmcid">PMC6617693</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hess</surname><given-names>N. C. L.</given-names></name><name name-style="western"><surname>Smart</surname><given-names>N. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Isometric exercise training for managing vascular risk factors in mild cognitive impairment and alzheimer&#8217;s disease</article-title>. <source>Front. Aging Neurosci.</source><volume>9</volume>, <fpage>48</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2017.00048</pub-id><pub-id pub-id-type="pmid">28316570</pub-id><pub-id pub-id-type="pmcid">PMC5334511</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Himali</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Baril</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Cavuoto</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Yiallourou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wiedner</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>Himali</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Association between slow-wave sleep loss and incident dementia</article-title>. <source>JAMA neurol.</source><volume>80</volume> (<issue>12</issue>), <fpage>1326</fpage>&#8211;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2023.3889</pub-id><pub-id pub-id-type="pmid">37902739</pub-id><pub-id pub-id-type="pmcid">PMC10616771</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sobol</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Frederiksen</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Beyer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vestergaard</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Moderate-to-high intensity physical exercise in patients with Alzheimer&#8217;s disease: a randomized controlled trial</article-title>. <source>J. Alzheimer&#8217;s Dis.</source><volume>50</volume> (<issue>2</issue>), <fpage>443</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-150817</pub-id><pub-id pub-id-type="pmid">26682695</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Hoiland</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Ainslie</surname><given-names>P. N.</given-names></name></person-group> (<year>2019</year>). &#8220;<article-title>Regulation of the cerebral circulation by arterial carbon dioxide</article-title>,&#8221; in <source>Comprehensive physiology</source> (<publisher-name>American Cancer Society</publisher-name>), <fpage>1101</fpage>&#8211;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1002/cphy.c180021</pub-id><pub-id pub-id-type="pmid">31187899</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holth</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Fritschi</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>N. P.</given-names></name><name name-style="western"><surname>Cirrito</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Mahan</surname><given-names>T. E.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans</article-title>. <source>Science</source><volume>363</volume> (<issue>6429</issue>), <fpage>880</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1126/science.aav2546</pub-id><pub-id pub-id-type="pmid">30679382</pub-id><pub-id pub-id-type="pmcid">PMC6410369</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoyer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oesterreich</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>O.</given-names></name></person-group> (<year>1988</year>). <article-title>Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type?</article-title><source>J. neurology</source><volume>235</volume>, <fpage>143</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/BF00314304</pub-id><pub-id pub-id-type="pmid">3367161</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name></person-group> (<year>2016</year>). <article-title>Role of oxidative stress in Alzheimer&#8217;s disease</article-title>. <source>Biomed. Rep.</source><volume>4</volume> (<issue>5</issue>), <fpage>519</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.3892/br.2016.630</pub-id><pub-id pub-id-type="pmid">27123241</pub-id><pub-id pub-id-type="pmcid">PMC4840676</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hurst</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dismore</surname><given-names>L.</given-names></name><name name-style="western"><surname>Granic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tullo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Noble</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Hillman</surname><given-names>S. J.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Attitudes and barriers to resistance exercise training for older adults living with multiple long-term conditions, frailty, and a recent deterioration in health: qualitative findings from the Lifestyle in Later life &#8211; older People&#8217;s medicine (LiLL-OPM) study</article-title>. <source>BMC Geriatr.</source><volume>23</volume> (<issue>1</issue>), <fpage>772</fpage>. <pub-id pub-id-type="doi">10.1186/s12877-023-04461-5</pub-id><pub-id pub-id-type="pmid">38001414</pub-id><pub-id pub-id-type="pmcid">PMC10675908</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hyde</surname><given-names>E. T.</given-names></name><name name-style="western"><surname>Whitfield</surname><given-names>G. P.</given-names></name><name name-style="western"><surname>Omura</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Fulton</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>S. A.</given-names></name></person-group> (<year>2021</year>). <article-title>Trends in meeting the physical activity guidelines: muscle-strengthening alone and combined with aerobic activity, United States, 1998&#8211;2018</article-title>. <source>J. Phys. Activity Health</source><volume>18</volume> (<issue>S1</issue>), <fpage>S37</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1123/jpah.2021-0077</pub-id><pub-id pub-id-type="pmid">34465652</pub-id><pub-id pub-id-type="pmcid">PMC11000248</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ionescu-Tucker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cotman</surname><given-names>C. W.</given-names></name></person-group> (<year>2021</year>). <article-title>Emerging roles of oxidative stress in brain aging and Alzheimer&#8217;s disease</article-title>. <source>Neurobiol. Aging</source><volume>107</volume>, <fpage>86</fpage>&#8211;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2021.07.014</pub-id><pub-id pub-id-type="pmid">34416493</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishiguro</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kodama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Horikawa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fujihara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hirose</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Hirasawa</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>In search of the ideal resistance training program to improve glycemic control and its indication for patients with type 2 diabetes mellitus: a systematic review and meta-analysis</article-title>. <source>Sports Med.</source><volume>46</volume> (<issue>1</issue>), <fpage>67</fpage>&#8211;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1007/s40279-015-0379-7</pub-id><pub-id pub-id-type="pmid">26604100</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iturria-Medina</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sotero</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Toussaint</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Mateos-P&#233;rez</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>M. W.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Early role of vascular dysregulation on late-onset alzheimer&#8217;s disease based on multifactorial data-driven analysis</article-title>. <source>Nat. Commun.</source><volume>7</volume> (<issue>1</issue>), <fpage>11934</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms11934</pub-id><pub-id pub-id-type="pmid">27327500</pub-id><pub-id pub-id-type="pmcid">PMC4919512</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iuliano</surname><given-names>E.</given-names></name><name name-style="western"><surname>di Cagno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aquino</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fiorilli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mignogna</surname><given-names>P.</given-names></name><name name-style="western"><surname>Calcagno</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Effects of different types of physical activity on the cognitive functions and attention in older people: a randomized controlled study</article-title>. <source>Exp. Gerontol.</source><volume>70</volume>, <fpage>105</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.exger.2015.07.008</pub-id><pub-id pub-id-type="pmid">26183691</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>M. W.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Hypothetical model of dynamic biomarkers of the Alzheimer&#8217;s pathological cascade</article-title>. <source>Lancet Neurology</source><volume>9</volume> (<issue>1</issue>), <fpage>119</fpage>&#8211;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(09)70299-6</pub-id><pub-id pub-id-type="pmid">20083042</pub-id><pub-id pub-id-type="pmcid">PMC2819840</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jafarzadeh</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shakerian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Farbood</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ghanbarzadeh</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Effects of eight weeks of resistance exercises on neurotrophins and trk receptors in alzheimer model Male wistar rats</article-title>. <source>Basic Clin. Neurosci.</source><volume>12</volume> (<issue>3</issue>), <fpage>349</fpage>&#8211;<lpage>359</lpage>. <pub-id pub-id-type="doi">10.32598/bcn.2021.2067.1</pub-id><pub-id pub-id-type="pmid">34917294</pub-id><pub-id pub-id-type="pmcid">PMC8666928</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jansson</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>Li X.</given-names></name><name name-style="western"><surname>Lubans</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Plotnikoff</surname><given-names>R. C.</given-names></name></person-group> (<year>2022</year>). <article-title>Effect of resistance training on HbA1c in adults with type 2 diabetes mellitus and the moderating effect of changes in muscular strength: a systematic review and meta-analysis</article-title>. <source>BMJ Open Diabetes Res. and Care</source><volume>10</volume> (<issue>2</issue>), <fpage>e002595</fpage>. <pub-id pub-id-type="doi">10.1136/bmjdrc-2021-002595</pub-id><pub-id pub-id-type="pmid">35273011</pub-id><pub-id pub-id-type="pmcid">PMC8915309</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Jay Widmer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lerman</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <source>Endothelial dysfunction and cardiovascular disease. Vol. 2014, global cardiology science and practice</source>. <publisher-loc>Doha, Qatar</publisher-loc>: <publisher-name>Hamad bin Khalifa University Press HBKU Press</publisher-name>. <comment>Available online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.qscience.com/" ext-link-type="uri">https://www.qscience.com/</ext-link></comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.5339/gcsp.2014.43</pub-id><pub-id pub-id-type="pmcid">PMC4352682</pub-id><pub-id pub-id-type="pmid">25780786</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jefferson</surname><given-names>M. E.</given-names></name></person-group> (<year>2014</year>). <article-title>Abstract 404: the effects of resistance training and weight loss on arterial stiffness in older adults</article-title>. <source>Arteriosclerosis, Thrombosis, Vasc. Biol.</source><volume>34</volume> (<issue>Suppl. l_1</issue>), <fpage>A404</fpage>. <pub-id pub-id-type="doi">10.1161/atvb.34.suppl_1.404</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jefferson</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Cambronero</surname><given-names>F. E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>E. E.</given-names></name><name name-style="western"><surname>Neal</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Terry</surname><given-names>J. G.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Higher aortic stiffness is related to lower cerebral blood flow and preserved cerebrovascular reactivity in older adults</article-title>. <source>Circulation</source><volume>138</volume> (<issue>18</issue>), <fpage>1951</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.032410</pub-id><pub-id pub-id-type="pmid">30018169</pub-id><pub-id pub-id-type="pmcid">PMC6394409</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>N. B.</given-names></name><name name-style="western"><surname>Sidney</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yaffe</surname><given-names>K.</given-names></name></person-group> (<year>2023</year>). <article-title>Premature cardiovascular disease and brain health in midlife: the CARDIA study</article-title>. <source>Neurology</source><volume>100</volume> (<issue>14</issue>), <fpage>e1454</fpage>&#8211;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000206825</pub-id><pub-id pub-id-type="pmid">36697246</pub-id><pub-id pub-id-type="pmcid">PMC10104620</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanaley</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Colberg</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Corcoran</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Malin</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Crespo</surname><given-names>C. J.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Exercise/physical activity in individuals with type 2 diabetes: a consensus statement from the American college of sports medicine</article-title>. <source>Med. and Sci. Sports and Exerc.</source><volume>54</volume> (<issue>2</issue>), <fpage>353</fpage>&#8211;<lpage>368</lpage>. <pub-id pub-id-type="doi">10.1249/MSS.0000000000002800</pub-id><pub-id pub-id-type="pmid">35029593</pub-id><pub-id pub-id-type="pmcid">PMC8802999</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Bateman</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>L. P.</given-names></name><name name-style="western"><surname>Cirrito</surname><given-names>J. R.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Amyloid-&#946; dynamics are regulated by orexin and the sleep-wake cycle</article-title>. <source>Science.</source><volume>326</volume> (<issue>5955</issue>), <fpage>1005</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1126/science.1180962</pub-id><pub-id pub-id-type="pmid">19779148</pub-id><pub-id pub-id-type="pmcid">PMC2789838</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawano</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Miyachi</surname><given-names>M.</given-names></name></person-group> (<year>2006</year>). <article-title>Resistance training and arterial compliance: keeping the benefits while minimizing the stiffening</article-title>. <source>J. Hypertens.</source><volume>24</volume> (<issue>9</issue>), <fpage>1753</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/01.hjh.0000242399.60838.14</pub-id><pub-id pub-id-type="pmid">16915024</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y. S.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H. J.</given-names></name></person-group> (<year>2017a</year>). <article-title>The effects of strength exercise on hippocampus volume and functional fitness of older women</article-title>. <source>Exp. Gerontol.</source><volume>97</volume>, <fpage>22</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.exger.2017.07.007</pub-id><pub-id pub-id-type="pmid">28716635</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Pilania</surname><given-names>N.</given-names></name><name name-style="western"><surname>Franke</surname><given-names>W. D.</given-names></name></person-group> (<year>2017b</year>). <article-title>Effects of blood flow restricted exercise training on muscular strength and blood flow in older adults</article-title>. <source>Exp. Gerontol.</source><volume>99</volume>, <fpage>127</fpage>&#8211;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.exger.2017.09.016</pub-id><pub-id pub-id-type="pmid">28986234</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>T. M.</given-names></name><name name-style="western"><surname>Lipford</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Craft</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S. N.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Relationship between cerebrovascular reactivity and cognition among people with risk of cognitive decline</article-title>. <source>Front. Physiology</source><volume>12</volume>, <fpage>645342</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2021.645342</pub-id><pub-id pub-id-type="pmid">34135768</pub-id><pub-id pub-id-type="pmcid">PMC8201407</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kinney</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Bemiller</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Murtishaw</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Leisgang</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Lamb</surname><given-names>B. T.</given-names></name></person-group> (<year>2018</year>). <article-title>Inflammation as a central mechanism in Alzheimer&#8217;s disease</article-title>. <source>Alzheimer&#8217;s and Dementia Transl. Res. and Clin. Interventions</source><volume>4</volume>, <fpage>575</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.trci.2018.06.014</pub-id><pub-id pub-id-type="pmid">30406177</pub-id><pub-id pub-id-type="pmcid">PMC6214864</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Santini</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Clemmensen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ettrup</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rios</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Blood BDNF concentrations reflect brain-tissue BDNF levels across species</article-title>. <source>Int. J. Neuropsychopharmacol.</source><volume>14</volume> (<issue>3</issue>), <fpage>347</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1017/S1461145710000738</pub-id><pub-id pub-id-type="pmid">20604989</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleinloog</surname><given-names>J. P. D.</given-names></name><name name-style="western"><surname>Mensink</surname><given-names>R. P.</given-names></name><name name-style="western"><surname>Ivanov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Adam</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Uluda&#287;</surname><given-names>K.</given-names></name><name name-style="western"><surname>Joris</surname><given-names>P. J.</given-names></name></person-group> (<year>2019</year>). <article-title>Aerobic exercise training improves cerebral blood flow and executive function: a randomized, controlled cross-over trial in sedentary older men</article-title>. <source>Front. Aging Neurosci.</source><volume>11</volume>, <fpage>333</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2019.00333</pub-id><pub-id pub-id-type="pmid">31866855</pub-id><pub-id pub-id-type="pmcid">PMC6904365</pub-id></mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knopman</surname><given-names>D. S.</given-names></name></person-group> (<year>2007</year>). <article-title>Cerebrovascular disease and dementia</article-title>. <source>BJR</source><volume>80</volume> (<issue>special_issue_2</issue>), <fpage>S121</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1259/bjr/75681080</pub-id><pub-id pub-id-type="pmid">18445742</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ivers</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gehrt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schnoor</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rump</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rieckert</surname><given-names>H.</given-names></name></person-group> (<year>2005</year>). <article-title>Cerebral autoregulation is temporarily disturbed in the early recovery phase after dynamic resistance exercise</article-title>. <source>Clin. Auton. Res.</source><volume>15</volume> (<issue>2</issue>), <fpage>83</fpage>&#8211;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1007/s10286-005-0249-8</pub-id><pub-id pub-id-type="pmid">15834764</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Komulainen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kivipelto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lakka</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>Savonen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hassinen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kiviniemi</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Exercise, fitness and cognition &#8211; a randomised controlled trial in older individuals: the DR&#8217;s EXTRA study</article-title>. <source>Eur. Geriatr. Med.</source><volume>1</volume> (<issue>5</issue>), <fpage>266</fpage>&#8211;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.eurger.2010.08.001</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korad</surname><given-names>S.</given-names></name><name name-style="western"><surname>M&#252;ndel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>B. G.</given-names></name></person-group> (<year>2024</year>). <article-title>The effects of habitual resistance exercise training on cerebrovascular responses to lower body dynamic resistance exercise: a cross-sectional study</article-title>. <source>Exp. Physiol.</source><volume>109</volume>, <fpage>1478</fpage>&#8211;<lpage>1491</lpage>. <pub-id pub-id-type="doi">10.1113/EP091707</pub-id><pub-id pub-id-type="pmid">38888986</pub-id><pub-id pub-id-type="pmcid">PMC11363110</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kovacevic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mavros</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Heisz</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Fiatarone Singh</surname><given-names>M. A.</given-names></name></person-group> (<year>2018</year>). <article-title>The effect of resistance exercise on sleep: a systematic review of randomized controlled trials</article-title>. <source>Sleep. Med. Rev.</source><volume>39</volume>, <fpage>52</fpage>&#8211;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.smrv.2017.07.002</pub-id><pub-id pub-id-type="pmid">28919335</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kovacevic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fenesi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Paolucci</surname><given-names>E.</given-names></name><name name-style="western"><surname>Heisz</surname><given-names>J. J.</given-names></name></person-group> (<year>2020</year>). <article-title>The effects of aerobic exercise intensity on memory in older adults</article-title>. <source>Appl. physiology, Nutr. metabolism</source><volume>45</volume> (<issue>6</issue>), <fpage>591</fpage>&#8211;<lpage>600</lpage>. <pub-id pub-id-type="doi">10.1139/apnm-2019-0495</pub-id><pub-id pub-id-type="pmid">31665610</pub-id></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kraemer</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Ratamess</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>French</surname><given-names>D. N.</given-names></name></person-group> (<year>2002</year>). <article-title>Resistance training for health and performance</article-title>. <source>Curr. Sports Med. Rep.</source><volume>1</volume> (<issue>3</issue>), <fpage>165</fpage>&#8211;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1249/00149619-200206000-00007</pub-id><pub-id pub-id-type="pmid">12831709</pub-id></mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kraemer</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Fragala</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Ratamess</surname><given-names>N. A.</given-names></name></person-group> (<year>2025</year>). <article-title>Evolution of resistance training in women: history and mechanisms for health and performance</article-title>. <source>Sports Med. Health Sci.</source><volume>7</volume>, <fpage>351</fpage>&#8211;<lpage>365</lpage>. <pub-id pub-id-type="doi">10.1016/j.smhs.2025.01.005</pub-id><pub-id pub-id-type="pmid">40936659</pub-id><pub-id pub-id-type="pmcid">PMC12421175</pub-id></mixed-citation></ref><ref id="B165"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krizbai</surname><given-names>I. A.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bresgen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Eckl</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Farkas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Szatm&#225;ri</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Effect of oxidative stress on the junctional proteins of cultured cerebral endothelial cells</article-title>. <source>Cell. Mol. Neurobiol.</source><volume>25</volume>, <fpage>129</fpage>&#8211;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1007/s10571-004-1378-7</pub-id><pub-id pub-id-type="pmid">15962510</pub-id><pub-id pub-id-type="pmcid">PMC11529493</pub-id></mixed-citation></ref><ref id="B166"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Bishayee</surname><given-names>K.</given-names></name></person-group> (<year>2022</year>). <article-title>Dysfunctional glucose metabolism in alzheimer&#8217;s disease onset and potential pharmacological interventions</article-title>. <source>Int. J. Mol. Sci.</source><volume>23</volume> (<issue>17</issue>), <fpage>9540</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23179540</pub-id><pub-id pub-id-type="pmid">36076944</pub-id><pub-id pub-id-type="pmcid">PMC9455726</pub-id></mixed-citation></ref><ref id="B167"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lachman</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Neupert</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jette</surname><given-names>A. M.</given-names></name></person-group> (<year>2006</year>). <article-title>The effects of strength training on memory in older adults</article-title>. <source>J. Aging Phys. Activity</source><volume>14</volume> (<issue>1</issue>), <fpage>59</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1123/japa.14.1.59</pub-id><pub-id pub-id-type="pmid">16648652</pub-id></mixed-citation></ref><ref id="B168"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landrigan</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>T.</given-names></name><name name-style="western"><surname>Crowe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clay</surname><given-names>O. J.</given-names></name><name name-style="western"><surname>Mirman</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Lifting cognition: a meta-analysis of effects of resistance exercise on cognition</article-title>. <source>Psychol. Res.</source><volume>84</volume> (<issue>5</issue>), <fpage>1167</fpage>&#8211;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1007/s00426-019-01145-x</pub-id><pub-id pub-id-type="pmid">30627769</pub-id></mixed-citation></ref><ref id="B169"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laron</surname><given-names>Z.</given-names></name></person-group> (<year>2001</year>). <article-title>Insulin-like growth factor 1 (IGF-1): a growth hormone</article-title>. <source>Mol. Pathol.</source><volume>54</volume> (<issue>5</issue>), <fpage>311</fpage>&#8211;<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1136/mp.54.5.311</pub-id><pub-id pub-id-type="pmid">11577173</pub-id><pub-id pub-id-type="pmcid">PMC1187088</pub-id></mixed-citation></ref><ref id="B170"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laufs</surname><given-names>U.</given-names></name><name name-style="western"><surname>Wassmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Czech</surname><given-names>T.</given-names></name><name name-style="western"><surname>M&#252;nzel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Eisenhauer</surname><given-names>M.</given-names></name><name name-style="western"><surname>B&#246;hm</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Physical inactivity increases oxidative stress, endothelial dysfunction, and atherosclerosis</article-title>. <source>Arteriosclerosis, thrombosis, Vasc. Biol.</source><volume>25</volume> (<issue>4</issue>), <fpage>809</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1161/01.ATV.0000158311.24443.af</pub-id><pub-id pub-id-type="pmid">15692095</pub-id></mixed-citation></ref><ref id="B171"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H. K.</given-names></name><name name-style="western"><surname>Shim</surname><given-names>Y. M.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Wearable device&#8211;based intervention for promoting patient physical activity after lung cancer surgery: a nonrandomized clinical trial</article-title>. <source>JAMA Netw. Open</source><volume>7</volume> (<issue>9</issue>), <fpage>e2434180</fpage>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.34180</pub-id><pub-id pub-id-type="pmid">39302678</pub-id><pub-id pub-id-type="pmcid">PMC11415788</pub-id></mixed-citation></ref><ref id="B172"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>West</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pellegrini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wilcox</surname><given-names>S.</given-names></name><name name-style="western"><surname>Neils-Strunjas</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>Walking interventions and cognitive health in older adults: a systematic review of randomized controlled trials</article-title>. <source>Am. J. Health Promot</source>, <fpage>08901171251328858</fpage>. <pub-id pub-id-type="doi">10.1177/08901171251328858</pub-id><pub-id pub-id-type="pmid">40165427</pub-id><pub-id pub-id-type="pmcid">PMC12284334</pub-id></mixed-citation></ref><ref id="B173"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lefferts</surname><given-names>W. K.</given-names></name><name name-style="western"><surname>Augustine</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Heffernan</surname><given-names>K. S.</given-names></name></person-group> (<year>2014</year>). <article-title>Effect of acute resistance exercise on carotid artery stiffness and cerebral blood flow pulsatility</article-title>. <source>Front. Physiol.</source><volume>5</volume>, <fpage>101</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2014.00101</pub-id><pub-id pub-id-type="pmid">24678301</pub-id><pub-id pub-id-type="pmcid">PMC3958641</pub-id></mixed-citation></ref><ref id="B174"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lepley</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Hatzel</surname><given-names>B. M.</given-names></name></person-group> (<year>2010</year>). <article-title>Effects of weightlifting and breathing technique on blood pressure and heart rate</article-title>. <source>J. Strength and Cond. Res.</source><volume>24</volume> (<issue>8</issue>), <fpage>2179</fpage>&#8211;<lpage>2183</lpage>. <pub-id pub-id-type="doi">10.1519/JSC.0b013e3181e2741d</pub-id><pub-id pub-id-type="pmid">20634749</pub-id></mixed-citation></ref><ref id="B175"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levinger</surname><given-names>I.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hare</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Jerums</surname><given-names>G.</given-names></name><name name-style="western"><surname>Selig</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>). <article-title>The effect of resistance training on functional capacity and quality of life in individuals with high and low numbers of metabolic risk factors</article-title>. <source>Diabetes Care</source><volume>30</volume> (<issue>9</issue>), <fpage>2205</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.2337/dc07-0841</pub-id><pub-id pub-id-type="pmid">17563342</pub-id></mixed-citation></ref><ref id="B176"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name></person-group> (<year>2024</year>). <article-title>Correlation of muscle strength, working memory, and activities of daily living in older adults</article-title>. <source>Front. Aging Neurosci.</source><volume>16</volume>, <fpage>1453527</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2024.1453527</pub-id><pub-id pub-id-type="pmid">39372646</pub-id><pub-id pub-id-type="pmcid">PMC11449751</pub-id></mixed-citation></ref><ref id="B177"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Liguori</surname><given-names>G.</given-names></name></person-group><collab>American College of Sports Medicine</collab> (<year>2020</year>). <source>ACSM&#8217;s guidelines for exercise testing and prescription</source>. <publisher-name>Lippincott williams and wilkins</publisher-name>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1249/JSR.0b013e31829a68cf</pub-id><pub-id pub-id-type="pmid">23851406</pub-id></mixed-citation></ref><ref id="B178"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.</given-names></name></person-group> (<year>2024</year>). <article-title>The effects of resistance training on pain, strength, and function in osteoarthritis: systematic review and meta-analysis</article-title>. <source>J. Personalized Med.</source><volume>14</volume> (<issue>12</issue>), <fpage>1130</fpage>. <pub-id pub-id-type="doi">10.3390/jpm14121130</pub-id><pub-id pub-id-type="pmid">39728043</pub-id><pub-id pub-id-type="pmcid">PMC11676110</pub-id></mixed-citation></ref><ref id="B179"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>J. M. T.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>R. C. C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Short-term resistance exercise inhibits neuroinflammation and attenuates neuropathological changes in 3xTg Alzheimer&#8217;s disease mice</article-title>. <source>J. neuroinflammation</source><volume>17</volume>, <fpage>4</fpage>&#8211;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1186/s12974-019-1653-7</pub-id><pub-id pub-id-type="pmid">31900170</pub-id><pub-id pub-id-type="pmcid">PMC6942350</pub-id></mixed-citation></ref><ref id="B180"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu-Ambrose</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nagamatsu</surname><given-names>L. S.</given-names></name><name name-style="western"><surname>Graf</surname><given-names>P.</given-names></name><name name-style="western"><surname>Beattie</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Ashe</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Handy</surname><given-names>T. C.</given-names></name></person-group> (<year>2010</year>). <article-title>Resistance training and executive functions: a 12-month randomized controlled trial</article-title>. <source>Archives Intern. Med.</source><volume>170</volume> (<issue>2</issue>), <fpage>170</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1001/archinternmed.2009.494</pub-id><pub-id pub-id-type="pmid">20101012</pub-id><pub-id pub-id-type="pmcid">PMC3448565</pub-id></mixed-citation></ref><ref id="B181"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lommatzsch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zingler</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schuhbaeck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schloetcke</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zingler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schuff-Werner</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>The impact of age, weight and gender on BDNF levels in human platelets and plasma</article-title>. <source>Neurobiol. aging</source><volume>26</volume> (<issue>1</issue>), <fpage>115</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2004.03.002</pub-id><pub-id pub-id-type="pmid">15585351</pub-id></mixed-citation></ref><ref id="B182"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopes</surname><given-names>K. G.</given-names></name><name name-style="western"><surname>Farinatti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bottino</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>M. das G. C.</given-names></name><name name-style="western"><surname>Maranh&#227;o</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bouskela</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Exercise with blood flow restriction improves muscle strength and mass while preserving the vascular and microvascular function and structure of older adults</article-title>. <source>Clin. Hemorheol. Microcirc.</source><volume>82</volume> (<issue>1</issue>), <fpage>13</fpage>&#8211;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.3233/CH-221395</pub-id><pub-id pub-id-type="pmid">35599474</pub-id></mixed-citation></ref><ref id="B183"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loprinzi</surname><given-names>P. D.</given-names></name></person-group> (<year>2016</year>). <article-title>Lower extremity muscular strength, sedentary behavior, and mortality</article-title>. <source>Age</source><volume>38</volume>, <fpage>32</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1007/s11357-016-9899-9</pub-id><pub-id pub-id-type="pmid">26931822</pub-id><pub-id pub-id-type="pmcid">PMC5005899</pub-id></mixed-citation></ref><ref id="B184"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loprinzi</surname><given-names>P. D.</given-names></name><name name-style="western"><surname>Frith</surname><given-names>E.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>M. K.</given-names></name></person-group> (<year>2018</year>). <article-title>Resistance exercise and episodic memory function: a systematic review</article-title>. <source>Clin. Physiology Funct. Imaging</source><volume>38</volume> (<issue>6</issue>), <fpage>923</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/cpf.12507</pub-id><pub-id pub-id-type="pmid">29368393</pub-id></mixed-citation></ref><ref id="B185"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Louren&#231;o</surname><given-names>C. F.</given-names></name><name name-style="western"><surname>Ledo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Laranjinha</surname><given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>Neurovascular uncoupling in the triple transgenic model of Alzheimer&#8217;s disease: impaired cerebral blood flow response to neuronal-derived nitric oxide signaling</article-title>. <source>Exp. Neurol.</source><volume>291</volume>, <fpage>36</fpage>&#8211;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2017.01.013</pub-id><pub-id pub-id-type="pmid">28161255</pub-id></mixed-citation></ref><ref id="B186"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nagappan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name></person-group> (<year>2014</year>). &#8220;<article-title>BDNF and synaptic plasticity, cognitive function, and dysfunction</article-title>,&#8221; in <source>Neurotrophic factors</source>. Editors <person-group person-group-type="editor"><name name-style="western"><surname>Lewin</surname><given-names>G. R.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>B. D.</given-names></name></person-group> (<publisher-loc>Berlin, Heidelberg</publisher-loc>: <publisher-name>Springer Berlin Heidelberg</publisher-name>), <fpage>223</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-642-45106-5_9</pub-id><pub-id pub-id-type="pmid">24668475</pub-id></mixed-citation></ref><ref id="B187"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Than</surname><given-names>S.</given-names></name><name name-style="western"><surname>Beare</surname><given-names>R.</given-names></name><name name-style="western"><surname>La Hood</surname><given-names>A.</given-names></name><name name-style="western"><surname>Collyer</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>Srikanth</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Interactions between muscle volume and body mass index on brain structure in the UK biobank</article-title>. <source>Front. Dementia</source><volume>3</volume>, <fpage>1456716</fpage>. <pub-id pub-id-type="doi">10.3389/frdem.2024.1456716</pub-id><pub-id pub-id-type="pmid">39376216</pub-id><pub-id pub-id-type="pmcid">PMC11456486</pub-id></mixed-citation></ref><ref id="B188"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyle</surname><given-names>A. N.</given-names></name><name name-style="western"><surname>Raaz</surname><given-names>U.</given-names></name></person-group> (<year>2017</year>). <article-title>Killing me unsoftly: causes and mechanisms of arterial stiffness</article-title>. <source>Arteriosclerosis, Thrombosis, Vasc. Biol.</source><volume>37</volume> (<issue>2</issue>), <fpage>e1</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.116.308563</pub-id><pub-id pub-id-type="pmid">28122777</pub-id><pub-id pub-id-type="pmcid">PMC5308873</pub-id></mixed-citation></ref><ref id="B189"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macaulay</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Hegarty</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kutch</surname><given-names>J. J.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Effects of a 12-Week periodized Resistance training program on resting brain activity and cerebrovascular function: a nonrandomized pilot trial</article-title>. <source>Neurosci. insights</source><volume>17</volume> (<issue>101760670</issue>), <fpage>26331055221119441</fpage>. <pub-id pub-id-type="doi">10.1177/26331055221119441</pub-id><pub-id pub-id-type="pmid">35983377</pub-id><pub-id pub-id-type="pmcid">PMC9379950</pub-id></mixed-citation></ref><ref id="B190"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacDougall</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>McKelvie</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Moroz</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Sale</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>McCartney</surname><given-names>N.</given-names></name><name name-style="western"><surname>Buick</surname><given-names>F.</given-names></name></person-group> (<year>1992</year>). <article-title>Factors affecting blood pressure during heavy weight lifting and static contractions</article-title>. <source>J. Appl. Physiology</source><volume>73</volume> (<issue>4</issue>), <fpage>1590</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1152/jappl.1992.73.4.1590</pub-id><pub-id pub-id-type="pmid">1447109</pub-id></mixed-citation></ref><ref id="B191"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maldonado</surname><given-names>E.</given-names></name><name name-style="western"><surname>Morales-Pison</surname><given-names>S.</given-names></name><name name-style="western"><surname>Urbina</surname><given-names>F.</given-names></name><name name-style="western"><surname>Solari</surname><given-names>A.</given-names></name></person-group> (<year>2023</year>). <article-title>Aging hallmarks and the role of oxidative stress</article-title>. <source>Antioxidants</source><volume>12</volume> (<issue>3</issue>), <fpage>651</fpage>. <pub-id pub-id-type="doi">10.3390/antiox12030651</pub-id><pub-id pub-id-type="pmid">36978899</pub-id><pub-id pub-id-type="pmcid">PMC10044767</pub-id></mixed-citation></ref><ref id="B192"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malpas</surname><given-names>S. C.</given-names></name></person-group> (<year>2010</year>). <article-title>Sympathetic nervous system overactivity and its role in the development of cardiovascular disease</article-title>. <source>Physiol. Rev.</source><volume>90</volume> (<issue>2</issue>), <fpage>513</fpage>&#8211;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00007.2009</pub-id><pub-id pub-id-type="pmid">20393193</pub-id></mixed-citation></ref><ref id="B193"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marko</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Finch</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Mohammad</surname><given-names>A.</given-names></name><name name-style="western"><surname>MacNeil</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Klentrou</surname><given-names>P.</given-names></name><name name-style="western"><surname>MacPherson</surname><given-names>R. E.</given-names></name></person-group> (<year>2022</year>). <article-title>Postexercise serum from humans influences the biological tug of war of APP processing in human neuronal cells</article-title>. <source>Am. J. Physiology-Cell Physiology</source><volume>322</volume> (<issue>4</issue>), <fpage>C614</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00418.2021</pub-id><pub-id pub-id-type="pmid">35196169</pub-id></mixed-citation></ref><ref id="B194"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marston</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Newton</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Rainey-Smith</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Bird</surname><given-names>S.</given-names></name><name name-style="western"><surname>Martins</surname><given-names>R. N.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Intense resistance exercise increases peripheral brain-derived neurotrophic factor</article-title>. <source>J. Sci. Med. Sport</source><volume>20</volume> (<issue>10</issue>), <fpage>899</fpage>&#8211;<lpage>903</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsams.2017.03.015</pub-id><pub-id pub-id-type="pmid">28511848</pub-id></mixed-citation></ref><ref id="B195"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marston</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Peiffer</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Rainey-Smith</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Teo</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Laws</surname><given-names>S. M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Resistance training enhances delayed memory in healthy middle-aged and older adults: a randomised controlled trial</article-title>. <source>J. Sci. Med. Sport</source><volume>22</volume> (<issue>11</issue>), <fpage>1226</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsams.2019.06.013</pub-id><pub-id pub-id-type="pmid">31281076</pub-id></mixed-citation></ref><ref id="B196"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattsson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tosun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Insel</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Simonson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jack</surname><given-names>C. R.</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Beckett</surname><given-names>L. A.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Association of brain amyloid-&#946; with cerebral perfusion and structure in Alzheimer&#8217;s disease and mild cognitive impairment</article-title>. <source>Brain</source><volume>137</volume> (<issue>5</issue>), <fpage>1550</fpage>&#8211;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awu043</pub-id><pub-id pub-id-type="pmid">24625697</pub-id><pub-id pub-id-type="pmcid">PMC3999717</pub-id></mixed-citation></ref><ref id="B197"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mavros</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gates</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>G. C.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Meiklejohn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brodaty</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Mediation of cognitive function improvements by strength gains after resistance training in older adults with mild cognitive impairment: Outcomes of the study of mental and resistance training</article-title>. <source>J. Am. Geriatrics Soc.</source><volume>65</volume> (<issue>3</issue>), <fpage>550</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/jgs.14542</pub-id><pub-id pub-id-type="pmid">28304092</pub-id></mixed-citation></ref><ref id="B198"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayhan</surname><given-names>W. G.</given-names></name><name name-style="western"><surname>Arrick</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Sharpe</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name></person-group> (<year>2008</year>). <article-title>Age-related alterations in reactivity of cerebral arterioles: role of oxidative stress</article-title>. <source>Microcirculation</source><volume>15</volume> (<issue>3</issue>), <fpage>225</fpage>&#8211;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1080/10739680701641421</pub-id><pub-id pub-id-type="pmid">18386218</pub-id></mixed-citation></ref><ref id="B199"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mcleod</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Currier</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Lowisz</surname><given-names>C. V.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>S. M.</given-names></name></person-group> (<year>2024</year>). <article-title>The influence of resistance exercise training prescription variables on skeletal muscle mass, strength, and physical function in healthy adults: an umbrella review</article-title>. <source>J. Sport Health Sci.</source><volume>13</volume> (<issue>1</issue>), <fpage>47</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.jshs.2023.06.005</pub-id><pub-id pub-id-type="pmid">37385345</pub-id><pub-id pub-id-type="pmcid">PMC10818109</pub-id></mixed-citation></ref><ref id="B200"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L. J.</given-names></name></person-group> (<year>2010</year>). <article-title>Oxidative stress, molecular inflammation and sarcopenia</article-title>. <source>Int. J. Mol. Sci.</source><volume>11</volume> (<issue>4</issue>), <fpage>1509</fpage>&#8211;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.3390/ijms11041509</pub-id><pub-id pub-id-type="pmid">20480032</pub-id><pub-id pub-id-type="pmcid">PMC2871128</pub-id></mixed-citation></ref><ref id="B201"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meysami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Raji</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Glatt</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Popa</surname><given-names>E. S.</given-names></name><name name-style="western"><surname>Ganapathi</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Bookheimer</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Handgrip strength is related to hippocampal and lobar brain volumes in a cohort of cognitively impaired older adults with confirmed amyloid burden</article-title>. <source>J. Alzheimer&#8217;s Dis.</source><volume>91</volume> (<issue>3</issue>), <fpage>999</fpage>&#8211;<lpage>1006</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-220886</pub-id><pub-id pub-id-type="pmid">36530088</pub-id><pub-id pub-id-type="pmcid">PMC9912728</pub-id></mixed-citation></ref><ref id="B202"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mielke</surname><given-names>M. M.</given-names></name></person-group> (<year>2018</year>). <article-title>Sex and gender differences in Alzheimer&#8217;s disease dementia</article-title>. <source>Psychiatric times</source><volume>35</volume> (<issue>11</issue>), <fpage>14</fpage>&#8211;<lpage>17</lpage>.
<pub-id pub-id-type="pmid">30820070</pub-id><pub-id pub-id-type="pmcid">PMC6390276</pub-id></mixed-citation></ref><ref id="B203"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>G. F.</given-names></name></person-group> (<year>1985)2008</year>). <article-title>Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage</article-title>. <source>J. Appl. Physiol.</source><volume>105</volume> (<issue>5</issue>), <fpage>1652</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1152/japplphysiol.90549.2008</pub-id><pub-id pub-id-type="pmid">18772322</pub-id><pub-id pub-id-type="pmcid">PMC2584844</pub-id></mixed-citation></ref><ref id="B204"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>G. F.</given-names></name></person-group> (<year>2011</year>). <article-title>Aortic stiffness and cerebral blood flow</article-title>. <source>Am. J. Hypertens.</source><volume>24</volume>, <fpage>1056</fpage>. <pub-id pub-id-type="doi">10.1038/ajh.2011.112</pub-id><pub-id pub-id-type="pmid">21927008</pub-id></mixed-citation></ref><ref id="B205"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>G. F.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Vasan</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Larson</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Pencina</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Hamburg</surname><given-names>N. M.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Arterial stiffness and cardiovascular events: the framingham heart study</article-title>. <source>Circulation</source><volume>121</volume> (<issue>4</issue>), <fpage>505</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.886655</pub-id><pub-id pub-id-type="pmid">20083680</pub-id><pub-id pub-id-type="pmcid">PMC2836717</pub-id></mixed-citation></ref><ref id="B206"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyachi</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Effects of resistance training on arterial stiffness: a meta-analysis</article-title>. <source>Br. J. Sports Med.</source><volume>47</volume> (<issue>6</issue>), <fpage>393</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1136/bjsports-2012-090488</pub-id><pub-id pub-id-type="pmid">22267567</pub-id></mixed-citation></ref><ref id="B207"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyachi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kawano</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sugawara</surname><given-names>J.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Unfavorable effects of resistance training on central arterial compliance: a randomized intervention study</article-title>. <source>Circulation</source><volume>110</volume> (<issue>18</issue>), <fpage>2858</fpage>&#8211;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1161/01.CIR.0000146380.08401.99</pub-id><pub-id pub-id-type="pmid">15492301</pub-id></mixed-citation></ref><ref id="B208"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mogensen</surname><given-names>F. L.</given-names></name><name name-style="western"><surname>Delle</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nedergaard</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>The glymphatic system (en)during inflammation</article-title>. <source>Int. J. Mol. Sci.</source><volume>22</volume> (<issue>14</issue>), <fpage>7491</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22147491</pub-id><pub-id pub-id-type="pmid">34299111</pub-id><pub-id pub-id-type="pmcid">PMC8305763</pub-id></mixed-citation></ref><ref id="B209"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molina-Sotomayor</surname><given-names>E.</given-names></name><name name-style="western"><surname>Castillo-Quezada</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Salazar</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Orb</surname><given-names>M.</given-names></name><name name-style="western"><surname>Espinoza-Salinas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gonzalez-Jurado</surname><given-names>J. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Effects of progressive resistance training on cognition and igf-1 levels in elder women who live in areas with high air pollution</article-title>. <source>Int. J. Environ. Res. Public Health</source><volume>17</volume> (<issue>17</issue>), <fpage>1</fpage>&#8211;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.3390/ijerph17176203</pub-id><pub-id pub-id-type="pmid">32859109</pub-id><pub-id pub-id-type="pmcid">PMC7503506</pub-id></mixed-citation></ref><ref id="B210"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. O.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S. H.</given-names></name></person-group> (<year>2019</year>). <article-title>Muscle strength is independently related to brain atrophy in patients with alzheimer&#8217;s disease</article-title>. <source>Dementia Geriatric Cognitive Disord.</source><volume>47</volume> (<issue>4&#8211;6</issue>), <fpage>306</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1159/000500718</pub-id><pub-id pub-id-type="pmid">31311027</pub-id></mixed-citation></ref><ref id="B211"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mirza</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Gimblet</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Ortlip</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Ancalmo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kalita</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Effect of an 11-Week Resistance training program on arterial stiffness in young women</article-title>. <source>J. Strength Cond. Res.</source><volume>37</volume> (<issue>2</issue>), <fpage>315</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1519/JSC.0000000000004280</pub-id><pub-id pub-id-type="pmid">35916876</pub-id></mixed-citation></ref><ref id="B212"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moroni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ammirati</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rocca</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Filippi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Magnoni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Camici</surname><given-names>P. G.</given-names></name></person-group> (<year>2018</year>). <article-title>Cardiovascular disease and brain health: focus on white matter hyperintensities</article-title>. <source>IJC Heart and Vasc.</source><volume>19</volume>, <fpage>63</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcha.2018.04.006</pub-id><pub-id pub-id-type="pmid">29946567</pub-id><pub-id pub-id-type="pmcid">PMC6016077</pub-id></mixed-citation></ref><ref id="B213"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moyaert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Padrela</surname><given-names>B. E.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Petr</surname><given-names>J.</given-names></name><name name-style="western"><surname>Versijpt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Imaging blood-brain barrier dysfunction: a state-of-the-art review from a clinical perspective</article-title>. <source>Front. aging Neurosci.</source><volume>15</volume>, <fpage>1132077</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2023.1132077</pub-id><pub-id pub-id-type="pmid">37139088</pub-id><pub-id pub-id-type="pmcid">PMC10150073</pub-id></mixed-citation></ref><ref id="B214"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muhire</surname><given-names>G.</given-names></name><name name-style="western"><surname>Iulita</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Vallerand</surname><given-names>D.</given-names></name><name name-style="western"><surname>Youwakim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gratuze</surname><given-names>M.</given-names></name><name name-style="western"><surname>Petry</surname><given-names>F. R.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Arterial stiffness due to carotid calcification disrupts cerebral blood flow regulation and leads to cognitive deficits</article-title>. <source>J. Am. Heart Assoc.</source><volume>8</volume> (<issue>9</issue>), <fpage>e011630</fpage>. <pub-id pub-id-type="doi">10.1161/JAHA.118.011630</pub-id><pub-id pub-id-type="pmid">31057061</pub-id><pub-id pub-id-type="pmcid">PMC6512142</pub-id></mixed-citation></ref><ref id="B215"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murawska-Cia&#322;owicz</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Assis</surname><given-names>G. G.</given-names></name><name name-style="western"><surname>Clemente</surname><given-names>F. M.</given-names></name><name name-style="western"><surname>Feito</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Stastny</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zuwa&#322;a-Jagie&#322;&#322;o</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Effect of four different forms of high intensity training on BDNF response to wingate and graded exercise test</article-title>. <source>Sci. Rep.</source><volume>11</volume> (<issue>1</issue>), <fpage>8599</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-88069-y</pub-id><pub-id pub-id-type="pmid">33883635</pub-id><pub-id pub-id-type="pmcid">PMC8060323</pub-id></mixed-citation></ref><ref id="B216"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagamatsu</surname><given-names>L. S.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Beattie</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Graf</surname><given-names>P.</given-names></name><name name-style="western"><surname>Voss</surname><given-names>M. W.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Physical activity improves verbal and spatial memory in older adults with probable mild cognitive impairment: a 6&#8208;month randomized controlled trial</article-title>. <source>J. aging Res.</source><volume>2013</volume> (<issue>1</issue>), <fpage>861893</fpage>. <pub-id pub-id-type="doi">10.1155/2013/861893</pub-id><pub-id pub-id-type="pmid">23509628</pub-id><pub-id pub-id-type="pmcid">PMC3595715</pub-id></mixed-citation></ref><ref id="B217"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kubo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Muraoka</surname><given-names>I.</given-names></name></person-group> (<year>2021</year>). <article-title>Effects of changes in large arterial compliance and small arterial buffer function with resistance training on cerebral blood flow pulsatility</article-title>. <source>Gazzetta Medica Ital. Arch. Sci. Mediche</source><volume>180</volume> (<issue>12</issue>), <fpage>805</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.23736/s0393-3660.19.04300-6</pub-id></mixed-citation></ref><ref id="B218"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Rejeski</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Blair</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>P. W.</given-names></name><name name-style="western"><surname>Judge</surname><given-names>J. O.</given-names></name><name name-style="western"><surname>King</surname><given-names>A. C.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Physical activity and public health in older adults: recommendation from the American college of sports medicine and the American heart association</article-title>. <source>Med. and Sci. Sports and Exerc.</source><volume>39</volume> (<issue>8</issue>), <fpage>1435</fpage>&#8211;<lpage>1445</lpage>. <pub-id pub-id-type="doi">10.1249/mss.0b013e3180616aa2</pub-id><pub-id pub-id-type="pmid">17762378</pub-id></mixed-citation></ref><ref id="B219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Sweeney</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Sagare</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Zlokovic</surname><given-names>B. V.</given-names></name></person-group> (<year>2016</year>). <article-title>Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer&#8217;s disease</article-title>. <source>Biochimica Biophysica Acta (BBA)-Molecular Basis Dis.</source><volume>1862</volume> (<issue>5</issue>), <fpage>887</fpage>&#8211;<lpage>900</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2015.12.016</pub-id><pub-id pub-id-type="pmid">26705676</pub-id><pub-id pub-id-type="pmcid">PMC4821735</pub-id></mixed-citation></ref><ref id="B220"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newman</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>O.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lyketsos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Dementia and Alzheimer&#8217;s disease incidence in relationship to cardiovascular disease in the cardiovascular health study cohort</article-title>. <source>J. Am. Geriatrics Soc.</source><volume>53</volume> (<issue>7</issue>), <fpage>1101</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/j.1532-5415.2005.53360.x</pub-id><pub-id pub-id-type="pmid">16108925</pub-id></mixed-citation></ref><ref id="B221"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicolakakis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hamel</surname><given-names>E.</given-names></name></person-group> (<year>2011</year>). <article-title>Neurovascular function in Alzheimer&#8217;s disease patients and experimental models</article-title>. <source>J. Cereb. Blood Flow and Metabolism</source><volume>31</volume> (<issue>6</issue>), <fpage>1354</fpage>&#8211;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2011.43</pub-id><pub-id pub-id-type="pmid">21468088</pub-id><pub-id pub-id-type="pmcid">PMC3130325</pub-id></mixed-citation></ref><ref id="B222"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieto-Bona</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Garc&#237;a-Segura</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Torres-alem&#225;n</surname><given-names>I.</given-names></name></person-group> (<year>1997</year>). <article-title>Transynaptic modulation by insulin-like growth factor I of dendritic spines in purkinje cells</article-title>. <source>Int. J. Dev. Neurosci.</source><volume>15</volume> (<issue>6</issue>), <fpage>749</fpage>&#8211;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/s0736-5748(97)00021-x</pub-id><pub-id pub-id-type="pmid">9402225</pub-id></mixed-citation></ref><ref id="B223"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nose</surname><given-names>D.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>H.</given-names></name><name name-style="western"><surname>Imaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saku</surname><given-names>K.</given-names></name><name name-style="western"><surname>Miura</surname><given-names>S. ichiro</given-names></name></person-group> (<year>2023</year>). <article-title>Effects of a 14-week community health program of exercise and learning/education in older adults: a single-arm pre-post comparison study</article-title>. <source>Geriatr. Nurs.</source><volume>51</volume>, <fpage>1</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.gerinurse.2023.02.012</pub-id><pub-id pub-id-type="pmid">36871326</pub-id></mixed-citation></ref><ref id="B224"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nouchi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Taki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sekiguchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hashizume</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nozawa</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Four weeks of combination exercise training improved executive functions, episodic memory, and processing speed in healthy elderly people: evidence from a randomized controlled trial</article-title>. <source>AGE</source><volume>36</volume> (<issue>2</issue>), <fpage>787</fpage>&#8211;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1007/s11357-013-9588-x</pub-id><pub-id pub-id-type="pmid">24065294</pub-id><pub-id pub-id-type="pmcid">PMC4039261</pub-id></mixed-citation></ref><ref id="B225"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okamoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Masuhara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ikuta</surname><given-names>K.</given-names></name></person-group> (<year>2006</year>). <article-title>Effects of eccentric and concentric resistance training on arterial stiffness</article-title>. <source>J. Hum. Hypertens.</source><volume>20</volume> (<issue>5</issue>), <fpage>348</fpage>&#8211;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1038/sj.jhh.1001979</pub-id><pub-id pub-id-type="pmid">16496019</pub-id></mixed-citation></ref><ref id="B226"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okamoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Masuhara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ikuta</surname><given-names>K.</given-names></name></person-group> (<year>2009</year>). <article-title>Upper but not lower limb resistance training increases arterial stiffness in humans</article-title>. <source>Eur. J. Appl. Physiol.</source><volume>107</volume> (<issue>2</issue>), <fpage>127</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1007/s00421-009-1110-x</pub-id><pub-id pub-id-type="pmid">19533164</pub-id></mixed-citation></ref><ref id="B227"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ostrowski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rohde</surname><given-names>T.</given-names></name><name name-style="western"><surname>Asp</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schjerling</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>B. K.</given-names></name></person-group> (<year>1999</year>). <article-title>Pro&#8208;and anti&#8208;inflammatory cytokine balance in strenuous exercise in humans</article-title>. <source>J. physiology</source><volume>515</volume> (<issue>1</issue>), <fpage>287</fpage>&#8211;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-7793.1999.287ad.x</pub-id><pub-id pub-id-type="pmid">9925898</pub-id><pub-id pub-id-type="pmcid">PMC2269132</pub-id></mixed-citation></ref><ref id="B228"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#214;zbeyli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sar&#305;</surname><given-names>G.</given-names></name><name name-style="western"><surname>&#214;zkan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Karademir</surname><given-names>B.</given-names></name><name name-style="western"><surname>Y&#252;ksel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kaya</surname><given-names>&#214;. T. &#199;.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Protective effects of different exercise modalities in an Alzheimer&#8217;s disease-like model</article-title>. <source>Behav. brain Res.</source><volume>328</volume>, <fpage>159</fpage>&#8211;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2017.03.044</pub-id><pub-id pub-id-type="pmid">28390878</pub-id></mixed-citation></ref><ref id="B229"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozturk</surname><given-names>E. D.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>C. O.</given-names></name></person-group> (<year>2018</year>). <article-title>Human cerebrovascular function in health and disease: insights from integrative approaches</article-title>. <source>J. Physiological Anthropol.</source><volume>37</volume> (<issue>1</issue>), <fpage>4</fpage>. <pub-id pub-id-type="doi">10.1186/s40101-018-0164-z</pub-id><pub-id pub-id-type="pmid">29454381</pub-id><pub-id pub-id-type="pmcid">PMC5816507</pub-id></mixed-citation></ref><ref id="B230"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Brien J</surname><given-names>T.</given-names></name><name name-style="western"><surname>Firbank</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>K.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>G. B.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>C. W.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Association between midlife dementia risk factors and longitudinal brain atrophy: the PREVENT-dementia study</article-title>. <source>J. Neurology, Neurosurg. and Psychiatry</source><volume>91</volume> (<issue>2</issue>), <fpage>158</fpage>&#8211;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp-2019-321652</pub-id><pub-id pub-id-type="pmid">31806724</pub-id></mixed-citation></ref><ref id="B231"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paluch</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>W. R.</given-names></name><name name-style="western"><surname>Franklin</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Laddu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lobelo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D. chul</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Resistance exercise training in individuals with and without cardiovascular disease: 2023 update: a scientific statement from the American heart association</article-title>. <source>Circulation</source><volume>149</volume> (<issue>3</issue>), <fpage>e217</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1161/CIR.0000000000001189</pub-id><pub-id pub-id-type="pmid">38059362</pub-id><pub-id pub-id-type="pmcid">PMC11209834</pub-id></mixed-citation></ref><ref id="B232"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Banks</surname><given-names>W. A.</given-names></name><name name-style="western"><surname>Fasold</surname><given-names>M. B.</given-names></name><name name-style="western"><surname>Bluth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kastin</surname><given-names>A. J.</given-names></name></person-group> (<year>1998</year>). <article-title>Transport of brain-derived neurotrophic factor across the blood&#8211;brain barrier</article-title>. <source>Neuropharmacology</source><volume>37</volume> (<issue>12</issue>), <fpage>1553</fpage>&#8211;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/s0028-3908(98)00141-5</pub-id><pub-id pub-id-type="pmid">9886678</pub-id></mixed-citation></ref><ref id="B233"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Inflammation and sarcopenia: a focus on circulating inflammatory cytokines</article-title>. <source>Exp. Gerontol.</source><volume>154</volume>, <fpage>111544</fpage>. <pub-id pub-id-type="doi">10.1016/j.exger.2021.111544</pub-id><pub-id pub-id-type="pmid">34478826</pub-id></mixed-citation></ref><ref id="B234"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>H.</given-names></name><name name-style="western"><surname>Poo</surname><given-names>M. ming</given-names></name></person-group> (<year>2013</year>). <article-title>Neurotrophin regulation of neural circuit development and function</article-title>. <source>Nat. Rev. Neurosci.</source><volume>14</volume> (<issue>1</issue>), <fpage>7</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3379</pub-id><pub-id pub-id-type="pmid">23254191</pub-id></mixed-citation></ref><ref id="B235"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ratna</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Ebenezer</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>ATP synthase and mitochondrial bioenergetics dysfunction in Alzheimer&#8217;s disease</article-title>. <source>Int. J. Mol. Sci.</source><volume>22</volume> (<issue>20</issue>), <fpage>11185</fpage>. <pub-id pub-id-type="doi">10.3390/ijms222011185</pub-id><pub-id pub-id-type="pmid">34681851</pub-id><pub-id pub-id-type="pmcid">PMC8539681</pub-id></mixed-citation></ref><ref id="B236"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peig-Chiello</surname><given-names>P.</given-names></name><name name-style="western"><surname>Perrig</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Ehrsam</surname><given-names>R.</given-names></name><name name-style="western"><surname>Staehelin</surname><given-names>H. B.</given-names></name><name name-style="western"><surname>Krings</surname><given-names>F.</given-names></name></person-group> (<year>1998</year>). <article-title>The effects of resistance training on well-being and memory in elderly volunteers</article-title>. <source>Age Ageing</source><volume>27</volume> (<issue>4</issue>), <fpage>469</fpage>&#8211;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1093/ageing/27.4.469</pub-id><pub-id pub-id-type="pmid">9884004</pub-id></mixed-citation></ref><ref id="B237"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rodrigue</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Park</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name></person-group> (<year>2018</year>). <article-title>Age-related changes in cerebrovascular reactivity and their relationship to cognition: a four-year longitudinal study</article-title>. <source>NeuroImage</source><volume>174</volume>, <fpage>257</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2018.03.033</pub-id><pub-id pub-id-type="pmid">29567504</pub-id><pub-id pub-id-type="pmcid">PMC5949266</pub-id></mixed-citation></ref><ref id="B238"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pereira</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>De Queiroz</surname><given-names>B. Z.</given-names></name><name name-style="western"><surname>Miranda</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Rocha</surname><given-names>N. P.</given-names></name><name name-style="western"><surname>Fel&#237;cio</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Mateo</surname><given-names>E. C.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Effects of physical exercise on plasma levels of brain-derived neurotrophic factor and depressive symptoms in elderly Women&#8212;A randomized clinical trial</article-title>. <source>Archives Phys. Med. rehabilitation</source><volume>94</volume> (<issue>8</issue>), <fpage>1443</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.apmr.2013.03.029</pub-id><pub-id pub-id-type="pmid">23602881</pub-id></mixed-citation></ref><ref id="B239"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perrone</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Fenwick-Smith</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vandenburgh</surname><given-names>H. H.</given-names></name></person-group> (<year>1995</year>). <article-title>Collagen and stretch modulate autocrine secretion of insulin-like growth Factor-1 and insulin-like growth factor binding proteins from differentiated skeletal muscle cells (&#8727;)</article-title>. <source>J. Biol. Chem.</source><volume>270</volume> (<issue>5</issue>), <fpage>2099</fpage>&#8211;<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.270.5.2099</pub-id><pub-id pub-id-type="pmid">7530717</pub-id></mixed-citation></ref><ref id="B240"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perry</surname><given-names>B. G.</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>S. J. E.</given-names></name></person-group> (<year>2021</year>). <article-title>The acute cardiorespiratory and cerebrovascular response to resistance exercise</article-title>. <source>Sports Med. - Open</source><volume>7</volume> (<issue>1</issue>), <fpage>36</fpage>. <pub-id pub-id-type="doi">10.1186/s40798-021-00314-w</pub-id><pub-id pub-id-type="pmid">34046740</pub-id><pub-id pub-id-type="pmcid">PMC8160070</pub-id></mixed-citation></ref><ref id="B241"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>F. H.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M. M. Z.</given-names></name><name name-style="western"><surname>Krassioukov</surname><given-names>A. V.</given-names></name><name name-style="western"><surname>Ainslie</surname><given-names>P. N.</given-names></name></person-group> (<year>2016</year>). <article-title>Neurovascular coupling in humans: physiology, methodological advances and clinical implications</article-title>. <source>J. Cereb. Blood Flow. Metab.</source><volume>36</volume> (<issue>4</issue>), <fpage>647</fpage>&#8211;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1177/0271678X15617954</pub-id><pub-id pub-id-type="pmid">26661243</pub-id><pub-id pub-id-type="pmcid">PMC4821024</pub-id></mixed-citation></ref><ref id="B242"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Planche</surname><given-names>V.</given-names></name><name name-style="western"><surname>Coup&#233;</surname><given-names>P.</given-names></name><name name-style="western"><surname>Helmer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Le Goff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amieva</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tison</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Evolution of brain atrophy subtypes during aging predicts long-term cognitive decline and future Alzheimer&#8217;s clinical syndrome</article-title>. <source>Neurobiol. aging</source><volume>79</volume>, <fpage>22</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2019.03.006</pub-id><pub-id pub-id-type="pmid">31026619</pub-id></mixed-citation></ref><ref id="B243"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Protas</surname><given-names>H. D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Langbaum</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Fleisher</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for alzheimer disease</article-title>. <source>JAMA neurol.</source><volume>70</volume> (<issue>3</issue>), <fpage>320</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1001/2013.jamaneurol.286</pub-id><pub-id pub-id-type="pmid">23599929</pub-id><pub-id pub-id-type="pmcid">PMC3745014</pub-id></mixed-citation></ref><ref id="B244"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulford</surname><given-names>B. E.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>D. N.</given-names></name></person-group> (<year>2001</year>). <article-title>Uptake of circulating insulin-like growth factors (IGFs) into cerebrospinal fluid appears to be independent of the IGF receptors as well as IGF-Binding proteins</article-title>. <source>Endocrinology</source><volume>142</volume> (<issue>1</issue>), <fpage>213</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1210/endo.142.1.7894</pub-id><pub-id pub-id-type="pmid">11145584</pub-id></mixed-citation></ref><ref id="B245"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>F.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Circulating insulin-like growth Factor-1 and risk of total and 19 site-specific cancers: Cohort study analyses from the UK biobank</article-title>. <source>Cancer Epidemiol. Biomarkers and Prev.</source><volume>29</volume> (<issue>11</issue>), <fpage>2332</fpage>&#8211;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-20-0743</pub-id><pub-id pub-id-type="pmid">32856611</pub-id><pub-id pub-id-type="pmcid">PMC7642199</pub-id></mixed-citation></ref><ref id="B246"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajan</surname><given-names>K. B.</given-names></name><name name-style="western"><surname>Weuve</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>L. L.</given-names></name><name name-style="western"><surname>McAninch</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>D. A.</given-names></name></person-group> (<year>2021</year>). <article-title>Population estimate of people with clinical Alzheimer&#8217;s disease and mild cognitive impairment in the United States (2020&#8211;2060)</article-title>. <source>Alzheimer&#8217;s and Dementia</source><volume>17</volume> (<issue>12</issue>), <fpage>1966</fpage>&#8211;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1002/alz.12362</pub-id><pub-id pub-id-type="pmid">34043283</pub-id><pub-id pub-id-type="pmcid">PMC9013315</pub-id></mixed-citation></ref><ref id="B247"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ram&#237;rez-V&#233;lez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Castro-Astudillo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Correa-Bautista</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Ru&#237;z</surname><given-names>K.</given-names></name><name name-style="western"><surname>Izquierdo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garc&#237;a-Hermoso</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The effect of 12 weeks of different exercise training modalities or nutritional guidance on cardiometabolic risk factors, vascular parameters, and physical fitness in overweight adults: cardiometabolic high-intensity interval training-resistance training randomized controlled study</article-title>. <source>J. Strength and Cond. Res.</source><volume>34</volume> (<issue>8</issue>), <fpage>2178</fpage>&#8211;<lpage>2188</lpage>. <pub-id pub-id-type="doi">10.1519/JSC.0000000000003533</pub-id><pub-id pub-id-type="pmid">32187150</pub-id></mixed-citation></ref><ref id="B248"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramos-Campo</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Alcaraz</surname><given-names>P. E.</given-names></name><name name-style="western"><surname>Rubio-Arias</surname><given-names>J. A.</given-names></name></person-group> (<year>2018</year>). <article-title>The efficacy of resistance training in hypoxia to enhance strength and muscle growth: a systematic review and meta-analysis</article-title>. <source>Eur. J. sport Sci.</source><volume>18</volume> (<issue>1</issue>), <fpage>92</fpage>&#8211;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1080/17461391.2017.1388850</pub-id><pub-id pub-id-type="pmid">29045191</pub-id></mixed-citation></ref><ref id="B249"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasmussen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Brassard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Adser</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Leick</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hart</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Evidence for a release of brain-derived neurotrophic factor from the brain during exercise</article-title>. <source>Exp. Physiol.</source><volume>94</volume> (<issue>10</issue>), <fpage>1062</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1113/expphysiol.2009.048512</pub-id><pub-id pub-id-type="pmid">19666694</pub-id></mixed-citation></ref><ref id="B250"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>O. C.</given-names></name><name name-style="western"><surname>van der Werf</surname><given-names>Y. D.</given-names></name></person-group> (<year>2020</year>). <article-title>The sleeping brain: harnessing the power of the glymphatic system through lifestyle choices</article-title>. <source>Brain Sci.</source><volume>10</volume> (<issue>11</issue>), <fpage>868</fpage>. <pub-id pub-id-type="doi">10.3390/brainsci10110868</pub-id><pub-id pub-id-type="pmid">33212927</pub-id><pub-id pub-id-type="pmcid">PMC7698404</pub-id></mixed-citation></ref><ref id="B251"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roher</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Garami</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tyas</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Maarouf</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Kokjohn</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>Belohlavek</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Transcranial doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer&#8217;s disease</article-title>. <source>Alzheimer&#8217;s Dement.</source><volume>7</volume> (<issue>4</issue>), <fpage>445</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.jalz.2010.09.002</pub-id><pub-id pub-id-type="pmid">21388892</pub-id><pub-id pub-id-type="pmcid">PMC3117072</pub-id></mixed-citation></ref><ref id="B252"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rojas&#8208;Gutierrez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mu&#241;oz&#8208;Arenas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Trevi&#241;o</surname><given-names>S.</given-names></name><name name-style="western"><surname>Espinosa</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chavez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rojas</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Alzheimer&#8217;s disease and metabolic syndrome: a link from oxidative stress and inflammation to neurodegeneration</article-title>. <source>Synapse</source><volume>71</volume> (<issue>10</issue>), <fpage>e21990</fpage>. <pub-id pub-id-type="doi">10.1002/syn.21990</pub-id><pub-id pub-id-type="pmid">28650104</pub-id></mixed-citation></ref><ref id="B253"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rond&#227;o</surname><given-names>C. A. de M.</given-names></name><name name-style="western"><surname>Mota</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Peixoto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Esteves</surname><given-names>D.</given-names></name></person-group> (<year>2022</year>). <article-title>Multicomponent exercise program effects on fitness and cognitive function of elderlies with mild cognitive impairment: involvement of oxidative stress and BDNF</article-title>. <source>Front. Aging Neurosci.</source><volume>14</volume>, <fpage>950937</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2022.950937</pub-id><pub-id pub-id-type="pmid">36092805</pub-id><pub-id pub-id-type="pmcid">PMC9453672</pub-id></mixed-citation></ref><ref id="B254"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossow</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Fahs</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Thiebaud</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Loenneke</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mouser</surname><given-names>J. G.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Arterial stiffness and blood flow adaptations following eight weeks of resistance exercise training in young and older women</article-title>. <source>Exp. Gerontol.</source><volume>53</volume>, <fpage>48</fpage>&#8211;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/j.exger.2014.02.010</pub-id><pub-id pub-id-type="pmid">24566193</pub-id></mixed-citation></ref><ref id="B255"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Labrecque</surname><given-names>L.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>B. G.</given-names></name><name name-style="western"><surname>Korad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smirl</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Brassard</surname><given-names>P.</given-names></name></person-group> (<year>2022</year>). <article-title>Directional sensitivity of the cerebral pressure-flow relationship in young healthy individuals trained in endurance and resistance exercise</article-title>. <source>Exp. Physiol.</source><volume>107</volume> (<issue>4</issue>), <fpage>299</fpage>&#8211;<lpage>311</lpage>. <pub-id pub-id-type="doi">10.1113/EP090159</pub-id><pub-id pub-id-type="pmid">35213765</pub-id></mixed-citation></ref><ref id="B256"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruiz</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Gil-Bea</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bustamante-Ara</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Romo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fiuza-Luces</surname><given-names>C.</given-names></name><name name-style="western"><surname>Serra-Rexach</surname><given-names>J. A.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Resistance training does not have an effect on cognition or related serum biomarkers in nonagenarians: a randomized controlled trial</article-title>. <source>Int. J. Sports Med.</source><volume>36</volume> (<issue>1</issue>), <fpage>54</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1055/s-0034-1375693</pub-id><pub-id pub-id-type="pmid">25329433</pub-id></mixed-citation></ref><ref id="B257"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabayan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oleksik</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>van Osch</surname><given-names>M. J. P.</given-names></name><name name-style="western"><surname>van Buchem</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>van Vliet</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Cerebrovascular hemodynamics in Alzheimer&#8217;s disease and vascular dementia: a meta-analysis of transcranial doppler studies</article-title>. <source>Ageing Res. Rev.</source><volume>11</volume> (<issue>2</issue>), <fpage>271</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.arr.2011.12.009</pub-id><pub-id pub-id-type="pmid">22226802</pub-id></mixed-citation></ref><ref id="B258"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Safar</surname><given-names>M. E.</given-names></name></person-group> (<year>2018</year>). <article-title>Arterial stiffness as a risk factor for clinical hypertension</article-title>. <source>Nat. Rev. Cardiol.</source><volume>15</volume> (<issue>2</issue>), <fpage>97</fpage>&#8211;<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1038/nrcardio.2017.155</pub-id><pub-id pub-id-type="pmid">29022570</pub-id></mixed-citation></ref><ref id="B259"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sagiv</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Safety of resistance training in the elderly</article-title>. <source>Eur. Rev. Aging Phys. Activity</source><volume>6</volume> (<issue>1</issue>), <fpage>1</fpage>&#8211;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1007/s11556-009-0047-8</pub-id></mixed-citation></ref><ref id="B260"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sartorius</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hellweg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Litzke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vogt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dormann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vollmayr</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats</article-title>. <source>Pharmacopsychiatry</source><volume>42</volume> (<issue>06</issue>), <fpage>270</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1055/s-0029-1224162</pub-id><pub-id pub-id-type="pmid">19924587</pub-id></mixed-citation></ref><ref id="B261"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schimidt</surname><given-names>H. L.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Izquierdo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mello-Carpes</surname><given-names>P. B.</given-names></name><name name-style="western"><surname>Carpes</surname><given-names>F. P.</given-names></name></person-group> (<year>2019</year>). <article-title>Strength training and running elicit different neuroprotective outcomes in a &#946;-amyloid peptide-mediated Alzheimer&#8217;s disease model</article-title>. <source>Physiology Behav.</source><volume>206</volume>, <fpage>206</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.physbeh.2019.04.012</pub-id><pub-id pub-id-type="pmid">30995451</pub-id></mixed-citation></ref><ref id="B262"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>T.</given-names></name><name name-style="western"><surname>Verdile</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sohrabi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Putland</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cheetham</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>A combination of physical activity and computerized brain training improves verbal memory and increases cerebral glucose metabolism in the elderly</article-title>. <source>Transl. Psychiatry</source><volume>4</volume> (<issue>12</issue>), <fpage>e487</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2014.122</pub-id><pub-id pub-id-type="pmid">25463973</pub-id><pub-id pub-id-type="pmcid">PMC4270308</pub-id></mixed-citation></ref><ref id="B263"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaito</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aramouni</surname><given-names>K.</given-names></name><name name-style="western"><surname>Assaf</surname><given-names>R.</given-names></name><name name-style="western"><surname>Parenti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Orekhov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yazbi</surname><given-names>A. E.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Oxidative stress-induced endothelial dysfunction in cardiovascular diseases</article-title>. <source>FBL</source><volume>27</volume> (<issue>3</issue>), <fpage>105</fpage>&#8211;<lpage>null</lpage>. <pub-id pub-id-type="doi">10.31083/j.fbl2703105</pub-id><pub-id pub-id-type="pmid">35345337</pub-id></mixed-citation></ref><ref id="B264"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaughnessy</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Hackney</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>B. C.</given-names></name><name name-style="western"><surname>Kraemer</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Terbizan</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>R. R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A narrative review of handgrip strength and cognitive functioning: bringing a new characteristic to muscle memory</article-title>. <source>J. Alzheimer&#8217;s Dis.</source><volume>73</volume> (<issue>4</issue>), <fpage>1265</fpage>&#8211;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-190856</pub-id><pub-id pub-id-type="pmid">31929158</pub-id><pub-id pub-id-type="pmcid">PMC7063546</pub-id></mixed-citation></ref><ref id="B265"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>JKTNF</given-names></name><name name-style="western"><surname>Men&#234;ses</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Parmenter</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Ritti-Dias</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Farah</surname><given-names>B. Q.</given-names></name></person-group> (<year>2021</year>). <article-title>Effects of resistance training on endothelial function: a systematic review and meta-analysis</article-title>. <source>Atherosclerosis</source><volume>333</volume>, <fpage>91</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2021.07.009</pub-id><pub-id pub-id-type="pmid">34399984</pub-id></mixed-citation></ref><ref id="B266"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silveira-Rodrigues</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Nogueira</surname><given-names>N. G. de H. M.</given-names></name><name name-style="western"><surname>Faria</surname><given-names>L. O.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>D. D.</given-names></name></person-group> (<year>2023</year>). <article-title>Combined training improves executive functions without changing brain-derived neurotrophic factor levels of middle-aged and older adults with type 2 diabetes</article-title>. <source>Exp. Clin. Endocrinol. and Diabetes</source><volume>131</volume> (<issue>06</issue>), <fpage>345</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1055/a-2069-4050</pub-id><pub-id pub-id-type="pmid">37019176</pub-id></mixed-citation></ref><ref id="B267"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silvestrini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pasqualetti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Baruffaldi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bartolini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Handouk</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Matteis</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Cerebrovascular reactivity and cognitive decline in patients with alzheimer disease</article-title>. <source>Stroke</source><volume>37</volume> (<issue>4</issue>), <fpage>1010</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1161/01.STR.0000206439.62025.97</pub-id><pub-id pub-id-type="pmid">16497984</pub-id></mixed-citation></ref><ref id="B268"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Sims-Robinson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>E. L.</given-names></name></person-group> (<year>2015</year>). &#8220;<article-title>Diabetes and cognitive dysfunction</article-title>,&#8221; in <source>Neurobiology of brain disorders</source><publisher-name>Elsevier</publisher-name>, <fpage>189</fpage>&#8211;<lpage>201</lpage>.</mixed-citation></ref><ref id="B269"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Trollor</surname><given-names>J. N.</given-names></name><name name-style="western"><surname>Baune</surname><given-names>B. T.</given-names></name><name name-style="western"><surname>Sachdev</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>E.</given-names></name></person-group> (<year>2014</year>). <article-title>Arterial stiffness, the brain and cognition: a systematic review</article-title>. <source>Ageing Res. Rev.</source><volume>15</volume>, <fpage>16</fpage>&#8211;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.arr.2014.02.002</pub-id><pub-id pub-id-type="pmid">24548924</pub-id></mixed-citation></ref><ref id="B270"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steensberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Keller</surname><given-names>C.</given-names></name><name name-style="western"><surname>Starkie</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Osada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Febbraio</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>B. K.</given-names></name></person-group> (<year>2002</year>). <article-title>IL-6 and TNF-&#945; expression in, and release from, contracting human skeletal muscle</article-title>. <source>Am. J. Physiology-Endocrinology Metabolism</source><volume>283</volume> (<issue>6</issue>), <fpage>E1272</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1152/ajpendo.00255.2002</pub-id><pub-id pub-id-type="pmid">12388119</pub-id></mixed-citation></ref><ref id="B271"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stefanidis</surname><given-names>K. B.</given-names></name><name name-style="western"><surname>Askew</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>Greaves</surname><given-names>K.</given-names></name><name name-style="western"><surname>Summers</surname><given-names>M. J.</given-names></name></person-group> (<year>2018</year>). <article-title>The effect of non-stroke cardiovascular disease states on risk for cognitive decline and dementia: a systematic and meta-analytic review</article-title>. <source>Neuropsychol. Rev.</source><volume>28</volume>, <fpage>1</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1007/s11065-017-9359-z</pub-id><pub-id pub-id-type="pmid">28856507</pub-id></mixed-citation></ref><ref id="B272"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stimson</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Holt</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>A. J.</given-names></name></person-group> (<year>2024</year>). <article-title>Why don&#8217;t women engage in muscle strength exercise? An integrative review</article-title>. <source>Health Promot. J. Aust.</source><volume>35</volume> (<issue>4</issue>), <fpage>911</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1002/hpja.857</pub-id><pub-id pub-id-type="pmid">38566279</pub-id></mixed-citation></ref><ref id="B273"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Gates</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sachdev</surname><given-names>P.</given-names></name><name name-style="western"><surname>Brodaty</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Therapeutically relevant structural and functional mechanisms triggered by physical and cognitive exercise</article-title>. <source>Mol. Psychiatry</source><volume>21</volume> (<issue>11</issue>), <fpage>1633</fpage>&#8211;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2016.19</pub-id><pub-id pub-id-type="pmid">27001615</pub-id><pub-id pub-id-type="pmcid">PMC5078857</pub-id></mixed-citation></ref><ref id="B274"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chiesa</surname><given-names>S. T.</given-names></name><name name-style="western"><surname>Zsoldos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Filippini</surname><given-names>N.</given-names></name><name name-style="western"><surname>Griffanti</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Accelerated aortic stiffness is associated with brain structure, perfusion and cognition in the whitehall II imaging Sub-study</article-title>. <source>Cardiovasc. Med.</source><pub-id pub-id-type="doi">10.1371/journal.pmed.1003467</pub-id><pub-id pub-id-type="pmid">33373359</pub-id><pub-id pub-id-type="pmcid">PMC7771705</pub-id></mixed-citation></ref><ref id="B275"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sweeney</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Kisler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Montagne</surname><given-names>A.</given-names></name><name name-style="western"><surname>Toga</surname><given-names>A. W.</given-names></name><name name-style="western"><surname>Zlokovic</surname><given-names>B. V.</given-names></name></person-group> (<year>2018a</year>). <article-title>The role of brain vasculature in neurodegenerative disorders</article-title>. <source>Nat. Neurosci.</source><volume>21</volume> (<issue>10</issue>), <fpage>1318</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1038/s41593-018-0234-x</pub-id><pub-id pub-id-type="pmid">30250261</pub-id><pub-id pub-id-type="pmcid">PMC6198802</pub-id></mixed-citation></ref><ref id="B276"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sweeney</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Sagare</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Zlokovic</surname><given-names>B. V.</given-names></name></person-group> (<year>2018b</year>). <article-title>Blood&#8211;brain barrier breakdown in alzheimer disease and other neurodegenerative disorders</article-title>. <source>Nat. Rev. Neurol.</source><volume>14</volume> (<issue>3</issue>), <fpage>133</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2017.188</pub-id><pub-id pub-id-type="pmid">29377008</pub-id><pub-id pub-id-type="pmcid">PMC5829048</pub-id></mixed-citation></ref><ref id="B277"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swift</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Johannsen</surname><given-names>N. M.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>V. H.</given-names></name><name name-style="western"><surname>Earnest</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Smits</surname><given-names>J. A. J.</given-names></name><name name-style="western"><surname>Blair</surname><given-names>S. N.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>The effect of exercise training modality on serum brain derived neurotrophic factor levels in individuals with type 2 diabetes</article-title>. <source>PLoS ONE</source><volume>7</volume> (<issue>8</issue>), <fpage>e42785</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0042785</pub-id><pub-id pub-id-type="pmid">22880108</pub-id><pub-id pub-id-type="pmcid">PMC3412800</pub-id></mixed-citation></ref><ref id="B278"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>ten Brinke</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>Bolandzadeh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nagamatsu</surname><given-names>L. S.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Miran-Khan</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Aerobic exercise increases hippocampal volume in older women with probable mild cognitive impairment: a 6-month randomised controlled trial</article-title>. <source>Br. J. Sports Med.</source><volume>49</volume> (<issue>4</issue>), <fpage>248</fpage>&#8211;<lpage>254</lpage>. <pub-id pub-id-type="doi">10.1136/bjsports-2013-093184</pub-id><pub-id pub-id-type="pmid">24711660</pub-id><pub-id pub-id-type="pmcid">PMC4508129</pub-id></mixed-citation></ref><ref id="B279"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ten Kate</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dicks</surname><given-names>E.</given-names></name><name name-style="western"><surname>Visser</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>van der Flier</surname><given-names>W. M.</given-names></name><name name-style="western"><surname>Teunissen</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Atrophy subtypes in prodromal Alzheimer&#8217;s disease are associated with cognitive decline</article-title>. <source>Brain</source><volume>141</volume> (<issue>12</issue>), <fpage>3443</fpage>&#8211;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awy264</pub-id><pub-id pub-id-type="pmid">30351346</pub-id><pub-id pub-id-type="pmcid">PMC6669409</pub-id></mixed-citation></ref><ref id="B280"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thapa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Bae</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.</given-names></name></person-group> (<year>2023</year>). <article-title>Effect of electrical muscle stimulation and resistance exercise intervention on physical and brain function in middle-aged and older women</article-title>. <source>Int. J. Environ. Res. Public Health</source><volume>20</volume> (<issue>1</issue>), <fpage>101</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph20010101</pub-id><pub-id pub-id-type="pmid">36612423</pub-id><pub-id pub-id-type="pmcid">PMC9819342</pub-id></mixed-citation></ref><ref id="B281"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>B. P.</given-names></name><name name-style="western"><surname>Tarumi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Womack</surname><given-names>K. B.</given-names></name><name name-style="western"><surname>Cullum</surname><given-names>C. M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Brain perfusion change in patients with mild cognitive impairment after 12 months of aerobic exercise training</article-title>. <source>J. Alzheimer&#8217;s Dis.</source><volume>75</volume> (<issue>2</issue>), <fpage>617</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-190977</pub-id><pub-id pub-id-type="pmid">32310162</pub-id><pub-id pub-id-type="pmcid">PMC8062932</pub-id></mixed-citation></ref><ref id="B282"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Naylor</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Ainslie</surname><given-names>P. N.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>H. H.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Resistance, but not endurance exercise training, induces changes in cerebrovascular function in healthy young subjects</article-title>. <source>Am. J. Physiol. Heart Circ. Physiol.</source><volume>321</volume> (<issue>5</issue>), <fpage>H881</fpage>&#8211;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.00230.2021</pub-id><pub-id pub-id-type="pmid">34559581</pub-id></mixed-citation></ref><ref id="B283"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kostroske</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tarumi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Pasha</surname><given-names>E. P.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>One-year aerobic exercise increases cerebral blood flow in cognitively normal older adults</article-title>. <source>J. Cereb. Blood Flow. Metab.</source><volume>43</volume>, <fpage>404</fpage>&#8211;<lpage>418</lpage>. <pub-id pub-id-type="doi">10.1177/0271678X221133861</pub-id><pub-id pub-id-type="pmid">36250505</pub-id><pub-id pub-id-type="pmcid">PMC9941859</pub-id></mixed-citation></ref><ref id="B284"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>T&#246;rpel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Herold</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hamacher</surname><given-names>D.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>N. G.</given-names></name><name name-style="western"><surname>Schega</surname><given-names>L.</given-names></name></person-group> (<year>2018</year>). <article-title>Strengthening the brain&#8212;is resistance training with blood flow restriction an effective strategy for cognitive improvement?</article-title><source>J. Clin. Med.</source><volume>7</volume> (<issue>10</issue>), <fpage>337</fpage>. <pub-id pub-id-type="doi">10.3390/jcm7100337</pub-id><pub-id pub-id-type="pmid">30304785</pub-id><pub-id pub-id-type="pmcid">PMC6210989</pub-id></mixed-citation></ref><ref id="B285"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F. C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T. H.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>F. Y.</given-names></name></person-group> (<year>2014</year>). <article-title>Executive function and endocrinological responses to acute resistance exercise</article-title>. <source>Front. Behav. Neurosci.</source><volume>8</volume> (<issue>AUG</issue>), <fpage>262</fpage>. <pub-id pub-id-type="doi">10.3389/fnbeh.2014.00262</pub-id><pub-id pub-id-type="pmid">25136300</pub-id><pub-id pub-id-type="pmcid">PMC4117935</pub-id></mixed-citation></ref><ref id="B286"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Ukropec</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ukropcov&#225;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pai</surname><given-names>M. C.</given-names></name></person-group> (<year>2018</year>). <article-title>An acute bout of aerobic or strength exercise specifically modifies circulating exerkine levels and neurocognitive functions in elderly individuals with mild cognitive impairment</article-title>. <source>NeuroImage Clin.</source><volume>17</volume>, <fpage>272</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.nicl.2017.10.028</pub-id><pub-id pub-id-type="pmid">29527475</pub-id><pub-id pub-id-type="pmcid">PMC5842646</pub-id></mixed-citation></ref><ref id="B287"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsao</surname><given-names>C. W.</given-names></name><name name-style="western"><surname>Seshadri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Beiser</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Westwood</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Decarli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Au</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Relations of arterial stiffness and endothelial function to brain aging in the community</article-title>. <source>Neurology</source><volume>81</volume> (<issue>11</issue>), <fpage>984</fpage>&#8211;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e3182a43e1c</pub-id><pub-id pub-id-type="pmid">23935179</pub-id><pub-id pub-id-type="pmcid">PMC3888200</pub-id></mixed-citation></ref><ref id="B288"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsutsumi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Don</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Zaichkowsky</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Delizonna</surname><given-names>L. L.</given-names></name></person-group> (<year>1997</year>). <article-title>Physical fitness and psychological benefits of strength training in community dwelling older adults</article-title>. <source>Appl. Hum. Sci.</source><volume>16</volume> (<issue>6</issue>), <fpage>257</fpage>&#8211;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.2114/jpa.16.257</pub-id><pub-id pub-id-type="pmid">9545677</pub-id></mixed-citation></ref><ref id="B289"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaishya</surname><given-names>R.</given-names></name><name name-style="western"><surname>Misra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vaish</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ursino</surname><given-names>N.</given-names></name><name name-style="western"><surname>D&#8217;Ambrosi</surname><given-names>R.</given-names></name></person-group> (<year>2024</year>). <article-title>Hand grip strength as a proposed new vital sign of health: a narrative review of evidences</article-title>. <source>J. Health, Popul. Nutr.</source><volume>43</volume> (<issue>1</issue>), <fpage>7</fpage>. <pub-id pub-id-type="doi">10.1186/s41043-024-00500-y</pub-id><pub-id pub-id-type="pmid">38195493</pub-id><pub-id pub-id-type="pmcid">PMC10777545</pub-id></mixed-citation></ref><ref id="B290"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Dam</surname><given-names>R.</given-names></name><name name-style="western"><surname>Van Ancum</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Verlaan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Scheerman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Meskers</surname><given-names>C. G.</given-names></name><name name-style="western"><surname>Maier</surname><given-names>A. B.</given-names></name></person-group> (<year>2018</year>). <article-title>Lower cognitive function in older patients with lower muscle strength and muscle mass</article-title>. <source>Dementia geriatric cognitive Disord.</source><volume>45</volume> (<issue>3&#8211;4</issue>), <fpage>243</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1159/000486711</pub-id><pub-id pub-id-type="pmid">29913450</pub-id><pub-id pub-id-type="pmcid">PMC6067649</pub-id></mixed-citation></ref><ref id="B291"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Dijk</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Drenth</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hafkemeijer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Labadie</surname><given-names>G.</given-names></name><name name-style="western"><surname>Witjes-An&#233;</surname><given-names>M. N. W.</given-names></name><name name-style="western"><surname>Blauw</surname><given-names>G. J.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Neurovascular coupling in early stage dementia &#8211; a case-control study</article-title>. <source>J. Cereb. Blood Flow. Metab.</source><volume>44</volume> (<issue>6</issue>), <fpage>1013</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1177/0271678X231214102</pub-id><pub-id pub-id-type="pmid">37994030</pub-id><pub-id pub-id-type="pmcid">PMC11318393</pub-id></mixed-citation></ref><ref id="B292"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaughan</surname><given-names>S.</given-names></name><name name-style="western"><surname>wallis</surname><given-names>M.</given-names></name><name name-style="western"><surname>polit</surname><given-names>D.</given-names></name><name name-style="western"><surname>steele</surname><given-names>M.</given-names></name><name name-style="western"><surname>shum</surname><given-names>D.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>N.</given-names></name></person-group> (<year>2014</year>). <article-title>The effects of multimodal exercise on cognitive and physical functioning and brain-derived neurotrophic factor in older women: a randomised controlled trial</article-title>. <source>Age Ageing</source><volume>43</volume> (<issue>5</issue>), <fpage>623</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/ageing/afu010</pub-id><pub-id pub-id-type="pmid">24554791</pub-id></mixed-citation></ref><ref id="B293"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Montiel-Rojas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kadi</surname><given-names>F.</given-names></name></person-group> (<year>2021</year>). <article-title>Engagement in muscle-strengthening activities lowers sarcopenia risk in older adults already adhering to the aerobic physical activity guidelines</article-title>. <source>Int. J. Environ. Res. public health</source><volume>18</volume> (<issue>3</issue>), <fpage>989</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph18030989</pub-id><pub-id pub-id-type="pmid">33499423</pub-id><pub-id pub-id-type="pmcid">PMC7908493</pub-id></mixed-citation></ref><ref id="B294"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vega</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Knicker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hollmann</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bloch</surname><given-names>W.</given-names></name><name name-style="western"><surname>Str&#252;der</surname><given-names>H. K.</given-names></name></person-group> (<year>2010</year>). <article-title>Effect of resistance exercise on serum levels of growth factors in humans</article-title>. <source>Hormone metabolic Res.</source><volume>42</volume> (<issue>13</issue>), <fpage>982</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1055/s-0030-1267950</pub-id><pub-id pub-id-type="pmid">21053157</pub-id></mixed-citation></ref><ref id="B295"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermeer</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Rinkel</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Algra</surname><given-names>A.</given-names></name></person-group> (<year>1997</year>). <article-title>Circadian fluctuations in onset of subarachnoid hemorrhage: new data on aneurysmal and perimesencephalic hemorrhage and a systematic review</article-title>. <source>Stroke</source><volume>28</volume> (<issue>4</issue>), <fpage>805</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1161/01.str.28.4.805</pub-id><pub-id pub-id-type="pmid">9099200</pub-id></mixed-citation></ref><ref id="B296"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vicenzini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ricciardi</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Altieri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Puccinelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bonaffini</surname><given-names>N.</given-names></name><name name-style="western"><surname>Di</surname><given-names>P. V.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Cerebrovascular reactivity in degenerative and vascular dementia: a transcranial doppler study</article-title>. <source>Eur. Neurol.</source><volume>58</volume> (<issue>2</issue>), <fpage>84</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1159/000103642</pub-id><pub-id pub-id-type="pmid">17565221</pub-id></mixed-citation></ref><ref id="B297"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vilela</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Damiani</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Macan</surname><given-names>T. P.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>S.</given-names></name><name name-style="western"><surname>Canteiro</surname><given-names>P. B.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Strength and aerobic exercises improve spatial memory in aging rats through stimulating distinct neuroplasticity mechanisms</article-title>. <source>Mol. Neurobiol.</source><volume>54</volume>, <fpage>7928</fpage>&#8211;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-016-0272-x</pub-id><pub-id pub-id-type="pmid">27878552</pub-id></mixed-citation></ref><ref id="B298"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vints</surname><given-names>W. A. J.</given-names></name><name name-style="western"><surname>&#352;eikinait&#279;</surname><given-names>J.</given-names></name><name name-style="western"><surname>G&#246;k&#231;e</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ku&#353;leikien&#279;</surname><given-names>S.</given-names></name><name name-style="western"><surname>&#352;arkinaite</surname><given-names>M.</given-names></name><name name-style="western"><surname>Valatkeviciene</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Resistance exercise effects on hippocampus subfield volumes and biomarkers of neuroplasticity and neuroinflammation in older adults with low and high risk of mild cognitive impairment: a randomized controlled trial</article-title>. <source>GeroScience</source><volume>46</volume> (<issue>4</issue>), <fpage>3971</fpage>&#8211;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1007/s11357-024-01110-6</pub-id><pub-id pub-id-type="pmid">38478179</pub-id><pub-id pub-id-type="pmcid">PMC11226571</pub-id></mixed-citation></ref><ref id="B299"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Scribbans</surname><given-names>T. D.</given-names></name><name name-style="western"><surname>Bentley</surname><given-names>R. F.</given-names></name><name name-style="western"><surname>Mikhail Kellawan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurd</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tschakovsky</surname><given-names>M. E.</given-names></name></person-group> (<year>2015</year>). <article-title>Neurotrophic growth factor responses to lower body resistance training in older adults</article-title>. <source>Appl. Physiology, Nutr. Metabolism</source><volume>41</volume> (<issue>3</issue>), <fpage>315</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1139/apnm-2015-0410</pub-id><pub-id pub-id-type="pmid">26886517</pub-id></mixed-citation></ref><ref id="B300"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Masters</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y. J.</given-names></name></person-group> (<year>2017</year>). <article-title>A systemic view of alzheimer disease &#8212; insights from amyloid-&#946; metabolism beyond the brain</article-title>. <source>Nat. Rev. Neurol.</source><volume>13</volume> (<issue>10</issue>), <fpage>703</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2017.147</pub-id><pub-id pub-id-type="pmid">29027541</pub-id></mixed-citation></ref><ref id="B301"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bulte</surname><given-names>D. P.</given-names></name><name name-style="western"><surname>Suri</surname><given-names>S.</given-names></name></person-group> (<year>2023</year>). <article-title>A systematic review of the association between dementia risk factors and cerebrovascular reactivity</article-title>. <source>Neurosci. and Biobehav. Rev.</source><volume>148</volume>, <fpage>105140</fpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2023.105140</pub-id><pub-id pub-id-type="pmid">36944391</pub-id></mixed-citation></ref><ref id="B302"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westcott</surname><given-names>W. L.</given-names></name></person-group> (<year>2012</year>). <article-title>Resistance training is medicine: effects of strength training on health</article-title>. <source>Curr. Sports Med. Rep.</source><volume>11</volume> (<issue>4</issue>), <fpage>209</fpage>&#8211;<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1249/JSR.0b013e31825dabb8</pub-id><pub-id pub-id-type="pmid">22777332</pub-id></mixed-citation></ref><ref id="B303"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westwood</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Beiser</surname><given-names>A.</given-names></name><name name-style="western"><surname>DeCarli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>T. B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>mei</surname><given-names>He X.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Insulin-like growth factor-1 and risk of alzheimer dementia and brain atrophy</article-title>. <source>Neurology</source><volume>82</volume> (<issue>18</issue>), <fpage>1613</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000000382</pub-id><pub-id pub-id-type="pmid">24706014</pub-id><pub-id pub-id-type="pmcid">PMC4013812</pub-id></mixed-citation></ref><ref id="B304"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Haskell</surname><given-names>W. L.</given-names></name><name name-style="western"><surname>Ades</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Amsterdam</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Bittner</surname><given-names>V.</given-names></name><name name-style="western"><surname>Franklin</surname><given-names>B. A.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Resistance exercise in individuals with and without cardiovascular disease: 2007 update: a scientific statement from the American heart association council on clinical cardiology and council on nutrition, physical activity, and metabolism</article-title>. <source>Circulation</source><volume>116</volume> (<issue>5</issue>), <fpage>572</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.185214</pub-id><pub-id pub-id-type="pmid">17638929</pub-id></mixed-citation></ref><ref id="B305"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willie</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Tzeng</surname><given-names>Y. C.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Ainslie</surname><given-names>P. N.</given-names></name></person-group> (<year>2014</year>). <article-title>Integrative regulation of human brain blood flow</article-title>. <source>J. Physiol. (Lond).</source><volume>592</volume> (<issue>5</issue>), <fpage>841</fpage>&#8211;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2013.268953</pub-id><pub-id pub-id-type="pmid">24396059</pub-id><pub-id pub-id-type="pmcid">PMC3948549</pub-id></mixed-citation></ref><ref id="B306"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolters</surname><given-names>F. J.</given-names></name><name name-style="western"><surname>Zonneveld</surname><given-names>H. I.</given-names></name><name name-style="western"><surname>Hofman</surname><given-names>A.</given-names></name><name name-style="western"><surname>van der Lugt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koudstaal</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Vernooij</surname><given-names>M. W.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Cerebral perfusion and the risk of dementia: a population-based study</article-title>. <source>Circulation</source><volume>136</volume> (<issue>8</issue>), <fpage>719</fpage>&#8211;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.027448</pub-id><pub-id pub-id-type="pmid">28588075</pub-id></mixed-citation></ref><ref id="B307"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Thiyagarajan</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Sleep drives metabolite clearance from the adult brain</article-title>. <source>science.</source><volume>342</volume> (<issue>6156</issue>), <fpage>373</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1126/science.1241224</pub-id><pub-id pub-id-type="pmid">24136970</pub-id><pub-id pub-id-type="pmcid">PMC3880190</pub-id></mixed-citation></ref><ref id="B308"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jerskey</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Cote</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>E. G.</given-names></name><name name-style="western"><surname>Hassenstab</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Ladino</surname><given-names>M. E.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Cerebrovascular perfusion among older adults is moderated by strength training and gender</article-title>. <source>Neurosci. Lett.</source><volume>560</volume>, <fpage>26</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2013.12.011</pub-id><pub-id pub-id-type="pmid">24355360</pub-id><pub-id pub-id-type="pmcid">PMC3920729</pub-id></mixed-citation></ref><ref id="B309"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamaguchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Meguro</surname><given-names>K.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hayasaka</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>H.</given-names></name><etal/></person-group> (<year>1997</year>). <article-title>Decreased cortical glucose metabolism correlates with hippocampal atrophy in Alzheimer&#8217;s disease as shown by MRI and PET</article-title>. <source>J. Neurology, Neurosurg. and Psychiatry</source><volume>62</volume> (<issue>6</issue>), <fpage>596</fpage>&#8211;<lpage>600</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp.62.6.596</pub-id><pub-id pub-id-type="pmid">9219745</pub-id><pub-id pub-id-type="pmcid">PMC1074143</pub-id></mixed-citation></ref><ref id="B310"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Gradual disturbances of the amplitude of low-frequency fluctuations (ALFF) and fractional ALFF in alzheimer spectrum</article-title>. <source>Front. Neurosci.</source><volume>12</volume>, <fpage>975</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2018.00975</pub-id><pub-id pub-id-type="pmid">30618593</pub-id><pub-id pub-id-type="pmcid">PMC6306691</pub-id></mixed-citation></ref><ref id="B311"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yarrow</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>White</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>McCoy</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Borst</surname><given-names>S. E.</given-names></name></person-group> (<year>2010</year>). <article-title>Training augments resistance exercise induced elevation of circulating brain derived neurotrophic factor (BDNF)</article-title>. <source>Neurosci. Lett.</source><volume>479</volume> (<issue>2</issue>), <fpage>161</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2010.05.058</pub-id><pub-id pub-id-type="pmid">20553806</pub-id></mixed-citation></ref><ref id="B312"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yew</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nation</surname><given-names>D. A.</given-names></name></person-group><collab>for the Alzheimer&#8217;s Disease Neuroimaging Initiative</collab> (<year>2017</year>). <article-title>Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia</article-title>. <source>Brain</source><volume>140</volume> (<issue>7</issue>), <fpage>1987</fpage>&#8211;<lpage>2001</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awx112</pub-id><pub-id pub-id-type="pmid">28575149</pub-id><pub-id pub-id-type="pmcid">PMC6059092</pub-id></mixed-citation></ref><ref id="B313"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sancheti</surname><given-names>H.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cadenas</surname><given-names>E.</given-names></name></person-group> (<year>2016</year>). <article-title>Energy metabolism and inflammation in brain aging and Alzheimer&#8217;s disease</article-title>. <source>Free Radic. Biol. Med.</source><volume>100</volume>, <fpage>108</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2016.04.200</pub-id><pub-id pub-id-type="pmid">27154981</pub-id><pub-id pub-id-type="pmcid">PMC5094909</pub-id></mixed-citation></ref><ref id="B314"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H. jae</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>W.</given-names></name></person-group> (<year>2017</year>). <article-title>Effect of elastic band-based high-speed power training on cognitive function, physical performance and muscle strength in older women with mild cognitive impairment</article-title>. <source>Geriatrics and Gerontology Int.</source><volume>17</volume> (<issue>5</issue>), <fpage>765</fpage>&#8211;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1111/ggi.12784</pub-id><pub-id pub-id-type="pmid">27396580</pub-id></mixed-citation></ref><ref id="B315"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zagrebelsky</surname><given-names>M.</given-names></name><name name-style="western"><surname>Korte</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Form follows function: BDNF and its involvement in sculpting the function and structure of synapses</article-title>. <source>Neuropharmacology</source><volume>76</volume>, <fpage>628</fpage>&#8211;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.05.029</pub-id><pub-id pub-id-type="pmid">23752094</pub-id></mixed-citation></ref><ref id="B316"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name></person-group> (<year>2021a</year>). <article-title>A review of brain atrophy subtypes definition and analysis for Alzheimer&#8217;s disease heterogeneity studies</article-title>. <source>J. Alzheimer&#8217;s Dis.</source><volume>80</volume> (<issue>4</issue>), <fpage>1339</fpage>&#8211;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-201274</pub-id><pub-id pub-id-type="pmid">33682711</pub-id></mixed-citation></ref><ref id="B317"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lyu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2021b</year>). <article-title>Cerebral blood flow in mild cognitive impairment and Alzheimer&#8217;s disease: a systematic review and meta-analysis</article-title>. <source>Ageing Res. Rev.</source><volume>71</volume>, <fpage>101450</fpage>. <pub-id pub-id-type="doi">10.1016/j.arr.2021.101450</pub-id><pub-id pub-id-type="pmid">34419673</pub-id></mixed-citation></ref><ref id="B318"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H. W.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>W. B.</given-names></name><name name-style="western"><surname>Korivi</surname><given-names>M.</given-names></name></person-group> (<year>2021c</year>). <article-title>Low-to-moderate-intensity resistance exercise is more effective than high-intensity at improving endothelial function in adults: a systematic review and meta-analysis</article-title>. <source>Int. J. Environ. Res. Public Health</source><volume>18</volume> (<issue>13</issue>), <fpage>6723</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph18136723</pub-id><pub-id pub-id-type="pmid">34206463</pub-id><pub-id pub-id-type="pmcid">PMC8297299</pub-id></mixed-citation></ref><ref id="B319"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group> (<year>2022</year>). <article-title>Effects of low-load blood flow restriction training on hemodynamic responses and vascular function in older adults: a meta-analysis</article-title>. <source>Int. J. Environ. Res. Public Health</source><volume>19</volume> (<issue>11</issue>), <fpage>6750</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph19116750</pub-id><pub-id pub-id-type="pmid">35682336</pub-id><pub-id pub-id-type="pmcid">PMC9180641</pub-id></mixed-citation></ref><ref id="B320"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Song</surname><given-names>G.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>The effect of resistance training on the rehabilitation of elderly patients with sarcopenia: a meta-analysis</article-title>. <source>Int. J. Environ. Res. Public Health</source><volume>19</volume> (<issue>23</issue>), <fpage>15491</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph192315491</pub-id><pub-id pub-id-type="pmid">36497565</pub-id><pub-id pub-id-type="pmcid">PMC9739568</pub-id></mixed-citation></ref><ref id="B321"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Benefits of different combinations of aerobic and resistance exercise for improving plasma glucose and lipid metabolism and sleep quality among elderly patients with metabolic syndrome: a randomized controlled trial</article-title>. <source>Endocr. J.</source><volume>69</volume> (<issue>7</issue>), <fpage>819</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1507/endocrj.EJ21-0589</pub-id><pub-id pub-id-type="pmid">35197411</pub-id></mixed-citation></ref><ref id="B322"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ziegenhorn</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Schulte-Herbr&#252;ggen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Danker-Hopfe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Malbranc</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>H. D.</given-names></name><name name-style="western"><surname>Anders</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Serum Neurotrophins&#8212;A study on the time course and influencing factors in a large old age sample</article-title>. <source>Neurobiol. aging</source><volume>28</volume> (<issue>9</issue>), <fpage>1436</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2006.06.011</pub-id><pub-id pub-id-type="pmid">16879899</pub-id></mixed-citation></ref><ref id="B323"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zlokovic</surname><given-names>B. V.</given-names></name></person-group> (<year>2004</year>). <article-title>Clearing amyloid through the blood&#8211;brain barrier</article-title>. <source>J. Neurochem.</source><volume>89</volume> (<issue>4</issue>), <fpage>807</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2004.02385.x</pub-id><pub-id pub-id-type="pmid">15140180</pub-id></mixed-citation></ref><ref id="B324"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zlokovic</surname><given-names>B. V.</given-names></name></person-group> (<year>2005</year>). <article-title>Neurovascular mechanisms of Alzheimer&#8217;s neurodegeneration</article-title>. <source>Trends Neurosci.</source><volume>28</volume> (<issue>4</issue>), <fpage>202</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2005.02.001</pub-id><pub-id pub-id-type="pmid">15808355</pub-id></mixed-citation></ref><ref id="B325"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zoeller</surname><given-names>R. F.</given-names></name><name name-style="western"><surname>Angelopoulos</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>B. C.</given-names></name><name name-style="western"><surname>Wenta</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Price</surname><given-names>T. B.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>P. D.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Vascular remodeling in response to 12 wk of upper arm unilateral resistance training</article-title>. <source>Med. Sci. sports Exerc.</source><volume>41</volume> (<issue>11</issue>), <fpage>2003</fpage>&#8211;<lpage>2008</lpage>. <pub-id pub-id-type="doi">10.1249/MSS.0b013e3181a70707</pub-id><pub-id pub-id-type="pmid">19812518</pub-id><pub-id pub-id-type="pmcid">PMC4107658</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id><journal-id journal-id-type="pmc-domain-id">1609</journal-id><journal-id journal-id-type="pmc-domain">bmjo</journal-id><journal-id journal-id-type="publisher-id">bmjopen</journal-id><journal-title-group><journal-title>BMJ Open</journal-title></journal-title-group><issn pub-type="epub">2044-6055</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12496098</article-id><article-id pub-id-type="pmcid-ver">PMC12496098.1</article-id><article-id pub-id-type="pmcaid">12496098</article-id><article-id pub-id-type="pmcaiid">12496098</article-id><article-id pub-id-type="pmid">41043835</article-id><article-id pub-id-type="doi">10.1136/bmjopen-2024-097002</article-id><article-id pub-id-type="publisher-id">bmjopen-2024-097002</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Geriatric Medicine</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1698</subject><subject>1506</subject></subj-group></article-categories><title-group><article-title>How do metacognitive beliefs about memory differ between older adults with low and high dementia worry? A focus group study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8797-1592</contrib-id><name name-style="western"><surname>Lund</surname><given-names initials="AE">Astrid Emilie</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Freiin von Stein zu Nord- und Ostheim</surname><given-names initials="A">Alexandra</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ridley</surname><given-names initials="H">Hayley</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bobyreva</surname><given-names initials="K">Kamilla</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Foster</surname><given-names initials="JLH">Juliet L H</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Russell</surname><given-names initials="C">Charlotte</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><aff id="aff1"><label>1</label><institution content-type="department">Department of Psychology</institution>, <institution>King&#8217;s College London</institution>, <addr-line content-type="city">London</addr-line>, <country>UK</country></aff></contrib-group><author-notes><fn><p>Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p></fn><fn fn-type="COI-statement" id="fn5"><p>None declared.</p></fn><corresp id="cor1">Astrid Emilie Lund; <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Astrid.lund@kcl.ac.uk">Astrid.lund@kcl.ac.uk</email></corresp></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>10</month><year>2025</year></pub-date><volume>15</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">498329</issue-id><elocation-id>e097002</elocation-id><history><date date-type="received"><day>22</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>15</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-05 16:25:16.243"><day>05</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bmjopen-15-10.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="bmjopen-15-10.pdf"/><abstract><sec><title> Abstract</title></sec><sec><title>Objectives</title><p>This study aimed to examine how older adults form beliefs about their memory and how these beliefs are influenced by their level of concern about dementia. Inaccurate beliefs and excessive worrying, indicative of erroneous metacognition, are associated with negative health outcomes. This research can help identify mitigation for these harmful effects.</p></sec><sec><title>Design</title><p>Qualitative focus groups; thematic analysis.</p></sec><sec><title>Setting</title><p>Focus group discussion with healthy older adults hosted at a university in central London.</p></sec><sec><title>Participants</title><p>35 healthy older individuals (women=29) without any psychiatric or neurological diagnoses, over the age of 65 years (mean 75.31, SD: 6.15). 13 participants were identified as having a high level of worry about dementia and 22 as having low worry. Groups were matched for cognitive performance on the Telephone Mini Addenbrooke&#8217;s cognitive assessment (Tele-MACE).</p></sec><sec><title>Outcome measures</title><p>Participants were assigned to a focus group depending on their level of worry about dementia. During focus groups, a vignette prompted discussion around lifespan changes in memory and how this affected concerns around memory. This allowed investigation of the differences in beliefs about memory.</p></sec><sec><title>Results</title><p>Thematic analysis revealed two key themes. First, older adults appear to base their definition of &#8216;normality&#8217; of their own memory on comparisons. These comparisons were between themselves and others and between themselves now and their own past self. Despite similar strategies to define &#8216;normality&#8217;, those with high dementia worry had stricter definitions of what they determined as normal. The second theme described narratives around the &#8216;self&#8217; and the &#8216;other&#8217;. There was a difference between those with high versus low worry; those with high worry had a strong focus on the &#8216;self&#8217;, while those with low dementia worry focused on &#8216;others&#8217;.</p></sec><sec><title>Conclusion</title><p>Comparison is a common metacognitive strategy used in forming beliefs about memory. Targeting the use of comparison is potentially valuable in interventions aiming to alleviate older adults&#8217; memory concerns. Addressing self-focused thinking, for example, with cognitive behavioural therapy, could improve harmful levels of high worry.</p></sec></abstract><kwd-group><kwd>Aging</kwd><kwd>Cognition</kwd><kwd>Dementia</kwd><kwd>QUALITATIVE RESEARCH</kwd><kwd>Old age psychiatry</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Department of Psychology, School of Mental Health and Psychological Sciences, Institute of Psychiatry, Psychology and Neuroscience, King&#8217;s College London</institution></institution-wrap></funding-source></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000269</institution-id><institution>Economic and Social Research Council</institution></institution-wrap></funding-source><award-id>ES/P000703/1</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>STRENGTHS AND LIMITATIONS OF THIS STUDY</title></caption><list list-type="bullet" list-content="ul"><list-item><p>Participants were distinguished by their level of worry about dementia but were matched on gender, age, ethnicity and cognitive abilities.</p></list-item><list-item><p>Vignettes were used to facilitate open discussions without necessitating participants sharing personal information.</p></list-item><list-item><p>People who specifically avoid discussions around dementia and memory due to fear were unlikely to participate in this study.</p></list-item><list-item><p>Measures of generalised anxiety and depression were not used.</p></list-item></list></boxed-text><sec sec-type="intro" id="s1"><title>Introduction</title><p> There has been an increased focus on dementia and its impacts across society, encompassing politicians, the media and general public.<xref rid="R1" ref-type="bibr"><sup>1 2</sup></xref> This focus has been accompanied by raised worry across the population about dementia, and dementia is now the second most feared disease after cancer.<xref rid="R3" ref-type="bibr"><sup>3 4</sup></xref> Some individuals are more burdened by these worries than others, which can be associated with negative life outcomes, such as poor mental health<xref rid="R5" ref-type="bibr">5</xref><xref rid="R7" ref-type="bibr">7</xref> and, crucially, future cognitive decline.<xref rid="R8" ref-type="bibr"><sup>8 9</sup></xref> The fear surrounding dementia in healthy older adults is likely fuelled by uncertainty, as many older adults struggle to determine whether their memory slips are signs of early dementia or simply a part of ageing. Here, we aimed to investigate how people evaluate their memory and how this might vary according to the amount of worry about dementia, as this may help identify points of intervention for negative self-beliefs.</p><sec id="s1-1"><title>The importance of metacognitive beliefs in older age</title><p>Subjective cognitive decline is a clinical diagnosis describing individuals who think they are experiencing cognitive decline but do not show any impaired cognitive abilities when assessed.<xref rid="R10" ref-type="bibr"><sup>10 11</sup></xref> It has been found that 25&#8211;50% of the older population experience such subjective cognitive decline.<xref rid="R12" ref-type="bibr"><sup>12 13</sup></xref> The cognitive skill we use to make such subjective judgements of our cognitive abilities is called metacognition.<xref rid="R14" ref-type="bibr"><sup>14 15</sup></xref> In older age, metacognitive beliefs of memory seem to be particularly important, as memory impairment is the key characteristic of dementia.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref> The high prevalence of subjective cognitive decline, therefore, suggests that metacognitive inaccuracies are common in older age and clinically relevant. For instance, it has been estimated that approximately 20&#8211;30% of those who seek assessment at memory clinics have subjective cognitive decline in the absence of objective cognitive impairments.<xref rid="R16" ref-type="bibr"><sup>16 17</sup></xref> This highlights the burden that these inaccurate metacognitive beliefs can have on the healthcare system and therefore the importance of understanding why such beliefs occur. Crucially, inaccurate metacognitive beliefs also burden and provide a health risk to the individual, as they have been associated with poor well-being, mental health difficulties and higher mortality rates.<xref rid="R5" ref-type="bibr">5</xref><xref rid="R20" ref-type="bibr">717</xref> Research even suggests that negative metacognitive beliefs of cognitive decline are associated with future cognitive decline.<xref rid="R10" ref-type="bibr">1021</xref><xref rid="R25" ref-type="bibr">25</xref> It is therefore important to understand what causes these negative and inaccurate metacognitive beliefs surrounding memory abilities.</p></sec><sec id="s1-2"><title>Reasons for inaccurate metacognitive beliefs in older age</title><p>While up to half of older adults have worries about their memory abilities and show signs of subjective cognitive decline,<xref rid="R12" ref-type="bibr"><sup>12 13</sup></xref> only around 5% will go on to develop Alzheimer&#8217;s disease.<xref rid="R26" ref-type="bibr"><sup>26</sup></xref> Therefore, for many people, these worries of dementia might be unfounded. One such reason for the high level of worry may be the difficulty in distinguishing typical age-related decline from pathological memory changes. For example, semantic memory, our knowledge including memory for facts, appears to be preserved and may even be enhanced in older age,<xref rid="R27" ref-type="bibr"><sup>27</sup></xref> while episodic memory, our memory of events, does tend to decline.<xref rid="R28" ref-type="bibr"><sup>28</sup></xref> These differential patterns of decline in episodic and semantic memory may explain some of the difficulties older adults face when trying to make metacognitive judgements of their cognitive state. In addition, episodic memory difficulties are the first sign of the most common form of dementia&#8212;Alzheimer&#8217;s disease.<xref rid="R2" ref-type="bibr"><sup>2 29</sup></xref> Knowledge of dementia varies between individuals and cultures, and greater awareness is encouraged.<xref rid="R30" ref-type="bibr"><sup>30 31</sup></xref> However, research suggests that many older adults know that incidents of forgetting what has happened or where one is may be signs of dementia.<xref rid="R32" ref-type="bibr"><sup>32 33</sup></xref> Both of these are examples of episodic memory slips. Thus, it seems plausible that older adults may be particularly wary about changes of this type. Furthermore, if a person notices such changes, it is likely that they will change their metacognitive beliefs about their ability to remember and may start to worry about dementia.</p><p>Another reason for inaccurate metacognitive beliefs may be the reliance on ineffective metacognitive strategies. Metacognitive strategies are the processes used to develop a specific belief. When it comes to metacognitive beliefs about one&#8217;s general traits, research suggests that one such metacognitive strategy is social comparison. This is the comparison we make between peers&#8217; and our own ability; the comparisons have been shown to influence a person&#8217;s self-belief.<xref rid="R34" ref-type="bibr"><sup>34 35</sup></xref> If these comparisons are made in a maladaptive manner, such as overestimating the discrepancy between oneself and one&#8217;s peers, it may lead to metacognitive inaccuracies. In the current study, we aimed to understand some of these underlying reasons for metacognitive inaccuracies in older age, centring the experiences of older individuals through focus group discussions. In particular, we were interested in investigating how older adults may form their metacognitive beliefs based on different types of memory information, such as information from experiences of episodic and semantic memory slips.</p></sec><sec id="s1-3"><title>The relationship between metacognitive beliefs and dementia worry</title><p>Evidence suggests a high association between fear of dementia and inaccurate metacognitive beliefs in older age.<xref rid="R36" ref-type="bibr">36</xref><xref rid="R41" ref-type="bibr">41</xref> The exact causal relationship between negative metacognitive beliefs and fear of dementia is not understood. However, it has been found that worry about dementia is associated with interpreting memory slips as more negative, leading to the tendency to seek out signs of cognitive decline in one&#8217;s own behaviour.<xref rid="R42" ref-type="bibr"><sup>42 43</sup></xref> This suggests that dementia worry is one possible factor underlying the development of inaccurate metacognitive beliefs in older age. A theoretical framework of dementia worry was set out by Kessler and Bowen,<xref rid="R44" ref-type="bibr"><sup>44</sup></xref> who suggested that the level of dementia worry is caused by a negative perception of (1) the risk of getting dementia, (2) the seriousness of the condition and (3) the access and effectiveness of coping mechanisms (eg, see the study by Maxfield <italic toggle="yes">et al</italic><xref rid="R45" ref-type="bibr"><sup>45</sup></xref>). Here, we will investigate people&#8217;s level of dementia worry in order to probe how it interacts with metacognitive strategies and beliefs about memory in older age. Understanding what influences metacognitive beliefs, and how this interacts with fear of dementia worry, may help us identify points of intervention to decrease the negative subjective beliefs and therefore minimise the associated burden to the individual and healthcare system.</p><p>Here, we conducted focus groups with adults aged 65 years and above. In order to understand how different levels of worry might lead to differing perceptions of memory, separate focus groups were run with individuals who showed respectively low and high worry of dementia. All groups were structured around a fictional vignette. The discussions were analysed with thematic analysis,<xref rid="R46" ref-type="bibr"><sup>46 47</sup></xref> as this is a widely used analysis framework in qualitative work and allows for the flexibility and depth of analysis we aimed to achieve.</p></sec></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2-1"><title>Participants</title><p>35 healthy participants (women=29) aged 65&#8211;85 years of age (mean=75.31, SD=6.15), without any current psychiatric or neurological diagnosis were recruited. Participants were recruited through internal advertisement at King&#8217;s College London and external advertisement at University of Third Age. Participants provided informed consent. Based on their scores on the Modified Dementia Worry Scale,<xref rid="R48" ref-type="bibr"><sup>48</sup></xref> participants were divided into high dementia worry and low dementia worry. 22 participants were identified as having low worry (mean=18.14, SD=4.54) and were divided into another four focus groups (four to seven participants in each group). 13 participants were identified as having high worry as they had scores over 30 (out of 60) (mean=36.08, SD=4.94) and were divided into three focus groups (three to four participants in each group). Participants were added to a group based on dementia worry level and availability for partaking in focus group discussions. The groups were matched on gender, age, ethnicity and cognitive ability as measured by the Telephone Mini Addenbrooke&#8217;s cognitive assessment (Tele-MACE) (see table 2). Previous studies suggest that three to four focus groups are adequate for thematic saturation; therefore, the study is sufficiently powered.<xref rid="R49" ref-type="bibr"><sup>49 50</sup></xref> Ethical approval was received from King&#8217;s College London Ethics Committee (ref: HR/DP-21/22&#8211;26212).</p></sec><sec id="s2-2"><title>Patient and public involvement</title><p>Participants were not involved in development of the study design. If participants indicated on the consent form they wished to receive the final manuscript, they will be provided with this via email.</p></sec><sec id="s2-3"><title>Materials</title><sec id="s2-3-1"><title>Telephone Mini Addenbrooke&#8217;s cognitive assessment</title><p>The Tele-MACE<xref rid="R51" ref-type="bibr"><sup>51</sup></xref> is a short telephone-adapted version of the standardised MACE, designed to assess cognitive ability. Participants completed four tasks testing memory, verbal fluency and attention. The maximum score was 25, with a threshold of 19 indicating mild cognitive impairment.</p></sec><sec id="s2-3-2"><title>Modified Dementia Worry Questionnaire</title><p>The Modified Dementia Worry questionnaire (mDMQ)<xref rid="R48" ref-type="bibr"><sup>48</sup></xref> is a 12-item questionnaire assessing the level of worry about dementia. Participants rate statements such as, &#8220;When I forget a word that I want to say, my thoughts immediately turn to Alzheimer&#8217;s disease and related dementias&#8221; on a scale from 1 &#8216;not at all typical of me&#8217; to 5 &#8216;very typical for me&#8217;. A score over 30 of 60 points was defined as high worry.</p></sec><sec id="s2-3-3"><title>Behavioural questions</title><p>Two questions were used to assess whether participants had sought advice due to memory worry. First, participants were asked to answer, &#8216;yes&#8217; or &#8216;no&#8217; to the question, &#8216;Have you contacted your general practitioner or another medical professional because you were worried about your ability to remember?&#8217;. Second, they were asked to rate the question, &#8216;How often have you talked to friends, family members, or another close relation because you were worried about your memory?&#8217;, on a scale from 1 &#8216;never&#8217; to 5 &#8216;very often&#8217;.</p></sec><sec id="s2-3-4"><title>Metacognitive memory question</title><p>One question directly assessed participants&#8217; metacognitive judgements of their memory ability. Participants were asked to rate on a scale from 1 &#8216;not very good&#8217; to 5 &#8216;extremely good&#8217;: &#8216;Please indicate how good you think you are at remembering things&#8217;.</p></sec><sec id="s2-3-5"><title>Vignette</title><p>A vignette was developed to facilitate the focus group discussions (see <xref rid="T1" ref-type="table">table 1</xref>). This was chosen as it allows focus on the fictional characters rather than on oneself.<xref rid="R52" ref-type="bibr"><sup>52</sup></xref> In addition, a vignette removes the focus from the researchers, minimising demand characteristics and potential outsider issues caused by age differences.<xref rid="R52" ref-type="bibr"><sup>52</sup></xref></p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><title>Procedure of the focus group discussions in chronological order</title></caption><table frame="hsides" rules="groups"><tbody><tr><td valign="bottom" rowspan="1" colspan="1">Icebreaker</td><td valign="bottom" rowspan="1" colspan="1">Which animal would you use to describe your morning routine?</td></tr><tr><td valign="top" rowspan="1" colspan="1">Vignette</td><td valign="top" rowspan="1" colspan="1">Mary lives in London, and she has two grandchildren whom she loves dearly. She visits them each Saturday, and they usually go to the park to look at the ducks. Mary has to take two tubes to get to their place, but she knows the route and is never late. She always makes sure to bring a few sweets that she gives to the grandchildren when they are in the park, so their mother does not notice. This Saturday, her tube journey goes smoothly, and her grandchildren are putting on their jackets when she arrives. On their way to the park, they meet an old friend of Mary&#8217;s, Paul, who is walking his dog. Mary and Paul talk for a bit, while the grandchildren pet the dog. Afterwards, they find the pond, which is crowded with ducks. The grandchildren ask Mary what the baby ducks are called, and she says they are called &#8216;ducklings&#8217;, and they count that there are seven of them. After a while, Mary puts her hands in her pockets to get the sweets for her grandchildren but realises that she has forgotten them. The grandchildren laugh and say it is okay. To make up for the missing sweets, Mary suggests that they buy ice cream instead, before they go home.</td></tr><tr><td valign="top" rowspan="1" colspan="1">Vignette questions</td><td valign="top" rowspan="1" colspan="1">1.1. How do you think Mary feels about forgetting the sweets?<break/>1.2. Do you think forgetting the sweets will affect Mary in any way next time she takes her grandchildren to the park?<break/>1.3. Do you think forgetting the sweets affects how Mary thinks about her ability to remember?<break/>1.4. Do you think Mary would feel differently had she forgotten the name of her old friend Paul?<break/>1.5. Do you think Mary would have felt differently had she forgotten her tube route?<break/>1.6. Do you think if Mary had forgotten that baby ducks are called ducklings, she would have been more or less concerned?<break/>1.7. How old do you think Mary is? How does this influence your answers?<break/>1.8. Do you think you would have answered differently if Mary had forgotten something in a work context instead of near her grandchildren? If, for instance, she had forgotten the keys to the charity shop where she volunteers.<break/>1.9. If Mary starts worrying about her memory, do you think there is a way for her to regain her confidence?</td></tr><tr><td valign="top" rowspan="1" colspan="1">General questions</td><td valign="top" rowspan="1" colspan="1">2.1. Some individuals think they are bad at remembering even though they are not. Why do you think that is?<break/>2.2. Based on our discussions today, can you list the two most important types of events that you think would cause someone to doubt their own memory ability?<break/>2.3. Based on our discussions today, which aspect of a person&#8217;s life do you think is most affected by doubting their own memory?</td></tr><tr><td valign="top" rowspan="1" colspan="1">Final question</td><td valign="top" rowspan="1" colspan="1">3.1. What do you think was the most important or interesting point that was brought up today?</td></tr></tbody></table></table-wrap><p>The vignette described the story of a fictional woman named Mary, who forgets things across different scenarios (see <xref rid="T1" ref-type="table">table 1</xref> and <xref rid="SP1" ref-type="supplementary-material">online supplemental material 1</xref> detailed protocol). These memory slips were developed to cover different aspects of memory, including semantic memory (eg, the word for baby ducks), episodic memory (eg, bringing keys and sweets), spatial episodic memory (tube route) and personal semantics (name of a friend<xref rid="R53" ref-type="bibr"><sup>53</sup></xref>), as well as incorporating different contexts in which the events occurred (professional and familial). Many of the predetermined questions concerned the vignette scenario. Additionally, a few general questions were developed to gain insight into the participants&#8217; perspectives on memory loss, and a final question was used to wrap up discussion (see <xref rid="T1" ref-type="table">table 1</xref>). Based on the progress of the conversation, some questions may not have been asked in all focus groups.</p></sec></sec><sec id="s2-4"><title>Procedure</title><p>As seen in <xref rid="F1" ref-type="fig">figure 1</xref>, participants filled in the consent form and provided demographic information regarding age, gender and ethnicity, which allowed screening for exclusion criteria (ie, no current neurological or psychiatric diagnosis, except subjective cognitive decline). These forms were either completed independently online or with a researcher on the telephone. All participants then completed a 15&#8201;min telephone interview, either immediately after having given consent or on a different day. During the telephone interview, the Tele-MACE<xref rid="R51" ref-type="bibr"><sup>51</sup></xref> and mDMQ Scale<xref rid="R48" ref-type="bibr"><sup>48</sup></xref> were administered. These were followed by the behavioural and metacognitive memory question.</p><fig position="float" id="F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><title>Procedure. Consent and demographics were done either independently by the participant online, or over the telephone. After division into groups (ie, low and high dementia worry) focus group discussions were held. Tele-MACE, Telephone Mini Addenbrooke&#8217;s cognitive assessment.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bmjopen-15-10-g001.jpg"/></fig><p>Following the interview, the participants were assigned to focus groups based on their dementia worry scores. Participants were split between low and high worry to facilitate safe spaces for discussion with individuals with similar perception and worries regarding memory. In addition, it allowed us to investigate how the level of dementia worry influenced participants&#8217; reports about their metacognitive beliefs and how they develop these beliefs. The focus groups lasted 1&#8201;hour long and were audio recorded. Focus group discussions started with an icebreaker (<xref rid="T1" ref-type="table">table 1</xref>). Following this, the researcher read the vignette aloud, which the participants had also been given in written form. The discussion was semistructured and guided by a researcher, who asked the questions provided in <xref rid="T1" ref-type="table">table 1</xref> and provided prompts like, &#8216;Please will you elaborate on that point?&#8217; or &#8216;Do the rest of you agree with this point?&#8217;, to guide and promote discussion among the participants.</p></sec></sec><sec id="s3"><title>Qualitative methodology</title><p>An inductive form of thematic analysis, where the data guide the analysis,<xref rid="R46" ref-type="bibr"><sup>46 47</sup></xref> was conducted. This is a widely used method, which is a flexible yet comprehensive analysis framework. According to thematic analysis, five steps were followed: (1) familiarisation: the authors AEL, AFSNO, HR and KB read and went through transcription and audio recordings of the focus group discussions several times aided by the software otter.ai. (2) Coding: the transcripts were coded in the software NVivo V.14 by AEL. Codes are labels describing specific parts of the data, such as &#8216;reason for worry&#8217;. These codes are then compared and combined to create themes. Codes were created separately for each group (low worry and high worry). (3) Generating themes: initial subthemes were created first for each group (low and high dementia) and then overarching themes were created covering both groups. (4) Reviewing themes: the themes and subthemes were reviewed several times, based on discussions between all authors, alongside the re-reading of codes and texts. (5) Defining themes: the final themes and subthemes were defined to describe the data.</p><p>A detailed coding diary was kept by the first author, including reflections of construction of themes and sub-themes as well as reflexivity, positionality and potential biases.<xref rid="R54" ref-type="bibr"><sup>54</sup></xref> A comprehensive audit trail was kept through audio recording, documents and NVivo coding. The development of themes and subthemes was regularly discussed between AEL, JF and CR, to facilitate critical feedback and reflection. In addition, these were shown to AFSNO, HR and KB who provided feedback. Finally, the study was retrospectively reviewed against the Consolidated Criteria for Reporting Qualitative Research checklist to ensure comprehensive reporting and reflection of each point;<xref rid="R55" ref-type="bibr"><sup>55</sup></xref> see <xref rid="SP1" ref-type="supplementary-material">online supplemental material 2</xref>. The sample was appropriately powered to achieve thematic saturation.<xref rid="R49" ref-type="bibr"><sup>49 50</sup></xref></p><sec id="s3-1"><title>Quantitative methodology</title><p>Quantitative differences between the two groups for the questionnaires and cognitive assessment were analysed. It is important to note that the aim of the current study was to examine qualitative differences between these groups, the quantitative results should be considered in this light, as the sample is slightly skewed (more people with low worry) and underpowered for quantitative analyses. Assuming a medium effect size of d=0.05, the power to detect this difference in a two-tailed t-test was &#946;=0.28, well below the standard of &#946;=0.80. Conservative non-parametric tests (Wilcoxon Signed Rank test and &#967;<sup>2</sup> tests) were employed to minimise these issues. The tests were used to ensure that the groups were appropriately matched and investigate differences between those with low and high dementia worry. Given the lack of power, these results should be interpreted cautiously.</p></sec></sec><sec sec-type="results" id="s4"><title>Results</title><sec id="s4-1"><title>Quantitative group differences</title><p>Based on mDMQ scores, participants were divided into three groups of individuals with high worry (n=13) and four groups of individuals with low worry (n=22). As groups were defined by scores on the mDMQ,<xref rid="R48" ref-type="bibr"><sup>48</sup></xref> a significant difference was found between the groups on this scale (W=286; p&lt;0.001). In addition, participants in the high worry group were significantly more likely to have discussed their dementia worry with relatives or a clinician (<xref rid="T2" ref-type="table">table 2</xref>). No difference was found between the two groups in their daily confidence about memory (see <xref rid="T2" ref-type="table">table 2</xref>). Importantly, as shown in <xref rid="T2" ref-type="table">table 2</xref>, there was no statistical difference in Tele-MACE scores between the groups, suggesting that any increased worry is not a result of memory decline in any of the group participants. One participant in the low worry group scored below the threshold for mild cognitive decline (MCI) (&lt;19), and one participant in the high worry group reported serious cognitive decline during the focus group. However, as neither of these constitutes an MCI diagnosis and statistical results remained stable with and without these participants (see <xref rid="SP1" ref-type="supplementary-material">online supplemental material 3</xref>), they were retained in the study.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><title>Mean and SD of questionnaires and cognitive assessment; dependent 2-group Wilcoxon signed rank test for numeric variables; &#967;<sup>2</sup> tests for categorical variables</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1"/><th valign="bottom" rowspan="1" colspan="1">Low (n=22)</th><th valign="bottom" rowspan="1" colspan="1">High (n=13)</th><th valign="bottom" rowspan="1" colspan="1">Total (n=35)</th><th valign="bottom" rowspan="1" colspan="1">Significance</th></tr></thead><tbody><tr><td valign="top" rowspan="1" colspan="1">Gender: women (men)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (8)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (1)</td><td align="left" valign="top" rowspan="1" colspan="1">26 (9)</td><td align="left" valign="top" rowspan="1" colspan="1">0.140</td></tr><tr><td valign="top" rowspan="1" colspan="1">Age (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">76.29 (6.50)</td><td align="left" valign="top" rowspan="1" colspan="1">73.64 (5.33)</td><td align="left" valign="top" rowspan="1" colspan="1">75.31 (6.15)</td><td align="left" valign="top" rowspan="1" colspan="1">0.371</td></tr><tr><td valign="top" rowspan="1" colspan="1">Ethnicity: white (other)<xref rid="T2_FN1" ref-type="table-fn">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">18 (3)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (2)</td><td align="left" valign="top" rowspan="1" colspan="1">29 (5)</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" rowspan="1" colspan="1">Tele-MACE (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">23.27 (2.05)</td><td align="left" valign="top" rowspan="1" colspan="1">23.92 (1.11)</td><td align="left" valign="top" rowspan="1" colspan="1">23.52 (1.77)</td><td align="left" valign="top" rowspan="1" colspan="1">0.54</td></tr><tr><td valign="top" rowspan="1" colspan="1">Dementia worry (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">18.14 (4.54)</td><td align="left" valign="top" rowspan="1" colspan="1">36.08 (4.94)</td><td align="left" valign="top" rowspan="1" colspan="1">24.8 (9.93)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001<xref rid="T2_FN2" ref-type="table-fn">&#8224;</xref></td></tr><tr><td valign="top" rowspan="1" colspan="1">Memory confidence (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">3.18 (0.73)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (1.08)</td><td align="left" valign="top" rowspan="1" colspan="1">3.11 (0.87)</td><td align="left" valign="top" rowspan="1" colspan="1">0.617</td></tr><tr><td valign="top" rowspan="1" colspan="1">Subjective cognitive decline diagnosis:</td><td align="left" valign="top" rowspan="1" colspan="1">No: 22 (yes: 0, I do not know: 0)</td><td align="left" valign="top" rowspan="1" colspan="1">No: 12 (yes: 0, I do not know: 1)</td><td align="left" valign="top" rowspan="1" colspan="1">No: 34 (yes: 0, I do not know: 1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.787</td></tr><tr><td valign="top" rowspan="1" colspan="1">Discussion with relatives (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">1.95 (0.84)</td><td align="left" valign="top" rowspan="1" colspan="1">2.77 (1.09)</td><td align="left" valign="top" rowspan="1" colspan="1">2.26 (1.01)</td><td align="left" valign="top" rowspan="1" colspan="1">0.022<xref rid="T2_FN2" ref-type="table-fn">&#8224;</xref></td></tr><tr><td valign="top" rowspan="1" colspan="1">General practitioner: yes (no)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (22)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (5)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (27)</td><td align="left" valign="top" rowspan="1" colspan="1">0.008<xref rid="T2_FN2" ref-type="table-fn">&#8224;</xref></td></tr></tbody></table><table-wrap-foot><fn id="T2_FN1" fn-type="other"><label>*</label><p>Ethnicity, Other: Indian (n=2), Asian (n=1), Jewish (n=2). Unknown (n=1).</p></fn><fn id="T2_FN2" fn-type="other"><label>&#8224;</label><p>Significant at p&lt;0.05.</p></fn><fn fn-type="abbr"><p>Tele-MACE, Telephone Mini Addenbrooke&#8217;s cognitive assessment.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s4-2"><title>Qualitative group differences and similarities</title><p>Through the iterative process of thematic analysis, themes were created across groups, with subthemes defined as either shared or distinct between low and high worry groups (see <xref rid="T3" ref-type="table">table 3</xref>). Below, participants are given identifying codes to represent both their group and gender: LW for low worry; HW for high worry; F for female; M for male, along with a unique number.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><title>Theme and subthemes defined based on the group discussions</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1">Themes</th><th valign="bottom" rowspan="1" colspan="1">Group</th><th valign="bottom" rowspan="1" colspan="1">Subthemes</th></tr></thead><tbody><tr><td rowspan="3" valign="top" colspan="1">1. The question of normality</td><td valign="top" rowspan="1" colspan="1">Shared</td><td valign="top" rowspan="1" colspan="1">1.1 Strategies for defining normality<break/>1.2 Characteristics and threshold of normality<break/>1.3 Preservation of normality</td></tr><tr><td valign="top" rowspan="1" colspan="1">Low worry</td><td valign="top" rowspan="1" colspan="1">1.4.a The normalisation of forgetting</td></tr><tr><td valign="top" rowspan="1" colspan="1">High worry</td><td valign="top" rowspan="1" colspan="1">1.4.b The normalisation of fear</td></tr><tr><td rowspan="2" valign="top" colspan="1">2. The importance of the self or others</td><td valign="top" rowspan="1" colspan="1">Low worry</td><td valign="top" rowspan="1" colspan="1">2.1.a An issue relevant to others<break/>2.2.a Consequences of dementia on others<break/>2.3.a Coping with potential dementia</td></tr><tr><td valign="top" rowspan="1" colspan="1">High worry</td><td valign="top" rowspan="1" colspan="1">2.1.b An issue relevant to oneself<break/>2.2.b Consequences of dementia on the self<break/>2.3.b Fear of potential dementia</td></tr></tbody></table><table-wrap-foot><fn id="T3_FN1" fn-type="other"><p>The two groups (low and high worry) share themes, while subthemes were either shared or split between the two groups.</p></fn></table-wrap-foot></table-wrap><sec id="s4-2-1"><title>Theme 1: the question of normality</title><p>The theme of normality was raised by all groups but discussed in different ways. This theme refers to how an individual&#8217;s perception of normality determines what is deemed as worrisome. This theme features three cross-group subthemes, some of which were shared while others were split between the groups (See <xref rid="T3" ref-type="table">table 3</xref>).</p><sec id="s4-2-1-1"><title>1.1 Strategies for defining normality (shared)</title><p>Both groups discussed the types of metacognitive strategies they used to build their metacognitive beliefs about their own (and others&#8217;) memory ability. In particular, participants reported relying on comparison. For example, comparing themselves to others:</p><disp-quote><p>LWF2: I think another element that Mary could be thinking of is, is, how her forgetfulness compares with other people&#8217;s forgetfulness. If she finds other people not remembering duckling or the word, then she wouldn&#8217;t feel that she was anything other than normal.</p></disp-quote><p>The quotation above shows how such comparison can give comfort, if they recognise the behaviour as normal. However, if recognised as different from others, this could also lead to worry: &#8216;But I&#8217;m concerned because of the way I am. And comparing with my wife who is 5&#8201;days older than me. Her memory is 100%.&#8217; (HWM1). Participants, however, also recognised that due to individual differences, comparing oneself to others may be misleading at times. They therefore also compared themselves to their past selves:</p><disp-quote><p>HWF2: Yes. I&#8217;ve always been terrible with names. [&#8230;] I think it would depend again, what her normal memory for names was, like so much of it is comparative, that it&#8217;s not actually what happens once, it&#8217;s how often it happens and how it relates to how you were in the past.</p></disp-quote><p>Participants also discussed the limitation in building one&#8217;s metacognitive beliefs on one&#8217;s own observations. Many participants therefore highlighted the importance of input from other people to inform their beliefs: &#8220;I find [that] on my own, I get away with murder. [&#8230;] Nobody notices, so I don&#8217;t notice; So, in a way, I&#8217;m a bit less aware of sinking into a memory loss&#8221; (LWF3). Overall, both groups reported primarily relying on comparisons to other people or their past selves. However, the groups differed in whether this comparison comforted them or added to their worry.</p></sec><sec id="s4-2-1-2"><title>1.2 Characteristics and threshold of normality (shared)</title><p>Both groups discussed the metacognitive beliefs or criteria they had for &#8216;normal&#8217; memory. First, events which can be explained by external factors were not deemed as worrisome, such as &#8220;distraction&#8221; (LWM1) and mood:</p><disp-quote><p>HWF1: I think it also depends on your kind of mood of the day [&#8230;]. If you&#8217;ve got things on your mind [&#8230;]. If it [edit: the brain] gets overloaded. And I think that&#8217;s quite interesting. Because I know that happens to me if I have too much going on, other things can go out the window.</p></disp-quote><p>Additionally, transient forgetting was seen as normal: &#8220;I don&#8217;t get stressed. I know it will come back because it&#8217;s in your head. It&#8217;s not something you&#8217;ve forgotten forever.&#8221; (HWF5). Generally, most of the scenarios presented were only deemed worrisome if they started to accumulate: &#8220;&#8230;if it keeps recurring, the next time and so on, but that&#8217;s when the worry starts to kick in, I think&#8221; (LWM2). We did not see a strong difference in the interpretation of memory slips depending on whether these were episodic or semantic in general. However, the specific exception to this was the scenario of forgetting the tube route, which relies on episodic memory. All participants viewed this as immediately worrisome:</p><disp-quote><p>LWF2: That&#8217;s scary. If you find yourself somewhere that, I know I&#8217;ve got to go somewhere else. But where do I go? Yeah, that would be, that would be worrying. Frightening. I think. If you&#8217;re losing your bearings, what would it feel like?</p></disp-quote><p>When participants started to share their own stories, it became clear that participants with high worry had a higher threshold for normality, as they explicitly voiced their worries: &#8220;You know, is that normal? I&#8217;m not so sure at that stage.&#8221; (HWF8) and seemed to be aware that they might worry more than other people: &#8220;I think if Mary is somebody other than myself, I would feel the same [edit: not worry]. But if Mary was myself, I wouldn&#8217;t feel the same&#8212;I would worry&#8221; (HWF3). Thus, while participants mostly show similar interpretations of what &#8216;normal memory&#8217; is in the main discussion, when participants started to share their personal stories, it became clear that the two groups differed in their definitions of normal/non-worrisome memory changes.</p></sec><sec id="s4-2-1-3"><title>1.3 Preservation of normality (shared)</title><p>Both those with high and low worry discussed the importance of prevention of cognitive decline to maintain normality. This was, for instance, by learning new things and solving cognitive tasks:</p><disp-quote><p>LWF8: It&#8217;s really important to learn languages and do mental things like Sudoku and cryptic crosswords and things, as I said, that it really does help people that are showing some symptoms, but I think it must, it must help your brain. Keep it alive.</p></disp-quote><p>Both groups therefore tried to prevent dementia to the extent that they could.</p></sec><sec id="s4-2-1-4"><title>1.4.a The normalisation of forgetting (low worry)</title><p>Participants in the low worry groups engaged in a process of normalising forgetting. In these groups, personal stories of forgetting were met by other participants with comments such as: &#8220;Oh, I do that all the time, and I don&#8217;t worry about it.&#8221; (LWF3) or &#8220;But we all forget things from time to time.&#8221; (LWF4). They therefore normalised forgetting, which was also seen in their way of normalising the use of coping strategies:</p><disp-quote><p>LWM3: But I mean what Mary could do is what everybody does. Is put a post-it note on the front door saying &#8216;put the sweets in your basket&#8217;. But that happens to me and I get the impression it happens to almost everybody, so should you worry about it?</p></disp-quote><p>Additionally, although they discussed heavy topics and expressed some degree of worry, they kept a light tone and even shared jokes: LWM3: &#8220;But isn&#8217;t there, that, the old joke about there are some benefits to getting old and having a bad memory, that you can watch a film for the second or third time&#8221;. These jokes are also a way of communicating that this is not an immediate worry to them. Interestingly, this normalisation of forgetting may be interpreted as avoiding the problem, these individuals also viewed denial of memory decline as very worrying: &#8220;Do you not agree? That is so worrying when people are in denial&#8221; (LWF7). Presumably, this was not viewed as contradictory, as they were less likely to consider themselves as having something to worry about (see the Consequences of dDementia on others (low w Worry) section).</p></sec><sec id="s4-2-1-5"><title>1.4.b The normalisation of fear (high worry)</title><p>Participants with high worry appeared to engage in a process of normalising fear. In these groups, when individuals shared personal stories about forgetting, such as getting lost in a park, these were often met with comments such as: &#8220;You are telling yourself: &#8216;is this normal?&#8217; or &#8216;is that &#8211; it&#8217;s okay?&#8217;&#8221; (HWF6) or &#8220;That is disturbing [&#8230;] but you forgive yourself&#8221; (HWF5). Thus, the participants&#8217; reactions indicate that these situations are abnormal and should be a reason to worry. As seen in the quotations, they did however also try to positively influence each other by encouraging forgiveness. Although this also assumes something is wrong for which one needs to be forgiven.</p></sec></sec></sec><sec id="s4-3"><title>Theme 2: the importance of the self and others</title><p>The theme of the importance of the Self and the Others captures how the two groups discussed similar topics but leaned differently on this dimension, where those with high worry tended to highlight the importance of the self. Each subtheme had an opposite yet corresponding meaning in each worry group.</p><sec id="s4-3-1"><title>2.1.a An issue relevant to others (low worry)</title><p>Participants with low worry seemed to view dementia as an issue that was not immediately relevant to themselves, but rather an issue concerning others. As seen in the subtheme Preservation of normality, they tended to maintain the sentiment not to worry about dementia and keep a light tone. Participants also shared fewer personal stories; instead, they focused on the vignette. The vignette did not include any explicit mentioning of dementia, and it took a while before the word &#8216;dementia&#8217; was mentioned by participants (average LW group 26&#8201;min.; HW group: 20&#8201;min 35&#8201;s) and it was mentioned fewer times than by those with high worry (average 12.5 times per group; HW: 15.3 times). They were also likely to bring up the issue from the perspective of the family and close friends, rather than that of the person with dementia:</p><disp-quote><p>LWM5: Well, then you, you know, if you&#8217;re a close family, you work around it. Now that means come, come and be with the children here, rather than go out with them and things like that.</p></disp-quote><p>Participants therefore tended to view dementia as something <italic toggle="yes">others</italic> develop rather than themselves, therefore creating a distance between themselves and the disorder.</p></sec><sec id="s4-3-2"><title>2.1.b An issue relevant to oneself (high worry)</title><p>Those with high worry viewed dementia as an issue immediately relevant to themselves. For instance, they related stories of dementia back to themselves: &#8220;&#8230;because of my father [edit: who had dementia], I&#8217;m [&#8230;] probably, I&#8217;m overcompensating and trying not to get dementia&#8221; (HWF1). Thus, clearly contemplating the possibility of them developing dementia themselves in the future. As proposed by one participant, the high worry may partly be caused by exposure to the disorder:</p><disp-quote><p>HWF8: I sometimes wonder if the reason why I&#8217;m worried is (a) because I&#8217;ve seen friends with dementia; and (b) because you just read more about it and we&#8217;re generally better informed.</p></disp-quote><p>Participants quickly removed their focus from the vignette to these personal stories, and the discussions therefore often surrounded dementia, although this was never mentioned by the researchers. These discussions were often more emotional and fearful, as seen in quotations like: &#8220;I&#8217;m afraid of it, I&#8217;m afraid.&#8221; (HWF3) or &#8220;I think the saddest thing is this. Sometimes there&#8217;s not a lot to look forward to.&#8221; (HWF7). Thus, these participants viewed dementia as a serious and relevant issue.</p></sec><sec id="s4-3-3"><title>2.2.a Consequences of dementia on others (low worry)</title><p>Those with low worry tended to focus on the consequences dementia can have on <italic toggle="yes">others,</italic> such as friends and relatives. A primary worry was therefore to be a burden: &#8220;It worries me being a burden&#8221; (LWF6). This also led to a distinction between &#8216;good&#8217; and &#8216;bad&#8217; dementia depending on the degree of harm the disorder would have to other people:</p><disp-quote><p>LWF6: And I think that&#8217;s the fear I have, is, going into dementia gently and being the dear old lady who can&#8217;t remember anything is fine. I don&#8217;t mind that. But I fear going into the, the other side where it&#8217;s inappropriate. And you disgust people.</p></disp-quote><p>As seen in the quotation, dementia was feared less if the harm to other people could be minimised. The reason why they focus on the consequences of dementia on friends and relatives may therefore be that this is whom they identify with (see the An issue relevant to others sectionIssue Relevant to Others ), rather than the person with dementia.</p></sec><sec id="s4-3-4"><title>2.2.b Consequences of dementia on the self (high worry)</title><p>Participants with high worry focused on the consequences dementia would have on the individual with dementia, that is, <italic toggle="yes">the self</italic>. Although those with high worry also expressed a fear of being a burden and the prospect of losing close relationships: &#8220;I do worry about getting it because I don&#8217;t want to be the one that is angry and [&#8230;] change my relationship with my children and everybody&#8221; (HWF4), this was not emphasised as much, as by those with low worry. Instead, the focus was on the symptoms of the disorder itself and the risk of them getting it: &#8220;Her mum had dementia. Is she fighting? Is she aware? I don&#8217;t know. [&#8230;] Sorry, it is just difficult to watch. And then you feel, am I going down that route too?&#8221; (HWF6). Those with high worry therefore did not draw a distinction between good and bad dementia, but instead were worried about dementia regardless of its specific symptoms.</p></sec><sec id="s4-3-5"><title>2.3.a Coping with potential dementia (low worry)</title><p>Participants with low worry mainly feared the potential harm on others caused by dementia. Participants even reported a wish for facilitated suicide, and thereby a sense of &#8216;sacrifice&#8217; of their own self for the sake of others:</p><disp-quote><p>LWM1: &#8230;I certainly don&#8217;t want to be a burden to anybody. And I want to be able, I rather object to the fact that one can&#8217;t just say I want to end my life &#8211; facilitated, please. I think you should have that option.</p></disp-quote><p>Lesser coping strategies were also discussed as a useful and positive way to control and minimise that harm:</p><disp-quote><p>LWF7: There was an amazing woman with Alzheimer&#8217;s on television. She knows she&#8217;s got it [&#8230;]. So, she knows exactly what to do if she forgets. [&#8230;] all the cues, all the little notelets, or everything, post-its [&#8230;] And she&#8217;s so content with herself, but she has Alzheimer&#8217;s quite badly. [&#8230;] but how many people do that? Not a lot.</p></disp-quote><p>This ability to cope would minimise the prospect of being a burden to others and therefore provide a sense of hope and control for managing their fears associated with potential dementia.</p></sec><sec id="s4-3-6"><title>2.3.b Fear of potential dementia (high worry)</title><p>Participants with high worry appeared to focus on the consequences dementia would have to themselves, for which they perceived little or no relevant resources to cope. Instead of a fear of being a burden, these participants feared dementia itself (see the Consequences of dementia on the s Dementia on the Self section). As their worry is tied to dementia itself, and there is currently no way to fully prevent or treat dementia, these individuals understandably sense they have no means to manage the object of their fears. Coping mechanisms were therefore not a prominent point of discussion. Instead, the prospect of dementia and their potential future was a source of fear and uncertainty: &#8220;I&#8217;m afraid of it, I&#8217;m afraid.&#8221; (HWF3) and &#8220;When I get to 87, I don&#8217;t know where I&#8217;ll be. And that&#8217;s a little bit&#8230; That&#8217;s, that&#8217;s the worry&#8221; (HWF4). The focus on the self and therefore the perceived lack of relevant coping strategies appears to lead to decreased sense of control and increased sense of fear.</p></sec></sec></sec><sec sec-type="discussion" id="s5"><title>Discussion</title><p>In this study, we aimed to qualitatively investigate how older individuals form their metacognitive beliefs about their memory ability. Employing thematic analysis,<xref rid="R46" ref-type="bibr"><sup>46 47</sup></xref> we defined two themes across both groups of low and high dementia worry. The first theme being &#8220;the question of normality&#8221; which incorporated analysis of older individuals&#8217; metacognitive beliefs and strategies, and how this differs between individuals with low and high dementia worry. Strikingly, we found that despite the aim of the study being &#8216;thinking about memory&#8217;, the focus group discussions quickly evolved to &#8216;thinking about dementia&#8217;, leading to the definition of the second theme, &#8216;the importance of the self&#8217;. Here we discuss these findings in relation to previous literature on dementia and subjective beliefs about memory, as well as highlighting how these findings shed light on relevant targets for interventions regarding memory and dementia worries in older adults.</p><sec id="s5-1"><title>Metacognitive beliefs and metacognitive strategies</title><p>Previous research has suggested that there is an association between inaccurate and negative metacognitive beliefs and dementia worry in older age,<xref rid="R36" ref-type="bibr">36</xref><xref rid="R41" ref-type="bibr">41</xref> possibly leading to a vicious cycle of increasing worry and inaccurate metacognitive beliefs. However, this interaction between dementia and metacognitive beliefs has not been investigated in detail. In the current study, we found evidence that individuals with high dementia worry were more likely to exhibit negative beliefs about memory slips. On the other hand, those with low dementia worry tended to normalise situations of forgetting. Interestingly, the 1-item questionnaire on subjective beliefs about memory ability found no statistically significant difference between the low and high dementia worry participants. This question asked participants to rate their ability to remember. The fact that there is evidence of lower confidence around memory abilities among those with high worry in the qualitative analysis but not the quantitative analysis may result from a number of reasons. As previously mentioned, the sample was not powered for quantitative analyses but rather qualitative analysis. Issues around power for quantitative analysis are also exacerbated by the use of a 1-item questionnaire as there are a small number of data points. Conversely, the qualitative data are richer, allowing us to explore the nuanced differences between the two groups. It is worth noting that this limitation is common in this field of research; many studies investigating insight into memory abilities in older adults rely on 1-item questionnaires similar to the one used in this study.<xref rid="R21" ref-type="bibr"><sup>21 56 57</sup></xref> The current study highlights the need for richer research to assess subjective memory beliefs.</p><p>In the current study, we were particularly interested in how different types of memory may influence metacognitive beliefs. The only difference we found between the scenarios was, however, the scenario in which Mary got lost. All participants found this scenario to be frightening and reported that it would lead to a change in their metacognitive beliefs about their memory abilities. This is in line with the intimate relationship between spatial processing and the episodic memory system,<xref rid="R58" ref-type="bibr"><sup>58</sup></xref> of which the disruption is a core symptom of dementia.<xref rid="R59" ref-type="bibr"><sup>59</sup></xref> Other events of forgetting discrete semantic or episodic details were less associated with severe cognitive decline, and participants rightfully only reported this to be worrisome if such incidents started to accumulate. However, when the participants started to share their own personal stories of such incidents, those with high dementia worry often deemed these worrisome as well. In line with previous research,<xref rid="R42" ref-type="bibr"><sup>42 43</sup></xref> this suggests that individuals with high dementia worry may interpret memory slips more negatively.</p><p>Turning to metacognitive strategies, all participants reported relying on comparisons to develop their metacognitive beliefs about their own cognitive states. They mentioned both social comparison, that is comparison to their peers, which is in line with social comparison theories,<xref rid="R34" ref-type="bibr"><sup>34 35</sup></xref> but also mentioned comparisons to their younger selves as another metacognitive strategy. These comparisons were used to define their perception of &#8216;normal ageing&#8217; and therefore the threshold for their worries. This suggests that those with high dementia worry may engage in maladaptive comparison strategies, leading to unhealthy perceptions of &#8216;normal ageing&#8217;, which in turn may lead to inaccurate metacognitive beliefs and dementia worry. We encourage future research to further investigate the causal relationships between comparison strategies, metacognitive beliefs and dementia worry, as this will be crucial for developing effective interventions.</p></sec><sec id="s5-2"><title>A self-other dimension as an important mechanism of dementia worry</title><p>In addition to findings related to differences in metacognitive beliefs dependent on dementia worry, our study also provided insight into the factors associated with dementia worry. Due to the negative outcomes associated with dementia worry, we argue that understanding the mechanisms of dementia worry is essential. Previous research has tried to explain some of the mechanisms associated with dementia worry. Most pertinently, the dementia worry model proposed by Kessler <italic toggle="yes">et al</italic>.<xref rid="R44" ref-type="bibr"><sup>44</sup></xref> They proposed that dementia worry depends on three dimensions: (1) the perception of risk of developing dementia, (2) the perception of seriousness of dementia and (3) the perception of coping resources available if developing dementia (see <xref rid="F2" ref-type="fig">figure 2</xref>). Our findings support this model as: (1) those with high dementia worry were more likely to identify with those with dementia; (2) those with high dementia worry viewed seriousness in relation to themselves, whereas those with low dementia worry viewed seriousness in relation to others; (3) those with low dementia worry had the perception of the presence of numerous relevant coping strategies, whereas those with high dementia worry did not. This original model has recently been supported by a qualitative study, in which they interviewed older adults and found themes supporting that perception of risk, seriousness and coping underlies dementia worry in this population.<xref rid="R45" ref-type="bibr"><sup>45</sup></xref> Kessler&#8217;s original model, however, does not give clear directions on how to positively alter individuals&#8217; perceptions of these dimensions.</p><fig position="float" id="F2" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><title>Blue: Original Model by Kessler <italic toggle="yes">et al,</italic><xref rid="R44" ref-type="bibr"><sup>44</sup></xref> green: behavioural component by Werner <italic toggle="yes">et al</italic>,<xref rid="R7" ref-type="bibr"><sup>7</sup></xref> red: behavioural inspired by Edmonds <italic toggle="yes">et al,</italic><xref rid="R97" ref-type="bibr"><sup>97</sup></xref> yellow: self-other dimension proposed by the authors of the current study.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bmjopen-15-10-g002.jpg"/></fig><p>Importantly, our findings suggest that there also is a &#8216;self-other&#8217; dimension, which is associated with the original dimensions (risk, seriousness and coping), thus providing new understanding of the reasons for dementia worry in older age. It appears to be the case that individuals with high dementia worry tended to relate issues of dementia to <italic toggle="yes">the self</italic>. Contrarily, those with low dementia worry tended to relate issues of dementia to <italic toggle="yes">others</italic>. We argue that this is associated with different interpretations of risk, seriousness and coping, as described in the previous paragraph, ultimately leading to different levels of dementia worry. The present study cannot provide evidence of the directional and causal relationship between the concepts, which should be investigated further. Nonetheless, our theory is supported by evidence suggesting a clear relationship between self-focused thinking and anxiety,<xref rid="R60" ref-type="bibr"><sup>60 61</sup></xref> and evidence showing that individuals with high dementia worry are likely to also have ageing anxiety,<xref rid="R62" ref-type="bibr"><sup>62 63</sup></xref> general anxiety<xref rid="R64" ref-type="bibr">64</xref><xref rid="R66" ref-type="bibr">66</xref> and illness worry.<xref rid="R66" ref-type="bibr"><sup>66</sup></xref> More broadly, evidence supports the idea that individuals tend to organise their thinking in terms of self-other themes, which supports the reliability of this finding.<xref rid="R67" ref-type="bibr"><sup>67 68</sup></xref> People tend to view various concepts such as &#8216;having dementia&#8217; or &#8216;having a mental health condition&#8217; as something related to either themselves or to others, and depending on this thinking pattern, their views and behaviours around that concept change.<xref rid="R67" ref-type="bibr"><sup>67 68</sup></xref> As we will describe in more detail, we view this as a relevant target for interventions of dementia worry.</p></sec><sec id="s5-3"><title>Interventions to increase metacognitive accuracies and decrease dementia worry</title><p>As described throughout this paper, metacognitive beliefs and dementia worry are associated with many negative health outcomes including an impact on mental health and importantly an increased risk of dementia.<xref rid="R8" ref-type="bibr">821 23 25 69</xref><xref rid="R73" ref-type="bibr">73</xref> Identifying effective interventions for these types of negative thinking patterns is therefore crucial both for the health of the individual and the burden of the healthcare system. First, we encourage the use of interventions focused on improving metacognitive abilities as previous research has found this to be successful in individuals with subjective memory complaints.<xref rid="R74" ref-type="bibr">74</xref><xref rid="R76" ref-type="bibr">76</xref> We encourage this to be extended to individuals with high dementia worry. Second, while national interventions focusing on increasing the awareness and knowledge of dementia have been frequently used,<xref rid="R77" ref-type="bibr">77</xref><xref rid="R79" ref-type="bibr">79</xref> our data might suggest these are not always effective for many individuals. Increased knowledge of dementia does not appear to be associated with decreased dementia worry.<xref rid="R80" ref-type="bibr"><sup>80 81</sup></xref> Instead, based on our findings, interventions focusing on a healthy perception of &#8216;normal ageing&#8217; and suitable comparison techniques may be more beneficial in decreasing dementia worry and negative metacognitive beliefs. This is also supported by previous evidence showing that negative stereotypical beliefs of ageing have negative effects on both metacognitive beliefs and dementia worry.<xref rid="R42" ref-type="bibr"><sup>42 65 82 83</sup></xref></p><p>In addition, our findings support the importance of decreasing negative self-focused thinking. Here, we propose psychological interventions focused on decreasing self-focused thinking. For instance, previous research has found that Cognitive Behavioural Therapy (CBT) focusing specifically on reducing self-focused thinking leads to reduced general anxiety,<xref rid="R84" ref-type="bibr"><sup>84 85</sup></xref> and some preliminary studies even suggest that general CBT can help decrease worries of dementia among older adults.<xref rid="R86" ref-type="bibr"><sup>86</sup></xref> Thus, combined with the findings of our study, it seems promising that CBT targeting self-focused thinking may be particularly effective in reducing dementia worry in older age. Similarly, mindfulness<xref rid="R87" ref-type="bibr"><sup>87 88</sup></xref> and meditation<xref rid="R89" ref-type="bibr"/>-focused<xref rid="R89" ref-type="bibr"><sup>89</sup></xref> interventions, which also aim to change self-referential thinking patterns,<xref rid="R90" ref-type="bibr">90</xref><xref rid="R92" ref-type="bibr">92</xref> may reduce dementia worry. In the current study, we did not measure mental health or mood, but it is likely that those with high dementia worry and negative metacognitive beliefs generally have a tendency for negative thinking patterns, anxiety and depression. Establishing the relation and causal relationship between mental health issues and negative thinking patterns will be an important step in identifying the specific targets of these interventions.</p><p>These types of interventions could be offered to individuals with a close relationship to individuals with dementia, because these are at a particular risk of high dementia worry. In our research, we found that those with high dementia worry more often told personal stories of individuals close to them with dementia. This is supported by previous research showing that exposure to dementia in the family is related to a higher risk of dementia worry and subjective cognitive decline,<xref rid="R6" ref-type="bibr"><sup>6 41 44 66 93 94</sup></xref> and may be of particular relevance if the relatives know of a genetic disposition to dementia.<xref rid="R6" ref-type="bibr"><sup>6 42 94</sup></xref> One potential obstacle to identifying these individuals has been described by Werner <italic toggle="yes">et al</italic>,<xref rid="R7" ref-type="bibr"><sup>7</sup></xref> who proposed to expand the original model by Kessler and Bowen.<xref rid="R44" ref-type="bibr"><sup>44</sup></xref> They argued that some individuals will avoid consulting professionals or thinking about dementia, due to their worries<xref rid="R95" ref-type="bibr"><sup>95 96</sup></xref> (see <xref rid="F2" ref-type="fig">figure 2</xref>). In our study, over half of those with high dementia worry had discussed their worries with a health professional. This is in line with an argument proposed by Edmonds <italic toggle="yes">et al</italic>,<xref rid="R97" ref-type="bibr"><sup>97</sup></xref> describing how some individuals may maladaptively seek help, which can lead to misdiagnoses. We would propose that there might be two groups of individuals with high dementia worry; those who &#8216;avoid&#8217; and those who &#8216;seek&#8217; help (see <xref rid="F2" ref-type="fig">figure 2</xref>). We argue that this distinction is important to keep in mind as both groups have separable and opposing risks.</p></sec><sec id="s5-4"><title>Limitations</title><p>This study used a qualitative framework to investigate metacognitive beliefs between individuals with different levels of dementia worry. We acknowledge the limitations of the current study. First, participants were aware of whether they were in a &#8216;low dementia worry&#8217; or a &#8216;high dementia worry&#8217; group which may have influenced the tones and narratives in the group discussion and may have caused greater differences between the groups. This was done to assure people that they were discussing in a group of people who had a similar experience of worry as themselves, and so the aim of disclosing this was to maximise comfortable discussion. Second, the current analysis sheds light on the potential presence of two behavioural groups: those who seek and those who avoid dementia-related situations. In the case of the presence of two groups, the findings of our study are limited to those who &#8216;seek&#8217;, as these were individuals who had volunteered to be part of a focus group discussion. Individuals who &#8216;avoid&#8217; would be assumed to avoid a study like this. Furthermore, as mentioned, one individual scored below the threshold of MCI on the Tele-MACE. The quantitative statistics were re-calculated without this individual, which did not change the pattern of results. However, this may have influenced the discussion in the respective focus group. In addition, it should be noted that some participants, particularly in the high dementia worry group, may be defined as having subjective cognitive decline. For example, those who have discussed memory issues with their family or medical professionals (n=8) would, in some research, be described as having subjective cognitive decline as they have these beliefs in the absence of a memory impairment on the Tele-MACE.<xref rid="R10" ref-type="bibr"><sup>10 11</sup></xref> An increasing amount of research suggests that such individuals may have subtle cognitive decline, undetectable on tests such as the Tele-MACE.<xref rid="R98" ref-type="bibr">98</xref><xref rid="R100" ref-type="bibr">100</xref> Thus, some individuals in the high dementia worry group may in fact experience more memory slips than those with low dementia worry, despite this being undetectable to the measure employed here. This difference may have directly influenced the discussion and increased the difference between the two groups.</p><p>Turning to the quantitative measures in this study, common mental health traits such as anxiety, depression and family history of dementia, which have been shown to be highly correlated with dementia worry.<xref rid="R7" ref-type="bibr"><sup>7 39</sup></xref> Finally, the sample was underpowered for the quantitative analysis presented in this study, and so this should be interpreted cautiously. The primary goal of this study was the qualitative analysis of focus group discussions.</p></sec></sec><sec sec-type="conclusions" id="s6"><title>Conclusion</title><p>In conclusion, our findings suggest that older individuals appear to employ comparative metacognitive strategies in order to build their metacognitive beliefs, and we propose that these strategies are a useful target for interventions. Specifically, we encourage knowledge-based interventions that encourage positive and effective social comparisons rather than focus on providing information on dementia occurrence. In addition, there appears to be a self-other dimension influencing the previously proposed dimensions of dementia worry, with a strong self-focus being associated with increased worry. Targeting this focus is likely to be useful in ameliorating harmful levels of dementia worry and could be supported through adapting current therapeutic tools for anxiety disorders.<xref rid="R84" ref-type="bibr"><sup>84 85</sup></xref> We argue that these should be seen as part of dementia prevention methods and could be offered to relatives and close associates of individuals with dementia.</p></sec><sec sec-type="supplementary-material" id="s7"><title>Supplementary material</title><supplementary-material id="SP1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/bmjopen-2024-097002</object-id><label>online supplemental file 1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bmjopen-15-10-s001.docx" id="d67e973" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> This work was funded by the Economic and Social Research Council (ESRC) through a London Interdisciplinary Social Science Doctoral Training Partnership (LISS-DTP) studentship to AEL (ES/P000703/1) and support from the Department of Psychology, King&#8217;s College London. The funder did not influence the results of the study despite author affiliations.</p></fn><fn fn-type="other"><p>Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1136/bmjopen-2024-097002" ext-link-type="uri">https://doi.org/10.1136/bmjopen-2024-097002</ext-link>).</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn fn-type="other"><p><bold>Patient consent for publication:</bold> Not applicable.</p></fn><fn fn-type="other"><p><bold>Ethics approval:</bold> This study involves human participants and was approved by King&#8217;s College London Ethics Committee (ref: HR/DP-21/22-26212). Participants gave informed consent to participate in the study before taking part.</p></fn><fn fn-type="other"><p><bold>Patient and public involvement:</bold> Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>MetLife Foundation</collab></person-group><article-title>What America thinks: metlife foundation alzheimer&#8217;s survey</article-title><publisher-name>Harris Interactive Rochester, NY</publisher-name><year>2011</year></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaugler</surname><given-names>J</given-names></name><name name-style="western"><surname>James</surname><given-names>B</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Alzheimer&#8217;s disease facts and figures</article-title><source>Alzheimers Dement</source><year>2019</year><volume>15</volume><fpage>321</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2019.01.010</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awang</surname><given-names>H</given-names></name><name name-style="western"><surname>Mansor</surname><given-names>N</given-names></name><name name-style="western"><surname>Nai Peng</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Understanding ageing: fear of chronic diseases later in life</article-title><source>J Int Med Res</source><year>2018</year><volume>46</volume><fpage>175</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1177/030006051771085</pub-id><pub-id pub-id-type="pmid">28760083</pub-id><pub-id pub-id-type="pmcid">PMC6011296</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watson</surname><given-names>R</given-names></name><name name-style="western"><surname>Sanson-Fisher</surname><given-names>R</given-names></name><name name-style="western"><surname>Bryant</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Dementia is the second most feared condition among Australian health service consumers: results of a cross-sectional survey</article-title><source>BMC Public Health</source><year>2023</year><volume>23</volume><elocation-id>876</elocation-id><pub-id pub-id-type="doi">10.1186/s12889-023-15772-y</pub-id><pub-id pub-id-type="pmid">37173717</pub-id><pub-id pub-id-type="pmcid">PMC10176813</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varshney</surname><given-names>LR</given-names></name><name name-style="western"><surname>Barbey</surname><given-names>AK</given-names></name></person-group><article-title>Beyond IQ: The Importance of Metacognition for the Promotion of Global Wellbeing</article-title><source>J Intell</source><year>2021</year><volume>9</volume><fpage>54</fpage><pub-id pub-id-type="doi">10.3390/jintelligence9040054</pub-id><pub-id pub-id-type="pmid">34842762</pub-id><pub-id pub-id-type="pmcid">PMC8628945</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spalding</surname><given-names>DM</given-names></name><name name-style="western"><surname>Hart</surname><given-names>R</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Age moderates associations between dementia worry and subjective cognition</article-title><source>Cogn Emot</source><year>2025</year><volume>39</volume><fpage>505</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1080/02699931.2024.2371095</pub-id><pub-id pub-id-type="pmid">38973175</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Werner</surname><given-names>P</given-names></name><name name-style="western"><surname>AboJabel</surname><given-names>H</given-names></name><name name-style="western"><surname>Maxfield</surname><given-names>M</given-names></name></person-group><article-title>Conceptualization, measurement and correlates of dementia worry: A scoping review</article-title><source>Arch Gerontol Geriatr</source><year>2021</year><volume>92</volume><fpage>104246</fpage><pub-id pub-id-type="doi">10.1016/j.archger.2020.104246</pub-id><pub-id pub-id-type="pmid">32980573</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlosser</surname><given-names>M</given-names></name><name name-style="western"><surname>Demnitz-King</surname><given-names>H</given-names></name><name name-style="western"><surname>Whitfield</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Repetitive negative thinking is associated with subjective cognitive decline in older adults: a cross-sectional study</article-title><source>BMC Psychiatry</source><year>2020</year><volume>20</volume><elocation-id>500</elocation-id><pub-id pub-id-type="doi">10.1186/s12888-020-02884-7</pub-id><pub-id pub-id-type="pmid">33036587</pub-id><pub-id pub-id-type="pmcid">PMC7547434</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dafsari</surname><given-names>FS</given-names></name><name name-style="western"><surname>Jessen</surname><given-names>F</given-names></name></person-group><article-title>Depression-an underrecognized target for prevention of dementia in Alzheimer&#8217;s disease</article-title><source>Transl Psychiatry</source><year>2020</year><volume>10</volume><elocation-id>160</elocation-id><pub-id pub-id-type="doi">10.1038/s41398-020-0839-1</pub-id><pub-id pub-id-type="pmid">32433512</pub-id><pub-id pub-id-type="pmcid">PMC7239844</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jessen</surname><given-names>F</given-names></name><name name-style="western"><surname>Amariglio</surname><given-names>RE</given-names></name><name name-style="western"><surname>Buckley</surname><given-names>RF</given-names></name><etal>et al</etal></person-group><article-title>The characterisation of subjective cognitive decline</article-title><source>Lancet Neurol</source><year>2020</year><volume>19</volume><fpage>271</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(19)30368-0</pub-id><pub-id pub-id-type="pmid">31958406</pub-id><pub-id pub-id-type="pmcid">PMC7062546</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jessen</surname><given-names>F</given-names></name><name name-style="western"><surname>Amariglio</surname><given-names>RE</given-names></name><name name-style="western"><surname>van Boxtel</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement</source><year>2014</year><volume>10</volume><fpage>844</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2014.01.001</pub-id><pub-id pub-id-type="pmid">24798886</pub-id><pub-id pub-id-type="pmcid">PMC4317324</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>R&#246;hr</surname><given-names>S</given-names></name><name name-style="western"><surname>Pabst</surname><given-names>A</given-names></name><name name-style="western"><surname>Riedel-Heller</surname><given-names>SG</given-names></name><etal>et al</etal></person-group><article-title>Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study</article-title><source><italic toggle="yes">Alz Res Therapy</italic></source><year>2020</year><volume>12</volume><fpage>167</fpage><pub-id pub-id-type="doi">10.1186/s13195-020-00734-y</pub-id><pub-id pub-id-type="pmcid">PMC7749505</pub-id><pub-id pub-id-type="pmid">33339532</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vlachos</surname><given-names>GS</given-names></name><name name-style="western"><surname>Cosentino</surname><given-names>S</given-names></name><name name-style="western"><surname>Kosmidis</surname><given-names>MH</given-names></name><etal>et al</etal></person-group><article-title>Prevalence and determinants of subjective cognitive decline in a representative Greek elderly population</article-title><source>Int J Geriatr Psychiatry</source><year>2019</year><volume>34</volume><fpage>846</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1002/gps.5073</pub-id><pub-id pub-id-type="pmid">30714214</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleming</surname><given-names>SM</given-names></name><name name-style="western"><surname>Lau</surname><given-names>HC</given-names></name></person-group><article-title>How to measure metacognition</article-title><source>Front Hum Neurosci</source><year>2014</year><volume>8</volume><elocation-id>443</elocation-id><pub-id pub-id-type="doi">10.3389/fnhum.2014.00443</pub-id><pub-id pub-id-type="pmid">25076880</pub-id><pub-id pub-id-type="pmcid">PMC4097944</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flavell</surname><given-names>JH</given-names></name></person-group><article-title>Metacognition and cognitive monitoring: A new area of cognitive&#8211;developmental inquiry</article-title><source>American Psychologist</source><year>1979</year><volume>34</volume><fpage>906</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1037/0003-066X.34.10.906</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Flier</surname><given-names>WM</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></name></person-group><article-title>Amsterdam Dementia Cohort: Performing Research to Optimize Care</article-title><source>J Alzheimers Dis</source><year>2018</year><volume>62</volume><fpage>1091</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.3233/JAD-170850</pub-id><pub-id pub-id-type="pmid">29562540</pub-id><pub-id pub-id-type="pmcid">PMC5870023</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luck</surname><given-names>T</given-names></name><name name-style="western"><surname>Roehr</surname><given-names>S</given-names></name><name name-style="western"><surname>Jessen</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Mortality in Individuals with Subjective Cognitive Decline: Results of the Leipzig Longitudinal Study of the Aged (LEILA75+)</article-title><source><italic toggle="yes">JAD</italic></source><year>2015</year><volume>48</volume><fpage>S33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.3233/JAD-150090</pub-id><pub-id pub-id-type="pmid">26402077</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valiente</surname><given-names>C</given-names></name><name name-style="western"><surname>Prados</surname><given-names>JM</given-names></name><name name-style="western"><surname>G&#243;mez</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>Metacognitive beliefs and psychological well-being in paranoia and depression</article-title><source>Cogn Neuropsychiatry</source><year>2012</year><volume>17</volume><fpage>527</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1080/13546805.2012.670504</pub-id><pub-id pub-id-type="pmid">22530974</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatterjee</surname><given-names>A</given-names></name><name name-style="western"><surname>Damodar</surname><given-names>SK</given-names></name><name name-style="western"><surname>Hema</surname><given-names>MA</given-names></name></person-group><article-title>Influence of positive metacognitions and meta-emotions, and mindfulness on well-being</article-title><source>Indian Journal of Health and Wellbeing</source><year>2021</year><volume>12</volume><fpage>51</fpage><lpage>6</lpage></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kinzer</surname><given-names>A</given-names></name><name name-style="western"><surname>Suhr</surname><given-names>JA</given-names></name></person-group><article-title>Dementia worry and its relationship to dementia exposure, psychological factors, and subjective memory concerns</article-title><source>Appl Neuropsychol Adult</source><year>2016</year><volume>23</volume><fpage>196</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1080/23279095.2015.1030669</pub-id><pub-id pub-id-type="pmid">26496236</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pike</surname><given-names>KE</given-names></name><name name-style="western"><surname>Cavuoto</surname><given-names>MG</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Subjective Cognitive Decline: Level of Risk for Future Dementia and Mild Cognitive Impairment, a Meta-Analysis of Longitudinal Studies</article-title><source>Neuropsychol Rev</source><year>2022</year><volume>32</volume><fpage>703</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1007/s11065-021-09522-3</pub-id><pub-id pub-id-type="pmid">34748154</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Beaumont</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis</article-title><source>Acta Psychiatr Scand</source><year>2014</year><volume>130</volume><fpage>439</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1111/acps.12336</pub-id><pub-id pub-id-type="pmid">25219393</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cappa</surname><given-names>SF</given-names></name><name name-style="western"><surname>Ribaldi</surname><given-names>F</given-names></name><name name-style="western"><surname>Chicherio</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Subjective cognitive decline: Memory complaints, cognitive awareness, and metacognition</article-title><source>Alzheimers Dement</source><year>2024</year><volume>20</volume><fpage>6622</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1002/alz.13905</pub-id><pub-id pub-id-type="pmid">39051174</pub-id><pub-id pub-id-type="pmcid">PMC11497716</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Pan</surname><given-names>F-F</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q</given-names></name><etal>et al</etal></person-group><article-title>Altered metamemory precedes cognitive impairment in subjective cognitive decline with positive amyloid-beta</article-title><source>Front Aging Neurosci</source><year>2022</year><volume>14</volume><fpage>1046445</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2022.1046445</pub-id><pub-id pub-id-type="pmid">36389070</pub-id><pub-id pub-id-type="pmcid">PMC9640736</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cacciamani</surname><given-names>F</given-names></name><name name-style="western"><surname>Sambati</surname><given-names>L</given-names></name><name name-style="western"><surname>Houot</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Awareness of cognitive decline trajectories in asymptomatic individuals at risk for AD</article-title><source>Alz Res Therapy</source><year>2020</year><volume>12</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s13195-020-00700-8</pub-id><pub-id pub-id-type="pmcid">PMC7557018</pub-id><pub-id pub-id-type="pmid">33054821</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niu</surname><given-names>H</given-names></name><name name-style="western"><surname>&#193;lvarez-&#193;lvarez</surname><given-names>I</given-names></name><name name-style="western"><surname>Guill&#233;n-Grima</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Prevalence and incidence of Alzheimer&#8217;s disease in Europe: A meta-analysis</article-title><source>Neurolog&#237;a (English Edition)</source><year>2017</year><volume>32</volume><fpage>523</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.nrleng.2016.02.009</pub-id><pub-id pub-id-type="pmid">27130306</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saumier</surname><given-names>D</given-names></name><name name-style="western"><surname>Chertkow</surname><given-names>H</given-names></name></person-group><article-title>Semantic memory</article-title><source>Curr Neurol Neurosci Rep</source><year>2002</year><volume>2</volume><fpage>516</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1007/s11910-002-0039-9</pub-id><pub-id pub-id-type="pmid">12359106</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nyberg</surname><given-names>L</given-names></name></person-group><article-title>Classifying Human Long-term Memory: Evidence from Converging Dissociations</article-title><source>Eur J Cogn Psychol</source><year>1996</year><volume>8</volume><fpage>163</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1080/095414496383130</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McDonough</surname><given-names>IM</given-names></name><name name-style="western"><surname>Festini</surname><given-names>SB</given-names></name><name name-style="western"><surname>Wood</surname><given-names>MM</given-names></name></person-group><article-title>Risk for Alzheimer&#8217;s disease: A review of long-term episodic memory encoding and retrieval fMRI studies</article-title><source>Ageing Res Rev</source><year>2020</year><volume>62</volume><fpage>101133</fpage><pub-id pub-id-type="doi">10.1016/j.arr.2020.101133</pub-id><pub-id pub-id-type="pmid">32717407</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aihara</surname><given-names>Y</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>K</given-names></name></person-group><article-title>Dementia Literacy and Willingness to Dementia Screening</article-title><source>Int J Environ Res Public Health</source><year>2020</year><volume>17</volume><elocation-id>8134</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph17218134</pub-id><pub-id pub-id-type="pmid">33158014</pub-id><pub-id pub-id-type="pmcid">PMC7662832</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marh&#225;nkov&#225;</surname><given-names>JH</given-names></name><name name-style="western"><surname>Honelov&#225;</surname><given-names>M</given-names></name></person-group><article-title>Making Sense of Dementia: Older Adults&#8217; Subjective Representations of Dementia and Alzheimer&#8217;s Disease</article-title><source>J Gerontol B Psychol Sci Soc Sci</source><year>2024</year><volume>79</volume><pub-id pub-id-type="doi">10.1093/geronb/gbae056</pub-id><pub-id pub-id-type="pmcid">PMC11075728</pub-id><pub-id pub-id-type="pmid">38572717</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jorge</surname><given-names>C</given-names></name><name name-style="western"><surname>Cet&#243;</surname><given-names>M</given-names></name><name name-style="western"><surname>Arias</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Level of understanding of Alzheimer disease among caregivers and the general population</article-title><source>Neurologia (Engl Ed)</source><year>2021</year><volume>36</volume><fpage>426</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.nrleng.2018.03.004</pub-id><pub-id pub-id-type="pmid">34238525</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McParland</surname><given-names>P</given-names></name><name name-style="western"><surname>Devine</surname><given-names>P</given-names></name><name name-style="western"><surname>Innes</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Dementia knowledge and attitudes of the general public in Northern Ireland: an analysis of national survey data</article-title><source>Int Psychogeriatr</source><year>2012</year><volume>24</volume><fpage>1600</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1017/S1041610212000658</pub-id><pub-id pub-id-type="pmid">22591515</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Festinger</surname><given-names>L</given-names></name></person-group><article-title>A Theory of Social Comparison Processes</article-title><source><italic toggle="yes">Human Relations</italic></source><year>1954</year><volume>7</volume><fpage>117</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1177/001872675400700202</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerber</surname><given-names>JP</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>L</given-names></name><name name-style="western"><surname>Suls</surname><given-names>J</given-names></name></person-group><article-title>A social comparison theory meta-analysis 60+ years on</article-title><source>Psychol Bull</source><year>2018</year><volume>144</volume><fpage>177</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1037/bul0000127</pub-id><pub-id pub-id-type="pmid">29144145</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boone</surname><given-names>KB</given-names></name></person-group><article-title>Fixed belief in cognitive dysfunction despite normal neuropsychological scores: neurocognitive hypochondriasis?</article-title><source>Clin Neuropsychol</source><year>2009</year><volume>23</volume><fpage>1016</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1080/13854040802441135</pub-id><pub-id pub-id-type="pmid">18923966</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alladi</surname><given-names>S</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>R</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Mild cognitive impairment: applicability of research criteria in a memory clinic and characterization of cognitive profile</article-title><source>Psychol Med</source><year>2006</year><volume>36</volume><fpage>507</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1017/S0033291705006744</pub-id><pub-id pub-id-type="pmid">16426486</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verhaeghen</surname><given-names>P</given-names></name><name name-style="western"><surname>Geraerts</surname><given-names>N</given-names></name><name name-style="western"><surname>Marcoen</surname><given-names>A</given-names></name></person-group><article-title>Memory complaints, coping, and well-being in old age: a systemic approach</article-title><source>Gerontologist</source><year>2000</year><volume>40</volume><fpage>540</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/geront/40.5.540</pub-id><pub-id pub-id-type="pmid">11037932</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Werner</surname><given-names>P</given-names></name></person-group><article-title>Assessing correlates of concern about developing Alzheimer&#8217;s dementia among adults with no family history of the disease</article-title><source><italic toggle="yes">Am J Alzheimers Dis Other Demen</italic></source><year>2002</year><volume>17</volume><fpage>331</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1177/153331750201700609</pub-id><pub-id pub-id-type="pmid">12501479</pub-id><pub-id pub-id-type="pmcid">PMC10833670</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cutler</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Hodgson</surname><given-names>LG</given-names></name></person-group><article-title>Correlates of personal concerns about developing Alzheimer&#8217;s disease among middle-aged persons</article-title><source><italic toggle="yes">Am J Alzheimers Dis Other Demen</italic></source><year>2001</year><volume>16</volume><fpage>335</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1177/153331750101600604</pub-id><pub-id pub-id-type="pmid">11765858</pub-id><pub-id pub-id-type="pmcid">PMC10833986</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Do</surname><given-names>C</given-names></name><name name-style="western"><surname>Suhr</surname><given-names>JA</given-names></name></person-group><article-title>Effects of personal dementia exposure on subjective memory concerns and dementia worry</article-title><source>Neuropsychol Dev Cogn B Aging Neuropsychol Cogn</source><year>2021</year><volume>28</volume><fpage>855</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1080/13825585.2020.1836119</pub-id><pub-id pub-id-type="pmid">33076757</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suhr</surname><given-names>JA</given-names></name><name name-style="western"><surname>Kinkela</surname><given-names>JH</given-names></name></person-group><article-title>Perceived threat of Alzheimer disease (AD): the role of personal experience with AD</article-title><source>Alzheimer Dis Assoc Disord</source><year>2007</year><volume>21</volume><fpage>225</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1097/WAD.0b013e31813e6683</pub-id><pub-id pub-id-type="pmid">17804955</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cutler</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Hodgson</surname><given-names>LG</given-names></name></person-group><article-title>Anticipatory dementia: a link between memory appraisals and concerns about developing Alzheimer&#8217;s disease</article-title><source>Gerontologist</source><year>1996</year><volume>36</volume><fpage>657</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1093/geront/36.5.657</pub-id><pub-id pub-id-type="pmid">8942109</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kessler</surname><given-names>E-M</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>CE</given-names></name><name name-style="western"><surname>Baer</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Dementia worry: a psychological examination of an unexplored phenomenon</article-title><source>Eur J Ageing</source><year>2012</year><volume>9</volume><fpage>275</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1007/s10433-012-0242-8</pub-id><pub-id pub-id-type="pmid">28804427</pub-id><pub-id pub-id-type="pmcid">PMC5549110</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maxfield</surname><given-names>M</given-names></name><name name-style="western"><surname>Peckham</surname><given-names>A</given-names></name><name name-style="western"><surname>James</surname><given-names>DL</given-names></name></person-group><article-title>&#8220;Terror Is a Better Word&#8221;: A Qualitative Analysis of Dementia-Related Anxiety</article-title><source>Gerontologist</source><year>2024</year><volume>64</volume><pub-id pub-id-type="doi">10.1093/geront/gnad146</pub-id><pub-id pub-id-type="pmcid">PMC11020257</pub-id><pub-id pub-id-type="pmid">37878745</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Braun</surname><given-names>V</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>V</given-names></name></person-group><source>Thematic analysis: a practical guide</source><publisher-loc>London, England</publisher-loc><publisher-name>Sage Publications Sage UK</publisher-name><year>2022</year></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braun</surname><given-names>V</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>V</given-names></name></person-group><article-title>Using thematic analysis in psychology</article-title><source>Qual Res Psychol</source><year>2006</year><volume>3</volume><fpage>77</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1191/1478088706qp063oa</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>JR</given-names></name><name name-style="western"><surname>Maxfield</surname><given-names>M</given-names></name></person-group><article-title>A 2-Study Psychometric Evaluation of the Modified Dementia Worry Scale</article-title><source><italic toggle="yes">Am J Alzheimers Dis Other Demen</italic></source><year>2021</year><volume>36</volume><fpage>1533317521995322</fpage><pub-id pub-id-type="doi">10.1177/1533317521995322</pub-id><pub-id pub-id-type="pmid">33635118</pub-id><pub-id pub-id-type="pmcid">PMC7992130</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guest</surname><given-names>G</given-names></name><name name-style="western"><surname>Bunce</surname><given-names>A</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>L</given-names></name></person-group><article-title>How many interviews are enough? An experiment with data saturation and variability</article-title><source>Field methods</source><year>2006</year><volume>18</volume><fpage>59</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1177/1525822X05279903</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Namey</surname><given-names>E</given-names></name><name name-style="western"><surname>Guest</surname><given-names>G</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Evaluating bang for the buck: a cost-effectiveness comparison between individual interviews and focus groups based on thematic saturation levels</article-title><source>Am J Eval</source><year>2016</year><volume>37</volume><fpage>425</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1177/1098214016630406</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larner</surname><given-names>AJ</given-names></name></person-group><article-title>Cognitive testing in the COVID-19 era: can existing screeners be adapted for telephone use?</article-title><source>Neurodegener Dis Manag</source><year>2021</year><volume>11</volume><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.2217/nmt-2020-0040</pub-id><pub-id pub-id-type="pmid">33172353</pub-id><pub-id pub-id-type="pmcid">PMC7659594</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erfanian</surname><given-names>F</given-names></name><name name-style="western"><surname>Roudsari</surname><given-names>RL</given-names></name><name name-style="western"><surname>Haidari</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>A Narrative on the Use of Vignette: Its Advantages and Drawbacks</article-title><source>Journal of Midwifery &amp; Reproductive Health</source><year>2020</year><volume>8</volume></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Renoult</surname><given-names>L</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>PSR</given-names></name><name name-style="western"><surname>Palombo</surname><given-names>DJ</given-names></name><etal>et al</etal></person-group><article-title>Personal semantics: at the crossroads of semantic and episodic memory</article-title><source>Trends Cogn Sci (Regul Ed)</source><year>2012</year><volume>16</volume><fpage>550</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.tics.2012.09.003</pub-id><pub-id pub-id-type="pmid">23040159</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engin</surname><given-names>M</given-names></name></person-group><article-title>Research Diary: A Tool for Scaffolding</article-title><source>Int J Qual Methods</source><year>2011</year><volume>10</volume><fpage>296</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1177/160940691101000308</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>A</given-names></name><name name-style="western"><surname>Sainsbury</surname><given-names>P</given-names></name><name name-style="western"><surname>Craig</surname><given-names>J</given-names></name></person-group><article-title>Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups</article-title><source>Int J Qual Health Care</source><year>2007</year><volume>19</volume><fpage>349</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1093/intqhc/mzm042</pub-id><pub-id pub-id-type="pmid">17872937</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cova</surname><given-names>I</given-names></name><name name-style="western"><surname>Grande</surname><given-names>G</given-names></name><name name-style="western"><surname>Cucumo</surname><given-names>V</given-names></name><etal>et al</etal></person-group><article-title>Self-Awareness for Memory Impairment in Amnestic Mild Cognitive Impairment: A Longitudinal Study</article-title><source><italic toggle="yes">Am J Alzheimers Dis Other Demen</italic></source><year>2017</year><volume>32</volume><fpage>401</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1177/1533317517725812</pub-id><pub-id pub-id-type="pmid">28840743</pub-id><pub-id pub-id-type="pmcid">PMC10852863</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolfsgruber</surname><given-names>S</given-names></name><name name-style="western"><surname>Polcher</surname><given-names>A</given-names></name><name name-style="western"><surname>Koppara</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment</article-title><source><italic toggle="yes">JAD</italic></source><year>2017</year><volume>58</volume><fpage>939</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.3233/JAD-161252</pub-id><pub-id pub-id-type="pmid">28527210</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burgess</surname><given-names>N</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>EA</given-names></name><name name-style="western"><surname>O&#8217;Keefe</surname><given-names>J</given-names></name></person-group><article-title>The human hippocampus and spatial and episodic memory</article-title><source>Neuron</source><year>2002</year><volume>35</volume><fpage>625</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/s0896-6273(02)00830-9</pub-id><pub-id pub-id-type="pmid">12194864</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jahn</surname><given-names>H</given-names></name></person-group><article-title>Memory loss in Alzheimer&#8217;s disease</article-title><source>Dialogues Clin Neurosci</source><year>2013</year><volume>15</volume><fpage>445</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.31887/DCNS.2013.15.4/hjahn</pub-id><pub-id pub-id-type="pmid">24459411</pub-id><pub-id pub-id-type="pmcid">PMC3898682</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norton</surname><given-names>AR</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>MJ</given-names></name></person-group><article-title>Self-Focused Cognition in Social Anxiety: A Review of the Theoretical and Empirical Literature</article-title><source>Behav change</source><year>2016</year><volume>33</volume><fpage>44</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1017/bec.2016.2</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ingram</surname><given-names>RE</given-names></name></person-group><article-title>Self-focused attention in clinical disorders: review and a conceptual model</article-title><source>Psychol Bull</source><year>1990</year><volume>107</volume><fpage>156</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1037/0033-2909.107.2.156</pub-id><pub-id pub-id-type="pmid">2181521</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowen</surname><given-names>CE</given-names></name><name name-style="western"><surname>Kessler</surname><given-names>E-M</given-names></name><name name-style="western"><surname>Segler</surname><given-names>J</given-names></name></person-group><article-title>Dementia worry in middle-aged and older adults in Germany: sociodemographic, health-related and psychological correlates</article-title><source>Eur J Ageing</source><year>2019</year><volume>16</volume><fpage>39</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1007/s10433-018-0462-7</pub-id><pub-id pub-id-type="pmid">30886559</pub-id><pub-id pub-id-type="pmcid">PMC6397106</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kessler</surname><given-names>E-M</given-names></name><name name-style="western"><surname>S&#252;dhof</surname><given-names>JK</given-names></name><name name-style="western"><surname>Fr&#246;lich</surname><given-names>L</given-names></name></person-group><article-title>&#8220;Dementia worry&#8221; in memory clinic patients not diagnosed with organic mental disorder</article-title><source>Int Psychogeriatr</source><year>2014</year><volume>26</volume><fpage>1049</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1017/S1041610214000349</pub-id><pub-id pub-id-type="pmid">24642089</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>French</surname><given-names>SL</given-names></name><name name-style="western"><surname>Floyd</surname><given-names>M</given-names></name><name name-style="western"><surname>Wilkins</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>The Fear of Alzheimer&#8217;s Disease Scale: a new measure designed to assess anticipatory dementia in older adults</article-title><source>Int J Geriat Psychiatry</source><year>2012</year><volume>27</volume><fpage>521</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/gps.2747</pub-id><pub-id pub-id-type="pmid">21721044</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fresson</surname><given-names>M</given-names></name><name name-style="western"><surname>Dardenne</surname><given-names>B</given-names></name><name name-style="western"><surname>Geurten</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>[Formula: see text]The effect of stereotype threat on older people&#8217;s clinical cognitive outcomes: investigating the moderating role of dementia worry</article-title><source>Clin Neuropsychol</source><year>2017</year><volume>31</volume><fpage>1306</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1080/13854046.2017.1307456</pub-id><pub-id pub-id-type="pmid">28349725</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norman</surname><given-names>AL</given-names></name><name name-style="western"><surname>Woodard</surname><given-names>JL</given-names></name><name name-style="western"><surname>Calamari</surname><given-names>JE</given-names></name><etal>et al</etal></person-group><article-title>The fear of Alzheimer&#8217;s disease: mediating effects of anxiety on subjective memory complaints</article-title><source>Aging Ment Health</source><year>2020</year><volume>24</volume><fpage>308</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1080/13607863.2018.1534081</pub-id><pub-id pub-id-type="pmid">30411628</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Markov&#225;</surname><given-names>I</given-names></name></person-group><source>Dialogicality and social representations: the dynamics of mind</source><publisher-name>Cambridge University Press</publisher-name><year>2003</year></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>D</given-names></name><name name-style="western"><surname>Foster</surname><given-names>J</given-names></name></person-group><article-title>A Contagious Other? Exploring the Public&#8217;s Appraisals of Contact with &#8220;Mental Illness&#8221;</article-title><source>Int J Environ Res Public Health</source><year>2020</year><volume>17</volume><elocation-id>2005</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph17062005</pub-id><pub-id pub-id-type="pmid">32197437</pub-id><pub-id pub-id-type="pmcid">PMC7142778</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchant</surname><given-names>NL</given-names></name><name name-style="western"><surname>Howard</surname><given-names>RJ</given-names></name></person-group><article-title>Cognitive debt and Alzheimer&#8217;s disease</article-title><source><italic toggle="yes">J Alzheimers Dis</italic></source><year>2015</year><volume>44</volume><fpage>755</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.3233/JAD-141515</pub-id><pub-id pub-id-type="pmid">25362035</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchant</surname><given-names>NL</given-names></name><name name-style="western"><surname>Lovland</surname><given-names>LR</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Repetitive negative thinking is associated with amyloid, tau, and cognitive decline</article-title><source>Alzheimers Dement</source><year>2020</year><volume>16</volume><fpage>1054</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1002/alz.12116</pub-id><pub-id pub-id-type="pmid">32508019</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Livingston</surname><given-names>G</given-names></name><name name-style="western"><surname>Huntley</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>KY</given-names></name><etal>et al</etal></person-group><article-title>Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission</article-title><source>Lancet</source><year>2024</year><volume>404</volume><fpage>572</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(24)01296-0</pub-id><pub-id pub-id-type="pmid">39096926</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byers</surname><given-names>AL</given-names></name><name name-style="western"><surname>Yaffe</surname><given-names>K</given-names></name></person-group><article-title>Depression and risk of developing dementia</article-title><source>Nat Rev Neurol</source><year>2011</year><volume>7</volume><fpage>323</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2011.60</pub-id><pub-id pub-id-type="pmid">21537355</pub-id><pub-id pub-id-type="pmcid">PMC3327554</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cherbuin</surname><given-names>N</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Anstey</surname><given-names>KJ</given-names></name></person-group><article-title>Dementia risk estimates associated with measures of depression: a systematic review and meta-analysis</article-title><source>BMJ Open</source><year>2015</year><volume>5</volume><elocation-id>e008853</elocation-id><pub-id pub-id-type="doi">10.1136/bmjopen-2015-008853</pub-id><pub-id pub-id-type="pmcid">PMC4691713</pub-id><pub-id pub-id-type="pmid">26692556</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saenz</surname><given-names>GD</given-names></name><name name-style="western"><surname>Geraci</surname><given-names>L</given-names></name><name name-style="western"><surname>Tirso</surname><given-names>R</given-names></name></person-group><article-title>Improving metacognition: A comparison of interventions</article-title><source>Appl Cogn Psychol</source><year>2019</year><volume>33</volume><fpage>918</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1002/acp.3556</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertrand</surname><given-names>E</given-names></name><name name-style="western"><surname>Marinho</surname><given-names>V</given-names></name><name name-style="western"><surname>Naylor</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Metacognitive Improvements Following Cognitive Stimulation Therapy for People with Dementia: Evidence from a Pilot Randomized Controlled Trial</article-title><source>Clin Gerontol</source><year>2023</year><volume>46</volume><fpage>267</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1080/07317115.2022.2155283</pub-id><pub-id pub-id-type="pmid">36482733</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>RL</given-names></name><name name-style="western"><surname>Bagwell</surname><given-names>DK</given-names><suffix>&#8727;</suffix></name><name name-style="western"><surname>Dark-Freudeman</surname><given-names>A</given-names></name></person-group><article-title>Self-Efficacy and Memory Aging: The Impact of a Memory Intervention Based on Self-Efficacy</article-title><source>Aging, Neuropsychology, and Cognition</source><year>2008</year><volume>15</volume><fpage>302</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1080/13825580701440510</pub-id><pub-id pub-id-type="pmid">19230269</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Asbroeck</surname><given-names>S</given-names></name><name name-style="western"><surname>van Boxtel</surname><given-names>MPJ</given-names></name><name name-style="western"><surname>Steyaert</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Increasing knowledge on dementia risk reduction in the general population: Results of a public awareness campaign</article-title><source>Prev Med</source><year>2021</year><volume>147</volume><fpage>106522</fpage><pub-id pub-id-type="doi">10.1016/j.ypmed.2021.106522</pub-id><pub-id pub-id-type="pmid">33744328</pub-id></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paauw</surname><given-names>D</given-names></name><name name-style="western"><surname>Heger</surname><given-names>I</given-names></name><name name-style="western"><surname>Bjerre</surname><given-names>JF</given-names></name><etal>et al</etal></person-group><article-title>Increasing awareness for dementia risk reduction through a public awareness campaign in Denmark: A pre-post study</article-title><source>Prev Med</source><year>2024</year><volume>179</volume><fpage>107848</fpage><pub-id pub-id-type="doi">10.1016/j.ypmed.2024.107848</pub-id><pub-id pub-id-type="pmid">38215992</pub-id></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hickey</surname><given-names>D</given-names></name><name name-style="western"><surname>Glynn</surname><given-names>RW</given-names></name><name name-style="western"><surname>Shelley</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>The impact of a national public awareness campaign on dementia knowledge and help-seeking in Ireland</article-title><source>Eur J Public Health</source><year>2019</year><volume>29</volume><pub-id pub-id-type="doi">10.1093/eurpub/ckz185.637</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scerri</surname><given-names>A</given-names></name><name name-style="western"><surname>Scerri</surname><given-names>C</given-names></name></person-group><article-title>Training older adults about Alzheimer&#8217;s disease &#8211; Impact on knowledge and fear</article-title><source>Educ Gerontol</source><year>2017</year><volume>43</volume><fpage>117</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1080/03601277.2016.1266445</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashworth</surname><given-names>R</given-names></name><name name-style="western"><surname>Bassett</surname><given-names>Z</given-names></name><name name-style="western"><surname>Webb</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Risk, worry and motivation: How is public knowledge of dementia shaped?</article-title><source>Dementia (London)</source><year>2022</year><volume>21</volume><fpage>851</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1177/14713012211064740</pub-id><pub-id pub-id-type="pmid">34967225</pub-id></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cherry</surname><given-names>KE</given-names><suffix>Professor</suffix></name><name name-style="western"><surname>Brigman</surname><given-names>S</given-names></name><name name-style="western"><surname>Reese-Melancon</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Memory Aging Knowledge and Memory Self-Appraisal in Younger and Older Adults</article-title><source>Educ Gerontol</source><year>2013</year><volume>39</volume><fpage>168</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1080/03601277.2012.699838</pub-id></element-citation></ref><ref id="R83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molden</surname><given-names>J</given-names></name><name name-style="western"><surname>Maxfield</surname><given-names>M</given-names></name></person-group><article-title>The impact of aging stereotypes on dementia worry</article-title><source>Eur J Ageing</source><year>2017</year><volume>14</volume><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1007/s10433-016-0378-z</pub-id><pub-id pub-id-type="pmid">28804392</pub-id><pub-id pub-id-type="pmcid">PMC5550617</pub-id></element-citation></ref><ref id="R84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>RL</given-names></name><name name-style="western"><surname>Arch</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Wolitzky-Taylor</surname><given-names>KB</given-names></name></person-group><article-title>The state of personalized treatment for anxiety disorders: A systematic review of treatment moderators</article-title><source>Clin Psychol Rev</source><year>2015</year><volume>38</volume><fpage>39</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.cpr.2015.02.004</pub-id><pub-id pub-id-type="pmid">25795293</pub-id></element-citation></ref><ref id="R85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuijpers</surname><given-names>P</given-names></name><name name-style="western"><surname>Sijbrandij</surname><given-names>M</given-names></name><name name-style="western"><surname>Koole</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Psychological treatment of generalized anxiety disorder: a meta-analysis</article-title><source>Clin Psychol Rev</source><year>2014</year><volume>34</volume><fpage>130</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.cpr.2014.01.002</pub-id><pub-id pub-id-type="pmid">24487344</pub-id></element-citation></ref><ref id="R86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Sun</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>The effectiveness of modified, group-based CBT for dementia worry among Chinese elders</article-title><source>J Affect Disord</source><year>2020</year><volume>274</volume><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2020.05.054</pub-id><pub-id pub-id-type="pmid">32469835</pub-id></element-citation></ref><ref id="R87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harper</surname><given-names>N</given-names></name><name name-style="western"><surname>Delgadillo</surname><given-names>M</given-names></name><name name-style="western"><surname>Erickson</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Mindfulness attenuates the impact of worry on late-life cognitive function</article-title><source>Aging Ment Health</source><year>2023</year><volume>27</volume><fpage>399</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1080/13607863.2021.2017851</pub-id><pub-id pub-id-type="pmid">35006021</pub-id></element-citation></ref><ref id="R88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchant</surname><given-names>NL</given-names></name><name name-style="western"><surname>Barnhofer</surname><given-names>T</given-names></name><name name-style="western"><surname>Klimecki</surname><given-names>OM</given-names></name><etal>et al</etal></person-group><article-title>The SCD-Well randomized controlled trial: Effects of a mindfulness-based intervention versus health education on mental health in patients with subjective cognitive decline (SCD)</article-title><source>Alzheimers Dement (N Y)</source><year>2018</year><volume>4</volume><fpage>737</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.trci.2018.10.010</pub-id><pub-id pub-id-type="pmid">30581979</pub-id><pub-id pub-id-type="pmcid">PMC6296291</pub-id></element-citation></ref><ref id="R89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poisnel</surname><given-names>G</given-names></name><name name-style="western"><surname>Arenaza&#8208;Urquijo</surname><given-names>E</given-names></name><name name-style="western"><surname>Collette</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>The Age&#8208;Well randomized controlled trial of the Medit&#8208;Ageing European project: Effect of meditation or foreign language training on brain and mental health in older adults</article-title><source>Alzheimers Dement (N Y)</source><year>2018</year><volume>4</volume><fpage>714</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.trci.2018.10.011</pub-id><pub-id pub-id-type="pmid">30581977</pub-id><pub-id pub-id-type="pmcid">PMC6296161</pub-id></element-citation></ref><ref id="R90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farb</surname><given-names>NAS</given-names></name><name name-style="western"><surname>Segal</surname><given-names>ZV</given-names></name><name name-style="western"><surname>Mayberg</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Attending to the present: mindfulness meditation reveals distinct neural modes of self-reference</article-title><source>Soc Cogn Affect Neurosci</source><year>2007</year><volume>2</volume><fpage>313</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1093/scan/nsm030</pub-id><pub-id pub-id-type="pmid">18985137</pub-id><pub-id pub-id-type="pmcid">PMC2566754</pub-id></element-citation></ref><ref id="R91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#246;lzel</surname><given-names>BK</given-names></name><name name-style="western"><surname>Carmody</surname><given-names>J</given-names></name><name name-style="western"><surname>Vangel</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Mindfulness practice leads to increases in regional brain gray matter density</article-title><source>Psychiatry Research: Neuroimaging</source><year>2011</year><volume>191</volume><fpage>36</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.pscychresns.2010.08.006</pub-id><pub-id pub-id-type="pmcid">PMC3004979</pub-id><pub-id pub-id-type="pmid">21071182</pub-id></element-citation></ref><ref id="R92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Svendsen</surname><given-names>JL</given-names></name><name name-style="western"><surname>Kvernenes</surname><given-names>KV</given-names></name><name name-style="western"><surname>Wiker</surname><given-names>AS</given-names></name><etal>et al</etal></person-group><article-title>Mechanisms of mindfulness: Rumination and self-compassion</article-title><source>Nord Psychol</source><year>2017</year><volume>69</volume><fpage>71</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1080/19012276.2016.1171730</pub-id></element-citation></ref><ref id="R93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bell</surname><given-names>TR</given-names></name><name name-style="western"><surname>Hill</surname><given-names>NL</given-names></name><name name-style="western"><surname>Bhargava</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Parental dementia and subjective memory impairment in the health and retirement study</article-title><source>Aging Ment Health</source><year>2022</year><volume>26</volume><fpage>992</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1080/13607863.2021.1910790</pub-id><pub-id pub-id-type="pmid">33855905</pub-id><pub-id pub-id-type="pmcid">PMC8517028</pub-id></element-citation></ref><ref id="R94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>JR</given-names></name><name name-style="western"><surname>Hill</surname><given-names>NL</given-names></name><name name-style="western"><surname>Brautigam</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>How Does Exposure to Dementia Relate to Subjective Cognition? A Systematic Review</article-title><source>Innov Aging</source><year>2023</year><volume>7</volume><elocation-id>igad056</elocation-id><pub-id pub-id-type="doi">10.1093/geroni/igad056</pub-id><pub-id pub-id-type="pmid">37497342</pub-id><pub-id pub-id-type="pmcid">PMC10368315</pub-id></element-citation></ref><ref id="R95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devoy</surname><given-names>S</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>EEA</given-names></name></person-group><article-title>Help-seeking intentions for early dementia diagnosis in a sample of Irish adults</article-title><source>Aging Ment Health</source><year>2017</year><volume>21</volume><fpage>870</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1080/13607863.2016.1179262</pub-id><pub-id pub-id-type="pmid">27149181</pub-id></element-citation></ref><ref id="R96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeda</surname><given-names>S</given-names></name><name name-style="western"><surname>Ota</surname><given-names>M</given-names></name><name name-style="western"><surname>Taniguchi</surname><given-names>T</given-names></name></person-group><article-title>Factors Affecting Intention to Undergo Dementia Screening</article-title><source>Yonago Acta Med</source><year>2017</year><volume>60</volume><fpage>47</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">28331421</pub-id><pub-id pub-id-type="pmcid">PMC5355844</pub-id></element-citation></ref><ref id="R97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edmonds</surname><given-names>EC</given-names></name><name name-style="western"><surname>Delano-Wood</surname><given-names>L</given-names></name><name name-style="western"><surname>Galasko</surname><given-names>DR</given-names></name><etal>et al</etal></person-group><article-title>Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment</article-title><source>J Int Neuropsychol Soc</source><year>2014</year><volume>20</volume><fpage>836</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1017/S135561771400068X</pub-id><pub-id pub-id-type="pmid">25156329</pub-id><pub-id pub-id-type="pmcid">PMC4172502</pub-id></element-citation></ref><ref id="R98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buckley</surname><given-names>RF</given-names></name><name name-style="western"><surname>Saling</surname><given-names>MM</given-names></name><name name-style="western"><surname>Frommann</surname><given-names>I</given-names></name><etal>et al</etal></person-group><article-title>Subjective Cognitive Decline from a Phenomenological Perspective: A Review of the Qualitative Literature</article-title><source><italic toggle="yes">JAD</italic></source><year>2015</year><volume>48</volume><fpage>S125</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.3233/JAD-150095</pub-id><pub-id pub-id-type="pmid">26402078</pub-id></element-citation></ref><ref id="R99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leder</surname><given-names>D</given-names></name></person-group><article-title>Clinical interpretation: the hermeneutics of medicine</article-title><source>Theor Med</source><year>1990</year><volume>11</volume><fpage>9</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1007/BF00489234</pub-id><pub-id pub-id-type="pmid">2339336</pub-id></element-citation></ref><ref id="R100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wulff</surname><given-names>H</given-names></name></person-group><article-title>The two cultures of medicine: objective facts versus subjectivity and values</article-title><source>J R Soc Med</source><year>1999</year><volume>92</volume><fpage>549</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1177/014107689909201101</pub-id><pub-id pub-id-type="pmid">10703488</pub-id><pub-id pub-id-type="pmcid">PMC1297426</pub-id></element-citation></ref></ref-list><sec sec-type="data-availability"><title>Data availability statement</title><p>No data are available.</p></sec></back><sub-article id="sub-article1" article-type="aggregated-review-documents"><front-stub><title-group><article-title>Review Process File</article-title></title-group><pub-date pub-type="epub"><day>02</day><month>10</month><year>2025</year></pub-date></front-stub><body><fig id="d67e3426" position="anchor" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bmjopen-2024-097002.reviewer_comments.pdf" position="float" orientation="portrait"/></fig></body></sub-article></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Sci Sleep</journal-id><journal-id journal-id-type="iso-abbrev">Nat Sci Sleep</journal-id><journal-id journal-id-type="pmc-domain-id">2069</journal-id><journal-id journal-id-type="pmc-domain">nss</journal-id><journal-id journal-id-type="publisher-id">nss</journal-id><journal-title-group><journal-title>Nature and Science of Sleep</journal-title></journal-title-group><issn pub-type="epub">1179-1608</issn><publisher><publisher-name>Dove Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12495962</article-id><article-id pub-id-type="pmcid-ver">PMC12495962.1</article-id><article-id pub-id-type="pmcaid">12495962</article-id><article-id pub-id-type="pmcaiid">12495962</article-id><article-id pub-id-type="pmid">41050639</article-id><article-id pub-id-type="doi">10.2147/NSS.S545905</article-id><article-id pub-id-type="publisher-id">545905</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Molecular and Clinical Perspectives on the Regulation of Sleep and Uric Acid Metabolism</article-title><alt-title alt-title-type="running-authors">Ha et al</alt-title><alt-title alt-title-type="running-title">Ha et al</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0271-0877</contrib-id><name name-style="western"><surname>Ha</surname><given-names initials="G">Guodong</given-names></name><xref rid="aff0001" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="J">Jiawei</given-names></name><xref rid="aff0001" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hu</surname><given-names initials="J">Jing</given-names></name><xref rid="aff0001" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="X">Xun</given-names></name><xref rid="aff0001" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xie</surname><given-names initials="Y">Yijie</given-names></name><xref rid="aff0001" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="Z">Zhengyu</given-names></name><xref rid="aff0001" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cai</surname><given-names initials="D">Dingjun</given-names></name><xref rid="aff0001" ref-type="aff">1</xref><xref rid="an0001" ref-type="corresp"/></contrib><aff id="aff0001"><label>1</label><institution>Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine</institution>, <addr-line>Chengdu</addr-line>, <addr-line>Sichuan</addr-line>, <addr-line>610075</addr-line>, <country>People&#8217;s Republic of China</country></aff></contrib-group><author-notes><corresp id="an0001">Correspondence: Dingjun Cai, <institution>Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine</institution>, <addr-line>No. 37 Shierqiao Road, Jinniu District</addr-line>, <addr-line>Chengdu</addr-line>, <addr-line>Sichuan</addr-line>, <country>People&#8217;s Republic of China</country>, Email djcai@cdutcm.edu.cn</corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">479220</issue-id><fpage>2321</fpage><lpage>2340</lpage><history><date date-type="received"><day>11</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 15:25:14.893"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Ha et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Ha et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#8211; Non Commercial (unported, v4.0) License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nss-17-2321.pdf"/><abstract><title>Abstract</title><p>Uric acid, the end product of purine metabolism, is closely associated with metabolic disorders, including gout and metabolic syndrome. Emerging evidence highlights a bidirectional relationship between uric acid metabolism and sleep regulation. Elevated uric acid levels can adversely affect sleep quality via oxidative stress and neuroinflammatory pathways, while sleep deprivation may promote uric acid synthesis and impair its excretion. This reciprocal interaction may form a vicious cycle, potentially accelerating the onset and progression of various metabolic diseases. This review summarizes recent clinical and experimental findings, focusing on the molecular mechanisms underlying the bidirectional regulation between uric acid metabolism and sleep. The implications of this relationship in the pathophysiology of metabolic disorders are discussed. Understanding this interplay underscores the importance of targeting uric acid levels and sleep quality as integrated strategies for managing metabolic diseases. These insights provide a foundation for the development of novel therapeutic interventions designed to enhance clinical outcomes in metabolic syndrome.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>uric acid metabolism</kwd><kwd>sleep</kwd><kwd>bidirectional regulation</kwd><kwd>metabolic disease</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>National Natural Science Foundation</institution></institution-wrap></funding-source></award-group><funding-statement>This work was supported by Funds for the National Natural Science Foundation of China (No.82274659).</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="4"/><ref-count count="130"/><page-count count="20"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s0001"><title>Introduction</title><p>Uric acid, the end product of purine metabolism, plays diverse physiological roles and is eliminated primarily by the kidneys.<xref rid="cit0001" ref-type="bibr">1</xref> Its synthesis and clearance are governed by diet, renal function, and genetic factors, underscoring the importance of maintaining uric acid homeostasis. As a potent antioxidant, uric acid scavenges reactive oxygen species, mitigating oxidative stress-induced cellular damage.<xref rid="cit0002" ref-type="bibr">2</xref> In the central nervous system, it provides neuroprotection against oxidative injury, potentially reducing risks of neurodegenerative diseases such as Alzheimer&#8217;s and Parkinson&#8217;s.<xref rid="cit0003" ref-type="bibr">3</xref>,<xref rid="cit0004" ref-type="bibr">4</xref> Similarly, in the cardiovascular system, uric acid helps preserve endothelial integrity by counteracting oxidative insults and modulating vasomotor function, which may reduce the risk of hypertension and atherosclerosis.<xref rid="cit0002" ref-type="bibr">2</xref>,<xref rid="cit0005" ref-type="bibr">5</xref>,<xref rid="cit0006" ref-type="bibr">6</xref> Additionally, uric acid modulates inflammatory responses and immune cell activity, supporting immune homeostasis.<xref rid="cit0007" ref-type="bibr">7</xref>,<xref rid="cit0008" ref-type="bibr">8</xref> Both hyperuricemia and hypouricemia pose health risks: elevated levels are linked to gout, nephrolithiasis, and increased cardiovascular disease, while low levels impair antioxidant defenses and neuroprotection, heightening oxidative damage susceptibility.<xref rid="cit0009" ref-type="bibr">9&#8211;12</xref> Therefore, the balance of uric acid metabolism is vital not only for normal physiological functions but also for the prevention and management of various diseases.</p><p>Sleep is a fundamental restorative process, and its architecture is essential for metabolic homeostasis. Alterations in sleep structure, especially the balance between non-rapid eye movement (NREM) and rapid eye movement (REM) sleep are closely linked to metabolic health.<xref rid="cit0013" ref-type="bibr">13</xref> Within NREM sleep, slow-wave activity (N3 stage) directly influences insulin sensitivity, energy expenditure, and lipid metabolism.<xref rid="cit0014" ref-type="bibr">14</xref> Moreover, the circadian fluctuations in circulating uric acid levels synchronize with increased antioxidant demands during NREM sleep, implying an adaptive regulatory role for uric acid across the sleep-wake cycle.<xref rid="cit0015" ref-type="bibr">15</xref>,<xref rid="cit0016" ref-type="bibr">16</xref> Unhealthy lifestyle factors, dysregulation of uric acid metabolism, and sleep disturbances form a bidirectional loop&#8212;sleep deprivation, mental disorder, or poor sleep quality can precipitate hyperuricemia and gout flares, while elevated uric acid promotes oxidative stress and inflammation, further disrupting sleep architecture.<xref rid="cit0017" ref-type="bibr">17&#8211;20</xref> This pathological feedback loop not only impairs metabolic homeostasis but also elevates risks of diabetes, hypertension, and cardiometabolic disorders.</p><p>Given the rhythmicity of uric acid levels in synchrony with sleep-wake cycles and their shared roles in energy balance, redox regulation, and immune modulation, elucidating the bidirectional mechanisms between uric acid metabolism and sleep is of substantial clinical importance. Sleep disturbances can alter biomarkers of metabolic diseases, including uric acid and inflammatory markers, exacerbating insulin resistance and cardiovascular risks through interconnected pathways of oxidative stress and circadian dysregulation. A more profound understanding could inform strategies for the early diagnosis, prevention, and management of hyperuricemia, sleep disorders, and related metabolic conditions. This review synthesizes existing evidence on the interaction between uric acid and sleep, delineates key molecular pathways, and assesses clinical implications. Despite recent advancements, significant gaps remain in longitudinal studies and mechanistic details, positioning this review as a foundational synthesis aimed at bridging these gaps and guiding future research toward more targeted therapeutic interventions.</p></sec><sec id="s0002"><title>Methodology</title><p>This narrative review explores the interplay between uric acid metabolism and sleep, emphasizing the bidirectional molecular mechanisms that regulate both processes. A structured search of PubMed, Web of Science, and Embase was conducted using MeSH terms and free-text keywords: (&#8220;Uric acid&#8221; OR &#8220;Uric acid metabolism&#8221; OR &#8220;Hyperuricemia&#8221;) AND (&#8220;sleep&#8221; OR &#8220;sleep architecture&#8221; OR &#8220;sleep quality&#8221; OR &#8220;REM sleep&#8221; OR &#8220;NREM sleep&#8221; OR &#8220;deep sleep&#8221; OR &#8220;sleep disturbance&#8221;). No date restriction was applied; studies in English involving human subjects or animal models were eligible. After deduplication, titles and abstracts were independently screened by two reviewers for relevance to the review topic. Potentially relevant articles underwent full-text evaluation to confirm reports of molecular mechanisms or clinical correlations between uric acid metabolism and sleep. The exclusion criteria included the absence of relevant mechanisms, ineligible study designs, or unobtainable full texts. The selection process is illustrated in <xref rid="f0001" ref-type="fig">Figure 1</xref>. Study characteristics, stratified by level of evidence, are summarized in <xref rid="t0001" ref-type="table">Table 1</xref>; Risk-of-bias ratings (good, fair, or poor) are presented in <xref rid="t0002" ref-type="table">Table 2</xref>. Findings are synthesized narratively with critical appraisal. The paper adheres to the SANRA guidelines for narrative reviews.<xref rid="cit0021" ref-type="bibr">21</xref>,<xref rid="cit0022" ref-type="bibr">22</xref>
<table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1</label><caption><p>Summary of Key Characteristics of Included Studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Study and Date of Publication</th><th rowspan="1" colspan="1">Types of Disorders</th><th rowspan="1" colspan="1">Sample</th><th rowspan="1" colspan="1">Age (Years)</th><th rowspan="1" colspan="1">Sample Size</th><th rowspan="1" colspan="1">Evaluation Basis</th><th rowspan="1" colspan="1">Results</th><th rowspan="1" colspan="1">Research Methods</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Yu et al (2022)<xref rid="cit0016" ref-type="bibr">16</xref></td><td rowspan="1" colspan="1">Sleep Disorder</td><td rowspan="1" colspan="1">Adults</td><td rowspan="1" colspan="1">&gt;18</td><td rowspan="1" colspan="1">34025</td><td rowspan="1" colspan="1">Questionnaire investigation, Blood biochemistry analysis</td><td rowspan="1" colspan="1">Sleep duration inversely correlates with hyperuricemia, suggesting longer sleep may protect against elevated uric acid.</td><td rowspan="1" colspan="1">Prospective Longitudinal Study</td></tr><tr><td rowspan="1" colspan="1">Shen et al (2019)<xref rid="cit0004" ref-type="bibr">4</xref></td><td rowspan="1" colspan="1">pRBD</td><td rowspan="1" colspan="1">Adults</td><td rowspan="1" colspan="1">&gt;18</td><td rowspan="1" colspan="1">12923</td><td rowspan="1" colspan="1">Questionnaire surveys, Blood biochemistry analysis, PSG</td><td rowspan="1" colspan="1">Higher serum urate is associated with lower pRBD risk, implying urate may modulate prodromal Parkinsonian pathology.</td><td rowspan="1" colspan="1">Prospective cohort study</td></tr><tr><td rowspan="1" colspan="1">Yang et al (2023)<xref rid="cit0006" ref-type="bibr">6</xref></td><td rowspan="1" colspan="1">OSAS</td><td rowspan="1" colspan="1">Adults</td><td rowspan="1" colspan="1">&gt;18</td><td rowspan="1" colspan="1">5584</td><td rowspan="1" colspan="1">Questionnaire surveys, Blood biochemistry analysis</td><td rowspan="1" colspan="1">Serum uric acid exhibits a U-shaped, nonlinear relationship with all-cause mortality.</td><td rowspan="1" colspan="1">Prospective cohort study</td></tr><tr><td rowspan="1" colspan="1">Dai et al (2025)<xref rid="cit0010" ref-type="bibr">10</xref></td><td rowspan="1" colspan="1">Sleep Disorder</td><td rowspan="1" colspan="1">Adults</td><td rowspan="1" colspan="1">&#8805;20</td><td rowspan="1" colspan="1">5837</td><td rowspan="1" colspan="1">Questionnaire surveys, Blood biochemistry analysis</td><td rowspan="1" colspan="1">In hyperuricemia subjects, sleep duration shows a U-shaped association with mortality, whereas self-reported sleep disturbances do not.</td><td rowspan="1" colspan="1">Prospective cohort study</td></tr><tr><td rowspan="1" colspan="1">Zou et al (2022)<xref rid="cit0019" ref-type="bibr">19</xref></td><td rowspan="1" colspan="1">Sleep Disorder</td><td rowspan="1" colspan="1">Adults</td><td rowspan="1" colspan="1">37-73</td><td rowspan="1" colspan="1">386439</td><td rowspan="1" colspan="1">Questionnaire surveys, Blood biochemistry analysis</td><td rowspan="1" colspan="1">Short sleep causally increases hyperuricemia risk in women but has minimal effect in men.</td><td rowspan="1" colspan="1">Cross-sectional study (combined with Mendelian Randomization)</td></tr><tr><td rowspan="1" colspan="1">Zhang et al (2023)<xref rid="cit0023" ref-type="bibr">23</xref></td><td rowspan="1" colspan="1">Sleep Rhythm Disorders</td><td rowspan="1" colspan="1">Adults</td><td rowspan="1" colspan="1">18-50</td><td rowspan="1" colspan="1">730</td><td rowspan="1" colspan="1">Questionnaire surveys, Blood biochemistry analysis</td><td rowspan="1" colspan="1">Frequent night shifts and heavy workload impair nurses&#8217; sleep and elevate metabolic risk factors.</td><td rowspan="1" colspan="1">Retrospective cohort study</td></tr><tr><td rowspan="1" colspan="1">Zhao et al (2017)<xref rid="cit0011" ref-type="bibr">11</xref></td><td rowspan="1" colspan="1">Chronic Insomnia</td><td rowspan="1" colspan="1">Adults</td><td rowspan="1" colspan="1">&#8805;18</td><td rowspan="1" colspan="1">600</td><td rowspan="1" colspan="1">Questionnaire surveys, Blood biochemistry analysis</td><td rowspan="1" colspan="1">Low serum uric acid is linked to both the occurrence and severity of chronic insomnia.</td><td rowspan="1" colspan="1">Case-control study</td></tr><tr><td rowspan="1" colspan="1">Hirotsu et al (2013)<xref rid="cit0024" ref-type="bibr">24</xref></td><td rowspan="1" colspan="1">OSAS</td><td rowspan="1" colspan="1">Adults</td><td rowspan="1" colspan="1">20-80</td><td rowspan="1" colspan="1">1042</td><td rowspan="1" colspan="1">Questionnaire investigation, PSG, Blood biochemistry analysis</td><td rowspan="1" colspan="1">Higher uric acid levels are strongly associated with OSAS severity.</td><td rowspan="1" colspan="1">Cross-sectional Study</td></tr><tr><td rowspan="1" colspan="1">Oh JS et al (2014)<xref rid="cit0025" ref-type="bibr">25</xref></td><td rowspan="1" colspan="1">Sleep Rhythm Disorders</td><td rowspan="1" colspan="1">Adults</td><td rowspan="1" colspan="1">&gt;18</td><td rowspan="1" colspan="1">1029</td><td rowspan="1" colspan="1">Questionnaire surveys, Blood biochemistry analysis</td><td rowspan="1" colspan="1">Among male steelworkers, shift work significantly increases hyperuricemia prevalence compared to day work.</td><td rowspan="1" colspan="1">Cross-sectional Study</td></tr><tr><td rowspan="1" colspan="1">Li et al (2018)<xref rid="cit0026" ref-type="bibr">26</xref></td><td rowspan="1" colspan="1">iRBD</td><td rowspan="1" colspan="1">Adults</td><td rowspan="1" colspan="1">50-91</td><td rowspan="1" colspan="1">87</td><td rowspan="1" colspan="1">Questionnaire surveys, Blood biochemistry analysis, PSG, CT/MRI</td><td rowspan="1" colspan="1">iRBD patients with lower uric acid demonstrate greater cognitive impairment, reflecting urate&#8217;s antioxidant and neuroprotective roles.</td><td rowspan="1" colspan="1">Cross-sectional Study</td></tr><tr><td rowspan="1" colspan="1">Chou et al (2020)<xref rid="cit0015" ref-type="bibr">15</xref></td><td rowspan="1" colspan="1">Sleep Disorder</td><td rowspan="1" colspan="1">Adults</td><td rowspan="1" colspan="1">&#8805;18</td><td rowspan="1" colspan="1">4555</td><td rowspan="1" colspan="1">Questionnaire investigation, Blood biochemistry analysis</td><td rowspan="1" colspan="1">Poor sleep quality associates with lower uric acid, while short sleep duration associates with higher uric acid.</td><td rowspan="1" colspan="1">Cross-sectional study</td></tr><tr><td rowspan="1" colspan="1">Wang et al (2021)<xref rid="cit0027" ref-type="bibr">27</xref></td><td rowspan="1" colspan="1">Daytime Drowsiness</td><td rowspan="1" colspan="1">Adults</td><td rowspan="1" colspan="1">30-79</td><td rowspan="1" colspan="1">22038</td><td rowspan="1" colspan="1">Questionnaire investigation, Blood biochemistry analysis</td><td rowspan="1" colspan="1">Longer daytime naps&#8212;but not nocturnal sleep&#8212;independently predict hyperuricemia risk in a Chinese population.</td><td rowspan="1" colspan="1">Cross-sectional Study</td></tr><tr><td rowspan="1" colspan="1">Yu et al (2021)<xref rid="cit0020" ref-type="bibr">20</xref></td><td rowspan="1" colspan="1">Sleep Disorder</td><td rowspan="1" colspan="1">Adults</td><td rowspan="1" colspan="1">&#8805;18</td><td rowspan="1" colspan="1">8289</td><td rowspan="1" colspan="1">Questionnaire surveys, Blood biochemistry analysis</td><td rowspan="1" colspan="1">Short sleep raises hyperuricemia risk irrespective of cardiometabolic status, especially in those without hypertension, diabetes, or obesity.</td><td rowspan="1" colspan="1">Cross-sectional Study</td></tr><tr><td rowspan="1" colspan="1">Has&#237;kova &#180; et al (2021)<xref rid="cit0028" ref-type="bibr">28</xref></td><td rowspan="1" colspan="1">iRBD</td><td rowspan="1" colspan="1">Adults</td><td rowspan="1" colspan="1">&#8805;50</td><td rowspan="1" colspan="1">85</td><td rowspan="1" colspan="1">Questionnaire surveys, Blood biochemistry analysis, PSG, DAT-SPECT</td><td rowspan="1" colspan="1">iRBD patients exhibit elevated serum allantoin and allantoin/urate ratios, indicating increased systemic oxidative stress.</td><td rowspan="1" colspan="1">Cross-sectional Study</td></tr><tr><td rowspan="1" colspan="1">Zhou et al (2023)<xref rid="cit0012" ref-type="bibr">12</xref></td><td rowspan="1" colspan="1">Sleep Disorders in Parkinson&#8217;s Patients</td><td rowspan="1" colspan="1">Adults</td><td rowspan="1" colspan="1">50-75</td><td rowspan="1" colspan="1">233</td><td rowspan="1" colspan="1">Questionnaire surveys, Blood biochemistry analysis, PSG</td><td rowspan="1" colspan="1">In Parkinson&#8217;s disease, low serum uric acid correlates with poor sleep quality, suggesting its utility as a sleep disorder biomarker.</td><td rowspan="1" colspan="1">Cross-sectional Study</td></tr><tr><td rowspan="1" colspan="1">Sunadome et al (2023)<xref rid="cit0029" ref-type="bibr">29</xref></td><td rowspan="1" colspan="1">SDB</td><td rowspan="1" colspan="1">Adults</td><td rowspan="1" colspan="1">34-80</td><td rowspan="1" colspan="1">7895</td><td rowspan="1" colspan="1">Questionnaire surveys, Blood biochemistry analysis, Pulse oximeters, Actiwatch Spectrum Plus</td><td rowspan="1" colspan="1">In women, serum uric acid &#8805;5 mg/dL doubles MS-SDB risk and is linked to higher diabetes prevalence.</td><td rowspan="1" colspan="1">Cross-sectional Study</td></tr><tr><td rowspan="1" colspan="1">Park et al (2025)<xref rid="cit0030" ref-type="bibr">30</xref></td><td rowspan="1" colspan="1">OSAS</td><td rowspan="1" colspan="1">Adults</td><td rowspan="1" colspan="1">&#8805;40</td><td rowspan="1" colspan="1">11728</td><td rowspan="1" colspan="1">Questionnaire surveys, Blood biochemistry analysis</td><td rowspan="1" colspan="1">High OSAS risk independently associates with hyperuricemia.</td><td rowspan="1" colspan="1">Cross-sectional Study</td></tr></tbody></table></table-wrap>
<table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2</label><caption><p>Results of Risk&#8208;of&#8208;bias Assessment for Included Studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Author(year)</th><th rowspan="1" colspan="1">Q1</th><th rowspan="1" colspan="1">Q2</th><th rowspan="1" colspan="1">Q3</th><th rowspan="1" colspan="1">Q4</th><th rowspan="1" colspan="1">Q5</th><th rowspan="1" colspan="1">Q6</th><th rowspan="1" colspan="1">Q7</th><th rowspan="1" colspan="1">Q8</th><th rowspan="1" colspan="1">Q9</th><th rowspan="1" colspan="1">Q10</th><th rowspan="1" colspan="1">Q11</th><th rowspan="1" colspan="1">Q12</th><th rowspan="1" colspan="1">Q13</th><th rowspan="1" colspan="1">Q14</th><th rowspan="1" colspan="1">Overall Assessment</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Yu et al (2022)<xref rid="cit0016" ref-type="bibr">16</xref></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NR</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NR</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Fair</td></tr><tr><td rowspan="1" colspan="1">Shen et al (2019)<xref rid="cit0004" ref-type="bibr">4</xref></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Good</td></tr><tr><td rowspan="1" colspan="1">Yang et al (2023)<xref rid="cit0006" ref-type="bibr">6</xref></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NR</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Good</td></tr><tr><td rowspan="1" colspan="1">Dai et al (2025)<xref rid="cit0010" ref-type="bibr">10</xref></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Fair</td></tr><tr><td rowspan="1" colspan="1">Zou et al (2022)<xref rid="cit0019" ref-type="bibr">19</xref></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Good</td></tr><tr><td rowspan="1" colspan="1">Zhang et al (2023)<xref rid="cit0023" ref-type="bibr">23</xref></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NR</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Good</td></tr><tr><td rowspan="1" colspan="1">Zhao et al (2017)<xref rid="cit0011" ref-type="bibr">11</xref></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NR</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Fair</td></tr><tr><td rowspan="1" colspan="1">Hirotsu et al (2013)<xref rid="cit0024" ref-type="bibr">24</xref></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Fair</td></tr><tr><td rowspan="1" colspan="1">Oh JS et al (2014)<xref rid="cit0025" ref-type="bibr">25</xref></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Fair</td></tr><tr><td rowspan="1" colspan="1">Li et al (2018)<xref rid="cit0026" ref-type="bibr">26</xref></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NR</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Fair</td></tr><tr><td rowspan="1" colspan="1">Chou et al (2020)<xref rid="cit0015" ref-type="bibr">15</xref></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Fair</td></tr><tr><td rowspan="1" colspan="1">Wang et al (2021)<xref rid="cit0027" ref-type="bibr">27</xref></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Fair</td></tr><tr><td rowspan="1" colspan="1">Yu et al (2021)<xref rid="cit0020" ref-type="bibr">20</xref></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Fair</td></tr><tr><td rowspan="1" colspan="1">Has&#237;kova et al (2021)<xref rid="cit0028" ref-type="bibr">28</xref></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Fair</td></tr><tr><td rowspan="1" colspan="1">Zhou et al (2023)<xref rid="cit0012" ref-type="bibr">12</xref></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NR</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Fair</td></tr><tr><td rowspan="1" colspan="1">Sunadome et al (2023)<xref rid="cit0029" ref-type="bibr">29</xref></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Fair</td></tr><tr><td rowspan="1" colspan="1">Park et al (2025)<xref rid="cit0030" ref-type="bibr">30</xref></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Fair</td></tr></tbody></table><table-wrap-foot><fn id="t0002-fn1"><p><bold>Notes</bold>: The items for the Risk of Bias Assessment were adapted from the Study Quality Assessment Tools developed by the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH). Available at: <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools" ext-link-type="uri">https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools</ext-link></underline>. Q1: Was the research question or objective in this paper clearly stated? Q2: Was the study population clearly specified and defined? Q3: Was the participation rate of eligible person at 50%? Q4: Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? Q5: Was a sample size justification, power description, or variance and effect estimates provided? Q6: For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? Q7: Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? Q8: For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (eg, categories of exposure, or exposure measured as continuous variable)? Q9: Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? Q10: Was the exposure(s) assessed more than once over time? Q11: Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? Q12: Were the outcome assessors blinded to the exposure status of participants? Q13: Was loss to follow-up after baseline 20% or less? Q14: Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?</p></fn><fn id="t0002-fn2"><p><bold>Abbreviations</bold>: NR, not reported; NA, not applicable.</p></fn></table-wrap-foot></table-wrap>
<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p>PRISMA flowchart of search results at each step of the review. Notes: The figure was prepared using the PRISMA 2020 flow-diagram template (<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://prisma-statement.org" ext-link-type="uri">https://prisma-statement.org</ext-link></underline>) and adapted from Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. doi:10.1136/bmj.n71. Creative Commons.<xref rid="cit0130" ref-type="bibr">130</xref></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="NSS-17-2321-g0001.jpg"/></fig></p></sec><sec id="s0003"><title>Physiological Pathways of Uric Acid Metabolism</title><sec id="s0003-s2001"><title>Uric Acid Synthesis and Elimination</title><p>Uric acid primarily arises from the catabolism of purine nucleotides. During cellular processes, the breakdown of DNA and RNA produces hypoxanthine and xanthine, which are further oxidized by xanthine oxidase (XO) to generate uric acid.<xref rid="cit0031" ref-type="bibr">31</xref> The activity of XO is regulated by hypoxia-inducible factor-1&#945; (HIF-1&#945;), with hypoxic conditions significantly upregulating XO activity, thereby increasing uric acid production.<xref rid="cit0032" ref-type="bibr">32</xref>,<xref rid="cit0033" ref-type="bibr">33</xref> Following synthesis mainly in the liver, uric acid circulates in the bloodstream and is excreted by the kidneys through a coordinated process involving glomerular filtration, tubular secretion, and reabsorption, maintaining a dynamic balance between production and excretion.<xref rid="cit0002" ref-type="bibr">2</xref>,<xref rid="cit0034" ref-type="bibr">34</xref> Under physiological conditions, uric acid serves as a potent antioxidant, protecting neural, cardiovascular, and renal tissues from oxidative stress.<xref rid="cit0035" ref-type="bibr">35&#8211;37</xref> However, when uric acid production exceeds renal clearance, hyperuricemia develops, increasing the risk of gout, metabolic syndrome, and other chronic conditions.</p></sec><sec id="s0003-s2002"><title>Dysregulation of Uric Acid Metabolism and Circadian Rhythms</title><p>The primary abnormality in uric acid metabolism is hyperuricemia, which results from increased synthesis, decreased renal clearance, or a combination of both. Beyond its central role in gout, hyperuricemia has been implicated in the pathogenesis of metabolic syndrome, type 2 diabetes mellitus, and cardiovascular diseases.<xref rid="cit0038" ref-type="bibr">38</xref> Mechanistically, elevated serum uric acid induces oxidative stress, activates inflammatory pathways, and disrupts lipid metabolism, all of which contribute to insulin resistance, impaired glycemic regulation, and lipid accumulation&#8212;factors that collectively increase the risk of diabetes and cardiovascular diseases.<xref rid="cit0029" ref-type="bibr">29</xref>,<xref rid="cit0039" ref-type="bibr">39</xref> In the kidneys, urate crystal deposition can lead to nephrolithiasis and tubular injury, creating a cycle of uric acid retention and progressive renal impairment.<xref rid="cit0040" ref-type="bibr">40</xref> In the central nervous system, physiological levels of uric acid protect neurons by scavenging reactive oxygen species (ROS) and inhibiting lipid peroxidation.<xref rid="cit0041" ref-type="bibr">41&#8211;44</xref> However, when uric acid is supersaturated, it can compromise the blood-brain barrier by downregulating tight junction proteins, promoting neuroinflammation, and activating astrocytes&#8212;alterations that may disrupt sleep-wake regulation.<xref rid="cit0045" ref-type="bibr">45</xref></p><p>Uric acid metabolism also exhibits robust circadian variation, regulated by biological clocks. Hepatic XO activity follows a diurnal rhythm, peaking during the night, indicating an intrinsic coupling between uric acid production and the sleep-wake cycle.<xref rid="cit0046" ref-type="bibr">46</xref>,<xref rid="cit0047" ref-type="bibr">47</xref> Animal studies have shown that knockout of the core clock gene BMAL1 disrupts normal uric acid rhythmicity and leads to fragmented sleep, highlighting the role of circadian genes in synchronizing uric acid handling with sleep architecture.<xref rid="cit0048" ref-type="bibr">48</xref> Clinically, prolonged daytime napping is associated with circadian misalignment and metabolic disturbances, potentially increasing uric acid synthesis and accumulation. This pattern has also been linked to a higher prevalence of metabolic syndrome and hyperuricemia.<xref rid="cit0027" ref-type="bibr">27</xref> Together, these findings underscore the close relationship between uric acid homeostasis, systemic metabolic regulation, renal function, and sleep processes. The diurnal fluctuations in uric acid and its responsiveness to lifestyle factors, such as daytime napping, emphasize the importance of circadian mechanisms and behavioral interventions in the prevention and management of uric acid-related disorders.</p></sec><sec id="s0003-s2003"><title>Impact of Uric Acid Dysmetabolism on Sleep</title><p>Hyperuricemia, particularly during acute gout flares, has been consistently associated with impairments in sleep efficiency and overall sleep quality. Clinical research indicates a negative correlation between serum uric acid levels and sleep parameters, suggesting that disturbances in uric acid metabolism may directly impair sleep continuity and architecture.<xref rid="cit0024" ref-type="bibr">24</xref> Patients with hyperuricemia often exhibit urate crystal deposition within joints, leading to acute inflammatory arthritis episodes. These episodes are characterized by intense pain and localized inflammation, which directly disrupt sleep initiation and continuity. The specific manifestations are as follows:</p><sec id="s0003-s2003-s3001"><title>Alterations in Sleep Architecture</title><p>Patients with hyperuricemia often exhibit a significant reduction in slow-wave sleep (N3 stage), likely driven by central nervous system inflammation and oxidative stress triggered by elevated uric acid levels.<xref rid="cit0049" ref-type="bibr">49&#8211;51</xref> The increase in pro-inflammatory cytokines amplifies neuroinflammation, disrupting the homeostatic regulation of deep sleep. Simultaneously, oxidative damage to cortical energy metabolism reduces the duration of N3 sleep and shifts the proportion towards lighter NREM and REM sleep stages. These alterations not only diminish restorative deep sleep but also increase nocturnal arousals, resulting in overall poorer sleep quality.<xref rid="cit0052" ref-type="bibr">52</xref></p></sec><sec id="s0003-s2003-s3002"><title>Neurotransmitter Modulation</title><p>Elevated serum uric acid levels exert a direct influence on central neurotransmitter systems integral to sleep-wake regulation and emotional homeostasis. Specifically, hyperuricemia may disrupt the synthesis and metabolism of key monoamines&#8212;including serotonin, norepinephrine, and dopamine&#8212;which are essential neuromodulators involved in sleep architecture, mood stabilization, and arousal states. Elevated uric acid concentrations can impair serotoninergic pathways, leading to decreased serotonergic tone and subsequent disturbances in REM sleep regulation. Simultaneously, hyperuricemia interferes with noradrenergic and dopaminergic pathways, which are critical for morning alertness, neurocognitive function, and emotional regulation.<xref rid="cit0053" ref-type="bibr">53&#8211;56</xref> These alterations may manifest as increased nocturnal awakenings, elevated sleep fragmentation, and morning fatigue, collectively impairing sleep&#8217;s restorative quality and the stability of affective states.</p></sec><sec id="s0003-s2003-s3003"><title>Molecular Regulatory Pathways</title><p>Uric acid influences sleep regulation through multiple molecular pathways, disrupting the complex neurochemical networks that govern sleep-wake cycles (<xref rid="f0002" ref-type="fig">Figure 2</xref>).<fig position="float" id="f0002" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><p>The molecular mechanism by which uric acid interferes with sleep regulation. Created in BioRender. Xie, Y. (2025) <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com/woqjmyt" ext-link-type="uri">https://BioRender.com/woqjmyt</ext-link></underline>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="NSS-17-2321-g0002.jpg"/></fig></p><sec id="s0003-s2003-s3003-s4001"><title>Competitive Regulation</title><p>Uric acid disrupts sleep regulation by inhibiting AMP-activated protein kinase (AMPK), the principal cellular energy sensor. Under energy deficit, AMP/ADP binding to AMPK&#8217;s &#947;-subunit induces a conformational shift that facilitates LKB1-mediated phosphorylation of the &#945;-subunit at Thr172, thereby activating downstream cascades controlling glucose uptake, fatty-acid &#946;-oxidation, and mitochondrial biogenesis to restore ATP homeostasis.<xref rid="cit0057" ref-type="bibr">57</xref> In the nervous system, AMPK not only governs neuronal bioenergetics but also directly modulates sleep-wake architecture, enhancing NREM sleep depth and restorative efficiency. Elevated uric acid impairs this mechanism via two synergistic pathways: competitive inhibition of upstream kinases (eg, LKB1) and ROS-mediated interference with Thr172 phosphorylation.<xref rid="cit0032" ref-type="bibr">32</xref>,<xref rid="cit0058" ref-type="bibr">58</xref> The resulting AMPK hypoactivity in hypothalamic and brainstem sleep centers diminishes neuronal energy sensing and markedly attenuates NREM slow-wave activity (&#948;-power). Ordinarily, active AMPK sustains neuronal ATP generation and ion-channel homeostasis to synchronize cortical slow-wave oscillations; its suppression leads to energy insufficiency, weakened slow waves, reduced sleep intensity, fragmented continuity, and impaired recovery.<xref rid="cit0059" ref-type="bibr">59</xref>,<xref rid="cit0060" ref-type="bibr">60</xref> Moreover, AMPK phosphorylates the core clock protein CRY1 at Ser71, promoting its recruitment by the E3 ubiquitin ligase FBXL3 for proteasomal degradation. This turnover prevents excessive nuclear accumulation of CRY1, allowing the CLOCK-BMAL1 complex to drive rhythmic transcription of clock genes. By blocking AMPK signaling, uric acid reduces CRY1 phosphorylation, impedes its clearance, and thereby amplifies CRY1-mediated repression of CLOCK-BMAL1, disrupting circadian oscillations and sleep-wake synchronization.<xref rid="cit0061" ref-type="bibr">61</xref> In sum, uric acid&#8217;s competitive inhibition of AMPK activation undermines neuronal energy metabolism and NREM sleep quality while derailing molecular clock dynamics&#8212;mechanisms that converge to produce sleep dysfunction.</p></sec><sec id="s0003-s2003-s3003-s4002"><title>Epigenetic Regulation</title><p>Chronic exposure to elevated uric acid acts as a metabolic stressor that triggers epigenetic reprogramming of monocytes, mirroring the molecular signature of trained immunity.<xref rid="cit0062" ref-type="bibr">62</xref> This imprint renders monocytes hypersensitive to inflammatory stimuli and primes them for exaggerated secretion of TNF-&#945;, IL-1&#946;, and IL-6 upon subsequent challenge with PAMPs or Damage-associated Molecular Patterns (DAMPs).<xref rid="cit0063" ref-type="bibr">63</xref> Mechanistically, this involves two layers of epigenetic control:
<list list-type="simple"><list-item><label>1)</label><p>DNA methylation: High uric acid up-regulates DNA Methyltransferase 3A (DNMT3A), increasing 5-mC density within CpG islands of anti-inflammatory promoters (NRF2, PGC-1&#945;, FOXP3), which results in the hypermethylation and transcriptional repression of anti-inflammatory gene promoters. Concurrently, it reduces the methylation levels of pro-inflammatory genes such as NLRP3, or indirectly enhances their expression, amplifying the inflammatory response.<xref rid="cit0064" ref-type="bibr">64</xref> Although this methylation pattern is reversible, prolonged exposure establishes a persistent epigenetic memory that lowers the threshold for cytokine release.</p></list-item><list-item><label>2)</label><p>Histone modifications: Uric acid- driven oxidative stress reshapes the histone modification landscape through three main routes:</p></list-item></list>
<list list-type="bullet"><list-item><p>Histone acetylation: Activation of the TLR4/NF-&#954;B pathway recruits HATs to pro-inflammatory gene promoters, elevates H3K27ac, and inhibits HDAC3, resulting in chromatin relaxation and enhanced transcription.<xref rid="cit0037" ref-type="bibr">37</xref>,<xref rid="cit0065" ref-type="bibr">65</xref></p></list-item><list-item><p>Histone methylation: Enhanced methyltransferase activity deposits H3K4me3 on pro-inflammatory genes, while genes involved in circadian rhythms (eg, CLOCK, PER2) may be downregulated due to H3K27me3 modifications, disrupting immune-metabolic homeostasis.<xref rid="cit0063" ref-type="bibr">63</xref>,<xref rid="cit0066" ref-type="bibr">66</xref></p></list-item><list-item><p>Other modifications: Include the phosphorylation and ubiquitination of signaling proteins, which further reinforce inflammatory signaling.</p></list-item></list></p><p>Consequently, the circadian secretion of pro-inflammatory cytokines becomes uncoupled from the sleep-wake cycle, undermining sleep-immune homeostasis and aggravating sleep disorders.<xref rid="cit0067" ref-type="bibr">67</xref>,<xref rid="cit0068" ref-type="bibr">68</xref> These events fuel a self-perpetuating cycle of chronic low-grade inflammation that increases the risk of metabolic syndrome, autoimmune diseases, and related complications. Collectively, these findings identify uric acid-driven epigenetic remodeling as a pivotal hub linking metabolic stress to chronic inflammation and sleep-immune dysregulation, offering potential therapeutic targets for hyperuricemia-associated pathologies.</p></sec><sec id="s0003-s2003-s3003-s4003"><title>Redox Interference</title><p>Hyperuricemia induces persistent oxidative stress, which gradually depletes intracellular glutathione (GSH). As a key thiol antioxidant, GSH normally neutralizes free radicals and peroxides to maintain redox homeostasis. In a high-uric acid environment, however, uric acid&#8217;s intrinsic pro-oxidant activity&#8212;and even its ability to inactivate endogenous antioxidant enzymes&#8212;promotes the accumulation of ROS.<xref rid="cit0069" ref-type="bibr">69&#8211;71</xref> Suppression of the Nrf2 pathway in this context further diminishes cellular antioxidant defenses, allowing ROS levels to rise unchecked. Elevated ROS not only cause direct molecular damage but also serve as second messengers to activate stress-responsive kinases. In particular, phosphorylation of p38 MAPK enhances the secretion of pro-inflammatory cytokines, which in turn exacerbates oxidative stress. This combined oxidative-inflammatory milieu disrupts central sleep-wake regulatory circuits, manifesting as prolonged sleep latency, increased light sleep, and reduced deep sleep.<xref rid="cit0037" ref-type="bibr">37</xref>,<xref rid="cit0072" ref-type="bibr">72</xref>,<xref rid="cit0073" ref-type="bibr">73</xref> Concurrent GSH depletion and oxidative stress impair the function of the hypothalamic-SCN-pineal axis, which governs circadian rhythms and melatonin synthesis. ROS-mediated suppression of Nrf2 signaling compromises cellular redox homeostasis, indirectly blunting AANAT&#8212;the rate-limiting enzyme in nocturnal melatonin biosynthesis&#8212;and downregulating other key enzymes such as HIOMT. The resulting decline in nocturnal melatonin secretion disrupts sleep architecture and reduces overall sleep quality.<xref rid="cit0041" ref-type="bibr">41</xref>,<xref rid="cit0051" ref-type="bibr">51</xref></p><p>In summary, uric acid dysmetabolism disrupts sleep architecture via direct impacts on neurotransmitter regulation and molecular circadian mechanisms. It also aggravates sleep disturbances through the activation of neuroinflammatory and oxidative stress pathways, creating a vicious cycle of sleep impairment.</p></sec></sec></sec></sec><sec id="s0004"><title>Sleep and Metabolic Regulation</title><sec id="s0004-s2001"><title>Physiological Features of Sleep Architecture</title><p>Sleep consists of NREM and REM stages. NREM is further divided into N1 (a light transition phase with reduced cortical activity but maintained arousability), N2 (characterized by spindles and K-complexes, promoting autonomic stability), and N3 (slow-wave sleep, which supports energy homeostasis, immune recovery, insulin sensitivity, and lipid metabolism). In contrast, REM sleep exhibits wake-like EEG yet is accompanied by skeletal muscle atonia and phasic cholinergic&#8211;monoaminergic surges that facilitate emotional regulation, memory consolidation, and cardiovascular variability.<xref rid="cit0074" ref-type="bibr">74&#8211;77</xref> Together, deep NREM (particularly N3) and REM constitute an integrated neuroendocrine network that orchestrates systemic metabolism through complementary restorative mechanisms.</p></sec><sec id="s0004-s2002"><title>Sleep Duration and Uric Acid Balance</title><p>Epidemiological data show short sleep (&lt;7&#160;h/night) increases hyperuricemia risk, while long sleep (&#8805;8&#160;h) is protective.<xref rid="cit0016" ref-type="bibr">16</xref> Sleep loss and fragmentation provoke insulin resistance, dyslipidemia, and pro-inflammatory cytokine release (IL-6, TNF-&#945;), elevating oxidative stress and impairing renal uric acid clearance.<xref rid="cit0078" ref-type="bibr">78</xref>,<xref rid="cit0079" ref-type="bibr">79</xref> Conversely, intact slow-wave sleep sustains fatty acid oxidation and limits purine overload.<xref rid="cit0015" ref-type="bibr">15</xref>,<xref rid="cit0080" ref-type="bibr">80</xref> Emerging mechanisms include (a) the gut-brain purine axis, whereby sleep deprivation alters microbiota purine metabolism and enhances systemic xanthine load;<xref rid="cit0081" ref-type="bibr">81</xref>,<xref rid="cit0082" ref-type="bibr">82</xref> (b) neuroinflammatory breach of the blood-brain barrier, enabling peripheral uric acid entry and glial activation via TLR4/NF-&#954;B pathways.<xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0083" ref-type="bibr">83&#8211;85</xref> These mechanisms link sleep disruption to dysregulated uric acid homeostasis and increased risk of metabolic and neurodegenerative disorders.</p></sec><sec id="s0004-s2003"><title>Stage-Specific Sleep Effects on Uric Acid Metabolism</title><p>Sleep stages differ markedly in metabolic rate, with N1 (transition) having the highest among NREM, N2 (spindle/K-complex stage) being intermediate, and N3 (slow-wave) being the lowest. To date, few studies have explored the potential link between N1 duration or quality and uric acid turnover, and the relationship between N2&#8212;which constitutes 45&#8211;55% of total sleep&#8212;and serum uric acid or renal clearance remains largely uninvestigated.<xref rid="cit0011" ref-type="bibr">11</xref>,<xref rid="cit0086" ref-type="bibr">86</xref>,<xref rid="cit0087" ref-type="bibr">87</xref></p><p>N3 slow&#8208;wave sleep minimizes cerebral and systemic ATP turnover, theoretically curbing uric acid production. Consistent with this, chronic insomnia&#8212;characterized by reduced N3&#8212;yields lower serum uric acid, likely due to excessive oxidative consumption of uric acid as an antioxidant.<xref rid="cit0011" ref-type="bibr">11</xref> In contrast, N3 disruption in obstructive sleep apnea (OSA) precipitates recurrent hypoxia-reoxygenation cycles; these cycles inhibit mitochondrial ATP synthesis yet accelerate its breakdown, elevating purine intermediates (eg, hypoxanthine) and driving uric acid generation via xanthine oxidase.<xref rid="cit0024" ref-type="bibr">24</xref> Thus, although N3 loss occurs in both insomnia and OSA, divergent oxidative&#8208;stress pathways produce opposite serum uric acid profiles.</p><p>REM sleep exhibits the highest brain metabolic rate of all stages, further amplifying ATP catabolism and uric acid synthesis.<xref rid="cit0087" ref-type="bibr">87</xref> In OSA, respiratory events peak in REM, intensifying intermittent hypoxemia and fueling excess uric acid production; nadir nocturnal oxygen saturation in REM strongly correlates with serum uric acid levels.<xref rid="cit0030" ref-type="bibr">30</xref>,<xref rid="cit0088" ref-type="bibr">88</xref>,<xref rid="cit0089" ref-type="bibr">89</xref> Clinically, nadir nocturnal oxygen saturation&#8212;typically occurring in REM&#8212;correlates strongly with serum uric acid concentrations in OSA patients, underscoring the impact of REM&#8217;s unique neuro-metabolic environment on uric acid metabolism.<xref rid="cit0024" ref-type="bibr">24</xref>,<xref rid="cit0026" ref-type="bibr">26</xref>,<xref rid="cit0028" ref-type="bibr">28</xref> Collectively, these findings highlight that stage-specific variations in sleep architecture critically modulate uric acid homeostasis. Future research should integrate high-resolution polysomnography with real-time uric acid monitoring to quantify each stage&#8217;s independent contribution to uric acid production and clearance, thereby informing stage-targeted interventions.</p></sec><sec id="s0004-s2004"><title>Sleep-Uric Acid Metabolism Confounders</title><p>Diet, exercise, medications, and lifestyle variables must be rigorously controlled in studies of the serum uric acid (SUA)-sleep relationship.
<list list-type="bullet"><list-item><p>Diet: purine-rich foods and alcohol increase SUA and disrupt sleep architecture, whereas caffeine lowers SUA but shortens sleep time and efficiency.<xref rid="cit0090" ref-type="bibr">90&#8211;92</xref></p></list-item><list-item><p>Exercise: acute high-intensity efforts transiently elevate SUA via lactate and may impair sleep;<xref rid="cit0093" ref-type="bibr">93</xref>,<xref rid="cit0094" ref-type="bibr">94</xref> habitual moderate exercise lowers SUA and improves sleep, yet vigorous or late-evening workouts can delay sleep onset.<xref rid="cit0095" ref-type="bibr">95</xref>,<xref rid="cit0096" ref-type="bibr">96</xref></p></list-item><list-item><p>Medications: thiazide diuretics, salicylates, and pyrazinamide reduce renal uric acid excretion and raise SUA,<xref rid="cit0097" ref-type="bibr">97</xref>,<xref rid="cit0098" ref-type="bibr">98</xref> whereas uric acid-lowering agents (allopurinol, febuxostat, etc) markedly decrease SUA and could mask true associations.<xref rid="cit0099" ref-type="bibr">99</xref>,<xref rid="cit0100" ref-type="bibr">100</xref> Benzodiazepines and Z-drugs alter sleep stages without affecting SUA;<xref rid="cit0101" ref-type="bibr">101</xref>,<xref rid="cit0102" ref-type="bibr">102</xref> failure to account for their use may overestimate sleep effects.</p></list-item><list-item><p>Lifestyle: shift work and circadian misalignment increase hyperuricemia risk;<xref rid="cit0025" ref-type="bibr">25</xref>,<xref rid="cit0103" ref-type="bibr">103</xref> obesity, hypertension, and insulin resistance are shared risk factors for elevated SUA and sleep disorders;<xref rid="cit0104" ref-type="bibr">104</xref>,<xref rid="cit0105" ref-type="bibr">105</xref> Chronic psychosocial stress raises SUA and disturbs sleep.<xref rid="cit0106" ref-type="bibr">106</xref>,<xref rid="cit0107" ref-type="bibr">107</xref></p></list-item></list></p><p>Most prior studies adjust only for age, sex, and BMI. Future work should prospectively collect detailed dietary, exercise, medication, and psychosocial data and include them as covariates to obtain unbiased estimates of the SUA-sleep association.</p></sec></sec><sec id="s0005"><title>Multi-Tiered Regulation of Sleep and Uric Acid Metabolism</title><p>Biological regulatory systems operate through complex, multi-layered networks that integrate signals across molecular, cellular, and systemic levels. Based on a comprehensive literature synthesis, these regulatory mechanisms can be broadly categorized into three hierarchical levels. Each level encompasses distinct biological processes and signaling pathways, ranging from gene and molecular regulation to organ-level coordination, together forming a dynamic and stratified framework of metabolic control (<xref rid="f0003" ref-type="fig">Figure 3</xref>).<fig position="float" id="f0003" fig-type="figure" orientation="portrait"><label>Figure 3</label><caption><p>The schematic diagram of multilevel regulation of sleep and uric acid metabolism. Created in BioRender. Xie, Y. (2025) <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com/woqjmyt" ext-link-type="uri">https://BioRender.com/woqjmyt</ext-link></underline>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="NSS-17-2321-g0003.jpg"/></fig></p><sec id="s0005-s2001"><title>Primary Regulation: Circadian Modulation of Uric Acid Metabolism via the Hypothalamic-Pituitary-Adrenal (HPA) Axis</title><p>The HPA axis is a central neuroendocrine system that governs both stress responses and circadian rhythms. Through rhythmic secretion of glucocorticoids&#8212;primarily cortisol&#8212;the HPA axis orchestrates a broad spectrum of metabolic activities, including uric acid metabolism. Under normal physiological conditions, cortisol levels peak approximately 30&#8211;60&#160;minutes after awakening (around 06:30&#8211;07:30), aligning with a critical phase of the circadian cycle.<xref rid="cit0108" ref-type="bibr">108</xref> Experimental studies have demonstrated that glucocorticoids, acting via the glucocorticoid receptor (GR), modulate downstream signaling pathways such as NF-&#954;B and AP-1. This signaling cascade leads to the suppression of urate transporter 1 (URAT1) expression in the renal proximal tubules, thereby reducing uric acid reabsorption and enhancing renal uric acid excretion.<xref rid="cit0109" ref-type="bibr">109</xref> This mechanism highlights a direct link between circadian HPA axis activity and renal uric acid handling. Clinically, circadian misalignment&#8212;as observed in shift workers&#8212;has been associated with blunted diurnal fluctuations in serum uric acid and delayed phase shifts in 24-hour uric acid rhythms. These findings suggest that HPA axis dysregulation may be a critical contributor to disrupted uric acid homeostasis in populations exposed to circadian stress.<xref rid="cit0023" ref-type="bibr">23</xref>,<xref rid="cit0025" ref-type="bibr">25</xref> Collectively, the circadian regulation exerted by the HPA axis represents a fundamental, first-tier mechanism in the control of uric acid metabolism. Therapeutic strategies aimed at restoring HPA axis rhythmicity hold promise not only for improving sleep and endocrine balance but also for correcting uric acid dysregulation. This highlights its translational potential in the management of hyperuricemia and related metabolic disorders.</p></sec><sec id="s0005-s2002"><title>Secondary Regulation: The Role of the Gut Microbiota in Purine and Uric Acid Metabolism</title><p>Recent advances have highlighted the gut microbiota as a key modulator of host circadian rhythms and metabolic homeostasis. A growing body of evidence suggests that the gut-brain axis facilitates bidirectional communication between microbial communities and the host&#8217;s central clock system, thereby contributing to the regulation of sleep-wake cycles and circadian alignment.<xref rid="cit0110" ref-type="bibr">110&#8211;112</xref> Beyond circadian control, the gut microbiota plays an increasingly recognized role in uric acid metabolism. Clinical and microbiome studies have consistently shown that individuals with gout exhibit significant dysbiosis&#8212;characterized by a depletion of microbial taxa involved in uricolysis, alongside an enrichment of pathways associated with de novo purine biosynthesis.<xref rid="cit0082" ref-type="bibr">82</xref> Large-scale metagenomic analyses have confirmed substantial alterations in both taxonomic composition and metabolic potential of the gut microbiota in hyperuricemia individuals, with these changes correlating closely with aberrant uric acid handling and chronic low-grade inflammation.<xref rid="cit0113" ref-type="bibr">113</xref> Mechanistically, certain gut microbes express xanthine oxidase homologs, contributing directly to the microbial conversion of purines into uric acid. Importantly, microbial purine metabolism exhibits circadian rhythmicity, which may exert time-dependent effects on host serum uric acid levels.<xref rid="cit0114" ref-type="bibr">114</xref>,<xref rid="cit0115" ref-type="bibr">115</xref> Animal models have further substantiated the pivotal role of the gut microbiota in maintaining purine homeostasis, particularly in modulating systemic uric acid concentrations.<xref rid="cit0115" ref-type="bibr">115</xref> Taken together, the gut microbiota functions as a secondary regulatory layer in uric acid metabolism, exerting multifaceted control over host purine flux and uric acid balance. Its circadian rhythmicity offers novel insight into the temporal dynamics of metabolic regulation and opens promising avenues for microbiota-targeted interventions in hyperuricemia and related disorders.</p></sec><sec id="s0005-s2003"><title>Tertiary Regulation: Positive Feedback Between Oxidative Stress and Inflammatory Signaling</title><p>Oxidative stress and inflammation constitute a central mechanistic axis linking sleep architecture disruption to altered uric acid metabolism. Sleep fragmentation (SF), a hallmark of disturbed sleep structure, has been shown to activate the NLRP3 inflammasome, resulting in elevated secretion of pro-inflammatory cytokines such as interleukin-1&#946; (IL-1&#946;), which in turn amplifies both systemic and local inflammatory responses.<xref rid="cit0116" ref-type="bibr">116</xref>,<xref rid="cit0117" ref-type="bibr">117</xref> Certain cytokines, notably IL-6, can further activate the JAK2/STAT3 signaling cascade, upregulating the transcription and expression of xanthine oxidase (XOR), a key enzyme in purine catabolism, thereby accelerating uric acid production.<xref rid="cit0118" ref-type="bibr">118</xref> Moreover, urate crystals function as DAMPs, capable of perpetuating immune activation via the TLR4/MyD88 pathway. This establishes a self-reinforcing inflammatory loop, which is critically implicated in the pathogenesis of gout and uric acid-associated nephropathies.<xref rid="cit0119" ref-type="bibr">119</xref> Experimental models support this mechanism: antioxidant intervention using agents such as N-acetylcysteine (NAC), alone or in combination with bioactive phytochemicals, has been shown to improve serum uric acid levels and renal function, underscoring the therapeutic value of targeting oxidative stress in uric acid-related disorders.<xref rid="cit0120" ref-type="bibr">120</xref> Collectively, oxidative stress and inflammation form a tertiary regulatory layer in uric acid metabolism, wherein sleep disturbance triggers inflammatory and oxidative signals that synergistically exacerbate uric acid accumulation. This pathological feedback loop serves as a key mechanistic substrate for the development and progression of hyperuricemia and related metabolic diseases.</p><p>In summary, the regulation of uric acid metabolism by sleep architecture is a complex, multilayered physiological process. Primary regulation is mediated by the circadian rhythmicity of the HPA axis, which modulates endocrine output and renal uric acid excretion. Secondary regulation involves the composition and metabolic activity of the gut microbiota, influencing purine metabolic flux and circadian oscillations of uric acid levels. Tertiary regulation comprises the oxidative stress-inflammation feedback loop, which sustains inflammatory signaling and promotes uric acid synthesis under conditions of sleep disruption. These three regulatory tiers interact synergistically to maintain uric acid homeostasis. This multidimensional framework not only advances our mechanistic understanding of uric acid metabolism but also identifies promising therapeutic targets for the precision management of hyperuricemia and associated metabolic disorders.</p></sec></sec><sec id="s0006"><title>Research Directions and Clinical Perspectives</title><sec id="s0006-s2001"><title>Research Priorities</title><sec id="s0006-s2001-s3001"><title>Elucidating the Bidirectional Regulation Between Uric Acid Metabolism and Sleep</title><p>The bidirectional regulatory mechanisms between uric acid and sleep remain incompletely elucidated at the molecular level. Future studies should focus on the role of uric acid in modulating sleep architecture and circadian rhythms, particularly its detailed mechanisms of action via oxidative stress, neuroinflammation, and clock genes (eg, BMAL1 and CLOCK). Employing cutting-edge technologies, researchers should dissect how uric acid influences sleep quality by affecting neuronal functions, neurotransmitter homeostasis, and inflammatory responses within the central nervous system. Additionally, the role of uric acid metabolism in neuroendocrine regulation warrants investigation, especially the complex interactions between uric acid metabolism and various neurotransmitters. Further exploration of clock genes as molecular hubs linking uric acid metabolism and sleep regulation may reveal novel therapeutic targets for clinical intervention.</p></sec><sec id="s0006-s2001-s3002"><title>Integrating Traditional Chinese Medicine (TCM) in Uric Acid and Sleep Regulation</title><p>TCM has a long history of regulating uric acid metabolism and improving sleep quality, offering a unique complement to modern medicine through its holistic approach and individualized treatment methods. Future research could explore the application of classical TCM formulas in addressing uric acid metabolism disorders and the associated sleep disturbances. Clinical randomized controlled trials, combined with modern scientific technologies such as metabolomics and genomics, should be conducted to investigate the molecular mechanisms by which herbal medicine influences uric acid metabolism. Additionally, traditional TCM therapies such as acupuncture and tuina massage warrant further investigation for their potential to regulate sleep quality and alleviate uric acid-related symptoms. A comprehensive intervention strategy combining both Western and Chinese medicine should be a research priority, focusing on multi-target, multi-level treatment models that integrate TCM with pharmacological therapies to optimize the combined therapeutic effects on uric acid metabolism and sleep quality.</p></sec></sec><sec id="s0006-s2002"><title>Clinical Perspectives</title><sec id="s0006-s2002-s3001"><title>Personalized Therapeutic Strategies in Precision Medicine</title><p>A structured &#8220;Assessment-Intervention-Monitoring-Follow-up&#8221; paradigm is proposed to address the bidirectional interplay between hyperuricemia and sleep disturbances, aiming for precise optimization of serum uric acid levels and restorative sleep.
<list list-type="bullet"><list-item><p>Assessment: During the initial consultation, quantify sleep disturbances by using the Pittsburgh Sleep Quality Index (PSQI). Supplement subjective data with objective measures&#8212;such as portable or wearable sleep monitors&#8212;to record nocturnal awakenings and the proportion of deep sleep. Simultaneously, document gout flare characteristics (severity and frequency), pain-related nighttime awakenings, mood disorders, and exposure histories (diet, alcohol, caffeine) to identify interactive risk factors linking sleep disturbances and hyperuricemia.</p></list-item><list-item><p>Intervention: Prioritize nonpharmacological strategies&#8212;particularly cognitive behavioral therapy for insomnia (CBT-I) and sleep environment optimization. When pain impairs sleep initiation, short-term use of low-dose zolpidem may be considered. Concurrently, colchicine or non-steroidal anti-inflammatory drugs (NSAIDs) administered at night can suppress inflammatory surges. To control uric acid levels in the long term, it is recommended to take allopurinol or febuxostat in the evening to maintain stable plasma concentrations. For diet, a low-purine, high-fiber dinner is advised, avoiding foods rich in purines. Engaging in light stretching or yoga 1.5&#160;hours before bedtime can help relax the body and improve sleep quality. Additionally, melatonin supplementation may be considered to improve sleep, potentially helping to reduce nocturnal uric acid peaks.</p></list-item><list-item><p>Monitoring: Reassess biomarkers of inflammation and oxidative stress (interleukin&#8209;1&#946;, tumor necrosis factor&#8209;&#945;, malondialdehyde, superoxide dismutase), eGFR, serum uric acid, and 24&#8209;hour urinary uric acid excretion every 1&#8211;3 months to gauge intervention impact on the inflammation-oxidative stress-renal function axis. Reevaluate the PSQI at 1, 3, and 6 months; if indicated, escalate to polysomnography to screen for sleep-disordered breathing.</p></list-item><list-item><p>Follow-up: Coordinate follow-up within a multidisciplinary team&#8212;led by rheumatology and endocrinology and supported by sleep medicine, psychiatry, nutrition, and physical therapy. During acute flares, adjust the analgesic-hypnotic regimen weekly; in the remission phase, fine-tune uric acid-lowering and sleep-maintenance strategies monthly. The ultimate goal is bidirectional optimization and precise management of both serum uric acid levels and sleep quality (<xref rid="f0004" ref-type="fig">Figure 4</xref>).</p></list-item></list><fig position="float" id="f0004" fig-type="figure" orientation="portrait"><label>Figure 4</label><caption><p>Decision Tree for Uric Acid Management Based on Sleep Assessment in Patients with Hyperuricemia.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="NSS-17-2321-g0004.jpg"/></fig></p></sec><sec id="s0006-s2002-s3002"><title>Management Strategies for Special Populations</title><p>Intervention strategies for elderly individuals, pediatric patients, and pregnant women should adhere to three overarching principles: non-pharmacological first-line therapy, individualized pharmacotherapy, and regular monitoring. All groups benefit initially from sleep hygiene education (eg, regular sleep-wake schedules, pre-sleep relaxation, minimization of noise and light), CBT-I, and acupuncture. When medication is indicated, it must be short-term, low-dose, and fast-acting. Elderly patients should avoid long-term benzodiazepines and antihistamines due to the risk of falls and cognitive decline.<xref rid="cit0121" ref-type="bibr">121&#8211;123</xref> Children require caution with sedatives to prevent neurodevelopmental impairment, and only minimal doses should be used when necessary.<xref rid="cit0124" ref-type="bibr">124</xref> Pregnant women may, after specialist risk assessment, receive minimal doses of lorazepam, but their intake should be strictly controlled.</p><p>For hyperuricemia management:
<list list-type="bullet"><list-item><p>Elderly individuals, who experience reduced N3 sleep and have compromised hepatic and renal clearance, should begin allopurinol at doses of less than 100 mg/day, with dose titration based on serum uric acid levels and clinical response.<xref rid="cit0125" ref-type="bibr">125</xref> Acute gout flares in this population warrant low-dose colchicine or a brief course of corticosteroids, along with vigilant monitoring of hepatic and renal function.<xref rid="cit0126" ref-type="bibr">126</xref></p></list-item><list-item><p>Although children have higher renal uric acid clearance and greater slow-wave sleep needs, lifestyle modification remains paramount. Under pediatric guidance, allopurinol or uricosuric agents may be used when necessary.<xref rid="cit0127" ref-type="bibr">127</xref></p></list-item><list-item><p>In pregnant women, the focus should be on dietary control, fluid-electrolyte balance, left lateral decubitus positioning with pillow support, and avoidance of standard uric acid-lowering drugs.<xref rid="cit0128" ref-type="bibr">128</xref> Acute gout in pregnancy is managed preferentially with low-dose corticosteroids and prophylactic colchicine.<xref rid="cit0129" ref-type="bibr">129</xref></p></list-item></list></p></sec><sec id="s0006-s2002-s3003"><title>Tiered Multi-Target Interventions</title><p>Building on the three-level regulatory framework, future research may implement combined multi-target interventions:
<list list-type="bullet"><list-item><p><bold>Tier I modulation</bold>: Optimization of uric acid excretion via circadian rhythm adjustment (eg, standardized sleep-wake schedules, phototherapy, or chronobiotic agents) and hormonal pathway modulation (eg, glucocorticoid receptor modulators).</p></list-item><list-item><p><bold>Tier II modulation</bold>: Intervention in the gut microbiota (eg, probiotic supplementation, increased dietary fiber intake, or fecal microbiota transplantation) or direct targeting of microbial purine-metabolizing enzymes (eg, engineered bacterial strains) to regulate host uric acid levels.</p></list-item><list-item><p><bold>Tier III modulation</bold>: Emphasis on anti-inflammatory and antioxidant strategies (eg, IL-1&#946;/IL-6 inhibitors and xanthine oxidase inhibitors) to disrupt the inflammation-uric acid positive-feedback loop.</p></list-item></list></p><p>By integrating Tier I (circadian-rhythm and hormonal regulation), Tier II (gut-microbiota modulation and microbial enzyme targeting), and Tier III (anti-inflammatory and antioxidant) interventions into a unified, multi-tiered framework, mechanistic synergy is achieved. This synergy optimizes uric acid homeostasis and disrupts pro-inflammatory feedback loops. Furthermore, by tailoring the combination of interventions to each patient&#8217;s individual circadian rhythm, gut&#8208;microbiota profile, and inflammatory status, a personalized, multi-tiered strategy can not only optimize therapeutic efficacy but also minimize drug-related side effects, thereby improving quality of life&#8212;particularly for patients with refractory hyperuricemia or gout. This comprehensive, multi-modal approach is expected to restore metabolic balance and substantially improve clinical outcomes.</p></sec></sec></sec><sec id="s0007"><title>Limitations</title><p>While preliminary evidence indicates an association between sleep disturbances and uric acid dysregulation, most findings to date rely on indirect observational data or small cohort studies. This reliance limits causal inference, especially given the lack of experimentally validated mechanistic data. Notably, shared pathophysiological mediators&#8212;for example, inflammatory cytokines (such as IL-1&#946; and TNF-&#945;) and oxidative stress markers (such as malondialdehyde) &#8212;may drive both conditions simultaneously and could exacerbate hyperuricemia. To address these gaps, future research should focus on several key areas:
<list list-type="bullet"><list-item><p>Randomized controlled trials that target the bidirectional links between sleep and uric acid.</p></list-item><list-item><p>Longitudinal human studies with repeated measurements of biomarkers, in order to clarify how changes in sleep architecture and uric acid homeostasis influence each other over time.</p></list-item><list-item><p>Integrated multi-omics analyses to uncover new molecular pathways and therapeutic targets involved in the comorbidity of sleep disorders and hyperuricemia.</p></list-item></list></p><p>By pursuing these approaches, the field can establish stronger mechanistic connections between sleep disturbances and uric acid dysregulation. Ultimately, this will facilitate a more stratified and effective clinical management of patients suffering from coexisting sleep disorders and hyperuricemia.</p></sec><sec id="s0008"><title>Conclusion</title><p>There exists a bidirectional regulatory relationship between uric acid metabolism and sleep architecture: elevated uric acid levels contribute to sleep disruption via pro-inflammatory and oxidative mechanisms, while sleep disturbances in turn exacerbate metabolic dysregulation of uric acid. This study highlights the necessity of an integrated therapeutic strategy that concurrently modulates uric acid homeostasis and improves sleep quality for the management of hyperuricemia and related metabolic disorders. Optimizing sleep as an adjunctive therapeutic strategy holds significant clinical promise and should be incorporated into the comprehensive treatment framework to enhance treatment efficacy and improve long-term patient outcomes.</p></sec></body><back><ack><title>Acknowledgments</title><p>The views expressed in this article are solely those of the authors and do not necessarily reflect the opinions of their affiliated institutions, the publisher, the editors, or the reviewers.</p></ack><sec id="s0009"><title>Abbreviations</title><p>NREM, non-rapid eye movement; REM, rapid eye movement; XO, xanthine oxidase; HIF-1&#945;, hypoxia-inducible factor-1&#945;; ROS, reactive oxygen species; AMPK, AMP-activated protein kinase; DAMPs, damage-associated molecular patterns; DNMT3A, DNA Methyltransferase 3A; GSH, glutathione; HPA, hypothalamic-pituitary-adrenal; GR, glucocorticoid receptor; URAT1, urate transporter 1; SF, sleep fragmentation; IL-1&#946;, interleukin-1&#946;; XOR, xanthine oxidase; NAC, N-acetylcysteine; TCM, Traditional Chinese Medicine; PSQI, Pittsburgh Sleep Quality Index; CBT-I, cognitive behavioral therapy for insomnia; NSAIDs, non-steroidal anti-inflammatory drugs.</p></sec><sec sec-type="data-availability" id="s0010"><title>Data Sharing Statement</title><p>Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.</p></sec><sec id="s0011"><title>Author Contributions</title><p>Guodong Ha and Jiawei Wu contributed to conceptualization, writing&#8212;review &amp; editing, and writing&#8212;original draft. Jing Hu, Xun Wang, Yijie Xie, Zhengyu Zhao, and Dingjun Cai, as the subsequent authors, all participated in formal analysis, supervision, and writing-review &amp; editing. All authors have contributed substantially to the drafting, writing, or critical revision of this paper. They have collectively agreed on the target journal for submission, reviewed and approved all versions of the paper at each stage&#8212;including submission, revision, final acceptance, and proofreading&#8212;and have accepted responsibility and accountability for the content of the paper.</p></sec><sec sec-type="COI-statement" id="s0012"><title>Disclosure</title><p>The authors report no conflicts of interest in this work.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Maiuolo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Oppedisano</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Gratteri</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Muscoli</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mollace</surname><given-names>V</given-names></string-name>. <article-title>Regulation of uric acid metabolism and excretion</article-title>. <source><italic toggle="yes">Int J Cardiol</italic></source>. <year>2016</year>;<volume>213</volume>:<fpage>8</fpage>&#8211;<lpage>14</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijcard.2015.08.109</pub-id><pub-id pub-id-type="pmid">26316329</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gherghina</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Peride</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Tiglis</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Neagu</surname><given-names>TP</given-names></string-name>, <string-name name-style="western"><surname>Niculae</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Checherita</surname><given-names>IA</given-names></string-name>. <article-title>Uric acid and oxidative stress-relationship with cardiovascular, metabolic, and renal impairment</article-title>. <source><italic toggle="yes">Int J Mol Sci</italic></source>. <year>2022</year>;<volume>23</volume>(<issue>6</issue>):<fpage>3188</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms23063188</pub-id><pub-id pub-id-type="pmid">35328614</pub-id><pub-id pub-id-type="pmcid">PMC8949471</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Desideri</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gentile</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Antonosante</surname><given-names>A</given-names></string-name>, et al. <article-title>Uric acid amplifies a&#946; amyloid effects involved in the cognitive dysfunction/dementia: evidences from an experimental model in vitro</article-title>. <source><italic toggle="yes">J Cell Physiol</italic></source>. <year>2017</year>;<volume>232</volume>(<issue>5</issue>):<fpage>1069</fpage>&#8211;<lpage>1078</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jcp.25509</pub-id><pub-id pub-id-type="pmid">27474828</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Shen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schwarzschild</surname><given-names>M</given-names></string-name>, et al. <article-title>Plasma urate concentrations and possible REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Ann Clin Transl Neurol</italic></source>. <year>2019</year>;<volume>6</volume>(<issue>12</issue>):<fpage>2368</fpage>&#8211;<lpage>2376</lpage>. doi:<pub-id pub-id-type="doi">10.1002/acn3.50929</pub-id><pub-id pub-id-type="pmid">31714690</pub-id><pub-id pub-id-type="pmcid">PMC6917330</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Otani</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Toyoda</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sakuma</surname><given-names>M</given-names></string-name>, et al. <article-title>Effects of uric acid on vascular endothelial function from bedside to bench</article-title>. <source><italic toggle="yes">Hypertens Res</italic></source>. <year>2018</year>;<volume>41</volume>(<issue>11</issue>):<fpage>923</fpage>&#8211;<lpage>931</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41440-018-0095-4</pub-id><pub-id pub-id-type="pmid">30185927</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>X</given-names></string-name>, et al. <article-title>Association of serum uric acid with all-cause and cardiovascular mortality in obstructive sleep apnea</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2023</year>;<volume>13</volume>(<issue>1</issue>):<fpage>19606</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-023-45508-2</pub-id><pub-id pub-id-type="pmid">37949893</pub-id><pub-id pub-id-type="pmcid">PMC10638300</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ghaemi-Oskouie</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>Y</given-names></string-name>. <article-title>The role of uric acid as an endogenous danger signal in immunity and inflammation</article-title>. <source><italic toggle="yes">Curr Rheumatol Rep</italic></source>. <year>2011</year>;<volume>13</volume>(<issue>2</issue>):<fpage>160</fpage>&#8211;<lpage>166</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11926-011-0162-1</pub-id><pub-id pub-id-type="pmid">21234729</pub-id><pub-id pub-id-type="pmcid">PMC3093438</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Eleftheriadis</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Pissas</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Sounidaki</surname><given-names>M</given-names></string-name>, et al. <article-title>Uric acid increases cellular and humoral alloimmunity in primary human peripheral blood mononuclear cells</article-title>. <source><italic toggle="yes">Nephrology</italic></source>. <year>2018</year>;<volume>23</volume>(<issue>7</issue>):<fpage>610</fpage>&#8211;<lpage>615</lpage>. doi:<pub-id pub-id-type="doi">10.1111/nep.13069</pub-id><pub-id pub-id-type="pmid">28477373</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>J</given-names></string-name>, et al. <article-title>Hyperuricemia and cardiovascular disease</article-title>. <source><italic toggle="yes">Curr Pharm Des</italic></source>. <year>2019</year>;<volume>25</volume>(<issue>6</issue>):<fpage>700</fpage>&#8211;<lpage>709</lpage>. doi:<pub-id pub-id-type="doi">10.2174/1381612825666190408122557</pub-id><pub-id pub-id-type="pmid">30961478</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Dai</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>G</given-names></string-name>, et al. <article-title>Association between sleep duration, sleep trouble and all-cause mortality in individuals with hyperuricemia in the United States</article-title>. <source><italic toggle="yes">Front Public Health</italic></source>. <year>2025</year>;<volume>13</volume>:<fpage>1521372</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fpubh.2025.1521372</pub-id><pub-id pub-id-type="pmid">40206179</pub-id><pub-id pub-id-type="pmcid">PMC11979105</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhao</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Luan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Z</given-names></string-name>, et al. <article-title>Low serum uric acid levels in chronic insomnia patients: a case-control study</article-title>. <source><italic toggle="yes">Neurosci Lett</italic></source>. <year>2017</year>;<volume>657</volume>:<fpage>102</fpage>&#8211;<lpage>105</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neulet.2017.08.015</pub-id><pub-id pub-id-type="pmid">28801272</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhou</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>L</given-names></string-name>, et al. <article-title>Low serum uric acid levels may be a potential biomarker of poor sleep quality in patients with Parkinson&#8217;s disease</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2023</year>;<volume>105</volume>:<fpage>9</fpage>&#8211;<lpage>13</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2023.03.011</pub-id><pub-id pub-id-type="pmid">36934617</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mao</surname><given-names>Y</given-names></string-name>. <article-title>Sleep architecture changes in diabetes</article-title>. <source><italic toggle="yes">J Clin Med</italic></source>. <year>2024</year>;<volume>13</volume>(<issue>22</issue>):<fpage>6851</fpage>. doi:<pub-id pub-id-type="doi">10.3390/jcm13226851</pub-id><pub-id pub-id-type="pmid">39597994</pub-id><pub-id pub-id-type="pmcid">PMC11594902</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Tasali</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Leproult</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ehrmann</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Van Cauter</surname><given-names>E</given-names></string-name>. <article-title>Slow-wave sleep and the risk of type 2 diabetes in humans</article-title>. <source><italic toggle="yes">Proc Natl Acad Sci USA</italic></source>. <year>2008</year>;<volume>105</volume>(<issue>3</issue>):<fpage>1044</fpage>&#8211;<lpage>1049</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0706446105</pub-id><pub-id pub-id-type="pmid">18172212</pub-id><pub-id pub-id-type="pmcid">PMC2242689</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chou</surname><given-names>Y-T</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C-H</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>W-C</given-names></string-name>, et al. <article-title>Association of sleep quality and sleep duration with serum uric acid levels in adults</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2020</year>;<volume>15</volume>(<issue>9</issue>):<fpage>e0239185</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0239185</pub-id><pub-id pub-id-type="pmid">32941519</pub-id><pub-id pub-id-type="pmcid">PMC7497980</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>H</given-names></string-name>, et al. <article-title>Association of sleep duration with hyperuricemia in Chinese adults: a prospective longitudinal study</article-title>. <source><italic toggle="yes">Int J Environ Res Public Health</italic></source>. <year>2022</year>;<volume>19</volume>(<issue>13</issue>). doi:<pub-id pub-id-type="doi">10.3390/ijerph19138105</pub-id><pub-id pub-id-type="pmcid">PMC9265381</pub-id><pub-id pub-id-type="pmid">35805762</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>You</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ablitip</surname><given-names>A</given-names></string-name>, et al. <article-title>&#8217;Life&#8217;s essential 8 and depression: a national cross-sectional analysis in US emerging adults</article-title>. <source><italic toggle="yes">J Adolesc Health</italic></source>. <year>2025</year>;<volume>77</volume>(<issue>1</issue>):<fpage>84</fpage>&#8211;<lpage>93</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jadohealth.2025.03.023</pub-id><pub-id pub-id-type="pmid">40445158</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>You</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>Q</given-names></string-name>. <article-title>Mitigation role of physical exercise participation in the relationship between blood cadmium and sleep disturbance: a cross-sectional study</article-title>. <source><italic toggle="yes">BMC Public Health</italic></source>. <year>2023</year>;<volume>23</volume>(<issue>1</issue>):<fpage>1465</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12889-023-16358-4</pub-id><pub-id pub-id-type="pmid">37525176</pub-id><pub-id pub-id-type="pmcid">PMC10391747</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zou</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>W</given-names></string-name>, et al. <article-title>Linear and non-linear Mendelian randomization analyses of sex-specific associations between sleep duration and hyperuricemia</article-title>. <source><italic toggle="yes">Front Nutr</italic></source>. <year>2022</year>;<volume>9</volume>:<fpage>920791</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fnut.2022.920791</pub-id><pub-id pub-id-type="pmid">36337652</pub-id><pub-id pub-id-type="pmcid">PMC9632753</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, et al. <article-title>Short sleep duration increases the risk of hyperuricemia among Chinese adults: findings from the china health and nutrition survey</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2021</year>;<volume>84</volume>:<fpage>40</fpage>&#8211;<lpage>45</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2021.05.014</pub-id><pub-id pub-id-type="pmid">34091320</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Baethge</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Goldbeck-Wood</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mertens</surname><given-names>S</given-names></string-name>. <article-title>SANRA&#8212;a scale for the quality assessment of narrative review articles</article-title>. <source><italic toggle="yes">Res Integrity Peer Rev</italic></source>. <year>2019</year>;<volume>4</volume>(<issue>1</issue>):<fpage>5</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s41073-019-0064-8</pub-id><pub-id pub-id-type="pmcid">PMC6434870</pub-id><pub-id pub-id-type="pmid">30962953</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sukhera</surname><given-names>J</given-names></string-name>. <article-title>Narrative reviews: flexible, rigorous, and practical</article-title>. <source><italic toggle="yes">J Grad Med Educ</italic></source>. <year>2022</year>;<volume>14</volume>(<issue>4</issue>):<fpage>414</fpage>&#8211;<lpage>417</lpage>. doi:<pub-id pub-id-type="doi">10.4300/jgme-d-22-00480.1</pub-id><pub-id pub-id-type="pmid">35991099</pub-id><pub-id pub-id-type="pmcid">PMC9380636</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, et al. <article-title>Relationship between night shift and sleep problems, risk of metabolic abnormalities of nurses: a 2 years follow-up retrospective analysis in the National Nurse Health Study (NNHS)</article-title>. <source><italic toggle="yes">Int Arch Occup Environ Health</italic></source>. <year>2023</year>;<volume>96</volume>(<issue>10</issue>):<fpage>1361</fpage>&#8211;<lpage>1371</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00420-023-02014-2</pub-id><pub-id pub-id-type="pmid">37874403</pub-id><pub-id pub-id-type="pmcid">PMC10635907</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hirotsu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tufik</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Guindalini</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mazzotti</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Bittencourt</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Andersen</surname><given-names>ML</given-names></string-name>. <article-title>Association between uric acid levels and obstructive sleep apnea syndrome in a large epidemiological sample</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2013</year>;<volume>8</volume>(<issue>6</issue>):<fpage>e66891</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0066891</pub-id><pub-id pub-id-type="pmid">23826169</pub-id><pub-id pub-id-type="pmcid">PMC3691311</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Oh</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>MK</given-names></string-name>, et al. <article-title>The association between shift work and hyperuricemia in steelmaking male workers</article-title>. <source><italic toggle="yes">Ann Occup Environ Med</italic></source>. <year>2014</year>;<volume>26</volume>(<issue>1</issue>):<fpage>42</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40557-014-0042-z</pub-id><pub-id pub-id-type="pmid">25551019</pub-id><pub-id pub-id-type="pmcid">PMC4280047</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></string-name>, et al. <article-title>Effect of serum uric acid on cognition in patients with idiopathic REM sleep behavior disorder</article-title>. <source><italic toggle="yes">J Neural Transm</italic></source>. <year>2018</year>;<volume>125</volume>(<issue>12</issue>):<fpage>1805</fpage>&#8211;<lpage>1812</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00702-018-1935-8</pub-id><pub-id pub-id-type="pmid">30284075</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, et al. <article-title>Daytime napping duration is positively associated with risk of hyperuricemia in a Chinese population</article-title>. <source><italic toggle="yes">J Clin Endocrinol Metab</italic></source>. <year>2021</year>;<volume>106</volume>(<issue>5</issue>):<fpage>e2096</fpage>&#8211;<lpage>e2105</lpage>. doi:<pub-id pub-id-type="doi">10.1210/clinem/dgab043</pub-id><pub-id pub-id-type="pmid">33507274</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Has&#237;kov&#225;</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Z&#225;vada</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Serranov&#225;</surname><given-names>T</given-names></string-name>, et al. <article-title>Patients with REM sleep behavior disorder have higher serum levels of allantoin</article-title>. <source><italic toggle="yes">Parkinsonism Relat Disord</italic></source>. <year>2021</year>;<volume>90</volume>:<fpage>38</fpage>&#8211;<lpage>43</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.parkreldis.2021.07.031</pub-id><pub-id pub-id-type="pmid">34352609</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sunadome</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Murase</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tabara</surname><given-names>Y</given-names></string-name>, et al. <article-title>Associations between sleep-disordered breathing and serum uric acid and their sex differences: the Nagahama study</article-title>. <source><italic toggle="yes">Nutrients</italic></source>. <year>2023</year>;<volume>15</volume>(<issue>19</issue>):<fpage>4237</fpage>. doi:<pub-id pub-id-type="doi">10.3390/nu15194237</pub-id><pub-id pub-id-type="pmid">37836522</pub-id><pub-id pub-id-type="pmcid">PMC10574205</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Park</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bak</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>KA</given-names></string-name>. <article-title>Association between obstructive sleep apnea and hyperuricemia/gout in the general population: a cross-sectional study</article-title>. <source><italic toggle="yes">BMC Musculoskelet Disord</italic></source>. <year>2025</year>;<volume>26</volume>(<issue>1</issue>):<fpage>14</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12891-024-08264-6</pub-id><pub-id pub-id-type="pmid">39754080</pub-id><pub-id pub-id-type="pmcid">PMC11697859</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Furuhashi</surname><given-names>M</given-names></string-name>. <article-title>New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity</article-title>. <source><italic toggle="yes">Am J Physiol Endocrinol Metab</italic></source>. <year>2020</year>;<volume>319</volume>(<issue>5</issue>):<fpage>E827</fpage>&#8211;<lpage>e834</lpage>. doi:<pub-id pub-id-type="doi">10.1152/ajpendo.00378.2020</pub-id><pub-id pub-id-type="pmid">32893671</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kimura</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yanagida</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Onda</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tsukui</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hosoyamada</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kono</surname><given-names>H</given-names></string-name>. <article-title>Soluble Uric Acid Promotes Atherosclerosis via AMPK (AMP-activated protein kinase)-mediated inflammation</article-title>. <source><italic toggle="yes">Arterioscler Thromb Vasc Biol</italic></source>. <year>2020</year>;<volume>40</volume>(<issue>3</issue>):<fpage>570</fpage>&#8211;<lpage>582</lpage>. doi:<pub-id pub-id-type="doi">10.1161/atvbaha.119.313224</pub-id><pub-id pub-id-type="pmid">31996020</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Nanduri</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vaddi</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>SA</given-names></string-name>, et al. <article-title>HIF-1&#945; activation by intermittent hypoxia requires NADPH oxidase stimulation by xanthine oxidase</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2015</year>;<volume>10</volume>(<issue>3</issue>):<fpage>e0119762</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0119762</pub-id><pub-id pub-id-type="pmid">25751622</pub-id><pub-id pub-id-type="pmcid">PMC4353619</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="expression-of-concern" ext-link-type="pmc" xlink:href="PMC10866470"/></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>So</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Thorens</surname><given-names>B</given-names></string-name>. <article-title>Uric acid transport and disease</article-title>. <source><italic toggle="yes">J Clin Invest</italic></source>. <year>2010</year>;<volume>120</volume>(<issue>6</issue>):<fpage>1791</fpage>&#8211;<lpage>1799</lpage>. doi:<pub-id pub-id-type="doi">10.1172/jci42344</pub-id><pub-id pub-id-type="pmid">20516647</pub-id><pub-id pub-id-type="pmcid">PMC2877959</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ni</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Niu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Guan</surname><given-names>H</given-names></string-name>. <article-title>Low serum uric acid levels are associated with incidence and severity in trigeminal neuralgia</article-title>. <source><italic toggle="yes">Neurol Sci</italic></source>. <year>2022</year>;<volume>43</volume>(<issue>10</issue>):<fpage>6053</fpage>&#8211;<lpage>6058</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10072-022-06223-4</pub-id><pub-id pub-id-type="pmid">35737186</pub-id></mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Alrouji</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Al-Kuraishy</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Al-Gareeb</surname><given-names>AI</given-names></string-name>, et al. <article-title>Role of uric acid in neurodegenerative diseases, focusing on Alzheimer and Parkinson disease: a new perspective</article-title>. <source><italic toggle="yes">Neuropsychopharmacol Rep</italic></source>. <year>2024</year>;<volume>44</volume>(<issue>3</issue>):<fpage>639</fpage>&#8211;<lpage>649</lpage>. doi:<pub-id pub-id-type="doi">10.1002/npr2.12445</pub-id><pub-id pub-id-type="pmid">39075837</pub-id><pub-id pub-id-type="pmcid">PMC11544450</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Du</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, et al. <article-title>Hyperuricemia and its related diseases: mechanisms and advances in therapy</article-title>. <source><italic toggle="yes">Signal Transduct Target Ther</italic></source>. <year>2024</year>;<volume>9</volume>(<issue>1</issue>):<fpage>212</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41392-024-01916-y</pub-id><pub-id pub-id-type="pmid">39191722</pub-id><pub-id pub-id-type="pmcid">PMC11350024</pub-id></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yanai</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Adachi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hakoshima</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Katsuyama</surname><given-names>H</given-names></string-name>. <article-title>Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease</article-title>. <source><italic toggle="yes">Int J Mol Sci</italic></source>. <year>2021</year>;<volume>22</volume>(<issue>17</issue>):<fpage>9221</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms22179221</pub-id><pub-id pub-id-type="pmid">34502127</pub-id><pub-id pub-id-type="pmcid">PMC8431537</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lou</surname><given-names>F</given-names></string-name>. <article-title>Changes in blood glucose and metabolism in hyperuricemia mice</article-title>. <source><italic toggle="yes">Open Life Sci</italic></source>. <year>2025</year>;<volume>20</volume>(<issue>1</issue>):<fpage>20221057</fpage>. doi:<pub-id pub-id-type="doi">10.1515/biol-2022-1057</pub-id><pub-id pub-id-type="pmid">40092731</pub-id><pub-id pub-id-type="pmcid">PMC11909573</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Miake</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hisatome</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Tomita</surname><given-names>K</given-names></string-name>, et al. <article-title>Impact of hyper- and hypo-uricemia on kidney function</article-title>. <source><italic toggle="yes">Biomedicines</italic></source>. <year>2023</year>;<volume>11</volume>(<issue>5</issue>):<fpage>1258</fpage>. doi:<pub-id pub-id-type="doi">10.3390/biomedicines11051258</pub-id><pub-id pub-id-type="pmid">37238929</pub-id><pub-id pub-id-type="pmcid">PMC10215381</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Xu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wan</surname><given-names>T</given-names></string-name>, et al. <article-title>Targeting uric acid: a promising intervention against oxidative stress and neuroinflammation in neurodegenerative diseases</article-title>. <source><italic toggle="yes">Cell Commun Signal</italic></source>. <year>2025</year>;<volume>23</volume>(<issue>1</issue>):<fpage>4</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12964-024-01965-4</pub-id><pub-id pub-id-type="pmid">39754256</pub-id><pub-id pub-id-type="pmcid">PMC11699683</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Fang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>XF</given-names></string-name>. <article-title>A double-edged sword: uric acid and neurological disorders</article-title>. <source><italic toggle="yes">Brain Disord Ther</italic></source>. <year>2013</year>;<volume>2</volume>(<issue>2</issue>):<fpage>109</fpage>. doi:<pub-id pub-id-type="doi">10.4172/2168-975x.1000109</pub-id><pub-id pub-id-type="pmid">24511458</pub-id><pub-id pub-id-type="pmcid">PMC3914730</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Shao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>F</given-names></string-name>, et al. <article-title>Uric acid induces cognitive dysfunction through hippocampal inflammation in rodents and humans</article-title>. <source><italic toggle="yes">J Neurosci</italic></source>. <year>2016</year>;<volume>36</volume>(<issue>43</issue>):<fpage>10990</fpage>&#8211;<lpage>11005</lpage>. doi:<pub-id pub-id-type="doi">10.1523/jneurosci.1480-16.2016</pub-id><pub-id pub-id-type="pmid">27798180</pub-id><pub-id pub-id-type="pmcid">PMC6705652</pub-id></mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gulec</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ozkol</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Selvi</surname><given-names>Y</given-names></string-name>, et al. <article-title>Oxidative stress in patients with primary insomnia</article-title>. <source><italic toggle="yes">Prog Neuropsychopharmacol Biol Psychiatry</italic></source>. <year>2012</year>;<volume>37</volume>(<issue>2</issue>):<fpage>247</fpage>&#8211;<lpage>251</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pnpbp.2012.02.011</pub-id><pub-id pub-id-type="pmid">22401887</pub-id></mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Leira</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Planas</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Chauhan</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Chamorro</surname><given-names>A</given-names></string-name>. <article-title>Uric acid: a translational journey in cerebroprotection that spanned preclinical and human data</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2023</year>;<volume>101</volume>(<issue>23</issue>):<fpage>1068</fpage>&#8211;<lpage>1074</lpage>. doi:<pub-id pub-id-type="doi">10.1212/wnl.0000000000207825</pub-id><pub-id pub-id-type="pmid">37848338</pub-id><pub-id pub-id-type="pmcid">PMC10752646</pub-id></mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kanemitsu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tsurudome</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kusunose</surname><given-names>N</given-names></string-name>, et al. <article-title>Periodic variation in bile acids controls circadian changes in uric acid via regulation of xanthine oxidase by the orphan nuclear receptor PPAR&#945;</article-title>. <source><italic toggle="yes">J Biol Chem</italic></source>. <year>2017</year>;<volume>292</volume>(<issue>52</issue>):<fpage>21397</fpage>&#8211;<lpage>21406</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M117.791285</pub-id><pub-id pub-id-type="pmid">29101234</pub-id><pub-id pub-id-type="pmcid">PMC5766946</pub-id></mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Schlesinger</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Brunetti</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Androulakis</surname><given-names>IP</given-names></string-name>. <article-title>Does seasonality of the microbiota contribute to the seasonality of acute gout flare?</article-title><source><italic toggle="yes">Clin Exp Rheumatol</italic></source>. <year>2022</year>;<volume>40</volume>(<issue>9</issue>):<fpage>1793</fpage>&#8211;<lpage>1800</lpage>. doi:<pub-id pub-id-type="doi">10.55563/clinexprheumatol/hdtge7</pub-id><pub-id pub-id-type="pmid">35383564</pub-id><pub-id pub-id-type="pmcid">PMC9869072</pub-id></mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Popov</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Alhilali</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dalbeth</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Poulsen</surname><given-names>RC</given-names></string-name>. <article-title>Monosodium urate crystals alter the circadian clock in macrophages leading to loss of NLRP3 inflammasome repression: implications for timing of the gout flare</article-title>. <source><italic toggle="yes">FASEB j</italic></source>. <year>2023</year>;<volume>37</volume>(<issue>6</issue>):<fpage>e22940</fpage>. doi:<pub-id pub-id-type="doi">10.1096/fj.202202035R</pub-id><pub-id pub-id-type="pmid">37243314</pub-id></mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Irwin</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Olmstead</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Carroll</surname><given-names>JE</given-names></string-name>. <article-title>Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis of cohort studies and experimental sleep deprivation</article-title>. <source><italic toggle="yes">Biol Psychiatry</italic></source>. <year>2016</year>;<volume>80</volume>(<issue>1</issue>):<fpage>40</fpage>&#8211;<lpage>52</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biopsych.2015.05.014</pub-id><pub-id pub-id-type="pmid">26140821</pub-id><pub-id pub-id-type="pmcid">PMC4666828</pub-id></mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Krueger</surname><given-names>JM</given-names></string-name>. <article-title>The role of cytokines in sleep regulation</article-title>. <source><italic toggle="yes">Curr Pharm Des</italic></source>. <year>2008</year>;<volume>14</volume>(<issue>32</issue>):<fpage>3408</fpage>&#8211;<lpage>3416</lpage>. doi:<pub-id pub-id-type="doi">10.2174/138161208786549281</pub-id><pub-id pub-id-type="pmid">19075717</pub-id><pub-id pub-id-type="pmcid">PMC2692603</pub-id></mixed-citation></ref><ref id="cit0051"><label>51.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Davinelli</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Medoro</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Savino</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Scapagnini</surname><given-names>G</given-names></string-name>. <article-title>Sleep and oxidative stress: current perspectives on the role of NRF2</article-title>. <source><italic toggle="yes">Cell Mol Neurobiol</italic></source>. <year>2024</year>;<volume>44</volume>(<issue>1</issue>):<fpage>52</fpage>. doi:<pub-id pub-id-type="doi">10.1007/s10571-024-01487-0</pub-id><pub-id pub-id-type="pmid">38916679</pub-id><pub-id pub-id-type="pmcid">PMC11199221</pub-id></mixed-citation></ref><ref id="cit0052"><label>52.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>An</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>. <article-title>Association between oxidative balance score and serum uric acid and hyperuricemia: a population-based study from the NHANES (2011&#8211;2018)</article-title>. <source><italic toggle="yes">Front Endocrinol</italic></source>. <year>2024</year>;<volume>15</volume>:<fpage>1414075</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fendo.2024.1414075</pub-id><pub-id pub-id-type="pmcid">PMC11222604</pub-id><pub-id pub-id-type="pmid">38966221</pub-id></mixed-citation></ref><ref id="cit0053"><label>53.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Tao</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>. <article-title>High serum uric acid level in adolescent depressive patients</article-title>. <source><italic toggle="yes">J Affect Disord</italic></source>. <year>2015</year>;<volume>174</volume>:<fpage>464</fpage>&#8211;<lpage>466</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jad.2014.12.031</pub-id><pub-id pub-id-type="pmid">25553407</pub-id></mixed-citation></ref><ref id="cit0054"><label>54.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ressler</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Nemeroff</surname><given-names>CB</given-names></string-name>. <article-title>Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders</article-title>. <source><italic toggle="yes">Depress Anxiety</italic></source>. <year>2000</year>;<volume>12</volume>(<issue>Suppl 1</issue>):<fpage>2</fpage>&#8211;<lpage>19</lpage>. doi:<pub-id pub-id-type="doi">10.1002/1520-6394(2000)12</pub-id><pub-id pub-id-type="pmid">11098410</pub-id></mixed-citation></ref><ref id="cit0055"><label>55.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mehta</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>B&#243;kkon</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Nath Mallick</surname><given-names>B</given-names></string-name>. <article-title>REM sleep and its loss-associated epigenetic regulation with reference to noradrenaline in particular</article-title>. <source><italic toggle="yes">Curr Neuropharmacol</italic></source>. <year>2016</year>;<volume>14</volume>(<issue>1</issue>):<fpage>28</fpage>&#8211;<lpage>40</lpage>. doi:<pub-id pub-id-type="doi">10.2174/1570159x13666150414185737</pub-id><pub-id pub-id-type="pmid">26813120</pub-id><pub-id pub-id-type="pmcid">PMC4787282</pub-id></mixed-citation></ref><ref id="cit0056"><label>56.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Radwan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chaudhury</surname><given-names>D</given-names></string-name>. <article-title>The role of dopamine in mood disorders and the associated changes in circadian rhythms and sleep-wake cycle</article-title>. <source><italic toggle="yes">Brain Res</italic></source>. <year>2019</year>;<volume>1713</volume>:<fpage>42</fpage>&#8211;<lpage>51</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.brainres.2018.11.031</pub-id><pub-id pub-id-type="pmid">30481503</pub-id></mixed-citation></ref><ref id="cit0057"><label>57.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Herzig</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shaw</surname><given-names>RJ</given-names></string-name>. <article-title>AMPK: guardian of metabolism and mitochondrial homeostasis</article-title>. <source><italic toggle="yes">Nat Rev Mol Cell Biol</italic></source>. <year>2018</year>;<volume>19</volume>(<issue>2</issue>):<fpage>121</fpage>&#8211;<lpage>135</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrm.2017.95</pub-id><pub-id pub-id-type="pmid">28974774</pub-id><pub-id pub-id-type="pmcid">PMC5780224</pub-id></mixed-citation></ref><ref id="cit0058"><label>58.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cicerchi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kratzer</surname><given-names>J</given-names></string-name>, et al. <article-title>Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids</article-title>. <source><italic toggle="yes">FASEB j</italic></source>. <year>2014</year>;<volume>28</volume>(<issue>8</issue>):<fpage>3339</fpage>&#8211;<lpage>3350</lpage>. doi:<pub-id pub-id-type="doi">10.1096/fj.13-243634</pub-id><pub-id pub-id-type="pmid">24755741</pub-id><pub-id pub-id-type="pmcid">PMC4101654</pub-id></mixed-citation></ref><ref id="cit0059"><label>59.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chikahisa</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fujiki</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kitaoka</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Shimizu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>S&#233;i</surname><given-names>H</given-names></string-name>. <article-title>Central AMPK contributes to sleep homeostasis in mice</article-title>. <source><italic toggle="yes">Neuropharmacology</italic></source>. <year>2009</year>;<volume>57</volume>(<issue>4</issue>):<fpage>369</fpage>&#8211;<lpage>374</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuropharm.2009.07.015</pub-id><pub-id pub-id-type="pmid">19615388</pub-id></mixed-citation></ref><ref id="cit0060"><label>60.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Jung</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Akber</surname><given-names>U</given-names></string-name>, et al. <article-title>Enhanced homeostatic sleep response and decreased neurodegenerative proteins in cereblon knock-out mice</article-title>. <source><italic toggle="yes">Commun Biol</italic></source>. <year>2024</year>;<volume>7</volume>(<issue>1</issue>):<fpage>1218</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s42003-024-06879-y</pub-id><pub-id pub-id-type="pmid">39349747</pub-id><pub-id pub-id-type="pmcid">PMC11442454</pub-id></mixed-citation></ref><ref id="cit0061"><label>61.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cho</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Kwon</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jung</surname><given-names>J</given-names></string-name>, et al. <article-title>AMP-activated protein kinase regulates circadian rhythm by affecting CLOCK in drosophila</article-title>. <source><italic toggle="yes">J Neurosci</italic></source>. <year>2019</year>;<volume>39</volume>(<issue>18</issue>):<fpage>3537</fpage>&#8211;<lpage>3550</lpage>. doi:<pub-id pub-id-type="doi">10.1523/jneurosci.2344-18.2019</pub-id><pub-id pub-id-type="pmid">30819799</pub-id><pub-id pub-id-type="pmcid">PMC6495122</pub-id></mixed-citation></ref><ref id="cit0062"><label>62.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cab&#259;u</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Cri&#537;an</surname><given-names>TO</given-names></string-name>, <string-name name-style="western"><surname>Kl&#252;ck</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Popp</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Joosten</surname><given-names>LAB</given-names></string-name>. <article-title>Urate-induced immune programming: consequences for gouty arthritis and hyperuricemia</article-title>. <source><italic toggle="yes">Immunol Rev</italic></source>. <year>2020</year>;<volume>294</volume>(<issue>1</issue>):<fpage>92</fpage>&#8211;<lpage>105</lpage>. doi:<pub-id pub-id-type="doi">10.1111/imr.12833</pub-id><pub-id pub-id-type="pmid">31853991</pub-id><pub-id pub-id-type="pmcid">PMC7065123</pub-id></mixed-citation></ref><ref id="cit0063"><label>63.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Badii</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gaal</surname><given-names>OI</given-names></string-name>, <string-name name-style="western"><surname>Cleophas</surname><given-names>MC</given-names></string-name>, et al. <article-title>Urate-induced epigenetic modifications in myeloid cells</article-title>. <source><italic toggle="yes">Arthritis Res Ther</italic></source>. <year>2021</year>;<volume>23</volume>(<issue>1</issue>):<fpage>202</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13075-021-02580-1</pub-id><pub-id pub-id-type="pmid">34321071</pub-id><pub-id pub-id-type="pmcid">PMC8317351</pub-id></mixed-citation></ref><ref id="cit0064"><label>64.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Beik-Khormizi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zare-Khormizi</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Firoozabadi</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Vakili</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hekmatimoghaddam</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pourrajab</surname><given-names>F</given-names></string-name>. <article-title>Alteration in epigenetic profile in subclinical atherosclerosis and in high uric acid</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2025</year>;<volume>15</volume>(<issue>1</issue>):<fpage>21079</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-025-06842-9</pub-id><pub-id pub-id-type="pmid">40594862</pub-id><pub-id pub-id-type="pmcid">PMC12214968</pub-id></mixed-citation></ref><ref id="cit0065"><label>65.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mijailovic</surname><given-names>NR</given-names></string-name>, <string-name name-style="western"><surname>Vesic</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Borovcanin</surname><given-names>MM</given-names></string-name>. <article-title>The influence of serum uric acid on the brain and cognitive dysfunction</article-title>. <source><italic toggle="yes">Front Psychiatry</italic></source>. <year>2022</year>;<volume>13</volume>:<fpage>828476</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fpsyt.2022.828476</pub-id><pub-id pub-id-type="pmid">35530021</pub-id><pub-id pub-id-type="pmcid">PMC9072620</pub-id></mixed-citation></ref><ref id="cit0066"><label>66.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wu</surname><given-names>YL</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>ZJ</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>CC</given-names></string-name>, et al. <article-title>Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study</article-title>. <source><italic toggle="yes">Signal Transduct Target Ther</italic></source>. <year>2023</year>;<volume>8</volume>(<issue>1</issue>):<fpage>98</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41392-023-01333-7</pub-id><pub-id pub-id-type="pmid">36864020</pub-id><pub-id pub-id-type="pmcid">PMC9981733</pub-id></mixed-citation></ref><ref id="cit0067"><label>67.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ni</surname><given-names>Y</given-names></string-name>, et al. <article-title>Histone modifications and their roles in macrophage-mediated inflammation: a new target for diabetic wound healing</article-title>. <source><italic toggle="yes">Front Immunol</italic></source>. <year>2024</year>;<volume>15</volume>:<fpage>1450440</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2024.1450440</pub-id><pub-id pub-id-type="pmid">39229271</pub-id><pub-id pub-id-type="pmcid">PMC11368794</pub-id></mixed-citation></ref><ref id="cit0068"><label>68.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ramos-Lopez</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Milagro</surname><given-names>FI</given-names></string-name>, <string-name name-style="western"><surname>Riezu-Boj</surname><given-names>JI</given-names></string-name>, <string-name name-style="western"><surname>Martinez</surname><given-names>JA</given-names></string-name>. <article-title>Epigenetic signatures underlying inflammation: an interplay of nutrition, physical activity, metabolic diseases, and environmental factors for personalized nutrition</article-title>. <source><italic toggle="yes">Inflamm Res</italic></source>. <year>2021</year>;<volume>70</volume>(<issue>1</issue>):<fpage>29</fpage>&#8211;<lpage>49</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00011-020-01425-y</pub-id><pub-id pub-id-type="pmid">33231704</pub-id><pub-id pub-id-type="pmcid">PMC7684853</pub-id></mixed-citation></ref><ref id="cit0069"><label>69.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>de Bari</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Scir&#232;</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Minnelli</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cianfruglia</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kalapos</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Armeni</surname><given-names>T</given-names></string-name>. <article-title>Interplay among oxidative stress, methylglyoxal pathway and S-Glutathionylation</article-title>. <source><italic toggle="yes">Antioxidants</italic></source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>). doi:<pub-id pub-id-type="doi">10.3390/antiox10010019</pub-id><pub-id pub-id-type="pmcid">PMC7824032</pub-id><pub-id pub-id-type="pmid">33379155</pub-id></mixed-citation></ref><ref id="cit0070"><label>70.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Saka</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Akhigbe</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Abidoye</surname><given-names>AO</given-names></string-name>, <string-name name-style="western"><surname>Dare</surname><given-names>OS</given-names></string-name>, <string-name name-style="western"><surname>Adekunle</surname><given-names>AO</given-names></string-name>. <article-title>Suppression of uric acid generation and blockade of glutathione dysregulation by L-arginine ameliorates dichlorvos-induced oxidative hepatorenal damage in rats</article-title>. <source><italic toggle="yes">Biomed Pharmacother</italic></source>. <year>2021</year>;<volume>138</volume>:<fpage>111443</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biopha.2021.111443</pub-id><pub-id pub-id-type="pmid">33667786</pub-id></mixed-citation></ref><ref id="cit0071"><label>71.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, et al. <article-title>Accumulation of renal fibrosis in hyperuricemia rats is attributed to the recruitment of mast cells, activation of the TGF-&#946;1/Smad2/3 pathway, and aggravation of oxidative stress</article-title>. <source><italic toggle="yes">Int J Mol Sci</italic></source>. <year>2023</year>;<volume>24</volume>(<issue>13</issue>). doi:<pub-id pub-id-type="doi">10.3390/ijms241310839</pub-id><pub-id pub-id-type="pmcid">PMC10341566</pub-id><pub-id pub-id-type="pmid">37446016</pub-id></mixed-citation></ref><ref id="cit0072"><label>72.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Do&#287;ru</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ya&#351;ar</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ye&#351;ilkaya</surname><given-names>A</given-names></string-name>. <article-title>Uric acid can enhance MAPK pathway-mediated proliferation in rat primary vascular smooth muscle cells via controlling of mitochondria and caspase-dependent cell death</article-title>. <source><italic toggle="yes">J Recept Signal Transduction Res</italic></source>. <year>2022</year>;<volume>42</volume>(<issue>3</issue>):<fpage>293</fpage>&#8211;<lpage>301</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10799893.2021.1931320</pub-id><pub-id pub-id-type="pmid">34057027</pub-id></mixed-citation></ref><ref id="cit0073"><label>73.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sun</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>H</given-names></string-name>, et al. <article-title>TCM and related active compounds in the treatment of gout: the regulation of signaling pathway and urate transporter</article-title>. <source><italic toggle="yes">Front Pharmacol</italic></source>. <year>2023</year>;<volume>14</volume>:<fpage>1275974</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fphar.2023.1275974</pub-id><pub-id pub-id-type="pmid">38094893</pub-id><pub-id pub-id-type="pmcid">PMC10716793</pub-id></mixed-citation></ref><ref id="cit0074"><label>74.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chouchou</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Desseilles</surname><given-names>M</given-names></string-name>. <article-title>Heart rate variability: a tool to explore the sleeping brain?</article-title><source><italic toggle="yes">Front Neurosci</italic></source>. <year>2014</year>;<volume>8</volume>:<fpage>402</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fnins.2014.00402</pub-id><pub-id pub-id-type="pmid">25565936</pub-id><pub-id pub-id-type="pmcid">PMC4263095</pub-id></mixed-citation></ref><ref id="cit0075"><label>75.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Shaw</surname><given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>McHill</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Schiavon</surname><given-names>M</given-names></string-name>, et al. <article-title>Effect of slow wave sleep disruption on metabolic parameters in adolescents</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2016</year>;<volume>39</volume>(<issue>8</issue>):<fpage>1591</fpage>&#8211;<lpage>1599</lpage>. doi:<pub-id pub-id-type="doi">10.5665/sleep.6028</pub-id><pub-id pub-id-type="pmid">27166229</pub-id><pub-id pub-id-type="pmcid">PMC4945319</pub-id></mixed-citation></ref><ref id="cit0076"><label>76.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Portas</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Krakow</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Allen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Josephs</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Armony</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Frith</surname><given-names>CD</given-names></string-name>. <article-title>Auditory processing across the sleep-wake cycle: simultaneous EEG and fMRI monitoring in humans</article-title>. <source><italic toggle="yes">Neuron</italic></source>. <year>2000</year>;<volume>28</volume>(<issue>3</issue>):<fpage>991</fpage>&#8211;<lpage>999</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0896-6273(00)00169-0</pub-id><pub-id pub-id-type="pmid">11163282</pub-id></mixed-citation></ref><ref id="cit0077"><label>77.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kakigi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Naka</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Okusa</surname><given-names>T</given-names></string-name>, et al. <article-title>Sensory perception during sleep in humans: a magnetoencephalograhic study</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2003</year>;<volume>4</volume>(<issue>6</issue>):<fpage>493</fpage>&#8211;<lpage>507</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s1389-9457(03)00169-2</pub-id><pub-id pub-id-type="pmid">14607343</pub-id></mixed-citation></ref><ref id="cit0078"><label>78.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hong</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Yoon</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Yoo</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>J</given-names></string-name>. <article-title>The effect of sleep disruption on cardiometabolic health</article-title>. <source><italic toggle="yes">Life (Basel)</italic></source>. <year>2025</year>;<volume>15</volume>(<issue>1</issue>). doi:<pub-id pub-id-type="doi">10.3390/life15010060</pub-id><pub-id pub-id-type="pmcid">PMC11766988</pub-id><pub-id pub-id-type="pmid">39860000</pub-id></mixed-citation></ref><ref id="cit0079"><label>79.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Brian&#231;on-Marjollet</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Weiszenstein</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Henri</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Godin-Ribuot</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Polak</surname><given-names>J</given-names></string-name>. <article-title>The impact of sleep disorders on glucose metabolism: endocrine and molecular mechanisms</article-title>. <source><italic toggle="yes">Diabetol Metab Syndr</italic></source>. <year>2015</year>;<volume>7</volume>:<fpage>25</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13098-015-0018-3</pub-id><pub-id pub-id-type="pmid">25834642</pub-id><pub-id pub-id-type="pmcid">PMC4381534</pub-id></mixed-citation></ref><ref id="cit0080"><label>80.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Nowak</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gaisl</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Miladinovic</surname><given-names>D</given-names></string-name>, et al. <article-title>Rapid and reversible control of human metabolism by individual sleep states</article-title>. <source><italic toggle="yes">Cell Rep</italic></source>. <year>2021</year>;<volume>37</volume>(<issue>4</issue>):<fpage>109903</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.celrep.2021.109903</pub-id><pub-id pub-id-type="pmid">34706242</pub-id></mixed-citation></ref><ref id="cit0081"><label>81.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>YB</given-names></string-name>, et al. <article-title>Alterations of the gut microbiota in response to total sleep deprivation and recovery sleep in rats</article-title>. <source><italic toggle="yes">Nat Sci Sleep</italic></source>. <year>2022</year>;<volume>14</volume>:<fpage>121</fpage>&#8211;<lpage>133</lpage>. doi:<pub-id pub-id-type="doi">10.2147/nss.S334985</pub-id><pub-id pub-id-type="pmid">35115853</pub-id><pub-id pub-id-type="pmcid">PMC8800865</pub-id></mixed-citation></ref><ref id="cit0082"><label>82.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Tong</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>Q</given-names></string-name>, et al. <article-title>The role of gut microbiota in gout: is gut microbiota a potential target for gout treatment</article-title>. <source><italic toggle="yes">Front Cell Infect Microbiol</italic></source>. <year>2022</year>;<volume>12</volume>:<fpage>1051682</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fcimb.2022.1051682</pub-id><pub-id pub-id-type="pmid">36506033</pub-id><pub-id pub-id-type="pmcid">PMC9730829</pub-id></mixed-citation></ref><ref id="cit0083"><label>83.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hurtado-Alvarado</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Dom&#237;nguez-Salazar</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Pavon</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Vel&#225;zquez-Moctezuma</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>G&#243;mez-Gonz&#225;lez</surname><given-names>B</given-names></string-name>. <article-title>Blood-brain barrier disruption induced by chronic sleep loss: low-grade inflammation may be the link</article-title>. <source><italic toggle="yes">J Immunol Res</italic></source>. <year>2016</year>;<volume>2016</volume>:<fpage>4576012</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2016/4576012</pub-id><pub-id pub-id-type="pmid">27738642</pub-id><pub-id pub-id-type="pmcid">PMC5050358</pub-id></mixed-citation></ref><ref id="cit0084"><label>84.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Tian</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>XR</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>TT</given-names></string-name>, et al. <article-title>Detrimental effects of long-term elevated serum uric acid on cognitive function in rats</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>6732</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-021-86279-y</pub-id><pub-id pub-id-type="pmid">33762656</pub-id><pub-id pub-id-type="pmcid">PMC7991666</pub-id></mixed-citation></ref><ref id="cit0085"><label>85.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zipp</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bittner</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Schafer</surname><given-names>DP</given-names></string-name>. <article-title>Cytokines as emerging regulators of central nervous system synapses</article-title>. <source><italic toggle="yes">Immunity</italic></source>. <year>2023</year>;<volume>56</volume>(<issue>5</issue>):<fpage>914</fpage>&#8211;<lpage>925</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.immuni.2023.04.011</pub-id><pub-id pub-id-type="pmid">37163992</pub-id><pub-id pub-id-type="pmcid">PMC10233069</pub-id></mixed-citation></ref><ref id="cit0086"><label>86.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sharma</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kavuru</surname><given-names>M</given-names></string-name>. <article-title>Sleep and metabolism: an overview</article-title>. <source><italic toggle="yes">Int J Endocrinol</italic></source>. <year>2010</year>;<volume>2010</volume>:<fpage>1</fpage>&#8211;<lpage>12</lpage>. doi:<pub-id pub-id-type="doi">10.1155/2010/270832</pub-id><pub-id pub-id-type="pmcid">PMC2929498</pub-id><pub-id pub-id-type="pmid">20811596</pub-id></mixed-citation></ref><ref id="cit0087"><label>87.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kayaba</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Iwayama</surname><given-names>K</given-names></string-name>, et al. <article-title>Energy metabolism differs between sleep stages and begins to increase prior to awakening</article-title>. <source><italic toggle="yes">Metabolism</italic></source>. <year>2017</year>;<volume>69</volume>:<fpage>14</fpage>&#8211;<lpage>23</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.metabol.2016.12.016</pub-id><pub-id pub-id-type="pmid">28285643</pub-id></mixed-citation></ref><ref id="cit0088"><label>88.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bonsignore</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Mazzuca</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Baiamonte</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bouckaert</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Verbeke</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Pevernagie</surname><given-names>DA</given-names></string-name>. <article-title>REM sleep obstructive sleep apnoea</article-title>. <source><italic toggle="yes">Eur Respir Rev</italic></source>. <year>2024</year>;<volume>33</volume>(<issue>171</issue>):<fpage>230166</fpage>. doi:<pub-id pub-id-type="doi">10.1183/16000617.0166-2023</pub-id><pub-id pub-id-type="pmid">38355150</pub-id><pub-id pub-id-type="pmcid">PMC10865098</pub-id></mixed-citation></ref><ref id="cit0089"><label>89.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sweed</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Bedair</surname><given-names>GMM</given-names></string-name>, <string-name name-style="western"><surname>Shaban</surname><given-names>AY</given-names></string-name>, <string-name name-style="western"><surname>Shaarwy</surname><given-names>HA</given-names></string-name>. <article-title>Correlation between serum uric acid and pulmonary arterial hypertension based on echo probability in patients with obstructive sleep apnea syndrome</article-title>. <source><italic toggle="yes">Egypt J Bronchol</italic></source>. <year>2023</year>;<volume>17</volume>(<issue>1</issue>):<fpage>49</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s43168-023-00219-0</pub-id></mixed-citation></ref><ref id="cit0090"><label>90.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>H</given-names></string-name>. <article-title>Gout and diet: a comprehensive review of mechanisms and management</article-title>. <source><italic toggle="yes">Nutrients</italic></source>. <year>2022</year>;<volume>14</volume>(<issue>17</issue>). doi:<pub-id pub-id-type="doi">10.3390/nu14173525</pub-id><pub-id pub-id-type="pmcid">PMC9459802</pub-id><pub-id pub-id-type="pmid">36079783</pub-id></mixed-citation></ref><ref id="cit0091"><label>91.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>TY</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>TY</given-names></string-name>, et al. <article-title>Pro-inflammatory diets promote the formation of hyperuricemia</article-title>. <source><italic toggle="yes">Front Endocrinol</italic></source>. <year>2024</year>;<volume>15</volume>:<fpage>1398917</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fendo.2024.1398917</pub-id><pub-id pub-id-type="pmcid">PMC11224156</pub-id><pub-id pub-id-type="pmid">38974578</pub-id></mixed-citation></ref><ref id="cit0092"><label>92.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gardiner</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Weakley</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Burke</surname><given-names>LM</given-names></string-name>, et al. <article-title>The effect of caffeine on subsequent sleep: a systematic review and meta-analysis</article-title>. <source><italic toggle="yes">Sleep Med Rev</italic></source>. <year>2023</year>;<volume>69</volume>:<fpage>101764</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smrv.2023.101764</pub-id><pub-id pub-id-type="pmid">36870101</pub-id></mixed-citation></ref><ref id="cit0093"><label>93.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>S</given-names></string-name>. <article-title>Exercise and hyperuricemia: an opinion article</article-title>. <source><italic toggle="yes">Ann Med</italic></source>. <year>2024</year>;<volume>56</volume>(<issue>1</issue>):<fpage>2396075</fpage>. doi:<pub-id pub-id-type="doi">10.1080/07853890.2024.2396075</pub-id><pub-id pub-id-type="pmid">39183708</pub-id><pub-id pub-id-type="pmcid">PMC11348809</pub-id></mixed-citation></ref><ref id="cit0094"><label>94.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Qiu</surname><given-names>S</given-names></string-name>. <article-title>Association between regular exercise and urinary uric acid excretion in chinese adults: a cross-sectional study</article-title>. <source><italic toggle="yes">J Physiol Investig</italic></source>. <year>2024</year>;<volume>67</volume>(<issue>2</issue>):<fpage>64</fpage>&#8211;<lpage>68</lpage>. doi:<pub-id pub-id-type="doi">10.4103/ejpi.EJPI-D-24-00001</pub-id><pub-id pub-id-type="pmid">39468016</pub-id></mixed-citation></ref><ref id="cit0095"><label>95.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Alnawwar</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Alraddadi</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Algethmi</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Salem</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Salem</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Alharbi</surname><given-names>AA</given-names></string-name>. <article-title>The effect of physical activity on sleep quality and sleep disorder: a systematic review</article-title>. <source><italic toggle="yes">Cureus</italic></source>. <year>2023</year>;<volume>15</volume>(<issue>8</issue>):<fpage>e43595</fpage>. doi:<pub-id pub-id-type="doi">10.7759/cureus.43595</pub-id><pub-id pub-id-type="pmid">37719583</pub-id><pub-id pub-id-type="pmcid">PMC10503965</pub-id></mixed-citation></ref><ref id="cit0096"><label>96.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wendt</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>da Silva</surname><given-names>ICM</given-names></string-name>, <string-name name-style="western"><surname>Gon&#231;alves</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Menezes</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Barros</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wehrmeister</surname><given-names>FC</given-names></string-name>. <article-title>Short-term effect of physical activity on sleep health: a population-based study using accelerometry</article-title>. <source><italic toggle="yes">J Sport Health Sci</italic></source>. <year>2022</year>;<volume>11</volume>(<issue>5</issue>):<fpage>630</fpage>&#8211;<lpage>638</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jshs.2020.04.007</pub-id><pub-id pub-id-type="pmid">32422346</pub-id><pub-id pub-id-type="pmcid">PMC9532894</pub-id></mixed-citation></ref><ref id="cit0097"><label>97.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ben Salem</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Slim</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fathallah</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Hmouda</surname><given-names>H</given-names></string-name>. <article-title>Drug-induced hyperuricaemia and gout</article-title>. <source><italic toggle="yes">Rheumatology</italic></source>. <year>2017</year>;<volume>56</volume>(<issue>5</issue>):<fpage>679</fpage>&#8211;<lpage>688</lpage>. doi:<pub-id pub-id-type="doi">10.1093/rheumatology/kew293</pub-id><pub-id pub-id-type="pmid">27498351</pub-id></mixed-citation></ref><ref id="cit0098"><label>98.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Raja</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kavita</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Amreek</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Shah</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sayeed</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Sehar</surname><given-names>A</given-names></string-name>. <article-title>Hyperuricemia associated with thiazide diuretics in hypertensive adults</article-title>. <source><italic toggle="yes">Cureus</italic></source>. <year>2019</year>;<volume>11</volume>(<issue>8</issue>):<fpage>e5457</fpage>. doi:<pub-id pub-id-type="doi">10.7759/cureus.5457</pub-id><pub-id pub-id-type="pmid">31641556</pub-id><pub-id pub-id-type="pmcid">PMC6802803</pub-id></mixed-citation></ref><ref id="cit0099"><label>99.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Xie</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>J-C</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>D-C</given-names></string-name>. <article-title>Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials</article-title>. <source><italic toggle="yes">BMC Pharmacol Toxicol</italic></source>. <year>2023</year>;<volume>24</volume>(<issue>1</issue>):<fpage>79</fpage>. doi:<pub-id pub-id-type="doi">10.2147/NSS.S334985</pub-id><pub-id pub-id-type="pmid">38098046</pub-id><pub-id pub-id-type="pmcid">PMC10722766</pub-id></mixed-citation></ref><ref id="cit0100"><label>100.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>Y</given-names></string-name>, et al. <article-title>Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2016</year>;<volume>6</volume>(<issue>1</issue>):<fpage>33082</fpage>. doi:<pub-id pub-id-type="doi">10.1183/16000617.0166-2023</pub-id><pub-id pub-id-type="pmid">27605442</pub-id><pub-id pub-id-type="pmcid">PMC5015109</pub-id></mixed-citation></ref><ref id="cit0101"><label>101.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Palagini</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bianchini</surname><given-names>C</given-names></string-name>. <article-title>Pharmacotherapeutic management of insomnia and effects on sleep processes, neural plasticity, and brain systems modulating stress: a narrative review</article-title>. <source><italic toggle="yes">Front Neurosci</italic></source>. <year>2022</year>;<volume>16</volume>:<fpage>893015</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fnins.2022.893015</pub-id><pub-id pub-id-type="pmid">35968380</pub-id><pub-id pub-id-type="pmcid">PMC9374363</pub-id></mixed-citation></ref><ref id="cit0102"><label>102.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>de Mendon&#231;a</surname><given-names>FMR</given-names></string-name>, <string-name name-style="western"><surname>de Mendon&#231;a</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Souza</surname><given-names>LC</given-names></string-name>, et al. <article-title>Benzodiazepines and sleep architecture: a systematic review</article-title>. <source><italic toggle="yes">CNS Neurol Disord Drug Targets</italic></source>. <year>2023</year>;<volume>22</volume>(<issue>2</issue>):<fpage>172</fpage>&#8211;<lpage>179</lpage>. doi:<pub-id pub-id-type="doi">10.2174/1871527320666210618103344</pub-id><pub-id pub-id-type="pmid">34145997</pub-id></mixed-citation></ref><ref id="cit0103"><label>103.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Dong</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>X</given-names></string-name>, et al. <article-title>The influence of night shift work and associated factors on serum uric acid in aircraft maintenance workers</article-title>. <source><italic toggle="yes">BMC Public Health</italic></source>. <year>2024</year>;<volume>24</volume>(<issue>1</issue>):<fpage>1969</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12889-024-18849-4</pub-id><pub-id pub-id-type="pmid">39044235</pub-id><pub-id pub-id-type="pmcid">PMC11267947</pub-id></mixed-citation></ref><ref id="cit0104"><label>104.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>van Durme</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Spaetgens</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Driessen</surname><given-names>J</given-names></string-name>, et al. <article-title>Obstructive sleep apnea and the risk of gout: a population-based case-control study</article-title>. <source><italic toggle="yes">Arthritis Res Ther</italic></source>. <year>2020</year>;<volume>22</volume>(<issue>1</issue>):<fpage>92</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13075-020-02176-1</pub-id><pub-id pub-id-type="pmid">32334617</pub-id><pub-id pub-id-type="pmcid">PMC7183677</pub-id></mixed-citation></ref><ref id="cit0105"><label>105.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Roddy</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Muller</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hayward</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mallen</surname><given-names>CD</given-names></string-name>. <article-title>The association of gout with sleep disorders: a cross-sectional study in primary care</article-title>. <source><italic toggle="yes">BMC Musculoskelet Disord</italic></source>. <year>2013</year>;<volume>14</volume>(<issue>1</issue>):<fpage>119</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1471-2474-14-119</pub-id><pub-id pub-id-type="pmid">23557073</pub-id><pub-id pub-id-type="pmcid">PMC3621781</pub-id></mixed-citation></ref><ref id="cit0106"><label>106.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kalil</surname><given-names>GZ</given-names></string-name>, <string-name name-style="western"><surname>Haynes</surname><given-names>WG</given-names></string-name>. <article-title>Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications</article-title>. <source><italic toggle="yes">Hypertens Res</italic></source>. <year>2012</year>;<volume>35</volume>(<issue>1</issue>):<fpage>4</fpage>&#8211;<lpage>16</lpage>. doi:<pub-id pub-id-type="doi">10.1038/hr.2011.173</pub-id><pub-id pub-id-type="pmid">22048570</pub-id><pub-id pub-id-type="pmcid">PMC3902842</pub-id></mixed-citation></ref><ref id="cit0107"><label>107.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Han</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shim</surname><given-names>I</given-names></string-name>. <article-title>Stress and sleep disorder</article-title>. <source><italic toggle="yes">Exp Neurobiol</italic></source>. <year>2012</year>;<volume>21</volume>(<issue>4</issue>):<fpage>141</fpage>&#8211;<lpage>150</lpage>. doi:<pub-id pub-id-type="doi">10.5607/en.2012.21.4.141</pub-id><pub-id pub-id-type="pmid">23319874</pub-id><pub-id pub-id-type="pmcid">PMC3538178</pub-id></mixed-citation></ref><ref id="cit0108"><label>108.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bowles</surname><given-names>NP</given-names></string-name>, <string-name name-style="western"><surname>Thosar</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Butler</surname><given-names>MP</given-names></string-name>, et al. <article-title>The circadian system modulates the cortisol awakening response in humans</article-title>. <source><italic toggle="yes">Front Neurosci</italic></source>. <year>2022</year>;<volume>16</volume>:<fpage>995452</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fnins.2022.995452</pub-id><pub-id pub-id-type="pmid">36408390</pub-id><pub-id pub-id-type="pmcid">PMC9669756</pub-id></mixed-citation></ref><ref id="cit0109"><label>109.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Li</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>R</given-names></string-name>, et al. <article-title>Glucocorticoids increase renal excretion of urate in mice by downregulating urate transporter 1</article-title>. <source><italic toggle="yes">Drug Metab Dispos</italic></source>. <year>2019</year>;<volume>47</volume>(<issue>11</issue>):<fpage>1343</fpage>&#8211;<lpage>1351</lpage>. doi:<pub-id pub-id-type="doi">10.1124/dmd.119.087700</pub-id><pub-id pub-id-type="pmid">31519697</pub-id></mixed-citation></ref><ref id="cit0110"><label>110.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Matenchuk</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Mandhane</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Kozyrskyj</surname><given-names>AL</given-names></string-name>. <article-title>Sleep, circadian rhythm, and gut microbiota</article-title>. <source><italic toggle="yes">Sleep Med Rev</italic></source>. <year>2020</year>;<volume>53</volume>:<fpage>101340</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smrv.2020.101340</pub-id><pub-id pub-id-type="pmid">32668369</pub-id></mixed-citation></ref><ref id="cit0111"><label>111.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sejbuk</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Siebieszuk</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Witkowska</surname><given-names>AM</given-names></string-name>. <article-title>The role of gut microbiome in sleep quality and health: dietary strategies for microbiota support</article-title>. <source><italic toggle="yes">Nutrients</italic></source>. <year>2024</year>;<volume>16</volume>(<issue>14</issue>):<fpage>2259</fpage>. doi:<pub-id pub-id-type="doi">10.3390/nu16142259</pub-id><pub-id pub-id-type="pmid">39064702</pub-id><pub-id pub-id-type="pmcid">PMC11279861</pub-id></mixed-citation></ref><ref id="cit0112"><label>112.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gutierrez Lopez</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Lashinger</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Weinstock</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Bray</surname><given-names>MS</given-names></string-name>. <article-title>Circadian rhythms and the gut microbiome synchronize the host&#8217;s metabolic response to diet</article-title>. <source><italic toggle="yes">Cell Metab</italic></source>. <year>2021</year>;<volume>33</volume>(<issue>5</issue>):<fpage>873</fpage>&#8211;<lpage>887</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cmet.2021.03.015</pub-id><pub-id pub-id-type="pmid">33789092</pub-id></mixed-citation></ref><ref id="cit0113"><label>113.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chu</surname><given-names>YL</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>YF</given-names></string-name>, et al. <article-title>Metagenomic analysis revealed the potential role of gut microbiome in gout</article-title>. <source><italic toggle="yes">Npj Biofilms Microb</italic></source>. <year>2021</year>;<volume>7</volume>(<issue>1</issue>):<fpage>66</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41522-021-00235-2</pub-id><pub-id pub-id-type="pmcid">PMC8352958</pub-id><pub-id pub-id-type="pmid">34373464</pub-id></mixed-citation></ref><ref id="cit0114"><label>114.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>M&#233;ndez-Salazar</surname><given-names>EO</given-names></string-name>, <string-name name-style="western"><surname>V&#225;zquez-Mellado</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Casimiro-Soriguer</surname><given-names>CS</given-names></string-name>, et al. <article-title>Taxonomic variations in the gut microbiome of gout patients with and without tophi might have a functional impact on urate metabolism</article-title>. <source><italic toggle="yes">Mol Med</italic></source>. <year>2021</year>;<volume>27</volume>(<issue>1</issue>):<fpage>50</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s10020-021-00311-5</pub-id><pub-id pub-id-type="pmid">34030623</pub-id><pub-id pub-id-type="pmcid">PMC8142508</pub-id></mixed-citation></ref><ref id="cit0115"><label>115.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Teichman</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Riordan</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Gahan</surname><given-names>CGM</given-names></string-name>, <string-name name-style="western"><surname>Dinan</surname><given-names>TG</given-names></string-name>, <string-name name-style="western"><surname>Cryan</surname><given-names>JF</given-names></string-name>. <article-title>When rhythms meet the blues: circadian interactions with the microbiota-gut-brain axis</article-title>. <source><italic toggle="yes">Cell Metab</italic></source>. <year>2020</year>;<volume>31</volume>(<issue>3</issue>):<fpage>448</fpage>&#8211;<lpage>471</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cmet.2020.02.008</pub-id><pub-id pub-id-type="pmid">32130879</pub-id></mixed-citation></ref><ref id="cit0116"><label>116.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>. <article-title>Objective short sleep duration is related to the peripheral inflammasome dysregulation in patients with chronic insomnia</article-title>. <source><italic toggle="yes">Nat Sci Sleep</italic></source>. <year>2020</year>;<volume>12</volume>:<fpage>759</fpage>&#8211;<lpage>766</lpage>. doi:<pub-id pub-id-type="doi">10.2147/nss.S270045</pub-id><pub-id pub-id-type="pmid">33117011</pub-id><pub-id pub-id-type="pmcid">PMC7585267</pub-id></mixed-citation></ref><ref id="cit0117"><label>117.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Fan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>WY</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yue</surname><given-names>XF</given-names></string-name>. <article-title>NLRP3 inflammasome activation mediates sleep deprivation-induced pyroptosis in mice</article-title>. <source><italic toggle="yes">PeerJ</italic></source>. <year>2021</year>;<volume>9</volume>:<fpage>e11609</fpage>. doi:<pub-id pub-id-type="doi">10.7717/peerj.11609</pub-id><pub-id pub-id-type="pmid">34268006</pub-id><pub-id pub-id-type="pmcid">PMC8269641</pub-id></mixed-citation></ref><ref id="cit0118"><label>118.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Qian</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Jackson</surname><given-names>FR</given-names></string-name>, <string-name name-style="western"><surname>Qian</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>G</given-names></string-name>. <article-title>Sequential activation of JAKs, STATs and xanthine dehydrogenase/oxidase by hypoxia in lung microvascular endothelial cells</article-title>. <source><italic toggle="yes">Int J Biochem Cell Biol</italic></source>. <year>2008</year>;<volume>40</volume>(<issue>3</issue>):<fpage>461</fpage>&#8211;<lpage>470</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biocel.2007.08.008</pub-id><pub-id pub-id-type="pmid">17920330</pub-id><pub-id pub-id-type="pmcid">PMC2276459</pub-id></mixed-citation></ref><ref id="cit0119"><label>119.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Liu&#8208;Bryan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Scott</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sydlaske</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rose</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Terkeltaub</surname><given-names>R</given-names></string-name>. <article-title>Innate immunity conferred by toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal&#8211;induced inflammation</article-title>. <source><italic toggle="yes">Arthritis Rheum</italic></source>. <year>2005</year>;<volume>52</volume>(<issue>9</issue>):<fpage>2936</fpage>&#8211;<lpage>2946</lpage>. doi:<pub-id pub-id-type="doi">10.1002/art.21238</pub-id><pub-id pub-id-type="pmid">16142712</pub-id></mixed-citation></ref><ref id="cit0120"><label>120.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ijaz</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Waheed</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tayyab</surname><given-names>M</given-names></string-name>, et al. <article-title>Reno protective role of N acetyl cysteine and aqueous extract of Berberis Lycium royale root bark on rats</article-title>. <source><italic toggle="yes">J Ayub Med Coll Abbottabad</italic></source>. <year>2021</year>;<volume>33</volume>(<issue>4</issue>):<fpage>553</fpage>&#8211;<lpage>557</lpage>.<pub-id pub-id-type="pmid">35124906</pub-id></mixed-citation></ref><ref id="cit0121"><label>121.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Soyka</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wild</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Caulet</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Leontiou</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lugoboni</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hajak</surname><given-names>G</given-names></string-name>. <article-title>Long-term use of benzodiazepines in chronic insomnia: a European perspective</article-title>. <source><italic toggle="yes">Front Psychiatry</italic></source>. <year>2023</year>;<volume>14</volume>:<fpage>1212028</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fpsyt.2023.1212028</pub-id><pub-id pub-id-type="pmid">37599882</pub-id><pub-id pub-id-type="pmcid">PMC10433200</pub-id></mixed-citation></ref><ref id="cit0122"><label>122.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Capiau</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Huys</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>van Poelgeest</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>van der Velde</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Petrovic</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Somers</surname><given-names>A</given-names></string-name>. <article-title>Therapeutic dilemmas with benzodiazepines and Z-drugs: insomnia and anxiety disorders versus increased fall risk: a clinical review</article-title>. <source><italic toggle="yes">Eur Geriatr Med</italic></source>. <year>2022</year>;<volume>14</volume>(<issue>4</issue>):<fpage>697</fpage>&#8211;<lpage>708</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s41999-022-00731-4</pub-id><pub-id pub-id-type="pmid">36576689</pub-id><pub-id pub-id-type="pmcid">PMC10447278</pub-id></mixed-citation></ref><ref id="cit0123"><label>123.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Praharaj</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Gaur</surname><given-names>N</given-names></string-name>. <article-title>Clinical practice guideline on management of sleep disorders in the elderly</article-title>. <source><italic toggle="yes">Indian J Psychiatry</italic></source>. <year>2018</year>;<volume>60</volume>(<issue>Suppl 7</issue>):<fpage>S383</fpage>&#8211;<lpage>s396</lpage>. doi:<pub-id pub-id-type="doi">10.4103/0019-5545.224477</pub-id><pub-id pub-id-type="pmid">29535472</pub-id><pub-id pub-id-type="pmcid">PMC5840912</pub-id></mixed-citation></ref><ref id="cit0124"><label>124.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ma</surname><given-names>Z-R</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>L-J</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>M-H</given-names></string-name>. <article-title>Efficacy of cognitive behavioral therapy in children and adolescents with insomnia: a systematic review and meta-analysis</article-title>. <source><italic toggle="yes">Braz J Med Biol Res</italic></source>. <year>2018</year>;<volume>51</volume>(<issue>6</issue>):<fpage>e7070</fpage>. doi:<pub-id pub-id-type="doi">10.1590/1414-431x20187070</pub-id><pub-id pub-id-type="pmid">29791593</pub-id><pub-id pub-id-type="pmcid">PMC6002144</pub-id></mixed-citation></ref><ref id="cit0125"><label>125.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Miyamoto</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hirata</surname><given-names>K</given-names></string-name>. <article-title>Sleep disorders in the elderly: diagnosis and management</article-title>. <source><italic toggle="yes">J Gen Fam Med</italic></source>. <year>2017</year>;<volume>18</volume>(<issue>2</issue>):<fpage>61</fpage>&#8211;<lpage>71</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jgf2.27</pub-id><pub-id pub-id-type="pmid">29263993</pub-id><pub-id pub-id-type="pmcid">PMC5689397</pub-id></mixed-citation></ref><ref id="cit0126"><label>126.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>FitzGerald</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Dalbeth</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Mikuls</surname><given-names>T</given-names></string-name>, et al. <article-title>American College of Rheumatology Guideline for the Management of Gout</article-title>. <source><italic toggle="yes">Arthritis Care Res</italic></source>. <year>2020</year>;<volume>72</volume>(<issue>6</issue>):<fpage>744</fpage>&#8211;<lpage>760</lpage>. doi:<pub-id pub-id-type="doi">10.1002/acr.24180</pub-id><pub-id pub-id-type="pmcid">PMC10563586</pub-id><pub-id pub-id-type="pmid">32391934</pub-id></mixed-citation></ref><ref id="cit0127"><label>127.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Honda</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Horiuchi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Torii</surname><given-names>T</given-names></string-name>, et al. <article-title>Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database</article-title>. <source><italic toggle="yes">BMC Pediatr</italic></source>. <year>2021</year>;<volume>21</volume>(<issue>1</issue>):<fpage>581</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12887-021-03051-x</pub-id><pub-id pub-id-type="pmid">34922491</pub-id><pub-id pub-id-type="pmcid">PMC8684120</pub-id></mixed-citation></ref><ref id="cit0128"><label>128.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mindell</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Cook</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Nikolovski</surname><given-names>J</given-names></string-name>. <article-title>Sleep patterns and sleep disturbances across pregnancy</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2015</year>;<volume>16</volume>(<issue>4</issue>):<fpage>483</fpage>&#8211;<lpage>488</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2014.12.006</pub-id><pub-id pub-id-type="pmid">25666847</pub-id></mixed-citation></ref><ref id="cit0129"><label>129.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Horta-Baas</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hern&#225;ndez-Cabrera</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Vergara-S&#225;nchez</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Romero-Figueroa Md</surname><given-names>S</given-names></string-name>. <article-title>Gotayembarazo: revisi&#243;n sistem&#225;tica, incluyendo el reporte de un nuevo caso</article-title>. <source><italic toggle="yes">Revista Colombiana de Reumatolog&#237;a</italic></source>. <year>2017</year>;<volume>24</volume>(<issue>4</issue>):<fpage>219</fpage>&#8211;<lpage>229</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.rcreu.2017.10.002</pub-id></mixed-citation></ref><ref id="cit0130"><label>130.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Page</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>McKenzie</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Bossuyt</surname><given-names>PM</given-names></string-name>, et al. <article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title>. <source><italic toggle="yes">BMJ</italic></source>. <year>2021</year>;<volume>372</volume>:<fpage>n71</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>